<SEC-DOCUMENT>0001564590-20-009541.txt : 20200310
<SEC-HEADER>0001564590-20-009541.hdr.sgml : 20200310
<ACCEPTANCE-DATETIME>20200310070159
ACCESSION NUMBER:		0001564590-20-009541
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200310
DATE AS OF CHANGE:		20200310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECISION BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001357874
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38841
		FILM NUMBER:		20699895

	BUSINESS ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
		BUSINESS PHONE:		919-314-5512

	MAIL ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dtil-10k_20191231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-10k_20191231.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2019</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom"  style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-38841</p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Precision BioSciences, Inc.</font><font style="font-size:10pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20-4206017</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:3pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">302 East Pettigrew St., Suite A-100</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Durham, North Carolina</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">27701</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (919) 314-5512 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom"  style="width:0.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:39.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_table_15_5"></a>Common Stock, par value $0.000005 per share</p></td>
<td valign="bottom"  style="width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DTIL</p></td>
<td valign="bottom"  style="width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Global Select Market</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act:<font style="font-weight:normal;"> </font>None</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES <font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-size:9pt;font-family:MS Gothic;">&#9744;</font> NO&#160;<font style="font-size:9pt;font-family:MS Gothic;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:MS Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:MS Gothic;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES <font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 28, 2019, was $589.0 million. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s common stock outstanding as of March 2, 2020 was 51,399,847. </p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Part_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr style="height:3.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Part_II"><font style="text-decoration:underline;">PART&#160;II</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Part_III"><font style="text-decoration:underline;">PART&#160;III</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Part_IV"><font style="text-decoration:underline;">PART&#160;IV</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
</tr>
<tr style="height:15pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of present and historical facts contained in this Annual Report on Form 10-K, including without limitation, statements regarding our future results of operations and financial position, business strategy and approach, including related results, prospective products, planned preclinical or greenhouse studies and clinical or field trials, the status and results of our preclinical and clinical studies, expected release of interim data, expectations regarding our allogeneic chimeric antigen receptor T cell immunotherapy product candidates, capabilities of our manufacturing facility, regulatory approvals, research and development costs, timing, expected results and likelihood of success, as well as plans and objectives of management for future operations, may be forward-looking statements. Without limiting the foregoing, in some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;seeks,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct.&nbsp;&nbsp;Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in Part I. Item 1A. &#8220;Risk Factors&#8221; and Part II. Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These risks and uncertainties include, but are not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to become profitable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to procure sufficient funding and requirements under our current debt instruments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our operating expenses and our ability to predict what those expenses will be; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our limited operating history; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of our programs and product candidates in which we expend our resources;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our dependence on our ARCUS technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, cost, timing, progress, achievement of milestones and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">public perception about genome editing technology and its applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our or our collaborators&#8217; ability to identify, develop and commercialize product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pending and potential liability lawsuits and penalties against us or our collaborators related to our technology and our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. and foreign regulatory landscape applicable to our and our collaborators&#8217; development of product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our or our collaborators&#8217; ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our or our collaborators&#8217; ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential manufacturing problems associated with the development or commercialization of any of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to achieve our anticipated operating efficiencies at our manufacturing facility;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays or difficulties in our and our collaborators&#8217; ability to enroll patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">if our product candidates do not work as intended or cause undesirable side effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the rate and degree of market acceptance of any of our product candidates;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the success of our existing collaboration agreements</font><font style="font-family:Times New Roman;">,</font><font style="font-family:Times New Roman;"> and our ability to enter into new collaboration arrangements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our current and future relationships with third parties including suppliers and manufacturers;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_cp_blt_1_111"></a><a name="_cp_text_1_112"></a><font style="font-family:Times New Roman;">our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential litigation relating to infringement or misappropriation of intellectual property rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_cp_blt_1_113"></a><a name="_cp_text_1_114"></a><font style="font-family:Times New Roman;">our ability to effectively manage the growth of our operations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_cp_blt_1_115"></a><font style="font-family:Times New Roman;">our ability to attract, retain, and motivate key scientific and management personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market and economic conditions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">effects of natural and manmade disasters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">insurance expenses and exposure to uninsured liabilities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fluctuations in our stock price.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_119"></a><a name="_cp_text_1_119"></a>You should read this Annual Report on Form 10-K and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. All forward-looking statements contained herein speak only as of the date of this Annual Report on Form 10-K.&nbsp;&nbsp;Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this Annual Report on Form 10-K, unless otherwise stated or the context requires otherwise, references to &#8220;Precision,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Precision BioSciences, Inc. and its subsidiaries on a consolidated basis.</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_I"></a><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a life sciences company dedicated to improving life through the application of our pioneering, proprietary ARCUS genome editing platform. We leverage ARCUS in the development of our product candidates, which are designed to treat human diseases and create healthy and sustainable food and agricultural solutions. We are actively developing product candidates in three innovative areas: allogeneic CAR T cell immunotherapy, <font style="font-style:italic;">in vivo </font>gene correction, and food. We are currently conducting a Phase 1/2a clinical trial of PBCAR0191 in adult patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL. PBCAR0191 is our first gene-edited allogeneic chimeric antigen receptor, or CAR, T cell therapy candidate targeting CD19 and is being developed in collaboration with Les Laboratoires Servier, or Servier. We have received orphan drug designation for PBCAR0191 from the U.S. Food and Drug Administration, or FDA, for the treatment of acute lymphoblastic leukemia, or ALL. Made from donor-derived T cells modified using our ARCUS genome editing technology, PBCAR0191 recognizes the well characterized tumor cell surface protein CD19, an important and validated target in several B-cell cancers, and is designed to avoid graft-versus-host disease, or GvHD, a significant complication associated with donor-derived, cell-based therapies. We believe that this trial, which is designed to assess the safety and tolerability of PBCAR0191 at increasing dose levels, as well as to evaluate anti-tumor activity, is the first U.S.-based clinical trial to evaluate an allogeneic CAR T therapy for R/R NHL. Furthermore, we believe that our proprietary, one-step engineering process for producing allogeneic CAR T cells with a potentially optimized cell phenotype, at large scale in a cost-effective manner, will enable us to overcome the fundamental clinical and manufacturing challenges that have limited the CAR T field to date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk32349903"></a>&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_122"></a>In December 2019, we announced initial data from the ongoing Phase 1/2a clinical trial of PBCAR0191 in adult patients with R/R NHL and R/R B-ALL.<font style="font-weight:bold;"> </font>A total of nine adult patients were reported in these initial Phase 1 trial results, including six with NHL (three treated at Dose Level 1 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> cells/kg), or DL1, and three treated at Dose Level 2 (1x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg), or DL2), and three with B-ALL (all treated at DL2). These data indicated no serious adverse events or dose limiting toxicities. In the NHL cohort, four of six patients demonstrated an objective tumor response by Lugano criteria at day 28, for an overall objective response rate of 67%, including three partial responses and one complete response. In the ALL cohort, one of three patients achieved a complete response at day 28 following treatment with PBCAR0191. As of December 31, 2019, dosing of patients at Dose Level 3 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg) was underway.&#160; Based on the data observed at DL1 and DL2, we filed a protocol amendment for this trial with the FDA in December 2019.&#160; The amended trial design is intended to specifically address key clinical questions. These include assessing the impact of higher total doses of cells on clinical activity and/or the impact of modified lymphodepletion on the ability to achieve durable clinical benefit with associated CAR T cell expansion and persistence. Following feedback from the FDA in late January 2020, the protocol amendment is now being implemented. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the FDA accepted our investigational new drug, or IND, application for our second allogeneic CAR T cell therapy product candidate, PBCAR20A, for which we expect to commence a Phase 1/2a clinical trial in the first quarter of 2020. PBCAR20A is wholly owned by us and targets the validated tumor cell surface target CD20. It will be investigated in subjects with NHL, chronic lymphocytic leukemia, or CLL, and small lymphocytic lymphoma, or SLL. A subset of the NHL patients will have the diagnosis of mantle cell lymphoma, or MCL, and we have received orphan drug designation for PBCAR20A from the FDA for the treatment of this disease.&nbsp;&nbsp;Based on the adverse events observed to date with PBCAR0191, the FDA has agreed to allow us to commence dosing with PBCAR20A directly at Dose Level 2, which we expect to accelerate the timing for our expected completion of the trial.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the FDA accepted our IND application for our third allogeneic CAR T cell therapy product candidate, PBCAR269A, for which we expect to commence a Phase 1/2a clinical trial in 2020. PBCAR269A is wholly owned by us and is designed to target the validated tumor cell surface target BCMA. It will be investigated in subjects with R/R multiple myeloma and we have received orphan drug designation from the FDA for this indication.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in January 2020, we announced that we expect to advance a program targeting the rare genetic disease primary hyperoxaluria type 1, or PH1 as our lead wholly owned <font style="font-style:italic;">in vivo</font> gene correction program. PH1 affects approximately 1-3 people per million in the United States and is caused by loss of function mutations in the AGXT gene, leading to the accumulation of calcium oxalate crystals in the kidneys. Patients suffer from painful kidney stones which may ultimately lead to renal failure. Using ARCUS, we are developing a potential therapeutic approach to the treatment of PH1 that involves knocking out a gene called hydroxyacid oxidase 1, or HAO1, which acts upstream of AGXT. Suppressing HAO1 has been shown in preclinical models by us to prevent the formation of calcium oxalate. We, therefore, believe that a one-time administration of an ARCUS nuclease targeting HAO1 may be a viable strategy for a durable treatment of PH1 patients. In preclinical studies we have demonstrated in a mouse model of PH1 that administration of an ARCUS nuclease targeting HAO1 resulted in approximately 70% reduction in urine calcium oxalate levels. We have also demonstrated that ARCUS efficiently knocked out the HAO1 gene in non-human primates. We plan to select a clinical candidate for this program during 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uring the fiscal year end</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> December 31, 2019, we opened our Manufacturing Center for Advanced Therapeutics, or MCAT, which we believe is the first in-house current good manufacturing practice, or cGMP, compliant manufacturing facility dedicated to genome-edited, off-the-shelf CAR T cell therapy product candidates in the United States.&nbsp;&nbsp;MCAT will enable in-house production of three different drug substances: allogeneic CAR T cells, messenger RNA (including formulations development) and adeno-associated viral vectors. We</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are currently using </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this new manufacturing center to create clinical trial material</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be used in our</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> BCMA targeting allogeneic CAR T </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical trials</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> beginning in 2020.&nbsp;&nbsp;We believe MCAT confers a number of strategic advantages including cost benefits, control of our manufacturing process</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and strategic flexibility as we execute our clinical trials. In the longer term, we believe MCAT has the potential to be a commercial launch facility with the capacity to generate up to 10,000 doses of CAR T cell therapies and 4,000 doses of gene therapies per year.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Allogeneic CAR T Immunotherapy </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we have developed a transformative allogeneic CAR T&#160;immunotherapy platform with the potential to overcome certain limitations of autologous CAR T&#160;cell therapies and significantly increase patient access to these cutting&#8209;edge treatments. Cancer immunotherapy is a type of cancer treatment that uses the body&#8217;s immune system to fight the disease. CAR&#160;T is a form of immunotherapy in which a specific type of immune cell, called a &#8220;T&#160;cell&#8221;, is genetically engineered to recognize and kill cancer cells. Current commercially available CAR&#160;T&#160;therapies are autologous, meaning the T&#160;cells used as the starting material for this engineering process are derived directly from the patient. As a consequence, the therapy is highly personalized, difficult to scale, and expensive. Our allogeneic approach uses donor&#8209;derived T&#160;cells that are gene edited using ARCUS and are designed for safe delivery to an unrelated patient. We believe that this donor-derived approach will allow us to consistently produce a potent product by selecting donors with high quality T cells and will lessen the product-to-product variability seen in autologous therapies. We are able to produce allogeneic CAR&#160;T&#160;cells at a large scale in a cost-effective manner and have the potential to overcome the &#8220;one patient: one product&#8221; burden of autologous CAR&#160;T&#160;cell therapies. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging the unique gene editing capabilities of ARCUS, we have developed a one-step cell engineering process for allogeneic CAR T&#160;cells that is designed to maintain na&#239;ve and central memory T cell phenotypes throughout the CAR T manufacturing process, which we believe to be important for an optimized CAR T therapy. Due to our one-step editing method and the decision early in the development of our allogeneic CAR T immunotherapy platform to invest in process development, we have scaled our manufacturing process and are currently producing allogeneic CAR T&#160;cells at large scale in accordance with good manufacturing practice, or GMP. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, we entered into a development and commercial license agreement, as subsequently amended, with predecessor entities of Les Laboratoires Servier, or Servier, which we refer to as the Servier Agreement. Pursuant to this agreement we have agreed to perform early-stage research and development on individual T&#160;cell modifications for up to six unique antigen targets, the first of which was selected at the inception of the agreement. Upon selection of an antigen target, we have agreed to develop the resulting therapeutic product candidates through Phase&#160;1 clinical trials and prepare the clinical supply of such product candidates for use in Phase&#160;2 clinical trials. We have the ability to opt-in to a 50/50 co&#8209;development and co-promotion agreement in the United States on all licensed products under the Servier Agreement. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced program, PBCAR0191, is an allogeneic CAR T cell therapy candidate targeting the well-validated tumor target CD19 and is being developed for the treatment of adult patients with NHL and B-ALL. CD19 is a protein that is expressed on the surface of B cells. The FDA has granted PBCAR0191 orphan drug designation for the treatment of ALL. In December 2019, we reported initial data from our ongoing Phase 1/2a clinical trial of PBCAR0191. A total of nine adult patients were reported in these initial Phase 1 trial results, including six with NHL (three treated at Dose Level 1 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> cells/kg), or DL1, and three treated at Dose Level 2 (1x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg), or DL2), and three with B-ALL (all treated at DL2). These data indicated no serious adverse events or dose limiting toxicities. In the NHL cohort, four of six patients demonstrated an objective tumor response by Lugano criteria at day 28, for an overall objective response rate of 67%, including three partial responses and one complete response. In the ALL cohort, one of three patients achieved a complete response at day 28 following treatment with PBCAR0191. As of December 31, 2019, dosing of patients at Dose Level 3 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg) was underway. Based on the data observed at DL1 and DL2, we filed a protocol amendment for this trial with the FDA in December 2019.&nbsp;&nbsp;The amended trial design is intended to specifically address key clinical questions. These include assessing the impact of higher total doses of cells on clinical activity and/or the impact of modified lymphodepletion on the ability to achieve durable clinical benefit with associated CAR T cell expansion and persistence. Following feedback from FDA in late January 2020, the protocol amendment is now being implemented. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_Hlk33537882"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>In vivo <font style="font-style:normal;">Gene Correction.</font><font style="font-weight:normal;font-style:normal;"> Our goal is to cure genetic diseases by correcting the DNA errors responsible for causing them. </font><font style="font-weight:normal;">In vivo</font><font style="font-weight:normal;font-style:normal;"> gene corrections are gene corrections that take place in a living organism. We have advanced a deep portfolio of diverse programs toward </font><font style="font-weight:normal;">in vivo</font><font style="font-weight:normal;font-style:normal;"> efficacy and toxicity studies. We have generated a significant large animal dataset that we believe to be the most comprehensive of any in the field and have observed high-efficiency </font><font style="font-weight:normal;">in vivo</font><font style="font-weight:normal;font-style:normal;"> genome editing in non-human primates in our preclinical studies, as highlighted in our July 2018 publication in </font><font style="font-weight:normal;">Nature Biotechnology</font><font style="font-weight:normal;font-style:normal;">. We believe this is the first peer-reviewed publication of </font><font style="font-weight:normal;">in vivo</font><font style="font-weight:normal;font-style:normal;"> genome editing data in non-human primates. In our preclinical studies, we observed the high-efficiency editing of the PCSK9 gene in non-human primates using ARCUS and, even at the highest dose, the treatment was observed to be well-tolerated. We have </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;">continued to observe the subjects for over three years since initial dosing and the benefit of the treatment in these studies appears to be permanent, which we believe is due to modifications to the DNA itself. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020 we announced that we expect to advance a program for the treatment of the rare genetic disease PH1 as our lead wholly owned gene correction program, based on preclinical data we have generated demonstrating high efficiency knock out of the HAO1 target gene in non-human primates using ARCUS, and evidence from a mouse model of clinically meaningful biomarker changes using our approach. We expect to nominate a clinical development candidate for this program during 2020. In addition, we are party to a collaboration agreement with Gilead Sciences, Inc. (&#8220;Gilead&#8221;) to co-develop an ARCUS-based product candidate that is designed to cure chronic hepatitis B infection. Submission of an IND to the FDA for this product candidate is currently targeted for 2021. We are also in the discovery stage for other <font style="font-style:italic;">in vivo</font> indications: familial amyloid polyneuropathy, hemophilia&#160;A, autosomal dominant retinitis pigmentosa, lipoprotein lipase deficiency and familial hypercholesterolemia. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Food.<font style="font-weight:normal;"> Our food platform, which we operate through our wholly owned subsidiary, Elo Life Systems, or Elo, is an integrated suite of gene discovery and crop engineering technologies that is designed to generate products in collaboration with leading food producers. We have a team with in-depth experience in crop genome editing. Over the last decade, we have worked with some of the largest plant biotechnology companies to edit gene targets and develop potential product candidates in a variety of crop plants. By combining the power of our ARCUS technology platform with target discovery, transformation and high throughput trait evaluation, we are enabling our partners to potentially address critical issues in food and agriculture created by climate change and dramatic shifts in consumer preference toward healthier eating. Our collaboration-driven business model enables us to remain capital efficient throughout the product development cycle while generating revenue through various revenue-sharing models. For example, since 2014, Elo and Cargill have been engaged in a collaboration to produce ARCUS-optimized canola varieties and have achieved significantly lower levels (less than 4.5%) of saturated fatty acids compared to the current levels (7%) in greenhouse studies. Elo achieved proof of concept with its ZeroMelon<sup style="font-size:85%;line-height:120%;vertical-align:top">TM </sup>watermelon-based sweetener program. This program is intended to leverage ARCUS to develop a scalable low-calorie sweetener. Elo will continue to advance the ZeroMelon program towards greenhouse trials in 2020. Prior to commercialization of any of our food product candidates, we must complete greenhouse studies and multiple phases of field testing.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Team </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our team, whom we call Precisioneers, has among the deepest scientific experience and capabilities of all genome editing companies. Derek Jantz, Ph.D., our Chief Scientific Officer and a co-founder of Precision, and Jeff Smith, Ph.D., our Chief Technology Officer and also a co-founder of Precision, have been working with genome editing technology for more than 15 years. They are pioneers in the genome editing field and developed our ARCUS genome editing platform to address what they perceived as limitations in the existing genome editing technologies. Our Chief Executive Officer, Matthew Kane, also a co-founder of Precision, has almost 20 years&#8217; experience in life sciences, most of which has been working in genome editing. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have selectively expanded our team of Precisioneers to include individuals with extensive industry experience and expertise in the discovery, development, manufacture and commercialization of cell and gene therapies and the creation of innovative solutions to myriad problems affecting food systems.&nbsp;&nbsp; Our team of Precisioneers includes more than 62 scientists with Ph.D. degrees.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a purpose-driven organization, and we have carefully promoted a culture that values innovation, accountability, respect, adaptability and perseverance. We strive to ensure that our open, collaborative culture empowers Precisioneers to be their best selves and do their best work. We strongly believe that our shared values will help our team navigate and overcome any challenges we may experience as we pursue our mission of improving life through genome editing. Our culture has helped build a world-class team with industry-leading experience in genome editing and continually attracts new talent to further build our capabilities. Our team is a group of motivated individuals that value the opportunity to contribute their time and talents toward the pursuit of improving life. Precisioneers appreciate high-quality research and are moved by the opportunity to translate their work into treatments and solutions that will impact human health. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dedicated to improving life. Our goal is to broadly translate the potential of genome editing into permanent genetic solutions for significant unmet needs. Our strategy to achieve this goal includes the following key elements: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Create a fully integrated genome editing company capable of delivering solutions that address unmet needs impacting human health.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">We believe that, to be a leader in the field of genome editing and maximize the impact of our ARCUS genome editing platform, we must be able to control those elements of our business that may provide us with certain strategic advantages or operational efficiencies. We intend to continue to invest in comprehensive research, development, manufacturing and commercial capabilities that provide control and oversight of our product candidates from discovery through commercialization. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Capitalize on our emerging leadership position in allogeneic CAR T immunotherapies.&#160;&#160; </font><font style="font-family:Times New Roman;">We believe that we have developed the first allogeneic CAR T cell platform capable of producing drug product at scale, with a potentially optimal cell profile for therapeutic efficacy and true off-the-shelf delivery without the need for harsh and potentially toxic lymphodepletion. We have selected three validated CAR T cell targets that we believe offer the greatest chance of clinical success for our initial product candidates, which we aim to rapidly advance through and into clinical development. In December 2019, we reported initial data from the first six patients with advanced NHL and first three patients with advanced ALL treated with PBCAR0191 at the lowest two dose levels in our ongoing Phase 1/2a clinical trial. These initial data indicated no serious adverse events or dose-limiting toxicities, and demonstrated initial evidence of cell-mediated anti-tumor activity. As of December 31, 2019, dosing of patients at the third dose level was underway. Our CAR T platform is modular, which we believe will allow us to leverage proof-of-concept from our ongoing and planned initial human trials for multiple other CAR T programs. We believe the combination of these factors, along with our unique ARCUS technology, puts us in a differentiated position to be the leader in the development of allogeneic CAR T therapies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Advance ARCUS-based </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-weight:bold;font-family:Times New Roman;"> gene correction programs into human clinical trials.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;In our preclinical studies, we observed the high-efficiency and tolerability of </font><font style="font-style:italic;font-family:Times New Roman;">in vivo </font><font style="font-family:Times New Roman;">genome editing using ARCUS in a non-human primate model, as published in </font><font style="font-style:italic;font-family:Times New Roman;">Nature Biotechnology</font><font style="font-family:Times New Roman;"> in July 2018. To our knowledge, we are the first company to complete this milestone, which we believe to be critical to successful </font><font style="font-style:italic;font-family:Times New Roman;">in vivo </font><font style="font-family:Times New Roman;">genome editing therapeutic development. We have built on this early success by diligently advancing a diverse portfolio of preclinical </font><font style="font-style:italic;font-family:Times New Roman;">in vivo </font><font style="font-family:Times New Roman;">gene correction programs through additional large animal studies, focusing initially on gene targets occurring in the liver and eye. Based on the results from these studies, we are advancing our lead wholly owned </font><font style="font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-family:Times New Roman;"> gene correction program for the rare genetic disease primary hyperoxaluria type 1.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Build a food business focused on developing products designed to improve human health and respond to the impacts of climate change.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;We believe that rapidly changing consumer preferences and food insecurity resulting from population growth and climate change will drive significant demand for genome-edited food products. We are building a fully integrated discovery and development platform that combines genome editing, gene discovery, plant transformation and high-throughput testing to enable accelerated innovation in the food industry. We employ a business model that is focused on collaborating with critical stakeholders within the supply chain from the outset of any given project. We believe that this approach will enable us to successfully respond to growing unmet needs within food supply to build a human health-focused business in a capital-efficient manner. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Continue investing in the optimization of ARCUS and enabling technologies.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">We believe that a key to our future success is the quality of the genome editing tools that we produce. Since our founding, we have devoted ourselves to continuously refining the precision and efficiency of our core genome editing platform. We intend to continue this investment in ARCUS while surrounding it with enabling technologies and expertise to retain what we believe is a leadership position in the field. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Create an environment that is a destination of choice for premier talent within the life sciences industry.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;We believe that we currently have among the deepest and strongest skill set within the genome editing industry and credit much of our past success to our commitment to our team and culture. Our future success will depend on our ability to continue to attract and retain world-class talent within our markets of interest. We intend to consciously invest in fostering an environment within our company that is both challenging and supportive and inspires our team to broadly translate genome editing into permanent genetic solutions. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Expand the breadth of our operations through additional product platforms and strategic relationships.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;We believe that the ARCUS genome editing platform has broad utility beyond our current areas of focus. We intend to invest in the development of additional product platforms and seek collaborations with companies with additive expertise in areas outside of our current target markets to maximize the value of our company.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview of Genome Editing </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deoxyribonucleic acid, or DNA, carries the genetic instructions for all basic functions of a living cell. These instructions are encoded in four different molecules, called bases, which are strung together in specific sequences to form genes. Each gene is responsible for a specific function in a cell, and the complete set of genes in a cell, which can consist of tens of thousands of genes and billions of individual bases, is known as a genome. The complete genome sequence has been determined for many organisms, including humans. This allows scientists to identify specific genes and determine how their unique sequences contribute to a particular cellular function. Studying variations in gene sequences further informs an understanding of why a cell behaves a certain way, which can greatly enhance understanding of what causes and how to treat aberrant behavior that leads to disease. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genome editing is a biotechnology process that removes, inserts or repairs a portion of DNA at a specific location in a cell&#8217;s genome. Early applications of genome editing focused on advancing genetic research. As genome editing technologies have advanced, their application is moving beyond understanding disease to treating or preventing disease by editing DNA. Genome editing is accomplished by delivering a DNA cutting enzyme, called an endonuclease, to a targeted segment of genetic code. Once the endonuclease cuts the DNA, the cell has to repair the break to survive and will generally do so in one of two ways, as shown below. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000001.jpg" title="" alt="" style="width:346px;height:294px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are two primary mechanisms of DNA repair, non-homologous end joining, or NHEJ, and homology directed repair, or HDR. As shown in A) above, NHEJ is a pathway that repairs breaks in DNA without a template. NHEJ is the less precise method of repair that prioritizes speed over accuracy, making it prone to leaving insertions and/or deletions of DNA bases at the cut site. These insertions or deletions can disrupt the gene sequence and can be used to inactivate or &#8220;knock out&#8221; the function of the gene. Accordingly, genome editing technologies can be used to permanently knock out a gene in a cell or organism by creating a break in the DNA sequence of that gene. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in B) above, HDR is a mechanism of DNA repair whereby the cell uses a second DNA molecule with a sequence similar to that of the cut DNA molecule to guide the repair process. Since HDR uses a &#8220;template&#8221; of similar genetic information to guide the repair process, it is the more precise mechanism of cellular repair. HDR results in the sequence of the template being copied permanently into the genome at the site of the DNA cut. If we provide a template DNA molecule directly to the edited cell and the cell repairs itself using HDR, a new gene can be incorporated or &#8220;knocked in&#8221; at a precise location in the genome. Alternatively, the use of HDR can &#8220;repair&#8221; a DNA mutation by correcting it to the proper functioning sequence when repairing the break. Thus, genome editing endonucleases can be used to introduce a variety of different changes to the genetic code of a cell or organism including gene knockout, gene insertion and gene repair. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several genome editing technologies, including ARCUS, zinc-finger nucleases, or ZFNs, TAL-effector nucleases, or TALENs, and CRISPR/Cas9. These technologies differ from one another principally in the properties of the endonuclease that they each employ. The different endonucleases have fundamentally different mechanisms of recognizing and cutting their DNA targets, which gives each technology advantages and disadvantages depending on how each is used. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Approach to Genome Editing </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are pioneers in the field of genome editing and have extensive experience with a breadth of genome editing technologies. Our ARCUS platform was developed to address limitations of other editing technologies that could impair their deployment for therapeutic applications. We looked to nature for examples of genome editing and found the I-CreI endonuclease from the algae <font style="font-style:italic;">Chlamydomonas reinhardtii</font>. Unlike ZFN, TALEN or CRISPR/Cas9, I-CreI is a natural enzyme that evolved to edit a large, complex genome. In nature, it is responsible for modifying a specific location in the algae genome by inserting a gene using the HDR process, according to scientific literature. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that I-CreI has a number of attributes that make it attractive for the development of novel genome editing endonucleases, such as: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Specificity.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">Complex genome editing applications, especially those involving the human body, require a high level of endonuclease specificity to limit the likelihood that the endonuclease will recognize and edit any genetic sequence other than its intended target. Based on scientific literature, we believe that several attributes of I-CreI naturally inhibit off-target cutting. I-CreI: </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recognizes and cuts a DNA sequence in the genome of algae that is 22 base pairs in length</font>.&#160;&#160;&#160;&#160;A sequence of this length is statistically expected to occur only once in a large genome. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recognizes its DNA target site through a large number of complex molecular interactions with the bases</font>.&#160;&#160;&#160;&#160;Relative to other endonucleases, an unusually high percentage of the I-CreI protein surface area is dedicated to specific contacts with the DNA bases. This method of site recognition enhances I-CreI&#8217;s ability to discriminate among similar sequences of DNA, reducing the likelihood that it will cut DNA sequences that differ even slightly from the intended DNA sequence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Physically couples the functions of DNA binding and DNA cutting</font>.<font style="font-weight:bold;">&#160;&#160;&#160;&#160;</font>The region of I-CreI that is responsible for DNA site recognition also contains the region that cuts the DNA, or the active site. Due to this structure, the active site is not in a position to cut unless the enzyme is seated properly on the correct DNA sequence. ZFN, TALEN and CRISPR/Cas9 are multi-domain endonucleases in which the DNA-binding and DNA-cutting functions reside in different regions of the enzyme.<font style="font-weight:bold;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000002.jpg" title="" alt="" style="width:618px;height:88px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Remains inactive in the absence of its DNA target site</font>.<font style="font-weight:bold;">&#160;&#160;&#160;&#160;</font>When I-CreI is not bound to its proper DNA target site, it folds up on itself such that its active site is blocked from external interaction. In this form, I-CreI is inert. This structural configuration provides a type of natural &#8220;on/off switch&#8221; that reduces I-CreI&#8217;s activity away from the target site. Other genome editing endonucleases lack this type of natural control over the enzyme&#8217;s cutting activity. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cuts slowly and with low turnover</font>.<font style="font-weight:bold;">&#160;&#160;&#160;&#160;</font>Relative to other genome editing endonucleases and to enzymes in general, I-CreI has a very slow mechanism of action. I-CreI takes a relatively long time to cut its DNA target site and, after doing so, remains bound to the cut DNA ends. These properties greatly reduce the likelihood that I-CreI will cut any other<font style="font-style:italic;"> </font>DNA site after making its initial on-target cut. We believe that this translates directly to a reduction in the frequency of off-target cutting without sacrificing on-target editing efficiency. In contrast, other editing endonucleases have high rates of catalysis and turnover because their natural function is defending bacteria from viruses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Efficiency.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Most applications of genome editing technology require that a sufficient portion of the targeted cells are edited to achieve the desired result. The activity level of the endonuclease is one factor that can affect how many cells are edited. The slow catalytic mechanism of I-CreI imparts specificity but does not impact its on-target efficiency for genome editing purposes because genome editing involves cutting only a single site in a cell. As such, I-CreI is able to achieve a high level of on-target editing while rarely cutting off-target, as supported by scientific literature. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Delivery.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">Size and structural simplicity affect the ease with which endonucleases can be delivered to cells for editing. I-CreI is very small relative to other genome editing endonucleases. It is approximately one quarter to one sixth of the size of the ZFN, TALEN and CRISPR/Cas9 endonucleases. Unlike those endonucleases, I-CreI can be delivered as a single gene. As such, we believe it is compatible with many different delivery mechanisms. Additionally, I-CreI&#8217;s size and structure facilitate the simultaneous delivery of multiple engineered endonucleases to introduce more than one edit to a cell. Both of these properties significantly broaden the spectrum of potential applications for I-CreI-based genome editing endonucleases. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;">Type of Cut.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">The three prime, or 3&#8217;, overhangs created when I-Cre</font><font style="font-family:Times New Roman;">I</font><font style="font-family:Times New Roman;"> cuts DNA have been shown to promote DNA repair through a mechanism called &#8220;homology directed repair,&#8221; or HDR. 3&#8217; overhangs are stretches of unpaired nucleotides in the end of a DNA molecule. A genome editing technology that facilitates cellular repair through HDR enables applications that require a gene insertion or gene repair. Unlike other editing endonucleases, I-CreI creates four base 3&#8217; overhangs when it cuts its DNA site, which increases the likelihood that the cell will repair the DNA cut through HDR. As such, the DNA cuts created by I-CreI can be exploited to efficiently insert or repair DNA, consistent with the natural role of I-CreI in catalyzing the targeted insertion of a gene in algae. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Programmability.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;I-CreI recognizes its DNA target site through a complex network of interactions that is challenging to re-program for new editing applications involving different DNA sequences. The challenges associated with re-programming I-CreI have, historically, hampered its adoption by the genome editing community in favor of more easily engineered endonucleases. This engineering challenge represents a high barrier to entry and has enabled us to secure a strong intellectual property position and control over what we believe to be a superior genome editing technology. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than the key programming challenge, we believed that the differentiated properties of I-CreI cited above made it an ideal &#8220;scaffold&#8221; for the development of novel genome editing tools. Moreover, we believed those properties were differentiated enough from other editing technologies to merit substantial investment in overcoming the key challenge of programmability. To that end, we invested 15 years of research effort to develop a robust, proprietary protein engineering method that now enables us to consistently re-program I-CreI to direct it to targeted sites in a genome. We call our approach ARCUS. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our ARCUS Genome Editing<font style="font-weight:normal;"> </font>Platform<font style="font-weight:normal;"> </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCUS is a collection of protein engineering methods that we developed specifically to re-program the DNA recognition properties of I-CreI. In nature, the I-CreI endonuclease recognizes and cuts a DNA sequence in the genome of algae. To apply I-CreI to genome editing in other cells or organisms, we must modify it to recognize and cut a different DNA sequence for each new application we pursue. Since the I-CreI endonuclease evolved to recognize its target sequence in the algae genome with a high degree of selectivity, as supported by scientific literature, it was necessary for us to develop sophisticated protein engineering methods to re-engineer I-CreI endonucleases to bind and cut a different DNA sequence. Using the ARCUS process, we create customized endonucleases for particular applications. We call these custom endonucleases &#8220;ARCUS nucleases.&#8221; Our process is proprietary and core components are claimed in an extensive international patent portfolio. Moreover, since the ARCUS process involves a sophisticated blend of protein engineering art and science, each ARCUS nuclease we create is novel and, we believe, patentable. As of December 31, 2019, we have obtained U.S. patents with claims directed to three ARCUS nucleases as compositions of matter, and currently claim over 270 ARCUS nucleases as compositions of matter in pending U.S. and foreign patent applications. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our objective with ARCUS is to redirect I-CreI to a new location in a genome without compromising its editing abilities. To accomplish this, we modify the parts of the enzyme that, as reported by scientific literature, are involved in recognizing the specific DNA target site. These enzyme parts are also reported to comprise the I-CreI active site and to be involved in anchoring the enzyme to its DNA site in the algae genome. In our preclinical studies, we have observed that these modifications allowed us to control how tightly an engineered variant of I-CreI binds to its intended DNA site, as well as how quickly it cuts, in a plant or animal cell. By adjusting these two parameters, we observed that we can generally control the efficiency with which the engineered endonuclease cuts its intended target site or any potential off-target sites. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The natural I-CreI target site is pseudo-palindromic, meaning the first half of the sequence is approximately a mirror image of the second half of the sequence. Palindromic DNA sites are rare in most genomes so it was necessary for us to develop additional technology that would overcome this limitation on the diversity of DNA sites that we can target. To this end, the ARCUS process involves the production of <font style="font-style:italic;">two</font> re-programmed I-CreI proteins for each target site. These two different proteins are then linked together into a single protein that can be expressed from a single gene. This approach, called a &#8220;single-chain endonuclease,&#8221; represents a major advancement in I-CreI engineering because it enables our ARCUS nucleases to recognize and cut <font style="font-style:italic;">non</font>-palindromic target sites using an endonuclease that, like natural I-CreI, is very small and easy to deliver to cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graphic below depicts the molecular structure of natural I-CreI in comparison to an engineered ARCUS nuclease called &#8220;M1PCSK9.&#8221; The regions of the structures colored in pink or cyan represent the amino acid building blocks that are responsible for contacting the DNA target site and determining the sequence of DNA bases that the endonuclease recognizes and cuts. The DNA target sites recognized by the two endonucleases are shown below the structures. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000003.jpg" title="" alt="" style="width:618px;height:277px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since creating an ARCUS nuclease requires such extensive reengineering of I-CreI, it is, generally, an iterative process that involves multiple cycles of design and testing. We can typically produce a first-generation ARCUS nuclease in seven weeks. First-generation nucleases are suitable for research and development, proof-of-concept studies or other non-therapeutic applications. For therapeutic applications requiring the lowest possible off-targeting, however, we are rarely satisfied with generation one and each endonuclease undergoes extensive optimization. To this end, we thoroughly interrogate the nuclease with respect to its on-and off-target cutting properties using ultra-sensitive tests that we developed specifically for use with ARCUS. These results then inform our design of a second-generation nuclease with the goal of optimizing on-target efficiency while minimizing off-target cutting. Therapeutic ARCUS nucleases typically require two to four cycles of design and testing, often resulting in off-target cutting frequencies that are below the limit of detection with our most sensitive assays. This process can take six months or longer and has resulted in development of &#8220;therapeutic-grade&#8221; editing endonucleases. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ARCUS process is robust and reproducible. It enables us to create engineered variants of the I-CreI endonuclease that recognize and cut DNA sites that bear little resemblance to I-CreI&#8217;s natural target site. Importantly, however, ARCUS retains the attributes of I-CreI that we believe make it highly suitable as a genome editing endonuclease for complex commercial applications. We expect ARCUS nucleases to be exquisitely specific as a result of the natural structure of I-CreI and the intricate design process we employ to create them. We believe ARCUS nucleases are the smallest and easiest to deliver genome editing endonucleases. Like I-CreI, in our preclinical studies, ARCUS nucleases have been observed to produce DNA cuts with 3&#8217; overhangs that promote HDR, facilitating gene insertions and gene repairs in addition to gene knockouts. We believe that these attributes will enable us to translate ARCUS into patient-based clinical trials and a wide array of product candidates that have the potential to address the limitations of other genome editing technologies and improve life. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that ARCUS is a leading genome editing platform for therapeutic and food applications. Realizing the potential of ARCUS, however, requires supporting technologies and capabilities. To facilitate the potential commercial deployment of ARCUS in different fields, we surround it with ancillary technologies, domain expertise and infrastructure specific to that area of development. Our goal is to leverage ARCUS to build additional product-development platforms designed to rapidly generate new products in a given field. We are currently developing products from three such platforms: allogeneic CAR T immunotherapy, <font style="font-style:italic;">in vivo</font> gene correction, and food. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Allogeneic CAR T Immunotherapy Platform </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000004.jpg" title="" alt="" style="width:713px;height:240px;"></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging the properties of ARCUS in an integrated platform for the development and large-scale production of off-the-shelf (allogeneic) CAR T cell immunotherapies. A key to the success of this platform is our proprietary, one-step method for modifying the genetics of T cells from a healthy donor to make them detect and kill cancer cells. This method allows us to produce allogeneic CAR T therapy candidates with a potentially optimal phenotype for clinical development and scaled manufacturing. We have demonstrated that our approach yields an allogeneic product with a high proportion of so-called na&#239;ve and central memory CAR T cells, which are the T cell phenotypes that have previously correlated best with good clinical benefit and fewer adverse events compared with terminally differentiated effector T cells. Additionally, because these cells are derived from healthy donors and maintain the phenotypic characteristics described, it is our hypothesis that they will be more capable of controlled <font style="font-style:italic;">in vivo</font> expansion and tumor killing without requiring harsh lymphodepletion regimens to be administered to the patient. As such, we believe that our allogeneic CAR T&#160;cell platform will greatly increase patient access to these cutting-edge treatments. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CAR T Cell Therapies </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR T cell therapy is a form of cancer immunotherapy that uses a patient&#8217;s immune system to kill cancer cells. T&#160;cells are a component of the immune system that can distinguish pathogen-infected or tumor cells from healthy cells and kill them. Recognition of pathogen-infected cells or tumor cells occurs through a protein called a T cell receptor, or TCR, that is expressed on the surface of T cells. Tumor cells, however, have evolved numerous ways to evade TCR-mediated killing by T cells. In CAR T cell therapy, T cells are engineered <font style="font-style:italic;">ex vivo</font> to express a protein called a chimeric antigen receptor, or CAR, that recognizes specific tumor cell surface targets and allows the T cells to function independently of the TCR, thus circumventing tumor cells&#8217; evasion of the TCR. CAR T cell therapy has been shown in clinical trials to be an effective treatment for patients who have not responded to traditional cancer treatments, and there are now two FDA approved CAR T cell products available to treat certain types of leukemia and lymphoma. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most common form of CAR T cell therapy, which includes the two approved therapies, is referred to as &#8220;autologous&#8221; CAR T cell therapy because the CAR T cells are generated using T cells taken directly from the cancer patient. T cells are harvested from the patient, genetically engineered <font style="font-style:italic;">ex vivo</font> to express a CAR, and then injected back into the patient. While autologous CAR T cell therapy has been shown to be effective for treating certain tumor types, it has several significant drawbacks: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Patient eligibility.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Many patients may not be eligible for the treatment because their cancer has lowered their T cell numbers and T cell quality, or because the risk of undergoing the process to harvest T cells is too great. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Consistency.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Since each autologous therapy is, by definition, unique, it is difficult to define standards of safety and efficacy or to thoroughly assess the quality of the product prior to infusion into the patient. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Delay in treatment.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">Because the process to make autologous CAR T cells can take several weeks, there is a significant delay in treating what can often be very aggressive tumors. Patients&#8217; disease often progresses before they can receive the CAR T therapy, or if manufacturing complications such as contamination, mislabeling or low yield are encountered, the patient may not survive long enough to attempt manufacturing a second time. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Cost.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">The autologous CAR T cell manufacturing process is complex and expensive and must be performed, in its entirety, for each patient. As such, scaling of the manufacturing process is exceedingly difficult, and the cost of product manufacturing has resulted in high treatment costs per patient. This high cost of treatment, along with the practical complexities described above, limits the availability of autologous CAR T cell therapies to patients. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the use of allogeneic, or donor-derived, CAR T cells will address many of the challenges associated with autologous CAR T cell therapy. An allogeneic approach allows selection of donors using specific criteria to define &#8220;healthy&#8221; T cells possessing specific phenotypes, which we believe are important to clinical efficacy and which may lessen the product-to-product variability seen in autologous therapies. Donor-derived cells could be used in any patient, eliminating the &#8220;one patient: one product&#8221; burden of autologous CAR T cell therapies. Because healthy donors would provide the starting material, patients that were too sick or otherwise unqualified for an autologous a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pproach may benefit from an allogeneic CAR T cell therapy. Additionally, patients receiving an off-the-shelf allogeneic treatment would not have to wait for the manufacture of a personalized autologous treatment, which could be further delayed by manufacturing difficulties. By scaling the manufacturing of CAR T cells and optimizing the manufacturing process for a specific pool of donors, we believe that allogeneic CAR T cells can be manufactured at costs that are significantly lower than autologous CAR T cells and that will, over time, approach the manufacturing costs for conventional biologic drugs. These potential advantages of an allogeneic approach should allow for a safer, more predictable product with defined quality standards and significantly increase patient access. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The major challenge to producing allogeneic CAR T cells is that donor-derived T cells still express their own TCR. Because the TCR enables T cells to recognize cells that are foreign to the donor, they may induce GvHD if introduced to the patient in their natural form. This is a dangerous condition in which the donor T cells indiscriminately attack cells in the body of the patient. Accordingly, expression of the TCR must be eliminated in donor cells before the cells can be engineered into CAR T cells and administered to a patient. An allogeneic CAR T cell therapy therefore requires the use of a genome editing technology like ARCUS to knock out TCR genes in the T cell DNA to produce &#8220;universal&#8221; donor cells that are designed to be incapable of eliciting GvHD. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and others have shown that genome editing can be used to eliminate expression of the TCR on donor cells, and there are several companies working on gene-edited allogeneic CAR T cell therapies. However, there are a number of challenges associated with manufacturing gene-edited allogeneic CAR T cells, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">T cell phenotype.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;T cells actually comprise several subtypes of different cells. Some subtypes of T cells are directly responsible for killing virus-infected or tumor cells, while other subtypes serve a helper function. Some subsets retain a &#8220;memory&#8221; function and can be recalled later if the target tumor reappears, and some subsets even decrease the killing activity of T cells. T cells undergo a process of differentiation in response to contact with their targets, which leads to young, na&#239;ve and central memory T cells changing into &#8220;terminally differentiated&#8221; or &#8220;effector&#8221; T cells. These effector T cells are good at killing pathogen-infected cells and other foreign cells, but do not survive for long periods of time in the body and are poorly expansile, in contrast to na&#239;ve and central memory T cells. T cell subsets are distinguished by the unique combination of proteins they express on their cell surface, which is described as their &#8220;phenotype.&#8221; Understanding what phenotypes of T cells are best for a CAR T cell therapy is important, as is the ability to maintain the stability of those phenotypes throughout the manufacturing process. The more genetic and other manipulation T cells undergo, the more likely they are to differentiate from the na&#239;ve and central memory phenotype into terminally differentiated cells. This can happen over the course of a manufacturing run, with the length of the process being directly related to the final cell phenotype. As a result, the final CAR T product may not comprise the desired mix of T cell subtypes for clinical development. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Consistency.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;">In most CAR&#160;T cell therapies, the CAR is introduced into the T&#160;cell using a viral vector, usually a lentiviral vector. Lentiviral vectors are retroviruses that are typically engineered to insert DNA, in this case the gene encoding a CAR, into a random location in the genome of a cell. When introduced in this manner, CAR expression typically varies significantly from cell-to-cell depending on the number of CARs that were delivered and where in the T cell genome they were inserted. This variability can cause CAR T cells to be inconsistent from cell-to-cell within the same CAR&#160;T cell batch. Too little expression could make the CAR T cell unable to activate and kill when it identifies a cancer cell. Too much expression could lead the CAR T cell to become hyper-stimulated, which can lead to an inactive state known as &#8220;exhaustion.&#8221; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Scalability.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Manufacturing scale drives the cost and availability of the final off-the-shelf product. While generating allogeneic CAR T cells at lab scale (a few million cells) is relatively straightforward, manufacturing them at a clinically relevant scale (billions of cells) is a major challenge that is impacted by, among other things, the efficiency of CAR gene insertion, the efficiency of on- and off-target genome editing, starting donor T cell phenotype and the duration of the manufacturing process. </font></p></td></tr></table></div>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Approach to Allogeneic CAR T Cells </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>We have used the unique qualities of ARCUS to create a one-step cell engineering process for allogeneic CAR T cells that we believe yields a well-defined cell product and is designed to maintain na&#239;ve and central memory T cell phenotypes throughout the CAR T manufacturing process; we believe this is of paramount importance for an optimized CAR T therapy. To produce an allogeneic CAR T cell, it is necessary to make two changes to the DNA of T cells from a healthy donor. First, it is necessary to knock out the gene that encodes the TCR to prevent the donor-derived T cells from eliciting GvHD in the patient. The TCR is actually a complex of several </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">different components encoded by different genes, and knocking out any one of them is generally sufficient to prevent the TCR from functioning. Second, it is necessary to add, or knock in, a gene that encodes the CAR to give the T cells the ability to recognize and kill cancer cells. We developed a proprietary, one-step method for achieving both genetic changes simultaneously. This method, aspects of which are protected by nine issued U.S. patents, involves the use of ARCUS to target the insertion of a CAR gene directly into the gene that encodes the alpha subunit of the TCR. This approach adds the DNA encoding the CAR while simultaneously disrupting the DNA encoding the TCR, essentially replacing one gene with the other. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">One-step engineered allogeneic CAR T cells </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000005.jpg" title="" alt="" style="width:561px;height:301px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our one-step engineering approach, and the differentiated attributes of the ARCUS nuclease used to implement it, will overcome many of the critical challenges associated with allogeneic CAR&#160;T cell production as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:12pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">T cell phenotype.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;According to scientific literature, T cell phenotype has a profound impact on the efficacy of CAR&#160;T cell therapy. Specifically, &#8220;young&#8221; CAR T cells with na&#239;ve and central memory phenotypes have been observed to undergo the most robust expansion following administration, which leads to a therapeutic effect. Therefore, we have established a T cell platform that is designed to maximize the percentage of cells with these ideal phenotypes. Our process starts with carefully screening donors to identify individuals with high percentages of na&#239;ve or central memory T cells and a ratio of CD4:CD8 T cells that we believe should yield the most potent cell product. To this end, we have developed our own set of analytics for screening candidate donors and have put significant effort into identifying individuals with the desired T cell profiles. We then use proprietary growth strategies and media to maintain na&#239;ve and central memory T cell phenotypes throughout the CAR T manufacturing process.&nbsp;&nbsp;We believe this is of paramount importance for an optimized CAR T therapy. Importantly, our one-step genome editing approach avoids making multiple breaks to the T cell&#8217;s DNA and also contributes to minimizing cell processing time, which helps prevent the CAR T cells from differentiating during the process. We believe our 10-day allogeneic manufacturing process is the shortest in the industry. The figure below shows results from three full-scale manufacturing campaigns, each of which produced a GMP batch of PBCAR0191. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000006.jpg" title="" alt="" style="width:571px;height:269px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The figure below shows phenotype data from PBCAR0191 CAR T cells that were produced as drug product for our ongoing Phase 1/2a clinical trial in adult patients with R/R NHL and R/R B-ALL. The drug product comprises mostly na&#239;ve (T<sub style="font-size:85%; vertical-align:bottom">N/SCM</sub>) and central memory (T<sub style="font-size:85%; vertical-align:bottom">CM</sub>) T cells. </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000007.jpg" title="" alt="" style="width:458px;height:252px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-family:Times New Roman;">Novel co-stimulatory domain.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;">Our genetically engineered CAR T cells incorporate a novel, proprietary, costimulatory domain called N6, which enables us to enhance cell proliferation and effector function while preserving cell phenotype. We engineered N6 to improve on the function of the 4-1bb costimulatory domain commonly used in autologous CAR T products. Our preclinical data suggests that, compared to 4-1bb, N6 provides an activation signal to the CAR T cells that better preserves cell expansion potential while maintaining na&#239;ve cell phenotype following exposure to cancer cells. We also believe N6 can help avoid CAR T cell hyperstimulation, which can contribute to adverse events seen with autologous products.&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000008.jpg" title="" alt="" style="width:503px;height:231px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Consistency.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;By consistently targeting the same insertion of the CAR gene to a defined location in the DNA of the cell, we are able to produce populations of T cells that are identical at the DNA level. This makes the cells in our CAR&#160;T cell drug formulation less heterogeneous as compared to manufacturing processes that use lentiviral vectors. Importantly, our genome editing process gives us greater control over the amount of CAR that is expressed on the surface of each CAR T cell, which determines how easily the CAR T cell is activated once it encounters a cancer cell. This allows us to &#8220;fine-tune&#8221; the CAR T cells to ensure that they respond appropriately to the cancer but do not become hyper&#8209;activated or exhausted. The below comparison demonstrates the difference in consistency achieved by using lentivirus delivery compared with targeted delivery through an ARCUS nuclease. CAR T cells produced using ARCUS exhibit reduced cell-to-cell variability as well as more controlled levels of CAR gene expression depending on whether the cells are tuned for high expression or low expression. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000009.jpg" title="" alt="" style="width:596px;height:191px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Scalability.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;To realize the potential benefits of allogeneic CAR T cell therapy, it will be important to manufacture as many cells as possible in each batch in accordance with GMP. Scaling efficiently requires scale-up at every step in the process and, as with all drug manufacturing, process development takes significant time and capital. In July 2019, we opened our MCAT facility, which we believe is the first in-house cGMP compliant manufacturing facility dedicated to genome-edited, off-the-shelf CAR T cell therapy product candidates in the United States. We made the decision early in the development of our CAR&#160;T cell platform to invest in process development and manufacturing rather than initiating clinical trials with a process that would not fully support development and commercialization. We did this, in part, because we believed that several attributes of ARCUS, such as high specificity and high knock-in efficiency, would allow us to scale manufacturing more effectively than our competitors. As a consequence of our early investment and the one-step editing method enabled by ARCUS, we have scaled our manufacturing process today, adding in-house capabilities through the opening of our MCAT facility. Over the last twelve months, we have manufactured our lead anti-CD19 allogeneic CAR&#160;T cell product candidate at a multi-billion cell scale consistently. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Key features of Precision&#8217;s allogeneic CAR T platform</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000010.jpg" title="" alt="" style="width:719px;height:328px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preventing CAR T Cell Rejection </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A patient&#8217;s immune system is expected to recognize allogeneic CAR&#160;T cells as foreign and destroy or reject the cells. This rejection could limit the efficacy of the CAR&#160;T therapy if the cells do not persist long enough in the patient to eradicate the tumor. Patients who receive CAR T therapy are typically preconditioned prior to being given the cell therapy using lymphodepleting drugs such as cyclophosphamide or fludarabine, which suppress the immune system of the patient. We believe that this degree of preconditioning will be sufficient to prevent CAR T cell rejection by patients who receive our treatments due to our unique approach to producing CAR T cells. Our CAR T production process preserves T cell phenotypes that we believe are highly expansile <font style="font-style:italic;">in vivo</font> and therefore do not require an aggressive lymphodepletion regime to survive and proliferate in the body. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ongoing Phase 1/2a clinical trial of PBCAR0191 employs a standard lymphodepletion regimen comprised of cyclophosphamide at a dose of 1,500mg/m</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2 </sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over three days and fludarabine at a dose of 90mg/m</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> over three days. Based on the initial clinical data from this trial, we believe this lymphodepletion regime to be effective given the high quality of our cell product. However, higher concentrations of fludarabine and cyclophosphamide have been delivered safely to patients. Therefore, we also have the option to increase or decrease the dose of lymphodepletion in the future to further optimize CAR T cell persistence and clinical efficacy if needed, and we will evaluate the need for this based on the assessment of clinical data from our ongoing trials. In addition, we have the ability to incorporate a novel piece of our technology that we call &#8220;stealth cell&#8221; into the CAR T product candidate. The stealth cell technology is a modified CAR&#160;T vector that is designed to suppress a gene called beta-2-microglobulin, or B2M, in CAR&#160;T cells using a short-hairpin RNA, or shRNA. B2M is a component of the major histocompatibility complex type 1, a cell surface receptor which activates T cells. In preclinical studies, we and others have observed that suppression or elimination of B2M reduces the rejection of CAR&#160;T cells by T&#160;cells from an unrelated individual. However, we have found that complete elimination of B2M, for example by knocking the gene out using gene editing, provokes rejection of the CAR&#160;T cells by an alternative immune cell called natural killer, or NK cells. As shown in the figure below, in preclinical studies, we have observed that suppression of</font><font style="font-style:italic;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B2M to a level that is approximately 5% to 20% of normal levels can significantly reduce rejection by T&#160;cells without inducing an NK response. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000011.jpg" title="" alt="" style="width:685px;height:270px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Allogeneic CAR&#160;T Immunotherapy Pipeline </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging our CAR&#160;T cell platform to develop product candidates against validated CAR&#160;T cell targets. By focusing on validated targets, we seek to avoid many technical hurdles associated with early clinical development and can validate our allogeneic platform in patients with fewer variables. This approach also allows us to leverage the abundance of available public resources for these targets, including CARs, cell and animal models, and clinical protocols. We believe that our modular CAR T platform will allow us to leverage proof-of-concept from our ongoing and planned initial human trials for multiple other CAR T programs. We believe that we have developed the first allogeneic CAR T cell platform capable of producing drug product at scale, with a potentially optimal cell profile for therapeutic efficacy and true off-the-shelf delivery without the need for harsh and potentially toxic lymphodepletion. We believe that the combination of these factors, along with our next generation ARCUS technology, puts us in a differentiated position to become the leader in the development of allogeneic CAR T therapies.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we reported initial data from the first six patients with advanced NHL and the first three patients with advanced ALL treated with PBCAR0191 at the lowest two dose levels from our ongoing Phase 1/2a clinical trial. These initial data indicated no serious adverse events or dose-limiting toxicities, and demonstrated initial evidence of cell-mediated anti-tumor activity. As of December 31, 2019, dosing of patients at the third dose level was underway.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first three product candidates in our allogeneic CAR&#160;T cell development pipeline are: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">PBCAR0191</font><font style="font-family:Times New Roman;">.&#160;We are developing&#160;PBCAR0191, an allogeneic anti-CD19 CAR&#160;T cell product candidate for the treatment of adult R/R NHL and adult R/R B-cell precursor ALL. CD19 is a protein that is expressed on the surface of B cells. It is a well-validated target for CAR&#160;T cell therapy and the two currently marketed autologous CAR&#160;T cell therapy products also target CD19. In February 2016, we entered into the Servier Agreement, pursuant to which we have agreed to develop allogeneic CAR T cell therapies for CD19. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently evaluating patients in a Phase 1/2a clinical trial of PBCAR0191 in adult patients with R/R NHL </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> R/R B-cell precursor ALL, the trial design of which is shown in the figure below. The primary objective of this trial is to evaluate the safety and tolerability of PBCAR0191, as well as to determine the maximum tolerated dose. Secondary objectives include evaluating the anti-tumor activity of PBCAR0191. We are also evaluating the expansion, trafficking and persistence of PBCAR0191 in this trial. NHL and ALL cohorts are evaluated independently. The base trial design includes up to three dose levels: 3.0&#160;x 10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cells/kg, 1.0&#160;x 10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cells/kg and 3.0 x 10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cells/kg. Patients will be further evaluated for a follow-up period of 11&#160;months. The trial is being conducted at the following four clinical sites across the United States: Moffitt Cancer Center in Florida, City of Hope Cancer Treatment and Research Center in California, Dana-Farber Cancer Institute in Massachusetts and MD Anderson Cancer Center in Texas.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A further eight to ten sites are expected to be initiated during the course of 2020</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000012.jpg" title="" alt="" style="width:714px;height:157px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Initial Data from Phase 1/2a Trial of PBCAR0191 in R/R NHL and R/R B-ALL</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we announced initial data from our ongoing Phase 1/2a clinical trial of PBCAR0191 in adult patients with R/R NHL or R/R B-ALL.<font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;"> </font><font style="Background-color:#FFFFFF;color:#000000;">A total of nine patients were reported in these initial Phase 1 trial results, including six with NHL (three treated at Dose Level 1, or DL1, and three treated at Dose Level 2, or DL2), and three with B-ALL (all treated at DL2). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Patients treated at Dose Level 1 </font><font style="Background-color:#FFFFFF;color:#000000;">(3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> cells/kg) </font><font style="Background-color:#FFFFFF;">included</font><font style="Background-color:#FFFFFF;color:#000000;"> three NHL patients, two with diffuse large B cell lymphoma and one with mantle cell lymphoma, with a mean age of 54 years (min-max 34-64 years). Patients had received a median of four prior lines of therapy, with two patients being refractory to their last treatment, and one having previously relapsed following treatment with Yescarta&#174;, an FDA-approved autologous CD19-targeted CAR T therapy. </font><font style="Background-color:#FFFFFF;">Dose Level 2 </font><font style="Background-color:#FFFFFF;color:#000000;">(1x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg) </font><font style="Background-color:#FFFFFF;">included t</font><font style="Background-color:#FFFFFF;color:#000000;">hree NHL patients</font><font style="Background-color:#FFFFFF;">, </font><font style="Background-color:#FFFFFF;color:#000000;">all with mantle cell lymphoma, with a mean age of 74 years (min-max 71-77 years) who had received a median of two prior lines of therapy, with one patient refractory to their last treatment and two who had relapsed. Three B-ALL patients were also treated at DL2, with a mean age of 56 years (min-max 48-72 years); these patients had received a median of four prior lines of therapy &#8211; all three patients were refractory to their last treatment, with two patients having poor prognostic indicators at trial entry.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Patients received a single infusion of PBCAR0191 on day 0, following three days of lymphodepletion using fludarabine 30mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>/day and cyclophosphamide 500mg/m<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>/day. The primary objective of this Phase 1 portion of the ongoing Phase 1/2a trial is to evaluate safety as measured by the occurrence of dose limiting toxicities. Secondary objectives include assessment of objective tumor responses using standard criteria, and further evaluation of adverse events, or AEs, and adverse events of special interest, including GvHD, cytokine release syndrome, or CRS, and immune effector cell</font><font style="Background-color:#FFFFFF;color:#1F497D;">-</font><font style="Background-color:#FFFFFF;">associated neurotoxicity syndrome, or ICANS. Data were presented as of a November 4, 2019 cutoff date, with additional critical data collected through December 2, 2019, including occurrence of CRS, ICANS, GvHD and evaluation of objective responses.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Safety of PBCAR0191</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">No serious adverse events or evidence of GvHD were observed through December 2, 2019. Three of the nine patients treated with PBCAR0191, or 33%, developed CRS including two Grade 1 cases and one Grade 2 case. One of the nine patients, or 11%, developed Grade 2 neurotoxicity. All events of CRS and neurotoxicity resolved, and no deaths occurred on study. In addition, one patient experienced a Grade 3 AE</font><font style="Background-color:#FFFFFF;color:#1F497D;"> </font><font style="Background-color:#FFFFFF;">that was deemed related to PBCAR0191 (pain at the site of the patient&#8217;s tumor mass for one day following infusion) and one patient experienced Grade 4 lymphopenia for a duration of seven days and deemed related to PBCAR0191.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="Background-color:#FFFFFF;">Clinical activity of PBCAR0191</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Of the nine patients treated with PBCAR0191, seven, or 78%, had objective evidence of tumor shrinkage at any time point. The data also provided preliminary evidence of dose-dependent CAR T cell expansion and persistence. In the NHL cohort, four of six patients, or 67%, achieved an objective response by Lugano 2014 criteria at day 28+, including three partial responses (two patients treated at DL1 and one patient treated at DL2) and one complete response (patient treated at DL2). As of December 2, 2019, one patient (treated at DL2) remained in complete response. One patient (treated at DL1) achieved a partial response then progressed six months after treatment with PBCAR0191. This was notable given the patient had relapsed following treatment with Yescarta&#174;. The remaining two NHL patients, one treated at DL1 and one at DL2, achieved early responses (one CR, one PR respectively) at day 14; both patients had evidence of disease progression at day 28.</font><font style="color:#000000;"> </font><font style="Background-color:#FFFFFF;">In the B-ALL cohort treated at DL2, one of three patients, or 33%, achieved a complete response by the National Comprehensive Cancer Network 2017 criteria at day 28+, with undetectable B-ALL in the bone marrow by flow cytometry, described as minimal residual disease (MRD) negative. The remaining two patients did not respond at day 28; these patients had poor prognostic indicators on entry into the trial: one with prior CNS involvement and 95% blast infiltration into the bone marrow, and one with 77% blast infiltration into the bone marrow and disease refractory to two previous lines of treatment.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CAR T cell expansion and persistence in the peripheral blood was assessed at DL1 and DL2 by flow cytometry and </font><font style="color:#000000;">quantitative polymerase chain reaction, or qPCR</font><font style="Background-color:#FFFFFF;">. Evidence of a dose-dependent increase in cell expansion was observed between subjects treated at DL1 and DL2, as was a dose-dependent increase in CAR T cell persistence. B-cell aplasia and serum cytokine analysis also anecdotally corresponded to observed clinical responses and CAR T cell expansion.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#160;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">As of December 31, 2019, dosing of patients at Dose Level 3 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg) was underway. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Recent trial amendment </font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Based on the safety profile and clinical activity observed at DL1 and DL2, we filed a protocol amendment for this trial with the FDA in December 2019.&nbsp;&nbsp;Following feedback from FDA in late January 2020, the protocol amendment is now being implemented. The amended trial design is intended to specifically address key clinical questions. These include assessing the impact of higher total doses of cells on clinical activity and/or the impact of modified lymphodepletion on the ability to achieve durable clinical benefit with associated CAR T cell expansion and persistence.</font><font style="color:#000000;"> </font><font style="Background-color:#FFFFFF;">The most important modification is the inclusion of two additional dose levels: Dose Level 4 (6x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg) and Dose Level 5 (9x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg). These higher doses will employ a split dosing strategy following a single lymphodepletion with the intention of optimizing clinical activity while preserving a favorable safety profile. Dose Level 4 will comprise two infusions of </font><font style="color:#000000;">3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> </font><font style="Background-color:#FFFFFF;">cells/kg, and Dose Level 5 will comprise three such infusions &#8211; this strategy will enable us to explore higher total doses of PBCAR0191 while limiting potential GvHD risk. In addition, we have introduced a modification to allow for the option to increase or decrease the doses of fludarabine and cyclophosphamide used in the lymphodepletion protocol if data suggest that CAR T cell rejection limits efficacy. The final modification allows for the option to re-dose patients with PBCAR0191 following evidence of clinical response but with subsequent disease progression.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>  </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We expect to present updated results from this trial during the course of 2020.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PBCAR20A.<font style="font-weight:normal;">&#160;&#160;&#160;&#160;Our second allogeneic CAR T therapy candidate is PBCAR20A, an allogeneic anti-CD20 CAR T cell product candidate for the treatment of NHL, chronic lymphocytic leukemia, or CLL, and small lymphocytic lymphoma, or SLL. Like CD19, CD20 is a protein expressed on the surface of B&#160;cells. It is a validated target for cancer treatment and several CD20-targeted therapies, such as the monoclonal antibody Rituxan, have long histories of clinical and commercial success.&nbsp;&nbsp;In September 2019, the FDA cleared our IND application for PBCAR20A and we expect to commence a Phase 1/2a clinical trial for PBCAR20A in the first quarter of 2020. It will be investigated in subjects in two cohorts: NHL and CLL/SLL. The trial will include patients with NHL, of which a subset will have the diagnosis of mantle cell lymphoma, or MCL. We have received Orphan Drug Designation for the treatment of MCL.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our planned Phase 1/2a clinical trial, the primary objective will be to evaluate the safety and tolerability of PBCAR20A, as well as to determine the maximum tolerated dose. Secondary objectives will include evaluating the anti-tumor activity of PBCAR20A. We also plan to evaluate the expansion, trafficking and persistence of PBCAR20A in this trial. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the adverse event</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> observed </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to date</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with PBCAR0191, the FDA has agreed to allow us to commence dosing with PBCAR20A directly at Dose Level 2, which we expect to accelerate </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the timing for our expected completion of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the trial. We therefore </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plan to investigate two dose levels</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in this trial,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1.0 x </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cells/kg and 3.0 x 10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cells/kg</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Our clinical plan for this trial is depicted in the graphic below:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000013.jpg" title="" alt="" style="width:720px;height:156px;"></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our accepted IND for PBCAR20A included data from our preclinical study in mice measuring cell proliferation, cytotoxic killing, and production of effector cytokines in response to co-culture with CD20+ or CD20- target cells. PBCAR20A CAR T cells were observed to proliferate in response to stimulation by CD20+ K20 cells (K562 myelogenous leukemia cells transfected to express human CD20) at a wide range of doses (effector to target ratios ranging from 1:1 to 1:9). These observations show that, in this study, PBCAR20A cells became activated by and killed CD20+ cells at a wide range of cell doses. In this study, we observed that PBCAR20A cells did not proliferate in response to co-culture with CD20 negative cell K562 cells. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also evaluated the potency of PBCAR20A <font style="font-style:italic;">in vivo</font>. As shown below, PBCAR20A was observed to prolong survival in a mouse model of lymphoma (Raji Sub-Q model) at both doses tested (1.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> and 5.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells per mouse), which we believe supports further development. PBCAR20A was observed to be well-tolerated in this study. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000014.jpg" title="" alt="" style="width:682px;height:223px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PBCAR269A<font style="font-weight:normal;">.&#160;&#160;We are developing&#160;PBCAR269A as an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. BCMA is a protein that is expressed on the surface of mature B cells called &#8220;plasma cells&#8221; that are responsible for the disease and is a validated CAR T cell target. In January 2020, the FDA cleared our IND for PBCAR269A.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to commence a Phase 1/2a open-label, multi-center, dose-escalation clinical trial in patients with R/R multiple myeloma in 2020. In this trial, the primary objective will be to evaluate the safety and tolerability of PBCAR269A, as well as to determine the maximum tolerated dose. Secondary objectives will include evaluating the anti-tumor activity of PBCAR269A. We also plan to evaluate the expansion, trafficking and persistence of PBCAR269A in this trial. We expect to investigate up to three dose levels: 6.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> cells/kg, 2.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg and 6.0 x 10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluated the potency of PBCAR269A CAR T cells in a preclinical study in mice by measuring cell proliferation, cytotoxic killing and production of effector cytokines in response to co-culture with BCMA+ or BCMA- target cells. In this study, PBCAR269A CAR T cells were observed to proliferate in response to stimulation by BCMA+ target cells including MM.1S (</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">human multiple myeloma</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cell line</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and KBCMA (K562 myelogenous leukemia cells transfected to express human BCMA) at a wide range of doses (effector to target ratios ranging from 1:1 to 1:8). These observations show that, in this study, PBCAR269A cells became activated by and killed BCMA+ cells at a wide range of cell doses. We further observed that PBCAR269A cells did not proliferate in response to co-culture with BCMA- K562 cells. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also evaluated the potency of PBCAR269A <font style="font-style:italic;">in vivo</font>. As shown below, PBCAR269A was observed to prolong survival in a mouse model of multiple myeloma, which we believe supports further development. PBCAR269A was observed to be well-tolerated in this study. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000015.jpg" title="" alt="" style="width:719px;height:289px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="font-style:italic;">in vivo</font> Gene Correction Platform </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000016.jpg" title="" alt="" style="width:713px;height:266px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect <font style="font-style:italic;">in vivo </font>genome editing to be a significant focus of our operations long-term because the differentiated attributes of ARCUS are particularly advantageous for this type of application. <font style="font-style:italic;">In vivo</font> gene correction involves the delivery of ARCUS nucleases directly into a patient&#8217;s cells to treat disease at the level of the underlying DNA. <font style="font-style:italic;">In vivo </font>genome editing is more complex and challenging than <font style="font-style:italic;">ex vivo</font> approaches like CAR T cells due to the need to safely deliver ARCUS directly to cells in the body. We believe that <font style="font-style:italic;">in vivo</font> applications are particularly well suited to ARCUS because they require extremely low levels of off-target editing and efficient delivery. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the demands of </font><font style="font-style:italic;">in vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> editing, we are taking a highly disciplined approach to managing our project portfolio that emphasizes studies in large animals, using both viral and non-viral delivery technologies. We believe that there is a remarkable lack of large animal data in the genome editing field and that demonstrating safety and efficacy in large animals is an important gating step prior to beginning human clinical studies. Thus, we are advancing an extensive and diverse portfolio of programs toward </font><font style="font-style:italic;">in vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> efficacy and toxicity studies and are generating a large animal dataset that, we believe, will be the most comprehensive of any in the field. Our two most advanced programs in this area are focused on chronic hepatitis B, in partnership with Gilead, and PH1 which is wholly owned by Precision.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Treatment of Genetic Disease </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genetic diseases are caused by errors in the DNA that lead to misfunction of a cell or tissue. While the underlying cause of a particular genetic disease can often be complex and variable, DNA errors generally fall into two categories: loss-of-function or gain-of-function. Genetic diseases are most frequently caused by loss-of-function errors in which a particular gene is mutated at the DNA level in such a way that it is either non-functional or less functional than it should be. In these cases, treating the disease requires <font style="font-style:italic;">adding</font> the function that the cell or tissue is otherwise lacking. Gain of function genetic disorders are the result of DNA errors that cause a gene to acquire a new, harmful function that leads to disease. In these cases, it is necessary to remove the unwanted function to treat the disorder. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genetic disease is a very active area of therapeutic development, and the therapies that are available or in development are, to a large extent, as variable and specialized as the diseases themselves. There are, however, two gene therapy platform approaches that are being broadly applied to the treatment of multiple genetic disorders. For the treatment of loss-of-function diseases, AAV-based gene therapy can often be an effective treatment. AAV is a non-integrating virus that can be used to deliver DNA to a wide range of different cell types in a patient. The virus can be engineered to deliver a functional copy of a gene that is otherwise missing or under-performing in the cell. This approach can, in some cases, restore normal function to the cell and alleviate the symptoms of the disease. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While a number of AAV-based gene therapies appear to be showing great promise in clinical trials, the approach is subject to a number of limitations. Many patients have antibodies in their blood that recognize and inactivate the AAV virus before it can deliver the DNA into the patient&#8217;s cells. In addition, among patients who do <font style="font-style:italic;">not</font> have antibodies upon initial treatment with the virus, most will develop antibodies following the first dose. Therefore, in most cases, it is only possible to dose a patient one time. Most importantly, although AAV-based gene therapy can be an effective treatment, it is probably not a permanent <font style="font-style:italic;">cure</font> because AAV-delivered genes do not generally persist for more than a few years in the body. While the duration of virus persistence varies from cell-to-cell and from patient-to-patient, it is not believed to be permanent and symptoms of the disease can return once the virus is no longer present in the body. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Approach to in vivo Gene Correction </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to cure genetic diseases by correcting the DNA errors responsible for causing them. In principle, <font style="font-style:italic;">in vivo</font> genome editing can likely be used to cure any genetic disorder. In practice, however, <font style="font-style:italic;">in vivo</font> genome editing is limited by several challenges that, we believe, are best addressed using ARCUS: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Specificity.&#160;&#160;&#160;&#160;</font><font style="font-style:italic;font-family:Times New Roman;">In vivo </font><font style="font-family:Times New Roman;">genome editing requires an extremely high degree of precision to minimize the occurrence of any unwanted off-target editing. Off-target changes to the DNA could, potentially, have significant safety implications that may not manifest themselves until well after administration of the therapy. As described above, we believe that the differentiated attributes of ARCUS enable us to create endonucleases that have a high degree of specificity and minimal levels of off-target editing to address this significant safety concern. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Delivery.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Gene therapy delivery technologies suitable for the delivery of genome editing tools to tissues </font><font style="font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-family:Times New Roman;"> have not been developed for all tissues. Delivery challenges are particularly pronounced for editing applications that require promoting DNA repair by HDR because it is necessary to deliver both the nuclease and the DNA &#8220;donor&#8221; template for HDR. We have focused our initial development efforts on genetic disorders of the liver and eye, two tissues for which we believe we have good options for delivery and in which we have shown ARCUS to be effective in preclinical studies. We believe the small size of our ARCUS nucleases and their ability to efficiently promote HDR will enable us to address a greater variety of genetic diseases requiring more complex delivery strategies. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Efficiency.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Genome editing efficiency is a critical parameter for </font><font style="font-style:italic;font-family:Times New Roman;">in vivo </font><font style="font-family:Times New Roman;">therapeutic efficacy because the requisite edit must be achieved in a sufficient number of cells to have therapeutic benefit. Efficiency is best measured </font><font style="font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-family:Times New Roman;"> in animals because it is affected by multiple parameters including delivery, endonuclease activity and the accessibility of the DNA target site in the organism. Moreover, we believe that only large</font><font style="font-style:italic;font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">animals such as non-human primates accurately model these different parameters and are representative of the human condition. As such, we have placed significant emphasis on large animal studies and have demonstrated, we believe, therapeutic levels of editing efficiency using ARCUS in the most relevant models. This gives us greater confidence that ARCUS will translate from the lab bench to the clinic. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential of ARCUS for </font><font style="font-style:italic;">in vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> genome editing is highlighted in a July 2018 publication in </font><font style="font-style:italic;">Nature Biotechnology</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that describes a research project performed as part of a sponsored research collaboration between our company and Dr.&#160;Jim Wilson&#8217;s Orphan Disease Center at the University of Pennsylvania. Co-authors of the publication include Derek Jantz and Jeff Smith, two of our co-founders. This publication is, to our knowledge, the first peer-reviewed publication of </font><font style="font-style:italic;">in vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> genome editing data in non-human primates. We reported well-tolerated, long-term, high-efficiency editing of the PCSK9 gene in non-human primates using ARCUS. A single IV administration of an AAV vector encoding a PCSK9-specific ARCUS nuclease was able to efficiently knock out the gene in the livers of Rhesus macaques, a species of monkey, resulting in up to approximately 85% reduced levels of PCSK9 protein in the blood. This reduction in PCSK9 then resulted in significantly reduced levels of LDL-C, commonly known as &#8220;bad cholesterol,&#8221; in the blood of treated animals. Because this therapeutic effect is due to modifications to the DNA itself, the benefit of the treatment appeared to be permanent. The first animals that were treated have maintained reduced levels of PCSK9 and LDL-C since they were treated in February 2017. Importantly, even at the highest dose the treatment was observed to be well tolerated in the study. These peer reviewed data exemplify the power of ARCUS for </font><font style="font-style:italic;">in vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> editing at therapeutically meaningful levels of efficiency. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PCSK9 and LDL Serum Levels </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000017.jpg" title="" alt="" style="width:697px;height:227px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that establishing collaborations with other groups that have additive domain expertise and access to the most relevant animal models will be important to advancing our <font style="font-style:italic;">in vivo</font> gene correction platform, and we have entered into a number of collaborations and licensing agreements with third parties to help us advance our <font style="font-style:italic;">in vivo</font> editing portfolio. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hepatitis B Program </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into a collaboration and license agreement with Gilead to co-develop an ARCUS-based treatment for chronic hepatitis B infection. Infection by the hepatitis B virus, or HBV, is in many ways analogous to a gain-of-function genetic disorder. In this case, the deleterious DNA that needs to be eliminated is the genome of the virus itself. To this end, we are collaborating with Gilead to develop an ARCUS-based product candidate that is designed to specifically target and eliminate both forms of viral DNA (integrated DNA and covalently closed circular DNA (&#8220;cccDNA&#8221;)) from infected liver cells.&nbsp;&nbsp;Our ARCUS-based product candidate is designed to cut and thereby inactivate or degrade cccDNA and to cut and thereby inactivate the integrated hepatitis B genome. We believe making these edits gives us the ability to permanently eliminate the chronic viral infection, and potentially cure the disease. Submission of an IND for this product candidate is currently targeted for 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, we developed a pair of ARCUS nucleases that recognized and cut conserved DNA sequences in the Hepatitis B genome. We observed that these nucleases reduced HBV S-antigen and cccDNA HBV-infected primary human hepatocytes, as shown below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000018.jpg" title="" alt="" style="width:369px;height:222px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Primary Hyperoxaluria Type 1 (PH1) Program</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we announced that we will advance a program designed to target the rare genetic disease PH1 as our lead wholly owned <font style="font-style:italic;">in vivo</font> gene correction program. PH1 affects approximately 1-3 people per million in the United States and is caused by loss of function mutations in the AGXT gene. This gene encodes an enzyme which is involved in the production of the amino acid glycine in the liver. In patients with PH1 who lack this enzyme, crystals of calcium oxalate form in the kidneys leading to painful kidney stones which may ultimately lead to renal failure. Approximately 40% of PH1 patients are found to have already progressed to end stage renal disease at the point of diagnosis, requiring a combined liver-kidney transplant. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using ARCUS, we are developing a potential therapeutic approach to PH1 that involves knocking out a gene called HAO1 which acts upstream of AGXT. Suppressing HAO1 has been shown in preclinical models to prevent the formation of calcium oxalate. We therefore believe that a one-time administration of an ARCUS nuclease targeting HAO1 may be a viable strategy for a durable treatment of PH1 patients.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies we have demonstrated that ARCUS efficiently knocked out the HAO1 gene in non-human primates. We have also demonstrated in a mouse model of PH1 that administration of an ARCUS nuclease targeting HAO1 resulted in approximately 70% reduction in urine calcium oxalate levels. We plan to select a clinical candidate for this program during 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000019.jpg" title="" alt="" style="width:720px;height:320px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Ethylene glycol</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Food Platform </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000020.jpg" title="" alt="" style="width:712px;height:241px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Technology-Centric Solutions to Meet Changing Demands in Food and Agriculture </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total global food and agriculture market, estimated to be worth $5 trillion (2015), is heavily influenced by the availability of critical raw material ingredients and changing consumer behavior. With the global population projected to reach 8.5 billion by 2030, demand for basic food and nutrition needs has already put a lot of pressure on traditional food production systems. In response, the food and agriculture industry is currently in the process of a slow, but massive, repositioning effort to reinvent its capital-intensive infrastructure, complex business structures and product pipelines. This is creating new opportunities to disrupt the otherwise archaic food industry by introducing technology solutions that address unmet needs. Of particular concern to the industry is the agronomic impact of climate change. Many staple foods and critical ingredients, such as citrus, bananas and coffee, are under threat from environmental changes and the new pathogens it can bring. The food and agriculture industry has also seen significant shifts in consumer preferences in which consumers are actively transitioning to high quality and healthier foods and beverages, while rejecting artificial ingredients, sugar and salt, creating a demand for natural and holistic ingredients built on a sustainable supply chain. Traditional approaches to agricultural innovation are slow, siloed, rely heavily on non-scalable academic advancements and continue to use inefficient crop improvement practices. We believe that many of the current pressures on the food and agriculture industry from climate-related threats and changing consumer preferences can be effectively addressed using biotechnology. However, consumers are generally opposed to genetically modified organisms, or GMOs, which makes food companies reluctant to incorporate them into their products. Our wholly-owned food and agriculture focused subsidiary, Elo Life Systems, was created to help food companies &#8220;thread the needle&#8221; between competing pressures to improve the genetics of their ingredients while avoiding the incorporation of GMO organisms. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Elo Life Systems: Innovation-Focused Technology Platform and Business Model </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elo Life Systems is our wholly owned subsidiary, dedicated to addressing the needs of consumers and consumer-facing industries in the food and agriculture sector. Our business model is heavily partner-focused. In the food and agriculture industry, timelines to market are long and the field is dominated by a relatively small number of entrenched companies. Therefore, it is a very difficult to bring a product to market without a larger partner. Thus, we seek partnerships early in the product development process to optimize our chances of market success. Under this partnership model, we are responsible for the early phases of the project, starting from concept through production of a &#8220;lead,&#8221; which is typically a gene edited plant that has the desired trait in greenhouse testing and is ready for scale-up and testing in the field. At that point, our partners typically assume responsibility for subsequent development and commercialization. Because large consumer-facing food companies are often not directly responsible for producing their own starting ingredients, this transfer may involve an intermediate in the supply chain such as a seed producer or grower who is responsible for pre-commercial activities. Whenever possible, we try to partner with the entire supply chain early in the project to ensure a smooth transition across phases of development. In general, our partners are responsible for financing all or a portion of our development costs, which greatly reduces our capital requirements. We are then generally eligible to share in revenues derived from successfully commercialized products developed under these partnerships. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gdzs1tysdsfm000021.jpg" title="" alt="" style="width:618px;height:69px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Elo&#8217;s Technology Platform </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our end-to-end food platform is built to support rapid innovation across multiple crop species. With the ARCUS genome editing platform as our cornerstone technology, we have integrated complementary tools and technologies both upstream and downstream to potentially be a complete solutions provider. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the core of our food platform is our ARCUS editing technology. We are one of the first to apply genome editing technology to crop plants and we believe we have the most in-depth experience in crop genome editing in the industry. Over the last decade, we have developed highly efficient methods to improve delivery and functionality of ARCUS nucleases in plants to edit DNA. These nucleases have been successfully validated in collaborative projects with major food and agriculture companies like Cargill, BASF, Bayer CropScience and DuPont Pioneer Hi-bred. Importantly, ARCUS can be used to create small deletions or insertions in plants using a non-plant pest- or pathogen-based delivery approach. As such, we believe that many of the food and agriculture product candidates we may develop have the potential to obtain nonregulated status in the United States and other territories and thereby avoid GMO labels. This aspect of the technology platform is critical to food producers, particularly as they respond to consumer demands for healthier products. Because Elo partners with large companies that generally lack significant biotechnology capabilities, it was necessary for us to build these capabilities in-house to complete Elo&#8217;s portion of the development process. This end-to-end platform is unusual in the industry and, we believe, makes Elo an attractive partner. In addition to ARCUS, Elo&#8217;s in-house capabilities include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Genomics.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Many of the most attractive opportunities for Elo involve emerging and under-studied crops, such as stevia and monk fruit. We have integrated genome sequencing and bioinformatic platforms in-house in order to identify the genome sequence of plants, enabling us to identify targets for editing with ARCUS nucleases. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Target discovery and validation.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Our informatics platform is built on principles of machine learning that allow us to synthesize, sequence and phenotype information from both public and internal datasets to correlate genome sequence with plant characteristics. This allows us to identify genetic targets for ARCUS editing that are predicted to yield a desired phenotype. These targets can then be validated in specific crops and at least partially validated in model systems such as tobacco and Arabidopsis using different molecular approaches such as editing or RNAi. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Multi-crop transformation.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Most of the crops of interest to Elo and our partners do not have established transformation protocols and are not readily amenable to gene editing. To this end, we have developed a sophisticated collection of plant transformation vectors and protocols over the last decade that allow us to rapidly develop gene-edited variants of otherwise intractable species. This technology allows us to overcome what is otherwise a significant barrier to entry into a new crop species. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Plant growth infrastructure.</font><font style="font-family:Times New Roman;">&#160;&#160;&#160;&#160;Elo has a dedicated facility and capabilities of cultivating gene edited plants from incubator to greenhouse. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Ultra-low saturated fatty acid canola oil (in collaboration with Cargill Inc.) </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canola oil is the third largest vegetable oil by volume after palm and soybean oil. In the United States, canola oil is one of the most widely consumed oils, second only to soybean oil. With worldwide production at 30&#160;million metric tons in 2017, global canola oil is estimated to be a $20&#160;billion industry. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cargill is one of the world&#8217;s largest growers and processors of canola. Since 2014, Elo and Cargill are engaged in a collaboration to produce ARCUS-optimized canola varieties and have achieved significantly lower levels (less than 4.5%) of saturated fatty acids compared to the current levels (7%) in greenhouse studies. This oil with the desirable premium trait is intended for the quick-service restaurants and food ingredients industries, and products made with it&#8212;particularly fried foods&#8212;may be able to use front-of-package nutrient content claims on saturated fat levels, such as &#8220;Low in Saturated Fat&#8221; or &#8220;No Saturated Fat,&#8221; depending on their overall nutritional profile. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This program has generated canola varieties with up to an approximately 33% decrease in total saturated fats compared to un-edited varieties in greenhouse studies and we have not observed any less desirable traits in these canola varieties in these greenhouse studies to date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">ZeroMelon<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> Low-Calorie Sweeteners from Watermelon </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Low calorie sweeteners are a rapidly growing segment of the food and beverage industry as companies respond to consumer demands for low-sugar snack foods and soda alternatives. Based on an April 2019 report by Mordor Intelligence, the global food sweetener market is estimated to be worth approximately $82 billion by 2024. In addition, the adoption of &#8220;sugar taxes&#8221; by many cities across the United States and Europe are significantly impacting profit margins and creating an acute need for alternatives to cane sugar and corn syrup such as the natural, high intensity sweeteners in stevia and monk fruit. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a potentially optimal</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> low calorie sweetener comes from monk fruit. The monk fruit compound mogroside&#160;V is approximately 250 times sweeter than cane sugar and contains zero calories, making it an excellent potential alternative to cane sugar and stevia. However, monk fruit currently is not scalable for large scale applications in the food and beverage industry as a result of lower productivity and a lack of reliable supply chain. We are currently collaborating with a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n industry partner </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to develop a watermelon</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> variety</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to produce this high value metabolite in a crop that is readily cultivated across North America and Europe.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are now focused on moving this program forward towards initiation of greenhouse trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Plant-Based Proteins </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shifting consumer preferences across the globe towards higher protein diets has created unprecedented demand for plant-based protein sources. We do not believe that this demand for plant-based proteins, projected to grow to a $10.5&#160;billion global industry by 2020, can be met without the application of biotechnology to increase protein content in different crop species. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we launched Elo Life Systems Australia, a subsidiary of Elo that will support research programs in Australia. Elo Life Systems Australia&#8217;s primary focus is developing climate-resilient legumes with improved protein and nutritional profiles, starting with chickpea. We aim for the resulting products to make a significant contribution towards the increasing demand for sustainable plant-based proteins as a healthful alternative to animal protein. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we have strong internal scientific process development and manufacturing capabilities, including our Manufacturing Center for Advanced Therapeutics, or MCAT, an in-house cGMP compliant manufacturing facility supporting our therapeutic product development platforms which we opened in 2019. We believe that MCAT is the first in-house cGMP compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf CAR T cell therapy products.&nbsp;&nbsp;We believe that having internal manufacturing capacity and expertise is a competitive advantage that enables enhanced control over process development timelines, costs and intellectual property. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have leased approximately 33,600 square feet of space for our MCAT facility at a location approximately seven miles from our headquarters in Durham, North Carolina. We have a modular, three-suite cleanroom setup, for CAR T cell, mRNA and AAV production, to process development for our allogeneic CAR T immunotherapy platform. Our manufacturing facility leverages single-use, disposable, closed-system operations aligned to our technology platforms to ensure both flexibility and cost effectiveness. The initial scope is creating clinical trial material for certain of our planned clinical trials in 2020. In the longer term, we believe MCAT has the potential to be a commercial launch facility.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently contract with third parties for the manufacturing of materials used in the production of our product candidates. To date, our third-party manufacturers have met our manufacturing requirements. We believe that there are alternate sources of supply that can satisfy our requirements. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process for our allogeneic CAR T immunotherapy platform utilizes a one-step cell engineering method in which a CAR gene is targeted directly into the T cell receptor alpha constant, or TRAC, locus. We believe this approach greatly streamlines the manufacturing process and have entered into a license agreement with a principal supplier for research and clinical licensed technology used in such process. Commercial raw materials and reagents for this production are readily available.&nbsp;&nbsp;Our manufacturing strategy for our <font style="font-style:italic;">in vivo</font> gene correction platform and our food platform is to internally control process development and manufacturing to safeguard the proprietary nature of our technology and facilitate our ability to function as an integrated life sciences company. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Servier </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, we entered into the Servier Agreement as subsequently amended, with predecessor entities of Servier. Pursuant to this agreement, we have agreed to develop allogeneic chimeric antigen receptor T cell therapies for up to six unique antigen targets, the first of which was selected at the inception of the agreement. Upon selection of an antigen target, we perform early-stage research and development on individual T cell modifications for the selected target, develop the resulting therapeutic product candidates through Phase 1 clinical trials and manufacture clinical trial material for use in Phase 2 clinical trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received an upfront payment of $105.0&#160;million under the Servier Agreement. At Phase 2 readiness for any product candidate covered by the Servier Agreement, Servier may exercise a commercial option to proceed with development and commercialization of the product candidate, subject to option fees. Following the exercise of any such commercial option, Servier must use commercially reasonable efforts to develop and commercialize the product candidate. We have the ability to receive total payments, including the upfront payment, option fees and milestone payments, in the aggregate across all six targets that may be selected, of up to approximately $1.6&#160;billion. This includes up to $1.5 billion in milestone payments, consisting of up to $401.3 million in development milestone payments and up to $1.1 billion in commercial milestone payments. We are also entitled to receive tiered royalties ranging from the mid-single digit percentages to sub-teen percentages on worldwide net sales of any products developed under the Servier Agreement, subject to customary potential reductions. Servier&#8217;s obligation to pay royalties to us expires on a country-by-country and licensed product-by-licensed product basis upon the latest of (1)&#160;the expiration of the last to expire valid claim of all Precision patents covering a licensed product, (2)&#160;expiration of all regulatory exclusivity with respect to a licensed product in the applicable country of sale, and (3)&#160;the expiration of 10&#160;years following the first commercial sale of such licensed product in such country. We also have the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States, subject to our payment of an option fee, which is exercisable after Servier&#8217;s commercial option exercise. So long as Servier holds a commercial license with respect to any particular licensed product, we may not develop, manufacture or commercialize any engineered human T cells with chimeric antigen receptors for use in humans directed to the same antigen target as the target of that licensed product. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the Servier Agreement expires upon the first to occur of (1)&#160;the expiration of the period in which Servier may nominate antigen targets, if there are no included targets under the agreement, (2)&#160;the expiration of the period in which Servier may exercise a commercial option on a licensed product candidate, if no commercial options have been exercised by Servier, or (3)&#160;the expiration of the last to expire royalty term for the licensed products and satisfaction of all of Servier&#8217;s payment obligations under the agreement. Servier has the right to terminate the agreement for convenience, either in its entirety or on a target-by-target or product-by-product basis, by providing advance notice to us. We may terminate immediately upon notice to Servier if Servier (itself or through the use of certain affiliates or a third party) or any sublicensee initiates or participates in a patent challenge against our patents licensed by Servier under the agreement. In addition, the Servier Agreement may be terminated (a)&#160;by either party for the other party&#8217;s material breach that remains uncured as specified in the agreement, (b)&#160;by either party upon the occurrence of certain insolvency-related events of the other party and (c)&#160;upon mutual agreement of the parties in the event either party suffers an event of force majeure as specified in the agreement. If Servier terminates the agreement for our uncured material breach of provisions in the agreement that restrict development, manufacture or commercialization of engineered human T cells with chimeric antigen receptors for use in humans directed to a target selected by Servier, certain licenses we grant to Servier will become royalty-free, fully paid-up, perpetual and irrevocable with respect to the licensed product candidates and licensed products directed to the target that was the subject of such breach, and Servier will be deemed to have previously exercised its commercial option for any then-existing licensed product candidates directed to such target. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gilead </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we entered into the Gilead Agreement to develop genome editing tools using ARCUS to target viral DNA associated with the Hepatitis&#160;B virus. Pursuant to the terms of the agreement, Gilead received an exclusive license to exploit the resulting synthetic nucleases and products that use them to treat the Hepatitis&#160;B virus in humans, and we are entitled to receive up to approximately $40&#160;million in research funding over an initial three year term and milestone payments of up to an aggregate of $445&#160;million, consisting of up to $105.0&#160;million in development milestone payments and up to $340.0&#160;million in commercial milestone payments. We are also entitled to receive tiered royalties ranging from the high single digit percentages to the mid-teen percentages on worldwide net sales of the products developed through the term of the agreement, subject to customary potential reductions. Gilead&#8217;s obligation to pay royalties to us expires on a country-by-country and licensed product-by-licensed product basis, upon the latest to occur of certain events related to expiration of applicable patents, expiration of regulatory exclusivity or 10 years following the first commercial sale of the first licensed product in such country. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the Gilead Agreement will continue, on a licensed-product-by-licensed-product and country-by-country basis until the expiration of a defined royalty term for each licensed product and country. Gilead has the right to terminate the Gilead Agreement for convenience by providing advance notice to us as specified in the Gilead Agreement. Gilead may also terminate the agreement during the collaboration term if we enter into certain change of control transactions with a third party that is clinically developing or commercializing products in the field of the Hepatitis&#160;B virus. In addition, either party may terminate the Gilead Agreement (1)&#160;for material breach by the other party and a failure to cure such breach within the time period specified in the Gilead Agreement and (2)&#160;upon the occurrence of certain insolvency-related events of the other party. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Duke University </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, we entered into the Duke License, pursuant to which Duke University (&#8220;Duke&#8221;) granted us an exclusive (subject to certain non-commercial rights reserved by Duke), sublicensable, worldwide license under certain patents related to certain meganucleases and methods of making such meganucleases owned by Duke to develop, manufacture, use and commercialize products and processes that are covered by such patents, in all fields and in all applications. The patents that we license pursuant to the Duke License have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. See Part I, Item 1A. &#8220;Risk Factors&#8212; Risks Related to Intellectual Property&#8212;Some of our in&#8209;licensed intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.&#8221; </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Duke License, in addition to upfront licensing fees, we are also required to pay Duke (1)&#160;a total of $0.3&#160;million in milestone payments, a portion of which we paid upon the completion of our Series A financing, a further portion of which we paid upon our first signed partnership in excess of $1&#160;million, and the remainder of which we will be required to pay upon successful commercialization of seed traits and human therapeutics, (2)&#160;royalties in the low single digit percentages on net sales of licensed products and licensed processes sold by us and our affiliates, subject to certain reductions in certain circumstances, with certain annual minimum royalties, and (3)&#160;certain percentages of sublicensing revenue received under sublicenses granted to third parties, which are creditable against annual minimum royalties and are subject to certain reductions in certain circumstances. For sublicenses of non-commercial products, the percentage of sublicensing revenue payable to Duke is in the mid-teen percentages for sublicense revenues owed from royalties received and low double-digits for sublicense revenues owed from non-royalty payments. For sublicenses of commercial products created by us and derivatives thereof, the percentage is determined by the highest negotiated royalty rate in such sublicense. If the highest negotiated royalty rate between us and our sublicensee exceeds a mid-single digit percentage, the percentage of sublicensing revenue payable to Duke will be high single digit, decreasing to low single digit as the highest negotiated royalty rate in such sublicense increases. The Duke License will expire upon the expiration of the last-to-expire patent that is licensed to us. We may terminate the Duke License by providing advance written notice as specified in the Duke License. Either party may terminate the Duke License in the event of the other party&#8217;s uncured material breach or for the other party&#8217;s fraud, willful misconduct or illegal conduct with respect to the subject matter of the Duke License. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cellectis S.A. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, we entered into a cross-license agreement with Cellectis S.A., which we refer to as the Cellectis License, in connection with a settlement of litigation matters (1)&#160;between Cellectis and us and (2)&#160;among Cellectis, Duke and us. Cellectis granted us a non-exclusive, sublicensable, worldwide, fully paid, royalty-free license to certain modified I&#8209;CreI homing endonuclease patents and Cellectis patents asserted in the litigation, to make, use and commercialize modified I-CreI homing nucleases and products developed using such nucleases, in all fields. The license we received from Cellectis is subject to the rights of a preexisting license agreement that Cellectis entered into with a third party, and the license granted to us excludes any rights exclusively granted by Cellectis under such preexisting license, which preexisting license is limited to certain specific applications unrelated to the fields of human therapeutics and plant agriculture, for so long as the rights under the preexisting license remain exclusive. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We granted Cellectis a non-exclusive, sublicensable, worldwide, fully paid-up, royalty-free license to certain modified I&#160;CreI homing endonuclease patents and our patents asserted in the litigation matters (1)&#160;between Cellectis and us and (2)&#160;among Cellectis, Duke and us to make, use and commercialize modified I-CreI homing nucleases and products developing using such nucleases, in all fields except those for which we did not receive rights from Cellectis due to the preexisting license. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Cellectis License will expire upon the expiration of the last-to-expire valid claim of all of the patents licensed to or from each of the parties to the agreement. Either party may terminate any of the licenses granted under the agreement (1)&#160;in the event of the other party&#8217;s material breach, subject to an opportunity to cure within the time period specified in the Cellectis License, or (2)&#160;if the other party directly or indirectly challenges a patent licensed to it by the other party. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Competition </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a diversified life sciences company, we compete in multiple different fields. The biotechnology, pharmaceutical and agricultural biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. We principally compete with others developing and utilizing genome editing technology in the human health and plant sciences sectors, including companies such as Allogene Therapeutics, Inc. Cellectis S.A., CRISPR Therapeutics, AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Sangamo Therapeutics, Inc, and Beam Therapeutics, Inc. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We compete with many biotechnology and pharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions. We expect that our operations focused on CAR T cell product candidate development and commercialization will face substantial competition from those focusing on immunotherapy solutions. Several companies, including Novartis Pharmaceuticals Corp. and Gilead have obtained FDA approval for autologous cell therapies, and a number of companies, including Cellectis S.A., Celgene Corp., Allogene Therapeutics and CRISPR Therapeutics AG, are pursuing allogeneic cell therapies. We expect that our operations focused on developing products for </font><font style="font-style:italic;">in vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> treatment of genetic disease will face substantial competition from others focusing on gene therapy treatments, especially those that may focus on conditions that our product candidates target. Moreover, any human therapeutics products that we may develop will compete with existing standards of care for the diseases and conditions that our product candidates target and other types of treatments, such as small molecule, antibody or protein therapies. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors in the therapeutics space, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. In addition to competing on the bases of safety, efficacy, timing of development and commercialization, convenience, cost, availability of reimbursement and rate of adoption of potential product candidates, we may also compete with these competitors in recruiting and retaining qualified personnel, establishing clinical sites, establishing relationships with collaborators or other third parties, registering patients for clinical trials and acquiring technologies complementary to, or necessary for, our product development platforms. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also compete with participants in the agricultural biotechnology space, including Pairwise Plants, LLC, Caribou Biosciences, Inc., Corteva Agriscience, Tropic Biosciences UK LTD, Calyxt, Inc. and Cibus. Competition for improving plant genetics comes from conventional and advanced plant breeding techniques, as well as from the development of genetically modified traits. Competition for providing more nutritious ingredients for food companies comes from chemical&#8209;based ingredients, additives and substitutes, which are developed by various companies. We also face less direct competition from trait research and development companies and agricultural research universities and institutions. We compete with respect to many aspects of the product development cycle in the plant sciences space, such as computational capabilities for identifying relevant gene targets, access to germplasm and enabling technologies and entry into strategic relationships to facilitate product development and commercialization. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors in the agricultural biotechnology space, either alone or with others, have significantly greater financial resources and expertise in research and development, manufacturing, testing and marketing approved products than we do. Mergers and acquisitions in the plant science, specialty food ingredient and agricultural biotechnology, seed and chemical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic relationships with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, our food platform. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we rely upon a combination of patents and trade secret protection, as well as license and confidentiality agreements to protect the intellectual property related to our proprietary technologies, product candidate development programs and product candidates. Our success depends in large part on our ability to secure and maintain patent protection in the United States and other countries with respect to the ARCUS nucleases used in our existing allogeneic CAR T immunotherapy, <font style="font-style:italic;">in vivo</font> gene correction and food programs, as well as any future product candidates. Moreover, the industries in which we operate are characterized by the existence of large numbers of patents and frequent allegations of patent infringement. If, therefore, we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained or in-licensed is not sufficiently broad or if the validity of such patent protection is threatened, we may not be able to compete effectively, as it could create opportunities for competitors to enter the market or dissuade other companies from collaborating with us to develop products and technology, any of which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property<sup style="font-size:85%;line-height:120%;vertical-align:top">, </sup></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>Our success depends in part on our abilities to (1)&#160;obtain and maintain proprietary protection for ARCUS, (2)&#160;defend and enforce our intellectual property rights, in particular, our patent rights, (3)&#160;preserve the confidentiality of our know-how and trade secrets, and (4)&#160;operate without infringing valid and enforceable intellectual property rights of others. We seek to protect our proprietary position by, among other things, exclusively licensing U.S. and certain foreign patent applications, and filing U.S. and certain foreign patent applications related to ARCUS, existing and planned programs, and improvements that are important to the development of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation and confidential information, and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the pursuit of licensing opportunities, to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their employment or term of service. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that patents will be granted with respect to any patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or which have been granted to us, or patents that may be licensed or granted to us in the future, will not be challenged, invalidated or circumvented or that such patents will be commercially useful in protecting our technology. Moreover, trade secrets can be difficult to protect. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. For more information regarding the risks related to our intellectual property, see Part I, Item 1A. &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221; </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio consists of a combination of issued patents and pending patent applications that are owned by us or licensed by us from third parties. As of December 31, 2019, we have an exclusive license from Duke under 12 issued U.S. patents and two pending U.S. patent applications. In addition, as of December 31, 2019, we own 18 issued U.S. patents, 20 pending non-provisional U.S. patent applications, and eight pending PCT international patent applications. We also exclusively license from Duke or own many corresponding patents and patent applications outside the United States, as described below. We intend to pursue, when possible, additional patent protection, including composition of matter, method of use and process claims, related to ARCUS. We also intend to obtain rights to existing delivery technologies through one or more licenses from third parties.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ARCUS Platform Patent Families </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We license one patent family from Duke and own three patent families that are directed to the core technologies employed in our ARCUS platform for nuclease design. Thus, each of our product candidates is protected by one or more patents in these families. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first family, licensed from Duke, includes 12 issued U.S. patents, eight issued European patents, three issued Japanese patents, and one issued patent in each of Australia and Canada. This family also includes one pending patent application in the United States and one pending patent application in each of Europe, Japan and Canada. Patents in this family include claims directed to (1)&#160;recombinant meganucleases having altered cleavage specificity, altered heterodimer formation, and/or altered DNA binding affinity, (2)&#160;methods for cleaving target recognition sites in DNA using such meganucleases, and (3)&#160;methods for producing genetically modified eukaryotic cells using such meganucleases. Patents in this family have a standard expiration date of October&#160;18, 2026, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second family, which we own, includes four issued U.S. patents, three issued patents in Europe, two issued patents in Japan, and one issued patent in Australia. This family also includes one pending patent application in each of the United States, Europe, Japan and Australia. Patents in this family include claims directed to (1)&#160;recombinant single-chain meganucleases, and (2)&#160;methods for producing isolated genetically modified eukaryotic cells using such meganucleases. Patents in this family have a standard expiration date of October&#160;31, 2028, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third family, which we own, includes three issued patents in the United States, and two issued patents in each of Europe and Australia. This family also includes one pending patent application in each of the United States and Europe. Patents in this family include claims directed to methods of cleaving DNA at specific four base pair sites using a recombinant meganuclease. Patents in this family have a standard expiration date of July&#160;14,&#160;2029, subject to potential extensions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fourth family, which we own, includes two pending provisional patent applications in the United States. Patent applications in this family include claims directed to recombinant meganucleases engineered to cleave recognition sequences having specific four base pair sites. Patents in this family, if issued, will likely have a standard expiration date of May 7, 2040, subject to potential extensions.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Immunotherapy Patent Families </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own seventeen patent families that are directed to immunotherapy, including CAR T cell therapies. Some of these are applicable to immunotherapies and/or CAR T cells directed to killing a variety of different types of infected or cancerous cells. Others are directed to specific indications in which cells expressing particular antigens are targeted. Each of our immunotherapy product candidates is protected by one or more patents in these families. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first family includes nine issued U.S. patents, and pending patent applications in each of the United States, Europe, Australia, Canada, China, Hong Kong, Israel, Japan, Mexico and South Korea. Patents in this family include claims directed to (1)&#160;populations of genetically modified human T cells in which 20%-65% of the cells have reduced expression of an endogenous TCR and express an anti-cancer antigen CAR from DNA inserted into the cells&#8217; TCR alpha constant region (TRAC) gene, (2)&#160;methods for using such populations of genetically modified human T cells for cancer immunotherapy, (3)&#160;pharmaceutical compositions comprising such populations of genetically modified human T cells, (4)&#160;genetically modified human T cells which have reduced expression of an endogenous TCR and express an anti-cancer antigen CAR from DNA inserted into the cells&#8217; TRAC gene, (5)&#160;methods for using such genetically modified human T cells for cancer immunotherapy, and (6)&#160;pharmaceutical compositions comprising such genetically modified human T cells. Patents in this family have a standard expiration date of October&#160;5, 2036, subject to potential extensions. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second family includes one issued patent in Europe and pending patent applications in each of the United States, Europe, Australia, Canada and Japan. Patent applications in this family include claims directed to (1)&#160;first-generation recombinant meganucleases that cleave a target in the TRAC gene, (2)&#160;nucleic acids and vectors encoding such recombinant meganucleases, (3)&#160;methods for producing genetically modified eukaryotic cells, including CAR T cells, using such meganucleases, and (4)&#160;methods of using such genetically modified eukaryotic cells for cancer immunotherapy. Patents in this family will have a standard expiration date of October&#160;5, 2036, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third family includes a pending PCT international patent application. That PCT patent application includes claims directed to (1)&#160;second-generation engineered meganucleases that cleave a specific target in the TRAC gene, (2)&#160;nucleic acids and vectors encoding such recombinant meganucleases, (3)&#160;methods for producing genetically modified eukaryotic cells, including CAR T cells, using such meganucleases, (4)&#160;genetically modified eukaryotic cells or populations of cells prepared by such methods, (5)&#160;pharmaceutical compositions comprising such cells or populations of cells, and (6)&#160;methods of treating diseases using such cells, populations of cells or pharmaceutical compositions to treat diseases, including cancer immunotherapy. Patents in this family, if issued, will likely have a standard expiration date of April&#160;11, 2039, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fourth family includes pending patent applications in the United States, Europe, Australia, Canada and Japan. Patent applications in this family include claims directed to (1)&#160;nucleic acids encoding co-stimulatory domains having certain amino acid sequences, (2)&#160;recombinant DNA constructs and vectors comprising such nucleic acids, (3)&#160;nucleic acids and vectors encoding such recombinant meganucleases, (4)&#160;genetically modified cells comprising such nucleic acids, (5)&#160;methods for producing such genetically modified cells, (6)&#160;pharmaceutical compositions comprising such cells, and (7)&#160;methods of immunotherapy using such cells. Patents in this family, if issued, will have a standard expiration date of October&#160;4, 2037, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fifth family includes pending patent applications in the United States and Europe. Patent applications in this family include claims directed to (1)&#160;methods of reducing cytotoxicity associated with DNA transfection in primary eukaryotic cells, (2)&#160;methods for increasing the number of gene-edited primary eukaryotic cells following DNA transfection, (3)&#160;methods for increasing gene editing frequency in primary eukaryotic cells following DNA transfection, (4)&#160;methods for increasing the number of primary eukaryotic cells comprising targeted insertion of an exogenous sequence of interest into the genome following DNA transfection, (5)&#160;methods for increasing insertion frequency of an exogenous sequence of interest into the genome in primary eukaryotic cells following DNA transfection, (6)&#160;methods for high throughput screening of primary human T cells expressing a CAR or exogenous TCR, (7)&#160;methods for high throughput screening of primary human T cells expressing a CAR or exogenous TCR, and (8)&#160;genetically modified primary eukaryotic cells produced by such methods. Patents in this family, if issued, will likely have a standard expiration date of April&#160;30, 2038, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sixth family includes pending patent applications in the United States, Europe, Australia, Canada and Japan. Patent applications in this family include claims directed to (1)&#160;recombinant meganucleases that recognize and cleave a recognition sequence within the human beta-2-microglobulin gene, (2)&#160;nucleic acids and vectors encoding such recombinant meganucleases, (3)&#160;methods for producing genetically modified eukaryotic cells, including CAR T cells, using such meganucleases, (4)&#160;populations of genetically modified eukaryotic cells in which 80% of the cells have reduced expression of an endogenous TCR and 80% of the cells have reduced expression of beta-2-microglobulin, (5) pharmaceutical compositions comprising such populations of genetically modified eukaryotic cells, and (6)&#160;methods for using such genetically modified eukaryotic cells for cancer immunotherapy. Patents in this family, if issued, will have a standard expiration date of December&#160;22, 2036, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The seventh family includes a pending PCT international patent application and pending patent applications in the United States, Europe, Australia, Canada and Japan. Patent applications in this family include claims directed to (1)&#160;nucleic acids encoding an engineered antigen receptor (e.g., a CAR) and an inhibitory molecule (e.g., an RNA interfering with beta-2-microglobulin expression), (2) genetically modified eukaryotic cells comprising such nucleic acids, (3)&#160;methods for producing such genetically modified eukaryotic cells using such nucleic acids and an engineered nuclease that promotes insertion of such nucleic acids, (4)&#160;genetically modified eukaryotic cells expressing an engineered antigen receptor and having expression of beta-2-microglobulin or MHC Class&#160;I molecules reduced by 10%-95%, (5) pharmaceutical compositions comprising such genetically modified eukaryotic cells, and (6)&#160;methods for using such genetically modified eukaryotic cells for immunotherapy. Patents in this family, if issued, will likely have a standard expiration date of May&#160;8, 2038, subject to potential extensions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The eighth family includes a pending PCT international patent application</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and pending patent applications in the United States, Europe, Australia, Canada and Japan</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent applications in this family</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> include claims directed to (1)&#160;engineered meganucleases that recognize and cleave a recognition sequence in an upstream intron of the human TRAC gene, (2)&#160;nucleic acids and vectors encoding such engineered meganucleases, (3)&#160;methods for producing genetically modified T cells using such nucleic acids or vectors, (4)&#160;genetically modified T cells in which an exogenous sequence is inserted into an upstream intron of the human TRAC gene and endogenous TCR expression is reduced, (5)&#160;populations of such genetically modified T cells, (6)&#160;pharmaceutical compositions comprising such genetically modified T cells, and (7)&#160;methods of treating disease using such genetically modified T cells and pharmaceutical compositions, including cancer immunotherapy. Patents in this family, if issued, will likely have a standard expiration date of June&#160;27, 2038, subject to potential extensions. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ninth family includes a pending PCT international patent application. That PCT patent application includes claims directed to (1)&#160;nucleic acids and vectors encoding certain modified human epidermal growth factor receptor, or EGFRs, (2) genetically modified cells and populations of cells, including T cells and CAR T cells, expressing such modified EGFRs, (3)&#160;methods for producing such genetically modified cells using such nucleic acids or vectors encoding such modified EGFRs, (4)&#160;pharmaceutical compositions comprising such genetically modified cells, (5)&#160;methods for isolating such genetically modified cells, (6)&#160;methods of treating disease using such genetically modified cells and pharmaceutical compositions, including cancer immunotherapy, and (7)&#160;methods of depleting such genetically modified cells in a subject using anti-modified EGFR antibodies. Patents in this family, if issued, will likely have a standard expiration date of October&#160;3, 2038, subject to potential extensions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own eight additional patent families that include pending provisional patent applications in the United States that are directed to immunotherapies, including CAR T cell therapies, or to technologies that are useful for the manufacture of immunotherapies. We jointly own one patent family that includes a pending provisional patent application in the United States directed to immunotherapies. We will determine in the future whether to pursue each of these applications.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, the Patent Trial and Appeal Board (the &#8220;PTAB&#8221;) of the USPTO initiated two patent interferences, administrative proceeding within the USPTO, involving the U.S. patents issued to us in the first family of immunotherapy patents described above and a pending U.S. patent application filed by a third party. An interference is conducted by the PTAB when opposing parties have applied for patent claims to the same invention or substantially the same invention. The interference is conducted to determine which party, if either, is entitled to claims to the subject matter of the interference. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hepatitis B Virus Gene Therapy Patent Families </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own three patent families that are directed to gene therapy for Hepatitis B virus. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first family includes pending patent applications in the United States, Europe, Japan, Canada, Australia, China, South Korea, Mexico, Israel, the African Regional Intellectual Property Organization, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Egypt, Eurasia, Guatemala, Hong Kong, India, Indonesia, Morocco, Malaysia, New Zealand, Nigeria, Panama, Peru, the Philippines, Saudi Arabia, Singapore, South Africa, Thailand, Ukraine, and Vietnam. Patent applications in this family include claims directed to (1)&#160;engineered meganucleases that recognize and cleave recognition sites in the Hepatitis B virus (&#8220;HBV&#8221;) genome, (2)&#160;nucleic acids and vectors encoding such engineered meganucleases, (3)&#160;pharmaceutical compositions comprising such nucleic acids or meganucleases, and (4)&#160;methods for treating HBV infection using such meganucleases, nucleic acids and/or pharmaceutical compositions. Patents in this family, if issued, will have a standard expiration date of October&#160;13, 2037, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second family includes a pending PCT application and patent applications in the United States, Argentina, Taiwan, and the Gulf Cooperation Council. Patent applications in this family include claims directed to (1)&#160;second-generation engineered meganucleases that recognize and cleave recognition sites in the Hepatitis B virus, or HBV genome, (2)&#160;nucleic acids and vectors encoding such engineered meganucleases, (3)&#160;pharmaceutical compositions comprising such nucleic acids or meganucleases, and (4)&#160;methods for treating HBV infection using such meganucleases, nucleic acids and/or pharmaceutical compositions. Patents in this family, if issued, will likely have a standard expiration date of April&#160;11, 2039, or April 12, 2039, subject to potential extensions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third family includes a pending provisional application in the United States.&nbsp;&nbsp;That provisional patent application is directed to engineered meganucleases that cleave recognition sequences in the HBV genome. Patents in this family, if issued, will likely have a standard expiration date of December 6, 2040, subject to potential extensions.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Patent Families </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to engineered meganucleases and methods of treatment targeting the PCSK9 gene, which is associated with familial hypercholesterolemia. This family includes a pending PCT international and pending patent applications in the United States, Europe, Australia, Canada, China, Israel, Japan, Mexico, and South Korea. Patents in this family, if issued, will have a standard expiration date of April&#160;20, 2038, subject to potential extensions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own two patent families directed to engineered meganucleases and methods of treatment targeting the rhodopsin gene, which is associated with retinitis pigmentosa. The first family includes pending patent applications in the United States, Europe, Australia, Canada and Japan. Patents in this family, if issued, will have a standard expiration date of September&#160;8, 2036, subject to potential extensions. The second family includes a pending provisional patent application in the United States. Patents in this family, if issued, will likely have a standard expiration date of April 11, 2040, subject to potential extensions.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own two patent families that are directed to engineered meganucleases and methods of treatment targeting the hydroxyacid oxidase 1 gene, which is associated with primary hyperoxaluria 1. The first family includes a pending PCT international application and one pending provisional patent application in the United States. Patents in this family, if issued, will likely have a standard expiration date of December 20, 2039, subject to potential extensions. The second family includes two pending provisional patent applications in the United States. Patents in this family, if issued, will likely have a standard expiration date of March 26, 2040, subject to potential extensions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own two patent families that are directed to engineered meganucleases and methods of treatment targeting the Factor VIII gene, which is associated with Hemophilia A. The first family includes pending patent applications in the United States, Europe, Australia, Canada, and Japan. Patents in this family, if issued, will have a standard expiration date of May&#160;3, 2037, subject to potential extensions. The second family includes a pending PCT international patent application. Patents in this family, if issued, will likely have a standard expiration date of November&#160;1, 2038, subject to potential extensions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to engineered meganucleases and methods of treatment targeting the ApoC3 gene, which is associated with diseases resulting from abnormal triglyceride synthesis. This family includes a pending provisional patent application in the United States. Patents in this family, if issued, will likely have a standard expiration date of August 9, 2040, subject to potential extensions.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to engineered meganucleases and methods of treatment targeting the transthyretin (TTR) gene, which is associated with TTR amyloidosis. This family includes two pending provisional patent applications in the United States. Patents in this family, if issued, will likely have a standard expiration date of March 26, 2040, subject to potential extensions.&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to engineered meganucleases and methods of treatment targeting the dystrophin gene, which is associated with Duchenne Muscular Dystrophy. This family includes pending patent applications in the United States, Europe, Australia, Canada and Japan. Patents in this family, if issued, will have a standard expiration date of March&#160;12, 2035, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to engineered meganucleases and methods of treatment targeting genomic trinucleotide repeats, which are associated with several trinucleotide repeat disorders. This family includes pending patent applications in the United States and Europe. Patents in this family, if issued, will have a standard expiration date of May&#160;2, 2036, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We license from Duke one patent family directed to engineered fusion proteins comprising engineered meganuclease domains and effector domains which may be useful in controlling gene expression. This patent family includes a pending patent application in the United States. Patents in this family, if issued, will have a standard expiration date of October&#160;18, 2026, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to engineered meganucleases that target amplifiable genetic loci and may be useful in producing cells with amplified transgenes. This family includes one patent and one pending patent application in each of the United States and Europe. Patents in this family will have a standard expiration date of June&#160;1, 2032, subject to potential extensions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to self-limiting viral vectors (e.g., AAV vectors) that encode engineered meganucleases which eliminate the vector after gene delivery. This family includes pending patent applications in the United States and Europe. Patents in this family, if issued, will have a standard expiration date of June&#160;20, 2036, subject to potential extensions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to eukaryotic cells comprising a modified transferrin gene that includes an exogenous nucleic acid sequence encoding a polypeptide of interest. This family includes one pending provisional patent application in the United States. Patents in this family, if issued, will likely have a standard expiration date of January 11, 2040.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own one patent family directed to methods for separation of empty and full AAV capsids during manufacturing. This family includes one pending provisional application in the United States. Patents in this family, if issued, will likely have a standard expiration date of February 7, 2040.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own, through our Elo Life Systems subsidiary, an issued U.S. patent directed to engineered meganucleases which target a genetic locus in maize and methods for genetically modifying that locus in maize. That patent has a standard expiration date of March 2, 2029, subject to potential extensions. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any individual patent, the term depends on the applicable law in the country in which the patent is granted. In most countries where we have filed patent applications or in-licensed patents and patent applications, patents have a term of 20 years from the application filing date or earliest claimed non-provisional priority date. In the United States, the patent term is 20 years but may be shortened if a patent is terminally disclaimed over another patent that expires earlier. The term of a U.S. patent may also be lengthened by a patent term adjustment to address administrative delays by the USPTO in granting a patent. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the term of a patent that covers an FDA-approved drug or biologic may be eligible for patent term extension in order to restore the period of a patent term lost during the premarket FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the natural expiration of the patent. The patent term restoration period is generally equal to the portion of the FDA regulatory review period for the approved product that occurs after the date the patent issued, subject to certain exceptions. Only one patent may be extended for a regulatory review period for any product, and the application for the extension must be submitted prior to the expiration of the patent. In the future, we may decide to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant BLA. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents or other intellectual property as an inventor or co-inventor. If we are required to and unable to obtain an exclusive license to any such third party co-owners&#8217; interest in such patent applications, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us. We or our licensors are subject to and may also become a party to similar proceedings or priority disputes in Europe or other foreign jurisdictions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registered trademark portfolio currently contains three registered trademarks, specifically ARCUS, ARC nuclease, and Elo Life Systems, in the United States.&#160;In addition, our international portfolio contains seven registered trademarks around the world for ARCUS and ARC nuclease and includes one pending application in Australia for Elo Life Systems. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Licensed Intellectual Property </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Duke University </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, we exclusively licensed from Duke families of patents and patent applications related to certain meganucleases and methods of making such nucleases owned by Duke. The patent family covered by the Duke License comprises the core patents covering ARCUS described above. See &#8220;&#8212;License and Collaboration Agreements&#8212;Duke University&#8221; above for additional information regarding the Duke License. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cellectis S.A<font style="font-weight:bold;">. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, we entered into the Cellectis License, which relates to certain modified I-CreI homing endonuclease patents and patents that had been subject to litigation between us and Cellectis. The patents to which we have rights under the cross-license include at least eight issued patents in each of the United States and Australia, seven issued patents in Europe, two issued patents in Canada and one issued patent in Japan. These patents have standard expiration dates prior to January&#160;29, 2034, subject to potential extensions. See &#8220;&#8212;License and Collaboration Agreements&#8212;Cellectis S.A.&#8221; above for additional information regarding the Cellectis License. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biological product candidates such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Biologics Regulation </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s Good Laboratory Practice requirements, or GLPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">approval by an IRB or ethics committee at each clinical site before the trial is commenced; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">satisfactory completion of an FDA Advisory Committee review, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and <font style="font-style:italic;">in vitro</font> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States,&#160;certain human clinical trials involving recombinant or synthetic nucleic acid molecules&#160;are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines.&#160;Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 1&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 2&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 3&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 4&#8212;In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">BLA Submission and Review by the FDA </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. The submission of a BLA requires payment of a substantial user fee to FDA, and the sponsor of an approved BLA is also subject to an annual program fee. These fees are typically increased annually. A waiver of user fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. Priority review designation will direct overall attention and resources to the evaluation of applications for products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase IV post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs. For example, in December 2016, the 21st Century Cures Act was signed into law. The Act is intended, among other things, to modernize the regulation of drugs and biologics and to spur innovation. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. A fast track designated product candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious disease or condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Food and Drug Administration Safety and Innovation Act, or the FDASIA, which was enacted and signed into law in 2012, established the breakthrough therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regenerative Medicine Advanced Therapy, or RMAT, designation facilitates an efficient development program for, and expedites review of, any drug that meets the following criteria:&nbsp;&nbsp;(1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition.&nbsp;&nbsp;Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review.&nbsp;&nbsp;Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites.&nbsp;&nbsp;RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast track designation, priority review, breakthrough therapy designation and RMAT designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation and Exclusivity </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. We plan to seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">mandated modification of promotional materials and labeling and the issuance of corrective information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biosimilars and Exclusivity </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act, signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Genetically Engineered Food Products </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA and the USDA are primarily responsible for overseeing food regulation and safety, although many other federal agencies also play a role in food regulation. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USDA has jurisdiction over certain genetically engineered crops through the Animal and Plant Health Inspection Services, or APHIS. Under the Plant Protection Act and APHIS&#8217; Part 340 regulations, USDA requires anyone who wishes to import, transport interstate, or release into the environment a &#8220;regulated article&#8221; to apply for a permit or, in some cases, notify APHIS that the introduction will be made. Regulated articles are defined as &#8220;any organism which has been altered or produced through genetic engineering which USDA determines is a plant pest or has reason to believe is a plant pest.&#8221; Regulated articles may be subject to extensive regulation, including both permitting requirements and inspections. However, to the extent products are subject to APHIS regulation, APHIS may make a determination of nonregulated status for a product following the submission of a petition requesting such a determination. The petition process can be a multi-year process that varies based on a number of factors, including APHIS&#8217;s familiarity with similar products, the type and scope of the environmental review conducted, and the number and types of public comments received. APHIS conducts a comprehensive science-based review of the petition to assess, among other things, plant pest risk, environmental considerations pursuant to the National Environmental Policy Act of 1969, or NEPA, and any potential impact on endangered species. If, upon the completion of the review, APHIS grants the petition, the product is no longer deemed a &#8220;regulated article&#8221; and the petitioner may commercialize the product, subject to any conditions set forth in the decision. In January 2017, APHIS proposed significant amendments to its Part 340 regulatory framework that would, among other things, clarify the types of genetically engineered plants subject to regulation thereunder. In November 2017, however, APHIS withdrew its proposed rule and stated that it would &#8220;begin a fresh stakeholder engagement aimed at exploring alternative policy approaches.&#8221; That process appears to remain ongoing. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;4, 2018, the USDA issued a proposed rule implementing the National Bioengineered Food Disclosure Standard, with a proposed compliance date of January&#160;1, 2020. Under this proposed rule, the label of a bioengineered, or BE, food must include a disclosure that the food is a BE food or contains a BE ingredient, with certain exceptions. This proposed rule defines BE food as &#8220;a food that contains genetic material that was has been modified through in vitro recombinant deoxyribonucleic acid, or DNA, techniques and for which the modification could not otherwise be obtained through conventional breeding or found in nature,&#8221; except in the case of an incidental additive present in food at an insignificant level and that does not have any technical or functional effect in the food. The USDA&#8217;s proposed rule may change significantly prior to being finalized. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s oversight of food safety and security is primarily carried out by the Center for Food Safety and Applied Nutrition. To execute its responsibilities, the FDA conducts inspections and collects and analyzes product samples. Foods are typically not subject to premarket review and approval requirements, with limited exceptions, such as the requirement for premarket review and approval of food additives. Under Section&#160;201(s) and 409 of the FDCA, any substance that is reasonably expected to become a component of food is considered a &#8220;food additive&#8221; that is subject to premarket approval by the FDA, unless it is already subject to a food additive regulation. Ingredients that are GRAS are exempt from the definition of food additive and from the premarket approval requirements. Under section 201(s), and FDA&#8217;s implementing regulations, the use of a food substance may be GRAS either through a determination by qualified experts or, for a substance used in food before 1958, through experience based on common use in food. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of GRAS substances may voluntarily provide the FDA with a notification of GRAS determination, which includes, among other things, a description of the substance, the applicable conditions of use, the dietary exposure and an explanation of how the substance was determined to be safe for the intended use. Upon review of such a notification, the FDA may respond with a &#8220;no questions&#8221; letter stating that while it has not made its own GRAS determination, it has no questions at the time regarding the applicant&#8217;s own GRAS determination. Alternatively, manufacturers may self-affirm that a given substance is GRAS without the voluntary FDA notification. A company may market a new food ingredient based on its independent determination that the substance is GRAS; however, the FDA can disagree with this determination and take enforcement action. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA regulates foods made with genetically modified organisms under the approach summarized in its 1992 &#8220;Statement of Policy: Foods Derived from New Plant Varieties.&#8221; Under this policy, updated in 2017, the FDA regulates foods derived from genetically modified plant varieties consistent with the framework for non-genetically modified foods. Under this framework, the FDA offers a voluntary consultation process to determine whether a food derived from a genetically modified plant variety raises any safety or other regulatory issues, such as whether any substance in the food from the plant may require premarket approval as a food additive.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To market a medicinal product in the European Economic Area, or EEA (which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, auto immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure, the maximum timeframe for the evaluation of an MA application is 210 days, excluding clock stops. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Priority medicines scheme. <font style="font-style:normal;">The EMA has a so-called Priority Medicines, or PRIME, scheme. The PRIME scheme was launched in 2016 by the EMA to support the development and accelerate the review of new therapies to treat patients with unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier. To qualify for PRIME, product candidates require early clinical evidence that the therapy has the potential to offer a therapeutic advantage over existing treatments or benefits patients without treatment options. Among the benefits of PRIME are the appointment of a rapporteur to provide continuous support and help build knowledge ahead of an MA application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Data and marketing exclusivity</font><font style="font-style:normal;">. In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10 year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric investigation plan<font style="font-style:normal;">. In the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan drug designation.<font style="font-style:normal;"> In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Community and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication.&nbsp;&nbsp;The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinical superiority&#8221; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs pursuant are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical trials<font style="font-style:normal;">. Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCPs. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2020, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other U.S. Healthcare Laws and Compliance Requirements </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our activities are potentially subject to regulation under various federal and state healthcare laws including, among others, the federal Anti-Kickback Statute, the federal False Claims Act and HIPAA. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. A person does not need to have knowledge of the statute or specific intent to violate it to have committed a violation. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Physician Payments Sunshine Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals beginning in 2022, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually to CMS certain ownership and investment interests held by physicians and their immediate family members. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, analogous state and non-U.S. laws and regulations may apply to our activities, such as state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by the patients themselves, state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources, state and local laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws which require the registration of pharmaceutical sales representatives and state and non-U.S. laws, such as the EU General Data Protection Regulation 2016/679, governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that current and future business arrangements with third parties complies with applicable healthcare laws and regulations involves substantial costs. If a business is found to be in violation of any of these or any other health regulatory laws that may apply to it, it may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status for newly approved therapeutics. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Moreover, the coverage provided may be more limited than the purposes for which the product is approved by the FDA. It is also possible that a third-party payor may consider a product as substitutable and only offer to reimburse patients for the less expensive product. Adequate third-party payor reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-weight:normal;color:#auto;font-family:Times New Roman;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, enacted in March 2010, has substantially changed healthcare financing and delivery by both governmental and private insurers. Among other things the Affordable Care Act included the following provisions: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to point-of-sale discounts of 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of the entities eligible for discounts under the 340B Drug Discount Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a licensure framework for follow on biologic products. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire Affordable Care Act is invalid based primarily on the fact that the legislation enacted on December 22, 2017, the Tax Cuts and Jobs Act of 2017, or the TCJA, repealed the tax-based shared responsibility payment imposed by the Affordable Care Act, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate&#8221;. On December 18, 2019, the U.S. Court of Appeals for the 5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how these decisions, subsequent appeals, if any, and other efforts to challenge, repeal or replace the Affordable Care Act will impact the Affordable Care Act.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2029 unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies, rebates and price negotiation for pharmaceutical products, some of which are included in the Trump administration&#8217;s budget proposals for fiscal years 2019 and 2020, as well as recent bills introduced by the U.S. Senate and House of Representatives, respectively. Additionally, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has begun soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. Although a number of these, and other potential, proposed measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product and medical device pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and medical devices to purchase and which suppliers will be included in their prescription drug and other healthcare programs. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we had 199 full-time Precisioneers, including 62 scientists with&#160;Ph.D. degrees. Of these full-time employees, 146 are engaged in research and development activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationships with our employees to be good. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in January 2006. Our principal executive offices are located at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, and our telephone number is (919) 314-5512. Our website address is www.precisionbiosciences.com. The information contained in, or accessible through, our website does not constitute a part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file annual, quarterly and current reports, proxy statements and other information with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at <font style="font-style:italic;text-decoration:underline;">www.sec.gov</font>. Our SEC filings are also available free of charge under the Investors and Media section of our website at <font style="font-style:italic;text-decoration:underline;">www.precisionbiosciences.com</font><font style="font-style:italic;"> </font>as soon as reasonably practicable after they are filed with or furnished to the SEC. Our website and the information contained on or connected to that site are not incorporated into this Annual Report on Form 10-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information included or incorporated by reference in this Annual Report on Form 10-K. The occurrence of any of the following risks could materially adversely affect our business, financial condition, results of operations and future growth prospects. In these circumstances, the market price of our common stock could decline. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Condition, Limited Operating History and Need for Additional Capital</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. We have never been profitable, and may never achieve or maintain profitability. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and do not expect to be profitable in the foreseeable future. Since inception, we have incurred significant operating losses. If our product candidates are not successfully developed and approved, we may never generate any revenue from product sales. Our net losses were $92.9 million for the year ended December&#160;31, 2019 and $46.0 million for the year ended December&#160;31, 2018. As of December 31, 2019, we had an accumulated deficit of $177.1&#160;million. In addition, we have not commercialized any products and have never generated any revenue from product sales. Substantially all of our losses have resulted from expenses incurred in connection with our research and development activities, including our preclinical development activities, and from general and administrative costs associated with our operations. We have financed our operations primarily through an initial public offering, or IPO, of our common stock, private placements of our convertible preferred stock and convertible debt and our development and commercial license agreement dated February 24, 2016, as amended, with Les Laboratoires Servier, which we refer to as the Servier Agreement. The amount of our future net losses will depend, in part, on the amount and growth rate of our expenses and our ability to generate revenues. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our current or future product candidates will require substantial additional development time and resources before we may realize revenue from product sales, if at all. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue our current research and development programs, including conducting laboratory, preclinical and greenhouse studies for product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to conduct or initiate clinical or field trials for product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to identify, assess, acquire or develop additional research programs or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek marketing approvals for any product candidates that may successfully complete development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a sales, marketing and distribution infrastructure to commercialize any products that may obtain marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">further develop and refine the manufacturing process for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">change or add additional manufacturers or suppliers of biological materials or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">validate our commercial-scale manufacturing facility, MCAT, as compliant with current Good Manufacturing Practices, or cGMP; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">further develop our genome editing technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acquire or in-license other technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek to attract and retain new and existing personnel; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">expand our facilities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">operate as a public company. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It will be several years, if ever, before we obtain regulatory approval for, and are ready for commercialization of, a therapeutic product candidate. Similarly, no product candidate from our food platform has advanced to field testing, and it will be several years, if ever, before we or our collaborators commercialize any such product candidate. New food and agriculture products using the precise editing approach generally take approximately three to five years to develop. Even if a therapeutic product candidate receives regulatory approval or a food or agriculture product advances through commercialization, future revenues for such product candidate will depend upon many factors, such as, as applicable, the size of any markets in which such product candidate is approved for sale, the market share captured by such product candidate, including as a result of the market acceptance of such product candidate and the effectiveness of manufacturing, sales, marketing and distribution operations related to such product candidate, the terms of any collaboration or other strategic arrangement we may have with respect to such product candidate and levels of reimbursement from third-party payors. If we are unable to develop and commercialize one or more product candidates either alone or with collaborators, or if revenues from any product candidate that receives marketing approval or is commercialized are insufficient, we may not achieve profitability.&#160;Even if we do achieve profitability, we may not be able to sustain or increase profitability.&#160;If we are unable to achieve and maintain profitability, the value of our common stock will be materially adversely affected. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of identifying product candidates and conducting preclinical or greenhouse studies and clinical or field trials is time consuming, expensive, uncertain and takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate and continue clinical or field trials of, and seek marketing approval for, product candidates. In addition, if any therapeutic product candidate that we develop alone or with collaborators obtains marketing approval, we may incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution efforts. Furthermore, with the closing of our IPO, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise sufficient capital when needed, we may be forced to delay, reduce or eliminate current or future research programs, product development activities and/or commercialization efforts. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents will be sufficient to fund our expected operating expenses and capital expenditure requirements into 2021. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors, including factors unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. We do not currently expect future grant revenues to be a material source of revenue. Attempting to secure additional financing may divert our management from our&#160;day-to-day&#160;activities, which may adversely affect our ability to develop product candidates. Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, scope, progress, costs, results and analysis of results of research activities, preclinical or greenhouse studies and clinical or field trials for any of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of future activities, including product manufacturing, sales, marketing and distribution activities for any product candidates that receive regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of our existing collaborative relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we exercise any development or commercialization rights under collaborative relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain additional collaborative relationships on favorable terms, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we expand our operations and the timing of such expansion, including with respect to facilities, employees and product development platforms; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending intellectual property-related claims; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the extent to which we acquire or in-license other technologies or product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in other businesses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of continuing to operate as a public company; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the amount of revenues, if any, received from commercial sales of any products that we develop alone or with collaborators that receive regulatory approval. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or in light of specific strategic considerations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain sufficient funding on a timely basis or on favorable terms, we may be required to significantly delay, reduce or eliminate one or more of our research or product development programs and/or commercialization efforts. We may also be unable to expand our operations or otherwise capitalize on business opportunities as desired. Any of these events could materially adversely affect our financial condition and business prospects. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions of our debt instruments may restrict our ability to pursue our business strategies.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into a loan and security agreement with Pacific Western Bank, or PWB, pursuant to which we may request advances on a revolving line of credit of up to an aggregate principal of $50.0 million, or the Revolving Line. The maturity date of the Revolving Line is May 15, 2022. As of December 31, 2019, we had no borrowings under our Revolving Line. Under the loan and security agreement, we granted PWB a security interest in substantially all of our assets, excluding any of the intellectual property now or hereafter owned, acquired or received by us (but including any rights to payment from the sale or licensing of any such intellectual property).&nbsp;&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our loan and security agreement with PWB requires us, and any debt instruments we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">dispose of assets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">change our name, location, executive office or executive management, business, fiscal year, or control; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">complete mergers or acquisitions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur indebtedness; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">encumber assets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pay dividends or make other distributions to holders of our capital stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">make specified investments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">make capitalized expenditures in excess of $40 million in the aggregate during each fiscal year; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">engage in certain transactions with our affiliates.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These restrictions could inhibit our ability to pursue our business strategies. In addition, we are subject to financial covenants based on minimum cash balances.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and/or debt financings and collaborations, licensing agreements or other strategic arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. To the extent that we raise additional capital through debt financing, it would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends. To the extent we raise additional capital through arrangements with collaborators or otherwise, we may be required to relinquish some of our technologies, research programs, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product development activities, product candidates and/or future revenue streams, license our technologies and/or product candidates on unfavorable terms or otherwise agree to terms unfavorable to us. Furthermore, any capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to advance research programs, product development activities or product candidates. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a genome editing company with a limited operating history. We formed our company in 2006 and spent the first nine years of our company&#8217;s history developing and refining our core technology, and only during the past several years have we focused our efforts on advancing the development of product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment in biopharmaceutical and agricultural biotechnology product development is a highly speculative endeavor. It entails substantial upfront capital expenditures, and there is significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain any required regulatory approvals or become commercially viable. Our genome editing platform and the technologies we are using are new and unproven. We have initiated a Phase 1/2a clinical trial in patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, and R/R B-cell acute lymphoblastic leukemia, or B-ALL, but we have not commenced field trials for any of our product candidates from our food platform. We have not yet demonstrated an ability to successfully complete any clinical or field trials, obtain any required marketing approvals, manufacture products, conduct sales, marketing and distribution activities, or arrange for a third party to do any of the foregoing on our behalf. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing products. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we encounter risks and difficulties frequently experienced by new and growing companies in rapidly developing and changing industries, including challenges in forecasting accuracy, determining appropriate investments of our limited resources, gaining market acceptance of our technology, managing a complex regulatory landscape and developing new product candidates, which may make it more difficult to evaluate our likelihood of success. Our current operating model may require changes in order for us to adjust to these challenges or scale our operations efficiently. Our limited operating history, particularly in light of the rapidly evolving nature of the biopharmaceutical and agricultural biotechnology industries and the genome editing field, may make it difficult to evaluate our technology and business prospects or to predict our future performance. Additionally, due to the stage of our operations, we expect that our financial condition and operating results may fluctuate significantly from quarter to quarter as a result of many factors as we build our business, and you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources on pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to identify new product candidates and product development platforms require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs, product candidates or product development platforms that ultimately prove to be unsuccessful. Any time, effort and financial resources we expend on identifying and researching new product candidates and product development platforms may divert our attention from, and adversely affect our ability to continue, development and commercialization of existing research programs, product candidates and product development platforms. Clinical trials or field trials, as applicable, of any of our product candidates may never commence despite the expenditure of significant resources in pursuit of their development, and our spending on current and future research and development programs, product candidates and product development platforms may not yield any commercially viable products. As a result of having limited financial and managerial resources, we may forego or delay pursuit of opportunities that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Additionally, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to take advantage of a Research&#160;and Development Tax Incentive program in Australia, which could be amended or changed. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a>We may be eligible to receive a financial incentive from the Australian government as part of its Research and Development Tax Incentive program, or R&amp;D Tax Incentive program. The R&amp;D Tax Incentive program is one of the key elements of the Australian government&#8217;s support for Australia&#8217;s innovation system and, if eligible, provides the recipient with a 43.5% refundable tax offset for research and development activities in Australia. There have been recent proposals to change the structure of the innovation and research and development funding landscape in Australia, which may impact the research and development tax incentive receivable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the 2019 financial year and beyond. There can be no assurance that we will qualify and be eligible for such incentives or that the Australian government will continue to provide incentives, offset, grants and rebates on similar terms or at all. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Identification, Development and Commercialization of Our Product Candidates</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of most of our product candidates in humans, and have only limited safety and efficacy information in humans to date regarding one of our product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on our ability to develop and commercialize product candidates using our novel genome editing technology. The novel nature of our technology makes it difficult to accurately predict the developmental challenges we may face for product candidates as they proceed through research, preclinical or greenhouse studies and clinical or field trials. There have been a limited number of clinical trials of products created with genome editing technologies, only one of which has utilized our technology, and only two therapeutic products created with other genome editing technologies have received marketing approval in the United States. Because our therapeutic research programs are all in preclinical or early clinical stages, we have only been able to assess limited safety and efficacy data for one of our product candidates in a human trial. Current or future product candidates may not meet safety and efficacy requirements for continued development or ultimate approval in humans and may cause significant adverse events or toxicities. All of our product candidates are designed to act at the level of DNA, and because animal DNA differs from human DNA, it will be difficult for us to test our therapeutic product candidates in animal models for either safety or efficacy, and any testing that we conduct may not translate to their effects in humans. Moreover, animal models may not exist for some of the targets, diseases or indications that we intend to pursue. Similarly, we and our collaborators have not yet completed field trials for any agricultural product candidates created with our technology. Our product candidates may not be able to properly implement desired genetic edits with sufficient accuracy to be viable therapeutic or agricultural products, and there may be long-term effects associated with them that we cannot predict at this time. Any problems we experience related to the development of our genome editing technology or any of our or our collaborators&#8217; research programs or product candidates may cause significant delays or unanticipated costs, and we may not be able to satisfactorily solve such problems. These factors may prevent us or our collaborators from completing our preclinical or greenhouse studies or any clinical or field trials that we or our collaborators may initiate, or profitably commercializing any product candidates on a timely basis, or at all. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process as we develop and prepare to commercialize product candidates. These factors make it more difficult for us to predict the time, cost and potential success of product candidate development. If our product development activities take longer or cost more than anticipated, or if they ultimately are not successful, it would materially adversely affect our business and results of operations. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The genome editing field is relatively new and evolving rapidly, and other existing or future technologies may provide significant advantages over our ARCUS platform, which could materially harm our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have focused our efforts on optimizing our proprietary genome editing technology and exploring its potential applications. ARCUS is a novel genome editing technology using sequence-specific DNA-cutting enzymes, or nucleases, that is designed to perform modifications in the DNA of living cells and organisms. Other companies have previously undertaken research and development of genome editing technologies using zinc finger nucleases, transcription activator-like effector nucleases, or TALENs, and clustered regularly interspaced short palindromic repeats associated protein-9 nuclease, or CRISPR/Cas9, although none has obtained marketing approval for a product candidate developed using such technologies. Other genome editing technologies in development or commercially available, or other existing or future technologies, may lead to treatments or products that may be considered better suited for use in human therapeutics or agriculture, which could reduce or eliminate our commercial opportunity. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are heavily dependent on the successful development and translation of ARCUS, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are at an early stage of development of the product candidates currently in our programs and are continuing to develop our ARCUS technology. To date, we have invested substantially all of our efforts and financial resources to develop ARCUS and advance our current product development programs, including conducting preclinical studies, early stage clinical trials and other early research and development activities, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop and, where applicable, obtain regulatory approval for, including marketing approval for, and then successfully commercialize, product candidates, either alone or with collaborators. We have not yet developed and commercialized any product candidates, and we may not be able to do so, alone or with collaborators. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development programs may not lead to the successful identification, development or commercialization of any products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business depends primarily upon our ability to identify, develop and commercialize products using our genome editing technology. With the exception of our CD19 product candidate, all current product candidates and product development programs are still in the discovery, preclinical or greenhouse stages. We may be unsuccessful in advancing those product candidates into clinical development or field trials or in identifying any developing additional product candidates. Our ability to identify and develop product candidates is subject to the numerous risks associated with preclinical and early stage biotechnology development activities, including that: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the use of ARCUS may be ineffective in identifying additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not be able to enter into collaborative arrangements to facilitate development of product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may be covered by third parties&#8217; patents or other exclusive rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the regulatory pathway for a product candidate may be too complex, expensive or otherwise difficult to navigate successfully; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our product candidates may be shown to not be effective, have harmful side effects or otherwise pose risks not outweighed by such product candidate&#8217;s benefits or have other characteristics that may make the products impractical to manufacture, unlikely to receive any required marketing approval, unlikely to generate sufficient market demand or otherwise not achieve profitable commercialization. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates currently being investigated in clinical trials, or that are expected to be investigated in clinical trials, and other product candidates we may identify may never be approved. Failure to successfully identify and develop new product candidates and obtain regulatory approvals for our products would have a material adverse effect on our business and financial condition and could cause us to cease operations. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies or clinical or field trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates. If we or our collaborators fail to achieve announced milestones in the expected timeframes, the commercialization of the product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed, and the trading price of our common stock may decline. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The developmental and commercial success of our current product candidates, or any that we develop alone or with collaborators in the future, will depend in part on public acceptance of the use of genome editing technology for the prevention or treatment of human diseases or for application in food or agricultural products. Adverse public perception of applying genome editing technology for these purposes may negatively impact our ability to raise capital or enter into strategic agreements for the development of product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial success of any food or agricultural products that we develop alone or with collaborators may be adversely affected by claims that biotechnology plant products are unsafe for consumption or use, pose risks of damage to the environment or create legal, social or ethical dilemmas. Additionally, the public may perceive any potential food or agricultural products created with ARCUS to constitute genetically modified organisms, or GMO, even if they do not constitute genetically modified organisms under relevant regulatory requirements, and may be unwilling to consume them because of negative opinions regarding consumption of genetically modified organisms. This may result in expenses, delays or other impediments to development programs in our food platform or the market acceptance and commercialization of any potential food or agricultural products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any therapeutic product candidates may involve editing the human genome. The commercial success of any such potential therapeutic products, if successfully developed and approved, may be adversely affected by claims that genome editing is unsafe, unethical or immoral. This may lead to unfavorable public perception and the inability of any therapeutic product candidates to gain the acceptance of the public or the medical community. Unfavorable public perceptions may also adversely impact our or our collaborators&#8217; ability to enroll clinical trials for therapeutic product candidates. Moreover, success in commercializing any therapeutic product candidates that receive regulatory approval will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of such product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. Publicity of any adverse events in, or unfavorable results of, preclinical studies or clinical trials for any current or future product candidates, or with respect to the studies or trials of our competitors or of academic researchers utilizing genome editing technologies, even if not ultimately attributable to our technology or product candidates, could negatively influence public opinion. Negative public perception about the use of genome editing technology in human therapeutics and food or agricultural products, whether related to our technology or a competitor&#8217;s technology, could result in increased governmental regulation, delays in the development and commercialization of product candidates or decreased demand for the resulting products, any of which may have a negative impact on our business and financial condition. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition in industries experiencing rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any of our product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new drug products is highly competitive, and the genome editing field is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We will face competition with respect to our current and future therapeutic product candidates from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization of products. Competition for improving plant genetics comes from conventional and advanced plant breeding techniques, as well as from the development of advanced biotechnology traits. Other potentially competitive sources of improvement in crop yields include improvements in crop protection chemicals, fertilizer formulations, farm mechanization, other biotechnology and information management. Programs to improve genetics and crop protection chemicals are generally concentrated within a relatively small number of large companies, while non-genetic approaches are underway with a broader set of companies. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. We principally compete with others developing and utilizing genome editing technology in the human health and plant sciences sectors, including companies such as Cellectis S.A., CRISPR Therapeutics, AG, Editas Medicine, Inc., Intellia Therapeutics, Inc. and Sangamo Therapeutics, Inc. Several companies, including Novartis Pharmaceuticals Corp. and Gilead Sciences, Inc., or Gilead, have obtained FDA approval for autologous immunotherapies, and a number of companies, including Cellectis S.A., Celgene Corp., Allogene Therapeutics and CRISPR Therapeutics AG, are pursuing allogeneic immunotherapies. We expect that our operations focused on developing products for <font style="font-style:italic;">in vivo</font> gene correction will face substantial competition from others focusing on gene therapy treatments, especially those that may focus on conditions that our product candidates target. Moreover, any human therapeutics products that we develop alone or with collaborators will compete with existing standards of care for the diseases and conditions that our product candidates target and other types of treatments, such as small molecule, antibody or protein therapies. Our competitors in the agricultural biotechnology space include Pairwise Plants, LLC, Caribou Biosciences, Inc., Corteva Agriscience, Tropic Biosciences UK LTD, Calyxt, Inc., Benson Hill Biosystems and Cibus. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors, either alone or with their collaborators, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical or greenhouse testing, conducting clinical or field trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and agricultural biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products we develop alone or with collaborators or that would render any such products obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we or our collaborators may obtain approval for any that we develop, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our product candidates uneconomical or obsolete, and we or our collaborators may not be successful in marketing any product candidates we may develop against competitors. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we develop alone or with collaborators. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future profitability, if any, depends in part on our and our collaborators&#8217; ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future profitability, if any, will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our collaborators pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced protection for intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">differing medical and agricultural practices and customs affecting acceptance in the marketplace; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">import or export licensing requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">governmental controls, trade restrictions or changes in tariffs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">longer accounts receivable collection times; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">longer lead times for shipping; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">language barriers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">foreign currency exchange rate fluctuations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">foreign reimbursement, pricing and insurance regimes; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no prior experience in these areas, and our collaborators may have limited experience in these areas. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that we or our collaborators may develop, which would limit their commercial potential and our revenues. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability and professional indemnity exposure related to the testing in clinical or field trials of our product candidates. We will face an even greater liability risk if we commercially sell any products that we or our collaborators may develop for human use or consumption. Manufacturing defects, errors in product distribution or storage processes, improper administration or application and known or unknown side effects of product usage may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting from acts by our collaborators, licensees and subcontractors over which we have little or no control. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, our liability could be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects, improper product administration or the deterioration of a patient&#8217;s condition, patient injury or even death. Criminal or civil proceedings might be filed against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates or products we develop alone or with collaborators caused harm, we could incur substantial liabilities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of merit or eventual outcome, liability claims may result in: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant time and costs to defend the related litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">diversion of management&#8217;s attention from pursuing our strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of clinical trial participants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delay or termination of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for any products that we develop alone or with collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to further develop or commercialize any products. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of such products. We could be adversely affected if we are subject to negative publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of such products or any similar products distributed by other companies. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage if we or our collaborators successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liabilities to which we may become subject. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Additional Risks Related to the Identification, Development and Commercialization of Our Therapeutic Product Candidates</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing products created with genome editing technology or involving gene therapy treatment have changed frequently and will likely continue to change in the future. Approvals by one regulatory agency may not be indicative of what any other regulatory agency may require for approval, and there has historically been substantial, and sometimes uncoordinated, overlap in those responsible for regulation of gene therapy products, cell therapy products and other products created with genome editing technology.&#160;For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Our product candidates will need to meet safety and efficacy standards applicable to any new biologic under the regulatory framework administered by the FDA. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA, before initiation of a clinical trial in the United States, certain human clinical trials subject to the NIH Guidelines are subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. We are subject to significant regulatory oversight by the FDA, and in addition to the government regulators, the applicable IBC and institutional review board, or IRB, of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, would need to review and approve the proposed clinical trial. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The same applies in the European Union, or the EU. The European Medicines Agency, or the EMA, has a Committee for Advanced Therapies, or CAT, that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. Advanced-therapy medical products include gene therapy medicine, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the EU, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any of our gene therapy or genome editing product candidates, but that remains uncertain at this point. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products.&#160;The regulatory approval process for product candidates created with novel genome editing technology such as ours can be more lengthy, rigorous and expensive than the process for other better known or more extensively studied product candidates and technologies. Since we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or comparable regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. This may be a particularly significant risk for many of the genetically defined diseases for which we may develop product candidates alone or with collaborators due to small patient populations for those diseases, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations.&#160;Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing genome editing technology in a timely manner or under technically or commercially feasible conditions. Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in applicable regulatory guidelines may lengthen the regulatory review process for our product candidates, require additional studies or trials, increase development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of such product candidates, or lead to significant post-approval limitations or restrictions.&#160;Additionally, adverse developments in clinical trials conducted by others of gene therapy products or products created using genome editing technology, such as products developed through the application of a CRISPR/Cas9 technology, or adverse public perception of the field of genome editing, may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing genome editing technologies, either of which could materially harm our business.&#160;Furthermore, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the development or commercialization of current or future product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we advance product candidates alone or with collaborators, we will be required to consult with these regulatory and advisory groups and comply with all applicable guidelines, rules and regulations. If we fail to do so, we or our collaborators may be required to delay or terminate development of such product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient product revenue to maintain our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to file IND applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to submit IND applications to enable us to conduct clinical trials for additional product candidates in the future, and we expect to file IND amendments to enable us to conduct additional clinical trials under existing INDs. We cannot be sure that submission of an IND application or IND amendment will result in us being allowed to proceed with clinical trials, or that, once begun, issues will not arise that could result in the suspension or termination such clinical trials. The manufacturing of allogeneic CAR T cell therapy remains an emerging and evolving field. Accordingly, we expect chemistry, manufacturing and controls-related topics, including product specifications, will be a focus of IND reviews, which may delay receipt of authorization to proceed under INDs. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any collaborators are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities and sufficient resources at the FDA. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. To date, we have not submitted a biologics license application, or BLA, or other marketing authorization application to the FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidate. We and any collaborators must complete additional preclinical or nonclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the regulatory authorities before we will be able to obtain these approvals. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our or our collaborators&#8217; clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we or our collaborators may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we or our collaborators may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our or our collaborators&#8217; interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the data collected from clinical trials of product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with collaborators; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our or our collaborators&#8217; clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS. Regulatory authorities may not approve the price we or our collaborators intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and usually takes many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. We have initiated a Phase 1/2a clinical trial in patients with R/R NHL or R/R B-ALL, and expect to initiate an additional Phase 1/2a clinical trial in subjects with NHL, chronic lymphocytic leukemia and small lymphocytic lymphoma in the first quarter of 2020. We do not know whether any current or planned clinical trials will need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including in connection with: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to generate sufficient preclinical, toxicology or other </font><font style="font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-family:Times New Roman;"> or </font><font style="font-style:italic;font-family:Times New Roman;">in vitro</font><font style="font-family:Times New Roman;"> data to support the initiation of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">applicable regulatory authorities disagreeing as to the design or implementation of the clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining regulatory authorization to commence a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining IRB approval at each site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developing and validating the companion diagnostic to be used in a clinical trial, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">insufficient or inadequate supply or quality of product candidates or other materials, including identification of lymphocyte donors meeting regulatory standards necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recruiting and retaining enough suitable patients to participate in a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">having enough patients complete a trial or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adding a sufficient number of clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical sites deviating from trial protocol or dropping out of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to demonstrate the efficacy and benefits of a product candidate; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">discovering that product candidates have unforeseen safety issues, undesirable side effects or other unexpected characteristics; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">addressing patient safety concerns that arise during the course of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">receiving untimely or unfavorable feedback from applicable regulatory authorities regarding the trial or requests from regulatory authorities to modify the design of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">non-compliance with applicable regulatory requirements by us or third parties or changes in such regulations or administrative actions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspensions or terminations by IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities due to a number of factors, including those described above; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">third parties being unable or unwilling to satisfy their contractual obligations to us; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in our financial priorities, greater than anticipated costs of completing a trial or our inability to continue funding the trial. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Additionally, we or our collaborators may experience unforeseen events during or resulting from clinical trials that could delay or prevent receipt of marketing approval for or commercialization of product candidates. For example, clinical trials of product candidates may produce negative, inconsistent or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs. Regulators may also revise the requirements for approving the product candidates, or such requirements may not be as we anticipate. If we or our collaborators are required to conduct additional clinical trials or other testing of product candidates beyond those that we or our collaborators currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of such product candidates, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">incur unplanned costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be delayed in obtaining or fail to obtain marketing approval for product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain marketing approval in some countries and not in others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to additional post-marketing testing requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to changes in the way the product is administered; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have regulatory authorities withdraw or suspend their approval of the product or impose restrictions on its distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be sued; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">experience damage to our reputation. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators experience delays in the commencement or completion of our clinical trials, or if we or our collaborators terminate a clinical trial prior to completion, we may experience increased costs, have difficulty raising capital and/or be required to slow down the development and approval process timelines. Furthermore, the product candidates that are the subject of such trials may never receive regulatory approval, and their commercial prospects and our ability to generate product revenues from them could be impaired or not realized at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any product candidates that we or our collaborators may develop will be novel and may be complex and difficult to manufacture, and if we experience manufacturing problems, it could result in delays in development and commercialization of such product candidates or otherwise harm our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>Our product candidates involve or will involve novel genome editing technology and will require processing steps that are more complex than those required for most small molecule drugs, resulting in a relatively higher manufacturing cost. Moreover, unlike small molecules, the physical and chemical properties of biologics generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that such product will perform in the intended manner. Although we intend to employ multiple steps to control the manufacturing process, we may experience manufacturing issues with any of our product candidates that could cause production interruptions, including contamination, equipment or reagent failure, improper installation or operation of equipment, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error, disruptions in the operations of our suppliers, inconsistency in cell growth and variability in product characteristics. We may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable standards or specifications with consistent and acceptable production yields and costs. For example, the FDA has required us to conduct testing of our allogeneic CAR T cell product candidates for the presence of certain human viruses prior to release of such products for clinical use. If the FDA concludes that further such viral testing of our product candidates is required and that any lots testing positive may not be used in clinical trials, we may need to produce new clinical trial materials, which could delay our clinical trials and result in higher manufacturing costs. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which such product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Our manufacturing process for any allogeneic CAR T cell product candidate that we develop alone or with collaborators will be susceptible to product loss or failure due to the quality of the raw materials, failure of the products to meet specifications, logistical issues associated with the collection of white blood cells, or starting material, from healthy third-party donors, shipping such material to the manufacturing site, ensuring standardized production batch-to-batch in the context of mass production, freezing the manufactured product, shipping the final product globally and infusing patients with such product. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, delays in initiating or completing clinical trials, product recalls, product liability claims or insufficient inventory. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, we expect that various aspects of the development program, such as manufacturing methods, may be altered along the way in an effort to help optimize processes and results. Such changes carry the risk that they will not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of future clinical trials or our reliance on results of trials that have previously been conducted using the product candidate in its previous form. If the manufacturing process is changed during the course of product development, we or our collaborators may be required to repeat some or all of the previously conducted trials or conduct additional bridging trials, which could increase our costs and delay or impede our ability to obtain marketing approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our manufacturing strategy for one or more of our product candidates may involve the use of contract manufacturing organizations, or CMOs, as well as our newly opened manufacturing facility, the MCAT. The facilities used by us and our contract manufacturers to manufacture therapeutic product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. We do not control the manufacturing process of, and are currently completely dependent on, our contract manufacturing partners for compliance with cGMP, for the manufacture of our product candidates. We may establish multiple manufacturing facilities as we expand our commercial footprint to multiple geographies, which will be costly and time consuming and may lead to regulatory delays. Even if we are successful, our manufacturing capabilities could be affected by cost-overruns, potential problems with scale-out, process reproducibility, stability issues, lot inconsistency, timely availability of reagents or raw materials, unexpected delays, equipment failures, labor shortages, natural disasters, utility failures, regulatory issues and other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any lot of any product that may receive approval together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the relevant agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us or our collaborators to delay product launches or clinical trials, which could be costly to us and otherwise harm our business. Problems in our manufacturing process also could restrict our or our collaborators&#8217; ability to meet market demand for products. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development opportunities. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will rely on donors of T cells to manufacture product candidates from our allogeneic CAR T immunotherapy platform, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells, which vary in type and quality. This variability in type and quality of a donor&#8217;s T cells makes producing standardized product candidates more difficult and makes the development and commercialization pathway of those product candidates more uncertain. We have developed a screening process designed to enhance the quality and consistency of T cells used in the manufacture of our CAR T cell product candidates. If we are unable to identify and obtain T cells from donors that satisfy our criteria in sufficient quantity, to obtain such cells in a timely manner or to address variability in donor T cells, development of our CAR T cell product candidates may be delayed or there may be inconsistencies in the product candidates we produce, which could negatively impact development of such product candidates, harm our reputation and adversely impact our business and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to achieve operating efficiencies from MCAT may require us to devote additional resources and management time to manufacturing operations and may delay our product development timelines. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have leased approximately 33,600 square feet of space for MCAT at a location approximately seven miles from our headquarters in Durham, North Carolina. We intend to begin using this new manufacturing center to create clinical trial material for certain of our planned clinical trials in 2020. We may not experience the anticipated operating efficiencies as we commence manufacturing. Any delays in manufacturing may disrupt or delay the supply of our product candidates if we have not maintained a sufficient back-up supply of such product candidates through third-party manufacturers. Moreover, changing manufacturing facilities may also require that we or our collaborators conduct additional studies, make notifications to regulatory authorities, make additional filings to regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. We will further need to comply with the FDA&#8217;s and applicable foreign regulatory authorities&#8217; cGMP requirements for the production of product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection. These requirements include the qualification and validation of our manufacturing equipment and processes. We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements. Should we fail to comply with cGMP requirements, the opening of our manufacturing facility will be delayed. If we fail to achieve the operating efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating results. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes. If we experience unanticipated employee shortage or turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from the new facility, which may negatively affect our product development timeline or result in difficulties in maintaining compliance with applicable regulatory requirements. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such problems could result in the delay, prevention or impairment of clinical development and commercialization of our product candidates. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or our collaborators may experience delays or difficulties in enrolling patients in clinical trials, which could delay or prevent receipt of regulatory approvals. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our collaborators may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we or our collaborators identify or develop if we or our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. Additionally, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as one or more of our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in our competitors&#8217; clinical trials. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment may also be affected by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">severity and difficulty of diagnosing of the disease under investigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">size of the patient population and process for identifying subjects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">eligibility and exclusion criteria for the trial in question; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our or our collaborators&#8217; ability to recruit clinical trial investigators with the appropriate competencies and experience; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">design of the trial protocol; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or condition under investigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">perceived risks and benefits of the product candidate under trial or testing, or of the application of genome editing to human indications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability of genetic testing for potential patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">efforts to facilitate timely enrollment in clinical trials; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">patient referral practices of physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to obtain and maintain subject consent; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">risk that enrolled subjects will drop out before completion of the trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to monitor patients adequately during and after treatment; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proximity and availability of clinical trial sites for prospective patients. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that some of our product candidates will focus on rare genetically defined diseases with limited patient pools from which to draw for enrollment in clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. In addition to the factors identified above, patient enrollment in any clinical trials we or our collaborators may conduct may be adversely impacted by any negative outcomes our competitors may experience, including adverse side effects, clinical data showing inadequate efficacy or failures to obtain regulatory approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our or our collaborators&#8217; ability to successfully initiate, enroll and conduct a clinical trial outside the United States is subject to numerous additional risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">difficulty in establishing or managing relationships with CROs and physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">differing standards for the conduct of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">differing standards of care for patients with a particular disease; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an inability to locate qualified local consultants, physicians and partners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment delays in clinical trials may result in increased development costs for any of our product candidates, which may cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which may have an adverse effect on our results of operations and prospects. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Results of preclinical studies and early clinical trials of product candidates may not be predictive of results of later studies or trials. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from preclinical studies or early clinical trials of a product candidate may not be predictive of the results from later preclinical studies or clinical trials, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks at later stages of development after achieving positive results in early stages of development, and we may face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported adverse events. Moreover, non-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. With the exception of our allogeneic anti-CD19 CAR T product candidate, which has undergone limited testing in humans to date, our gene editing technology and our product candidates have never undergone testing in humans and have only been tested in a limited manner in animals, and results from animal studies may not be predictive of clinical trial results. Even if product candidates progress to clinical trials, these product candidates may fail to show the safety and efficacy in clinical development required to obtain regulatory approval, despite the observation of positive results in animal studies. Our or our collaborators&#8217; failure to replicate positive results from early research programs and preclinical or greenhouse studies may prevent us from further developing and commercializing those or other product candidates, which would limit our potential to generate revenues from them and harm our business and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the foregoing reasons, we cannot be certain that any ongoing or future preclinical studies or clinical trials will be successful. Any safety or efficacy concerns observed in any one of our preclinical studies or clinical trials in a targeted area could limit the prospects for regulatory approval of product candidates in that and other areas, which could have a material adverse effect on our business and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim&#160;&#8220;top-line&#8221;&#160;and initial data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim&#160;&#8220;top-line&#8221;&#160;or initial data from preclinical or greenhouse studies or clinical or field trials. For example, we recently reported initial results from our ongoing Phase 1/2a clinical trial of PBCAR0191. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.&#160;As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Initial or&#160;&#8220;top-line&#8221;&#160;data also remain subject to audit and verification procedures that may result in the final data being materially different from these initial data we previously published. As a result, interim and initial data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between initial or interim data and final data could significantly harm our business prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of our product candidates do not work as intended or cause undesirable side effects, it could hinder or prevent receipt of regulatory approval or realization of commercial potential for them or our other product candidates and could substantially harm our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may be associated with off-target editing or other serious adverse events, undesirable side effects or unexpected characteristics. Results of clinical trials could reveal severe or recurring side effects, toxicities or unexpected events, including death.&#160;Off-target cuts could lead to disruption of a gene or a genetic regulatory sequence at an unintended site in the DNA. In those instances where we also provide a segment of DNA, it is possible that following off-target cut events, such DNA could be integrated into the genome at an unintended site, potentially disrupting another important gene or genomic element. There may also be delayed adverse events following exposure to therapeutics made with genome editing technologies due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. In addition to serious adverse events or side effects caused by product candidates we develop alone or with collaborators, the administration process or related procedures may also cause undesirable side effects. Any side effects may not be appropriately recognized or managed by the treating medical staff. We or our collaborators expect to have to educate medical personnel using any product candidates we may develop to understand the side effect profiles for our clinical trials and upon any commercialization of such product candidates. Inadequate recognition or management of the potential side effects of such product candidates could result in patient injury or death. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any such events occur, clinical trials or commercial distribution of any product candidates or products we develop alone or with collaborators could be suspended or terminated, and our business and reputation could suffer substantial harm. Treatment-related side effects could affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us or our collaborators to cease further development of, deny approval of or require us to cease selling any product candidates or products for any or all targeted indications. If we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if we successfully develop a product candidate alone or with collaborators and it receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators. Such identification could also have several additional significant negative consequences, such as: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be required to change the way a product is administered or conduct additional trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the product may become less competitive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we or our collaborators may decide to remove the product from the marketplace; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we could be sued and be held liable for harm caused to patients; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us or our collaborators from achieving or maintaining market acceptance of any potential product. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to federal, state and non-U.S. healthcare and data privacy and security laws and regulations relating to our business, and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations, as well as our current and anticipated future arrangements with investigators, healthcare professionals, consultants, third-party payors, customers and patients, expose or will expose us to broadly applicable foreign, federal, and state fraud and abuse and other healthcare and privacy laws and regulations. These laws constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any potential products for which we may obtain marketing approval. Such laws include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a U.S. healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the U.S. federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, among other things, individuals and entities from knowingly presenting, or causing to be presented, to the U.S. government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors)</font><font style="font-family:Times New Roman;">, certain other health care professionals beginning in 2022, and </font><font style="font-family:Times New Roman;">teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the Centers for Medicare and Medicaid Services, or CMS, ownership and investment interests held by the physicians described above and their immediate family members; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">analogous state and non-U.S. laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws which require the registration of pharmaceutical sales representatives.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities may conclude that our business practices, including our relationships with certain physicians, some of whom are compensated in the form of stock options for consulting services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards can be high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information on covered entities (defined as health plans, health care clearinghouses and certain health care providers) and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, California enacted the California Consumer Privacy Act (CCPA) on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. In the event that we are subject to or affected by HIPAA, the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, the European Union General Data Protection Regulation (GDPR) went into effect in May 2018 and introduces strict requirements for processing the personal data of EU data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements. We are also subject to evolving EU laws on data export, as we may transfer personal data from the EU to other jurisdictions. Following Brexit, we will have to comply with the GDPR and the UK GDPR, each regime having the ability to fine up to the greater of &#8364;20 million/ &#163;17 million or 4% of global turnover. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, e.g. how data transfers between EU member states. These changes will lead to additional costs and increase our overall risk.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_cp_text_2_32"></a>We have received orphan drug designation for PBCAR0191 for the treatment of ALL<a name="_cp_text_2_32"></a>, PBCAR20A for the treatment of mantle cell lymphoma, or MCL, and PBCAR269A for the treatment of multiple myeloma, and we may seek orphan drug designation for some or all of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, which may negatively impact our ability to develop or obtain regulatory approval for such product candidates and may reduce our revenue if we obtain such approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a biologics license application, or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. We have received orphan drug designation in the United States for PBCAR0191 for the treatment of ALL. Although we may seek orphan product designation for some or all of our other product candidates, we may never receive such designations. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a>If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Even if we or our collaborators obtain orphan drug designation for a product candidate, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Exclusive marketing rights in the United </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States may be limited if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if a product obtains orphan drug exclusivity, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Furthermore, the FDA can waive orphan exclusivity if we or our collaborators are unable to manufacture sufficient supply of the product. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, in Europe, a medicinal product may receive orphan designation under Article 3 of Regulation (EC) 141/2000. This applies to products that are intended for a life-threatening or chronically debilitating condition and either (1)&#160;such condition affects no more than five in 10,000 persons in the EU when the application is made, or (2)&#160;the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment. Moreover, in order to obtain orphan designation in the EU it is necessary to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product will be of significant benefit to those affected by the condition. In the EU, orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and applicants can benefit from specific regulatory assistance and scientific advice. Products receiving orphan designation in the EU can receive 10 years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. However, the 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation&#8212;for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the first applicant consents to a second orphan medicinal product application; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the first applicant cannot supply enough orphan medicinal product. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators do not receive or maintain orphan drug designation for product candidates for which we seek such designation, it could limit our ability to realize revenues from such product candidates. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek fast track designation, breakthrough therapy designation, Regenerative Medicine Advanced Therapy, or RMAT, designation, or priority review from the FDA or access to the PRIME scheme from the EMA for some or all of our product candidates, but we may not receive such designations, and even if we do, it may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that such product candidates will receive marketing approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek fast track designation, breakthrough therapy designation, Regenerative Medicine Advanced Therapy, or RMAT, designation or priority review from the FDA, or access to the PRIME scheme from the EMA for some or all of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition or disease, and nonclinical or clinical data demonstrate the potential to address an unmet medical need, the product may qualify for FDA fast track designation, for which sponsors must apply. The FDA has broad discretion whether or not to grant this designation.&nbsp;&nbsp;If granted, fast track designation makes a drug eligible for more frequent interactions with FDA to discuss the development plan and clinical trial design, as well as rolling review of the application, which means that the company can submit completed sections of its marketing application for review prior to completion of the entire submission.&nbsp;&nbsp;Products with fast track designation may also be eligible for accelerated approval and priority review, if the relevant criteria are met.&nbsp;&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breakthrough therapy designation is intended to expedite the development and review of product candidates that treat serious or life-threatening diseases when "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." The designation of a product candidate as a breakthrough therapy provides the same potential benefits as a fast track designation, with more intensive FDA guidance on an efficient development program and an organizational commitment at FDA involving senior managers. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a>A company may also request RMAT designation of its product candidate, which designation may be granted if the drug meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product&nbsp;&nbsp;using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designation provides potential benefits that include more frequent meetings with FDA&nbsp;&nbsp;to discuss the development plan for the product candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. RMAT- designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRIME is a scheme provided by the EMA to enhance support for the development of medicines that target an unmet medical need. To qualify for PRIME, product candidates require early clinical evidence that the therapy has the potential to offer a therapeutic advantage over existing treatments or benefits patients without treatment options. Among the benefits of PRIME are the appointment of a rapporteur to provide continuous support and help build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that we will obtain fast track designation, breakthrough therapy designation, RMAT designation or access to PRIME for any of our product candidates. Fast track designation, breakthrough therapy designation, RMAT designation and PRIME eligibility do not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the fast track designation, breakthrough therapy designation, RMAT designation or PRIME eligibility. Additionally, fast track designation, breakthrough therapy designation, RMAT designation and access to PRIME can each be revoked if the criteria for eligibility cease to be met as clinical data emerges.</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the product candidates that we or our collaborators may develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for such product candidate and adversely affect our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or our collaborators&#8217; ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the EU and many other jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or our collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely affect the prices for such product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United&#160;States and certain non-U.S. jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our or our collaborators&#8217; ability to profitably sell any product candidates that obtain marketing approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States. Among the provisions of the Affordable Care Act of importance to our product candidates, the Affordable Care Act established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, expanded eligibility criteria for Medicaid programs, expanded the entities eligible for discounts under the Public Health program, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, and created a licensure framework for follow-on biologic products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the entire Affordable Care Act is invalid based primarily on the fact that the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TCJA</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enacted on December 22, 2017, repealed the tax-based shared responsibility payment imposed by the Affordable Care Act, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate&#8221;.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Affordable Care Act </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are invalid as well.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t is unclear how </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> decision</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, subsequent appeals,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if any,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other efforts to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenge, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">repeal </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> replace the Affordable Care Act will impact the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law or our business</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2029 unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies, rebates and price negotiation for pharmaceutical products, some of which are included in the Trump administration&#8217;s budget proposals for fiscal years 2019 and 2020, as well as recent bills introduced by the U.S. Senate and House of Representatives, respectively. Additionally, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has begun soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. Although a number of these, and other potential measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product and medical device pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and medical devices to purchase and which suppliers will be included in their prescription drug and other healthcare programs. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a framework for certain patients with life-threatening diseases or conditions to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we or our collaborators may receive for any approved or cleared product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, any of our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if products we develop alone or with collaborators receive regulatory approval, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, distribution, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information, among other things. Any regulatory approvals received for such products may also be subject to limitations on the approved indicated uses for which they may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance studies. For example, the holder of an approved BLA in the United States is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with some types of gene therapy undergo follow-up observations for potential adverse events for as long as 15 years. Similarly, in the EU, pharmacovigilance obligations are applicable to all medicinal products. In addition to those, holders of a marketing authorization for gene or cell therapy products must detail, in their application, the measures they envisage to ensure follow-up of the efficacy and safety of these products. In cases of particular concern, marketing authorization holders for gene or cell therapy products in the EU may be required to design a risk management system with a view to identifying, preventing or minimizing risks and may be obliged to carry out post-marketing studies. In the United States, the holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Similar provisions apply in the EU. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Similarly, in the EU any promotion of medicinal products is highly regulated and, depending on the specific jurisdiction involved, may require prior vetting by the competent national regulatory authority. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, our collaborators or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a regulatory agency may impose restrictions relative to that product, the manufacturing facility or us or our collaborators, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, if any of our product candidates are approved, our product labeling, advertising, promotion and distribution will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators fail to comply with applicable regulatory requirements following approval of any potential products we may develop, authorities may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issue an untitled enforcement letter or a warning letter asserting a violation of the law; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek an injunction, impose civil and criminal penalties, and impose monetary fines, restitution or disgorgement of profits or revenues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend or withdraw regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend or terminate any ongoing clinical trials or implement requirements to conduct post-marketing studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrict the labeling, marketing, distribution, use or manufacturing of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seize or detain products or otherwise require the withdrawal or recall of products from the market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to approve pending applications or supplements to approved applications that we or our collaborators submit; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to permit the import or export of products; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to allow us or our collaborators to enter into government contracts. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our or our collaborators&#8217; ability to commercialize products and our ability to generate revenues. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA&#8217;s policies, and policies of foreign regulatory agencies, may change, and additional regulations may be enacted that could prevent, limit or delay regulatory approval of product candidates. For example, in December 2016, the 21st Century Cures Act, or the Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of biologics and spur innovation, but its ultimate implementation is unclear. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements, or if we or our collaborators are unable to maintain regulatory compliance, marketing approval that has been obtained may be lost and we may not achieve or sustain profitability. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if any product we develop alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial success of any potential therapeutic products we develop alone or with collaborators will depend upon their degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any potential therapeutic products we develop alone or with collaborators receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any product we develop alone or with collaborators, if approved for commercial sale, will depend on a number of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the efficacy and safety of such product as demonstrated in clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical indications for which the product is approved by FDA, the EMA or other regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">public attitudes regarding genome editing technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our and any collaborators&#8217; ability to educate the medical community about the safety and effectiveness of the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies, as well as their willingness to accept a therapeutic intervention that involves the editing of the patient&#8217;s genome; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential and perceived advantages compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any restrictions on the use of such product together with other treatments or products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market introduction of competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">publicity concerning such product or competing products and treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to offer such product for sale at a competitive price; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sufficient third-party coverage and adequate reimbursement. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any products we develop alone or with collaborators do not achieve an adequate level of acceptance, we may not generate significant product revenues, and we may not become profitable. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any products we develop alone or with collaborators, the commercialization of such products may not be successful if and when they are approved. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical or other commercial products. To achieve commercial success for any approved products for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, certain product candidates if and when they are approved. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, restricted or closed distribution channels may make it difficult to distribute products to segments of the patient population, and the lack of complementary medicines to be offered by sales personnel may put us at a competitive disadvantage relative to companies with more extensive product lines. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and training a sales force or reimbursement specialists are expensive and time consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, and our investment would be lost if we cannot retain or reposition our commercialization personnel. Factors that may inhibit our efforts to commercialize products on our own include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unforeseen costs and expenses associated with creating an independent commercialization organization; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to recruit, train, retain and effectively manage adequate numbers of effective sales, marketing, customer service and other support personnel, including for reimbursement or medical affairs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability of sales personnel to educate adequate numbers of physicians on the benefits of our future medicines; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we choose to enter into arrangements with third parties to perform sales, marketing, commercial support or distribution services, we may not be successful in entering into such arrangements or may be unable to do so on terms that are favorable to us. Entering into such third-party arrangements may subject us to a variety of risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product revenues or profitability to us being lower than if we were to market and sell any products we or our collaborators may develop ourselves; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to exercise direct control over sales and marketing activities and personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure of the third parties to devote necessary resources and attention to, or other inability to, sell and market any products we or our collaborators may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential disputes with third parties concerning sales and marketing expenses, calculation of royalties and sales and marketing strategies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unforeseen costs and expenses associated with sales and marketing. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not establish effective commercialization capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our product candidates that may receive approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the market opportunities for any products we develop alone or with collaborators are smaller than our estimates, or if we are unable to successfully identify enough patients, our revenues may be adversely affected.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus some of our research and product development on treatments for rare genetic diseases. Our and our collaborators&#8217; projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with product candidates we may develop, are based on estimates. These estimates may prove to be incorrect, and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with products that we may develop alone or with collaborators, or may become increasingly difficult to identify or gain access to, any of which would decrease our ability to realize revenue from any such products for such diseases. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The successful commercialization of potential products will depend in part on the extent to which governmental authorities and health insurers establish coverage, and the adequacy of reimbursement levels and pricing policies, and failure to obtain or maintain coverage and adequate reimbursement for any potential products that may receive approval, could limit marketability of those products and decrease our ability to generate revenue. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability of coverage and adequacy of reimbursement by government healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors is essential for most patients to be able to afford prescription medications such as the potential therapeutic products we develop alone or with collaborators. The ability to achieve acceptable levels of coverage and reimbursement for any potential products that may be approved by governmental authorities will have an effect on our and our collaborators&#8217; ability to successfully commercialize such products. Even if products we develop alone or with collaborators obtain coverage by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. If coverage and reimbursement in the United States, the EU or elsewhere is not available for any products we develop alone or with collaborators that may be approved, or any reimbursement that may become available is decreased or eliminated in the future, we and our collaborators may be unable to commercialize such products. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved drugs and biologics. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. In August 2019, the CMS published its decision to cover autologous treatment for cancer with T-cells expressing at least one CAR when administered at healthcare facilities enrolled in the FDA risk evaluation and mitigation strategies and used for an FDA-approved indication or for other uses when the product has been FDA-approved and the use is supported in one or more CMS-approved compendia. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for any product that we develop alone or with collaborators. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us or our collaborators to provide scientific and clinical support for the use of any potential products that may be approved to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice. Obtaining coverage and adequate reimbursement for products we develop alone or with collaborators may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. In certain instances, payors may not separately reimbursement for the product itself, but only for the treatments or procedures in which such product is used. A decision by a third-party payor not to cover or separately reimburse for products that we develop alone or with collaborators or procedures using such products, could reduce physician utilization of any such products that may receive approval. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a>Third-party payors are increasingly challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. If approved, it is possible that a third-party payor may consider any products that we develop alone or with collaborators as substitutable and only offer to reimburse patients for the less expensive product. Pricing of existing third-party therapeutics may limit the amount we will be able to charge for any products that may receive approval even if we or our collaborators show improved efficacy or improved convenience of administration such products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in the product. If reimbursement is not available or is available only at limited levels, we or our collaborators may not be able to successfully commercialize any of the products that we develop, even if approved, and we may not be able to obtain a satisfactory financial return on them. Moreover, increasing efforts by governmental and&#160;third-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party&#160;payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any products we develop alone or with collaborators that may receive approval. We expect to experience pricing pressures in connection with the sale of any products that may receive approval due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on&#160;cost-containment&#160;initiatives in Europe and elsewhere have and will continue to put pressure on the pricing and usage of any products we develop alone or with collaborators that may receive approval. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional international price controls or other changes in pricing regulation could restrict the amount that we or our collaborators are able to charge for products that we develop that may receive approval. Accordingly, in markets outside the United States, the reimbursement for such products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are successful in achieving regulatory approval to commercialize any biologic product candidate we develop alone or with collaborators, it may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products subject to approval under the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or the BPCIA, created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products following the approval of an original BLA. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product may not be submitted until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years after the reference product was first licensed by the FDA. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for biological product candidates. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our product candidates that are approved as biological products under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider such product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our or our collaborators&#8217; reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing any products that we develop alone or with collaborators that may be approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Additional Risks Related to the Identification, Development and Commercialization of Our Food and Agricultural Product Candidates</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory landscape that may govern any potential food or agricultural products that we or our collaborators may develop is uncertain and may adversely impact the development and commercialization activities of our food platform. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a>In the United States, the United States Department of Agriculture, or the USDA, regulates, among other things, the introduction (including the importation, interstate movement or release into the environment) of organisms and products altered or produced through genetic engineering determined to be plant pests or for which there is reason to believe are plant pests. Such organisms and products are considered &#8220;regulated articles.&#8221; However, a petitioner may submit a request for a determination by the USDA of &#8220;nonregulated status&#8221; for a particular article. A petition for determination of nonregulated status must include detailed information, including relevant experimental data and publications, field trial reports and a description of the genotypic differences between the regulated article and the nonmodified recipient organism, among other things. Neither we nor, to our knowledge, our collaborators </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have obtained a determination from the USDA that any product candidates are not &#8220;regulated articles&#8221; under these regulations. We cannot predict whether the USDA, advocacy groups or other third parties will contend that these products are regulated articles. The USDA&#8217;s regulations also require that companies obtain a permit or file a notification before engaging in the introduction (including the importation, interstate movement or release into the environment such as in field trials) of &#8220;regulated articles.&#8221; Additionally, a change in the way the USDA interprets its regulations, or a change in its regulations, could subject our or our collaborators&#8217; products to more burdensome regulations, thereby substantially increasing the time and costs associated with developing product candidates. Complying with the USDA&#8217;s Part 340 regulations, including permitting requirements, is a costly, time-consuming process and could delay or prevent the commercialization of any potential food or agricultural products we or our collaborators may develop. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any potential food or agricultural products that we or our collaborators develop may also be subject to extensive FDA food product regulations. Under sections 201(s) and 409 of the Federal Food, Drug, and Cosmetic Act, or the FDCA, any substance that becomes or is reasonably expected to become a component of food is a food additive and is therefore subject to FDA premarket review and approval, unless the substance is generally recognized, among qualified experts, as having been adequately shown to be safe under the conditions of its intended use (generally recognized as safe, or GRAS), or unless the use of the substance is otherwise excluded from the definition of a food additive, and any food that contains an unsafe food additive is considered adulterated under section 402(a)(2)(C) of the FDCA. The FDA may classify some or all of the potential food or agricultural products that we or our collaborators may develop as containing a food additive that is not GRAS or otherwise determine that such products contain significant compositional differences from existing plant products that require further review. Such classification would cause these potential products to require pre-market approval, which could delay the commercialization of these products. In addition, the FDA is currently evaluating its approach to the regulation of gene-edited plants. For example, on January&#160;19, 2017, the FDA issued a notice in the Federal Register requesting public comment on the use of genome editing techniques to produce new plant varieties that are used for human or animal food or foods that are derived from such new plant varieties produced using genome editing. Among other things, the notice asked for data and information in response to questions about the safety of foods from gene-edited plants, such as whether categories of gene-edited plants present food safety risks different from other plants produced through traditional plant breeding. If the FDA enacts new regulations or policies with respect to gene-edited plants, such policies could result in additional compliance costs and delay or even prevent the commercialization of any of our product candidates, which could negatively affect our profitability. Any delay in the regulatory consultation process, or a determination that any potential products we or our collaborators may develop do not meet regulatory requirements by the FDA or other regulators, could cause a delay in, or prevent, the commercialization of our products, which may lead to reduced acceptance by the public and an increase in competitor products that may directly compete with ours, or could otherwise negatively impact our business, prospects and results of operations. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 4, 2018, the USDA issued a proposed rule implementing the National Bioengineered Food Disclosure Standard, with a proposed compliance date of January 1, 2020. Under this proposed rule, the label of a bioengineered, or BE, food must include a disclosure that the food is a BE food or contains a BE ingredient, with certain exceptions. This proposed rule defines BE food as &#8220;a food that contains genetic material that was has been modified through in vitro recombinant deoxyribonucleic acid, or DNA, techniques and for which the modification could not otherwise be obtained through conventional breeding or found in nature,&#8221; except in the case of an incidental additive present in food at an insignificant level and that does not have any technical or functional effect in the food. If this proposed rule is passed and products developed by our collaborators based on our ARCUS technology are required to be labeled &#8220;BE,&#8221; consumer perception of these products may be adversely affected. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, genetically modified foods, or GM foods, can only be authorized for sale on the market once they have been subject to rigorous safety assessments. The procedures for evaluation and authorization of GM foods are governed by Regulation (EC) 1829/2003 on GM food and feed and Directive 2001/18/EC on the release of genetically modified organisms, or GMOs, into the environment. If the GMO is not to be used in food or feed, then an application must be made under Directive 2001/18/EC. If the GMO is to be used in food or feed (but it is not grown in the EU) then a single application for both food and feed purposes under Regulation 1829/2003 should be made. If the GMO is used in feed or food and it is also grown in the EU, an application for both cultivation and food/feed purposes needs to be carried out under Regulation (EC) 1829/2003. A different EU regulation, Regulation (EC) 1830/2003, regulates the labeling of products that contain GMOs that are placed on the EU market. Directive 2001/18/EC was amended by Directive (EU) 2015/412 which gives EU Member States more flexibility to allow, restrict or prohibit growing GMOs in their territory, on a range of environmental grounds, even if such crops were previously authorized at EU level. Under Directive 2015/412, EU Member State restrictions or prohibitions can only cover cultivation, and not the free circulation and import of genetically modified seeds and plant propagation material, and should be in conformity with the internal market rules of the EU Treaties. In March 2018, the Commission adopted Commission Directive (EU) 2018/350 amending Directive 2001/18/EC as regards the environmental risk assessment of GMOs. This measure aims to bring the assessment of the environmental risk of GM foods in the EU up to date with developments in scientific knowledge and technical progress. Member States have to transpose the Directive by September&#160;29, 2019. Further EU level legislation on GM foods includes Directive 2009/41/EC on contained use of genetically modified micro-organisms and Regulation (EC) 1946/2003 on transboundary movements of GMOs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict whether or when any governmental authority will change its regulations with respect to any potential food or agricultural products that we develop alone or with collaborators. Advocacy groups have engaged in publicity campaigns and filed lawsuits in various countries against companies and regulatory authorities seeking to halt biotechnology approval activities or influence public opinion against genetically engineered products. In addition, governmental reaction to negative publicity concerning genetically edited agricultural products could result in greater regulation of genetic research and derivative products or regulatory costs that render our or our collaborators&#8217; development of potential food or agricultural products cost prohibitive. Our collaborators may use or integrate our products or technology into other products in ways that could subject those collaborators or products to additional regulation. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The overall agricultural industry is susceptible to agricultural price changes, and we may be exposed to risks from changes in commodity prices. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the prices of agricultural products could result in changes in demand for and prices of food and agricultural products that we or our collaborators may develop. We may be susceptible to these changes as a result of factors beyond our control, such as general economic conditions, seasonal fluctuations, weather conditions, demand, food safety concerns, product recalls and government regulations, subsidies or market export tariffs. If demand for agricultural products that we or our collaborators may develop is negatively impacted, our potential revenues under collaboration agreements for such products may decline, which could adversely affect our results of operations. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The successful commercialization of any food or agricultural products we develop will depend in part on our collaborators&#8217; ability to produce high-quality plants and seeds cost-effectively on a large scale and to accurately forecast demand for such potential products, and they may be unable to do so. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The production of commercial-scale quantities of food or agricultural products or seeds for them requires the multiplication of the plants or seeds through a succession of plantings and seed harvests. The cost-effective production of high-quality, high-volume quantities of such products or seeds may depend in part on our collaborators&#8217; abilities to scale production processes to produce plants and seeds in sufficient quantity to meet demand. Our collaborators&#8217; existing or future plant and seed production techniques may not enable timely meeting of large-scale production goals cost-effectively for any potential food or agricultural products that we and our collaborators may develop. Although we have worked with some of the largest plant biotechnology companies to edit gene targets and develop potential product candidates in a variety of crop plants, no commercial food or agricultural products have ever been developed using our technology. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because of the length of time it takes to produce commercial quantities of marketable plants and seeds, our collaborators will need to make seed production decisions well in advance of food product sales. The ability to accurately forecast demand can be adversely affected by a number of factors outside of their control, including changes in market conditions, environmental factors, such as pests and diseases, and adverse weather conditions. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The commercial success of any consumer-centric food or agricultural products that we or our collaborators may develop is reliant on the needs of food manufacturers and the recognition of shifting consumer preferences. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial success of any consumer-centric products depends in part on the ability of the food manufacturer to accurately determine the shifting needs and desires of the ultimate consumer. We will not control the marketing, distribution labeling or any other aspects of the sale and commercialization of the manufacturers&#8217; food products. Consumer preferences may be a significant driver in the success of food manufacturers in their efforts to sell food and agricultural products, including products that we or our collaborators may develop. While current trends indicate that consumer preferences may be moving towards &#8220;healthier&#8221; options, we cannot predict whether such trends will continue or which types of food products will be demanded by consumers in the future. Additionally, as health and nutritional science continues to progress, consumer perception of what foods, nutrients and ingredients are considered &#8220;healthy&#8221; may shift. We and our collaborators may not be dynamic enough in responding to consumer trends and creating products that will be demanded by consumers in the future. In addition, if consumer demand is lower than our estimates or those of our collaborators, our ability to realize revenues from potential food or agricultural products may be limited. Failure by our collaborators to successfully recognize consumer trends could lower demand for potential food or agricultural products that we or our collaborators may develop, which could harm our business, results of operations and financial condition. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Some of the potential food products we develop alone or with collaborators may be distributed into markets or countries in which they have not received regulatory approval, which may result regulatory challenges or lawsuits. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scale of the agricultural industry may make it difficult to monitor and control the distribution of any potential food products that we develop alone or with collaborators. As a result, such products may be sold inadvertently within jurisdictions where they are not approved for distribution. Such sales may lead to regulatory challenges or lawsuits against us, which could result in significant expenses and divert our management&#8217;s attention, which could harm our business, results of operations and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have entered into significant arrangements with collaborators and expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any such collaborations are not successful, it may harm our business and prospects. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have sought in the past, and anticipate that we will continue to seek in the future, third-party collaborators for the research, development and commercialization of certain product candidates and the research and development of certain technologies. For example, we are party to the Servier Agreement, pursuant to which we are focused on research and development of allogeneic CAR T cell therapies for up to six oncology targets that utilize or incorporate our genome editing technologies, and we are also party to a collaboration with Gilead focused on research and development of therapeutic product candidates for the treatment of Hepatitis B using ARCUS nucleases. In addition, our food platform is based on a consumer-centric model, whereby our research and development activities and potential revenues are based on the needs and commercial success of our collaborators. For example, we are a party to a commercial license agreement with Cargill focused on targeting and modifying certain genes related to saturated oil production in canola plants. Our likely collaborators for other product research and development arrangements include large and mid-size pharmaceutical and biotechnology companies biotechnology and food, beverage, nutrition and agricultural biotechnology companies, and our likely collaborators for other technology research and development arrangements include universities and other research institutions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working with collaborators poses several significant risks. We have limited control over the amount and timing of resources that our collaborators dedicate to the product candidates or technologies we may seek to develop with them. A variety of factors may impact resource allocation decisions of collaborators, such as study or trial results, changes in the collaborator&#8217;s strategic focus, turnover in personnel responsible for the development activities, financial capacity or external factors such as a business combination or change in control that diverts resources or creates competing priorities. Collaboration agreements may not lead to development or commercialization of product candidates or the development of technologies in the most efficient manner or at all. Resource allocation and other developmental decisions made by our collaborators may result in the delay or termination of research programs, studies or trials, repetition of or initiation of new studies or trials or provision of insufficient funding or resources for the completion of studies or trials or the successful marketing and distribution of any product candidates that may receive approval. Collaborators could independently develop, or develop with third parties, product candidates or technologies that compete directly or indirectly with our product candidates or technologies if the collaborators believe that competitive products or technologies are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. Disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization activities or that result in costly litigation or arbitration that diverts management attention and resources. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. If our collaborations do not result in the successful development and commercialization of product candidates or technologies, or if one of our collaborators terminates its agreement with us, we may not receive any future funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates or technologies could be delayed, and we may need additional resources to develop such product candidates or technologies. In addition, if one of our collaborators terminates its agreement with us, we may be unable to find a suitable replacement collaborator or any replacement collaborator or attract new collaborators and may need to raise additional capital to pursue further development or commercialization of the applicable product candidates or technologies. These events could delay development programs, negatively impact the perception of our company in business and financial communities or cause us to have to cease development of the product candidate covered by the collaboration arrangement. Failure to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which we operate. Moreover, all of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K apply to the activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish in the future are not effective and successful, it may damage our reputation and business prospects, delay or prevent the development and commercialization of product candidates and inhibit or preclude our ability to realize any revenues. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and product development programs and the potential commercialization of any product candidates we develop alone or with collaborators will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current or future collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential collaborators. For example, we have granted exclusive rights or options to Servier and Gilead for certain targets, and during the terms of our respective collaboration agreements with them we will be restricted from granting rights to other parties to use our ARCUS technology to pursue potential products that address those targets. Similarly, our collaboration agreements have in the past and may in the future contain non-competition provisions that could limit our ability to enter into strategic collaborations with future collaborators. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may rely on medical institutions, universities, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct preclinical studies and future clinical trials for our product candidates. Nevertheless, we will be responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we intend to design the trials for our product candidates either alone or with collaborators, third parties may conduct all of the trials. As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Outside parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors. We also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For any violations of laws and regulations during the conduct of our preclinical studies and future clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results of such completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization and require significantly greater expenditures. As a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to rely on third parties to supply raw materials or manufacture product supplies that are necessary for the conduct of preclinical studies, clinical trials and manufacturing of our product candidates, and failure by third parties to provide us with sufficient quantities of products, or to do so at acceptable quality levels or prices and on a timely basis, could harm our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on third parties for the supply of various biological materials, such as cells, cytokines and antibodies, and the manufacture of product supplies, such as media, plasmids, mRNA and AAV viral vectors, that are necessary to produce our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all. If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially reasonable terms or at acceptable quality levels, if at all. If we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur additional costs in procuring such materials. In addition, manufactured product supplies are subject to stringent manufacturing processes and rigorous testing. Delays in the completion and validation of facilities and manufacturing processes of these materials could adversely affect the ability to complete studies or trials and commercialize any product candidates that may receive approval. Furthermore, if our suppliers or manufacturers encounter challenges relating to employee turnover, the supply and manufacturing of our materials could be delayed or adversely affected as such parties seek to hire and train new employees. These factors could cause the delay of studies or trials, regulatory submissions, required approvals or commercialization of product candidates that we or our collaborators may develop, cause us to incur higher costs and prevent us from commercializing products successfully. Furthermore, if our suppliers or manufacturers fail to meet contractual requirements, and we are unable to secure one or more replacements capable of production at a substantially equivalent cost, our or our collaborators&#8217; studies or trials may be delayed and we could lose potential revenue. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may rely on third parties for at least a portion of the manufacturing process of product candidates, and failure by those parties to adequately perform their obligations could harm our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect to use our MCAT facility for certain of our clinical-scale manufacturing and processing needs, we may continue to rely on outside vendors for at least a portion of the manufacturing process of product candidates that we or our collaborators may develop. The facilities used by our contract manufacturers to manufacture product candidates must be approved by the FDA or other foreign regulatory agencies pursuant to inspections that will be conducted after we submit an application to the FDA or other foreign regulatory agencies. To the extent that we or our collaborators engage third parties for manufacturing services, we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing providers for compliance with cGMP requirements for manufacture of the product candidates. We have not yet caused any product candidates to be manufactured or processed on a commercial scale and may not be able to do so. We will make changes as we work to optimize the manufacturing process, and we cannot be sure that even minor changes in the process will result in products that are safe and effective. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market any of our or our collaborators&#8217; potential products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to compete may decline if we do not adequately protect our proprietary rights, and if our proprietary rights do not provide a competitive advantage. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon obtaining and maintaining proprietary rights to our intellectual property estate, including rights relating to ARCUS and to our product candidates, as well as successfully defending these rights against third-party challenges and successfully enforcing these rights to prevent third-party infringement. We will only be able to protect ARCUS and product candidates from unauthorized use by third parties to the extent that valid and enforceable patents cover them. Our ability to obtain and maintain patent protection for ARCUS and our product candidates is uncertain due to a number of factors, including that: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not have been the first to invent the technology covered by our pending patent applications or issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not be the first to file patent applications covering product candidates, including their compositions or methods of use, as patent applications in the United States and most other countries are confidential for a period of time after filing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our compositions and methods may not be patentable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any or all of our pending patent applications may not result in issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">others may independently develop identical, similar or alternative technologies, products or compositions or methods of use thereof; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">others may design around our patent claims to produce competitive technologies or products that fall outside of the scope of our patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages or may be successfully challenged by third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">others may identify prior art or other bases upon which to challenge and ultimately invalidate our patents or otherwise render them unenforceable; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the growing scientific and patent literature relating to engineered endonucleases, including our own patents and publications, may make it increasingly difficult or impossible to patent new engineered nucleases in the future. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we have or obtain patents covering ARCUS or any product candidates or compositions, we and our collaborators may still be barred from making, using and selling such product candidates or technologies because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop any product candidates or to successfully commercialize any approved products alone or with collaborators. In addition, because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that we or our collaborators may infringe. These patent applications may have priority over patent applications filed by us. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a>The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. For example, in August 2019, the Patent Trial and Appeal Board, or the PTAB, of the United States Patent and Trademark Office, or the USPTO, initiated two patent interferences, administrative proceedings within the USPTO, involving a family of patents that have been issued to us and a pending patent application filed by a third party. An interference is conducted by the PTAB when opposing parties have applied for patent claims to the same invention or substantially the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same invention. The interference is conducted to determine which party, if either, is entitled to claims to the subject matter of the interference. An adverse outcome in such proceedings could affect our competitive position, including, without limitation, loss of some or all of our involved patent claims, limiting our ability to stop others from using or commercializing similar or identical technology and products, which could harm our business, financial condition and results of operations. Protecting our patent rights in connection with such proceeding may also be expensive and may involve the diversion of significant management time.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we cannot guarantee that any patents will be issued from any pending or future owned or licensed patent applications. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. In addition, third parties may be able to develop products that are similar to, or better than, ours in a way that is not covered by the claims of our patents, or may have blocking patents that could prevent us from marketing our products or practicing our own patented technology. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Without patent protection for current or future product candidates, we may be open to competition from generic versions of such potential products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to those we or our collaborators may develop. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining a patent portfolio entails significant expense, including periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and patent applications. These expenditures can be at numerous stages of prosecuting patent applications and over the lifetime of maintaining and enforcing issued patents. We may or may not choose to pursue or maintain protection for particular intellectual property in our portfolio. If we choose to forgo patent protection or to allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. There are situations, however, in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal action that may be required to enforce our patent rights can be expensive and may involve the diversion of significant management time. There can be no assurance that we will have sufficient financial or other resources to file and pursue infringement claims, which typically last for years before they are concluded. In addition, these legal actions could be unsuccessful and result in the invalidation of our patents, a finding that they are unenforceable or a requirement that we enter into a licensing agreement with or pay monies to a third party for use of technology covered by our patents. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or have used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to successfully protect or enforce our intellectual property rights, our competitive position could suffer, which could harm our results of operations. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many biotechnology companies and academic institutions are currently pursuing a variety of different nuclease systems for genome engineering, such a TAL endonucleases, zinc-finger nucleases, and CRISPR/Cas9 nucleases, and the use of those nucleases in cancer immunotherapy, gene therapy and genome editing. Although those nucleases are physically and chemically different from our ARCUS nucleases, those companies and institutions may seek patents that broadly cover aspects of cancer immunotherapy, gene therapy and genome editing using nucleases generally. Such patents, if issued, valid and enforceable, could prevent us from marketing our product candidates, if approved, practicing our own patented technology, or might require us to take a license which might not be available on commercially reasonable terms or at all. While we expect that we will continue to be able to patent our ARCUS nucleases for the foreseeable future, as the scientific and patent literature relating to engineered endonucleases increases, including our own patents and publications, it may become more difficult or impossible to patent new engineered endonucleases in the future. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. We may need to outsource and rely on&#160;third parties&#160;for many aspects of the development, sales and marketing of any products covered under our&#160;current and future license&#160;agreements. Delay or failure by these&#160;third parties&#160;could adversely affect the continuation of our&#160;license&#160;agreements with our licensors. If we fail to comply with any of our obligations under these agreements, or we are subject to a bankruptcy, our licensors may have the right to terminate the license, in which event we would not be able to market any products covered by the license. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disputes may arise regarding the payment of the royalties due to licensors in connection with our exploitation of the rights we license from them. Licensors may contest the basis of royalties we retained and claim that we are obligated to make payments under a broader basis. In addition to the costs of any litigation we may face as a result, any legal action against us could increase our payment obligations under the respective agreement and require us to pay interest and potentially damages to such licensors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, patent prosecution of our licensed technology is controlled solely by the licensor. If such licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we license from such licensor, we could lose our rights to such intellectual property or the exclusivity of such rights, and our competitors could market competing products using such intellectual property. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we or our collaborators may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. In other cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, our license agreement with Duke University, or Duke, which we refer to as the Duke License, imposes various payment, royalty and other obligations on us in order to maintain the license.<font style="font-weight:bold;font-style:italic;"> </font>If we fail to make royalty payments or milestone payments required under the Duke License, Duke may terminate the agreement. If we or our affiliates obtain a license from a third party to practice the Duke technology, we must use commercially reasonable efforts to secure a covenant not to sue Duke, or any of its faculty, students, employees or agents, for any research and development efforts conducted at Duke that resulted in the creation of any of its inventions or intellectual property rights arising therefrom. Additionally, because development of the Duke technology was funded in part by the U.S. government, it is subject to certain government rights and obligations, including the requirement that any products sold in the United States based upon such technology be substantially manufactured in the United States. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our cross-license agreement with Cellectis, or the Cellectis License, imposes various obligations on us in order to maintain the license.<font style="font-weight:bold;font-style:italic;"> </font>In particular, if we participate in or provide assistance to a third party challenging the validity, enforceability and/or patentability of any claim of any patent licensed to us by Cellectis under this agreement, Cellectis may terminate the agreement. The Cellectis License does not provide exclusive rights to use the licensed intellectual property and technology or rights in all relevant fields in which we may wish to develop or commercialize our technology and products in the future. As a result, we are not able to prevent competitors from developing and commercializing competitive products and technology that may use this technology. Additionally, we do not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from Cellectis. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained and defended in a manner consistent with the best interests of our business. If Cellectis or other licensors fail to prosecute, maintain, enforce and defend the patents subject to such licenses, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with our obligations under the Duke License or the Cellectis License, or arrangements with any other licensors, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product candidate that is covered by these agreements, which could materially adversely affect the value of any such product candidate. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may arise regarding intellectual property subject to a license agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the amounts of royalties, milestones or other payments due to our licensors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the sublicensing of patent and other rights under our collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the priority of invention of patented technology. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such disputes may be costly to resolve and may divert management&#8217;s attention away from day-to-day activities. If disputes over intellectual property that we have licensed from third parties prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we or our collaborators may be unable to successfully develop and commercialize the affected product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Some of our in-licensed intellectual property has been discovered through government funded research and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain intellectual property rights that have been in-licensed pursuant to the Duke License have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Patent and Trademark Law Amendment. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that (1)&#160;adequate steps have not been taken to commercialize the invention, (2)&#160;government action is necessary to meet public health or safety needs or (3)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States, and the Duke License requires that we comply with this requirement. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or licensed future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation with respect to our product candidates, thereby potentially extending the term of marketing exclusivity for such product candidates, our business may be harmed. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biopharmaceutical and biotechnology companies and other actors in our fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biopharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the USPTO and its foreign counterparts are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S.&#160;patents and patent applications may also be subject to interference or derivation proceedings, and U.S.&#160;patents may be subject to reexamination proceedings, post-grant review and/or<font style="font-style:italic;">&#160;inter partes</font>&#160;review in the USPTO. International patents may also be subject to opposition or comparable proceedings in the corresponding international patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, derivation, reexamination, post-grant review, <font style="font-style:italic;">inter partes</font> review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, even if not challenged, our patents and patent applications may not adequately protect our technology and any product candidates or products that we develop alone or with collaborators or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to product candidates or potential products is threatened, it could dissuade companies from collaborating with us to develop, and could threaten our or their ability to successfully commercialize, such product candidates. Furthermore, for U.S. applications in which any claim is entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO in order to determine who was the first to invent any of the subject matter covered by such patent claims. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries or to develop and commercialize our technology and product candidates or products without providing any compensation to us, or may limit the scope of patent protection that we are able to obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S.&#160;laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we hold or have in-licensed with respect to our current and future research and development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our technology or any products and product candidates that we or our collaborators may develop, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our or our collaborators&#8217; ability to commercialize future product candidates. Any such outcome could have a material adverse effect on our business. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of product candidates, prohibit our use of proprietary technology or sale of potential products or put our patents and other proprietary rights at risk. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part upon our ability to develop, manufacture, market and sell product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical, biotechnology and agricultural biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding international patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual&#160;property-dependent&#160;industries, including the biotechnology, agricultural biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous United States, EU and other internationally issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates, and as the biotechnology, agricultural biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. For example, we are aware of certain patents held by third parties relating to the modification of T cells, including the production of CAR T cells. Although conducting clinical trials and other development activities with respect to our CAR T product candidates is not considered an act of infringement in the United States, if and when any of our CAR T product candidates may be approved by the FDA, those third parties may seek to enforce their patents by filing a patent infringement lawsuit against us. As a result of any patent infringement claims, or in order to avoid any potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights, similar to the cross license we granted Cellectis as part of our patent litigation settlement. These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we or our collaborators could be prevented from commercializing one or more product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. We or our collaborators might also be forced to redesign or modify our technology or product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, if a patent infringement suit is brought against us, our collaborators or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. In addition, defending such claims has in the past and may in the future cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. These damages potentially include increased damages and attorneys&#8217; fees if we are found to have infringed such rights willfully. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. In addition, if the breadth or strength of protection provided by the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been and may in the future be subject to third-party claims and similar adversarial proceedings or litigation in other jurisdictions regarding our infringement of the patent rights of third parties. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our or our collaborators&#8217; ability to further develop or commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our technologies, compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those technologies, compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our or our collaborators&#8217; ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we or our collaborators obtain a license. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering our technology or a product candidate, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and Europe, defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or&#160;non-enablement. Third parties might allege unenforceability of our patents because during prosecution of the patent an individual connected with such prosecution withheld relevant information, or made a misleading statement. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution, but that an adverse third party may identify and submit in support of such assertions of invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or product candidates. Our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Developments in patent law could have a negative impact on our business. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the United States Supreme Court, or the Supreme Court, other federal courts, the United&#160;States Congress, or Congress, the USPTO and similar international authorities may change the standards of patentability, and any such changes could have a negative impact on our business. For example, the America Invents Act, or the AIA, which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. Circumstances could prevent us from promptly filing patent applications on our inventions. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The AIA limited where a patentee may file a patent infringement suit and provided opportunities for third parties to challenge any issued patent in the USPTO. Those provisions apply to all of our U.S. patents, regardless of when issued. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. These provisions could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of our patents and patent applications. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we were unable to protect the confidentiality of our trade secrets and enforce our intellectual property assignment agreements, our business and competitive position would be harmed. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, because we operate in the highly technical field of development of product candidates and products using genome editing, we rely significantly on trade secret protection in order to protect our proprietary technology and processes. Trade secrets are difficult to protect. Our policy is to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, these agreements may be held unenforceable and may not effectively assign intellectual property rights to us. If our trade secrets and other unpatented or unregistered proprietary information are disclosed, we are likely to lose such trade secret protection. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, agreements with third parties typically restrict the ability of such third parties to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified period of time in order to secure our intellectual property rights arising from the arrangement. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and product development activities that may require us to share trade secrets under the terms of our research and development collaborations or similar agreements. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not provide adequate protection for our proprietary information. For example, our security measures may not prevent an employee or consultant with authorized access from misappropriating our trade secrets and providing them to a competitor, and the recourse we have available against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Furthermore, our proprietary information may be independently developed by others in a manner that could prevent legal recourse by us. Competitors could purchase any products we may develop and commercialize and attempt to reverse engineer and replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights or design around our protected technology. In addition, our key employees, consultants, suppliers or other individuals with access to our proprietary technology and know-how may incorporate that technology and know-how into projects and inventions developed independently or with third parties. As a result, disputes may arise regarding the ownership of the proprietary rights to such technology or know-how, and any such dispute may not be resolved in our favor. If any of our confidential or proprietary information, including our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed and such disclosure or misappropriation could have a material adverse effect on our business. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States, assuming that rights are obtained in the United States. In-licensing patents covering product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally apply for patents in those countries where we intend to make, have made, use, offer for sale or sell products and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but where our ability to enforce our patent rights is not as strong as in the United States. These products may compete with any products that we or our collaborators may develop, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biopharmaceuticals or biotechnologies. As a result, many companies have encountered significant difficulties in protecting and defending intellectual property rights in certain jurisdictions outside the United States. Such issues may make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many other countries, including countries in the EU, have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents and could limit our potential revenue opportunities. Accordingly, our and our licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, subject our patents to the risk of being invalidated or interpreted narrowly, subject our patent applications to the risk of not issuing or provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful, while the damages and other remedies we may be ordered to pay such third parties may be significant. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have rights, through licenses from third parties and under patents that we own, to the intellectual property to develop the product candidates we are currently developing alone or with collaborators. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, product candidates may require specific formulations to work effectively and efficiently, and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies, or companies that have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive to develop or commercialize product candidates. These established companies may have a competitive advantage over us due to their size and greater cash resources and clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding product candidates that we may seek to acquire. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the strategic alliance. Regardless of such right of first negotiation, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us, and the institution may license such intellectual property rights to third parties, potentially blocking our ability to pursue our development and commercialization plans. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license to us intellectual property rights that we require in order to successfully develop and commercialize potential products. We also may be unable to obtain such a license or assignment on terms that would allow us to make an appropriate return on our investment. In either event, our business and prospects for growth could suffer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We may not be able to protect our rights to our trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights and other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Organization, Structure and Operations</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, we had 199 employees. We will need to significantly expand our organization, and our future financial performance, ability to develop and commercialize product candidates alone or with collaborators and ability to compete effectively will depend in part on our ability to effectively manage any future growth. We may have difficulty identifying, hiring and integrating new personnel. Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can identify and develop product candidates, enter into collaborative arrangements and otherwise operate our business will be limited. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources from other projects, such as the development of product candidates. If we are not able to effectively manage the expansion of our operations, it may result in weaknesses in our infrastructure, increase our expenses more than expected, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity. Our future financial performance, ability to successfully commercialize any of our product candidates and our ability to compete effectively will depend, in part, on our ability to effectively manage any future growth. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may engage in transactions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire or in-license rights to product candidates, products or technologies or to acquire other businesses. If we do identify suitable candidates, we may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions or in-licenses may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or in-license, which may negatively impact our financial condition and restrict our operations, or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or in-licenses or the effect that they might have on our operating results. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our Chief Executive Officer, Chief Scientific Officer, Chief Technology Officer, Chief Operating Officer, Chief Medical Officer and other key executives and to attract, retain and motivate qualified personnel. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the research and development experience, technical skills, leadership and continued service of certain members of our management and scientific teams, including Matthew Kane, our Chief Executive Officer, Derek Jantz, our Chief Scientific Officer, Jeff Smith, our Chief Technology Officer, David Thomson, our Chief Operating Officer and Christopher Heery, our Chief Medical Officer. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time upon thirty days&#8217; written notice. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and, if we retain commercialization responsibility for any product candidate we develop alone or with collaborators, sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms or at all given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The inability to recruit, integrate, motivate and retain additional skilled and qualified personnel, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to increased costs as a result of operating as a public company, and our management will be required to devote substantial time to maintaining compliance initiatives and corporate governance practices, including establishing and maintaining proper and effective internal control over financial reporting. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the Securities Exchange Act of 1934, as amended, or the Exchange Act, including the reporting requirements thereunder, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other applicable securities rules and regulations, including requirements related to the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs, making some activities more difficult, time consuming or costly, and increasing demand on our systems and resources. When we no longer qualify as an emerging growth company, legal, accounting and other expenses are expected to further increase. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second annual report following the completion of our IPO. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 of the Sarbanes-Oxley Act within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. We may need to hire more employees in the future or engage outside consultants to comply with these requirements, which will further increase our costs and expenses. If we fail to implement the requirements of Section&#160;404 of the Sarbanes-Oxley Act in the required timeframe, we may be subject to sanctions or investigations by regulatory authorities, including the SEC and Nasdaq. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, our investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by regulatory authorities. Failure to implement or maintain an effective internal control system could also restrict our future access to the capital markets. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of system failures or security breaches. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our computer systems, as well as those of third parties with which we have relationships, are vulnerable to damage from computer viruses, unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our or their operations, it could result in delays and/or material disruptions of our research and development programs. For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal and various state and foreign governments have enacted or proposed requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals, and U.S. federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use and dissemination of data. In the ordinary course of our business, we and third parties with which we have relationships will continue to collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#8217; security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance or other disruptions. A number of proposed and enacted federal, state and international laws and regulations obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors or other organizations with which we have formed strategic relationships. Although, to our knowledge, neither we nor any such third parties have experienced any material security breach, and even though we may have contractual protections with such third parties, any such breach could compromise our or their networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure, notifications, follow-up actions related to such a security breach or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant costs, including regulatory penalties, fines and legal expenses, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or such third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or third parties with whom we have relationships may be adversely affected by natural or manmade disasters, public health emergencies and other natural catastrophic events, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural or manmade disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, public health emergency, power outage or other event occurred that prevented us from using all or a significant portion of our facilities, that damaged our infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time, and our research and development activities could be setback or delayed. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, and such an event could disrupt our operations, cause us to incur remediation costs, damage our reputation and cause a loss of confidence in us and our or third parties&#8217; ability to conduct clinical trials, which could adversely affect our reputation and delay our research and development programs. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China. In January 2020, the World Health Organization declared the novel coronavirus outbreak a &#8220;Public Health Emergency of International Concern&#8221; and the U.S. Department of State instructed travelers to avoid all nonessential travel to China. The coronavirus has impacted the global economy and may impact our operations, including the potential interruption of our clinical trial activities and our supply chain. For example, the coronavirus outbreak may delay enrollment in our clinical trials for PBCAR0191 and PBCAR20A due to prioritization of hospital resources toward the outbreak, and some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to release clinical results and could impact our product candidate testing, development and timelines. Additionally, any required or elective quarantine or other condition that prevents us or the third parties upon whom we depend from using all or a significant portion of our or their offices, manufacturing and/or laboratory spaces or that delays delivery of necessary testing supplies, could adversely impact our product candidate testing, development and timelines. The extent to which the coronavirus will impact our business will depend on future developments and, given the uncertainty around the extent and timing of the potential future spread or mitigation and around the imposition or relaxation of protective measures, we cannot reasonably estimate the impact to our business at this time. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a>We do not carry insurance for all categories of risk that our business may encounter. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and clinical trials or regulatory approvals for any of our product candidates could be suspended. We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors, our board committees or as our executive officers. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance coverage is becoming increasingly expensive, and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. A successful liability claim or series of claims brought against us could require us to pay substantial amounts and cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, and similar deterioration in the credit and financial markets and confidence in economic conditions may occur in the future. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers or others with whom we have strategic relationships may not survive any difficult economic times, which could directly affect our ability to attain our operating goals. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, we had cash and cash equivalents of $180.9 million. While we are not aware of any downgrades, material losses or other significant deterioration in the fair value of our cash equivalents since December 31, 2019, deterioration of the global credit and financial markets could negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives. Furthermore, our stock price may decline due in part to the volatility of the stock market and any general economic downturn. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we or any of our contract manufacturers or other suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur significant costs. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any of our contract manufacturers and suppliers are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies (under which we currently have an aggregate of approximately $10&#160;million in coverage) specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals for any product candidate we develop alone or with collaborators could be suspended, which could have a material adverse effect on our business and financial condition. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a>In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations and permitting requirements, and any third-party contract manufacturers and suppliers we engage will also be subject to such current and future regulations and requirements. These current or future laws, regulations and permitting requirements may impair our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements, either by us or by any third-party contract manufacturers and suppliers we engage, also may result in substantial fines, penalties or other sanctions or business disruption. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business operations, including our current and future relationships with third parties, will expose us to penalties for potential misconduct or improper activity, including non-compliance with regulatory standards and requirements. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complex laws constrain our business and the financial arrangements and relationships through which we conduct our operations, including how we may research, market, sell and distribute product candidates alone or with collaborators. We are exposed to the risk of fraud or other misconduct by our employees, consultants and collaborators and, if we or our collaborators commence clinical trials and proceed to commercialization, our principal investigators and commercial partners, as well as healthcare professionals, third-party payors, patient organizations and customers. For example, misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, false and/or misleading statements, corruption of government officials, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing, promotion, sales commission and customer incentive programs and other business arrangements. Such misconduct also could involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in preclinical studies or clinical trials, illegal misappropriation of study materials or other property, or improper interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our or our collaborators&#8217; reputations. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and current and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to similar penalties, such as criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent such activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of any of the penalties discussed above and have a significant impact on our business and financial condition. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to complex tax rules relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to income and non-income taxes in the United States. Income tax accounting often involves complex issues, and judgment is required in determining our provision for income taxes and other tax liabilities. In May 2018 we formed a subsidiary in Australia, in June 2019 we formed a subsidiary in the United Kingdom, and we may operate in other non-US jurisdictions in the future. We could become subject to income and non-income taxes in non-US jurisdictions as well. In addition, many jurisdictions have detailed transfer pricing rules, which require that all transactions with non-resident related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of withholding tax, goods and services tax, sales taxes and other non-income taxes is not always clear and we may be subject to tax audits relating to such withholding or non-income taxes. We believe that our tax positions are reasonable and our tax reserves are adequate to cover any potential liability. We are currently not subject to any tax audits. However, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to utilize all, or any, of our net operating loss carryforwards. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred substantial losses during our history, do not expect to become profitable in the near future, and we may never achieve profitability. As of December&#160;31, 2019, we had U.S. federal, state, and foreign net operating loss carryforwards of $101.3&#160;million, $101.7 million, and $0.4 million, respectively. Our federal net operating loss carryforwards of $19.7 million will begin to expire in 2030 while the remaining federal net operating loss carryforwards of $81.6 million carry forward indefinitely. The state net operating loss carryforwards begin to expire in 2025. In addition, we have U.S. federal and state research and development tax credits of $7.2&#160;million and an amount less than $0.1&#160;million as of December&#160;31, 2019, respectively, available to offset future U.S. federal and state income taxes, which begin to expire in 2027 and 2030, respectively.  At December 31, 2019 and December 31, 2018, we had federal Orphan Drug credits of $1.8 million and $0.7 million, respectively, which begin to expire in 2038. Unused losses generated in taxable years ending after December&#160;31, 2017 will not expire and may be carried forward indefinitely, but will be deductible only to the extent of 80% of current year taxable income (computed without regard to the deduction for the net operating losses) in any given year. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, we have a valuation allowance for the full amount of our net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. In addition, Sections&#160;382 and 383 of the Code limit a corporation&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. A Section&#160;382 ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change, and any increased liabilities could adversely affect the corporation&#8217;s business, results of operations, financial condition and cash flow. We have not yet determined if any prior change in the ownership of our equity or any change in such ownership in connection with our IPO, would trigger a Section 382 ownership change. It is possible that such a Section 382 ownership change has already occurred in prior periods. Furthermore, additional ownership changes may occur in the future as a result of events over which we will have little or no control, including purchases and sales of our equity by our 5% stockholders, the emergence of new 5% stockholders, additional equity offerings or redemptions of our stock or certain changes in the ownership of any of our 5% stockholders. As a result, our&#160;pre-2018 net operating loss&#160;carryforwards (and research tax credits) may expire prior to being used, and our net operating loss carryforwards and tax credits generated in 2018 and thereafter will be subject to a percentage limitation, upon an ownership change. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Owning Our Common Stock</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_cp_text_1_562"></a><font style="Background-color:#FFFFFF;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_563"></a><font style="Background-color:#FFFFFF;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">inconsistent trading volume levels of our common stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">announcements or expectations regarding debt or equity financing efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">sales of common stock by us, our insiders or our other stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">actual or anticipated fluctuations in our financial condition and operating results;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">results from or delays in our studies or trials, or those of our collaborators, competitors or companies perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">delay, failure or discontinuation of any of our product development and research programs, or those of our collaborators, competitors or companies perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">announcements about new research programs or product candidates from us or our collaborators, our competitors or companies perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">announcements by us, our collaborators, our competitors or companies perceived to be similar to us relating to significant acquisitions, strategic partnerships or alliances, joint ventures, collaborations or capital commitments;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="Background-color:#FFFFFF;font-family:Times New Roman;">actual or anticipated changes in our growth rate relative to our competitors or companies perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">fluctuations in the valuation of our collaborators, our competitors or companies perceived to be comparable to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">a lack of, limited or withdrawal of coverage by security analysts, or positive or negative recommendations by them;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">actual or expected changes in estimates as to financial results, development timelines or recommendations by securities analysts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">publication of research reports about us, genome editing or the biopharmaceutical and agricultural biotechnology industries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">developments or changing views regarding the use of genomic products, including those that involve genome editing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">our ability to effectively manage our growth;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">the recruitment or departure of key personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">the results of any efforts by us to identify, develop, acquire or in-license additional product candidates, products or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">unanticipated serious safety concerns related to the use of any of our product candidates, or those of our competitors or companies perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">the termination of a collaboration agreement, licensing agreement or other strategic arrangement or the inability to establish additional strategic arrangements on favorable terms, or at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">regulatory actions with respect to any of our product candidates, or those of our competitors or companies perceived to be similar to us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">changes in physician, hospital, healthcare provider or agricultural practices that may make our or our collaborators&#8217; products less useful;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">changes in the structure of healthcare payment systems;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">significant lawsuits, such as products liability, patent or stockholder litigation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="Background-color:#FFFFFF;font-family:Times New Roman;">general economic, industry and market conditions.</font></p></td></tr></table></div>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance. These factors may have a material adverse effect on the market price and liquidity of our common stock, which may limit or prevent you from readily selling your shares of common stock and may affect our ability to obtain financing or enter into desired strategic relationships.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not currently intend to pay dividends on our common stock. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a>We do not intend to pay any dividends to holders of our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. In addition, pursuant to our loan and security agreement with PWB we are prohibited from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">paying cash dividends without the prior written consent of PWB and future debt instruments may materially restrict our ability to pay dividends on our common stock. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future, and the success of an investment in our common stock will depend upon any future appreciation in its value. Consequently, you may need to sell all or part of your common stock after price appreciation, which may never occur, as the only way to realize any future gains on your investment. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock relies in part on the research and reports that industry or securities analysts publish about us or our business. We do not control these analysts. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and restated bylaws or Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and therefore depress the trading price of our common stock. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and our restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, our chief executive officer (or our president, in the absence of a chief executive officer) or a majority of our board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&#160;any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, or (5) any action asserting a claim governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. For example, stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (1) December 31, 2024, (2)&#160;the last day of the fiscal year in which we have total annual gross revenue of $1.07&#160;billion or more, (3)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the previous three years, or (4)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June&#160;30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">being permitted to present only two years of &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Annual Report on Form 10-K; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation in this Annual Report on Form 10-K and our periodic reports, proxy statements and registration statements; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a>We have taken advantage of reduced reporting burdens in this Annual Report on Form 10-K. In particular, we have provided only two years of &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure, and we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to take advantage of this extended transition period. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W<font style="color:#000000;">e currently occupy approximately 68,000 square feet of office and laboratory space at our corporate headquarters in Durham, North Carolina under a lease that expires in 2024. We also occupy approximately 15,500 square feet of laboratory and office space used by our wholly owned subsidiary, Elo Life Systems, in Durham, North Carolina under a lease that expires in 2026, and we occupy approximately 33,600 square feet of manufacturing, laboratory and office space used for our Manufacturing Center for Advanced Technologies in Research Triangle Park, North Carolina under a lease that expires in 2027.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently party to any material legal proceedings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_II"></a><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. <a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2019, our common stock began trading on The Nasdaq Global Select Market under the symbol &#8220;DTIL.&#8221; Prior to that time, there was no public market for our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Common Stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 2, 2020, there were approximately 221 holders of record of our common stock. This number does not include &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. In addition, pursuant to our loan and security agreement with Pacific Western Bank (&#8220;PWB&#8221;), we are prohibited from paying cash dividends without the prior written consent of PWB and future debt instruments may materially restrict our ability to pay dividends on our common stock. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors our board of directors deems relevant, and subject to any restrictions applicable to us contained in any future financing instruments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected Financial Data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our selected consolidated financial data.&nbsp;&nbsp;We derived the consolidated statement of operations data for the years ended December 31, 2019 and December 31, 2018 and the consolidated balance sheet data as of December 31, 2019 and December 31, 2018, from our audited consolidated financial statements, included elsewhere in this Annual Report on Form 10-K. We have derived the consolidated statement of operations data for the year ended December 31, 2017 from our audited consolidated financial statements not included in this report. The selected financial data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 of Part II to this Annual Report on Form 10-K and our consolidated financial statements and the related notes thereto, included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of our future results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232161"></a>(in thousands, except share and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,484</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,416</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,122</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,324</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,795</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,458</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,912</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible note payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,267</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,991,162</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,775,541</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,906,793</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet Data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,886</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,802</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,682</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,932</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,075</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,203</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total noncurrent liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,987</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,565</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,848</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,314</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,369</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,682</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">You should read the following discussion and analysis of financial condition and operating results together with the section captioned &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K.&nbsp;&nbsp;This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section of the Annual Report on Form 10-K captioned &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in these forward-looking statements</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a life sciences company dedicated to improving life through the application of our pioneering, proprietary ARCUS genome editing platform. We leverage ARCUS in the development of our product candidates, which are designed to treat human diseases and create healthy and sustainable food and agricultural solutions. We are actively developing product candidates in three innovative areas: allogeneic CAR T cell immunotherapy, <font style="font-style:italic;">in vivo</font> gene correction, and food. We are currently conducting a Phase 1/2a clinical trial of PBCAR0191 in adult patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL. PBCAR0191 is our first gene-edited allogeneic chimeric antigen receptor, or CAR, T cell therapy candidate targeting CD19 and is being developed in collaboration with Les Laboratoires Servier, or Servier. We have received orphan drug designation for PBCAR0191 from the U.S. Food and Drug Administration, or FDA, for the treatment of ALL. Made from donor-derived T cells modified using our ARCUS genome editing technology, PBCAR0191 recognizes the well characterized tumor cell surface protein CD19, an important and validated target in several B-cell cancers, and is designed to avoid graft-versus-host disease, or GvHD, a significant complication associated with donor-derived, cell-based therapies. We believe that this trial, which is designed to assess the safety and tolerability of PBCAR0191 at increasing dose levels, as well as to evaluate anti-tumor activity, is the first U.S.-based clinical trial to evaluate an allogeneic CAR T therapy for R/R NHL. Furthermore, we believe that our proprietary, one-step engineering process for producing allogeneic CAR T cells with a potentially optimized cell phenotype, at large scale in a cost-effective manner, will enable us to overcome the fundamental clinical and manufacturing challenges that have limited the CAR T field to date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we announced initial data from this ongoing Phase 1/2a clinical trial of PBCAR0191 in adult patients with R/R NHL and R/R B-ALL. A total of nine adult patients were reported in these initial Phase 1 trial results, including six with NHL (three treated at Dose Level 1 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> cells/kg), or DL1, and three treated at Dose Level 2 (1x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg), or DL2), and three with B-ALL (all treated at DL2). These data indicated no serious adverse events or dose limiting toxicities. In the NHL cohort, four of six patients demonstrated an objective tumor response by Lugano criteria at day 28, for an overall objective response rate of 67%, including three partial responses and one complete response. In the ALL cohort, one of three patients achieved a complete response at day 28 following treatment with PBCAR0191. As of December 31, 2019, dosing of patients at Dose Level 3 (3x10<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> cells/kg) was underway.&nbsp;&nbsp;Based on the data observed at DL1 and DL2, we filed a protocol amendment for this trial with the FDA in December 2019.&nbsp;&nbsp;The amended trial design is intended to specifically address key clinical questions. These include assessing the impact of higher total doses of cells on clinical activity and/or the impact of modified lymphodepletion on the ability to achieve durable clinical benefit with associated CAR T cell expansion and persistence. Following feedback from the FDA in late January 2020, the protocol amendment is now being implemented.<font style="font-family:Arial;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the FDA accepted our investigational new drug, or IND, application for our second allogeneic CAR T cell therapy product candidate, PBCAR20A, for which we expect to commence a Phase 1/2a clinical trial in the first quarter of 2020. PBCAR20A is wholly owned by us and targets the validated tumor cell surface target CD20. It will be investigated in subjects with NHL, chronic lymphocytic leukemia, or CLL, and small lymphocytic lymphoma, or SLL. A subset of the NHL patients will have the diagnosis of mantle cell lymphoma, or MCL, and we have received orphan drug designation for PBCAR20A from the FDA for the treatment of this disease.&nbsp;&nbsp;Based on the adverse events observed to date with PBCAR0191, the FDA has agreed to allow us to commence dosing with PBCAR20A directly at Dose Level 2, which we expect to accelerate the timing for our expected completion of the trial.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the FDA accepted our IND application for our third allogeneic CAR T cell therapy product candidate, PBCAR269A, for which we expect to commence a Phase 1/2a clinical trial in 2020. PBCAR269A is wholly owned by us and is designed to target the validated tumor cell surface target BCMA. It will be investigated in subjects with R/R multiple myeloma and we have received orphan drug designation from the FDA for this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in January 2020, we announced that we expect to advance a program targeting the rare genetic disease primary hyperoxaluria type 1, or PH1 as our lead wholly owned <font style="font-style:italic;">in vivo</font> gene correction program. PH1 affects approximately 1-3 people per million in the United States and is caused by loss of function mutations in the AGXT gene, leading to the accumulation of calcium oxalate crystals in the kidneys. Patients suffer from painful kidney stones which may ultimately lead to renal failure. Using ARCUS, we are developing a potential therapeutic approach to the treatment of PH1 that involves knocking out a gene called HAO1 which acts upstream of AGXT. Suppressing HAO1 has been shown in preclinical models by us to prevent the formation of calcium oxalate. We therefore believe that a one-time administration of an ARCUS nuclease targeting HAO1 may be a viable strategy for a durable treatment of PH1 patients. In preclinical studies we have demonstrated in a mouse model of PH1 that administration of an ARCUS nuclease targeting HAO1 resulted in approximately 70% reduction in urine calcium oxalate levels. We have also demonstrated that ARCUS efficiently knocked out the HAO1 gene in non-human primates. We plan to select a clinical candidate for this program during 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> December 31, 2019, we opened our Manufacturing Center for Advanced Therapeutics, or MCAT, which we believe is the first in-house current good manufacturing practice, or cGMP, compliant manufacturing facility dedicated to genome-edited, off-the-shelf CAR T cell therapy product candidates in the United States.&nbsp;&nbsp;MCAT will enable in-house production of three different drug substances: allogeneic CAR T cells, messenger RNA (including formulations development) and adeno-associated viral vectors. We are currently using this new manufacturing center to create clinical trial material to be used in our BCMA targeting allogeneic CAR T clinical trials beginning in 2020.&nbsp;&nbsp;We believe MCAT confers a number of strategic advantages including cost benefits, control of our manufacturing process and strategic flexibility as we execute our clinical trials. In the longer term, we believe MCAT has the potential to be a commercial launch facility.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our formation in 2006, we have devoted substantially all of our resources to developing ARCUS, conducting research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing our intellectual property portfolio and providing general and administrative support for these operations. We have financed our operations primarily with proceeds from our IPO, the sale of our convertible preferred stock and upfront payments from licensing arrangements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, we completed our IPO of 9,085,000 shares of common stock, including the underwriters&#8217; full exercise of their option to purchase an additional 1,185,000 additional shares of common stock, at an offering price of $16.00 per share, for net proceeds of approximately $130.5 million after deducting underwriting discounts and commissions and offering expenses payable by us. To date, we have generated approximately $475.4&#160;million from third parties through a combination of financings including through our IPO, preferred stock and convertible note financings, an upfront payment under the Servier Agreement and additional funding from other strategic alliances and grants. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses and have not generated any revenue from the sale of products. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates or the product candidates of our collaborators for which we may receive milestone payments or royalties. Our net losses were $92.9&#160;million and $46.0&#160;million for the years ended December&#160;31, 2019 and December 31, 2018, respectively. As of December 31, 2019, we had an accumulated deficit of $177.1&#160;million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our operating expenses to increase substantially in connection with the expansion of our product development programs and capabilities. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one of our product candidates or the product candidates of our collaborators for which we may receive milestone payments or royalties. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution.&nbsp;&nbsp;In addition, we expect to continue to incur additional costs associated with operating as a public company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our cash needs through a combination of public equity, debt financings or other sources, which may include current and new collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot assure you that we will ever generate significant revenue to achieve profitability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development of therapeutic and agricultural products, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be required to raise additional capital on terms that are unfavorable to us or we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently conduct our operations through two reportable segments: Therapeutics and Food. Our Therapeutics segment is focused on allogeneic CAR T immunotherapy and <font style="font-style:italic;">in vivo</font> gene correction. Our Food segment focuses on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaborations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Gilead</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, we and Gilead entered into a collaboration and license agreement, which we refer to as the Gilead Agreement, to develop genome editing tools using ARCUS to target viral DNA associated with the Hepatitis B virus. Pursuant to the terms of the agreement, Gilead received an exclusive license to exploit the resulting synthetic nucleases and products that use them to treat the Hepatitis B virus in humans, and we are entitled to receive up to approximately $40.0 million in research funding over an initial three year term and milestone payments of up to an aggregate of $445.0 million, consisting of up to $105.0 million in development milestone payments and up to $340.0 million in commercial milestone payments. We are also entitled to receive tiered royalties ranging from the high single digit percentages to the mid-teen percentages on worldwide net sales of the products developed through the term of the agreement, subject to customary potential reductions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized $13.3 million and $3.7 million in revenues under the Gilead Agreement during the years ended December&#160;31, 2019 and December 31, 2018, respectively, and recorded $1.5 million and $2.3 million in deferred revenue as of December 31, 2019 and December 31, 2018, respectively. We did not receive any milestone payments under the Gilead Agreement during the years ended December 31, 2019 or December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>Servier</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, we entered into the Servier Agreement, pursuant to which we have agreed to develop allogeneic CAR T cell therapies for up to six unique antigen targets. One target was selected at the agreement&#8217;s inception. Upon selection of an antigen target under the agreement, we have agreed to perform early-stage research and development on individual T cell modifications for the selected target, develop the resulting therapeutic product candidates through Phase 1 clinical trials and prepare clinical trial material of such product candidates for use in Phase 2 clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received an upfront payment of $105.0 million under the Servier Agreement. We have the ability to receive total payments, including the upfront payment, option fees and milestone payments, in the aggregate across all six targets, of up to approximately $1.6 billion. This includes up to $1.5 billion in milestone payments, consisting of up to $401.3 million in development milestone payments and up to $1.1 billion in commercial milestone payments. We are also entitled to receive tiered royalties ranging from the mid-single digit percentages to the sub-teen percentages on worldwide net sales, subject to potential customary reductions. We also have the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States, subject to our payment of an option fee, which is exercisable after Servier&#8217;s commercial option exercise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Servier Agreement, we recognized $7.3&#160;million and $5.8 million in revenues during the years ended December&#160;31, 2019 and December 31, 2018, respectively. The amount recorded as deferred revenue was $80.9&#160;million and $88.6&#160;million as of December&#160;31, 2019 and December 31, 2018, respectively. No development or sales-based milestones were received for the fiscal years ended December&#160;31, 2019 or December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Our Results of Operations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. We record revenue from collaboration agreements, including amounts related to upfront payments, annual fees for licenses of our intellectual property and research and development funding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates. These include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">salaries, benefits and other related costs, including share-based compensation expense, for personnel engaged in research and development functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct preclinical research and development activities and clinical trials on our behalf;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs of developing and scaling our manufacturing process and manufacturing drug products for use in our preclinical studies and ongoing and future clinical trials, including the costs of contract manufacturing organizations, or CMOs, and our MCAT facility that will manufacture our clinical trial material for use in our preclinical studies and ongoing and potential future clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs of outside consultants, including their fees and related travel expenses;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">license payments made for intellectual property used in research and development activities; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs if specifically identifiable to research activities.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>We expense research and development costs as incurred.&#160;We track external research and development costs, including the costs of laboratory supplies and services,&#160;outsourced research and development, clinical trials, contract&#160;manufacturing, laboratory equipment and&#160;maintenance and certain other development costs, by product candidate when&#160;the program IND application is accepted by the FDA. Internal and external costs associated with infrastructure resources, other&#160;research and development costs, facility related costs and depreciation and amortization that are not&#160;identifiable to a specific product candidate are included in the platform development, early-stage research and&#160;unallocated expenses category&#160;in the table below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses by product candidate or development&#160;program for the periods presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by product candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CD19 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,726</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CD20 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BCMA external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,599</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies and services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,061</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,645</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,416</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,361</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs and research organizations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,770</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,770</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and maintenance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,599</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we continue our Phase 1/2a clinical trial for our CD19 product candidate, commence a Phase 1/2a clinical trial for our CD20 product candidate, commence a Phase 1/2a clinical trial for our BCMA product candidate, and continue to discover and develop additional product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the duration and costs of ongoing and future clinical trials of our CD19, CD20, and BCMA product candidates, or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our CD19, CD20, and BCMA product candidates, and any other our product candidate we may develop will depend on a variety of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, rate of progress, expense and results of clinical trials of our </font><font style="color:#000000;font-family:Times New Roman;">CD19, CD20, and BCMA</font><font style="font-family:Times New Roman;"> product candidates, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">uncertainties in clinical trial design and patient enrollment rates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the actual probability of success for our product candidates, including their safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant and changing government regulation and regulatory guidance;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and receipt of any marketing approvals; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>General and&#160;Administrative&#160;Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in our executive, finance, business development, operations and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and expenses for rent and maintenance of facilities and other operating costs that are not specifically attributable to research activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our continued research activities and development of product candidates.&#160;&#160;We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Convertible Notes Payable</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We elected on issuance to account for the convertible notes payable we issued in March 2019, or the 2019 Notes, at fair value until their settlement.&#160;&#160;The change in fair value of the 2019 Notes was recognized through the statement of operations.&#160;&#160;The 2019 Notes settled into 2,921,461 shares of common stock on the closing of our IPO on April 1, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Expense</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists of interest from the 2019 Notes at a rate of 6% per annum.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest income earned on our cash and cash equivalents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since<font style="color:#000000;"> our inception in 2006, we have generated cumulative federal and state net operating loss and R&amp;D credit carryforwards for which we have not recorded any net tax benefit due to the uncertainty around utilizing these tax attributes within their respective carryforward periods. As of December&#160;31, 2019, we had federal, state, and foreign net operating loss carryforwards of $101.3&#160;million, $101.7 million, and $0.4&#160;million, respectively, which may be available to offset future taxable income. The U.S. federal net operating loss carryforwards of $19.7 million will begin to expire in 2030 while the remaining federal net operating loss carryforwards of $81.6 million carry forward indefinitely. The state net operating loss carryforwards begin to expire in 2025.  As of December&#160;31, 2019, we also had federal research and development tax credit carryforwards of $7.2&#160;million, which begin to expire in 2027. As of December 31, 2019 and December 31, 2018, we had federal Orphan Drug credits of $1.8 million and $0.7 million, respectively, which begin to expire in 2038.&nbsp;&nbsp;As of December 31, 2019, we also have federal contribution carryforwards of $0.1 million, which begin to expire in 2020. We have recorded a full </font>valuation allowance against our net deferred tax assets at each balance sheet date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December<font style="color:#000000;">&#160;22, 2017, the TCJA was signed into United States law. The TCJA includes a number of changes to existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal tax rate of 35% to a flat rate of 21%, effective as of January&#160;1, 2018, as well as a limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely). The federal tax rate change resulted in a reduction in the gross amount of our deferred tax assets and liabilities recorded as of December&#160;31, 2017, and a corresponding reduction in our valuation allowance. As a result, no income tax expense or benefit was recognized as of the enactment date of the TCJA. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2019 and December 31, 2018</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2019 and <font style="color:#000000;">December 31,</font> 2018, together with the changes in those items in dollars:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232164"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,353</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,795</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,912</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible note payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,267</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,392</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,548</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,840</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue for the year ended December 31, 2019 was $22.2 million, compared to $10.9 million for the year ended December 31, 2018. The increase of $11.3 million in revenue during the year ended December 31, 2019 was primarily the result of a $9.6 million increase in research revenue recognized from Gilead as 2019 was the first full year of revenue recognized under the Gilead agreement initiated in September 2018 and a $1.5 million increase in collaboration revenue recognized from Servier. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232165"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by product candidate:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CD19 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,726</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CD20 external development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,375</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BCMA external development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development, early-stage research and unallocated expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,784</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,599</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies and services</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,061</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,645</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outsourced research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,416</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,361</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs and research organizations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,770</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,770</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and maintenance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility-related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,599</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,186</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensing fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,593</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,294</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December 31, 2019 were $82.4 million, compared to $45.1 million for the year ended December 31, 2018. The increase of $37.3 million was primarily due to a $31.9 million increase in platform development, early-stage research and unallocated expenses, a $9.4 million and $4.9 million increase in direct research and development expenses related to our CD20 and BCMA programs, respectively, partially offset by a decrease in direct research and development expenses related to our CD19 program of $8.9 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in direct research and development expenses for our CD20 and BCMA programs was due to increases in lab services and CMO and research organization costs as we prepare to enter planned Phase 1/2a clinical trials in 2020. This was partially offset by a decrease in our CD19 expenses primarily due to lower spending on CMO and research organization costs.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Platform development</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">early-stage research </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and unallocated </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses increased primarily due to a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $11.6 </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million increase in employee-related costs associated with increased headcount to support our technology platform development and manufacturing capabilities, a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $7.6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million increase in laboratory supplies and services</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $5.4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million increase in outsourced research and development spending</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $2.4 million increase in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depreciation and amortization</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the year ended December 31, 2019 compared to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the year ended December 31, 2018.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General<font style="color:#000000;"> and administrative expenses were $27.0 million for the year ended December 31, 2019 compared to $13.7 million for the year ended December 31, 2018. The increase of $13.3 million was primarily due to an increase of $6.2 million in employee-related costs as we increased our general and administrative headcount, $2.7 million in consulting fees, $2.1 million in increased administrative costs, including insurance, franchise and property taxes, bank fees, and costs related to operating as a public company, and $1.4 million in facility related costs.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Convertible Notes <font style="color:#000000;">Payable</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We elected<font style="color:#000000;"> on issuance to account for the 2019 Notes at fair value until their settlement.&nbsp;&nbsp;For the year ended December 31, 2019, we recognized $9.8 million of expense as changes in fair value.&nbsp;&nbsp;The 2019 Notes were settled on the closing of the IPO in April 2019.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>Interest <font style="color:#000000;">Expense</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense<font style="color:#000000;"> of $0.2 million for the year ended December 31, 2019 consists of interest from the 2019 Notes at a rate of 6% per annum.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income was $4.3 million for the year ended December 31, 2019 compared to $1.9 million for the year ended December 31, 2018.&nbsp;&nbsp;The increase of $2.4 million of interest income generated on our cash and cash equivalent balances was the result of lower interest rates and having higher cash balances invested in the year ended December 31, 2019 compared to the year ended December 31, 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Segment Results</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize segment revenues and segment operating loss (see Note 13 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information regarding our segments):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232166"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,632</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,523</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operational cash expenditures:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,125</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operational cash expenditures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,170</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation of centralized research and development operational</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash expenditures:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,605</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,901</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total allocation of centralized research and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; operational cash expenditures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,506</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operating income (loss):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,378</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,805</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,793</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluate the operating performance of each segment based on segment operating loss. Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are specifically identifiable to the reportable segment (including specifically identifiable research and development and property, equipment and software expenditures).&nbsp;&nbsp;For the year ended December 31, 2018, we allocated centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies to the Therapeutics and Food segments based on headcount. In January 2019, the Food segment moved into a new leased facility </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Durham</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, North Carolina.&nbsp;&nbsp;We have determined that the Food segment is no longer deriving benefit from the Company&#8217;s centralized research and development expenditures, thus all these expenditures were allocated to the Therapeutics segment for the year ended December 31, 2019.&nbsp;&nbsp;The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation, laboratory supplies, purchases of property, equipment and software and procuring services from CROs, CMOs and research organizations. We do not allocate general operational expenses or non-cash income statement amounts to our reportable segments</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Therapeutics Segment</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue for the year ended December 31, 2019 was $20.6 million, compared to $9.5 million for the year ended December 31, 2018. The increase of $11.1 million was primarily the result of a $9.6 million increase in research funding from Gilead and $1.5 million increase in revenue from Servier. Segment operational cash expenditures for the year ended December 31, 2019 were $45.9 million, compared to $35.0 million for the year ended December 31, 2018. The increase of $10.9 million in operational cash expenditures was primarily due to an increase in payments made to service providers for contract manufacturing and clinical trial research, laboratory supplies and services, employee headcount and fixed assets for the build out of our manufacturing capabilities, offset by a decrease in payments made to the University of Pennsylvania, which is early stage research and not considered specific to any one therapeutic area. As a result, these payments were classified as centralized research and development expenditures in the year ended December 31, 2019 as opposed to being classified as Therapeutics operational cash expenditures in the year ended December 31, 2018. Segment operating loss increased $12.3 million from $37.1 million for the year ended December 31, 2018 to $49.4 million for the year ended December 31, 2019 primarily due to the factors discussed above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Food Segment </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue for the year ended December 31, 2019 was $1.6 million, compared to $1.4 million for the year ended December 31, 2018. The increase of $0.2 million was primarily attributable to $0.4 million from a new customer agreement with a collaboration partner entered into during the year ended December 31, 2019 offset by a $0.2 million decrease in revenue from a collaboration partner. Segment operational cash expenditures for the year ended December 31, 2019 were $7.0 million, compared to $9.1 million for the year ended December 31, 2018. The decrease of $2.1 million was primarily due to a decrease in leasehold improvements, which is attributable to large construction expenditures made in the year ended December 31, 2018 for work done to our leased facility that did not occur in the year ended December 31, 2019, as our Food segment moved into the facility in January 2019. This decrease in spending was offset by increases in laboratory equipment, furniture and fixtures, laboratory supplies, employee headcount and rent. Segment operating loss decreased $5.3 million from $10.7 million for the year ended December 31, 2018 to $5.4 million for the year ended December 31, 2019 primarily due to the factors discussed above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase, including in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with CROs and CMOs, the addition of laboratory equipment to MCAT in support of preclinical studies and clinical trials, expanding our intellectual property portfolio and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. We do not currently have any approved products and have never generated any revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have financed our operations primarily with proceeds from our IPO, the sale of our convertible preferred stock and upfront payments from collaboration and licensing arrangements. On April 1, 2019, we completed our IPO of 9,085,000 shares of common stock, including the underwriters&#8217; full exercise of their option to purchase an additional 1,185,000 additional shares of common stock, at an offering price of $16.00 per share, for net proceeds of approximately $130.5 million after deducting underwriting discounts and commissions and offering expenses payable by us. To date, we have generated approximately $475.4 million from third parties through a combination of financings including through our IPO, preferred stock and convertible note financings, an upfront payment under the Servier Agreement and additional funding from other strategic alliances and grants.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into a loan and security agreement</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the &#8220;Pacific Western Loan Agreement&#8221;) with PWB</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pursuant to which we may request advances on a revolving line of credit of up to an aggregate principal of $50.0 million </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revolving Line</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pacific Western Loan Agreement</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was amended (the &#8220;PWB Amendment&#8221;) in December 2019 to allow the Company to maintain a bank account with a non-affiliated bank in the United Kingdom provided that the account balance does not exceed 1.5 million GBP or its U.S. dollar equivalent at any time</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> As of December 31, 2019, we had no borrowings under our Revolving Line</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and were in compliance with its financial covenants</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents totaled $180.9 million as of December 31, 2019, compared to $103.2 million as of December 31, 2018. As of December 31, 2019, we had no borrowings under our revolving line of credit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131160"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,723</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,374</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,777</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,693</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,391</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flows for the Year ended December 31, 2019</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2019 was $71.0 million, driven primarily by our net loss of $92.9 million as we incurred expenses associated with our CD19, CD20, and BCMA programs, platform development and early-stage research, and general and administrative expenses, and a decrease in operating assets and liabilities of $2.4 million, partially offset by net non-cash expenses of $24.2 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December 31, 2019 was $24.7 million, which was attributable to purchases of property, equipment and software. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December 31, 2019 was $173.4 million, consisting of $130.5 million in proceeds from our IPO, net of issuance costs, the net proceeds from the issuance of our 2019 Notes of $39.6 million, and $1.3 million in proceeds from stock option exercises. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Debt Obligations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, we issued an aggregate principal amount of $39.6 million of 2019 Notes in a private placement transaction.&nbsp;&nbsp;Upon settlement, the change in fair value of the 2019 Notes was $9.8 million and the accrued interest on the 2019 Notes was $0.2 million.&nbsp;&nbsp;Pursuant to their terms, the 2019 Notes were settled in 2,921,461 shares of our common stock upon the closing of our IPO at a settlement price of $13.60 per share, which is equal to 85% of the IPO price per share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into a loan and security agreement with Pacific Western Bank pursuant to which we may request advances on a $50.0 million revolving line of credit.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>Cash Flows for the Year Ended December 31, 2018 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December 31, 2018 was $51.7 million, primarily consisting of our net loss of $46.0 million as we incurred expenses associated with our CD19 program, platform development and early-stage research and general and administrative expenses. In addition, we had non-cash charges of $4.8 million for depreciation and amortization and share-based compensation expense. Net cash used in operating activities was also impacted by $10.5 million in changes in operating assets and liabilities, including $7.5 million in prepaid expenses, $3.2 million in deferred revenue, $0.5 million in accounts receivable, $0.7 million in accounts payable and $0.4 million in other current assets and other assets, which were partially offset by changes of $1.8 million in accrued expenses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December 31, 2018 was $15.7 million, which was attributable to purchases of property, equipment and software of $14.3 million and the acquisition of intellectual property of $1.4 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided in financing activities for the year ended December 31, 2018 was $107.8 million, consisting of the net proceeds from the issuance of our Series B convertible preferred stock financing of $109.7 million, net of offering costs, and $0.2 million in proceeds from stock option exercises, partially offset by $2.1 million in payments for deferred offering costs associated with our initial public offering. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Loan and Security Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into the Pacific Western Loan Agreement pursuant to which we may request advances on a $50.0 million Revolving Line. The maturity date of the Revolving Line is May 15, 2022.&nbsp;&nbsp;The Revolving Line bears interest at an annual rate equal to the greater of (i) 1.25% below the prime rate then in effect, or (ii) 4.25% at all times when we maintain a daily balance of cash in our demand deposit accounts at PWB of at least $25.0 million, and the greater of (i) 0.25% above the prime rate then in effect; or (ii) 5.75% at all times when we do not maintain a daily balance of cash in demand deposit accounts at PWB of at least $25.0 million; provided that, we are permitted to maintain a bank account with a non-affiliated bank in the United Kingdom so long as the account balance does not exceed 1.5 million GBP or its U.S. dollar equivalent at any time, pursuant to the PWB Amendment.&nbsp;&nbsp;We are required to pay a fee in an amount equal to 0.50% per annum of the unused portion of the Revolving Line each quarter, or the Unused Fee.&nbsp;&nbsp;The Unused Fee shall be waived for any quarter in which we maintain a daily balance of cash in our demand deposit account at PWB of at least $25.0 million at all times during such quarter. If the Revolving Line is terminated prior to the maturity date, we are required to pay an early termination fee equal to 1.0% of the Revolving Line.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Pacific Western Loan Agreement, we granted PWB a security interest in substantially all of our assets, excluding any of the intellectual property now or hereafter owned, (but including any rights to payment from the sale or licensing of any such intellectual property). We must maintain an aggregate balance of unrestricted cash and cash equivalents on hand at PWB (or PWB&#8217;s affiliates) at least equal to any amounts borrowed under the Revolving Line and any other outstanding obligations the we have to PWB.&nbsp;&nbsp;The agreement was amended in December 2019 to allow a bank account with a non-affiliated bank in the United Kingdom provided that the account balance does not exceed 1.5 million GBP or its U.S. dollar equivalent at any time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Agreement includes customary representations, warranties and covenants (affirmative and negative), and includes standard events of default, including in the event of a material adverse change. Upon the occurrence of an event of default, PWB may declare all outstanding obligations immediately due and payable and take such other actions as are set forth in the loan and security agreement and increase the interest rate otherwise applicable to the amount outstanding under the Revolving Line by an additional 3.00%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, we had no borrowings under our Revolving Line, and we were in compliance with the financial covenants, under the Pacific Western Loan Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Funding Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses increased substantially in 2019 and are expected to increase substantially in the future in connection with the initiation of additional human clinical trials and capital expenditures for MCAT. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2021. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical and agricultural products, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress, costs and results of our clinical development for our CD19, CD20, and BCMA programs as we initiate and progress clinical trials, including CRO costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress, costs and results of our additional research and preclinical development programs; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of internal process development and manufacturing scale-up activities and contract with CMOs associated with our CD19, CD20, and BCMA programs and other programs we advance through preclinical and clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of any product candidates that we may derive from ARCUS or any other product candidates we may develop alone or with collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we in-license or acquire rights to other products, product candidates or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidates for which we or our collaborators obtain marketing approval. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public or private equity or debt financings, collaboration agreements, other third&#8209;party funding, strategic alliances, licensing arrangements and marketing and/or distribution arrangements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, shareholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders. Debt financing and preferred equity<font style="font-weight:bold;"> </font>financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, product development and research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of our contractual obligations and commitments as of December&#160;31, 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due by Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1-3 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3-5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Lease Obligations<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,295</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,899</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents future minimum lease payments under our operating leases for office and/or lab space at the following locations: 302 East Pettigrew Street, Durham, North Carolina expiring in July 2024, 3054 Cornwallis Road, Durham, North Carolina expiring in April 2026 and 20 TW Alexander Drive, Research Triangle Park, North Carolina expiring in August 2027 (see Note 7 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information on these lease agreements). </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have entered into a license agreement with an undisclosed licensee for intellectual property used in our research programs. The agreement requires us to pay annual license fees and milestones payments for achievement of specified clinical and commercial events. We have excluded these potential milestone payments in the contractual obligations table because the timing and likelihood of these contingent payments are not currently known and would be difficult to predict or estimate.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This table does not reflect principal and interest payments payable pursuant to our Pacific Western Loan Agreement. which we entered into in May 2019, pursuant to which we may request advances on a revolving line of credit of up to an aggregate principal of $50.0 million, or the Revolving Line. As of December 31, 2019, we had no borrowings under our Revolving Line. The maturity date of the Revolving Line is May 15, 2022. The Revolving Line bears interest at an annual rate equal to the greater of (i) 1.25% below the prime rate then in effect, or (ii) 4.25% at all times when we maintain a daily balance of cash in our demand deposit accounts at PWB of at least $25.0 million, and the greater of (i) 0.25% above the prime rate then in effect; or (ii) 5.75% at all times when we do not maintain a daily balance of cash in demand deposit accounts at PWB of at least $25.0 million. The Pacific Western Loan Agreement requires that we pay a quarterly fee in an amount equal to 0.50% per annum of the unused portion of the Revolving Line. The unused fee shall be waived for any quarter we maintain a daily balance in our demand deposit accounts of at least $25.0 million. If the Revolving Line is terminated prior to the maturity date, we are required to pay an early termination fee equal to 1.0% of the Revolving Line.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have entered into the Duke License, under which we are obligated to make aggregate future milestone payments of up to $0.2&#160;million upon the achievement of specified corporate milestones as well as low-single digit percent royalty payments based on future net sales of applicable products and generally mid-teen percent royalties based on sublicensing revenue. See &#8220;Business&#8212;License and Collaboration Agreements&#8221; for more information regarding our payment obligations under the Duke License. We have not included future payments under the Duke License in the table above since the payment obligations under the Duke License are contingent upon future events, such as the achievement of specified milestones or generating product sales, and we are unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also enter into contracts in the normal course of business with CROs, CMOs, universities and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the table above as the amount and timing of such payments are not known.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues are generated primarily through collaborative research, license, development and commercialization agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (1)&#160;licenses, or options to obtain licenses, to use our technology, (2)&#160;research and development activities to be performed on behalf of the collaborative partner, and (3)&#160;in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments we receive under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales. We classify payments received under these agreements as revenues within our consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted Accounting Standards Update, or ASU, No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC 606, on January 1, 2019 using the modified retrospective transition method. Under this method, results for reporting periods beginning on January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, <font style="font-style:italic;">Revenue Recognition</font> (&#8220;ASC 605&#8221;). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, we evaluate the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options.&nbsp;&nbsp;We assess if these options provide a material right to the customer and, if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue.&nbsp;&nbsp;Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in our consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue &#8211; noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the Other line item in our consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone Payments &#8211; If an arrangement includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties &#8211; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant Financing Component &#8211; In determining the transaction price, we adjust consideration for the effects of the time value of money if the timing of payments provides us with a significant benefit of financing.&nbsp;&nbsp;We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&nbsp;&nbsp;We assessed each of our revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements &#8211; We have entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use our technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments we receive under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We analyze our collaboration arrangements to assess whether they are within the scope of ASU No. 2018-18 <font style="font-style:italic;">Collaborative Arrangements</font>, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&nbsp;&nbsp;For those elements of the arrangement that are accounted for pursuant to ASC 606, we apply the five-step model described above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, we entered into the Servier Agreement for the licensing of our ARCUS proprietary genome editing platform and the research, development, and manufacturing of product for clinical trials and commercialization of products. In September 2018, we entered into a collaboration and license agreement with Gilead, which we refer to as the Gilead Agreement, to develop genome editing tools using our ARCUS proprietary genome editing platform. Both agreements use our genome editing technology for the treatment of certain diseases. Consideration we received, or may receive, under these collaboration and license agreements include upfront nonrefundable payments, research funding payments and payments based upon the achievement of certain milestones and royalties on any resulting net product sales.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the guidance of ASC 606, certain judgments affect revenue recognition. Our primary performance obligations under our agreements consist of research and development services. Measuring the amount of time it takes for us to complete these services includes estimating our total effort to satisfy our performance obligations at the outset of the agreement and then comparing that amount to the actual effort expended for a given accounting period. In certain instances, significant judgment is required to estimate the timing of satisfying these obligations and timing may change due to efforts beyond our control, such as changes in the customer&#8217;s direction of a particular research program or changes to the contractual terms of an agreement. Accordingly, our estimates may change in the future. Such changes to estimates will result in a change in prospective revenue recognition amounts</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CROs and other third parties in connection with performing research and development activities, conducting preclinical studies and clinical trials on our behalf; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Vendors in connection with preclinical development activities; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CMOs and other vendors in connection with product manufacturing and development and distribution of preclinical supplies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials and CMOs that manufacture product for our research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may cause us to report amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-Based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock options and other share-based awards granted to our employees, directors, consultants and advisors based on the fair value on the date of the grant and recognize compensation expense for those awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. As we have limited trading history, we estimate our expected volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded share price. The expected term of our options has been determined utilizing a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date.&nbsp;&nbsp;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 1 to our audited consolidated financial statements included elsewhere in this&#160;Annual Report on Form 10-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards. The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section 404(b). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an &#8220;emerging growth company&#8221; until the earliest of (1) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (2) the last day of the fiscal year following the fifth anniversary of the completion of our IPO, (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30th, we have been a public company for at least 12 months and have filed one Annual Report on Form 10-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a><a name="ITEM_7A_MARKET_RISK"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_MARKET_RISK"></a>I<a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>tem 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash and cash equivalents, which are denominated in U.S. dollars. We had cash and cash equivalents of $180.9 million, or 77% of our total assets, at December&#160;31, 2019 and $103.2 million, or 74% of our total assets, at December 31, 2018. Interest income earned on these assets was $4.3 million and $1.9 million for the years ended December 31, 2019 and December 31, 2018, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. At December&#160;31, 2019, our cash equivalents consisted of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. Such interest-earning instruments carry a degree of interest rate risk; however, we do not anticipate fluctuations in interest rates to have a significant impact on our financial statements. We had no debt outstanding as of December 31, 2019 or 2018<font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also exposed to foreign exchange rate risk with respect to our global subsidiaries from foreign currency transactions.&nbsp;&nbsp;We do not anticipate foreign exchange rate risk to have a material impact on our financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item 8 are appended to this report and are incorporated herein by reference. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk29899614"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations on Effectiveness of Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of disclosure controls and procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s annual report on internal control over financial reporting</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding our internal control over financial reporting or an attestation report of our independent registered accounting firm due to a transition period established by rules of the SEC for newly public companies. Additionally, our independent registered accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 of Sarbanes-Oxley Act of 2002 until we are no longer an &#8220;emerging growth company&#8221; as defined in the JOBS Act.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in internal control over financial reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.<font style="font-weight:bold;color:#FF0000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_III"></a><a name="_AEIOULastRenderedPageBreakAEIOU112"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_OFFICERS"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_OFFICERS"></a>Ite<a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>m 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers and Directors</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the name, age and position of each of our executive officers and directors as of March 2, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derek Jantz, Ph.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer and Director</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari </p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Heery, M.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Scimeca</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Counsel and Secretary </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fayaz Khazi, Ph.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer, Elo Life Systems</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Thomson, Ph.D.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin Buehler (1)(3)</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raymond Schinazi Ph.D. (2)(3)</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shalini Sharp (1)(2)</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Yao, M.D., Ph.D. (1)(2)(3)</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the audit committee. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the compensation committee. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the nominating and corporate governance committee. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive Officers </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Matthew Kane<font style="font-style:normal;">, a co-founder of Precision, has served as our President and Chief Executive Officer and a director since our inception in 2006. Mr.&#160;Kane has nearly 20 years of experience in the life sciences industry, most of which has been spent specifically working in genome editing. Prior to co-founding Precision, Mr.&#160;Kane was with Suros Surgical Systems. Mr.&#160;Kane received a B.S. in mechanical engineering and an M.S. in biomedical engineering from the Rose-Hulman Institute of Technology and an M.B.A. from Duke University. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Mr.&#160;Kane is qualified to serve on our board of directors because of the perspective and experience he provides as one of our founders and as our President and Chief Executive Officer, as well as his many years of experience within the life sciences and agricultural biotechnology industries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Derek Jantz<font style="font-style:normal;">, </font>Ph.D.<font style="font-style:normal;">, a co-founder of Precision, has been our Chief Scientific Officer since August 2013 and has served on our board of directors since January 2006. He previously served as our Vice President of Scientific Development from our inception in 2006 to August 2013. Dr.&#160;Jantz is the co-inventor of several of our foundational patents and other intellectual property. As a protein engineer, he was an early developer of zinc finger technology and has spent most of his research career designing proteins for genome editing applications. Dr.&#160;Jantz received a B.A. in biology from the University of Colorado at Boulder and a Ph.D. in biophysics from the Johns Hopkins University School of Medicine. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Dr.&#160;Jantz&#8217;s extensive experience in genome editing and as an inventor of ARCUS, in addition to his perspective as one of our founders and senior executives, qualifies him to serve on our board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Abid Ansari<font style="font-style:normal;"> has served as our Chief Financial Officer since February 2019. Mr. Ansari previously served as our Vice President, Finance&#160;&amp; Operations from July 2016 to February 2019. Prior to joining us, Mr.&#160;Ansari served as Senior Director, Deal Finance and M&amp;A from November 2013 to July 2016 and Senior Director, Head of Portfolio Analysis Group from September 2011 to November 2013 for GlaxoSmithKline plc, a multinational pharmaceutical company. Before that, he served for five years in commercial and capital finance roles at MedImmune, LLC and three years as a plant controller at Uniqema (previously a division of Imperial Chemical Industries Plc). Mr.&#160;Ansari received a B.S. in chemical engineering and an M.B.A. from Purdue University. Mr.&#160;Ansari is also a Certified Public Accountant. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Christopher Heery, M.D.</font><font style="font-style:normal;"> has served as our Chief Medical Officer since May 2019. Prior to joining us, Dr. Heery served as Chief Medical Officer at Bavarian Nordic A/S</font><font style="font-style:normal;">, a biotechnology company,</font><font style="font-style:normal;"> from October 2016 to April 2019, where he oversaw clinical development programs for its immune-oncology and infectious disease portfolios. Prior to that, he was a Staff Clinician and then an Associate Research Physician and Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, or NCI, </font><font style="font-style:normal;">a U.S. government health agency, </font><font style="font-style:normal;">from April 2012 to November 2013 and November 2013 to September 2016, respectively, where he was part of a larger effort to create new immunotherapies for the treatment of cancer.&nbsp;&nbsp;He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. Dr. Heery is board certified in Medical Oncology and Internal Medicine.&nbsp;&nbsp;He received a B.A. from Duke University and a M.D. from East Carolina University Brody School of Medicine, and completed his internal medicine residency at the University of Illinois at Chicago.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dario Scimeca <font style="font-style:normal;">has served as our General Counsel since June 2019. Prior to joining us, Mr. Scimeca served in various roles for Genentech, a biotechnology company, U.S. affiliate of Roche, from January 2013 to June 2019, including most recently as Assistant General Counsel, where he counseled on legal issues associated with the development and commercialization of multiple drug oncology and rare disease products.&nbsp;&nbsp;Prior to that, he was corporate counsel at Elan Pharmaceuticals where he, among other things, oversaw FDA and EMA regulatory compliance matters.&nbsp;&nbsp;He has previously worked in both corporate transactional law and patent litigation at three national law firms. Mr. Scimeca received a B.S. from Santa Clara University, his J.D. from the University of California, Berkeley, School of Law, and clerked for Judge James L. Dennis on the United States Fifth Circuit Court of Appeals in New Orleans, Louisiana.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fayaz Khazi<font style="font-style:normal;">, </font>Ph.D.<font style="font-style:normal;">, has served as the CEO of our food-focused subsidiary, Elo Life Systems, since May 2018 and, prior to that, served as President of Elo Life Systems beginning in May 2017. From May 2014 to April 2017, Dr.&#160;Khazi served as the CEO of KeyGene USA, an agricultural biotechnology company. Dr.&#160;Khazi also held several executive leadership positions at Intrexon Corporation directing translation programs in the food, human health and agricultural biotechnology sectors, including serving as Vice President, Business Analytics and Strategy from January 2012 to January 2014, and also serving as Intrexon&#8217;s founding Director of Translational Medicine. Dr.&#160;Khazi received a B.Sc. from the University of Agricultural Sciences, Bangalore, and a Ph.D. in biological sciences from Auburn University. He trained as a Howard Hughes Medical Institute post-doctoral fellow and a senior researcher at the Children&#8217;s Hospital of Philadelphia, where he studied the genotoxicity of gene therapy vectors and developed </font>in vivo<font style="font-style:normal;"> genome-editing technologies to treat genetic diseases. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">David Thomson, Ph.D.<font style="font-style:normal;">, has served as our Chief Operating Officer since August 2019 and, prior to that, served as our Chief Development Officer beginning in June 2017. Prior to joining us, he served as&#160;Senior Vice President Research and Nonclinical Development for Shire plc, a specialty biopharmaceutical company, beginning in May 2016 until May&#160;2017 where he was responsible for the strategy and operational direction of the Global Research and Nonclinical Development Organization, including transitioning programs from research into clinical development and support of programs through commercialization. Prior to that, he served as Senior Vice President and Global Head, Research and Development Operations for Shire from February 2015 to May 2016. From May 2014 to January 2015, Dr.&#160;Thomson served as the Director of the Biomanufacturing Research Institute and Technology Enterprise and a Professor in the Department of Pharmaceutical Sciences of North Carolina Central University. From September 2012 to April 2014, Dr.&#160;Thomson served as Vice President, Shire Human Genetic Therapies and later Senior Vice President, Global Head of Research and Nonclinical Development for Shire plc.&#160;He received a B.Sc. in chemistry from the University of Strathclyde and a Ph.D. in organic chemistry from the University of Toronto, and he completed post-doctoral work at Yale University. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Directors </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Kevin Buehler<font style="font-style:normal;"> has served on our board of directors since November 2019. Mr. Buehler has over 30 years of experience in the healthcare industry, having most recently served from April 2011 to May 2014 as the Division Head of Alcon Laboratories, Inc., a division of Novartis AG, a multinational pharmaceutical company. Prior to that, from April 2009 to April 2011, he served as the Chief Executive Officer and President of Alcon Inc., after having served from 2007 to 2009 as Alcon Inc.&#8217;s Senior Vice President, Global Markets and Chief Marketing Officer and, from 2006 to 2007, as its Senior Vice President of the U.S. market and the Chief Marketing Officer. Mr. Buehler began his career with Alcon, Inc. in August 1984. Mr. Buehler holds a B.A. degree from Carroll University in Waukesha, WI, with concentrations in Business Administration and Political Science, and is a graduate of the Harvard Executive Program for Management Development.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Mr. Buehler&#8217;s more than 30 years of experience in the healthcare and industry, including both executive and board roles, qualify him to serve as member of our board of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34141788"></a>Raymond Schinazi, Ph.D., D.Sc<font style="font-style:normal;">., has served on our board of directors since March 2019. Dr. Schinazi has been the Frances Winship Walters Professor of Pediatrics and the Director of the Laboratory of Biochemical Pharmacology at Emory University, a private research university, since 2008 and 1992 respectively. From November 2014 to January 2019, Dr. Schinazi served on the board of directors of Cocrystal Pharma, Inc. Dr. Schinazi was also instrumental in the founding of a number of biotechnology companies, including Triangle Pharmaceuticals, Idenix Pharmaceuticals and Pharmasset, Inc. Dr.&#160;Schinazi currently serves on the board of directors of Brace Pharma Capital, ReViral Pharmaceuticals Ltd, Gliknik Inc., and serves on the board of trustees of amfAR, ICMEC and GVN. Dr. Schinazi is also a Charter Fellow of the National Academy of Inventors and a Fellow of the American Society of Microbiology. Dr. Schinazi received a B.Sc. and Ph.D. in chemistry and D.Sc. in biotechnology from the University of Bath. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Dr. Schinazi&#8217;s medical background and biotechnology experience qualify him to serve as a member of our board of directors. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shalini Sharp<font style="font-style:normal;"> has served on our board of directors since December 2018. Since 2012, Ms. Sharp has served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, holding the position of Chief Financial Officer since May 2012 and the position of Executive Vice President since January 2016. Between May 2012 and January 2016, she served as Senior Vice President of Ultragenyx. Prior to Ultragenyx, Ms. Sharp served in various executive capacities, and ultimately as Chief Financial Officer, of Agenus Inc., a biotechnology company, from August 2003 until May 2012. Ms. Sharp currently serves on the board of directors of Neurocrine Biosciences, Inc.. and Sutro Biopharma, Inc. and previously served on the board of directors of Agenus, Inc. and Array BioPharma Inc. Ms. Sharp received a B.A. in English literature and an M.B.A. from Harvard University. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Ms. Sharp&#8217;s more than 20 years of experience in the life sciences industry including both executive and board roles as well as her expertise in biotechnology, corporate strategy and finance qualify her to serve as a member of our board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tony Yao, M.D., Ph.D.,<font style="font-style:normal;"> has served on our board of directors since May 2018. Since April 2012, Dr.&#160;Yao has served as a portfolio manager at ArrowMark Partners, an asset management firm, where he leads the healthcare team and manages the healthcare portfolio. Dr.&#160;Yao currently serves on the board of directors of 4D Molecular Therapeutics, Inc. and NexImmune, Inc. Dr.&#160;Yao began his investment career in February 2002 as an analyst and later an assistant portfolio manager at Janus Capital Group. Dr.&#160;Yao received a Sc.B. in biochemistry from Brown University and a M.D. and Ph.D. in immunology from Stanford University. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Dr.&#160;Yao&#8217;s medical background and experience in private equity investing, particularly with healthcare companies, qualify him to serve as a member of our board of directors. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Audit Committee </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a separately designated standing audit committee. The current members of our audit committee are&#160;Kevin J. Buehler, Shalini Sharp and Tony Yao, M.D., Ph.D.&#160;Shalini Sharp serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the Nasdaq rules. Our board of directors has determined that&#160;each of Kevin J. Buehler, Shalini Sharp and Tony Yao, M.D., Ph.D. meet the independence requirements of Rule&#160;10A-3&#160;under the Exchange Act and the applicable Nasdaq rules. Our board of directors has determined that each of Kevin Buehler and Shalini Sharp is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Code of Ethics </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our code of business conduct and ethics is available under the Corporate Governance section of our website at <font style="font-style:italic;">www.precisionbiosciences.com</font>. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this Annual Report on Form 10-K.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This section discusses the material components of our 2019 compensation program for our principal executive officer and next two most highly compensated executive officers who are named in the Summary Compensation Table below. These &#8220;named executive officers&#8221; and their positions are: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Matthew Kane, President and Chief Executive Officer; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Christopher Heery, Chief Medical Officer; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Dario Scimeca, General Counsel. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a><font style="font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Summary Compensation Table</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information concerning the compensation of our named executive officers for the years presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and principal position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards&#160;($)(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">compensation($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232168"></a>Matthew Kane</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,990</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,166,460</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068,616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587,132</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Heery(5)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Chief Medical Officer</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,534</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,737,812</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,832</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,181,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Scimeca(7)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; General Counsel</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,375</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,055</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,532</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,710,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amounts reported for 2019 represent bonuses based upon our board&#8217;s assessment of the achievement of company and individual performance objectives for 2019, which were paid in February 2020. For Dr. Heery and Mr. Scimeca, the amounts shown also include one-time signing bonuses of $50,000 for Dr. Heery and $35,000 for Mr. Scimeca that were paid in connection with their commencing employment with us during 2019.  </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amounts reported reflect the grant date fair value of stock options computed in accordance with Accounting Standards Codification&#160;718, Compensation&#8212;Stock Compensation, or ASC&#160;718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of the option awards in Note 5 to our consolidated financial statements included in this Annual Report on Form 10-K. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amount reported includes 401(k) matching contributions by us of $10,672, nondiscriminatory life insurance premiums of $1,353, supplemental disability insurance premiums available to certain executives of $2,327, and tax&#160;gross-ups&#160;of $8 in connection with nondiscriminatory wellness and phone reimbursements for 2019.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amount reported includes 401(k) matching contributions by us of $5,733, nondiscriminatory life insurance premiums of $789, and supplemental disability insurance premiums available to certain executives of $310.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Dr. Heery was not employed with the company in 2018, and accordingly, compensation information for 2018 is not included in the table above.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amount reported represents relocation and housing expenses of $45,666 and $18,853 of tax gross-ups in connection therewith, nondiscriminatory life insurance premiums of $789, supplemental disability insurance premiums available to certain executives of $207, and tax gross-ups of $17 in connection with nondiscriminatory wellness and phone reimbursements for 2019.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Scimeca was not employed with the company in 2018, and accordingly, compensation information for 2018 is not included in the table above.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Annual Base Salaries</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. The following table shows the annual base salaries for 2019 of our named executive officers: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232169"></a>Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">salary ($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Heery</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Scimeca</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Mr. Kane&#8217;s annual base salary was increased from $350,000 to $523,000 in connection with our IPO. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a><font style="font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Bonuses </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to base salaries, our named executive officers were eligible to receive a cash bonus based on company and individual performance for 2019. The performance objectives for 2019 cash bonuses related to attaining certain clinical and non-clinical milestones, as well as financial and administrative achievements.&nbsp;&nbsp;In connection with our IPO, the target bonus amount for Mr.&#160;Kane was set at 50% of his base salary.&nbsp;&nbsp;The target bonus amount for Dr. Heery and Mr. Scimeca is 35% of their respective base salaries. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The actual bonus amounts paid to our named executive officers for 2019 are set forth above in the 2019 Summary Compensation Table in the column entitled &#8220;Bonus.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to their 2019 annual bonuses, Dr. Heery and Mr. Scimeca received sign-on bonuses of $50,000 and $35,000, respectively, in connection with commencing employment with us during 2019. Each sign-on bonus is subject to repayment in the event the executive voluntarily resigns or is terminated for cause within the first year of employment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Equity Compensation </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our equity award program is the primary vehicle for offering long-term incentives to our executives. We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. To date, we have used stock option grants for this purpose because we believe they are an effective means by which to align the long-term interests of our executive officers with those of our stockholders. The use of options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention tool for our executive officers, as well as for our other employees. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk32541630"></a>We award stock options broadly to our employees, including to our non-executive employees. Grants to our executives and other employees are made at the discretion of our board of directors and are not made at any specific time period during a year.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our IPO, we adopted our 2019 Incentive Award Plan, referred to as the 2019 Plan, to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and to enable our company to obtain and retain services of these individuals, which we believe are essential to our long-term success. Following the effectiveness of our 2019 Plan, we ceased making grants under our 2015 Plan. However, our 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We granted the following stock options to our named executive officers during 2019 under our 2019 Plan: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131164"></a>Named executive officers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane(1)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,252</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Heery(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Scimeca(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;font-style:italic;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;;font-weight:normal;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vests as to 25% of the underlying shares on May 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;;font-weight:normal;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vests as to 25% of the underlying shares on June 10, 2020 and vests in equal installments at the end of each successive three-month period over the following 36 months.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Retirement Plans</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently maintain the Precision BioSciences, Inc. 401(k) Plan, a defined contribution retirement savings plan, or the 401(k) Plan, for the benefit of our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. The Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. In 2019, we matched participants&#8217; elective salary deferral contributions to the 401(k) Plan up to 100% of the first 4% of the employee&#8217;s salary deferred. Matching contributions made by us vest immediately. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) Plan, and making matching contributions, adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU117"></a><font style="font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Employee Benefits and Perquisites</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers are eligible to participate in our employee benefit plans and programs, which include medical, dental and vision benefits, health and flexible spending accounts, life, short-term, long-term and supplemental individual disability, and supplemental insurance and wellness and tuition reimbursement to the same extent as our other full-time employees generally, subject to the terms and eligibility requirements of those plans. We also provide Messrs. Kane and Scimeca and Dr. Heery, along with certain other executive officers and senior employees, with certain supplemental disability insurance benefits. We also provide relocation benefits to our named executive officers as determined in our board&#8217;s discretion. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Outstanding Equity Awards at 2019 Fiscal Year-End</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each of our named executive officers as of December&#160;31, 2019. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option awards</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#) exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#) unexercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price ($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322,711</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.04</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/17/2021</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,318</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/23/2027</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,917</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/27/2028</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/22/2029</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Heery</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/3/2029</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Scimeca</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.39</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/3/2029</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;font-style:italic;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;;font-weight:normal;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vested as to 25% of the underlying shares on March 24, 2018 and vests in equal installments at the end of each successive three-month period over the following 36 months.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vested as to 25% of the underlying shares on September 28, 2019 and vests in equal installments at the end of each successive three-month period over the following 36 months.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the following 36 months.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vests as to 25% of the underlying shares on May 1, 2020 and vests in equal installments at the end of each successive three-month period over the following 36 months.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The option vests as to 25% of the underlying shares on June 10, 2020 and vests in equal installments at the end of each successive three-month period over the following 36 months.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into employment agreements with each of our named executive officers that set forth the terms and conditions of each executive&#8217;s employment with us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each employment agreement establishes an annual base salary and target bonus opportunity for each named executive officer,<font style="font-size:12pt;"> </font>the current amounts of which are described above under the headings &#8220;Annual Base Salaries&#8221; and &#8220;Bonuses&#8221;.&nbsp;&nbsp;The named executive officers are eligible to participate in our medical, dental and disability insurance, the 401(k), personal leave and other employee benefit plans and programs for which the named executive officer is eligible, subject to the terms and conditions of such plans and programs. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each named executive officer&#8217;s employment agreement and employment are terminable by either the named executive officer or us without cause on 30-days&#8217; notice. In the event that a named executive officer&#8217;s employment is terminated by us without cause or by the executive for good reason, in each case as defined in the employment agreements, then in addition to payment of any accrued amounts and subject to such named executive officer&#8217;s timely executing a release of claims and continuing to comply with obligations under his proprietary information agreement, he will be entitled to receive (1)&#160;base salary continuation for 12 months in the case of Mr.&#160;Kane or nine months in the case of Dr. Heery and Mr. Scimeca, and (2)&#160;reimbursement for additional costs the executive incurs for continued coverage under our group health insurance under the Consolidated Budget Reconciliation Act of 1985, or COBRA, for up to 12 months in the case of Mr. Kane or nine months in the case of Dr. Heery and Mr. Scimeca. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU118"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In lieu of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the foregoing, the employment agreements provide that, in the event a named executive officer&#8217;s employment is terminated by us without cause or by the named executive officer for good reason three months prior to or 12 months after the occurrence of a change in control, then, subject to his timely executing a release of claims and continuing to comply with obligations under his proprietary information</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement, then such named executive officer shall be entitled to (1) </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a lump sum payment equal to, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the case of Mr. Kane, 18 months of his then current base salary plus 1.5 times his target bonus, and in the case of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Heery and Mr. Scimeca, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 12 months of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">base salary</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> plus one times </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">his </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">target bonus, (2) reimbursement </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the additional costs the executive incurs for continued coverage under our group health insurance under COBRA </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for up to 18 months</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the case of Mr.&#160;Kane</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> up to 12 months</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the case of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Heery and Mr. Scimeca,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and (3)&#160;accelerated vesting of all unvested time-based equity grants. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the separate proprietary information, inventions, non-competition and non-solicitation agreement with each of Mr.&#160;Kane, Dr. Heery and Mr. Scimeca, referred to as the proprietary information agreement above, each named executive officer has agreed to refrain from competing with us or soliciting our employees, independent contractors, customers or suppliers, in each case, while employed and following the termination of his employment for any reason for a period of one year. Notwithstanding the foregoing, no such post-employment restrictions are intended to restrain Mr. Scimeca&#8217;s ability to practice law or violate any rules of professional conduct to which he is subject.&nbsp;&nbsp;Each named executive officer has acknowledged our ownership rights in any intellectual property and assigned any such ownership rights to us.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Director Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">2019 Option Grants to Non-Employee Directors</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our IPO, Dr. Schinazi was granted an option to purchase 34,544 shares, which option will vest as to 34% of the underlying shares on March 27, 2020 and in equal installments at the end of each three-month period over the following 24 months. In November 2019 in connection with his election to our board, Mr. Buehler was granted an option as an initial award under our non-employee director compensation program to purchase 60,776 shares of common stock. This option vests in 36 substantially equal monthly installments following November 8, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Policy</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our IPO, we adopted and our stockholders approved a compensation program for our non-employee directors under which each non-employee director is eligible to receive the following amounts for their services on our board of directors: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Upon the director&#8217;s initial election or appointment to our board of directors, an option to purchase shares of our common stock having an aggregate fair value of $350,000 (as determined under the policy); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">If the director has served on our board of directors for at least six months as of the date of an annual meeting of stockholders and will continue to serve as a director immediately following such meeting, an option to purchase shares of our common stock on the date of the annual meeting having an aggregate fair value of $175,000 (as determined under the policy); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">An annual director fee of $40,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">If the director serves on a committee of our board of directors, an additional annual fee as follows: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Chairman of the audit committee, $15,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Audit committee member other than the chairman, $7,500; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Chairman of the compensation committee, $12,250; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Compensation committee member other than the chairman, $6,000; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Chairman of the nominating and corporate governance committee, $8,250; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Nominating and corporate governance committee member other than the chairman, $4,500. </font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment will be prorated for any portion of a quarter that a director is not serving on our board.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU119"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted to our non-employee directors under the program have an exercise price equal to the fair market value of our common stock on the date of grant and expire not later than ten years after the date of grant. The stock options granted upon a director&#8217;s initial election or appointment vest in thirty-six substantially equal monthly installments following the date of grant. The stock options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vest in full upon the occurrence of a change in control</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#auto;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">2019 Director Compensation </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the compensation earned by our non-employee directors for their service on our board during 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232171"></a>Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees earned or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid in cash ($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards ($)(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total ($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin Buehler</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,599</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,962</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raymond Schinazi, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,195</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,081</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">326,276</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shalini Sharp</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,178</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,178</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Yao, M.D., Ph.D. (2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,644</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,644</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amounts reported reflect the grant date fair value of stock options computed in accordance with Accounting Standards Codification 718, Compensation&#8212;Stock Compensation, or ASC 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of the option awards in Note 5 to our consolidated financial statements included in this Annual Report.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The amount shown represents cash fees earned by Dr. Yao for his service on our board during 2019. Due to his association with ArrowMark Funds (as defined below), Dr. Yao is not permitted to receive compensation for his service on our board and elected to forego $29,000 of such fees. Dr. Yao was not granted options to purchase shares of our common stock during 2019.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below shows the aggregate numbers of option awards held as of December 31, 2019 by each non-employee director who was serving as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232172"></a>Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">securities underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unexercised options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#) vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of&#160;securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">underlying&#160;unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(#) unvested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin Buehler</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,688</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raymond Schinazi, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,985</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shalini Sharp</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,391</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Yao, M.D., Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Own</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ers and Management and Related Stockholder Matters. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information on our equity compensation plans as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to be Issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rights</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Rights</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Future</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plans</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(excluding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">reflected in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">column (a))(4)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plans Approved by Stockholders <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,204,041</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plans Not Approved by Stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,204,041</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of the Company&#8217;s 2006 Stock Incentive Plan, as amended (the &#8220;2006 Plan&#8221;), 2015 Stock Incentive Plan, as amended (the &#8220;2015 Plan&#8221;), 2019 Incentive Award Plan (the &#8220;2019 Plan&#8221;) and 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 1,385,203 outstanding options to purchase shares of our common stock under the 2006 Plan, 5,462,954 outstanding options to purchase shares of our common stock under the 2015 Plan and 2,070,959 outstanding options to purchase shares of our common stock under the 2019 Plan. Excludes purchase rights accruing under the 2019 ESPP.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As of December 31, 2019, the weighted-average exercise price of outstanding options under the 2006 Plan was $0.04, under the 2015 Plan was $7.27, and under the 2019 Plan was $11.05. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 2,679,041 shares available for future issuance under the 2019 Plan and 525,000 shares available for future issuance under the 2019 ESPP (of which 44,197 shares were issued with respect to the purchase period in effect as of December 31, 2019, which ended February 29, 2020).&nbsp;&nbsp;The 2019 Plan provides for an annual increase on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029 equal to the lesser of (A) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by the board. The number of shares available for issuance under the 2019 ESPP will be annually increased on the first day of each calendar year beginning on January 1, 2020 and ending on and including January 1, 2029, by an amount equal to the lesser of (A) 1% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares of common stock as determined by the board.&nbsp;&nbsp;The 2006 Plan expired in accordance with its terms in May 2016, and no further stock awards may be granted under the 2006 Plan. Additionally, following the effective date of the 2019 Plan, we ceased making grants under the 2015 Plan. To the extent outstanding stock options under the 2006 Plan or the 2015 Plan are forfeited or lapse unexercised, the shares of common stock subject to such stock options will be available for issuance under the 2019 Plan<font style="font-weight:bold;">.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34164893"></a>Security Ownership of Certain Beneficial Owners and Management</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information with respect to the beneficial ownership of our common stock as of March 2, 2020 by: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">each of our named executive officers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">each of our directors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">all of our executive officers and directors as a group. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU121"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares beneficially owned by each individual or entity listed in the table below is determined under rules promulgated by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which includes the power to dispose of or to direct the disposition of such security</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of such person, shares of common stock subject to options or other rights held by such person that are currently exercisable or will become exercisable within 60&#160;days of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2, 2020</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise noted, the address of all listed individuals or entities is c/o&#160;Precision BioSciences, 302&#160;East Pettigrew St., Suite&#160;A-100, Durham, North Carolina 27701. Each of individual and entity listed has sole voting and investment power with respect to the shares beneficially owned by such person unless otherwise noted, subject to community property laws where applicable.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Beneficial Owner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficially Owned</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficially Owned</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232174"></a>5% or Greater Shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venBio Global Strategic Fund, L.P. (1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265,141</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derek Jantz, Ph.D.&nbsp;&nbsp;(2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216,178</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital World Investors (3)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,062,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FMR LLC (4)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,630,134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Named Executive Officers and Directors</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane (5)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,298,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Heery, M.D. (6)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dario Scimeca (7)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,072</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin J. Buehler (8)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raymond F. Schinazi, Ph.D. (9)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shalini Sharp (10)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,345</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Yao, M.D., Ph.D. (11)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160,416</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All executive officers and directors as a group (11 persons) (12)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,522,381</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Represents less than 1%.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on information reported on a Schedule 13D filed on April 9, 2019, each of venBio Global Strategic Fund, L.P. (the &#8220;Fund&#8221;), venBio Global Strategic GP, L.P. (the &#8220;General Partner&#8221;), venBio Global Strategic GP, Ltd. (the &#8220;GP Ltd.&#8221;) and Robert Adelman and Corey Goodman (collectively, the &#8220;Directors&#8221;) have shared voting power and shared dispositive power over 4,265,141 shares of our common stock. The Fund directly holds 4,265,141 shares of our common stock. As the sole general partner of the Fund, the General Partner may be deemed to beneficially own the shares held by the Fund and as the sole general partner of the General Partner, the GP Ltd. may be deemed to beneficially own the shares held by the Fund. As directors of the GP Ltd., each of the Directors may be deemed to beneficially own the shares held by the Fund. The business address of each of the reporting persons listed in this footnote is 1700 Owens Street, Suite 595, San Francisco, CA 94158.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of (a) 3,858,346 shares of common stock and (b) 357,832 shares of common stock underlying options exercisable within 60 days of March 2, 2020. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on information reported on a Schedule 13G filed on February 14, 2020, <font style="color:#000000;">Capital World Investors, a division of Capital Research and Management Company (CRMC), has sole voting power and sole dispositive power over 4,062,000 shares of our common stock. </font>The business address of <font style="color:#000000;">Capital World Investors</font> is <font style="color:#000000;">333 South Hope Street, Los Angeles, CA 90071.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on information reported on a Schedule 13G/A filed on February 7, 2020, FMR LLC <font style="color:#000000;">has sole voting power over 2,534,287 shares of our common stock and sole dispositive power over 2,630,134 shares of our common stock, and Abigail P. Johnson has sole dispositive power over 2,630,134 shares of our common stock.&nbsp;&nbsp;The business address of each of the reporting persons listed in this footnote is 245 Summer Street, Boston, Massachusetts 02210.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of (a) 1,815,922 shares of common stock held directly by Mr.&#160;Kane, (b) 8,718 shares of common stock held by Chelsea Lynam, Mr.&#160;Kane&#8217;s wife, (c) 448,542 shares of common stock underlying options held by Mr.&#160;Kane exercisable within 60 days of March 2, 2020 and (d) 25,474 shares of common stock underlying options held by Ms.&#160;Lynam exercisable within 60 days of March 2, 2020.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consists of (a) </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,485</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock and (b) </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock underlying options exercisable within 60 days of March 2, 2020.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 2,072 shares of common stock.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of (a) 8,440 shares of common stock underlying options exercisable within 60 days of March 2, 2020.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of (a) 93,048 shares of common stock held by RFS Partners, LP, or RFS. RFS &amp; Associates, LLC, or RFS &amp; Associates, is the general partner of RFS and Dr. Schinazi is a limited partner of RFS as well as the manager of RFS &amp; Associates. Dr. Schinazi may be considered the beneficial owner of the shares held by RFS and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The principal business address of RFS is 1860 Montreal Road, Tucker, GA 30084 and (b) 15,258 shares of common stock underlying options held by Dr. Schinazi exercisable within 60 days of March 2, 2020. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 62,345 shares of common stock underlying options exercisable within 60 days of March 2, 2020.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of (a) 4,450 shares of common stock held directly by Dr.&#160;Yao, (b)&#160;151,516 shares of common stock held by ArrowMark Life Science Fund, LP, or ArrowMark Fund, and (c) 4,450 shares of common stock held by THB Iron Rose, LLC Life Science Portfolio, or THB Fund. ArrowMark Colorado Holdings LLC, or ArrowMark Colorado, is an investment advisor to ArrowMark Fund and THB Fund. Dr. Yao, one of our directors, is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by ArrowMark Fund and THB Fund. Dr. Yao may be considered the beneficial owner of the shares held by ArrowMark Fund and THB Fund and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The principal business address of ArrowMark Fund and THB Fund is 100 Fillmore Street, Suite 325, Denver, Colorado 80206. &nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of (a) 6,184,909 shares of common stock and (b) 1,337,472 shares of common stock underlying options exercisable within 60 days of March 2, 2020.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors recognizes that transactions with related persons present a heightened risk of conflicts of interests and/or improper valuation (or the perception thereof). Our board of directors has adopted a written policy on transactions with related persons, which requires that our audit committee approve or ratify related person transactions required to be disclosed pursuant to Item 404(a) or, if applicable, Item 404(d) of Regulation S-K.&nbsp;&nbsp;Item 404 of Regulation S-K requires disclosure, subject to certain exceptions, of transactions in which we were or are to be a participant and the amount involved exceeds $120,000 (or such other amount is applicable while we remain a smaller reporting company) and in which any &#8220;related person&#8221; as defined under Item 404(a) of Regulation S-K had or will have a direct or indirect material interest). It is our policy that directors interested in a related person transaction will recuse themselves from any vote on a related person transaction in which they have an interest. Each of the transactions described below entered into following the adoption of our related person transaction policy was approved in accordance with such policy.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Duke License </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As more fully described in Part I, Item 1. &#8220;Business&#8212;License and Collaboration Agreements&#8212;Duke University,&#8221; we are party to the Duke License, pursuant to which Duke granted us an exclusive license (subject to certain exceptions) under certain patents owned by Duke related to certain meganucleases and methods of making such meganucleases. The patents in-licensed by us from Duke pursuant to the Duke License were invented by Dr. Jantz, one of our executive officers, a director and a beneficial owner of more than 5% of our common stock, Jeff Smith, Ph.D., one of our employees and formerly a beneficial owner of more than 5% of our common stock, and another inventor who is not affiliated with us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Duke&#8217;s inventors&#8217; policy, inventors of intellectual property invented at Duke, including the inventors of patents licensed to us under the Duke License, are entitled to a portion of the income derived from such inventions. Accordingly, Drs. Jantz and Smith are entitled to receive a portion of the amounts we pay to Duke under the Duke License, together with amounts received by Duke from sales of common stock that we issued to Duke at the inception of the Duke License, are payable by Duke directly to Drs. Jantz and Smith. In connection with the Duke License, Drs. Jantz and Smith each received $284,869 from Duke during the year ended December 31, 2018, and each received $440,625 from Duke during the year ended December 31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Participation in our Initial Public Offering</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our IPO, certain of our stockholders and members of our board of directors purchased shares of our common stock from the underwriters at the initial public offering price of $16.00 per share, and on the same terms as other investors in our IPO. The following table summarizes purchases of shares of our common stock in our IPO by beneficial owners of more than 5% of our capital stock and entities affiliated with members of our board of directors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Purchased</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Purchase Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5% or greater stockholders and directors</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-Prime Capital Partners Healthcare Fund IV LP</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Capital Healthcare Fund, L.P.</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venBio Global Strategic Fund, L.P.(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:-3.4%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Robert Adelman, M.D., a former member of our board of directors, is a partner at venBio Global Strategic Fund, L.P. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Series B Preferred Stock Financing </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From May 2018 to July 2018, we issued and sold to investors in a private placement 21,956,095 shares of our Series B preferred stock at a price per share of $5.01, for aggregate gross proceeds of $110.0&#160;million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Series B preferred stock purchased by directors, executive officers, then beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred&#160;Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Purchase Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131173"></a>5% or greater stockholders and directors</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen Investments Ltd.(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">499,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-Prime Capital Partners Healthcare Fund IV LP(2)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">873,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,374,997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RA Capital Healthcare Fund, L.P.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venBio Global Strategic Fund, L.P.(3)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">998,004</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,500,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Yao(4)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,595</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RFS Partners, LP(5)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,761</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,003</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.4%;text-indent:-3.4%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Series B preferred stock was purchased by Amgen Ventures LLC, an affiliate of Amgen Investment Ltd. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ben Auspitz, a former member of our board of directors, is a partner at F-Prime Capital Partners, a fund affiliated with FMR LLC. Mr.&#160;Auspitz does not hold voting or dispositive power over the shares held by F-Prime Capital Partners Healthcare Fund IV LP. See Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for more information. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Robert Adelman, M.D., a former member of our board of directors, is a partner at venBio Global Strategic Fund, L.P. See Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for more information. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Tony Yao, M.D., Ph.D. is a current member of our board of directors. Dr.&#160;Yao is associated with the ArrowMark Funds (as defined below). See Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for more information. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Raymond Schinazi, Ph.D. is a current member of our board of directors. Dr. Schinazi is associated with RFS Partners, LP. See Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for more information. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Convertible Note Financing </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, we sold and issued $39.6 million aggregate principal amount of convertible notes payable, or the 2019 Notes, in a private placement transaction. ArrowMark Fundamental Opportunity Fund, L.P. purchased $0.6 million of 2019 Notes, and ArrowMark Life Science Fund, L.P. purchased $0.5 million of 2019 Notes. Tony Yao, M.D., Ph.D. is a current member of our board of directors and is associated with the ArrowMark Funds (as defined below). RFS Partners, LP purchased $0.5 million of 2019 Notes. Raymond Schinazi, Ph.D. is a current member of our board of directors and is associated with RFS Partners, LP. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Notes </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">converted </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into 2,921,461 shares of common stock immediately prior to the closing of our IPO. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investors&#8217; Rights Agreement </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to an amended and restated investors&#8217; rights agreement, as amended, which we refer to as our investors&#8217; rights agreement, with each holder of our convertible preferred stock and 2019 Notes and certain holders of our common stock (Derek Jantz, Matthew Kane and Jeff Smith), which includes each holder of more than 5% of our capital stock and certain of our directors (Matthew Kane, Derek Jantz, Raymond Schinazi and Tony Yao, M.D., Ph.D.) (or, in some cases, entities affiliated therewith). Our investors&#8217; rights agreement imposes certain affirmative obligations on us and also grants certain rights to the holders, including certain registration rights with respect to the registrable securities held by them that survived our IPO.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director and Officer Indemnification and Insurance </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have agreed to indemnify each of our directors and executive officers against certain liabilities, costs and expenses and have purchased directors&#8217; and officers&#8217; liability insurance.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into employment agreements with certain of our executive officers, including our named executive officers. For more information regarding the agreements with our named executive officers, see Part III, Item 11, &#8220;Executive Compensation&#8212;Employment Agreements.&#8221; </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Option Grants to Executive Officers and Directors </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted stock options to our executive officers as more fully described in Part III, Item 11, &#8220;Executive Compensation.&#8221; </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Transactions </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_28_951"></a><a name="_cp_text_1_953"></a>Chelsea Lynam, Mr. Kane&#8217;s wife, serves as our Manager, Facilities Planning &amp; Design. Ms. Lynam earned total compensation of $273,375 in 2018 in respect of base salary, bonus and the grant date fair value of options to purchase 28,106 shares of our common stock. <a name="_cp_text_28_951"></a>Ms. Lynam earned total compensation of $111,518<a name="_cp_text_1_953"></a> in 2019 in respect of base salary and bonus. Ms. Lynam also participates in other employee benefit plans and arrangements that are made generally available to other employees.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Independence</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_954"></a><a name="_cp_text_28_955"></a>Our board of directors has determined that, of our six directors serving as of March 2, 2020<a name="_cp_text_1_954"></a>, Kevin Buehler, Raymond Schinazi Ph.D., Shalini Sharp and Tony Yao, M.D., Ph.D. do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the applicable listing rules of The Nasdaq Stock Market LLC, or the Nasdaq rules. <a name="_cp_text_28_955"></a>Furthermore, the board of directors determined that, during his service as a director during 2019, Robert Adelman, M.D., qualified as an independent director under applicable Nasdaq rules. There are no family relationships among any of our directors or executive officers. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accountant Fees and Services. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fees of Deloitte &amp; Touche LLP, our independent registered public accounting firm, billed to us in each of the last two fiscal years (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fee Category</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131174"></a><a name="_cp_text_1_979"></a>Audit fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,492</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Audit Fees</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit fees consisted of the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#2E2E2E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#2E2E2E;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#2E2E2E;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#2E2E2E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_cp_text_1_965"></a><a name="_cp_blt_1_971"></a><font style="color:#000000;font-family:Times New Roman;">F<a name="_cp_text_1_965"></a>ees for the audit of our consolidated financial statements, the review of the unaudited interim financial statements included in our quarterly reports on Form 10-Q and other professional services provided in connection with statutory and regulatory filings or engagements<a name="_cp_blt_1_971"></a>. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#2E2E2E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#2E2E2E;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#2E2E2E;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;color:#2E2E2E;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_cp_text_1_970"></a><font style="color:#000000;font-family:Times New Roman;">F<a name="_cp_text_1_970"></a>ees for assurance and related services that are reasonably related to the performance of the audit or review of the registrant's financial statements, including for assurance reporting on our historical financial information included in our SEC registration statement in connection with our initial public offering.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Tax Fees</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_974"></a><a name="_cp_text_1_976"></a><a name="_cp_text_1_974"></a>Tax fees <a name="_cp_text_1_976"></a>consisted of fees for tax compliance, tax advice, and tax planning services.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">All Other Fees</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other fees consisted of subscription fees for accounting research software.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_978"></a><a name="_cp_text_1_983"></a><a name="_cp_text_1_983"></a>Audit Committee Pre-Approval Policy and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_984"></a>The formal written charter for our audit committee requires that the audit committee pre-approve all audit services to be provided to us, whether provided by our principal auditor or other firms, and all other services (review, attest and non-audit) to be provided to us by our independent registered public accounting firm, other than <font style="font-style:italic;">de minimis</font> non-audit services approved in accordance with applicable SEC rules. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_985"></a>The audit committee has adopted a policy (the &#8220;Pre-Approval Policy&#8221;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by our independent registered public accounting firm may be pre-approved. The Pre-Approval Policy generally provides that the audit committee will not engage an independent registered public accounting firm to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the audit committee (&#8220;specific pre-approval&#8221;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#8220;general pre-approval&#8221;). Unless a type of service to be provided by our independent registered public accounting firm has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the audit committee or by a designated member of the audit committee to whom the committee has delegated the authority to grant pre-approvals.&nbsp;&nbsp;Any member of the audit committee to whom the committee delegates authority to make pre-approval decisions must report any such pre-approval decisions to the audit committee at its next scheduled meeting. If circumstances arise where it becomes necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval categories or above the pre-approved amounts, the audit committee requires pre-approval for such additional services or such additional amounts.&nbsp;&nbsp;Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval.&nbsp;&nbsp;For both types of pre-approval, the audit committee will consider whether such services are consistent with the SEC&#8217;s rules on auditor independence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_986"></a>On an annual basis, the audit committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that may be provided by our independent registered accounting firm without first obtaining specific pre-approval from the Audit Committee.&nbsp;&nbsp;The audit committee may revise the list of general pre-approved services from time to time, based on subsequent determinations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The services provided to us by Deloitte &amp; Touche LLP in 2019 and 2018 were provided in accordance with our pre-approval policies and procedures, as then applicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_IV"></a><a name="_AEIOULastRenderedPageBreakAEIOU126"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(1) Financial Statements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are included on pages F-1 through F-24 attached hereto and are filed as part of this Annual Report on Form 10-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Auditor_Report"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets as of December 31, 2019 and December 31, 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERAT"><font style="text-decoration:underline;">Consolidated Statements of Operations for the Years Ended December 31, 2019 and December 31, 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_EQUITY"><font style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2019 and December 31, 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2019 and December 31, 2018</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_CONSOLIDATED_FS"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(2) Financial Statement Schedules</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(3) Exhibits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU127"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Index</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:6.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:47.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="top"  style="width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;3.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8&#8209;K</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001&#8209;38841</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%; border-top:solid 0.75pt #000000;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;3.2</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of Precision BioSciences, Inc.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8&#8209;K</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001&#8209;38841</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex41.htm"><font style="text-decoration:underline;">Specimen Common Stock Certificate</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.2</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex42.htm"><font style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement among Precision BioSciences, Inc. and certain of its stockholders and the holders of the 2019 Notes, dated May&#160;25, 2018, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.3</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000156459020003581/dtil-ex101_6.htm"><font style="text-decoration:underline;">Amendment No. 2, dated February 3, 2020, to the Amended and Restated Investors&#8217; Rights Agreement among Precision BioSciences, Inc. and certain of its stockholders and the holders of the 2019 Notes, dated May&#160;25, 2018, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8&#8209;K</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38841</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/6/2020</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;4.4</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex44_578.htm"><font style="text-decoration:underline;">Description of the Registrant's Securities</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000156459019019846/dtil-ex101_33.htm"><font style="text-decoration:underline;">Loan and Security Agreement, dated May&#160;15, 2019, among Precision BioSciences, Inc., Elo Life Systems,&#160;Inc. and Pacific Western Bank</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8&#8209;K</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001&#8209;38841</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/20/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000156459019042519/dtil-ex101_167.htm"><font style="text-decoration:underline;">First Amendment, dated September&#160;18, 2019, to Loan and Security Agreement, dated May&#160;15, 2019, among Precision BioSciences, Inc., Elo Life Systems,&#160;Inc. and Pacific Western Bank</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10&#8209;Q</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001&#8209;38841</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex103_740.htm"><font style="text-decoration:underline;">Second Amendment, dated December 3, 2019, to Loan and Security Agreement, dated May&#160;15, 2019, among Precision BioSciences, Inc., Elo Life Systems,&#160;Inc. and Pacific Western Bank</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex101.htm"><font style="text-decoration:underline;">Development and Commercial License Agreement by and between Les Laboratoires Servier and Precision BioSciences, Inc., dated February&#160;24, 2016, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;&#8224;</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000156459019042519/dtil-ex102_380.htm"><font style="text-decoration:underline;">Amendment No.&#160;5, dated September 18, 2019, to Development and Commercial License Agreement by and between Les Laboratoires Servier and Precision BioSciences, Inc., dated February&#160;24, 2016, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10&#8209;Q</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001&#8209;38841</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex102.htm"><font style="text-decoration:underline;">License Agreement by and between Duke University and Precision BioSciences, Inc., dated April&#160;17, 2006, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex103.htm"><font style="text-decoration:underline;">Patent Cross&#8209;License Agreement by and between Cellectis&#160;SA and Precision BioSciences, Inc., dated January&#160;23, 2014</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex104.htm"><font style="text-decoration:underline;">Collaboration and License Agreement by and between Gilead Sciences,&#160;Inc. and Precision BioSciences, Inc., dated September&#160;10, 2018</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/13/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex109_943.htm"><font style="text-decoration:underline;">Lease Agreement between Precision BioSciences, Inc. and Venable Tenant, LLC, dated April&#160;5, 2010, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex106.htm"><font style="text-decoration:underline;">Lease Agreement between Elo Life Systems,&#160;Inc. and ARE&#8209;NC Region No.&#160;17,&#160;LLC, dated March&#160;29, 2018, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex1011_944.htm"><font style="text-decoration:underline;">Lease Agreement between Precision BioSciences, Inc. and Durham TW Alexander,&#160;LLC, dated October&#160;2, 2018, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex108.htm"><font style="text-decoration:underline;">2006 Stock Incentive Plan, as amended, and form of award agreements thereunder</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:6.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:0.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:47.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="top"  style="width:1.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU128"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></font></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519061192/d717633dex109.htm"><font style="text-decoration:underline;">2015 Stock Incentive Plan, as amended, and form of award agreements thereunder</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1010.htm"><font style="text-decoration:underline;">2019 Incentive Award Plan, and forms of award agreements thereunder</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1011.htm"><font style="text-decoration:underline;">2019 Employee Stock Purchase Plan</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1012.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and Matthew Kane, dated February&#160;27, 2019</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1013.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and Derek Jantz, dated February&#160;27, 2019</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1014.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and Abid Ansari, dated February&#160;27, 2019</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex1019_945.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and David Thomson, dated February&#160;27, 2019, as amended</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1016.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and Fayaz Khazi, dated February&#160;27, 2019</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1/A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex1021_743.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and Christopher Ryan Heery, dated April 1, 2019</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex1022_742.htm"><font style="text-decoration:underline;">Employment Agreement between Precision BioSciences, Inc. and Dario, Scimeca dated April 11, 2019</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1017.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between Precision BioSciences, Inc. and its directors and officers</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24<sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex1018.htm"><font style="text-decoration:underline;">Non&#8209;Employee Director Compensation Plan</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#8209;1A</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333&#8209;230034</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/18/2019</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex211_699.htm"><font style="text-decoration:underline;">Subsidiaries of Precision BioSciences, Inc.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex231_741.htm"><font style="text-decoration:underline;">Consent of Deloitte &amp; Touche LLP</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex312_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex321_6.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex322_7.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top"  style="width:0.88%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:47.28%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.46%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11.48%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.84%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.94%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.5%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:73.33%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;</sup></font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment of certain provisions has been granted by the SEC pursuant to Rule&#160;406 under the Securities Act of 1933, as amended.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#8224;&#8224;</sup></font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">#</sup></font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Denotes a management contract or compensation plan or arrangement</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU129"></a><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company Name</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
</tr>
<tr style="height:10.95pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Matthew Kane&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">principal executive officer</font>)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Abid Ansari&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">principal financial officer</font>)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 10, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Raymond Schinazi</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 10, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Raymond Schinazi, PhD, DSc</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Shalini Sharp</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 10, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shalini Sharp</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Kevin Buehler</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 10, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kevin Buehler</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Tony Yao</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 10, 2020</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tony Yao, MD, PhD</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU130"></a><a name="Auditor_Report"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Auditor_Report"></a>Re</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>port of Independent Regist</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ered Public Accounting Firm</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the stockholders and the Board of Directors of Precision BioSciences, Inc. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Precision BioSciences, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2019 and 2018, the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit) and cash flows, for each of the two years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change in Accounting Principle</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 1 to the financial statements, the Company has changed its method of accounting for revenue from contracts with customers in 2019 due to the adoption of Accounting Standards Update No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raleigh, North Carolina </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2020</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a><a name="PART_I_FINANCIAL_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I_FINANCIAL_INFORMATION"></a>PART I. FINANCI</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AL INFORMATION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1.&#160;&#160;Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34553330"></a>Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,193</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,913</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,324</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,046</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,672</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,675</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment, and software&#8212;net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,571</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,147</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets&#8212;net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,466</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">558</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">312</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,218</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,486</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,932</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue&#8212;noncurrent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,895</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,807</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent&#8212;noncurrent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,092</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,758</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,919</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,640</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock; $0.0001 par value&#8212; no shares issued and outstanding as of December 31, 2019; 25,650,000 shares authorized, issued and outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock; $0.0001 par value&#8212; no shares issued and outstanding as of December 31, 2019; 21,956,100 shares authorized; 21,956,095 shares issued and outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.0001 par value&#8212; 10,000,000 shares authorized as of December 31, 2019 and no shares authorized as of December 31, 2018; no shares issued and outstanding as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock; $0.000005 par value&#8212; 200,000,000 shares authorized, 51,965,708 shares issued and 51,155,236 shares outstanding as of December 31, 2019; 16,717,117 shares issued and 15,906,645 shares outstanding as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316,333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,094</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,067</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,187</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treasury stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,314</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,233</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERAT"></a><a name="CONSOLIDATED_STATEMENTS_OPERAT"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"><a name="_Hlk532384106"></a>&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232177"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,416</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,795</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,912</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,267</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock outstanding-</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,991,162</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,775,541</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU133"></a><a name="CONSOLIDATED_STATEMENTS_EQUITY"></a><font style="font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_EQUITY"></a>PRE</font><font style="font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">CISION BIOSCIENCES, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">CONSOLIDATED STATEMENTS OF CHANGES IN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Treasury</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholder's</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance- January 1,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,650,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,496,801</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,691</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,111</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,369</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock, net of issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,956,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option exercises</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,316</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,492</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,037</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance- December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,650,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,956,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,717,117</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,094</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,187</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment to beginning</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accumulated deficit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; from adoption of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; ASU 2014-09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,650,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,956,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,301,190</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock upon conversion</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of convertible notes</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,921,461</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,490</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,490</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock in initial public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offering, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; discounts and issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,085,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,543</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,543</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option exercises</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">940,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance- December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,965,708</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316,333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,067</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,314</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU134"></a><font style="font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">PRECISION BIOSCIENCES, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232180"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,037</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,317</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,354</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of property, equipment, and software</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(584</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,476</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(523</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(448</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,790</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,866</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,177</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,723</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of license rights</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property, equipment and software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,278</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from disposal of property, equipment, and software</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from stock option exercises</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,136</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from IPO, net of underwriting discounts and commissions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,374</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,391</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents&#8212;beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,802</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents &#8212;end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,193</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash financing and investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued on conversion of convertible notes payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,490</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software additions included in accounts payable,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,340</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs included in accounts payable, accrued expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_118"></a><a name="_AEIOULastRenderedPageBreakAEIOU135"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_CONSOLIDATED_FS"></a><a name="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"></a><a name="NOTES_CONSOLIDATED_FS"></a>No<a name="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"></a>tes to Consolidated Financial Statements (Unaudited)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc. (the &#8220;Company&#8221;) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is focused on utilizing its proprietary genome editing platform to help overcome cancers, cure genetic diseases and enable the development of safer, more productive food sources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc.&#160;&#160;Elo Life Systems Australia Pty Ltd was incorporated on May 29, 2018 as a 100% owned subsidiary of Elo Life Systems, Inc.&#160;&#160;The Company&#8217;s 100% owned subsidiary, Precision BioSciences UK Limited, was incorporated on June 17, 2019.&#160;&#160;The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company&#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, the Company completed its initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold 9,085,000 shares of its common stock at a public offering price of $16.00 per share and received approximately $130.5 million in net proceeds, after deducting underwriting discounts and commission of approximately $10.2 million and issuance costs of approximately $4.6 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO, on March 15, 2019 the Company effected a reverse split of shares of the Company&#8217;s common stock on a 1-for-2.134686 basis (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company&#8217;s Series A and Series B preferred stock.&#160;&#160;Accordingly, all common shares, stock option shares, and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this Reverse Stock Split and adjustment of the preferred stock conversion ratios.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized common shares were not affected by the Reverse Stock Split.&#160;&#160;Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 22,301,190 shares of common stock at the applicable ratio then in effect and the outstanding convertible notes payable, including accrued interest, were settled into 2,921,461 shares of common stock. Subsequent to the closing of the IPO, there were no shares of Series A or Series B convertible preferred stock or convertible notes payable outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ from those estimates. Significant estimates include recording revenue for performance obligations recognized over time, determination of the fair value of share-based compensation grants and estimating services expended by third-party service providers used to recognize research and development expense. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements have been prepared in accordance with GAAP. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. During the year ended December&#160;31, 2019, the Company incurred a net loss of $92.9&#160;million and, as of December&#160;31, 2019, has an accumulated deficit of $177.1 million. The Company has financed operations primarily through its IPO, private placements of convertible preferred stock and convertible debt and with proceeds from its development and commercial license agreement with Les Laboratoires Servier, (&#8220;Servier&#8221;) and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) (see Note 12). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU136"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that existing cash and cash equivalents will allow the Company to continue its operations into 2021. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the presentation of amounts in our Consolidated Balance Sheet as of December&#160;31, 2019 to conform to the prior year presentation. Specifically, certain current liabilities were reclassified from accrued expenses and other current liabilities and are now presented separately on our Consolidated Balance Sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2019 and December 31, 2018, the Company held cash equivalents composed of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. All of the Company&#8217;s cash and cash equivalents are held at financial institutions that management believes to be of high credit quality. The Company may maintain cash deposits in financial institutions in excess of government insured limits. The Company regularly invests excess cash deposits in money market funds and repurchase agreements. The Company believes that the credit risk arising from the holdings of these financial instruments is mitigated by the fact that these securities are of short duration, government backed and of high credit rating. The Company has not experienced any losses on cash and cash equivalents to date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from two development and license agreements accounted for 60% and 33% of revenue during 2019 and 34% and 53% of revenue during 2018, as well as 2% and 98% of deferred revenue as of December&#160;31, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Equity Offering Costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes incremental legal, professional accounting and other third-party fees directly associated with the Company&#8217;s planned equity offerings as other current assets until the equity offering is consummated. After consummation, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital. If the equity offering is not completed, any costs deferred will be expensed immediately. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, Equipment and Software </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software are stated at cost, net of depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciation and amortization periods for the Company&#8217;s significant property, equipment and software categories are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:307.45pt;"></td>
<td style="width:232.55pt;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 to 7 years</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 years</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser&#160;of&#160;remaining&#160;lease&#160;term&#160;or&#160;useful&#160;life</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repairs and maintenance are charged to operations as incurred, and expenditures for additions and improvements that extend the useful life of the asset are capitalized. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU137"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets primarily include licenses and patents. The Company capitalizes license fees paid to acquire access to proprietary technology if the technology is expected to have alternative future use in multiple research and development projects. The cost of licensed technology rights is amortized using the straight-line method over the estimated useful life of the technology. If the access to use the technology rights is one year or less, the cost is recorded as a prepaid expense and amortized over the period identified in the agreement. Amortization expense for licensed technology and capitalized patent costs is included in research and development expenses within the accompanying consolidated statement of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, such as property, equipment and software and intangible assets, subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is assessed when future undiscounted cash flows are less than the assets&#8217; carrying value and recognized when the carrying value of the asset exceeds fair value. Fair value is calculated by estimating the discounted future cash flows expected to be generated by the asset as well as other valuation techniques. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value of the asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition for Contracts with Customers</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenues are generated primarily through collaborative research, license, development and commercialization agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;), using the modified retrospective transition method. Under this method, results for reporting periods beginning on January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, <font style="font-style:italic;">Revenue Recognition</font> (&#8220;ASC 605&#8221;). The Company applied the modified retrospective transition method to contracts that were not completed as of January 1, 2019. For the year ended December 31, 2019, the Company reduced revenue recognition by $1.4 million for changes in total estimated time to be incurred in the future to satisfy the performance obligation. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options.&#160;&#160;The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue.&#160;&#160;Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue &#8211; noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the other current assets line item in the accompanying consolidated balance sheets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU138"></a><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments </font><font style="font-style:normal;">&#8211;</font><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> </font><font style="font-style:normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, </font><font style="font-style:normal;">are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is</font><font style="font-style:normal;"> </font><font style="font-style:normal;">unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment</font><font style="font-style:normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties <font style="font-style:normal;">&#8211;</font> <font style="font-style:normal;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation linked to some or all of the royalty has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Significant Financing Component <font style="font-style:normal;">&#8211; In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.&#160;&#160;The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&#160;&#160;The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements <font style="font-style:normal;">&#8211; The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company&#8217;s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaboration arrangements to assess whether the collaboration agreements are within the scope of accounting standards codification (&#8220;ASC&#8221;) ASC 808, <font style="font-style:italic;">Collaborative Arrangements</font> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&#160;&#160;For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional discussion of accounting for collaboration revenues, see Note 12, &#8220;Collaboration and license agreements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities including salaries, benefits, share-based compensation, allocations for rent and facility costs, depreciation, preclinical manufacturing expenses, costs of services provided by contract research organizations (&#8220;CROs&#8221;) in connection with preclinical trials and contract manufacturing organizations (&#8220;CMOs&#8221;) engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU139"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate accrued research and development expenses resulting from its obligations under contracts with CROs, CMOs, research organizations, service providers, vendors and consultants in connection with research and development activities. The financial terms of these contracts are subject to negotiations and vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate research and development expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#8217;s estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to prior estimates of accrued research and development expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Valuation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted prior to the IPO, the Company considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock was determined based upon a variety of factors, including the illiquid nature of the common stock, the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2019 and December 31, 2018, there was no difference between net loss and comprehensive loss in the accompanying consolidated financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2019 and December 31, 2018 since all potential shares of common stock are anti-dilutive as a result of the net loss. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-Based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all share-based compensation, including stock options and the employee stock purchase plan at fair value and recognizes compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each equity grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the Company&#8217;s expected dividend yield. As the Company has limited trading history, expected volatility is estimated based on the historical volatility of publicly traded peer companies and the Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of our traded share price. The expected term of the options has been determined utilizing a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date.&nbsp;&nbsp;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU140"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined based on the temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than the enactment of changes in the tax law or rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting Standards Updates</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section&#160;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The JOBS Act also exempts the Company from having to provide an auditor attestation of internal controls over financial reporting under Sarbanes-Oxley Act Section&#160;404(b). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will remain an &#8220;emerging growth company&#8221; until the earliest of (i)&#160;December 31, 2024, (ii) the last day of the fiscal year in which it has total annual gross revenues of $1.07&#160;billion or more, (iii)&#160;the date on which it has issued more than $1.0&#160;billion in nonconvertible debt during the previous three years or (iv)&#160;the date on which it is deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), which generally is when it has more than $700&#160;million in market value of its stock held by non-affiliates, has been a public company for at least 12 months and have filed one annual report on Form 10-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company&#8217;s collaboration agreements under prior revenue recognition guidance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of January 1, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131179"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,029</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,217</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,807</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,187</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU141"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232181"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,486</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,895</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,067</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,410</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,477</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statement of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,825</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Cash Flows for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232183"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption&#160;of ASC 606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,866</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,453</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="eolPage14"></a><a name="eolPage14"></a>During the year ended December 31, 2019, the Company recorded $9.4 million in revenue that was included in deferred revenue as of December 31, 2018.&#160;&#160;The most significant change to the Company&#8217;s revenue recognition as a result of the adoption of ASC 606 relates to the accounting for certain option fees and milestone payments in determining the transaction price (step (iii)), and the revenue recognition pattern (step (v)) related to the Company&#8217;s development and commercial license agreement with Servier. Under ASC 605, the option fees payable by the Company to exercise the 50/50 co-development and co-promotion option was accounted for as a reduction in the arrangement consideration, and certain development milestones that may be earned for early-stage pre-IND development milestones were included in the arrangement consideration as the early-stage pre-IND development milestones were deemed to be non-substantive. Under ASC 606, the option fees were not accounted for as a reduction in the transaction price as the option fees are contingent upon Servier&#8217;s exercise of its commercial (customer) options on licensed product candidates, and the milestone payments were excluded from the transaction price based on the assessment of the most likely amount and application of the variable consideration constraint, since the milestones relate to successful achievement of certain developmental goals, which may not be achieved. In addition, under ASC 605, the Company recognized revenue on a straight&#8209;line basis over the period the Company expected to complete its obligations. Under ASC 606, the Company recognizes revenue based on the proportional performance of the services related to the performance obligation expected. For further discussion of the adoption of ASC 606 see Note 12, &#8220;Collaboration and license agreements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DTIL_10Q_20190930_HTM_LD_TABLE_29"></a>In June 2018, the FASB issued ASU 2018-07,&#160;<font style="font-style:italic;">Compensation-Stock Compensation Improvements to Nonemployee Share-Based Payment Accounting&#160;</font>(&#8220;ASU 2018-07&#8221;). ASU 2018-07 substantially aligns accounting for share-based payments to employees and non-employees. This ASU became effective for annual periods beginning after December 15, 2018 including interim periods within that period, and early adoption is permitted.&nbsp;&nbsp;The Company adopted ASU 2018-07 effective January 1, 2019.&nbsp;&nbsp;The adoption of the standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13,&#160;<font style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen</font>t (&#8220;ASU 2018-13&#8221;). ASU 2018-13 is intended to improve the effectiveness of disclosures in the notes to financial statements related to fair value measurements in Topic 820. This ASU will become effective for annual periods beginning after December 15, 2019, including interim periods within that period, and early adoption is permitted.&#160;The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU142"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18, </font><font style="font-style:italic;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and ASC 606</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (&#8220;ASU 2018-18&#8221;). The amendments in ASU 2018-18 make targeted improvements to GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASU 2018-18 was aligned with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606.&#160;&#160;ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of ASC 606. The Company adopted this guidance effective January 1, 2019 with its initial application of ASC 606. The adoption of the standard did not have an impact on the Company&#8217;s consolidated financial statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the FASB issued ASU 2019-10, <font style="font-style:italic;">Financial Instruments &#8212; Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) </font>(&#8220;ASU 2019-10&#8221;)<font style="font-style:italic;">,</font> which provides a one-year deferral of the effective dates of ASU No.&#160;2016-02, <font style="font-style:italic;">Leases (Topic 842)</font> (&#8220;ASU 2016-02&#8221;), issued in February 2016.&nbsp;&nbsp;ASU 2016-02 was issued in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term.&nbsp;&nbsp;ASU 2019-10 is effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and expects to have an increase in total assets and total liabilities as a result of adopting the lease standard.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards updates issued, but not effective until after December 31, 2019, are not expected to have a material effect on the Company&#8217;s consolidated financial position, statements of operations or cash flows.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"><a name="_cp_blt_1_117"></a><a name="_cp_text_1_116"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">PROPERTY, EQUIPMENT AND SOFTWARE</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software consisted of the following as of December&#160;31 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131183"></a>Construction in progress</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,969</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,733</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,251</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,057</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, equipment and software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,220</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,649</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,484</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software - net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,571</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,147</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31727541"></a>In July 2019, we completed construction and opened our Manufacturing Center for Advanced Therapeutics, or MCAT, a manufacturing facility supporting our therapeutic product development platform, in a leased facility in Research Triangle Park.&#160; Of the $8.6 million construction-in-progress (CIP) balance as of December 31, 2018, $2.5 million related to the MCAT and $4.4 million related to our other leased facilities in Durham was recognized as leasehold improvements in the year ending December 31, 2019. &nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense, including amortization of leasehold improvements and software, was $5.3 million and $2.3 million for the years ended December&#160;31, 2019 and December 31, 2018, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3:</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">INTANGIBLE ASSETS</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net, consisted of the following as of December&#160;31 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131184"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31727568"></a>License cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,831</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,831</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: impairments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,466</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense of the intangible assets was $0.1 million for the years ended December&#160;31, 2019 and December 31, 2018. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a license agreement to obtain the rights to intellectual property for the production of biological materials for use in its development programs. The Company paid the licensor a one-time, non-refundable license fee of $1.4&#160;million for rights to a cell line that can be used on up to four product candidates. The intellectual property rights are being amortized on a straight-line basis over a period of 216 to 257 months depending on the date the company adds product candidates to the agreement. Amortization expense will be approximately $0.1 million for each of the next five years with the remaining $0.9 million amortized to expense in 2025 and beyond. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital Structure</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all of the Company&#8217;s outstanding shares of the Series A and Series B convertible preferred stock automatically converted into 22,301,190 shares of common stock and the Company&#8217;s outstanding convertible notes payable, including accrued interest, converted into 2,921,461 shares of common stock at the applicable conversion ratio. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, the Company filed an amendment to its amended and restated certificate of incorporation pursuant to which, among other things, the Company increased its authorized shares to 210,000,000 shares of capital stock, of which 200,000,000 shares were designated as $0.000005 par value common stock and 10,000,000 shares were designated as $0.0001 par value preferred stock.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">SHARE-BASED COMPENSATION</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:-13.33%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of its equity incentive award plans, the Company&#8217;s board of directors may grant equity or equity-based awards to employees, directors and other service providers. The Company granted stock options under the 2006 Stock Incentive Plan (&#8220;2006 Plan&#8221;) until April 2015 when the 2015 Stock Incentive Plan (&#8220;2015 Plan&#8221;) was adopted. The 2006 Plan expired in 2016 and there are no remaining shares available to be granted under the 2006 Plan. There were 1,385,203 stock options outstanding under the 2006 Plan as of December 31, 2019.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of the 2015 Plan, there were 5,270,095 shares of common stock reserved for issuance. In May 2018, the Company amended the 2015 Plan to increase the number of shares reserved for issuance to 8,211,980. The 2015 Plan had 5,462,954 stock options outstanding as of December 31, 2019. The Company&#8217;s board of directors determined the terms of stock options granted under the 2015 Plan, including option exercise prices and vesting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2019, the Company&#8217;s board of directors adopted, and, on or about March 14, 2019 the Company&#8217;s stockholders approved, the Precision BioSciences, Inc. 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) and the 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;), both of which became effective on March 27, 2019. On March 27, 2019, the Company ceased granting new awards under the 2015 Plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other share-based awards initially equal to 4,750,000 shares of common stock.&#160;&#160;The 2019 Plan provides for an annual increase to the number of shares of common stock available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the board of directors.&nbsp;&nbsp;The number of shares available for issuance under the 2019 Plan was increased by 2,046,209 on January 1, 2020 pursuant to this provision. Any shares that are subject to awards outstanding under the Company&#8217;s 2006 Plan and 2015 Plan as of the effective date of the 2019 Plan that expire, lapse, or are terminated, exchanged for cash, surrendered, repurchased, or canceled without having been fully exercised or forfeited, to the extent so unused, will become available for award grants under the 2019 Plan.&#160;&#160;The 2019 Plan had 2,070,959 stock options outstanding as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Up to 525,000 shares of the Company&#8217;s common stock were initially reserved for issuance under the 2019 ESPP.&nbsp;&nbsp;The 2019 ESPP provides for an annual increase to the number of shares available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors.&nbsp;&nbsp;The number of shares available for issuance under the 2019 ESPP was increased by 511,552 shares on January 1, 2020 pursuant to this provision. No more than 5,250,000 shares of our common stock may be issued under our 2019 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date.&#160;&#160;The first ESPP offering period commenced on October 21, 2019 and ended on February 29, 2020;&#160;44,197 shares were issued with respect to this offering period.&nbsp;&nbsp;The next ESPP offering period commenced on March 1, 2020 and will end on August 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131185"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonemployee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense related to stock options is included in the following line items in the consolidated statements of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131186"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,639</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,817</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,301</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the appropriate fair value model to measure the fair value of the stock option grants on the date of grant and the related assumptions requires judgment. The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131187"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average expected stock price volatility</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term of options (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.61</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value per option</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term represents the average time that stock options that vest are expected to be outstanding.<font style="font-size:12pt;"> </font>The Company does not have sufficient history of exercising stock options to estimate the expected term of employee stock options and thus utilizes a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date. The risk-free rate is based on the United States Treasury yield curve during the expected life of the option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity in the Company&#8217;s stock option plans for the years ended December 31, 2019 and December 31, 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,416,025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,160,097</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(220,308</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.78</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(592,350</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,647,236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(940,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(550,644</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of stock options exercised was $10.6 million and $2.7 million during the years ended December 31, 2019 and December 31, 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was approximately $29.0 million of total unrecognized compensation cost related to unvested stock options as of December 31, 2019, which is expected to be recognized over a weighted-average period of 2.9 years.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information about stock options granted under the stock option plans which are vested or expected to vest as of December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be exercisable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,082,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.08</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be exercisable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information about stock options outstanding under the stock option plans for the years ending December 31, 2019 and December 31, 2018, respectively: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="12" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.01 - $0.04</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.41 - $1.20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721,811</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.74 - $9.46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266,454</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.44</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.17 - $13.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,891,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.96</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">844,005</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14.91 - $16.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,082,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.01 - $0.04</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397,203</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440,920</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,166,591</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.18 - $1.20</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846,255</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748,922</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,376</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,408</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,708</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.98</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,070,029</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.78</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,193</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.20</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428,626</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.93</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">RETIREMENT PLAN</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2011, the Company established a defined contribution 401(k) retirement savings plan (the &#8220;Retirement Plan&#8221;) to all full-time employees. Employee contributions to the Retirement Plan can be 100% of annual compensation up to the prescribed annual maximum under the Internal Revenue Code. Administrative fees of less than $0.1&#160;million were paid by the Company for the years ended December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Retirement Plan includes a safe-harbor matching employer contribution equal to 100% of participants&#8217; deferral contributions up to 4%. The Company made contributions of $0.6&#160;million and $0.4&#160;million to the Retirement Plan during the years ended December&#160;31, 2019 and December 31, 2018, respectively.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">COMMITMENTS AND CONTINGENCIES</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to various legal matters and claims in the ordinary course of business. Although the results of legal proceedings and claims cannot be predicted with certainty, in the opinion of management, there are currently no such known matters that will have a material effect on the consolidated financial condition, results of operations or cash flows of the Company.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU143"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office and laboratory space under long-term operating leases.&#160;&#160;These leases provide tenant improvement allowances and rent abatements as incentives for the Company to either enter into the initial lease agreement or expand within existing premises already under lease and represent all of the Company&#8217;s lease obligations as of December 31, 2019.&nbsp;&nbsp;These leases include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk31720886"></a><font style="font-size:10pt;">Office and laboratory space at 302 East Pettigrew Street, Durham, North Carolina, which is the Company&#8217;s corporate headquarters. The property is leased through July 2024 with the option to extend. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Laboratory and office space at 3054 Cornwallis Road Durham, North Carolina. The property is leased through April 2026 with the option to extend.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Laboratory space at 20 TW Alexander Drive, Research Triangle Park, North Carolina. In December 2019, the Company expanded the amount of spaced leased at this site and extended to lease to August 2027. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a schedule of future minimum lease payments for all leases as of December 31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232190"></a>2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,196</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,611</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and beyond</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supply Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with CMOs for the manufacture of clinical trial materials and CROs for clinical trial services. These agreements provide for termination at the request of either party with less than one-year notice and are, therefore, cancelable contracts and, if canceled, are not anticipated to have a material effect on the consolidated financial condition, results of operations, or cash flows of the Company.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">NET LOSS PER SHARE</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,015,814</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,285,376</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding share-based compensation awards converted to common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,032,359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,796,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,032,359</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,097,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">DEBT</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:-13.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $39.6 million of convertible notes payable (the &#8220;2019 Notes&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU144"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Notes accrued interest at a rate of 6% per annum.&#160;&#160;The 2019 Notes were settled in 2,921,461 shares of common stock in connection with the closing of the Company&#8217;s IPO (see Note 1) at a settlement price of $13.60 per share (equal to 85% of the IPO price per share).&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On issuance, the Company elected to account for the 2019 Notes at fair value with any changes in fair value being recognized through the consolidated statements of operations until the 2019 Notes were settled. The fair value of the 2019 Notes was determined to be $39.6 million on issuance and $49.4 million as of April 1, 2019, the settlement date. For the year ended December 31, 2019, the Company recognized $9.8 million of expense as changes in fair value and $0.2 million of interest expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revolving Line</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a loan and security agreement with Pacific Western Bank (the &#8220;Pacific Western Loan Agreement&#8221;) pursuant to which the Company may request advances on a revolving line of credit of up to an aggregate principal of $50.0 million (the &#8220;Revolving Line&#8221;). The maturity date of the Revolving Line is May 15, 2022.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Revolving Line bears interest at an annual rate equal to the greater of (i) 1.25% below the prime rate then in effect, or (ii) 4.25% at all times when the Company maintains a daily balance of cash in its demand deposit accounts at Pacific Western Bank of at least $25.0 million, and the greater of (i) 0.25% above the prime rate then in effect; or (ii) 5.75% at all times when the Company does not maintain a daily balance of cash in demand deposit accounts at Pacific Western Bank of at least $25.0 million.&#160;&#160;The Pacific Western Loan Agreement requires that the Company pay a quarterly fee in an amount equal to 0.50% per annum of the unused portion of the Revolving Line. The unused fee shall be waived for any quarter the Company maintains a daily balance in its demand deposit accounts of at least $25.0 million. If the Revolving Line is terminated prior to the maturity date, the Company is required to pay an early termination fee equal to 1.0% of the Revolving Line. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted Pacific Western Bank a security interest in substantially all of its assets, excluding any of the intellectual property now or hereafter owned, but including any rights to payment from the sale or licensing of any such intellectual property. The Company is prohibited from paying cash dividends without the prior written consent of Pacific Western Bank. The Pacific Western Loan Agreement includes customary representations, warranties and covenants (affirmative and negative) and was amended in December 2019 to allow the Company to maintain a bank account with a non-affiliated bank in the United Kingdom provided that the account balance does not exceed 1.5 million GBP or its U.S. dollar equivalent at any time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no borrowings, and the Company was in compliance with its financial covenants, under the Pacific Western Loan Agreement as of December 31, 2019.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded no income tax expense due to the operating losses incurred for the years ended December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,454</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">573</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,734</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,736</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, noncurrent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax liability:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities, noncurrent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU145"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. The net increase in the valuation allowance for the year ended December&#160;31, 2019 of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million is comprised of an increase in deferred tax assets, primarily related to deferred revenue and net operating loss carryforwards, for the year.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reasons for the difference between actual income tax benefit for the years ended December&#160;31, 2019 and December 31, 2018 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232193"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Pre-Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Pre-Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense at statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,505</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,668</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,827</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(909</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and orphan drug credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,810</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,934</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(639</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,272</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (benefit) expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had federal, state, and foreign net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $101.3 million, $101.7 million, and $0.4 million respectively. At December&#160;31, 2018, the Company had federal and state NOL carryforwards of approximately $40 million and $39.8 million, respectively. Federal NOL carryforwards of $19.7 million begin to expire in 2030 while the remaining federal NOL carryforward of $81.6 million carries forward indefinitely. The state NOL carryforwards begin to expire in 2025. The foreign NOLs carryforward indefinitely. At December&#160;31, 2019, the Company had federal and state research and development (&#8220;R&amp;D&#8221;) tax credits of $7.2 million and an amount less than $0.1 million, which begin to expire in 2027 and 2030, respectively. At December&#160;31, 2018, the Company had federal and state tax R&amp;D credits of $3.6 million and an amount less than $0.1 million which begin to expire in 2027 and 2030, respectively. At December 31, 2019 and December 31, 2018, the Company had federal Orphan Drug credits of $1.8 million and $0.7 million, respectively, which begin to expire in 2038. At December&#160;31, 2019 and December 31, 2018, the Company had federal contribution carryforwards of $0.1 million and an amount less than $0.1 million, respectively, which begin to expire in 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incorporated a subsidiary in Australia in 2018. However, the subsidiary has had minimal losses since inception. As such, there are no undistributed earnings as of December 31, 2019.&nbsp;&nbsp;The Company incorporated a subsidiary in the United Kingdom in 2019. However, the subsidiary has had minimal activity since inception. As such, there are no undistributed earnings as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ability to utilize its NOL and R&amp;D credit carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change,&#8221; as defined by Section&#160;382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed a study to assess whether one or more ownership changes have occurred since the Company became a loss corporation under the definition of Section&#160;382. If the Company has experienced an ownership change, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any possible limitation will have an impact on the results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reflects in the accompanying consolidated financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only if it is considered &#8216;more-likely-than-not&#8217; that the position taken will be sustained by the appropriate taxing authority. As of December&#160;31, 2019 and December 31, 2018, the Company had no unrecognized income tax benefits. The Company&#8217;s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations. As of December&#160;31, 2019 and December 31, 2018, the Company had no such accruals. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU146"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognized deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. The Company does not have a GILTI inclusion in years ends December 31, 2019 or December 31, 2018 and therefore, no GILTI tax has been recorded for the years then ended.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11:</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">FAIR VALUE MEASUREMENTS</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, including accounts receivable, accounts payable, and accrued expenses and other current liabilities, approximate their respective fair values due to their short-term nature. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis and to minimize the use of unobservable inputs when determining their fair value. The three tiers are defined as follows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs, other than quoted prices in active markets, that are observable either directly or indirectly</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs for which there is little or no market date, which require the Company to develop its own assumptions</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets. Investments in repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019 and December 31, 2018, the Company held cash equivalents which are composed of money market funds and repurchase agreements that were purchased through repurchase intermediary banks and collateralized by deposits in the form of government securities and obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following represents assets measured at fair value on a recurring basis by the Company (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk33131197"></a>December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COLLABORATION AND LICENSE AGREEMENTS</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Development and Commercial License Agreement with Servier</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 24, 2016, the Company entered into a development and commercial license agreement, as subsequently amended, with predecessor entities to Servier. This agreement establishes a collaboration between the Company and Servier to develop allogeneic chimeric antigen receptor T (&#8220;CAR T&#8221;) cell therapies for up to six unique antigen targets selected by Servier. Servier selected one target at the agreement&#8217;s inception. Servier is required to make a milestone payment to the Company upon achievement of an early-stage pre- investigational new drug application (&#8220;IND&#8221;) development milestone event completed for each of the remaining five targets selected, if any. The Company granted Servier a development license and will perform early-stage R&amp;D on the selected targets and develop the resulting therapeutic product candidates through Phase 1 clinical trials and manufacture clinical trial material for use in Phase 2 clinical trials. Also, the Company and Servier have formed a joint steering committee (&#8220;JSC&#8221;) to provide high-level oversight and decision making regarding the activities covered under the agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU147"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $105.0 million under the agreement. At the Phase 2 readiness stage for any product candidate, Servier may exercise a commercial option, subject to payment of commercial option exercise fees, to proceed with development and commercialization of the product candidate and perform late-stage R&amp;D, including Phase 2 and Phase 3 clinical trials and obtaining regulatory approvals. The Company has the ability to receive total payments, in the aggregate across all six targets that may be selected by Servier, of up to approximately $1.6 billion, including the upfront payment of $105.0 million and up to $1.5 billion in milestone payments, consisting of up to $401.3 million in development milestone payments and up to $1.1 billion in commercial milestone payments. The Company is also entitled to receive tiered royalties ranging from the mid-single digit percentages to the sub-teen percentages on worldwide net sales of any products developed, subject to customary potential reductions. The Company also has the right to opt in and participate in the development and commercialization of any products resulting from the collaboration through a 50/50 codevelopment and co-promotion option in the United States. This will require the Company to pay a codevelopment and co-promotion option fee on each licensed product for which the Company elects to participate. This option is exercisable at the Phase 2 readiness stage and only after Servier exercises its commercial option.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the promises in the agreement represent transactions with a customer. The Company has determined that the promises associated with the research and development activities for each of the six targets are not distinct because they are all based on the ARCUS proprietary genome editing platform. The Company has concluded that the agreement with Servier contains the following promises: (i) a development license; (ii) performance of early-stage R&amp;D services, (iii) the manufacture of clinical trial material for use in Phase 2 clinical trials, and (iv) JSC participation. The Company determined that the license, manufacture of clinical trial material, and R&amp;D services were not distinct from each other, as the license, pre-clinical and clinical supply, and R&amp;D services are highly interdependent upon one another. Participation on the JSC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;D services. As such, the Company determined that these promises should be combined into a single performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement with Servier, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of $105.0 million constituted the entire consideration to be included in the transaction price as of the outset of the arrangement.&#160;&#160;As such, this amount was allocated to the single performance obligation. The commercial option exercise fees that may be received are excluded from the transaction price until each customer option is exercised as it was determined that the options are not material rights. The potential development milestone payments that the Company is eligible to receive prior to the exercise of the options as well as commercial milestones, were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain developmental goals, which might not be achieved. None of the future royalty payments were included in the transaction price, as the potential payments represent sales-based consideration. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue from the upfront payment of $105.0 million based on an input method in the form of research effort relative to expected research effort at the completion of the performance obligation, which is based on the actual time of R&amp;D activities performed relative to expected time to be incurred in the future to satisfy the performance obligation. Management evaluates and adjusts the total expected research effort for the performance obligation on a quarterly basis based upon actual research accomplishments and the probability of continuing research efforts in the future. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The remaining performance obligation associated with the $105.0 million upfront payment is expected to be satisfied over a four year period as of December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2019 and December 31, 2018, the Company recognized revenue under the agreement with Servier of approximately $7.3 million and $5.8 million, respectively. Deferred revenue related to the agreement with Servier amounted to $80.9 million and $88.6 million as of December 31, 2019 and December&#160;31, 2018, respectively, of which $15.0 million and $5.8 million, respectively is included in current liabilities. No development or sales-based milestone payments were received during the year ended December 31, 2019 and December 31, 2018.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Gilead</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU148"></a>On September 10, 2018, the Company and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) entered into a collaboration and license agreement to develop genome editing tools to target viral DNA associated with Hepatitis B. Pursuant to the terms of the agreement, Gilead will receive an exclusive license to exploit the resulting synthetic nucleases and products that use them to treat Hepatitis B in humans (&#8220;development license&#8221;), and the Company is entitled to receive up to $40.0 million in research funding for early-stage R&amp;D services, paid in semi-annual increments, over an initial three year term and development and commercial milestone payments of up to an aggregate of $445.0 million, consisting of up to $105.0 million in development milestone payments and up to $340.0 million in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial milestone payments. The Company is also entitled to receive tiered royalties ranging from the high single digit percentages to the mid-teen percentages on worldwide net sales of the products developed through the term of the agreement, subject to customary potential reductions. Gilead is responsible for obtaining regulatory approvals and, upon completion of the collaboration, will assume sole responsibility for the development and commercialization of such gene editing therapies and products. The Company will provide technology transfer of its development know-how prior to Gilead assuming responsibility. Also, the Company and Gilead will negotiate a separate supply agreement for the Company to manufacture specifically identified products for Gilead to use in clinical trials at price based on the Company&#8217;s costs. The Company and Gilead have formed a joint steering committee (&#8220;JSC&#8221;) and a joint research and development committee (&#8220;JRDC&#8221;) that collectively will provide oversight, decision making and implementation guidance regarding the collaboration activities covered under the agreement.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the promises in the agreement represent transactions with a customer. The Company has concluded that the agreement with Gilead contains the following promises: (i) a development license; (ii) performance of early-stage R&amp;D services, including technology transfer services, iii) JSC and JRDC participation, and (iv) regulatory responsibilities related to non-clinical and chemistry, manufacturing and control (&#8220;CMC&#8221;) reports. The Company determined that the license and R&amp;D services were not distinct from each other, as the license and R&amp;D services are highly interdependent upon one another. Participation on the JSC and JRDC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;D services. The regulatory responsibilities related to non-clinical and CMC filings do not represent separate performance obligations based on their dependence on the research and development efforts. As such, the Company determined that these promises should be combined into a single performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement with Gilead, in order to evaluate the appropriate transaction price, the Company determined that the $40.0 million research funding for early-stage R&amp;D services, paid in semi-annual increments over an initial three-year term, constituted the entire consideration to be included in the transaction price as of the outset of the arrangement. As such, this amount was allocated to the single performance obligation. The potential development and commercial milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain developmental goals, which might not be achieved. None of the future royalty payments were included in the transaction price, as the potential payments represent sales-based consideration.&#160;&#160;The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with the combined performance obligation is being recognized as revenue on a straight-line basis as the R&amp;D services are provided over the initial three-year term.&#160;&#160;The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2019 and December 31, 2018, the Company recognized revenue under the agreement with Gilead of approximately $13.3 million and $3.7 million, respectively. Deferred revenue related to the agreement with Gilead amounted to $1.5 million and $2.3 million as of December 31, 2019 and December&#160;31, 2018, respectively, all of which is included in current liabilities. No development or sales-based milestone payments were received during the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research, Collaboration and License Agreement with the Trustees of the University of Pennsylvania</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;1, 2018, the Company entered into a Research, Collaboration and License Agreement with the University of Pennsylvania (&#8220;Penn&#8221;) to collaborate on the preclinical development for gene editing products involving the delivery of an ARCUS nuclease. The Company will provide semi-annual research funding payments of up to $5.0&#160;million for a three-year term to fund the cost of research programs as specified in a mutually agreed-upon research budget and be responsible for&#160;post-IND&#160;enabling study development activities. The research funding payments will be expensed as incurred; however, if payments made by the Company exceed the costs incurred by Penn in the six-month period, the excess amount will be credited to the Company in the next semi-annual period.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the research funding payments, if the Company elects to use certain Penn technology, the Company will be required to make development and sales milestone payments totaling up to $16.1&#160;million per product in any one year, assuming the maximum development and sales milestones are met in any one year. An additional $12.3&#160;million per product in sales milestone payments could be payable in other years if other sales thresholds are achieved, thus totaling $28.4&#160;million in aggregate milestone payments per product. Low single-digit royalty percentages are also payable on net sales of certain products.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn provided the Company a&#160;non-exclusive&#160;license for patent rights and&#160;know-how&#160;to be used in exchange for an upfront payment of $0.3&#160;million. Once the Company has paid $15.0&#160;million in research funding, it then has the option to pay a $1.0&#160;million option fee to obtain a license for additional patent rights.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU149"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, both parties agreed to adjust the activities conducted under the agreement to focus exclusively on the collaboration&#8217;s program to edit the PCSK9 gene to reduce levels of LDL-C in the blood, commonly known as &#8220;bad cholesterol&#8221;.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement&#8217;s termination provisions allow the Company to terminate the agreement by providing written notice at least 60 days prior to the due date of the next semi-annual research funding payment. In this event, the Company would not make termination payments to Penn other than for&#160;non-cancelable&#160;costs and reasonable wind-down costs. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">SEGMENT REPORTING</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has developed a genome editing platform and performed related research for human therapeutic and agricultural applications. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) evaluates the Company&#8217;s financial performance based on two reportable segments: Therapeutics and Food. The Therapeutics segment is focused on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment is focused on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies. The CODM reviews segment performance and allocates resources based upon segment revenue and segment operating loss of the Therapeutics and Food reportable segments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are directly attributable to the reportable segment (including directly attributable research and development and property, equipment, and software expenditures).&#160;&#160;For the year ended December 31, 2018, the Company allocated centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies to the Therapeutics and Food segments based on headcount.&#160;&#160;In January 2019, the Food segment moved into a new leased facility in Durham, North Carolina. The Company has determined that the Food segment is no longer deriving benefit from the Company&#8217;s centralized research and development expenditures, thus all these expenditures are allocated to the Therapeutics segment for the year ended December 31, 2019. The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation, laboratory supplies, purchases of property, equipment, and software and procuring services from CROs, CMOs, and research organizations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain cost items are not allocated to the Company&#8217;s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company&#8217;s executive, business development, finance, operations, human resources and legal functions. The Company does not allocate non-cash income statement amounts to its reportable segments, such as share based compensation, depreciation and amortization, intangible asset impairment charges, non-cash interest expense and losses on the disposal of assets. When reconciling segment operating loss to consolidated loss from operations, the Company makes an adjustment to convert the cash expenditures to the accrual basis to reflect GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="eolPage22"></a><a name="eolPage22"></a>All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.<font style="font-size:12pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU150"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presented below is the financial information with respect to the Company&#8217;s reportable segments</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34232195"></a>(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,632</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,523</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operational cash expenditures:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,125</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operational cash expenditures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,170</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation of centralized research and development operational cash expenditures:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,605</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,901</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total allocation of centralized research and development operational</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash expenditures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,506</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operating loss:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,378</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,666</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operating loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,805</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,793</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile segment operating loss to consolidated loss from operations:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate general and administrative cash expenditures</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,569</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,892</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income received</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,267</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,317</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,354</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,453</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile cash expenditures to GAAP expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,716</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total consolidated loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,204</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,912</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>dtil-ex44_578.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex44_578.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.4</p>
<p style="text-align:center;margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES <br />REGISTERED PURSUANT TO SECTION 12 OF THE <br />SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, Precision BioSciences, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to Precision BioSciences, Inc. and not to any of its subsidiaries.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which have been publicly filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).&nbsp;&nbsp;We encourage you to read our amended and restated certificate of incorporation and our amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) for additional information.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Authorized Capital Stock</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.000005 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which are undesignated.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast. All other elections and questions presented to the stockholders shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third&#8209;party to acquire, or could discourage a third&#8209;party from seeking to acquire, a majority of our outstanding voting stock.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti&#8209;takeover Provisions</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transactions that stockholders may otherwise consider to be in their best interests or in our best interests, including transactions that provide for payment of a premium over the market price for our shares.</font></p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Undesignated Preferred Stock</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of our board of directors, without action by our stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of the Company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of the Company.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stockholder Meetings</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by the chairman of our board of directors, our chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Requirements for Advance Notification of Stockholder Nominations and Proposals</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Elimination of Stockholder Action by Written Consent</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Staggered Board</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes. The directors in each class serve for a three&#8209;year term, with one class being elected each year by our stockholders. Our amended and restated certificate of incorporation and amended and restated bylaws provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one&#8209;third of the directors. This system of electing and removing directors may delay or prevent a change of our management or a change in control of our company and may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Removal of Directors</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two&#8209;thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stockholders not Entitled to Cumulative Voting</p>
<p style="margin-bottom:11pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors will be able to elect all of the directors standing for election, if they choose, other than any directors that holders of our convertible preferred stock may be entitled to elect.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Choice of Forum</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws, (4)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws, or (5)&#160;any action asserting a claim governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision does not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Our amended and restated certificate of incorporation also provides that any person or entity holding, purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our amended and restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amendment of Charter Provisions</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two&#8209;thirds in voting power of the outstanding shares of stock entitled to vote thereon.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Section&#160;203 of the Delaware General Corporation Law</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section&#160;203 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;), which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti&#8209;takeover effect with respect to transactions not approved in advance by our board of directors.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>dtil-ex103_740.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex103_740.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;margin-left:76.92%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 10.3</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECOND AMENDMENT<br />TO<br /><font style="text-decoration:underline;">LOAN AND SECURITY AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Second Amendment to Loan and Security Agreement (this &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is made and entered into as of December 3, 2019, by and among PACIFIC WESTERN BANK, a California state chartered bank (&#8220;<font style="font-weight:bold;font-style:italic;">Bank</font>&#8221;), and <font style="Background-color:#FFFFFF;text-transform:uppercase;">PRECISION BIOSCIENCES, inc. </font><font style="Background-color:#FFFFFF;">and </font><font style="Background-color:#FFFFFF;text-transform:uppercase;">elo life systems, inc.</font> <font style="Background-color:#FFFFFF;">(individually and collectively, jointly and severally, &#8220;</font><font style="font-weight:bold;font-style:italic;Background-color:#FFFFFF;">Borrower</font><font style="Background-color:#FFFFFF;">&#8221;).</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrower and Bank are parties to that certain Loan and Security Agreement dated as of May 15, 2019 (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;).  The parties desire to amend the Agreement in accordance with the terms of this Amendment.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, the parties agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Section 6.6 of the Agreement is hereby amended and restated, as follows:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:3.85%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.6<font style="margin-left:36pt;">Primary Depository.</font><font style="font-weight:normal;">&nbsp;&nbsp;At all times when the aggregate balance of Borrower&#8217;s Cash at Bank and Bank&#8217;s affiliates is less than the Deposit Account Threshold, Borrower shall maintain, and shall cause all of its Subsidiaries to maintain, all depository and operating accounts with Bank and all investment accounts with Bank or Bank&#8217;s affiliates. At all times when the aggregate balance of Borrower&#8217;s Cash at Bank and Bank&#8217;s affiliates equals or exceeds the Deposit Account Threshold, Borrower and its Subsidiaries may maintain Cash balances that exceed the Deposit Account Threshold in depository, operating, and investments accounts outside of Bank or Bank&#8217;s affiliates, so long as each such account outside of Bank is subject to a duly-executed account control agreement in favor of Bank, and in form and substance reasonably satisfactory to Bank.  Notwithstanding the foregoing, Precision UK may maintain a bank account in the United Kingdom, with such account not subject to an account control agreement in favor of Bank, so long as the balance in such account does not exceed &#163;1,500,000 (or its US Dollar equivalent) at any time.&nbsp;&nbsp;Prior to Borrower maintaining any investment accounts with Bank&#8217;s affiliates, Borrower, Bank, and any such affiliate shall have entered into a securities account control agreement with respect to any such investment accounts, in form and substance reasonably satisfactory to Bank.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:3.85%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Section 7.13 of the Agreement is hereby amended and restated, as follows:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:3.85%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.13<font style="margin-left:36pt;">UK Subsidiary.</font><font style="font-weight:normal;">&nbsp;&nbsp;Permit Precision UK to maintain cash exceeding &#163;1,500,000 or non-cash assets exceeding a book value of $50,000 at any time.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Precision Biosciences, Inc. &#8211; 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> Amendment to LSA </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:76.92%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement.&nbsp;&nbsp;The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects.&nbsp;&nbsp;Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Each</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Each Borrower represents and warrants that the representations and warranties contained in the Agreement are true and correct in all material respects as of the date of this Amendment (except that any representations and warranties that expressly refer to an earlier date shall be true and correct in all material respects as of such date, and except for representations and warranties that by their terms include a materiality qualification, which shall be true and correct in all respects). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">this Amendment, duly executed by each Borrower;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">payment for all Bank Expenses incurred through the date of this Amendment, including Bank&#8217;s expenses for the documentation of this Amendment and any UCC, good standing or intellectual property search or filing fees, which may be debited from any of Borrower&#8217;s accounts; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">such other documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Precision Biosciences, Inc. &#8211; 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> Amendment to LSA </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:76.92%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:45%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="Background-color:#FFFFFF;">PRECISION BIOSCIENCES, inc</font></p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="top"  style="width:45%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PACIFIC WESTERN BANK</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Abid Ansari</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Joseph Holmes Dague</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joseph Holmes Dague</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFO</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="Background-color:#FFFFFF;">elo life systems, inc.</font></p></td>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Abid Ansari</p></td>
<td valign="top"  style="width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari</p></td>
<td valign="top"  style="width:51%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFO</p></td>
<td valign="top"  style="width:51%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">[Signature Page to Second Amendment to Loan and Security Agreement]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Precision Biosciences, Inc. &#8211; 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> Amendment to LSA </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>4
<FILENAME>dtil-ex109_943.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex109_943.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.9</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M1"></a><a name="_Toc202777485"></a>LEASE AGREEMENT BY AND BETWEEN</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M2"></a><a name="_DV_M3"></a><a name="_Toc202777486"></a>VENABLE TENANT, LLC, as Landlord</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M4"></a><a name="_DV_M5"></a><a name="_Toc202777487"></a>AND</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M6"></a><a name="_Toc202777488"></a>PRECISION BIOSCIENCES, INC., as Tenant</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M7"></a><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M8"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defined Terms </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M9"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recitals </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M10"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M11"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M12"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M13"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M14"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Utilities and </font>Services </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M15"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct Tenant Expenses </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M16"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security Deposit </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M17"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and Repairs </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M18"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alterations </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M19"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignments and Subletting </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M20"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M21"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Condemnation </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M22"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Default </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M23"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holding Over and Termination </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M24"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with Laws </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M25"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inspection </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M26"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Property </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M27"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[Intentionally Deleted]</font> </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M28"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rules and Regulations </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M29"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignments by Landlord </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M30"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quiet Enjoyment </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M31"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M32"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgages </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M33"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signs </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M34"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Keys and Locks </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M35"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brokers </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M36"></a>Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices </p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M37"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M38"></a>EXHIBITS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description of the Land</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Floor Plan of Premises</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises Specifications</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work Letter</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-1</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary Plans</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-2</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final Plans</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rules and Regulations</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Security Procedures</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top"  style="width:5.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G</p></td>
<td valign="top"  style="width:80.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">List of Hazardous Materials</p></td>
<td valign="top"  style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M49"></a><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#auto;">Defined Terms.</font><font style="color:#auto;font-weight:normal;">&nbsp;&nbsp;Capitalized words and phrases used in this Lease have the following meanings:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.01</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M50"></a><font style="color:#auto;">Additional Rent</font><font style="color:#auto;font-weight:normal;"> - all sums other than Base Annual Rent payable by Tenant to Landlord pursuant to the terms of this Lease, including, but not limited to, Tenant&#8217;s Proportionate Share of Operating Expenses.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.02</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M51"></a><font style="color:#auto;">Applicable Laws</font><font style="color:#auto;font-weight:normal;"> &#8211; collectively, any local, state or Federal laws, statutes, rules, regulations, ordinances, and court or judicial orders and decrees.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.03</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M52"></a><font style="color:#auto;">Audit Notice</font><font style="color:#auto;font-weight:normal;"> - a written notice that Tenant wishes to examine itself or to employ a nationally-recognized consulting firm (on a capped contingency fee basis) or an independent certified public accounting firm (on an hourly rate basis) reasonably acceptable to Landlord, to inspect and audit Landlord&#8217;s books and records in order to confirm the accuracy of the Statement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.04</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M53"></a><font style="color:#auto;">Base Annual Rent </font><font style="color:#auto;font-weight:normal;">- a base annual rental equal to the product of (x) the Base Rate multiplied by (y) the Net Rentable Area.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.05</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M54"></a><font style="color:#auto;">Base Annual Rent Escalation</font><font style="color:#auto;font-weight:normal;"> &#8211;&nbsp;&nbsp;the increase in the CPI with a floor of&nbsp;&nbsp;two and one-half percent (2.5%) and a ceiling of three percent (3%).<strike> </strike></font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.06</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M55"></a><font style="color:#auto;">Base Rate </font><font style="color:#auto;font-weight:normal;">- Seventeen and 85/100 Dollars ($17.85) per rentable square foot for the first twelve (12) months following the Commencement Date, and thereafter increased by the Base Annual Rent Escalation.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.07</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M56"></a><font style="color:#auto;">Building</font><font style="color:#auto;font-weight:normal;"> &#8211; the Dibrell A Warehouse Building</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> at</font><font style="color:#auto;font-weight:normal;"> 302 East Pettigrew Street, Durham, North Carolina.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.08</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M57"></a><a name="_DV_C4"></a><a name="_DV_M58"></a><a name="_DV_C5"></a><font style="color:#auto;">Commencement Date</font><font style="color:#auto;font-weight:normal;"> - the later to occur of: (i) </font><font style="text-decoration:none;color:#auto;font-weight:normal;">October</font><font style="color:#auto;font-weight:normal;"><a name="_DV_C4"></a> 1, 2010, or (ii) completion of the Tenant Improvements as evidenced by the issuance of a certificate of occupancy by the City of Durham and certification of substantial completion by the </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M58"></a>Tenant&#8217;s</font><font style="font-weight:normal;"> </font><font style="color:#auto;font-weight:normal;">architect</font><font style="font-weight:normal;"><a name="_DV_C5"></a>.</font><font style="color:#FF0000;font-weight:normal;"><strike>&nbsp;&nbsp;</strike></font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.09</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M60"></a><font style="color:#auto;">Common Areas</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- the driveways, </font><font style="color:#auto;font-weight:normal;">parking </font><font style="font-weight:normal;">areas, pedestrian sidewalks, common conference rooms, kitchen areas, lobbies, stairways, entranceways, bathrooms and canteens, if any, provided by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">as a convenience for use in common by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">and all tenants of the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">as an appurtenance to the </font><font style="color:#auto;font-weight:normal;">Premises</font><font style="text-decoration:none;color:#000000;font-weight:normal;">, each </font><font style="text-decoration:none;color:#auto;font-weight:normal;">building </font><font style="text-decoration:none;color:#000000;font-weight:normal;">in the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Project</font><font style="text-decoration:none;color:#000000;font-weight:normal;">, and the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Project</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.010</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M61"></a><font style="color:#auto;">Controllable Expenses</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- all </font><font style="color:#auto;font-weight:normal;">Operating Expenses</font><font style="font-weight:normal;">, excluding utilities (e.g., electricity, gas, water and sewer), property taxes, and insurance, for which </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">has an opportunity to select vendors and negotiate rates with the selected vendors, as reasonably determined by </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.011</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M62"></a><font style="color:#auto;letter-spacing:-0.15pt;">CPI</font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;"> </font><font style="letter-spacing:-0.15pt;font-weight:normal;">- shall mean an amount determined by multiplying the </font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;">Base Annual Rent </font><font style="letter-spacing:-0.15pt;font-weight:normal;">by a fraction, the denominator of which is the Revised Consumer Price Index for All Urban Consumers &#8211; New Series (</font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;">1982-1984 </font><font style="letter-spacing:-0.15pt;font-weight:normal;">= 100) U.S. City Average, All Items, as published by the Bureau of Labor Statistics, U.S. Department of Labor (the &#8220;</font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;">Price Index</font><font style="letter-spacing:-0.15pt;font-weight:normal;">&#8221;), for the first month of the First </font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;">Lease Year</font><font style="letter-spacing:-0.15pt;font-weight:normal;">, and the numerator of which is said </font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;">Price Index </font><font style="letter-spacing:-0.15pt;font-weight:normal;">for the next to last month of the </font><font style="color:#auto;letter-spacing:-0.15pt;font-weight:normal;">Lease Year </font><font style="letter-spacing:-0.15pt;font-weight:normal;">just concluding.</font><font style="font-weight:normal;">&nbsp;&nbsp;In the event that the United States Bureau of Labor Statistics shall </font><font style="letter-spacing:-0.15pt;font-weight:normal;">discontinue</font><font style="font-weight:normal;"> the issuance of the </font><font style="color:#auto;font-weight:normal;">Price Index</font><font style="font-weight:normal;">, then the rental adjustment provided for herein shall be made on the basis of changes in the most comparable and recognized cost of living index then issued and available, which is published by the United States Government.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.012</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M63"></a><font style="color:#auto;">Force Majeure</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- delays beyond the control of </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> </font><font style="text-decoration:none;color:#000000;font-weight:normal;">or </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">, including, but not limited to, permitting, availability of materials, acts of God, </font><font style="color:#auto;font-weight:normal;">Tenant Delays</font><font style="font-weight:normal;">, and inclement weather.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.013</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M64"></a><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#auto;">Guarantor</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">- </font><font style="font-weight:normal;">N/A.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.014</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M65"></a><a name="_DV_C6"></a><a name="_DV_M66"></a><font style="color:#auto;">Hazardous Material</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- any </font><font style="letter-spacing:-0.15pt;font-weight:normal;">hazardous</font><font style="font-weight:normal;"><a name="_DV_C6"></a> or toxic substance, pollutant, contaminant, gas, toxic </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M66"></a>mold,</font><font style="font-weight:normal;"> or petroleum product defined as such in (or for purposes of) </font><font style="color:#auto;font-weight:normal;">Hazardous Material Laws</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.015</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M67"></a><font style="color:#auto;">Hazardous Material Laws</font>-<font style="font-weight:normal;"> collectively, the Comprehensive Environmental Response, Compensation, </font><font style="color:#auto;font-weight:normal;">and Liability </font><font style="letter-spacing:-0.15pt;font-weight:normal;">Act</font><font style="font-weight:normal;">, as amended, any so-called &#8220;Superfund&#8221; or &#8220;Superlien&#8221;, law, the </font><font style="color:#auto;font-weight:normal;">Toxic Substances Control Act</font><font style="font-weight:normal;">, as amended, or any other Federal, state or local statute, law, ordinance, code, rule, regulation, order or decree regulating, relating to, or imposing liability or standards of conduct concerning, any hazardous, toxic or dangerous waste, substance or material, as now or at any time hereafter in effect, or any other hazardous, toxic or dangerous, waste, substance or material, gas or petroleum product.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.016</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M68"></a><font style="color:#auto;">Land</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- certain land in the County of Durham, City of Durham, State of North Carolina, upon which the </font><font style="letter-spacing:-0.15pt;font-weight:normal;">Building</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">and </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">are located and which is more particularly described in Exhibit A.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.017</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M69"></a><font style="color:#auto;">Landlord</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; Venable </font><font style="letter-spacing:-0.15pt;font-weight:normal;">Tenant</font><font style="font-weight:normal;">, </font><font style="color:#auto;font-weight:normal;">LLC, a North Carolina limited liability company</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.018</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M70"></a><font style="color:#auto;">Landlord Party</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; </font><font style="letter-spacing:-0.15pt;font-weight:normal;">collectively</font><font style="font-weight:normal;">, the </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">and its agents, employees, officers, invitees, licensees and independent contractors. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.019</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M71"></a><font style="color:#auto;">Lease </font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; this Lease </font><font style="letter-spacing:-0.15pt;font-weight:normal;">Agreement</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.020</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M72"></a><font style="color:#auto;">Lease Year</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- the first </font><font style="letter-spacing:-0.15pt;font-weight:normal;">twelve</font><font style="font-weight:normal;"> (12) months following the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Rent </font><font style="color:#auto;font-weight:normal;">Commencement Date </font><font style="font-weight:normal;">(said first twelve (12) month period will be the first &#8220;</font><font style="color:#auto;font-weight:normal;">Lease Year</font><font style="font-weight:normal;">&#8221;) and each successive twelve-month period during the </font><font style="color:#auto;font-weight:normal;">Term </font><font style="font-weight:normal;">following the expiration of the first </font><font style="color:#auto;font-weight:normal;">Lease Year</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.021</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M73"></a><font style="color:#auto;">Master Lease</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- that </font><font style="color:#auto;font-weight:normal;">Master Lease </font><font style="font-weight:normal;">dated July 11, 2006, pursuant to which the </font><font style="color:#auto;font-weight:normal;">Prime Tenant </font><font style="font-weight:normal;">leased the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">and the </font><font style="color:#auto;font-weight:normal;">Land </font><font style="font-weight:normal;">from the </font><font style="color:#auto;font-weight:normal;">Prime Landlord</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.022</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M74"></a><a name="_DV_M75"></a><font style="color:#auto;">Net Rentable Area</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- Eight Thousand Two Hundred Seventy-Four (8,274) rentable square feet</font><font style="text-decoration:none;color:#000000;font-weight:normal;">, per BOMA measurement standards.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.023</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M76"></a><font style="color:#auto;">Operating Expenses</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- </font><font style="letter-spacing:-0.15pt;font-weight:normal;">any</font><font style="font-weight:normal;"> and all </font><font style="text-decoration:none;color:#000000;font-weight:normal;">reasonable </font><font style="font-weight:normal;">charges, fees, </font><font style="color:#auto;font-weight:normal;">costs</font><font style="font-weight:normal;">, and expenses </font><font style="text-decoration:none;color:#000000;font-weight:normal;">actually </font><font style="font-weight:normal;">incurred by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">in connection with the management, operation, ownership, </font><font style="color:#auto;font-weight:normal;">maintenance</font><font style="font-weight:normal;">, security, servicing, insuring, and repair of the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">or </font><font style="color:#auto;font-weight:normal;">Project</font><font style="font-weight:normal;">, and will include, without limitation, the following:</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M77"></a>(1)<font style="margin-left:36pt;"></font><font style="color:#auto;">Premiums</font>, deductibles, and other charges for insurance;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M78"></a>(2)<font style="margin-left:36pt;"></font><font style="color:#auto;">Real Estate Taxes</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M79"></a>(3)<font style="margin-left:36pt;">Management fees and personnel </font><font style="color:#auto;">costs </font>(including all fringe benefits, workers&#8217; compensation insurance <font style="color:#auto;">premiums </font>and payroll taxes);</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M80"></a>(4)<font style="margin-left:36pt;"></font><font style="color:#auto;">Costs </font>of service, access control, and <font style="color:#auto;">maintenance </font>contracts;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M81"></a>(5)<font style="margin-left:36pt;"></font><font style="color:#auto;">Maintenance</font>, repair, and replacement expenses and supplies;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M82"></a>(6)<font style="margin-left:36pt;"></font><font style="color:#auto;">Depreciation</font>/amortization for capital <font style="text-decoration:none;color:#000000;">repairs or </font>expenditures made by <font style="color:#auto;">Landlord </font>to reduce <font style="color:#auto;">operating expenses </font>if <font style="color:#auto;">Landlord </font>reasonably estimates<font style="text-decoration:none;color:#000000;"> (and documents)</font> that the annual reduction in <font style="color:#auto;">Operating </font><font style="text-decoration:none;color:#auto;">Expenses</font><font style="color:#auto;"> </font>will exceed such depreciation or to comply with legal, insurance, or governmental requirements<font style="text-decoration:none;color:#000000;"> (or repair/</font><font style="text-decoration:none;color:#auto;">maintenance </font><font style="text-decoration:none;color:#000000;">requirements under the </font><font style="text-decoration:none;color:#auto;">Lease</font><font style="text-decoration:none;color:#000000;">)</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M83"></a>(7)<font style="margin-left:36pt;">Charges for janitorial, window, day porter, and cleaning services and supplies;</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M84"></a>(8)<font style="margin-left:36pt;">Any business, professional, or occupational license tax payable by </font><font style="color:#auto;">Landlord </font>or other tax or surcharge (or alternative payment or fee levied, charged, or assessed by a governmental entity in addition to or in lieu of a tax, license, or fee);</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M85"></a>(9)<font style="margin-left:36pt;">Reasonable reserves for such replacements, repairs, and contingencies that would be treated as </font><font style="color:#auto;">Operating Expense </font>under this <font style="color:#auto;">Lease</font>;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M86"></a><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font><font style="margin-left:36pt;"></font><font style="color:#auto;">Sales</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, use, and personal property taxes payable in connection with tangible personal property and services </font><font style="text-decoration:none;color:#000000;">purchased;</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M87"></a>(11)<font style="margin-left:36pt;">Accounting and audit fees relating to the determination of </font><font style="color:#auto;">Operating Expenses </font>(and of <font style="color:#auto;">Tenant&#8217;s Proportionate Share </font>thereof) and the preparation of statements required by <font style="color:#auto;">tenant </font>leases and legal fees (except as provided below); </p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M88"></a>(12)<font style="margin-left:36pt;">Expenses incurred in connection with any concierge services;</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M89"></a>(13)<font style="margin-left:36pt;">The rental value of any management office;</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M90"></a>(14)<font style="margin-left:36pt;">Special assessments, fees, charges, levies, penalties, service payments, excises, assessment charges and </font><font style="color:#auto;">costs </font>for transit, transit encouragement traffic reduction programs, or any similar purpose; </p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M91"></a>(15)<font style="margin-left:36pt;">All </font><font style="color:#auto;">costs </font>of operating maintaining, repairing and replacing improvements in any <font style="color:#auto;">Common Areas</font>; and</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M92"></a>(16)<font style="margin-left:36pt;">Any other </font><font style="text-decoration:none;color:#000000;">reasonable </font>expense <font style="text-decoration:none;color:#000000;">actually </font>incurred by <font style="color:#auto;">Landlord </font>in maintaining, repairing, or operating the <font style="color:#auto;">Building </font>or the <font style="color:#auto;">Project</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M93"></a>The following <font style="color:#auto;">costs </font>and expenses will be excluded from <font style="color:#auto;">Operating Expenses</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">for the </font><font style="text-decoration:none;color:#auto;">Building </font><font style="text-decoration:none;color:#000000;">and the </font><font style="text-decoration:none;color:#auto;">Project</font>:</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M94"></a>(1)<font style="margin-left:36pt;"></font><font style="color:#auto;">Costs </font>in connection with any structural repair or major change in the <font style="color:#auto;">Building</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M95"></a>(2)<font style="margin-left:36pt;"></font><font style="color:#auto;">Costs</font>, including permit, license, and inspection costs, associated with alterations or improvements of the <font style="color:#auto;">Premises</font>, the <font style="color:#auto;">premises </font>of other tenants or occupants of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project</font>, or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants or other occupants of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M96"></a>(3)<font style="margin-left:36pt;"></font><font style="color:#auto;">Depreciation of the Building or Project</font>, fixtures or equipment;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M97"></a>(4)<font style="margin-left:36pt;"></font><font style="color:#auto;">Interest</font>, points, fees, and principal payments on mortgages and other debt <font style="color:#auto;">costs</font>, if any, or amortization on any mortgage or mortgages or any other debt instrument encumbering the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>or the <font style="color:#auto;">Land</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M98"></a>(5)<font style="margin-left:36pt;"></font><font style="color:#auto;">Costs </font>for which <font style="color:#auto;">Landlord </font>is reimbursed by its insurance carrier, any <font style="color:#auto;">tenant</font>&#8217;s carrier, any <font style="color:#auto;">tenant</font>, any warrantor, or any other <font style="color:#auto;">third party</font>, to the extent of the reimbursement and not including deductibles;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M99"></a>(6)<font style="margin-left:36pt;">Any bad debt loss, </font><font style="color:#auto;">rent </font>loss, reserves for bad debts or <font style="color:#auto;">rent </font>loss, or legal fees incurred in collecting <font style="color:#auto;">rent </font>or other obligations from other <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>tenants;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M100"></a>(7)<font style="margin-left:36pt;">The cost of services provided to certain tenants of the </font><font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>beyond those provided to all <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>tenants, and <font style="color:#auto;">costs </font>incurred by <font style="color:#auto;">Landlord </font>in respect of breaches of other leases in the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M101"></a>(8)<font style="margin-left:36pt;"></font><font style="color:#auto;">Costs </font>associated with the operation of the business of the person or entity which constitutes <font style="color:#auto;">Landlord</font>, as distinguished from the <font style="color:#auto;">costs </font>of operation of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project</font>, including accounting and legal matters, <font style="color:#auto;">costs </font>of defending any lawsuits with any mortgagee, <font style="color:#auto;">costs </font>of selling, syndicating, financing, mortgaging or hypothecating any of <font style="color:#auto;">Landlord</font>&#8217;s <font style="color:#auto;">interest </font>in the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project</font>, <font style="color:#auto;">costs </font>of any disputes between <font style="color:#auto;">Landlord </font>and its employees, disputes of <font style="color:#auto;">Landlord </font>with <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>management, and outside fees paid in connection with disputes with other tenants<font style="text-decoration:none;color:#000000;"> and salaries, wages or other compensation above the level of property manager</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M102"></a>(9)<font style="margin-left:36pt;">Any expenditures which under normal accounting rules should be treated as capital expenditures, except </font><font style="color:#auto;">depreciation</font>/amortization for such capital <font style="text-decoration:none;color:#000000;"> repairs or </font>expenditures made by <font style="color:#auto;">Landlord </font>for the purpose of reducing <font style="color:#auto;">Operating Expenses </font>of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>as set forth above;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M103"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font><font style="margin-left:36pt;"></font><font style="color:#auto;">Costs </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of repairs or replacements caused by the exercise of any condemnation rights by any public or quasi-public authority;</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M104"></a>(11)<font style="margin-left:36pt;">Charitable and political contributions, advertising, marketing, and promotional expenditures, including </font><font style="color:#auto;">costs </font>of staging special events (unless applied for the benefit of all tenants or the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>as a whole, or as necessary to provide service in accordance with a first-class standard, e.g., expenses for an annual <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>holiday party); </p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M105"></a>(12)<font style="margin-left:36pt;">Marketing </font><font style="color:#auto;">costs </font>and other <font style="color:#auto;">costs </font>and expenses incurred in connection with <font style="color:#auto;">lease</font>, <font style="color:#auto;">sublease </font>and/or assignment negotiations and transactions with present or prospective tenants or other occupants of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project</font>;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M106"></a><font style="text-decoration:none;">(13)</font><font style="text-decoration:none;margin-left:36pt;">Property management fees in excess of 4% of gross rental receipts;</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M107"></a><font style="text-decoration:none;">(14)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;color:#auto;">Costs </font><font style="text-decoration:none;">representing amounts paid to an affiliate of </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">for services or materials which are in excess of the amounts which would have been paid in the absence of such relationship; and</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M108"></a><font style="text-decoration:none;">(15)</font><font style="text-decoration:none;margin-left:36pt;">Any </font><font style="text-decoration:none;color:#auto;">costs</font><font style="text-decoration:none;">, fines, or penalties incurred because </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">violated any </font><font style="text-decoration:none;color:#auto;">Applicable Law</font><font style="text-decoration:none;">.&nbsp;&nbsp; </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.024</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M109"></a><font style="color:#auto;">Parking</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; non-exclusive use of twenty (20) parking spaces.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:none;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.025</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M110"></a><a name="_DV_M111"></a><a name="_DV_M112"></a><font style="text-decoration:none;"></font><font style="color:#auto;">Permitted Use &#8211; </font><font style="color:#auto;font-weight:normal;">general office and laboratory use for a biotechnology company</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> (or for any other legal use with Landlord&#8217;s prior written consent which Landlord may withhold in its reasonable discretion.</font><font style="text-decoration:none;font-weight:normal;"><a name="_DV_M111"></a><a name="_DV_M112"></a>&nbsp;&nbsp; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.026</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M113"></a>Premises - certa<font style="font-weight:normal;">in </font><font style="color:#auto;font-weight:normal;">premises </font><font style="font-weight:normal;">known as </font><font style="color:#auto;font-weight:normal;">Dibrell A</font><font style="font-weight:normal;">-100, a floor plan of which </font><font style="color:#auto;font-weight:normal;">is attached hereto and made a part hereof as Exhibit B.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.027</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M114"></a><font style="color:#auto;">Premises Specifications</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; the specifications to which the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">are to be constructed as described in </font><font style="color:#auto;font-weight:normal;">Exhibits C and D.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.028</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M115"></a><font style="color:#auto;">Prime Landlord</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- Pettigrew Street Partners, LLC.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.029</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M116"></a><font style="color:#auto;">Prime Tenant</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- Venable Investor, LLC.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.030</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M117"></a><font style="color:#auto;">Project</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; The </font><font style="color:#auto;font-weight:normal;">Venable Center</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.031</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M118"></a><a name="_DV_C11"></a><a name="_DV_M119"></a><a name="_DV_C13"></a><a name="_DV_M120"></a><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="color:#auto;">Real Estate Taxes</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- any and all taxes (including special assessments) that are payable within a particular calendar year, including all taxes imposed on the </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">and the </font><font style="color:#auto;font-weight:normal;">Land</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Real Estate Taxes </font><font style="font-weight:normal;">will include, without limitation, (i) all real estate taxes, rates, and assessments (including general and special assessments, if any), ordinary and extraordinary, foreseen and unforeseen, which are imposed upon </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">or assessed against the </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">or the </font><font style="color:#auto;font-weight:normal;">Land</font><font style="font-weight:normal;">, (ii) personal property taxes applicable to the personalty of </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">, whether used by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">or its agent, related to or used in the management or operation of the </font><font style="color:#auto;font-weight:normal;">Project</font><font style="font-weight:normal;">, (other than such taxes based upon </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s net income), (iii) any other present or future taxes or charges that are imposed upon </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">or assessed against the </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">or the </font><font style="color:#auto;font-weight:normal;">Land </font><font style="font-weight:normal;">which are in the nature of or in substitute for real estate taxes, including any tax levied on or measured by the gross rents payable by tenants of the </font><font style="color:#auto;font-weight:normal;">Project</font><font style="font-weight:normal;">, any public safety fee or similar charge, any transit, </font><font style="color:#auto;font-weight:normal;">sales</font><font style="font-weight:normal;">, rental, use, receipts, or occupancy tax or fee, and any assessment imposed in connection with business improvement or similar districts, (iv) public space rentals, including but not limited to vault rentals, and (v) all </font><font style="text-decoration:none;color:#000000;font-weight:normal;">reasonable </font><font style="color:#auto;font-weight:normal;">costs </font><font style="font-weight:normal;">and expenses </font><font style="text-decoration:none;color:#000000;font-weight:normal;">actually </font><font style="font-weight:normal;">incurred by </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">, including without limitation reasonable attorneys&#8217; fees and consultants&#8217; fees and court </font><font style="color:#auto;font-weight:normal;">costs</font><font style="font-weight:normal;"><a name="_DV_C11"></a>, in connection with<a name="_DV_M119"></a> reviewing<a name="_DV_C13"></a>, protesting, or seeking a reduction or abatement of, or defending or otherwise participating in any challenge to, real estate taxes, </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M120"></a>but only if (i) Tenant approves such protest; or (ii) to the extent said</font><font style="font-weight:normal;"> protest or reduction is ultimately successful.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;">If the levy will be levied or imposed on the </font><font style="color:#auto;font-weight:normal;">Project</font><font style="font-weight:normal;">, and/or </font><font style="color:#auto;font-weight:normal;">Land </font><font style="font-weight:normal;">and/or </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">, in substitution for real estate taxes and/or personal property taxes presently levied or imposed on immovables in North Carolina, and including also without limitation any </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">dues or assessments, any taxes on rents, or alternative which may be enacted by the taxing municipality to pay for municipal services or as a money raising action, whether temporary or permanent, then any such new tax or levy will be included within the amount of </font><font style="color:#auto;font-weight:normal;">Real Estate Taxes </font><font style="font-weight:normal;">of which </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">will pay its Proportionate Share.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Real Estate Taxes </font><font style="font-weight:normal;">will not include, nor will </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">be obligated to pay pursuant to this </font><font style="color:#auto;font-weight:normal;">Lease</font><font style="font-weight:normal;">, such taxes as capital gains, corporation, unincorporated business, income, profit, excess profit, inheritance, transfer, recordation, estate, gift or franchise taxes, or any fines, penalties and/or </font><font style="color:#auto;font-weight:normal;">interest </font><font style="font-weight:normal;">on late payments of any </font><font style="color:#auto;font-weight:normal;">Real Estate Taxes </font><font style="font-weight:normal;">(unless such late payment is caused by </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">&#8217;s failure to make timely payment of any installments of its Proportionate Share of increases in </font><font style="color:#auto;font-weight:normal;">Real Estate Taxes</font><font style="font-weight:normal;">, in which case </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">will be solely liable to reimburse </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">for the entirety of any such fine, penalty and/or </font><font style="color:#auto;font-weight:normal;">interest</font><font style="font-weight:normal;">).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.032</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M121"></a><font style="color:#auto;">Renewal Term</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211;two (2), three (3) year options to renew at the lesser of the (i) then escalated </font><font style="color:#auto;font-weight:normal;">Base Annual Rate</font><font style="font-weight:normal;">, or (ii) ninety five (95%) percent of the then current market rental rate for comparable laboratory space in downtown </font><font style="color:#auto;font-weight:normal;">Durham</font><font style="font-weight:normal;">, as reasonably determined by </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.033</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M122"></a><font style="color:#auto;">Rent</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; collectively, the </font><font style="color:#auto;font-weight:normal;">Base Annual Rent </font><font style="font-weight:normal;">and the </font><font style="color:#auto;font-weight:normal;">Additional Rent</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.034</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M123"></a><font style="color:#auto;">Rent Abatement </font>&#8211; <font style="font-weight:normal;">the first five (5) months of the </font><font style="color:#auto;font-weight:normal;">Term</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.035</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M124"></a><font style="text-decoration:none;color:#auto;">Rent Commencement Date </font><font style="text-decoration:none;color:#000000;">&#8211; </font><font style="text-decoration:none;color:#000000;font-weight:normal;">the date which is the first day following expiration of the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Rent Abatement </font><font style="text-decoration:none;color:#000000;font-weight:normal;">period.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.036</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M125"></a><font style="color:#auto;">Security Deposit</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211;the equivalent of six (6) months </font><font style="color:#auto;font-weight:normal;">Base Annual Rent</font><font style="font-weight:normal;">, Seventy-Three Thousand Eight Hundred Forty-Five and 45/100 dollars ($73,845.45) in the form of a Letter of Credit to be held by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">as security for the performance by </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">of all obligations imposed on </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">pursuant to the </font><font style="color:#auto;font-weight:normal;">Lease</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.037</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M126"></a><font style="color:#auto;">Statement</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- a written statement submitted within one hundred and twenty (120) days after the end of each calendar year by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">to </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">showing (i) </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">&#8217;s actual </font><font style="color:#auto;font-weight:normal;">Proportionate Share </font><font style="font-weight:normal;">of the amount by which </font><font style="color:#auto;font-weight:normal;">Operating Expenses </font><font style="font-weight:normal;">incurred during the preceding calendar year exceed the </font><font style="color:#auto;font-weight:normal;">Operating Expenses </font><font style="font-weight:normal;">for the </font><font style="color:#auto;font-weight:normal;">Base Year</font><font style="font-weight:normal;">, (ii) the amount thereof paid by </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">, and (iii) the balance due or the overpayment. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.038</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M127"></a><font style="color:#auto;">Sublease</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; that sublease dated July 11, 2006, pursuant to which the </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">has leased the entirety of the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">and the </font><font style="color:#auto;font-weight:normal;">Land </font><font style="font-weight:normal;">from the </font><font style="color:#auto;font-weight:normal;">Prime Tenant</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.039</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M128"></a><font style="color:#auto;">Tenant</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- Precision BioSciences, Inc.</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.040</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M129"></a><font style="color:#auto;">Tenant Delay</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; any </font><font style="text-decoration:none;color:#000000;font-weight:normal;">verifiable </font><font style="font-weight:normal;">act or omission by </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">, or a </font><font style="color:#auto;font-weight:normal;">Tenant Party </font><font style="font-weight:normal;">that </font><font style="text-decoration:none;color:#000000;font-weight:normal;">proximately results</font><font style="font-weight:normal;"> in a delay hereunder</font><font style="color:#000000;font-weight:normal;"><strike>.</strike></font><font style="text-decoration:none;color:#000000;font-weight:normal;"> (as reasonably documented by </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord</font><font style="text-decoration:none;color:#000000;font-weight:normal;">).&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.041</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M130"></a><font style="color:#auto;">Tenant&#8217;s Forecast Operating Expenses</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- a written </font><font style="color:#auto;font-weight:normal;">statement </font><font style="font-weight:normal;">of </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s reasonable estimate of </font><font style="color:#auto;font-weight:normal;">Tenant&#8217;s Proportionate Share </font><font style="font-weight:normal;">of </font><font style="color:#auto;font-weight:normal;">Operating Expenses </font><font style="font-weight:normal;">for each calendar year (or portion thereof) during the </font><font style="color:#auto;font-weight:normal;">Term </font><font style="font-weight:normal;">or </font><font style="color:#auto;font-weight:normal;">Renewal Term </font><font style="font-weight:normal;">presented to </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">prior to the beginning of each calendar year.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Operating Expenses </font><font style="font-weight:normal;">for 2010 are estimated to be $3.91 </font><font style="color:#auto;font-weight:normal;">per rentable square foot</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.042</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M131"></a><font style="color:#auto;">Tenant Improvements</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; the improvements constructed to prepare the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">for occupancy by </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">as described in Exhibit D. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.043</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M132"></a><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="color:#auto;">Tenant Improvement Allowance </font>&#8211; <font style="font-weight:normal;">Fifty dollars </font>(<font style="font-weight:normal;">$50.00) </font><font style="color:#auto;font-weight:normal;">per rentable square foot </font><font style="font-weight:normal;">for a total of Four Hundred Thirteen Thousand Seven Hundred Dollars ($413,700.00).&nbsp;&nbsp;The </font><font style="color:#auto;font-weight:normal;">Tenant Improvement Allowance </font><font style="font-weight:normal;">shall be used to fund (listed in order of payment): </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;">Landlord Design Oversight (5% of Construction and Design Costs), Design Fees, Permit Fees, Construction Contingency (5% of </font><font style="color:#auto;font-weight:normal;">Construction Costs</font><font style="font-weight:normal;">), Construction Payment and Performance Bonds, and </font><font style="color:#auto;font-weight:normal;">Construction Costs</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.044</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M133"></a><font style="color:#auto;">Tenant Improvement Overage</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- all </font><font style="color:#auto;font-weight:normal;">costs </font><font style="font-weight:normal;">for the </font><font style="color:#auto;font-weight:normal;">Tenant Improvements </font><font style="font-weight:normal;">minus the </font><font style="color:#auto;font-weight:normal;">Tenant Improvement Allowance</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.045</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M134"></a><font style="color:#auto;">Tenant Party</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- collectively, the </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">and its agents, employees, officers, invitees, licensees and independent contractors. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.046</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M135"></a><a name="_DV_C14"></a><a name="_DV_M136"></a><font style="color:#auto;">Tenant&#8217;s Proportionate Share</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">- a percentage which represents the ratio that the number of rentable square feet of the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">bears to (i) the rentable square footage of the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">for invoices associated specifically with the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">(e.g., </font><font style="color:#auto;font-weight:normal;">building </font><font style="font-weight:normal;">common area janitorial, common area utilities, termite treatment, etc.) which is 16.01409% or (ii) the rentable square footage of the </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">for invoices associated with the </font><font style="color:#auto;font-weight:normal;">Project </font><font style="font-weight:normal;">(e.g. property taxes, insurance </font><font style="color:#auto;font-weight:normal;">premiums</font><font style="font-weight:normal;">, landscaping, security, snow/ice removal, etc.) which is 9.63404%.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Tenant&#8217;s Proportionate Share </font><font style="font-weight:normal;">for any partial calendar year during the </font><font style="color:#auto;font-weight:normal;">Lease Term </font><font style="font-weight:normal;">will be determined by multiplying the amount of </font><font style="color:#auto;font-weight:normal;">Tenant&#8217;s Proportionate Share </font><font style="font-weight:normal;">of increases in </font><font style="color:#auto;font-weight:normal;">Operating Expenses </font><font style="font-weight:normal;">for the full calendar year by a fraction, the numerator of which is the number of days during such calendar year falling within the </font><font style="color:#auto;font-weight:normal;">Lease Term </font><font style="font-weight:normal;">or </font><font style="color:#auto;font-weight:normal;">Renewal Term </font><font style="font-weight:normal;">and the denominator of which is three hundred sixty-five (365)</font><font style="text-decoration:none;color:#000000;font-weight:normal;"> </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant </font><font style="text-decoration:none;color:#000000;font-weight:normal;">shall have the right to confirm the measurement of the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Premises </font><font style="text-decoration:none;color:#000000;font-weight:normal;">and its Proportionate Share, and receive appropriate </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_C14"></a>Rent</font><font style="border-bottom:double 2.5pt;color:#0000FF;font-weight:normal;"> </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M136"></a>and Tenant Improvement Allowance </font><font style="text-decoration:none;color:#000000;font-weight:normal;">adjustments, increases, and/or refunds, to the extent </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant </font><font style="text-decoration:none;color:#000000;font-weight:normal;">discovers an error and provides evidence of same to </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord </font><font style="text-decoration:none;color:#000000;font-weight:normal;">for reasonable confirmation by </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.047</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M137"></a><font style="color:#auto;">Term</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; sixty-five (65) months.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.048</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M138"></a><font style="color:#auto;">Termination Date</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">&#8211; that date which is sixty-five (65) months after the </font><font style="color:#auto;font-weight:normal;">Commencement Date</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;"><a name="_DV_M139"></a>&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Recitals.<font style="font-weight:normal;">&nbsp;&nbsp;This Lease is made and entered into as of the 5th day of April, 2010, by and between the Landlord and the Tenant.&nbsp;&nbsp;The parties hereto acknowledge that Landlord has leased the entirety of the Building and the Land from the Prime Tenant pursuant to the Sublease and that the Prime Tenant has leased the Building and the Land from the Prime Landlord pursuant to the Master Lease.&nbsp;&nbsp;Upon the execution of this instrument, Landlord will sublease the Premises to Tenant.&nbsp;&nbsp;While the transaction effected hereby would be a sublease, and the Landlord and Tenant are respectively, sublandlord and subtenant, for ease of reference, this instrument is referred to as a Lease, and the parties referred to as Landlord and Tenant, and Landlord hereby confirms that it has authority to sublease the Premises to Tenant.&nbsp;&nbsp;Now therefore, in consideration of the foregoing and the mutual covenants provided herein, the parties hereto agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"><a name="_DV_M140"></a>&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>3.<font style="margin-left:36pt;"></font>Premises.<font style="font-weight:normal;">&nbsp;&nbsp;In consideration of the obligation of Tenant to pay rent as herein provided, and in consideration of the other terms, provisions and covenants hereof, Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises for the Permitted Use. The Premises are comprised of the Net Rentable Area in the Building situated on the Land in the County of Durham, City of Durham, State of North Carolina, more particularly described on Exhibit A, attached hereto and incorporated herein by reference, together with all rights, privileges, easements, appurtenances and immunities belonging to or in any way pertaining to the Premises. Except as provided herein (and subject to latent defects not readily apparent through visual inspection and identified &#8220;punchlist&#8221; items, which Landlord shall repair within a reasonable </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">amount of time), Tenant shall lease the Premises &#8220;as is&#8221; with no representations or warranties made by Landlord as to the condition of the Premises To the best of its knowledge, Landlord represents and warrants that as of this date, the Premises are in material compliance with all Applicable Laws, and are in good condition and repair subject to reasonable wear and tear. In addition, Landlord shall use all reasonable efforts to insure that as of the Commencement Date (modified as provided herein), the Premises will be in material compliance with all Applicable Laws and are in good condition and repair.&nbsp;&nbsp;To the best of Landlord's knowledge, Applicable Laws and any recorded restrictive covenants permit the Premises to be used for the Permitted Use.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M141"></a>The <font style="color:#auto;">Building </font>is part of the <font style="text-decoration:none;color:#auto;">Project </font><font style="text-decoration:none;color:#000000;">and consists of a total of Eighty-Five Thousand Six Hundred and Twenty-Two (85,622) rentable square feet with the </font><font style="text-decoration:none;color:#auto;">Building </font><font style="text-decoration:none;color:#000000;">being comprised of Fifty One Thousand Six Hundred Sixty-Seven (51,667) rentable square feet.&nbsp;&nbsp;</font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">hereby represents and warrants to </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">that the foregoing representations regarding rentable square feet are consistent with the definition of rentable area calculated pursuant to </font><font style="text-decoration:none;color:#auto;">Building Owners and Managers Association Standards</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font>A floor plan of the <font style="color:#auto;">Premises is attached hereto and made a part hereof as Exhibit B.&nbsp;&nbsp;</font>As an appurtenance to the <font style="color:#auto;">Premises</font>, <font style="color:#auto;">Tenant</font>, its employees and invitees will have the nonexclusive right to use the <font style="color:#auto;">Common Areas </font>at the <font style="color:#auto;">Building</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M142"></a>Within five <font style="text-decoration:none;">business </font>days <font style="color:#000000;">of the </font>Commencement Date<font style="color:#000000;">, </font>Tenant <font style="color:#000000;">will, upon demand of </font>Landlord<font style="color:#000000;">, execute and deliver to </font>Landlord <font style="color:#000000;">a letter of acceptance of delivery of the </font>Premises<font style="text-decoration:none;"> </font><font style="text-decoration:none;color:#000000;">(subject to latent defects not readily apparent through&nbsp;&nbsp; visual inspection and identified &#8220;</font><font style="text-decoration:none;">punchlist</font><font style="text-decoration:none;color:#000000;">&#8221; items, which </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall repair within a reasonable amount of time)</font><font style="color:#000000;">, acknowledging the Commencement and </font>Termination Dates <font style="color:#000000;">of this </font>Lease<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C15"></a><a name="_DV_M143"></a><a name="_DV_M144"></a><a name="_DV_C17"></a><a name="_DV_M145"></a><a name="_DV_C18"></a><a name="_DV_M146"></a><font style="text-decoration:none;"><a name="_DV_M143"></a>Except for any items the cost of which is paid out of the Tenant Improvement Allowance, Landlord shall perform, at its sole cost and expense, all work detailed on Exhibit C hereto.&nbsp;&nbsp;</font><a name="_DV_M144"></a>The upfit of the Premises,<a name="_DV_C17"></a> will be performed by Landlord in accordance with the <font style="text-decoration:none;"><a name="_DV_M145"></a>Premises Specifications in the </font><a name="_DV_C18"></a>Work Letter,<font style="text-decoration:none;"><a name="_DV_M146"></a> if applicable</font> attached hereto and made a part hereof Exhibit D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M147"></a>Subject to reasonable rules and regulations as <font style="color:#auto;">Landlord </font>may from time to time prescribe and subject to rights of ingress and egress of other tenants of the <font style="color:#auto;">Project</font>, <font style="color:#auto;">Tenant </font>and its invitees will have the right to the non-exclusive usage of twenty (20) <font style="color:#auto;">parking </font>spaces.&nbsp;&nbsp;<font style="color:#auto;">Landlord </font>will not be responsible for enforcing <font style="color:#auto;">Tenant</font>&#8217;s <font style="color:#auto;">parking </font>rights against any third parties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M148"></a><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">is granted a non-exclusive right to use, in common with the other tenants and users of the </font><font style="text-decoration:none;">Project</font><font style="text-decoration:none;color:#000000;">, all of the </font><font style="text-decoration:none;">Common Areas</font><font style="text-decoration:none;color:#000000;">. </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall have exclusive control and management responsibility of the </font><font style="text-decoration:none;">Common Areas</font><font style="text-decoration:none;color:#000000;">. </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">may, from time to time, alter the </font><font style="text-decoration:none;">Common Areas</font><font style="text-decoration:none;color:#000000;">, install kiosks, planters, fountains, sculptures, signs, and other structures within the </font><font style="text-decoration:none;">Common Areas </font><font style="text-decoration:none;color:#000000;">provided however that any such alterations shall not materially and adversely interfere with </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s use or enjoyment of the </font><font style="text-decoration:none;">Premises </font><font style="text-decoration:none;color:#000000;">or decrease </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s </font><font style="text-decoration:none;">parking </font><font style="text-decoration:none;color:#000000;">spaces.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall have the right to establish, modify, and enforce reasonable rules and regulations with respect to the </font><font style="text-decoration:none;">Common Areas </font><font style="text-decoration:none;color:#000000;">and to grant to individual tenants the right to conduct retail </font><font style="text-decoration:none;">sales </font><font style="text-decoration:none;color:#000000;">within the </font><font style="text-decoration:none;">Common Areas</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">makes no representation or warranty concerning the size of the </font><font style="text-decoration:none;">Common Areas </font><font style="text-decoration:none;color:#000000;">and may, in the future, reduce the size of the </font><font style="text-decoration:none;">Common Areas </font><font style="text-decoration:none;color:#000000;">in its reasonable discretion, provided however that such reduction shall not materially and adversely interfere with </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s use or enjoyment of the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">, and shall result in a commensurate reduction in </font><font style="text-decoration:none;">Tenant&#8217;s Proportionate Share</font><font style="text-decoration:none;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M149"></a>Landlord <font style="color:#000000;">hereby grants to </font>Tenant <font style="color:#000000;">a continuing right of first refusal to </font>lease <font style="color:#000000;">vacant and available space in the Building (the &#8220;</font>Additional Space<font style="color:#000000;">&#8221;) under the terms and conditions as provided below:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M150"></a>(i) <font style="color:#000000;">Subordinate to other tenants at the </font>Project <font style="color:#000000;">with pre-existing </font>First Right of Refusal<font style="color:#000000;">, and so long as there is no event of default by </font>Tenant <font style="color:#000000;">hereunder beyond any applicable grace and/or cure period, </font>Landlord <font style="color:#000000;">will notify </font>Tenant <font style="color:#000000;">when it has all or a portion of the </font>Additional Space <font style="color:#000000;">for </font>lease <font style="color:#000000;">to a </font>third party <font style="color:#000000;">(the &#8220;</font>Third Party<font style="color:#000000;">&#8221;) and the terms and conditions upon which it is willing to </font>lease <font style="color:#000000;">such space (&#8220;</font>Landlord&#8217;s Notice<font style="color:#000000;">&#8221;).</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M151"></a>(ii) Tenant <font style="color:#000000;">shall provide written notice to </font>Landlord<font style="color:#000000;">, as to </font>Tenant<font style="color:#000000;">&#8217;s decision to </font>lease <font style="color:#000000;">or not to </font>lease <font style="color:#000000;">the </font>Additional Space within five (5) business days <font style="color:#000000;">after </font>Landlord&#8217;s Notice <font style="color:#000000;">is received.&nbsp;&nbsp;If </font>Tenant <font style="color:#000000;">does provide to </font>Landlord <font style="color:#000000;">notice to </font>lease <font style="color:#000000;">the </font>Additional Space<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">will execute a </font>lease <font style="text-decoration:none;">amendment </font><font style="text-decoration:none;color:#000000;">adding</font><font style="color:#000000;"> the </font>Additional Space<font style="text-decoration:none;"> </font><font style="text-decoration:none;color:#000000;">to the </font><font style="text-decoration:none;">Premises</font> <font style="color:#000000;">within twenty (20) days after </font>Landlord<font style="color:#000000;">&#8217;s receipt of </font>Tenant<font style="color:#000000;">&#8217;s notice of intent to </font>lease <font style="color:#000000;">on all the same terms provided to the </font>Third Party<font style="color:#000000;">.&nbsp;&nbsp; If </font>Tenant <font style="color:#000000;">does not provide written notice to </font>Landlord within five (5) business days <font style="color:#000000;">after receipt of the </font>Landlord's Notice<font style="color:#000000;">, </font>Tenant <font style="color:#000000;">will have been deemed to have waived its right to </font>lease <font style="color:#000000;">the </font>Additional Space <font style="color:#000000;">and </font>Landlord <font style="color:#000000;">shall be free to enter into a </font>lease <font style="color:#000000;">with the </font>Third Party<font style="color:#000000;">.&nbsp;&nbsp;Should all or any portion of the </font>Additional Space <font style="color:#000000;">become vacant thereafter, </font>Tenant <font style="color:#000000;">shall again have the right of first refusal provided herein.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M152"></a>(iii) <font style="color:#000000;">The rights provided to </font>Tenant <font style="color:#000000;">in this Section are personal to the </font>Tenant <font style="color:#000000;">and may not be assigned in connection with an assignment of this </font>Lease<font style="color:#000000;">, subletting of the </font>Premises <font style="color:#000000;">or otherwise</font><font style="text-decoration:none;color:#000000;">, except for any </font><font style="text-decoration:none;">Permitted Transferee </font><font style="text-decoration:none;color:#000000;">(as hereinafter defined)</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.63%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M153"></a><a name="_DV_M154"></a><a name="OLE_LINK6"></a><a name="OLE_LINK9"></a><a name="_DV_M155"></a><a name="_DV_C20"></a><a name="_DV_M156"></a><a name="_DV_C22"></a><a name="_DV_M157"></a>4.<font style="margin-left:36pt;"></font><font style="color:#auto;">Term</font>.<font style="font-weight:normal;">&nbsp;&nbsp;The </font><font style="color:#auto;font-weight:normal;">Term </font><font style="font-weight:normal;">of the Lease</font><font style="color:#auto;font-weight:normal;"> </font><font style="font-weight:normal;">will begin on the </font><font style="color:#auto;font-weight:normal;">Commencement Date </font><font style="font-weight:normal;">and end on the </font><font style="color:#auto;font-weight:normal;">Termination Date</font><font style="font-weight:normal;">, unless sooner terminated or extended pursuant to the provisions hereof. The </font><font style="color:#auto;font-weight:normal;">Commencement Date </font><font style="font-weight:normal;">and </font><font style="color:#auto;font-weight:normal;">Termination Date </font><font style="font-weight:normal;">will be extended at the option of </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">due to </font><font style="color:#auto;font-weight:normal;">Force Majeure</font><font style="font-weight:normal;"><a name="_DV_M154"></a><a name="OLE_LINK6"></a><a name="OLE_LINK9"></a>.</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;">Landlord</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> </font><font style="text-decoration:none;color:#000000;font-weight:normal;">shall use commercially reasonable measures to ensure that the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Commencement Date </font><font style="text-decoration:none;color:#000000;font-weight:normal;"><a name="_DV_M155"></a>is no later than October 1, 2010.&nbsp;&nbsp;In the event that the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Commencement Date </font><font style="text-decoration:none;color:#000000;font-weight:normal;">is later than February 1, 2011 for reasons other than a </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant Delay </font><font style="text-decoration:none;color:#000000;font-weight:normal;">or </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Force Majeure</font><font style="text-decoration:none;color:#000000;font-weight:normal;">, and </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_C20"></a>provided there is no<a name="_DV_M156"></a> <a name="_DV_C22"></a>default or event of default by Tenant hereunder, Tenant shall, by written notice to Landlord on or prior to <a name="_DV_M157"></a>February 6, 2011 (time being of the essence), have the right to terminate this Lease and all of its obligations hereunder</font><font style="text-decoration:none;color:#000000;font-weight:normal;"> (as of the date of giving such notice), and the parties hereto shall have no further obligation to each other hereunder.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M158"></a><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>Provided there is no default or event of default <font style="color:#000000;">by </font>Tenant <font style="color:#000000;">hereunder at the time such rights are exercised or when a </font>Renewal Term <font style="color:#000000;">will commence, </font>Tenant <font style="color:#000000;">will have the option to extend the </font>term <font style="color:#000000;">of this Lease for two (2) Renewal Terms each of </font>three (3) Lease Years <font style="color:#000000;">by providing </font>Landlord <font style="color:#000000;">written notice of its desire to do so at least one hundred and eighty (180) days prior to the end of the then current </font>term <font style="color:#000000;">hereof. The date of the commencement of the </font>Renewal Term <font style="color:#000000;">will be the day after the expiration of the then current </font>term <font style="color:#000000;">of the </font>Lease <font style="color:#000000;">(unless sooner terminated as provided herein).&nbsp;&nbsp;All terms and conditions of this </font>Lease <font style="color:#000000;">will be in effect during the </font>Renewal Term<font style="color:#000000;">, except that </font>(i) <font style="color:#000000;">the </font>Base Annual Rent <font style="color:#000000;">will be the lesser of </font>(a) n<font style="color:#000000;">inety-five percent (95%) of the then market rate</font><font style="text-decoration:none;color:#000000;"> for comparable laboratory space in downtown </font><font style="text-decoration:none;">Durham</font><font style="color:#000000;">, as</font><font style="color:#000000;"><strike> </strike></font><font style="color:#000000;"> determined </font><font style="text-decoration:none;color:#000000;">in accordance with this </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;color:#000000;">Section </font><font style="text-decoration:none;">4</font><font style="text-decoration:none;color:#000000;">,</font><font style="color:#000000;"> or </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font><font style="color:#000000;">the increase in the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CPI </font><font style="color:#000000;">with a floor of&nbsp;&nbsp;two and one-half percent (2.5%) and a ceiling of three percent (3%) but in no event shall </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base Annual Rent </font><font style="color:#000000;">be less than that paid the previous </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Year</font><font style="color:#000000;">, and </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) </font><font style="color:#000000;">upon the exercise of the right to renew hereunder, a right of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">to renew or extend the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term </font><font style="color:#000000;">hereof will have lapsed.&nbsp;&nbsp;Failure of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">to comply strictly with the provisions of this subparagraph will render the rights of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">in this subparagraph null and void.&nbsp;&nbsp;The rights granted to </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">in this subparagraph are personal to </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">and will not inure to the benefit of any successor or </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assign </font><font style="color:#000000;">of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="text-decoration:none;color:#000000;">, except for any </font><font style="text-decoration:none;">Permitted Transferee</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M159"></a><font style="text-decoration:none;">The market rate shall mean the fair market base </font><font style="text-decoration:none;color:#auto;">rent</font><font style="text-decoration:none;">, without deduction for the cash value of free </font><font style="text-decoration:none;color:#auto;">rent </font><font style="text-decoration:none;">and leasehold improvements, which renewing, non-equity tenants are then receiving in connection with a </font><font style="text-decoration:none;color:#auto;">lease </font><font style="text-decoration:none;">for comparable space in the Durham, North Carolina area.&nbsp;&nbsp;</font><font style="font-weight:bold;text-decoration:none;">&nbsp;&nbsp;</font><font style="text-decoration:none;">Promptly following receipt by </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">of </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="text-decoration:none;">&#8217;s renewal notice, </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">shall notify </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">of the amount that, in </font><font style="text-decoration:none;color:#auto;">Landlord</font><font style="text-decoration:none;">&#8217;s reasonable opinion, represents the market rate during the </font><font style="text-decoration:none;color:#auto;">Renewal Term</font><font style="text-decoration:none;">.&nbsp;&nbsp;Within fifteen (15) days of such notice, </font><font style="text-decoration:none;color:#auto;">(a) </font><font style="text-decoration:none;">if </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">agrees, </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">shall notify </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">that </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">so agrees that the </font><font style="text-decoration:none;color:#auto;">Base Annual Rent </font><font style="text-decoration:none;">therein provided constitutes the market rate, or </font><font style="text-decoration:none;color:#auto;">(b) </font><font style="text-decoration:none;">if </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">disagrees, </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">shall specify what </font><font style="text-decoration:none;color:#auto;">Base Annual Rent</font><font style="text-decoration:none;">, in </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="text-decoration:none;">&#8217;s opinion, constitutes the market rate, or </font><font style="text-decoration:none;color:#auto;">(c) </font><font style="text-decoration:none;">if </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">does not respond, </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">shall be deemed to agree.&nbsp;&nbsp;In the event </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">agrees, then the </font><font style="text-decoration:none;color:#auto;">Base Annual Rent </font><font style="text-decoration:none;">set forth in </font><font style="text-decoration:none;color:#auto;">Landlord</font><font style="text-decoration:none;">&#8217;s said notice shall be deemed the market rate.&nbsp;&nbsp;In the event </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">disagrees as provided in clause </font><font style="text-decoration:none;color:#auto;">(b) </font><font style="text-decoration:none;">above, the following procedure shall be used in determining the market rate:&nbsp;&nbsp;The parties shall use due diligence to attempt to agree upon the market rate within seven (7) business days following the foregoing fifteen (15) day period, but, if they do not so agree, then at the request of either party to the other (the &#8220;</font><font style="text-decoration:none;color:#auto;">Initial Request</font><font style="text-decoration:none;">&#8221;), the parties shall jointly choose a real estate broker (who shall have had at least ten (10) years experience as a broker in commercial office leasing in the Durham, North Carolina area) and who has not been employed by either party, whose decision shall be final and binding.&nbsp;&nbsp;If the parties do not agree upon such a </font><font style="text-decoration:none;color:#auto;">third party </font><font style="text-decoration:none;">broker and notify in writing the other thereof within seven (7) business days of the </font><font style="text-decoration:none;color:#auto;">Initial Request</font><font style="text-decoration:none;">, then within six (6) additional business days each party shall choose a real estate broker (having the foregoing credentials) and notify in writing the other thereof, and the joint decision of such real estate </font><font style="text-decoration:none;color:#auto;">brokers </font><font style="text-decoration:none;">regarding the market rate shall be final and binding (or, failing such notice, or if such choice is made, failing notice to the other within such six (6) additional business day period, the decision of one such real estate broker timely chosen and noticed shall be final and binding).&nbsp;&nbsp;If the two (2) real estate </font><font style="text-decoration:none;color:#auto;">brokers </font><font style="text-decoration:none;">timely chosen and noticed do not agree within seven (7) business days of the end of the six (6) business day period mentioned above during which they were chosen, then they shall choose a third such real estate broker (having the foregoing credentials) </font><font style="text-decoration:none;color:#auto;">within five (5) business days</font><font style="text-decoration:none;">, and the decision of such third real estate broker regarding the market rate shall be final and binding.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M160"></a><a name="_DV_M162"></a><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>5.<font style="margin-left:36pt;"></font>Rent.<font style="font-weight:normal;"><a name="_DV_M162"></a>&nbsp;&nbsp;Beginning on the Rent Commencement Date and continuing thereafter throughout the Term, Tenant will pay the Rent in monthly installments in advance, without demand, deduction or offset, in lawful money of the United States commencing on the Rent Commencement Date, and continuing on the first day of each and every month thereafter until the Termination Date.&nbsp;&nbsp;Rent payments for any fractional calendar month at the end, or the beginning of the term of the Lease, will be prorated. In the event Tenant fails to pay any installment of Rent hereunder within ten days of the due date of such installment, Tenant will pay to Landlord on demand a late charge in an amount equal to four percent (4%) of such installment.  The provision for such late charge will be in addition to all of Landlord&#8217;s other rights and remedies hereunder or at law and will not </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">be construed as liquidated damages or as limiting Landlord&#8217;s remedies in any manner.&nbsp;&nbsp;Commencing with the second Lease Year hereunder, Base Annual Rent will increase on each anniversary of the Rent Commencement Date by the Base Annual Rent Escalation over the Base Annual Rent paid the previous Lease Year.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M165"></a>Commencing January 1 of the year following the <font style="color:#auto;">Commencement Date </font>and continuing thereafter for each calendar year during the <font style="color:#auto;">Term</font>, <font style="color:#auto;">Landlord </font>will present to <font style="color:#auto;">Tenant Tenant<strike>'</strike></font><font style="text-decoration:none;color:#auto;">s</font><font style="color:#auto;"> Forecast Operating Expenses</font><font style="text-decoration:none;color:#000000;">.</font>&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>will pay without deduction, offset, or counter claim, and otherwise in the same manner as <font style="color:#auto;">Base Annual Rent </font>on the first day of each calendar month during the <font style="color:#auto;">Term</font>, an amount equal to one twelfth <font style="color:#auto;">(1/12) </font>of <font style="color:#auto;">Tenant&#8217;s Forecast Operating Expenses </font>as <font style="color:#auto;">Additional Rent</font>.&nbsp;&nbsp;From time to time during any calendar year, <font style="color:#auto;">Landlord </font>may revise <font style="color:#auto;">Tenant&#8217;s Forecast Operating Expense </font>and adjust <font style="color:#auto;">Tenant</font>&#8217;s monthly payments to reflect <font style="color:#auto;">Landlord</font>&#8217;s such revisions. <font style="text-decoration:none;color:#000000;">Promptly after the full execution of this </font><font style="text-decoration:none;color:#auto;">Lease </font><font style="text-decoration:none;color:#000000;">(and delivery to </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">of a copy thereof), </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">shall pay </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">the first month's </font><font style="text-decoration:none;color:#auto;">Rent </font><font style="text-decoration:none;color:#000000;">due hereunder.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M166"></a>Notwithstanding the foregoing, and <font style="color:#auto;">provided there is no default or event of default </font>hereunder by <font style="color:#auto;">Tenant</font>, <font style="color:#auto;">Base Annual Rent </font>(but not <font style="color:#auto;">Operating Expenses</font>) shall be abated hereunder for the first five (5) months after the Commencement Date (the <font style="text-decoration:none;color:#000000;">"</font><font style="color:#auto;">Rent Abatement</font><font style="text-decoration:none;color:#000000;">"</font>).&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>will be responsible for its <font style="color:#auto;">Proportionate Share </font>of the <font style="color:#auto;">Operating Expenses </font>for the <font style="color:#auto;">Building </font>as well as its utilities and janitorial services.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M167"></a>6.<font style="margin-left:36pt;"></font>Operating Expenses.<font style="font-weight:normal;"> The accounting of the Operating Expenses will be performed in accordance with Generally Accepted Accounting Principles.&nbsp;&nbsp;For the purpose of calculating the Operating Expenses, no Controllable Expense will increase more than five percent (5%) over the charge paid by Tenant the previous Lease Year. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M168"></a>If the average occupancy rate of the <font style="color:#auto;">Building Rentable Area </font>will be less than ninety-five percent (95%) during any calendar year, or if any <font style="color:#auto;">tenant </font>is separately paying for (or does not require) electricity, janitorial, or other services furnished to its <font style="color:#auto;">premises</font>, then,<font style="font-weight:bold;"> </font>for purposes of calculating <font style="color:#auto;">Operating Expenses</font>, the <font style="color:#auto;">Operating Expenses </font>for such period that vary with the level of occupancy of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>will be increased by the additional <font style="color:#auto;">costs </font>and expenses that <font style="color:#auto;">Landlord </font>reasonably estimates would have been incurred if the average occupancy rate had been ninety-five percent (95%) for such period.&nbsp;&nbsp;In no event will the <font style="color:#auto;">Project </font>tenants be required to pay, in the aggregate, more than 100% of the actual <font style="color:#auto;">Operating Expenses </font>of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>for any calendar year, and <font style="color:#auto;">Tenant </font>will not be required to pay more than one hundred percent (100%) of its <font style="color:#auto;">Proportionate Share </font>of the total increase in <font style="color:#auto;">Operating Expenses </font>actually incurred for the calendar year, with such actual <font style="color:#auto;">Operating Expenses </font>to be determined and payments reconciled through the process described above.&nbsp;&nbsp;At <font style="color:#auto;">Tenant</font>&#8217;s written request, <font style="color:#auto;">Landlord </font>will provide information sufficient to disclose or quantify adjustments made to each category of <font style="color:#auto;">Operating Expenses </font>increased pursuant to the provisions of this Section.&nbsp;&nbsp;For the purpose of this Section, the <font style="color:#auto;">term </font>&#8220;<font style="color:#auto;">Building</font>&#8221; will be deemed to include the roof of the <font style="color:#auto;">Building </font>and any extensions therefrom, courtyards, sidewalks, landscaping, and all other areas, facilities, improvements, and appurtenances relating to any of the foregoing; provided, however, that <font style="color:#auto;">Operating Expenses </font>for the <font style="color:#auto;">Building </font>will not include <font style="color:#auto;">Operating Expenses </font>for the <font style="color:#auto;">Project</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M169"></a><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><a name="_DV_M170"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 120 days after the end of each calendar year, </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will submit to </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#auto;">Statement </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">showing </font><font style="color:#auto;">(i) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the actual </font><font style="color:#auto;">Tenant&#8217;s Proportionate Share </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the amount by which </font><font style="color:#auto;">Operating Expenses </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incurred during the preceding calendar year exceed the </font><font style="color:#auto;">Tenant</font><font style="color:#auto;"><strike>'</strike></font><font style="text-decoration:none;color:#auto;">s</font><font style="color:#auto;"> Forecast Operating Expenses</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#auto;">(ii) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the amount thereof paid by </font><font style="color:#auto;">Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and </font><font style="color:#auto;">(iii) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the balance due or the overpayment.&nbsp;&nbsp;If there is a balance due, </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will pay the balance due as </font><font style="color:#auto;">Additional Rent </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within thirty (30) days following receipt of such </font><font style="color:#auto;">Statement</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If the </font><font style="color:#auto;">Statement </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indicates an overpayment, then </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will credit the net overpayment toward </font><font style="color:#auto;">Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s next estimated payment(s) pursuant to this Section or if at the end of the </font><font style="color:#auto;">Term</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, will refund such excess to </font><font style="color:#auto;">Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or its designated representative, at its sole expense, will have the right once per calendar year during the </font><font style="color:#auto;">Term </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to audit </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s books and records relating to the </font><font style="color:#auto;">Operating Expenses </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the immediately preceding calendar year.&nbsp;&nbsp;This audit must take place on a mutually agreeable date during reasonable business hours at </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s office at the address stated above and only after </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has given </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at least fourteen (14) calendar days prior written notice of the date and time </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">desires to commence such audit.&nbsp;&nbsp;If </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elects to audit </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s books and records, </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will have the right to perform an audit of the </font><font style="color:#auto;">Operating Expenses </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M170"></a>for the immediately preceding two (2) calendar years, such audit to be conducted by a reputable accounting firm</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reasonably approved by </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-style:italic;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any such audit reveals an error by </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulting in an overcharge to </font><font style="color:#auto;">Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, then </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will promptly reimburse </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the amount erroneously charged to </font><font style="color:#auto;">Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Likewise, if any such audit reveals an error resulting in </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being undercharged, then </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will promptly reimburse </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the amount of such deficiency.&nbsp;&nbsp;If any audit performed by </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reveals that the </font><font style="color:#auto;">Operating Expenses </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in total have been overstated by more than five percent (5%), </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will pay and/or reimburse </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the cost of the audit not to exceed </font><font style="text-decoration:none;color:#000000;">Two</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Thousand</font><font style="text-decoration:none;color:#000000;">, Five Hundred</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Dollars ($</font><font style="text-decoration:none;color:#000000;">2,500.00</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M171"></a>7.<font style="margin-left:36pt;"></font>Utilities and Services. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_C26"></a><a name="_DV_M172"></a><a name="_DV_C28"></a><a name="_DV_M173"></a>(a)<font style="margin-left:36pt;"><a name="_DV_C26"></a>Landlord shall furnish connections for each utility </font><font style="text-decoration:none;"><a name="_DV_M172"></a>to</font><a name="_DV_C28"></a> the <font style="text-decoration:none;"><a name="_DV_M173"></a>Premises</font> to include electricity, water and sewer, and telephone as specified<font style="color:#000000;"> in Exhibit C. </font><font style="color:#000000;">Landlord shall not be liable in any respect for damages to person, property or otherwise due to the interruption in any utility to the </font>Building<font style="color:#000000;">, nor be construed as an eviction of </font>Tenant<font style="color:#000000;">, nor work an abatement of </font>rent<font style="color:#000000;">, nor relieve </font>Tenant <font style="color:#000000;">from fulfillment of any covenant or agreement hereof nor give rise to any right or remedy by </font>Tenant<font style="text-decoration:none;"> </font><font style="text-decoration:none;color:#000000;">unless caused by the gross negligence or willful misconduct of </font><font style="text-decoration:none;">Landlord</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall provide conduit and boxes for phone and data at the </font>Premises<font style="color:#000000;">. </font>Tenant <font style="color:#000000;">shall bear the </font>costs <font style="color:#000000;">and be responsible for pulling cable for phone and data from the </font>Demarcation <font style="color:#000000;">closet (telephone closet) and providing cabling and jacks.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">Landlord </font><font style="color:#000000;">shall provide the following services to </font>Common Areas <font style="color:#000000;">of the </font>Building<font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&nbsp;&nbsp; Common Area <font style="color:#000000;">Cleaning (M, W, T, F):&#160;&#160;&#160;&#160;(Restrooms, </font>Halls<font style="color:#000000;">, </font>Stairs<font style="color:#000000;">, </font>Lobby<font style="color:#000000;">, </font>Elevator <font style="color:#000000;">and </font>Entrance<font style="color:#000000;">):</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clean and restock restrooms on 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> and 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> floors</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clean elevator</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sweep stairwell and spot mop for spills</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vacuum carpet</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dust mop hard surface floors and spot mop to remove spills</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clean entrance glass doors and sills </font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dust security desk and <font style="color:#auto;">Lobby </font>furniture; and</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Weekly:&#160;&#160;Dust and damp wipe stairwell railings.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) <font style="color:#000000;">Lights on throughout </font>Common Areas <font style="color:#000000;">throughout the business day and </font>parking <font style="color:#000000;">lot illuminated every night</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) <font style="color:#000000;">Security guard on duty Monday through Friday 8-5</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)&nbsp;&nbsp;<font style="color:#000000;">HVAC to condition </font>Common Areas <font style="color:#000000;">during each business day with override after-hours (HVAC annual service contracts included in </font>Operating Expenses<font style="color:#000000;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)&nbsp;&nbsp;<font style="color:#000000;">Landscaping every 7-10 days with day porter services to patrol, weed and clean site three times week</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)&nbsp;&nbsp;<font style="color:#000000;">Fire alarm and controlled access door system monitored 24/7 (</font>contract <font style="color:#000000;">paid through </font>Operating Expenses<font style="color:#000000;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii) <font style="color:#000000;">Elevator preventative </font>maintenance contract <font style="color:#000000;">and service; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii) <font style="color:#000000;">Routine </font>maintenance <font style="color:#000000;">of </font>common areas <font style="color:#000000;">including, but not limited to, bulb replacements, door adjustments, HVAC adjustments, plumbing repairs, etc. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M174"></a>8.<font style="margin-left:36pt;"></font>Direct Tenant Expenses.<font style="font-weight:normal;">&nbsp;&nbsp;Tenant will arrange for the provision of service and shall pay directly to each service provider all charges for all electricity, gas, and other utilities, janitorial, telephone and internet/data used on or from the Premises, together with any taxes, penalties, surcharges or the like pertaining thereto.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M175"></a>9.<font style="margin-left:36pt;"></font>Security Deposit.<font style="font-weight:normal;">&nbsp;&nbsp;Promptly after the full execution of the Lease (with a copy thereof delivered to Tenant), Tenant will provide Landlord with an amount equal to six (6) months of the Base Annual Rent, Seventy-Three Thousand Eight Hundred Forty-Five and 45/100 dollars ($73,845.45) to be held as Security Deposit.&nbsp;&nbsp;Provided that Landlord reasonably approves the form and substance of such, Tenant may provide a Letter of Credit in lieu of cash.&nbsp;&nbsp;Any such Letter of Credit shall be irrevocable, unconditional, payable to the order of Landlord, from an issuer reasonably approved by Landlord, in place for the Term of the Lease and any Renewal Terms hereof, and be for the full amount of the Security Deposit.&nbsp;&nbsp;Landlord will not be required to apply all or any portion of the Security Deposit with respect to any particular violation or default by Tenant but Landlord may apply all or any portion (as reasonably required to effect a cure) of the Security Deposit to any violation, breach, or default by Tenant hereunder.&nbsp;&nbsp;Landlord will be entitled to hold the Security Deposit in an account maintained by Landlord for such funds from all tenants of Landlord.&nbsp;&nbsp;Any interest paid on such an account will become a part of the Security Deposit, accrue to the benefit of the Tenant (less any customary bank fees or charges for maintaining such account), and be delivered to Tenant upon termination of this Lease provided that the Security Deposit and interest thereon have not been applied by Landlord to an event of default hereunder.&nbsp;&nbsp;Tenant will reimburse Landlord for such portions of the Security Deposit as Landlord will from time to time apply with respect to any violation, breach, or default by Tenant hereunder promptly upon written notice of such application by Landlord.&nbsp;&nbsp;Any portion of the Security Deposit which has not been appropriated by Landlord in accordance with the provisions hereof will be returned to Tenant within thirty (30) days after the termination of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M176"></a><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>If <font style="color:#auto;">Landlord </font>conveys <font style="color:#auto;">Landlord</font>&#8217;s <font style="color:#auto;">interest </font>under this <font style="color:#auto;">Lease</font>, the <font style="color:#auto;">Security Deposit</font>, or any part thereof not previously applied, <font style="text-decoration:none;color:#000000;">shall</font> be released by <font style="color:#auto;">Landlord </font>to <font style="color:#auto;">Landlord</font>&#8217;s grantee (to the extent not </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applied to any default by </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereunder), and if so released, </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agrees to look solely to such grantee for the proper application and return thereof in accordance with the </font><font style="color:#auto;">Lease</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">provided that </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">receives written notice of such conveyance</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agrees that </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will not </font><font style="color:#auto;">assign</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and that neither </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, nor its successors and assigns, will be bound by any such assignment, encumbrance or pledge, attempted assignment, attempted pledge, or attempted encumbrance of the </font><font style="color:#auto;">Security Deposit</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M177"></a>Any mortgagee or ground lessor will not be responsible to <font style="color:#auto;">Tenant </font>for the return or application of the <font style="color:#auto;">Security Deposit</font>, whether or not it succeeds to the position of <font style="color:#auto;">Landlord </font>hereunder, unless the <font style="color:#auto;">security deposit </font>will have been received in hand by such mortgagee or ground lessor.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M178"></a>Any unperformed obligations of <font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">or </font><font style="color:#auto;">Tenant </font>under this Section will survive the termination of the <font style="color:#auto;">Lease</font>, for whatever reason, or any extension or renewal hereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M179"></a><a name="_DV_M180"></a>Notwithstanding the foregoing and <font style="color:#auto;"><a name="_DV_M180"></a>provided there is no default or event of default </font>hereunder by <font style="color:#auto;">Tenant </font>(or if <font style="color:#auto;">Tenant </font>has committed a default or event of default more than one (1) time in any twelve (12) month period, then regardless of whether same has been cured), <font style="color:#auto;">Landlord </font>shall reduce the <font style="color:#auto;">Security Deposit </font>by the equivalent of one (1) month<font style="text-decoration:none;color:#000000;">'</font>s <font style="color:#auto;">Base Annual Rent</font>, Twelve Thousand Three Hundred Seven and 58/100 dollars ($12,307.58) every three (3) months during the <font style="color:#auto;">Lease Term </font>commencing upon the later of <font style="color:#auto;">(i) </font>the satisfactory repayment of <font style="color:#auto;">Tenant</font>&#8217;s loan as reported on <font style="color:#auto;">Precision BioSciences</font>, <font style="color:#auto;">Inc. Balance Sheet </font>dated January 8, 2010, or <font style="color:#auto;">(ii) </font>December 31, 2011, until such time that the equivalent of one (1) month's <font style="color:#auto;">Base Annual Rent</font>, Twelve Thousand Three Hundred Seven and 58/100 dollars ($12,307.58), remains as <font style="color:#auto;">Security Deposit</font>. With the third reduction of the <font style="color:#auto;">Security Deposit</font>, if paid as aforesaid, <font style="color:#auto;">Landlord </font>shall remit to <font style="color:#auto;">Tenant </font>the net <font style="color:#auto;">interest </font>that has accrued on the <font style="color:#auto;">Security Deposit</font>.&nbsp;&nbsp;<font style="color:#auto;">Landlord </font>shall provide <font style="color:#auto;">Tenant </font>written notice of any reduction in the <font style="color:#auto;">Security Deposit </font>and <font style="color:#auto;">within five (5) business days </font>thereafter, <font style="color:#auto;">Tenant </font>will be responsible for the re-issuance of an approved Letter of Credit each time that <font style="color:#auto;">Security Deposit </font>is eligible for reduction and until <font style="color:#auto;">Tenant </font>provides a re-issued Letter of Credit, <font style="color:#auto;">Landlord </font>shall have the right to use and draw upon the currently provided Letter of Credit.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M181"></a><a name="_DV_M182"></a><a name="_DV_M183"></a><a name="_DV_M184"></a>10.<font style="margin-left:36pt;"></font>Maintenance and Repairs.<font style="font-weight:normal;"><a name="_DV_M182"></a>&nbsp;&nbsp;<a name="_DV_M183"></a>Landlord will maintain all Common Areas and Systems serving the Common Areas, the roof, downspouts, gutters, foundation, and the exterior walls (and any structural interior walls or other structural elements) of the Building in good repair, reasonable wear and tear excepted.&nbsp;&nbsp;Tenant will repair, replace and pay for, any damage to the foregoing caused by the <a name="_DV_M184"></a>negligence or misconduct of Tenant or any Tenant Party, or caused by Tenant&#8217;s default hereunder. The term &#8220;walls&#8221; as used herein will not include windows, glass or plate glass, doors, special store fronts or office entries.&nbsp;&nbsp;Tenant will promptly give Landlord written notice of defect or need for repairs, after which Landlord will have reasonable opportunity to repair same or cure such defect. Landlord's liability with respect to any defects, repairs or maintenance for which Landlord is responsible under any of the provisions of this Lease will be limited to the cost of such repairs or maintenance or the curing of such defect.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M185"></a><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><a name="_DV_C34"></a>Tenant <font style="color:#000000;">will at its own cost and expense maintain, repair and replace the entirety of the </font>Premises <font style="color:#000000;">(except those for which </font>Landlord <font style="color:#000000;">is expressly responsible under the terms of this </font>Lease<font style="color:#000000;">) in</font><font style="text-decoration:none;color:#000000;">&nbsp;&nbsp;as</font><font style="color:#000000;"> good condition</font><font style="text-decoration:none;color:#000000;"> as received (ordinary wear and tear excepted)</font><font style="color:#000000;">, promptly making all necessary repairs and replacements, including, but not limited to, heating, ventilation, cooling, plumbing, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">telecommunications, electrical and any other systems</font><font style="text-decoration:none;color:#000000;"> (the &#8220;</font><font style="text-decoration:none;">Systems</font><font style="text-decoration:none;color:#000000;">&#8221;)</font><font style="color:#000000;"> within or serving the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</font><font style="color:#000000;">, lighting fixtures, ballasts and bulbs, windows and window treatments, windows, glass and plate glass, doors, any special office entry, interior walls, finish work, and floors and floor coverings within or serving the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;color:#000000;">unless any such damage is caused by parties other than </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">or a </font><font style="text-decoration:none;">Tenant Party</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall insure that the </font><font style="text-decoration:none;">Systems </font><font style="text-decoration:none;color:#000000;">will be in good working order and condition upon the </font><font style="text-decoration:none;">Commencement Date</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall </font><font style="text-decoration:none;">assign </font><font style="text-decoration:none;color:#000000;">to </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">all warranties that are legally assignable, and if not assignable, shall cooperate with </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">to enforce such warranties. </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">agrees to </font><font style="text-decoration:none;">assign</font><font style="text-decoration:none;color:#000000;">, to the extent legally assignable, any and all manufacturers&#8217; warranties for the </font><font style="text-decoration:none;">Tenant Improvements</font><font style="text-decoration:none;color:#000000;">, directly to the </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">, which warranties shall include, but not be limited to, warranties for the </font><font style="text-decoration:none;">Systems</font><font style="text-decoration:none;color:#000000;">, which shall be the standard warranties available from the manufacturers</font><font style="text-decoration:none;"><a name="_DV_C34"></a>.&nbsp;&nbsp;</font><font style="text-decoration:none;">Additionally, Landlord acknowledges and agrees that any replacements made to any Systems, or any material components thereof (during the last 24 months of the then-existing Lease Term), shall be made by Landlord, and amortized over its useful life, and charged as a capital expense under the Operating Expense formula.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M186"></a><font style="text-decoration:none;">Subject to compliance with any notice and right to cure provisions contained in this </font><font style="text-decoration:none;color:#auto;">Lease</font><font style="text-decoration:none;">, if</font><font style="color:#000000;"> </font><font style="color:#auto;">Tenant </font><font style="color:#000000;">shall fail to fulfill its obligations under this Section, the </font><font style="color:#auto;">Landlord </font><font style="color:#000000;">may enter upon the area of the </font><font style="color:#auto;">Building </font><font style="color:#000000;">or the </font><font style="color:#auto;">Premises </font><font style="color:#000000;">as required to perform the obligations of the </font><font style="color:#auto;">Tenant</font><font style="color:#000000;">, and will be entitled to reimbursement from the </font><font style="color:#auto;">Tenant </font><font style="color:#000000;">for its actual </font><font style="color:#auto;">costs </font><font style="color:#000000;">and expenses in conducting such obligations.&nbsp;&nbsp;The </font><font style="color:#auto;">Tenant </font><font style="color:#000000;">will reimburse the </font><font style="color:#auto;">Landlord </font><font style="color:#000000;">for its actual </font><font style="color:#auto;">costs </font><font style="color:#000000;">and expense promptly upon demand made by the </font><font style="color:#auto;">Landlord</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this subparagraph will not be interpreted to obligate the </font><font style="color:#auto;">Landlord </font><font style="color:#000000;">to perform obligations of the </font><font style="color:#auto;">Tenant</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M187"></a>Tenant <font style="color:#000000;">will not damage any demising wall of the </font>Building<font style="color:#000000;">, or disturb the integrity and support provided by any demising wall and will, at its sole cost and expense, promptly repair any damage or injury to any demising wall caused by </font>Tenant <font style="color:#000000;">or any </font>Tenant Party<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M188"></a><a name="_DV_C35"></a><a name="_DV_M189"></a><a name="_DV_M190"></a><a name="_DV_C37"></a><a name="_DV_M191"></a><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>11.<font style="margin-left:36pt;"></font>Alterations.<font style="font-weight:normal;"><a name="_DV_C35"></a> <a name="_DV_M189"></a>Except for the Tenant Improvements, <a name="_DV_M190"></a>Tenant will not make any alterations, additions or improvements to the Premises (including, but not limited to, roof and wall penetrations <a name="_DV_C37"></a>without the prior written consent of Landlord<a name="_DV_M191"></a> (not to be unreasonably withheld, or delayed). Tenant may, without the consent of Landlord, but at its own cost and expense and in a good workmanlike manner, erect such shelves, bins, machinery, movable lab benches, equipment, trade fixtures (defined as any fixtures used by Tenant in its specific business and not paid for by Landlord) and other non-structural interior improvements as it may deem advisable, without altering the basic character or structure of the Premises or improvements and without overloading or damaging the Premises or Building, and in each case complying with all Applicable Laws. Tenant will not make any alterations, additions or improvements to the Premises which will contravene Landlord&#8217;s policies insuring against loss or damage by fire or other hazards, including but not limited to commercial general liability, or which will prevent Landlord from securing such policies in companies reasonably acceptable to Landlord.&nbsp;&nbsp;If any such alterations, additions or improvements cause the rate of fire or other insurance on the Premises by companies acceptable to Landlord to be increased beyond the minimum rate from time to time applicable to the Premises for permitted uses thereof (as reasonably documented by Landlord), Tenant will pay as Additional Rent the amount of any such increase promptly upon demand by Landlord. Within thirty (30) days receipt of reasonable documentation from Landlord following the completion of any alteration, addition, or improvement at the Premises by Tenant that requires the prior consent of Landlord, Landlord </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">will be reimbursed for any reasonable outside consultant or design professional costs actually incurred by Landlord to review any plans or supervise construction work (not to exceed the lesser of $1,500.00 or 5% of Tenant&#8217;s &#8220;hard&#8221; construction costs). No such reimbursement will be required for any alteration, addition or improvement that does not require the consent of Landlord.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M192"></a>Any and all alterations, additions, improvements, partitions and fixtures erected by <font style="color:#auto;">Tenant </font>will be the property of <font style="color:#auto;">Landlord </font>and will remain at the <font style="color:#auto;">Premises </font>upon termination of the <font style="color:#auto;">Lease </font>or upon earlier vacating of the <font style="color:#auto;">Premises</font>.&nbsp;&nbsp;All shelves, bins, machinery, trade fixtures, and other interior non-structural improvements installed by <font style="color:#auto;">Tenant </font>will remain the personal property of <font style="color:#auto;">Tenant </font>and may be removed by <font style="color:#auto;">Tenant </font>prior to the termination of this <font style="color:#auto;">Lease </font>provided such removal may be accomplished without damage to the <font style="color:#auto;">Premises </font>or <font style="color:#auto;">Building</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">that cannot be repaired by </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">as set forth in this subparagraph</font>.&nbsp;&nbsp;Prior to vacating the <font style="color:#auto;">Premises</font>, <font style="color:#auto;">Tenant </font>will repair any damage to the <font style="color:#auto;">Premises </font>or <font style="color:#auto;">Building </font>as a result of any alteration, addition, improvement, or repair to the <font style="color:#auto;">Premises</font>, or the removal of personal property or trade fixtures by <font style="color:#auto;">Tenant</font>, or any <font style="color:#auto;">Tenant Party</font>.&nbsp;&nbsp;Should <font style="color:#auto;">Tenant </font>fail to conduct any such repair <font style="color:#auto;">within ten </font><font style="text-decoration:none;color:#auto;">(10) </font><font style="color:#auto;">days of </font>written notice from <font style="color:#auto;">Landlord</font>, <font style="color:#auto;">Landlord </font>may, at its option, perform same, and <font style="color:#auto;">Tenant </font>will remit payment to <font style="color:#auto;">Landlord </font>for the actual cost and expense incurred by <font style="color:#auto;">Landlord </font>in effecting such repair <font style="text-decoration:none;color:#000000;">promptly</font> upon demand.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M193"></a>Tenant <font style="color:#000000;">will have no authority, express or implied, to create or place any lien or encumbrance of any kind or nature whatsoever upon, or in any manner to bind, the </font>interest <font style="color:#000000;">of </font>Landlord <font style="color:#000000;">in the </font>Premises <font style="color:#000000;">or to charge the rentals payable hereunder for any claim in favor of any person dealing with </font>Tenant<font style="color:#000000;">, including those who may furnish materials or perform labor for any construction or repairs, and each such claim will affect and each such lien will attach to, if at all, only the leasehold </font>interest <font style="color:#000000;">granted to </font>Tenant <font style="color:#000000;">by this instrument. </font>Tenant <font style="color:#000000;">covenants and agrees that it will pay or cause to be paid all sums legally due and payable by it on account of any labor performed or materials furnished in connection with any work performed on the </font>Premises <font style="color:#000000;">at the request of </font>Tenant <font style="color:#000000;">on which any lien is or can be validly and legally asserted against its leasehold </font>interest <font style="color:#000000;">in the </font>Premises <font style="color:#000000;">or the improvements thereon and that it will save and hold </font>Landlord <font style="color:#000000;">harmless from any and all loss, cost or expense based on or arising out of asserted claims or liens against the leasehold estate or against the right, title and </font>interest <font style="color:#000000;">of </font>Landlord <font style="color:#000000;">in the </font>Premises <font style="color:#000000;">or under the terms of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M194"></a><a name="_DV_C39"></a><a name="_DV_M195"></a><a name="_DV_C40"></a><a name="_DV_M196"></a><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>12.<font style="margin-left:36pt;"></font>Assignment and Subletting.<font style="font-weight:normal;"><a name="_DV_C39"></a>&nbsp;&nbsp;Tenant may assign this Lease in its entirety or sublease all or any portion of the Premises without the consent of Landlord to (i) any entity resulting from a merger or consolidation with Tenant, (ii) any entity succeeding to all or substantially all of the business and assets of Tenant, or (iii) any company or professional corporation or association affiliated with, owned by, or under common corporate control with Tenant (each a &#8220;Permitted Transferee&#8221;); provided, however, that the financial capacity of the Permitted Transferee must be at least equal to that of the Tenant on the date of transfer and the transfer must not be effected by Tenant as a sham transaction or a means to circumvent the intent of this Section or adversely affect the liability of Tenant hereunder<a name="_DV_M195"></a>. Except<a name="_DV_C40"></a> as herein otherwise provided, Tenant may not assign or encumber this Lease or its interest in the Premises arising under this Lease, and may not sublet any part or all of the Premises without the prior consent of Landlord, which consent Landlord <a name="_DV_M196"></a>will not unreasonably withhold, or delay.&nbsp;&nbsp;For the purpose of the preceding sentence, the word &#8220;assign&#8221; will be defined and deemed to include the sale or other transfer of a controlling percentage (hereafter defined) of capital stock of Tenant other than to an affiliate or subsidiary or the sale of at least fifty-one percent (51%) of the value of the assets of Tenant.&nbsp;&nbsp;The phrase &#8220;controlling </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">percentage&#8221; means the ownership of, and the right to vote, stock possessing at least fifty-one percent (51%) of the total combined voting power of all classes of Tenant&#8217;s capital stock issued, outstanding and entitled to vote for the election of directors, or such lesser percentage as is required to provide actual control over the affairs of the corporation.&nbsp;&nbsp;Acceptance of Rent by Landlord after any non-permitted assignment will not constitute approval thereof by Landlord. Notwithstanding any contrary provision contained herein, in no event will any assignment by Tenant of all or any interest in this Lease or any subletting of all or any part of the Premises result in Tenant being released from its obligations hereunder.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M197"></a>In no event will this <font style="color:#auto;">Lease </font>be assignable by operation of any law except as provided herein, and <font style="color:#auto;">Tenant</font>&#8217;s rights hereunder may not become, and will not be listed by <font style="color:#auto;">Tenant </font>as an asset under any bankruptcy, insolvency or reorganization proceedings.&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>is not, may not become, and will never represent itself to be an agent of <font style="color:#auto;">Landlord</font>, and <font style="color:#auto;">Tenant </font>acknowledges that <font style="color:#auto;">Landlord</font>&#8217;s title is paramount, and that it can do nothing to affect or impair <font style="color:#auto;">Landlord</font>&#8217;s title.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M198"></a><a name="_DV_M199"></a><a name="_DV_M200"></a>If this <font style="color:#auto;">Lease </font>will be assigned or the <font style="color:#auto;">Premises </font>or any portion thereof sublet by <font style="color:#auto;">Tenant </font>at a rental that exceeds the rentals to be paid to <font style="color:#auto;">Landlord </font><a name="_DV_M199"></a>hereunder, then sixty-five percent <a name="_DV_M200"></a>(65%) of such excess (after reduction for any expenses incurred by <font style="color:#auto;">Tenant </font>in conjunction with such assignment or subletting) will be due to the <font style="color:#auto;">Landlord</font><font style="text-decoration:none;color:#000000;">, upon actual receipt by </font><font style="text-decoration:none;color:#auto;">Tenant</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M201"></a>If <font style="color:#auto;">Tenant </font>desires to enter into any <font style="color:#auto;">sublease </font>of all or any portion of the <font style="color:#auto;">Premises </font>or <font style="color:#auto;">assign </font>its <font style="color:#auto;">interest </font>in this <font style="color:#auto;">Lease</font>, <font style="color:#auto;">Landlord </font>will have the option to exclude from the <font style="color:#auto;">Premises </font>the space proposed to be sublet by <font style="color:#auto;">Tenant </font>or if an assignment is proposed, the entire <font style="color:#auto;">Premises</font>.&nbsp;&nbsp;Such exclusion or recapture by <font style="color:#auto;">Landlord </font>will be effective as of the proposed <font style="color:#auto;">commencement date </font>of the <font style="color:#auto;">sublease </font>or assignment.&nbsp;&nbsp;<font style="color:#auto;">Landlord </font>may exercise said option by giving <font style="color:#auto;">Tenant </font>written notice <font style="color:#auto;">within ten (10) business days after </font>receipt by <font style="color:#auto;">Landlord </font>of <font style="color:#auto;">Tenant</font>&#8217;s request for consent to the proposed <font style="color:#auto;">sublease </font>or assignment.&nbsp;&nbsp;If <font style="color:#auto;">Landlord </font>exercises said option, <font style="color:#auto;">Tenant </font>will surrender possession of such space to <font style="color:#auto;">Landlord </font>on the effective date of exclusion or recapture of such space and neither party hereto will have any future rights or liabilities with respect to said space under this <font style="color:#auto;">Lease</font>.&nbsp;&nbsp;Effective as of the date of exclusion of any portion of the <font style="color:#auto;">Premises </font>covered by this <font style="color:#auto;">Lease </font>pursuant to this paragraph, <font style="color:#auto;">(i) </font>the <font style="color:#auto;">Base Annual Rent </font>will be reduced in the same proportion as the number of square feet of <font style="color:#auto;">Net Rentable Area </font>contained in the portion of the <font style="color:#auto;">Premises </font>so excluded bears to the number of square feet of <font style="color:#auto;">Net Rentable Area </font>contained in the <font style="color:#auto;">Premises </font>immediately prior to such exclusion, and <font style="color:#auto;">(ii) </font>the <font style="color:#auto;">Net Rentable Area </font>of the <font style="color:#auto;">Premises </font>will be decreased by the number of square feet of <font style="color:#auto;">Net Rentable Area </font>contained in the portion of the <font style="color:#auto;">Premises </font>so excluded, for all purposes under this <font style="color:#auto;">Lease</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M202"></a>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">acknowledge and agree that the foregoing provisions have been freely negotiated by the parties hereto and that </font>Landlord <font style="color:#000000;">would not have entered into this </font>Lease <font style="color:#000000;">without </font>Tenant<font style="color:#000000;">&#8217;s consent to the terms of this Section.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M203"></a><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>13.<font style="margin-left:36pt;"></font>Insurance.<font style="font-weight:normal;"> Landlord agrees to maintain standard fire and extended coverage insurance for the Building (including the Tenant Improvements) in an amount not less than the replacement cost, insuring against special causes of loss, including, the perils of fire, and lightning, such coverages and endorsements to be as defined, provided and limited in the standard bureau forms prescribed </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">by the insurance regulatory authority for the State of North Carolina.&nbsp;&nbsp;Subject to the provisions of this Lease, such insurance will be for the sole benefit of Landlord and under its sole control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M204"></a><a name="_DV_C46"></a><a name="_DV_M205"></a><a name="_DV_M206"></a><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a><a name="_DV_M207"></a>If the <font style="color:#auto;">Premises </font>should be damaged or destroyed by any peril covered by the insurance to be provided by <font style="color:#auto;">Landlord </font>according to this section, <font style="color:#auto;"><a name="_DV_C46"></a>Tenant will give </font><font style="text-decoration:none;color:#auto;"><a name="_DV_M205"></a>prompt</font><font style="color:#auto;"><a name="_DV_M206"></a><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a> written notice thereof to Landlord. This Lease will not terminate</font><font style="text-decoration:none;color:#auto;"> (except as specifically provided herein)</font><font style="color:#auto;">, and Landlord will, at its sole cost and expense, thereupon proceed with reasonable diligence to rebuild and repair the Premises to substantially the condition in which they existed prior to such damage, except that Landlord will not be required to rebuild, repair or replace any part of the partitions, fixtures, additions and other improvements which may have been placed in, on or about the Premises by Tenant</font><font style="text-decoration:none;color:#auto;"> (other than the Tenant Improvements)</font><font style="color:#auto;">. If the Premises are untenantable </font><font style="text-decoration:none;color:#auto;">for the normal conduct of Tenant&#8217;s business </font><font style="color:#auto;">in whole or in part following such damage, the </font><font style="text-decoration:none;color:#auto;">rent</font><font style="color:#auto;"> payable hereunder during the period in which they are untenantable will</font><font style="text-decoration:none;color:#auto;"> be reduce</font><font style="color:#auto;"><strike>d</strike></font><font style="text-decoration:none;color:#auto;"><a name="_DV_M207"></a> proportionately.&nbsp;&nbsp;If such repair work is not completed within one hundred eighty (180) days of such casualty, and provided there is no </font><font style="color:#auto;">default or event of default </font>hereunder by <font style="color:#auto;">Tenant </font>(or if <font style="color:#auto;">Tenant </font>has committed a default or event of default more than one (1) time in any twelve (12) month period, then regardless of whether same has been cured)<font style="text-decoration:none;color:#auto;">, then Tenant shall have the right to terminate this Lease upon</font><font style="text-decoration:none;color:#000000;"> written notice to </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">(prior to actual completion of said work).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M208"></a><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall maintain contractual and comprehensive general liability insurance, including public liability and property damage, with a minimum combined single limit of liability of two million dollars ($2,000,000.00) for personal injuries or deaths of persons occurring in or about the </font><font style="text-decoration:none;">Building </font><font style="text-decoration:none;color:#000000;">and </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M209"></a>Notwithstanding anything herein to the contrary, in the event the holder of any indebtedness secured by a mortgage or deed of trust covering the <font style="color:#auto;">Premises </font>requires that the insurance proceeds be applied to such indebtedness<font style="text-decoration:none;color:#000000;">, and </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">is unable to rebuild as confirmed by </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">in writing to </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="text-decoration:none;color:#000000;">, then either</font> <font style="color:#auto;">Landlord</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">or </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="color:#auto;"> </font>will have the right to terminate this <font style="color:#auto;">Lease </font>by delivering written notice of termination to <font style="text-decoration:none;color:#000000;">the other party</font> within fifteen (15) days after such requirement is made by any such holder, whereupon all rights and obligations hereunder thereafter accruing will cease and terminate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M210"></a>Each of <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant </font>hereby waives all rights to recover against each other or against any other <font style="color:#auto;">tenant </font>or occupant of the <font style="color:#auto;">Building</font>, or against the officers, directors, shareholders, partners, joint venturers, employees, agents, customers, invitees, or business visitors of each other or of any other <font style="color:#auto;">tenant </font>or occupant of the <font style="color:#auto;">Building</font>, for any loss or damage arising from any cause covered by any insurance required to be carried by each of them pursuant to this <font style="color:#auto;">Lease</font>, or any other insurance actually carried by either of them.&nbsp;&nbsp;<font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant </font>will cause their respective insurers to issue waiver of subrogation rights endorsements to all policies of insurance carried in connection with the <font style="color:#auto;">Building </font>or the <font style="color:#auto;">Premises </font>or the contents of either of them, and any cost for the issuance of such endorsements will be borne by the original insured under such policies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M211"></a>The obligation of <font style="color:#auto;">Landlord </font>in this Section to repair and restore the <font style="color:#auto;">Premises </font>and the <font style="color:#auto;">Building </font>as provided herein, does not include an obligation of <font style="color:#auto;">Landlord </font>to repair the fixtures, equipment, or personal property of <font style="color:#auto;">Tenant</font>, which <font style="color:#auto;">Tenant </font>will insure for its benefit, and <font style="color:#auto;">Tenant </font>will have the obligation to repair and restore in the event of a casualty or other loss.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M212"></a>The period of time within which repair and restoration of the <font style="color:#auto;">Premises </font>must be completed will be extended due to delays occasioned by <font style="color:#auto;">Force Majeure</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M213"></a><a name="_DV_C48"></a><a name="_DV_M214"></a><a name="_DV_M215"></a><a name="_DV_M217"></a>Tenant <font style="color:#000000;">will procure and maintain, at its expense</font><a name="_DV_C48"></a>, (i) <a name="_DV_M214"></a><strike Style="text-decoration:none;">special </strike>form property<font style="color:#000000;"> insurance insuring against special causes of loss covering </font>Tenant<font style="color:#000000;"><a name="_DV_M215"></a>&#8217;s personal property, equipment,  trade fixtures and any improvements performed by </font>Tenant <font style="color:#000000;">(specifically excluding the </font>Tenant Improvements)<font style="color:#000000;"> in the </font>Premises<font style="color:#000000;">; and </font>(ii) <font style="color:#000000;">a policy or policies of commercial general liability insurance applying to </font>Tenant<font style="text-decoration:none;color:#000000;">&#8217;</font><font style="color:#000000;">s operations and use of the </font>Premises<font style="color:#000000;">, providing a minimum limit of $1,000,000.00 per occurrence and $2,000,000.00 in the aggregate, naming </font>Landlord <font style="color:#000000;">and </font>Landlord<font style="text-decoration:none;color:#000000;">&#8217;</font><font style="color:#000000;"><a name="_DV_M217"></a>s property manager as additional insureds. </font>Tenant <font style="color:#000000;">will maintain the foregoing insurance coverages in effect commencing on the earlier to occur of the </font>Commencement Date <font style="color:#000000;">and the date </font>Tenant <font style="color:#000000;">takes possession of the </font>Premises<font style="color:#000000;">, and continuing to the end of the </font>Lease Term<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M219"></a><a name="_DV_C51"></a><a name="_DV_M220"></a>The insurance requirements set forth in this Section are independent of the waiver, indemnification, and other obligations under this <font style="color:#auto;">Lease </font>and will not be construed or interpreted in any way to restrict, limit or modify the waiver, indemnification and other obligations or to in any way limit any party<font style="color:#000000;"><strike>'</strike></font><font style="text-decoration:none;color:#000000;">s</font> liability under this <font style="color:#auto;">Lease</font>.&nbsp;&nbsp;In addition to the requirements set forth in this section, <font style="color:#auto;">(i) </font>the insurance required of <font style="color:#auto;">Tenant </font>under this <font style="color:#auto;">Lease </font>must be issued by an insurance company with a rating of no less than A-VIII in the current <font style="color:#auto;">Best<strike>'</strike></font><font style="text-decoration:none;color:#auto;">s</font><font style="color:#auto;"> Insurance Guide </font>or that is otherwise <font style="text-decoration:none;color:#000000;">reasonably </font>acceptable to <font style="color:#auto;">Landlord</font>,<font style="text-decoration:none;color:#000000;"> and</font> <font style="color:#auto;">(ii) </font>the company issuing the coverage must be authorized to conduct the business of insurance in the state in which the <font style="color:#auto;">Building </font><a name="_DV_C51"></a>is located; <font style="color:#auto;">(iii) </font>the insurance must be primary insurance for all claims thereunder and provide that any liability insurance carried by <font style="color:#auto;">Landlord</font>, <font style="color:#auto;">Landlord</font>'s property manager, and <font style="color:#auto;">Landlord</font>'s lenders is strictly excess, secondary, and noncontributing with any insurance carried by <font style="color:#auto;">Tenant</font>; <font style="color:#auto;">(iv) Tenant </font><a name="_DV_M220"></a>must insure that its insurance company shall endeavor to provide at least thirty (30) days prior written notice of cancellation or non-renewal of a policy to <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Landlord</font>'s lenders; and <font style="color:#auto;">(v) Tenant </font>shall provide <font style="color:#auto;">Landlord </font>a copy of any notice of cancellation or non-renewal of a policy immediately upon receipt by <font style="color:#auto;">Tenant</font>.&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>will deliver to <font style="color:#auto;">Landlord </font>a legally enforceable certificate of insurance on all policies procured by <font style="color:#auto;">Tenant </font>in compliance with <font style="color:#auto;">Tenant</font><font style="font-weight:bold;text-decoration:none;color:#000000;">&#8217;</font>s obligations under this <font style="color:#auto;">Lease </font>on or before the date <font style="color:#auto;">Tenant </font>first occupies any portion of the <font style="color:#auto;">Premises</font>, at least ten (10) days before the <font style="color:#auto;">expiration date </font>of any policy and upon the renewal of any policy.&nbsp;&nbsp;<font style="color:#auto;">Landlord </font>will have the right to approve all deductibles and self-insured retentions under <font style="color:#auto;">Tenant</font><font style="font-weight:bold;text-decoration:none;color:#000000;">&#8217;</font>s policies, which approval will not be unreasonably withheld,&nbsp;&nbsp;or delayed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M223"></a>14.<font style="margin-left:36pt;"></font>Condemnation.<font style="font-weight:normal;">&nbsp;&nbsp;If the whole or any substantial portion of the Premises should be taken for any public or quasi-public use under governmental law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof, and the taking would prevent or materially interfere with the use of the Premises by Tenant for the purposes provided herein as mutually and reasonably determined by Landlord and Tenant, each party hereto will have the right to terminate this Lease by notice to the other party hereto within forty-five (45) days after the date of such taking and the Rent will be abated during the unexpired portion of this Lease, effective when the physical taking of the Premises will occur.&nbsp;&nbsp;If this Lease is not terminated in accordance with the foregoing, this Lease will remain in full force and effect as to the portion of the Premises remaining, except that the Rent will be reduced in the proportion that the taken floor area of the Premises bears to the total floor area of the Premises as reasonably determined by Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M224"></a>If a portion of the Premises will be taken for any public or quasi-public use under any governmental law, ordinance or regulation, or by right of eminent domain, or by private purchase in lieu thereof, and there is no material interference with the use by Tenant of the Premises as reasonably determined, this Lease will remain in full force and effect as to the portion of the Premises remaining, except that the Rent will be reduced in the proportion that the taken floor area of the Premises bears to the total floor area of the Premises.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M225"></a>In the event of any such taking or private purchase in lieu thereof, <font style="color:#auto;">Landlord </font>will be entitled to receive and retain all awards as may be awarded in any condemnation proceedings with <font style="color:#auto;">Tenant </font>hereby expressly waiving all claim thereto other than those specifically awarded <font style="color:#auto;">Tenant </font>for a taking of <font style="color:#auto;">Tenant</font>&#8217;s personal property, loss of business and moving expenses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M226"></a>15.<font style="margin-left:36pt;"></font>Default.<font style="font-weight:normal;">&nbsp;&nbsp;The following events will be deemed to be events of default by Tenant under this Lease:</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M227"></a><a name="_DV_C52"></a>(a) Tenant <font style="color:#000000;">will fail to pay any installment of the </font>Rent <font style="color:#000000;">herein reserved, or payment with respect to taxes hereunder, or any other payment or reimbursement to </font>Landlord <font style="color:#000000;">required herein, </font>within five (5) days <font style="color:#000000;">of when </font><a name="_DV_C52"></a>due<font style="text-decoration:none;">; provided, however, on one occasion during each calendar year of the term of this Lease, it shall not be an event of default hereunder if Tenant makes full payment within five (5) days after receipt of written notice from Landlord. </font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M229"></a>(b) Tenant <font style="color:#000000;">will become insolvent, or will make a transfer in fraud of creditors, or will make an assignment for the benefit of creditors.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M230"></a>(c) Tenant <font style="color:#000000;">will file a petition under any section or chapter of the </font>Bankruptcy Reform Act<font style="color:#000000;">, as amended or under any similar law or statute of the United States or any state thereof; or </font>Tenant <font style="color:#000000;">will be adjudged bankrupt or insolvent in proceedings filed against </font>Tenant <font style="color:#000000;">thereunder.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M231"></a>(d) <font style="color:#000000;">A receiver or trustee will be appointed for all or substantially all of the assets of </font>Tenant<font style="color:#000000;">.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M232"></a><a name="_DV_C54"></a><a name="_DV_M233"></a>(e) Tenant <font style="color:#000000;">will desert or vacate all or a portion of the </font>Premises<font style="color:#000000;"><a name="_DV_C54"></a>, </font><font style="text-decoration:none;"><a name="_DV_M233"></a>and cease paying Rent at</font> the Premises.</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M234"></a>(f) Tenant <font style="color:#000000;">will fail to yield up immediate possession of the </font>Premises <font style="color:#000000;">to </font>Landlord <font style="color:#000000;">upon termination of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M235"></a>(g) Tenant <font style="color:#000000;">will fail to comply with any </font>term<font style="color:#000000;">, provision or covenant of this </font>Lease <font style="color:#000000;">(other than the provisions of subparagraphs </font>(a)<font style="color:#000000;">, </font>(b)<font style="color:#000000;">, </font>(c)<font style="color:#000000;">, </font>(d)<font style="color:#000000;">, </font>(e) <font style="color:#000000;">and </font>(f) <font style="color:#000000;">of this Section&nbsp;&nbsp;</font>15)<font style="color:#000000;">, and will not cure such failure within </font><font style="text-decoration:none;color:#000000;">thirty</font><font style="color:#000000;"> (</font><font style="text-decoration:none;color:#000000;">30</font><font style="color:#000000;">) days after written notice thereof to </font>Tenant <font style="color:#000000;">or such additional period of time as will be reasonably granted by </font>Landlord <font style="color:#000000;">if </font>Tenant <font style="color:#000000;">is acting in good faith and with diligence to complete such cure.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M236"></a>Upon the occurrence of any event of default in the preceding section hereof, <font style="color:#auto;">Landlord </font>will have the option to pursue any remedy at law or in equity, including, but not limited to, one or more of the following remedies without any <font style="text-decoration:none;color:#000000;">separate </font>notice or demand whatsoever:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M237"></a><a name="_DV_M238"></a><a name="_DV_M239"></a><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>(a) <font style="color:#000000;">Terminate this </font>Lease<font style="color:#000000;">, in which event </font>Tenant <font style="color:#000000;">will immediately surrender the </font>Premises <font style="color:#000000;">to </font>Landlord, <font style="color:#000000;">and if </font>Tenant <font style="color:#000000;">fails to do so, </font>Landlord <font style="color:#000000;">may, without prejudice to any other remedy which it may have for possession or arrearage in </font>Rent<font style="color:#000000;">, enter upon and take possession of the </font>Premises <font style="color:#000000;">and expel and remove </font>Tenant <font style="color:#000000;">and any other person who may be occupying the </font>Premises <font style="color:#000000;"><a name="_DV_M238"></a>or any part thereof, <a name="_DV_M239"></a>by any legal means necessary without being liable for prosecution or any claim of damages therefore; secure the </font>Premises <font style="color:#000000;">against unauthorized entry; and </font>Tenant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">agrees to pay to </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">on demand the amount of all loss and damage which </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">may suffer by reason of such termination, whether through inability to relet the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises </font><font style="color:#000000;">on satisfactory terms or otherwise.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M240"></a><a name="_DV_M241"></a><a name="_DV_M242"></a>(b) <font style="color:#000000;">Enter upon and take possession of the </font>Premises <font style="color:#000000;">and expel or remove </font>Tenant <font style="color:#000000;">and any other person who may be occupying such </font>Premises <font style="color:#000000;"><a name="_DV_M241"></a>or any part thereof, <a name="_DV_M242"></a>by any legal means necessary without being liable for prosecution and receive the </font>Rent <font style="color:#000000;">thereof; secure the </font>Premises <font style="color:#000000;">against unauthorized entry; store any property located on the </font>Premises <font style="color:#000000;">at the expense of the owner thereof and </font>Tenant <font style="color:#000000;">agrees to pay to </font>Landlord <font style="color:#000000;">on demand any deficiency that may arise by reason of such reletting. In the event </font>Landlord <font style="color:#000000;">is successful in reletting the </font>Premises <font style="color:#000000;">at a rental in excess of that agreed to be paid by </font>Tenant <font style="color:#000000;">pursuant to the terms of this </font>Lease<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">each mutually agree that </font>Tenant <font style="color:#000000;">will not be entitled, under any circumstances, to such excess rental, and </font>Tenant <font style="color:#000000;">does hereby specifically waive any claim to such excess rental.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M243"></a><a name="_DV_M244"></a><a name="_DV_M245"></a>(c) <font style="color:#000000;">Enter upon the </font>Premises<font style="color:#000000;"><a name="_DV_M244"></a>, <a name="_DV_M245"></a>by any legal means necessary without being liable for prosecution or any claim for damages therefore, secure the </font>Premises <font style="color:#000000;">against unauthorized entry, remove all property of </font>Tenant <font style="color:#000000;">from the </font>Premises <font style="color:#000000;">and store it at the cost and expense of </font>Tenant<font style="color:#000000;">, and do whatever </font>Tenant <font style="color:#000000;">is obligated to do under the terms of this </font>Lease<font style="color:#000000;">; and </font>Tenant <font style="color:#000000;">agrees to reimburse </font>Landlord <font style="color:#000000;">on demand for any expenses which </font>Landlord <font style="color:#000000;">may incur in thus effecting compliance with </font>Tenant<font style="color:#000000;">&#8217;s obligations under this </font>Lease<font style="color:#000000;">, and </font>Tenant <font style="color:#000000;">further agrees that </font>Landlord <font style="color:#000000;">will not be liable for any damages resulting to </font>Tenant <font style="color:#000000;">from such action, whether caused by the negligence of </font>Landlord <font style="color:#000000;">or otherwise.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="color:#000000;">Subject to the obligation of </font>Landlord <font style="color:#000000;">to mitigate its damages under </font>Applicable Law<font style="color:#000000;">, accelerate and demand the payment of all </font>Rent <font style="color:#000000;">and other charges due and payable hereunder over the </font>term <font style="color:#000000;">of this </font>Lease <font style="color:#000000;">to an amount equal to the aggregate sum which at the time of such termination represents the excess, if any, of the present value of the aggregate </font>Rent <font style="color:#000000;">which would have been payable after the </font>termination date <font style="color:#000000;">had this </font>Lease <font style="color:#000000;">not been terminated, including, without limitation, the amount projected by </font>Landlord <font style="color:#000000;">as </font>Rent <font style="color:#000000;">for the remainder of the </font>Lease Term<font style="color:#000000;">, over the then present value of the then aggregate fair </font>rent <font style="color:#000000;">value of the </font>Premises <font style="color:#000000;">for the balance of the </font>Lease Term<font style="color:#000000;">, such present worth to be computed in each case on the basis of the lesser of: (i) the rate on a United States Treasury bill with a maturity date equal to the </font>termination date <font style="color:#000000;">of the </font>Lease<font style="color:#000000;">, or (ii) five percent (5%) per annum discount from the respective dates upon which such </font>Rent <font style="color:#000000;">would have been payable hereunder had this </font>Lease <font style="color:#000000;">not been terminated.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M246"></a><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">&#8217;s failure to perform or observe any of its </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">obligations after a period of thirty (30) days or the additional time, if any, that is reasonably necessary to promptly and diligently cure the failure after receiving written notice from </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">is a </font><font style="text-decoration:none;">Landlord Default</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;The notice shall reasonably detail the nature and extent of the failure and identify the </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">provision(s) containing the obligation(s).&nbsp;&nbsp;If </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">commits a </font><font style="text-decoration:none;">Landlord Default</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">may pursue any remedies given in this </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">or under </font><font style="text-decoration:none;">Applicable Law</font><font style="text-decoration:none;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M247"></a><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>Pursuit of any of the foregoing remedies will not preclude pursuit of any of the other remedies herein provided or any other remedies provided by law or equity, nor will pursuit of any remedy herein provided constitute a forfeiture or waiver of any <font style="color:#auto;">Rent </font>due to <font style="color:#auto;">Landlord </font>hereunder </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or of any damages accruing to </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by reason of the violation of any of the terms, provisions and covenants herein contained.&nbsp;&nbsp;No act or thing done by </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or its agents during the </font><font style="color:#auto;">term </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereby granted will be deemed a termination of this </font><font style="color:#auto;">Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or an acceptance of the surrender of the </font><font style="color:#auto;">Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and no agreement to terminate this </font><font style="color:#auto;">Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or accept a surrender of the </font><font style="color:#auto;">Premises </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be valid unless in writing signed by </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. No waiver by </font><font style="color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">or </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any violation or breach of any of the terms, provisions and covenants herein contained will be deemed or construed to constitute a waiver of any other violation or breach of any of the terms, provisions and covenants herein contained. </font><font style="color:#auto;">Landlord</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s acceptance of the payment of rental or other payments hereunder after the occurrence of an event of default will not be construed as a waiver of such default, unless </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so notifies </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in writing, and no receipt of money by </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after the termination of this </font><font style="color:#auto;">Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or after service of any notice or after the commencement of any suit or after final judgment for possession of the </font><font style="color:#auto;">Premises </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will reinstate, continue or extend the </font><font style="color:#auto;">term </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of this </font><font style="color:#auto;">Lease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or affect any such termination, notice, suit or judgment, unless </font><font style="color:#auto;">Landlord </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so notifies </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in writing. Forbearance by </font><font style="color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">or </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enforce one or more of the remedies herein provided upon an event of default will not be deemed or construed to constitute waiver of such default or of </font><font style="text-decoration:none;color:#000000;">said party</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s right to enforce any such remedies with respect to such default or any subsequent default.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M248"></a><font style="text-decoration:none;">Notwithstanding any provision contained in this </font><font style="text-decoration:none;color:#auto;">Lease </font><font style="text-decoration:none;">to the contrary, should either party institute any legal proceeding against the other for breach of any provision herein contained and prevail in such action, such other party shall reimburse the prevailing party for the expenses of such prevailing party, including, without limitation, its reasonable attorneys&#8217; fees actually incurred at standard and reasonable billing rates.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M249"></a>16.<font style="margin-left:36pt;"></font>Holding Over and Termination.<font style="font-weight:normal;">&nbsp;&nbsp;Tenant will upon the termination of this Lease by lapse of time or otherwise, yield up immediate possession to Landlord without the requirement of notice by Landlord to Tenant of the termination of this Lease, nor any grace or cure period should Tenant fail to yield up immediate possession to Landlord.&nbsp;&nbsp;Unless the parties hereto will otherwise agree in writing, if Landlord agrees in writing that Tenant may hold over after the expiration or termination of this Lease, the hold over tenancy will be subject to termination by Landlord at any time upon thirty (30) days advance written notice, or by Tenant at any time upon not less than thirty (30) days advance written notice, and all of the other terms and provisions of this Lease will be applicable during that period, except that Tenant will pay Landlord from time to time upon demand, as rental for the period of any hold over, an amount equal to one and one-half (1-1/2) the Base Annual Rent plus Additional Rent in effect on the Termination Date, computed on a daily basis for each day of the hold over period.&nbsp;&nbsp;No holding over by Tenant, whether with or without consent of Landlord, will operate to extend this Lease except as otherwise expressly provided. The preceding provisions of this Section 16 will not be construed as Landlord&#8217;s consent for Tenant to hold over.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M250"></a><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>Upon the termination of this Lease for whatever reason, Tenant will quit and immediately surrender the Premises to Landlord, broom clean, in as good order and condition as received with all repairs and maintenance required by Tenant hereunder having been performed, ordinary wear and tear excepted, and Tenant will remove its personal property from the Premises in accordance with this Lease.&nbsp;&nbsp;Should any of the personal property or trade fixtures of Tenant remain upon the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises after the Termination Date, all such property will be deemed abandoned by Tenant, and Landlord may remove same at the cost and expense of Tenant with no liability to Tenant therefore, and Tenant hereby releases Landlord from all liability therefore.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M251"></a><a name="_DV_M252"></a><a name="_DV_M253"></a><a name="_DV_C64"></a><a name="_DV_M254"></a>17.<font style="margin-left:36pt;"></font>Compliance with Laws.<font style="font-weight:normal;"><a name="_DV_M252"></a>&nbsp;&nbsp;The Premises will be used only for the Permitted Use.&nbsp;&nbsp;Landlord acknowledges that Tenant will be using the Premises as a laboratory for a biotechnology company and is aware that with respect to such usage, Tenant may bring a pre-approved list of Hazardous Materials onto the Premises.&nbsp;&nbsp; Tenant will conduct no activity that will result in the discharge of harmful gases, effluents or other wastes or toxic substances beyond the Premises or in violation of Applicable Laws.&nbsp;&nbsp;Outside storage, including, without limitation, trucks and other vehicles, is prohibited without Landlord&#8217;s prior written consent.&nbsp;&nbsp;Tenant will at its sole cost and expense obtain any and all licenses and permits necessary for its use of the Premises.&nbsp;&nbsp;Tenant will promptly comply with all governmental orders and directives for the correction, prevention, and abatement of nuisances connected with or arising from Tenant's use of the Premises, all at Tenant's sole expense.&nbsp;&nbsp;<a name="_DV_M253"></a>During the Term, Landlord shall comply with all Applicable Laws regarding the Premises and Building, except to the extent Tenant must comply under this Section 17.&nbsp;&nbsp;Except as to pre-existing defects, violations or conditions, Tenant shall comply with all Applicable Laws: (i) regarding the physical condition of the Premises, but only to the extent the Applicable Laws pertain to the particular manner in which Tenant uses the Premises; or (ii) that do not relate to the physical condition of the Premises but relate to the lawful use of the Premises and with which only the occupant can comply, such as laws governing maximum occupancy, workplace smoking, and illegal business operations, such as gambling. <a name="_DV_C64"></a>Tenant will not permit any objectionable or unpleasant odors, smoke, dust, gas, noise or vibrations to emanate from the Premises, nor take any other action which would constitute a nuisance, disturb or endanger any other tenants of the Building, or unreasonably interfere with the quiet enjoyment by any tenant of the Building.&nbsp;&nbsp;Without Landlord&#8217;s prior written consent<a name="_DV_M254"></a> (not to be unreasonably withheld, or delayed), Tenant will not receive, store or otherwise handle any product, material or merchandise which is explosive, inflammable, combustible, corrosive, caustic or poisonous (except as provided herein).&nbsp;&nbsp;Tenant will not permit the Premises to be used for any purpose or in any manner (including, without limitation, any method of storage) which would render the insurance thereon void or the insurance risk more hazardous or cause the State Board of Insurance or other insurance authority to disallow any sprinkler credits.&nbsp;&nbsp;Tenant will give notice to Landlord promptly upon the known occurrence of any accident in the Premises or upon Tenant&#8217;s discovery of any defects thereon or in any fixtures or equipment located therein or upon the occurrence of any emergency in the Premises, Building, or Project.&nbsp;&nbsp;Tenant will be permitted to use and store at the Premises in compliance with Hazardous Material Laws and the provisions hereof commercially reasonable quantities of (i) generally available standard office and janitorial supplies that may contain chemicals categorized as Hazardous Material, and (ii) such other substances that are required in the ordinary course of Tenant's business conducted on the Premises. Tenant, at its expense, in its use of the Premises and in making any alterations, renovations, or modifications of the Premises will comply with all Applicable Laws relating to the use, condition and occupancy of the Premises.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M255"></a><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>Tenant <font style="color:#000000;">agrees that it will not release, discharge, place, hold, or dispose of any </font>Hazardous Material <font style="color:#000000;">on, </font>under<font style="color:#000000;"> or at the </font>Premises<font style="color:#000000;">, in the </font>Building<font style="color:#000000;">, or on the </font>Land<font style="color:#000000;">, and that it will not use the </font>Premises<font style="color:#000000;">, the </font>Building<font style="color:#000000;">, the </font>Land<font style="color:#000000;">, or any other portion thereof as a site for the treatment, storage</font><font style="text-decoration:none;color:#000000;"> (except in accordance with this Section </font><font style="text-decoration:none;">17)</font><font style="color:#000000;">, or disposal (whether permanent or temporary) of any </font>Hazardous </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Material</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">further agrees that it will not cause or allow any asbestos to be incorporated into any improvements or alterations which </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">makes or causes to be made to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</font><font style="color:#000000;">, or the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M256"></a><a name="_DV_C66"></a><a name="_DV_M257"></a><a name="_DV_M259"></a><a name="_DV_M260"></a>Tenant <font style="color:#000000;">hereby agrees to indemnify, defend (with counsel reasonably approved by </font>Landlord<font style="color:#000000;">) and hold harmless </font>Landlord <font style="color:#000000;">of from and against any and all losses, liabilities, damages, injuries, </font>costs<font style="color:#000000;">, expenses and claims of any and every kind whatsoever (including without limitation, court </font>costs <font style="color:#000000;">and attorneys&#8217; fees at all tribunal levels) which at any time and from time to time may be paid, incurred or suffered by, or asserted against </font>Landlord <font style="color:#000000;"><a name="_DV_C66"></a>for, with respect to, or as a direct or indirect result of any </font><font style="text-decoration:none;"><a name="_DV_M257"></a>breach or default by Tenant of the provisions of</font><font style="color:#000000;"> this Section </font>17.<font style="color:#000000;"><a name="_DV_M259"></a>&nbsp;&nbsp;<a name="_DV_M260"></a>The provisions of and undertakings and indemnification set forth in this </font><font style="text-decoration:none;color:#000000;"> Section</font><font style="color:#000000;"> will survive the termination or expiration of this </font>Lease<font style="color:#000000;">, for any reason, and will continue to be the liability, obligation and indemnification of </font>Tenant<font style="color:#000000;">, binding upon </font>Tenant <font style="color:#000000;">forever. The provisions of the preceding sentence will govern and control over any inconsistent provision of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M262"></a><a name="_DV_C68"></a><a name="_DV_M263"></a><a name="_DV_C70"></a><a name="_DV_M264"></a><a name="_DV_M265"></a>Tenant <font style="color:#000000;">will provide </font>Landlord <font style="color:#000000;">with a list of any and all </font>Hazardous Materials <font style="color:#000000;">released, discharged, placed, held, or disposed of on the </font>Premises<font style="color:#000000;">, and certification to </font>Landlord <font style="color:#000000;">of compliance by </font>Tenant <font style="color:#000000;">with all </font>Applicable Laws<font style="color:#000000;">, concurrently with the execution of this </font>Lease <font style="color:#000000;">which shall be </font>attached<font style="color:#000000;"> hereto and made a part as Exhibit G, and thereafter, </font><a name="_DV_C68"></a>within <font style="text-decoration:none;"><a name="_DV_M263"></a>ten<a name="_DV_C70"></a> (<a name="_DV_M264"></a>10<a name="_DV_M265"></a>) business days of a request therefore by Landlord (which Landlord shall not request more than four times in any calendar year).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M266"></a><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">hereby represents and warrants, to the best of </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">&#8217;s actual knowledge, that no </font><font style="text-decoration:none;">Hazardous </font><font style="color:#000000;">Materials</font><font style="text-decoration:none;"> </font><font style="text-decoration:none;color:#000000;">exist on, under, in or about the </font><font style="text-decoration:none;">Premises </font><font style="text-decoration:none;color:#000000;">as of the </font><font style="text-decoration:none;">Commencement Date </font><font style="text-decoration:none;color:#000000;">except as disclosed in the </font><font style="text-decoration:none;">Phase I Environmental Site Assessment </font><font style="text-decoration:none;color:#000000;">obtained by </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">for the </font><font style="text-decoration:none;">Building </font><font style="text-decoration:none;color:#000000;">(the &#8220;</font><font style="text-decoration:none;">Report</font><font style="text-decoration:none;color:#000000;">&#8221;). </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall have the right to review the </font><font style="text-decoration:none;">Report </font><font style="text-decoration:none;color:#000000;">at the offices of </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">upon written notice to the </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall indemnify, defend and hold harmless </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">from and against any and all </font><font style="text-decoration:none;">Claims </font><font style="text-decoration:none;color:#000000;">which at any time and from time to time may be paid, incurred or suffered by or assessed against </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">as a direct or indirect result of the presence of any </font><font style="text-decoration:none;">Hazardous Materials </font><font style="text-decoration:none;color:#000000;">in, on or under the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;">Building </font><font style="text-decoration:none;color:#000000;">or </font><font style="text-decoration:none;">Project </font><font style="text-decoration:none;color:#000000;">prior to the </font><font style="text-decoration:none;">Commencement Date </font><font style="text-decoration:none;color:#000000;">or after the termination of this </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">so long as such presence was not due to an act or omission of </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">or a </font><font style="text-decoration:none;">Tenant Party</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M267"></a><a name="_DV_C73"></a><a name="_DV_M268"></a><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>18.<font style="margin-left:36pt;"></font>Inspection.<font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord and Landlord&#8217;s agents and representatives will have the right to enter and inspect the Premises at any reasonable time during business hours, for the purpose of ascertaining the condition of the Premises,&nbsp;&nbsp;in order to make such repairs as may be required or permitted to be made by Landlord to the Building or any adjacent space, under the terms of this Lease, or in order to show the Premises to any prospective purchaser or lender</font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_C73"></a>; provided that (i) except in the case of an emergency, Landlord has given Tenant a written or verbal notice of the intent to enter at least two (2) business days in advance of the entry, (ii) such entry and any related inspection or repairs do not unreasonably interfere with Tenant&#8217;s business operations, (iii) Landlord complies with Tenant&#8217;s reasonable security measures and protocols which are detailed on Exhibit F<a name="_DV_M268"></a> (as Tenant shall be entitled to reasonably update), attached hereto, and Tenant provides Landlord protective gear, and (iv) Landlord is accompanied by a representative of Tenant at all times, except in an emergency.</font><font style="font-weight:normal;">&nbsp;&nbsp;During the period that is six (6) months prior to the </font><font style="text-decoration:none;color:#auto;letter-spacing:0.35pt;font-weight:normal;">end</font><font style="font-weight:normal;"> of the </font><font style="color:#auto;font-weight:normal;">term </font><font style="font-weight:normal;">hereof</font><font style="text-decoration:none;color:#000000;font-weight:normal;"> (and subject to the same access caveats listed above)</font><font style="font-weight:normal;">, </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">and </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">agents and representatives will have the right to enter the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">at any reasonable time during business hours for the purpose of showing the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">to any prospective </font><font style="color:#auto;font-weight:normal;">tenant </font><font style="font-weight:normal;">and will have the right to erect on the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">a suitable sign indicating the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">are available. </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">will </font><font style="color:#auto;font-weight:normal;">schedule </font><font style="font-weight:normal;">with </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> </font><font style="text-decoration:none;color:#000000;font-weight:normal;">(at </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&#8217;s request)</font><font style="font-weight:normal;"> at least sixty (60) days prior to vacating the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">a time mutually agreeable to the parties hereto for a joint inspection of the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">prior to vacating.&nbsp;&nbsp;In the event of </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">&#8217;s failure to </font><font style="text-decoration:none;color:#000000;font-weight:normal;">reasonably</font><font style="font-weight:normal;"> arrange such joint inspection, </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s inspection at or after </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">&#8217;s vacating the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">will be conclusively deemed correct for purposes of determining </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">&#8217;s responsibilities for repairs and restoration.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M269"></a><a name="_DV_C75"></a><font style="text-decoration:none;">19.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="color:#000000;">Tenant Property</font><font style="font-weight:normal;color:#000000;"><a name="_DV_C75"></a>.&nbsp;&nbsp;</font><font style="text-decoration:none;color:#auto;letter-spacing:0.35pt;font-weight:normal;">Upon reasonable request, so long as Tenant is not in default under this Lease, Landlord agrees to execute, within twenty (20) days following written request, any </font><font style="font-weight:normal;color:#000000;">commercially</font><font style="text-decoration:none;color:#auto;letter-spacing:0.05pt;font-weight:normal;"> reasonable document reflecting the subordination of any such Landlord&#8217;s interest </font><font style="text-decoration:none;color:#auto;letter-spacing:0.1pt;font-weight:normal;">to Tenant&#8217;s lender(s) and in such event Tenant shall pay Landlord&#8217;s reasonable and actual &#8220;out-</font><font style="text-decoration:none;color:#auto;letter-spacing:0.25pt;font-weight:normal;">of-pocket&#8221; costs therefore</font><font style="text-decoration:none;color:#auto;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M274"></a>20.<font style="margin-left:36pt;"></font>[<font style="color:#auto;">INTENTIONALLY</font> DELETED.]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M275"></a><a name="_DV_C77"></a><a name="_DV_M276"></a>21.<font style="margin-left:36pt;"></font>Rules and Regulations.<font style="font-weight:normal;">&nbsp;&nbsp;Tenant, at its expense, will comply with the Rules and Regulations of the Building attached hereto and made a part hereof as</font> <font style="font-weight:normal;">Exhibit E, as </font><font style="text-decoration:none;color:#auto;font-weight:normal;">reasonably </font><font style="font-weight:normal;">modified by Landlord from time to time and such other Rules and Regulations adopted by Landlord during the Lease Term and Tenant will </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_C77"></a>use </font><font style="color:#auto;font-weight:normal;"><strike Style="text-decoration:none;">all </strike></font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M276"></a>commercially reasonable efforts to </font><font style="font-weight:normal;">cause all Tenant Parties to do so.</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&nbsp;&nbsp;Provided, however, that </font><font style="text-decoration:none;color:#auto;font-weight:normal;">(a) </font><font style="text-decoration:none;color:#000000;font-weight:normal;">such rules and regulations do not increase the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Rent </font><font style="text-decoration:none;color:#000000;font-weight:normal;">payable hereunder; </font><font style="text-decoration:none;color:#auto;font-weight:normal;">(b) </font><font style="text-decoration:none;color:#000000;font-weight:normal;">such rules and regulations do not unreasonably and materially interfere with </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&#8217;s conduct of its business or </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&#8217;s use and enjoyment of the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Premises </font><font style="text-decoration:none;color:#000000;font-weight:normal;">for the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Permitted Use</font><font style="text-decoration:none;color:#000000;font-weight:normal;">; </font><font style="text-decoration:none;color:#auto;font-weight:normal;">(c) Landlord </font><font style="text-decoration:none;color:#000000;font-weight:normal;">provides reasonable advance written notice thereof; and </font><font style="text-decoration:none;color:#auto;font-weight:normal;">(d) </font><font style="text-decoration:none;color:#000000;font-weight:normal;">such rules and regulations are uniformly enforced in a non-discriminatory manner.</font><font style="font-weight:normal;">&nbsp;&nbsp;All such additions or changes to Rules and Regulations will be sent by Landlord to Tenant in writing and shall become effective ten (10) days thereafter.&nbsp;&nbsp;In the event of a conflict between the rules and regulations and the terms of this Lease, the terms of this Lease will control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M277"></a>22.<font style="margin-left:36pt;"></font>Assignments by <font style="color:#auto;">Landlord</font><font style="font-style:italic;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">will have the right to transfer and </font><font style="color:#auto;font-weight:normal;">assign</font><font style="font-weight:normal;">, in whole or in part, all its rights and obligations hereunder and in the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">and </font><font style="color:#auto;font-weight:normal;">Project</font><font style="font-weight:normal;">, and in such event and upon its transferee&#8217;s assumption of </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s obligations thereafter accruing hereunder, no further liability or obligation will thereafter accrue against </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">hereunder</font><font style="text-decoration:none;color:#000000;font-weight:normal;"> (provided that any such successor in </font><font style="text-decoration:none;color:#auto;font-weight:normal;">interest </font><font style="text-decoration:none;color:#000000;font-weight:normal;">expressly assumes the obligations of </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord </font><font style="text-decoration:none;color:#000000;font-weight:normal;">hereunder, in writing)</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon request by </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">, </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">agrees to execute a certificate certifying such facts as </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">may reasonably require in connection with any such assignment by </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">.&nbsp;&nbsp;This paragraph shall not affect </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s liability for matters arising prior to the transfer of the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="font-weight:normal;">including the </font><font style="color:#auto;font-weight:normal;">Security Deposit</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M278"></a>23.<font style="margin-left:36pt;"></font>Quiet Enjoyment.<font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">represents and warrants that it has full right and authority to enter into this </font><font style="color:#auto;font-weight:normal;">Lease </font><font style="font-weight:normal;">and that </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;">, upon paying the rental herein set forth and performing its other covenants and agreements herein set forth, will peaceably and quietly have, hold and enjoy the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">for the </font><font style="color:#auto;font-weight:normal;">term </font><font style="font-weight:normal;">hereof without hindrance or molestation from </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="text-decoration:none;color:#auto;font-weight:normal;"> </font><font style="text-decoration:none;color:#000000;font-weight:normal;">or any other lawful claimant to ownership or possession of the </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Premises</font><font style="font-weight:normal;">, subject to the terms and provisions of this </font><font style="color:#auto;font-weight:normal;">Lease</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M279"></a><a name="_DV_C78"></a><a name="_DV_M280"></a>24.<font style="margin-left:36pt;"></font>Liability.<font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">specifically agrees to look solely to </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">&#8217;s (or its successors&#8217;) </font><font style="color:#auto;font-weight:normal;">interest </font><font style="font-weight:normal;">in the </font><font style="color:#auto;font-weight:normal;">Building </font><font style="text-decoration:none;color:#000000;font-weight:normal;">(including rental income and insurance/condemnation proceeds) </font><font style="font-weight:normal;">for the recovery of any judgment (or other judicial decree) from </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">(or if </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">is a limited liability company, its members, or if </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">is a corporation, its directors, officers or any successors in </font><font style="color:#auto;font-weight:normal;">interest</font><font style="font-weight:normal;">) shall never be personally liable for any such judgment.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;"><a name="_DV_C78"></a>In no event shall Landlord be liable under this Lease for any consequential or punitive damages except to the extent caused by the gross negligence or willful misconduct of Landlord</font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M280"></a>.</font><font style="color:#auto;font-weight:normal;">&nbsp;&nbsp;This exculpation of liability to be absolute and without exception whatsoever.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M281"></a>Landlord <font style="color:#000000;">will not be liable to </font>Tenant <font style="color:#000000;">or any </font>Tenant Party<font style="color:#000000;">, or to any other person whomsoever, for any damage to property on or about the </font>Premises <font style="color:#000000;">belonging to </font>Tenant <font style="color:#000000;">or any other person, due to any cause whatsoever, unless caused by the </font><font style="text-decoration:none;color:#000000;">gross negligence or </font><font style="color:#000000;">willful or intentional misconduct of </font>Landlord<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M282"></a>Tenant <font style="color:#000000;">hereby covenants and agrees that it will at all times indemnify, defend (with counsel </font><font style="text-decoration:none;color:#000000;">reasonably </font><font style="color:#000000;">approved by </font>Landlord<font style="color:#000000;">) and hold safe and harmless </font>Landlord <font style="color:#000000;">(including, without limitation, its trustees and beneficiaries if </font>Landlord <font style="color:#000000;">is a trust), and the </font>Landlord Parties <font style="color:#000000;">from any loss, liability, claims, suits, </font>costs<font style="color:#000000;">, expenses, including without limitation </font><font style="text-decoration:none;color:#000000;">reasonable </font><font style="color:#000000;">attorney&#8217;s fees and damages, both real and alleged, incurred by </font>Landlord <font style="color:#000000;">or a </font>Landlord Party <font style="color:#000000;">arising out of or resulting from the </font><font style="text-decoration:none;color:#000000;">negligence or misconduct of</font><font style="color:#000000;"> </font>Tenant<font style="color:#000000;">, a breach by </font>Tenant <font style="color:#000000;">of any provision of this </font>Lease<font style="color:#000000;">, or the conduct by </font>Tenant <font style="color:#000000;">of its business in the </font>Building<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M283"></a>Landlord <font style="color:#000000;">hereby covenants and agrees that it will at all times indemnify, defend (with counsel reasonably approved by </font>Tenant<font style="color:#000000;">) and hold safe and harmless </font>Tenant<font style="color:#000000;">, and the </font>Tenant Parties <font style="color:#000000;">from any loss, liability, claims, suits, </font>costs<font style="color:#000000;">, expenses, including without limitation </font><font style="text-decoration:none;color:#000000;">reasonable </font><font style="color:#000000;">attorney&#8217;s fees and damages, both real and alleged, incurred by </font>Tenant <font style="color:#000000;">or a </font>Tenant Party <font style="color:#000000;">arising out of or resulting from the operation by </font>Landlord <font style="color:#000000;">of the </font>Building<font style="color:#000000;">,</font><font style="text-decoration:none;color:#000000;"> the negligence or misconduct of </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">,</font><font style="color:#000000;"> or a breach by </font>Landlord <font style="color:#000000;">of any provision of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M284"></a><a name="_DV_C79"></a><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><a name="_DV_M285"></a><font style="text-decoration:none;">25.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="color:#000000;">Mortgages.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;color:#000000;">accepts this </font><font style="color:#auto;font-weight:normal;">Lease </font><font style="font-weight:normal;color:#000000;">subject and subordinate to any mortgage(s) and/or deed(s) of trust now or at any time hereafter constituting a lien or charge upon the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;color:#000000;">or the improvements situated thereon; provided, however, that if the mortgagee, trustee, or holder of any such mortgage or deed of trust elects to have </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;color:#000000;">'s </font><font style="color:#auto;font-weight:normal;">interest </font><font style="font-weight:normal;color:#000000;">in this </font><font style="color:#auto;font-weight:normal;">Lease </font><font style="font-weight:normal;color:#000000;">superior to any such instrument, then by notice to </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;color:#000000;">from such mortgagee, trustee or holder, this </font><font style="color:#auto;font-weight:normal;">Lease </font><font style="font-weight:normal;color:#000000;">will be deemed superior to such lien, whether this </font><font style="color:#auto;font-weight:normal;">Lease </font><font style="font-weight:normal;color:#000000;">was executed before or after said mortgage or deed of trust. </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;color:#000000;">will at any time hereafter on demand execute and provide to </font><font style="color:#auto;font-weight:normal;">Landlord within </font><font style="text-decoration:none;color:#auto;font-weight:normal;">ten (10) business</font><font style="color:#auto;font-weight:normal;"> days of </font><font style="font-weight:normal;color:#000000;">a request therefore, any </font><font style="text-decoration:none;font-weight:normal;">commercially reasonable </font><font style="font-weight:normal;color:#000000;">instruments, releases or other documents which may be </font><font style="text-decoration:none;font-weight:normal;">reasonably </font><font style="font-weight:normal;color:#000000;">required by any mortgagee or trustee for the purpose of further subjecting and subordinating this </font><font style="color:#auto;font-weight:normal;">Lease </font><font style="font-weight:normal;color:#000000;">to the lien of any such mortgage or deed to trust in form and substance as</font><font style="text-decoration:none;font-weight:normal;"> reasonably</font><font style="font-weight:normal;color:#000000;"> required by such mortgagee or trustee. </font><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_C79"></a>Notwithstanding the foregoing, it shall be a condition precedent to any subordination that Tenant be provided with a written non-disturbance agreement in the form stipulated by Landlord&#8217;s lender (provided that: (i) Tenant shall be entitled to request of Landlord's lender commercially reasonable revisions to said form at its cost which costs include payment of any attorneys' fees charged to Landlord by Landlord's lender (as reasonably documented by Landlord); and (ii) said form provides that, if the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;color:#auto;font-weight:normal;"><a name="_DV_M285"></a>holder of any mortgage or deed of trust shall take title to the Premises through foreclosure or deed in lieu of foreclosure or otherwise, Tenant shall be allowed to continue in possession of the Premises as provided in this Lease so long as Tenant is not in default, beyond any applicable cure period)</font><font style="text-decoration:none;color:#auto;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M286"></a><font style="text-decoration:none;">26.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="color:#000000;">Signs.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Tenant will not be permitted any signage visible from outside of its </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;color:#000000;">which has not been approved in writing in advance by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;color:#000000;">in its </font><font style="text-decoration:none;font-weight:normal;">reasonable</font><font style="font-weight:normal;color:#000000;"> discretion.&nbsp;&nbsp;The cost of or related to any approved signage will be entirely at </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;color:#000000;">&#8217;s own expense, and all such signage shall be removed by </font><font style="color:#auto;font-weight:normal;">Tenant</font><font style="font-weight:normal;color:#000000;">, at its cost at the end of the </font><font style="color:#auto;font-weight:normal;">term </font><font style="font-weight:normal;color:#000000;">and any damage due to such removal repaired by </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;color:#000000;">prior to vacating the </font><font style="color:#auto;font-weight:normal;">Premises</font><font style="font-weight:normal;color:#000000;">. </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;color:#000000;">shall provide at its expense signage on the entry door to the </font><font style="color:#auto;font-weight:normal;">Premises</font><font style="font-weight:normal;color:#000000;">, and signage on the directory for the </font><font style="color:#auto;font-weight:normal;">Building</font><font style="font-weight:normal;color:#000000;">.</font><font style="text-decoration:none;font-weight:normal;">&nbsp;&nbsp;</font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord </font><font style="text-decoration:none;font-weight:normal;">shall provide </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Tenant </font><font style="text-decoration:none;font-weight:normal;">its exterior signage criteria prior to the execution of this </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Lease</font><font style="text-decoration:none;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M287"></a>27.<font style="margin-left:36pt;"></font>Keys and Locks<font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">, at its expense, shall provide </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">with </font><font style="text-decoration:none;color:#000000;font-weight:normal;">forty</font><font style="font-weight:normal;"> (</font><font style="text-decoration:none;color:#000000;font-weight:normal;">40</font><font style="font-weight:normal;">) card keys for access to the </font><font style="color:#auto;font-weight:normal;">Building</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">acknowledges that </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">shall have the right to install its own access control system to the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">and </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">shall furnish and provide </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">with duplicate keys and/or access cards, as applicable, to ensure that </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">and its representatives can gain access to the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">when permitted by the terms of this </font><font style="color:#auto;font-weight:normal;">Lease</font><font style="font-weight:normal;">.&nbsp;&nbsp;Upon termination of this </font><font style="color:#auto;font-weight:normal;">Lease</font><font style="font-weight:normal;">, </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">shall surrender to </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">all keys to the </font><font style="color:#auto;font-weight:normal;">Premises </font><font style="font-weight:normal;">and give to </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">the combination of all locks for safes, safe cabinets and vault doors, if any, remaining in the </font><font style="color:#auto;font-weight:normal;">Premises</font><font style="font-weight:normal;">.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M288"></a>28.<font style="margin-left:36pt;"></font><font style="color:#auto;">Brokers</font>.<font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">acknowledges that </font><font style="color:#auto;font-weight:normal;">Cassidy Turley </font><font style="text-decoration:none;color:#000000;font-weight:normal;">(and its successors and assigns)</font><font style="font-weight:normal;"> is acting as the sole agent for </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">in this transaction and shall be paid a brokerage fee by </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">pursuant to a separate agreement with </font><font style="color:#auto;font-weight:normal;">Landlord</font><font style="font-weight:normal;">. </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">confirms that no broker other than </font><font style="color:#auto;font-weight:normal;">Cassidy Turley </font><font style="font-weight:normal;">is assisting </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">in this matter.</font><font style="text-decoration:none;color:#000000;font-weight:normal;">&nbsp;&nbsp;</font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord </font><font style="text-decoration:none;color:#000000;font-weight:normal;">confirms that no broker is assisting </font><font style="text-decoration:none;color:#auto;font-weight:normal;">Landlord </font><font style="text-decoration:none;color:#000000;font-weight:normal;">in this matter.&nbsp;&nbsp;</font><font style="text-decoration:none;color:#auto;font-weight:normal;">L</font><font style="text-decoration:none;color:#auto;letter-spacing:-0.15pt;font-weight:normal;">andlord </font><font style="text-decoration:none;color:#000000;letter-spacing:-0.15pt;font-weight:normal;">and </font><font style="text-decoration:none;color:#auto;letter-spacing:-0.15pt;font-weight:normal;">Tenant </font><font style="text-decoration:none;color:#000000;letter-spacing:-0.15pt;font-weight:normal;">covenant to pay, hold harmless and indemnify the other from and against any and all </font><font style="text-decoration:none;color:#auto;letter-spacing:-0.15pt;font-weight:normal;">costs</font><font style="text-decoration:none;color:#000000;letter-spacing:-0.15pt;font-weight:normal;">, expenses or liability for any compensation, commissions and charges claimed by any other broker or agent, with respect to the transactions contemplated hereby or the negotiation thereof and arising by virtue of the acts of the indemnifying party</font><font style="text-decoration:none;color:#000000;font-weight:normal;">.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M289"></a>&nbsp;&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M290"></a>29.<font style="margin-left:36pt;"></font>Notices.<font style="font-weight:normal;"> Each provision of this instrument or of any </font><font style="color:#auto;font-weight:normal;">Applicable Law </font><font style="font-weight:normal;">with reference to the sending, </font><font style="text-decoration:none;color:#auto;font-weight:normal;">mailing</font><font style="font-weight:normal;">, or </font><font style="color:#auto;font-weight:normal;">delivery</font><font style="font-weight:normal;"> of any notice by </font><font style="text-decoration:none;color:#000000;font-weight:normal;">either party,</font><font style="font-weight:normal;"> or with reference to the making of any payment by </font><font style="color:#auto;font-weight:normal;">Tenant </font><font style="font-weight:normal;">to </font><font style="color:#auto;font-weight:normal;">Landlord </font><font style="font-weight:normal;">will be deemed to be complied with when and if the following steps are taken:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M291"></a>(a)<font style="margin-left:36pt;">All </font><font style="color:#auto;">Rent </font>and other payments required to be made by <font style="color:#auto;">Tenant </font>to <font style="color:#auto;">Landlord </font>hereunder will be payable to <font style="color:#auto;">Landlord </font>at the address below or at such other address as <font style="color:#auto;">Landlord </font>may specify from time to time by written notice delivered in accordance herewith.&nbsp;&nbsp;<font style="color:#auto;">Tenant</font>&#8217;s obligations to pay <font style="color:#auto;">Rent </font>and any other amounts to <font style="color:#auto;">Landlord </font>under the terms of this <font style="color:#auto;">Lease </font>will not be deemed satisfied until such <font style="color:#auto;">Rent </font>and other amounts have been actually received by <font style="color:#auto;">Landlord</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M292"></a><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>(b)<font style="margin-left:36pt;">Any notice or document required or permitted to be delivered hereunder will be deemed to be delivered </font><font style="text-decoration:none;color:#000000;">upon actual receipt or refusal thereof, and shall be:</font> (i) <font style="text-decoration:none;color:#000000;">sent </font>by standard, commercial overnight delivery service, such as Federal Express, or (ii) sent by Certified or Registered Mail, return receipt requested, postage prepaid, and addressed to the parties hereto </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the respective addresses set out below, or at other such addresses as they have heretofore specified by written notice delivered in accordance therewith. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M293"></a>Landlord<font style="color:#000000;">:</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M294"></a>Venable Tenant&nbsp;&nbsp;LLC</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M295"></a>c/o Scientific Properties, LLC</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M296"></a>280 Mangum Street, Suite 340</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M297"></a>Durham, NC 27701</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M298"></a>Tenant<font style="color:#000000;">:</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M299"></a><font style="text-decoration:none;">Precision BioSciences, Inc.</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M300"></a><font style="text-decoration:none;">104 T. W. Alexander Drive</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M301"></a><font style="text-decoration:none;">PO Box 12292</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M302"></a><font style="text-decoration:none;">Research Triangle Park, NC&nbsp;&nbsp;27709</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M303"></a><font style="text-decoration:none;">Attention: </font><font style="text-decoration:none;color:#auto;">Todd Melby</font><font style="text-decoration:none;">, Chief Financial Officer/Chief Operations Officer</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:3.85%;width:92.35%;">
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">with a copy to:</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Smith, Anderson, Blount, Dorsett</font><font style="text-decoration:none;color:#000000;">,</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:8.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:41.1%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Mitchell &amp; Jernigan, L.L.P.</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Post Office Box 2611</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Raleigh, North Carolina&nbsp;&nbsp; 27602-2611</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Attention: </font><font style="text-decoration:none;color:#auto;">Michael P. Saber, Esq.</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">overnight delivery address:</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">2500 Wachovia Capitol Center</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">150 Fayetteville Street</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:2.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:49.36%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Raleigh, North Carolina&nbsp;&nbsp;27601</font></p></td>
<td valign="top"  style="width:47.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M314"></a>30.<font style="margin-left:36pt;"></font>Miscellaneous.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M315"></a>(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">Words of any gender used in this </font>Lease <font style="color:#000000;">will be held and construed to include any other gender, and words in the singular number will be held to include the plural, unless the context otherwise requires.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M316"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The terms, provisions and covenants and conditions contained in this </font>Lease <font style="color:#000000;">will apply to, inure to the benefit of, and be binding upon the parties hereto and upon their respective heirs, legal representatives, successors and permitted assigns, except as otherwise herein expressly provided. </font>Landlord <font style="color:#000000;">will have the right to </font>assign <font style="color:#000000;">any of its rights and obligations under this </font>Lease<font style="color:#000000;">. Each party agrees to furnish to the other, promptly upon demand, a resolution, or other appropriate documentation evidencing the due authorization of such party to enter into this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M317"></a>(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">The captions inserted in this </font>Lease <font style="color:#000000;">are for convenience only and in no way define, limit or otherwise describe the scope or intent of this </font>Lease<font style="color:#000000;">, or any provision hereof, or in any way affect the interpretation of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M318"></a><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font><font style="margin-left:36pt;">Tenant </font><font style="color:#000000;">agrees from time to time, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within ten (10) </font><font style="text-decoration:none;">business </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">days after </font><font style="color:#000000;">request of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">, to deliver to </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">, or </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">&#8217;s designee, an estoppel certificate stating</font><font style="text-decoration:none;color:#000000;">, to the extent true and to </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s actual knowledge,</font><font style="color:#000000;"> that this </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease </font><font style="color:#000000;">is in full force and effect, the date to which </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent </font><font style="color:#000000;">has been paid, the unexpired </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term </font><font style="color:#000000;">of this </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease </font><font style="color:#000000;">and such other matters pertaining to this </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease </font><font style="color:#000000;">as may be</font><font style="text-decoration:none;color:#000000;"> reasonably</font><font style="color:#000000;"> requested by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">. It is understood and agreed that </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="color:#000000;">&#8217;s obligation to furnish such estoppel certificates in a timely fashion is a material inducement for </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">&#8217;s execution of this </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M319"></a>(e)<font style="margin-left:36pt;"></font><font style="color:#000000;">This </font>Lease <font style="color:#000000;">may not be altered, changed or amended except by an instrument in writing signed by both parties hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M320"></a>(f)<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#000000;">All</font><font style="color:#000000;"> obligations of </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">and </font>Tenant <font style="color:#000000;">hereunder not fully performed as of the expiration or earlier termination of the </font>term <font style="color:#000000;">of this </font>Lease <font style="color:#000000;">will survive the expiration or earlier termination of the </font>term <font style="color:#000000;">hereof, including, without limitation, all payment obligations concerning the condition of the </font>Premises <font style="color:#000000;">and all obligations of </font>Tenant <font style="color:#000000;">as provided in Section </font>5 <font style="color:#000000;">hereof. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M321"></a>(g)<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#000000;">In the case of a foreclosure or deed in lieu of foreclosure on a mortgage or deed of trust existing prior to the date of this </font><font style="text-decoration:none;">Lease</font><font style="text-decoration:none;color:#000000;">, in</font><font style="color:#000000;"> the event of a transfer by </font>Landlord <font style="color:#000000;">of its </font>interest <font style="color:#000000;">in the </font>Premises<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">will be released from all obligations and liabilities under the terms of this </font>Lease <font style="text-decoration:none;color:#000000;">arising </font><font style="color:#000000;">subsequent to the date of such transfer. In the event a transferee will agree to assume the obligations and liabilities of </font>Landlord <font style="color:#000000;">under the </font>Lease <font style="color:#000000;">prior to the date of the transfer, </font>Landlord <font style="color:#000000;">will be released from all obligations and liabilities under the </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M322"></a>(h)<font style="margin-left:36pt;"></font><font style="color:#000000;">If any clause or provision of this </font>Lease <font style="color:#000000;">is illegal, invalid or unenforceable under present or future laws effective during the </font>term <font style="color:#000000;">of this </font>Lease<font style="color:#000000;">, then and in that event, it is the intention of the parties hereto that the remainder of this </font>Lease <font style="color:#000000;">will not be affected thereby, and it is also the intention of the parties to this </font>Lease <font style="color:#000000;">that in lieu of each clause or provision of this </font>Lease <font style="color:#000000;">that is illegal, invalid or unenforceable, there be added as a part of this </font>Lease <font style="color:#000000;">a clause or provision as similar in terms to such illegal, invalid or unenforceable clause or provision as may be possible and be legal, valid and enforceable.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M323"></a>(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">Because the </font>Premises <font style="color:#000000;">are on the open market and are presently being shown, this </font>Lease <font style="color:#000000;">will be treated as an offer with the </font>Premises <font style="color:#000000;">being subject to prior </font>lease <font style="color:#000000;">and such offer subject to the withdrawal or non-acceptance by </font>Landlord <font style="color:#000000;">or to other use of the </font>Premises <font style="color:#000000;">without notice, and this </font>Lease <font style="color:#000000;">will not be valid or binding unless and until accepted by </font>Landlord <font style="color:#000000;">in writing and a fully executed copy delivered to both parties hereto.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M324"></a>(j)<font style="margin-left:36pt;"></font><font style="color:#000000;">All references in this </font>Lease <font style="color:#000000;">to &#8220;</font>the date hereof<font style="color:#000000;">&#8221; or similar references will be deemed to refer to the last date, in point of time, on which all parties hereto have executed this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M325"></a>(k)<font style="margin-left:36pt;"></font><font style="color:#000000;">Time is of the essence of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M326"></a><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>(l)<font style="margin-left:36pt;">Landlord </font><font style="color:#000000;">will not be in default in the performance of any of </font>Landlord<font style="color:#000000;">&#8217;s obligations hereunder unless and until </font>Landlord <font style="color:#000000;">will have failed to perform such duties or obligations within thirty (30) days (or such additional time as is reasonably required to correct any such default) after written notice by </font>Tenant <font style="color:#000000;">to </font>Landlord <font style="color:#000000;">properly specifying wherein </font>Landlord <font style="color:#000000;">has failed to perform any such duty or obligation.</font><font style="text-decoration:none;color:#000000;">&nbsp;&nbsp;In cases where there is an imminent threat of harm to person or property at the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">, or if </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">cannot conduct its business at the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall effect a cure within a reasonable period of time using all reasonable efforts.&nbsp;&nbsp;Should a cure be required and </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">fail to effect a cure </font><font style="text-decoration:none;">within ten (10) business days after </font><font style="text-decoration:none;color:#000000;">the date after receipt by </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">from </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">of written notice with respect to such default, </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall have the right to effect such cure.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="text-decoration:none;color:#000000;">Except as expressly provided in this </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">to the contrary, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">will have no liability for any incidental or consequential damages of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="color:#000000;">, or anyone claiming by, through or under </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="color:#000000;">, for any reason whatsoever.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M327"></a>(m)<font style="margin-left:36pt;"></font><font style="color:#000000;">This </font>Lease <font style="color:#000000;">does not create the relationship of partner or joint venturer between </font>Landlord <font style="color:#000000;">and </font>Tenant<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M328"></a>(n)<font style="margin-left:36pt;"></font><font style="color:#000000;">The laws of the State of North Carolina will govern the interpretation, the validity, performance and enforcement of this </font>Lease<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M329"></a>(o)<font style="margin-left:36pt;">(i) </font><font style="color:#000000;">If </font>Tenant <font style="color:#000000;">is a corporation, the undersigned officer of </font>Tenant <font style="color:#000000;">does hereby warrant and certify to </font>Landlord <font style="color:#000000;">that </font>Tenant <font style="color:#000000;">is a corporation in good standing and duly organized under the laws of the State of North Carolina, or if chartered in a state other than the State of North Carolina, is a corporation in good standing and duly organized under the laws of such state and is authorized to do business in the State of North Carolina.&nbsp;&nbsp;The undersigned officer of </font>Tenant <font style="color:#000000;">hereby further warrants and certifies to </font>Landlord <font style="color:#000000;">that such officer is authorized and empowered to bind the corporation to the terms of this </font>Lease <font style="color:#000000;">by such officer&#8217;s signature hereto; </font>(ii) <font style="color:#000000;">If </font>Tenant <font style="color:#000000;">is a general or limited partnership, the undersigned general partner of </font>Tenant <font style="color:#000000;">does hereby warrant and certify to </font>Landlord <font style="color:#000000;">that </font>Tenant <font style="color:#000000;">is a general partnership or limited partnership, as the case may be, validly existing under the laws of the State of North Carolina, or if formed in a state other than the State of North Carolina, is a general partnership or limited partnership validly existing under the laws of such state and is authorized to do business in the State of North Carolina.&nbsp;&nbsp;The undersigned general partner of </font>Tenant <font style="color:#000000;">hereby further warrants and certifies to </font>Landlord <font style="color:#000000;">that such general partner is authorized and empowered to bind </font>Tenant <font style="color:#000000;">to the terms of this </font>Lease <font style="color:#000000;">by such general partner&#8217;s signature hereto. </font>(iii) Landlord <font style="color:#000000;">confirms that those persons signing below on its behalf are duly authorized to do so.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M330"></a>(p)<font style="margin-left:36pt;"></font><font style="text-decoration:none;color:#000000;">The provisions of any Exhibits referenced herein, whether or not attached hereto, are incorporated herein by reference and made a part of this </font><font style="text-decoration:none;">Lease</font><font style="text-decoration:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M331"></a>(q)<font style="margin-left:36pt;"></font><font style="color:#000000;">Although the printed provisions of this </font>Lease <font style="color:#000000;">were drafted by </font>Landlord<font style="color:#000000;">, such fact will not cause this </font>Lease <font style="color:#000000;">to be construed either for or against </font>Landlord <font style="color:#000000;">or </font>Tenant<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M332"></a>(r)<font style="margin-left:36pt;"></font><font style="color:#000000;">This </font>Lease <font style="color:#000000;">may not be recorded.&nbsp;&nbsp;Upon the request and at the expense of </font>Tenant<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">will execute a memorandum of this </font>Lease <font style="color:#000000;">suitable for recording which will omit the financial terms herein but which will identify the </font>Premises<font style="text-decoration:none;color:#000000;">, the </font><font style="text-decoration:none;">Parties</font><font style="text-decoration:none;color:#000000;">,</font><font style="color:#000000;"> and the </font>term <font style="color:#000000;">of this </font>Lease<font style="color:#000000;">.&nbsp;&nbsp;Upon the expiration of this </font>Lease<font style="color:#000000;">, a recorded memorandum of this </font>Lease <font style="color:#000000;">may be canceled of record by a document executed by </font>Landlord<font style="color:#000000;">, or its successor in </font>interest <font style="color:#000000;">for such purpose.</font><font style="text-decoration:none;color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M333"></a><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>(s)<font style="margin-left:36pt;">Tenant will provide to Landlord within ninety (90) days of the close of its fiscal year, and thereafter within ten </font><font style="text-decoration:none;">(10 business</font> days of the reasonable request of Landlord<font style="text-decoration:none;">, but no more than once per calendar year except during any default or event of default by Tenant when this limitation shall not apply</font>, financial statements of Tenant<font style="text-decoration:none;"> (consisting of summarized profit and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">loss statement, balance sheet, and cash flow statement)</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> certified by the chief financial officer of Tenant.</font><font style="color:#000000;"><strike> </strike></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M334"></a>(t)<font style="margin-left:36pt;"></font><font style="color:#000000;">No remedy conferred herein is intended to be exclusive of any other remedy and each and every remedy will be cumulative and will be in addition to every other remedy given hereunder or thereunder or now or hereafter existing at law or in equity or by statute or otherwise.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(u)&nbsp;&nbsp;<font style="color:#000000;">[INTENTIONALLY DELETED.]</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M335"></a><font style="text-decoration:none;">(v) Tenant</font><font style="text-decoration:none;color:#000000;">, its employees, and invitees shall have access to the </font><font style="text-decoration:none;">Premises </font><font style="text-decoration:none;color:#000000;">twenty-four (24) hours a day, seven (7) days a week.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M336"></a>(w)&nbsp;&nbsp;<font style="color:#000000;">The provisions of this </font>Lease <font style="color:#000000;">and any information regarding </font>Landlord<font style="color:#000000;">, including its construction process, and the materials and standards used, will be maintained confidential by </font>Tenant<font style="color:#000000;">, its agents, employees, officers, and legal and tax advisors.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M337"></a>(x)<font style="margin-left:36pt;">Tenant </font><font style="color:#000000;">shall be responsible for all ad valorem taxes on its personal property and on the value of the leasehold improvements to the extent that such improvements do not constitute fixtures, or additions or improvements to real property</font><font style="text-decoration:none;color:#000000;"> (as reasonably documented by </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">)</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant<font style="color:#000000;">, within thirty (30) days of receipt of an invoice, shall also pay to </font>Landlord <font style="color:#000000;">all </font>sales <font style="color:#000000;">or use taxes or excise taxes imposed or levied by the State of North Carolina or any other governmental body or agency, if any, against any </font>rent <font style="color:#000000;">or any other charge or payment required hereunder to be made by </font>Tenant <font style="color:#000000;">to </font>Landlord<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M338"></a>(y) <font style="color:#000000;">This </font>Lease <font style="color:#000000;">does not grant any rights to light, view or air over adjacent property, and any diminution or shutting off of light, view or air by any structure that may be erected adjacent to the </font>Building <font style="color:#000000;">shall not affect this </font>Lease <font style="color:#000000;">or impose any obligation or liability upon </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M339"></a><font style="text-decoration:none;">(z) </font><font style="text-decoration:none;color:#000000;">In coordination with the General Contractor and </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">'s Construction Manager and in compliance with the procedures required for them, </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall be permitted reasonable access to the </font><font style="text-decoration:none;">Premises </font><font style="text-decoration:none;color:#000000;">prior to the </font><font style="text-decoration:none;">Commencement Date </font><font style="text-decoration:none;color:#000000;">for the purposes of taking measurements, making </font><font style="text-decoration:none;">plans</font><font style="text-decoration:none;color:#000000;">, installing trade fixtures, and doing such other work as may be appropriate or desirable to enable </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">to assume possession of and operate in the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">; provided, however, that such access does not unreasonably interfere with or delay construction work on the </font><font style="text-decoration:none;">Premises </font><font style="text-decoration:none;color:#000000;">and if </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall unreasonably interfere with or delay construction work on the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall have the right to deny the </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">access to the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;Prior to any such entry, </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall comply with all insurance provisions of the </font><font style="text-decoration:none;">Lease</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;All waiver and indemnity provisions of the </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">shall apply upon </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s entry onto the </font><font style="text-decoration:none;">Premises</font><font style="text-decoration:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[SIGNATURE PAGE FOLLOWS]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M340"></a><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have duly executed </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this Lease</font><font style="color:#auto;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of the day and year </font><font style="text-decoration:none;color:#000000;">first set forth above</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M341"></a><a name="_DV_M342"></a><a name="_Toc202777489"></a>LANDLORD<font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M343"></a><a name="_Toc202777490"></a>VENABLE TENANT, LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M344"></a>By: SCIENTIFIC PROPERTIES, LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:35.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc202777491"></a><a name="_DV_M346"></a><a name="_DV_M346"></a>/s/ Barbra Rothschild<font style="text-decoration:none;color:#000000;"> </font></p></td>
<td valign="top"  style="width:12.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;7/6/10</p></td>
<td valign="top"  style="width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:41.52%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc202777492"></a>Barbra Rothschild, Manager</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:35.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:35.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:41.52%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:35.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:41.52%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:35.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:35.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:12.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:39.74%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:35.5%; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Todd Melby</p></td>
<td valign="top"  style="width:12.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:6.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;4-2-10</p></td>
<td valign="top"  style="width:30.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Todd Melby, Chief Financial Officer / Chief Operations Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M347"></a><a name="_Toc202777493"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;border-bottom:Solid 1.5pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;border-bottom:Solid 1.5pt #000000;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M353"></a><a name="_DV_M352"></a><a name="_Toc202777497"></a>EXHIBIT <font style="color:#000000;">A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M355"></a><a name="_DV_M354"></a><a name="_Toc202777498"></a>THE LAND</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M356"></a>BEGINNING <font style="color:#000000;">at an existing PK nail in the western right of way of Pettigrew Street (100&#8217; public r/w) and the eastern right of way of Roxboro Street, thence running south along said western right of way </font>along the arc of a circular curve with a radius of 2125<font style="color:#000000;">.0 feet, a chord length of 52.03 feet, subtended by a chord that bears S 42&#186;37&#8217;26&#8221;E, for an arc length of 52.04 </font>feet to an existing iron pipe<font style="color:#000000;">, thence continuing along said right of way </font>along the arc of a circular curve with a radius of 2125<font style="color:#000000;">.0 feet, a chord length of 124.74 feet, subtended by a chord that bears </font>S40&#186;<font style="color:#000000;">30&#8217;08&#8221;E, for an arc length of 124.76 feet to an existing PK nail, being the northwestern corner of </font>Durham Foundry &amp; Machine <font style="color:#000000;">property, thence running along said property </font>S45&#186;<font style="color:#000000;">24&#8217;44&#8221;W for a distance of 175.48 </font>feet to an existing iron pipe, thence continuing with said property S41<font style="color:#000000;">&#8217;05&#8217;06&#8221;E for a distance of 71.0 </font>feet to an iron pipe set, thence continuing with said property N47&#186;<font style="color:#000000;">22&#8217;04&#8221;E for a distance of 30.62 </font>feet to an iron pipe set, thence continuing with said property S41&#186;<font style="color:#000000;">29&#8217;07&#8221;E for a distance of 60.52 </font>feet to an iron pipe set, thence continuing with said property N52&#186;<font style="color:#000000;">25&#8217;05&#8221;E for a distance of 133.09 feet to an existing PK nail in the western right of way of Pettigrew Street, thence running along said right of way </font>along the arc of a circular curve with a radius of 2125<font style="color:#000000;">.0 feet, a chord length of 81.56 feet, subtended by a chord that bears </font>S33<font style="color:#000000;">&#8217;40&#8217;35&#8221;E, for an arc length of 81.57 </font>feet to an existing iron pipe<font style="color:#000000;">, thence running&nbsp;&nbsp;</font>S50&#186;<font style="color:#000000;">19&#8217;45&#8221;W for a distance of 151.69 </font>feet to an existing iron pipe<font style="color:#000000;">, thence running </font>S41&#186;<font style="color:#000000;">34&#8217;48E for a distance of 79.86 </font>feet to an existing iron pipe<font style="color:#000000;">, thence running along the western 30 foot Ingress/Egress Easement with Hendrick Automotive Group </font>S35&#186;<font style="color:#000000;">06&#8217;35&#8221;W for a distance of 119.31 </font>feet to an iron pipe <font style="color:#000000;">set, thence running with the northern property line of Thomas and Howard of </font>Greensboro N42&#186;<font style="color:#000000;">54&#8217;51&#8221;W for a distance of 48.93 </font>feet to an iron pipe set, thence continuing with said property N64&#186;<font style="color:#000000;">41&#8217;55&#8221;W for a distance of 246.14 </font>feet to an existing iron rod, thence continuing with said property N64&#186;<font style="color:#000000;">35&#8217;38&#8221;W for a distance of 94.86 </font>feet to an existing iron rod <font style="color:#000000;">in the eastern public right of way of Roxboro Street, thence along said right of way </font>N26&#186;<font style="color:#000000;">54&#8217;18&#8221;E for a distance of 99.65 </font>feet to an existing iron rod<font style="color:#000000;">, thence continuing with said right of way </font>N26&#186;<font style="color:#000000;">35&#8217;12&#8221;E for a distance of 39.07 </font>feet to an existing iron pipe, thence continuing with said right <font style="color:#000000;">of way </font>N29&#186;<font style="color:#000000;">23&#8217;01&#8221;E for a distance of 96.73 feet to an existing PK nail, thence continuing with said right of way </font>N28&#186;<font style="color:#000000;">09&#8217;00&#8221;E for a distance of 207.93 </font>feet to an iron pipe set, thence running N81&#186;<font style="color:#000000;">39&#8217;58&#8221;E for a distance of 14.62 feet to an existing PK nail, the place and point of BEGINNING for the &#8216;</font>Main Parcel<font style="color:#000000;">&#8217; and containing117,484 square feet or 2.697 acres, more or less, and being all of the </font>Main <font style="color:#000000;">parcel of </font>West Property<font style="color:#000000;">, as appears on map captioned &#8220;As- Built Survey of West Property, Pettigrew Street Partners, L.L.C.&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M357"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>BEGINNING at an iron pipe in the western right of way of Pettigrew Street (100&#8217; public r/w) and the northeastern corner of the &#8216;<font style="color:#auto;">Main Parcel</font>&#8217; of <font style="color:#auto;">West Property</font>, thence running with the right of way of Pettigrew Street <font style="color:#auto;">along the arc of a circular curve with a radius of 2125</font>.00 feet, a delta angle of 03&#186;09&#8217;36&#8221; for an arc length of 117.20 feet, subtended by a chord that bears <font style="color:#auto;">S30&#186;</font>59&#8217;49&#8221;<font style="color:#auto;">E to an existing iron pipe</font>, thence running along the Hendrick Automotive Group property <font style="color:#auto;">S52&#186;</font>56&#8217;13&#8221;W for a distance of 128.22 <font style="color:#auto;">feet to an iron pipe </font>set, thence running along the western 30 foot Hendrick Automotive Group <font style="color:#auto;">Ingress</font>/<font style="color:#auto;">Egress Easement N45&#186;</font>46&#8217;23&#8221;W for a distance of 30.37 <font style="color:#auto;">feet to an existing iron pipe</font>, thence running along the property line of the &#8216;<font style="color:#auto;">Main Parcel</font>&#8217; of <font style="color:#auto;">West Property N41&#186;</font>34&#8217;48&#8221;W for a distance of 79.86 <font style="color:#auto;">feet to an existing iron pipe, thence continuing with said </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;">property line N50&#186;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19&#8217;45&#8221;E for a distance of 151.69 </font><font style="color:#auto;">feet to an existing iron pipe</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the place and point of BEGINNING for the &#8216;</font><font style="color:#auto;">Hatched Parcel</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; and containing 15,963 square feet or 0.366 acres, more or less, and being all of tract 2 </font><font style="color:#auto;">West Property</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as appears on map captioned &#8220;As- Built Survey of West Property, Pettigrew Street Partners, L.L.C.&#8221; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M358"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT </font><font style="color:#000000;">B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M359"></a>FLOOR PLAN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000001.jpg" title="" alt="" style="width:492px;height:582px;"></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M360"></a><a name="_DV_M360"></a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT </font><font style="color:#000000;">C</font></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M361"></a>PREMISES SPECIFICATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M362"></a><a name="_DV_M363"></a>FLOORS<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing flooring consists of pine planking and or &#190;&#8221; sub-flooring installed to provide accessibility for plumbing and electrical rough-ins. Additional sub-flooring required to accommodate Tenant Improvements shall be funded from the Tenant Improvement Allowance.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M364"></a>Any demolition of existing flooring required to accommodate <font style="color:#auto;">Tenant Improvements </font>shall be funded from the <font style="color:#auto;">Tenant Improvement Allowance</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M365"></a>WALLS, DOORS &amp; WINDOWS<font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M366"></a>Common <font style="color:#000000;">area walls shall consist of hollow metal frames, single pane glazing, and gypsum assemblies (painted or wall covering) typical throughout the Venable campus.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M367"></a>All masonry construction/repair is per approved sand blasted and clear finish sealer method. Repairs or replacement of brick as required will be made using existing salvaged brick or new brick to match existing. New mortar is to match existing.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M368"></a>Interior corridor doors opening onto <font style="color:#auto;">Common Areas </font>will be stained birch veneer doors per the <font style="color:#auto;">Venable Campus Standard</font>. <font style="color:#auto;">Landlord </font>reserves the right to substitute alternate commercial grade materials. All door locksets will be coded and/or keyed in accordance with the <font style="color:#auto;">building </font>requirements. Codes and/or keys are to be delivered to <font style="color:#auto;">tenant </font>properly tested and/or tagged. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M369"></a>Exterior perimeter windows will be &#189;&#8221; insulated clear glass in black hollow metal and steel frames.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord <font style="color:#000000;">shall provide for demolition of any existing interior walls. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M370"></a>CEILING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M371"></a>The ceiling is the existing, historic, natural heart pine.&nbsp;&nbsp;Any exposed ceilings will be sealed by <font style="color:#auto;">Landlord </font>in accordance with best practices.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M372"></a><font style="text-decoration:none;">PLUMBING</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M373"></a>All piping and fixtures within the <font style="color:#auto;">Tenant </font><font style="text-decoration:none;color:#auto;">Improvements</font><font style="color:#auto;"> </font>shall be funded from the <font style="color:#auto;">Tenant Improvement Allowance</font>.&nbsp;&nbsp;The <font style="text-decoration:none;color:#auto;">Landlord</font><font style="color:#auto;"> </font>shall provide water and standard DWV to and from the space.&nbsp;&nbsp;Any additional piping (specialty water or waste) shall be installed from the <font style="color:#auto;">Tenant Improvement </font><font style="text-decoration:none;color:#000000;">space</font> to the closest source/sewer,<font style="text-decoration:none;color:#000000;"> and</font> this piping would be funding from the <font style="color:#auto;">Tenant Improvement Allowance</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M374"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HVAC</font><font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M375"></a>Premises <font style="color:#000000;">will be conditioned to office load standards by a rooftop </font>Trane <font style="color:#000000;">(or equivalent) zoned </font>systems <font style="color:#000000;">thru rated vertical chases (to lower floors only).&nbsp;&nbsp;All rooftop units to include minimum fresh air settings for anticipated office load occupancy levels. HVAC controls to be located in </font>tenant <font style="color:#000000;">space with single zone distribution.&nbsp;&nbsp;Additional cooling or ventilation requirements will be funded from the </font>Tenant Improvement <font style="text-decoration:none;">Allowance</font><font style="color:#000000;">.&nbsp;&nbsp;HVAC distribution within the </font>tenant <font style="color:#000000;">space and additional control zones shall be funded from the </font>Tenant Improvement Allowance<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M376"></a>ELECTRICAL CAPACITY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M377"></a>Building <font style="color:#000000;">load is calculated on approximately 2 watts </font>per square foot <font style="color:#000000;">for the base </font>building <font style="color:#000000;">and approximately 2 watts </font>per square foot <font style="color:#000000;">for usable </font>tenant <font style="color:#000000;">space per typical office demand.&nbsp;&nbsp;Electrical service and meter shall be provided to a subpanel within the </font>tenant <font style="color:#000000;">space.&nbsp;&nbsp;The subpanel, circuit distribution (conductors and raceways), and fixtures shall be funded from the </font>Tenant Improvement Allowance<font style="color:#000000;">.&nbsp;&nbsp; Voice and </font>Data Conduits <font style="color:#000000;">will be provided within interior walls and will be funded from the </font>Tenant Improvement Allowance<font style="color:#000000;">.&nbsp;&nbsp;The </font>Tenant <font style="color:#000000;">shall </font>contract <font style="color:#000000;">directly with a voice/data contractor who will provide and pull cables to the Building Telecommunications Room.&nbsp;&nbsp;The </font>Tenant<font style="color:#000000;">&#8217;s voice/data contractor will provide and terminate devices and related equipment.&nbsp;&nbsp;The voice/data contractor and any security work shall not be funded from the </font>Tenant Improvement Allowance<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M378"></a>FIRE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M379"></a>Wet pipe sprinkler system based on ordinary hazard NFPA 13 design with upright heads.</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M380"></a>Adjustment of sprinkler heads specific to <font style="color:#auto;">Tenant Improvements </font>shall be funded from the <font style="color:#auto;">Tenant Improvement Allowance</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M381"></a>A <font style="color:#auto;">building </font>standard fire alarm and security system shall be installed and funded from the <font style="color:#auto;">Tenant Improvement Allowance</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M382"></a>[END OF EXHIBIT C]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M383"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT </font><font style="color:#000000;">D</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M384"></a>WORK LETTER</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M385"></a>This Exhibit D sets forth the rights and obligations of Landlord and Tenant with respect to the construction of the improvements to the Premises as described on the Plans ("Tenant Improvements"). This Exhibit contemplates that the following work will be performed, as further described herein, all subject to the prior review and approval by Landlord: (i) preparation of a space plan by the Architect; (ii) final design and engineering and preparation of plans, specifications, and working drawings by the Architect (collectively, the "Plans"); (iii) preparation by the general contractor of Landlord (the "General Contractor") of an estimate of the cost of the Tenant Improvements; (iv) submission to, and approval of Plans by, appropriate governmental authorities; and (v) construction and installation of the Tenant Improvements by the Landlord pursuant to the Plans on or prior to the Commencement Date, subject to Force Majeure and any Tenant Delay.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;border-top:Solid 0.75pt #FFFFFF;padding-top:0pt;border-bottom:Solid 0.75pt #FFFFFF;padding-bottom:0pt;border-left:Solid 0.75pt #FFFFFF;padding-left:15pt;border-right:Solid 0.75pt #FFFFFF;padding-right:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M386"></a><font style="text-decoration:none;">1.</font><font style="text-decoration:none;color:#000000;margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Allowance/Payment of </font><font style="text-decoration:underline;">Construction Costs</font><font style="text-decoration:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M387"></a><a name="_DV_C82"></a><a name="_DV_M388"></a><a name="_DV_C84"></a><a name="_DV_M389"></a><a name="_DV_C86"></a><a name="_DV_M390"></a><a name="_DV_M391"></a><a name="_DV_M392"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><a name="_DV_C90"></a><a name="_DV_M393"></a><a name="_DV_C94"></a><a name="_DV_M394"></a><a name="_DV_C97"></a><a name="_DV_M395"></a><font style="text-decoration:none;"></font><font style="text-decoration:none;color:#auto;">(a)</font><font style="text-decoration:none;color:#auto;margin-left:36pt;">Landlord </font><font style="text-decoration:none;">shall construct the </font><font style="text-decoration:none;color:#auto;">Tenant Improvements </font><font style="text-decoration:none;">in accordance with a milestone </font><font style="text-decoration:none;color:#auto;">schedule </font><font style="text-decoration:none;">(the &#8220;</font><font style="text-decoration:none;color:#auto;">Schedule</font><font style="text-decoration:none;">&#8221;), a copy of which shall be provided to </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">for </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="text-decoration:none;">&#8217;s reasonable approval prior to commencement of construction of the </font><font style="text-decoration:none;color:#auto;">Tenant Improvements</font><font style="text-decoration:none;"><a name="_DV_C82"></a>.&nbsp;&nbsp;</font><font style="color:#auto;"><a name="_DV_M388"></a>Landlord and Tenant shall prepare<a name="_DV_C84"></a> and <a name="_DV_M389"></a>mutually and reasonably approve <a name="_DV_C86"></a>a budget (the &#8220;Budget&#8221;) for the costs to construct the Tenant Improvements (the &#8220;Construction Costs&#8221;)</font><font style="text-decoration:none;color:#auto;"><a name="_DV_M390"></a> which shall be attached hereto as Exhibit D-3. T</font><font style="color:#000000;">he </font><font style="color:#auto;">Budget </font><font style="text-decoration:none;">does</font><font style="color:#000000;"> not include any amounts for furniture, fixtures</font><font style="text-decoration:none;"> (other than lighting)</font><font style="color:#000000;">, equipment, voice/data </font><font style="color:#auto;">systems</font><font style="color:#000000;">, or personal property of </font><font style="color:#auto;">Tenant</font><font style="color:#000000;">, which items will be paid for by </font><font style="color:#auto;">Tenant </font><font style="color:#000000;"><a name="_DV_M391"></a>separately at its expense.  The </font><font style="color:#auto;">Budget </font><font style="text-decoration:none;">includes</font><font style="color:#000000;"> a </font><font style="color:#auto;">Construction Contingency </font><font style="color:#000000;">which shall be 5% of the </font><font style="color:#auto;">Construction Costs</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Any unspent </font><font style="text-decoration:none;color:#auto;">Construction Contingency</font><font style="color:#auto;"> </font><font style="color:#000000;">will accrue to the </font><font style="color:#auto;">Tenant</font><font style="color:#000000;">. </font><font style="text-decoration:none;color:#auto;">Change Orders </font><font style="text-decoration:none;">(as hereinafter defined)</font><font style="color:#000000;"> shall be funded from increases in the </font><font style="color:#auto;">Contract </font><font style="color:#000000;">(as hereinafter defined).&nbsp;&nbsp;</font><font style="color:#auto;">Landlord </font><font style="color:#000000;">agrees to fund a portion of the </font><font style="color:#auto;">Construction Costs </font><font style="color:#000000;">through the provision of the </font><font style="color:#auto;">Tenant Improvement Allowance</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">The </font><font style="text-decoration:none;color:#auto;">Tenant Improvement Allowance </font><font style="text-decoration:none;">shall be used for items specifically outlined in the </font><font style="text-decoration:none;color:#auto;">Budget </font><font style="text-decoration:none;">and mutually agreed upon by both </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">and </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="text-decoration:none;">.&nbsp;&nbsp;The </font><font style="text-decoration:none;color:#auto;">Tenant Improvement Allowance </font><font style="text-decoration:none;">shall be used only for construction, design, and management </font><font style="text-decoration:none;color:#auto;">costs </font><font style="text-decoration:none;">related to fixed improvements to the </font><font style="text-decoration:none;color:#auto;">Building </font><font style="text-decoration:none;">that are part of the </font><font style="text-decoration:none;color:#auto;">Tenant Improvements</font><font style="text-decoration:none;">. </font><font style="color:#000000;"> The </font><font style="color:#auto;">Tenant Improvement Allowance </font><font style="color:#000000;">may not be used to offset any </font><font style="color:#auto;">Rent </font><font style="color:#000000;">payments owed to </font><font style="color:#auto;">Landlord </font><font style="color:#000000;">by </font><font style="color:#auto;">Tenant</font><font style="color:#000000;">. Any </font><font style="color:#auto;">costs </font><font style="color:#000000;">incurred due to a </font><font style="color:#auto;">Tenant Delay </font><font style="color:#000000;">shall be charged against the </font><font style="color:#auto;">Tenant Improvement Allowance</font><font style="text-decoration:none;">; provided, however, </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">shall be given two (2) days&#8217; notice and opportunity to cure any </font><font style="text-decoration:none;color:#auto;">Tenant Delay </font><font style="text-decoration:none;">(including payment by </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">of any </font><font style="text-decoration:none;color:#auto;">costs </font><font style="text-decoration:none;"><a name="_DV_M392"></a>associated with such cure such as higher shipping charges) before any </font><font style="text-decoration:none;color:#auto;">costs </font><font style="text-decoration:none;">are charged against the </font><font style="text-decoration:none;color:#auto;">Tenant Improvement Allowance</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#auto;">Landlord </font><font style="color:#000000;">and </font><font style="color:#auto;">Tenant </font><font style="color:#000000;">acknowledge and agree that the </font><font style="color:#auto;">Construction Costs </font><font style="color:#000000;">will be in excess of the </font><font style="color:#auto;">Tenant Improvement Allowance</font><font style="color:#000000;">, and all </font><font style="color:#auto;">costs </font><font style="color:#000000;">for the </font><font style="color:#auto;">Tenant Improvements </font><font style="color:#000000;">in excess of the </font><font style="color:#auto;">Tenant Improvement Allowance </font><font style="color:#000000;">shall be borne by </font><font style="color:#auto;">Tenant</font><font style="color:#000000;">.&nbsp;&nbsp;Therefore, </font><font style="color:#auto;">Tenant </font><font style="color:#000000;">has agreed to place into an </font><font style="color:#auto;">escrow account </font><font style="color:#000000;">maintained with </font><font style="color:#auto;">Landlord </font><font style="color:#000000;">(the "</font><font style="color:#auto;">Escrow Account</font><font style="color:#000000;">") an amount equal to the </font><font style="color:#auto;">Construction Costs </font><font style="color:#000000;">as specified in the </font><font style="color:#auto;">Budget </font><font style="color:#000000;">minus the Tenant Improvement Allowance (the &#8220;</font><font style="color:#auto;">Tenant Improvement Overage</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;</font><font style="color:#auto;">Landlord </font><font style="color:#000000;">shall establish the </font><font style="color:#auto;">Escrow Account </font><font style="color:#000000;">as a separate, </font><font style="color:#auto;">interest </font><font style="color:#000000;">bearing account in an FDIC insured institution. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;"><a name="_DV_C90"></a>set forth below, Landlord shall have the authority to make periodic deductions from the Escrow Account as payment for the Construction Costs</font><font style="color:#auto;"><a name="_DV_M393"></a> and the Escrow Account shall be funded in full by Tenant prior </font><font style="color:#auto;"><a name="_DV_C94"></a>to Landlord&#8217;s issuance of a Notice to Proceed to the General Contractor</font><font style="color:#auto;"><a name="_DV_M394"></a>.</font><font style="color:#auto;"><a name="_DV_C97"></a>&nbsp;&nbsp;Failure by Tenant to deposit the Tenant Improvement Overage into the Escrow Account within five (5)</font><font style="text-decoration:none;color:#auto;"><a name="_DV_M395"></a> business</font><font style="color:#auto;"> days after a request from Landlord hereunder shall be a Tenant Delay and a default in payment hereunder.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#auto;">Tenant </font><font style="color:#000000;">shall receive all </font><font style="color:#auto;">interest </font><font style="color:#000000;">that accrues under the </font><font style="color:#auto;">Escrow Account</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M396"></a><font style="text-decoration:none;"></font><font style="text-decoration:none;color:#auto;">(b)</font><font style="text-decoration:none;color:#auto;margin-left:36pt;"></font><font style="text-decoration:none;">The </font><font style="text-decoration:none;color:#auto;">Tenant Improvement Allowance </font><font style="text-decoration:none;">and </font><font style="text-decoration:none;color:#auto;">Tenant Improvement Overage </font><font style="text-decoration:none;">shall be disbursed by </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">upon satisfaction of the following conditions precedent: </font><font style="text-decoration:none;color:#auto;">(i) Landlord </font><font style="text-decoration:none;">shall have received applications for payment certified by the </font><font style="text-decoration:none;color:#auto;">Architect</font><font style="text-decoration:none;">, accompanied by evidence of the portion of the </font><font style="text-decoration:none;color:#auto;">Tenant Improvements </font><font style="text-decoration:none;">that have been completed per the </font><font style="text-decoration:none;color:#auto;">Plans</font><font style="text-decoration:none;">, invoices and paid receipts for all such work completed, and copies of executed lien waivers from those persons providing such work; and </font><font style="text-decoration:none;color:#auto;">(ii) </font><font style="text-decoration:none;">all information and documentation provided to </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">must be in form and substance reasonably approved by </font><font style="text-decoration:none;color:#auto;">Landlord</font><font style="text-decoration:none;">.&nbsp;&nbsp;Upon </font><font style="text-decoration:none;color:#auto;">Tenant</font><font style="text-decoration:none;">&#8217;s request, </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">shall provide </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">an opportunity to review such information and documentation.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M397"></a><font style="color:#auto;">(</font><font style="text-decoration:none;color:#auto;">c)</font><font style="text-decoration:none;color:#auto;margin-left:36pt;"></font><font style="text-decoration:none;color:#000000;">Provided the aforesaid conditions are met, </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">shall pay the </font><font style="text-decoration:none;color:#auto;">Construction Costs </font><font style="text-decoration:none;color:#000000;">at monthly intervals based upon design and construction billing cycles. </font>Each monthly payment of the <font style="color:#auto;">Construction Costs </font>shall be paid as follows: fifty percent (50%) of such payment shall be paid from the <font style="color:#auto;">Tenant Improvement Allowance </font>and the remaining fifty percent (50%) of such payment shall be paid from the <font style="color:#auto;">Tenant Improvement Overage </font>through the <font style="color:#auto;">Escrow Account</font>. Within thirty (30) days after the <font style="color:#auto;">Commencement Date</font>, <font style="color:#auto;">Landlord </font>shall prepare and submit to <font style="color:#auto;">Tenant </font>a final <font style="color:#auto;">statement </font>that illustrates the total cost to construct the <font style="color:#auto;">Tenant Improvements </font>and the amount paid from and remaining with respect to each of the <font style="color:#auto;">Tenant Improvement Overage </font>as held in the <font style="color:#auto;">Escrow Account</font>, and the <font style="color:#auto;">Tenant Improvement Allowance</font>.&nbsp;&nbsp;If such <font style="color:#auto;">statement </font>indicates that <font style="color:#auto;">Landlord </font>has paid less than the total amount of the <font style="color:#auto;">Tenant Improvement Allowance</font>, then <font style="color:#auto;">Landlord </font>shall pay <font style="color:#auto;">Tenant </font>an amount equal to the <font style="color:#auto;">Tenant Improvement Allowance </font>minus the total amount previously paid by <font style="color:#auto;">Landlord within ten (10) days of </font>the date of such <font style="color:#auto;">statement</font>.&nbsp;&nbsp;If such <font style="color:#auto;">statement </font>reflects that the amount deposited into <font style="color:#auto;">Escrow Account </font>by <font style="color:#auto;">Tenant </font>as the <font style="color:#auto;">Tenant Improvement Overage </font>was greater than the amount required to be paid by <font style="color:#auto;">Tenant</font>, then <font style="color:#auto;">Tenant </font>shall be entitled to a prompt refund of any such amounts.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M398"></a>(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">Unless otherwise specified in the </font>Plans<font style="color:#000000;">, materials used </font><font style="text-decoration:none;color:#000000;">for the</font><font style="color:#000000;"> </font>Tenant <font style="text-decoration:none;">Improvements</font> <font style="color:#000000;">at the </font>Building <font style="color:#000000;">shall be </font><font style="text-decoration:none;color:#000000;">good quality, new, and </font><font style="color:#000000;">customary for </font><font style="text-decoration:none;color:#000000;">the</font><font style="color:#000000;"> type of upfit </font><font style="text-decoration:none;color:#000000;">contemplated in this </font><font style="text-decoration:none;">Lease </font><font style="text-decoration:none;color:#000000;">and in facilities comparable to</font><font style="color:#000000;"> the </font>Building <font style="color:#000000;">and readily available in the market where the </font>Building <font style="color:#000000;">is located, all as reasonably determined by </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M399"></a><font style="color:#auto;">(e)</font><font style="color:#auto;margin-left:36pt;"></font>During construction of the <font style="color:#auto;">Tenant Improvements</font>, <font style="color:#auto;">Landlord </font>shall provide <font style="text-decoration:none;">weekly</font> written progress reports to <font style="color:#auto;">Tenant </font>necessary for <font style="color:#auto;">Tenant </font>to review work schedules, <font style="color:#auto;">costs</font>, expenses and construction issues regarding the construction of the <font style="text-decoration:none;color:#auto;">Tenant Improvements</font><font style="text-decoration:none;">.&nbsp;&nbsp;The parties</font> will hold periodic meetings, at mutually agreed upon times and locations, to discuss the progress of the construction of the <font style="text-decoration:none;color:#auto;">Tenant Improvements</font><font style="text-decoration:none;">. The </font><font style="text-decoration:none;color:#auto;">General Contractor</font><font style="color:#auto;"> </font>will provide an updated <font style="color:#auto;">Budget</font>, <font style="color:#auto;">Schedule</font>, and RFI log every two weeks during construction of the <font style="color:#auto;">Tenant Improvements</font>.&nbsp;&nbsp;The <font style="color:#auto;">General Contractor </font>and <font style="color:#auto;">Landlord </font>reserve the right to cure self imposed delays in the <font style="color:#auto;">Schedule</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M400"></a><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="text-decoration:none;"></font><font style="text-decoration:none;color:#auto;">(f)</font><font style="text-decoration:none;color:#auto;margin-left:36pt;"></font><font style="text-decoration:none;">Should a default or event of default occur by </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;">hereunder prior to the </font><font style="text-decoration:none;color:#auto;">Commencement Date</font><font style="text-decoration:none;">, </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;">shall have the right to cease all construction of the </font><font style="text-decoration:none;color:#auto;">Tenant Improvements</font><font style="text-decoration:none;">, and pursue all of its rights and remedies hereunder, or available at law or in equity for any such default or event of default.</font><font style="text-decoration:none;margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M401"></a><font style="text-decoration:none;"></font>&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M402"></a>2.<font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Space Planning, Design and Working Drawings. </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall engage Integrated Design (the &#8220;</font><font style="text-decoration:none;">Architect</font><font style="text-decoration:none;color:#000000;">&#8221;) to prepare the </font><font style="text-decoration:none;">Plans</font><font style="text-decoration:none;color:#000000;">. After execution of this </font><font style="text-decoration:none;">Lease</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">may seek reimbursement from the </font><font style="text-decoration:none;">Tenant Improvement Allowance </font><font style="text-decoration:none;color:#000000;">for fees paid to the </font><font style="text-decoration:none;">Architect</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;The </font><font style="text-decoration:none;">Architect</font><font style="text-decoration:none;color:#000000;">&#8217;s fees shall be paid from the </font><font style="text-decoration:none;">Tenant Improvement Allowance </font><font style="text-decoration:none;color:#000000;">by </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">upon receipt and approval by </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">of invoices and lien waivers for work performed.&nbsp;&nbsp;</font><font style="text-decoration:none;">Belk Architecture or another architect with historic tax credit expertise (the &#8220;Landlord&#8217;s Architect&#8221;) shall review the Plans to insure compliance with the requirements of State and Federal law for historic tax credits and all the costs for such review shall be borne by Landlord.&nbsp;&nbsp;If the Landlord&#8217;s Architect identifies any changes that must be made to the Plans solely for the purposes of complying with requirements for historic tax credits, the costs of designing and constructing such changes shall be borne by Landlord provided there has been no material deviation from the Plans attached as Exhibit D-1.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall review and respond to any request for approval of the</font><font style="text-decoration:none;color:#000000;"> draft </font><font style="text-decoration:none;">plans </font><font style="text-decoration:none;color:#000000;">or final</font><font style="color:#000000;"> </font>Plans<font style="text-decoration:none;"> </font><font style="text-decoration:none;color:#000000;">(by U.S. Mail, facsimile, or email)</font><font style="color:#000000;"> </font>within five (5) <font style="text-decoration:none;">business </font>days <font style="color:#000000;">after a request from either the </font>Architect <font style="color:#000000;">or </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;Any modifications of the </font>Plans <font style="color:#000000;">sought by </font>Tenant <font style="color:#000000;">shall be reviewed and subject to the</font><font style="text-decoration:none;color:#000000;"> </font><font style="color:#000000;">approval of </font>Landlord <font style="color:#000000;">prior to the modification of the </font>Plans<font style="color:#000000;">.&nbsp;&nbsp;All communication by </font>Tenant <font style="color:#000000;">to </font>Landlord <font style="color:#000000;">with respect to the </font>Tenant Improvements <font style="color:#000000;">shall be in writing. </font>Tenant <font style="color:#000000;">shall designate an Authorized Representative to work with </font>Landlord <font style="color:#000000;">with respect to the </font>Tenant Improvements<font style="color:#000000;">, and </font>Landlord <font style="color:#000000;">shall not be obligated to respond to any instructions, approvals, changes, or other communications from anyone claiming to act on </font>Tenan<font style="text-decoration:none;">t</font><font style="text-decoration:none;color:#000000;">'</font><font style="color:#000000;">s behalf other than Tenant</font><font style="color:#000000;"><strike>'</strike></font><font style="text-decoration:none;color:#000000;">s</font><font style="color:#000000;"> Authorized Representative.&nbsp;&nbsp;Review and approval by </font>Landlord <font style="color:#000000;">of the </font>Plans <font style="color:#000000;">shall not be construed as any </font>statement <font style="color:#000000;">by </font>Landlord <font style="color:#000000;">as to the compliance of the </font>Plans <font style="color:#000000;">with </font>Applicable Laws<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M403"></a><a name="_DV_C99"></a><a name="_DV_M404"></a><a name="_DV_M405"></a><a name="_DV_M406"></a><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="text-decoration:none;">3.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;color:#000000;">Construction of </font><font style="text-decoration:none;">Tenant Improvements</font><font style="text-decoration:none;color:#000000;">.</font><font style="font-weight:bold;text-decoration:none;color:#000000;">&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall obtain all state and local licenses, permits and approvals (whether governmental or non&#8209;governmental) required to construct the </font><font style="text-decoration:none;">Tenant Improvements </font><font style="text-decoration:none;color:#000000;">and </font><font style="text-decoration:none;"><a name="_DV_C99"></a>for Tenant's occupancy of the Premises<a name="_DV_M404"></a>.&nbsp;&nbsp;Landlord shall provide access to the General Contractor for Construction of the Tenant Improvements and to the extent such access requires entry through space occupied by other tenants, Landlord shall provide for such access at its sole cost and expense.</font><font style="text-decoration:none;color:#000000;">&nbsp;&nbsp;The </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall engage, subject to </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s reasonable approval, a </font><font style="text-decoration:none;">general contractor </font><font style="text-decoration:none;color:#000000;">to construct the </font><font style="text-decoration:none;">Tenant Improvements </font><font style="text-decoration:none;color:#000000;">(the &#8220;</font><font style="text-decoration:none;">General Contractor</font><font style="text-decoration:none;color:#000000;">&#8221;).</font><font style="font-weight:bold;text-decoration:none;color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">The </font>General Contractor <font style="color:#000000;">shall construct and install the </font>Tenant Improvements <font style="color:#000000;">in accordance with the </font>Plans <font style="color:#000000;">which expense shall be deducted from the </font>Tenant Improvement Allowance<font style="color:#000000;">. The </font>Tenant Improvements <font style="color:#000000;">shall be delivered via </font>Associated General Contractors (AGC) Guaranteed Maximum Price Contract <font style="color:#000000;">(the </font><font style="text-decoration:none;color:#000000;">"</font>Contract<font style="text-decoration:none;color:#000000;">"</font><font style="color:#000000;">) with Liquidated Damages of $500.00 per day for each day of delay in achieving in substantial completion beyond the date specified in the </font>Contract<font style="color:#000000;">, which date shall be no later than October 1, 2010, and a payment and performance bond.&nbsp;&nbsp;</font><font style="text-decoration:none;color:#000000;">Any</font><font style="color:#000000;"> </font>Liquidated Damages <font style="color:#000000;">(less cost of collection) paid to </font><a name="_DV_M405"></a>Landlord <font style="text-decoration:none;color:#000000;">shall</font><font style="color:#000000;"> accrue to the </font><a name="_DV_M406"></a>Tenant<font style="color:#000000;">; provided, however, any paid </font>Liquidated Damages <font style="color:#000000;">for any </font>Tenant Delay <font style="color:#000000;">shall accrue to </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;The </font>General Contractor <font style="color:#000000;">shall obtain at least three (3) bids for all major trade work at the </font>Premises<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">will work with the </font>General Contractor <font style="color:#000000;">to complete the </font>Tenant Improvements <font style="color:#000000;">by the </font>Commencement Date<font style="color:#000000;">.&nbsp;&nbsp;All contracts with vendors and subcontractors for construction of the </font>Tenant Improvements <font style="color:#000000;">will be negotiated by the </font>General Contractor<font style="color:#000000;">.&nbsp;&nbsp;All work performed in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">connection with the construction of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises </font><font style="color:#000000;">shall be performed in a good and workmanlike manner, in accordance with all </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Laws </font><font style="color:#000000;">and the final approved </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;color:#000000;">If materials are not readily available, require quick ship charges, or require substitution, the </font><font style="text-decoration:none;">Tenant will be given notice and the opportunity to select alternate materials</font><font style="text-decoration:none;color:#000000;">.</font><font style="text-decoration:none;color:#000000;">&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;">shall insure that the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Architect </font><font style="color:#000000;">conducts a periodic review (a minimum of once every two weeks) of the progress of construction to ensure compliance with the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans</font><font style="color:#000000;">. </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">may from time to time request in writing changes to the </font><font style="text-decoration:none;">Plans </font><font style="text-decoration:none;color:#000000;">(a &#8220;</font><font style="text-decoration:none;">Change Order</font><font style="text-decoration:none;color:#000000;">&#8221;), subject to </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">&#8217;s consent, which shall not be unreasonably withheld.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall cause </font><font style="text-decoration:none;">Contractor </font><font style="text-decoration:none;color:#000000;">to provide an estimate of any change in the </font><font style="text-decoration:none;">Construction Cost </font><font style="text-decoration:none;color:#000000;">and/or </font><font style="text-decoration:none;">Schedule</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall have the right to elect whether or not to proceed with the </font><font style="text-decoration:none;">Change Order within five (5) business days </font><font style="text-decoration:none;color:#000000;">after receipt of such estimate. Upon such approval by </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">, or confirmation by </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">that the </font><font style="text-decoration:none;">Change Order </font><font style="text-decoration:none;color:#000000;">will not result in any change in cost and/or </font><font style="text-decoration:none;">Schedule</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall implement the </font><font style="text-decoration:none;">Change Order </font><font style="text-decoration:none;color:#000000;">as part of the </font><font style="text-decoration:none;">Tenant Improvements</font><font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M407"></a>Tenant <font style="color:#000000;">acknowledges that the following items may result in changes to the </font>Budget <font style="color:#000000;">and</font><font style="text-decoration:none;color:#000000;">/or</font><font style="color:#000000;"> </font>Schedule<font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;color:#auto;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M408"></a>(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">Municipal or other governmental inspectors require changes to the </font>Premises <font style="color:#000000;">such as code </font><font style="text-decoration:none;color:#000000;">compliance</font><font style="color:#000000;"> changes.&nbsp;&nbsp;In such event, </font>Landlord <font style="color:#000000;">will notify </font>Tenant <font style="color:#000000;">of the required changes, but the increased cost of such changes, if any, and any delay associated with such changes shall be the responsibility of </font>Tenant<font style="text-decoration:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M409"></a>(ii) <font style="margin-left:36pt;"></font><font style="text-decoration:none;">Change Orders </font><font style="text-decoration:none;color:#000000;">approved by </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">. </font><font style="color:#000000;"> Any increased </font>costs <font style="color:#000000;">and delays due to such</font><font style="text-decoration:none;color:#000000;"> approved</font><font style="color:#000000;"> </font><font style="text-decoration:none;">Change Orders</font> <font style="color:#000000;">shall be the responsibility of </font>Tenant<font style="color:#000000;">.&nbsp;&nbsp;Any delays caused by such </font><font style="text-decoration:none;color:#000000;">approved </font><font style="text-decoration:none;">Change Orders</font> <font style="color:#000000;">shall not delay the </font>Commencement Date <font style="color:#000000;">of the </font>Lease<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall not charge </font>Tenant <font style="color:#000000;">any administrative fees in respect of any </font>Change Orders<font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall </font>have five<font style="text-decoration:none;"> (5) business</font> days <font style="color:#000000;">to review and approve all </font>Change Orders <font style="color:#000000;">and any additional review time by </font>Tenant <font style="color:#000000;">shall be a </font>Tenant Delay<font style="color:#000000;">.&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M410"></a><a name="_DV_C103"></a><a name="_DV_M411"></a>(iii)<font style="margin-left:36pt;"></font><font style="color:#000000;">If materials are not readily available, require quick ship charges, or require substitution</font><a name="_DV_C103"></a>, <font style="text-decoration:none;"><a name="_DV_M411"></a>provided Landlord shall identify any such materials within ten (10) days of final approval of the Plans, </font>and in any such case, Tenant will be given notice and the opportunity to select alternate materials.<font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_DV_M412"></a><font style="color:#auto;">(</font><font style="text-decoration:none;color:#auto;">iv</font><font style="color:#auto;">)</font><font style="color:#auto;margin-left:36pt;"></font>Any <font style="color:#auto;">Tenant Delay</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M413"></a><a name="_DV_M414"></a><a name="_DV_M415"></a><a name="_DV_C105"></a><a name="_DV_C106"></a><a name="_DV_M417"></a><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>4.<font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Repairs and Corrections<a name="_DV_M414"></a>. </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall require of the </font><font style="text-decoration:none;">General Contractor </font><font style="text-decoration:none;color:#000000;">and any subcontractor constructing the </font><font style="text-decoration:none;">Tenant Improvements </font><font style="text-decoration:none;color:#000000;">no less than a one year express repair and/or replacement warranty covering such work.&nbsp;&nbsp;</font><font style="color:#000000;">All manufacturers&#8217; and builders&#8217; warranties with respect to the </font>Tenant Improvements <font style="color:#000000;"><a name="_DV_M415"></a>shall  be </font><font style="text-decoration:none;color:#000000;">assigned</font><font style="color:#000000;"> to </font>Tenant <font style="color:#000000;">to the extent </font><font style="text-decoration:none;color:#000000;">possible and </font><font style="color:#000000;">necessary to assist </font>Tenant <font style="color:#000000;">in </font><font style="text-decoration:none;color:#000000;">effecting</font><font style="color:#000000;"> any of </font>Tenant<font style="color:#000000;">&#8217;s repair obligations under the </font><a name="_DV_C105"></a>Lease <font style="color:#000000;">without recourse to </font>Landlord<font style="color:#000000;"><a name="_DV_C106"></a>.&nbsp;&nbsp;</font><font style="text-decoration:none;"><a name="_DV_M417"></a>Landlord agrees to enforce for the benefit of Tenant any warranties or guarantees issued in connection with construction of the Tenant Improvements.</font><font style="text-decoration:none;color:#000000;">&nbsp;&nbsp;</font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">shall repair or correct any defective work or materials installed by </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">or any contractor other than the </font><font style="text-decoration:none;">General Contractor </font><font style="text-decoration:none;color:#000000;">(except subcontractors engaged by the </font><font style="text-decoration:none;">General Contractor</font><font style="text-decoration:none;color:#000000;">), or any work or materials that prove defective as a result of any act or omission of </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">or any </font><font style="text-decoration:none;">Tenant Party</font><font style="text-decoration:none;color:#000000;">, provided that selection of materials by </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">is not such an act or omission, and provided further that work and materials done or installed by the </font><font style="text-decoration:none;">General Contractor </font><font style="text-decoration:none;color:#000000;">or its vendors and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;color:#000000;">subcontractors is not such an act or omission.&nbsp;&nbsp;For purposes of this Section, </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">will not be considered to be </font><font style="text-decoration:none;">Tenant</font><font style="text-decoration:none;color:#000000;">&#8217;s agent, invitee, licensee, subtenant, customer, client, or guest</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M418"></a>5.<font style="margin-left:36pt;color:#000000;"></font>Punchlist<font style="color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">shall provide </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">with written notice when </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">believes that substantial completion of the </font><font style="text-decoration:none;">Tenant Improvements </font><font style="text-decoration:none;color:#000000;">has been achieved.&nbsp;&nbsp;Promptly following delivery of such notice, Tenant&#8217;s Representative and </font><font style="text-decoration:none;">Landlord</font><font style="text-decoration:none;color:#000000;">&#8217;s Representative shall jointly inspect the </font><font style="text-decoration:none;">Tenant Improvements</font><font style="text-decoration:none;color:#000000;">, and</font><font style="color:#000000;">, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">shall mutually and reasonably prepare a </font>punchlist <font style="color:#000000;">of items remaining with respect to the </font>Tenant Improvements <font style="color:#000000;">that require repair or completion (the </font><font style="text-decoration:none;color:#000000;">&#8220;</font>Punchlist<font style="text-decoration:none;color:#000000;">&#8221;</font><font style="color:#000000;">).&nbsp;&nbsp;</font>Pursuant to its Contract with Landlord<font style="color:#000000;">, </font>General Contractor <font style="color:#000000;">shall make all repairs</font><font style="text-decoration:none;color:#000000;"> and completions</font><font style="color:#000000;"> noted on the </font>Punchlist <font style="text-decoration:none;color:#000000;">with respect to the </font><font style="text-decoration:none;">Tenant Improvements </font><font style="color:#000000;">within forty-five (45) days (extended for </font>Force Majeure <font style="color:#000000;">and any </font>Tenant Delay<font style="color:#000000;">) after receipt of the </font>Punchlist<font style="color:#000000;">, with any </font>Liquidated Damages <font style="color:#000000;">paid by the </font>General Contractor <font style="color:#000000;">for a delay in completion of the </font>Punchlist <font style="color:#000000;">accruing to the benefit of </font>Tenant<font style="text-decoration:none;color:#000000;">.&nbsp;&nbsp;</font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">acknowledges and represents that the </font><font style="text-decoration:none;">Contract </font><font style="text-decoration:none;color:#000000;">will include liquidated damages for delays in final completion (including completion of </font><font style="text-decoration:none;">Punchlist </font><font style="text-decoration:none;color:#000000;">items) in the amount of at least $150.00 per calendar day of delay in completing the </font><font style="text-decoration:none;">Punchlist </font><font style="text-decoration:none;color:#000000;">repairs beyond the time provided in this paragraph.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M421"></a>6.<font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Move-In by </font>Tenant<font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall </font>schedule <font style="color:#000000;">its move into the </font>Premises <font style="color:#000000;">with </font>Landlord <font style="color:#000000;">prior to occupying any portion of the </font>Premises<font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M422"></a><font style="text-decoration:none;">7.</font><font style="text-decoration:none;color:#000000;margin-left:36pt;"></font><font style="text-decoration:none;color:#000000;">Tenant Representative.&nbsp;&nbsp;Whenever </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">or any contractor responsible for the </font><font style="text-decoration:none;">Tenant Improvements </font><font style="text-decoration:none;color:#000000;">shall need to communicate with </font><font style="text-decoration:none;">Tenant </font><font style="text-decoration:none;color:#000000;">about the </font><font style="text-decoration:none;">Tenant Improvement </font><font style="text-decoration:none;color:#000000;">related matters, including Change Orders, </font><font style="text-decoration:none;">Landlord </font><font style="text-decoration:none;color:#000000;">or such contractor shall contact Todd Melby at todd.melby@precisionbiosciences.com or (330) 329-4015.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M423"></a>8.<font style="margin-left:36pt;color:#000000;"></font>Landlord <font style="color:#000000;">Representative.&nbsp;&nbsp;Whenever </font>Tenant <font style="color:#000000;">or any contractor responsible for the </font>Tenant Improvements <font style="color:#000000;">shall need to communicate with </font>Landlord <font style="color:#000000;">about the </font>Tenant Improvement <font style="color:#000000;">related matters, including Change Orders, </font>Tenant <font style="color:#000000;">or such contractor shall contact Steven Hess at</font><font style="text-decoration:none;color:#000000;"> </font><font style="color:#000000;"> steven.hess@scientificproperties.com, or (919) 600-3435.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M424"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000002.jpg" title="" alt="" style="width:623px;height:807px;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M426"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M427"></a><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT </font><font style="color:#000000;">D-2</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M428"></a>FINAL PLANS</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M429"></a>[TO BE ATTACHED UPON THE MUTUAL AND REASONABLE APPROVAL OF LANDLORD AND TENANT]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT E </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M430"></a><a name="_Toc202777500"></a>RULES AND REGULATIONS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M431"></a><a name="_Toc202777501"></a><font style="color:#auto;">Building </font>holidays are New Year&#8217;s Day, Martin Luther King, Jr. <font style="color:#auto;">Day</font>, <font style="color:#auto;">Memorial Day</font>, <font style="color:#auto;">Independence Day</font>, <font style="color:#auto;">Labor Day</font>, <font style="color:#auto;">Thanksgiving Day</font>, and <font style="color:#auto;">Christmas Day</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M432"></a><a name="_Toc202777502"></a>The sidewalks, <font style="color:#auto;">common areas</font>, and public portions of the <font style="color:#auto;">Building </font>and <font style="color:#auto;">Project</font>, such as entrances, passages, courts, elevators, vestibules, stairways, corridors or halls, and the streets, alleys or ways surrounding or in the vicinity of the <font style="color:#auto;">Building </font>or <font style="color:#auto;">Project </font>will not be obstructed by <font style="color:#auto;">Tenant</font>, even temporarily, or encumbered by <font style="color:#auto;">Tenant </font>or used for any purpose other than ingress to and egress from the <font style="color:#auto;">Premises</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M433"></a><a name="_Toc202777503"></a>No awnings or other projections will be attached to the outside walls of the <font style="color:#auto;">Building</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M434"></a><a name="_Toc202777504"></a>No sign, advertisement, notice or other lettering will be exhibited, inscribed, painted or affixed by <font style="color:#auto;">Tenant </font>on any part of the outside of the <font style="color:#auto;">Premises </font>or <font style="color:#auto;">Building </font>unless approved by <font style="color:#auto;">Landlord</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">(in accordance with the </font><font style="text-decoration:none;color:#auto;">Lease</font><font style="text-decoration:none;color:#000000;">)</font>.&nbsp;&nbsp;Signs on entrance doors will, at <font style="color:#auto;">Tenant</font>&#8217;s expense, be inscribed, painted or affixed for each <font style="color:#auto;">tenant </font>by sign makers <font style="text-decoration:none;color:#000000;">reasonably </font>approved by <font style="color:#auto;">Landlord</font>.&nbsp;&nbsp;In the event of the violation of the foregoing by <font style="color:#auto;">Tenant</font>, <font style="color:#auto;">Landlord </font>may remove same without notice to <font style="color:#auto;">Tenant </font>or any liability therefore, and may charge the expense incurred by such removal to <font style="color:#auto;">Tenant</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M435"></a><a name="_Toc202777505"></a>The sashes, sash doors, skylights, windows, heating, ventilating and air conditioning vents and doors that reflect or admit light and air into the halls, passageways or other public places in the <font style="color:#auto;">Building </font>will not be covered or obstructed by <font style="color:#auto;">Tenant</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M436"></a><a name="_Toc202777506"></a>No show cases or other articles will be put in front of or affixed to any part of the exterior of the <font style="color:#auto;">Building</font>, nor placed in the public halls, corridors, or vestibules without the prior written consent of <font style="color:#auto;">Landlord</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M437"></a><a name="_Toc202777507"></a>The bathrooms and plumbing fixtures will not be used for any purposes other than those for which they were designed, and no sweepings, rubbish, rags, or other substances will be thrown therein.&nbsp;&nbsp;All damages resulting from any misuse of the bathrooms or fixtures will be the responsibility of <font style="color:#auto;">Tenant</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M438"></a><a name="_Toc202777508"></a><font style="color:#auto;">Tenant </font>will not in any way deface any part of the <font style="color:#auto;">Premises </font>or the <font style="color:#auto;">Building</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M439"></a><a name="_Toc202777509"></a><a name="_DV_M440"></a><a name="_DV_M441"></a><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><a name="_DV_M440"></a>No vehicles or animals of any kind, except <a name="_DV_M441"></a>leashed animals, and animals assisting disabled persons or used for laboratory purposes, will be brought into or kept in or about the <font style="color:#auto;">Premises </font>or in the <font style="color:#auto;">Building</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">except that vehicles may be parked and stored in designated areas; provided, however, only animals assisting disabled persons shall be allowed in areas of the </font><font style="text-decoration:none;color:#auto;">Building </font><font style="text-decoration:none;color:#000000;">other than the </font><font style="text-decoration:none;color:#auto;">Premises</font><font style="text-decoration:none;color:#000000;">, </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">shall have no liability to </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">or any </font><font style="text-decoration:none;color:#auto;">Tenant Party </font><font style="text-decoration:none;color:#000000;">with respect to the presence of animals at the </font><font style="text-decoration:none;color:#auto;">Project </font><font style="text-decoration:none;color:#000000;">as permitted by </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">or any </font><font style="text-decoration:none;color:#auto;">Tenant Party</font><font style="text-decoration:none;color:#000000;">, and </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">shall indemnify, defend and hold harmless </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">of, from and against all loss, liability cost, or expense incurred by </font><font style="text-decoration:none;color:#auto;">Landlord </font><font style="text-decoration:none;color:#000000;">or any </font><font style="text-decoration:none;color:#auto;">Landlord Party </font><font style="text-decoration:none;color:#000000;">due to the presence of animals at the </font><font style="text-decoration:none;color:#auto;">Project </font><font style="text-decoration:none;color:#000000;">as permitted by </font><font style="text-decoration:none;color:#auto;">Tenant </font><font style="text-decoration:none;color:#000000;">or a </font><font style="text-decoration:none;color:#auto;">Tenant Party</font><font style="text-decoration:none;color:#000000;">. </font> No cooking will be done or permitted by <font style="color:#auto;">Tenant </font>on the <font style="color:#auto;">Premises </font>except in conformity with all <font style="color:#auto;">Applicable Laws </font>and then </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">only in the area designated as a kitchen, if any, on the </font><font style="color:#auto;">Premises </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which is to be primarily used by </font><font style="color:#auto;">Tenant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">'s employees for preparing their food and beverages while within the </font><font style="color:#auto;">Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will not cause or permit any unusual or objectionable odors to be produced upon or permeate from the </font><font style="color:#auto;">Premises</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><strike Style="text-decoration:none;">10.</strike></font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M442"></a><strike Style="text-decoration:none;"></strike><strike Style="text-decoration:none;">All desks will be serviced by chairs with rollers that are equipped with floor mats underneath each chair in carpeted areas.</strike></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M443"></a><a name="_Toc202777511"></a>No space in the <font style="color:#auto;">Building </font>will be used for the sale of merchandise, goods, or property of any kind at auction except in the ordinary course of business of <font style="color:#auto;">Tenant</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M444"></a><a name="_Toc202777512"></a><font style="color:#auto;">Tenant </font>will not make, or permit to be made, any unseemly or disturbing noises or <font style="text-decoration:none;color:#000000;">unreasonably </font>disturb or interfere with occupants of the <font style="color:#auto;">Building </font>or neighboring buildings or <font style="color:#auto;">premises </font>or those having business with them, whether by the use of any musical instrument, radio, talking machine, unmusical noise, whistling, singing, or in any other way. <font style="color:#auto;">Tenant </font>will not throw anything out of the doors, windows or skylights or down the passageways.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M445"></a><a name="_Toc202777513"></a><font style="text-decoration:none;color:#000000;">Except in accordance with the </font><font style="text-decoration:none;color:#auto;">Lease</font><font style="text-decoration:none;color:#000000;">, neither</font> <font style="color:#auto;">Tenant</font>, nor any <font style="color:#auto;">Tenant Party </font>will at any time bring or keep upon the <font style="color:#auto;">Premises </font>any inflammable, combustible or explosive fluid, or chemical substance, other than reasonable amounts of cleaning fluids or solvents required in the normal operation of <font style="color:#auto;">Tenant</font>&#8217;s business offices<font style="text-decoration:none;color:#000000;"> and reasonable amounts of butane or similar &#8220;cigarette&#8221; lighters</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M446"></a><a name="_Toc202777514"></a>No additional locks or bolts of any kind will be placed upon any of the doors, walls, access-ways, or windows by <font style="color:#auto;">Tenant</font>, nor will any changes be made in existing locks or the mechanism thereof, without the prior written approval of <font style="color:#auto;">Landlord </font>and unless and until a duplicate key or access card, as applicable, is delivered to <font style="color:#auto;">Landlord</font>.&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>will, upon the termination of its tenancy <font style="color:#auto;">(i) </font>return to <font style="color:#auto;">Landlord </font>all keys for the <font style="color:#auto;">Premises </font>and for any area of the <font style="color:#auto;">Building</font>, or <font style="color:#auto;">common areas</font>, either furnished to, or otherwise procured by <font style="color:#auto;">Tenant</font>, <font style="color:#auto;">(ii) </font>restore the locks, walls, access-ways, windows, and doors to their original condition on the date of this <font style="color:#auto;">Lease </font>by removing any security measures installed by <font style="color:#auto;">Tenant</font>, repairing any damage to the <font style="color:#auto;">Premises </font>or to the <font style="color:#auto;">Building </font>as a result of the restoration and removal, and <font style="color:#auto;">(iii) </font>in the event of the loss of any keys furnished to <font style="color:#auto;">Tenant </font>by <font style="color:#auto;">Landlord</font>, <font style="color:#auto;">Tenant </font>will pay to <font style="color:#auto;">Landlord </font>the cost thereof.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M447"></a><a name="_Toc202777515"></a><a name="_DV_M448"></a><font style="color:#auto;">Tenant </font><a name="_DV_M448"></a>will not overload any floor.<font style="text-decoration:none;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M449"></a><a name="_Toc202777516"></a><font style="color:#auto;">Tenant </font>will not occupy or permit any portion of the <font style="color:#auto;">Premises </font>to be used for the possession, storage, manufacture or sale of liquor, narcotics, or tobacco in any form.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M450"></a><a name="_Toc202777517"></a><font style="color:#auto;">Tenant </font>will be responsible for all persons for whom it issues passes and/or keys and will be liable to <font style="color:#auto;">Landlord </font>for all acts of such persons.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M451"></a><a name="_Toc202777518"></a>The <font style="color:#auto;">Premises </font>will not be used for lodging or sleeping.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M452"></a><a name="_Toc202777519"></a>The requirements of <font style="color:#auto;">Tenant </font>will be attended to only by <font style="color:#auto;">Landlord </font>or the property manager of the <font style="color:#auto;">Premises</font>.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M453"></a><a name="_Toc202777520"></a><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canvassing, soliciting, and peddling in the </font><font style="color:#auto;">Building </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are prohibited and </font><font style="color:#auto;">Tenant </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will cooperate to prevent the same.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M454"></a><a name="_Toc202777521"></a>All paneling, and other wood products not considered furniture will be of fire retardant materials.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M455"></a><a name="_Toc202777522"></a><a name="_DV_M456"></a>No smoking is permitted in the <font style="color:#auto;">Premises</font>, in the <font style="color:#auto;">Building</font>, on the <font style="color:#auto;">Project </font>or on the <font style="color:#auto;">Land</font><a name="_DV_M456"></a>.&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M457"></a><a name="_Toc202777523"></a>No weapons concealed or visible are permitted in the <font style="color:#auto;">Premises</font>, in the <font style="color:#auto;">Building</font>, or on the <font style="color:#auto;">Land</font>.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_DV_M458"></a><a name="_Toc202777524"></a>In the event the <font style="color:#auto;">Premises </font>constitute an outdoor patio, exterior <font style="color:#auto;">generator </font>area, or any open area adjacent to the <font style="color:#auto;">Premises </font>or on the <font style="color:#auto;">Land </font>designated under the <font style="color:#auto;">Lease </font>for the exclusive use of <font style="color:#auto;">Tenant</font>, <font style="color:#auto;">Tenant </font>will use furniture and other equipment in any such areas in form, coloring, substance, design and quality subject to the prior approval of <font style="color:#auto;">Landlord</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">(not to be unreasonably withheld, or delayed)</font>.&nbsp;&nbsp;In addition, any outdoor patio, exterior <font style="color:#auto;">generator </font>area, or other open area must be screened on all sides using materials in form, substance, coloring, design, and quality are subject to the prior approval of <font style="color:#auto;">Landlord</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">(not to be unreasonably withheld, or delayed)</font>, and must be designed and constructed in accordance with <font style="color:#auto;">plans </font>and specifications that are subject to the prior approval of <font style="color:#auto;">Landlord</font><font style="text-decoration:none;color:#auto;"> </font><font style="text-decoration:none;color:#000000;">(not to be unreasonably withheld, or delayed)</font>.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M459"></a>Whenever the above rules conflict with any of the rights or obligations of <font style="color:#auto;">Tenant </font>pursuant to the provisions of the <font style="color:#auto;">Lease</font>, the provisions of the <font style="color:#auto;">Lease </font>will govern. <font style="color:#auto;">Landlord </font>will not be responsible to <font style="color:#auto;">Tenant </font>or liable for the non-observance or violation of any of these Rules and Regulations by any other <font style="color:#auto;">tenant</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M460"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M461"></a><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#auto;">EXHIBIT </font><font style="font-weight:bold;">F</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M462"></a>TENANT SECURITY PROCEDURES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_DV_M463"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:0%;letter-spacing:-0.35pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences Security Protocol:</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:0%;letter-spacing:-0.35pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guests:</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:0%;letter-spacing:-0.35pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Invited<font style="letter-spacing:-0.3pt;"> guests are welcome at Precision BioSciences. All guests must sign into the guest log at the front desk when entering the premises. They will receive a visitor pass from the Executive Assistant which is to be displayed at all times while in the premises.</font></p>
<p style="text-align:justify;margin-top:1pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.35pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During their visit, guests must be escorted at all times. While in lab areas, all guests must wear lab coats and safety glasses. Photographs or videos are not allowed unless permission has been granted by an employee. Cell phone use is to be restricted to areas outside of the laboratories and preferably in an office or the conference room.</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:0pt;line-height:13pt;text-indent:0%;letter-spacing:-0.3pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon exit, guests must sign out and return the visitor pass.<font style="color:#0000FF;"> </font></p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:1pt;margin-top:1pt;line-height:13pt;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT </font><font style="color:#000000;">G</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M464"></a>LIST OF HAZARDOUS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MATERIALS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000003.jpg" title="" alt="" style="width:557px;height:582px;"></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIRST </font><font style="color:#000000;">AMENDMENT TO THE LEASE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS FIRST AMENDMENT TO LEASE AGREEMENT (the &#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;) is made and entered into as of the 19<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of August, 2011 by and between VENABLE TENANT, LLC, a North Carolina limited liability company (the &#8220;<font style="text-decoration:underline;">Landlord</font>&#8221;), and PRECISION BIOSCIENCES, INC., a Delaware Corporation (the &#8220;<font style="text-decoration:underline;">Tenant</font>&#8221;). </p>
<p style="text-align:center;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESSETH:</p>
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, pursuant to that certain Lease Agreement dated April 5, 2010 by and between Landlord and Tenant (the &#8220;<font style="text-decoration:underline;">Lease</font>&#8221;), Tenant leased certain premises located in the Dibrell A Warehouse Building at 302 East Pettigrew Street, Durham, North Carolina (the &#8220;Building&#8221;) and consisting of approximately 8,274 rentable square feet, as more particularly described in the Lease (the &#8220;<font style="text-decoration:underline;">Premises</font>&#8221;); and</p>
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the parties desire to modify the Lease as provided herein.</p>
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of cash in hand paid and the promises and the provisions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant hereby agree to amend and modify the Lease as follows:</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Roof Access.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Tenant has requested and Landlord has agreed that Tenant, its agents, employees, and independent contractors (all of the foregoing, together with Tenant shall be referred to herein collectively, as the &#8220;Tenant Parties&#8221; or each as a &#8220;Tenant Party&#8221;) may have access to the roof of the Building (the &#8220;Roof&#8221;) provided that Tenant complies with the following terms and conditions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Tenant shall maintain insurance against loss or damage to person (including death) or property due to any act or omission of any Tenant Party in connection with the access of the Roof and conduct of work thereon;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>The sole purpose for access by a Tenant Party to the Roof is the repair, maintenance and replacement of HVAC units, and/or generators owned by Tenant and located on the Roof;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>To the extent caused by a Tenant Party&#8217;s access to the Roof or conduct of work thereon, Tenant shall promptly repair any damage to the Roof, or any property of Landlord or of any other tenant of the Building located thereon caused by Tenant Party. Landlord reserves the right to make said repairs, at the sole expense of the Tenant, if Tenant repairs do not occur in a timely fashion or in the event other Tenants of the building are negatively impacted as a result of the repair timing and Tenant shall remit payment to the Landlord of its actual and reasonable costs incurred in effecting any such repairs within ten business days after demand made by Landlord and documentation of Landlord&#8217;s costs provided to Tenant therefore;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord shall have the right to limit access by Tenant to the Roof in the event of an emergency or other circumstance that requires such limitation;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>No act or omission by a Tenant Party shall result in penetration of the membrane of the Roof; and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font>Tenant shall comply with all Applicable Laws (as defined in the Lease) in connection with its access to the Roof and conduct of work thereon.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Notwithstanding any provision of this Amendment to the contrary, if any Tenant Party shall fail to comply with the terms and conditions stated herein, Landlord may terminate the right of Tenant to access the Roof upon ten (10) days prior written notice to Tenant specifying the reason for such termination.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Tenant acknowledges on behalf of each Tenant Party that there are no walls, railings, barriers, or other structures on the edges of the Roof (defined as the &#8220;Roof Condition&#8221;), and understands the potential danger and risk associated with its entry thereon, and Tenant acknowledges that Tenant is not aware of any obligation Landlord has to modify the Roof Condition existing as of this date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Landlord shall not be liable and Tenant hereby remises, releases and forever discharges Landlord, and its owners, directors, members, shareholders, members, managers, affiliates, partners, officers, insurers, agents (including, but not limited to, the property manager of Landlord, Scientific Properties, LLC), accountants, employees, attorneys, and assigns of and from any and all claims resulting from a Tenant Party&#8217;s breach of the terms of this Amendment.&nbsp;&nbsp;Tenant shall indemnify, defend and hold Landlord harmless from and against any and all loss, liability, damages (including, but not limited to personal injury, death, or property damage), costs, expenses, and attorneys&#8217; fees incurred by Landlord arising from (i) any breach by a Tenant Party of this Amendment; or (ii) any entry by a Tenant Party upon the Roof, unless any such loss, liability, damages (including, but not limited to, personal injury, death or property damage) is due to a breach by Landlord of this Amendment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Acknowledgement.</font>&nbsp;&nbsp;Landlord acknowledges and agrees that nothing in this Amendment shall limit Landlord&#8217;s obligation to maintain and repair the Roof and the Building pursuant to Sections 7 and 10 of the Lease for any maintenance and/or repairs not resulting from damage by a Tenant Party.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability.</font>&nbsp;&nbsp;In the event any term, covenant or condition of this Amendment, the Lease, or any amendments thereto shall to any extent be invalid or unenforceable, the remainder shall not be affected thereby and each term, covenant or condition shall be valid and enforceable to the full extent permitted by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Successors and Assigns.</font>&nbsp;&nbsp;This Amendment shall apply to, inure to the benefit of, and be binding upon the parties hereto and upon their respective heirs, legal representatives, successors and permitted assigns, except as otherwise provided herein.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Authority of Parties.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Each party hereto hereby certifies that it is authorized to enter into this Amendment, and that those persons signing below on its behalf are authorized to do so.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Full Force and Effect.</font>&nbsp;&nbsp;Except as modified hereby, the Lease is hereby reaffirmed, unmodified and in full force and effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law.</font>&nbsp;&nbsp;This Amendment shall be governed by and construed in accordance with the laws of the State of North Carolina.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Mutual Acknowledgment of Non-Existence of Claims.</font>&nbsp;&nbsp;Except as provided herein, Landlord and Tenant acknowledge and agree that as of the day hereof there are no known claims by either party against the other party hereto arising from the relationship as Landlord and Tenant, respectively, pursuant to the Lease, as amended.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;;font-weight:normal;font-style:normal;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">[SIGNATURE PAGE FOLLOWS]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have hereunto executed this Amendment as of the day and year first above written.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="7" valign="top"  style="width:50.5%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  style="width:50.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  style="width:50.5%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VENABLE TENANT, LLC</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  style="width:50.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="7" valign="top"  style="width:50.5%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: SCIENTIFIC PROPERTIES, LLC</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.78%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:34.38%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:3.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="3" valign="top"  style="width:42.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;/s/ Barbra B. Rothschild</p></td>
<td valign="top"  style="width:4.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barbra B. Rothschild, Manager</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:46.16%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:4.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:3.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="4" valign="top"  style="width:42.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;/s/ Todd Melby</p></td>
<td valign="top"  style="width:4.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:12.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:</p></td>
<td valign="top"  style="width:33.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Todd Melby</p></td>
<td valign="top"  style="width:4.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td colspan="5" valign="top"  style="width:42.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;CFO/COO</p></td>
<td valign="top"  style="width:4.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECOND </font><font style="color:#000000;">AMENDMENT TO THE LEASE AGREEMENT</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">THIS </font>SECOND <font style="color:#auto;">AMENDMENT </font>TO THE LEASE AGREEMENT (the "<font style="text-decoration:underline;color:#auto;">Amendment</font>") is made and entered into as of July 13, 2015 <font style="color:#auto;">by and between VENABLE TENANT, LLC, a North Carolina limited liability company </font>(the "<font style="text-decoration:underline;color:#auto;">Landlord</font><font style="color:#auto;">"), and PRECISION BIOSCIENCES, INC., a Delaware corporation </font>(the "<font style="text-decoration:underline;color:#auto;">Tenant</font>").</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESSETH<font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">WHEREAS</font>, pursuant to that certain <font style="color:#auto;">Lease Agreement </font>dated April 5, 2010, as amended by that certain <font style="color:#auto;">First Amendment to Lease Agreement </font>dated August 19, 2011, by and between <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant</font>, <font style="color:#auto;">Tenant </font>leased certain <font style="color:#auto;">premises </font>known as Suite 100 in the <font style="color:#auto;">Dibrell A Building </font>at 302 East Pettigrew Street, Durham, NC (the <font style="color:#auto;">Lease Agreement </font>and all amendments thereto shall be referred to herein collectively as the "<font style="text-decoration:underline;color:#auto;">Lease</font>"); and</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">WHEREAS</font>, <font style="color:#auto;">Tenant </font>has requested and <font style="color:#auto;">Landlord </font>has agreed to modify the <font style="color:#auto;">Lease </font>as provided herein.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">NOW</font>, THEREFORE, in consideration of cash in hand paid and the promises and the provisions <font style="color:#auto;">contained herein, and for other good and valuable consideration, the receipt and sufficiency of which </font>is hereby acknowledged, <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant </font>hereby agree as follows:</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Definition of </font><font style="text-decoration:underline;">Terms</font><font style="color:#000000;">.&nbsp;&nbsp;All capitalized terms contained herein and not otherwise defined shall be defined as provided in the </font>Lease<font style="color:#000000;">.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Term</font><font style="color:#000000;">.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">The </font>term <font style="color:#000000;">of the </font>Lease <font style="color:#000000;">currently expires on February 28, 2016.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">has agreed to extend the </font>term <font style="color:#000000;">of the </font>Lease <font style="color:#000000;">for a period of sixty-five (65) months (the "</font><font style="text-decoration:underline;">Extended Term</font><font style="color:#000000;">") for a revised </font>Termination Date <font style="color:#000000;">of July 31, 2021.&nbsp;&nbsp;</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">During the </font>Extended Term<font style="color:#000000;">, the </font>Premises <font style="color:#000000;">shall be leased by </font>Tenant <font style="color:#000000;">"as is" except as expressly provided herein, and subject to </font>Landlord<font style="color:#000000;">&#8217;s continuing </font>Lease <font style="color:#000000;">obligations (such as repair and </font>maintenance<font style="color:#000000;">).</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Premises</font><font style="color:#000000;">.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Tenant <font style="color:#000000;">has requested and </font>Landlord <font style="color:#000000;">has agreed to an expansion of the </font>Premises <font style="color:#000000;">(collectively, the "</font><font style="text-decoration:underline;">Expansion Space</font><font style="color:#000000;">") to include the addition of </font>(i) <font style="color:#000000;">approximately 8,427 rentable square feet on the second floor of the </font>Building <font style="color:#000000;">known as Suite 200, and </font>(ii) <font style="color:#000000;">approximately 2,863 rentable square feet known as Suite 30 in the </font>building <font style="color:#000000;">known as the </font>Receiving Room<font style="color:#000000;">.&nbsp;&nbsp;A floor plan of the </font>Expansion Space is attached hereto and made a part hereof as <font style="text-decoration:underline;">Exhibit A</font>.</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a>(b)<font style="margin-left:36pt;"></font><font style="color:#000000;">The term of the Lease for the Expansion Space shall commence upon the date that the Expansion Space is substantially complete (as evidenced by a certificate of occupancy issued by the City of Durham and certification of substantial completion by the Architect), which it is estimated shall occur on September 1, 2015 (the "</font><font style="text-decoration:underline;color:#000000;">Expansion Commencement Date</font><font style="color:#000000;">"), and shall terminate on the revised Termination Date. On the Expansion Commencement Date, the term "Premises" under the Lease shall include the Expansion Premises, and the term "Building" shall be deemed to include the Receiving Room Building. Notwithstanding the foregoing, upon Tenant's </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">request and within a reasonable timeframe thereafter, Landlord shall advise Tenant if a portion of the Expansion Space (the "</font><font style="text-decoration:underline;color:#000000;">Early Portion</font><font style="color:#000000;">") may be occupied by Tenant before the entirety of the Expansion Space is completed and Tenant shall advise Landlord if it desires to occupy the Early Portion. Early occupancy of the Early Portion shall not trigger the Expansion Commencement Date or the Expansion Rent Abatement (as defined herein) and for such occupancy, Tenant shall pay an equitable portion of the Base Rent based upon the then current rate for the Premises, and any other charges for the Early Portion (including increased charges for Operating Expenses based upon the increased Tenant's</font><font style="color:#000000;"> </font><font style="color:#000000;">Proportionate Share), with Landlord and Tenant negotiating reasonably and in good faith to determine such charges based on the square footage of the Early Portion and the number of days Tenant occupies the Early Portion for the conduct of its business prior to the actual Expansion Commencement Date at which time, Tenant shall pay the Base Rent set forth in the Landlo</font><font style="color:#000000;">rd's Notice (as defined herein)</font><font style="color:#000000;">.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="color:#000000;">Effective upon the </font>Expansion Commencement Date<font style="color:#000000;">, </font>Tenant<font style="color:#000000;">'s </font>Proportionate Share <font style="color:#000000;">of the </font>Dibrell A Warehouse Building <font style="color:#000000;">shall be 32.32431 percent, </font>Tenant<font style="color:#000000;">&#8217;s </font>Proportionate Share <font style="color:#000000;">of the </font>Receiving Room <font style="color:#000000;">/ </font>Prizery Building <font style="color:#000000;">shall be 8.41119 percent, and </font>Tenant<font style="color:#000000;">&#8217;s </font>Proportionate Share <font style="color:#000000;">of the </font>Project <font style="color:#000000;">shall be 22.82741 percent.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Upfit of </font><font style="text-decoration:underline;">Expansion Space</font><font style="color:#000000;">. </font>Landlord <font style="color:#000000;">shall provide an allowance to </font>Tenant <font style="color:#000000;">for its use in the upfit of the </font>Expansion Space <font style="color:#000000;">in an amount of up to $250,000 (the "</font><font style="text-decoration:underline;">Upfit Allowance</font><font style="color:#000000;">").&nbsp;&nbsp;The </font>Upfit Allowance <font style="color:#000000;">may be used by </font>Tenant <font style="color:#000000;">for permitting, construction, architectural and engineering </font>costs<font style="color:#000000;">, including, </font>costs <font style="color:#000000;">for cable and information technology. The manner in which </font>Upfit Allowance <font style="color:#000000;">is to be provided and details of construction of the upfit for the </font>Expansion Space <font style="color:#000000;">shall proceed per the terms of the </font>Work Letter attached hereto and made a part hereof as <font style="text-decoration:underline;">Exhibit B</font>.</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base </font><font style="text-decoration:underline;">Rent</font><font style="color:#000000;">.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="color:#000000;">Commencing upon the </font>Expansion Commencement Date<font style="color:#000000;">, Base Rent shall be due and payable for the portion of the </font>Premises <font style="color:#000000;">located in the </font>(i) <font style="color:#000000;">Dibrell </font>Building <font style="color:#000000;">of approximately 16,539 rentable square feet (</font>Suites A-100 <font style="color:#000000;">and A-200) at the rate of $18.50 per rentable square feet, triple-net, with a </font>Base Annual Rent Escalation <font style="color:#000000;">of 2.75 percent each </font>Lease Year<font style="color:#000000;">, and </font>(ii) <font style="color:#000000;">Receiving Room Building (Suite RR-30) of approximately 2,863 rentable square feet at the rate of $21.25 per rentable square feet, full service, with a </font>Base Annual Rent Escalation <font style="color:#000000;">of 2.75 percent each </font>Lease Year<font style="color:#000000;">.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Provided there is no event of default <font style="color:#000000;">under the </font>Lease <font style="color:#000000;">then in effect, commencing with the </font>Expansion Commencement Date<font style="color:#000000;">, Base Rent under the </font>Lease <font style="color:#000000;">shall be abated for a period of five months (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Expansion Rent Abatement</font><font style="color:#000000;">&#8221;).</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base Year</font><font style="color:#000000;">. The Base Year for the purposes of calculating </font>Additional Rent <font style="color:#000000;">attributable to increases in </font>Operating Expenses <font style="color:#000000;">for the Receiving Room, Suite 30 shall be 2016.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>7.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Operating Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;During the </font>Extended Term<font style="color:#000000;">, </font>Tenant <font style="color:#000000;">shall continue to pay </font>Tenant<font style="color:#000000;">'s </font>Proportionate Share <font style="color:#000000;">of </font>Operating Expenses <font style="color:#000000;">as provided in the </font>Lease<font style="color:#000000;">, and amended hereby for the portion of the </font>Expansion Space <font style="color:#000000;">located in the </font>Dibrell Building<font style="color:#000000;">.&nbsp;&nbsp;During 2015 and the Base Year of 2016, </font>Tenant <font style="color:#000000;">will not pay for </font>Operating Expenses <font style="color:#000000;">attributable to Suite RR-30, as the Base Rent for the Receiving Room space is a full-service rate with a 2016 base stop. In subsequent </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Years</font><font style="color:#000000;">, , </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">will be charged for increases in </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses </font><font style="color:#000000;">attributable to Suite RR-30 over and above the Base Year 2016.</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Direct Tenant Expenses</font><font style="color:#000000;">. </font>Tenant <font style="color:#000000;">will arrange for the provision of service and shall pay directly to each service provider all charges as follows:</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">a. Suites A-100 </font>and A-200: all electricity, gas, and other utilities; janitorial, <font style="color:#auto;">telephone and internet/data used on or from the Premises together with any taxes, penalties, surcharges, or the like pertaining thereto</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">b. </font>Suite RR-30: all <font style="color:#auto;">telephone and internet/data used on or from the Premises together with any taxes, penalties, surcharges, or the like pertaining thereto</font></p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Security Deposit</font><font style="color:#000000;">.&nbsp;&nbsp;Section 9 of the </font>Lease <font style="color:#000000;">is hereby deleted and the following new Section </font>9 <font style="color:#000000;">inserted in lieu thereof:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promptly upon the full execution of this Amendment (with delivery of a copy thereof to Tenant), Tenant shall deposit the amount required to increase the Security Deposit under the Lease to $123,269.08, four months Base Rent for the Premises on the Expansion Commencement Date.&nbsp;&nbsp;Provided there is no default or event of default by Tenant under the Lease, the Security Deposit shall be reduced to (i) three months Base Rent on the first anniversary of the Expansion Commencement Date, and (ii) one month Base Rent on the second anniversary of the Expansion Commencement Date.&nbsp;&nbsp;Landlord will not be <font style="color:#000000;">required to apply all or any portion of the </font>Security Deposit <font style="color:#000000;">with respect to any particular violation or default by </font>Tenant <font style="color:#000000;">but </font>Landlord <font style="color:#000000;">may apply all or any portion (as reasonably required to effect a cure) of the </font>Security Deposit <font style="color:#000000;">to any violation, breach, or default by </font>Tenant <font style="color:#000000;">hereunder.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">will be entitled to hold the </font>Security Deposit <font style="color:#000000;">in an account maintained by </font>Landlord <font style="color:#000000;">for such funds from all tenants of </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;Any </font>interest <font style="color:#000000;">paid on such an account will become a part of the </font>Security Deposit<font style="color:#000000;">, accrue to the benefit of the</font> Tenant (less any customary bank fees or charges for maintaining such account), and be delivered to Tenant upon termination of this Lease provided that the Security Deposit and interest thereon have not been applied by Landlord to an event of default hereunder.&nbsp;&nbsp;Tenant will reimburse Landlord for such portions of the Security Deposit as Landlord will from time to time apply with respect to any violation, breach, or default by Tenant hereunder promptly upon written notice of such application by Landlord.&nbsp;&nbsp;Any portion of the Security Deposit which has not been appropriated by Landlord in accordance with the provisions hereof will be returned to Tenant within thirty (30) days after the termination of this Lease.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Landlord conveys Landlord&#8217;s interest under this Lease, the Security Deposit, or any part thereof not previously applied, <font style="color:#000000;">shall</font> be released by Landlord to Landlord&#8217;s grantee (to the extent not applied to any default by Tenant hereunder), and if so released, Tenant agrees to look solely to such grantee for the proper application and return thereof in accordance with the Lease <font style="color:#000000;">provided that </font>Tenant <font style="color:#000000;">receives written notice of such conveyance</font>.&nbsp;&nbsp;Tenant agrees that Tenant will not assign, and that neither Landlord, nor its successors and assigns, will be bound by any such assignment, encumbrance or pledge, attempted assignment, attempted pledge, or attempted encumbrance of the Security Deposit.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any mortgagee or ground lessor will not be responsible to Tenant for the return or application of the Security Deposit, whether or not it succeeds to the position of Landlord hereunder, unless the security deposit will have been received in hand by such mortgagee or ground lessor.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any unperformed obligations of Landlord <font style="color:#000000;">or </font>Tenant under this Section will survive the termination of the Lease, for whatever reason, or any extension or renewal hereof.</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Right of Refusal</font><font style="color:#000000;">.&nbsp;&nbsp; </font>Landlord <font style="color:#000000;">hereby grants to </font>Tenant <font style="color:#000000;">a one-time right of first refusal to </font>lease <font style="color:#000000;">space in the Project (the &#8220;</font><font style="text-decoration:underline;">Refusal Space</font><font style="color:#000000;">&#8221;) under the terms and conditions as provided below:</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:6.63%;text-indent:0.1%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="color:#000000;">So long as there is no default (beyond any applicable grace and/or cure period) or event of default by </font>Tenant <font style="color:#000000;">under the </font>Lease<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">will notify </font>Tenant <font style="color:#000000;">when it has all or a portion of the </font>Refusal Space <font style="color:#000000;">offered for </font>lease <font style="color:#000000;">to a </font>third party <font style="color:#000000;">(the &#8220;</font><font style="text-decoration:underline;">Third Party</font><font style="color:#000000;">&#8221;) and the terms and conditions upon which </font>Landlord <font style="color:#000000;">is willing to </font>lease <font style="color:#000000;">such space (&#8220;</font><font style="text-decoration:underline;">Landlord&#8217;s Notice</font><font style="color:#000000;">&#8221;) .</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:6.63%;text-indent:0.1%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) Tenant <font style="color:#000000;">shall provide written notice to </font>Landlord<font style="color:#000000;">, as to </font>Tenant<font style="color:#000000;">&#8217;s decision to </font>lease <font style="color:#000000;">or not to </font>lease <font style="color:#000000;">the </font>Refusal Space within ten (10) business days after Landlord&#8217;s Notice <font style="color:#000000;">is received.&nbsp;&nbsp;If </font>Tenant <font style="color:#000000;">does provide to </font>Landlord <font style="color:#000000;">notice to </font>lease <font style="color:#000000;">the </font>Refusal Space<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">will negotiate in good faith to agree upon an </font>amendment <font style="color:#000000;">to the </font>Lease <font style="color:#000000;">to add the </font>Refusal Space within ten (10) business days after Landlord<font style="color:#000000;">&#8217;s receipt of </font>Tenant<font style="color:#000000;">&#8217;s notice of intent to </font>lease <font style="color:#000000;">on all the same terms provided to the Third-Party.&nbsp;&nbsp;If </font>Tenant <font style="color:#000000;">does not provide written notice to </font>Landlord within ten (10) business days after <font style="color:#000000;">receipt of the </font>Landlord's Notice<font style="color:#000000;">, </font>Tenant <font style="color:#000000;">will have been deemed to have waived its right to </font>lease <font style="color:#000000;">the </font>Refusal Space <font style="color:#000000;">and </font>Landlord <font style="color:#000000;">shall be free to enter into a </font>lease <font style="color:#000000;">with the </font>Third Party <font style="color:#000000;">(upon substantially the same terms and conditions listed in </font>Landlord&#8217;s Notice<font style="color:#000000;">), and </font>Tenant <font style="color:#000000;">shall have no further rights with respect to that particular </font>Refusal Space <font style="color:#000000;">within the </font>Project<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:6.63%;text-indent:0.1%;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once <font style="color:#auto;">Landlord </font>has offered a specific portion of the <font style="color:#auto;">Refusal Space </font>to <font style="color:#auto;">Tenant</font>, and <font style="color:#auto;">Tenant </font>has not leased such specific  portion under the terms and conditions provided in this Section, <font style="color:#auto;">Tenant </font>shall have no further right to such specific portion; provided, however, the balance of the Refusal Space that has not been offered to Tenant under this section<font style="color:#auto;"> </font>remains subject to <font style="color:#auto;">Tenant</font>&#8217;s <font style="color:#auto;">Right of First Refusal provided herein</font>.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:6.63%;text-indent:0.1%;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rights provided to Tenant in this Section (i) are subject to the pre-existing rights of other tenants of the Building as described on <font style="text-decoration:underline;">Exhibit C</font>, attached hereto and made a part hereof, and (ii) shall not inure to the benefit of any subtenant of all or a portion of the Premises.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Option to Extend</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall have the option to extend the </font>term <font style="color:#000000;">of the </font>Lease <font style="color:#000000;">for one period of five </font>Lease Years <font style="color:#000000;">(the "</font><font style="text-decoration:underline;">Renewal Term</font><font style="color:#000000;">") provided that </font>Tenant <font style="color:#000000;">shall give written notice to </font>Landlord <font style="color:#000000;">of its desire to exercise its right to the </font>Renewal Term <font style="color:#000000;">at least one hundred and eighty days prior to the end of the then current </font>term<font style="color:#000000;">; failing which the rights of </font>Tenant <font style="color:#000000;">under this Section shall be null and void and of no further force and effect.&nbsp;&nbsp;During the </font>Renewal Term<font style="color:#000000;">, the terms of the </font>Lease <font style="color:#000000;">shall continue in full force and effect, including, that Base Rent shall continue to increase by the </font>Base Rent Escalation<font style="color:#000000;">.&nbsp;&nbsp;During the </font>Renewal Term<font style="color:#000000;">,&nbsp;&nbsp;the </font>Premises <font style="color:#000000;">shall be leased by </font>Tenant <font style="color:#000000;">"as is,&#8221;</font><font style="color:#000000;"> subject to </font>Landlord<font style="color:#000000;">&#8217;s continuing </font>Lease <font style="color:#000000;">obligations (such as repair and </font>maintenance<font style="color:#000000;">)</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="color:#auto;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Parking</font><font style="color:#000000;">.&nbsp;&nbsp;With its </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease </font><font style="color:#000000;">of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expansion Space</font><font style="color:#000000;">, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">shall have the non-exclusive right to the use of up to </font><font style="color:#000000;">forty-five</font><font style="color:#000000;"> (</font><font style="color:#000000;">45</font><font style="color:#000000;">) </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parking </font><font style="color:#000000;">spaces at the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Keys to Premises</font>. Tenant shall be provided one key and/or fob for each of its employees (now or hereafter employed) for use at the Premises. Landlord shall have the right to charge a reasonable fee for replacement of any lost key or fob.<font style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Brokerage</font>.&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>and <font style="color:#auto;">Landlord </font>each warrants and represents to the other that it has had no dealings with <font style="color:#auto;">any real estate broker or agent </font>in connection with this <font style="color:#auto;">Lease </font>other than DTZ, the &#8220;Tenant Broker,&#8221; and <font style="color:#auto;">Landlord </font>agrees to pay a fee to the <font style="color:#auto;">Tenant Broker </font>pursuant to separate written agreement.&nbsp;&nbsp;<font style="color:#auto;">Tenant </font>and <font style="color:#auto;">Landlord </font>each covenants to pay, hold harmless, and indemnify the other from and against any and all <font style="color:#auto;">costs</font>, expenses, liabilities (including reasonable attorneys&#8217; fees), causes of action, claims or suits in connection with any compensation, commission, fee, or charges claimed by <font style="color:#auto;">any other real estate broker or agent </font>with respect to this <font style="color:#auto;">Lease </font>or the negotiation thereof, arising out of any act of said party.</p>
<p style="margin-top:10pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>. In the event any term, covenant<font style="color:#000000;"> or condition of this </font>Amendment<font style="color:#000000;">, the </font>Lease<font style="color:#000000;">, or any amendments thereto shall to any extent be invalid or unenforceable, the remainder shall not be affected thereby and each </font>term<font style="color:#000000;">, covenant or condition shall be valid and enforceable to the full extent permitted by law.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successors and </font><font style="text-decoration:underline;">Assigns</font><font style="color:#000000;">. This </font>Amendment <font style="color:#000000;">shall apply to, inure to the benefit of, and be binding upon the parties hereto and upon their respective heirs, legal representatives, successors and permitted assigns, except as otherwise provided herein.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Authority of Parties</font><font style="color:#000000;">.&nbsp;&nbsp;Each party hereto hereby certifies that it is authorized to enter into this </font>Amendment<font style="color:#000000;">, and that those persons signing below on its behalf are authorized to do so.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Full Force and Effect</font><font style="color:#000000;">. Except as modified hereby, the </font>Lease <font style="color:#000000;">remains unmodified and in full force and effect.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;This </font>Amendment <font style="color:#000000;">shall be governed by and construed in accordance with the laws of the State of </font>North Carolina<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Mutual Acknowledgment of Non-Existence of Claims</font><font style="color:#000000;">.&nbsp;&nbsp;Except as provided herein, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">acknowledge and agree that as of the day hereof there are no known claims by either party against the other party hereto arising from the relationship as </font>Landlord <font style="color:#000000;">and </font>Tenant<font style="color:#000000;">, respectively, pursuant to the </font>Lease<font style="color:#000000;">, as amended.</font><font style="margin-left:36pt;color:#000000;"></font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Effective Date</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this </font>Amendment <font style="color:#000000;">shall be effective as of the day and year first written above.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rights of </font><font style="text-decoration:underline;">Tenant</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall have no options to renew or extend the </font>term <font style="color:#000000;">of the </font>Lease<font style="color:#000000;">, rights to expand the </font>Premises <font style="color:#000000;">or rights of refusal except as expressly provided in this </font>Amendment<font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[SIGNATURE PAGE FOLLOWS]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have hereunto executed this </font><font style="color:#auto;">Amendment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of the day and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  style="width:50.42%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT<font style="color:#000000;">:</font></p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:50.42%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:49.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="3" valign="top"  style="width:39.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;/s/ Matthew Kane</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:</p></td>
<td valign="top"  style="width:31.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Matthew Kane</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:5.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td colspan="2" valign="top"  style="width:37.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;CEO</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:5.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: </p></td>
<td colspan="2" valign="top"  style="width:37.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;June 20, 2015</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD<font style="color:#000000;">:</font></p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VENABLE TENANT, LLC</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: SCIENTIFIC PROPERTIES, LLC</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="4" valign="top"  style="width:39.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;/s/ <font style="text-decoration:none;color:#auto;">Barbra Rothschild</font></p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barbra Rothschild, Manager</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:5.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td colspan="2" valign="top"  style="width:37.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;20 June, 2015</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT </font><font style="color:#000000;">A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FLOOR PLAN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Suite A-200</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000004.jpg" title="" alt="" style="width:360px;height:349px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receiving Room Suite-30</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000005.jpg" title="" alt="" style="width:367px;height:306px;"></p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WORK LETTER</p>
<div style="border-top:Solid 0.75pt #FFFFFF;padding-top:0pt;border-bottom:Solid 0.75pt #FFFFFF;padding-bottom:0pt;border-left:Solid 0.75pt #FFFFFF;padding-left:0pt;border-right:Solid 0.75pt #FFFFFF;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Exhibit B sets forth the rights and obligations of Landlord and Tenant with respect to the construction of the improvements to the Expansion Space Premises as described on the Plans (<font style="color:#000000;">"</font>Tenant Improvements<font style="color:#000000;">"</font>). This Exhibit contemplates that the following work will be performed<font style="color:#000000;">, as further described herein,</font> all subject to the prior review and approval by Landlord: (i) preparation of a space plan<font style="color:#000000;"> by the </font>Architect; (ii) final design and engineering and preparation of plans, specifications, and working drawings <font style="color:#000000;">by the </font>Architect (collectively, the <font style="color:#000000;">"</font>Plans<font style="color:#000000;">"</font>); (iii) preparation by the general contractor of Landlord (the <font style="color:#000000;">"</font>General Contractor<font style="color:#000000;">"</font>) of an estimate of the cost of the Tenant Improvements; (iv) submission to, and approval of Plans by, appropriate governmental authorities; and (v) construction and installation of the Tenant Improvements pursuant to the Plans on or prior to the Commencement Date<font style="color:#000000;">,</font> subject to Force Majeure and any Tenant Delay.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Allowance/Payment of </font><font style="text-decoration:underline;">Construction Costs</font><font style="color:#000000;">.</font></p></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="color:#auto;">(a)</font><font style="color:#auto;margin-left:36pt;">Landlord </font>and <font style="color:#auto;">Tenant </font>shall mutually-approve and select a <font style="color:#auto;">General Contractor </font>to construct the <font style="color:#auto;">Tenant Improvements </font>in accordance with a milestone <font style="color:#auto;">schedule </font>(the &#8220;<font style="color:#auto;">Schedule</font>&#8221;), a copy of which shall be reasonably approved by <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant </font>prior to commencement of construction of the <font style="color:#auto;">Tenant Improvements</font>.&nbsp;&nbsp;<font style="color:#auto;">Landlord </font>acknowledges and agrees that <font style="color:#auto;">Clancy &amp; Theys </font>is deemed approved as a potential <font style="color:#auto;">Contractor</font>, should <font style="color:#auto;">Tenant </font>so choose.&nbsp;&nbsp;<font style="color:#auto;">Landlord and Tenant shall prepare and mutually and reasonably approve a budget (the &#8220;Budget&#8221;) for the costs to construct the Tenant Improvements (the &#8220;Construction Costs&#8221;)</font>. T<font style="color:#auto;">he Budget </font>will<font style="color:#auto;"> not include any amounts for furniture, fixtures</font> (other than lighting)<font style="color:#auto;">, equipment, or personal property of Tenant, which items will be paid for by Tenant separately at its expense.&nbsp;&nbsp;The Budget shall </font>include<font style="color:#auto;"> a Construction Contingency which shall be 5% of the Construction Costs.&nbsp;&nbsp;Any unspent Construction Contingency will accrue to the Tenant.&nbsp;&nbsp;Change Orders </font>(as hereinafter defined)<font style="color:#auto;"> shall be funded from increases in the Contract (as hereinafter defined).&nbsp;&nbsp;Landlord agrees to fund a portion of the Construction Costs through the provision of the Upfit Allowance of $250,000.&nbsp;&nbsp;</font>The <font style="color:#auto;">Upfit Allowance </font>shall be used for items specifically outlined in the <font style="color:#auto;">Budget </font>and mutually agreed upon by both <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant</font>.&nbsp;&nbsp;The <font style="color:#auto;">Upfit Allowance </font>shall be used only for construction, design, and management <font style="color:#auto;">costs </font>related to fixed improvements to the <font style="color:#auto;">Building </font>that are part of the <font style="color:#auto;">Tenant Improvements</font>. <font style="color:#auto;"> The Upfit Allowance may not be used to offset any Rent payments owed to Landlord by Tenant. Any costs incurred due to a Tenant Delay shall be charged against the Upfit Allowance</font>; provided, however, <font style="color:#auto;">Tenant </font>shall be given two (2) days&#8217; notice and opportunity to cure any <font style="color:#auto;">Tenant Delay </font>(including payment by <font style="color:#auto;">Tenant </font>of any <font style="color:#auto;">costs </font>associated with such cure such as higher shipping charges) before any <font style="color:#auto;">costs </font>are charged against the <font style="color:#auto;">Upfit Allowance.&nbsp;&nbsp;Landlord and Tenant acknowledge and agree that the Construction Costs will be in excess of the Upfit Allowance, and all costs for the Tenant Improvements in excess of the Upfit Allowance shall be borne by Tenant.&nbsp;&nbsp;Therefore, Tenant has agreed to place into an escrow account maintained with Landlord (the "Escrow Account") an amount equal to the Construction Costs as specified in the Budget minus the Upfit Allowance (the &#8220;Tenant Improvement Overage&#8221;).&nbsp;&nbsp;Landlord shall establish the Escrow Account as a separate, interest bearing account in an FDIC insured institution. set forth below, Landlord shall have the authority to make periodic deductions from the Escrow Account as payment for the Construction Costs and the Escrow Account shall be funded in full by Tenant prior to Landlord&#8217;s issuance of a Notice to Proceed to the General Contractor. Failure by Tenant </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;">to deposit the Tenant Improvement Overage into the Escrow Account within five (5) business days after a request from Landlord hereunder shall be a Tenant Delay and a default in payment hereunder.&nbsp;&nbsp;Tenant shall receive all interest that acc</font><font style="color:#auto;">rues under the Escrow Account.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">(b)</font><font style="color:#auto;margin-left:36pt;"></font>The <font style="color:#auto;">Upfit Allowance </font>and <font style="color:#auto;">Tenant Improvement Overage </font>shall be disbursed by <font style="color:#auto;">Landlord </font>upon satisfaction of the following conditions precedent: <font style="color:#auto;">(i) Landlord </font>shall have received applications for payment certified by the <font style="color:#auto;">Architect</font>, accompanied by evidence of the portion of the <font style="color:#auto;">Tenant Improvements </font>that have been completed per the <font style="color:#auto;">Plans</font>, invoices and paid receipts for all such work completed, and copies of executed lien waivers from those persons providing such work; and <font style="color:#auto;">(ii) </font>all information and documentation provided to <font style="color:#auto;">Landlord </font>must be in form and substance reasonably approved by <font style="color:#auto;">Landlord</font>.&nbsp;&nbsp;Upon <font style="color:#auto;">Tenant</font>&#8217;s request, <font style="color:#auto;">Landlord </font>shall provide <font style="color:#auto;">Tenant </font>an opportunity to review such information and documentation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">(c)</font><font style="color:#auto;margin-left:36pt;"></font>Provided the aforesaid conditions are met, <font style="color:#auto;">Landlord </font>shall pay the <font style="color:#auto;">Construction Costs </font>at monthly intervals based upon design and construction billing cycles. Each monthly payment of the <font style="color:#auto;">Construction Costs </font>shall be paid as follows: fifty percent (50%) of such payment shall be paid from the <font style="color:#auto;">Upfit Allowance </font>and the remaining fifty percent (50%) of such payment shall be paid from the <font style="color:#auto;">Tenant Improvement Overage </font>through the <font style="color:#auto;">Escrow Account</font>. Within thirty (30) days after the <font style="color:#auto;">Commencement Date</font>, <font style="color:#auto;">Landlord </font>shall prepare and submit to <font style="color:#auto;">Tenant </font>a final <font style="color:#auto;">statement </font>that illustrates the total cost to construct the <font style="color:#auto;">Tenant Improvements </font>and the amount paid from and remaining with respect to each of the <font style="color:#auto;">Tenant Improvement Overage </font>as held in the <font style="color:#auto;">Escrow Account</font>, and the <font style="color:#auto;">Upfit Allowance</font>.&nbsp;&nbsp;If such <font style="color:#auto;">statement </font>indicates that <font style="color:#auto;">Landlord </font>has paid less than the total amount of the <font style="color:#auto;">Upfit Allowance</font>, then <font style="color:#auto;">Landlord </font>shall pay <font style="color:#auto;">Tenant </font>an amount equal to the <font style="color:#auto;">Upfit Allowance </font>minus the total amount previously paid by <font style="color:#auto;">Landlord within ten (10) days of </font>the date of such <font style="color:#auto;">statement</font>.&nbsp;&nbsp;If such <font style="color:#auto;">statement </font>reflects that the amount deposited into <font style="color:#auto;">Escrow Account </font>by <font style="color:#auto;">Tenant </font>as the <font style="color:#auto;">Tenant Improvement Overage </font>was greater than the amount required to be paid by <font style="color:#auto;">Tenant</font>, then <font style="color:#auto;">Tenant </font>shall be entitled to a prompt refund of any such amounts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="color:#000000;">Unless otherwise specified in the </font>Plans<font style="color:#000000;">, materials used for the </font>Tenant Improvements <font style="color:#000000;">at the </font>Building <font style="color:#000000;">shall be good quality, new, and customary for the type of upfit contemplated in this </font>Lease <font style="color:#000000;">and in facilities comparable to the </font>Building <font style="color:#000000;">and readily available in the market where the </font>Building <font style="color:#000000;">is located, all as reasonably determined by </font>Landlord<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">(e)</font><font style="color:#auto;margin-left:36pt;"></font>During construction of the <font style="color:#auto;">Tenant Improvements</font>, <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant </font>or their agents shall, on a weekly basis review work schedules, <font style="color:#auto;">costs</font>, expenses and construction issues regarding the construction of the <font style="color:#auto;">Tenant Improvements</font>.&nbsp;&nbsp;The parties will hold periodic meetings, at mutually agreed upon times and locations, to discuss the progress of the construction of the <font style="color:#auto;">Tenant Improvements</font>. The <font style="color:#auto;">General Contractor </font>will provide an updated <font style="color:#auto;">Budget</font>, <font style="color:#auto;">Schedule</font>, and RFI log every two weeks during construction of the <font style="color:#auto;">Tenant Improvements</font>.&nbsp;&nbsp;The <font style="color:#auto;">General Contractor </font>and <font style="color:#auto;">Landlord </font>reserve the right to cure self imposed delays in the <font style="color:#auto;">Schedule</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">(f)</font><font style="color:#auto;margin-left:36pt;"></font>Should a default or event of default occur by <font style="color:#auto;">Tenant </font>hereunder prior to the <font style="color:#auto;">Commencement Date</font>, <font style="color:#auto;">Landlord </font>shall have the right to cease all construction of the <font style="color:#auto;">Tenant Improvements</font>, and pursue all of its rights and remedies hereunder, or available at law or in equity for any such default or event of default.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Space Planning, Design and Working Drawings</font><font style="color:#000000;">. </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">shall engage Integrated Design (the &#8220;</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Architect</font><font style="color:#000000;">&#8221;) to prepare the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans</font><font style="color:#000000;">. </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">may include fees previously paid to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Architect </font><font style="color:#000000;">in the approved </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Budget</font><font style="color:#000000;">.&nbsp;&nbsp;Any </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Architect</font><font style="color:#000000;">&#8217;s fees reimbursed to </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">from the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfit Allowance </font><font style="color:#000000;">shall be paid from the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfit Allowance </font><font style="color:#000000;">by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">upon receipt and approval by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">of invoices and lien waivers for work performed.&nbsp;&nbsp;If the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Architect </font><font style="color:#000000;">used by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">is not qualified with respect to compliance of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans </font><font style="color:#000000;">with historic tax credit laws, statutes and regulations, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Belk Architecture </font><font style="color:#000000;">or another </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">architect </font><font style="color:#000000;">with historic tax credit expertise shall review the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans </font><font style="color:#000000;">to insure compliance with the requirements of State and Federal law for historic tax credits and all the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs </font><font style="color:#000000;">for such review shall be borne by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">. </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">shall review and respond to any request for approval of the draft </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plans </font><font style="color:#000000;">or final </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans </font><font style="color:#000000;">(by U.S. Mail, facsimile, or email) </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within five (5) business days </font><font style="color:#000000;">after a request from either the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Architect </font><font style="color:#000000;">or </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">.&nbsp;&nbsp;Any modifications of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans </font><font style="color:#000000;">sought by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">shall be reviewed and subject to the approval of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">prior to the modification of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans</font><font style="color:#000000;">.&nbsp;&nbsp;All communication by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">to </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">with respect to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements </font><font style="color:#000000;">shall be in writing. </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">shall designate an Authorized Representative to work with </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">with respect to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements</font><font style="color:#000000;">, and </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">shall not be obligated to respond to any instructions, approvals, changes, or other communications from anyone claiming to act on </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="color:#000000;">'s behalf other than Tenant</font><font style="color:#000000;"><strike>'</strike></font><font style="color:#000000;">s Authorized Representative.&nbsp;&nbsp;Review and approval by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans </font><font style="color:#000000;">shall not be construed as any </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statement </font><font style="color:#000000;">by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">as to the compliance of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plans </font><font style="color:#000000;">with </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Laws</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a>3.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Construction of </font><font style="text-decoration:underline;">Tenant Improvements</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall, via the </font>General Contractor<font style="color:#000000;">, obtain all state and local licenses, permits and approvals (whether governmental or non&#8209;governmental) required to construct the </font>Tenant Improvements <font style="color:#000000;">and for </font>Tenant<font style="color:#000000;">'s occupancy of the </font>Expansion Space<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall provide access to the </font>General Contractor <font style="color:#000000;">for Construction of the </font>Tenant Improvements <font style="color:#000000;">and to the extent such access requires entry through space occupied by other tenants, </font>Landlord <font style="color:#000000;">shall provide for such access at its sole cost and expense.&nbsp;&nbsp;The </font>Landlord <font style="color:#000000;">shall engage, subject to </font>Tenant<font style="color:#000000;">&#8217;s reasonable approval, a </font>general contractor <font style="color:#000000;">to construct the </font>Tenant Improvements <font style="color:#000000;">(the &#8220;</font>General Contractor<font style="color:#000000;">&#8221;).&nbsp;&nbsp;The </font>General Contractor <font style="color:#000000;">shall construct and install the </font>Tenant Improvements <font style="color:#000000;">in accordance with the </font>Plans <font style="color:#000000;">which expense shall be deducted from the </font>Upfit Allowance<font style="color:#000000;">. The </font>Tenant Improvements <font style="color:#000000;">shall be delivered via Associated General Contractors (AGC) Guaranteed Maximum Price Contract (the "</font>Contract<font style="color:#000000;">") with Liquidated Damages of $500.00 per day, and a payment and performance bond.&nbsp;&nbsp;Any </font>Liquidated Damages <font style="color:#000000;">(less cost of collection) paid to </font>Landlord <font style="color:#000000;">shall accrue to the </font>Tenant<font style="color:#000000;">; provided, however, any paid </font>Liquidated Damages <font style="color:#000000;">for any </font>Tenant Delay <font style="color:#000000;">shall accrue to </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;The </font>General Contractor <font style="color:#000000;">shall obtain at least three (3) bids for all major trade work at the </font>Expansion Space<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">will work with the </font>General Contractor <font style="color:#000000;">to complete the </font>Tenant Improvements <font style="color:#000000;">by the </font>Commencement Date<font style="color:#000000;">.&nbsp;&nbsp;All contracts with vendors and subcontractors for construction of the </font>Tenant Improvements <font style="color:#000000;">will be negotiated by the </font>General Contractor<font style="color:#000000;">.&nbsp;&nbsp;All work performed in connection with the construction of the </font>Expansion Space <font style="color:#000000;">shall be performed in a good and workmanlike manner, in accordance with all </font>Applicable Laws <font style="color:#000000;">and the final approved </font>Plans<font style="color:#000000;">.&nbsp;&nbsp;If materials are not readily available, require quick ship charges, or require substitution,</font><font style="border-bottom:double 2.5pt;"> </font><font style="color:#000000;">the </font>Tenant will be given notice and the opportunity to select alternate materials<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall insure that the </font>Architect <font style="color:#000000;">conducts a periodic review (a minimum of once every two weeks) of the progress of construction to ensure compliance with the </font>Plans<font style="color:#000000;">. </font>Tenant <font style="color:#000000;">may from time to time request in writing changes to the </font>Plans <font style="color:#000000;">(a &#8220;</font>Change Order<font style="color:#000000;">&#8221;), subject to </font>Landlord<font style="color:#000000;">&#8217;s consent, which shall not be unreasonably withheld.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall cause </font>Contractor <font style="color:#000000;">to provide an estimate of any change in the </font>Construction Cost <font style="color:#000000;">and/or </font>Schedule<font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">shall have the right to elect whether or not to proceed with the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change Order within five (5) business days </font><font style="color:#000000;">after receipt of such estimate. Upon such approval by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="color:#000000;">, or confirmation by </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">that the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change Order </font><font style="color:#000000;">will not result in any change in cost and/or </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule</font><font style="color:#000000;">, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">shall implement the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change Order </font><font style="color:#000000;">as part of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">acknowledges that </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">may hire the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Contractor </font><font style="color:#000000;">and/or any subcontractors to perform other work items (in accordance with the terms and conditions of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease</font><font style="color:#000000;">) within the original </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises </font><font style="color:#000000;">concurrently with the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements</font><font style="color:#000000;">, provided such work does not require changes to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant acknowledges that the following items may result in changes to the Budget and<font style="text-decoration:none;">/or</font> Schedule:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;color:#auto;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="color:#000000;">Municipal or other governmental inspectors require changes to the </font>Expansion Space <font style="color:#000000;">such as code compliance changes.&nbsp;&nbsp;In such event, </font>Landlord <font style="color:#000000;">will notify </font>Tenant <font style="color:#000000;">of the required changes, but the increased cost of such changes, if any, and any delay associated with such changes shall be the responsibility of </font>Tenant<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) <font style="margin-left:36pt;">Change Orders </font><font style="color:#000000;">approved by </font>Tenant<font style="color:#000000;">.&nbsp;&nbsp;Any increased </font>costs <font style="color:#000000;">and delays due to such approved </font>Change Orders <font style="color:#000000;">shall be the responsibility of </font>Tenant<font style="color:#000000;">.&nbsp;&nbsp;Any delays caused by such approved </font>Change Orders <font style="color:#000000;">shall not delay the </font>Commencement Date <font style="color:#000000;">of the </font>Lease<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">shall not charge </font>Tenant <font style="color:#000000;">any administrative fees in respect of any </font>Change Orders<font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall </font>have five (5) business days <font style="color:#000000;">to review and approve all </font>Change Orders <font style="color:#000000;">and any additional review time by </font>Tenant <font style="color:#000000;">shall be a </font>Tenant Delay<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="color:#000000;">If materials are not readily available, require quick ship charges, or require substitution, provided </font>Landlord <font style="color:#000000;">shall identify any such materials </font>within ten (10) days of <font style="color:#000000;">final approval of the </font>Plans<font style="color:#000000;">, and in any such case, </font>Tenant will be given notice and the opportunity to select alternate materials<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">(iv)</font><font style="color:#auto;margin-left:36pt;"></font>Any <font style="color:#auto;">Tenant Delay</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Repairs and Corrections</font><font style="color:#000000;">. </font>Landlord <font style="color:#000000;">shall require of the </font>General Contractor <font style="color:#000000;">and any subcontractor constructing the </font>Tenant Improvements <font style="color:#000000;">no less than a one year express repair and/or replacement warranty covering such work.&nbsp;&nbsp;All manufacturers&#8217; and builders&#8217; warranties with respect to the </font>Tenant Improvements <font style="color:#000000;">shall be assigned to </font>Tenant <font style="color:#000000;">to the extent possible and necessary to assist </font>Tenant <font style="color:#000000;">in effecting any of </font>Tenant<font style="color:#000000;">&#8217;s repair obligations under the </font>Lease <font style="color:#000000;">without recourse to </font>Landlord<font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">agrees to enforce for the benefit of </font>Tenant <font style="color:#000000;">any warranties or guarantees issued in connection with construction of the </font>Tenant Improvements<font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">shall repair or correct any defective work or materials installed by </font>Tenant <font style="color:#000000;">or any contractor other than the </font>General Contractor <font style="color:#000000;">(except subcontractors engaged by the </font>General Contractor<font style="color:#000000;">), or any work or materials that prove defective as a result of any act or omission of </font>Tenant <font style="color:#000000;">or any </font>Tenant Party<font style="color:#000000;">, provided that selection of materials by </font>Tenant <font style="color:#000000;">is not such an act or omission, and provided</font><font style="border-bottom:double 2.5pt;"> </font><font style="color:#000000;">further that work and materials done or installed by the </font>General Contractor <font style="color:#000000;">or its vendors and subcontractors is not such an act or omission.&nbsp;&nbsp;For purposes of this Section, </font>Landlord <font style="color:#000000;">will not be considered to be </font>Tenant<font style="color:#000000;">&#8217;s agent, invitee, licensee, subtenant, customer, client, or guest.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Punchlist</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">shall provide </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">with written notice when </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">believes that substantial completion of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements </font><font style="color:#000000;">has been achieved.&nbsp;&nbsp;Promptly following delivery of such notice, Tenant&#8217;s Representative and </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">&#8217;s Representative shall jointly inspect the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements</font><font style="color:#000000;">, and, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord </font><font style="color:#000000;">and </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="color:#000000;">shall mutually and reasonably prepare a </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">punchlist </font><font style="color:#000000;">of items remaining with respect to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements </font><font style="color:#000000;">that require repair or completion (the &#8220;</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Punchlist</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Pursuant to its </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contract </font><font style="color:#000000;">with </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</font><font style="color:#000000;">, </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Contractor </font><font style="color:#000000;">shall make all repairs and completions noted on the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Punchlist </font><font style="color:#000000;">with respect to the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements </font><font style="color:#000000;">within forty-five (45) days (extended for </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure </font><font style="color:#000000;">and any </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Delay</font><font style="color:#000000;">) after receipt of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Punchlist </font><font style="color:#000000;">with any </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liquidated Damages </font><font style="color:#000000;">paid by the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Contractor </font><font style="color:#000000;">for a delay in completion of the </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Punchlist </font><font style="color:#000000;">accruing to the benefit of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Move-In by Tenant</font>.&nbsp;&nbsp;Tenant shall schedule its move into the Expansion Space with Landlord prior to occupying any portion of the Expansion Space. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tenant Representative</font><font style="color:#000000;">.&nbsp;&nbsp;Whenever </font>Landlord <font style="color:#000000;">or any contractor responsible for the </font>Tenant Improvements <font style="color:#000000;">shall need to communicate with </font>Tenant <font style="color:#000000;">about the </font>Tenant Improvement <font style="color:#000000;">related matters, including Change Orders, </font>Landlord <font style="color:#000000;">or such contractor shall contact Todd Melby at todd.melby@precisionbiosciences.com or (330) 329-4015.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Landlord </font><font style="text-decoration:underline;color:#000000;">Representative</font><font style="color:#000000;">.&nbsp;&nbsp;Whenever </font>Tenant <font style="color:#000000;">or any contractor responsible for the </font>Tenant Improvements <font style="color:#000000;">shall need to communicate with </font>Landlord <font style="color:#000000;">about the </font>Tenant Improvement <font style="color:#000000;">related matters, including Change Orders, </font>Tenant <font style="color:#000000;">or such contractor shall contact David.Green@scientificproperties.com, or (919) 605-0804.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT C</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANTS WITH SUPERIOR RIGHTS OF REFUSAL</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Cumming Construction Management, Inc. (first floor of Prizery Building); and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Roivant Sciences, Inc. (continuous &#8220;right of offer&#8221; for contiguous space on second floor of Prizery Builidng).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIRD </font><font style="color:#000000;">AMENDMENT TO THE LEASE AGREEMENT</font></p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">THIS </font>THIRD <font style="color:#auto;">AMENDMENT </font>TO THE LEASE AGREEMENT (the "<font style="text-decoration:underline;color:#auto;">Amendment</font>") is made and entered into as of January 12, 2016 <font style="color:#auto;">by and between VENABLE TENANT, LLC, a North Carolina limited liability company </font>(the "<font style="text-decoration:underline;color:#auto;">Landlord</font><font style="color:#auto;">"), and PRECISION BIOSCIENCES, INC., a Delaware corporation </font>(the "<font style="text-decoration:underline;color:#auto;">Tenant</font>").</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESSETH<font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">WHEREAS</font>, pursuant to that certain <font style="color:#auto;">Lease Agreement </font>dated April 5, 2010 by and between <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant</font>, as amended by that certain First Amendment to Lease Agreement dated August 19, 2011, <font style="color:#auto;">Tenant </font>leased certain <font style="color:#auto;">premises </font>known as Suite 100 in the <font style="color:#auto;">Dibrell A Building </font>at 302 East Pettigrew Street, Durham, NC (the <font style="color:#auto;">Lease Agreement </font>and all amendments thereto shall be referred to herein collectively as the "<font style="text-decoration:underline;color:#auto;">Lease</font>"); and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="color:#000000;">, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">have amended the </font>Lease <font style="color:#000000;">by </font>Second Amendment to Lease Agreement <font style="color:#000000;">dated July 13, 2015 (the "</font><font style="text-decoration:underline;">Second Amendment</font><font style="color:#000000;">");</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="color:#auto;">NOW</font>, THEREFORE, in consideration of cash in hand paid and the promises and the provisions <font style="color:#auto;">contained herein, and for other good and valuable consideration, the receipt and sufficiency of which </font>is hereby acknowledged, <font style="color:#auto;">Landlord </font>and <font style="color:#auto;">Tenant </font>hereby agree as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;line-height:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Definition of </font><font style="text-decoration:underline;">Terms</font><font style="color:#000000;">.&nbsp;&nbsp;All capitalized terms contained herein and not otherwise defined shall be defined as provided in the </font>Lease<font style="color:#000000;">.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rent Abatement Payment</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">have agreed that in consideration of the payment by </font>Landlord <font style="color:#000000;">to </font>Tenant <font style="color:#000000;">of $51,023.00, </font>Tenant <font style="color:#000000;">hereby waives and releases any and all right </font>Tenant <font style="color:#000000;">may have for any further abatement of </font>Rent <font style="color:#000000;">(</font>Landlord <font style="color:#000000;">having already waived </font>Tenant<font style="color:#000000;">&#8217;s </font>Rent <font style="color:#000000;">obligation for January, 2016) as described in the </font>Second Amendment <font style="color:#000000;">with respect to the portion of their </font>Premises <font style="color:#000000;">located in </font>Suite A-100 <font style="color:#000000;">in the </font>Dibrell Building <font style="color:#000000;">at the </font>Project<font style="color:#000000;">.&nbsp;&nbsp;For purposes of clarity, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">acknowledge and agree that the </font>Expansion Commencement Date <font style="color:#000000;">(as such </font>term <font style="color:#000000;">is defined in the </font>Second Amendment<font style="color:#000000;">) shall be January 1, 2016.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Dibrell Building</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Notwithstanding any provision in the Second Amendment to the contrary, Landlord and Tenant hereby confirm and agree that the total rentable square footage leased by Tenant in the Dibrell Building is 16,701 rentable square, consisting of Suite A-100 of 8,274 rentable square feet, and Suite A-200 of 8,427 rentable square feet<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Brokerage</font><font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">and </font>Landlord <font style="color:#000000;">each warrants and represents to the other that it has had no dealings with </font>any real estate broker or agent <font style="color:#000000;">in connection with this </font>Amendment<font style="color:#000000;">.&nbsp;&nbsp;</font>Tenant <font style="color:#000000;">and </font>Landlord <font style="color:#000000;">each covenants to pay, hold harmless, and indemnify the other from and against any and all </font>costs<font style="color:#000000;">, expenses, liabilities (including reasonable attorneys&#8217; fees), causes of action, claims or suits in connection with any compensation, commission, fee, or charges claimed by </font>any real estate broker or agent <font style="color:#000000;">with respect to this </font>Amendment <font style="color:#000000;">or the negotiation thereof, arising out of any act of said party.</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a>4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>. In the event any term, covenant<font style="color:#000000;"> or condition of this </font>Amendment<font style="color:#000000;">, the </font>Lease<font style="color:#000000;">, or any amendments thereto shall to any extent be invalid or unenforceable, the remainder </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">shall not be affected thereby and each </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="color:#000000;">, covenant or condition shall be valid and enforceable to the full extent permitted by law.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successors and </font><font style="text-decoration:underline;">Assigns</font><font style="color:#000000;">. This </font>Amendment <font style="color:#000000;">shall apply to, inure to the benefit of, and be binding upon the parties hereto and upon their respective heirs, legal representatives, successors and permitted assigns, except as otherwise provided herein.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Authority of Parties</font><font style="color:#000000;">.&nbsp;&nbsp;Each party hereto hereby certifies that it is authorized to enter into this </font>Amendment<font style="color:#000000;">, and that those persons signing below on its behalf are authorized to do so.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Full Force and Effect</font><font style="color:#000000;">. Except as modified hereby, the </font>Lease <font style="color:#000000;">remains unmodified and in full force and effect.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;This </font>Amendment <font style="color:#000000;">shall be governed by and construed in accordance with the laws of the State of </font>North Carolina<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Mutual Acknowledgment of Non-Existence of Claims</font><font style="color:#000000;">.&nbsp;&nbsp;Except as provided herein, </font>Landlord <font style="color:#000000;">and </font>Tenant <font style="color:#000000;">acknowledge and agree that as of the day hereof there are no known claims by either party against the other party hereto arising from the relationship as </font>Landlord <font style="color:#000000;">and </font>Tenant<font style="color:#000000;">, respectively, pursuant to the </font>Lease<font style="color:#000000;">, as amended.</font><font style="margin-left:36pt;color:#000000;"></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Effective Date</font><font style="color:#000000;">.&nbsp;&nbsp;The provisions of this </font>Amendment <font style="color:#000000;">shall be effective as of the day and year first written above.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;line-height:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[SIGNATURE PAGE FOLLOWS]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties hereto have hereunto executed this </font><font style="color:#auto;">Amendment </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of the day and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="6" valign="top"  style="width:50.42%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT<font style="color:#000000;">:</font></p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="6" valign="top"  style="width:50.42%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:49.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="3" valign="top"  style="width:39.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;/s/ Todd Melby</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:</p></td>
<td valign="top"  style="width:31.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Todd Melby</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:5.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td colspan="2" valign="top"  style="width:37.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;CFO/COO</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:5.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: </p></td>
<td colspan="2" valign="top"  style="width:37.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;January 18, 2016</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD<font style="color:#000000;">:</font></p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VENABLE TENANT, LLC</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:11.54%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: SCIENTIFIC PROPERTIES, LLC,</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its managing member</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="4" valign="top"  style="width:39.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;/s/ Garril Kueber</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:42.96%;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Garril Kueber, Limted Manager / CEO</p></td>
<td valign="top"  style="width:7.46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:5.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td colspan="2" valign="top"  style="width:37.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;January 18, 2016</p></td>
<td valign="top"  style="width:7.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:49.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;">FOURTH AMENDMENT TO lease agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-weight:bold;">THIS FOURTH AMENDMENT TO LEASE AGREEMENT </font>(this "Amendment") is made as of the 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of September, 2016 by and between <font style="font-weight:bold;">VENABLE CENTER, LLC</font>, a North Carolina limited liability company ("Landlord"), and <font style="font-weight:bold;">PRECISION BIOSCIENCES, INC.</font>, a Delaware corporation ("Tenant"), with respect to the following recitals:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Landlord is the current owner of a group of interconnected buildings situated at 302 East Pettigrew Street, Durham, North Carolina known collectively as &#8220;Venable Center&#8221; (the &#8220;Project&#8221;), which comprises Dibrell A (&#8220;Dibrell A&#8221;), Dibrell B (&#8220;Dibrell B&#8221;), the Receiving Room (the &#8220;Receiving Room&#8221;) and the Prizery (the &#8220;Prizery&#8221;).&nbsp;&nbsp;The first and second floors of the Prizery are shown in more detail on <font style="font-weight:bold;text-decoration:underline;">Exhibit B</font> attached hereto and incorporated herein by reference.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Pursuant to that certain Lease Agreement dated April 5, 2010, as modified by a First Amendment to Lease Agreement dated August 19, 2011 and by a Second Amendment to the Lease Agreement dated July 13, 2015 (the &#8220;Second Amendment&#8221;) and by a Third Amendment to the Lease Agreement dated January 12, 2016 (collectively, the "Lease"), Landlord (as successor to Venable Tenant LLC) leases to Tenant certain office space in the Project (the "Current Premises") consisting of approximately 16,701 square feet of rentable area in Dibrell A (Suite A-100 = 8,274 RSF; Suite A-200 = 8,427 RSF, collectively referred to herein as the &#8220;Current DA Premises&#8221;) and 2,863 square feet of rentable area in the Receiving Room (referred to herein as the &#8220;Current RR Premises&#8221;), as more particularly described in the Lease;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The term of the Lease is currently scheduled to expire July 31, 2021.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Landlord and Tenant have agreed to extend the term of the Lease, to add certain space to the premises demised under the Lease, and to make certain other modifications to the Lease as set forth hereinbelow;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>All capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>The Term of the Lease is hereby extended through July 31, 2024 (the &#8220;Expiration Date&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Effective as of the respective Expansion Dates set forth below, Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the following additional premises in the Project, as outlined on Exhibit A attached hereto:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately 11,621 Rentable Square Feet (&#8220;RSF&#8221;) located in the Receiving Room (the &#8220;RR Expansion Premises&#8221;).&nbsp;&nbsp;The Expansion Date for the RR Expansion Premises shall be the 150</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> day following the date that Landlord delivers possession of the RR Expansion Premises to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order), which delivery date is anticipated to be September 15, 2016 (resulting in an anticipated Expansion Date of February 15, 2017);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>approximately 7,494 RSF located on the 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> floor of the Prizery (the &#8220;PR Second Floor Expansion Premises&#8221;), as shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit B</font>.&nbsp;&nbsp;Tenant acknowledges that certain portions of the PR Second Floor Expansion Premises are currently vacant and other portions of the PR Second Floor Expansion Premises are currently occupied by various tenants.&nbsp;&nbsp;Landlord shall deliver possession of each portion of the PR Second Floor Expansion Premises to Tenant as such portion of the PR Second Floor Expansion Premises is vacant and available to be delivered to Tenant (but, so long as Tenant does not commence the conduct of business in any portion of the PR Second Floor Expansion Premises, such partial delivery shall not trigger commencement of the term with respect to the same, nor commencement of the Base Rent &#8220;clock,&#8221; as Tenant will be unable to commence its construction activities until the full floor is delivered in accordance with this Amendment; however, if Tenant commences the conduct of business in any portion of the PR Second Floor Expansion Premises, then the term will commence with respect to all portions of the PR Second Floor Expansion Premises that have been delivered to Tenant).&nbsp;&nbsp;Landlord agrees to endeavor in good faith to terminate or relocate the existing tenants of the PR Second Floor Expansion Premises, so as to deliver possession of each portion of the PR Second Floor Expansion Premises to Tenant as promptly as practicable.&nbsp;&nbsp;The Expansion Date with respect to the entire PR Second Floor Expansion Premises (unless occurring sooner with respect to portions of the PR Second Floor Expansion Premises pursuant to the foregoing provisions of this Section 2(b)) shall be the thirtieth (30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day following the date that possession of the entire PR Second Floor Expansion Premises is delivered to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>approximately 7,416 RSF on the first floor of Dibrell B (the &#8220;DB First Floor Expansion Premises&#8221;).&nbsp;&nbsp;Tenant acknowledges that the DB First Floor Expansion Premises is currently occupied by a tenant whose lease term expires June 30, 2019, but that such current tenant may be induced to vacate the DB First Floor Expansion Premises sooner than such scheduled lease expiration date.&nbsp;&nbsp;Tenant will take possession of the DB First Floor Expansion Premises as soon as such space is vacant and available.&nbsp;&nbsp;The Expansion Date for the DB First Floor Expansion Premises shall be the 90<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day following the date that Landlord delivers possession of the DB First Floor Expansion Premises to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order).&nbsp;&nbsp;Rent shall be paid on the same terms (on a per square foot basis) as the RR Expansion Premises;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:3.85%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>(d)<font style="margin-left:36pt;"></font>approximately 7,416 RSF on the second floor of Dibrell B (the &#8220;DB Second Floor Expansion Premises&#8221;).&nbsp;&nbsp;Tenant acknowledges that the DB Second Floor Expansion Premises is currently occupied by a tenant whose lease term expires June 30, 2019.&nbsp;&nbsp;Landlord will use best efforts to cause the current tenant of the DB Second Floor Expansion </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises to vacate such space as soon as possible; provided that Landlord shall not be obligated to offer such current tenant any payment or other economic inducement to vacate such space prior to the expiration of such current tenant&#8217;s lease term.&nbsp;&nbsp;Tenant will take possession of the DB Second Floor Expansion Premises as soon as such space is vacant and available.&nbsp;&nbsp;The Expansion Date for the DB Second Floor Expansion Premises shall be the 30</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> day following the date that Landlord delivers possession of the DB Second Floor Expansion Premises to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order).&nbsp;&nbsp;Rent shall be paid on the same terms (on a per square foot basis) as the PR Second Floor Expansion Premises;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>Base Rent with respect to each Expansion Premises shall be as set forth in the following tables:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RR Expansion Premises (11,621 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Months Following RR<br />Expansion Premises<br />Expansion Date</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 - 24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 - 36</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37 - 48</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49 - 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 - 72</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 - 84</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 - Expiration Date</p></td>
<td valign="top"  style="width:35.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot<br />(NNN)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.25</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.78<br />$20.32<br />$20.88<br />$21.46</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.65</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.28</p></td>
<td valign="top"  style="width:29.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,642.02</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19,155.29<br />$19,678.23<br />$20,220.54<br />$20,782.23</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21,353.59</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21,934.64</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22,544.74</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PR Second Floor Expansion Premises (or respective portions thereof) (7,494 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Months Following PR<br />Second Floor Expansion<br />Premises Expansion Date</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 - 24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 - 36</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37 - 48</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49 - 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 - 72</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 - 84</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 - Expiration Date</p></td>
<td valign="top"  style="width:35.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(FS)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.69<br />$26.39<br />$27.12<br />$27.87</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.63</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.42</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.23</p></td>
<td valign="top"  style="width:29.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,612.50</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16,043.41<br />$16,480.56<br />$16,936.44<br />$17,404.82</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17,879.44</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,372.79</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,878.64</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant agree to reasonably document (via e-mail or otherwise in writing) the relevant Expansion Date for each of the Expansion Premises, for the avoidance of confusion or misunderstanding.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DB First Floor Expansion Premises (7,416 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:151.65pt;">
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Months Following RR<br />Expansion Premises<br />Expansion Date*</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 - 24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 - 36</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37 - 48</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49 - 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 - 72</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 - 84</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 - Expiration Date</p></td>
<td valign="top"  style="width:35.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(NNN)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.25</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.78<br />$20.32<br />$20.88<br />$21.46</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.65</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.28</p></td>
<td valign="top"  style="width:29.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11,896.50</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,224.04<br />$12,557.76<br />$12,903.84<br />$13,262.28</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13,626.90</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13,997.70</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14,387.04</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;">
<tr style="height:29.25pt;">
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DB Second Floor Expansion Premises (7,416 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Months Following PR<br />Second Floor Expansion<br />Premises Expansion Date*</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 - 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 - 24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 - 36</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37 - 48</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49 - 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 - 72</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 - 84</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 - Expiration Date</p></td>
<td valign="top"  style="width:35.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(FS)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.69<br />$26.39<br />$27.12<br />$27.87</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.63</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.42</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.23</p></td>
<td valign="top"  style="width:29.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,450.00</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,876.42<br />$16,309.02<br />$16,760.16<br />$17,223.66</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17,693.34</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,181.56</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,682.14</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;margin-left:11.54%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a>*Base Rent with respect to the DB First Floor Expansion Premises and the DB Second Floor Expansion Premises shall commence to accrue only as of the respective Expansion Dates applicable to each of such spaces.&nbsp;&nbsp;From and after the respective Expansion Date applicable to each of such spaces, Base Rent shall be payable in the amounts set forth in the foregoing tables (and any rental amounts shown in the foregoing tables as being in effect during the periods preceding such Expansion Dates shall be relevant only for the purpose of determining the applicable escalated rental amounts due from and after such Expansion Dates).&nbsp;&nbsp;The purpose of measuring the periods in the foregoing tables from the Expansion Dates applicable to the RR Expansion Premises and the PR Second Floor Expansion Premises is so that the Base Rent per rentable square foot in effect from time-to-time with respect to the DB First Floor Expansion Premises will be the same as the Base Rent per rentable square foot </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:6pt;margin-left:11.54%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in effect with respect to the RR Expansion Premises, and the Base Rent per rentable square foot in effect from time-to-time with respect to the DB Second Floor Expansion Premises will be the same as the Base Rent per rentable square foot in effect with respect to the PR Second Floor Expansion Premises.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything in the foregoing to the contrary, provided no Event of Default then exists under the Lease, Landlord agrees to grant Tenant an abatement of the Base Rent due with respect to each of the Expansion Premises, in an amount as set forth herein.&nbsp;&nbsp;With respect to the RR Expansion Premises and the PR Second Floor Expansion Premises, the rental abatement shall be five (5) monthly installments of the Base Rent.&nbsp;&nbsp;With respect to each Expansion Premises having an Expansion Date later than February 1, 2017 (other than the RR Expansion Premises and the PR Second Floor Expansion Premises), the rental abatement shall be the product of (i) five (5) monthly installments of the Base Rent multiplied by (ii) a fraction, the numerator of which is the number of full calendar months remaining in the Term of this Lease as of the Expansion Date applicable to such Expansion Premises and the denominator of which is eighty-nine (89).&nbsp;&nbsp;Such abatement shall be applied to the monthly installments of Base Rent that would otherwise be due for the months commencing with January 2018; provided that, with respect to any Expansion Premises whose Expansion Date occurs later than January 1, 2018, the abatement period shall be the first full and partial calendar months following the Expansion Date applicable to such Expansion Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>Effective as of the Expansion Date for the RR Expansion Premises (which date is referred to herein as the &#8220;RR Adjustment Date&#8221;), the Base Rent with respect to the Current RR Premises shall be converted to a &#8220;triple-net&#8221; rental rate, and Tenant shall pay, with respect to the Current RR Premises, its Proportionate Share of all Operating Expenses from and after the Expansion Date for the RR Expansion Premises.&nbsp;&nbsp;Effective as of the RR Adjustment Date, the Base Rent with respect to the Current RR Premises shall be as set forth in the following table:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:11.86%;width:78.54%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Current RR Premises (2,863 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:40.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RR Adjustment Date<font style="letter-spacing:-0.1pt;"> &#8211; 2/28/17</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/17 - 2/28/18</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/18 &#8211; 2/28/19</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/19 &#8211;2/28/20</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/20 &#8211; 2/29/21</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/21 &#8211; 7/31/21</p></td>
<td valign="top"  style="width:30.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(NNN)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15.25</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15.67</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.10</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.54</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.00</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.47</p></td>
<td valign="top"  style="width:28.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,638.40</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,738.45</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,841.26</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,946.89</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4,055.43</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4,166.96</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>Effective as of August 1, 2021, Base Rent with respect to the Current RR Premises and the Current DA Premises shall be the then-current rates of the Receiving Room (both on a NNN basis), as illustrated in the following tables:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="text-decoration:underline;">Current RR Premises (2,863 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period*</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/1/21 &#8211; 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 &#8211; 72</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 &#8211; 84</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 &#8211; Expiration Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot<br />(NNN)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.46</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.65</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.28</p></td>
<td valign="top"  style="width:29.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,120.00</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,260.76</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,403.91</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,554.22</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Escalations based on number of months following RR Expansion Premises Expansion Date, consistent with Section 3 of this Amendment.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.33%;width:75.57%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Current DA Premises (16,701 SF)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period*</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/1/21 &#8211; 60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 &#8211; 72</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 &#8211; 84</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 &#8211; Expiration Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rentable Square Foot</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(NNN)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />$21.46</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.65</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.28</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />$29,866.96</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30,688.09</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31,523.14</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$32,399.94</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Escalations based on number of months following RR Expansion Premises Expansion Date, consistent with Section 3 of this Amendment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>Tenant&#8217;s Proportionate Share of Operating Expenses with respect to the respective Expansion Premises is as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.08%;width:87.02%;">
<tr>
<td valign="top"  style="width:44.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Expansion Premises</font></p></td>
<td valign="top"  style="width:27.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Tenant&#8217;s&#160;Proportionate<br />Share of the Building</font></p></td>
<td valign="top"  style="width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Tenant&#8217;s&#160;Proportionate<br />Share of the Project</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:44.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RR Expansion Premises</p></td>
<td valign="top"  style="width:27.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.25482%</p></td>
<td valign="top"  style="width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.76767%</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PR Second Floor Expansion Premises</p></td>
<td valign="top"  style="width:27.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.07039%</p></td>
<td valign="top"  style="width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.70729%</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DB First Floor Expansion Premises</p></td>
<td valign="top"  style="width:27.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.00000%</p></td>
<td valign="top"  style="width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.62655%</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DB Second Floor Expansion Premises</p></td>
<td valign="top"  style="width:27.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.00000%</p></td>
<td valign="top"  style="width:28.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.62655%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a>The Base Rent stated above with respect to the RR Expansion Premises and the DB First Floor Expansion Premises is a &#8220;triple-net&#8221; rental rate, and Tenant shall pay, with respect to each such Expansion Premises, its Proportionate Share of all Operating Expenses from and after the Expansion Date applicable to each such Expansion Premises.&nbsp;&nbsp;The Base Rent stated above with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect to the PR Second Floor Expansion Premises and the DB Second Floor Expansion Premises is a &#8220;full-service&#8221; rental rate, and Tenant shall pay, with respect to each such Expansion Premises, from and after January 1, 2018, its Proportionate Share of increases in Operating Expenses over the Operating Expenses incurred in calendar year 2017.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>Landlord hereby agrees to grant Tenant an allowance (&#8220;Improvements Allowance&#8221;) with respect to each Expansion Premises.&nbsp;&nbsp;The Improvements Allowance granted with respect to each Expansion Premises shall be calculated by reference to the Base Improvements Allowance per Rentable Square Foot (&#8220;Base Amount&#8221;) set forth in the following table:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.08%;width:87.02%;">
<tr>
<td valign="top"  style="width:61.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Expansion Premises</font></p></td>
<td valign="top"  style="width:38.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Base Improvements Allowance<br />per Rentable Square Foot</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:61.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RR Expansion Premises</p></td>
<td valign="top"  style="width:38.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$45.00</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PR Second Floor Expansion Premises</p></td>
<td valign="top"  style="width:38.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DB First Floor Expansion Premises</p></td>
<td valign="top"  style="width:38.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$45.00</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DB Second Floor Expansion Premises</p></td>
<td valign="top"  style="width:38.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.00</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the RR Expansion Premises and the PR Second Floor Expansion Premises, the Improvements Allowance shall be the Base Amount set forth in the foregoing table.&nbsp;&nbsp;For each Expansion Premises having an Expansion Date later than February 1, 2017 (other than the RR Expansion Premises and the PR Second Floor Expansion Premises), the Improvements Allowance shall be the product of (i) the Base Amount set forth in the foregoing table multiplied by (ii) a fraction, the numerator of which is the number of full calendar months remaining in the Term of this Lease as of the Expansion Date applicable to such Expansion Premises and the denominator of which is eighty-nine (89).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Improvements Allowances shall <font style="letter-spacing:-0.1pt;">be applied toward the cost of the design and construction of any alterations Tenant desires to perform in the Expansion Premises in conjunction with Tenant&#8217;s initial occupancy of such Expansion Premises.&nbsp;&nbsp;Any portion of the Improvements Allowances may be applied to pay the fees of the architect and engineers and any project manager employed by Tenant with respect to such alterations, as well as any permit costs and fees. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a>The cost of Tenant's alterations in each of the Expansion Premises shall be paid first out of the applicable <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance until the <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance is exhausted.&nbsp;&nbsp;Tenant shall deliver to Landlord, no more frequently than once per month, invoices for work performed hereunder together with any other supporting documentation reasonably requested by Landlord.&nbsp;&nbsp;Provided no Event of Default then exists under the Lease, the <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance (or portions thereof) shall be disbursed to Tenant within thirty (30) days following Tenant's submission <font style="letter-spacing:-0.1pt;">to Landlord of paid invoices for work related to alterations performed by Tenant in the Expansion Premises, accompanied by waivers of liens executed by all contractors employed by Tenant for the performance of such work</font>.&nbsp;&nbsp;If the cost of Tenant's alterations in the Expansion Premises exceeds the amount of the applicable <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance, the excess shall be paid by Tenant after the <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance is fully exhausted.&nbsp;&nbsp;Notwithstanding the foregoing, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.1pt;">the Improvements Allowance associated with any particular Expansion Premises may be utilized by Tenant in the Expansion Premises with which it is associated and/or in any other Expansion Premises that is delivered to Tenant either concurrently with or following the delivery date of the Expansion Premises with which such Improvements Allowance is associated.&nbsp;&nbsp;Tenant may also submit invoices for an existing or completed Expansion Premises project when a new Improvements Allowance becomes available.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any portion of the Improvements Allowance that has not been utilized by the date that is twelve (12) months following the last Expansion Date applicable to any of the Expansion Premises (as referenced in Section 2 of this Amendment) shall revert to Landlord.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In no event may any portion of the Improvements Allowances may be utilized with respect to alterations or refurbishment performed in the Current Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font>Landlord hereby agrees to grant Tenant an allowance in <font style="letter-spacing:-0.1pt;">the amount of $97,820.00 </font>(the "Refurbishment Allowance"), to be applied toward the cost of performing alterations and refurbishment in the Current Premises.&nbsp;&nbsp;<font style="letter-spacing:-0.1pt;">Any portion of the </font>Refurbishment <font style="letter-spacing:-0.1pt;">Allowances may be applied to pay the fees of the architect and engineers and any project manager employed by Tenant with respect to such alterations, as well as any permit costs and fees.&nbsp;&nbsp;</font>Provided no Event of Default then exists under the Lease, the Refurbishment Allowance (or portions thereof) shall be disbursed to Tenant within thirty (30) days following Tenant's submission <font style="letter-spacing:-0.1pt;">to Landlord of paid invoices for alterations or refurbishment performed by Tenant in the Current Premises after the date of this Amendment, accompanied by waivers of liens executed by all contractors employed by Tenant for the performance of such work (to the extent reasonably required)</font>.&nbsp;&nbsp;Requisitions shall be submitted by Tenant no more frequently than once per month.&nbsp;&nbsp;If the cost of Tenant's alterations and refurbishment in the Current Premises exceeds the amount of the Refurbishment<font style="letter-spacing:-0.1pt;"> </font>Allowance, the excess shall be paid by Tenant after the Refurbishment Allowance is exhausted.&nbsp;&nbsp;Additionally, Tenant may elect to apply any unexpended Refurbishment Allowance toward work in any Expansion Premises, on the same terms and conditions as listed in Section 7 above.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font>Landlord acknowledges that, following delivery of the RR Expansion Premises to Tenant, Tenant will be the exclusive user of the &#8220;private shipping and receiving area&#8221; of the loading dock in the Receiving Room, as shown on the attached <font style="font-weight:bold;text-decoration:underline;">Exhibit A</font> (the &#8220;S&amp;R Area&#8221;), except as specifically provided herein.&nbsp;&nbsp;Landlord shall reasonably cooperate with Tenant to facilitate Tenant&#8217;s use of the loading dock as the primary user thereof; and Tenant agrees to afford Landlord and other tenants of the Receiving Room reasonable access to and use of such loading dock, provided that such access and use does not materially impair Tenant&#8217;s use of such facility. Landlord agrees that it will use best efforts to give Tenant not less than twenty-four (24) hours&#8217; prior notice (which need not be in writing) to access and to use the loading dock so that Tenant can appropriately coordinate (clearance of space and security of items in the space).&nbsp;&nbsp;Tenant, at Tenant&#8217;s sole cost, shall relocate the existing mailboxes in the loading dock to a mutually-agreeable location outside the S&amp;R Area, and shall provide a means of access to the IT cabinet that does not require access through the S&amp;R Area, such work to be subject to Landlord&#8217;s reasonable prior approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font><font style="margin-left:36pt;"></font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have the right, at Tenant&#8217;s expense and for its own use, to purchase, install, maintain and operate at the Project an emergency power generator (the "Generator") and a fuel tank (the "Tank") for the Generator, subject to the following terms and conditions:&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">The Generator and Tank and associated wiring shall be installed by contractors reasonably pre-approved by Landlord, in a good and workmanlike manner and in accordance with the reasonable directions of Landlord relative thereto.&nbsp;&nbsp;Tenant and/or its contractors shall provide all appropriate insurance for such installation.&nbsp;&nbsp;Tenant shall deliver to Landlord detailed plans and specifications for the Generator and the Tank (including the proposed location of the Generator and the Tank) and a copy of Tenant's contract for installing the Generator and the Tank, which plans and specifications and contract and the location of the Generator and Tank shall be subject to Landlord's reasonable approval.&nbsp;&nbsp;If deemed desirable by Landlord, Tenant shall cause the space within which the Generator and Tank are located to be screened in a manner that is reasonably acceptable to Landlord.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">Tenant shall pay all costs of design, installation, operation, utilization, replacement, maintenance and removal of the Generator and the Tank, including (without limitation) the cost of any piping needed to connect the Generator and the Tank.&nbsp;&nbsp;Any damage to the Project or other property of Landlord or any other tenant resulting from the installation or maintenance of the Generator and Tank shall be promptly repaired at Tenant's sole cost and expense.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Tenant covenants that it will not use its Generator or the Tank in a manner that will unreasonably interfere with Landlord's and/or any current or future tenant's use of the Project.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Tenant shall be responsible for procuring all licenses and permits required for the installation, use or operation of the Generator and the Tank.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">The Generator and Tank shall be designed, constructed, installed, maintained and operated in strict compliance with all applicable environmental laws.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;">Landlord shall have no liability for any damage to, or caused by, the Generator and Tank.&nbsp;&nbsp;Tenant hereby indemnifies and agrees to hold Landlord harmless from any loss or damage which Landlord may sustain in connection with the Generator and Tank, including all liabilities, costs or expenses of any kind or nature incurred in connection with any claim or proceeding brought thereon and the defense thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;">Tenant is hereby granted nonexclusive easements and licenses for (i) use of any shafts required to install the electrical wiring for the Generator; and (ii) access to the Generator and the Tank at all reasonable times and in emergencies.&nbsp;&nbsp;The Generator shall be connected to the Premises by electrical wiring, the installation of which shall be performed by Tenant&#8217;s contractor, at Tenant's sole expense.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a>(h)<font style="margin-left:36pt;">At Landlord's request, the Generator and Tank and associated wiring and piping and any screening surrounding the Generator and Tank installed by Tenant hereunder shall be removed by Tenant, by contractors reasonably pre-approved by Landlord, in a good and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">workmanlike manner, upon the expiration or earlier termination of the Lease, at Tenant's sole cost and expense.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font>The parking rights granted to Tenant under the Lease shall increase proportionately upon the Expansion Date applicable to each Expansion Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="letter-spacing:-0.15pt;">This Amendment and all provisions contained herein are contingent upon an executed lease termination agreement between Landlord and the existing tenant (&#8220;Roivant&#8221;) for the PR Second Floor Expansion Premises, providing that the PR Second Floor Expansion Premises shall be surrendered to Landlord on or before January 1, 2017 (the &#8220;PR Termination Agreement&#8221;).&nbsp;&nbsp;If Landlord does not enter into said PR Termination Agreement within fifteen (15) days of the date of full execution of this Amendment, then Tenant shall be entitled to terminate this Amendment (and all of its obligations hereunder) by written notice delivered to Landlord within thirty (30) days following the date of full execution of this Amendment (unless Landlord has entered into the PR Termination Agreement prior to Tenant&#8217;s delivery of its termination notice, in which event this Amendment shall remain in force and effect).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font>The Right of Refusal granted to Tenant pursuant to Paragraph 10 of the Second Amendment shall remain in force and effect during the Term of the Lease as extended by this Amendment. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font>Except to the extent any of such suites are sooner leased by Tenant pursuant to its Right of First Refusal, Landlord and Tenant hereby agree to the following &#8220;must-take&#8221; expansion provisions with respect to Suites 110, 120, 130, and 140 of the Prizery, as shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit B</font>:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">Landlord shall deliver Suite 130 and Suite 140, comprising approximately 3,162 rentable square feet (&#8220;PR First Floor Expansion Premises A&#8221;) to Tenant on or around September 1, 2017 (the PR First Floor Expansion Premises A Target Date&#8221;).&nbsp;&nbsp;Landlord will use commercially reasonable efforts to meet the PR First Floor Expansion Premises A Target Date.&nbsp;&nbsp;In the event Landlord is unable to deliver possession of the PR First Floor Expansion Premises A to Tenant on the PR First Floor Expansion Premises A Target Date due to an existing tenant&#8217;s failure to vacate such space or any other cause beyond Landlord&#8217;s reasonable control, Landlord shall have no liability to Tenant, and Tenant&#8217;s obligation to lease the PR First Floor Expansion Premises A shall not be nullified, provided Landlord shall use commercially reasonable efforts to deliver possession of the PR First Floor Expansion Premises A to Tenant as soon as possible following the PR First Floor Expansion Premises A Target Date.&nbsp;&nbsp;The Expansion Date for the PR First Floor Expansion Premises A shall be the 30</font><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day following the date that Landlord delivers possession of PR First Floor Expansion Premises A to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order).&nbsp;&nbsp;Rent shall be paid on the same terms (on a per square foot basis) as the PR Second Floor Expansion Premises, and Tenant shall receive the same Improvement Allowance as the PR Second Floor Expansion Premises, on a per square foot basis, and prorated in accordance with Section 7 of this Amendment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a>(b)<font style="margin-left:36pt;">Landlord shall deliver Suite 110 and Suite 120, comprising approximately 2,722 rentable square feet (&#8220;PR First Floor Expansion Premises B&#8221;) to Tenant on or around November 1, 2018 (the &#8220;PR First Floor Expansion Premises B Target Date&#8221;).&nbsp;&nbsp;Landlord will use commercially reasonable efforts to meet the PR First Floor Expansion Premises B Target Date.&nbsp;&nbsp;In </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the event Landlord is unable to deliver possession of the PR First Floor Expansion Premises B to Tenant on the PR First Floor Expansion Premises B Target Date due to an existing tenant&#8217;s failure to vacate such space or any other cause beyond Landlord&#8217;s reasonable control, Landlord shall have no liability to Tenant, and Tenant&#8217;s obligation to lease the PR First Floor Expansion Premises B shall not be nullified, provided Landlord shall use commercially reasonable efforts to deliver possession of the PR First Floor Expansion Premises B to Tenant as soon as possible following the PR First Floor Expansion Premises B Target Date.&nbsp;&nbsp;The Expansion Date for the PR First Floor Expansion Premises B shall be the 30</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> day following the date that Landlord delivers possession of PR First Floor Expansion Premises B to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order).&nbsp;&nbsp;Rent shall be paid on the same terms (on a per square foot basis) as the PR Second Floor Expansion Premises, and Tenant shall receive the same Improvement Allowance as the PR Second Floor Expansion Premises, on a per square foot basis, and prorated in accordance with Section 7 of this Amendment.&nbsp;&nbsp;Following the addition of PR First Floor Expansion Premises B to the Premises, Landlord agrees that Tenant may add the previously shared &#8220;common space&#8221; to its secured area, and Landlord and Tenant will mutually, in good faith, enter into a Lease amendment to document same.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">Notwithstanding anything in Paragraph 14(b) above, Tenant acknowledges that the current tenant of Suite 110 has the option to renew the term of its lease for an additional period of three (3) years.&nbsp;&nbsp;In the event the current tenant of Suite 110 timely exercises its renewal option, Landlord shall so notify Tenant in writing (the &#8220;Suite 110 Notice&#8221;) within fifteen (15) business days of Landlord&#8217;s receipt of same.&nbsp;&nbsp;In the event Landlord does not deliver the Suite 110 Notice to Tenant within fifteen (15) business days of the current tenant&#8217;s renewal deadline (which renewal deadline Landlord represents, for the purposes of this Amendment, to be April 30, 2018), Landlord shall be conclusively deemed to have represented that the current Suite 110 tenant no longer has any valid right to renew, and Landlord shall initiate work promptly and diligently to meet the PR First Floor Expansion Premises B Target Date.&nbsp;&nbsp;Within thirty (30) days following Tenant&#8217;s receipt of the Suite 110 Notice, Tenant may elect, by written notice to Landlord, to delete Suite 110 from the expansion space that is subject to the provisions of this Paragraph 14, in which event Landlord shall have no obligation to deliver possession of Suite 110 to Tenant at any time and Tenant shall have no obligation to lease Suite 110 from Landlord at any time.&nbsp;&nbsp;In the event Tenant does not timely exercise its right to delete Suite 110 from the expansion space under this Paragraph 14, then the delivery date for Suite 110 shall be extended to be the last day of the current tenant&#8217;s three-year renewal term.&nbsp;&nbsp;Tenant&#8217;s right pursuant to Paragraph 14(b) above to convert common space into secured area shall be inapplicable unless and until Suite 110 (as well as the remainder of PR First Floor Expansion Premises B) becomes part of the Premises demised to Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font>The Option to Extend granted to Tenant pursuant to Paragraph 11 of the Second Amendment shall remain in force and effect and shall be applicable to the period immediately following the Term of the Lease as extended by this Amendment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a>16.<font style="margin-left:36pt;"></font>Landlord and Tenant each warrant to the other that in connection with this Amendment neither has employed or dealt with any broker, agent or finder, other than CBRE-Raleigh, LLC and Cushman &amp; Wakefield (the "Brokers").&nbsp;&nbsp;Landlord acknowledges that it shall pay any commission or fee due to the Brokers, pursuant to a separate written agreement.&nbsp;&nbsp;Each party shall indemnify and hold the other harmless from and against any claim for brokerage or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other commissions asserted by any broker, agent or finder employed by the indemnifying party or with whom the indemnifying party has dealt, other than the Brokers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, Landlord and Tenant have executed and delivered this Amendment as of the day and year first above written.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>WITNESS:</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VENABLE CENTER, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Illegible</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Esko I. Korhonen</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member</p></td>
<td valign="top"  style="width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESS:</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:42.04%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:normal;font-size:12pt;color:#auto;font-family:Times New Roman;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Illegible</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Todd Melby</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COO</p></td>
<td valign="top"  style="width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLOOR PLANS OF EXPANSION PREMISES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000006.jpg" title="" alt="" style="width:622px;height:402px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000007.jpg" title="" alt="" style="width:633px;height:478px;"></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><img src="gvxjy5si4hmk000008.jpg" title="" alt="" style="width:633px;height:478px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-weight:bold;font-style:normal;font-variant: normal;">FIFTH AMENDMENT TO lease agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.58%;"><font style="font-weight:bold;">THIS FIFTH AMENDMENT TO LEASE AGREEMENT </font>(this "Amendment") is made as of the 24<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day of January, 2018 by and between <font style="font-weight:bold;">VENABLE CENTER, LLC</font>, a North Carolina limited liability company ("Landlord"), and <font style="font-weight:bold;">PRECISION BIOSCIENCES, INC.</font>, a Delaware corporation ("Tenant"), with respect to the following recitals:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.79%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Landlord is the current owner of a group of interconnected buildings situated at 302 East Pettigrew Street, Durham, North Carolina known collectively as &#8220;Venable Center&#8221; (the &#8220;Project&#8221;), of which one of the buildings is known as the Prizery (the &#8220;Prizery&#8221;) and one of the buildings is known as Dibrell C (&#8220;Dibrell C&#8221;).&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.79%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Pursuant to that certain Lease Agreement dated April 5, 2010, as modified by a First Amendment to Lease Agreement dated August 19, 2011 and by a Second Amendment to the Lease Agreement dated July 13, 2015 (the &#8220;Second Amendment&#8221;) and by a Third Amendment to the Lease Agreement dated January 12, 2016, and by a Fourth Amendment to the Lease Agreement dated September 30, 2016 (collectively, the "Lease"), Landlord (as successor to Venable Tenant LLC) leases to Tenant certain office space in the Project (the "Current Premises"), as more particularly described in the Lease;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.79%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Landlord and Tenant have agreed to add certain space to the premises demised under the Lease, and to make certain other modifications to the Lease as set forth hereinbelow;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.79%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Lease.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>Effective as of a date to be selected by Landlord and falling between May 1, 2018 and May 15, 2018 (the &#8220;Third Floor Expansion Date&#8221;), Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, Suite 300 (6,358 rsf), Suite 330 (546 rsf) and Suite 340 (202 rsf) in the Prizery (collectively, the &#8220;Third Floor Expansion Premises&#8221;), as outlined on Exhibit A attached hereto.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Base Rent with respect to the Third Floor Expansion Premises shall commence to be payable on the date which is three (3) months following the Third Floor Expansion Date (the &#8220;TFEP Rent Date&#8221;), and shall thereafter be as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.13%;width:74.47%;"></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.13%;width:74.47%;">
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TFEP Rent Date<font style="letter-spacing:-0.1pt;"> &#8211; 2/28/19</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/19 &#8211; 2/29/20</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/20 &#8211; 2/28/21</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/21 &#8211; 2/28/22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/22 &#8211; 2/28/23</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/23 &#8211; 2/29/24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/24 &#8211; 7/31/24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot (FS)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.69<br />$26.39<br />$27.12<br />$27.87</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.63</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.42</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.23</p></td>
<td valign="top"  style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,212.76*<br />$15,627.28<br />$16,059.56<br />$16,503.68</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16,953.73</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17,421.54</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17,901.20</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*prorated for any<br />partial month</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything in the foregoing to the contrary, provided no Event of Default then exists under the Lease, Landlord agrees to grant Tenant an abatement of the Base Rent due with respect to the Third Floor Expansion Premises, in an amount equal to $63,065.73.&nbsp;&nbsp;Such abatement shall be applied to the first monthly installments of Base Rent that would otherwise be due for the Third Floor Expansion Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>Tenant&#8217;s Proportionate Share of Operating Expenses with respect to the Third Floor Expansion Premises is 20.92770% of the Prizery and 8.25647% of the Project.&nbsp;&nbsp;Tenant shall pay, with respect to the Third Floor Expansion Premises, from and after the thirtieth (30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day following the Third Floor Expansion Date, its Proportionate Share of increases in Operating Expenses over the Operating Expenses incurred in calendar year 2017.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>Landlord hereby agrees to grant Tenant an allowance (&#8220;Third Floor Improvements Allowance&#8221;) with respect to the Third Floor Expansion Premises in the amount of $151,701.12.&nbsp;&nbsp;The Third Floor Improvements Allowance shall be applied toward the cost of the design and construction of any alterations Tenant desires to perform in the Third Floor Expansion Premises in conjunction with Tenant&#8217;s initial occupancy of such Third Floor Expansion Premises.&nbsp;&nbsp;Any portion of the Third Floor Improvements Allowance may be applied to pay the fees of the architect and engineers and any construction supervision, contractors&#8217; overhead and profit charges, along with fees for any project manager employed by Tenant with respect to such alterations, as well as any licensing and permitting costs and fees. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of Tenant's alterations in the Third Floor Expansion Premises shall be paid first out of the Third Floor <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance until the Third Floor <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance is exhausted.&nbsp;&nbsp;Tenant shall deliver to Landlord, no more frequently than once per month, invoices for work performed hereunder together with any other supporting documentation reasonably requested by Landlord.&nbsp;&nbsp;Provided no Event of Default then exists under the Lease, the Third Floor <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance (or portions thereof) shall be disbursed to Tenant within thirty (30) days following Tenant's submission <font style="letter-spacing:-0.1pt;">to Landlord of paid invoices for work related to alterations performed by Tenant in the </font>Third Floor <font style="letter-spacing:-0.1pt;">Expansion Premises, accompanied by waivers of liens executed by all contractors employed by Tenant for the performance of such work</font>.&nbsp;&nbsp;If the cost of Tenant's alterations in the Third Floor Expansion Premises exceeds the amount of the Third Floor <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance, the excess shall be paid by Tenant after the Third Floor <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance is fully exhausted.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any portion of the Third Floor Improvements Allowance that has not been utilized by the date that is twelve (12) months following the Third Floor Expansion Date shall revert to Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>The parking rights granted to Tenant under the Lease shall increase proportionately upon the Third Floor Expansion Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>Effective as of the &#8220;Dibrell Expansion Date&#8221; (as defined below), Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, approximately 2,848 rentable square feet of space in the Dibrell C building (collectively, the &#8220;Dibrell Expansion Premises&#8221;), as outlined on Exhibit B attached hereto.&nbsp;&nbsp;In the event the final BOMA calculation of the rentable area of the Dibrell Expansion Premises discloses that the rentable area of such space is less than 2,848 rentable square feet, the Monthly Rent set forth in Paragraph 7 below and Tenant&#8217;s Proportionate Share of Operating Expenses with respect to the Dibrell Expansion Premises set forth in Paragraph 8 below shall be reduced pro rata. The &#8220;Dibrell Expansion Date&#8221; shall be the date following the date that the current tenant of a portion of the Dibrell Expansion Premises, One Cow Standing, LLC, vacates the space occupied by such tenant, so that the space may be delivered by Landlord to Tenant.&nbsp;&nbsp;The Dibrell Expansion Date is anticipated to occur on April 1, 2020, but Landlord shall have no liability to Tenant and this Amendment shall not be rendered void or voidable in the event Landlord is unable to deliver possession of the Dibrell Expansion Premises to Tenant by the anticipated Dibrell Expansion Date because the current tenant fails to vacate by such date (despite Landlord&#8217;s commercially reasonable efforts to achieve same).&nbsp;&nbsp;In the event the current tenant vacates the Dibrell Expansion Premises prior to the anticipated Dibrell Expansion Date (such vacancy Landlord shall use commercially reasonable efforts to notify Tenant of at least thirty (30) days in advance), the Dibrell Expansion Date shall be the 90<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day following the date that Landlord delivers possession of the Dibrell Expansion Premises to Tenant (in good and tenantable condition, broom clean, with all systems serving same in good working order).&nbsp;&nbsp;Landlord and Tenant agree to reasonably document (via e-mail or otherwise in writing) the Dibrell Expansion Date, for the avoidance of confusion or misunderstanding.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>Base Rent with respect to the Dibrell Expansion Premises shall commence to be payable on the date which is three months following the Dibrell Expansion Date, and shall thereafter be as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:13.13%;width:74.47%;">
<tr>
<td valign="top"  style="width:35.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/20 &#8211; 3/31/21</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/21 &#8211; 3/31/22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/22 &#8211; 3/31/23</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/23 &#8211; 3/31/24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/24 &#8211; 7/31/24</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent per<br />Rentable Square Foot (NNN)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.88<br />$21.46</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.65</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.28</p></td>
<td valign="top"  style="width:27.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$4,955.52<br />$5,093.17</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,233.20</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,375.60</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,525.12</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a>The foregoing rent schedule presumes that the Dibrell Expansion Date will be no earlier than April 1, 2020.&nbsp;&nbsp;In the event the Dibrell Expansion Date occurs earlier than April 1, 2020, then (i) Annual Base Rent for any period falling between April 1, 2018 and March 31, 2019 for which rent is payable with respect to the Dibrell Expansion Premises shall be calculated based upon an annual rate of $19.78 per rentable square foot, and (ii) Annual Base Rent for any period falling between April 1, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 and March 31, 2020 for which rent is payable with respect to the Dibrell Expansion Premises shall be calculated based upon an annual rate of $20.32 per rentable square foot.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything in the foregoing to the contrary, provided no Event of Default then exists under the Lease, Landlord agrees to grant Tenant an abatement of the Base Rent due with respect to the Dibrell Expansion Premises, in an amount equal to the product of (i) five (5) monthly installments of the Base Rent initially applicable to the Dibrell Expansion Premises multiplied by (ii) a fraction, the numerator of which is the number of full calendar months remaining in the Term of the Lease as of the Dibrell Expansion Date and the denominator of which is eighty-nine (89).&nbsp;&nbsp;Such abatement shall be applied to the first monthly installments of Base Rent that would otherwise be due for the Dibrell Expansion Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;">Tenant&#8217;s Proportionate Share of Operating Expenses with respect to the Dibrell Expansion Premises is 14.19% of Dibrell C and 3.30909% of the Project.&nbsp;&nbsp;Tenant shall pay, with respect to the Dibrell Expansion Premises, from and after the thirtieth (30</font><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day following the Dibrell Expansion Date, its Proportionate Share of increases in Operating Expenses over the Operating Expenses incurred in calendar year 2017.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font>Landlord hereby agrees to grant Tenant an allowance (&#8220;Dibrell Improvements Allowance&#8221;) with respect to the Dibrell Expansion Premises in an amount (per rentable square foot in the Dibrell Expansion Premises) equal to the product of (i) $45.00 multiplied by (ii) a fraction, the numerator of which is the number of full calendar months remaining in the Term of this Lease as of the Dibrell Expansion Date and the denominator of which is eighty-nine (89).&nbsp;&nbsp;The Improvements Allowance shall be applied toward the cost of the design and construction of any alterations Tenant desires to perform in the Dibrell Expansion Premises in conjunction with Tenant&#8217;s initial occupancy of such Dibrell Expansion Premises.&nbsp;&nbsp;Any portion of the Dibrell Improvements Allowance may be applied to pay the fees of the architect and engineers and any construction supervision, contractors&#8217; overhead and profit charges, along with fees for any project manager employed by Tenant with respect to such alterations, as well as any licensing and permitting costs and fees. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of Tenant's alterations in the Dibrell Expansion Premises shall be paid first out of the Dibrell <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance until the Dibrell <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance is exhausted.&nbsp;&nbsp;Tenant shall deliver to Landlord, no more frequently than once per month, invoices for work performed hereunder together with any other supporting documentation reasonably requested by Landlord.&nbsp;&nbsp;Provided no Event of Default then exists under the Lease, the Dibrell <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance (or portions thereof) shall be disbursed to Tenant within thirty (30) days following Tenant's submission <font style="letter-spacing:-0.1pt;">to Landlord of paid invoices for work related to alterations performed by Tenant in the </font>Dibrell Expansion <font style="letter-spacing:-0.1pt;">Premises, accompanied by waivers of liens executed by all contractors employed by Tenant for the performance of such work</font>.&nbsp;&nbsp;If the cost of Tenant's alterations in the Dibrell Expansion Premises exceeds the amount of the Dibrell <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance, the excess shall be paid by Tenant after the Dibrell <font style="letter-spacing:-0.1pt;">Improvements </font>Allowance is fully exhausted.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any portion of the Dibrell Improvements Allowance that has not been utilized by the date that is twelve (12) months following the Dibrell Expansion Date shall revert to Landlord.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font><font style="margin-left:36pt;"></font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parking rights granted to Tenant under the Lease shall increase proportionately upon the Dibrell Expansion Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font>Landlord acknowledges that it is currently still working with Tenant to resolve certain HVAC issues, and will continue to work together with Tenant in good faith to accommodate Tenant&#8217;s laboratory requirements related to same.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font>Landlord and Tenant further anticipate that, as previously discussed, a small amount of space may be added to the Dibrell Expansion Premises, after execution of this Amendment (and the parties agree that such space shall be subject to all economic terms and conditions of Section 7, 8, and 9 of this Amendment)&nbsp;&nbsp;To the extent reasonably requested by Landlord or Tenant, the parties shall enter into a confirmatory amendment or side letter after such space is added.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font>Landlord and Tenant each warrant to the other that in connection with this Amendment neither has employed or dealt with any broker, agent or finder, other than CBRE-Raleigh, LLC and Cushman &amp; Wakefield (the "Brokers").&nbsp;&nbsp;Landlord acknowledges that it shall pay any commission or fee due to the Brokers, pursuant to a separate written agreement.&nbsp;&nbsp;Each party shall indemnify and hold the other harmless from and against any claim for brokerage or other commissions asserted by any broker, agent or finder employed by the indemnifying party or with whom the indemnifying party has dealt, other than the Brokers.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font>As modified by this Amendment, the Lease continues in full force and effect.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, Landlord and Tenant have executed and delivered this Amendment as of the day and year first above written.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>WITNESS:</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VENABLE CENTER, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Illegible</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Esko I. Korhonen</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President</p></td>
<td valign="top"  style="width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESS:</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:42.04%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:normal;font-size:11pt;color:#auto;font-family:Times New Roman;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&nbsp;&nbsp;Renee Cramer</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Todd Melby</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COO</p></td>
<td valign="top"  style="width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.58%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLOOR PLAN OF THIRD FLOOR EXPANSION PREMISES (Suite 300 &amp; Suite 340)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000009.jpg" title="" alt="" style="width:622px;height:421px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLOOR PLAN OF DIBRELL EXPANSION PREMISES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000010.jpg" title="" alt="" style="width:588px;height:592px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">SIXTH AMENDMENT TO LEASE AGREEMENT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS SIXTH AMENDMENT TO LEASE AGREEMENT <font style="font-weight:normal;">(this "Amendment") is made as of the 06 day of August, 2018 by and between </font>VC OWNER, LLC<font style="font-weight:normal;">, a North Carolina limited liability company ("Landlord"), and </font>PRECISION BIOSCIENCES, INC.<font style="font-weight:normal;">, a Delaware corporation ("Tenant"), with respect to the following recitals:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.&nbsp;&nbsp;Pursuant to that certain Lease Agreement dated April 5, 2010, as modified by a First Amendment to Lease Agreement dated August 19, 2011, and by a Second Amendment to Lease Agreement dated July 13, 2015, and by a Third Amendment to Lease Agreement dated January 12, 2016, and by a Fourth Amendment to Lease Agreement dated September 30, 2016, and by a Fifth Amendment to Lease Agreement dated January 24, 2018 (collectively, the "Lease"), Landlord (as successor to Venable Tenant LLC) leases to Tenant certain office space in the group of interconnected buildings situated at 302 East Pettigrew Street, Durham, North Carolina known collectively as &#8220;Venable Center&#8221; (the &#8220;Project&#8221;), as more particularly described in the Lease;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.&nbsp;&nbsp;Landlord and Tenant have agreed to add certain space to the premises demised under the Lease, and to make certain other modifications to the Lease as set forth hereinbelow;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.&nbsp;&nbsp;All capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, approximately 1,626 rentable square feet of space known as Suite C-185 (the "Suite C-185 Premises") in the Dibrell Building (the &#8220;Building&#8221;) in the Project, as outlined on Exhibit A attached hereto.&nbsp;&nbsp;The Term of the Lease with respect to the Suite C-185 Premises shall commence as of September 1, 2018, and shall be coterminous with the Term applicable to the remainder of the Premises.&nbsp;&nbsp;From and after September 1, 2018, the Suite C-185 Premises shall constitute a portion of the "Premises" for all purposes under the Lease.&nbsp;&nbsp;Landlord shall have no liability to Tenant in the event Landlord is unable to deliver possession of the Suite C-185 Premises to Tenant on September 1, 2018 due to the holding over by the prior tenant thereof or due to any other matter beyond Landlord&#8217;s reasonable control; however, in such event, rent with respect to the Suite C-185 Premises will not begin to accrue until the first business day after Landlord is able to deliver possession of the Suite C-185 Premises to Tenant, broom clean and free of any prior tenancy.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>From and after September 1, 2018, Tenant shall pay monthly Base Rent with respect to the Suite C-185 Premises in the amount of $3,929.50 per month, which amount shall escalate by 3.0% per annum on September 1, 2019 and each September 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> thereafter.&nbsp;&nbsp;Notwithstanding the foregoing, provided Tenant is not then in default under the Lease beyond any applicable notice and cure period, Landlord agrees to abate the first four (4) monthly installments of Base Rent with respect to the Suite C-185 Premises (only).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencing on January 1, 2019, Tenant shall pay Additional Rent with respect to the Suite C-185 Premises pursuant to Section 6 of the Lease.&nbsp;&nbsp;With respect to the Suite C-185 Premises (only), Tenant's Proportionate Share shall be 3.14714% for the Building and 1.89723% for the Project, and Tenant shall pay its Proportionate Share of increases in Operating Expenses over the Operating Expenses incurred in calendar year 2018.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>Tenant shall accept the Suite C-185 Premises in their "as is" condition (subject to Landlord&#8217;s continuing repair and maintenance obligations, as outlined in Section 10 of the Lease (as may be amended)), and Landlord shall have no obligation to make any alterations or improvements thereto whatsoever.&nbsp;&nbsp;Any alterations that Tenant desires to make in the Suite C-185 Premises shall be subject to all the terms and conditions set forth in Section 11 of the Lease.&nbsp;&nbsp;Landlord hereby agrees to grant Tenant an allowance (the "Granted Allowance") in the amount of $32,520.00, to be applied toward the cost (including architectural and engineering fees) of alterations performed by Tenant in the Suite C-185 Premises.&nbsp;&nbsp;The Granted Allowance will be disbursed to Tenant within thirty (30) days following Tenant's submission to Landlord of paid invoices with respect to such alterations, together with lien releases from Tenant's contractor(s) and any other supporting documentation reasonably required by Landlord.&nbsp;&nbsp;Any portion of the Granted Allowance that has not been applied (or contracted to be applied) in the manner set forth above by March 1, 2019 shall revert to Landlord, and Tenant shall have no further rights with respect thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>Concurrently with its execution of this Amendment, Tenant shall deliver to Landlord the sum of $3,929.50, which shall be added to Tenant's existing Security Deposit, and which combined sum shall continue to be held by Landlord throughout the Term pursuant to the provisions of Section 9 of the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>Landlord and Tenant each warrant to the other that in connection with this Amendment neither has employed or dealt with any broker, agent or finder, other than CBRE-Raleigh, LLC and Cushman &amp; Wakefield (the "Brokers").&nbsp;&nbsp;Landlord acknowledges that it shall pay any commission or fee due to the Brokers, pursuant to a separate written agreement.&nbsp;&nbsp;Each party shall indemnify and hold the other harmless from and against any claim for brokerage or other commissions asserted by any broker, agent or finder employed by the indemnifying party or with whom the indemnifying party has dealt, other than the Brokers.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="letter-spacing:-0.15pt;">This Amendment and all provisions contained herein are contingent upon an executed lease termination agreement between Landlord and the existing tenant (&#8220;RS&amp;H, Inc.&#8221;) for the </font>Suite C-185 <font style="letter-spacing:-0.15pt;">Premises, providing that the </font>Suite C-185 <font style="letter-spacing:-0.15pt;">Premises shall be surrendered to Landlord on or before August 31, 2018 (the &#8220;RS&amp;H Termination Agreement&#8221;).&nbsp;&nbsp;If Landlord does not enter into said RS&amp;H Termination Agreement within fifteen (15) days of the date of full execution of this Amendment, then Tenant shall be entitled to terminate this Amendment (and all of its obligations hereunder) by written notice delivered to Landlord within thirty (30) days following the date of full execution of this Amendment (unless Landlord has entered into the RS&amp;H Termination Agreement prior to Tenant&#8217;s delivery of its termination notice, in which event this Amendment shall remain in force and effect).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font>As modified by this Amendment, the Lease continues in full force and effect.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, Landlord and Tenant have executed and delivered this Amendment as of the day and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>WITNESS:</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.98%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:49.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:normal;font-size:12pt;color:#auto;font-family:Times New Roman;text-transform:none;font-variant: normal;">VC OWNER, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Illegible</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeff Sheehan</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signatory</p></td>
<td valign="top"  style="width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESS:</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:42.04%;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:42.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:normal;font-size:12pt;color:#auto;font-family:Times New Roman;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:35.76%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matt Kane</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matt Kane</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:36.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO</p></td>
<td valign="top"  style="width:7.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:12pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLOOR PLAN OF SUITE C-185 PREMISES</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000011.jpg" title="" alt="" style="width:607px;height:396px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:3pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED SEVENTH AMENDMENT TO LEASE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS <font style="font-weight:bold;">AMENDED AND RESTATED SEVENTH AMENDMENT TO LEASE AGREEMENT</font> (this &#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;) is made as of the day of February, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;) by and between <font style="font-weight:bold;">VC OWNER, LLC</font>, a Delaware limited liability company (&#8220;<font style="text-decoration:underline;">Landlord</font>&#8221;), and <font style="font-weight:bold;">PRECISION BIOSCIENCES, INC.</font>, a Delaware corporation (&#8220;<font style="text-decoration:underline;">Tenant</font>&#8221;), with respect to the following recitals:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font>Pursuant to that certain Lease Agreement dated April 5, 2010, as modified by a First Amendment to Lease Agreement dated August 19, 2011, and by a Second Amendment to Lease Agreement dated July 13, 2015, and by a Third Amendment to Lease Agreement dated January 12, 2016, and by a Fourth Amendment to Lease Agreement dated September 30, 2016 (the &#8220;<font style="text-decoration:underline;">Fourth Amendment</font>&#8221;), and by a Fifth Amendment to Lease Agreement dated January 24, 2018 (the &#8220;<font style="text-decoration:underline;">Fifth Amendment</font>&#8221;), by a Sixth Amendment to Lease Agreement dated August 6, 2018, and by a Seventh Amendment to Lease Agreement (the &#8220;<font style="text-decoration:underline;">Seventh Amendment</font>&#8221;) dated November 14, 2018 (collectively, the &#8220;<font style="text-decoration:underline;">Lease</font>&#8221;), Landlord (as successor to Venable Tenant LLC) leases to Tenant certain office space in the group of interconnected buildings situated at 302 East Pettigrew Street, Durham, North Carolina known collectively as &#8220;Venable Center&#8221; (the &#8220;<font style="text-decoration:underline;">Project</font>&#8221;), as more particularly described in the Lease;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;"></font>Landlord and Tenant have agreed to add certain space to the premises demised under the Lease, to amend, restate, supersede, and replace that certain Seventh Amendment, and to make certain other modifications to the Lease as set forth hereinbelow; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;"></font>All capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Lease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a>1.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Premises</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 7</font> of this Amendment, Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, (i) approximately 7,416 rentable square feet of space known as Suite WB100 (the &#8220;<font style="text-decoration:underline;">Suite WB100 Premises</font>&#8221;) in Dibrell B, which is located within the Dibrell Building (the &#8220;<font style="text-decoration:underline;">Building</font>&#8221;) in the Project, as outlined on <font style="text-decoration:underline;">Exhibit A-1</font> attached hereto and incorporated herein and (ii) approximately 7,416 rentable square feet of space known as Suite WB200 (the &#8220;<font style="text-decoration:underline;">Suite WB200 Premises</font>&#8221;, together with the Suite WB100 Premises, collectively, the &#8220;<font style="text-decoration:underline;">Premises</font>&#8221;) in the Building in the Project, as outlined on <font style="text-decoration:underline;">Exhibit A-2</font> attached hereto and incorporated herein.&nbsp;&nbsp;The Term of the Lease with respect to the Suite WB100 Premises shall commence as of March 1, 2019 (the &#8220;<font style="text-decoration:underline;">Suite WB100 Premises Seventh Amendment Commencement Date</font>&#8221;) and shall be coterminous with the Term applicable to the remainder of the Premises.&nbsp;&nbsp;The Term of the Lease with respect to the Suite WB200 Premises shall commence as of May 1, 2019 (the &#8220;<font style="text-decoration:underline;">Suite WB200 Premises Seventh Amendment Commencement Date</font>&#8221;, together with the Suite WB100 Premises Seventh Amendment Commencement Date, collectively, the &#8220;<font style="text-decoration:underline;">Seventh Amendment Commencement Date</font>&#8221;) and shall be coterminous with the Term applicable to the remainder of the Premises.&nbsp;&nbsp;From and after the Suite WB100 Premises Seventh </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Commencement Date and the Suite WB200 Premises Seventh Amendment Commencement Date, respectively, the Suite WB100 Premises and the Suite WB200 Premises, respectively, shall constitute a portion of the &#8220;Premises&#8221; for all purposes under the Lease. Landlord shall have no liability to Tenant in the event Landlord is unable to deliver possession of the Suite WB100 Premises and the Suite WB200 Premises to Tenant on the Suite WB100 Premises Seventh Amendment Commencement Date and the Suite WB200 Premises Seventh Amendment Commencement Date, respectively, due to the holding over by the prior tenants thereof or due to any other matter beyond Landlord's reasonable control (and further provided that Landlord shall use commercially reasonable efforts to enforce its rights under the existing lease agreements as modified by the Amended and Restated Lease Termination Agreement, as hereinafter defined); however, in such event, Base Rent with respect to the Suite WB100 Premises and the Suite WB200 Premises, respectively, will not begin to accrue until the first business day after Landlord is able to deliver possession of the Suite WB100 Premises and the Suite WB200 Premises to Tenant, broom clean and free of any prior tenancy.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the Effective Date, the Suite WB100 Premises and the Suite WB200 Premises are occupied collectively by Hutson Law Office, P.A. (&#8220;<font style="text-decoration:underline;">Hutson Law</font>&#8221;) and Richard M. Hutson II, Chapter 13 Standing Trustee (&#8220;<font style="text-decoration:underline;">Chapter 13</font>&#8221;) with Hutson Law occupying a portion of Suite WB200 Premises in premises known as of the Effective Date as Suite B-260 and with Chapter 13 occupying Suite WB100 Premises and a portion of Suite WB200 Premises in premises known as of the Effective Date as Suite B-140.&nbsp;&nbsp;For purposes of clarity, as of the Seventh Amendment Commencement Date, the suites designated as of the Effective Date as Suite B-140 and Suite B-260 shall no longer have such designations and such premises shall be reconfigured and thereafter be known as Suite WB100 Premises and Suite WB200 Premises.&nbsp;&nbsp;Additionally, for purposes of clarity, Suite WB100 Premises is referred to in the Fourth Amendment as DB First Floor Expansion Premises and Suite WB200 Premises is referred to in the Fourth Amendment as DB Second Floor Expansion Premises.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Rent</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Suite WB100 Premises</font>.&nbsp;&nbsp;Except as set forth in Section 2(c) hereof, from the Suite WB100 Premises Seventh Amendment Commencement Date until the 90<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day thereafter (the &#8220;<font style="text-decoration:underline;">100 Rent Commencement Date</font>&#8221;), Tenant shall not be obligated to pay Base Rent or Operating Expenses with respect to the Suite WB100 Premises while it constructs the tenant improvements in Suite WB100 Premises.&nbsp;&nbsp;From and after the 100 Rent Commencement Date, Tenant shall pay Base Rent with respect to the Suite WB100 Premises only in accordance with the following rent table:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period</font></p></td>
<td valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rate</font></p></td>
<td valign="top"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent</font></p></td>
<td valign="top"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Base Rent</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100RCD*&#8211; January 31, 2020</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.32</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,557.76**</p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2020 &#8211; January 31, 2021</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.88</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$154,846.08 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,903.84 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2021 &#8211; January 31, 2022</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.46</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$159,147.36 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13,262.28 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2022 &#8211; January 31, 2023</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$163,522.80 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13,626.90 </p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2023 &#8211; January 31, 2024</font></p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.65</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$167,972.40 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13,997.70 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 1, 2024 &#8211; July 31, 2024</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.28</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14,387.04 </p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*100 Rent Commencement Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**Notwithstanding anything in the Lease to the contrary (and specifically deleting the reference to the abatement of Base Rent for the DB First Floor Expansion Premises set forth in <font style="text-decoration:underline;">Section 3</font> of the Fourth Amendment), Landlord will forebear the obligation of Tenant to pay Base Rent only for the first three (3) months following the 100 Rent Commencement Date and a portion of the fourth (4<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) month following the 100 Rent Commencement Date in the total amount of $39,831.14 (the &#8220;<font style="text-decoration:underline;">Suite WB100 Abated Payments</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Suite WB200 Premises</font>. Except as set forth in Section 2(c) hereof, from the Suite WB200 Premises Seventh Amendment Commencement Date until the 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> day thereafter (the &#8220;<font style="text-decoration:underline;">200 Rent Commencement Date</font>&#8221;), Tenant shall not be obligated to pay Base Rent or Operating Expenses with respect to the Suite WB200 Premises while it constructs the tenant improvements in Suite WB200 Premises.&nbsp;&nbsp;From and after the 200 Rent Commencement Date, Tenant shall pay Base Rent with respect to the Suite WB200 Premises only in accordance with the following rent table: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period</font></p></td>
<td valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rate</font></p></td>
<td valign="top"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual/Periodic Base Rent</font></p></td>
<td valign="top"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Base Rent</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200RCD* &#8211; March 31, 2020</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.39</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16,309.02** </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2020 &#8211; March 31, 2021</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.12</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$201,121.92 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16,760.16 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2021 &#8211; March 31, 2022</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.87</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$206,683.92 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17,223.66</p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2022 &#8211; March 31, 2023</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.63</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$212,320.08 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17,693.34 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2023 &#8211; March 31, 2024</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.42</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$218,178.72 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,181.56 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2024 &#8211; July 31, 2024</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.23</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,682.14</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*200 Rent Commencement Date</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**Notwithstanding anything in the Lease to the contrary (and specifically deleting the reference to the abatement of Base Rent for the DB Second Floor Expansion Premises set forth in <font style="text-decoration:underline;">Section 3</font> of the Fourth Amendment), Landlord will forebear the obligation of Tenant to pay Base Rent only for the first three (3) months following the 200 Rent Commencement Date and a portion of the fourth (4<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) month following the 200 Rent Commencement Date in the total amount of $52,078.65 (the &#8220;<font style="text-decoration:underline;">Suite WB200 Abated Payments</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">As a part of Tenant&#8217;s willingness to incentivize Hutson Law and Chapter 13&#8217;s early terminations of the Premises in order to facilitate Tenant&#8217;s own leasing of the Premises, Tenant has agreed to pay a portion of the rent payments owed by Hutson Law and Chapter 13 to Landlord for the Premises.&nbsp;&nbsp; Notwithstanding anything in the Lease to the contrary, Landlord and Tenant hereby acknowledge and agree that Tenant shall make the following payments for the Premises to Landlord on or before the following dates:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.69%;width:84.61%;">
<tr>
<td valign="top"  style="width:29.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Payment Due Date</font></p></td>
<td valign="top"  style="width:70.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Amount Due</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:29.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:70.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2019</p></td>
<td valign="top"  style="width:70.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,557.76</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2019</p></td>
<td valign="top"  style="width:70.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12,557.76</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 1, 2019</p></td>
<td valign="top"  style="width:70.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28,866.78</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 1, 2019</p></td>
<td valign="top"  style="width:70.82%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28,866.78</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Additional Rent</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Suite WB100 Premises</font>.&nbsp;&nbsp;Commencing on the 100 Rent Commencement Date, Tenant shall pay Additional Rent with respect to the Suite WB100 Premises pursuant to <font style="text-decoration:underline;">Section 6</font> of the Lease. With respect to the Suite WB100 Premises only, Tenant&#8217;s Proportionate Share shall be (i) 14.36179%, which is the ratio of 7,416 (the rentable square footage of the Suite WB100 Premises) to 51,637 (the rentable square footage of the Building) for the Building, and (ii) 8.66436%, which is the ratio of 7,416 (the rentable square footage of the Suite WB100 Premises) to 85,592 (the rentable square footage of the Project) for the Project. Notwithstanding anything in the Lease to the contrary, with respect to the Suite WB100 Premises only, the Base Rent is a &#8220;triple-net&#8221; rental rate, and Tenant shall pay its Proportionate Share of all Operating Expenses from and after the Suite WB100 Premises Seventh Amendment Commencement Date.&nbsp;&nbsp;For purposes of clarity, the percentages set forth in the table in <font style="text-decoration:underline;">Section 6</font> of the Fourth Amendment for Tenant&#8217;s Proportionate Share of the Building and Tenant&#8217;s Proportionate Share of Project for DB First Floor Expansion Premises are hereby deleted in their entirety.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk529363606"></a><a name="_Hlk529363572"></a><a name="_Hlk529363622"></a><a name="_Hlk529363563"></a>(b)<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Suite WB200 Premises</font>.&nbsp;&nbsp;Commencing on the 200 Rent Commencement Date, Tenant shall pay Additional Rent with respect to the Suite WB200 Premises pursuant to <font style="text-decoration:underline;">Section 6</font><a name="_Hlk529363606"></a> of the Lease. With respect to the Suite WB200 Premises (only), Tenant&#8217;s Proportionate Share shall be (i) 14.36179%, <a name="_Hlk529363572"></a>which is the ratio of 7,416 (the rentable square footage of the Suite WB200 Premises) to 51,637 <a name="_Hlk529363622"></a>(the rentable square footage of the Building) for the Building, and (ii) 8.66436%<a name="_Hlk529363563"></a>, which is the ratio of 7,416 (the rentable square footage of the Suite WB200 Premises) to 85,592 (the rentable square footage of the Project) for the Project. Notwithstanding anything in the Lease to the contrary, with respect to the Suite WB200 Premises only, the Base Rent is a modified &#8220;full-service&#8221; rental rate, and commencing on the Suite WB200 Premises Seventh Amendment Commencement Date, Tenant shall pay its Proportionate Share of increases in Operating Expenses over the Operating Expenses incurred in calendar year 2017.&nbsp;&nbsp;For purposes of clarity, the percentages set forth in the table in <font style="text-decoration:underline;">Section 6</font> of the Fourth Amendment for the Tenant&#8217;s Proportionate Share of the Building and Tenant&#8217;s Proportionate Share of Project for DB Second Floor Expansion Premises are hereby deleted in their entirety.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><a name="_Hlk536688830"></a>4.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Tenant Improvements</font>.&nbsp;&nbsp;Subject to this <font style="text-decoration:underline;">Section 4</font>, Tenant shall accept the Suite WB100 Premises and Suite WB200 Premises in their &#8220;as is&#8221; condition (subject to Landlord's continuing repair and maintenance obligations, as outlined in <font style="text-decoration:underline;">Section 10</font> of the Lease (as may be amended)), and Landlord shall have no obligation to make any alterations or improvements thereto whatsoever (provided that Landlord shall deliver same in good and tenantable condition, broom clean, with all systems serving same in good working order). Any alterations that Tenant desires to make in the Suite WB100 Premises and Suite WB200 Premises shall be subject to all the terms </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and conditions set forth in </font><font style="text-decoration:underline;">Section 11</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Lease.&nbsp;&nbsp;Notwithstanding anything in the Lease to the contrary (and specifically deleting the references to the Improvements Allowances (as defined in </font><font style="text-decoration:underline;">Section 7</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Fourth Amendment) for the DB First Floor Expansion Premises and the DB Second Floor Expansion Premises in </font><font style="text-decoration:underline;">Section 7</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Fourth Amendment), Landlord hereby agrees to grant Tenant (i) an allowance in the amount of $217,480.45 (i.e. $29.33 per rentable square foot multiplied by 7,416 rentable square feet) (the &#8220;</font><font style="text-decoration:underline;">Suite WB100 Granted Allowance</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk536688830"></a>&#8221;) to be applied toward the cost (including architectural and engineering fees) of alterations performed by Tenant in the Suite WB100 Premises and (ii) an allowance in the amount of </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$124,988.76 </font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(the &#8220;</font><font style="text-decoration:underline;">Suite WB200 Granted Allowance</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;, together with the Suite WB100 Granted Allowance, collectively, the &#8220;</font><font style="text-decoration:underline;">Granted Allowance</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) to be applied toward the cost of the design and construction of any alterations Tenant desires to perform in Suite WB100 Premises and Suite WB200 Premises, respectively, in conjunction with Tenant&#8217;s initial occupancy of Suite WB100 Premises and Suite WB200. </font><font style="color:#202020;">Any portion of the Granted Allowance may be applied to pay the fees of the architect and engineers and any construction supervision, contractors' overhead and profit charges, along with fees for any project manager employed by Tenant with respect to such alterations, as well as any licensing and permitting costs and fees; provided, the Suite WB100 Granted Allowance may only be used for the Suite WB100 Premises and the Suite WB200 Granted Allowance may only be used for the Suite WB200 Premises.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of Tenant&#8217;s alterations in the Suite WB100 Premises shall be paid first out the Suite WB100 Granted Allowance until the Suite WB100 Granted Allowance is exhausted (at which time Tenant shall be fully responsible for the cost of any further alterations), and the cost of Tenant&#8217;s alteration in the Suite WB200 Premises shall be paid first out the Suite WB200 Granted Allowance until the Suite WB200 Allowance is exhausted (at which time Tenant shall be fully responsible for the cost of any further alterations).&nbsp;&nbsp;<font style="color:#202020;">Provided no Event of Default then exists under the Lease, the Granted Allowance (or portions thereof) shall be disbursed to Tenant within thirty (30) days following Tenant's submission to Landlord of paid invoices for work related to alterations performed by Tenant in the Suite WB100 Premises and Suite WB200 Premises, accompanied by waivers of liens executed by all contractors employed by Tenant for the performance of such work. If the cost of Tenant's alterations in the Suite WB100 Premises or the Suite WB200 Premises exceeds the amount of the Suite WB100 Granted Allowance or the Suite WB200 Granted Allowance, t</font><font style="color:#252525;">he excess shall be paid by Tenant after the Suite WB100 Granted Allowance or the Suite WB200 Granted Allowance is fully exhausted.&nbsp;&nbsp;</font>Any portion of the (i) Suite WB100 Granted Allowance that has not been applied (or contracted to be applied) in the manner set forth above by the date which is twelve (12) months following the Suite WB100 Premises Seventh Amendment Commencement Date shall revert to Landlord, and Tenant shall have no further rights with respect thereto and (ii) Suite WB200 Granted Allowance that has not been applied (or contracted to be applied) in the manner set forth above by the date which is twelve (12) months following the Suite WB200 Premises Seventh Amendment Commencement Date shall revert to Landlord, and Tenant shall have no further rights with respect thereto.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Security Deposit</font>.&nbsp;&nbsp;Concurrently with its execution of this Amendment, Tenant shall deliver the sum of $28,434.18 to Landlord as an additional portion of the Security Deposit, and accordingly the Security Deposit shall be increased by $28,434.18, which shall be held by Landlord throughout the Term pursuant to the provisions of <font style="text-decoration:underline;">Section 9</font> of the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font><font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Brokers</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord and Tenant each warrant to the other that in connection with this Amendment neither has employed or dealt with any broker, agent or finder, other than CBRE&#173;Raleigh, LLC (the &#8220;</font><font style="text-decoration:underline;">Landlord&#8217;s Broker</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and Cushman &amp; Wakefield (the &#8220;</font><font style="text-decoration:underline;">Tenant&#8217;s Broker</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;, together with Landlord&#8217;s Broker, collectively, &#8220;</font><font style="text-decoration:underline;">Brokers</font><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;). Landlord acknowledges that it shall pay any commission or fee due to the Landlord&#8217;s Broker, pursuant to a separate written agreement.&nbsp;&nbsp;Landlord&#8217;s Broker shall pay any commission or fee due to Tenant&#8217;s Broker, pursuant to a separate written agreement.&nbsp;&nbsp;Each party shall indemnify and hold the other harmless from and against any claim for brokerage or other commissions asserted by any broker, agent or finder employed by the indemnifying party or with whom the indemnifying party has dealt, other than the Brokers.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Contingency</font>.&nbsp;&nbsp;This Amendment and all provisions contained herein are contingent upon (i) an executed amended and restated lease termination agreement between Landlord and Hutson Law for the premises that Hutson Law leases from Landlord (the &#8220;<font style="text-decoration:underline;">Amended and Restated Hutson Law Lease Termination Agreement</font>&#8221;) and (ii) an executed amended and restated lease termination agreement between Landlord and Chapter 13 for the premises that Chapter 13 leases from Landlord (the &#8220;<font style="text-decoration:underline;">Amended and Restated Chapter 13 Lease Termination Agreement</font>&#8221;, together with the Amended and Restated Hutson Law Lease Termination Agreement, collectively, the &#8220;<font style="text-decoration:underline;">Amended and Restated Lease Termination Agreement</font>&#8221;), providing that the Suite WB100 Premises and the Suite WB200 Premises shall be surrendered to Landlord on or before February 28, 2019 or April 30, 2019, respectively, in accordance with the Amended and Restated Lease Termination Agreement.&nbsp;&nbsp;In the event Landlord does not obtain the Amended and Restated Lease Termination Agreement by February 28, 2019, Landlord or Tenant shall thereafter have the right to terminate this Amendment (prior to date of receipt of a fully executed Amended and Restated Lease Termination Agreement).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Notices</font>.&nbsp;&nbsp;The Landlord notice information and payment information in <font style="text-decoration:underline;">Section 29(b)</font><font style="font-weight:bold;font-style:italic;"> </font>of the Lease is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">For Notice Information</font>:&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord</font>:</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VC Owner, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Trinity Capital Advisors</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440 S. Church Street, Suite 800</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charlotte, NC 28202</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Asset Manager</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Longleaf Law Partners</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2235 Gateway Access Point, Suite 201</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raleigh, NC&#160; 27607</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attnention:&nbsp;&nbsp;L. Penn Clarke</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:84.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">For Payment Information</font>:</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Landlord</font>:</p></td>
<td valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VC Owner, LLC</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o TP Triangle</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3020 Carrington Mill Blvd., Suite 425</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:23.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:61.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Morrisville, NC 27560</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Acknowledgement</font>.&nbsp;&nbsp;Landlord and Tenant acknowledge that, to their actual knowledge, each party has complied with all of its obligations under the Lease to date, and, to the extent not expressly modified hereby, all of the terms and conditions of said Lease shall remain unchanged and in full force and effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Seventh Amendment</font>.&nbsp;&nbsp;This Amendment amends, restates, supersedes and replaces that certain Seventh Amendment in its entirety.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.14%;text-indent:7.6%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Dibrell Expansion Premises Clarification</font>.&nbsp;&nbsp;Sections 6 and 7 of the Fifth Amendment are clarified as follows: (i) the Dibrell Expansion Date is agreed to be June 1, 2018; (ii) Base Rent for the Dibrell Expansion Premises, from 1/1/2019 through 3/31/2020 shall be as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.14%;text-indent:7.6%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2019 &#8211; 1/31/2019:<font style="margin-left:36pt;">$3,708.62 (21% abatement)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/1/2019 &#8211; 3/31/2019:<font style="margin-left:36pt;">$4,694.45 per month</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2019 &#8211; 3/31/2020:<font style="margin-left:36pt;">$4,822.61 per month.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning 4/1/2020, Base Rent for the Dibrell Expansion Premises shall follow the existing table in Section 7 of the Fifth Amendment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.08%;margin-right:2.14%;text-indent:7.6%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Miscellaneous</font>.&nbsp;&nbsp;The foregoing is intended to be an addition and a modification to the Lease.&nbsp;&nbsp;Except as modified and amended by this Amendment, the Lease shall remain in full force and effect.&nbsp;&nbsp;If anything contained in this Amendment conflicts with any terms of the Lease, then the terms of this Amendment shall govern and any conflicting terms in the Lease shall be deemed deleted in their entirety.&nbsp;&nbsp;Each party to this Amendment shall execute all instruments and documents and take such further action as may be reasonably required to effectuate the purposes of this Amendment.&nbsp;&nbsp;This Amendment may be modified only by a writing executed by the parties hereto.&nbsp;&nbsp;This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, and all such counterparts shall together constitute one and the same instrument.&nbsp;&nbsp;The invalidity of any portion of this Amendment shall not have any effect on the balance hereof.&nbsp;&nbsp;This Amendment shall be binding upon the parties hereto, as well as their successors, heirs, executors and assigns.&nbsp;&nbsp;This Amendment shall be governed by, and construed in accordance with North Carolina law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of this page intentionally left blank]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, Landlord and Tenant have executed and delivered this Amendment as of the day and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:47.41%;"></td>
<td style="width:6.43%;"></td>
<td style="width:43.59%;"></td>
<td style="width:2.56%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VC OWNER, LLC</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey B. Sheehan</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey B. Sheehan</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Partner</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matt Kane</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matt Kane</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><font style="text-decoration:underline;">EXHIBIT A-1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FLOOR PLAN OF SUITE WB100 PREMISES</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000012.jpg" title="" alt="" style="width:265px;height:750px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><font style="text-decoration:underline;">EXHIBIT A-2</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FLOOR PLAN OF SUITE WB200 PREMISES</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvxjy5si4hmk000013.jpg" title="" alt="" style="width:290px;height:744px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EIGHTH AMENDMENT TO LEASE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS <font style="font-weight:bold;">EIGHTH AMENDMENT TO LEASE AGREEMENT</font> (this &#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;) is made as of the 03 day of March, 2020 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;) by and between <font style="font-weight:bold;">VC OWNER, LLC</font>, a Delaware limited liability company (&#8220;<font style="text-decoration:underline;">Landlord</font>&#8221;), and <font style="font-weight:bold;">PRECISION BIOSCIENCES, INC.</font>, a Delaware corporation (&#8220;<font style="text-decoration:underline;">Tenant</font>&#8221;), with respect to the following recitals:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="margin-left:36pt;"></font>Pursuant to that certain Lease Agreement dated April 5, 2010, as modified by a First Amendment to Lease Agreement dated August 19, 2011, and by a Second Amendment to Lease Agreement dated July 13, 2015, and by a Third Amendment to Lease Agreement dated January 12, 2016, and by a Fourth Amendment to Lease Agreement dated September 30, 2016 (the &#8220;<font style="text-decoration:underline;">Fourth Amendment</font>&#8221;), and by a Fifth Amendment to Lease Agreement dated January 24, 2018, and by a Sixth Amendment to Lease Agreement dated August 6, 2018, and by a Seventh Amendment to Lease Agreement dated November 14, 2018, and an Amended and Restated Seventh Amendment to Lease Agreement dated February <font style="text-decoration:underline;margin-left:36pt;"></font>, 2019 (collectively, the &#8220;<font style="text-decoration:underline;">Lease</font>&#8221;), Landlord (as successor to Venable Tenant LLC) leases to Tenant certain office space in the group of interconnected buildings situated at 302 East Pettigrew Street, Durham, North Carolina known collectively as &#8220;Venable Center&#8221; (the &#8220;<font style="text-decoration:underline;">Project</font>&#8221;), as more particularly described in the Lease;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.<font style="margin-left:36pt;"></font>All capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Lease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Premises</font>.&nbsp;&nbsp;Subject to <font style="text-decoration:underline;">Section 6</font> of this Amendment, Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, approximately 1,164 rentable square feet of space known as Suite 110 (the &#8220;<font style="text-decoration:underline;">Suite 110 Premises</font>&#8221;) in the Prizery Building (the &#8220;<font style="text-decoration:underline;">Building</font>&#8221;) located within the Project, as outlined on <font style="text-decoration:underline;">Exhibit A</font> attached hereto and incorporated herein.&nbsp;&nbsp;The Term of the Lease with respect to the Suite 110 Premises shall commence as of April 1, 2020 (the &#8220;<font style="text-decoration:underline;">Eighth Amendment Commencement Date&#8221;)</font> and shall be coterminous with the Term applicable to the remainder of the Premises.&nbsp;&nbsp;From and after the Eighth Amendment Commencement Date, Suite 110 Premises shall constitute a portion of the &#8220;Premises&#8221; for all purposes under the Lease. Landlord shall have no liability to Tenant in the event Landlord is unable to deliver possession of the Suite 110 Premises to Tenant on the Eighth Amendment Commencement Date due to the holding over by the prior tenant thereof or due to any other matter beyond Landlord's reasonable control (and further provided that Landlord shall use commercially reasonable efforts to enforce its rights under the existing lease agreement as modified by the Lease Termination Agreement, as hereinafter defined); however, in such event, Base Rent with respect to the Suite 110 Premises will not begin to accrue until the first business day after Landlord is able to deliver possession of the Suite 110 Premises, broom clean and free of any prior tenancy.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Suite 110 Premises was a &#8220;must-take&#8221; expansion premises as set forth in <font style="text-decoration:underline;">Section 14</font> of the Fourth Amendment.&nbsp;&nbsp;Provided, however, and for purposes of clarity, due to the early termination of Weinstein&#8217;s (as hereinafter defined) occupancy of the Suite 110 Premises in order to facilitate Tenant&#8217;s own leasing of the Suite 110 Premises, the parties acknowledge and agree that the &#8220;must-take provisions&#8221; of <font style="text-decoration:underline;">Section 14</font> of the Fourth Amendment shall not be applicable to Tenant&#8217;s leasing of the Suite 110 Premises, and instead, the terms and conditions of this Eighth Amendment shall govern.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Rent</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Suite 110 Premises</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;From and after the Eighth Amendment Commencement Date, Tenant shall pay Base Rent with respect to the Suite 110 Premises only in accordance with the following rent table:&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Period</font></p></td>
<td valign="top"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Rate</font></p></td>
<td valign="top"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Annual Base Rent</font></p></td>
<td valign="top"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Monthly Base Rent</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EACD* &#8211; January 31, 2021</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$32.50</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,152.50</p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">February 1, 2021 &#8211; January 31, 2022</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.48</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$38,970.72</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,247.56</p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">February 1, 2022 &#8211; January 31, 2023</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$34.48</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$40,134.72 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,344.56 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">February 1, 2023 &#8211; January 31, 2024</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$35.51</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$41,333.64 </p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,444.47 </p></td>
</tr>
<tr>
<td valign="top"  style="width:37.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:11pt;font-style:italic;color:#auto;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">February 1, 2024 &#8211; July 31, 2024</p></td>
<td valign="middle"  style="width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$36.58</p></td>
<td valign="middle"  style="width:29.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
<td valign="middle"  style="width:22.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3,548.26 </p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Eighth Amendment Commencement Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">As a part of Tenant&#8217;s willingness to incentivize Weinstein&#8217;s early termination of the Suite 110 Premises in order to facilitate Tenant&#8217;s own leasing of the Suite 110 Premises, Tenant has agreed to pay a portion of the rent payments owed by Weinstein to Landlord for the Suite 110 Premises.&nbsp;&nbsp; Notwithstanding anything in the Lease to the contrary, Landlord and Tenant hereby acknowledge and agree that Tenant shall make the following payment for the Premises to Landlord on or before the following date: $19,000.00 on the date that is ten (10) days following the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Additional Rent</font>.&nbsp;&nbsp;Commencing on the Eighth Amendment Commencement Date, Tenant shall pay Additional Rent with respect to the Suite 110 Premises pursuant to <font style="text-decoration:underline;">Section 6</font> of the Lease. With respect to the Suite 110 Premises (only), Tenant&#8217;s Proportionate Share shall be (i) 5.59% which is the ratio of 1,164 (the rentable square footage of the Suite 110 Premises) to 20,814 (the rentable square footage of the Building, and (ii) 1.33%, which is the ratio of 1,164 (the rentable square footage of the Suite 110 Premises) to 87,416 (the rentable square footage of the Project) for the Project. Notwithstanding anything in the Lease to the contrary, with respect to the Suite 110 Premises only, the Base Rent is a modified &#8220;full-service&#8221; rental rate, and commencing on January 1, 2021, Tenant shall pay its Proportionate Share of increases in Operating Expenses over the Operating Expenses incurred in calendar year 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Tenant Improvements</font>.&nbsp;&nbsp;Subject to this <font style="text-decoration:underline;">Section 4</font>, Tenant shall accept the Suite 110 Premises in its &#8220;as is&#8221; condition (subject to Landlord's continuing repair and maintenance obligations, as outlined in <font style="text-decoration:underline;">Section 10</font> of the Lease (as may be amended)), and Landlord shall have no obligation to make any alterations or improvements thereto whatsoever (provided that Landlord shall deliver same in good and tenantable condition, broom clean, with all systems serving same in good working order). Any alterations that Tenant desires to make in the Suite 110 Premises shall be subject to all the terms and conditions set forth in <font style="text-decoration:underline;">Section 11</font> of the Lease.&nbsp;&nbsp;Notwithstanding anything in the Lease to the contrary, Landlord hereby agrees to grant Tenant an allowance in the amount of $10,000 to be applied toward the cost (including architectural and engineering fees) of alterations performed by Tenant in the Suite 110 Premises (the &#8220;<font style="text-decoration:underline;">Granted Allowance</font>&#8221;) in conjunction with Tenant&#8217;s initial occupancy of Suite 110 Premises. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#202020;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a>Provided no Event of Default then exists under the Lease, the Granted Allowance (or portions thereof) shall be disbursed to Tenant within thirty (30) days following Tenant's submission to Landlord of paid invoices for work related to alterations performed by Tenant in the Suite 110 Premises, accompanied by waivers of liens executed by all contractors employed by Tenant for the performance of such work. If the cost of Tenant's alterations in the Suite 110 Premises exceeds the amount of the Granted Allowance, t<font style="color:#252525;">he excess shall be paid by Tenant after the Granted Allowance is fully exhausted.&nbsp;&nbsp;</font><font style="color:#000000;">Any portion of the Granted Allowance that has not been applied (or contracted to be applied) in the manner set forth above by </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;color:#202020;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">the date which is twelve (12) months following the Eighth Amendment Commencement Date shall revert to Landlord, and Tenant shall have no further rights with respect thereto.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Brokers</font>.&nbsp;&nbsp;Landlord and Tenant each warrant to the other that in connection with this Amendment neither has employed or dealt with any broker, agent or finder, other than CBRE&#173;Raleigh, LLC (the &#8220;<font style="text-decoration:underline;">Landlord&#8217;s Broker</font>&#8221;) and Cushman &amp; Wakefield (the &#8220;<font style="text-decoration:underline;">Tenant&#8217;s Broker</font>&#8221;, together with Landlord&#8217;s Broker, collectively, &#8220;<font style="text-decoration:underline;">Brokers</font>&#8221;). Landlord acknowledges that it shall pay any commission or fee due to the Landlord&#8217;s Broker, pursuant to a separate written agreement.&nbsp;&nbsp;Landlord&#8217;s Broker shall pay any commission or fee due to Tenant&#8217;s Broker, pursuant to a separate written agreement.&nbsp;&nbsp;Each party shall indemnify and hold the other harmless from and against any claim for brokerage or other commissions asserted by any broker, agent or finder employed by the indemnifying party or with whom the indemnifying party has dealt, other than the Brokers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Contingency</font>.&nbsp;&nbsp;This Amendment and all provisions contained herein are contingent upon an executed lease termination agreement between Landlord and Weinstein Friedlein Architects, P.A. (&#8220;<font style="text-decoration:underline;">Weinstein</font>&#8221;) for the Suite 110 Premises (the &#8220;<font style="text-decoration:underline;">Lease Termination Agreement</font>&#8221;), providing that the Suite 110 Premises shall be surrendered to Landlord on or before March 31, 2020, in accordance with the Lease Termination Agreement.&nbsp;&nbsp;In the event Landlord does not obtain the Lease Termination Agreement by March 31, 2020, Landlord or Tenant shall thereafter have the right to terminate this Amendment (prior to date of receipt of a fully executed Lease Termination Agreement).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Parking</font>.&nbsp;&nbsp;The parties acknowledge and agree that Landlord (or an affiliate of Landlord) is constructing an office building on a nearby and/or adjacent parcel.&nbsp;&nbsp;Notwithstanding anything in the Lease to the contrary, during the period of time in which Landlord is constructing said office building, (i) Tenant shall not be able to use the parking lot in front of the Building as shown on <font style="text-decoration:underline;">Exhibit B</font> and (ii) Landlord shall provide Tenant with off-site parking and transportation to and from said off-site parking area to and from the Building.&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Acknowledgement</font>.&nbsp;&nbsp;Landlord and Tenant acknowledge that, to their actual knowledge, each party has complied with all of its obligations under the Lease to date, and, to the extent not expressly modified hereby, all of the terms and conditions of said Lease shall remain unchanged and in full force and effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.<font style="margin-left:36pt;"></font><font style="font-style:italic;text-decoration:underline;">Miscellaneous</font>.&nbsp;&nbsp;The foregoing is intended to be an addition and a modification to the Lease.&nbsp;&nbsp;Except as modified and amended by this Amendment, the Lease shall remain in full force and effect.&nbsp;&nbsp;If anything contained in this Amendment conflicts with any terms of the Lease, then the terms of this Amendment shall govern and any conflicting terms in the Lease shall be deemed deleted in their entirety.&nbsp;&nbsp;Each party to this Amendment shall execute all instruments and documents and take such further action as may be reasonably required to effectuate the purposes of this Amendment.&nbsp;&nbsp;This Amendment may be modified only by a writing executed by the parties hereto.&nbsp;&nbsp;This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, and all such counterparts shall together constitute one and the same instrument.&nbsp;&nbsp;The invalidity of any portion of this Amendment shall not have any effect on the balance hereof.&nbsp;&nbsp;This Amendment shall be binding upon the parties hereto, as well as their successors, heirs, executors and assigns.&nbsp;&nbsp;This Amendment shall be governed by, and construed in accordance with North Carolina law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Remainder of this page intentionally left blank]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, Landlord and Tenant have executed and delivered this Amendment as of the day and year first above written.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:47.41%;"></td>
<td style="width:6.43%;"></td>
<td style="width:25.64%;"></td>
<td style="width:20.51%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD<font style="font-weight:normal;">:</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VC OWNER, LLC</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeff Sheehan</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeff Sheehan</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signator</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT<font style="font-weight:normal;">:</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sinu Bhandaru</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sinu Bhandaru</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td colspan="2" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice-President Operations &amp; IT</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03March2020</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><font style="text-decoration:underline;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FLOOR PLAN OF SUITE 110 PREMISES</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PARKING LOT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>dtil-ex1011_944.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex1011_944.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.11</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="exf"></a><a name="zAutoNum"></a><a name="cvr"></a><a name="zbkTOC"></a><a name="toc"></a><a name="zbkTOI"></a><font style="text-decoration:underline;">LEASE</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">BIOPOINT INNOVATION LABS </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DURHAM TW ALEXANDER, LLC<font style="font-weight:normal;">,&nbsp;&nbsp; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />a Delaware limited liability company</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as Landlord,</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.<font style="font-weight:normal;">,</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation,</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as Tenant.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREMISES, BUILDING, PROJECT, AND COMMON AREAS</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE TERM; OPTION TERM</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASE RENT</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADDITIONAL RENT</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF PREMISES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SERVICES AND UTILITIES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPAIRS</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADDITIONS AND ALTERATIONS</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVENANT AGAINST LIENS</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INSURANCE</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DAMAGE AND DESTRUCTION</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NONWAIVER</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONDEMNATION</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASSIGNMENT AND SUBLETTING</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HOLDING OVER</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESTOPPEL CERTIFICATES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBORDINATION</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFAULTS; REMEDIES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVENANT OF QUIET ENJOYMENT</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECURITY DEPOSIT</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBSTITUTION OF OTHER PREMISES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIGNS</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPLIANCE WITH LAW</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LATE CHARGES</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD&#8217;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENTRY BY LANDLORD</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT PARKING</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS PROVISIONS</p></td>
<td valign="top"  style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBITS</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6.94%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</p></td>
<td valign="top"  style="width:93.06%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FIRST OFFER SPACE</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORM OF NOTICE OF LEASE TERM DATES</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PREMISES</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WORK LETTER</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RULES AND REGULATIONS</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FORM OF TENANT&#8217;S ESTOPPEL CERTIFICATE </p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENVIRONMENTAL QUESTIONNAIRE</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RESPONSIBILITY MATRIX</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.94%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</p></td>
<td valign="top"  style="width:93.06%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STORAGE AREA</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abatement Period</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Rent</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advocate Arbitrators</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all risks</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alterations</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Laws</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as built</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank Prime Loan</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base Rent</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BMBL</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brokers</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42, 72</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Builder&#8217;s All Risk</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building Common Areas,</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clean-up</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Closure Letter</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Areas</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comparable Buildings</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comparable Transactions</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concessions</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemplated Effective Date</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemplated Transfer Space</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Control</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Controllable Operating Expenses</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DHHS</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct Expenses</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Environmental Assessment</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18, 32</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Environmental Questionnaire</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Environmental Report</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimate</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimate Statement</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated Direct Expenses</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expense Year</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair Rental Value</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Class Life Sciences Projects</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Offer Commencement Date</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Offer Notice</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Offer Rent</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Offer Space</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generator</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guarantor</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hazardous Materials</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intention to Transfer Notice</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1, 39</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord Parties</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 24</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord Repair Notice</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Commencement Date</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Expiration Date</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Year</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lines</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mail</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Material Service Interruption</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Worth</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neutral Arbitrator</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New Improvements</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notices</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Conditions</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Rent</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option Term</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Original Tenant</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5, 6</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside Agreement Date</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PCBs</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Assignee</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Transferee</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project Common Areas</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project,</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Released</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Releases</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rules and Regulations</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service Interruption</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service Interruption Notice</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statement</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Storage Area</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject Space</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summary</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior Right Holders</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental HVAC</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Expenses</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9, 12</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1, 39</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Subleasing Costs</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant's Agents</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant's Share</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9, 12</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer Notice</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer Premium</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28, 29</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transferee</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfers</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underlying Documents</p></td>
<td valign="top"  style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">BIOPOINT INNOVATION LABS</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LEASE</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Lease (the &#8220;</a><font style="font-weight:bold;">Lease</font>&#8221;), dated as of the date set forth in <font style="text-decoration:underline;">Section&#160;1</font> of the Summary of Basic Lease Information (the &#8220;<font style="font-weight:bold;">Summary</font>&#8221;), below, is made by and between <font style="font-weight:bold;">DURHAM TW ALEXANDER, LLC, </font>a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and <font style="font-weight:bold;">PRECISION BIOSCIENCES, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SUMMARY OF BASIC LEASE INFORMATION</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERMS OF LEASE</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.&#160;&#160;&#160;&#160;&#160;Date:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup>, 2018</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.&#160;&#160;&#160;&#160;&#160;Premises</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 1</font>).</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1&#160;&#160;&#160;&#160;&#160;Building:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That certain office building containing approximately 148,989 rentable square feet of space located at 20 TW Alexander Drive, Research Triangle Park, NC 27709.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2&#160;&#160;&#160;&#160;&#160;Premises:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 17,296 rentable square feet of space on the first (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>) floor of the Building and commonly known as Suite 130, as further set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;C</font> to the Lease.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.&#160;&#160;&#160;&#160;&#160;Lease Term</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:56pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 2</font>).</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1&#160;&#160;&#160;&#160;&#160;Length of Term:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eighty-six (86) months.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:56pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2&#160;&#160;&#160;&#160;&#160;Lease Commencement</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:81pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />The date of Lease execution.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3&#160;&#160;&#160;&#160;&#160;Rent Commencement Date:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nine (9) months after the Lease Commencement Date.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4&#160;&#160;&#160;&#160;&#160;Lease Expiration Date:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eighty-six (86) months after the Rent Commencement Date.</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base Rent</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:20pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 3</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:25%;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Time Period</font></p></td>
<td valign="bottom"  style="width:18.58%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Base Rent</font></p></td>
<td valign="bottom"  style="width:31.42%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monthly</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Installment</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">of Base Rent</font></p></td>
<td valign="bottom"  style="width:25%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Base</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">per Rentable</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Square Foot</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 1**</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$449,696.04 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$37,474.67 </p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.00 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 2</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$463,186.92 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$38,598.91 </p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.78 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 3</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$477,023.64 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$39,751.97 </p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.58 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 4</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$491,379.36 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$40,948.28 </p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.41 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 5</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$506,080.92 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$42,173.41 </p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.26 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 6</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$521,301.48 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$43,441.79 </p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.14 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 7</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$537,040.80 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44,753.40</p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.05 </p></td>
</tr>
<tr>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year 8</p></td>
<td valign="top"  style="width:18.58%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$553,126.08 </p></td>
<td valign="top"  style="width:31.42%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$46,093.84</p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.98 </p></td>
</tr>
<tr>
<td colspan="4" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:40pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Note:&nbsp;&nbsp;Provided Tenant is not in default of the terms of this Lease, after expiration of any applicable notice and cure period, Tenant shall have no obligation to pay any Base Rent attributable to the first two (2) months of the Lease Term following the Rent Commencement Date (the &#8220;<font style="font-weight:bold;">Abatement Period</font>&#8221;).&nbsp;&nbsp;Tenant shall be obligated to pay Tenant&#8217;s Share of Direct Expenses attributable to the Abatement Period.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.&#160;&#160;&#160;&#160;&#160;Tenant Improvements Allowance:</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_195"></a>The improvements in the Premises shall be constructed in accordance with the terms of the Tenant Work Letter attached hereto as <font style="font-weight:bold;text-decoration:underline;"><a name="_cp_text_1_195"></a>Exhibit D</font> up to a cost of $70.58 per rentable square foot.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.&#160;&#160;&#160;&#160;&#160;NNN Lease.</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the Base Rent, Tenant shall be responsible to pay Tenant&#8217;s Share of Direct Expenses in accordance with the terms of <font style="text-decoration:underline;">Article 4</font> of the Lease.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.&#160;&#160;&#160;&#160;&#160;Tenant&#8217;s Share</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:56pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 4</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Approximately 11.61%.&nbsp;&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.&#160;&#160;&#160;&#160;&#160;Permitted Use</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:56pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 5</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />The Premises may only be used for any or all of the following uses: general office, research and development, engineering, GMP manufacturing, laboratory, storage and/or warehouse uses, including, but not limited to, administrative offices and other lawful uses reasonably related to or incidental to such specified uses, all (i) consistent with substantially similar life sciences and/or office projects in the Durham, North Carolina area (&#8220;<font style="font-weight:bold;">First Class Life Sciences Projects</font>&#8221;), and (ii) in compliance with, and subject to, all Applicable Laws (as defined herein), and the terms of this Lease. </p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security Deposit</font></p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:56pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 21</font>): </p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$149,898.68</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So long as Tenant is not in default under this Lease beyond applicable notice and cure periods at any time during the first three (3) years of the Lease Term then thereafter the Security Deposit shall be reduced to $112,424.01.&nbsp;&nbsp;So long as Tenant is not in default under this Lease beyond applicable notice and cure periods at any time during the first five (5) years of the Lease Term then thereafter the Security Deposit shall be reduced to $74,949.34 for the remainder of the Lease Term.&nbsp;&nbsp;In such event, if the Security Deposit has been posted in the form of a cash deposit Landlord shall refund the additional amount to Tenant within thirty (30) days and if the Security Deposit is in the form of a letter of credit then Landlord shall return the existing letter of credit to Tenant upon Tenant&#8217;s posting of a new letter of credit in the correct amount or the posting of a cash deposit by Tenant.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.&#160;&#160;&#160;&#160;Parking Pass Ratio</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:57pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Article 28</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5 unreserved parking spaces for every 1,000 rentable square feet of the Premises, subject to the terms of <font style="text-decoration:underline;">Article&#160;28</font> of the Lease.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;&#160;&#160;&#160;Address of Tenant</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:57pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Section&#160;29.18</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302 E. Pettigrew ST.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Durham, NC 27701</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;Sinu Bhandaru, Director, Head of Operations &amp; IT</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">With a Copy of any default notices to</font>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smith, Anderson, Blount, Dorsett,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mitchell &amp; Jernigan, L.L.P.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post Office Box 2611</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raleigh, North Carolina&nbsp;&nbsp; 27602-2611</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Michael P. Saber, Esq.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">overnight delivery address</font>:</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smith, Anderson, Blount, Dorsett,</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mitchell &amp; Jernigan, L.L.P.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2300 Wells Fargo Capitol Center</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150 Fayetteville Street</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raleigh, North Carolina&nbsp;&nbsp;27601</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.&#160;&#160;&#160;&#160;Address of Landlord</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:57pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Section&#160;29.18</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />See <font style="text-decoration:underline;">Section&#160;29.18</font> of the Lease.</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.&#160;&#160;&#160;&#160;Broker(s)</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:57pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Section&#160;29.24</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Cushman &amp; Wakefield</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:43.58%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.&#160;&#160;&#160;&#160;Guarantor(s)</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:57pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="text-decoration:underline;">Section&#160;29.33</font>):</p></td>
<td colspan="2" valign="top"  style="width:56.42%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />None (&#8220;<font style="font-weight:bold;">Guarantors</font>&#8221;)</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653733"></a><a name="_Toc525822974"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PREMISES, BUILDING, PROJECT, AND COMMON AREAS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Premises, Building, Project and Common Areas</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">The Premises</font>.&nbsp;&nbsp;Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the premises set forth in <font style="text-decoration:underline;">Section&#160;2.2</font> of the Summary (the &#8220;</a><font style="font-weight:bold;">Premises</font>&#8221;).&nbsp;&nbsp;The outline of the Premises is set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;C</font> attached hereto and has the number of rentable square feet as set forth in <font style="text-decoration:underline;">Section&#160;2.2</font> of the Summary.&nbsp;&nbsp;The parties hereto agree that the lease of the Premises is upon and subject to the terms, covenants and conditions herein set forth, and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all of such terms, covenants and conditions by it to be kept and performed and that this Lease is made upon the condition of such performance.&nbsp;&nbsp;The parties hereto hereby acknowledge that the purpose of <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;C</font> is to show the approximate location of the Premises in the &#8220;Building,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;1.1.2</font>, below, only, and such Exhibit is not meant to constitute an agreement, representation or warranty as to the construction of the Premises, the precise area thereof or the specific location of the &#8220;Common Areas,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;1.1.3</font>, below, or the elements thereof or of the accessways to the Premises or the &#8220;Project,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;1.1.2</font>, below.&nbsp;&nbsp;Tenant shall accept the Premises in its presently existing &#8220;as-is&#8221; condition and Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises except Landlord shall deliver the Premises in broom clean condition, with all currently existing Premises systems in good working order (provided that (i) Tenant acknowledges and agrees that demolition work has been performed to a portion of the space, separating same from the remaining, functioning standard office portion; and (ii) Tenant shall promptly notify Landlord of any known/discovered defects or needed repairs to same so that Landlord may fulfill any repair obligations under Section 7.3 of this Lease), and except as otherwise expressly set forth in this Lease or in the Tenant Work Letter attached hereto as <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font>.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Premises shall exclude Common Areas, including without limitation exterior faces of exterior walls, the entry, vestibules and main lobby of the Building, lobbies and common lavatories, the common stairways and stairwells, boiler room, sprinkler rooms, mechanical rooms, loading and receiving areas, electric and telephone closets, janitor closets, and pipes, ducts, conduits, wires and appurtenant fixtures and equipment serving exclusively or in common with other parts of the Building..</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">The Building and The Project</font>.&nbsp;&nbsp;The Premises are a part of the building set forth in <font style="text-decoration:underline;">Section&#160;2.1</font> of the Summary (the &#8220;</a><font style="font-weight:bold;">Building</font>&#8221;).&nbsp;&nbsp;The term &#8220;<font style="font-weight:bold;">Project</font>,&#8221; as used in this Lease, shall mean (i) the Building and the Common Areas, (ii) the land (which is improved with landscaping, parking facilities and other improvements) upon which the Building and the Common Areas are located, (iii) the other buildings located in the project known as &#8220;BioPoint Innovation Labs&#8221;, and the land upon which such adjacent buildings are located, and (iv) at Landlord&#8217;s discretion, any additional real property, areas, land, buildings or other improvements added thereto outside of the Project. Landlord may only own portions of the Project and any rights granted within portions of the Project not owned by Landlord shall be pursuant to recorded declarations and easements to the extent such documents exist.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Common Areas</font>.&nbsp;&nbsp;Tenant shall have the non-exclusive right to use in common with other tenants in the Project, and subject to the Rules and Regulations referred to in <font style="text-decoration:underline;">Article 5</font> of this Lease, those portions of the Project which are provided, from time to time, for use in common by Landlord, Tenant and any other tenants of the Project (such areas, together with such other portions of the Project designated by Landlord, in its discretion, including certain areas designated for the exclusive use of certain tenants, or to be shared by Landlord and certain tenants, are collectively referred to herein as the &#8220;</a><font style="font-weight:bold;">Common Areas</font>&#8221;).&nbsp;&nbsp;The Common Areas shall consist of the &#8220;<font style="font-weight:bold;">Project Common Areas</font>&#8221; and the &#8220;<font style="font-weight:bold;">Building Common Areas</font>.&#8221;&nbsp;&nbsp;The term &#8220;<font style="font-weight:bold;">Project Common Areas</font>,&#8221; as used in this Lease, shall mean the portion of the Project designated as such by Landlord or areas within the Project that the occupants of the Building are permitted to utilize pursuant to a recorded declaration and which areas shall be maintained in accordance with the declaration.&nbsp;&nbsp;The term &#8220;<font style="font-weight:bold;">Building Common Areas</font>,&#8221; as used in this Lease, shall mean the portions of the Common Areas located within the Building reasonably designated as such by Landlord.&nbsp;&nbsp;The manner in which the Common Areas are maintained and operated shall be at the reasonable discretion of Landlord and the use thereof shall be subject to the Rules and Regulations as Landlord may make from time to time.&nbsp;&nbsp;Landlord reserves the right to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas, provided that, in connection therewith, Landlord shall perform such closures, alterations, additions or changes in a commercially reasonable manner and, in connection therewith, shall use commercially reasonable efforts to minimize any material interference with Tenant&#8217;s use of and access to the Premises.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Stipulation of Rentable Square Feet of Premises</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;For purposes of this Lease, &#8220;rentable square feet&#8221; of the Premises shall be deemed as set forth in </font><font style="text-decoration:underline;">Section 2.2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Summary.&nbsp;&nbsp;Notwithstanding the foregoing,&nbsp;&nbsp;the useable area of the Premises shall be determined in accordance with a standard promulgated by the Building Owners and Managers Association which standard is selected by Landlord.&nbsp;&nbsp;The rentable area of the Premises shall be determined by multiplying the useable area of the Premises by a &#8220;core factor&#8221;.&nbsp;&nbsp;Landlord may, at any time, have its architect or engineer measure the actual total usable and rentable square footage of the Premises.&nbsp;&nbsp;In the event the Premises shall contain an amount of rentable square footage different than the amount of rentable square feet referenced in </font><font style="text-decoration:underline;">Section 2.2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Summary, the Premises shall be redefined to reflect the actual rentable square footage but the Base Rent and Additional Rent shall not change from/based what is listed in Section 4 of the Summary. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_263"></a><a name="_cp_text_1_264"></a>1.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Right of First Offer</font><a name="_cp_text_2_263"></a><a name="_cp_text_1_264"></a>.&nbsp;&nbsp;Beginning on the date which is six (6) months after the Rent Commencement Date Landlord hereby grants to the Tenant named in the Summary (the &#8220;<font style="font-weight:bold;">Original Tenant</font>&#8221;) and its &#8220;Permitted Assignees&#8221;, as defined in <font style="text-decoration:underline;">Section 14.8</font>, below, a continuing right of first offer with respect to <font style="font-weight:bold;text-decoration:underline;">Suite 012 containing approximately 12,128 rentable square feet</font> located in the Building as set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit A</font> attached hereto, (the &#8220;<font style="font-weight:bold;">First Offer Space</font>&#8221;).&nbsp;&nbsp;Notwithstanding the foregoing, such first offer right of Tenant shall commence only following the expiration or earlier termination of the initial lease (including renewals) of the First Offer Space, and such right of first offer shall be subordinate to all rights of which are set forth in leases of space in the Project as of the date hereof, including any renewal rights set forth in such leases, regardless of whether such renewal rights are executed strictly in accordance with their terms, or pursuant to a lease amendment or a new lease (collectively, the &#8220;<font style="font-weight:bold;">Superior Right Holders</font>&#8221;) with respect to such First Offer Space.&nbsp;&nbsp;Tenant&#8217;s right of first offer shall not be applicable during any Option Term.&nbsp;&nbsp;Tenant&#8217;s right of first offer shall be on the terms and conditions set forth in this <font style="text-decoration:underline;">Section 1.3.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Procedure for Offer</font>.&nbsp;&nbsp;If Landlord receives a bona fide offer from a third party for the First Offer Space, any portion of the First Offer Space or such larger space that includes the First Offer Space, Landlord shall notify Tenant (the &#8220;<font style="font-weight:bold;">First Offer Notice</font></a>&#8221;), provided that no Superior Right Holder wishes to lease such space.&nbsp;&nbsp;Pursuant to such First Offer Notice, Landlord shall offer to lease to Tenant the then available First Offer Space and any additional space noted within the First Offer Notice.&nbsp;&nbsp;The First Offer Notice shall describe the space so offered to Tenant (which the parties acknowledge may include a portion of the First Offer Space, only the First Offer Space, or the First Offer Space plus additional contiguous space the Landlord is offering for lease) and shall set forth the &#8220;First Offer Rent,&#8221; as that term is defined in <font style="text-decoration:underline;">Section 1.3.3</font> below, and the other economic terms upon which Landlord is willing to lease such space to Tenant. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Procedure for Acceptance</font>.&nbsp;&nbsp;If Tenant wishes to exercise Tenant&#8217;s right of first offer with respect to the space described in the First Offer Notice, then within ten (10) business days of delivery of the First Offer Notice to Tenant, Tenant shall deliver notice to Landlord of Tenant&#8217;s election to exercise its right of first offer with respect to the entire space described in the First Offer Notice on the terms contained in such notice.&nbsp;&nbsp;If Tenant does not so notify Landlord within the ten (10) business day period, then Landlord shall be free to lease the space described in the First Offer Notice to anyone to whom Landlord desires on any terms Landlord desires.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant must elect to exercise its right of first offer, if at all, with respect to all of the space offered by Landlord to Tenant at any particular time, and Tenant may not elect to lease only a portion thereof.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">First Offer Space Rent</font>.&nbsp;&nbsp;The &#8220;Rent,&#8221; as that term is defined in Section&#160;4.1, below, payable by Tenant for the First Offer Space (the &#8220;<font style="font-weight:bold;">First Offer Rent</font></a>&#8221;) shall be equal to the &#8220;Fair Rental Value&#8221;, as defined in <font style="text-decoration:underline;">Section 2.2.2</font>, below, as of the &#8220;First Offer Commencement Date,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;1.3.5</font>, below.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Construction In First Offer Space</font>.&nbsp;&nbsp;Tenant shall take the First Offer Space in its &#8220;as is&#8221; condition, subject to any improvement allowance granted as a component of the Fair Rental Value, and the construction of improvements in the First Offer Space shall comply with the terms of <font style="text-decoration:underline;">Article 8</font> of this Lease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3.5</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Amendment to Lease</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If Tenant timely exercises Tenant&#8217;s right to lease the First Offer Space as set forth herein, Landlord and Tenant shall promptly thereafter execute an amendment to this Lease for such First Offer Space upon the terms and conditions as set forth in the First Offer Notice and this </font><font style="text-decoration:underline;">Section 1.3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall commence payment of Rent for the First Offer Space, and the term of the First Offer Space shall commence upon the date of delivery of the First Offer Space to Tenant (the &#8220;</font><font style="font-weight:bold;">First Offer Commencement Date</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and terminate on the date set forth in the First Offer Notice.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK2"></a>1.3.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Termination of Right of First Offer</font>.&nbsp;&nbsp;The rights contained in this <font style="text-decoration:underline;">Section&#160;1.3</font> shall be personal to the Original Tenant and its Permitted Assignees, and may only be exercised by the Original Tenant or a Permitted Assignee (and not any other assignee, sublessee or other transferee of the Original Tenant&#8217;s interest in this Lease) if the Original Tenant occupies the majority of the Premises.&nbsp;&nbsp;Tenant shall not have the right to lease First Offer Space, as provided in this <font style="text-decoration:underline;">Section 1.3</font><a name="OLE_LINK2"></a>, if, as of the date of the attempted exercise of any right of first offer by Tenant, or as of the scheduled date of delivery of such First Offer Space to Tenant, Tenant is in default under this Lease, after the expiration of any applicable notice and cure period, or Tenant has previously been in default, after the expiration of any applicable notice and cure period, under this Lease more than twice.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653734"></a><a name="_Toc525822975"></a>2.<font style="margin-left:36pt;"></font>LEASE TERM; OPTION TERM</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Lease Term</font>.&nbsp;&nbsp;The terms and provisions of this Lease shall be effective as of the date of this Lease.&nbsp;&nbsp;The term of this Lease (the &#8220;</a><font style="font-weight:bold;">Lease Term</font>&#8221;) shall be as set forth in <font style="text-decoration:underline;">Section&#160;3.1</font> of the Summary, shall commence on the date set forth in <font style="text-decoration:underline;">Section&#160;3.2</font> of the Summary (the &#8220;<font style="font-weight:bold;">Lease Commencement Date</font>&#8221;), and shall terminate on the date set forth in <font style="text-decoration:underline;">Section&#160;3.4</font> of the Summary (the &#8220;<font style="font-weight:bold;">Lease Expiration Date</font>&#8221;) unless this Lease is sooner terminated as hereinafter provided.&nbsp;&nbsp;For purposes of this Lease, the term &#8220;<font style="font-weight:bold;">Lease Year</font>&#8221; shall mean each consecutive twelve (12) month period during the Lease Term.&nbsp;&nbsp;At any time during the Lease Term, Landlord may deliver to Tenant a notice in the form as set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;B</font>, attached hereto, as a confirmation only of the information set forth therein, which Tenant shall execute and return to Landlord within ten (10) business days of receipt thereof.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Option Term</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Option Right</font>.&nbsp;&nbsp;Landlord hereby grants to the originally named Tenant herein (&#8220;<font style="font-weight:bold;">Original Tenant</font></a>&#8221;), and its &#8220;Permitted Assignees&#8221;, as that term is defined in <font style="text-decoration:underline;">Section 14.8</font>, below, one (1) option to extend the Lease Term for a period of five (5)&nbsp;&nbsp;years (the &#8220;<font style="font-weight:bold;">Option Term</font>&#8221;), which option shall be irrevocably exercised only by written notice delivered by Tenant to Landlord not more than eighteen (18) months nor less than nine (9) months prior to the expiration of the initial Lease Term, provided that the following conditions <font style="font-weight:bold;">(</font>the &#8220;<font style="font-weight:bold;">Option Conditions</font>&#8221;) are satisfied:&nbsp;&nbsp;(i)&#160;as of the date of delivery of such notice, Tenant is not in default under this Lease, after the expiration of any applicable notice and cure period; (ii)&#160;as of the end of the Lease Term, Tenant is not in default under this Lease, after the expiration of any applicable notice and cure period; (iii)&#160;Tenant has not previously been in default under this Lease, after the expiration of any applicable notice and cure period, more than twice; and (iv)&#160;the Lease then remains in full force and effect and Original Tenant or a Permitted Assignee occupies the majority of the Premises at the time the option to extend is exercised and as of the commencement of the Option Term.&nbsp;&nbsp;Landlord may, at Landlord&#8217;s option, exercised in Landlord&#8217;s sole and absolute discretion, waive any of the Option Conditions in which case the option, if otherwise properly exercised by Tenant, shall remain in full force and effect.&nbsp;&nbsp;Upon the proper exercise of such option to extend, and provided that Tenant satisfies all of the Option Conditions (except those, if any, which are waived by Landlord), the Lease Term, as it applies to the Premises, shall be extended for a period of five (5) years.&nbsp;&nbsp;The rights contained in this <font style="text-decoration:underline;">Section&#160;2.2</font> shall be personal to Original Tenant and any Permitted Assignees, and may be exercised by Original Tenant or such Permitted Assignees (and not by any assignee, sublessee or other &#8220;Transferee,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;14.1</font> of this Lease, of Tenant&#8217;s interest in this Lease).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.2</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Option Rent</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">The annual Rent payable by Tenant during the Option Term (the &#8220;</font><font style="font-weight:bold;color:#000000;">Option Rent</font><font style="color:#000000;"></font><font style="color:#000000;"></font><font style="color:#000000;">&#8221;) shall be equal to the &#8220;Fair Rental Value,&#8221; as that term is defined below, for the Premises as of the commencement date of the Option Term.&nbsp;&nbsp;</font><font style="color:#000000;">The &#8220;</font><font style="font-weight:bold;color:#000000;">Fair Rental Value</font><font style="font-weight:bold;color:#000000;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">,&#8221; as used in this Lease, shall be equal to the annual rent per rentable square foot (including additional rent and considering any &#8220;base year&#8221; or &#8220;expense stop&#8221; applicable thereto), including all escalations, at which tenants </font><font style="color:#000000;">(pursuant to leases consummated within the twelve (12) month period preceding the first day of the Option Term), </font><font style="color:#000000;">are leasing non-sublease, non-encumbered, non-equity space which is not significantly greater or smaller in size than the subject space, for a comparable lease term, in an arm&#8217;s length transaction, which comparable space is located in the &#8220;Comparable Buildings,&#8221; as that term is defined in this </font><font style="text-decoration:underline;color:#000000;">Section&#160;2.2.2</font><font style="color:#000000;">, below (transactions satisfying the foregoing criteria shall be known as the &#8220;</font><font style="font-weight:bold;color:#000000;">Comparable Transactions</font><font style="font-weight:bold;color:#000000;"></font><font style="font-weight:bold;color:#000000;"></font><font style="color:#000000;">&#8221;), taking into consideration the following concessions (the &#8220;</font><font style="font-weight:bold;color:#000000;">Concessions</font><font style="color:#000000;"></font><font style="color:#000000;"></font><font style="color:#000000;">&#8221;):&nbsp;&nbsp;(a) rental abatement concessions, if any, being granted such tenants in connection with such comparable space; (b) tenant improvements or allowances provided or to be provided for such comparable space, and taking into account the value, if any, of the existing improvements in the subject space, such value to be based upon the age, condition, design, quality of finishes and layout of the improvements and the extent to which the same can be utilized by a general office user other than Tenant; and (c) other reasonable monetary concessions being granted such tenants in connection with such comparable space; provided, however, that in calculating the Fair Rental Value, no consideration shall be given to (i)&#160;the fact that Landlord is or is not required to pay a real estate brokerage commission in connection with Tenant&#8217;s exercise of its right to extend the Lease Term</font><font style="color:#000000;">, </font><font style="color:#000000;">or the fact that landlords are or are not paying real estate brokerage commissions in connection with such comparable space, and (ii) any period of rental abatement, if any, granted to tenants in comparable transactions in connection with the design, permitting and construction of tenant improvements in such comparable spaces.&nbsp;&nbsp;The </font><font style="color:#000000;">Fair Rental Value shall additionally include a determination as to whether, and if so to what extent, Tenant must provide Landlord with financial security, such as a letter of credit or guaranty, for Tenant&#8217;s Rent obligations in connection with Tenant&#8217;s lease of the Premises during the Option Term.&nbsp;&nbsp;Such determination shall be made by reviewing the extent of financial security then generally being imposed in Comparable Transactions from tenants of comparable financial condition and credit history to the then existing financial condition and credit history of Tenant (with appropriate adjustments to account for differences in the then-existing financial condition of Tenant and such other tenants).&nbsp;&nbsp;</font><font style="color:#000000;">The Concessions (A)&#160;shall be reflected in the effective rental rate (which effective rental rate shall take into consideration the total dollar value of such Concessions as amortized on a straight-line basis over the applicable term of the Comparable Transaction (in which case such Concessions evidenced in the effective rental rate shall not be granted to Tenant)) payable by Tenant, or (B)&#160;at Landlord&#8217;s election, all such Concessions shall be granted to Tenant in kind.&nbsp;&nbsp;The term &#8220;</font><font style="color:#000000;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Comparable Buildings</font><font style="color:#000000;">&#8221; shall mean the Building and those other </font><font style="color:#000000;">class A life sciences or class A office buildings</font><font style="color:#000000;"> which are comparable to the Building in terms of age (based upon the date of completion of construction or major renovation of to the building), quality of construction, level of services and amenities, size and appearance, and are located in </font><font style="color:#000000;">Durham, North Carolina&nbsp;&nbsp;and the surrounding commercial area.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Determination of Option Rent</font>.&nbsp;&nbsp;In the event Tenant timely and appropriately exercises an option to extend the Lease Term, Landlord shall notify Tenant of Landlord&#8217;s determination of the Option Rent at least sixty (60) days before the Lease Expiration Date.&nbsp;&nbsp;If Tenant, on or before the date which is ten&#160;(10) business days following the date upon which Tenant receives Landlord&#8217;s determination of the Option Rent, in good faith objects to Landlord&#8217;s determination of the Option Rent, then Landlord and Tenant shall attempt to agree upon the Option Rent using their best good-faith efforts.&nbsp;&nbsp;If Landlord and Tenant fail to reach agreement within ten (10) business days following Tenant&#8217;s objection to the Option Rent (the &#8220;<font style="font-weight:bold;">Outside Agreement Date</font></a>&#8221;), then each party shall make a separate determination of the Option Rent, as the case may be, within five (5) business days, and such determinations shall be submitted to arbitration in accordance with <font style="text-decoration:underline;">Sections&#160;2.2.3.1</font> through <font style="text-decoration:underline;">2.2.3.7</font>, below.&nbsp;&nbsp;If Tenant fails to object to Landlord&#8217;s determination of the Option Rent within the time period set forth herein, then Tenant shall be deemed to have objected to Landlord&#8217;s determination of Option Rent.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><a name="_cp_text_2_283"></a><a name="_cp_text_1_284"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.1</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant shall each appoint one arbitrator who shall be, at the option of the appointing party, a real estate broker or appraiser who shall have been active over the five (5) year period ending on the date of such appointment in the leasing or appraisal (not currently or formerly in the employ of Landlord or Tenant), as the case may be, of other</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">class A life sciences buildings</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_283"></a><a name="_cp_text_1_284"></a> located in the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Durham, North Carolina market area.&nbsp;&nbsp;The determination of the arbitrators shall be limited solely to the issue of whether Landlord&#8217;s or Tenant&#8217;s submitted Option Rent is the closest to the actual Option Rent, taking into account the requirements of </font><font style="text-decoration:underline;">Section&#160;2.2.2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Lease, as determined by the arbitrators.&nbsp;&nbsp;Each such arbitrator shall be appointed within fifteen (15) days after the Outside Agreement Date.&nbsp;&nbsp;Landlord and Tenant may consult with their selected arbitrators prior to appointment and may select an arbitrator who is favorable to their respective positions.&nbsp;&nbsp;The arbitrators so selected by Landlord and Tenant shall be deemed &#8220;</font><font style="font-weight:bold;">Advocate Arbitrators</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#8221;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.2<font style="margin-left:36pt;"></font>The two (2) Advocate Arbitrators so appointed shall be specifically required pursuant to an engagement letter within ten (10) business days of the date of the appointment of the last appointed Advocate Arbitrator to agree upon and appoint a third arbitrator (&#8220;<font style="font-weight:bold;">Neutral Arbitrator</font></a>&#8221;) who shall be qualified under the same criteria set forth hereinabove for qualification of the two Advocate Arbitrators, except that neither the Landlord or Tenant or either parties&#8217; Advocate Arbitrator may, directly or indirectly, consult with the Neutral Arbitrator prior or subsequent to his or her appearance.&nbsp;&nbsp;The Neutral Arbitrator shall be retained via an engagement letter jointly prepared by Landlord&#8217;s counsel and Tenant&#8217;s counsel.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.3<font style="margin-left:36pt;"></font>The three arbitrators shall, within thirty (30) days of the appointment of the Neutral Arbitrator, reach a decision as to whether the parties shall use Landlord&#8217;s or Tenant&#8217;s submitted Option Rent, and shall notify Landlord and Tenant thereof.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.4<font style="margin-left:36pt;"></font>The decision of the majority of the three arbitrators shall be binding upon Landlord and Tenant.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.5<font style="margin-left:36pt;"></font>If either Landlord or Tenant fails to appoint an Advocate Arbitrator&nbsp;&nbsp;within fifteen (15) days after the Outside Agreement Date, then either party may petition the presiding judge of the Superior Court of Durham County to appoint such Advocate Arbitrator subject to the criteria in <font style="text-decoration:underline;">Section&#160;2.2.3.1</font> of this Lease, or if he or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such Advocate Arbitrator.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.6<font style="margin-left:36pt;"></font>If the two (2) Advocate Arbitrators fail to agree upon and appoint the Neutral Arbitrator, then either party may petition the presiding judge of the Superior Court of Durham County to appoint the Neutral Arbitrator, subject to criteria in <font style="text-decoration:underline;">Section&#160;2.2.3.1</font> <font style="text-decoration:underline;">2</font> of this Lease, or if he or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such arbitrator.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.3.7<font style="margin-left:36pt;"></font>The cost of the arbitration shall be paid by Landlord and Tenant equally.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK3"></a>2.2.3.8<font style="margin-left:36pt;"><a name="OLE_LINK3"></a></font>In the event that the Option Rent shall not have been determined pursuant to the terms hereof prior to the commencement of the Option Term, Tenant shall be required to pay the Option Rent initially provided by Landlord to Tenant, and upon the final determination of the Option Rent, the payments made by Tenant shall be reconciled with the actual amounts of Option Rent due, and the appropriate party shall make any corresponding payment to the other party.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653735"></a><a name="_Toc525822976"></a><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">BASE RENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font>Beginning on the Rent Commencement Date, Tenant shall pay, without prior notice or demand, to Landlord or Landlord&#8217;s agent at the management office of the Project, or, at Landlord&#8217;s option, at such other place as Landlord may from time to time designate in advance and in writing, (i) by a check for currency which, at the time of payment, is legal tender for private or public debts in the United States of America, or (ii) if so elected by Tenant, by electronic funds transfer to the account of Landlord as provided to Tenant, base rent (&#8220;</a><font style="font-weight:bold;">Base Rent</font>&#8221;) as set forth in <font style="text-decoration:underline;">Section&#160;4</font> of the Summary, payable in equal monthly installments as set forth in <font style="text-decoration:underline;">Section&#160;4</font> of the Summary&nbsp;&nbsp;in advance on or before the first day of each and every calendar month during the Lease Term, without any setoff or deduction whatsoever.&nbsp;&nbsp;The Base Rent for the first full month of the Lease Term shall be paid at the time of Tenant&#8217;s execution of this Lease.&nbsp;&nbsp;If any Rent payment date (including the Rent Commencement Date) falls on a day of the month other than the first day of such month or if any payment of Rent is for a period which is shorter than one month, the Rent for any fractional month shall accrue on a daily basis for the period from the date such payment is due to the end of such calendar month or to the end of the Lease Term at a rate per day which is equal to 1/365 of the applicable annual Rent.&nbsp;&nbsp;All other payments or adjustments required to be made under the terms of this Lease that require proration on a time basis shall be prorated on the same basis. Base Rent and Additional Rent, as defined below, shall together be denominated &#8220;<font style="font-weight:bold;">Rent</font>.&#8221;&nbsp;&nbsp;Without limiting the foregoing, Tenant&#8217;s obligation to pay Rent shall not be discharged or otherwise affected by any law or regulation now or hereafter applicable to the Premises, or any other restriction on Tenant&#8217;s use, or (except as expressly provided herein) any casualty or taking, or any failure by Landlord to perform any covenant contained herein, or any other occurrence.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653736"></a><a name="_Toc525822977"></a>4.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">ADDITIONAL RENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">General Terms</font>.&nbsp;&nbsp;In addition to paying the Base Rent specified in <font style="text-decoration:underline;">Article 3</font> of this Lease, Tenant shall pay &#8220;<font style="font-weight:bold;">Tenant&#8217;s Share</font></a>&#8221; of the annual &#8220;<font style="font-weight:bold;">Direct Expenses</font>,&#8221; as those terms are defined in <font style="text-decoration:underline;">Sections 4.2.6 and 4.2.2</font> of this Lease, respectively.&nbsp;&nbsp;Such payments by Tenant, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of this Lease, are hereinafter collectively referred to as the &#8220;<font style="font-weight:bold;">Additional Rent</font>&#8221;.&nbsp;&nbsp;All amounts due under this <font style="text-decoration:underline;">Article 4</font> as Additional Rent shall be payable for the same periods and in the same manner as the Base Rent.&nbsp;&nbsp;Without limitation on other obligations of Tenant which survive the expiration of the Lease Term, the obligations of Tenant to pay the Additional Rent provided for in this <font style="text-decoration:underline;">Article 4</font> shall survive the expiration of the Lease Term.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Definitions of Key Terms Relating to Additional Rent</font>.&nbsp;&nbsp;As used in this <font style="text-decoration:underline;">Article&#160;4</font>, the following terms shall have the meanings hereinafter set forth:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.1<font style="margin-left:36pt;"></font>Intentionally Omitted.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.2<font style="margin-left:36pt;"></font>&#8220;</a><font style="font-weight:bold;">Direct Expenses</font>&#8221; shall mean &#8220;<font style="font-weight:bold;">Operating Expenses</font>&#8221; and &#8220;<font style="font-weight:bold;">Tax Expenses</font>.&#8221;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.3<font style="margin-left:36pt;"></font>&#8220;</a><font style="font-weight:bold;">Expense Year</font>&#8221; shall mean each calendar year in which any portion of the Lease Term falls, through and including the calendar year in which the Lease Term expires, provided that Landlord, upon advance written notice to Tenant, may change the Expense Year from time to time to any other twelve (12) consecutive month period, and, in the event of any such change, Tenant&#8217;s Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.4</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Operating Expenses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean all reasonable expenses, costs and amounts of every kind and nature which Landlord actually pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of the Project, or any portion thereof.&nbsp;&nbsp;Without limiting the generality of the foregoing, Operating Expenses shall specifically include any and all of the following:&nbsp;&nbsp;(i) the cost of supplying all utilities, the cost of operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems (if applicable), and the cost of maintenance and service contracts in connection therewith; (ii) the cost of licenses, certificates, permits and inspections and the cost of contesting any governmental enactments which affect Operating Expenses, and the costs incurred in connection with a governmentally mandated transportation system management program or similar program; (iii) the cost of all insurance carried by Landlord in connection with the Project as reasonably determined by Landlord; (iv) the cost of landscaping, re-lamping, and all supplies, tools, equipment and materials used in the operation, repair and maintenance of the Project, or any portion thereof; (v) the cost of parking area operation, repair, restoration, and maintenance; (vi) fees and other costs, including market management and/or incentive fees, consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation, maintenance and repair of the Project; (vii) payments under any equipment rental agreements and the fair rental value of any management office space; (viii) subject to item (f), below, wages, salaries and other compensation and benefits, including taxes levied thereon, of all persons engaged in the operation, maintenance and security of the Project (at or below the level of property manager); (ix) costs under any instrument pertaining to the sharing of costs by the Project; (x) operation, repair, maintenance and replacement of all systems and equipment and components thereof of the Project; (xi) the cost of janitorial, alarm, security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in Common Areas, maintenance and replacement of curbs and walkways, repair to roofs and re-roofing; (xii) amortization (including reasonable interest on the unamortized cost) over such period of time as Landlord shall reasonably determine, of the cost of acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project, or any portion thereof; (xiii) the cost of capital improvements or other costs incurred in connection with the Project (A) which are intended to reduce expenses in the operation or maintenance of the Project, or any portion thereof, or to reduce current or future Operating Expenses or to enhance the safety or security of the Project or its occupants, (B) that are required to comply with present or anticipated mandatory conservation programs, (C) which are replacements or modifications of nonstructural items located in the Common Areas required to keep the Common Areas in the same good order or condition as on the Commencement Date, or (D) that are required under any governmental law or regulation that was not in force or effect as of the Commencement Date; provided, however, that any capital expenditure shall be amortized (including reasonable interest on the amortized cost as reasonably determined by Landlord) in accordance with IRS regulations; and (xiv) costs, fees, charges or assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or local government for fire and police protection, trash removal, community services, or other services which do not constitute &#8220;Tax Expenses&#8221; as that term is defined in </font><font style="text-decoration:underline;">Section&#160;4.2.5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, below, (xv)&#160;cost of tenant relation programs reasonably established by Landlord, and (xvi)&#160;payments under any easement, license, operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of costs by the Building, including, without limitation, any covenants, conditions and restrictions affecting the property, and reciprocal easement agreements affecting the property, any parking licenses, and any agreements with transit agencies affecting the Property (collectively, &#8220;</font><font style="font-weight:bold;">Underlying Documents</font><font style="font-weight:bold;"></font><font style="font-weight:bold;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;In the event that Landlord or Landlord&#8217;s managers or agents perform services for the benefit of the Building off-site which would otherwise be performed on-site (e.g. accounting), the cost of such services shall be reasonably allocated among the properties benefitting from such service and shall be included in Operating Expenses.&nbsp;&nbsp;Notwithstanding the foregoing, for purposes of this Lease, Operating Expenses shall not, however, include: </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>costs, including legal fees, space planners&#8217; fees, advertising and promotional expenses, and brokerage fees incurred in connection with the original construction or development, or original or future leasing of the Project, and costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for new tenants initially occupying space in the Project after the Lease Commencement Date or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Project (excluding, however, such costs relating to any common areas of the Project);</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>except as set forth in items (xii), (xiii), and (xiv) above, depreciation, interest and principal payments on mortgages and other debt costs, if any, penalties and interest, and costs of capital improvements (as distinguished from repairs or replacements);</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs for which the Landlord is reimbursed by any tenant or occupant of the Project or by insurance by its carrier or any tenant&#8217;s carrier or by anyone else, and electric power costs for which any tenant directly contracts with the local public service company;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>any bad debt loss, rent loss, or reserves for bad debts or rent loss;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>costs associated with the operation of the business of the partnership or entity which constitutes the Landlord, as the same are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting costs associated with the operation of the Project).&nbsp;&nbsp;Costs associated with the operation of the business of the partnership or entity which constitutes the Landlord include costs of partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions of the Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of the Landlord&#8217;s interest in the Project, and costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Project management, or between Landlord and other tenants or occupants;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to personnel above the level of Project manager;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>amount paid as ground rental for the Project by the Landlord;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>except for a property management fee to the extent expressly allowed above, overhead and profit increment paid to the Landlord or to subsidiaries or affiliates of the Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by qualified, first-class unaffiliated third parties on a competitive basis;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>any compensation paid to clerks, attendants or other persons in commercial concessions operated by the Landlord, provided that any compensation paid to any concierge at the Project shall be includable as an Operating Expense;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font>rentals and other related expenses incurred in leasing air conditioning systems, elevators (if applicable) or other equipment which if purchased the cost of which would be excluded from Operating Expenses as a capital improvement, except equipment not affixed to the Project which is used in providing janitorial or similar services and, further excepting from this exclusion such equipment rented or leased to remedy or ameliorate an emergency condition in the Project ;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font>all items and services for which Tenant or any other tenant in the Project reimburses Landlord or which Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font>any costs expressly excluded from Operating Expenses elsewhere in this Lease;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font>rent for any office space occupied by Project management personnel to the extent the size or rental rate of such office space exceeds the size or fair market rental value of office space occupied by management personnel of the comparable buildings in the vicinity of the Building, with adjustment where appropriate for the size of the applicable project;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)<font style="margin-left:36pt;"></font>costs arising from the gross negligence or willful misconduct of Landlord or its agents, employees, vendors, contractors, or providers of materials or services; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs incurred to comply with laws relating to the removal of hazardous material (as defined under Applicable Law) which was in existence in the Building or on the Project prior to the Lease Commencement Date, and was of such a nature that a federal, State or municipal governmental authority, if it had then had knowledge of the presence of such hazardous material, in the state, and under the conditions that it then existed in the Building or on the Project, would have then required the removal of such hazardous material or other remedial or containment action with respect thereto; and costs incurred to remove, remedy, contain, or treat hazardous material, which hazardous material is brought into the Building or onto the Project after the date hereof by Landlord or any other tenant of the Project and is of such a nature, at that time, that a federal, State or municipal governmental authority, if it had then had knowledge of the presence of such hazardous material, in the state, and under the conditions, that it then exists in the Building or on the Project, would have then required the removal of such hazardous material or other remedial or containment action with respect thereto;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)<font style="margin-left:36pt;"></font>costs incurred to comply with laws relating to the removal of Hazardous Materials (other than Hazardous Materials typically found in first class office buildings, such as recyclable materials and typical construction materials, and costs to comply with the Operation and Maintenance Plan described on <font style="font-weight:bold;">Exhibit G</font>);</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)<font style="margin-left:36pt;"></font>the cost of special services, goods or materials provided to any other tenant of the Project free of charge, and not provided to Tenant;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(r)<font style="margin-left:36pt;"></font>Landlord&#8217;s general overhead expenses not related to the Project;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(s)<font style="margin-left:36pt;"></font>legal fees, accountants&#8217; fees (other than normal bookkeeping expenses) and other expenses incurred in connection with disputes of tenants or other occupants of the Project or associated with the enforcement of the terms of any leases with tenants or the defense of Landlord&#8217;s title to or interest in the Project or any part thereof;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(t)<font style="margin-left:36pt;"></font>costs incurred due to a violation by Landlord or any other tenant of the Project of the terms and conditions of a lease; and</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(u)<font style="margin-left:36pt;"></font>any reserve funds.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Landlord is not furnishing any particular work or service (the cost of which, if performed by Landlord, would be included in Operating Expenses) to a tenant who has undertaken to perform such work or service in lieu of the performance thereof by Landlord, Operating Expenses shall be deemed to be increased by an amount equal to the additional Operating Expenses which would reasonably have been incurred during such period by Landlord if it had at its own expense furnished such work or service to such tenant.&nbsp;&nbsp;If the Project is not at least one hundred percent (100%) occupied during all or a portion of any Expense Year, Landlord shall make an appropriate adjustment to the components of Operating Expenses for such year to determine the amount of Operating Expenses that would have been incurred had the Project been one hundred percent (100%) occupied; and the amount so determined shall be deemed to have been the amount of Operating Expenses for such year.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Taxes</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.5.1<font style="margin-left:36pt;"></font>&#8220;</a><font style="font-weight:bold;">Tax Expenses</font>&#8221; shall mean all federal, state, county, or local governmental or municipal taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without limitation, real estate taxes, general and special assessments, transit taxes, leasehold taxes or taxes based upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent, unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and equipment, appurtenances, furniture and other personal property used in connection with the Project, or any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used by such governmental or municipal authority) because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.5.2</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Expenses shall include, without limitation:&nbsp;&nbsp;(i) Any tax on the rent, right to rent or other income from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii) Any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously included within the definition of real property tax; (iii) Any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable hereunder, including, without limitation, any business or gross income tax or excise tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises, or any portion thereof; and (iv) Any assessment, tax, fee, levy or charge, upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements thereon.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.5.3<font style="margin-left:36pt;"></font>Any reasonable costs and expenses (including, without limitation, reasonable attorneys&#8217; and consultants&#8217; fees) incurred in attempting to protest, reduce or minimize Tax Expenses shall be included in Tax Expenses in the Expense Year such expenses are incurred.&nbsp;&nbsp;Tax refunds shall be credited against Tax Expenses and refunded to Tenant regardless of when received, based on the Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such Expense Year exceed the total amount paid by Tenant as Additional Rent under this Article 4 for such Expense Year.&nbsp;&nbsp;The foregoing sentence shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;If Tax Expenses for any period during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, error or reassessment by applicable governmental or municipal authorities, Tenant shall pay Landlord upon demand Tenant&#8217;s Share of any such increased Tax Expenses.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this <font style="text-decoration:underline;">Section&#160;4.2.5</font>, there shall be excluded from Tax Expenses (i) all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes, estate taxes, transfer tax or fee, federal and state income taxes, and other taxes to the extent applicable to Landlord&#8217;s general or net income (as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included as Operating Expenses, and (iii) any items paid by Tenant under <font style="text-decoration:underline;">Section&#160;4.5</font> of this Lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_322"></a><a name="_cp_text_1_323"></a>4.2.6<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Tenant&#8217;s Share</font><a name="_cp_text_2_322"></a><a name="_cp_text_1_323"></a>&#8221; is based upon the ratio that the rentable square feet of the Premises bears to the rentable square feet of the Building and, subject to adjustment pursuant to Section 1.2 above, is the percentage set forth in <font style="text-decoration:underline;">Section&#160;7</font> of the Summary.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally omitted</font>.&nbsp;&nbsp;.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_324"></a>4.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Calculation and Payment of Additional Rent</font>.&nbsp;&nbsp;Tenant shall pay to Landlord, in the manner set forth in <font style="text-decoration:underline;">Section&#160;4.4.1</font><a name="_cp_text_1_324"></a>, below, and as Additional Rent, Tenant&#8217;s Share of Direct Expenses for each Expense Year. If the Rent Commencement Date is a day other than the first day of an Expense Year, or if this Lease terminates or expires on a day other than the last day of an Expense Year, then Additional Rent shall be prorated in the manner provided in Section 3.1 above.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>4.4.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Statement of Actual Direct Expenses and Payment by Tenant</font>.&nbsp;&nbsp;Landlord shall use good faith efforts to give to Tenant within six (6) months following the end of each Expense Year, a statement (the &#8220;<font style="font-weight:bold;">Statement</font>&#8221;) which shall state the Direct Expenses incurred or accrued for such preceding Expense Year, and which shall indicate the amount of Tenant&#8217;s Share of Direct Expenses.&nbsp;&nbsp;Upon receipt of the Statement for each Expense Year commencing or ending during the Lease Term, Tenant shall pay, with<font style="letter-spacing:-0.6pt;"> </font>its next installment of Base Rent due, the full amount of Tenant&#8217;s Share of Direct Expenses for such Expense Year, less the amounts, if any, paid during such Expense Year as &#8220;<font style="font-weight:bold;">Estimated Direct Expenses</font>,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;4.4.2</font>, below, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#8217;s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant&#8217;s overpayment against Rent next due under this Lease.&nbsp;&nbsp;The failure of Landlord to timely furnish the Statement for any Expense Year shall not prejudice Landlord or Tenant from enforcing its rights under this <font style="text-decoration:underline;">Article 4</font>.&nbsp;&nbsp;Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made of Tenant&#8217;s Share of Direct Expenses for the Expense Year in which this Lease terminates, Tenant shall pay to Landlord such amount within thirty (30) days, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#8217;s Share of Direct Expenses, Landlord shall, within thirty (30) days, deliver a check payable to Tenant in the amount of the overpayment.&nbsp;&nbsp;The provisions of this <font style="text-decoration:underline;">Section&#160;4.4.1</font> shall survive the expiration or earlier termination of the Lease Term.&nbsp;&nbsp;Notwithstanding the immediately preceding sentence, Tenant shall not be responsible for Tenant&#8217;s Share of any Direct Expenses attributable to any Expense Year which are first billed to Tenant more than two </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)&#160;calendar years after the earlier of the expiration of the applicable Expense Year or the Lease Expiration Date, provided that in any event Tenant shall be responsible for Tenant&#8217;s Share of Direct Expenses levied by any governmental authority or by any public utility companies at any time following the Lease Expiration Date which are attributable to any Expense Year (provided that Landlord delivers Tenant a bill for such amounts within two (2)&#160;years following Landlord&#8217;s receipt of the bill therefor).</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Statement of Estimated Direct Expenses</font>.&nbsp;&nbsp;In addition, Landlord shall give Tenant a yearly expense estimate statement (the &#8220;</a><font style="font-weight:bold;">Estimate Statement</font>&#8221;) which shall set forth Landlord&#8217;s reasonable estimate (the &#8220;<font style="font-weight:bold;">Estimate</font>&#8221;) of what the total amount of Direct Expenses for the then-current Expense Year shall be and the estimated Tenant&#8217;s Share of Direct Expenses (the &#8220;<font style="font-weight:bold;">Estimated Direct Expenses</font>&#8221;).&nbsp;&nbsp;The failure of Landlord to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect any Estimated Direct Expenses under this <font style="text-decoration:underline;">Article 4</font>, nor shall Landlord be prohibited from revising any Estimate Statement or Estimated Direct Expenses theretofore delivered to the extent necessary.&nbsp;&nbsp;Thereafter, Tenant shall pay, with its next installment of Base Rent due, a fraction of the Estimated Direct Expenses for the then-current Expense Year (reduced by any amounts paid pursuant to the last sentence of this <font style="text-decoration:underline;">Section&#160;4.4.2</font>).&nbsp;&nbsp;Such fraction shall have as its numerator the number of months which have elapsed in such current Expense Year, including the month of such payment, and twelve (12) as its denominator.&nbsp;&nbsp;Until a new Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time), Tenant shall pay monthly, with the monthly Base Rent installments, an amount equal to one-twelfth (1/12) of the total Estimated Direct Expenses set forth in the previous Estimate Statement delivered by Landlord to Tenant.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_164"></a><a name="_cp_text_4_165"></a><a name="_cp_text_4_166"></a><a name="_cp_text_1_167"></a>4.4.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Audit Right</font><a name="_cp_text_1_164"></a>. In the event the Controllable Operating Expenses (as defined below) increase by more than three percent (3%) in any given Lease Year (as measured against the Controllable Operating Expenses for the immediately preceding Lease Year), or as otherwise reasonably requested by Tenant (or required by Tenant&#8217;s business partners and/or applicable law), then Tenant may audit Landlord&#8217;s records and all information pertaining to Operating Expenses in order to verify the accuracy of Landlord&#8217;s determination of the Tenant&#8217;s Share subject to the procedure noted below.&nbsp;&nbsp;Controllable Operating Expenses shall include all Operating Expenses other than <a name="_cp_text_4_165"></a>utilities (e.g., electricity, gas, water and sewer), management fees, security expenses<a name="_cp_text_4_166"></a>, insurance, taxes, assessments, snow and ice removal and other weather related charges, association fees and charges under any declaration, storm water fees and similar governmental or quasi-governmentally imposed fees, and <a name="_cp_text_1_167"></a>any other expenses which are set or determined by a governmental entity or other third party and non-negotiable, or are otherwise beyond Landlord&#8217;s reasonable control including minimum wage increases, hereafter, &#8220;<font style="font-weight:bold;">Controllable Operating Expenses</font>&#8221;.&nbsp;&nbsp; Tenant must comply with the following in order to audit Landlord&#8217;s records and information pertaining to Operating Expenses:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">Tenant must give notice to Landlord of its election to undertake said audit within one hundred twenty (120) days after receipt of the statement of the actual amount of Tenant&#8217;s Share for the preceding calendar year from Landlord, and with respect to such audit, Tenant may audit the two preceding calendar years;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;">Such audit will be conducted only during regular business hours at the office where Landlord maintains records of Operating Expenses and only after Tenant gives Landlord fourteen (14) days&#8217; advance written notice; </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">Tenant shall deliver to Landlord a copy of the results of such audit within fifteen (15) days of its receipt by Tenant and no such audit shall be conducted if any other tenant of the Building has conducted an independent audit for the time period Tenant intends to audit and Landlord furnishes to Tenant a copy of such audit;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;">No audit shall be conducted at any time that Tenant is in default (after the expiration of any applicable grace and/or cure period) of any of the terms of this Lease;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;">No subtenant shall have any right to conduct an audit and no assignee shall conduct an audit for any period during which such assignee was not in possession of the Premises; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font><font style="margin-left:36pt;">Such audit review by Tenant shall not postpone or alter the liability and obligation of Tenant to pay any amounts due under the terms of this Lease; and</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;">Such audit shall be conducted by an independent, reputable accounting firm which is not being compensated by Tenant on a contingency fee basis.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within thirty (30) days after Tenant&#8217;s receipt of such audit, Tenant must give notice to Landlord of any disputed amounts and identify all items being contested in Landlord&#8217;s statement of the Tenant Share.&nbsp;&nbsp;If Landlord and Tenant cannot agree upon any such item as to which Tenant shall have given such notice, the dispute shall be resolved by an audit by a major accounting firm mutually and reasonably acceptable to Landlord and Tenant and the cost of said joint audit shall be paid by the non-prevailing party.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any adjustment required as a result of any audit shall be paid within 30 days, or adjusted in the next installment(s) of Tenant&#8217;s Share. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Taxes and Other Charges for Which Tenant Is Directly Responsible</font>.&nbsp;&nbsp;Tenant shall be liable for and shall pay before delinquency, taxes levied against Tenant&#8217;s equipment, furniture, fixtures and any other personal property located in or about the Premises.&nbsp;&nbsp;If any such taxes on Tenant&#8217;s equipment, furniture, fixtures and any other personal property are levied against Landlord or Landlord&#8217;s property or if the assessed value of Landlord&#8217;s property is noticeably increased by the inclusion therein of a value placed upon such equipment, furniture, fixtures or any other personal property (as reasonably documented by Landlord) and if Landlord pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof but only under proper protest if requested by Tenant, Tenant shall upon demand repay to Landlord the taxes so levied against Landlord or the proportion of such taxes resulting from such increase in the assessment, as the case may be. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Limit of Increases in Tenant&#8217;s Share of Operating Expenses</font><font style="font-weight:bold;">.</font>&nbsp;&nbsp;The Controllable Operating Expenses (as hereinafter defined) which may be passed through to Tenant under this Section 4 shall not increase in any year by an amount which exceeds five percent (5%) of such Controllable Operating Expenses for the immediately preceding year (as measured on a cumulative and compounded basis).&nbsp;&nbsp;For purposes hereof, &#8220;<font style="font-weight:bold;">Controllable Operating Expenses</font></a>&#8221; shall be deemed to include all Operating Expenses other than utilities (e.g., electricity, gas, water and sewer), management fees, security expenses, insurance, taxes, assessments, snow and ice removal and other weather related charges, association fees and charges under any declaration, storm water fees and similar governmental or quasi-governmentally imposed fees, and any other expenses which are set or determined by a governmental entity or other third party or are otherwise beyond Landlord&#8217;s reasonable control including minimum wage increases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653737"></a><a name="_Toc525822978"></a>5.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">USE OF PREMISES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Permitted Use</font>.&nbsp;&nbsp;Tenant shall use the Premises solely for the Permitted Use set forth in <font style="text-decoration:underline;">Section&#160;8</font> of the Summary and Tenant shall not use the Premises or the Project for any other purpose or purposes whatsoever without the prior written consent of Landlord, which may be withheld in Landlord&#8217;s sole discretion.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>5.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Prohibited Uses</font>.&nbsp;&nbsp;Tenant further covenants and agrees that Tenant shall not use, or suffer or permit any person or persons to use, the Premises or any part thereof for any use or purpose contrary to the provisions of the Rules and Regulations set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;E</font>, attached hereto (the &#8220;<font style="font-weight:bold;">Rules and Regulations</font>&#8221;), or in violation of the laws of the United States of America, the State of North Carolina, or the ordinances, regulations or requirements of the local municipal or county governing body or other lawful authorities having jurisdiction over the Project, including, without limitation, any such laws, ordinances, regulations or requirements relating to hazardous materials or substances, as those terms are defined by Applicable Laws now or hereafter in effect, or any Underlying Documents.&nbsp;&nbsp;Tenant shall not do or permit anything to be done in or about the Premises which will damage the reputation of the Project or obstruct or unreasonably interfere with the rights of other tenants or occupants of the Building, or injure or annoy them or use or allow the Premises to be used for any improper, unlawful or objectionable purpose, nor shall Tenant cause or maintain any nuisance in, on or about the Premises.&nbsp;&nbsp;Tenant shall comply with, and Tenant&#8217;s rights and obligations under the Lease and Tenant&#8217;s use of the Premises shall be subject and subordinate to, all recorded easements, covenants, conditions, and restrictions now or hereafter affecting the Project.&nbsp;&nbsp;Provided, however, that (a)&#160;in the event of any conflict between any Rules and Regulations and the express terms of this Lease, the Lease terms </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall control; (b)&#160;such Rules and Regulations do not require payment of additional material sum of money; (c) such Rules and Regulations do not unreasonably and materially interfere with Tenant&#8217;s conduct of its business or Tenant&#8217;s use and enjoyment of the Premises; (d) Landlord provides reasonable advance written notice thereof; and (e)&#160;such Rules and Regulations are uniformly enforced in a non-discriminatory manner.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally Omitted</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Hazardous Materials</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Obligations</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Prohibitions</font>.&nbsp;&nbsp;As a material inducement to Landlord to enter into this Lease with Tenant, Tenant has, to the best of its knowledge, completed Landlord&#8217;s Pre-Leasing Environmental Exposure Questionnaire (the &#8220;<font style="font-weight:bold;">Environmental Questionnaire</font></a>&#8221;), which is attached as <font style="font-weight:bold;text-decoration:underline;">Exhibit G</font>.&nbsp;&nbsp;Tenant hereby represents, warrants and covenants that except for those chemicals or materials, and their respective quantities, specifically listed on the Environmental Questionnaire, neither Tenant nor Tenant&#8217;s employees, contractors and subcontractors of any tier, entities with a contractual relationship with Tenant (other than Landlord), or any entity acting as an agent or sub-agent of Tenant (collectively, &#8220;<font style="font-weight:bold;">Tenant&#8217;s Agents</font>&#8221;) will produce, use, store or generate any &#8220;Hazardous Materials,&#8221; as that term is defined below, on, under or about the Premises, nor cause or permit any Hazardous Material to be brought upon, placed, stored, manufactured, generated, blended, handled, recycled, used or &#8220;Released,&#8221; as that term is defined below, on, in, under or about the Premises.&nbsp;&nbsp;If any information provided to Landlord by Tenant on the Environmental Questionnaire, or otherwise relating to information concerning Hazardous Materials is knowingly false, incomplete, or misleading in any material respect, the same shall be deemed a default by Tenant under this Lease.&nbsp;&nbsp;Tenant shall deliver to Landlord an updated Environmental Questionnaire at least once a year, upon Landlord's request, and in the event of any material change in Tenant's use of Hazardous Materials at the Premises.&nbsp;&nbsp;Landlord&#8217;s prior written consent shall be required to any Hazardous Materials use for the Premises not described on the initial Environmental Questionnaire, such consent not to be unreasonably withheld, conditioned, or delayed.&nbsp;&nbsp;Tenant shall not install or permit any underground storage tank on the Premises.&nbsp;&nbsp;In addition, Tenant agrees that it:&nbsp;&nbsp;(i)&#160;shall not cause or suffer to occur, the Release of any Hazardous Materials at, upon, under or within the Premises or any contiguous or adjacent premises; and (ii)&#160;shall not engage in activities at the Premises that result in, give rise to, or lead to the imposition of liability upon Tenant or Landlord or the creation of an environmental lien or use restriction upon the Premises.&nbsp;&nbsp;For purposes of this Lease, &#8220;<font style="font-weight:bold;">Hazardous Materials</font>&#8221; means all flammable explosives, petroleum and petroleum products, waste oil, radon, radioactive materials, toxic pollutants, asbestos, polychlorinated biphenyls (&#8220;<font style="font-weight:bold;">PCBs</font>&#8221;), medical waste, chemicals known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials, including without limitation any chemical, element, compound, mixture, solution, substance, object, waste or any combination thereof, which is or may be hazardous to human health, safety or to the environment due to its radioactivity, ignitability, corrosiveness, reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially harmful properties or effects, or defined as, regulated as or included in, the definition of &#8220;hazardous substances,&#8221; &#8220;hazardous wastes,&#8221; &#8220;hazardous materials,&#8221; or &#8220;toxic substances&#8221; under any Environmental Laws.&nbsp;&nbsp;The term &#8220;Hazardous Materials&#8221; for purposes of this Lease shall also include any mold, fungus or spores, whether or not the same is defined, listed, or otherwise classified as a &#8220;hazardous material&#8221; under any Environmental Laws, if such mold, fungus or spores may pose a risk to human health or the environment or negatively impact the value of the Premises.&nbsp;&nbsp;For purposes of this Lease, &#8220;<font style="font-weight:bold;">Release</font>&#8221; or &#8220;<font style="font-weight:bold;">Released</font>&#8221; or &#8220;<font style="font-weight:bold;">Releases</font>&#8221; shall mean any release, deposit, discharge, emission, leaking, spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping, disposing, or other movement of Hazardous Materials into the environment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any use or storage of Hazardous Materials by Tenant permitted pursuant to this Article 5 shall not exceed Tenant&#8217;s proportionate share (measured on a per floor basis), based on the standards of the BMBL (as defined below), of similarly classed Hazardous Materials.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing to the contrary, in no event shall Tenant or anyone claiming by through or under Tenant perform work at or above the risk category Biosafety Level 2&nbsp;&nbsp;as established by the Department of Health and Human Services (&#8220;</font><font style="font-weight:bold;">DHHS</font><font style="font-weight:bold;"></font><font style="font-weight:bold;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and as further described in the DHHS publication Biosafety in Microbiological and Biomedical Laboratories (5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Edition) (as it may be or may have been further revised, the &#8220;</font><font style="font-weight:bold;">BMBL</font><font style="font-weight:bold;"></font><font style="font-weight:bold;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) or such nationally recognized new or replacement standards as Landlord may reasonable designate). </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall comply with all applicable provisions of the standards of the BMBL to the extent applicable to Tenant&#8217;s operations in the Premises.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally Omitted</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Notices to Landlord</font>.&nbsp;&nbsp;Unless Tenant is required by Applicable Laws to give earlier notice to Landlord, Tenant shall notify Landlord in writing as soon as reasonably possible but in no event later than five (5) days after knowledge of (i) the occurrence of any actual, alleged or threatened Release of any Hazardous Material in, on, under, from, about or in the vicinity of the Premises (whether past or present), regardless of the source or quantity of any such Release, or (ii) Tenant becomes aware of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or abatement proceedings (including any threatened or contemplated investigations or proceedings) relating to or potentially affecting the Premises, or (iii) Tenant becomes aware of any claims by any person or entity relating to any Hazardous Materials in, on, under, from, about or in the vicinity of the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury.&nbsp;&nbsp;Collectively, the matters set forth in clauses (i), (ii) and (iii) above are hereinafter referred to as &#8220;Hazardous Materials Claims&#8221;.&nbsp;&nbsp;Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and other communications and reports in connection with any Hazardous Materials Claims.&nbsp;&nbsp;Additionally, Tenant shall promptly advise Landlord in writing of Tenant&#8217;s discovery of any occurrence or condition on, in, under or about the Premises that could subject Tenant or Landlord to any liability, or restrictions on ownership, occupancy, transferability or use of the Premises under any &#8220;Environmental Laws,&#8221; as that term is defined below.&nbsp;&nbsp;Tenant shall not enter into any legal proceeding or other action, settlement, consent decree or other compromise with respect to any Hazardous Materials Claims without first notifying Landlord of Tenant&#8217;s intention to do so and affording Landlord the opportunity to join and participate, as a party if Landlord so elects, in such proceedings and in no event shall Tenant enter into any agreements which are binding on Landlord or the Premises without Landlord&#8217;s prior written consent.&nbsp;&nbsp;Landlord shall have the right to appear at and participate in, any and all legal or other administrative proceedings concerning any Hazardous Materials Claim.&nbsp;&nbsp;For purposes of this Lease, &#8220;Environmental Laws&#8221; means all applicable present and future laws, including principles of common law, relating to the protection of human health, safety, wildlife or the environment, including, without limitation, (i) all requirements pertaining to reporting, licensing, permitting, investigation and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or gaseous in nature, into the air, surface water, groundwater, or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii) all requirements pertaining to the health and safety of employees or the public.&nbsp;&nbsp;Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 USC &#167; 9601, et seq., the Hazardous Materials Transportation Authorization Act of 1994, 49 USC &#167; 5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42 USC &#167; 6901, et seq., the Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 USC &#167; 1251, et seq., the Clean Air Act of 1966, 42 USC &#167; 7401, et seq., the Toxic Substances Control Act of 1976, 15 USC &#167; 2601, et seq., the Safe Drinking Water Act of 1974, 42 USC &#167;&#167; 300f through 300j, the Occupational Safety and Health Act of 1970, as amended, 29 USC &#167; 651 et seq., the Oil Pollution Act of 1990, 33 USC &#167; 2701 et seq., the Emergency Planning and Community Right-To-Know Act of 1986, 42 USC &#167; 11001 et seq., the National Environmental Policy Act of 1969, 42 USC &#167; 4321 et seq., the Federal Insecticide, Fungicide and Rodenticide Act of 1947, 7 USC &#167; 136 et seq., North Carolina Oil Pollution and Hazardous Substances Control Act, N.C. Gen. Stat.&nbsp;&nbsp;&#167; 143-215.75 et seq., North Carolina Inactive Hazardous Sites Act, N.C. Gen. Stat. &#167; 130A-310, North Carolina Water and Air Resources Act, N.C. Gen. Stat. &#167; 143-211 et seq., 15A N.C. Admin. Code Subchapter 2L, , and any other state or local law counterparts, as amended, as such Applicable Laws, are in effect as of the Lease Commencement Date, or thereafter adopted, published, or promulgated.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><a name="_cp_text_2_122"></a><a name="_cp_text_5_123"></a><a name="_cp_text_2_124"></a><a name="_cp_text_5_125"></a><a name="_cp_text_2_126"></a><a name="_cp_text_5_127"></a><a name="_cp_text_2_128"></a><a name="_cp_text_5_129"></a><a name="_cp_text_2_130"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.4</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Releases of Hazardous Materials</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If any Release of any Hazardous Material in, on, under, from or about the Premises shall occur at any time during the Lease and/or if any other Hazardous Material condition exists at the Premises proximately due to the breach of Tenant&#8217;s obligations under this </font><font style="text-decoration:underline;">Section 5.4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that requires response actions under Environmental Laws, in addition to notifying Landlord as specified above, Tenant, at its own sole cost and expense, shall (i)&#160;immediately comply with any and all reporting requirements imposed pursuant to any and all Environmental Laws, (ii)&#160;provide a written certification to Landlord indicating that Tenant has complied with all applicable reporting requirements, (iii)&#160;take any and all necessary investigation, corrective and remedial action in accordance with any and all applicable Environmental Laws, utilizing an environmental consultant reasonably approved by Landlord, all in accordance with the provisions and requirements of this </font><font style="text-decoration:underline;">Section 5.4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including, without limitation, </font><font style="text-decoration:underline;">Section&#160;5.4.4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_122"></a>, and (iv)&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_123"></a>take </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_124"></a>any such </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_125"></a>additional investigative, remedial and corrective actions as </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_126"></a>Landlord shall </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_127"></a>in its reasonable discretion deem necessary such that the Premises are remediated to a condition allowing unrestricted use of the Premises (i.e. to a level that will allow any future use </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_128"></a>of the Premises, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_5_129"></a>including residential, without any engineering controls or deed restrictions), all </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_130"></a>in accordance with </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the provisions and requirements of this </font><font style="text-decoration:underline;">Section 5.4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord may, as required by any and all Environmental Laws, report the Release of any Hazardous Material to the appropriate governmental authority, identifying Tenant as the responsible party.&nbsp;&nbsp;Tenant shall deliver to Landlord copies of all administrative orders, notices, demands, directives or other communications directed to Tenant from any governmental authority with respect to any Release of Hazardous Materials in, on, under, from, or about the Premises, together with copies of all investigation, assessment, and remediation plans and reports prepared by or on behalf of Tenant in response to any such regulatory order or directive.&nbsp;&nbsp;Notwithstanding the foregoing, if Tenant provides Landlord with substantial proof that a Release in the Premises was caused by another tenant or occupant in the Project then Landlord shall use good faith efforts to assist Tenant in pursuing such party to cause it to remediate the Release or pay for such remediation, but ultimately Tenant&#8217;s obligations under this Section 5.4 shall remain as stated herein.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Indemnification</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.5.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">In General</font>.&nbsp;&nbsp;Without limiting in any way Tenant&#8217;s obligations under any other provision of this Lease, Tenant shall be solely responsible for and shall protect, defend, indemnify and hold the Landlord Parties harmless from and against any and all claims, judgments, losses, damages, costs, expenses, penalties, enforcement actions, taxes, fines, remedial actions, liabilities (including, without limitation, actual attorneys&#8217; fees, litigation, arbitration and administrative proceeding costs, expert and consultant fees and laboratory costs) including, without limitation, consequential damages and sums paid in settlement of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, directly or indirectly arising out of or attributable to the presence, use, generation, manufacture, treatment, handling, refining, production, processing, storage, Release or presence of Hazardous Materials in, on, under or about the Premises by Tenant, except to the extent such liabilities result from the gross negligence or willful misconduct of Landlord following the Lease Commencement Date.&nbsp;&nbsp;The foregoing obligations of Tenant shall include, including without limitation:&nbsp;&nbsp;(i)&#160;the costs of any required or necessary removal, repair, cleanup or remediation of the Premises, and the preparation and implementation of any closure, removal, remedial or other required plans; (ii)&#160;judgments for personal injury or property damages; and (iii)&#160;all costs and expenses incurred by Landlord in connection therewith.&nbsp;&nbsp;It is the express intention of the parties to this Lease that Tenant assumes all such liabilities, and holds Landlord harmless from all such liabilities, associated with the environmental condition of the Premises, arising on or after the date Tenant takes possession of the Premises.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.5.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Limitations</font>.&nbsp;&nbsp;Landlord warrants and represents that Landlord has not engaged in the Release of any Hazardous Materials subsequent to the date of the &#8220;Phase I Environmental Site Assessment Report&#8221; bearing ECS Project No. 49-1782, prepared on behalf of Longfellow Real Estate Ventures, LLC as of April 18, 2016&nbsp;&nbsp;(&#8220;ECS Phase I&#8221;) Landlord further warrants and represents that, to Landlord&#8217;s knowledge, on or after the effective date of the ECS Phase I report, Landlord has not received a summons, citation, directive, letter or other communication, written or oral, from any state agency or the U.S. Government concerning the Project or any intentional or unintentional action on Landlord or any occupant&#8217;s part as a result of a Release of any Hazardous Materials.&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.1.6</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Compliance with Environmental Laws</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Without limiting the generality of Tenant&#8217;s obligation to comply with Applicable Laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental Laws.&nbsp;&nbsp;Tenant shall obtain and maintain any and all necessary permits, licenses, certifications and approvals appropriate or required for the use, handling, storage, and disposal of any Hazardous Materials used, stored, generated, transported, handled, blended, or recycled by Tenant on the Premises.&nbsp;&nbsp;Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all such permits, licenses, certifications and approvals, together with copies of any and all Hazardous Materials management plans and programs, any and all Hazardous Materials risk management and pollution prevention programs, and any and all Hazardous Materials emergency response and employee training programs respecting Tenant&#8217;s use of Hazardous Materials.&nbsp;&nbsp;Upon request of Landlord, Tenant shall deliver to Landlord a narrative description explaining the nature and scope of Tenant&#8217;s activities involving Hazardous Materials and showing to Landlord&#8217;s satisfaction compliance with all Environmental Laws and the terms of this Lease.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Assurance of Performance</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.2.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Environmental Assessments In General</font>.&nbsp;&nbsp;Landlord may, but shall not be required to, engage from time to time such contractors as Landlord determines to be appropriate (and with reasonable advance notice to Tenant, not less than 5 business days) to perform &#8220;Environmental Assessments,&#8221; as that term is defined below, to ensure Tenant&#8217;s compliance with the requirements of this Lease with respect to Hazardous Materials.&nbsp;&nbsp;For purposes of this Lease, &#8220;<font style="font-weight:bold;">Environmental Assessment</font></a>&#8221; means an assessment including, without limitation:&nbsp;&nbsp;(i)&#160;an environmental site assessment conducted in accordance with the then-current standards of the American Society for Testing and Materials and meeting the requirements for satisfying the &#8220;all appropriate inquiries&#8221; requirements; and (ii)&#160;sampling and testing of the Premises based upon potential recognized environmental conditions or areas of concern or inquiry identified by the environmental site assessment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.2.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Costs of Environmental Assessments</font>.&nbsp;&nbsp;All costs and expenses incurred by Landlord in connection with any such Environmental Assessment initially shall be paid by Landlord; provided that if any such Environmental Assessment shows that Tenant has failed to comply with the provisions of this <font style="text-decoration:underline;">Section 5.4</font>, then all of the costs and expenses of such Environmental Assessment shall be reimbursed by Tenant as Additional Rent within thirty (30)&#160;days after receipt of written demand therefor (and reasonable documentation of Tenant&#8217;s material breach of its environmental obligations).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Obligations upon Surrender</font>.&nbsp;&nbsp;At the expiration or earlier termination of the Lease Term, Tenant, at Tenant&#8217;s sole cost and expense, shall:&nbsp;&nbsp;(i)&#160;cause an Environmental Assessment of the Premises to be conducted in accordance with <font style="text-decoration:underline;">Section 15.3</font>; (ii)&#160;cause all Hazardous Materials to be removed from the Premises and disposed of in accordance with all Environmental Laws and as necessary to allow the Premises to be used for any purpose; and (iii)&#160;cause to be removed all containers installed or used by Tenant or Tenant&#8217;s Agents to store any Hazardous Materials on the Premises, and cause to be repaired any damage to the Premises caused by such removal.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Clean-up</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.4.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Environmental Reports; Clean-Up</font>.&nbsp;&nbsp;If any written report, including any report containing results of any Environmental Assessment (an &#8220;<font style="font-weight:bold;">Environmental Report</font></a>&#8221;) shall indicate (i)&#160;the presence of any Hazardous Materials as to which Tenant has a removal or remediation obligation under this <font style="text-decoration:underline;">Section 5.4</font>, and (ii)&#160;that as a result of same, the investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other clean-up (the &#8220;<font style="font-weight:bold;">Clean-up</font>&#8221;) of any Hazardous Materials is required, Tenant shall promptly prepare and submit to Landlord within thirty (30)&#160;days after receipt of the Environmental Report a comprehensive plan, subject to Landlord&#8217;s written approval, specifying the actions to be taken by Tenant to perform the Clean-up so that the Premises are restored to the conditions required by this Lease.&nbsp;&nbsp;Upon Landlord&#8217;s approval of the Clean-up plan, Tenant shall, at Tenant&#8217;s sole cost and expense, without limitation on any rights and remedies of Landlord under this Lease, immediately implement such plan with a consultant reasonably acceptable to Landlord and proceed to Clean-Up Hazardous Materials in accordance with all Applicable Laws and as required by such plan and this Lease.&nbsp;&nbsp;If, within thirty (30)&#160;days after receiving a copy of such Environmental Report, Tenant fails either (a)&#160;to complete such Clean-up, or (b)&#160;with respect to any Clean-up that cannot be completed within such thirty-day period, fails to proceed with diligence to prepare the Clean-up plan and complete the Clean-up as promptly as practicable, then Landlord shall have the right, but not the obligation, and without waiving any other rights under this Lease, to carry out any Clean-up recommended by the Environmental Report or required by any governmental authority having jurisdiction over the Premises, and recover all of the costs and expenses thereof from Tenant as Additional Rent, payable within ten (10)&#160;business days after receipt of written demand therefor.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.4.2</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Rent Abatement</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall continue to pay all Rent due or accruing under this Lease during any Clean-up, and shall not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease during any such Clean-up.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.4.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Surrender of Premises</font>.&nbsp;&nbsp;Tenant shall complete any Clean-up prior to surrender of the Premises upon the expiration or earlier termination of this Lease, and shall fully comply with all Environmental Laws and requirements of any governmental authority with respect to such completion, including, without limitation, fully comply with any requirement to file a risk assessment, mitigation plan or other information with any such governmental authority in conjunction with the Clean-up prior to such surrender.&nbsp;&nbsp;Tenant shall obtain and deliver to Landlord a letter or other written determination from the overseeing governmental authority confirming that the Clean-up has been completed in accordance with all requirements of such governmental authority and that no further response action is required for the unrestricted use of the Premises from an Environmental Law standpoint (&#8220;<font style="font-weight:bold;">Closure Letter</font></a>&#8221;).&nbsp;&nbsp;Upon the expiration or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous Materials in accordance with applicable laws.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.4.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Failure to Timely Clean-Up</font>.&nbsp;&nbsp;Should any Clean-up for which Tenant is responsible not be completed, or should Tenant not receive the Closure Letter and any governmental approvals required under Environmental Laws in conjunction with such Clean-up prior to the expiration or earlier termination of this Lease, and Tenant&#8217;s failure to receive the Closure Letter is prohibiting Landlord from leasing the Premises or any part thereof to a third party, or prevents the occupancy or use of the Premises or any part thereof by a third party, then Tenant shall be liable to Landlord as a holdover tenant (as more particularly provided in <font style="text-decoration:underline;">Article&#160;16</font>) until Tenant has fully complied with its obligations under this <font style="text-decoration:underline;">Section 5.4</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Confidentiality</font>.&nbsp;&nbsp;Unless compelled to do so by Applicable Law, Tenant agrees that Tenant shall not disclose, discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental condition of the Premises to any Person (other than Tenant&#8217;s consultants, attorneys, property managers and employees that have a need to know such information), including any governmental authority, without the prior written consent of Landlord, not to be unreasonably withheld, conditioned, or delayed.&nbsp;&nbsp;In the event Tenant reasonably believes that disclosure is compelled by Applicable Law, it shall provide Landlord ten (10)&#160;days&#8217; advance notice of disclosure of confidential information so that Landlord may attempt to obtain a protective order.&nbsp;&nbsp;Tenant may additionally release such information to bona fide prospective purchasers or lenders, subject to any such parties&#8217; written agreement to be bound by the terms of this <font style="text-decoration:underline;">Section 5.4</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Copies of Environmental Reports</font>.&nbsp;&nbsp;Within thirty (30)&#160;days of receipt thereof, Tenant shall provide Landlord with a copy of any and all environmental assessments, audits, studies and reports regarding Tenant&#8217;s activities with respect to the Premises, or ground water beneath the Land, or the environmental condition or Clean-up thereof.&nbsp;&nbsp;Tenant shall be obligated to provide Landlord with a copy of such materials without regard to whether such materials are generated by Tenant or prepared for Tenant, or how Tenant comes into possession of such materials.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.7<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally Omitted</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.8<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Signs, Response Plans, Etc</font>.&nbsp;&nbsp;Tenant shall be responsible for posting on the Premises any signs required under applicable Environmental Laws.&nbsp;&nbsp;Tenant shall also complete and file any business response plans or inventories required by any Applicable Laws.&nbsp;&nbsp;Tenant shall concurrently file a copy of any such business response plan or inventory with Landlord.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4.9<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Survival</font>.&nbsp;&nbsp;Each covenant, agreement, representation, warranty and indemnification made by Tenant set forth in this <font style="text-decoration:underline;">Section 5.4</font> shall survive the expiration or earlier termination of this Lease and shall remain effective until all of Tenant&#8217;s obligations under this <font style="text-decoration:underline;">Section 5.4</font> have been completely performed and satisfied.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653738"></a><a name="_Toc525822979"></a><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">SERVICES AND UTILITIES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Provided Services</font>.&nbsp;&nbsp;Landlord shall provide the following services on all days (unless otherwise stated below) during the Lease Term. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1.1<font style="margin-left:36pt;"></font>Subject to limitations imposed by all governmental rules, regulations and guidelines applicable thereto, Landlord shall provide adequate electrical wiring and facilities for connection to Tenant&#8217;s lighting fixtures and incidental use equipment, provided that the connected electrical load of the incidental use equipment and the connected electrical load of Tenant&#8217;s lighting fixtures does not exceed Tenant&#8217;s Share of the system capacity (as reasonably documented by Landlord).&nbsp;&nbsp;Tenant shall bear the cost of replacement of lamps, starters and ballasts for lighting fixtures within the Premises.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_411"></a>6.1.2<font style="margin-left:36pt;"></font><a name="_cp_text_2_411"></a>Landlord shall provide city water from the regular Building outlets for drinking, lavatory and toilet purposes in the Building Common Areas and service to the Premises.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1.3<font style="margin-left:36pt;"></font>Landlord shall provide a dumpster and/or trash compactor at the Building for use by Tenant and other tenants for ordinary office waste (and not for Hazardous Materials).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_387"></a><a name="_cp_text_1_388"></a>6.1.4<font style="margin-left:36pt;"></font>Landlord shall provide landscaping, snow and ice removal in the Common Areas.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1.5<font style="margin-left:36pt;"></font>Landlord shall provide access to the rooftop as stated in <font style="text-decoration:underline;">Section 7.2</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_413"></a>6.1.6<font style="margin-left:36pt;"></font>Landlord shall provide Building standard heating, ventilation (including exhaust) and air conditioning (&#8220;<font style="font-weight:bold;">HVAC</font>&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818425"></a><a name="_cp_text_2_415"></a>6.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant Provided Services and Utilities</font>.&nbsp;&nbsp;Except as otherwise expressly set forth in <font style="text-decoration:underline;">Section&#160;6.1</font><a name="_cp_text_2_415"></a>, above, Tenant will be responsible, at its sole cost and expense, for the furnishing of all services and utilities to the Premises including internet, telephone, janitorial and interior Building security services. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2.1<font style="margin-left:36pt;"></font>Landlord shall not provide janitorial or trash services for the Premises except as expressly provided in <font style="text-decoration:underline;">Section 6.1.3</font>, above.&nbsp;&nbsp;Tenant shall be solely responsible for performing all janitorial and trash services and other cleaning of the Premises, all in compliance with Applicable Laws.&nbsp;&nbsp;In the event such service is provided by a third party janitorial service, and not by employees of Tenant, such service shall be a janitorial service approved in advance by Landlord, (Landlord shall provide Tenant with a list of approved vendors upon Tenant&#8217;s request).&nbsp;&nbsp;The janitorial and cleaning of the Premises shall be adequate to maintain the Premises in a manner consistent with Comparable Buildings.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2.2<font style="margin-left:36pt;"></font>Subject to Applicable Laws and the other provisions of this Lease (including, without limitation, the Rules and Regulations, and except in the event of an emergency), Tenant shall have access to the Building, the Premises and the Common Areas of the Building, other than Common Areas requiring access with a Building engineer, twenty-four (24) hours per day, seven (7) days per week, every day of the year; provided, however, that Tenant shall only be permitted to have access to and use of the limited-access areas of the Building during the normal operating hours of such portions of the Building.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall reasonably cooperate with Landlord at all times and abide by all regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2.3</font><font style="margin-left:36pt;">Tenant shall pay for all water, gas, heat, light, power, telephone, internet service, cable television, other telecommunications and other utilities supplied to the Premises, together with any fees, surcharges and taxes thereon, whether part of Operating Expenses or as provided under this Article 6.&nbsp;&nbsp;Tenant shall pay all costs and expenses for any separately metered utilities provided exclusively to the Premises directly to the applicable service provider.&nbsp;&nbsp;Tenant shall pay all actual out-of-pocket costs and expenses, without mark-up, for utility charges that are based on a check- or sub-metering metering installation based on Landlord&#8217;s reading of such meters and directly to Landlord, including without limitation for utility charges for power, gas and water serving the HVAC system of the Building (which are measured by the control management system of the Building based on air volume provided to each tenant space).&nbsp;&nbsp;Additional Rent for such utilities may be reasonably estimated monthly by Landlord, based on actual readings of sub- and &#8220;check&#8221; meters where applicable, and shall be paid monthly by Tenant within thirty (30) days after being billed with a final accounting based upon actual bills received from the utility providers following the conclusion of each fiscal year of the Building.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818426"></a>6.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Metering</font>.&nbsp;&nbsp;If necessary, Landlord may install devices to separately meter any utility use (or use other reasonable industry standard methods to reasonably estimate such use) and in such event Tenant shall pay the cost directly to Landlord, within thirty (30) days after Tenant&#8217;s receipt of an invoice therefor, at the rates charged by the public utility company furnishing the same, including the cost of installing, testing and maintaining of such metering devices.&nbsp;&nbsp;Tenant&#8217;s use of electricity and any other utility shall never exceed the capacity of the feeders to the Project or the risers or wiring installation or Tenant&#8217;s Share of the per floor limits as reasonably determined and documented by Landlord.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818427"></a>6.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Interruption of Use</font>.&nbsp;&nbsp;Tenant agrees that, to the extent permitted pursuant to Applicable Laws, Landlord shall not be liable for damages, by abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service (including telephone and telecommunication services), or for any diminution in the quality or quantity thereof, when such failure or delay or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Building or Project after reasonable effort to do so, by any riot or other dangerous condition, emergency, accident or casualty whatsoever, by act or default of Tenant or other parties, or by any other cause not under Landlord&#8217;s reasonable control; and such failures or delays or diminution shall never be deemed to constitute an eviction or disturbance of Tenant&#8217;s use and possession of the Premises or relieve Tenant from paying Rent or performing any of its obligations under this Lease.&nbsp;&nbsp;Furthermore, Landlord shall not be liable under any circumstances for a loss of, or injury to, property or for injury to, or interference with, Tenant&#8217;s business, including, without limitation, loss of profits, however occurring, through or in connection with or incidental to a failure to furnish any of the services or utilities as set forth in this <font style="text-decoration:underline;">Article 6</font>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing to the contrary, in the event that there shall be an interruption, curtailment or suspension of any service required to be provided by Landlord pursuant to Section 6.1 (and no reasonably equivalent alternative service or supply is provided by Landlord) that shall materially interfere with Tenant&#8217;s use and enjoyment of a material portion of the Premises, and Tenant actually ceases to use affected portion of the Premises (any such event, a &#8220;<font style="font-weight:bold;">Service Interruption</font></a>&#8221;), and if (i) such Service Interruption shall continue for seventy-two (72) consecutive hours following receipt by Landlord of written notice from Tenant describing such Service Interruption (the &#8220;<font style="font-weight:bold;">Service Interruption Notice</font>&#8221;), (ii) such Service Interruption shall not have been caused, in whole or in part, by reasons beyond Landlord&#8217;s reasonable control or by an act or omission in violation of this Lease by Tenant or by any negligence of Tenant, or Tenant&#8217;s agents, employees, contractors or invitees, and (iii) either (A)&#160;Landlord does not diligently commence and pursue to completion the remedy of such Service Interruption or (B)&#160;Landlord receives proceeds from its rental interruption insurance that covers such Service Interruption (a Service Interruption that satisfies the foregoing conditions being referred to hereinafter as a &#8220;<font style="font-weight:bold;">Material Service Interruption</font>&#8221;) then, as liquidated damages and Tenant&#8217;s sole remedy at law or equity, Tenant shall be entitled to an equitable abatement of Base Rent and Tenant&#8217;s Share of Direct Expenses, based on the nature and duration of the Material Service Interruption, the area of the Premises affected, and the then current Rent amounts, for the period that shall begin on the commencement of such Material Service Interruption and that shall end on the day such Material Service Interruption shall cease.&nbsp;&nbsp;To the extent a Material Service Interruption is caused by an event covered by Articles&#160;11 or 13 of this Lease, then Tenant&#8217;s right to abate rent shall be governed by the terms of such Article&#160;11 or 13, as applicable, and the provisions of this paragraph shall not apply</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_434"></a><a name="_cp_text_2_435"></a><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Responsibility Matrix</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The matrix attached hereto as </font><font style="font-weight:bold;text-decoration:underline;">Exhibit H</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and incorporated by reference provides the maintenance, repair, services, and utilities responsibilities for Landlord and Tenant at the Premises and Building (&#8220;</font><font style="font-weight:bold;">Responsibility Matrix</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;Landlord reserves the right at any time to make reasonable changes to the Responsibility Matrix based on current conditions at the Building as in Landlord&#8217;s reasonable judgment may from time to time be necessary for the management, safety, care and cleanliness of the Premises and Building.&nbsp;&nbsp;The parties shall perform the obligations as noted in the Responsibility Matrix and to the extent of any discrepancies between this </font><font style="text-decoration:underline;">Article 6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the Responsibility Matrix the details in the Responsibility Matrix shall control.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653739"></a><a name="_Toc525822980"></a>7.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">REPAIRS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_436"></a><a name="_cp_text_2_437"></a><a name="_cp_text_2_438"></a>7.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant Repairs</font><a name="_cp_text_2_436"></a>.&nbsp;&nbsp;Tenant shall, at Tenant&#8217;s own expense, keep the Premises, including all improvements, fixtures, furnishings, <a name="_cp_text_2_437"></a>supplemental/non-Building heating, ventilation (including exhaust) and air conditioning (which Tenant installs as part of the Tenant Improvements) (&#8220;<font style="font-weight:bold;">Supplemental HVAC</font>&#8221;), and systems and equipment therein (including, without limitation, plumbing fixtures and equipment such as dishwashers, garbage disposals, and insta<a name="_cp_text_2_438"></a>&#8209;hot dispensers), and the floor of the Building on which the Premises are located, in good order, repair and condition as received (ordinary wear and tear and casualty damage excepted) at all times during the Lease Term.&nbsp;&nbsp;In addition, Tenant shall, at Tenant&#8217;s own expense, but under the supervision and subject to the prior reasonable approval of Landlord, and within any reasonable period of time specified by Landlord, promptly and adequately repair all damage to the Premises and replace or repair all damaged, broken, or worn fixtures and appurtenances, except for damage caused by ordinary wear and tear or beyond the reasonable control of Tenant; provided however, that, at Landlord&#8217;s option, or if Tenant fails to make such repairs (after notice from Landlord a reasonable opportunity to do so), Landlord may, but need not, make such repairs and replacements, and Tenant shall pay Landlord the cost thereof, including a percentage of the cost thereof (to be uniformly established for the Building and/or the Project) sufficient to reimburse Landlord for all overhead, general conditions, fees and other costs or expenses arising from Landlord&#8217;s involvement with such repairs and replacements forthwith upon being billed for same.&nbsp;&nbsp;Without limitation, Tenant shall be responsible for the Supplemental HVAC and Tenant shall secure, pay for, and keep in force contracts with appropriate and reputable service companies reasonably approved by Landlord providing for the regular maintenance of such systems. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_440"></a>7.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Riser Room and Rooftop Rights</font><a name="_cp_text_2_440"></a>.&#160; Landlord grants Tenant the right, subject to the terms and conditions of this Lease, to access the riser room and the roof of the Building in order to maintain, repair and replace the Supplemental HVAC equipment and any other mechanical equipment located in the riser room or on the roof for which Tenant is responsible to repair, maintain and replace.&#160; Tenant may not install additional locks on any access doors or any equipment in such areas.&#160; In the event the Tenant desires to move any rooftop equipment or install any new rooftop equipment the exact location and layout of such items must be approved in advance in writing by Landlord, such approval not to be unreasonably withheld, conditioned, or delayed.&#160; Tenant&#8217;s access to the riser room for the purposes of exercising its rights and obligations under this <font style="text-decoration:underline;">Section 7.2</font> shall be limited to Building Hours by prior appointment with the property manager, except in the case of emergencies.&#160; In the event of an emergency Tenant shall utilize Landlord&#8217;s after-hours contact information. &#160;Tenant shall be provided access to the rooftop at all times except during an emergency through card access with Tenant&#8217;s personnel who are approved in advance by Landlord.&nbsp;&nbsp;Tenant shall engage Landlord&#8217;s roofer before beginning any rooftop installations or repairs which affect the roof whether under this <font style="text-decoration:underline;">Section 7.2</font> or otherwise, and shall always comply with the roof warranty governing the protection of the roof and modifications to the roof.&#160; Tenant shall obtain a letter from Landlord&#8217;s roofer following completion of such work stating that the roof warranty remains in effect. &#160;Tenant agrees that Tenant&#8217;s access to the riser room or roof and any work on the roof shall be at Tenant&#8217;s sole risk.&#160; Tenant shall indemnify, defend and hold Landlord harmless against any liability, claim or cost, including reasonable attorneys&#8217; fees, incurred in connection with the loss of life, personal injury, damage to property or business or any other loss or injury (except to the extent due to the grossly negligent act or willful misconduct of Landlord or its employees, agents or contractors) arising out of the access to the riser room or rooftop or any work on the rooftop by Tenant or its employees, agents, or contractors, including any liability arising out of Tenant&#8217;s violation of this <font style="text-decoration:underline;">Section 7.2</font>. &#160;Tenant shall specifically be responsible for Landlord&#8217;s costs to repair any damage or remedy any infraction caused by Tenant or Tenant&#8217;s vendor in the riser room or on the roof of the Building.&nbsp;&nbsp;Landlord shall not be responsible for any damage or harm that result from Tenant&#8217;s inability or delay to access the riser room or rooftop and Tenant hereby waives any claims against Landlord arising from such delays in access.&#160; The provisions of this paragraph shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Repairs</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Notwithstanding the foregoing, Landlord shall be responsible for repairs to the exterior walls, windows, foundation and roof (including roof membrane) of the Building, the structural portions of the floors of the Building, and the base building systems and equipment of the Building and Common Areas (to the extent not serving Tenant exclusively (but Landlord acknowledges and agrees that the air handler currently serving the Premises constitutes part of the base Building)), except to the extent that such repairs are required due to the gross negligence or willful misconduct of Tenant; provided, however, that if such repairs are due to the gross negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant&#8217;s expense, or, if covered by Landlord&#8217;s insurance, Tenant shall only be obligated to pay any deductible in connection therewith.&nbsp;&nbsp;Subject to the terms of </font><font style="text-decoration:underline;">Article 27</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, below, Landlord may, but shall not be required to, enter the Premises at all reasonable times and upon reasonable prior notice to make such repairs, alterations, improvements or additions to the Premises or to the Project or to any equipment located in the Project as Landlord shall reasonably desire or deem necessary or as Landlord may be required to do by governmental or quasi-governmental authority or court order or decree.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653740"></a><a name="_Toc525822981"></a>8.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">ADDITIONS AND ALTERATIONS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Consent to Alterations</font>.&nbsp;&nbsp;Tenant may not make any improvements, alterations, additions or changes to the Premises or any mechanical, plumbing or HVAC facilities or systems pertaining to the Premises (collectively, the &#8220;</a><font style="font-weight:bold;">Alterations</font>&#8221;) without first procuring the prior written consent of Landlord to such Alterations, which consent shall be requested by Tenant not less than ten (10) business days prior to the commencement thereof, and which consent shall not be unreasonably withheld, conditioned or delayed by Landlord, provided it shall be deemed reasonable for Landlord to withhold its consent to any Alteration which adversely affects the structural portions or the systems or equipment of the Building or is visible from the exterior of the Building.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant shall be permitted to make non-structural Alterations following ten (10) business days&#8217; notice to Landlord, but without Landlord&#8217;s prior consent, to the extent that such Alterations (i) do not materially affect the Building roof, systems or equipment, (ii) are not visible from the exterior of the Building, and (iii) cost less than fifty thousand and 00/100 ($50,000.00) per year.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2<font style="margin-left:36pt;"></font>Prior to commencing any Alterations affecting air distribution or disbursement from ventilation systems serving Tenant or the Building, including without limitation the installation of Tenant&#8217;s exhaust systems, Tenant shall provide Landlord with a third party report from a consultant, and in a form reasonably acceptable to Landlord, showing that such work will not materially and adversely affect the ventilation systems or air quality of the Building (or of any other tenant in the Building) and shall, upon completion of such work, provide Landlord with a certification reasonably satisfactory to Landlord from such consultant confirming that no such adverse effects have resulted from such work. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818433"></a>8.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Manner of Construction</font>.&nbsp;&nbsp;Landlord may impose, as an express condition of its consent (at the time said consent is given) to any and all Alterations (other than the Tenant Improvements) or repairs of the Premises or about the Premises, such requirements as Landlord in its reasonable discretion may deem desirable, including, but not limited to, the requirement that Tenant utilize for such purposes only contractors, subcontractors, materials, mechanics and materialmen selected by Tenant and approved by Landlord (which approval shall not be unreasonably withheld, conditioned or delayed), the requirement that upon Landlord&#8217;s request at the time Landlord approves said Alterations (subject to the terms of <font style="text-decoration:underline;">Section&#160;8.5</font>, below), Tenant shall, at Tenant&#8217;s expense, remove such Alterations upon the expiration or any early termination of the Lease Term.&nbsp;&nbsp;Tenant shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any and all applicable federal, state, county or municipal laws, rules and regulations and pursuant to a valid building permit, issued by the city in which the Building is located (or other applicable governmental authority).&nbsp;&nbsp;Tenant shall not use (and upon notice from Landlord shall cease using) contractors, services, workmen, labor, materials or equipment that, in Landlord&#8217;s reasonable judgment, would disturb labor harmony with the workforce or trades engaged in performing other work, labor or services in or about the Building or the Common Areas.&nbsp;&nbsp;Upon completion of any Alterations (or repairs), Tenant shall deliver to Landlord final lien waivers from all contractors, subcontractors and materialmen who performed such work.&nbsp;&nbsp;In addition to Tenant&#8217;s obligations under <font style="text-decoration:underline;">Article 9</font> of this Lease, upon completion of any Alterations, Tenant shall deliver to the Project construction manager a reproducible copy of the &#8220;<font style="font-weight:bold;">as built</font>&#8221; drawings of the Alterations as well as all permits, approvals and other documents issued by any governmental agency in connection with the Alterations.&nbsp;&nbsp;Landlord shall make its construction rules and a pre-approved vendor list available to Tenant upon request.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818434"></a><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><a name="_cp_text_1_402"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Payment for Improvements</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_402"></a>.&nbsp;&nbsp;If Tenant orders any work directly from Landlord, Tenant shall pay to Landlord an amount equal to four percent (4%) of the cost of such work to compensate Landlord for all overhead, general conditions, fees and other costs and expenses arising from Landlord&#8217;s involvement with such work.&nbsp;&nbsp;If Tenant does not order any work directly from Landlord, Tenant shall reimburse Landlord for Landlord&#8217;s reasonable, actual, out-of-pocket costs and expenses actually incurred in connection with Landlord&#8217;s review of such work</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> including a construction management fee in the amount of two and one-half percent (2.5%) of the total costs of such work, up to but not to exceed a total payment by Tenant to Landlord of Forty Thousand and 00/100 Dollars ($40,000.000).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818435"></a>8.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Construction Insurance</font>.&nbsp;&nbsp;In addition to the requirements of <font style="text-decoration:underline;">Article 10</font> of this Lease, in the event that Tenant makes any Alterations, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant carries &#8220;<font style="font-weight:bold;">Builder&#8217;s All Risk</font>&#8221; insurance (to the extent that the cost of the work shall exceed $100,000.00) in an amount approved by Landlord covering the construction of such Alterations, and such other standard and reasonable insurance as Landlord may reasonably require, it being understood and agreed that all of such Alterations shall be insured by Tenant pursuant to <font style="text-decoration:underline;">Article 10</font> of this Lease immediately upon completion thereof.&nbsp;&nbsp;In addition, Tenant&#8217;s contractors and subcontractors shall be required to carry Commercial General Liability Insurance in an amount approved by Landlord and otherwise in accordance with the requirements of <font style="text-decoration:underline;">Article 10</font> of this Lease and such general liability insurance shall name the Landlord Parties as additional insureds.&nbsp;&nbsp;In addition, Tenant&#8217;s contractors and subcontractors shall be required to carry workers compensation insurance with a waiver of subrogation in favor of Landlord Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653741"></a><a name="_Toc525822982"></a>9.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">COVENANT AGAINST LIENS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall keep the Project and Premises free from any liens or encumbrances arising out of the work performed, materials or services furnished or obligations incurred by or on behalf of Tenant, and shall protect, defend, indemnify and hold Landlord harmless from and against any claims, liabilities, judgments or costs (including, without limitation, reasonable attorneys&#8217; fees and costs) arising out of same or in connection therewith.&nbsp;&nbsp;Tenant shall give Landlord notice at least twenty (20) days prior to the commencement of any work, services or obligations related to the Premises giving rise to any such liens or encumbrances (or such additional time as may be necessary under Applicable Laws) to afford Landlord the opportunity of posting and recording appropriate notices of non-responsibility (to the extent applicable pursuant to then Applicable Laws).&nbsp;&nbsp;Tenant shall remove any such lien or encumbrance by statutory lien bond or otherwise within ten (10) business days after notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove such lien or encumbrance, without being responsible for investigating the validity thereof.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653742"></a><a name="_Toc525822983"></a>10.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">INSURANCE</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Indemnification and Waiver</font>.&nbsp;&nbsp;Tenant hereby assumes all risk of damage to property or injury to persons in, upon or about the Premises from any cause whatsoever (including, but not limited to, any personal injuries resulting from a slip and fall in, upon or about the Premises) and agrees that Landlord, its lenders, partners, subpartners and their respective officers, agents, servants, employees, and independent contractors (collectively, &#8220;</a><font style="font-weight:bold;">Landlord Parties</font>&#8221;) shall not be liable for, and are hereby released from any responsibility for, any damage either to person or property or resulting from the loss of use thereof, which damage is sustained by Tenant or by other persons claiming through Tenant.&nbsp;&nbsp;Tenant shall indemnify, defend, protect, and hold harmless the Landlord Parties from any and all loss, cost, damage, injury, expense and liability (including without limitation court costs and reasonable attorneys&#8217; fees) during the Lease Term, or any period of Tenant&#8217;s occupancy of the Premises prior to the commencement or after the expiration of the Lease Term, incurred in connection with or arising from any cause in, on or about the Premises (including, but not limited to, a slip and fall), any acts, omissions or negligence of Tenant or of any person claiming by, through or under Tenant, or of the contractors, agents, servants, employees, invitees, guests or licensees of Tenant or any such person, in, on or about the Project or any breach of the terms of this Lease, either prior to, during, or after the expiration of the Lease Term, provided that the terms of the foregoing indemnity shall not apply to the gross negligence or willful misconduct of Landlord.&nbsp;&nbsp;Should Landlord be named as a defendant in any suit brought against Tenant in connection with or arising out of Tenant&#8217;s occupancy of the Premises, Tenant shall pay to Landlord its reasonable costs and expenses incurred in such suit, including without limitation, its actual professional fees such as reasonable appraisers&#8217;, accountants&#8217; and attorneys&#8217; fees.&nbsp;&nbsp;The provisions of this <font style="text-decoration:underline;">Section&#160;10.1</font> shall survive the expiration or sooner termination of this Lease with respect to any claims or liability arising in connection with any event occurring prior to such expiration or termination.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Compliance With Landlord&#8217;s Property Insurance</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall, at Tenant&#8217;s expense, comply with all reasonable insurance company requirements pertaining to the use of the Premises.&nbsp;&nbsp;If Tenant&#8217;s conduct or use of the Premises for any purpose other than customary, general office use causes any increase in the premium for such insurance policies (as reasonably documented by Landlord) then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant&#8217;s expense, shall comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board of Fire Underwriters) and with any similar body. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Insurance</font>.&nbsp;&nbsp;Tenant shall maintain the following coverages in the following amounts.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.1<font style="margin-left:36pt;"></font>Commercial General Liability Insurance on an occurrence form covering the insured against claims of bodily injury, personal and advertising injury and property damage (including loss of use thereof) arising out of Tenant&#8217;s operations, products/completed operations, and contractual liability including a Broad Form endorsement covering the insuring provisions of this Lease and the performance by Tenant of the indemnity agreements set forth in <font style="text-decoration:underline;">Section&#160;10.1</font> of this Lease, and including, solely on a claims-made basis, products and completed operations coverage, for limits of liability of not less than:</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  style="width:49.84%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bodily Injury and</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property Damage Liability</p></td>
<td valign="top"  style="width:50.16%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,000,000 each occurrence</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,000,000 annual aggregate</p></td>
</tr>
<tr>
<td valign="top"  style="width:49.84%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personal and Advertising Injury Liability</p></td>
<td valign="top"  style="width:50.16%;">
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,000,000 each occurrence</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5,000,000 annual aggregate</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0% Insured&#8217;s participation</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.2<font style="margin-left:36pt;"></font>Property Insurance covering (i) all office furniture, business and trade fixtures, office equipment, free-standing cabinet work, movable partitions, merchandise and all other items of Tenant&#8217;s property on the Premises installed by, for, or at the expense of Tenant, and (ii) any other improvements which exist in the Premises as of the Lease Commencement Date (excluding the Base Building) (the &#8220;</a><font style="font-weight:bold;">New Improvements</font>&#8221;).&nbsp;&nbsp;Such insurance shall be written on an &#8220;<font style="font-weight:bold;">all risks</font>&#8221; of physical loss or damage basis, for the full replacement cost value (subject to reasonable deductible amounts) new without deduction for depreciation of the covered items and in amounts that meet any co-insurance clauses of the policies of insurance and shall include coverage for damage or other loss caused by fire or other peril including, but not limited to, vandalism and malicious mischief, theft, water damage of any type, including sprinkler leakage, bursting or stoppage of pipes, and explosion.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.3<font style="margin-left:36pt;"></font>Business Income Interruption for one (1) year plus Extra Expense insurance in such amounts as will reimburse Tenant for actual direct or indirect loss of earnings attributable to the risks outlined in <font style="text-decoration:underline;">Section 10.3.2</font> above.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3.4<font style="margin-left:36pt;"></font>Worker&#8217;s Compensation and Employer&#8217;s Liability or other similar insurance pursuant to all applicable state and local statutes and regulations.&nbsp;&nbsp;The policy will include a waiver of subrogation in favor of the Landlord Parties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Form of Policies</font>.&nbsp;&nbsp;The minimum limits of policies of insurance required of Tenant under this Lease shall in no event limit the liability of Tenant under this Lease.&nbsp;&nbsp;Such insurance shall (i) name Landlord, its subsidiaries and affiliates and any other party the Landlord so specifies, as an additional insured, as applicable, including Landlord&#8217;s managing agent, if any; (ii) cover the liability assumed by Tenant under this Lease; (iii) be issued by an insurance company having a rating of not less than A:VIII in Best&#8217;s Insurance Guide or which is otherwise acceptable to Landlord and licensed to do business in the State of North Carolina; (iv) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess and is non-contributing with any insurance required of Tenant; (v) be in form and content reasonably acceptable to Landlord; and (vi) provide that said insurer shall endeavor to provide written notice to Landlord and any mortgagee of Landlord,&nbsp;&nbsp;to the extent such names are furnished to Tenant prior to the cancellation of such policy.&nbsp;&nbsp;Tenant shall deliver said policy or policies or certificates thereof to Landlord on or before the earlier to occur of (A)&#160;the Lease Commencement Date, and (B)&#160;the date upon which Tenant is first provided access to the Premises, and at least ten (10) days before the expiration dates thereof.&nbsp;&nbsp;In the event Tenant shall fail to procure such insurance, or to deliver such policies or certificate within ten (10) days after written notice from Landlord, Landlord may, at its option (upon notice to Tenant), procure such policies for the account of Tenant, and the cost thereof shall be paid to Landlord within five (5) days after delivery to Tenant of bills therefor.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subrogation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord and Tenant intend that their respective property loss risks shall be borne by reasonable insurance carriers to the extent above provided, and Landlord and Tenant hereby agree to look solely to, and seek recovery only from, their respective insurance carriers in the event of a property loss to the extent that such coverage is agreed to be provided hereunder.&nbsp;&nbsp;The parties each hereby waive all rights and claims against each other for such losses, and waive all rights of subrogation of their respective insurers, provided such waiver of subrogation shall not affect the right to the insured to recover thereunder.&nbsp;&nbsp;The parties agree that their respective insurance policies are now, or shall specify that the waiver of subrogation shall not affect the right of the insured to recover thereunder.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional Insurance Obligations</font>.&nbsp;&nbsp;Tenant shall carry and maintain during the entire Lease Term, at Tenant&#8217;s sole cost and expense, increased amounts of insurance to the extent required by any lender or mortgagee on the Building. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Insurance Obligations</font>.&nbsp;&nbsp;Landlord shall keep in force during the term of this Lease at least the following coverage: (i) commercial general liability insurance against any and all claims for bodily injury and property damage occurring in or about the Building or the Common Areas having a combined single limit of not less than One Million Dollars ($1,000,000) per occurrence and Two Million Dollars ($2,000,000) in the aggregate, and (ii) property insurance for fire, casualty and special causes of loss in such amounts and coverages as Landlord deems appropriate or is otherwise required of Landlord by its lender or Applicable Law, but in no event less than the lesser of (a) at least one hundred percent (100%) percent of the replacement cost of the Building or (b) the maximum insurable value of the Building. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653743"></a><a name="_Toc525822984"></a>11.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">DAMAGE AND DESTRUCTION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818447"></a>11.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Repair of Damage to Premises by Landlord</font>.&nbsp;&nbsp;Tenant shall promptly notify Landlord of any damage to the Premises resulting from fire or any other casualty.&nbsp;&nbsp;If the Premises or any Common Areas serving or providing access to the Premises shall be damaged by fire or other casualty, Landlord shall promptly and diligently, subject to reasonable delays for insurance adjustment or other matters beyond Landlord&#8217;s reasonable control, and subject to all other terms of this <font style="text-decoration:underline;">Article 11</font>, restore such Common Areas and the Premises to substantially the same condition as existed prior to the casualty, except for modifications required by zoning and building codes and other laws or by the holder of a mortgage on the Building or Project or any other modifications to the Common Areas deemed desirable by Landlord, which are consistent with the character of the Project, provided that access to the or the use of Premises shall not be materially impaired.&nbsp;&nbsp;Upon the occurrence of any damage to the Premises, upon notice (the &#8220;<font style="font-weight:bold;">Landlord Repair Notice</font>&#8221;) to Tenant from Landlord, Tenant shall assign to Landlord (or to any party designated by Landlord) all insurance proceeds payable to Tenant under Tenant&#8217;s insurance required under <font style="text-decoration:underline;">Section&#160;10.3.2(ii)</font> of this Lease and Landlord&#8217;s obligation to restore any Alterations or Tenant Improvements shall be limited to the extent of such proceeds received by Landlord.&nbsp;&nbsp;To the extent permitted pursuant to Applicable Laws, Landlord shall not be liable for any inconvenience or annoyance to Tenant or its visitors, or injury to Tenant&#8217;s business resulting in any way from such damage or the repair thereof; provided however, that if such fire or other casualty shall have damaged the Premises or Common Areas necessary to Tenant&#8217;s occupancy, and the Premises, or a material portion of the Premises, are not occupied by Tenant as a result thereof, then during the time and to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of rentable square feet of the Premises which is unfit for occupancy for the purposes permitted under this Lease bears to the total rentable square feet of the Premises.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>11.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Option to Repair</font>.&nbsp;&nbsp;Notwithstanding the terms of <font style="text-decoration:underline;">Section&#160;11.1</font> of this Lease, Landlord may elect not to rebuild and/or restore the Premises, Building and/or Project, and instead terminate this Lease, by notifying Tenant in writing of such termination within forty-five (45) days after the date of discovery of the damage, such notice to include a termination date giving Tenant sixty (60) days to vacate the Premises, but Landlord may so elect only if the Building or Project shall be damaged by fire or other casualty or cause, whether or not the Premises are affected, and one or more of the following conditions is present: (i) in Landlord&#8217;s reasonable judgment, repairs cannot reasonably be completed within one hundred eighty (180) days after the date of discovery of the damage (when such repairs are made without the payment of overtime or other premiums); (ii) the holder of any mortgage on the Building or Project or ground lessor with respect to the Building or Project shall require that the insurance proceeds or any portion thereof be used to retire the mortgage debt, or shall terminate the ground lease, as the case may be; (iii) at least Ten Thousand and 00/100 Dollars ($10,000.00) of damage is not fully covered by Landlord&#8217;s insurance policies; (iv) intentionally omitted; (v) the damage occurs during the last twelve (12) months of the Lease Term; or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi) any owner of any other portion of the Project, other than Landlord, does not intend to repair the damage to such portion of the Project; provided, however, that if Landlord does not elect to terminate this Lease pursuant to Landlord&#8217;s termination right as provided above, and the repairs cannot, in the reasonable opinion of Landlord, be completed within one hundred eighty (180) days after the date of the damage, Tenant may elect, no earlier than thirty (30) days after the date of the damage and not later than ninety (90) days after the date of such damage, to terminate this Lease by written notice to Landlord effective as of the date specified in the notice, which date shall not be less than thirty (30) days nor more than sixty (60) days after the date such notice is given by Tenant.&nbsp;&nbsp;Notwithstanding the provisions of this Section 11.2, Tenant shall have the right to terminate this Lease under this Section 11.2 only if each of the following conditions is satisfied:&nbsp;&nbsp;(a) the damage to the Project by fire or other casualty was not caused by the gross negligence or intentional act of Tenant or its partners or subpartners and their respective officers, agents, servants, employees, and independent contractors; and (b) as a result of the damage, Tenant cannot reasonably conduct business from the Premises.&nbsp;&nbsp;In addition, Tenant may terminate this Lease if the damage to the Premises occurs during the last twelve (12) months of the Lease Term and such repair will take more than 10% of the remaining Term to repair.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653744"></a><a name="_Toc525822985"></a>12.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">NONWAIVER</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision of this Lease shall be deemed waived by either party hereto unless expressly waived in a writing signed thereby.&nbsp;&nbsp;The waiver by either party hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of same or any other term, covenant or condition herein contained.&nbsp;&nbsp;The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant to pay the particular Rent so accepted, regardless of Landlord&#8217;s knowledge of such preceding breach at the time of acceptance of such Rent.&nbsp;&nbsp;No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a waiver of Landlord&#8217;s right to receive the full amount due, nor shall any endorsement or statement on any check or payment or any letter accompanying such check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the full amount due.&nbsp;&nbsp;No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Lease Term or of Tenant&#8217;s right of possession hereunder, or after the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit, or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or judgment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653745"></a><a name="_Toc525822986"></a>13.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">CONDEMNATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the whole or any part of the Premises, Building or Project shall be taken by power of eminent domain or condemned by any competent authority for any public or quasi-public use or purpose, or if any adjacent property or street shall be so taken or condemned, or reconfigured or vacated by such authority in such manner as to require the use, reconstruction or remodeling of any part of the Premises, Building or Project, or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation, Landlord shall have the option to terminate this Lease effective as of the date possession is required to be surrendered to the authority.&nbsp;&nbsp;Tenant shall not because of such taking assert any claim against Landlord or the authority for any compensation because of such taking and Landlord shall be entitled to the entire award or payment in connection therewith, except that Tenant shall have the right to file any separate claim available to Tenant for any taking of Tenant&#8217;s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Lease Term pursuant to the terms of this Lease, and for moving expenses, so long as such claims do not diminish the award available to Landlord, its ground lessor with respect to the Building or Project or its mortgagee, and such claim is payable separately to Tenant.&nbsp;&nbsp;All Rent shall be apportioned as of the date of such termination.&nbsp;&nbsp;If any part of the Premises shall be taken, and this Lease shall&nbsp;&nbsp;not be so terminated, the Rent shall be proportionately abated.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this <font style="text-decoration:underline;">Article 13</font>, in the event of a temporary taking of all or any portion of the Premises for a period of one hundred and eighty (180) days or less, and provided that such temporary taking does not materially preclude or unreasonably diminish Tenant&#8217;s ability to conduct business from the Premises, then this Lease shall not terminate but the Base Rent and the Additional Rent shall be abated for the period of such taking in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to the total rentable square feet of the Premises.&nbsp;&nbsp;Landlord shall be entitled to receive the entire award made in connection with any such temporary taking, provided, however, that Tenant shall be entitled to a share of the award for any loss of fixtures and improvements and for moving and other reasonable expenses that do not otherwise reduce Landlord&#8217;s recovery.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653746"></a><a name="_Toc525822987"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">ASSIGNMENT AND SUBLETTING</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transfers</font>.&nbsp;&nbsp;Tenant shall not, without the prior written consent of Landlord, assign, mortgage, pledge, hypothecate, encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment, or other transfer of this Lease or any interest hereunder by operation of law, sublet the Premises or any part thereof, or enter into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons other than Tenant and its employees and contractors (all of the foregoing are hereinafter sometimes referred to collectively as &#8220;<font style="font-weight:bold;">Transfers</font></a>&#8221; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a &#8220;<font style="font-weight:bold;">Transferee</font>&#8221;).&nbsp;&nbsp;If Tenant desires Landlord&#8217;s consent to any Transfer, Tenant shall notify Landlord in writing, which notice (the &#8220;<font style="font-weight:bold;">Transfer Notice</font>&#8221;) shall include (i) the proposed effective date of the Transfer, which shall not be less than twenty (20) days nor more than one hundred eighty (180) days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred (the &#8220;<font style="font-weight:bold;">Subject Space</font>&#8221;), (iii) all of the terms of the proposed Transfer and the consideration therefor, including calculation of the &#8220;<font style="font-weight:bold;">Transfer Premium</font>&#8221;, as that term is defined in <font style="text-decoration:underline;">Section&#160;14.3</font> below, in connection with such Transfer, the name and address of the proposed Transferee, and a copy of all existing executed and/or proposed documentation pertaining to the proposed Transfer, and (iv) current financial statements of the proposed Transferee certified by an officer, partner or owner thereof, business credit and personal references and history of the proposed Transferee and any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such Transferee&#8217;s business and proposed use of the Subject Space.&nbsp;&nbsp;Any Transfer made without Landlord&#8217;s prior written consent shall, at Landlord&#8217;s option, be null, void and of no effect, and shall, at Landlord&#8217;s option, constitute a default by Tenant under this Lease.&nbsp;&nbsp;Whether or not Landlord consents to any proposed Transfer, Tenant shall pay Landlord&#8217;s reasonable review and processing fees(not to exceed $1,500.00 for Landlord&#8217;s internal costs) plus any reasonable professional fees (including, without limitation, attorneys&#8217;, accountants&#8217;, architects&#8217;, engineers&#8217; and consultants&#8217; fees) incurred by Landlord, within thirty (30) days after written request by Landlord.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Consent</font>.&nbsp;&nbsp;Landlord shall not unreasonably withhold, condition or delay its consent to any proposed Transfer of the Subject Space to the Transferee on the terms specified in the Transfer Notice.&nbsp;&nbsp;Without limitation as to other reasonable grounds for withholding consent, the parties hereby agree that it shall be reasonable under this Lease and under any applicable law for Landlord to withhold consent to any proposed Transfer where one or more of the following apply:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.1<font style="margin-left:36pt;"></font>The Transferee is of a character or reputation or engaged in a business which is not consistent with the quality of the Building or the Project;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.2<font style="margin-left:36pt;"></font>The Transferee is either a governmental agency or instrumentality thereof;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.3<font style="margin-left:36pt;"></font>The Transferee is not a party of reasonable financial worth and/or financial stability in light of the responsibilities to be undertaken in connection with the Transfer on the date consent is requested;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.4<font style="margin-left:36pt;"></font>The proposed Transfer would cause a violation of another lease for space in the Project, or would give an occupant of the Project a right to cancel its lease; or</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.5<font style="margin-left:36pt;"></font>Either the proposed Transferee, or any person or entity which directly or indirectly, controls, is controlled by, or is under common control with, the proposed Transferee, is actively negotiating with Landlord or has negotiated with Landlord during the four (4) month period immediately preceding the date Landlord receives the Transfer Notice, to lease space in the Project (and Landlord has suitable space available in the Project to meet Transferee&#8217;s needs).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.6</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Landlord&#8217;s reasonable determination, the sub-rent, additional rent or other amounts received or accrued by Tenant from subleasing, assigning or otherwise Transferring all or any portion of the Premises is based on the income or profits of any person, or the assignment of sublease could cause any portion of the amounts received by Landlord pursuant to this Lease to fail to qualify as &#8220;rents from real property&#8221; within the meaning of section 856(d) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or any similar or successor provision thereto or which would cause any other income of Landlord to fail to qualify as income described in section 856(c)(2) of the Code.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Landlord consents to any Transfer pursuant to the terms of this <font style="text-decoration:underline;">Section&#160;14.2</font> (and does not exercise any recapture rights Landlord may have under <font style="text-decoration:underline;">Section&#160;14.4</font> of this Lease), Tenant may within six (6) months after Landlord&#8217;s consent, but not later than the expiration of said six-month period, enter into such Transfer of the Premises or portion thereof, upon substantially the same terms and conditions as are set forth in the Transfer Notice furnished by Tenant to Landlord pursuant to <font style="text-decoration:underline;">Section&#160;14.1</font> of this Lease, provided that if there are any material changes in the terms and conditions from those specified in the Transfer Notice such that Landlord would initially have been entitled to refuse its consent to such Transfer under this <font style="text-decoration:underline;">Section&#160;14.2</font>, Tenant shall again submit the Transfer to Landlord for its approval and other action under this <font style="text-decoration:underline;">Article 14</font> (including Landlord&#8217;s right of recapture, if any, under <font style="text-decoration:underline;">Section&#160;14.4</font> of this Lease).&nbsp;&nbsp;Notwithstanding anything to the contrary in this Lease, if Tenant or any proposed Transferee claims that Landlord has unreasonably withheld or delayed its consent under <font style="text-decoration:underline;">Section&#160;14.2</font> or otherwise has breached or acted unreasonably under this <font style="text-decoration:underline;">Article 14</font>, their sole remedies shall be a suit for contract damages (other than damages for injury to, or interference with, Tenant&#8217;s business including, without limitation, loss of profits, however occurring) or declaratory judgment and an injunction for the relief sought, and Tenant hereby waives all other remedies, including, without limitation, any right at law or equity to terminate this Lease, on its own behalf and, to the extent permitted under all Applicable Laws, on behalf of the proposed Transferee.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transfer Premium</font>.&nbsp;&nbsp;If Landlord consents to a Transfer, as a condition thereto which the parties hereby agree is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any &#8220;<font style="font-weight:bold;">Transfer Premium</font></a>,&#8221; as that term is defined in this <font style="text-decoration:underline;">Section&#160;14.3</font>, received by Tenant from such Transferee (other than any Permitted Transferee).&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Transfer Premium</font>&#8221; shall mean all rent, additional rent or other consideration payable by such Transferee in connection with the Transfer in excess of the Rent and Additional Rent payable by Tenant under this Lease during the term of the Transfer on a per rentable square foot basis if less than all of the Premises is transferred, after deducting the reasonable third party expenses incurred by Tenant for (i)&#160;any design and construction costs incurred on account of changes, alterations and improvements to the Premises in connection with the Transfer, (ii)&#160;any free base rent and tenant improvement allowances reasonably provided to the Transferee in connection with the Transfer (provided that such free rent and tenant improvement allowances shall be deducted only to the extent the same is included in the calculation of total consideration payable by such Transferee), (iii)&#160;any brokerage commissions in connection with the Transfer, (iv) legal fees and disbursements reasonably incurred in connection with the Transfer, and (v) any unamortized Excess Costs, as defined in <font style="text-decoration:underline;">Exhibit D </font> (as determined on a straight line basis over the initial term of this Lease, without interest) paid by Tenant for the Tenant Improvements (collectively, &#8220;<font style="font-weight:bold;">Tenant&#8217;s Subleasing Costs</font>&#8221;).&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Transfer Premium</font>&#8221; shall also include, but not be limited to, key money, bonus money or other cash consideration paid by Transferee to Tenant in connection with such Transfer, and any payment in excess of fair market value for services rendered by Tenant to Transferee or for assets, fixtures, inventory, equipment, or furniture transferred by Tenant to Transferee in connection with such Transfer.&nbsp;&nbsp;The determination of the amount of Landlord&#8217;s applicable share of the Transfer Premium shall be made on a monthly basis as rent or other consideration is received by Tenant under the Transfer.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>14.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Option as to Subject Space</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this <font style="text-decoration:underline;">Article 14</font>, in the event Tenant contemplates a Transfer which, together with all prior Transfers then remaining in effect, would cause seventy-five percent (75%) or more of the Premises to be Transferred for more than fifty percent (50%) of the then remaining Lease Term (assuming all sublease renewal or extension rights are exercised), Tenant shall give Landlord notice (the &#8220;<font style="font-weight:bold;">Intention to Transfer Notice</font>&#8221;) of such contemplated Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined).&nbsp;&nbsp;The Intention to Transfer Notice shall specify the portion of and amount of rentable square feet of the Premises which Tenant intends to Transfer (the &#8220;<font style="font-weight:bold;">Contemplated Transfer Space</font>&#8221;), the contemplated date of commencement of the Contemplated Transfer (the &#8220;<font style="font-weight:bold;">Contemplated Effective Date</font>&#8221;), and the contemplated length of the term of such contemplated Transfer, and shall specify that such Intention to Transfer Notice is delivered to Landlord pursuant to this <font style="text-decoration:underline;">Section&#160;14.4</font> in order to allow Landlord to elect to recapture the Contemplated Transfer Space.&nbsp;&nbsp;Thereafter, Landlord shall have the option, by giving </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written notice to Tenant within fifteen (15) days after receipt of any Intention to Transfer Notice, to recapture the Contemplated Transfer Space.&nbsp;&nbsp;Such recapture shall cancel and terminate this Lease with respect to such Contemplated Transfer Space as of the Contemplated Effective Date.&nbsp;&nbsp;In the event of a recapture by Landlord, if this Lease shall be canceled with respect to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable square feet retained by Tenant in proportion to the number of rentable square feet contained in the Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of the same.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Effect of Transfer</font>.&nbsp;&nbsp;If Landlord consents to a Transfer, (i) the terms and conditions of this Lease shall in no way be deemed to have been waived or modified, (ii) such consent shall not be deemed consent to any further Transfer by either Tenant or a Transferee, (iii) Tenant shall deliver to Landlord, promptly after execution, an original executed copy of all documentation pertaining to the Transfer in form reasonably acceptable to Landlord, (iv) intentionally omitted, and (v) no Transfer relating to this Lease or agreement entered into with respect thereto, whether with or without Landlord&#8217;s consent, shall relieve Tenant or any guarantor of the Lease from any liability under this Lease, including, without limitation, in connection with the Subject Space. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Sublease/Transfer Restrictions</font>.&nbsp;&nbsp;Notwithstanding anything contained herein to the contrary and without limiting the generality of <font style="text-decoration:underline;">Section 14.1</font> above, Tenant shall not:&nbsp;&nbsp;(a) sublet all or part of the Premises or assign or otherwise Transfer this Lease on any basis such that the rental or other amounts to be paid by the subtenant or assignee thereunder would be based, in whole or in part, on the income or profits derived by the business activities of the subtenant or assignee; (b) sublet all or part of the Premises or assign this Lease to any person or entity in which, under Section 856(d)(2)(B) of the Code, Longfellow Atlantic REIT, Inc., a Delaware corporation (the &#8220;Company&#8221;), or any affiliate of the Company owns, directly or indirectly (by applying constructive ownership rules set forth in Section 856(d) (5) of the Code), a ten percent (10%) or greater interest; or (c) sublet all or part of the Premises or assign this Lease in any other manner or otherwise derive any income which could cause any portion of the amounts received by Landlord pursuant hereto or any sublease to fail to qualify as &#8220;rents from real property&#8221; within the meaning of Section 856(d) of the Code, or which could cause any other income received by Landlord to fail to qualify as income described in Section 856(c) (2) of the Code.&nbsp;&nbsp;The requirements of this <font style="text-decoration:underline;">Section 14.4</font> shall likewise apply to any further subleasing, assignment or other Transfer by any subtenant or assignee.&nbsp;&nbsp;All references herein to Section 856 of the Code also shall refer to any amendments thereof or successor provisions thereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Occurrence of Default</font>.&nbsp;&nbsp;Any Transfer hereunder shall be subordinate and subject to the provisions of this Lease, and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to:&nbsp;&nbsp;(i) treat such Transfer as cancelled and repossess the Subject Space by any lawful means, or (ii) require that such Transferee attorn to and recognize Landlord as its landlord under any such Transfer.&nbsp;&nbsp;If Tenant shall be in default under this Lease (beyond applicable notice and cure period), Landlord is hereby irrevocably authorized to direct any Transferee to make all payments under or in connection with the Transfer directly to Landlord (which Landlord shall apply towards Tenant&#8217;s obligations under this Lease) until such default is cured.&nbsp;&nbsp;Such Transferee shall rely on any representation by Landlord that Tenant is in default hereunder, without any need for confirmation thereof by Tenant.&nbsp;&nbsp;Upon any assignment, the assignee shall assume in writing all obligations and covenants of Tenant thereafter to be performed or observed under this Lease.&nbsp;&nbsp;No collection or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this <font style="text-decoration:underline;">Article 14</font> or the approval of any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore or thereafter accruing.&nbsp;&nbsp;In no event shall Landlord&#8217;s enforcement of any provision of this Lease against any Transferee be deemed a waiver of Landlord&#8217;s right to enforce any term of this Lease against Tenant or any other person.&nbsp;&nbsp;If Tenant&#8217;s obligations hereunder have been guaranteed, Landlord&#8217;s consent to any Transfer shall not be effective unless the guarantor also consents to such Transfer. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><a name="_DV_M622"></a><a name="_DV_M623"></a><a name="_DV_C946"></a><a name="_DV_M624"></a><a name="_DV_C948"></a><a name="_DV_M625"></a>14.8<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Non-Transfers</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this <font style="text-decoration:underline;">Article&#160;14</font>, (i) an assignment or subletting of all or a portion of the Premises to an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with, Tenant), <font style="color:#auto;">(ii)&#160;an assignment of the Premises to an entity which acquires all or substantially all of the assets or interests (partnership, stock or other) of Tenant, (iii)&#160;an assignment of the Premises to an entity which is the resulting entity of a merger or consolidation of Tenant, or (iv) </font>a sale of corporate shares of capital stock in Tenant in connection with an initial public offering of Tenant&#8217;s stock on a nationally-recognized stock exchange (collectively, a &#8220;<font style="font-weight:bold;">Permitted Transferee</font>&#8221;), shall not be deemed a Transfer under this <font style="text-decoration:underline;">Article 14</font>, provided that (A) Tenant notifies Landlord of any such assignment or sublease and promptly supplies Landlord with any documents or information reasonably requested by Landlord regarding such assignment or sublease or such affiliate, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M622"></a>(B) such assignment or sublease is not a subterfuge by Tenant to avoid its obligations under this Lease, (C) such Permitted Transferee shall be of a character and reputation consistent with the quality of the Building, and (</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D)&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M623"></a><a name="_DV_C946"></a>such </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Transferee shall have a tangible net worth (not including goodwill as an asset) computed</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M624"></a><a name="_DV_C948"></a> in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accordance with generally accepted accounting principles (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Net Worth</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) at least</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M625"></a> equal to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Net Worth of Tenant on the day immediately preceding the effective date of such assignment or sublease</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;An assignee of Tenant&#8217;s entire interest that is also a Permitted Transferee may also be known as a &#8220;</font><font style="font-weight:bold;">Permitted Assignee</font><font style="font-weight:bold;"></font><font style="font-weight:bold;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;">Control</font><font style="font-weight:bold;"></font><font style="font-weight:bold;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#8221; as used in this </font><font style="text-decoration:underline;">Section&#160;14.8</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, shall mean the ownership, directly or indirectly, of at least fifty-one percent (51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of at least fifty-one percent (51%) of the voting interest in, any person or entity.&nbsp;&nbsp;No such permitted assignment or subletting shall serve to release Tenant from any of its obligations under this Lease.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman Bold;font-size:10pt;"><a name="_Toc253653747"></a><a name="_Toc525822988"></a><font style="font-family:Times New Roman;">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Surrender of Premises</font>.&nbsp;&nbsp;No act or thing done by Landlord or any agent or employee of Landlord during the Lease Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically acknowledged in writing by Landlord.&nbsp;&nbsp;The delivery of keys to the Premises to Landlord or any agent or employee of Landlord shall not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained by Landlord, and notwithstanding such delivery Tenant shall be entitled to the return of such keys at any reasonable time upon request until this Lease shall have been properly terminated.&nbsp;&nbsp;The voluntary or other surrender of this Lease by Tenant, whether accepted by Landlord or not, or a mutual termination hereof, shall not work a merger, and at the option of Landlord shall operate as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or subtenancies.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_510"></a>15.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Removal of Tenant Property by Tenant</font>.&nbsp;&nbsp;Upon the expiration of the Lease Term, or upon any earlier termination of this Lease, Tenant shall, subject to the provisions of this <font style="text-decoration:underline;">Article 15</font><a name="_cp_text_1_510"></a>, quit and surrender possession of the Premises to Landlord in as good order and condition as when Tenant took possession and as thereafter improved by Landlord and/or Tenant, reasonable wear and tear and repairs which are specifically made the responsibility of Landlord hereunder excepted.&nbsp;&nbsp;Upon such expiration or termination, Tenant shall, without expense to Landlord, remove or cause to be removed from the Premises all debris and rubbish, and such items of furniture, equipment, free-standing cabinet work, movable partitions (not including modular &#8220;clean rooms&#8221; built into the Premises as part of the Tenant Improvements) and other articles of personal property owned by Tenant or installed or placed by Tenant at its expense in the Premises, and such similar articles of any other persons claiming under Tenant, as Landlord may, in its sole discretion, require to be removed, and Tenant shall repair at its own expense all damage to the Premises and Building resulting from such removal. In no event shall any Landlord&#8217;s Work be deemed to be Tenant&#8217;s personal property, it being the intent that Tenant&#8217;s personal property includes only those items that are not built into the Premises and that have not been constructed or installed by Landlord pursuant to the Work Letter.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818463"></a><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>15.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Environmental Assessment</font>.&nbsp;&nbsp;Prior to the expiration of the Lease (or within thirty (30) days after any earlier termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing in or serving the Premises, and all exhaust or other ductwork in or serving the Premises, in each case that has carried, released or otherwise been exposed to any Hazardous Materials due to Tenant&#8217;s use or occupancy of the Premises, and shall otherwise clean the Premises so as to permit the Environmental Assessment called for by this <font style="text-decoration:underline;">Section 15.3</font> to be issued.&nbsp;&nbsp;Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant, at Tenant&#8217;s expense, shall obtain for Landlord a report (an &#8220;<font style="font-weight:bold;">Environmental Assessment</font>&#8221;) addressed to Landlord (and, at Tenant&#8217;s election, Tenant) by a reputable licensed environmental consultant or industrial hygienist that is designated by Tenant and acceptable to Landlord in Landlord&#8217;s reasonable discretion, which report shall be based on the environmental consultant&#8217;s inspection of the Premises and shall state, to the Landlord&#8217;s reasonable satisfaction, that (a) the Hazardous Materials described in the first sentence of this paragraph, to the extent, if any, existing prior to such decommissioning, have been removed in accordance with Applicable Laws; (b) all Hazardous Materials described in the first sentence of this paragraph, if any, have been removed in accordance with Applicable Laws from the interior surfaces of the Premises (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing, and all such exhaust or other ductwork in the Premises, may be reused by a subsequent tenant or disposed of in compliance with Applicable Laws without incurring special costs or undertaking special procedures for demolition, disposal, investigation, assessment, cleaning or removal of such Hazardous Materials and without giving notice in connection with such Hazardous Materials; and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) the Premises may be reoccupied for office, research and development, or laboratory use, demolished or renovated without incurring special costs or undertaking special procedures for disposal, investigation, assessment, cleaning or removal of Hazardous Materials described in the first sentence of this paragraph and without giving notice in connection with Hazardous Materials.&nbsp;&nbsp;Further, for purposes of clauses (b) and (c), &#8220;special costs&#8221; or &#8220;special procedures&#8221; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous Materials as Hazardous Materials instead of non-hazardous materials.&nbsp;&nbsp;The report shall also include reasonable detail concerning the clean-up measures taken, the clean-up locations, the tests run and the analytic results.&nbsp;&nbsp;Tenant shall submit to Landlord the scope of the proposed Environmental Assessment for Landlord&#8217;s reasonable review and approval at least 30 days prior to commencing the work described therein or at least 60 days prior to the expiration of the Lease Term, whichever is earlier. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818464"></a>If Tenant fails to perform its obligations under this <font style="text-decoration:underline;">Section 15.3</font> without limiting any other right or remedy, Landlord may, on five (5) business days&#8217; prior written notice to Tenant perform such obligations at Tenant&#8217;s expense if Tenant has not commenced to do so within said five day period, and Tenant shall within 10 days of written demand reimburse Landlord for all reasonable out-of-pocket costs and expenses incurred by Landlord in connection with such work.&nbsp;&nbsp;Tenant&#8217;s obligations under this <font style="text-decoration:underline;">Section 15.3</font> shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;In addition, at Landlord&#8217;s election, Landlord may inspect the Premises and/or the Project for Hazardous Materials at Landlord&#8217;s cost and expense within sixty (60) days of Tenant&#8217;s surrender of the Premises at the expiration or earlier termination of this Lease.&nbsp;&nbsp;Tenant shall pay for all such costs and expenses incurred by Landlord in connection with such inspection if such inspection reveals that a release of Hazardous Materials exists at the Project or Premises as a proximate result of the acts or omissions of Tenant, its officers, employees, contractors, and agents (except to the extent resulting from (i) Hazardous Materials existing in the Premises as at the delivery of possession to Tenant (in which event Landlord shall be responsible for any Clean-up, as provided in this Lease), or (ii) the acts or omissions of Landlord or Landlord&#8217;s agents, employees or contractors).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653748"></a><a name="_Toc525822989"></a>16.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">HOLDING OVER</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Tenant holds over after the expiration of the Lease Term or earlier termination thereof, with the express or implied consent of Landlord, such tenancy shall be from month-to-month only, and shall not constitute a renewal hereof or an extension for any further term.&nbsp;&nbsp;If Tenant holds over after the expiration of the Lease Term of earlier termination thereof, without the express or implied consent of Landlord, such tenancy shall be deemed to be a tenancy by sufferance only, and shall not constitute a renewal hereof or an extension for any further term.&nbsp;&nbsp;In either case, Base Rent shall be payable at a monthly rate equal to one hundred twenty-five percent (125%) of the Base Rent applicable during the last rental period of the Lease Term under this Lease for the first two (2) months of such holdover with such rate increasing to one hundred fifty percent (150%) of the Base Rent if Tenant holdsover longer than two (2) months.&nbsp;&nbsp;Such month-to-month tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant and agreement contained herein.&nbsp;&nbsp;Nothing contained in this <font style="text-decoration:underline;">Article 16</font> shall be construed as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of this Lease.&nbsp;&nbsp;The provisions of this <font style="text-decoration:underline;">Article 16</font> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law.&nbsp;&nbsp;If Tenant fails to surrender the Premises upon the termination or expiration of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys&#8217; fees) and liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender and any lost profits to Landlord resulting therefrom.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653749"></a><a name="_Toc525822990"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">ESTOPPEL CERTIFICATES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within ten (10) business days following a request in writing by Landlord, Tenant shall execute, acknowledge and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form of <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;F</font>, attached hereto (or such other commercially reasonable form as may be required by any prospective mortgagee or purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and shall also contain any other information reasonably requested by Landlord or Landlord&#8217;s mortgagee or prospective mortgagee.&nbsp;&nbsp;Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project.&nbsp;&nbsp;Tenant shall execute and deliver whatever other instruments may be reasonably required for such purposes.&nbsp;&nbsp;At any time during the Lease Term, but not more often than twice per year, Landlord may require Tenant to provide Landlord with a current financial statement and financial statements of the two (2) years prior to the current financial statement year.&nbsp;&nbsp;Such statements shall be prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public accountant.&nbsp;&nbsp;Failure of Tenant to timely execute, acknowledge and deliver such estoppel certificate or other instruments shall constitute an acceptance of the Premises and an acknowledgment by Tenant that statements included in the estoppel certificate are true and correct, without exception.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653750"></a><a name="_Toc525822991"></a>18.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">SUBORDINATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Lease shall be subject and subordinate to all present and future ground or underlying leases of the Building or Project and to the lien of any mortgage, trust deed or other encumbrances now or hereafter in force against the Building or Project or any part thereof, if any, and to all renewals, extensions, modifications, consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security of such mortgages or trust deeds, unless the holders of such mortgages, trust deeds or other encumbrances, or the lessors under such ground lease or underlying leases, require in writing that this Lease be superior thereto.&nbsp;&nbsp;Tenant covenants and agrees in the event any proceedings are brought for the foreclosure of any such mortgage or deed in lieu thereof (or if any ground lease is terminated), to attorn, without any deductions or set-offs whatsoever, to the lienholder or purchaser or any successors thereto upon any such foreclosure sale or deed in lieu thereof (or to the ground lessor), if so requested to do so by such purchaser or lienholder or ground lessor, and to recognize such purchaser or lienholder or ground lessor as the lessor under this Lease, provided such lienholder or purchaser or ground lessor shall agree to accept this Lease and not disturb Tenant&#8217;s occupancy, so long as Tenant timely pays the rent and observes and performs the terms, covenants and conditions of this Lease to be observed and performed by Tenant.&nbsp;&nbsp;Landlord&#8217;s delivery to Tenant of commercially reasonable non-disturbance agreement(s) in favor of Tenant from any ground lessors, mortgage holders or lien holders of Landlord who come into existence following the date hereof but prior to the expiration of the Lease Term shall be in consideration of, and a condition precedent to, Tenant&#8217;s agreement to subordinate this Lease to any such ground lease, mortgage or lien.&nbsp;&nbsp;Landlord&#8217;s interest herein may be assigned as security at any time to any lienholder.&nbsp;&nbsp;Tenant shall, within ten (10) business days of request by Landlord, execute such further commercially reasonable instruments or assurances as Landlord may reasonably deem necessary to evidence or confirm the subordination or superiority of this Lease to any such mortgages, trust deeds, ground leases or underlying leases.&nbsp;&nbsp;Tenant waives the provisions of any current or future statute, rule or law which may give or purport to give Tenant any right or election to terminate or otherwise adversely affect this Lease and the obligations of the Tenant hereunder in the event of any foreclosure proceeding or sale.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653751"></a><a name="_Toc525822992"></a>19.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">DEFAULTS; REMEDIES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Events of Default</font>.&nbsp;&nbsp;The occurrence of any of the following shall constitute a default of this Lease by Tenant:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1.1<font style="margin-left:36pt;"></font>Any failure by Tenant to pay any Rent or any other charge required to be paid under this Lease, or any part thereof, when due (provided, however, that it shall not be a default if Tenant makes full payment within five (5)&#160;business days after receipt of written notice of any delinquency; provided that Landlord shall not be required to provide more than one (1) such notices in any twelve (12) month period during the Lease Term); or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1.2</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except where a specific time period is otherwise set forth for Tenant&#8217;s performance in this Lease, in which event the failure to perform by Tenant within such time period shall be a default by Tenant under this </font><font style="text-decoration:underline;">Section&#160;19.1.2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, any failure by Tenant to observe or perform any other provision, covenant or condition of this Lease to be observed or performed by Tenant where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that if the nature of such default is such that the same cannot reasonably be cured within a thirty (30) day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify and cure such default; or</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1.3<font style="margin-left:36pt;"></font>Abandonment of the Premises by Tenant and failure to perform any obligation under this Lease regarding the maintenance, cleanliness or operation of the Premises within five (5) business days after notice from Landlord; or </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1.4<font style="margin-left:36pt;"></font>The failure by Tenant to observe or perform according to the provisions of <font style="text-decoration:underline;">Articles 5</font>, <font style="text-decoration:underline;">14</font>, <font style="text-decoration:underline;">17</font> or <font style="text-decoration:underline;">18</font> of this Lease where such failure continues for more than two (2) business days after notice from Landlord.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The notice periods provided herein are in lieu of, and not in addition to, any notice periods provided by law.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Remedies Upon Default</font>.&nbsp;&nbsp;Upon the occurrence of any event of default by Tenant, Landlord shall have, in addition to any other remedies available to Landlord at law or in equity (all of which remedies shall be distinct, separate and cumulative), the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and nonexclusive, without any separate notice or demand whatsoever.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.1<font style="margin-left:36pt;"></font>Landlord may, immediately or at any time thereafter, elect to terminate this Lease by notice of termination, by entry, or by any other means available under law and may recover possession of the Premises as provided herein.&nbsp;&nbsp;Upon termination by notice, by entry, or by any other means available under law, Landlord shall be entitled immediately, in the case of termination by notice or entry, and otherwise in accordance with the provisions of law to recover possession of the Premises from Tenant and those claiming through or under the Tenant.&nbsp;&nbsp;Such termination of this Lease and repossession of the Premises shall be without prejudice to any remedies which Landlord might otherwise have for arrears of rent or for a prior breach of the provisions of this Lease.&nbsp;&nbsp;Tenant waives any statutory notice to quit and equitable rights in the nature of further cure or redemption, and Tenant agrees that upon Landlord&#8217;s termination of this Lease Landlord shall be entitled to re-entry and possession in accordance with the terms hereof.&nbsp;&nbsp;Landlord may, without notice, store Tenant&#8217;s personal property (and those of any person claiming under Tenant) at the expense and risk of Tenant or, if Landlord so elects, Landlord may sell such personal property at public auction or auctions or at private sale or sales after seven days&#8217; notice to Tenant and apply the net proceeds to the earliest of installments of rent or other charges owing Landlord.&nbsp;&nbsp;Tenant agrees that a notice by Landlord alleging any default shall, at Landlord&#8217;s option (the exercise of such option shall be indicated by the inclusion of the words &#8220;notice to quit&#8221; in such notice), constitute a statutory notice to quit.&nbsp;&nbsp;If Landlord exercises its option to designate a notice of default hereunder as a statutory notice to quit, any grace periods provided for herein shall run concurrently with any statutory notice periods.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.2<font style="margin-left:36pt;"></font>In the case of termination of this Lease pursuant to <font style="text-decoration:underline;">Section&#160;19.2.1</font>, Tenant shall reimburse Landlord for all expenses arising out of such termination, including without limitation, all reasonable costs incurred in collecting amounts due from Tenant under this Lease (including reasonable attorneys&#8217; fees, costs of litigation and the like); all expenses incurred by Landlord in attempting to relet the Premises or parts thereof (including advertisements, brokerage commissions, Tenant&#8217;s allowances, costs of preparing space, and the like); and all Landlord&#8217;s other reasonable expenditures necessitated by the termination.&nbsp;&nbsp;The reimbursement from Tenant shall be due and payable immediately from time to time upon notice from Landlord that an expense has been incurred, without regard to whether the expense was incurred before or after the termination. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.3</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord may elect by written notice to Tenant within one year following such termination to be indemnified for loss of rent by a lump sum payment representing the then present value of the amount of Rent that would have been paid in accordance with this Lease for the remainder of the Lease Term minus the then present value of the aggregate fair market rent and additional charges payable for the Premises for the remainder of the Lease Term (if less than the Rent payable hereunder), estimated as of the date of the termination, and taking into account reasonable projections of vacancy and time required to re-lease the Premises.&nbsp;&nbsp;(For the purposes of calculating the Rent that would have been paid hereunder for the lump sum payment calculation described herein, the last full year&#8217;s Additional Rent under Article 4 is to be deemed constant for each year thereafter.&nbsp;&nbsp;The Federal Reserve discount rate (or equivalent) shall be used in calculating present values.)&nbsp;&nbsp;Should the parties be unable to agree on a fair market rent, the matter shall be submitted, upon the demand of either party, to the Charlotte, North Carolina office of the American Arbitration Association, with a request for arbitration in accordance with the rules of the Association by a single arbitrator who shall be an MAI appraiser with at least ten years&#8217; experience as an appraiser of life sciences buildings in the Research Triangle Park and Durham markets.&nbsp;&nbsp;The parties agree that a decision of the arbitrator shall be conclusive and binding upon them.&nbsp;&nbsp;If, at the end of the Lease Term, the rent that Landlord has actually received from the Premises is less than the aggregate fair market rent estimated as aforesaid, Tenant shall thereupon pay Landlord the amount of such difference.&nbsp;&nbsp;If and for so long as Landlord does not make the election provided for in this </font><font style="text-decoration:underline;">Section&#160;19.2.3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Tenant shall indemnify Landlord for the loss of Rent by a payment at the end of each month which would have been included in the Lease Term, representing the excess of the Rent that would have been paid in accordance with this Lease (Base Rent together with any Additional Rent that would have been payable under Article 4, to be ascertained monthly) over the rent actually derived from the Premises by Landlord for such month (the amount of rent deemed derived shall be the actual amount less any portion thereof attributable to Landlord&#8217;s reletting expenses described in </font><font style="text-decoration:underline;">Section&#160;19.2.2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that have not been reimbursed by Tenant thereunder).</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.4<font style="margin-left:36pt;"></font>Intentionally Omitted.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.5<font style="margin-left:36pt;"></font>In lieu of any other damages or indemnity and in lieu of full recovery by Landlord of all sums payable under all the foregoing provisions of this <font style="text-decoration:underline;">Section&#160;19.2</font>, Landlord may by written notice to Tenant within six (6)&#160;months after termination under any of the provisions contained in <font style="text-decoration:underline;">Section&#160;19.1</font> and before such full recovery, elect to recover, and Tenant shall thereupon pay, as minimum liquidated damages under this <font style="text-decoration:underline;">Section&#160;19.2</font>, an amount equal to the lesser of (i)&#160;the aggregate of the Base Rent and Additional Rent for the balance of the Lease Term had it not been terminated or (ii)&#160;the aggregate thereof for the 12&#160;months ending one year after the termination date, plus in either case (iii)&#160;the amount of Base Rent and Additional Rent of any kind accrued and unpaid at the time of termination and minus (iv)&#160;the amount of any recovery by Landlord under the foregoing provisions of this <font style="text-decoration:underline;">Section&#160;19.2</font> up to the time of payment of such liquidated damages (but reduced by any amounts of reimbursement under <font style="text-decoration:underline;">Section&#160;19.2.2</font>).&nbsp;&nbsp;Liquidated damages hereunder shall not be in lieu of any claims for reimbursement under <font style="text-decoration:underline;">Section&#160;19.2.2</font>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.6<font style="margin-left:36pt;"></font>If Landlord does not elect to terminate this Lease on account of any default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.7<font style="margin-left:36pt;"></font>Landlord shall at all times have the rights and remedies (which shall be cumulative with each other and cumulative and in addition to those rights and remedies available under <font style="text-decoration:underline;">Sections 19.2.1 and 19.2.2</font>, above, or any law or other provision of this Lease), without prior demand or notice except as required by Applicable Law, to seek any declaratory, injunctive or other equitable relief, and specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof.&nbsp;&nbsp;The provisions of this <font style="text-decoration:underline;">Section 19.2.7</font> are not dependent upon the occurrence of a default.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.8<font style="margin-left:36pt;"></font>Any obligation imposed by law upon Landlord to relet the Premises after any termination of the Lease shall be subject to the reasonable requirements of Landlord to lease to high quality tenants on such terms as Landlord may from time to time deem reasonably appropriate and to develop the Building in a harmonious manner with an appropriate mix of uses, tenants, floor areas and terms of tenancies, and the like, and Landlord shall not be obligated to relet the Premises to any party to whom Landlord or its affiliate may desire to lease other available space in the Building.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.2.9</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nothing herein shall limit or prejudice the right of Landlord to prove and obtain in a proceeding for bankruptcy, insolvency, arrangement or reorganization, by reason of the termination, an amount equal to the maximum allowed by a statute of law in effect at the time when, and governing the proceedings in which, the damages are to be proved, whether or not the amount is greater to, equal to, or less than the amount of the loss or damage which Landlord has suffered.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subleases of Tenant</font>.&nbsp;&nbsp;Whether or not Landlord elects to terminate this Lease on account of any default by Tenant, as set forth in this <font style="text-decoration:underline;">Article 19</font>, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord&#8217;s sole discretion, succeed to Tenant&#8217;s interest in such subleases, licenses, concessions or arrangements.&nbsp;&nbsp;In the event of Landlord&#8217;s election to succeed to Tenant&#8217;s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.4<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Efforts to Relet</font>.&nbsp;&nbsp;No re-entry or repossession, repairs, maintenance, changes, alterations and additions, reletting, appointment of a receiver to protect Landlord&#8217;s interests hereunder, or any other action or omission by Landlord shall be construed as an election by Landlord to terminate this Lease or Tenant&#8217;s right to possession, or to accept a surrender of the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant&#8217;s obligations hereunder, unless express written notice of such intention is sent by Landlord to Tenant.&nbsp;&nbsp;Tenant hereby irrevocably waives any right otherwise available under any law to redeem or reinstate this Lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Default</font>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.5.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">General</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in this Lease, Landlord shall not be in default in the performance of any obligation required to be performed by Landlord pursuant to this Lease unless Landlord fails to perform such obligation within thirty (30) days after the receipt of notice from Tenant specifying in detail Landlord&#8217;s failure to perform; provided, however, if the nature of Landlord&#8217;s obligation is such that more than thirty (30) days are required for its performance, then Landlord shall not be in default under this Lease if it shall commence such performance within such thirty (30) day period and thereafter diligently pursue the same to completion.&nbsp;&nbsp;Upon any such default by Landlord under this Lease, Tenant may, except as otherwise specifically provided in this Lease to the contrary, exercise any of its rights provided at law or in equity.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.5.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally Omitted</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653752"></a><a name="_Toc525822993"></a>20.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">COVENANT OF QUIET ENJOYMENT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord covenants that Tenant, on paying the Rent, charges for services and other payments herein reserved and on keeping, observing and performing all the other terms, covenants, conditions, provisions and agreements herein contained on the part of Tenant to be kept, observed and performed, shall, during the Lease Term, peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants, conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or through Landlord.&nbsp;&nbsp;The foregoing covenant is in lieu of any other covenant express or implied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653753"></a><a name="_Toc525822994"></a>21.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">SECURITY DEPOSIT </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a>Concurrently with Tenant&#8217;s execution and delivery of this Lease, Tenant shall deposit with Landlord cash in the amount set forth in <font style="text-decoration:underline;">Section 9</font> of the Summary as security for the faithful performance by Tenant of all of its obligations under this Lease.&nbsp;&nbsp;The Security Deposit shall be held by Landlord as security for the faithful performance by Tenant of all of the terms, covenants and conditions of this Lease to be kept and performed by Tenant during the period commencing on the Execution Date and ending upon the expiration or termination of Tenant&#8217;s obligations under this Lease.&nbsp;&nbsp;After an Event of Default Landlord may (but shall not be required to) use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&#8217;s default as provided in this Lease.&nbsp;&nbsp;The provisions of this Article shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;In the event of bankruptcy or other debtor-creditor proceedings against Tenant, the Security Deposit then being held by Landlord shall be deemed </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be applied first to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings.&nbsp;&nbsp;Landlord shall deliver or credit to any purchaser of Landlord&#8217;s interest in the Premises the funds then held hereunder by Landlord, and thereupon (and upon confirmation by the transferee of such funds, whether expressly or by written assumption of this Lease, generally) Landlord shall be discharged from any further liability with respect to such funds.&nbsp;&nbsp;This provision shall also apply to any subsequent transfers. If Tenant shall fully and faithfully perform every provision of this Lease to be performed by it, then the Security Deposit, if any, or any balance thereof, shall be returned to Tenant (or, at Landlord&#8217;s option, to the last assignee of Tenant&#8217;s interest hereunder) within 90 days after the expiration or earlier termination of this Lease. Landlord shall hold the Security Deposit in an account at a banking organization selected by Landlord; provided, however, that Landlord shall not be required to maintain a separate account for the Security Deposit, but may intermingle it with other funds of Landlord.&nbsp;&nbsp;Landlord shall be entitled to all interest and/or dividends, if any, accruing on such Security Deposit. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653754"></a><a name="_Toc525822995"></a>22.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">SUBSTITUTION OF OTHER PREMISES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intentionally omitted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653755"></a><a name="_Toc525822996"></a>23.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">SIGNS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818478"></a><a name="_cp_blt_2_478"></a><a name="_cp_text_2_479"></a>23.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Interior Signage</font><a name="_cp_blt_2_478"></a><a name="_cp_text_2_479"></a>.&nbsp;&nbsp;All letters and numerals on doors or other signs on the Premises shall be in the standard form of graphics for the Building, and no others shall be used or permitted without Landlord&#8217;s prior written consent, not to be unreasonably withheld, conditioned, or delayed.&nbsp;&nbsp;Furthermore, Tenant shall not place signs on or in the Premises which are visible from outside the Premises.&nbsp;&nbsp;Tenant&#8217;s name and suite number shall be included by Landlord on the lobby directory for the Building, at Landlord&#8217;s cost.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818479"></a>23.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally omitted</font>. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818480"></a>23.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Prohibited Signage and Other Items</font>.&nbsp;&nbsp;Any signs, notices, logos, pictures, names or advertisements which are installed and that have not been separately approved by Landlord may be removed without notice by Landlord at the sole expense of Tenant.&nbsp;&nbsp;Tenant may not install any signs on the exterior or roof of the Project or the Common Areas.&nbsp;&nbsp;Any signs, window coverings, or blinds (even if the same are located behind the Landlord-approved window coverings for the Building), or other items visible from the exterior of the Premises or Building, shall be subject to the prior approval of Landlord, in its sole discretion.&nbsp;&nbsp;Tenant shall not place or install any projections, antennae, aerials, or similar devices inside or outside of the Building, without the prior written approval of Landlord (not to be unreasonably withheld, conditioned, or delayed), subject to Tenant&#8217;s rights pursuant to Section 23.1, above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653756"></a><a name="_Toc525822997"></a>24.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">COMPLIANCE WITH LAW</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>Tenant shall not do anything or suffer anything to be done in or about the Premises or the Project which will conflict with any law, statute, ordinance or other governmental rule, regulation or requirement now in force or which may hereafter be enacted or promulgated (collectively, &#8220;<font style="font-weight:bold;">Applicable Laws</font>&#8221;).&nbsp;&nbsp;At its sole cost and expense, Tenant shall promptly comply with all such Applicable Laws which relate to (i)&#160;Tenant&#8217;s use of the Premises, (ii)&#160;&#160;any Alterations or Tenant Improvements, or (iii)&#160;the Building, but as to the Building (and as to any improvements to exterior walls, structural floors and the portions of the electrical, heating, ventilation and air conditioning and other systems of the Building that serve other tenants and that are located within the Premises), only to the extent such obligations are triggered by Alterations or Tenant Improvements, or Tenant&#8217;s use of the Premises for non&#8209;general office and laboratory use. Tenant shall be responsible, at its sole cost and expense, to make all alterations to the Premises as are required to comply with the Applicable Laws to the extent required in this <font style="text-decoration:underline;">Article 24</font>.&nbsp;&nbsp;Notwithstanding the foregoing terms of this <font style="text-decoration:underline;">Article 24</font> to the contrary, Tenant may defer such compliance with Applicable Laws while Tenant contests, in a court of proper jurisdiction, in good faith, the applicability of such Applicable Laws to the Premises or Tenant&#8217;s specific use or occupancy of the Premises; provided, however, Tenant may only defer such compliance if such deferral shall not (a)&#160;prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, (b)&#160;prohibit Landlord from obtaining or maintaining a certificate of occupancy for the Building or any portion thereof, (c)&#160;unreasonably and materially affect the safety of the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (d)&#160;create a significant health hazard for the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (e)&#160;otherwise materially and adversely affect Tenant&#8217;s use of or access to the Buildings or the Premises, or (f)&#160;impose material obligations, liability, fines, or penalties upon </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord or any other tenant of the Building, or would materially and adversely affect the use of or access to the Building by Landlord or other tenants or invitees of the Building.&nbsp;&nbsp;The judgment of any court of competent jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of said governmental measures, shall be conclusive of that fact as between Landlord and Tenant.&nbsp;&nbsp;Landlord shall comply with all Applicable Laws relating to the Base Building and the Common Areas, provided that compliance with such Applicable Laws is not the responsibility of Tenant under this Lease, and provided further that Landlord&#8217;s failure to comply therewith would prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, or would unreasonably and materially affect the safety of Tenant&#8217;s employees or create a significant health hazard for Tenant&#8217;s employees, or would otherwise materially and adversely affect Tenant&#8217;s use of or access to the Premises.&nbsp;&nbsp;Landlord shall be permitted to include in Operating Expenses any costs or expenses incurred by Landlord under this </font><font style="text-decoration:underline;">Article&#160;24</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the extent not prohibited by the terms of </font><font style="text-decoration:underline;">Section&#160;4.2.7</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> above.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653757"></a><a name="_Toc525822998"></a>25.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">LATE CHARGES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any installment of Rent or any other sum due from Tenant shall not be received by Landlord or Landlord&#8217;s designee within five (5) business days after Tenant&#8217;s receipt of written notice from Landlord that said amount is due, then Tenant shall pay to Landlord a late charge equal to five percent (5%) of the overdue amount plus any reasonable attorneys&#8217; fees incurred by Landlord by reason of Tenant&#8217;s failure to pay Rent and/or other charges when due hereunder.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord shall not charge Tenant a late charge for the first (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>)&#160;late payment in any twelve (12)&#160;month period (but in no event with respect to any subsequent late payment in any twelve (12) month period) during the Lease Term that Tenant fails to timely pay Rent or another sum due under this Lease, provided that such late payment is made within three (3) days following the expiration of the five (5) business day period set forth in the first sentence of this <font style="text-decoration:underline;">Article&#160;25</font>.&nbsp;&nbsp;The late charge shall be deemed Additional Rent and the right to require it shall be in addition to all of Landlord&#8217;s other rights and remedies hereunder or at law and shall not be construed as liquidated damages or as limiting Landlord&#8217;s remedies in any manner.&nbsp;&nbsp;In addition to the late charge described above, any Rent or other amounts owing hereunder which are not paid when due shall bear interest from the date when due until paid at a rate per annum equal to the lesser of (i) the annual &#8220;<font style="font-weight:bold;">Bank Prime Loan</font></a>&#8221; rate cited in the Federal Reserve Statistical Release Publication G.13(415), published on the first Tuesday of each calendar month (or such other comparable index as Landlord and Tenant shall reasonably agree upon if such rate ceases to be published) plus four (4) percentage points, and (ii) the highest rate permitted by Applicable Law.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653758"></a><a name="_Toc525822999"></a>26.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">LANDLORD&#8217;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Cure</font>.&nbsp;&nbsp;All covenants and agreements to be kept or performed by Tenant under this Lease shall be performed by Tenant at Tenant&#8217;s sole cost and expense and without any reduction of Rent, except to the extent, if any, otherwise expressly provided herein.&nbsp;&nbsp;If Tenant shall fail to perform any obligation under this Lease, and such failure shall continue after notice in excess of the time allowed under <font style="text-decoration:underline;">Section&#160;19.1.2</font>, above, unless a specific time period is otherwise stated in this Lease, Landlord may, but shall not be obligated to, make any such payment or perform any such act on Tenant&#8217;s part without waiving its rights based upon any default of Tenant and without releasing Tenant from any obligations hereunder.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Reimbursement</font>.&nbsp;&nbsp;Except as may be specifically provided to the contrary in this Lease, Tenant shall pay to Landlord, upon delivery by Landlord to Tenant of statements therefor:&nbsp;&nbsp;(i) sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant&#8217;s defaults pursuant to the provisions of <font style="text-decoration:underline;">Section&#160;26.1</font>; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred to in <font style="text-decoration:underline;">Article 10</font> of this Lease; and (iii) sums equal to all expenditures made and obligations incurred by Landlord in collecting or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant to law, including, without limitation, all reasonable legal fees and other amounts so expended.&nbsp;&nbsp;Tenant&#8217;s obligations under this <font style="text-decoration:underline;">Section&#160;26.2</font> shall survive the expiration or sooner termination of the Lease Term.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653759"></a><a name="_Toc525823000"></a><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">27.</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">ENTRY BY LANDLORD</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provided, however, that any such entry by Landlord shall (i) remain subject to Tenant&#8217;s reasonable security and privacy measures; and (ii) not unreasonably interfere with Tenant&#8217;s use and occupancy of the Premises, or the conduct of its business therein, then Landlord reserves the right at all reasonable times and upon not less than one (1) day&#8217;s prior written (e-mail is acceptable) notice to Tenant (except in the case of an emergency) to enter the Premises to (i) inspect them; (ii) show the Premises to prospective purchasers, or to current or prospective mortgagees, ground or underlying lessors or insurers or, during the last nine (9) months of the Lease Term, to prospective tenants; (iii) post notices of nonresponsibility (to the extent applicable pursuant to then Applicable Law); or (iv) alter, improve or repair the Premises or the Building, or for structural alterations, repairs or improvements to the Building or the Building&#8217;s systems and equipment.&nbsp;&nbsp;Provided that Landlord employs commercially reasonable efforts to minimize interference with the conduct of Tenant&#8217;s business in connection with entries into the Premises, Landlord may make any such entries without the abatement of Rent, except as otherwise provided in this Lease, and shall take such reasonable steps as required to accomplish the stated purposes.&nbsp;&nbsp;In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and to the Premises.&nbsp;&nbsp;Any entry into the Premises by Landlord in the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653760"></a><a name="_Toc525823001"></a>28.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">TENANT PARKING</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have the right, without the payment of any parking charge or fee (other than as a reimbursement of operating expenses to the extent allowed pursuant to the terms of <font style="text-decoration:underline;">Article&#160;4</font> of this Lease, above), commencing on the Lease Commencement Date, to use the amount of unreserved parking spaces set forth in <font style="text-decoration:underline;">Section&#160;10</font> of the Summary, on a monthly basis throughout the Lease Term, which parking spaces shall pertain to the on-site and/or off-site, as the case may be, parking facility (or facilities) which serve the Project.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant shall be responsible for the full amount of any taxes imposed by any governmental authority in connection with the renting of such parking spaces by Tenant or the use of the parking facility by Tenant.&nbsp;&nbsp;Tenant&#8217;s continued right to use the parking spaces is conditioned upon Tenant abiding by all rules and regulations which are prescribed from time to time for the orderly operation and use of the parking facility where the parking spaces are located (including any sticker or other identification system established by Landlord and the prohibition of vehicle repair and maintenance activities in the parking facilities), and shall reasonably cooperate in seeing that Tenant&#8217;s employees and visitors also comply with such rules and regulations.&nbsp;&nbsp;Tenant&#8217;s use of the Project parking facility shall be at Tenant&#8217;s sole risk and Tenant acknowledges and agrees that Landlord shall have no liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property damage or theft relating to or connected with the parking rights granted herein or any of Tenant&#8217;s, its employees&#8217; and/or visitors&#8217; use of the parking facilities.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc253653761"></a><a name="_Toc525823002"></a>29.<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">MISCELLANEOUS PROVISIONS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Terms; Captions</font>.&nbsp;&nbsp;The words &#8220;<font style="font-weight:bold;">Landlord</font></a>&#8221; and &#8220;<font style="font-weight:bold;">Tenant</font>&#8221; as used herein shall include the plural as well as the singular.&nbsp;&nbsp;The necessary grammatical changes required to make the provisions hereof apply either to corporations or partnerships or individuals, men or women, as the case may require, shall in all cases be assumed as though in each case fully expressed.&nbsp;&nbsp;The captions of Articles and Sections are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such Articles and Sections.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Binding Effect</font>.&nbsp;&nbsp;Subject to all other provisions of this Lease, each of the covenants, conditions and provisions of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of Landlord and of Tenant, but also of their respective heirs, personal representatives, successors or assigns, provided this clause shall not permit any assignment by Tenant contrary to the provisions of <font style="text-decoration:underline;">Article 14</font> of this Lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.3<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Air Rights</font>.&nbsp;&nbsp;No rights to any view or to light or air over any property, whether belonging to Landlord or any other person, are granted to Tenant by this Lease.&nbsp;&nbsp;If at any time any windows of the Premises are temporarily darkened or the light or view therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or about the&nbsp;&nbsp;Project, the same shall be without liability to Landlord and without any reduction or diminution of Tenant&#8217;s obligations under this Lease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.4</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Modification of Lease</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Should any current or prospective mortgagee or ground lessor for the Building or Project require a modification of this Lease, which modification will not cause an increased cost or expense to Tenant or in any other way materially and adversely change the rights and obligations of Tenant hereunder, then and in such event, Tenant agrees that this Lease may be so modified and agrees to execute whatever documents are reasonably required therefor and to deliver the same to Landlord within ten (10) business days following a request therefor.&nbsp;&nbsp;At the request of Landlord or any mortgagee or ground lessor, Tenant agrees to execute a short form of Lease and deliver the same to Landlord within ten (10) business days following the request therefor.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.5<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transfer of Landlord&#8217;s Interest</font>.&nbsp;&nbsp;Tenant acknowledges that Landlord has the right to transfer all or any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer, Landlord shall automatically be released from all liability under this Lease and Tenant agrees to look solely to such transferee for the performance of Landlord&#8217;s obligations hereunder after the date of transfer and such transferee shall be deemed to have fully assumed and be liable for all obligations of this Lease to be performed by Landlord, including the return of any Security Deposit, and Tenant shall attorn to such transferee.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818495"></a>29.6<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Prohibition Against Recording</font>.&nbsp;&nbsp;In the event this Lease, a copy or any notice or memorandum thereof shall be recorded by Tenant without Landlord&#8217;s consent, then such recording shall constitute a default by Tenant under Article&#160;19 hereof entitling Landlord to immediately terminate this Lease.&nbsp;&nbsp;At the request of either Landlord or Tenant, the parties shall execute a memorandum of lease in recordable form containing such information as is necessary to constitute a notice of lease under North Carolina law.&nbsp;&nbsp;All costs of preparation and recording such notice shall be borne by the party requesting the memorandum.&nbsp;&nbsp;At the expiration or earlier termination of this Lease, Tenant shall provide Landlord with an executed termination of the memorandum in recordable form, which obligation shall survive such expiration or earlier termination. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.7<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Title</font>.&nbsp;&nbsp;Landlord&#8217;s title is and always shall be paramount to the title of Tenant.&nbsp;&nbsp;Nothing herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.8<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Relationship of Parties</font>.&nbsp;&nbsp;Nothing contained in this Lease shall be deemed or construed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.9<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Application of Payments</font>.&nbsp;&nbsp;Landlord shall have the right to apply payments received from Tenant pursuant to this Lease, regardless of Tenant&#8217;s designation of such payments, to satisfy any obligations of Tenant hereunder, in such order and amounts as Landlord, in its sole discretion, may elect.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.10<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Time of Essence</font>.&nbsp;&nbsp;Time is of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.11<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Partial Invalidity</font>.&nbsp;&nbsp;If any term, provision or condition contained in this Lease shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.12<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Warranty</font>.&nbsp;&nbsp;In executing and delivering this Lease, Tenant has not relied on any representations, including, but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at all, on the same level or on the same basis, or any warranty or any statement of Landlord which is not set forth herein or in one or more of the exhibits attached hereto.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.13</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Exculpation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The liability of Landlord or the Landlord Parties to Tenant for any default by Landlord under this Lease or arising in connection herewith or with Landlord&#8217;s operation, management, leasing, repair, renovation, alteration or any other matter relating to the Project or the Premises shall be limited solely and exclusively to an amount which is equal to the interest of Landlord in the Building (including rental income and insurance/condemnation proceeds).&nbsp;&nbsp;Neither Landlord, nor any of the Landlord Parties shall have any personal liability therefor, and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons claiming by, through or under Tenant.&nbsp;&nbsp;The limitations of liability contained in this </font><font style="text-decoration:underline;">Section&#160;29.13</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall inure to the benefit of Landlord&#8217;s and the Landlord Parties&#8217; present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents and employees, and their respective partners, heirs, successors and assigns.&nbsp;&nbsp;Under no circumstances shall any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust), have any liability for the performance of Landlord&#8217;s obligations under this Lease.&nbsp;&nbsp;Notwithstanding any contrary provision herein, neither Landlord nor the Landlord Parties, not Tenant (except with respect to any holdover tenancy) shall be liable under any circumstances for consequential or indirect damages, including without limitation injury or damage to, or interference with, Tenant&#8217;s business, including but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring. </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.14<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Entire Agreement</font>.&nbsp;&nbsp;It is understood and acknowledged that there are no oral agreements between the parties hereto affecting this Lease and this Lease constitutes the parties&#8217; entire agreement with respect to the leasing of the Premises and supersedes and cancels any and all previous negotiations, arrangements, brochures, agreements and understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Lease.&nbsp;&nbsp;None of the terms, covenants, conditions or provisions of this Lease can be modified, deleted or added to except in writing signed by the parties hereto.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.15<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Right to Lease</font>.&nbsp;&nbsp;Landlord reserves the absolute right to effect such other tenancies in the Project as Landlord in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project.&nbsp;&nbsp;Tenant does not rely on the fact, nor does Landlord represent, that any specific tenant or type or number of tenants shall, during the Lease Term, occupy any space in the Building or Project.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.16<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Force Majeure</font>.&nbsp;&nbsp;Any prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorist acts, governmental action or inaction, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, fire or other casualty, and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease (collectively, a &#8220;</a><font style="font-weight:bold;">Force Majeure</font>&#8221;), notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party&#8217;s performance caused by a Force Majeure.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.17<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Waiver of Redemption by Tenant</font>.&nbsp;&nbsp;Tenant hereby waives, for Tenant and for all those claiming under Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal process or writ, Tenant&#8217;s right of occupancy of the Premises after any termination of this Lease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.18</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;All notices, demands, statements, designations, approvals&nbsp;&nbsp;or other communications (collectively, &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Notices</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) given or required to be given by either party to the other hereunder or by law shall be in writing, shall be (A) sent by United States certified or registered mail, postage prepaid, return receipt requested (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Mail</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), (B) delivered by a nationally recognized overnight courier, or (D) delivered personally.&nbsp;&nbsp;Any Notice shall be sent, transmitted, or delivered, as the case may be, to Tenant at the appropriate address set forth in </font><font style="text-decoration:underline;">Section&#160;11</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Summary, or to such other place as Tenant may from time to time designate in a Notice to Landlord, or to Landlord at the addresses set forth below, or to such other places as Landlord may from time to time designate in a Notice to Tenant.&nbsp;&nbsp;Any Notice will be deemed given (i) upon receipt or refusal, (ii) the date the overnight courier delivery is made, or (iii) the date personal delivery is made.&nbsp;&nbsp;As of the date of this Lease, any Notices to Landlord must be sent, transmitted, or delivered, as the case may be, to the following addresses:</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DURHAM TW ALEXANDER, LLC<br />c/o Longfellow Real Estate Partners</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260 Franklin Street, Suite 1920</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, MA 02110</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Asset Management </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David E. Wagner </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">K&amp;L Gates LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4350 Lassiter at North Hills Avenue </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 300 (27609) </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post Office Box 17047</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raleigh, North Carolina 27619-7047</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.19<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Joint and Several</font>.&nbsp;&nbsp;If there is more than one Tenant, the obligations imposed upon Tenant under this Lease shall be joint and several.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.20<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Authority</font>.&nbsp;&nbsp;Landlord and Tenant each hereby represents and warrants that it is a duly formed and existing entity qualified to do business in the State of North Carolina and that said party has full right and authority to execute and deliver this Lease and that each person signing on behalf of said party is authorized to do so.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.21<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Attorneys&#8217; Fees</font>.&nbsp;&nbsp;In the event that either Landlord or Tenant should bring suit for the possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for any other relief against the other, then all costs and expenses, including reasonable attorneys&#8217; fees, incurred by the prevailing party therein shall be paid by the other party, which obligation on the part of the other party shall be deemed to have accrued on the date of the commencement of such action and shall be enforceable whether or not the action is prosecuted to judgment.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.22<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Governing Law; WAIVER OF TRIAL BY JURY</font>.&nbsp;&nbsp;This Lease shall be construed and enforced in accordance with the laws of the State of North Carolina.&nbsp;&nbsp;Landlord and Tenant waive trial by jury in any action to which they are parties, and further agree that any action arising out of this Lease (except an action for possession by Landlord, which may be brought in whatever manner or place provided by law) shall be brought in the Trial Court, Superior Court Department, in the county where the Premises are located.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.23<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Submission of Lease</font>.&nbsp;&nbsp;Submission of this instrument for examination or signature by Tenant does not constitute a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by both Landlord and Tenant.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.24</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Brokers</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord and Tenant hereby warrant to each other that it has had no dealings with any real estate broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in </font><font style="text-decoration:underline;">Section&#160;13</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Summary (the &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;">Brokers</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and that it knows of no other real estate broker or agent which represented said party who is entitled to a commission in connection with this Lease.&nbsp;&nbsp;Landlord and Tenant each agree to indemnify and defend each other against and hold the indemnified party harmless from any and all claims, demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys&#8217; fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party.&nbsp;&nbsp;The terms of this </font><font style="text-decoration:underline;">Section 29.24</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall survive the expiration or earlier termination of the Lease Term.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.25<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Independent Covenants</font>.&nbsp;&nbsp;This Lease shall be construed as though the covenants herein between Landlord and Tenant are independent and not dependent and Tenant hereby expressly waives the benefit of any statute to the contrary and agrees that if Landlord fails to perform its obligations set forth herein, Tenant shall not be entitled to make any repairs or perform any acts hereunder at Landlord&#8217;s expense or to any setoff of the Rent or other amounts owing hereunder against Landlord.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.26<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Project or Building Name, Address and Signage</font>.&nbsp;&nbsp;Landlord shall have the right at any time to change the name and/or address of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior of the Project or Building as Landlord may, in Landlord&#8217;s sole discretion, desire.&nbsp;&nbsp;Tenant shall not use the name of the Project or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.27<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Counterparts</font>.&nbsp;&nbsp;This Lease may be executed in counterparts with the same effect as if both parties hereto had executed the same document.&nbsp;&nbsp;Both counterparts shall be construed together and shall constitute a single lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.28<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Confidentiality</font>.&nbsp;&nbsp;Tenant acknowledges that the content of this Lease and any related documents are confidential information.&nbsp;&nbsp;Tenant shall keep such confidential information confidential and shall not disclose such confidential information to any person or entity other than Tenant&#8217;s lawyers, accountants, auditors, agents, lenders, and prospective purchasers/investors for reasonable business purposes.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.29<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Development of the Project</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.29.1<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subdivision</font>.&nbsp;&nbsp;Landlord reserves the right to subdivide all or a portion of the buildings and Common Areas.&nbsp;&nbsp;Tenant agrees to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any additional documents needed to conform this Lease to the circumstances resulting from a subdivision and any all maps in connection therewith.&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in this Lease, the separate ownership of any buildings and/or Common Areas by an entity other than Landlord shall not affect the calculation of Direct Expenses or Tenant&#8217;s payment of Tenant&#8217;s Share of Direct Expenses.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.29.2<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Construction of Property and Other Improvements</font>.&nbsp;&nbsp;Tenant acknowledges that portions of the Project and/or the Other Improvements may be under construction following Tenant&#8217;s occupancy of the Premises, and that such construction may result in levels of noise, dust, obstruction of access, etc. which are in excess of that present in a fully constructed project.&nbsp;&nbsp;Tenant hereby waives any and all rent offsets or claims of constructive eviction which may arise in connection with such construction.&nbsp;&nbsp;Provided, however, that Landlord shall use good faith efforts to provide Tenant with fourteen (14) days&#8217; notice, which may be verbal, in advance of commencing any construction activities that Landlord anticipates could disrupt Tenant&#8217;s use of the Premises, including a reasonable description of the scope of work to be performed and the anticipated duration of such activity.&nbsp;&nbsp;At all times Landlord shall use commercially reasonable efforts to minimize any disruption with the conduct of Tenant&#8217;s business within the Premises.&nbsp;&nbsp;Upon request from Tenant Landlord will inform Tenant of the general construction schedule for any work adjacent to the Premises or which adversely affects access to the Premises.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.30</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Violation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord and Tenant each hereby warrant and represent that neither its execution of nor performance under this Lease shall cause said party to be in violation of any agreement, instrument, contract, law, rule or regulation by which said party is bound, and said party shall protect, defend, indemnify and hold the indemnified party harmless against any claims, demands, losses, damages, liabilities, costs and expenses, including, without limitation, reasonable attorneys&#8217; fees and costs, arising from the indemnifying party&#8217;s breach of this warranty and representation.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.31<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Communications and Computer Lines</font>.&nbsp;&nbsp;Tenant may install, maintain, replace, remove or use any communications or computer wires and cables serving the Premises (collectively, the &#8220;</a><font style="font-weight:bold;">Lines</font>&#8221;), provided that (i) Tenant shall obtain Landlord&#8217;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), use an experienced and qualified contractor reasonably approved in writing by Landlord, and comply with all of the other provisions of <font style="text-decoration:underline;">Articles 7</font> and <font style="text-decoration:underline;">8</font> of this Lease.&nbsp;&nbsp;Tenant shall pay all costs in connection therewith.&nbsp;&nbsp;Landlord reserves the right, upon notice to Tenant prior to the expiration or earlier termination of this Lease, to require that Tenant, at Tenant&#8217;s sole cost and expense, remove any Lines located in or serving the Premises prior to the expiration or earlier termination of this Lease.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.32<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transportation Management</font>.&nbsp;&nbsp;Tenant shall reasonably comply with all present or future programs intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located at the Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities.&nbsp;&nbsp;Such programs may include, without limitation: (i) restrictions on the number of peak-hour vehicle trips generated by Tenant; (ii) increased vehicle occupancy; (iii) implementation of an in-house ridesharing program and an employee transportation coordinator; (iv) working with employees and any Project, Building or area-wide ridesharing program manager; (v) instituting employer-sponsored incentives (financial or in-kind) to encourage employees to rideshare; and (vi) utilizing flexible work shifts for employees.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc346818521"></a>29.33<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Guarantor</font>.&nbsp;&nbsp;Intentionally omitted.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.34<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">REIT</font>.&nbsp;&nbsp;Tenant acknowledges that the Company, an affiliate of Landlord, elects to be taxed as a real estate investment trust (a &#8220;REIT&#8221;) under the Code.&nbsp;&nbsp;Tenant hereby agrees to modifications of this Lease required to retain or clarify the Company&#8217;s status as a REIT, provided such modifications: (a) are reasonable, (b) do not adversely affect in a material manner Tenant&#8217;s use of the Premises as herein permitted, and (c) do not increase the Base Rent, Additional Rent and other sums to be paid by Tenant or Tenant&#8217;s other obligations pursuant to this Lease, or reduce any rights of Tenant under this Lease, then Landlord may submit to Tenant an amendment to this Lease incorporating such required modifications, and Tenant shall execute, acknowledge and deliver such amendment to Landlord within ten (10) business days after Tenant&#8217;s receipt thereof.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.35<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional Storage</font>.&nbsp;&nbsp;Landlord shall provide Tenant with access to and use an exterior storage area as shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;I</font> (&#8220;<font style="font-weight:bold;">Storage Area</font></a>&#8221;).&nbsp;&nbsp;Tenant shall use the Storage Area in compliance with all Environmental Laws and in compliance with Section 5.4 of this Lease.&nbsp;&nbsp;Other tenants may utilize other portions of the structure or area in which the Storage Area is located, provided that Tenant shall always have access to no less than one-half of the capacity of the larger structure (as shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit I</font>).&nbsp;&nbsp;Tenant shall not exceed its share of any storage allocation applicable to the Storage Area, as reasonably determined by Landlord.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.36</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Generator</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Subject to the provisions of this Section 29.36, Tenant shall be entitled to install, operate and maintain a generator and any other equipment related thereto, including, without limitation, a fuel system, wiring and shaft space </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;</font><font style="font-weight:bold;">Generator</font><font style="font-weight:bold;"></font><font style="font-weight:bold;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> next to the Building at Tenant&#8217;s sole cost and expense (without paying any additional fee or rental to Landlord for the use thereof).&nbsp;&nbsp;Prior to the installation of the Generator, Tenant shall inspect the proposed location to determine a suitable location for the Generator, and Tenant shall submit written plans and specifications relative to the type, size and proposed location (including any proposed screening) of the Generator to Landlord for its review and written approval.&nbsp;&nbsp;Tenant shall be solely responsible for the cost of acquisition, installation, operation, and maintenance of the Generator; and Tenant shall install, maintain and operate the Generator in accordance with all federal, state, and local laws, statutes, ordinances, rules and regulations, including without limitation, obtaining and maintaining any and all permits, approvals and licenses required to install and operate the Generator by any governmental authority having jurisdiction.&nbsp;&nbsp;Landlord and Tenant agree that, upon the expiration of earlier termination of the Lease Term, Tenant shall not be required to remove the Generator, any associated cabling, wiring and screening or other improvements.&nbsp;&nbsp;Tenant shall not be entitled to grant or assign to any third party (other than a permitted assignee of Tenant&#8217;s rights under the Lease or a permitted subtenant relative to the Premises (or a portion thereof)) the right to use the Generator without Landlord&#8217;s prior written consent (which consent may be granted or withheld in Landlord&#8217;s discretion).&nbsp;&nbsp;Upon reasonable advance notice to Tenant (and provided Landlord reasonably coordinates with Tenant and provides an alternate source of backup generator capacity during said transition), Landlord shall be entitled to cause the Generator to be moved to another location near the Building, at Landlord&#8217;s cost and expense. Tenant shall pay all personal property taxes on the Generator.&nbsp;&nbsp;Tenant shall also pay any increases in the real property taxes of the Building due to the installation of the Generator within thirty (30) days of receipt of notice from Landlord which includes proof of such increase in taxes.&nbsp;&nbsp;Tenant&#8217;s indemnity obligations under Section 5.4.1.5 of the Lease, relating to the use of Hazardous Materials, shall apply to the use and operation of the Generator.&nbsp;&nbsp;Finally, Tenant&#8217;s insurance obligations under Section 10.3 of the Lease shall apply to the Generator.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be executed the day and date first above written.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="5" valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LANDLORD:</font></p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">TENANT</font>:</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DURHAM TW ALEXANDER, LLC,</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.,</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:16.3pt;">
<td colspan="5" valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="5" valign="top"  style="width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:42.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:42.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jamison N. Peschel</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matt Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jamison N. Peschel</p></td>
<td valign="top"  style="width:4.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matt Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signatory</p></td>
<td valign="top"  style="width:4.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:42.88%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="exa"></a><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="text-decoration:underline;">EXHIBIT A</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="OLE_LINK1"></a><font style="text-decoration:underline;">BioPoint Innovation Labs</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FIRST OFFER SPACE</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000001.jpg" title="" alt="" style="width:549px;height:722px;"><font style="text-decoration:underline;"></font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="exb"></a><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">NOTICE OF LEASE TERM DATES</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:30%;">
<tr>
<td valign="top"  style="width:25.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To:</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:73.64%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:25.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:73.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:25.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:73.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:25.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:73.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Re:</font></p></td>
<td valign="top">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Lease dated ____________, 20__ between ____________________, a _____________________ (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and _______________________, a _______________________ (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;) concerning Suite ______ on floor(s) __________ of the office building located at <font style="font-weight:bold;">[INSERT BUILDING ADDRESS]</font>.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gentlemen:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Lease (the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;), we wish to advise you and/or confirm as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Lease Term shall commence on or has commenced on _____________ for a term of _______________ ending on _______________.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Rent commenced to accrue on ____________, in the amount of ____________.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If the Lease Commencement Date is other than the first day of the month, the first billing will contain a pro rata adjustment.&nbsp;&nbsp;Each billing thereafter, with the exception of the final billing, shall be for the full amount of the monthly installment as provided for in the Lease.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Your rent checks should be made payable to __________ at ______________.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The exact number of rentable/usable square feet within the Premises is _________ square feet.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Tenant&#8217;s Share as adjusted based upon the exact number of usable square feet within the Premises is ____________%.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="5" valign="top"  style="width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Landlord&#8221;:</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</p></td>
<td colspan="4" valign="top"  style="width:92.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:91.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreed to and Accepted as</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of <font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#160;</font>, 20_.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="5" valign="top"  style="width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant&#8221;:</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</p></td>
<td colspan="4" valign="top"  style="width:92.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:91.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="text-decoration:underline;">EXHIBIT C</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PREMISES</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000002.jpg" title="" alt="" style="width:541px;height:720px;"></p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;"><a name="exc"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="exd"></a><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="text-decoration:underline;">EXHIBIT D</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">tenant WORK LETTER</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Tenant Work Letter sets forth the terms and conditions relating to the construction of the initial tenant improvements in the Premises.&nbsp;&nbsp;This Tenant Work Letter is essentially organized chronologically and addresses the issues of the construction of the Premises, in sequence, as such issues will arise during the actual construction of the Premises.&nbsp;&nbsp;All references in this Tenant Work Letter to Articles or Sections of &#8220;this Lease&#8221; shall mean the relevant portion of the Lease to which this Tenant Work Letter is attached as Exhibit D and of which this Tenant Work Letter forms a part, and all references in this Tenant Work Letter to Sections of &#8220;this Tenant Work Letter&#8221; shall mean the relevant portion of this Tenant Work Letter.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>LANDLORD&#8217;S INITIAL CONSTRUCTION IN THE PREMISES</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Landlord Work</font>.&nbsp;&nbsp;Landlord shall, at Landlord&#8217;s sole cost and expense, complete the work described on the attached <font style="text-decoration:underline;">Attachment 1 </font> (collectively, the &#8220;<font style="text-decoration:underline;">Landlord Work</font>&#8221;).&nbsp;&nbsp;The Landlord Work shall be performed in a first-class, workmanlike manner.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>TENANT IMPROVEMENTS</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant Improvements Allowance</font>.&nbsp;&nbsp;Tenant shall be entitled to a tenant improvement allowance (the &#8220;<font style="text-decoration:underline;">Tenant Improvements Allowance</font>&#8221;) in the maximum aggregate amount of&nbsp;&nbsp;<font style="font-weight:bold;">$1,220,720.00</font> (in a total amount equivolent to $70.58 per rentable square foot of the entire Premises initially leased hereunder)&nbsp;&nbsp;and adjusted based on the actual square footage) (the &#8220;<font style="text-decoration:underline;">Maximum Allowance Amount</font>&#8221;) for the hard costs and customary soft costs, as noted below, incurred by Tenant, including, without limitation,&nbsp;&nbsp;architectural and engineering fees, construction contractor fees, Tenant&#8217;s project management fees, a 2%<font style="font-weight:bold;"> </font>fee payable to Landlord or its affiliates for oversight and administrative costs related to the Tenant Improvements (&#8220;<font style="text-decoration:underline;">Landlord&#8217;s Project Oversight Fee</font>&#8221;), permits, and such other costs arising from or relating to the design and construction of Tenant&#8217;s improvements which are to be permanently affixed to the Premises in accordance with this Work Letter (the &#8220;<font style="text-decoration:underline;">Tenant Improvements</font>&#8221;).<font style="font-weight:bold;">&nbsp;&nbsp;</font>Landlord&#8217;s Project Oversight Fee shall be equivolent to, but not exceed, a total of 2% of the Tenant Improvement Allowance paid to Tenant.<font style="font-weight:bold;"> </font>For the avoidance of any doubt, the purchase and installation of data and telecommunications cabling shall not be included in the definition of Tenant Improvements and there shall not be any Landlord&#8217;s Project Oversight Fee payable with respect to costs and expenses related thereto. Tenant agrees to keep the Landlord advised as to the progress of the work by providing copies of the Contractor&#8217;s applications for payment.&nbsp;&nbsp;In no event shall Landlord be obligated to make disbursements pursuant to this Tenant Work Letter in a total amount which exceeds the Maximum Allowance Amount.&nbsp;&nbsp;All Tenant Improvements for which the Tenant Improvements Allowance has been used to pay shall be deemed Landlord&#8217;s property under the terms of the Lease. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Disbursement of the Tenant Improvements Allowance</font>.&nbsp;&nbsp;Except as otherwise set forth in this Tenant Work Letter, the Tenant Improvements Allowance shall be disbursed by Landlord (each of which disbursements shall be made pursuant to Landlord&#8217;s reasonable disbursement process) for costs incurred by Tenant related to the design and construction of the Tenant Improvements and for the following items and costs (collectively, the &#8220;<font style="text-decoration:underline;">Tenant Improvements Allowance Items</font>&#8221;):&nbsp;&nbsp;(i) payment of the fees of the &#8220;<font style="text-decoration:underline;">Architect</font>&#8221; as that term is defined in Section 3.1 of this Tenant Work Letter in connection with the preparation and review of the &#8220;<font style="text-decoration:underline;">Construction Documents</font>,&#8221; as that term is defined in Section 3.1 of this Tenant Work Letter; (ii) payment of the Landlord&#8217;s Project Oversight Fee, (iii) the cost of any changes to the Construction Documents or Tenant Improvements required by all applicable building codes (the &#8220;<font style="text-decoration:underline;">Code</font>&#8221;) enacted after approval of the Construction Documents, (iv) costs payable to the Contractor and any subcontractors, and (v) other costs incurred in connection with the Tenant Improvements to the extent the same can be paid using the Tenant Improvements Allowance pursuant to the specific provisions of this Tenant Work Letter.<font style="font-weight:bold;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Landlord is required to disburse any portion of the Tenant Improvement Allowance as noted herein, Landlord shall disburse the applicable portion of the Tenant Improvements Allowance within thirty (30) calendar days of receiving from Tenant a Payment Request (as hereinafter defined), an amount equal to the portion of the actual costs and expenses Tenant has incurred and paid in connection with the design and construction of the Tenant Improvements to date, over the amount Tenant is required to pay as noted in Section 4.3.1, which are to be paid for from the Tenant Improvement Allowance provided the following conditions have been satisfied:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;">Tenant has delivered to Landlord a payment request (&#8220;Payment Request&#8221;) in a form reasonably satisfactory to Landlord specifying the work which has been completed; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;">Tenant&#8217;s general contractor and/or architect shall have submitted an application for payment and sworn statement substantially in the form of AIA Document G702 and AIA Document G703; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;">Tenant has submitted to Landlord lien waivers or partial lien waivers from all contractors, first tier subcontractors, artchitects, and first tier materialmen who performed such work to cover the work included under the Payment Request and all prior work Tenant was required to pay for before utilizing the Tenant Improvements Allowance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything herein to the contrary, the Tenant Improvements Allowance must be requested by Tenant, if at all, in accordance with this paragraph on or before the date that is one year following the Rent Commencement Date, and any portion not requested by such date may no longer be utilized by Tenant and shall be deemed forfeited to Landlord.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>CONSTRUCTION DOCUMENTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Selection of Architect/Construction Documents</font>.&nbsp;&nbsp;Landlord consents to Tenant retaining Integrated Design, PA&nbsp;&nbsp;(the &#8220;<font style="text-decoration:underline;">Architect</font>&#8221;) to prepare the &#8220;Construction Documents,&#8221; as that term is defined in this Section 3.1 for the Tenant Improvements, together with the consulting engineers selected by the Architect and reasonably approved by Landlord.&nbsp;&nbsp;Tenant is not obligated to retain Integrated Design, PA and may retain another Architect or Architects from time to time, provided, however, that any such other Architects shall be subject to Landlord&#8217;s reasonable approval.&nbsp;&nbsp;The plans and drawings to be prepared by Architect hereunder shall be known collectively as the &#8220;<font style="text-decoration:underline;">Construction Documents</font>.&#8221;&nbsp;&nbsp;All Construction Documents shall reasonably comply with the drawing format and specifications as reasonably determined by Landlord, and shall be subject to Landlord&#8217;s and Tenant&#8217;s approval.&nbsp;&nbsp;Landlord may hire an architectural firm to conduct a peer review, and the fees associated with this peer review shall be paid from the Landlord&#8217;s Project Oversight Fee and shall not result in an additional charge to Tenant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord has no obligation to approve any Tenant Change or any Tenant Improvements not shown on the plans previously approved by Landlord and Tenant or reasonably inferable therefrom if, in Landlord&#8217;s reasonable judgment, such Tenant Improvements (i)&#160;would materially increase the cost of performing any other work in the Building, not including the Tenant Improvements, unless in each case Tenant agrees to pay such costs based on Landlord&#8217;s Change Estimate Notice (as defined below), (ii)&#160;are incompatible with the design, quality, equipment or systems of the Building or otherwise require a change to the existing Building systems or structure, each in a manner that would not otherwise be required in connection with the improvements contemplated by the Fit Plan (as defined below), (iii)&#160;is not consistent with the existing quality and nature of the Building, or (iv)&#160;otherwise do not comply with the provisions of the Lease. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Final Space Plan</font>.&nbsp;&nbsp;Landlord and Tenant have reviewed and approved the preliminary space plan prepared by the Architect attached as <font style="text-decoration:underline;">Attachment 3</font> hereto (the &#8220;<font style="text-decoration:underline;">Fit Plan</font>&#8221;).&nbsp;&nbsp;Tenant shall use commercially reasonable efforts to cause the Architect to prepare a space plan for the Premises which space plan shall be reasonably consistent with the Fit Plan and shall include a layout and designation of all labs, offices, rooms and other partitioning, their intended use, and equipment to be contained therein, and shall deliver the space plan to Landlord and Tenant for their approval. Landlord and Tenant shall review and provide any changes to the space plan within five Business Days of receipt thereof.&nbsp;&nbsp;Once Landlord and Tenant approve the final space plan, the space plan shall be considered final (the &#8220;<font style="text-decoration:underline;">Final Space Plan</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Construction Documents</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall cause&nbsp;&nbsp;the Architect to complete final Construction Documents consistent with the Final Space Plan and shall submit the same to Landlord and Tenant for their approval.&nbsp;&nbsp;Landlord and Tenant shall review and provide any changes to the construction documents within five (5) Business Days of receipt thereof, and the Tenant shall use reasonable efforts to cause the Architect to prepare and circulate modified documents within ten (10) Business Days of its receipt of any requested changes from Tenant or Landlord. Such process of submittal and response within the time frame specified in the preceding sentence shall continue until each of Landlord and Tenant gives written approval to such documents, and the Construction Documents shall be considered final once approved by the Landlord and the Tenant. In no event may either Tenant or Landlord require any changes that are inconsistent with the Final Space Plan.&nbsp;&nbsp;The Construction Documents shall comply with Applicable&#160;Laws existing on the date of this Tenant Work Letter and which may be enacted prior to approval of completed Construction Documents. Subject to the provisions of Sections 3.1 and 5.4 of this Work Letter, Tenant may, from time to time, by written request to Landlord on a form reasonably specified by Landlord (&#8220;</font><font style="text-decoration:underline;">Tenant Change</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), request a change in the Tenant Improvements shown on the Construction Documents, which Landlord approval shall not be unreasonably withheld or conditioned, and shall be granted or denied within five (5) business days after delivery of such Tenant Change to Landlord.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Permits</font>.&nbsp;&nbsp;The Construction Documents as approved (or deemed approved) pursuant to Section 3.3 shall be the &#8220;<font style="text-decoration:underline;">Approved Working Drawings</font>&#8221;.&nbsp;&nbsp;Following approval or deemed approval of the Cost Proposal, as described below, Tenant shall promptly thereafter submit or cause to be submitted, the Approved Working Drawings to the appropriate municipal authorities for all applicable building permits necessary to allow &#8220;Contractor,&#8221; as that term is defined in Section 4.1, below, to commence and fully complete the construction of the applicable Tenant Improvements (the &#8220;<font style="text-decoration:underline;">Permits</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Time Deadlines</font>.&nbsp;&nbsp;Intentionally omitted.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>CONSTRUCTION OF THE TENANT IMPROVEMENTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Contractor</font>.&nbsp;&nbsp;A contractor designated by Tenant and reasonably approved by Landlord (&#8220;<font style="text-decoration:underline;">Contractor</font>&#8221;) shall construct the Tenant Improvements.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cost Proposal</font>.&nbsp;&nbsp;After the Approved Working Drawings are approved by Landlord and Tenant, Tenant shall provide Landlord with a cost proposal (or cost proposals) in accordance with the Approved Working Drawings for Landlord&#8217;s approval, which approval shall not be unreasonably withheld, which cost proposal(s) shall include, as nearly as possible, the cost of all Tenant Improvements Allowance Items to be incurred by Tenant in connection with the design and construction of the Tenant Improvements (the &#8220;<font style="text-decoration:underline;">Cost Proposal</font>&#8221;).&nbsp;&nbsp;Tenant will consult with Landlord prior to approving the contractors to whom it will be bid and Landlord may review bid packages at Landlord&#8217;s written request.&nbsp;&nbsp;The date on which Landlord approves the Cost Proposal shall be known hereafter as the &#8220;<font style="text-decoration:underline;">Cost Proposal Delivery Date</font>&#8221;.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Construction of Tenant Improvements by Contractor</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment of Tenant Improvements Allowance</font>.&nbsp;&nbsp;Tenant shall be responsible to fund the entire cost of the Tenant Improvements less the amount of the Tenant Improvements Allowance prior to Landlord being required to fund any portion of the Tenant Improvements Allowance.&nbsp;&nbsp;Once Tenant has funded the required portion of the Tenant Improvements, as verified with paid invoices, then Tenant may submit a Payment Request to Landlord seeking disbursement of the Tenant Improvements Allowance to fund Tenant Improvements costs incurred by Tenant up to but not to exceed the full value of the Tenant Improvements Allowance.&nbsp;&nbsp;Unless otherwise agreed by the parties, all Tenant Improvements paid for by the Tenant Improvements Allowance shall be deemed Landlord&#8217;s property under the terms of the Lease.&nbsp;&nbsp;Tenant hereby acknowledges and agrees that Tenant shall be responsible for all costs associated with the Tenant Improvements to the extent the same exceed the Tenant Improvements Allowance.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Retention of Contractor</font>. Tenant shall independently retain Contractor to construct the Tenant Improvements in accordance with the applicable Approved Working Drawings and the applicable Cost Proposal.&nbsp;&nbsp;Landlord shall be entitled to review the Tenant&#8217;s construction contract with the Contractor upon Landlord&#8217;s written request. Tenant shall be responsible to ensure the Contractor performs the construction work in a good and workmanlike manner and shall endeavor to oversee the Contractor&#8217;s performance of its work to protect Landlord from construction defects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COMPLETION OF THE TENANT IMPROVEMENTS;</font><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br />LEASE COMMENCEMENT DATE</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Substantial Completion</font>.&nbsp;&nbsp;Tenant shall give Landlord at least twenty (20) days prior written notice of the date that Tenant reasonably anticipates that the Tenant Improvements will be Substantially Complete (as defined below).&nbsp;&nbsp;For purposes of this Lease, &#8220;<font style="text-decoration:underline;">Substantial Completion</font>&#8221; shall occur upon the completion of the last of the following to occur: (i) the completion of construction of the Tenant Improvements substantially pursuant to the Approved Working Drawings for such Tenant Improvements (each as reasonably determined by the Architect and Tenant), with the exception of any punch list items which do not impair Tenant&#8217;s ability to occupy the Premises for their contemplated use, (ii) the acquisition of a certificate of occupancy or its legal equivalent allowing occupancy of the Premises (a &#8220;<font style="text-decoration:underline;">Sign Off</font>&#8221;), and (iii) delivery of a certificate of substantial completion from the Architect confirming the matters set forth in the foregoing clause (i).&nbsp;&nbsp;In the event that the Sign Off is not a final certificate of occupancy, Tenant shall diligently prosecute the work necessary to achieve a full certificate of occupancy and use commercially reasonable efforts to obtain such full certificate of occupancy as soon as reasonably practicable following Substantial Completion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Walk-through and Punchlist</font>.&nbsp;&nbsp;After the Tenant Improvements are Substantially Completed and prior to Tenant&#8217;s move-in into the Premises, following two (2) days&#8217; advance written notice from Tenant to Landlord, Tenant shall cause the Contractor to inspect the Premises with a representative of Landlord and complete a punch list of unfinished items of the Tenant Improvements.&nbsp;&nbsp;After Landlord and Tenant have mutually agreed upon the punch list, authorized representatives for Landlord and Tenant shall execute said punch list.&nbsp;&nbsp;The items listed on such punch list shall be completed by the Contractor within thirty (30) days after the approval of such punch list or as soon thereafter as reasonably practicable, provided that in the event a punch list item reasonably requires longer than thirty (30) days to complete, then Tenant shall cause Contractor to commence the completion of such particular item within thirty (30) days and diligently pursue the same to completion.&nbsp;&nbsp;The terms of this Section 5.3 will not affect the occurrence of the Substantial Completion of the Premises or the occurrence of the Rent Commencement Date. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Delay Not Caused by Parties</font>.&nbsp;&nbsp;Neither the Landlord nor Tenant shall be considered to be in default of the provisions of this Tenant Work Letter for delays in performance due to Force Majeure.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>MISCELLANEOUS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Entry Into the Premises</font>.&nbsp;&nbsp;As a condition to Tenant&#8217;s entry into the Premises, Tenant shall comply with and perform, and shall cause its employees, agents, contractors, subcontractors, material suppliers and laborers to comply with and perform, all of Tenant&#8217;s insurance and indemnity obligations and other obligations governing the conduct of Tenant at the Property under this Lease.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_209"></a><a name="_cp_text_2_208"></a><a name="_cp_text_2_209"></a>Any independent contractor of Tenant (or any employee or agent of Tenant) performing any work or invasive inspections in the Premises shall be <a name="_cp_text_2_208"></a>reasonably subject to all of the terms, conditions and requirements contained in the Lease (including without limitation the provisions of Article 10) and, prior to such entry, Tenant shall provide Landlord with evidence of the insurance coverages required pursuant to Article 10.&nbsp;&nbsp;Tenant and any Tenant contractor performing any work or invasive inspections in the Premises shall use reasonable efforts not to interfere in any way with construction of, and shall not damage the Landlord Work or the common areas or other parts of the Building.&nbsp;&nbsp; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Representative</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant has designated Sinu Bhandaru and Sam Stubbs as its sole representatives with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Landlord&#8217;s Representative</font>.&nbsp;&nbsp;Landlord has designated J. Randal Long as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Tenant Work Letter. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font>.&nbsp;&nbsp;This Work Letter shall not be deemed applicable to any additional space added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the Premises or any additions to the Premises in the event of a renewal or extension of the original Lease Term, whether by any options under the Lease or otherwise, unless and to the extent expressly provided in the Lease or any amendment or supplement to the Lease that such additional space is to be delivered to Tenant in the same condition the initial Premises is to be delivered.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Insurance</font>.&nbsp;&nbsp;In addition to the requirements of <font style="text-decoration:underline;">Article 8.5</font> and <font style="text-decoration:underline;">Article 10</font> of this Lease, prior to the commencement of the Tenant Improvements, Tenant shall provide Landlord with evidence that Tenant carries Builder&#8217;s All Risk insurance in an amount reasonably approved by Landlord covering the construction of such Tenant Improvements, and such other insurance as Landlord may reasonably require, it being understood and agreed that all of such Tenant Improvements shall be insured by Tenant pursuant to <font style="text-decoration:underline;">Article 10</font> of this Lease immediately upon completion thereof. In addition, Tenant&#8217;s contractors, subcontractors, and architects shall be required to carry Commercial General Liability Insurance in an amount approved by Landlord and otherwise in accordance with the requirements of <font style="text-decoration:underline;">Article 10</font> of this Lease and such general liability insurance shall name the Landlord Parties as additional insureds. In addition, Tenant&#8217;s contractors and subcontractors shall be required to carry workers compensation insurance with a waiver of subrogation in favor of Landlord Parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="text-decoration:underline;">ATTACHMENT 1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LANDLORD&#8217;S WORK</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-Add one (1) 7&#8217; x 22&#8217; window to the Building which is similar to existing windows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-Add one (1) 6&#8217; x 8&#8217; insulated electronically controlled roll-up door exiting onto the loading dock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="text-decoration:underline;">ATTACHMENT 2</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Intentionally omitted</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="text-decoration:underline;">ATTACHMENT 3</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PRELIMINARY PLANS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[to be attached]</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="text-decoration:underline;">EXHIBIT E</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">RULES AND REGULATIONS</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall faithfully observe and comply with the following Rules and Regulations.&nbsp;&nbsp;Landlord shall not be responsible to Tenant for the nonperformance of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of the Project.&nbsp;&nbsp;In the event of any conflict between the Rules and Regulations and the other provisions of this Lease, the latter shall control.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">Tenant shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises without obtaining Landlord&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;If Tenant shall affix additional locks on doors then Tenant shall furnish Landlord with copies of keys or pass cards or similar devices for said locks.&nbsp;&nbsp;Tenant shall bear the cost of any lock changes or repairs required by Tenant.&nbsp;&nbsp;Two initial keys will be furnished by Landlord for the Premises, and any additional keys required by Tenant must be obtained from Landlord at a reasonable cost to be established by Landlord.&nbsp;&nbsp;Upon the termination of this Lease, Tenant shall restore to Landlord all keys of stores, offices, and toilet rooms, either furnished to, or otherwise procured by, Tenant and in the event of the loss of keys so furnished, Tenant shall pay to Landlord the cost of replacing same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary for comparable buildings in the vicinity of the Building.&nbsp;&nbsp;Tenant, its employees and agents must be sure that the doors to the Building are securely closed and locked when leaving the Premises if it is after the normal hours of business for the Building.&nbsp;&nbsp;Any tenant, its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when it is considered to be after normal business hours for the Building, may be required to sign the Building register.&nbsp;&nbsp;Access to the Building may be refused unless the person seeking access has proper identification or has a previously arranged pass for access to the Building.&nbsp;&nbsp;Landlord will furnish passes to persons for whom Tenant requests same in writing.&nbsp;&nbsp;Tenant shall be responsible for all persons for whom Tenant requests passes and shall be liable to Landlord for all acts of such persons.&nbsp;&nbsp;The Landlord and his agents shall in no case be liable for damages for any error with regard to the admission to or exclusion from the Building of any person.&nbsp;&nbsp;In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building or the Project during the continuance thereof by any means it deems appropriate for the safety and protection of life and property.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;">Except for shipments by Tenant of its product or receipt by Tenant of goods in the ordinary course of the operation of its business, no furniture, freight or equipment of any kind shall be brought into the Building without prior notice to Landlord.&nbsp;&nbsp;All moving activity into or out of the Building shall be scheduled with Landlord and done only at such time and in such manner as Landlord reasonably designates.&nbsp;&nbsp;Landlord shall have the right to prescribe the weight, size and position of all safes and other heavy property brought into the Building and also the times and manner of moving the same in and out of the Building.&nbsp;&nbsp;Safes and other heavy objects shall, if considered necessary by Landlord, stand on supports of such thickness as is necessary to properly distribute the weight.&nbsp;&nbsp; Landlord will not be responsible for loss of or damage to any such safe or property in any case.&nbsp;&nbsp;Any damage to any part of the Building, its contents, occupants or visitors by moving or maintaining any such safe or other property shall be the sole responsibility and expense of Tenant.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">Intentionally omitted.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;">The requirements of Tenant will be attended to only upon application at the management office for the Project or at such office location designated by Landlord.&nbsp;&nbsp;Employees of Landlord shall not perform any work or do anything outside their regular duties unless under special instructions from Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font><font style="margin-left:36pt;">No sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by Tenant on any part of the Premises or the Building without the prior written consent of the Landlord.&nbsp;&nbsp;Tenant shall not disturb, solicit, peddle, or canvass any occupant of the Project and shall cooperate with Landlord and its agents of Landlord to prevent same.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;">The toilet rooms, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed, and no foreign substance of any kind whatsoever shall be thrown therein.&nbsp;&nbsp;The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the tenant who, or whose servants, employees, agents, visitors or licensees shall have caused same.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9. <font style="margin-left:36pt;">Discharge of industrial sewage to the Building plumbing system shall only be permitted if Tenant, at its sole expense, shall have obtained all necessary permits and licenses therefor, including without limitation permits from state and local authorities having jurisdiction thereof.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;">Tenant shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into the partitions, woodwork or drywall or in any way deface the Premises or any part thereof without Landlord&#8217;s prior written consent; provided, however, that Landlord&#8217;s prior written consent shall not be required for the hanging of normal and customary office artwork and personal items.&nbsp;&nbsp;Tenant shall not purchase spring water, ice, towel, linen, maintenance or other like services from any person or persons not included on an approved list that Landlord shall provide to Tenant upon request. Landlord reserves the right to have Landlord&#8217;s structural engineer review Tenant&#8217;s floor loads on the Building at Landlord&#8217;s expense, unless such study reveals that Tenant has exceeded the floor loads, in which case Tenant shall pay the cost of such survey.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;">Except for vending machines intended for the sole use of Tenant&#8217;s employees and invitees, no vending machine or machines other than fractional horsepower office machines shall be installed, maintained or operated upon the Premises without the written consent of Landlord.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;">Tenant shall not use or keep in or on the Premises, the Building, or the Project any kerosene, gasoline or other inflammable or combustible fluid, chemical, substance or material.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;">Tenant shall not without the prior written consent of Landlord (not to be unreasonably withheld, conditioned, or delayed) use any method of heating or air conditioning other than that supplied by Landlord (other than as part of the Tenant Improvements).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;">Tenant shall not use, keep or permit to be used or kept, any foul or noxious gas or substance in or on the Premises, or permit or allow the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Project by reason of noise, odors, or vibrations, or interfere with other tenants or those having business therein, whether by the use of any musical instrument, radio, phonograph, or in any other way.&nbsp;&nbsp;Tenant shall not throw anything out of doors, windows or skylights or down passageways.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;">Tenant shall not bring into or keep within the Project, the Building or the Premises any animals (other than service animals), birds, aquariums, or, except in areas designated by Landlord, bicycles or other vehicles.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:36pt;">No cooking shall be done or permitted on the Premises, nor shall the Premises be used for the storage of merchandise, for lodging or for any improper, objectionable or immoral purposes.&nbsp;&nbsp;Notwithstanding the foregoing, Underwriters&#8217; laboratory-approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages for employees and visitors, provided that such use is in accordance with all applicable federal, state, county and city laws, codes, ordinances, rules and regulations.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font><font style="margin-left:36pt;">The Premises shall not be used for manufacturing or for the storage of merchandise except as such storage may be incidental to the use of the Premises provided for in the Summary.&nbsp;&nbsp;Tenant shall not occupy or permit any portion of the Premises to be occupied as an office for a messenger-type operation or dispatch office, public stenographer or typist, or for the manufacture or sale of liquor, narcotics, or tobacco in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau without the express prior written consent of Landlord.&nbsp;&nbsp;Tenant shall not engage or pay any employees on the Premises except those actually working for such tenant on the Premises nor advertise for laborers giving an address at the Premises.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.<font style="margin-left:36pt;">Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.<font style="margin-left:36pt;">Tenant, its employees and agents shall not loiter in or on the entrances, corridors, sidewalks, lobbies, courts, halls, stairways, vestibules or any Common Areas for the purpose of smoking tobacco products or for any other purpose, nor in any way obstruct such areas, and shall use them only as a means of ingress and egress for the Premises.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.<font style="margin-left:36pt;">Tenant shall not waste electricity, water or air conditioning and agrees to reasonably cooperate with Landlord to ensure the most effective operation of the Building&#8217;s heating and air conditioning system, and shall refrain from attempting to adjust any controls.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.<font style="margin-left:36pt;">Tenant shall store all its trash and garbage within the interior of the Premises.&nbsp;&nbsp;No material shall be placed in the trash boxes or receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash and garbage in the city in which the Building is located without violation of any law or ordinance governing such disposal.&nbsp;&nbsp;All trash, garbage and refuse disposal shall be made only through entry-ways provided for such purposes at such times as Landlord shall designate.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.<font style="margin-left:36pt;">Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.<font style="margin-left:36pt;">Any persons employed by Tenant to do janitorial work shall be subject to the prior written approval of Landlord (not to be unreasonably withheld, conditioned, or delayed), and while in the Building and outside of the Premises, shall be subject to and under the control and direction of the Building manager (but not as an agent or servant of such manager or of Landlord), and Tenant shall be responsible for all acts of such persons.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.<font style="margin-left:36pt;">No awnings or other projection shall be attached to the outside walls of the Building without the prior written consent of Landlord (not to be unreasonably withheld, conditioned, or delayed), and no curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord standard drapes.&nbsp;&nbsp;All electrical ceiling fixtures hung in the Premises or spaces along the perimeter of the Building must be fluorescent and/or of a quality, type, design and a warm white bulb color approved in advance in writing by Landlord.&nbsp;&nbsp;Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without the prior written consent of Landlord.&nbsp;&nbsp;Tenant shall abide by Landlord&#8217;s regulations concerning the opening and closing of window coverings which are attached to the windows in the Premises, if any, which have a view of any interior portion of the Building or Building Common Areas.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.<font style="margin-left:36pt;">The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into the halls, passageways or other public places in the Building shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed on the windowsills.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.<font style="margin-left:36pt;">Tenant must comply with requests by the Landlord concerning the informing of their employees of items of importance to the Landlord.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.</font><font style="margin-left:36pt;">No smoking is permitted in the Building or on the Project.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.<font style="margin-left:36pt;">Tenant hereby acknowledges that Landlord shall have no obligation to provide guard service or other security measures for the benefit of the Premises, the Building or the Project.&nbsp;&nbsp;Tenant hereby assumes all responsibility for the protection of Tenant and its agents, employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises closed, whether or not Landlord, at its option, elects to provide security protection for the Project or any portion thereof.&nbsp;&nbsp;Tenant further assumes the risk that any safety and security devices, services and programs which Landlord elects, in its sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage to the extent Tenant desires protection against losses related to such occurrences.&nbsp;&nbsp;Tenant shall cooperate in any reasonable safety or security program developed by Landlord or required by law.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.<font style="margin-left:36pt;">All non-standard office equipment of any electrical or mechanical nature shall be placed by Tenant in the Premises in settings approved by Landlord, to absorb or prevent any vibration, noise and annoyance.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.<font style="margin-left:36pt;">Tenant shall not use in any space or in the public halls of the Building, any hand trucks except those equipped with rubber tires and rubber side guards.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.<font style="margin-left:36pt;">No auction, liquidation, fire sale, going-out-of-business or bankruptcy sale shall be conducted in the Premises without the prior written consent of Landlord.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.<font style="margin-left:36pt;">No tenant shall use or permit the use of any portion of the Premises for living quarters, sleeping apartments or lodging rooms.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord reserves the right at any time to change or rescind any one or more of these Rules and Regulations, or to make such other and further reasonable Rules and Regulations as in Landlord&#8217;s judgment may from time to time be necessary for the management, safety, care and cleanliness of the Premises, Building, the Common Areas and the Project, and for the preservation of good order therein, as well as for the convenience of other occupants and tenants therein.&nbsp;&nbsp;Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular tenants, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules or Regulations against any or all tenants of the Project.&nbsp;&nbsp;Tenant shall be deemed to have read these Rules and Regulations and to have agreed to abide by them as a condition of its occupancy of the Premises.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="exe"></a><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="text-decoration:underline;">EXHIBIT F</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">[</font><font style="font-style:italic;text-decoration:underline;">Property Center Name</font><font style="text-decoration:underline;">]</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FORM OF TENANT&#8217;S ESTOPPEL CERTIFICATE</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned as Tenant under that certain Lease (the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;) made and entered into as of ___________, 201_ by and between _______________ as Landlord, and the undersigned as Tenant, for Premises on the ______________ floor(s) of the office building located at <font style="font-weight:bold;">[INSERT BUILDING ADDRESS]</font>, certifies as follows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">Attached hereto as </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;F</font> is a true and correct copy of the Lease and all amendments and modifications thereto.&nbsp;&nbsp;The documents contained in <font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;F</font> represent the entire agreement between the parties as to the Premises.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">The undersigned currently occupies the Premises described in the Lease, the Lease Term commenced on __________, and the Lease Term expires on ___________, and the undersigned has no option to terminate or cancel the Lease or to purchase all or any part of the Premises, the Building and/or the Project.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">Base Rent became payable on ____________.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;">The Lease is in full force and effect and has not been modified, supplemented or amended in any way except as provided in </font><font style="font-weight:bold;text-decoration:underline;">Exhibit&#160;F</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">Tenant has not transferred, assigned, or sublet any portion of the Premises nor entered into any license or concession agreements with respect thereto except as follows:</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;">Intentionally Omitted.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;">All monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated Additional Rent have been paid when due through ___________.&nbsp;&nbsp;The current monthly installment of Base Rent is $_____________________.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;">All conditions of the Lease to be performed by Landlord necessary to the enforceability of the Lease have been satisfied and, to Tenant&#8217;s actual knowledge, Landlord is not in default thereunder.&nbsp;&nbsp;In addition, the undersigned has not delivered any notice to Landlord regarding a default by Landlord thereunder.&nbsp;&nbsp; </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;">No rental has been paid more than thirty (30) days in advance and no security has been deposited with Landlord except as provided in the Lease.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;">As of the date hereof, there are no existing defenses or offsets, or, to the undersigned&#8217;s knowledge, claims or any basis for a claim, that the undersigned has against Landlord.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;">If Tenant is a corporation or partnership, each individual executing this Estoppel Certificate on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in North Carolina and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is authorized to do so.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;">There are no actions pending against the undersigned under the bankruptcy or similar laws of the United States or any state.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font><font style="margin-left:36pt;">To Tenant&#8217;s actual knowledge, Tenant is in full compliance with all federal, state and local laws, ordinances, rules and regulations affecting its use of the Premises, including, but not limited to, those laws, ordinances, rules or regulations relating to hazardous or toxic materials.&nbsp;&nbsp;Tenant has never permitted or suffered, nor does Tenant have any knowledge of, the generation, manufacture, treatment, use, storage, disposal or discharge of any hazardous, toxic or dangerous waste, substance or material in, on, under or about the Project or the Premises or any adjacent premises or property in violation of any federal, state or local law, ordinance, rule or regulation.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;">To the undersigned&#8217;s knowledge, all tenant improvement work to be performed by Landlord under the Lease has been completed in accordance with the Lease and has been accepted by the undersigned and all reimbursements and allowances due to the undersigned under the Lease in connection with any tenant improvement work have been paid in full.&nbsp;&nbsp;All work (if any) in the common areas required by the Lease to be completed by Landlord has been completed and all parking spaces required by the Lease have been furnished and/or all parking ratios required by the Lease have been met.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned acknowledges that this Estoppel Certificate may be delivered to Landlord or to a prospective mortgagee or prospective purchaser, and acknowledges that said prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in making the loan or acquiring the property of which the Premises are a part and that receipt by it of this certificate is a condition of making such loan or acquiring such property.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executed at ______________ on the ____ day of ___________, 201__.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="5" valign="top"  style="width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant&#8221;:</p></td>
</tr>
<tr>
<td colspan="5" valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</p></td>
<td colspan="4" valign="top"  style="width:92.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:91.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:91.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:6.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Its:</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:83.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="text-decoration:underline;">EXHIBIT G</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">[</font><font style="font-style:italic;text-decoration:underline;">Property Center Name</font><font style="text-decoration:underline;">]</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ENVIRONMENTAL QUESTIONNAIRE</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ENVIRONMENTAL QUESTIONNAIRE<br />FOR COMMERCIAL AND INDUSTRIAL PROPERTIES</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:17.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property Name:</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.84%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:17.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property Address:</p></td>
<td valign="top"  style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Instructions</font><font style="font-weight:normal;">:&nbsp;&nbsp;The following questionnaire is to be completed by the Lessee representative with knowledge of the planned operations for the specified building/location.&nbsp;&nbsp;Please print clearly and attach additional sheets as necessary.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.0<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">PROCESS INFORMATION</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Describe planned use, and include brief description of manufacturing processes employed.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.0<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">HAZARDOUS MATERIALS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are hazardous materials used or stored?&nbsp;&nbsp;If so, continue with the next question.&nbsp;&nbsp;If not, go to Section&#160;3.0.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.7%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="width:52.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are any of the following materials handled on the Property?</p></td>
<td valign="top"  style="width:39.74%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A material is handled if it is used, generated, processed, produced, packaged, treated, stored, emitted, discharged, or disposed.)&nbsp;&nbsp;If so, complete this section.&nbsp;&nbsp;If this question is not applicable, skip this section and go on to Section&#160;5.0.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.69%;width:62.31%;">
<tr>
<td valign="top"  style="width:39.56%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> Explosives</p></td>
<td valign="top"  style="width:20.88%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Fuels</p></td>
<td valign="top"  style="width:39.56%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Oils</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Solvents</p></td>
<td valign="top"  style="width:20.88%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Oxidizers</p></td>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Organics/Inorganics</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Acids</p></td>
<td valign="top"  style="width:20.88%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Bases</p></td>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Pesticides</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Gases</p></td>
<td valign="top"  style="width:20.88%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> PCBs</p></td>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Radioactive Materials</p></td>
</tr>
<tr>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Other (please specify)</p></td>
<td valign="top"  style="width:20.88%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.56%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If any of the groups of materials checked in Section&#160;2.1, please list the specific material(s), use(s), and quantity of each chemical used or stored on the site in the Table below.&nbsp;&nbsp;If convenient, you may substitute a chemical inventory and list the uses of each of the chemicals in each category separately.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Material</p></td>
<td valign="bottom"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Physical State (Solid, Liquid, or Gas)</p></td>
<td valign="bottom"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Usage</p></td>
<td valign="bottom"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Container Size</p></td>
<td valign="bottom"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Containers</p></td>
<td valign="bottom"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Quantity</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:double 2.5pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000; border-left:solid 0.75pt #000000; border-right:double 2.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Describe the planned storage area location(s) for these materials.&nbsp;&nbsp;Please include site maps and drawings as appropriate.</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.0<font style="font-weight:normal;margin-left:36pt;"></font><font style="text-decoration:underline;">HAZARDOUS WASTES</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.32%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are hazardous wastes generated?</p></td>
<td valign="top"  style="width:33.34%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:33.34%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes, continue with the next question.&nbsp;&nbsp;If not, skip this section and go to section&#160;4.0.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Are any of the following wastes generated, handled, or disposed of (where applicable) on the Property?</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.69%;width:52.31%;">
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> Hazardous wastes</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Industrial Wastewater</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Waste oils</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> PCBs</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Air emissions</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Sludges</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Regulated Wastes</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font> Other (please specify)</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">List and quantify the materials identified in Question&#160;3&#8209;1 of this section.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASTE </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERATED</p></td>
<td valign="bottom"  style="width:13.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RCRA listed </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Waste?</p></td>
<td valign="bottom"  style="width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SOURCE</p></td>
<td valign="bottom"  style="width:23.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">APPROXIMATE </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MONTHLY QUANTITY</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASTE </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CHARACTERIZATION</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DISPOSITION</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:23.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:23.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:23.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:23.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Please include name, location, and permit number (e.g. EPA ID No.) for transporter and disposal facility, if applicable).&nbsp;&nbsp;Attach separate pages as necessary.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:32.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transporter/Disposal Facility Name</p></td>
<td valign="bottom"  style="width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facility Location</p></td>
<td valign="bottom"  style="width:35.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transporter (T) or Disposal (D) Facility</p></td>
<td valign="bottom"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Permit Number</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:35.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.7%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3&#8209;4.</p></td>
<td colspan="2" valign="top"  style="width:92.3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are pollution controls or monitoring employed in the process to prevent or minimize the release of wastes</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.7%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into the environment?</p></td>
<td valign="top"  style="width:33.34%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If so, please describe.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.0</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">USTS/ASTS</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.7%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td colspan="2" valign="top"  style="width:92.3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the storage of petroleum products, chemicals, or liquid wastes present on site (lease renewals) or required</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.7%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:58.98%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for planned operations (new tenants)?</p></td>
<td valign="top"  style="width:33.34%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-36pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If not, continue with section&#160;5.0.&nbsp;&nbsp;If yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any associated leak detection/spill prevention measures.&nbsp;&nbsp;Please attach additional pages if necessary.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capacity</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contents</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Installed</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Type (Steel, </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fiberglass, etc)</p></td>
<td valign="bottom"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Associated Leak Detection / Spill </p>
<p style="margin-top:0pt;text-align:center;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prevention Measures<sup style="font-size:85%;line-height:120%;vertical-align:top">*</sup></p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">*</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following are examples of leak detection / spill prevention measures:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.69%;width:60.25%;">
<tr>
<td valign="top"  style="width:33.96%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Integrity testing</p></td>
<td valign="top"  style="width:33.96%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory reconciliation</p></td>
<td valign="top"  style="width:32.08%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leak detection system</p></td>
</tr>
<tr>
<td valign="top"  style="width:33.96%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overfill spill protection</p></td>
<td valign="top"  style="width:33.96%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secondary containment</p></td>
<td valign="top"  style="width:32.08%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cathodic protection</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Please provide copies of written tank integrity test results and/or monitoring documentation, if available.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#8209;3.</p></td>
<td valign="top"  style="width:72.68%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Is the UST/AST registered and permitted with the appropriate regulatory agencies?</p></td>
<td valign="top"  style="width:19.88%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:72.68%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, please attach a copy of the required permits.</p></td>
<td valign="top"  style="width:19.88%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If this Questionnaire is being completed for a lease renewal, and if any of the USTs/ASTs have leaked, please state the substance released, the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and all remedial responses to the incident.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#8209;5.</p></td>
<td colspan="2" valign="top"  style="width:92.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this Questionnaire is being completed for a lease renewal, have USTs/ASTs been removed from the</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:59.22%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property?</p></td>
<td valign="top"  style="width:33.34%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes, please provide any official closure letters or reports and supporting documentation (e.g., analytical test results, remediation report results, etc.).</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4&#8209;6.</p></td>
<td colspan="2" valign="top"  style="width:92.56%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Lease renewals, are there any above or below ground pipelines on site used to transfer chemicals or</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:59.24%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wastes?</p></td>
<td valign="top"  style="width:33.32%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For new tenants, are installations of this type required for the planned operations?</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes to either question, please describe.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.0</font><font style="font-weight:normal;margin-left:36pt;"></font><font style="text-decoration:underline;">ASBESTOS CONTAINING BUILDING MATERIALS</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please be advised that an asbestos survey may have been performed at the Property.&nbsp;&nbsp;If provided, please review the information that identifies the locations of known asbestos containing material or presumed asbestos containing material.&nbsp;&nbsp;All personnel and appropriate subcontractors should be notified of the presence of these materials, and informed not to disturb these materials.&nbsp;&nbsp;Any activity that involves the disturbance or removal of these materials must be done by an appropriately trained individual/contractor.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.0<font style="font-weight:normal;margin-left:36pt;"></font><font style="text-decoration:underline;">REGULATORY</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6&#8209;1.</p></td>
<td colspan="2" valign="top"  style="width:91.92%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Does the operation have or require a National Pollutant Discharge Elimination System (NPDES) or</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equivalent permit?</p></td>
<td valign="top"  style="width:13.34%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.4%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.58%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, please attach a copy of this permit.</p></td>
<td valign="top"  style="width:13.34%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6&#8209;2.</p></td>
<td valign="top"  style="width:62.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Has a Hazardous Materials Business Plan been developed for the site?</p></td>
<td valign="top"  style="width:30.52%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></a> No <font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:7.44%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:62.06%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, please attach a copy.</p></td>
<td valign="top"  style="width:30.52%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I am familiar with the real property described in this questionnaire.&nbsp;&nbsp;By signing below, I represent and warrant that the answers to the above questions are complete and accurate to the best of my knowledge.&nbsp;&nbsp;I also understand that Lessor will rely on the completeness and accuracy of my answers in assessing any environmental liability risks associated with the property.</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="text-decoration:underline;">EXHIBIT H&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESPONSIBILITY MATRIX</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000003.jpg" title="" alt="" style="width:542px;height:749px;"><font style="font-weight:bold;text-decoration:underline;">&nbsp;</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="text-decoration:underline;">EXHIBIT I</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">STORAGE AREA</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000004.jpg" title="" alt="" style="width:623px;height:310px;"></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIRST AMENDMENT TO LEASE </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr19A45BMBmoooqs8"></a><a name="_9kR3WTr19A45CYAjnmy5v"></a><a name="_9kR3WTr19A45DhMnkl5"></a><a name="_9kR3WTr19A45BMBmoooqs8"></a>THIS FIRST AMENDMENT TO LEASE (this &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is made and entered into as of the 23 day of December 2019 (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;), by and between <font style="font-weight:bold;">DURHAM TW ALEXANDER, LLC</font><a name="_9kR3WTr19A45CYAjnmy5v"></a>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;font-style:italic;">Landlord</font>&#8221;), and <font style="font-weight:bold;">PRECISION BIOSCIENCES, INC.</font><a name="_9kR3WTr19A45DhMnkl5"></a>, a Delaware corporation (formerly a North Carolina corporation) (&#8220;<font style="font-weight:bold;font-style:italic;">Tenant</font>&#8221;). </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">STATEMENT OF PURPOSE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt3DE6BFXGcrw"></a><a name="_9kR3WTr26649FN8s01vv7dS46F21A6CkSp8"></a><a name="_9kMIH5YVt3DE6BFXGcrw"></a><a name="_9kMHG5YVt3DE6BFXGcrw"></a>WHEREAS, Landlord and Tenant entered into that certain Lease dated October 2, 2018 (the &#8220;<font style="font-weight:bold;font-style:italic;">Existing Lease</font>&#8221;), for certain premises containing approximately 17,296 rentable square feet on the first (1st) floor (the &#8220;<font style="font-weight:bold;font-style:italic;">Existing Premises</font><a name="_9kR3WTr26649FN8s01vv7dS46F21A6CkSp8"></a>&#8221;) located in the building known as Biopoint Innovation Labs located at 20 TW Alexander Drive, Research Triangle Park, North Carolina 27709 (the &#8220;<font style="font-weight:bold;font-style:italic;">Building</font><a name="_9kMIH5YVt3DE6BFXGcrw"></a>&#8221;), as more particularly described in the Lease. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr19A467SEapu"></a><a name="_9kR3WTr24449BTEapu"></a><a name="_9kR3WTr1BC49DVEapu"></a><a name="_9kR3WTr19A467SEapu"></a><a name="_9kR3WTr24449BTEapu"></a><a name="_9kR3WTr1BC49DVEapu"></a>WHEREAS, Landlord and Tenant desire to amend the terms of the Existing Lease: (i) to expand the Existing Premises, (ii) to extend the Lease Term, and (iii) to modify certain other terms of the Lease.&nbsp;&nbsp;For purposes hereof, the Existing Lease as amended by this Amendment is referred to as the &#8220;<font style="font-weight:bold;font-style:italic;">Lease</font>.&#8221;&nbsp;&nbsp;All capitalized terms not otherwise defined herein shall have the meanings set forth in the Existing Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the statement of purpose, the mutual covenants contained herein and other valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Recitals</font>.&nbsp;&nbsp;The recitals shall form a part of this Amendment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Expansion of the Premises</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26646Bdbyyv4EE"></a><a name="_cp_text_1_3"></a><a name="_9kR3WTr19A46CQ8ggeu141hwBz58uSgO21KGDJv"></a><a name="_9kR3WTr1AB46DR8ggeu141hwBz58uSgO21KGDJv"></a><a name="_cp_text_4_4"></a><a name="_cp_text_1_5"></a><a name="_cp_text_4_6"></a><a name="_cp_text_1_7"></a><a name="_cp_text_4_8"></a><a name="_9kMIH5YVt48868AZXtpu1yz"></a><a name="_9kR3WTr1AB49GeKv0yvhTcyuz634"></a>(a)<font style="margin-left:36pt;"></font><a name="_9kR3WTr26646Bdbyyv4EE"></a>Tenant desires to expand the Existing Premises to include an additional approximately 16,339 rentable square feet commonly known as Suite 140 located in the first (1st) floor of the Building, all as further shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit A</font> attached hereto and incorporated herein by reference (the &#8220;<font style="font-weight:bold;font-style:italic;">Expansion Premises</font><a name="_cp_text_1_3"></a><a name="_9kR3WTr19A46CQ8ggeu141hwBz58uSgO21KGDJv"></a><a name="_9kR3WTr1AB46DR8ggeu141hwBz58uSgO21KGDJv"></a>&#8221;).&nbsp;&nbsp;<a name="_cp_text_4_4"></a>For avoidance of ambiguity, Section 1.2 <a name="_cp_text_1_5"></a>of the <a name="_cp_text_4_6"></a>Existing <a name="_cp_text_1_7"></a>Lease shall also apply <a name="_cp_text_4_8"></a>to the measurement of the Expansion Premises.&nbsp;&nbsp;Effective as of the Expansion Premises Rent Commencement Date (as defined in <font style="text-decoration:underline;">Section 2(b)</font><a name="_9kMIH5YVt48868AZXtpu1yz"></a> below), the Existing Premises shall be expanded by adding the Expansion Premises and the term &#8220;Premises&#8221; under the Lease shall be redefined to be that area shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit A</font><a name="_9kR3WTr1AB49GeKv0yvhTcyuz634"></a> as the Existing Premises plus the Expansion Premises, totaling approximately 33,635 rentable square feet of space (the &#8220;<font style="font-weight:bold;font-style:italic;">Revised Premises</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>The Expansion Premises shall be added to the Lease on the &#8220;<font style="font-weight:bold;font-style:italic;">Expansion Premises Rent Commencement Date</font>&#8221; which shall be defined as the earlier of: (i) delivery of the certificate of occupancy for the Expansion Premises; or (ii) July 1, 2020.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord shall allow limited beneficial occupancy of up to ten (10) Tenant employees in that area of the Expansion Premises as shown on <font style="font-weight:bold;text-decoration:underline;">Exhibit D</font><font style="font-weight:bold;"> (</font>&#8220;<font style="font-weight:bold;font-style:italic;">Limited Occupancy Space</font>&#8221;<font style="font-weight:bold;">)</font>.&nbsp;&nbsp;Tenant shall ensure that such limited beneficial occupancy falls under an existing certificate of occupancy and complies with any and all occupancy laws and applicable regulations. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0.92%;text-indent:6.77%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt3BC68ESAiigw363jyD17AwUiQ43MIF"></a><a name="_9kMHG5YVt3CD68FTAiigw363jyD17AwUiQ43MIF"></a>3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">First Extension Term</font><a name="_9kMHG5YVt3BC68ESAiigw363jyD17AwUiQ43MIF"></a><a name="_9kMHG5YVt3CD68FTAiigw363jyD17AwUiQ43MIF"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26649HSQ8ml40x3fe0w1856fWDC576y9"></a>(a)<font style="margin-left:36pt;"></font><a name="_9kR3WTr26649HSQ8ml40x3fe0w1856fWDC576y9"></a>The Lease Term for the Existing Premises is hereby extended for a period commencing on the Expansion Premises Rent Commencement Date and expiring on August 31, 2027 (the &#8220;<font style="font-weight:bold;font-style:italic;">First Extension Term Expiration Date</font>&#8221;), which comprises a period of approximately eighty-six (86) months (the &#8220;<font style="font-weight:bold;font-style:italic;">Existing Premises Extension Term</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr1AB49ITQ8ml40x3fe0w1856wd8H"></a>(b)<font style="margin-left:36pt;"></font>The Lease Term with respect to the Expansion Premises shall commence on the Expansion Premises Rent Commencement Date and shall expire on the First Extension Term Expiration Date <a name="_9kR3WTr1AB49ITQ8ml40x3fe0w1856wd8H"></a>(the &#8220;<font style="font-weight:bold;font-style:italic;">Expansion Premises Term</font>&#8221; and together with the Existing Premises Extension Term, collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">First Extension Term</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Landlord and Tenant hereby acknowledge that Tenant&#8217;s option to extend the Lease Term as set forth in <font style="text-decoration:underline;">Section 2.2</font> of the Lease remains in full force and effect and is not modified by this Amendment.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Base Rent</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26646EP0otTOr7"></a>(a)<font style="margin-left:36pt;"></font><a name="_9kR3WTr26646EP0otTOr7"></a>As of the Effective Date Tenant shall pay Base Rent for the Existing Premises in accordance with the following rent schedule. (The schedule below is the same as the Base Rent schedule listed in the Existing Lease with an extended period added to cover the full First Extension Term):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:27.9pt;">
<td valign="top"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time Period</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Base Rent</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664ACJ0otTOr7"></a>Monthly Installment<br /><a name="_9kR3WTr2664ACJ0otTOr7"></a>of Base Rent</p></td>
<td valign="top"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664ADaKn3ramqYfEzx2RWCI"></a>Annual Base Rent<br /><a name="_9kR3WTr2664ADaKn3ramqYfEzx2RWCI"></a>per Rentable Square Foot</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2019 - 06/30/2020</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$449,696.04</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$37,474.67</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.00</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2020 - 06/30/2021</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$463,186.92</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$38,598.91</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.78</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2021 - 06/30/2022</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$477,023.64</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$39,751.97</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.58</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2022 - 06/30/2023</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$491,379.36</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$40,948.28</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.41</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2023 - 06/30/2024</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$506,080.92</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$42,173.41</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.26</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2024 - 06/30/2025</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$521,301.48</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$43,441.79</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.14</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2025 - 06/30/2026</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$537,040.80</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44,753.40</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.05</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2026 - 06/30/2027</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$553,126.08</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$46,093.84</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.98</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2027 - 08/31/2027</p></td>
<td valign="middle"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$569,730.24</p></td>
<td valign="middle"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47,477.52</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$32.94</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMIH5YVt4886BJUSAon62z5hg2y3A78hYFE798"></a><a name="_9kMHG5YVt4886CDUClpo07xhxZC05fa3J"></a><a name="_9kMHG5YVt48868GR2qvVQt9"></a>(b)<font style="margin-left:36pt;"></font><a name="_9kMIH5YVt4886BJUSAon62z5hg2y3A78hYFE798"></a>Notwithstanding anything contained in the Lease to the contrary, commencing on the Expansion Premises Rent Commencement Date<a name="_9kMHG5YVt4886CDUClpo07xhxZC05fa3J"></a> and continuing through the First Extension Term Expiration Date, Tenant shall, at the time and in the manner provided in the Lease, pay to <a name="_9kMHG5YVt48868GR2qvVQt9"></a>Landlord as Base Rent for the Expansion Premises, the amounts set forth in the following rent schedule, plus any applicable tax thereon:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:27.9pt;">
<td valign="top"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Time Period*</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Base Rent</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMJI5YVt4886CEL2qvVQt9"></a>Monthly Installment<br /><a name="_9kMJI5YVt4886CEL2qvVQt9"></a>of Base Rent</p></td>
<td valign="top"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886CFcMp5tcosahG1z4TYEK"></a>Annual Base Rent<br /><a name="_9kMHG5YVt4886CFcMp5tcosahG1z4TYEK"></a>per Rentable Square Foot</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2020 - 06/30/2021**</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$457,491.96</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$38,124.33</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.00 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2021 - 06/30/2022</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$471,216.72</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$39,268.06</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.84 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2022 - 06/30/2023</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$485,431.68</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$40,452.64</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.71 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2023 - 06/30/2024</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$499,973.40</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$41,664.45</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.60 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2024 - 06/30/2025</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$514,841.88</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$42,903.49</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$31.51 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2025 - 06/30/2026</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$530,364.00</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44,197.00</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$32.46 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2026 - 06/30/2027</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$546,212.76</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$45,517.73</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.43 </p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="middle"  style="width:32.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/01/2027 - 08/31/2027</p></td>
<td valign="top"  style="width:15.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$562,715.16</p></td>
<td valign="top"  style="width:22.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$46,892.93</p></td>
<td valign="middle"  style="width:29.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$34.44 </p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMJI5YVt4886BJUSAon62z5hg2y3A78hYFE798"></a><a name="_9kMJI5YVt4886BJUSAon62z5hg2y3A78hYFE798"></a>*Note:&nbsp;&nbsp;Notwithstanding the above table, the dates of the time periods set forth therein will be adjusted based on the actual Expansion Premises Rent Commencement Date if such date occurs on a date earlier than July 1, 2020, but the final date shall remain the same.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><a name="_9kMKJ5YVt4886CEL2qvVQt9"></a><a name="_9kR3WTr5DA49E"></a><a name="_9kMHG5YVt4886CGeQfqvtvLJ41n3gfN54JBC"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMKJ5YVt4886CEL2qvVQt9"></a>**Note:&nbsp;&nbsp;Provided Tenant is not in monetary default of the terms of this Lease, after expiration of any applicable notice and cure period, Tenant shall have no obligation to pay any </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base Rent</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attributable to: (i) the first two (2) months of for the Expansion Premises, and only the Expansion Premises, following the Expansion Premises Rent Commencement Date (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Expansion Premises Abatement Period</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr5DA49E"></a>&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886CGeQfqvtvLJ41n3gfN54JBC"></a>&nbsp;&nbsp;Tenant shall be obligated to pay all of Tenant&#8217;s </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of Direct Expenses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attributable to the Expansion Premises during the Expansion Premises Abatement Period.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional Rent</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr26646GiOdotrtJH2zl1edL32H9A"></a>(a)<font style="margin-left:36pt;"></font><a name="_9kR3WTr26646GiOdotrtJH2zl1edL32H9A"></a>Tenant shall continue to pay Tenant&#8217;s Share of Direct Expenses for the Existing Premises in accordance with the Lease until the Expansion Premises Rent Commencement Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt48868IkQfqvtvLJ41n3gfN54JBC"></a>(b)<font style="margin-left:36pt;"></font><a name="_9kMHG5YVt48868IkQfqvtvLJ41n3gfN54JBC"></a>Commencing on the Expansion Premises Rent Commencement Date and continuing until the First Extension Term Expiration Date, as may be extended, Tenant shall pay Tenant&#8217;s Share of Direct Expenses for the Revised Premises, as more particularly described in <font style="text-decoration:underline;">Article 4</font> of the Lease with an updated Tenant&#8217;s Share.&nbsp;&nbsp;The term &#8220;Tenant&#8217;s Share&#8221; under the Lease shall be redefined to be 22.58% as of the Expansion Premises Rent Commencement Date.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref534601621"></a><a name="EXP__SPACE_COMM__DATE"></a>6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-weight:bold;">Delivery of </font><font style="font-weight:bold;text-decoration:underline;">Expansion Premises</font><a name="_Ref534601621"></a>.<a name="EXP__SPACE_COMM__DATE"></a>&nbsp;&nbsp;Tenant shall accept the Expansion Premises and all components thereof including, but not limited to, electrical and mechanical in its presently existing &#8220;as-is&#8221;, &#8220;where-is&#8221;, with all faults condition and Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Expansion Premises except as otherwise expressly set forth in the Tenant Work Letter attached hereto as <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font> attached hereto and incorporated herein by reference.&nbsp;&nbsp;The acceptance of the Expansion Premises in &#8220;as-is&#8221; condition shall in no way limit Landlord&#8217;s repair obligations set forth in the Lease.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_30"></a><a name="_9kMML5YVt4886CEL2qvVQt9"></a><a name="_9kR3WTr266478ZLct9y1IdEx8C79"></a><a name="_9kR3WTr2664AGXEapubWft"></a><a name="_9kMHG5YVt7FC6BG"></a><a name="_9kMHG5YVt4886CIZGcrwdYhv"></a><a name="_cp_text_4_29"></a><a name="_9kMHG5YVt4886BLlOt2"></a>7.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Security Deposit</font><a name="_cp_text_1_30"></a>.&nbsp;&nbsp;Prior to <a name="_9kMML5YVt4886CEL2qvVQt9"></a>the Effective Date, Tenant shall provide an additional One Hundred Fifty-Two Thousand Four Hundred Ninety-Seven and 32/100 Dollars ($152,497.32) (which is four (4) months Base Rent<a name="_9kR3WTr266478ZLct9y1IdEx8C79"></a> for the Expansion Premises at a rate of $38,124.33 per month) to be added to the Security Deposit under the Lease, which shall mean the total Security Deposit amount required under the Lease shall be Three Hundred Two Thousand Three Hundred Ninety-Six and 00/100 Dollars ($302,396.00) (the &#8220;<font style="font-weight:bold;font-style:italic;">Revised Premises Security Deposit</font>&#8221;).&nbsp;&nbsp;For the avoidance of doubt, the Revised Premises Security Deposit shall be held pursuant to <font style="text-decoration:underline;">Article 21</font> of the Lease and this <font style="text-decoration:underline;">Section 7</font> shall control future reductions of the Revised Premises Security Deposit.&nbsp;&nbsp;So long as Tenant has not been in default beyond any applicable notice and cure period at any time during the Term of the Lease, then at the end of the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup><a name="_9kR3WTr2664AGXEapubWft"></a>) Lease Year<a name="_9kMHG5YVt7FC6BG"></a>, the Revised Premises Security Deposit shall be reduced to Two Hundred Twenty-Six Thousand Seven Hundred Ninety-Seven and 00/100 Dollars ($226,797.00).&nbsp;&nbsp;So long as Tenant has not been in default beyond any applicable notice and cure period at any time during the Term of the Lease, then at the end of the fifth (5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup><a name="_9kMHG5YVt4886CIZGcrwdYhv"></a>) Lease Year<a name="_cp_text_4_29"></a>, the Revised Premises Security Deposit shall be <a name="_9kMHG5YVt4886BLlOt2"></a>reduced to One Hundred Fifty-One Thousand One Hundred Ninety-Eight and 00/100 Dollars ($151,198.00) for the remainder of the Lease Term, as extended.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional Right of First Offer</font>.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664AJgOkky6tLJ2DGnUss5"></a>(a)<font style="margin-left:36pt;"></font>T<a name="_9kR3WTr2664AJgOkky6tLJ2DGnUss5"></a>he right of first offer provided in <font style="text-decoration:underline;">Section 1.3</font> of the Existing Lease for Tenant shall continue to apply as stated therein.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664AIcUvlmunmgUvstD"></a><a name="_9kR3WTr2664AKibyyv4EE"></a><a name="_9kR3WTr2664BCWV1ulfv"></a><a name="_9kR3WTr2664BDWS4yu0gSx6"></a>(b)<font style="margin-left:36pt;"></font><a name="_9kR3WTr2664AIcUvlmunmgUvstD"></a>Beginning on the Effective Date, Landlord hereby grants to the Original Tenant<a name="_9kR3WTr2664AKibyyv4EE"></a>, a one-time right of first offer with respect to <font style="font-weight:bold;text-decoration:underline;">Suite 100 containing 29,191 rentable square feet</font> located in the Building as set forth in <font style="font-weight:bold;text-decoration:underline;">Exhibit B</font> attached hereto, (the &#8220;<font style="font-weight:bold;font-style:italic;">Suite 100 First Offer Space</font><font style="font-style:italic;">&#8221;</font><a name="_9kR3WTr2664BCWV1ulfv"></a>).&nbsp;&nbsp;Notwithstanding the foregoing, such first offer right of Tenant shall commence only following the expiration or earlier termination of the initial lease (including renewals) of the Suite 100 First Offer Space, and such right of first offer shall be subordinate to all rights of which are set forth in leases of space in the Project as of the date hereof, including any renewal, extension or expansion rights set forth in such leases, regardless of whether such renewal, extension or expansion rights are executed strictly in accordance with their terms, or pursuant to a lease amendment or a new lease (collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Superior Right Holders</font><a name="_9kR3WTr2664BDWS4yu0gSx6"></a>&#8221;) with respect to such Suite 100 First Offer Space.&nbsp;&nbsp;Tenant&#8217;s right of first offer shall not be applicable during any Option Term.&nbsp;&nbsp;Tenant&#8217;s right of first offer shall be on the terms and conditions set forth in this <font style="text-decoration:underline;">Section 8.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Procedure for Offer</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Landlord shall notify Tenant (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Suite 100 First Offer Notice</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) when the Suite 100 First Offer Space, any portion thereof, or such larger space that includes the Suite 100 First Offer Space becomes available for lease to third parties, provided that no Superior Right Holder wishes to lease such space.&nbsp;&nbsp;Pursuant to such Suite 100 First Offer Notice, Landlord shall offer to lease to Tenant the then available Suite 100 First Offer Space and any additional space noted within the Suite 100 First Offer Notice.&nbsp;&nbsp;The Suite 100 First Offer Notice shall describe the space so offered to Tenant (which the parties acknowledge may include a portion of the Suite 100 First Offer Space, only the Suite 100 First Offer Space, or the Suite 100 First Offer Space plus additional contiguous space the Landlord is offering for lease) and shall set forth the &#8220;Suite 100 First Offer Rent,&#8221; as that term is defined in </font><font style="text-decoration:underline;">Section 8(e)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below, and the other economic terms upon which Landlord is willing to lease such space to Tenant. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Procedure for Acceptance</font>.&nbsp;&nbsp;If Tenant wishes to exercise Tenant&#8217;s right of first offer with respect to the space described in the Suite 100 First Offer Notice, then within ten (10) business days of delivery of the Suite 100 First Offer Notice to Tenant, Tenant shall deliver notice to Landlord of Tenant&#8217;s election to exercise its right of first offer with respect to the entire space described in the Suite 100 First Offer Notice on the terms contained in such notice.&nbsp;&nbsp;If Tenant does not so notify Landlord within the ten (10) business day period, then Landlord shall be free to lease the space described in the Suite 100 First Offer Notice to anyone to whom Landlord desires on any terms Landlord desires.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, Tenant must elect to exercise its right of first offer, if at all, with respect to all of the space offered by Landlord to Tenant at any particular time, and Tenant may not elect to lease only a portion thereof.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664BEaKn3"></a><a name="_9kR3WTr2664BFP4ewgOr7vokUrC6"></a>(e)<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Suite 100 First Offer Space Rent</font><a name="_9kR3WTr2664BEaKn3"></a>.&nbsp;&nbsp;The &#8220;Rent&#8221; payable by Tenant for the Suite 100 First Offer Space (the &#8220;<font style="font-weight:bold;font-style:italic;">Suite 100</font> <font style="font-weight:bold;font-style:italic;"><a name="_9kR3WTr2664BFP4ewgOr7vokUrC6"></a>First Offer Rent</font>&#8221;) shall be equal to the Fair Rental Value (as defined in <font style="text-decoration:underline;">Section 2.2.2</font> of the Lease) as of the &#8220;Suite 100 First Offer Commencement Date,&#8221; as that term is defined in <font style="text-decoration:underline;">Section&#160;8(g)</font>, below.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886DHR6gyiQt9xqmWtE8"></a>(f)<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Construction In Suite 100 First Offer Space</font><a name="_9kMHG5YVt4886DHR6gyiQt9xqmWtE8"></a>.&nbsp;&nbsp;Tenant shall take the Suite 100 First Offer Space in its &#8220;as is&#8221; condition (subject to Landlord&#8217;s repair obligations in the Lease), subject to any improvement allowance granted as a component of the Fair Rental Value, and the construction of improvements in the Suite 100 First Offer Space shall comply with the terms of the Lease for Alterations. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886DGcMp5"></a>(g)<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Amendment to Lease</font>.&nbsp;&nbsp;If Tenant timely exercises Tenant&#8217;s right to lease the Suite 100 First Offer Space as set forth herein, Landlord and Tenant shall promptly thereafter execute an amendment to this Lease for such Suite 100 First Offer Space upon the terms and conditions as set forth in the Suite 100 First Offer Notice and this <font style="text-decoration:underline;">Section 8</font><a name="_9kMHG5YVt4886DGcMp5"></a>.&nbsp;&nbsp;Tenant shall commence payment of Rent for the Suite 100 First Offer Space, and the term of the Suite 100 First Offer Space shall commence upon the date of delivery of the Suite 100 First Offer Space to Tenant (the &#8220;<font style="font-weight:bold;font-style:italic;">Suite 100</font> <font style="font-weight:bold;font-style:italic;">First Offer Commencement Date</font>&#8221;) and terminate on the date set forth in the Suite 100 First Offer Notice.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886CKeWxnowpoiWxuvF"></a><a name="_9kR3WTr2664BIcIr0s0CyjGQF6v10s7"></a><a name="_9kR3WTr2664BGZUvlmunmgUvstDFE1aZ8H9HTF0"></a><a name="_9kR3WTr2664BHaUvlmunmgUvstDJ"></a><a name="_9kMIH5YVt4886CKeWxnowpoiWxuvF"></a><a name="_9kMHG5YVt4886CJeXtpu1yz"></a>(h)<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Termination of Suite 100 Right of First Offer</font>.&nbsp;&nbsp;The rights contained in this <font style="text-decoration:underline;">Section&#160;8</font><a name="_9kMHG5YVt4886CKeWxnowpoiWxuvF"></a> shall be personal to the Original Tenant<a name="_9kR3WTr2664BIcIr0s0CyjGQF6v10s7"></a> and its Permitted Assignees<a name="_9kR3WTr2664BGZUvlmunmgUvstDFE1aZ8H9HTF0"></a>, and may only be exercised by the Original Tenant or a Permitted Assignee<a name="_9kR3WTr2664BHaUvlmunmgUvstDJ"></a> (and not any other assignee, sublessee or other transferee of the Original Tenant&#8217;s<a name="_9kMIH5YVt4886CKeWxnowpoiWxuvF"></a> interest in this Lease) if the Original Tenant<a name="_9kMHG5YVt4886CJeXtpu1yz"></a> occupies the majority of the Revised Premises.&nbsp;&nbsp;The right of first offer granted herein shall terminate as to particular Suite 100 First Offer Space upon the failure by Tenant to exercise its right of first offer with respect to such Suite 100 First Offer Space as offered by Landlord.&nbsp;&nbsp;Tenant shall not have the right to lease Suite 100 First Offer Space, as provided in this <font style="text-decoration:underline;">Section 8</font>, if, as of the date of the attempted exercise of any right of first offer by Tenant, or as of the scheduled date of delivery of such Suite 100 First Offer Space to Tenant, Tenant is in default under this Lease, after the expiration of any applicable notice and cure period, or Tenant has previously been in default, after the expiration of any applicable notice and cure period, under this Lease more than twice. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_42"></a><a name="_cp_text_1_43"></a><a name="_cp_text_4_44"></a><a name="_cp_text_1_45"></a><a name="_cp_text_4_46"></a><a name="_cp_text_1_47"></a><a name="_cp_text_4_48"></a>9.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Brokers</font><a name="_cp_text_4_42"></a>.&nbsp;&nbsp;<a name="_cp_text_1_43"></a>Landlord and Tenant <a name="_cp_text_4_44"></a>hereby warrant to each other that it has had no dealings with any real estate broker or agent <a name="_cp_text_1_45"></a>in connection with the negotiation of this Amendment, excepting only the real estate brokers or agents specified in Section&#160;13 of the Existing Lease Summary (the &#8220;<font style="font-weight:bold;">Brokers</font><a name="_cp_text_4_46"></a>&#8221;), and that it knows of no other real estate broker or agent which represented said party who is entitled to a commission in connection with this Amendment.&nbsp;&nbsp;<a name="_cp_text_1_47"></a>Landlord and Tenant <a name="_cp_text_4_48"></a>each agree to indemnify and defend each other against and hold the indemnified party harmless from any and all claims, demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys&#8217; fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><a name="_9kMIH5YVt7FC6BG"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Counterparts/Signatures</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMIH5YVt7FC6BG"></a>This Amendment may be executed in counterparts</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;All executed counterparts shall constitute one agreement, and each counterpart shall be deemed an original.&nbsp;&nbsp;The parties hereby acknowledge and agree that electronic signatures, facsimile signatures or signatures transmitted by electronic mail in so-called &#8220;pdf&#8221; format shall be legal and binding and shall have the same full force and effect as if an original of this Amendment had been delivered.&nbsp;&nbsp;Landlord and Tenant (i) intend to be bound by the signatures (whether original, faxed or electronic) on any document sent by facsimile or electronic mail, (ii) are aware that the other party will rely on such signatures, and (iii) hereby waive any defenses to the enforcement of the terms of this Amendment based on the foregoing forms of signature.</font></p>
<p style="text-align:justify;margin-bottom:24pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Miscellaneous</font><font style="color:#000000;">.&nbsp;&nbsp;This Amendment shall become effective only upon full execution and delivery of this Amendment by Landlord and Tenant.&nbsp;&nbsp;This Amendment contains the parties&#8217; entire agreement regarding the subject matter covered by this Amendment, and supersedes all prior correspondence, negotiations, and agreements, if any, whether oral or written, between the parties concerning such subject matter.&nbsp;&nbsp;There are no contemporaneous oral agreements, and there are no representations or warranties between the parties not contained in this Amendment.&nbsp;&nbsp;This Amendment shall be construed and enforced in accordance with the laws of the State of North Carolina.&nbsp;&nbsp;Except as modified by this Amendment, the terms and provisions of the Lease shall remain in full force and effect, and the Lease, as modified by this Amendment, shall be binding upon and shall inure to the benefit of the parties hereto, their successors and permitted assigns.</font></p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-weight:bold;font-style:italic;">Signature Page Follows</font>]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-weight:bold;font-style:italic;">The remainder of this page has been intentionally left blank</font>]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD AND TENANT enter into this Amendment as of the Effective Date above.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DURHAM TW ALEXANDER, LLC<font style="font-weight:normal;">,</font></p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:normal;text-transform:none;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;">a Delaware limited liability company</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:88.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Adam B. Sichol</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:88.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adam B. Sichol</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:88.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signatory</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.<font style="font-weight:normal;">,</font></p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:88.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matt Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:88.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matt Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:88.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="text-decoration:underline;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">THE EXPANSION PREMISES</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Suite 140</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000005.jpg" title="" alt="" style="width:613px;height:407px;"></p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"></font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="text-decoration:underline;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FIRST OFFER SPACE</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Suite 100</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000006.jpg" title="" alt="" style="width:588px;height:291px;"><font style="font-weight:bold;text-decoration:underline;text-transform:uppercase;">&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="text-decoration:underline;">EXHIBIT C</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">tenant WORK LETTER</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Tenant Work Letter sets forth the terms and conditions relating to the construction of improvements in the Expansion Premises. All references in this Tenant Work Letter to Articles or Sections of &#8220;this Lease&#8221; shall mean the relevant portion of the Existing Lease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>LANDLORD&#8217;S INITIAL CONSTRUCTION IN THE PREMISES</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664BJZAjnmy5vbh96"></a>1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Landlord Work</font>.&nbsp;&nbsp;<a name="_9kR3WTr2664BJZAjnmy5vbh96"></a>None.&nbsp;&nbsp;There is no Landlord Work.&nbsp;&nbsp;Tenant accepts the Expansion Premises in its &#8220;as-is&#8221;, &#8220;where-is&#8221; condition. &nbsp;&nbsp;The acceptance of the Expansion Premises in &#8220;as-is&#8221; condition shall in no way limit Landlord&#8217;s repair obligations set forth in the Lease.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>TENANT IMPROVEMENTS</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_61"></a><a name="_cp_text_4_62"></a><a name="_cp_text_1_68"></a><a name="_9kMNM5YVt4886CEL2qvVQt9"></a><a name="_cp_text_1_1779"></a><a name="_cp_text_4_1780"></a><a name="_cp_text_1_1781"></a>2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant Improvements Allowance</font>.&nbsp;&nbsp;So long as Tenant is not in default, Tenant shall be entitled to an one-time tenant improvements allowance (the &#8220;<font style="text-decoration:underline;">Tenant Improvements Allowance</font>&#8221;) in the maximum aggregate amount of: (i) <font style="font-weight:bold;">$898,645.00</font> for the Expansion Premises (<font style="font-style:italic;">i.e.</font>, <font style="font-weight:bold;">$55.00</font> per rentable square foot of the Expansion Premises) (the &#8220;<font style="text-decoration:underline;">Maximum Allowance Amount</font><a name="_cp_text_1_61"></a>&#8221;) for the hard costs and customary soft costs, as noted below, incurred by Tenant including, without limitation out-of-pocket architectural and engineering fees<a name="_cp_text_4_62"></a>, construction contractor fees, Tenant&#8217;s project management fees, and a two percent (2%) project management fee payable to Landlord or its affiliates (&#8220;<font style="text-decoration:underline;">Landlord&#8217;s Project Oversight Fee</font><a name="_cp_text_1_68"></a>&#8221;), and permits, and such other costs arising from or relating to the design and construction of Tenant&#8217;s improvements which are to be permanently affixed to the Expansion Premises in accordance with this Work Letter (the &#8220;<font style="text-decoration:underline;">Tenant Improvements</font><a name="_9kMNM5YVt4886CEL2qvVQt9"></a>&#8221;).&nbsp;&nbsp;Landlord&#8217;s Project Oversight Fee shall be equivolent to, but not exceed, a total of 2% of the Tenant Improvement Allowance paid to Tenant.&nbsp;&nbsp;In no event shall Tenant be permitted to use any excess Tenant Improvements Allowance toward the Base Rent<a name="_cp_text_1_1779"></a> or any soft costs that are not directly related to the design and construction within the Expansion Premises.&nbsp;&nbsp;For the avoidance of any doubt, the purchase and installation of data and telecommunications cabling shall not be included in the definition of Tenant Improvements and there shall not be any Landlord&#8217;s Project Oversight Fee payable with respect to costs and expenses related thereto. The Tenant agrees to keep the Landlord advised as to the progress of the work by providing copies of the Contractor&#8217;s applications for payment.&nbsp;&nbsp;In no event shall Landlord be obligated to make disbursements pursuant to this Tenant Work Letter in a total amount which exceeds the Maximum Allowance<font style="Background-color:#FFFFFF;"><a name="_cp_text_4_1780"></a> Amount and in no event <a name="_cp_text_1_1781"></a>shall Tenant be entitled to any credit for any unused portion of the Tenant Improvements Allowance</font>.&nbsp;&nbsp;All Tenant Improvements for which the Tenant Improvements Allowance has been made available shall be deemed Landlord&#8217;s property under the terms of the Lease. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr19A4DKNGpgn0xhx"></a><a name="_cp_text_1_1782"></a>2.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Disbursement of the Tenant Improvements Allowance</font>.&nbsp;&nbsp;Except as otherwise set forth in this Tenant Work Letter, the Tenant Improvements Allowance shall be disbursed by Landlord (each of which disbursements shall be made pursuant to Landlord&#8217;s reasonable disbursement process) for costs incurred and paid by Tenant related to the design and construction of the Tenant Improvements and for the following items and costs (collectively, the &#8220;<font style="text-decoration:underline;">Tenant Improvements Allowance Items</font><a name="_9kR3WTr19A4DKNGpgn0xhx"></a>&#8221;):&nbsp;&nbsp;(i) payment of the fees of the &#8220;<font style="text-decoration:underline;">Architect</font><a name="_cp_text_1_1782"></a>&#8221; as that term is defined in Section 3.1 of this Tenant Work Letter in connection with the preparation and review of the &#8220;Construction Documents,&#8221; as that term is defined in Section 3.1 of this Tenant Work Letter; (ii) payment of the Landlord&#8217;s Project Oversight Fee, (iii) the cost of any changes to the Construction Documents or Tenant Improvements required by all applicable building codes (the &#8220;<font style="text-decoration:underline;">Code</font>&#8221;) enacted after approval of the Construction Documents, (iv) costs payable to the Contractor and any subcontractors, and (v) other costs incurred in connection with the Tenant Improvements to the extent the same can be paid using the Tenant Improvements Allowance pursuant to the specific provisions of this Tenant Work Letter.<font style="font-weight:bold;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><a name="_9kR3WTr19A4DLdEu7oq6lRxE32I"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Landlord is required to disburse any portion of the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr19A4DLdEu7oq6lRxE32I"></a>Tenant Improvements Allowance as noted above, Landlord shall disburse the applicable portion of the Tenant Improvements Allowance within thirty (30) calendar days of receiving from Tenant a </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment Request</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (as hereinafter defined), an amount equal to the lesser of: (A) the amounts so requested by Tenant of the actual costs and expenses Tenant has incurred and paid in connection with the design and construction of the Tenant Improvements to date less a ten percent (10%) retention (the aggregate amount of such retentions to be known as the &#8220;</font><font style="text-decoration:underline;">Final Retention</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), and (B) the balance of any remaining available portion of the Tenant Improvements Allowance (not including the Final Retention) provided the following conditions have</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> been satisfied:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt3BC6FNfGw9qs8nTzG54K"></a>(1)<font style="margin-left:36pt;"><a name="_9kMHG5YVt3BC6FNfGw9qs8nTzG54K"></a>Tenant has delivered to Landlord a payment request (&#8220;</font>Payment Request&#8221;) in a form reasonably satisfactory to Landlord specifying the work which has been completed; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;">Tenant&#8217;s general contractor and/or architect shall have submitted an application for payment and sworn statement substantially in the form of AIA Document G702 and AIA Document G703; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;">Tenant has submitted to Landlord lien waivers or partial lien waivers from all contractors, first tier subcontractors, artchitects, and first tier materialmen who performed such work to cover the work included under the Payment Request and all prior work Tenant was required to pay for before utilizing the Tenant Improvements Allowance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything herein to the contrary, the Tenant Improvements Allowance must be requested in writing by Tenant, if at all, in accordance with this paragraph on or before the date that is one year following the Effective Date of this Amendment, and any portion not requested by such date may no longer be utilized by Tenant and shall be deemed forfeited to Landlord.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr8HB4DFACC"></a>2.2.1<font style="margin-left:-222pt;"></font><font style="text-decoration:underline;">Final Retention</font>. Subject to the provisions of this Tenant Work Letter, a check for the Final Retention payable to Tenant shall be delivered by Landlord to Tenant not later than thirty (30) days following the completion of construction of the Expansion Premises, provided that (i) Tenant delivers to Landlord properly executed mechanics lien releases in compliance with the applicable laws in the state where the Building is located, (ii) Landlord has reasonably determined that no defective work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the Building, the curtain wall of the Building, the structure or exterior appearance of the Building, or any other tenant&#8217;s use of such other tenant&#8217;s leased premises in the Building and (iii) Architect delivers to Landlord a certificate, in a form reasonably acceptable to Landlord, certifying that the construction of the Tenant Improvements in the Expansion Premises has been substantially completed.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>CONSTRUCTION DOCUMENTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMMAM6ZWu9A6AGN"></a><a name="_9kMMAM6ZWu9A6AHI"></a><a name="_9kMHG5YVt3BC6FMPIrip2zjz"></a><a name="_9kMMAM6ZWu9A6AHF"></a><a name="_9kMMAM6ZWu9A6AHJ"></a><a name="_9kMMBN6ZWu9A6AGN"></a><a name="_9kMMBN6ZWu9A6AHI"></a><a name="_9kMMBN6ZWu9A6AHF"></a><a name="_9kMMBN6ZWu9A6AHJ"></a><a name="_9kMMCO6ZWu9A6AGN"></a><a name="_9kMMCO6ZWu9A6AHI"></a><a name="_9kMMCO6ZWu9A6AHF"></a><a name="_9kMMCO6ZWu9A6AHJ"></a><a name="_9kMH56I7aXvAB7BIH"></a><a name="_9kMH56I7aXvAB7BIO"></a>3.1<font style="margin-left:-222pt;"></font><font style="text-decoration:underline;">Selection of Architect/Construction Documents</font>.&nbsp;&nbsp;<a name="_9kMMAM6ZWu9A6AGN"></a><a name="_9kMMAM6ZWu9A6AHI"></a>Landlord consents to Tenant retaining Integrated Design, PA (collectively, the <a name="_9kMHG5YVt3BC6FMPIrip2zjz"></a>&#8220;<font style="text-decoration:underline;"><a name="_9kMMAM6ZWu9A6AHF"></a><a name="_9kMMAM6ZWu9A6AHJ"></a>Architect</font>&#8221;<a name="_9kMMBN6ZWu9A6AGN"></a><a name="_9kMMBN6ZWu9A6AHI"></a>) to prepare the &#8220;<a name="_9kMMBN6ZWu9A6AHF"></a><a name="_9kMMBN6ZWu9A6AHJ"></a>Construction Documents,&#8221; as that term is defined in this <font style="text-decoration:underline;">Section 3.1</font> for the Tenant Improvements.&nbsp;&nbsp;Tenant shall also retain the engineering consultants designated by Landlord (the &#8220;<font style="text-decoration:underline;">Engineers</font><a name="_9kMMCO6ZWu9A6AGN"></a><a name="_9kMMCO6ZWu9A6AHI"></a>&#8221;) to prepare all plans and engineering working drawings relating to the structural, mechanical, electrical, plumbing, HVAC and lifesafety work of the Tenant Improvements.&nbsp;&nbsp;The plans and drawings to be prepared by Architect and the Engineers hereunder shall be known collectively as the &#8220;<font style="text-decoration:underline;">Construction Documents</font><a name="_9kMMCO6ZWu9A6AHF"></a><a name="_9kMMCO6ZWu9A6AHJ"></a>.&#8221;<a name="_9kMH56I7aXvAB7BIH"></a><a name="_9kMH56I7aXvAB7BIO"></a>&nbsp;&nbsp;All Construction Documents shall reasonably comply with the drawing format and specifications as reasonably determined by Landlord, and shall be subject to Landlord&#8217;s reasonable approval. Tenant and Architect shall verify, in the field, the dimensions and conditions as shown on the relevant portions of the base building plans, and Tenant and Architect shall be solely responsible for the same, and Landlord shall have no responsibility in connection therewith. Landlord&#8217;s review of the Construction Documents as set forth in this Section 3, shall be for its sole purpose and shall not imply Landlord&#8217;s review of the same, or obligate Landlord to review the same, for quality, design, Code compliance or other like matters. Accordingly, notwithstanding that any Construction Documents are reviewed by Landlord or its space planner, architect, engineers and consultants, and notwithstanding any advice or assistance which may be rendered to Tenant by Landlord or Landlord&#8217;s space planner, architect, engineers, and consultants, Landlord shall have no liability whatsoever in connection therewith and shall not be responsible for any omissions or errors contained in the Construction Documents.&nbsp;&nbsp;Landlord may hire an architectural firm to conduct a peer review, and the fees associated with this peer review shall be paid from the Landlord&#8217;s Project Oversight Fee and shall not result in an additional charge to Tenant.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord has no obligation to approve or perform any Tenant Change or any Tenant Improvements not shown on the plans previously approved by Landlord and Tenant or reasonably inferable therefrom if, in Landlord&#8217;s reasonable judgment, such Tenant Improvements (i)&#160;would materially increase the cost of performing any other work in the Building, not including the Tenant Improvements, unless in each case Tenant agrees to pay such costs based on Landlord&#8217;s Change Estimate Notice (as defined below), (ii)&#160;are incompatible with the design, quality, equipment or systems of the Building or otherwise require a change to the existing Building systems or structure, each in a manner that would not otherwise be required in connection with the improvements contemplated by the Fit Plan (as defined below), (iii)&#160;is not consistent with the existing quality and nature of the Building, or (iv)&#160;otherwise do not comply with the provisions of the Lease.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664DMQK8xtqwBXA2L"></a>3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Final Space Plan</font>.&nbsp;&nbsp;Tenant has approved the preliminary space plan prepared by the Architect attached as <font style="text-decoration:underline;">Attachment 1</font> hereto (the &#8220;<font style="text-decoration:underline;">Fit Plan</font><a name="_9kR3WTr2664DMQK8xtqwBXA2L"></a>&#8221;).&nbsp;&nbsp;Tenant shall use commercially reasonable efforts to cause the Architect to prepare a space plan for the Expansion Premises which space plan shall be reasonably consistent with the Fit Plan and shall include a layout and designation of all labs, offices, rooms and other partitioning, their intended use, and equipment to be contained therein, and shall deliver the space plan to Landlord and Tenant for their approval. Landlord and Tenant shall review and provide any changes to the space plan within five (5) Business Days of receipt thereof.&nbsp;&nbsp;Once Landlord and Tenant approve the final space plan, the space plan shall be considered final (the &#8220;<font style="text-decoration:underline;">Final Space Plan</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kMHG5YVt4886FOSMAzvsyDZC4N"></a><a name="_9kMIH5YVt4886FOSMAzvsyDZC4N"></a><a name="_9kR3WTr2664DNQE0xrjccosTK2L"></a>3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Construction Documents</font><a name="_9kMHG5YVt4886FOSMAzvsyDZC4N"></a>.&nbsp;&nbsp;Tenant shall cause&nbsp;&nbsp;the Architect to complete final Construction Documents consistent with the Final Space Plan and shall submit the same to Landlord and Tenant for their approval.&nbsp;&nbsp;Landlord and Tenant shall review and provide any changes to the construction documents within five (5) Business Days<a name="_9kMIH5YVt4886FOSMAzvsyDZC4N"></a> of receipt thereof, and the Tenant shall use reasonable efforts to cause the Architect to prepare and circulate modified documents within five (5) Business Days<a name="_9kR3WTr2664DNQE0xrjccosTK2L"></a> of its receipt of any requested changes from Tenant or Landlord. Such process of submittal and response within the time frame specified in the preceding sentence shall continue until each of Landlord and Tenant gives written approval to such documents, and the Construction Documents shall be considered final once approved by the Landlord and the Tenant. In no event may either Tenant or Landlord require any changes that are inconsistent with the Final Space Plan.&nbsp;&nbsp;The Construction Documents shall comply with Applicable&#160;Laws existing on the date of this Tenant Work Letter and which may be enacted prior to approval of completed Construction Documents. Subject to the provisions of Sections 3.1 and 5.4 of this Work Letter, Tenant may, from time to time, by written request to Landlord on a form reasonably specified by Landlord (&#8220;<font style="text-decoration:underline;">Tenant Change</font>&#8221;), request a change in the Tenant Improvements shown on the Construction Documents, which approval shall not be unreasonably withheld or conditioned, and shall be granted or denied within five (5) Business Days after delivery of such Tenant Change to Landlord.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Permits</font>.&nbsp;&nbsp;The Construction Documents as approved (or deemed approved) pursuant to Section 3.3 shall be the &#8220;<font style="text-decoration:underline;">Approved Working Drawings</font>&#8221;.&nbsp;&nbsp;Following approval or deemed approval of the Cost Proposal, as described below, Tenant shall promptly thereafter submit or cause to be submitted, the Approved Working Drawings to the appropriate municipal authorities for all applicable building permits necessary to allow &#8220;Contractor,&#8221; as that term is defined in Section 4.1, below, to commence and fully complete the construction of the applicable Tenant Improvements (the &#8220;<font style="text-decoration:underline;">Permits</font>&#8221;).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Time Deadlines</font>.&nbsp;&nbsp;Intentionally omitted.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>CONSTRUCTION OF THE TENANT IMPROVEMENTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Contractor</font>.&nbsp;&nbsp;A contractor designated by Tenant and reasonably approved by Landlord (&#8220;<font style="text-decoration:underline;">Contractor</font>&#8221;) shall construct the Tenant Improvements.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cost Proposal</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;After the Approved Working Drawings are approved by Landlord and Tenant, Tenant shall provide Landlord with a cost proposal (or cost proposals) in accordance with the Approved Working Drawings for Landlord&#8217;s approval, which approval shall not be unreasonably withheld, which cost proposal(s) shall include, as nearly as possible, the cost of all Tenant Improvements Allowance Items to be incurred by Tenant in connection with the design and construction of the Tenant Improvements (the &#8220;</font><font style="text-decoration:underline;">Cost Proposal</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;Tenant will consult with Landlord prior to approving the contractors to whom it will be bid and Landlord may review bid packages at Landlord&#8217;s written request.&nbsp;&nbsp;The date on which Landlord approves the Cost Proposal shall be known hereafter as the &#8220;</font><font style="text-decoration:underline;">Cost Proposal Delivery Date</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Construction of Tenant Improvements by Contractor</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Intentionally Deleted</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Retention of Contractor</font>. Tenant shall independently retain Contractor to construct the Tenant Improvements in accordance with the applicable Approved Working Drawings and the applicable Cost Proposal.&nbsp;&nbsp;Landlord shall be entitled to review the Tenant&#8217;s construction contract with the Contractor upon Landlord&#8217;s written request. Tenant shall be responsible to ensure the Contractor performs the construction work in a good and workmanlike manner and shall endeavor to oversee the Contractor&#8217;s performance of its work to protect Landlord from construction defects. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>COMPLETION OF THE TENANT IMPROVEMENTS;<br />LEASE COMMENCEMENT DATE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664ELfbrq9sn73lp1FhS9BB1AB"></a>5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Substantial Completion</font><a name="_9kR3WTr2664ELfbrq9sn73lp1FhS9BB1AB"></a>.&nbsp;&nbsp;Tenant shall give Landlord at least twenty (20) days prior written notice of the date that Tenant reasonably anticipates that the Tenant Improvements will be Substantially Complete (as defined below).&nbsp;&nbsp;For purposes of this Lease, &#8220;<font style="text-decoration:underline;">Substantial Completion</font>&#8221; shall occur upon the completion of the last of the following to occur: (i) the completion of construction of the Tenant Improvements substantially pursuant to the Approved Working Drawings for such Tenant Improvements (each as reasonably determined by Tenant and Architect), with the exception of any punch list items which do not impair Tenant&#8217;s ability to occupy the Expansion Premises for their contemplated use, (ii) the acquisition of a certificate of occupancy or its legal equivalent allowing occupancy of the Expansion Premises (a &#8220;<font style="text-decoration:underline;">Sign Off</font>&#8221;), and (iii) delivery of a certificate of substantial completion from the Architect confirming the matters set forth in the foregoing clause (i).&nbsp;&nbsp;In the event that the Sign Off is not a final certificate of occupancy, Tenant shall diligently prosecute the work necessary to achieve a full certificate of occupancy and use commercially reasonable efforts to obtain such full certificate of occupancy as soon as reasonably practicable following Substantial Completion. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664EMgbrq9sn73lp1FhS9BB1ABw"></a>5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Walk-through and Punchlist</font><a name="_9kR3WTr2664EMgbrq9sn73lp1FhS9BB1ABw"></a>.&nbsp;&nbsp;After the Tenant Improvements are Substantially Completed and prior to Tenant&#8217;s move-in into the Expansion Premises, following two (2) days&#8217; advance written notice from Tenant to Landlord, Tenant shall cause the Contractor to inspect the Expansion Premises with a representative of Landlord and complete a punch list of unfinished items of the Tenant Improvements.&nbsp;&nbsp;After Landlord and Tenant have mutually agreed upon the punch list, authorized representatives for Landlord and Tenant shall execute said punch list.&nbsp;&nbsp;The items listed on such punch list shall be completed by the Contractor within thirty (30) days after the approval of such punch list or as soon thereafter as reasonably practicable, provided that in the event a punch list item reasonably requires longer than thirty (30) days to complete, then Tenant shall cause Contractor to commence the completion of such particular item within thirty (30) days and diligently pursue the same to completion.&nbsp;&nbsp;The terms of this Section 5.3 will not affect the occurrence of the Substantial Completion of the Expansion Premises or the occurrence of the Expansion Premises Rent Commencement Date. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant Changes</font>.&nbsp;&nbsp;Landlord shall reasonably approve any Tenant Change on the condition that Tenant shall pay in full, in advance (or cause to be paid in full from the Tenant Improvements Allowance), any and all additional costs or expenses associated with the approval of said Tenant Change. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr2664EOVI1qePGkp1F0"></a>5.5<font style="margin-left:-222pt;"></font><font style="text-decoration:underline;">Delay Not Caused by Parties</font><a name="_9kR3WTr2664EOVI1qePGkp1F0"></a>.&nbsp;&nbsp;Neither the Landlord nor Tenant shall be considered to be in default of the provisions of this Tenant Work Letter for delays in performance due to Force Majeure.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr266566WV10ruAI"></a>6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Entry Into the Expansion Premises</font><a name="_9kR3WTr266566WV10ruAI"></a>.&nbsp;&nbsp;As a condition to Tenant&#8217;s entry into the Expansion Premises, Tenant shall comply with and perform, and shall cause its employees, agents, contractors, subcontractors, material suppliers and laborers to comply with and perform, all of Tenant&#8217;s insurance and indemnity obligations and other obligations governing the conduct of Tenant at the Property under this Lease.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Representative</font>.&nbsp;&nbsp;Tenant has designated Sinu Bhandaru as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3<font style="margin-left:-222pt;"></font><font style="text-decoration:underline;">Landlord&#8217;s Representative</font>.&nbsp;&nbsp;Landlord has designated Jim McGlade as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Tenant Work Letter.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4<font style="margin-left:-222pt;"></font><font style="text-decoration:underline;">Intentionally omitted</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">General</font>.&nbsp;&nbsp;This Work Letter shall not be deemed applicable to any additional space added to the Expansion Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the Expansion Premises or any additions to the Expansion Premises in the event of a renewal or extension of the original Lease Term, whether by any options under the Lease or otherwise, unless and to the extent expressly provided in the Lease or any amendment or supplement to the Lease that such additional space is to be delivered to Tenant in the same condition the initial Expansion Premises is to be delivered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Insurance</font>.&nbsp;&nbsp;In addition to the requirements of Article 8.5 and Article 10 of the Lease, prior to the commencement of the Tenant Improvements, Tenant shall provide Landlord with evidence that Tenant carries Builder&#8217;s All Risk insurance in an amount reasonably approved by Landlord covering the construction of such Tenant Improvements, and such other insurance as Landlord may reasonably require, it being understood and agreed that all of such Tenant Improvements shall be insured by Tenant pursuant to Article 10 of the Lease immediately upon completion thereof. In addition, Tenant&#8217;s contractors, subcontractors, and architects shall be required to carry Commercial General Liability Insurance in an amount reasonably approved by Landlord and otherwise in accordance with the requirements of Article 10 of the Lease and such general liability insurance shall name the Landlord Parties as additional insureds. In addition, Tenant&#8217;s contractors and subcontractors shall be required to carry workers compensation insurance with a waiver of subrogation in favor of Landlord Parties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="text-decoration:underline;">ATTAC</font><font style="text-decoration:underline;">H</font><font style="text-decoration:underline;">MENT 1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FIT PLAN</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000007.jpg" title="" alt="" style="width:444px;height:681px;"><font style="font-weight:bold;">&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_9kR3WTr8HB4DGN04qlm51"></a><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="text-decoration:underline;">EXHIBIT D</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LIMITED OCCUPANCY SPACE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcilxvfwaiqx000008.jpg" title="" alt="" style="width:416px;height:706px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>6
<FILENAME>dtil-ex1019_945.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex1019_945.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.19</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Amended and Restated </p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Executive<font style="font-family:Times New Roman;text-transform:none;"> EMPLOYMENT AGREEMENT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amended and Restated Executive Employment Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made and entered into as of this 27th day of February, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), by and between Precision BioSciences, Inc. (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and David Thomson (&#8220;<font style="text-decoration:underline;">Executive</font>&#8221;).&nbsp;&nbsp;The Company and Executive are sometimes referred to in this Agreement individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Executive has been employed by the Company and subject to the terms of an Employment Agreement, dated July 3, 2017 (the &#8220;<font style="text-decoration:underline;">Prior Agreement</font>&#8221;), the terms of which are currently in effect. Executive and the Company wish to update the Prior Agreement, and provide for additional compensation and benefits to Executive. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Both Executive and the Company wish to continue the employment relationship on the updated terms set forth in this Agreement, which provide Executive with greater benefits than those under the Prior Agreement, some of which will be conditioned upon the Company&#8217;s consummation of its initial public offering (the &#8220;<font style="text-decoration:underline;">IPO</font>&#8221;), which offering will be effective with the filing of an effective registration statement under the Securities Act of 1933, as amended (the &#8220;<font style="text-decoration:underline;">Effective Date of the IPO</font>&#8221;).&nbsp;&nbsp;This Agreement is intended to replace and supersede the Prior Agreement as of the Effective Date of this Agreement.&nbsp;&nbsp; </p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in <font style="letter-spacing:-0.15pt;">consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, including the continued employment of the Executive by the Company and the compensation to be received by the Executive from the Company from time to time, and specifically the compensation to be received by the Executive pursuant to Section 4 hereof, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">EMPLOYMENT</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">As of the Effective Date, the Company hereby continues to employ the Executive and Executive hereby accepts employment as the Chief Development Officer of the Company upon the terms and conditions of this Agreement.&nbsp;&nbsp;As of the Effective Date, the parties agree that the Prior Agreement shall terminate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">NATURE OF EMPLOYMENT/DUTIES</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive shall serve as the Chief Development Officer of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive&#8217;s title and position.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># 7254994_4.Docx</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.2</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;"> shall devote substantially all working time, best efforts, knowledge and experience to perform successfully</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-weight:normal;">duties and advance the Company&#8217;s interests. </font><font style="font-family:Times New Roman;font-weight:normal;">During Executive&#8217;s employment, Executive may, with the Board&#8217;s consent (which shall not be unreasonably withheld), engage in other business activities </font><font style="font-family:Times New Roman;font-weight:normal;">for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the </font><font style="font-family:Times New Roman;font-weight:normal;">Restrictive Covenant Agreement (defined in S</font><font style="font-family:Times New Roman;font-weight:normal;">e</font><font style="font-family:Times New Roman;font-weight:normal;">ct</font><font style="font-family:Times New Roman;font-weight:normal;">i</font><font style="font-family:Times New Roman;font-weight:normal;">on </font><font style="font-family:Times New Roman;font-weight:normal;">6</font><font style="font-family:Times New Roman;font-weight:normal;">),</font><font style="font-family:Times New Roman;font-weight:normal;"> nor otherwise prohibit Executive from fulfilling</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-weight:normal;">obligations hereunder.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COMPENSATION</font><font style="font-family:Times New Roman;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Base Salary</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s initial annual base salary for all services rendered shall be Three Hundred Fifty Five Thousand and 00/100 Dollars ($355,000) (less applicable taxes and withholdings) payable in accordance with the Company&#8217;s payroll practices as they may exist from time to time (such salary, as adjusted in accordance with this Section 3.1, referred to herein as &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Base Salary</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;Effective as of the Effective Date of the IPO, Executive&#8217;s Base Salary shall be raised to Three Hundred Seventy Thousand and 00/100 Dollars ($370,000) (less applicable taxes and withholdings).&nbsp;&nbsp;Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company&#8217;s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Business Expenses</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time.&nbsp;&nbsp;All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Bonus</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans.</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">Effective as of the Effective Date of the IPO</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">, Executive&#8217;s annual incentive compensation under such bonus plan (the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Annual Bonus</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">&#8221;) shall be targeted at 35% of Executive&#8217;s Base Salary (such target, as may be increased by the Board from time to time, the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Target Annual Bonus</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">&#8221;). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive&#8217;s continued employment with the Company through the date of payment. </font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Equity</font><font style="font-family:Times New Roman;font-weight:normal;">. Executive shall be eligible to participate in any equity compensation plan or similar program adopted by the Company when approved by the Board and, if applicable, the Company&#8217;s shareholders, for executives at Executive&#8217;s level.&nbsp;&nbsp;The amount awarded, if any, to the Executive under any such plan shall be in the discretion of the Board or any committee administering such plan and shall be subject to the terms and conditions of any plan or program adopted or approved by the Board.&nbsp;&nbsp;  </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.5</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Benefits</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;"> may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;"> is eligible, provided, however, that </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;">&#8217;s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator&#8217;s discretion, as they may exist from time to time.&nbsp;&nbsp;The Company shall pay annual dues and expenses for </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;">&#8217;s membership and participation in such professional organizations as may be approved by the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">TERM OF EMPLOYMENT AND TERMINATION</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company and Executive acknowledge that Executive's employment is and shall continue to be &#8220;at-will,&#8221; as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive&#8217;s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4.&nbsp;&nbsp;The date on which Executive&#8217;s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Separation Date</font><font style="font-family:Times New Roman;font-weight:normal;">.&#8221;&nbsp;&nbsp;Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Without Cause, Upon Notice</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Either the Company or Executive may terminate Executive&#8217;s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days&#8217; written notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a814304"></a>4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">For Cause</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company may terminate Executive&#8217;s employment and this Agreement immediately without notice at any time for &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Cause</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a814304"></a>,&#8221; which shall mean the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a169380"></a>4.2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive's material failure to perform Executive&#8217;s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board of Directors <a name="a169380"></a>(other than any such failure resulting from incapacity due to physical or mental illness);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a368280"></a>4.2.2<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a368280"></a>Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a771579"></a>4.2.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">E</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a771579"></a>xecutive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a784851"></a>4.2.4<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a784851"></a>;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.5</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive&#8217;s failure to cooperate with the Company in any investigation or formal proceeding;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a521863"></a><a name="a45249"></a>4.2.6<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">Executive's material breach of any material obligation under this Agreement, the </font><font style="font-family:Times New Roman;font-weight:normal;">Restrictive Covenant Agreement (as defined in Section 6)</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">, or any other written agreement between t</font><font style="font-family:Times New Roman;font-weight:normal;">he Executive and the Company;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a45249"></a> or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.7<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">any material failure by</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"> Executive to comply with the Company's written policies or rules, as they may be in effect from time to time</font><font style="font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provided, however, that prior to termination based on Sections 4.2.1, 4.2.7 or 4.2.8, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a906391"></a>4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By Death or Disability</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s employment and this Agreement shall terminate upon Executive&#8217;s Disability or death.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Disability</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a906391"></a>&#8221; shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a635313"></a>4.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">For Good Reason</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may terminate Executive&#8217;s employment for &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Good Reason</font><font style="font-family:Times New Roman;font-weight:normal;">,&#8221; which </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a635313"></a>shall mean the occurrence of any of the following, in each case without the Executive's written consent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a998478"></a><a name="a699401"></a>4.4.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">a material reduction in Executive's Base Salary <a name="a998478"></a><a name="a699401"></a>other than a general reduction in Base Salary that affects all similarly situated executives;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a276193"></a>4.4.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">an involuntary </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">relocation of the Executive's principal place of employment by more than thirty five</font><font style="font-family:Times New Roman;font-weight:normal;"> (35) </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a276193"></a>miles; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a1034587"></a>4.4.3<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a1034587"></a>the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law</font><font style="font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive cannot terminate</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within thirty (30) days of the initial existence of such grounds and the Company has had at least </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thirty </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0) days from the date on which such notice is provided to cure such circumstances. If the Executive does not terminate</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">emp</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loyment for Good Reason within sixty </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right to terminate for Good Reason with respect to such grounds</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COMPENSATION AND BENEFITS UPON TERMINATION</font><font style="font-family:Times New Roman;font-weight:normal;">. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Accrued Obligations</font><font style="font-family:Times New Roman;font-weight:normal;">"). Except as otherwise expressly required by law (</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">e.g</font><font style="font-family:Times New Roman;font-weight:normal;">., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By the Company for Cause or because of Executive&#8217;s Death or Disability, or by Executive Without Cause, Upon Notice</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If Executive&#8217;s employment and this Agreement are terminated by the Company for Cause or because of Executive&#8217;s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company&#8217;s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By the Company Without Cause or by Executive for Good Reason</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;If the Company terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive&#8217;s continued compliance with Executive&#8217;s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>5.2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">pay Executive an amount equal to nine (9) months of Executive&#8217;s then current monthly base salary (less applicable taxes and withholdings (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Severance Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive&#8217;s separation from service and commencing on the first such payroll date on or following the date on which the release of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">claims required by Section 5.5</font><font style="font-family:Times New Roman;font-weight:normal;"> becomes effective and non-revocable, but not later than ninety (90) days following termination from employment; provided however that if the 90th day following </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;">&#8217;s termination from employment occurs in the year following the year in which </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;">&#8217;s termination&nbsp;&nbsp;occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided further that if such payments commence in such subsequent year, the first such payment shall be a lump sum in an amount equal to the payments that would have come due since </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;">&#8217;s separation from s</font><font style="font-family:Times New Roman;font-weight:normal;">ervice, and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">COBRA</font><font style="font-family:Times New Roman;font-weight:normal;">"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive for and the monthly premium amount paid by Executive immediately prior to the date that Executive&#8217;s employment terminated.&nbsp;&nbsp;Such reimbursement shall be paid to the Executive on or before the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the twelfth-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">ACA</font><font style="font-family:Times New Roman;font-weight:normal;">"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Following a Change in Control, by the Company Without Cause or by Executive for Good Reason</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If within three (3) month prior to or twelve (12) months following the occurrence of a Change in Control, as defined herein, either the Company terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any benefits under Section 5.2, and subject to Executive&#8217;s continue compliance with Executive&#8217;s obligations under the Restrictive Covenant Agreement, the Company shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">The Company shall pay Executive an amount equal to twelve (12) months of Executive&#8217;s then current monthly base salary (less applicable taxes and withholdings) (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">CIC Severance Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;) plus 1 times Executive&#8217;s target bonus for the year during which the Separation Date occurs, payable in lump sum Seventy-five (75) days following the Separation Date;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.2</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If Executive timely and properly elects health continuation coverage under </font><font style="font-family:Times New Roman;font-weight:normal;">COBRA</font><font style="font-family:Times New Roman;font-weight:normal;">, </font><font style="font-family:Times New Roman;font-weight:normal;">during the CIC Severance Period, </font><font style="font-family:Times New Roman;font-weight:normal;">the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive for and the monthly premium amount paid by Executive immediately prior to the date that Executive&#8217;s employment terminated.&nbsp;&nbsp;Such reimbursement shall be paid to the Executive on or before the tenth (10</font><font style="font-family:Times New Roman;font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="font-family:Times New Roman;font-weight:normal;">) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence </font><font style="font-family:Times New Roman;font-weight:normal;">in the month following the month the release under Section 5.4 becomes effective and non-revocable.</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive shall be eligible to receive such reimbursement until the earliest of: (i) the twelfth-month anniversary of the </font><font style="font-family:Times New Roman;font-weight:normal;">Separation </font><font style="font-family:Times New Roman;font-weight:normal;">Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company's making</font><font style="font-family:Times New Roman;font-weight:normal;"> payments under this Section 5.3</font><font style="font-family:Times New Roman;font-weight:normal;">.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties </font><font style="font-family:Times New Roman;font-weight:normal;">agree to reform this Section 5.3</font><font style="font-family:Times New Roman;font-weight:normal;">.2 in a manner as is necessary to comply with the ACA. Executive</font><font style="font-family:Times New Roman;font-weight:normal;"> shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage</font><font style="font-family:Times New Roman;font-weight:normal;">; an</font><font style="font-family:Times New Roman;font-weight:normal;">d</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Definition of Change in Control</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Change in Control</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; means and includes each of the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, &#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of Directors (the &#8220;</font><font style="text-decoration:underline;">Board</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">together with any new </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irector(s) </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Board </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(other than a </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irector designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) or (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)) whose election by the Board or nomination for election by the Company&#8217;s </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holders was approved by a vote of at least two-thirds of the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irectors then still in office who either were </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irectors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<font style="text-decoration:underline;">Successor Entity</font>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Notwithstanding the foregoing, (i) a Change in Control shall not include an IPO (referenced in Background, Section B of this Agreement); and (ii) if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Code</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), and the regulations thereunder (collectively, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Section 409A</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.3</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">The </font><font style="font-family:Times New Roman;font-weight:normal;">Company </font><font style="font-family:Times New Roman;font-weight:normal;">shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Required Release</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, the Company&#8217;s obligation to provide the payments and reimbursements under Sections 5.2.1, 5.2.2, 5.3.1 and 5.3.2 is conditioned upon Executive&#8217;s execution of a standard form of an enforceable release of claims and Executive&#8217;s compliance with the Restrictive Covenant Agreement.&nbsp;&nbsp;If Executive chooses not to execute such a release or fails to comply with the Restrictive Covenant Agreement, then the Company&#8217;s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time.&nbsp;&nbsp;The release of claims shall be provided to Executive within ten (10) days of Executive&#8217;s separation from service and Executive must execute it within the time period specified in the release (which shall not be longer than forty-five (45) days from the date of receipt).&nbsp;&nbsp;Such release shall not be effective until any applicable revocation period has expired.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Benefits in Lieu of Other Severance</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive is not entitled to receive any compensation or benefits upon Executive&#8217;s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Restrictive Covenants</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive shall continue to be obligated under the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, dated July 3, 2017 (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Restrictive Covenant Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;). Executive agrees to abide by the terms of the Restrictive Covenant Agreement, or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement, or any subsequent similar agreement, will survive the termination of Executive's employment and/or the termination of this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">7.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Company Property</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Upon the termination of </font><font style="font-family:Times New Roman;font-weight:normal;">Executive&#8217;s </font><font style="font-family:Times New Roman;font-weight:normal;">employment or upon Company&#8217;s earlie</font><font style="font-family:Times New Roman;font-weight:normal;">r request</font><font style="font-family:Times New Roman;font-weight:normal;">, </font><font style="font-family:Times New Roman;font-weight:normal;">Executive</font><font style="font-family:Times New Roman;font-weight:normal;"> shall:&nbsp;&nbsp;(i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to </font><font style="font-family:Times New Roman;font-weight:normal;">t</font><font style="font-family:Times New Roman;font-weight:normal;">rade </font><font style="font-family:Times New Roman;font-weight:normal;">s</font><font style="font-family:Times New Roman;font-weight:normal;">ecrets or </font><font style="font-family:Times New Roman;font-weight:normal;">c</font><font style="font-family:Times New Roman;font-weight:normal;">onfidential </font><font style="font-family:Times New Roman;font-weight:normal;">i</font><font style="font-family:Times New Roman;font-weight:normal;">nformation, including all copies thereof, which are in</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-weight:normal;">possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-weight:normal;">possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s </font><font style="font-family:Times New Roman;font-weight:normal;">work and transferring that work to other individuals designated by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">EMPLOYEE REPRESENTATION</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive represents and warrants that Executive&#8217;s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Amendments; Waivers</font><font style="font-family:Times New Roman;font-weight:normal;">. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="font-style:italic;font-family:Times New Roman;font-weight:normal;">provided, however</font><font style="font-family:Times New Roman;font-weight:normal;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">ENTIRE AGREEMENT</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written, with respect to Executive&#8217;s employment with the Company; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter.&nbsp;&nbsp;Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid.&nbsp;&nbsp;No change or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">SEVERABILITY</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">12.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Assignment and Successors</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;">indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">GOVERNING LAW</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Applicable Federal Law</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction.&#160;Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COUNTERPARTS</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Notices</font><font style="font-family:Times New Roman;font-weight:normal;">. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If to the Company, to the Chief Executive Officer of the Company at the Company's headquarters,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If to Executive, to the last address that the Company has in its personnel records for Executive, or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">At any other address as any Party shall have specified by notice in writing to the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>16.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">SECTION 409A OF THE INTERNAL REVENUE CODE</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The parties intend that the provisions of this Agreement comply with Section 409A of the Code and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Separation from Service</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following&nbsp;&nbsp;a termination of employment unless such termination also constitutes a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Separation from Service</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; &#8220;separation from service&#8221; or like terms shall mean Separation from Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Separate Payments</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Delayed Distribution to Specified Employee</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company&#8217;s sole discretion, that Executive is a Specified Employee of the Company on the date Executive&#8217;s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the date of termination of Executive&#8217;s employment (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">409A Delay Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Specified Employee</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; shall mean an employee who, on an Identification Date (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Identification Date</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof.&nbsp;&nbsp;If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a745504"></a><a name="a175349"></a><a name="a416975"></a>16.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;"> Reimbursements</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a745504"></a>To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following:&nbsp;&nbsp;(a) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;<a name="a175349"></a> (b) any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and<a name="a416975"></a> (c) any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Parachute Payments</font><font style="font-family:Times New Roman;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">Notwithstanding</font><font style="font-family:Times New Roman;font-weight:normal;"> any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under</font><font style="font-family:Times New Roman;font-weight:normal;"> Section 5</font><font style="font-family:Times New Roman;font-weight:normal;"> hereof, being hereinafter referred to as the </font><font style="font-family:Times New Roman;font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Total Payments</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;</font><font style="font-family:Times New Roman;font-weight:normal;">), would be subject (in whole or in part) to the excise tax imposed by</font><font style="font-family:Times New Roman;font-weight:normal;"> Section 4999 of the Code (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Excise Tax</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;</font><font style="font-family:Times New Roman;font-weight:normal;">), then the Total Payments shall be reduced (in the order provided in</font><font style="font-family:Times New Roman;font-weight:normal;"> Section 16.1</font><font style="font-family:Times New Roman;font-weight:normal;">) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Order of Reduction</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code, (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Determinations</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Independent Advisors</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Additional Reductions.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 17, the excess amount shall be returned promptly by Executive to the Company.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[The remainder of this page is intentionally left blank.]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-style:italic;">Signature Page for </font><font style="font-style:italic;">Amended and Restated </font><font style="font-style:italic;">Executive </font><font style="font-style:italic;">Employment Agreement</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">David Thomson</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Thomson</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Precision Biosciences, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matthew Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">Amendment to</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:12pt;font-style:normal;font-variant: normal;">Amended and Restated Employment Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment to<font style="text-transform:uppercase;"> </font>the Amended and Restated Employment Agreement (&#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;) is effective on the 30th day of September, 2019<font style="letter-spacing:-0.15pt;"> (the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;">Effective Date</font><font style="letter-spacing:-0.15pt;">&#8221;)</font><font style="font-weight:bold;letter-spacing:-0.15pt;"> </font>by and between Precision BioSciences, Inc. (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and David Thomson (&#8220;<font style="text-decoration:underline;">Executive</font>&#8221;).&nbsp;&nbsp;The Company and Executive are sometimes referred to in this Agreement individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221;&nbsp;&nbsp;Capitalized terms not defined herein shall have the meaning given to them in the Employment Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive and the Company entered into an Amended and Restated Employment Agreement as of February 27, 2019 (the &#8220;<font style="text-decoration:underline;">Employment Agreement</font>&#8221;).&nbsp;&nbsp;Executive and the Company wish to amend the Employment Agreement to reflect Executive&#8217;s appointment as the Chief Operating Officer of the Company.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual terms and conditions set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree that the Employment Agreement is hereby amended as follows:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Nature of Employment/Duties</font><font style="text-transform:uppercase;">.&nbsp;&nbsp;</font>As of the Effective Date, Section 2 of the Employment Agreement shall be amended to provide that Executive will serve as the &#8220;Chief Operating Officer (&#8220;<font style="text-decoration:underline;">COO</font>&#8221;)&#8221; of the Company and references to &#8220;Chief Development Officer&#8221; shall be deleted.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compensation</font>.&nbsp;&nbsp;Beginning on October 1, 2019, Executive&#8217;s Base Salary under Section 3.1 of the Employment Agreement shall be Four Hundred Fifteen Thousand and 00/100 Dollars ($415,000) (less applicable withholdings), and Executive&#8217;s Target Annual Bonus shall be 40%<font style="letter-spacing:-0.15pt;"> of Executive&#8217;s Base Salary.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Effective Date of this Amendment</font>.&nbsp;&nbsp;This Amendment will become effective as of the Effective Date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Effect of Amendment</font>.&nbsp;&nbsp;Except as amended by this Amendment, the Employment Agreement shall remain in full force and effect in accordance with its terms.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts</font>.&nbsp;&nbsp;This Amendment may be executed in more than one counterpart, each of which shall be deemed an original, and all of which shall be deemed a single agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:12pt;font-weight:normal;text-transform:none;font-variant: normal;">(Signature Page Follows)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;">(Signature page to Amendment to </font><font style="font-style:italic;">Amended and Restated Employment Agreement</font><font style="font-style:italic;">)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have entered into this Amendment to Amended and Restated Employment Agreement as of the day and year first written above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">David Thomson</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Thomson</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Precision Biosciences, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matthew Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>7
<FILENAME>dtil-ex1021_743.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex1021_743.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Executive<font style="font-family:Times New Roman;text-transform:none;"> EMPLOYMENT AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Executive Employment Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made and entered into as of this <font style="text-decoration:underline;">1st</font> day of May, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;),  by and between Precision BioSciences, Inc. (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Christopher Heery (&#8220;<font style="text-decoration:underline;">Executive</font>&#8221;).&nbsp;&nbsp;The Company and Executive are sometimes referred to in this Agreement individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company wishes to employ Executive on the terms set forth in this Agreement, and Executive wishes to accept such employment on the same terms.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in <font style="letter-spacing:-0.15pt;">consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">EMPLOYMENT</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">As of the Effective Date, the Company hereby employs Executive and Executive hereby accepts employment as the Chief Medical Officer of the Company upon the terms and conditions of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">NATURE OF EMPLOYMENT/DUTIES</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive shall serve as the Chief Medical Officer of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive&#8217;s title and position.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:75pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:75pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive shall devote substantially all working time, best efforts, knowledge and experience to perform successfully Executive&#8217;s duties and advance the Company&#8217;s interests. During Executive&#8217;s employment, Executive may, with the Board&#8217;s consent (which shall not be unreasonably withheld), engage in other business activities for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the Restrictive Covenant Agreement (defined in Section 6), nor otherwise prohibit Executive from fulfilling Executive&#8217;s obligations hereunder.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COMPENSATION</font><font style="font-family:Times New Roman;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Base Salary</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s annual base salary for all services rendered shall be Four Hundred Thirty Thousand and 00/100 Dollars ($430,000.00) (less applicable taxes and withholdings) payable in accordance with the Company&#8217;s payroll practices as they may exist from time to time (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Base Salary</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company&#8217;s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># 7294063_3.Docx</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.2</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Business Expenses</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time.&nbsp;&nbsp;All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Bonus</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans.</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s annual incentive compensation under the bonus plan (the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Annual Bonus</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">&#8221;) shall be targeted at 35% of Executive&#8217;s Base Salary (the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Target Annual Bonus</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">&#8221;). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive&#8217;s continued employment with the Company through the date of payment. </font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Equity</font><font style="font-family:Times New Roman;font-weight:normal;">. Executive shall be eligible to participate in any equity compensation plan or similar program adopted by the Company when approved by the Board and, if applicable, the Company&#8217;s shareholders, for executives at Executive&#8217;s level.&nbsp;&nbsp;The amount awarded, if any, to the Executive under any such plan shall be in the discretion of the Board or any committee administering such plan and shall be subject to the terms and conditions of any plan or program adopted or approved by the Board. </font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Subject to approval by the Board, the Company will make an initial grant to Executive of no less than 180,000 options to purchase shares of common stock of the Company, priced at fair market value at the time of grant.&#160; Such grant will be effective when made and shall be subject to terms and conditions to be imposed by the Board under the Company&#8217;s plans, programs or applicable award agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.5<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Benefits</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which Executive is eligible, provided, however, that Executive&#8217;s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator&#8217;s discretion, as they may exist from time to time.&nbsp;&nbsp;The Company shall pay annual dues and expenses for Executive&#8217;s membership and participation in such professional organizations as may be approved by the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">TERM OF EMPLOYMENT AND TERMINATION</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company and Executive acknowledge that Executive's employment is and shall continue to be &#8220;at-will,&#8221; as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive&#8217;s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4.&nbsp;&nbsp;The date on which Executive&#8217;s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Separation Date</font><font style="font-family:Times New Roman;font-weight:normal;">.&#8221;&nbsp;&nbsp;Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.1</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Without Cause, Upon Notice</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Either the Company or Executive may terminate Executive&#8217;s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days written notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a814304"></a>4.2<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">For Cause</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company may terminate Executive&#8217;s employment and this Agreement immediately without notice at any time for &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Cause</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a814304"></a>,&#8221; which shall mean the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a169380"></a>4.2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a169380"></a>Executive's material failure to perform Executive&#8217;s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board of Directors (other than any such failure resulting from incapacity due to physical or mental illness);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a368280"></a>4.2.2<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a368280"></a>Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a771579"></a>4.2.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">E</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a771579"></a>xecutive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a784851"></a>4.2.4<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a784851"></a>;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.5<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive&#8217;s failure to cooperate with the Company in any investigation or formal proceeding;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a521863"></a><a name="a45249"></a>4.2.6<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">Executive's material breach of any material obligation under this Agreement, the </font><font style="font-family:Times New Roman;font-weight:normal;">Restrictive Covenant Agreement (as defined in Section 6)</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">, or any other written agreement between t</font><font style="font-family:Times New Roman;font-weight:normal;">he Executive and the Company;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a45249"></a> or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.7<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">any material failure by</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"> Executive to comply with the Company's written policies or rules, as they may be in effect from time to time</font><font style="font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provided, however, that prior to termination based on Sections 4.2.1, 4.2.6 or 4.2.7, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a906391"></a><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>4.3<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By Death or Disability</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s employment and this Agreement shall terminate upon Executive&#8217;s Disability or death.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Disability</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a906391"></a>&#8221; shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;"> The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a635313"></a>4.4<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">For Good Reason</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may terminate Executive&#8217;s employment for &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Good Reason</font><font style="font-family:Times New Roman;font-weight:normal;">,&#8221; which </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a635313"></a>shall mean the occurrence of any of the following, in each case without the Executive's written consent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a998478"></a><a name="a699401"></a>4.4.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a998478"></a><a name="a699401"></a>a material reduction in Executive's Base Salary other than a general reduction in Base Salary that affects all similarly situated executives;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a276193"></a>4.4.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">an involuntary </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">relocation of the Executive's principal place of employment by more than thirty five</font><font style="font-family:Times New Roman;font-weight:normal;"> (35) </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a276193"></a>miles; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a1034587"></a>4.4.3<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a1034587"></a>the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law</font><font style="font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive cannot terminate Executive&#8217;s employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within thirty (30) days of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances. If the Executive does not terminate Executive&#8217;s employment for Good Reason within sixty (60) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived Executive&#8217;s right to terminate for Good Reason with respect to such grounds.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COMPENSATION AND BENEFITS UPON TERMINATION</font><font style="font-family:Times New Roman;font-weight:normal;">. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Accrued Obligations</font><font style="font-family:Times New Roman;font-weight:normal;">"). Except as otherwise expressly required by law (</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">e.g</font><font style="font-family:Times New Roman;font-weight:normal;">., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.1</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By the Company for Cause or because of Executive&#8217;s Death or </font><font style="text-decoration:underline;font-family:Times New Roman;">Disability, or </font><font style="text-decoration:underline;font-family:Times New Roman;">by Executive Without Cause, Upon Notice</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If Executive&#8217;s employment and this Agreement are terminated by the Company for Cause or because of Executive&#8217;s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company&#8217;s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By the Company Without Cause or by Executive for Good Reason</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;If the Company terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive&#8217;s continued compliance with Executive&#8217;s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">pay Executive an amount equal to nine (9) months of Executive&#8217;s then current monthly base salary (less applicable taxes and withholdings (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Severance Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive&#8217;s separation from service and commencing on the first such payroll date on or following the date on which the release of claims required by Section 5.5 becomes effective and non-revocable, but not later than ninety (90) days following termination from employment; provided however that if the 90th day following Executive&#8217;s termination from employment occurs in the year following the year in which Executive&#8217;s termination&nbsp;&nbsp;occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided further that if such payments commence in such subsequent year, the first such payment shall be a lump sum in an amount equal to the payments that would have come due since Executive&#8217;s separation from service, and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">COBRA</font><font style="font-family:Times New Roman;font-weight:normal;">"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive for and the monthly premium amount paid by Executive immediately prior to the date that Executive&#8217;s employment terminated.&nbsp;&nbsp;Such reimbursement shall be paid to the Executive on or before the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the twelfth-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">ACA</font><font style="font-family:Times New Roman;font-weight:normal;">"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Following a Chang</font><font style="text-decoration:underline;font-family:Times New Roman;">e</font><font style="text-decoration:underline;font-family:Times New Roman;"> in Control, by the Company Without Cause or by </font><font style="text-decoration:underline;font-family:Times New Roman;">Executive</font><font style="text-decoration:underline;font-family:Times New Roman;"> for Good Reason</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If within three (3) month prior to or twelve (12) months following the occurrence of a Change in Control, as defined herein, either the Company terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any benefits under Section 5.2, and subject to Executive&#8217;s continue compliance with Executive&#8217;s obligations under the </font><font style="font-family:Times New Roman;font-weight:normal;">Restrictive Covenant Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">,</font><font style="font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">the Company shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">The Company shall pay Executive an amount equal to twelve (12)</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;font-weight:normal;">months of Executive&#8217;s then current monthly base salary (less applicable taxes and withholdings) (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">CIC Severance Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;) plus one (1) times Executive&#8217;s target bonus for the year during which the Separation Date occurs, payable in lump sum Seventy-five (75) days following the Separation Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If Executive timely and properly elects health continuation coverage under COBRA, during the CIC Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive for and the monthly premium amount paid by Executive immediately prior to the date that Executive&#8217;s employment terminated.&nbsp;&nbsp;Such reimbursement shall be paid to the Executive on or before the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence in the month following the month the release under Section 5.4 becomes effective and non-revocable. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the twelfth-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company's making payments under this Section 5.3.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.3.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Definition of Change in Control</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Change in Control</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; means and includes each of the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:72pt;"></font>A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, &#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:72pt;"></font>During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board of Directors (the &#8220;<font style="text-decoration:underline;">Board</font>&#8221;) together with any new director(s) of the Board (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:72pt;"></font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<font style="text-decoration:underline;">Successor Entity</font>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="text-decoration:underline;">provided</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="text-decoration:underline;">however</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that no person or group shall be treated for purposes of this clause (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consummation of the transaction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Notwithstanding the foregoing, (i) a Change in Control shall not include an IPO (referenced in Background, Section B of this Agreement); and (ii) if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Code</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), and the regulations thereunder (collectively, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Section 409A</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">The Company shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Required Release</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, the Company&#8217;s obligation to provide the payments and reimbursements under Sections 5.2.1, 5.2.2, 5.3.1 and 5.3.2 is conditioned upon Executive&#8217;s execution of a standard form of an enforceable release of claims and Executive&#8217;s compliance with the Restrictive Covenant Agreement.&nbsp;&nbsp;If Executive chooses not to execute such a release or fails to comply with the Restrictive Covenant Agreement, then the Company&#8217;s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time.&nbsp;&nbsp;The release of claims shall be provided to Executive within ten (10) days of Executive&#8217;s separation from service and Executive must execute it within the time period specified in the release (which shall not be longer than forty-five (45) days from the date of receipt).&nbsp;&nbsp;Such release shall not be effective until any applicable revocation period has expired.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.6<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Benefits in Lieu of Other Severance</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive is not entitled to receive any compensation or benefits upon Executive&#8217;s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">6.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Restrictive Covenants</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-weight:normal;">As a condition of employment, </font><font style="font-family:Times New Roman;font-weight:normal;">Executive </font><font style="font-family:Times New Roman;font-weight:normal;">will </font><font style="font-family:Times New Roman;font-weight:normal;">be obligated under the </font><font style="font-family:Times New Roman;font-weight:normal;">Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">, </font><font style="font-family:Times New Roman;font-weight:normal;">executed simultaneously herewith (</font><font style="font-family:Times New Roman;font-weight:normal;">th</font><font style="font-family:Times New Roman;font-weight:normal;">e</font><font style="font-family:Times New Roman;font-weight:normal;"> &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Restrictive Covenant</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;"> Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;)</font><font style="font-family:Times New Roman;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive agrees to abide by the terms of the Restrictive Covenant Agreement, </font><font style="font-family:Times New Roman;font-weight:normal;">or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of</font><font style="font-family:Times New Roman;font-weight:normal;"> which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">, or any subsequent similar agreement,</font><font style="font-family:Times New Roman;font-weight:normal;"> will survive the termination of Executive's employment and</font><font style="font-family:Times New Roman;font-weight:normal;">/or the termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Company Property</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Upon the termination of Executive&#8217;s employment or upon Company&#8217;s earlier request, Executive shall:&nbsp;&nbsp;(i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to trade secrets or confidential information, including all copies thereof, which are in Executive&#8217;s possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in Executive&#8217;s possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up Executive&#8217;s work and transferring that work to other individuals designated by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">EMPLOYEE REPRESENTATION</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive represents and warrants that Executive&#8217;s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Amendments; Waivers</font><font style="font-family:Times New Roman;font-weight:normal;">. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="font-style:italic;font-family:Times New Roman;font-weight:normal;">provided, however</font><font style="font-family:Times New Roman;font-weight:normal;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">ENTIRE AGREEMENT</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written, with respect to Executive&#8217;s employment with the Company; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter.&nbsp;&nbsp;Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid.&nbsp;&nbsp;No change or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">11.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">SEVERABILITY</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Assignment and Successors</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;">indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">GOVERNING LAW</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Applicable Federal Law</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction.&#160;Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COUNTERPARTS</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Notices</font><font style="font-family:Times New Roman;font-weight:normal;">. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.1<font style="margin-left:75pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If to the Company, to the Chief Executive Officer of the Company at the Company's headquarters,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.2<font style="margin-left:75pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If to Executive, to the last address that the Company has in its personnel records for Executive, or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.3<font style="margin-left:75pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">At any other address as any Party shall have specified by notice in writing to the other Party.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">SECTION 409A OF THE INTERNAL REVENUE CODE</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The parties intend that the provisions of this Agreement comply with Section 409A of the Code and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.1<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Separation from Service</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following&nbsp;&nbsp;a termination of employment unless such termination also constitutes a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Separation from Service</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; &#8220;separation from service&#8221; or like terms shall mean Separation from Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.2<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Separate Payments</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.3<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Delayed Distribution to Specified Employee</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company&#8217;s sole discretion, that Executive is a Specified Employee of the Company on the date Executive&#8217;s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the date of termination of Executive&#8217;s employment (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">409A Delay Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Specified Employee</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; shall mean an employee who, on an Identification Date (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Identification Date</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof.&nbsp;&nbsp;If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><a name="a745504"></a><a name="a175349"></a><a name="a416975"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.4</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;"> </font><font style="text-decoration:underline;font-family:Times New Roman;">Reimbursements</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a745504"></a>To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided i</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">n accordance with the following:&nbsp;&nbsp;(a) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a175349"></a> (b) </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">any reimbursement of an eligi</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">ble expense shall be paid to</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"> Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a416975"></a> (c) </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Parachute Payments</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 5 hereof, being hereinafter referred to as the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Total Payments</font><font style="font-family:Times New Roman;font-weight:normal;">"), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Excise Tax</font><font style="font-family:Times New Roman;font-weight:normal;">"), then the Total Payments shall be reduced (in the order provided in Section 16.1) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.1<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Order of Reduction</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code, (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.2<font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Determinations</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Independent Advisors</font><font style="font-family:Times New Roman;font-weight:normal;">"). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.3</font><font style="margin-left:75pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Additional Reductions.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this </font><font style="font-family:Times New Roman;font-weight:normal;">Section 17</font><font style="font-family:Times New Roman;font-weight:normal;">, the excess amount shall be returned promptly by Executive to the Company.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[The remainder of this page is intentionally left blank.]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-style:italic;">Signature Page for </font><font style="font-style:italic;">Executive </font><font style="font-style:italic;">Employment Agreement</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Christopher Heery</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Heery __May 1, 2019</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Precision Biosciences, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matthew Kane</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CEO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>8
<FILENAME>dtil-ex1022_742.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex1022_742.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.22</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:0pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Executive<font style="font-family:Times New Roman;text-transform:none;"> EMPLOYMENT AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Executive Employment Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made and entered into as of this <font style="text-decoration:underline;">15th</font> day of March, 2019 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;),  by and between Precision BioSciences, Inc. (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and Dario Scimeca (&#8220;<font style="text-decoration:underline;">Executive</font>&#8221;).&nbsp;&nbsp;The Company and Executive are sometimes referred to in this Agreement individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BACKGROUND</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company wishes to employ Executive on the terms set forth in this Agreement, and Executive wishes to accept such employment on the same terms.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in <font style="letter-spacing:-0.15pt;">consideration of the foregoing, of the mutual promises herein, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">EMPLOYMENT</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">As of the Effective Date, the Company hereby employs Executive and Executive hereby accepts employment as the General Counsel of the Company upon the terms and conditions of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">NATURE OF EMPLOYMENT/DUTIES</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive shall serve as the General Counsel of the Company and shall have such responsibilities and authority as the Company may designate from time to time consistent with Executive&#8217;s title and position.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive shall perform all duties and exercise all authority in accordance with, and otherwise comply with, all Company policies, procedures, practices and directions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive shall devote substantially all working time, best efforts, knowledge and experience to perform successfully Executive&#8217;s duties and advance the Company&#8217;s interests. During Executive&#8217;s employment, Executive may, with the Board&#8217;s consent (which shall not be unreasonably withheld), engage in other business activities for compensation (including board memberships), provided that, such activities do not present a conflict of interest nor violate the Restrictive Covenant Agreement (defined in Section 6), nor otherwise prohibit Executive from fulfilling Executive&#8217;s obligations hereunder.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COMPENSATION</font><font style="font-family:Times New Roman;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Base Salary</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s annual base salary for all services rendered shall be Three Hundred Ten Thousand and 00/100 Dollars ($310,000.00) (less applicable taxes and withholdings) payable in accordance with the Company&#8217;s payroll practices as they may exist from time to time (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Base Salary</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;Base Salary may be reviewed and adjusted by the Company, at its discretion, in accordance with the Company&#8217;s policies, procedures, and practices as they may exist from time to time, provided that the Base Salary shall not be decreased unless the decrease is an across-the-board decrease for all senior management employees of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Business Expenses</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive shall be reimbursed for reasonable and necessary expenses actually incurred by Executive in performing services under this Agreement </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">in accordance with and subject to the terms and conditions of the applicable Company reimbursement policies, procedures, and practices as they may exist from time to time.&nbsp;&nbsp;All such reimbursements shall be made no later than the end of the calendar year following the year in which the expense was incurred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Bonus</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may participate in any Company bonus plan the Company may adopt for senior management subject to the terms, conditions, and any eligibility requirements that may exist in such plan or plans.</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;"> Executive&#8217;s annual incentive compensation under the bonus plan (the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Annual Bonus</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">&#8221;) shall be targeted at 35% of Executive&#8217;s Base Salary (the &#8220;</font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Target Annual Bonus</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">&#8221;). The Annual Bonus payable under the bonus plan shall be based on the achievement of performance goals to be determined by the Board. The payment of any Annual Bonus pursuant to the bonus plan shall be subject to Executive&#8217;s continued employment with the Company through the date of payment. </font><font style="text-decoration:underline;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Equity</font><font style="font-family:Times New Roman;font-weight:normal;">. Executive shall be eligible to participate in any equity compensation plan or similar program adopted by the Company when approved by the Board and, if applicable, the Company&#8217;s shareholders, for executives at Executive&#8217;s level.&nbsp;&nbsp;The amount awarded, if any, to the Executive under any such plan shall be in the discretion of the Board or any committee administering such plan and shall be subject to the terms and conditions of any plan or program adopted or approved by the Board. </font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;">Subject to approval by the Board, the Company will make an initial grant to Executive of no fewer than 140,000 options to purchase shares of common stock of the Company, priced at fair market value at the time of grant.&#160; Such grant will be effective when made and shall be subject to terms and conditions to be imposed by the Board under the Company&#8217;s plans, programs or applicable award agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">3.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Benefits</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may participate in all medical, dental and disability insurance, 401(k), personal leave and other employee benefit plans and programs of the Company for which Executive is eligible, provided, however, that Executive&#8217;s participation in benefit plans and programs is subject to the applicable terms, conditions and eligibility requirements of these plans and programs, some of which are within the plan administrator&#8217;s discretion, as they may exist from time to time.&nbsp;&nbsp;The Company shall pay annual dues and expenses for Executive&#8217;s membership and participation in such professional organizations as may be approved by the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">TERM OF EMPLOYMENT AND TERMINATION</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company and Executive acknowledge that Executive's employment is and shall continue to be &#8220;at-will,&#8221; as defined under applicable law, and that Executive's employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of this Section 4). This "at-will" nature of Executive's employment shall remain unchanged during Executive's tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement and Executive&#8217;s employment hereunder shall commence on the Effective Date and continue until terminated as set forth in this Section 4.&nbsp;&nbsp;The date on which Executive&#8217;s employment terminates, as determined by the Company, regardless of the reason, shall be referred to herein as the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Separation Date</font><font style="font-family:Times New Roman;font-weight:normal;">.&#8221;&nbsp;&nbsp;Upon termination of Executive's employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.1</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Without Cause, Upon Notice</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Either the Company or Executive may terminate Executive&#8217;s employment and this Agreement without Cause at any time upon giving the other party thirty (30) days written notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a814304"></a>4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">For Cause</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company may terminate Executive&#8217;s employment and this Agreement immediately without notice at any time for &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Cause</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a814304"></a>,&#8221; which shall mean the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a169380"></a>4.2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a169380"></a>Executive's material failure to perform Executive&#8217;s duties or to carryout the reasonable and lawful instructions of the Chief Executive Officer or the Board of Directors (other than any such failure resulting from incapacity due to physical or mental illness);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a368280"></a>4.2.2<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a368280"></a>Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, materially injurious to the Company or its affiliates;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a771579"></a>4.2.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">E</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a771579"></a>xecutive's embezzlement, misappropriation, or fraud, whether or not related to the Executive's employment with the Company;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a784851"></a>4.2.4<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a784851"></a>;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.5<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Executive&#8217;s failure to cooperate with the Company in any investigation or formal proceeding;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a521863"></a><a name="a45249"></a>4.2.6<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">Executive's material breach of any material obligation under this Agreement, the </font><font style="font-family:Times New Roman;font-weight:normal;">Restrictive Covenant Agreement (as defined in Section 6)</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">, or any other written agreement between t</font><font style="font-family:Times New Roman;font-weight:normal;">he Executive and the Company;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a45249"></a> or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">4.2.7<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">any material failure by</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"> Executive to comply with the Company's written policies or rules, as they may be in effect from time to time</font><font style="font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provided, however, that prior to termination based on Sections 4.2.1, 4.2.7 or 4.2.8, Executive shall be given written notice of the facts allegedly constituting Cause and a ten (10) day opportunity to cure.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a906391"></a><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By Death or Disability</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s employment and this Agreement shall terminate upon Executive&#8217;s Disability or death.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Disability</font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a906391"></a>&#8221; shall mean Executive's inability, due to physical or mental incapacity, to perform the essential functions of Executive's job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period; provided however, in the event that the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement.</font><font style="font-family:Times New Roman;font-weight:normal;"> The Company shall give Executive written notice of termination for Disability and the termination shall be effective as of the date specified in such notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a635313"></a>4.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">For Good Reason</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive may terminate Executive&#8217;s employment for &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Good Reason</font><font style="font-family:Times New Roman;font-weight:normal;">,&#8221; which </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a635313"></a>shall mean the occurrence of any of the following, in each case without the Executive's written consent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a998478"></a><a name="a699401"></a>4.4.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;"><a name="a998478"></a><a name="a699401"></a>a material reduction in Executive's Base Salary other than a general reduction in Base Salary that affects all similarly situated executives;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a276193"></a>4.4.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">an involuntary </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">relocation of the Executive's principal place of employment by more than thirty five</font><font style="font-family:Times New Roman;font-weight:normal;"> (35) </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a276193"></a>miles; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a1034587"></a>4.4.3<font style="margin-left:36pt;"></font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a1034587"></a>the Company's failure to obtain an agreement from any successor to the Company to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law</font><font style="font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive cannot terminate Executive&#8217;s employment for Good Reason unless Executive has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within thirty (30) days of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances. If the Executive does not terminate Executive&#8217;s employment for Good Reason within sixty (60) days after the first occurrence of the applicable grounds, then the Executive will be deemed to have waived Executive&#8217;s right to terminate for Good Reason with respect to such grounds.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COMPENSATION AND BENEFITS UPON TERMINATION</font><font style="font-family:Times New Roman;font-weight:normal;">. If Executive's employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. Upon termination of Executive's employment pursuant to any of the circumstances listed in Section 4, Executive (or Executive's estate) shall be entitled to receive the sum of: (i) the portion of Executive's Base Salary earned through the Separation Date, but not yet paid to Executive; (ii) any expense reimbursements owed to Executive pursuant to Section 3.2; and (iii) any amount accrued and arising from Executive's participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Accrued Obligations</font><font style="font-family:Times New Roman;font-weight:normal;">"). Except as otherwise expressly required by law (</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">e.g</font><font style="font-family:Times New Roman;font-weight:normal;">., COBRA) or as specifically provided herein, all of Executive's rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive's employment hereunder. In the event that Executive's employment is terminated by the Company for any reason, Executive's sole and exclusive remedy shall be to receive the payments and benefits described in this Section 5.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.1</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By the Company for Cause or because of Executive&#8217;s Death or </font><font style="text-decoration:underline;font-family:Times New Roman;">Disability, or </font><font style="text-decoration:underline;font-family:Times New Roman;">by Executive Without Cause, Upon Notice</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If Executive&#8217;s employment and this Agreement are terminated by the Company for Cause or because of Executive&#8217;s death or Disability, or by Executive pursuant to Section 4.1 (Without Cause, Upon Notice), then the Company&#8217;s obligation to compensate Executive ceases on the Separation Date except for the Accrued Obligations.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">By the Company Without Cause or by Executive for Good Reason</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;If the Company terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.4 (for Good Reason), subject to Executive&#8217;s continued compliance with Executive&#8217;s obligations under the Restrictive Covenant Agreement then the Company shall pay Executive the Accrued Obligations and subject to Section 5.5 (Required Release), Executive shall be entitled to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.2.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">pay Executive an amount equal to nine (9) months of Executive&#8217;s then current monthly base salary (less applicable taxes and withholdings (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Severance Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), payable in substantially equal monthly installments on the same payroll schedule applicable to Executive immediately prior to Executive&#8217;s separation from service and commencing on the first such payroll date on or following the date on which the release of claims required by Section 5.5 becomes effective and non-revocable, but not later than ninety (90) days following termination from employment; provided however that if the 90th day following Executive&#8217;s termination from employment occurs in the year following the year in which Executive&#8217;s termination&nbsp;&nbsp;occurs, then the payments shall commence no earlier than January 1 of such subsequent year and provided further that if such payments commence in such subsequent year, the first such payment shall be a lump sum in an amount equal to the payments that would have come due since Executive&#8217;s separation from service, and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>5.2.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">COBRA</font><font style="font-family:Times New Roman;font-weight:normal;">"), during the Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive for and the monthly premium amount paid by Executive immediately prior to the date that Executive&#8217;s employment terminated.&nbsp;&nbsp;Such reimbursement shall be paid to the Executive on or before the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the month immediately following the month in which the Executive timely remits the premium payment, with such reimbursements to commence when the payments under Section 5.2.1 commence. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the twelfth-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company's making payments under this Section 5.2.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">ACA</font><font style="font-family:Times New Roman;font-weight:normal;">"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2.2 in a manner as is necessary to comply with the ACA. Executive shall provide </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Following a Change in Control, by the Company Without Cause or by Executive for Good Reason</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If within three (3) month prior to or twelve (12) months following the occurrence of a Change in Control, as defined herein, either the Company terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.1 (Without Cause, Upon Notice) or Executive terminates Executive&#8217;s employment and this Agreement pursuant to Section 4.4 (for Good Reason), then in lieu of any benefits under Section 5.2, and subject to Executive&#8217;s continue compliance with Executive&#8217;s obligations under the Restrictive Covenant Agreement, the Company shall pay Executive the Accrued Obligations and, subject to Section 5.5 (Required Release), Executive shall be entitled to the following:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">The Company shall pay Executive an amount equal to twelve (12)</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;font-weight:normal;">months of Executive&#8217;s then current monthly base salary (less applicable taxes and withholdings) (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">CIC Severance Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;) plus one (1) times Executive&#8217;s target bonus for the year during which the Separation Date occurs, payable in lump sum Seventy-five (75) days following the Separation Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If Executive timely and properly elects health continuation coverage under COBRA, during the CIC Severance Period, the Company shall reimburse Executive for the difference between the monthly COBRA premium paid by the Executive for and the monthly premium amount paid by Executive immediately prior to the date that Executive&#8217;s employment terminated.&nbsp;&nbsp;Such reimbursement shall be paid to the Executive on or before the tenth (10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day of the month immediately following the month in which Executive timely remits the premium payment, with such reimbursements to commence in the month following the month the release under Section 5.4 becomes effective and non-revocable. Executive shall be eligible to receive such reimbursement until the earliest of: (i) the twelfth-month anniversary of the Separation Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source.&nbsp;&nbsp;Notwithstanding the foregoing, if the Company's making payments under this Section 5.3.2 would violate the nondiscrimination rules applicable to non-grandfathered plans under the ACA, or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.3.2 in a manner as is necessary to comply with the ACA. Executive shall provide the Company with notice of subsequent employment and comparable coverage within thirty (30) days of commencement of such comparable coverage; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.3.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">All unvested time-based equity grants shall vest in full as of the Separation Date, provided that such equity shall remain subject to the other terms and conditions of the applicable Company incentive award plan(s) and individual award agreement(s).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Definition of Change in Control</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.1</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;">&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Change in Control</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; means and includes each of the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection&#160;(c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections&#160;13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;)) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; provided, however, that for purposes of this Agreement, &#8220;<font style="text-decoration:underline;">Subsidiary</font>&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board of Directors (the &#8220;<font style="text-decoration:underline;">Board</font>&#8221;) together with any new director(s) of the Board (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case other than a transaction:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:46.15%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<font style="text-decoration:underline;">Successor Entity</font>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:46.15%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; </font><font style="text-decoration:underline;">provided</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="text-decoration:underline;">however</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that no person or group shall be treated for purposes of this clause (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consummation of the transaction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">Notwithstanding the foregoing, (i) a Change in Control shall not include an IPO (referenced in Background, Section B of this Agreement); and (ii) if a Change in Control constitutes a payment event under this Agreement that provides for the deferral of compensation that is subject to Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Code</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), and the regulations thereunder (collectively, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Section 409A</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;), to the extent required to avoid the imposition of additional taxes under Section&#160;409A, the transaction or event described in subsection&#160;(a), (b) or (c) with respect to such payment (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:23.08%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.4.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">The Company shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Required Release</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, the Company&#8217;s obligation to provide the payments and reimbursements under Sections 5.2.1, 5.2.2, 5.3.1 and 5.3.2 is conditioned upon Executive&#8217;s execution of a standard form of an enforceable release of claims and Executive&#8217;s compliance with the Restrictive Covenant Agreement.&nbsp;&nbsp;If Executive chooses not to execute such a release or fails to comply with the Restrictive Covenant Agreement, then the Company&#8217;s obligation to compensate Executive ceases on the Separation Date except as to amounts due at the time.&nbsp;&nbsp;The release of claims shall be provided to Executive within ten (10) days of Executive&#8217;s separation from service and Executive must execute it within the time period specified in the release (which shall not be longer than forty-five (45) days from the date of receipt).&nbsp;&nbsp;Such release shall not be effective until any applicable revocation period has expired.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Benefits in Lieu of Other Severance</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive is not entitled to receive any compensation or benefits upon Executive&#8217;s termination except as: (i) set forth in this Agreement; (ii) otherwise required by law; or (iii) otherwise required by any employee benefit plan in which Executive participates. Moreover, the terms and conditions afforded Executive under this Agreement are in lieu of any severance benefits to which Executive otherwise might be entitled pursuant to any severance plan, policy and practice of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Restrictive Covenants</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-weight:normal;"> As a condition of employment, Executive will be obligated under the Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, executed simultaneously herewith (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Restrictive Covenant </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;)</font><font style="font-family:Times New Roman;font-weight:normal;">.</font><font style="font-family:Times New Roman;font-weight:normal;"> Executive agrees to abide by the terms of the Restrictive Covenant Agreement, </font><font style="font-family:Times New Roman;font-weight:normal;">or any other subsequent agreement with the Company relating to proprietary information, inventions, intellectual property, non-competition or non-solicitation, the terms of</font><font style="font-family:Times New Roman;font-weight:normal;"> which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement</font><font style="font-family:Times New Roman;font-weight:normal;">, or any subsequent similar agreement,</font><font style="font-family:Times New Roman;font-weight:normal;"> will survive the termination of Executive's employment and</font><font style="font-family:Times New Roman;font-weight:normal;">/or the termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Company Property</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Upon the termination of Executive&#8217;s employment or upon Company&#8217;s earlier request, Executive shall:&nbsp;&nbsp;(i) deliver to the Company all records, memoranda, data, documents and other property of any description which refer or relate in any way to trade secrets or confidential information, including all copies thereof, which are in Executive&#8217;s possession, custody or control; (ii) deliver to the Company all Company property (including, but not limited to, keys, credit cards, customer files, contracts, proposals, work in process, manuals, forms, computer-stored work in process and other computer data, research materials, other items of business information concerning any Company customer, or Company business or business methods, including all copies thereof) which is in Executive&#8217;s possession, custody or control; (iii) bring all such records, files and other materials up to date before returning them; and (iv) fully cooperate with the Company in winding up Executive&#8217;s work and transferring that work to other individuals designated by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">EMPLOYEE REPRESENTATION</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Executive represents and warrants that Executive&#8217;s employment and obligations under this Agreement will not (i) breach any duty or obligation Executive owes to another or (ii) violate any law, recognized ethics standard or recognized business custom.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Amendments; Waivers</font><font style="font-family:Times New Roman;font-weight:normal;">. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="font-style:italic;font-family:Times New Roman;font-weight:normal;">provided, however</font><font style="font-family:Times New Roman;font-weight:normal;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">ENTIRE AGREEMENT</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Except as expressly provided in this Agreement, this Agreement: (i) supersedes and cancels all other understandings and agreements, oral or written, with respect to Executive&#8217;s employment with the Company; (ii) supersedes all other understandings and agreements, oral or written, between the parties with respect to the subject matter of this Agreement; and (iii) constitutes the sole agreement between the parties with respect to this subject matter.&nbsp;&nbsp;Each party acknowledges that: (i) no representations, inducements, promises or agreements, oral or written, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement; and (ii) no agreement, statement or promise not contained in this Agreement shall be valid.&nbsp;&nbsp;No change or modification of this Agreement shall be valid or binding upon the parties unless such change or modification is in writing and is signed by the parties.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">11.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">SEVERABILITY</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;">Assignment and Successors</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;margin-left:36pt;">indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive's rights or obligations may be assigned or transferred by Executive, other than Executive's rights to payments hereunder, which may be transferred only by will or operation of law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">GOVERNING LAW</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;This Agreement shall be construed, interpreted, and governed in accordance with and by North Carolina law and the applicable provisions of federal law (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Applicable Federal Law</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort, or statute, shall be governed by the laws of the state of North Carolina, including its statutes of limitations, except for Applicable Federal Law, without giving effect to any North Carolina conflict-of-laws rule that would result in the application of the laws of a different jurisdiction.&#160;Both Executive and the Company acknowledge and agree that the state or federal courts located in North Carolina have personal jurisdiction over them and over any dispute arising under this Agreement, and both Executive and the Company irrevocably consent to the jurisdiction of such courts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">COUNTERPARTS</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Notices</font><font style="font-family:Times New Roman;font-weight:normal;">. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.1<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If to the Company, to the Chief Executive Officer of the Company at the Company's headquarters,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.2<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">If to Executive, to the last address that the Company has in its personnel records for Executive, or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">15.3<font style="margin-left:36pt;"></font><font style="font-family:Times New Roman;font-weight:normal;">At any other address as any Party shall have specified by notice in writing to the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>16.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">SECTION 409A OF THE INTERNAL REVENUE CODE</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;The parties intend that the provisions of this Agreement comply with Section 409A of the Code and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. If any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause Executive to incur any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-weight:normal;">additional tax or interest under Section 409A, the Company shall, upon the specific request of Executive, use its reasonable business efforts to in good faith reform such provision to comply with Code Section 409A; provided, that to the maximum extent practicable, the original intent and economic benefit to Executive and the Company of the applicable provision shall be maintained, and the Company shall have no obligation to make any changes that could create any additional economic cost or loss of benefit to the Company. The Company shall timely use its reasonable business efforts to amend any plans and programs in which Executive participates to bring it in compliance with Section 409A. Notwithstanding the foregoing, the Company shall have no liability with regard to any failure to comply with Section 409A so long as it has acted in good faith with regard to compliance therewith.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Separation from Service</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following&nbsp;&nbsp;a termination of employment unless such termination also constitutes a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Separation from Service</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment,&#8221; &#8220;separation from service&#8221; or like terms shall mean Separation from Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Separate Payments</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Each installment payment required under this Agreement shall be considered a separate payment for purposes of Section 409A.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">16.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Delayed Distribution to Specified Employee</font><font style="font-family:Times New Roman;">.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;If the Company determines in accordance with Sections 409A and 416(i) of the Code and the regulations promulgated thereunder, in the Company&#8217;s sole discretion, that Executive is a Specified Employee of the Company on the date Executive&#8217;s employment with the Company terminates and that a delay in benefits provided under this Agreement is necessary to comply with Code Section 409A(A)(2)(B)(i), then any severance payments and any continuation of benefits or reimbursement of benefit costs provided by this Agreement, and not otherwise exempt from Section 409A, shall be delayed for a period of six (6) months following the date of termination of Executive&#8217;s employment (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">409A Delay Period</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221;).&nbsp;&nbsp;In such event, any severance payments and the cost of any continuation of benefits provided under this Agreement that would otherwise be due and payable to Executive during the 409A Delay Period shall be paid to Executive in a lump sum cash amount in the month following the end of the 409A Delay Period.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Specified Employee</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; shall mean an employee who, on an Identification Date (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Identification Date</font><font style="font-family:Times New Roman;font-weight:normal;">&#8221; shall mean each December 31) is a specified employee as defined in Section 416(i) of the Code without regard to paragraph (5) thereof.&nbsp;&nbsp;If Executive is identified as a Specified Employee on an Identification Date, then Executive shall be considered a Specified Employee for purposes of this Agreement during the period beginning on the first April 1 following the Identification Date and ending on the following March 31.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="a745504"></a><a name="a175349"></a><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><a name="a416975"></a>16.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;"> Reimbursements</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a745504"></a>To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following:&nbsp;&nbsp;(a) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;<a name="a175349"></a> (b) any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">calendar year in which the expense was incurred; and</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;"><a name="a416975"></a> (c) </font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit</font><font style="color:#000000;font-family:Times New Roman;font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;text-transform:uppercase;font-family:Times New Roman;">Parachute Payments</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section 5 hereof, being hereinafter referred to as the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Total Payments</font><font style="font-family:Times New Roman;font-weight:normal;">"), would be subject (in whole or in part) to the excise tax imposed by Section 4999 of the Code (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Excise Tax</font><font style="font-family:Times New Roman;font-weight:normal;">"), then the Total Payments shall be reduced (in the order provided in Section 16.1) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Order of Reduction</font><font style="font-family:Times New Roman;font-weight:normal;">.&nbsp;&nbsp;The Total Payments shall be reduced in the following order: (i) reduction on a pro-rata basis of any cash severance payments that are exempt from Section 409A of the Code, (ii) reduction on a pro-rata basis of any non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro-rata basis of any other payments or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Determinations</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-weight:normal;">All determinations regarding the application of this Section 17 shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the "</font><font style="text-decoration:underline;font-family:Times New Roman;font-weight:normal;">Independent Advisors</font><font style="font-family:Times New Roman;font-weight:normal;">"). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent Advisors, (i) does not constitute a "parachute payment" within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the "base amount" (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">17.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;font-family:Times New Roman;">Additional Reductions.</font><font style="font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and intent of this Section 17, the excess amount shall be returned promptly by Executive to the Company.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[The remainder of this page is intentionally left blank.]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[</font><font style="font-style:italic;">Signature Page for </font><font style="font-style:italic;">Executive </font><font style="font-style:italic;">Employment Agreement</font><font style="letter-spacing:-0.15pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have entered into this Agreement on the day and year first written above.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk34554488"></a>&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Dario Scimeca</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Dario Scimeca</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Precision Biosciences, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="middle"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Michael Nicholson</p></td>
</tr>
<tr>
<td valign="middle"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="middle"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief People Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>dtil-ex211_699.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex211_699.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES OF PRECISION BIOSCIENCES, INC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal Name of Subsidiary</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Organization</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elo Life Systems, Inc.</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elo Life Systems Australia Pty Ltd</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Queensland, Australia</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences UK Limited</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">England and Wales</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>dtil-ex231_741.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex231_741.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#666666;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#666666;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We consent to the incorporation by reference in Registration Statement No. 333-230671 on Form S-8 of our report dated March 9, 2020, relating to the financial statements of Precision BioSciences, Inc., appearing in this Annual Report on Form 10-K for the year ended December 31, 2019. </font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#666666;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">/s/ Deloitte &amp; Touche LLP</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#666666;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Raleigh, North Carolina</font><font style="Background-color:#FFFFFF;font-family:Arial;font-size:11pt;"><br /></font><font style="Background-color:#FFFFFF;">March 9, 2020 </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:-5.75pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>dtil-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Matthew Kane, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2019 of Precision BioSciences, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">[intentionally omitted];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>dtil-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Abid Ansari, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2019 of Precision BioSciences, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">[intentionally omitted];</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.43%;text-indent:-5.43%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Abid Ansari</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>dtil-ex321_6.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex321_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Precision BioSciences, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>dtil-ex322_7.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex322_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Precision BioSciences, Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Abid Ansari</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gvxjy5si4hmk000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'L HL# 2(  A$! Q$!_\0
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MOQU\<=9\*^--2T2VTJPFAM'55DE+[CE%;G!QWKW2OCGXQ_\ )6=>_P"ND?\
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MO$/_ $!-,_.3_P"*KQ6B@#VK_AI+Q#_T!-,_.3_XJC_AI+Q#_P! 33/SD_\
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M/_BJ/^&DO$/_ $!-,_.3_P"*KQ6B@#VK_AI+Q#_T!-,_.3_XJC_AI+Q#_P!
M33/SD_\ BJ\5HH ]J_X:2\0_] 33/SD_^*H_X:2\0_\ 0$TS\Y/_ (JO%:*
M/:O^&DO$/_0$TS\Y/_BJ/^&DO$/_ $!-,_.3_P"*KQ6B@#VK_AI+Q#_T!-,_
M.3_XJC_AI+Q#_P! 33/SD_\ BJ\5HH ]J_X:2\0_] 33/SD_^*H_X:2\0_\
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MW\<:5/\ %K6/$I=[.SN+6XC@9D)8L8=B$A<X+$ ^V:\RHHH'<****!!1110
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M/\'7[N>1Z9/K67110![A^S7_ ,C!KO\ UZQ_^A&OH^OG#]FO_D8-=_Z]8_\
MT(U]'T %%%% !1110 5\<_&/_DK.O?\ 72/_ -%)7V-7E'BOX&:;XK\3WNN3
MZS=P27;*S1I&I"X4+P3]* /E>BOH_P#X9KTC_H8+[_ORE'_#->D?]#!??]^4
MH ^<**^C_P#AFO2/^A@OO^_*4?\ #->D?]#!??\ ?E* /G"BOH__ (9KTC_H
M8+[_ +\I1_PS7I'_ $,%]_WY2@#YPHKZ/_X9KTC_ *&"^_[\I1_PS7I'_0P7
MW_?E* /G"BOH_P#X9KTC_H8+[_ORE'_#->D?]#!??]^4H ^<**^C_P#AFO2/
M^A@OO^_*4?\ #->D?]#!??\ ?E* /G"BOH__ (9KTC_H8+[_ +\I1_PS7I'_
M $,%]_WY2@#YPHKZ/_X9KTC_ *&"^_[\I1_PS7I'_0P7W_?E* /G"BOH_P#X
M9KTC_H8+[_ORE'_#->D?]#!??]^4H ^<**^C_P#AFO2/^A@OO^_*4?\ #->D
M?]#!??\ ?E* /G"BOH__ (9KTC_H8+[_ +\I1_PS7I'_ $,%]_WY2@#YPHKZ
M/_X9KTC_ *&"^_[\I1_PS7I'_0P7W_?E* /G"BOH_P#X9KTC_H8+[_ORE'_#
M->D?]#!??]^4H ^<**^C_P#AFO2/^A@OO^_*4?\ #->D?]#!??\ ?E* /G"B
MOH__ (9KTC_H8+[_ +\I1_PS7I'_ $,%]_WY2@#YPHKZ/_X9KTC_ *&"^_[\
MI1_PS7I'_0P7W_?E* /G"BOH_P#X9KTC_H8+[_ORE'_#->D?]#!??]^4H ^<
M**^C_P#AFO2/^A@OO^_*4?\ #->D?]#!??\ ?E* /G"BOH__ (9KTC_H8+[_
M +\I1_PS7I'_ $,%]_WY2@#YPHKZ/_X9KTC_ *&"^_[\I1_PS7I'_0P7W_?E
M* /G"BOH_P#X9KTC_H8+[_ORE'_#->D?]#!??]^4H ^<**^C_P#AFO2/^A@O
MO^_*4?\ #->D?]#!??\ ?E* /G"BOH__ (9KTC_H8+[_ +\I1_PS7I'_ $,%
M]_WY2@#YPHKZ/_X9KTC_ *&"^_[\I1_PS7I'_0P7W_?E* /G"BOH_P#X9KTC
M_H8+[_ORE'_#->D?]#!??]^4H ^<**^C_P#AFO2/^A@OO^_*4?\ #->D?]#!
M??\ ?E* /G"BOH__ (9KTC_H8+[_ +\I1_PS7I'_ $,%]_WY2@#YPHKZ/_X9
MKTC_ *&"^_[\I1_PS7I'_0P7W_?E* /G"BOH_P#X9KTC_H8+[_ORE'_#->D?
M]#!??]^4H ^<**^C_P#AFO2/^A@OO^_*4?\ #->D?]#!??\ ?E* /G"BOH__
M (9KTC_H8+[_ +\I1_PS7I'_ $,%]_WY2@#YPHKZ/_X9KTC_ *&"^_[\I1_P
MS7I'_0P7W_?E* /G"BOH_P#X9KTC_H8+[_ORE'_#->D?]#!??]^4H ^<**^C
M_P#AFO2/^A@OO^_*4?\ #->D?]#!??\ ?E* /G"BOH__ (9KTC_H8+[_ +\I
M1_PS7I'_ $,%]_WY2@#YPHKZ/_X9KTC_ *&"^_[\I1_PS7I'_0P7W_?E* /G
M"BOH_P#X9KTC_H8+[_ORE'_#->D?]#!??]^4H P/V:_^1@UW_KUC_P#0C7T?
M7 ?#[X667P^OKRZM=2N+MKJ)8V65%4+@YSQ7?T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9T3L?$ETFYM@LX
M2%SP"7ER<?@/RH T:*BN21:S$'!"-@CZ56T9F?0M/=V+,UM&2Q.23M% %ZBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,!4_P */^$?T7_H#Z=_X"I_A6/^MU+_ )]/[_\ @%?49=S?\VR_Z&Z3_O\
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M_P!O_P#$5@?\(_HO_0'T[_P%3_"E7P_HNX?\2?3NO_/JG^%'^MU+_GT_O_X
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M.K?+CAM@4G/3-:/AK5]3U=;QM1TPV/E2[(P=V2.>N1SCCD<'-5?$'B"6SN+
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M"N5(P,=:@T6[\6W.HV<.I+<Q6KK(LDHA"G,BET/3Y2F-GU/-=Y10!B^%!?\
M_".VSZI+<27C[FD^T*%8<G P ,# K:HHH **** "BBB@ K!U'Q']@.MC[+O_
M ++M$N?OX\S<'..G'W/UK>KGM:AM8]0\\^%YM3FF@,4D\*0_<Z;&WNI(Y/'(
MH8T9]QXUN;6"":72EV"S:\N0961D0/LPJL@+'G.#C/:NKCG$PE\M'W1G;\ZE
M0QP#P>XYZCWKDL6N;8_\(!>'[*,092U/E\YX_>\<\UH1ZU=PM(T?A'5D:5M[
MD-;_ #-@#)_>^@'Y4"*<_C9H=&T^_P#[.#-<0RW$L?GX\N.,@/@X^8_,,#C-
M7]7\13V%K?7%M9)<1VCK&Q>;9N8C) X.3DJH ZLWM5&6>.>"WAE\"W[Q6S[X
M49;;$;>H'F\43SI=6GV6Y\#ZE-!YIFV2&W8;R2=W,O7)- &K#JJ0ZK/8RVB6
MT4=H+TR;AQN8[@1C@@@\Y.:J/XEN(;NQCFTT+#=6[W#%9LR(JJ6)*8Z !022
M.7 &:AFOWN%<2^#-4;?$(6.;<$H#G;GS>GM2/>&744U!_!.I->(FQ9S]FWA?
M3/F].3Q0"$M/&,MSIOVE]-5'6YMXGC$^X!)@I5@=O) <9'UYJY:>)OM/BZZT
M/[(52%25N-_#L A('&,_.. 21CD#(JE;W"6EJ;6W\"W\5N9!*8U6V"[P00V/
M-ZY _(4Z.],6HR:A'X)U);R0;7F'V;<1QW\WV'Y"CJ!BW7_'WXN_[!=Q_P"A
M25Y6OW%^E>BW-YJ)3Q/>GP]J(@EL[B!F+P_NV^9B6'F= &'3->8K<R[1_H4_
M3U7_ !KLPKLF>EE\DE*_D6J*K?:I?^?*?\U_QH^U2_\ /E/^:_XUU<R/1YU_
M299HJM]JE_Y\I_S7_&HS>S_:X8OL4H23[SMCY?RS1S(3J17_  S+M%%%46%%
M%% "K]X?6J>CSR2:5 TK&0DMDN<G[Q[T^YO%M""8V?Y2YVD< $#OWR146D1O
M'I-NKJ5;!8@]LL2/YU+LY&;LYV_KH7V P&7[I_2FU#<W8M(06CDDWN%&P=#S
MR?056_M1?^>$GYBBZ6C'S):,OT53AU!)IEB\ME+=R1QP3_0U<III[%)I[!11
M13&%%%% !1110 R;_42?[I_E7JOAW_D%C_@'_HJ.O*IO]1)_NG^5=]X=N[J7
M49[!)E2&.VAE7Y ?F,<8.?:ODN,*?/@HZVM*_P"#.:L[5(_/]#K:*KQSNLHA
MN%"NWW&7[K_X'VJQ7Y?.#@[,I.X4445 PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "LW5]:M]&C5[B*9P59OW04D %1W(R<L  .36E6%K?&L:1
M_P!=/_:D5;4(QE42EM_P"9MI71K65W#?V,%Y;MNAGC$B-Z@C-4M<UZWT&&"2
MXM[J?SI#&B6T8<Y )R<D8'%5?!7_ ")&B_\ 7HE:J-YM\64_)"I3([L>OY ?
MK6GLH0K34E>,;_Y+\2>9N*MNSF_^%@6/_0)UC_OPG_Q=3VOC?3[H/BSOHBAP
M1,B(?PR_/X5T^YO4_G1N;U/YT.KA[:4__)O^ '+/N<Q?^)+2[T^XMXXI0\L;
M(I9X\ D8Y^>H;;7;:.UM=,:*9WEN/*W1[64AI"<\-D#'M76[F]3^=&X^IIQQ
M%.*24-G??K]P.#?42L+PZ6B^+%_$\;CSK99XWQ\K*$5#SZY!X^GK6[2V'_(S
MZ>/^F,__ +)7?P_/EQ\%;?3]?T,\4KTV:-G<O9Z+JUS'$LKPW-S($9MH;#$X
MS@X_*I;W76MO#$>LQVAD+Q1R>7N.$#XR6(!.U<Y) / Z55COX--T+4[JZB:6
M 7TR.B@'<&EV]_K5.[UC1K76-6L)-/9_L6G#SAN7:854OL5,],'TQTK].Z'D
M%_3_ !(]_+I -B8X]1M'N02^2A7;QC'((8$']*DT;7I]4TZ\G>Q,-U;,5:SW
M'S =H8*VX#!((]1SUIFG:OINIR#[19&TO+<K"(IU4LHE4$!2I(PP'KVYZ4L-
MSH>F:LOANW@AADN8FF>-0 I!XP?5B >/133?8$9L7C.>5M)B73U:XO99(YT1
MI";8H5RK#9G<-_.0 /7!KL*Y:&^TC2SIAM=&V6\UR]M!/$J *6;;GKG#%<\=
MES5BS\7V=Y;WDRVUP@@59(PX&9T9BJ%<'NRD8.#TI =#17/7'BN*UNKZWFTZ
M[62V5"@PI\[>^Q0.>,MTW8R,FI[3Q)!=OIBK;3K]O,J@MM_=/'G<K<]?E/3(
MXH VJ*R])U@ZI<7T+64UNUG*(G+LK!F(S@%2>@(S]:U* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .&U'6+*#0_%5@\DGVHBZ;8L+MPR
M$ Y QC(ZUX^OW1]*]4NO^/OQ=_V"[C_T*2O*U^XOTKMPFS/4R[:7R%HHHKK/
M1"BBB@ HHHH **** *%[_P ?$7^Z/_1B5?JA??\ 'Q%_NC_T8E7ZE;LE?$PI
M<GU-)15%%&;_ )#,'^Y_1ZO50F_Y#,'^Y_1ZOU*ZDQZA1115%!1110 4444
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ML<?4<UE/A2A&+E[1Z>A2QLF[6(_[5T[_ *"-G_W_ %_QH_M73?\ H(V?_?\
M7_&H#H&G9/[J7_P)D_\ BJ/[ T[_ )Y2_P#@3)_\57QO[CS_  .[WR?^U=-_
MZ"-G_P!_U_QH_M73?^@C9_\ ?]?\:@_L#3O^>4O_ ($R?_%54O\ 2[2S6VE@
M216-S&AW3.P()P0020:J,:$G9-_@#<D;BL&4,I!4C((.012U2TC_ ) FG_\
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MDYZUW]% '#V?C_PK80M%;1:HBM(TC?\ $LN269B2Q)*9))-6/^%F>'?35/\
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M)W?_ 'W1_:VJ?]!.[_[[JI175[.'9'H>QI_RK[BW_:VJ?]!.[_[[H_M;5/\
MH)W?_?=5**/9P[(/8T_Y5]Q;_M;5/^@G=_\ ?=5CK^K)=S1F_P!0=5"$;#G&
M<YIM0/;DS-(DTD98 $+C!Q]0:3IP[$NC3Z17W(M_\)!JG_/WJGY57EU.]FG$
MSW6J[AMR!T.T[ES]"<TS[/)_S]S_ ))_\31]GD_Y^Y_R3_XFE[./87L8?RK[
MD7!XAU4 @7FJC/7 ZTG_  D&J?\ /WJGY54^SR?\_<_Y)_\ $T?9Y/\ G[G_
M "3_ .)H]G'L'L8?RK[D6_\ A(-4_P"?O5/RI#XBU)1EKW4E&0,L.!DXJK]G
MD_Y^Y_R3_P")JO(7^RW"NY?9,J@L!G&4/;ZT<D>P.E!?97W(T?[>UG^T3;_V
MK=>5MW;=XZX^E6?[6U3_ *"=W_WW6-_S&S_N?TJ]35.'8<:-/7W5]Q;_ +6U
M3_H)W?\ WW1_:VJ?]!.[_P"^ZJ44_9P[(KV-/^5?<1#4M2_MDC^T;K )E'S#
M[VP+G.,].*T/[6U3_H)W?_?=8P_Y#3?[G]%J]25.'8B-&GK[J^XMG5=388.I
M71![%Z9]OO\ _G^N/^^A_A5>BG[.'9%^QI_RK[B634;]8G87]QD*2/F'^%>X
M>"I'FT+S9&+R.X9F/4DQIDUX/-_J)/\ =/\ *O=O O\ R+B?5?\ T6E<F*BH
MVLCSL?",>7E5MSI:***Y3SPKA/$FC0:3:P&&6>3<?+ E?=L5<D*..GS&N[KE
MO&P4VEMOFBA4%V,DS$(N%SR0"1T]#6=5.5.279CB[-$)ZFDK%/B*VS_Q^:5_
MX%2__&:3_A(K;_G\TK_P*E_^,U^9_P!@9C_SZ_%?YGK_ %FEW-NCKTK$_P"$
MBMO^?S2O_ J7_P",U2U74+/5;(VLNIZ7%'O220B]E5BH8<#]T.I('XTX\/Y@
MY).G9>J_S$\52MHSIO,C_P">B?\ ?0JO&5BO2B,I252^ >C#K^>:XZVTOPG#
M:0Q2Z?X9ED2-5>0E\N0,$_ZGO5^PE\.Z5.TNGQ>';29AM)AF=&(ZXXASCC]*
MZ?[!Q<%)*$G?_#\OM$?68.UW_7W'65#=VL=[:2VTI81RKM8J<$?0UE?\)%;?
M\_FE?^!4O_QFFOXGLXU!:^TGDD "[D)XQG@0Y[C\ZYED.9)W5/\ %?YE_6:7
M<U;2S6S67$LLK2R>8[RL"Q. .P'8"K%<]_PEMC_S^:;_ -_YO_C-'_"6V/\
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M&?\ ]DK#_P"$BMO^?S2O_ J7_P",U9T;6[.?Q39;[S3P%@G.8[AC_<_O(O\
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MD_\ 0:["N.^(O_($&,YVRXP,\[#CN.] '$%CN/)ZTFX^IK*,NMY/^CP_DO\
M\<I/-UK_ )]X?R7_ ..50C6W'U-96K$^?#R?N?\ M6*D\W6O^?>'\E_^.5%)
M!J=S*C3P(,84%2H &]&)/S'/"T ;98YZFLIB?^$F3D_ZK_V5JFNM4%M<-%_9
M^H3XYWP0;U_/-4K6>6\\0+-]@OH(A%R]Q#L&<$8Z^XH W-Q]365:$_VU/R>L
MW\XJU*RK7_D,S?6;^<5 &MN/J:-Q]3244 +N/J:-Q]3244 +N/J:-Q]3244
M+N/J:-Q]3244 +N/J:RM3)_M'3N3_K/_ &>.M2LK4_\ D(Z=_P!=/_9XZ -;
M<?4T;CZFDHH 7<?4T;CZFDHH 7<?4T;CZFDHH 7<?4UI^%(H[CQK:)-&DJ_8
M[@[74,/O1^M9=:_@_P#Y'BT_Z\[C_P!"CI,#MO"2JND2JJA5%W/@ 8 ^<UNU
MA^%/^05-_P!?<_\ Z&:W*0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,1GY?EY(]SUHM_&D]RND70-O'97EW+"V4)E.)=B#86!'^T0#@]L4=; =O17
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MBBBF 4444 %%%% !1110 455$MQ]N,9C_<Y^]L/3;G.[..O&*M4)@G<****
M"60>4Y=0V%/L37N_@N\O+WPU;M?/"\T8";H8RBE=JD<$GG!QU[5X+-_J)/\
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MO]GVWI-_X$2?_%4?V?;>DW_@1)_\50 G]J6/_/RO_?)_PH_M2Q_Y^5_[Y/\
MA2_V?;>DW_@1)_\ %4?V?;>DW_@1)_\ %4 )_:EC_P _*_\ ?)_PKG/&$\5W
MI@%NQEVE =JGC,T6.U;E[:+% K0),S&10V))7VJ>IVA@32V^GP7%I;O=6[^;
M\LA1Y7(5QR."QZ&D!I/]]OK526_M+6X,,]Q'&Y <*QYQTS],U:K&UZ&-8EN5
M4B9LQ%PQ&4VL<$=",\TP-FBG,K;C\IZ^E)M;^Z?RH 2BEVM_=/Y4;6_NG\J
M$K7\'_\ (\6G_7G<?^A1UD[6_NG\JUO!X(\<6F01_H=Q_P"A1TF!WVA?ZB]_
MZ_I__0S6K7-?;+G3M U2]M8UD>WO9I&1@>4$F7Q[[<X]ZQ[KQ[<VL6ESFWC,
M-T[7,V(W)BLR^U'..C$$-DX& :0SO:*Y.#Q4ROJMU>7=E'#8F<?8 #]HVQG
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M / 2/_"@".QT'1=/EAFCD\R:)Y7$DLVXLTFW<Q]3\HK9^U6__/>+_OL5E?\
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M_P#B*/\ A!](_NO_ -\1_P#Q%=+10!S7_"#Z1_=?_OB/_P"(H_X0?2/[K_\
M?$?_ ,172T4 <M<_#_0[NVEMIDD:*5"C@!%)!&#R%!'U%;2:'I*(J+IEF%4
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M 4444 %%%% '$WFB:;>:-XFNI[5#<%KE?. ^8 +Q^7I7"#X9>*<#F/\ ./\
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MX:2V5]@;#C<,8!]5(H]M4[A]9K?S,\^A^''B6X@CFC9"DBAU)\OH1D=ZBE\
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M5BP^(.@ZEJ%O8VLZRSSOL18[B&0YZYPDA...N* .JIDLT<$+S32)'&@W,[L
M%'J2>E/KG_%>KZ?8:>UKJ$=RT5S"[%H-H*A<9Y8@9Y&!STH VK:[MKV(RVMQ
M%/&#M+Q.&&?3(J:N/L?$VFZ;]H3;>RRR3%Y6FE@+;P I'#@# 4#'M5H^.--
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MT5.I*MAA[;AWKGM/T+Q5XCAM(V:3P]I-D[BTE)S>O W_ "S/]P8P/7Y5/.*
M#6/$>EV)DT^QEDNI;PKJ6D16B>9)#.3ED*_P@DYP>SN*?;:OXGT'7+?7-=L[
M?3]%U:98KBRC8.UM*5 65V[9P <<<=,UVGA[PEHOA>W,6EV:QNQ)>9_FD<DY
M)+'GKVZ5<UG2;;7-&NM,NUS#<1E#ZJ>Q'N#@_A0!?HKDO >K7-QIT^BZFW_$
MUTA_LT^?^6BC[C_0C^5=;0!Y_P"$HXY?'7BE)$5U\P':PR/]9)BN_50JA5
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MI0!LZ%_J+W_K^G_]#-:M96A?ZB]_Z_I__0S6K0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !116;?ZO'9R>0D;2W!Z( <?_7^@S0!I5E'7 T\T
M<&G7\XAD,;/&B[2PZXRPIMK#JEPYENK@P(V/W: ;L>G?'ZGZ4XZ&%GFD@U&_
M@$TAD9(W7:&/7&5- !_;,O\ T!M3_P"^$_\ BZ/[9E_Z VI_]\)_\71_8TO_
M $&=3_[[3_XBC^QI?^@SJ?\ WVG_ ,10 ?VS+_T!M3_[X3_XNC^V9?\ H#:G
M_P!\)_\ %T?V-+_T&=3_ .^T_P#B*/[&E_Z#.I_]]I_\10 ?VS+_ - ;4_\
MOA/_ (NC^V9?^@-J?_?"?_%U%/IPM8_,GUW447IS(G/L/DY-986_O9MFG:AJ
M956YDD>/'T/R8'ZGV% %JPCEU+0M;BCB:&6XGN$5)^"I(P-V,_UKF+OP]X@T
M>&^OK?4KFUMFD:XDAMIE8Y/7 *#)P .HSBNML_#<UL)6;6M1WS2&5PC(%#'K
MC*Y_.I;CP]]JMY()M7U-HI!M9?,09'X+0!RG]E^(O^@YXD_\!H?_ (NC^RO$
M7_0<\2?^ T/_ ,773_\ ",0_\_\ >_\ D/\ ^(H_X1B'_G_O?_(?_P 10!SV
MDZ59>'[J":+1+^\U>[EV&_U.1=Q;:6/S9;;]T\ 5T=UJVJ6,*SW&D1M%YB1D
M076]_F8*, H >3ZBH)_#$2!+A+O49)8&\R-8GB5MV".,J!T)ZFJMSI]S=P^3
M<0^(9(]RMM,UKC*D,/XO4"@#7_MF7_H#:G_WPG_Q=']LR_\ 0&U/_OA/_BZQ
MO[*D_P"?37/^^[3_ !H_LJ3_ )]-<_[[M/\ &@"C?Q7Q\>:9J^E:?-;W$T3P
M7<=V1&D\:C(Y7=\P/3BNH^U:U_T"K7_P-/\ \;K#&D2"YBN%M=>66+(1EEM1
MC/![U9\F_P#[OB+_ +_6O^- %'1=%U[2?$.K:F]G8R+?ME8UNV!3YF;G]W_M
M?I6]'K-V%Q/H=^LH)#"/8Z\'J&W#(/7H*S_)O_[OB+_O]:_XT>3?_P!WQ%_W
M^M?\: -+^V9?^@-J?_?"?_%T?VS+_P! ;4_^^$_^+K-\F_\ [OB+_O\ 6O\
MC1Y-_P#W?$7_ '^M?\: -+^V9?\ H#:G_P!\)_\ %T?VS+_T!M3_ .^$_P#B
MZS?)O_[OB+_O]:_XT>3?_P!WQ%_W^M?\: -"36;K8?(T/4'E/"J_EHN?<[C@
M?@:?]JUK_H%6O_@:?_C=9GDW_P#=\1?]_K7_ !H\F_\ [OB+_O\ 6O\ C0!I
M_:M:_P"@5:_^!I_^-UE6=IKMGJM[??V=9N+CH@O3D<Y_YYT[R;_^[XB_[_6O
M^-'DW_\ =\1?]_K7_&@ 7Q%KQ4$^$KI21R/M2<4O_"0Z[_T*=S_X$I2>3?\
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MQ 7^_8N ,8;@<Y/''/M6E_PD.N_]"G<_^!*5H_V-+_T&=3_[[3_XBC^QI?\
MH,ZG_P!]I_\ $4 9W_"0Z[_T*=S_ .!*4?\ "0Z[_P!"G<_^!*5H_P!C2_\
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MM6M?] JU_P# T_\ QNC[5K7_ $"K7_P-/_QND_L:7_H,ZG_WVG_Q%']C2_\
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M37V6*YV=%(O**?:EKUQA16+XJN9[30I);>5XI Z ,AP>M<'_ &[JW_01N?\
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MF,?WNM(/A=KPDA<:3\T0 3_24X Z?Q5[Y12^L/LB?KDOY5]QX;_PK_Q1_P!
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MH96'0@\@UX/?ZOXE4W5A>S7D+W)F1+6.T")<[Q/OW@+URJ;><G)Z\UZ?\/\
M^TH]#N;74I+J0VMT88'N4"N8@B$= ,@$L,^U '64444 %%%% !1110 4444
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M]$TRZU:WU6>QADOK==L4[+ED'/3\S],GUJ_110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gcilxvfwaiqx000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *J ;T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **P=<U&X0B+3]2TZWD4D2BZ/(],<TOAF>=--BL]0U:WU"^3.98NK+
MVR/6@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ+\?YFKM06GF?9E\U55^<A>G6IZ "BBB@ HHHH **** "BBB@ HHHH ****
M,[6O^0:W^^O\Q6!X5TO4;+7]1FNG5K=UQ$FY"8_FS@!>1]*W];_Y!C?[R_S%
M<[X2:W;6[U8H(HW2/#E#\^=W27U;W]* .SHHHH **** "J]Z4%N#(I9=Z\ X
MYW#%6*JWZLUL H)/F(<#_>% %JBBB@ JI/\ \A&S^C_R%6ZKR[/MEON#%\-M
M(Z#CG- %BBBDR/6@!:*** "BBB@ HHHH *IZI_QX/]5_F*N56O\ R_LC>8&*
MY&0O7K0!9HHHH **** "BBB@ HHHH J:E_QX2_A_,5;'2J][L^R/Y@8KQD+U
MZBK':@#(\2_\@;_MO#_Z,6M>L?Q-QHCM@D+-"S8&< 2*2:?_ ,)'I/\ S^)^
M1_PH U:*RO\ A(])_P"?Q?\ OD_X4?\ "1Z3_P _B_\ ?)_PH U:*RO^$CTG
M_G\7_OD_X4?\)'I/_/XO_?)_PH U'W;&V %L<9Z9K%T0W9OKXWJQK<97<(SE
M>^*E?Q'I>QMEXF['RY4XS^55/#-Q/>27EQ<%&=F4%H_NG'I0!T-%%% %+2O^
M0=%^/\S5VJUAY?V)/*#!.<!NO6K- !1110 4444 %%%% !1110 4444 %%%%
M &=K?_(,;_>7^8KF?!VGM:^(-1NI I:[3>N-@*@-C:P4<&NFUO\ Y!CCU9?Y
MUS7A6S:Q\4ZA"T*#%NF)D8$2 '&?KZT =M1110 4444 %076?)&)1'\Z_,?J
M./QZ5/534?\ CU'_ %T3_P!"% %NBBB@ JO+*ZWEO&#\KAMWX"K%5ID+7ML^
M5&T/P3R<CM0!8;[I^E<6)I-B1F4E9/-#.[D 8/'/^%=K7*7EO-?V*WW[M%B6
M96P,?Q8S^E '260 LH0"#\@Y!R/SJ>JNF'.F6Q_Z9BK5 !1110 4444 %5KZ
M9X+1I(SA@1CCWJS5;4(S+9L@95R1RQP.HH LT444 %%%% !1110 4444 5[V
M5X;1Y$.&&,?G5CM5>^0R6<B @9QRQP.HJQVH **** "BBB@ HHHH **** "B
MBB@"M83//9I)(<L<YX]ZLU5TZ,Q64:%E8C/*G(ZU:H **** "BBB@ HHHH *
M*** "BBB@ HHHH SM:_Y!K?[Z_S%87AZ>S;Q5J,$6FVUO<11#?-!<>9O!;N.
MU;NM_P#(,?\ WE_G7,^!=42XOK[3ELK>/[+PLZILDE7=P67K^.: .WHJ-[B&
M-MKRQJWHS &HI;J POMN$R%S\L@R* +-%8!OX1'YAU!@F<;C<Q8_.FG4[8==
M3QGUNHJ .AJ"[_U _=^9\Z_+^(Y_"L@WT2MM-^X;T-Q'FJ.I:W;VMNC?VC(=
M\B@;)XV[\].U '645S*ZA)??9VTW4RI:8QDS*'4_*3T&*MLNKH2&UJQ4CJ#;
M_P#V= &W5>4QB\MPR9<[MK9Z<<UF*FKLK,NLV)"]2+;I_P"/UFWEWJ,&HVZO
MJMJ=H),@MN%R/]_F@#K&944LS!5'4DX K&T^V6_\.R6[,569Y1D#L7-4)M)U
M"]U&.XEU^VEV#"6_D_N\^NT-R?K5T1ZL$.W6; *G!Q;<#_Q^@#7MX1;6T<"G
M*QJ%'T%2UA9U3_H.:?\ ^ __ -G4GE:SOV?VQ9;L9Q]FYQ_WW0!LT5A_\33_
M *#EA_X#_P#V=+MU;;N_MJQVDXS]GXS_ -]T ;=%8C+JR-M?6K%6]#;X/_H=
M"KJSYVZU8M@9.+?/_L] &W5:^:-;1C*F],C(S[UFE=6"ACK5B%/0_9^#_P"/
MUG:K<:G';B,:K:3/(?E2.WY.""?XJ .LHK"A.JSQ>8FL66W&2#;<K]?GHSJG
M_0<T_P#\!_\ [.@#=HK%V:OE1_;-CEONC[-U^GSTT_VJ#@ZW8 CJ/L__ -G0
M!N45B;=6*%QK5CM'!/V?@?\ C]#+JR8W:U8C(R,V_4?]]T ;=%8BKJSMM76K
M%CZ"WS_[/1LU?9O_ +9L=F<;OLW&?^^Z -2],:VCF5-Z<97UYJ?M7+:G-J<5
MD0=7LI2[*JHEOR3G_?JU;OJUS%O75[,<'*FVY&.O\= &_16%G5/^@YI__@/_
M /9TB7-_"\WVG5;,QH%*NL&,YS_M<T ;U%8!UA0<'5K<$=C;-_C2C5@P)&JP
M$#J1;-Q^M &]16"=7  )U:  ]";9N?UI!JZL0%U: D] +9C_ %H WZ*P?[6&
M"?[5@P.I^S-Q^M)_;*?]!>W_ / =O\: -^BL+^U#NV_VG#N(SC[*V<?G31K"
MDX&KVV<$X,!'09/4T :U@T36:&%-B<X7/3FK-<YH>HL]K;,;N%X7=D/R[<'!
M/7-;S7,"-M::-2.Q<4 2T54FOHP4C@>.2:0X50P_$_A3;6[=Y%1WCE5\[9(^
MF1U&* +M%%% !1110 4444 %%%% !1110!G:U_R#6_WU_F*CTOP]IVDW5Q=6
M<+)-<<R,6)SSGO4FM?\ (-;_ 'U_F*T!]T?2@!K0Q.VYXT8^I4&F_9H,$>3'
M@C!^05+10!5.FV!C\LV5L4SG:8EQ_*FG2M.;KI]J<>L*_P"%7** *QT^R+;C
M9VY/J8E_PJO=:;IRP@FUMH\.N&$*_P!X<=.]:-07DGE0!MH;YU&#[L!0!2N?
M#NDW4RRRV2>8O(*DKC\JJV^CZ:FK1O:0#,6[S7+%@21C'/4UL7,,-Q"8YP"A
M]\54MMMC/':+('ADSY?/*D<D'UH O"&)00(D /4!1S5.XL;22_M9'CBWH&"J
M5Z\?TJ6[U&VLF59W*E@6&%)X'TJ-I4GN[&5"2CJY!(QQ@4 6E@A5@RQ(".A"
MBE\F+!'E)@\D;1S3Z* (OLT'_/&/_O@4_P M-V[8N[&,XYQ3J* (OLT'_/&/
M_O@4OD1;=OE)MSG&T8J2B@!C0Q.VYHD8^I44BP1+G;$@R,'"BI** (S!$5"F
M)"HZ#:,"JFHV5K+:$2)&@!!#;>G/M5^J>J?\@]_JO\Q0!86"%5*K$@!&" HY
MI/LT'_/&/_O@5+10 SR8LJ?+3*]/E'%(;> G)AC)/^R*DHH C\B(*5\I-IZC
M:,&@P1-C=$AP,#*CBI** (U@B4Y6) ?4**7R8MFSRTVYSC:,4^B@"C?V=K)9
M2*\<2*<?-LZ<U9CMX8UVI$BC&.%[5#J7_(/E_#^8JV.E $7V:#_GC'_WP*S;
MN.,/> (ORK'M^4<=>E:]95W_ *R^_P!V/^M &B(8F )C0DCDE13A'& 0$4 ]
M0!UI5^XOTI: &&*,@ QJ0.F1TH$4:G(C0$=PHI]% #/+CP1L7!ZC'6D\B'_G
MDG_?(J2B@!-B[MVT9QC.*K7.GP7**&785;<&0 '^56J* ,#38D$5K%N294N9
M &V 9P#[=:VV@A8Y:)"3W*BL+1_]5;?]?4O\C70T 5IK**15**L<BG*NJC(-
M)!:&.422.&*C"A5VJ,]3CUJU10 4444 %%%% !1110 4444 %%%% &=K7_(-
M;_?7^8K0'W1]*S]:_P"0:W^^O\Q6@/NCZ4 +1110 45!=7EO91K)<S)$K,%!
M8XR3VJ?J,B@ JO>QM+;A4&3O0_DP-6*R/$5Y-9:>DD4!FS*H8#L,YS^= %*^
MMK.]UU(+F REI!G(;;C8>,]*O)I>BZ5<Q3I;PP3%MD;$\DGL*R[.^O;JU34)
M8$6?S#(L:(Y4KM('..M:%C9-J%O]OON;F>,A$/2%3V'O[T )K,4%['+(EV%D
MM$;>JC)&15G33FQTTB/>##]\CE>!_.JUUH9;3AY4FV]6(HTB_P#+7/4-]:I0
MZI.HL$B6!%5&782_RX'1N.M '445%;2F>VCE8 %U!(':I: "BBB@ HHHH **
M** "H+O/V=L1"7D?(>_-3U4U)BMBY4D'*\CZB@"W1110 4444 %%%% !1110
M!#=9^SOB+S#Q\GKS4U5=1)6QD*D@\<CZBK0Z4 %95W_K+[_=C_K6K65=_P"L
MOO\ =C_K0!J+]Q?I2TB_<7Z4M !1137=47<[!1ZDT .HJ&VNHKN+S(6W+G&<
M5-0 4444 8EAG?#F(1?Z5+\@[<&MNN?TEBT=N6))^U2\GZ&N@H **** "BBB
M@ HHHH **** "BBB@ HHHH SM:_Y!K?[Z_S%: ^Z/I6?K7_(-;_?7^8K0'W1
M]* %IK[]AV8W8XW=*@FBN7DS%<^6O]W8#4$_VZUMIIQ.)VC0L(RH7) ]: ,+
MQA"ZV5O>SL@\J94(7/(;C ![YK0&I2:1;00W5J45P$@ DW%G[*?>L2]7Q)KV
MB11/80A966;>)1]WJ!44FG^*[D1B[19_+_U99D&P]F&.I^M '32ZE=1RK:S1
M+#/)@QN#N!&>?Q&14>IO,+.\AEE$@54(.T#J:Q%MO%+7 N+FV2>0#"$NHV#V
M ]:J:[_PD0L9KN]@BCBCPTA5Q]T?_KH [#0CG0[0YS^[ZUHUD:)',="L#'/M
M78&/R#D'M5QX+MI&*7>U2>%\L'% %NN2(3S;@L2'$TFT <'GFNDCBN51P]SN
M8CY3L VURC"X$DR"9<M+)N8H,Y![>E '66'_ !X0?[@JQ6=IT-T+6W9KK<FT
M978!G\:L>3=;''VKYB?E.P?** +-%4OL][_S^C_OT*G$<WG!C-E-N"FT=?7-
M $U%4_L][G_C]'_?H4_R;KR@OVKY]V2WECIZ4 6:*K2PW32$QW6Q<?=V T1P
MW2EM]UOR,#Y ,'UH LU6OQ&;-A*Q5,C) R>HH:&Z,2*+K#C.YO+'-96L6VH"
MW1_M'G1JWSQ8";L].?:@#>HJG;P7:0%9+G+E<*=H.W_&C[/>_P#/Z/\ OT*
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MNP50,DGM3(+F"Y!,,JN!UVFJ%S!=*8I)9S-"C9>,1C\#^'6DL%E:XC+R^>R
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M]H-_S[/_ -]"JDTAD2\E=1&'"!06&3BM+[#:?\^T/_? H^Q6F0?LT/'(^04
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M*WZY?Q[=P1>%;VV>0":6/*)W8 C- &OH'_(OV'_7!?Y5HUG:!_R +#_K@O\
M*M&@ KG--_Y#+?\ 76;^=='6!I0']J3$HQ(EEPPZ+SWH WZ*** "N8\27]Y9
M7:26UP\8C0-Y8QM<E@.:Z>L;5]";5;F-_M1BBV[9$"9+<YX/:@#&CN9KJ\!.
M21=QL^&( R/K795S7_"/7"7_ )B,GE?:(Y.6.=JCO[UTM !1110!CV?_ ",N
MH?\ 7)/ZU+XAE:#0KJ5,;T3<N1QG-16?_(RZA_UR3^M6M9@^TZ1<P;2QD7:
M/4T 8_AK5-1OM1OX+V9)?L[*H:./8.45NG/][UJYXLEMH/"]_)>*&MU0;P1G
MC<*J^']'O]/U*\GO#$1,0P\H\#"JN.?]VMO4-/M-5L)K&^@6>UF7;)&W1A0
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MVX5T>)@5/Y5:UU-6CTV_U;P]<K))+$&2 0;V<C@[22.<9X/<5IC5H-0M@VE
M732CY)0I" ?WMQ'(^E:-K +6VCA4YVCD^I[G\Z /.- UWQ'?3W+^=?K90VX+
MR7^GA3YN<;5&X9)SUZ5TFFZVEE9IIXMI3-;R"%_,PN22.1^=;FJQO+IDZ1H7
M? (4=3@@UQ\UE=SWMQ<-92HDMV&0N,?*-O/'TH W-'_U5M_U]2_R-=#6%IH
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M!BR@?P]>]:I 8$$ @]0::D21C"(JY]!0 ^BBB@ HHHH **** "BBB@ HHHH
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M$\I-VXMC/3I5G2?%]K>16\$D92]DW*(5;=N*D@X/&>E00.?^%G7'R#G3$/\
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M_,."O<5Z/'_JU^@KDO'ER\G@O45-M+'\JG<V /O"NF2X<6JO]FESP-F!GZT
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MVKN: &21I,A210RGL:9#:PVY)B3!/4DDG]:FHH **** "BBB@ HHHH ****
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M--BL=3FGDCC<2!E;:Q8=#D5N5A>(O%%MH%I'((9+VXEE$,=O R[BQ]<G@>]
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M@([%A0!+156:^B7:D3I)*YPJAOU^@IEI??:&4%H7#YVO"^Y21U'UH NT444
M%%%% !1110 4444 %%%% &=K7_(-;_?7^8K0'W1]*S]:_P"0:W^^O\Q6@/NC
MZ4 -:&-SED4GU(H6&)3E8U!]0*?10 SR8]NW8NW.<8IAM;=OO01MCU0&IJ*
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MW_ ?YBM&J>J!CIL^V,2';]T_S_"@!FB_\@:U_P!RK]4-%_Y UI_US%7Z "N
MOGF3XK2F")9&_LKH6Q_%^M=_7'7NE73>.9M5BF2.,69M\'DYX;/ZT =):9^U
M29Z^6E4_%.GQZIX=N;*4@1RE02>GW@:N6G_'U)SG]VG/X5<90RE6 (/4$4 >
M>S_#[2I(DB6YA5$F$H'I[5'>>!M,-W!+%<1J\DO[P]<KM/''X5Z%]G@_YXQ_
M]\BL;7KJ33U#VJ0($B>5]T620N.!0!R\WP]T^1[4K?(%MY-P4]QZ4VY\)66F
M7\&HPSK).IDW8SELH:[ZRDAO+&"Y6)0LJ!Q\H[BLWQ&B):1D(HY;H/\ 9- #
MYW(T?3CM/,L(Q\W'(_'\ZV:YYM1#K;VOED",V[;^>2QZ8SQ^9K1UBZGMK:+[
M,R+)+.D09QD#<<9Q0!H57O(Q);%6<(,CD_45G^'M6?5;.8RX\Z">2%R%P#M8
M@''T%7[]U2T9G3>H(^7/N* ,2'P\;JW:0:IJ$.^9WVQRX"_,>![4V\\.E&$I
MU74&WL%VF7@9[CWK<.G6Q).UQDYP)& _G33IEJWWD<X.>9&_QH RSX78QHG]
MM:G\ASGSN3]>*AC\.%M0OO\ B;:B"RH.)>G':MO^SK;TD_[^M_C2#3+4$D(^
M3U/F-S^M &3)X9*P+_Q.-2;R\GF;[WL>*99^&RUIN&KZDOFH.!+PGTXK:.FV
MQ&"KX_ZZM_C0-,M54*JN .@$C?XT 9EMH_V#5K*0W]W<8C=-LTF1TZ_6MZJ\
M5E!#*)$5MX! +.3C/U-6* ."U;4'&LWM@(8&66X"LSQ$LB^6#NSTZ\5T7A/_
M ) ,7^\:65E6SU@NN]1(?ESU^1:3PG_R 8O]XT ;=%5M1GDM=+N[B( R10NZ
M ]"0I(K@]/N/B;J6GP7L5QX>1)T#JK129 /KS0!Z+17(Z-+XSM]7A3Q#-I,E
MG,&4?9(W5@V,CJ>E5O%>O>(X/%NF:!X?%@LEY;23M)=JQ"[3['TH [>BN#\K
MXH?\_?AS_OS)_C2%/B>@WO=>'BJ\D+#)DC\Z .]HKG?$6NW6E> [S6[=8FNH
M;43*&'R;N,@^U2:3K-S?^";?5Y!$MW+:^8 /N;R.!],XH WJH:W?R:9HEY?1
M(LDD$1=5;H2.U<A&GQ2>)'-SX=4LH)4PR9'MUJ*\TWXE:A9RV=Q=^'Q#,NQ]
MD4@;'?'- %'P-?WVI^(4O;R&&+SX$D01'/RE6Q^/6O4:\X\'V9T[7;>R(4-;
MVT<9VG(R%;I7H] !1110 4444 %%%% !1110 4444 %%%% &=K7_ "#6_P!]
M?YBM ?='TK/UK_D&M_OK_,5H#[H^E "T56GT^UN)/,EC+,1C.XC^1I(M-M()
M-\<1# 8SO8_UH M456_L^U\@P>6?++;L;CU_.H_[(L0<^2?^^V_QH NUF:_/
M'!I$IDE6/<0 2V,\]*N?8X#(\FSYG7:QW'D5A^(/#VFW&F[I-\7DMO4JQ.3C
M '/UH U-%_Y UI_US%7ZR-&L;<Z+8@QGY%##YCU_.KDFEV<LC2/$2S').]O\
M: +=<]J7V;[9+]I<(FYL'=CG8M;$>GVL4<B)&0L@PPW'G]:YC6-'AU'6+2RR
MT<?FL2P!.-L:D#\Z .AL762XD9#E=B#./:K<TT=O$9)6VH.IQ658Z=':ZHT>
MW<$B5U8 CYB2#W]JI^+D&G>%;Z>S@=YLH0J,<L=XZ?G0!N?;H/[S?]\'_"L;
M70+X(D+(1(CPL)-R\,.2..3Q7G]WK^JKY0&D:A"[7 1@P;IGUSBI[WQ%K(U"
M!Q97R&.7:CLA'F?*?E ]?\* /2K%[.PL8+2$N(X4"+\K=JH>(+F*:VC5"2<M
MP5(_A->>WFNZLES9*NFZA&9)L2(P;.,=,]_6I?[6U"^U.UTZYLKN*S9I3NE5
ME#$(<=: .P$$@U)'9/W)CM@GR<9#?6M[5K6:ZMHOLX0R13)*%<X#;3G&>U9]
MSIMK+IMBSHQ/F0C.3V([9P*U8].M82Q2,C<-I^<GC\Z *7A_1AI-M,64">XF
M>:7:Q(RS$X_6I=8N8HK4Q.V';! QV!%6&TZT:)(C$=B9*C>W&?QK)U;P_;2H
M)$E^SJ, MEB<Y^OO0!MV]S#=*S0ON"MM/&,&I:S;+28[9+@2?.9VRV"1P  !
MU]JD_LBQ_P">)_[^-_C0!>HJM]@MMT;>6<Q#"?,>/UJ-M*LF8LT)R3D_.W^-
M %VBJHTVT6%H1$=C$$C>W4?C1)IUI+MWQ$[%VK\[# _.@"U156+3;2"3?'$0
MV,9WL?ZTO]GVOV?R/+/E[MV-QZ_7- &3?31PZ?JYD8+NEVKGN=JT_P )$'0(
MB.A9JS[_ $.SN;/4AN,'E3[@X)/1!QUJSX3LX3HBNRY=]RL<GD?G0!J:WSH&
MHC:6_P!%E^4'K\IXJKX3_P"12TOC'^CKQZ<4W6-*LTT2_9(&+"VD( D;KM/O
M69930:?\.[*^DA=S;6H=5!.0WY\\T =1<VT=U"8I <9R"#@@CH17%WUE+!\4
M?#T\UUYI^R7$2@C!QC.3ZU9T;-]XAO(+R3S0L2.JC*\L,YZ_A46J6%O'\0O#
M\:1D(\%P&&\\_+]<_E0!VU%<KXDCQ+!;0O+"L=O)(&CD()(Z ^U7?#MK'+ID
M%S,F;@$Y;S"<\_7% %#QEHAF\'ZS!;W)AAEMG+QE=R^IQZ9Q4OA/267POI N
M+EI8EMHW2(+M7D C/KC-6O$=E;P^%=7V(1FVD8_,3R%-,\.Z79R^&=*D>(EF
MLXB?G8<E![T =!37=8T9W8*JC)8G  K@KW5;M];\VW:2 1726GE&3Y63!R?K
M767.A6%W:20M&RB52"0[9&?QH Y70V5_&LK(P8;$Y4Y'W6KO:\YT/2+2V\92
M6ZNT\:1IM<DKGY3Z?2N[ETVTFD,DD1+'J=[#^M $UQ.MO'N8%B3A54<L?05'
M#=^9+Y3Q/$^,@-CD>U5WTJ&)XY[6,":,DKN<X(/!%%G9M%,&\I88U)(4.6))
MZ]: -&BBB@ HHHH **** "BBB@ HHHH SM:_Y!K?[Z_S%: ^Z/I6?K7_ "#6
M_P!]?YBM ?='TH 6BBB@ HHHH *HZO(8M+F90"< <C/4XJ]5'6$,FES*" <
M\GT- ":+_P @:U_ZYU?JAHO_ "!K7_KG5^@ K N)4B\1P.YPJM*Q.,X B7-;
M]<SJF/[6Y4-\L^,C_IB* -BWGCN+\R1'*O;HZG;C()./\XJ34;9KNQDA548G
M!VN2 <'/.*H:&=T%HS*H<V$62!]>/6MF@#&;3[AQAK&T;!R,SN?Z4R72YYI(
M6>SM,1OO_P!<Y[$>GO6Y10!D-IKN5+6=JVTY7,K'!_*LW6K5XH8G:"%<%L,K
MLQ'RGUKJ:Q/$O%G&?=O_ $$T /FW_P!D:?@\^;#G@>H]ZV*Q9W(T;36^7F:
M=!ZBMJ@ JGJG_(/?ZK_,5<J&Z#FW81QK(V1\K=.M $U%5C?VH)'G+P<<4AU&
MT7K.H^M %JBJWV^U_P">HI/[0M"2!,N1U'I0!:HJM_:%J!DS+0-0M" 1,I!Z
M$4 6:*@CO+>601I*I8]!ZU/0!AW/_'AK7_70_P#H*T>$V4Z%& P)#'(!Z5CZ
MAJ6I0ZG>6MM;>=#+<['!CX"^6"6S5;P+;QP:_JK1 CSK:"1QN."V7&<>N *
M.LUV2--"U!9' W6TH W8)^4]/>LC18[*_P# =G8SS1;)K0(0SC(XJ#Q/IMEK
M;2SW$'FQV:"-26."S.N>GIC]:YGXA^&]*TG0[633K>VLC)*%E9I-NY0,[1D]
M?3% '7:-IQL-8N;VXO;6031J@V.!C:,=*J:O<VY^(OAUO.C($-QSN! ^7U[5
MS_B3P/HNG>&/[1@^TK,WDAF>X.-I89ZG'0TOA;PKI.HZ;I-S?6EO=SO)-')/
M&Y8.H!QRIQ0!VNL6-OJ;I)%J$%O*(WB9\!\JPY'48JUI:6NF:?%:"]CD$8QN
M9P":\[^(_AW3=*TZS?3(K>R>1V21WDVAD SM^9NOTI-5\%:39_#]M8M_/6^6
MQ1U>2X.P$@=<G&.: .\\375L?"^J@7$1/V63HX_NFE\-W=N/"^D@W$0(LX<_
M./[@KE_!?A31;_08KB\M(+N49C\W?N## R.#C&<_A7"ZQX<NF72[6WL;FR7_
M $N*:XAAF8H-_P"[+ #TZ8[4 >I7GAVQN-46[BU**",3K</$FT[I ",Y)[@]
M,5T8N[8#'VF'C_;%>":-H3Z;XADCO%GN=.ATS9"]W%,BO.?O$9&<_P"-;>F>
M&[81:5+-;B&25)$<7#S!02#@C(QD4 =5HCJ_C:0JP;Y%Z'/\+5WM>9>#K.SM
M/&%TEI#'&J,%PA)&=AS7IM !1110 4444 %%%% !1110 4444 %%%% &=K7_
M "#6_P!]?YBM ?='TK/UK_D&M_OK_,5H#[H^E "U%<7$5K;R3S-MCC&YF]!4
MM(RAE*L 0>H(H P_^$QT('!OES_NG_"C_A,="_Y_EY_V3_A6O]CMO^?>+_O@
M4QH+-3@P1$^@0$T 99\8:$!DWR_]\G_"JNH^*M#N-/FC%V7)' 53G.>*W?LL
M3=+6%1ZE!7/>)+6*.XLRD2Y.[.%% &WH;!]#LV'0Q@CBM"LWP^,:!9#.?W?6
MM*@ K GC#^)[7<,C?*,8]8EK?KF]6@U-=9M9M/CA+AW8&4\$; "/4'B@#6AA
M2+57"*%46Z*  . &:G:I=&ST^2<.$VD#<5SC) Z5F:+=7T^KW<6H&W$\42*5
MAY]3G/XT[QC8/JGA>\LHW9'EV@%3@CYA0 L]])#AI-0DC4G:,VG4U!<:I+;O
M KZA(OFR;!NL\9.">/?BN,U#X;7<\4*QW=S(R2 LTLX)*YZ=:74_ %T]]:R1
MW-PX:?[LDP/EC;U7G@\4 =M)J3PM&LFI2H9&VH#9_>/H*I:G<M*UO%-=/('9
M@$>WV;OE/>N7N_AU?/>6,T5U</Y,^^1WF&XCUZ]:?+X.N-/UZPU%KB62-&<%
M)7#!?E.,4 =_%H6F1K%MM$Q&59!DX4K]T_A6E2+]T?2EH *J:D2+)L''S+_,
M5;JM?>7]D;S2P3(R5'/44 846OBU@9/[)OI=DSINCAR&^8\CVIMYX@5W$7]D
M7PV,&W&' ..P]ZV;=KNWB\K[(7PS'<)%YR2?ZTVY:\G1%%DPVN&_UJ]J ,W_
M (2=?+1_[$U+YSC'D<CZU%'XA5-0O?\ B3WYVJAXAZ\5N_:+K_GQ;_OXM0QM
M>)=32FR;$@7 \U>,"@#,D\2*\"_\274!YF5Y@^[[FF6GB)4M-G]C:@?)0<B'
MA_IZUM237;QLHL6Y!'^M6FVTEW#;1Q&R8E% )\U: ,^UU87^K6:#3[JWS&[[
MI8]HZ#CZUOU1'VB:]@D>V,21ALDN#U'M5Z@#*U+3X_LMU(LLZ>:07"R8!Z#^
M59>A:% PFNUGG0N/(94?&50G'\S70WNPV<GF%@G&2O7K5+P__P @YO\ KL_\
MZ &ZQ!%;:!)%"@2-2F%'^\*Y7XJ_V?\ \(_IXOY)(Q]I7RF1@,/CC/MFNNU_
M_D#3?5/_ $(5<EMH+J!8[B&.5,?==01^M '->,3&/!,?FR;5WV^7# 8^9><T
MWP!-IT/@NU:TE*VGF.$:5P2?F/>MH>'=+^4&U5E4A@C$E<CIQ65XJMX5BLXD
MB18P)B%5<#/EGG% '.?$O4-'U'0+&6ZDF6$73(I4[#Y@'OVK5\0&'_A4$OGD
M^1_9T>_:<';A<XK8T&PCDTIH[VUC;,K';(H;KW^IJTOAS2E54^RJ8UZ1DDK]
M,>E &7X ^R?\(S$+.1I(01AV8-D;1C\A@?A74TR*&*!-D,:1H/X47 I] %>Z
ML+6^55NH$E"] PZ5G:U<0V4^EM)'(T8F*A8XBY^X<<"MFL3Q!(\<^FLDDR-Y
MYYAB\P_<;M0!QW@V5)_&.HR(&"FY;AE*G[I[&O3*\S\'LI\::@$:5U-PQW2I
ML/W3U%>F4 %%%% !1110 4444 %%%% !1110 4444 9VM?\ (-;_ 'U_F*T!
M]T?2L_6O^0:W^^O\Q6@/NCZ4 +2$D*2*6D=UC0N[!5')). * (E_>]9/JJ\5
M*J*OW0!55K[3VZW4&?7S!3?M]JI^6^@(]&D% %VN>\0[_MMEL<*V'Y/ICFM3
M^U;$'#W4*_\ ;08K"\1W-O<7%GY,\<F-V=C XZ4 :_A[/_"/V6>OEUIUF>'\
M_P!@66>OEUIT %9>L7=U:FW^S)N#%C)@995 Y*CN?:M2L&\^WSZTJP7*QI&2
MJC:#_"">M %_2;>T@L]]G(9(YF,A=FR23U__ %5<DC2:,QR('0]01D&N8L?M
MEEXAFM(Y(V,R%WWY"@C'*J.!G/-6KC76M[F6WDN[-98S@J8I#@XS_C0!K?V=
M9?\ /M%_WS2_V=9@@_9HLCH=M9MAK#ZL"=/N;64+G<3&X';_ .O56*_U6[U>
M[M1<00K:J-VQ.&)]VZ4 ;OV*U_YX)^59>MV\,4=NT<:J=YY ]C4?VZX+;!=W
M&_.,F)-F?][&*H:E+?)J5O;7-RLT3Q-*N$ P1QU'7K0!UR_='TI:1?NCZ4M
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M)F;S=W"YXQCWK<H P!8Z\.FH1C_@ _PK/E\+ZC-<M<2WQ:5AACG@_ATKKZ*
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M JHC8_$J:KOX>N9RGVC6[V78=R?+&NT^O"UNU0U.^EL_LZ0Q*\DTFP!CQG%
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M#'85JT4 %%%% !1110 4444 %%%% !1110!G:U_R#6_WU_F*T!]T?2L_6O\
MD&M_OK_,5H#[H^E "T44R65(8FDD.$49)Q0 ^BL[^W=._P"?C_QQO\*/[=T[
M_GX_\<;_  H T:KWJJ]N SA!O0Y/^\.*K?V[IW_/Q_XXW^%07>O:<L&?-#?.
MO#(V.HYZ4 ;%%1PS1W$*31-NC<95AW%24 %5+R$W#Q1>;L!W'CKD="/I5NL+
M5-:@LM5MTDBF.S<"57()*B@"Q<ZE-IGD"\B$B2S+"LD9Y+-TR.W2M6N5UJ^.
MHBQA2UN(V2[CE)E3 VKU_G6YJNJ1:1:"XFCD=2P4*@&<GZT 7J*QM/\ $EKJ
M,5U)%%.JVZ[CO4<CVYI$\20.VQ;.[+;0VWR^<'O0!M45D'7T52S6-X% R28^
M!^M1V_B:WNX%FM[2\DB;HPBX- &W5+5X9;C2;B*! \K+\JDXR<U7@UZWENUM
MGAN(792P,J8&/K6A'<P2OL256;K@&@#A[&QO(M2GB:(B5KA99%7G:A8GK^-=
MM=EQ;,4D$;9'S'MS3I)H8&'F.J,W3/>L?6]9MX8! J2S/)@CRER!@CK0!NT5
MCR>(8XHWD>QO0B LQ\KH!38?$<%Q DT-G=O%(NY66/@B@#:HK&?Q%#&5#V=V
MI;@ Q]:$\0Q2KNCLKQE]1'0!LT5D_P!NK_SX7O\ WZH_MU?^?"]_[]4 :U%9
M/]NK_P ^%[_WZH_MU?\ GPO?^_5 &A=%A;.4D$;<88]N:Q]$U"R@LI(Y;RWC
M<3/E6E4$<^F:IZIXPTR*QE$N],8!SCCGTS7*0->_:?M=GI,=[ [2,)/LJN"&
M((^;/- &W!I]O]N2XDNK"-K6.40O'=J3*SG@D'I70:->VEIH]M!<7]H)D3#C
M[0IYSZYKB(GUF/4;JY/AJ(I*D:JOV->"N<\9]Z8K:T+2ZB/AN+=,SE3]C7C/
MX\4 >D?VMIO_ $$+7_O\O^-9VHWMI<WVF)!=02L+D':D@8]/:N*G?6I+6&)?
M#409'C8G[&O.T@GO[58M1J%UXIT6:XTF.QBAF8EE@$98E< <=: .UT3[MY_U
M\O\ SJW>ZA;V$:O,V2[B-$7EF8] !531/NWG_7R_\ZX#Q#IN/$5X_G:>[W.I
M6Q5S>L)(  ."G0=,_C0!IVL%_::BFISQZWQ=2R2QNP\I8N<<9Z 8KMK/4[&_
M53:W<,I9 X5) 3@^P-9E_K>E7JZOHT5[&;Z"V<S18.8P5ZG\ZXW0OL]G=VM_
M;W>GQW"Z;'!Y:0,IVY'[P],C_.: .Y\4?\BW>_[H_P#0A6E;?\>L/^X/Y5QD
M6IR:KX-U6>5][+)L) P#A\9%=G;?\>L/^X/Y4 9]Z7/AN[+R"1O(DRPZ'@U'
MX<_X]KW_ *_)/Z4C_P#(IW/_ %PD_K2^'/\ CVO?^OR3^E &S1110 4444 %
M%%% !1110 4444 %%%% &=K7_(-;_?7^8K0'W1]*S]:_Y!K?[Z_S%: ^Z/I0
M M! (P1FBB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\JHZO;^9I<RQQJ6P#T'0')
MK0JEJVW^RY][L@QU'UH ;HO_ "!K7_KF*OU0T7_D#6O_ %S%7Z "N*\575OI
MNI0R7]G<36URQ57@Y92%';WKM:YKQ(DTFO>'!&CO&+IS)M7( V]3[4 9!OK*
M90S:=K\@(^4[<C!]*BO)[>ZA\L6&NXW D20[P?PS78-:SV),EC\\1.7MV/Y[
M3V/MTH_MB*7,5JIENL<P="A_VO0?Y% '%&\TNQM)'N-/UQ P_>N(]H;\*U(/
M$%NE[;WUO:7D\%Q9)Y:QQ[G4 _Q#\*WI;)OLLUS=R>;<")L ?<3C^$?UK"\&
M?ZJR_P"O ?\ H9H ;K&O'4;584TO5-F\-)$82HE7^Z2.0*V_#VMV^KZ=&\<#
M6C@E/LT@VLN..GI6Q7+65_8^(]9:1;J%(K.8K'"K@22NO5F'7:.P_&@#=NKZ
MSMYU@G;,K+N5 A8D?@*;;0F2Z-VT?EJ%VQH0,^Y-4=7,T6I0S6SQ"9(6($@/
M3OT%8J>++N1W1)[7<L1F.0>4'>@#J[R%F:*>.-9'B)^0_P 0/7\:JS:A9LOD
M+%F=N1"R%2<$9[=JPK?Q/=W"AEN+4*5W#Y68D'I@ <]#1J-_=VSV5_</'(LH
MVQ/!D$=#WH ZN\N/LEC<7/EO)Y,;2;$&6; S@>YKF] OKHQO>Q:;=+9W:K+%
M;J481D]3G/'N.Q%;4NJJF@3ZJD1*Q0/,$)&3M!../I6)X?DU@V_]HBPB2*^1
M)UMTFRD989R,]SGF@"Y>WDMQJ&GJ]E<0 2D[I-N#P?0FKV@_\@>'ZM_,UGWD
M][+J&GBYM%A3S#A@^[G!K0T'_D#P_5OYF@#2HHHH **** ,&XAL;.&6.]LK=
M@6W([H,/DYY/8C-;-OY'D+]F\OR?X?*QM_#%8_BD;M/MU/1KA :G\.J%TPJH
MPJRN /;- &M1110 5DZQ_P ?FE_]?(_E6M63K'_'YI?_ %\C^5 "Z)]V\_Z^
M7_G7G'B,,GB#4_*222W?5+;[4_V1/W;;1@!BV6&,=J]'T3[MY_U\O_.LW4_!
M%CJ%U<74=S=6\UQ-'/)M?*,R=,J: ,1M%6T\8>+-2>Y9EEL-WEA -N4(//\
MP']:S-%M)]1U"TM[B.22=M*B,*S$")X@5X)&3FFV6LSZKXNU+2I-4MC<7/\
MHDL7V;G8"X)Z^F/SKNM!\(:-X=\M[&T5;A8A$9B26(&..3P..E &*L-U;>#M
M5MKJ%8O)DVH%7 *[\\'N.>M=E;?\>L/^X/Y5F^*/^1;O?]T?^A"M*V_X]8?]
MP?RH SKO'_",W>(?*'D2?)Z<&F>'/^/:]_Z_)/Z43.\GA:Z=V+,8),D_C1X<
M_P"/:]_Z_)/Z4 ;-%%% !1110 4444 %%%% !1110 4444 9VM?\@UO]]?YB
MM ?='TK/UK_D&M_OK_,5H#[H^E "T444 %%%% !6=KG_ "")OP_F*T:J:GO_
M +-G\M5+;>C=,=Z (]%_Y UK_N5?JAHO_(%M/^N8J_0 57F"?;+=FDVLH? ]
M>.:L5Q7B.SO-6US[!').L97Y6CFV;.!G% '2&ZFOV,=B0L0X:Y(R/HH[_7I2
M?V-#$!):NT-R#DS=3(?]OU%<\O@W5$4*OB/4E4#  NGX_2E_X0_5?^ADU/\
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M,\4 :-%%% !4%S9P7BJL\8<*<C/:IZ* *4.E65O,LL<"AUZ'TJ[110 4444
M%%%% %73HWBL8T<889R/QJU5:Q\O[&GE,S)S@MUZU9H **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gdzs1tysdsfm000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 FL# 2(  A$! Q$!_\0
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MM'*8CC;YP15.!G(7)ST((-=%)X7T&:5Y9='L7D=BS,T"DDGJ3Q3/^$2\._\
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M:G_LO3_^?&V_[]+_ (58BBC@C$<4:QH.BJ, 4 /HHHH **** "BBB@ HHHH
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MA5#5M+CU6T\AV*X.015^BDTFK,#G/L^C^%85GN"2[':&(RQ^E7_^$ATW[3#
M+@%I0"I XYZ9KC/'=PTFLQP9^6./('N?_P!5<_:,2&&3P>*PQ%1T8<T4:4H*
M3L>J+K^FF2=#<!?(!+$CCCT]:Y'PSKFG6/B3Q)"L_P#HD\L=Y%\IZN,, /J*
MYV8EK!SDY Y_.J]F0+@' RRXSWK&&)E*C*=M4=4\+"-:,+Z,];;6]/2XA@-R
MN^897'3GID]JCLO$.EZAJ4]A:W2R7$/WU _/![UYID^>RDGH,>U8GAVZDL/%
MEI(K$$7&QCGJ"<&NC U?K/.GHUL<V)I^Q:2/>J* <C-%;&04444 %<[KMH\<
MOVI%+(1A\=O>NBI&4,I5@"#U!K*M1C6@X2V94)N$N9'#!@1D$8I=U;=]X>#,
MTEFXC8\E#]T_X5ASP7-H<7$#K_M 9%?.5\MK4G=*Z\CT(8B$M]!=U&ZH!(K=
M&!_&EW5PN+6C-[DVZC=4.ZC=2Y0N3;JADO+>&5(I)D21_NJ3R:1Y5C1G=MJJ
M"6)[ 5FQP&XTVZFE3]]<J7 (Y4 ?(/PP*N,$]6)LV=U&ZJEI/Y]G#+G.Y 2?
M4]_UJ7=4N-G8=R;=1NJ'=09 H^9@/J:.4+DVZDW4R))KEMMO"\A]0./SK:L_
M#KN0]\_'_/-/ZFNRAEU:J]K+S,9XB$?,@T>U>[NEDP?)C.2Q[GVKJJ9'$D,8
M2-0JCH!3Z^CP^'A0I\D3SZDW.5V%%%%;D!7+>*?%L>C(UM;;9+PKD]Q&/4^_
MM6IXBU;^Q]'EN1@RGY8P?[QKQR:1[B2229B[R$EF)Y.:ZL-0Y_>EL959\NB*
M\FNIJ5P\\UR\DA/S-("/?OVI&O;90A\]#O.%P<Y[5571;559<N<\=0.V.PIS
MZ1;NV[=(N2"=I'..17<N=+8YWRDJ:A;R/M5FZ9+%3M'&>O2I4N87F:%)%:11
MDJ#T&<57.FP_. \BHXY0-QG&,T^VL8[61I$9RS AMQZY)/\ ,U2YNHM"U7H'
MA+P_I&H:2+F1!-(25=6_A->?UWWP[AN46[E((@?&T'N?6L,5_#W-*/Q'/>*]
M/L=,U;[-9'HN77LI]*YVXN8K5%>5B QVC"DDG\*V?$5O<0:Y=&X!W/(6#'N*
MPKRS2]B5'8J%;<, 'G\:TIW]FK.Y,OBU'1W=O*H995P<8SQG/-#WMM&[*TR@
MKU]NO^!JHNBVRC&^0X&!DCC@#^E*FC6Z%LO(RLNW:<?YSS57GV%:);ANX)U+
M(_ _O#:?UK2T;7;C39ENK"?*$X9<Y5\=B*Q'TI9 OF7$S%>,G'3TZ>U6K:W6
MU@$2$E021GW.:+.6DEH&BU1[5H6NVVNV?FQ?)*O$D1/*G_"M6O%M#U272-4B
MN8R=N=LB_P!Y>]>SQNLD:NIRK#(KS<12]G+39G33GS(\<^(EF]OXF><@[)U!
M!]QQ7)'I7O/B'P];:_9^3,,.O*..H-<$OPQO?M.UKE?*SU YQ711Q$5"TNA,
MJ;O=&CX9N5NO#MFRD91/+<>C#K6G,"87 ZD59M_"BZ39+'I^"1RZL?O'U^M)
M'8ZA*^S[+Y?JS-P*Q]I%CY&9<3!HE(]*?6I<>'9;:,-:'S">74G&3ZBJ\&D7
M\\@5H?)7NS'-9\R'RLU?#RGR)6[%L"MJH;6V2TMUACZ*.OK4U9MW9H@I#RI'
MM2T4@//;M"EW,K=0YJ&NJUK0WNI/M%MCS#]Y3WK&AT+499 K0B,=V8UUPK1Y
M=3!P=]"M8?-<.1T5<&M&K,F@36*;K3][GEU)P<^HIL&G7UP^UH?(3NS'G\*G
MVL7J5R,\;\974=YXKNVC(*Q!8LCN5'/\ZPL$\ 9)X%>P^(_A?#?SFYTZ7R9&
M^^",ACZ_6F>'/A<EC>I=:E*)C&<J@'&:SYT58ZWP992:?X4L+>4$.(\D'L3S
M6]2*H50JC  P*6LBPHHHH RO$T;2^&]01>IA:O$M"8+J@']Z,@?SKWZ>)9X'
MB;[KJ0:\OMOA]?PZS++D"&,EHCZY[5;M*A.GU:'3ER58S[,J)_K)5]\_I65(
M<#/HPS^==B/"U_Y33^7A_N[,]15>?P5?,\84 K+]_P#V:\O"49PD^9:-'HXR
MO3J17*]4S'<_Z1&>Q!JI-_Q\./I79IX+N#*5=QL0?(W<FH)/!%Y) TFY1/G
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gcilxvfwaiqx000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +1 AX# 2(  A$! Q$!_\0
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M>&/^@3%_WVW^-'_"">&/^@3%_P!]M_C0!'_PG_AO_G[N?_ "X_\ B*/^$_\
M#?\ S]W/_@!<?_$5)_P@GAC_ *!,7_?;?XT?\()X8_Z!,7_?;?XT 1_\)_X;
M_P"?NY_\ +C_ .(H_P"$_P##?_/W<_\ @!<?_$5)_P ()X8_Z!,7_?;?XT?\
M()X8_P"@3%_WVW^- $?_  G_ (;_ .?NY_\  "X_^(H_X3_PW_S]W/\ X 7'
M_P 13F\ >%7.7T:!L>I8_P!:;_PKWPG_ - .V_\ 'O\ &@ _X3_PW_S]W/\
MX 7'_P 11_PG_AO_ )^[G_P N/\ XBC_ (5[X3_Z =M_X]_C1_PKWPG_ - .
MV_\ 'O\ &@ _X3_PW_S]W/\ X 7'_P 11_PG_AO_ )^[G_P N/\ XBC_ (5[
MX3_Z =M_X]_C1_PKWPG_ - .V_\ 'O\ &@ _X3_PW_S]W/\ X 7'_P 11_PG
M_AO_ )^[G_P N/\ XBC_ (5[X3_Z =M_X]_C1_PKWPG_ - .V_\ 'O\ &@ _
MX3_PW_S]W/\ X 7'_P 11_PG_AO_ )^[G_P N/\ XBC_ (5[X3_Z =M_X]_C
M1_PKWPG_ - .V_\ 'O\ &@ _X3_PW_S]W/\ X 7'_P 11_PG_AO_ )^[G_P
MN/\ XBC_ (5[X3_Z =M_X]_C1_PKWPG_ - .V_\ 'O\ &@ _X3_PW_S]W/\
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MJ/\ V$9/_04H ;\4?^1=A_[?/_3?=5W%</\ %'_D78?^WS_TWW5=Q0 4444
M<]X[U;^PO >N:B+@V\D5G((95ZK*PVQX]]Y6J?PY6QLO NBZ;;7UM<216B%Q
M%(K$%AN/ /N:UO$7AC1O%>G+8:W8K=VRR"54+LA5@",@J01P3W[URL_P8\(L
M(19)J.G+$X8K;7TA#\YP0Y88^F* .VU-K=-,NI+N&.:".)I'2105(49Y!^E>
M6P>#_!^@Z+H6H7&K7OA_4I(?M NK.Y9=P;!=<,&0)F0<  <_6J[^$77XF3^$
MK+Q!K%KI\V@&]8I,NXR&;RR"=HRNWMZ]ZW]9\&^);G6-%N$;0-3LM.C:,VUW
M'+;Y!&!@CS!D#H<#! .#0!S>HR^%KOQ"-<NO&MIK+Z>\$=N]_9;HX7^9Q^^@
M5$(R02<$*=H8\@5I:=X=U:;5;>_TKQI=07FLI>7LLMK*MW9;!*NS9'(.PD1>
MO&T@5BW?A#7(Y-;DNH-0MK*6Z,L]II[2312(=BH(HPN92NSYF8+C@@8&#V5F
MFJZ!I&C:N+*.6SLM$B@DBD,RW"R.4,A,20N?X4XP,?-G % "ZCJ/Q \+P">=
M-$\0V:>5"HC#V5W/*[*@X^>/JV>W&>G2K'_"P+S3Y;"VU[P;KMC=7C%1]E1+
MV)2,G[T3%C\H)QLSP>#C-0R^(K_7$\+W8\-:BUE=RK?!H&20",0%E+\@+\[Q
MX!.3L;I@9MW.O03^*+&>YL=5MK2RAG+2SV,HC\UA$%Y"D?=:09]<C/6@"6R^
M)W@J^EFB3Q%9P20G#I>EK4@^F)0N?PKIK2\M;^V2YL[F&YMW&4EA<.K?0C@U
MYW=_V%K]IXBO&BM9C=:O:6$CS1KYBQ_Z.K(V>1@^8<<>M&N^ _!UWXRT6T?P
M]IZ6[03[Q9-]F97^0H["+:2!M902>KT >ET5YIIO@*675M0BC\9>+H8=/ECM
MXPNJ%MY\M)"6#J1_RT4   <=ZDFTGQW>ZK?QZ/X[>*WL[V.W9;W3K>1BABCD
M9LI&N3\^ N!TZB@#T>BN!T#XE6"^&]*G\43&PO[JW65F-K((GSW#8('3D$CG
MIP5)MZK\4/"MCH=[?VFLZ?>3P0&6.U%R$>9NR#@G)/'0T =G17/P:EXH>VAD
MF\.6<4CQJS1#5-QC)'*D^5@D=.,CT-8.K_$>\\.:K#9ZWX6O8HIE9HIK2=+C
MS-I0':HP>#(N=VWVS0!WU%8<'B[2+FXB@B:],DKA%!T^X49)P,DI@#W/ K<H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZD]2&QD$U?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P (E\0_^BG_ /E M_\ &IOC&ML_PHUP7<LL4.V'+Q1"1L^='M&"R\$X!.>
M2><8-=/C;\/_ "U\SQ"N_ W;;*XQGOCY* *.LZ+\0](L8[G_ (63YN^[MK;;
M_85NN/.F2+=G)Z;\X[XQQUHTCP[XROH]0N=)\=_V78OJNH>79_V1#/Y>+N4'
MYV.3D@GGIG':JOBCXO\ @C4--M8;+7E=DU*RFE5K.<'RX[F-W()0<@+GW (
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MP\/^&7U.*^UU/)N[02'^W[H9C:XC5QF28*,HS#+$ 9SD8S2)II6-5/AGQTY
M +-XC&6]SB]Q^57==U#6]4LK:&'P=JX,=[;7#K+/9[66.9'(R+C.1MR.Q8 '
M@FM3_A(=4_Z$S7/^_P!9?_)% ')ZI;:;:V#7&K>'/%T-G$Z.TEWXE58T8."A
M):^P"&VX/KC'-6-01=6^!5A+J?B"32BVF6-U+JK[I'C=?*DW_>#,Y90!@Y)(
MQD\4GQ!U_5W\":JL?@6_G8QKE+Y+:>$#>N69(YF<X&2" <$ G@$UO>);:"R\
M*:=:6JJMO!J&EQQ*H  5;R  #'&,"@#/\+>&K+4?">D7MSJ&N3S3VD4C3?VW
M>KYN5!W[1+A=WWL=LX[5IS^%-%M;>6XN+_688(D+R22>(+U510,DDF;  '>N
MDHH YN#PIHMU;Q7%O?ZS-!*@>.2/Q!>LKJ1D$$38(([UD^+_  O8V/@O7+VW
MN];6XM;">XA9M;O&"R(A96P92#A@#R.U=U6!XYP? 'B)20H;3;A2QZ*#&P+'
M'.!U.,G X!/% #_!D\UUX%\/7%Q+)-/+IEL\DDC%F=C$I))/))/>I-9\+Z3K
M]Y8W>H0SFZL/,^S3074L#Q;P V&C93R !_\ K-1^#(UA\"^'HDFCG1-,ME66
M,,%<")?F&X X/7D ^H%;E 'C]CX+T3Q3\1_%^DZ\E]J5CI'V+[!%=ZE<R>1Y
ML):3!,F?F*@\GL*]0T31-.\.:/!I.DV_V>Q@W>7%O9]NYBQY8DGDD\FN/\)?
M\E>^(O\ W#?_ $0U>@4 >4?%3X2ZEX\U&/4K'7$BD@@6**RN5;RL[B68."=N
M1CHISM'/IS?@'P[XI^&GBRX%WX-BO;?5KN"U2_L9]Z6<98EB 0TGE\@G?M_U
M8R3P:[WQQX_UOPGK$%GI_@K4-;MY8%D-U;LX57+,/+^6-AG"@]?XAQ7%:GXM
M\5>-M9\+V5Q\/=9TJ"TUVTO)+F1)7555B#G,2@##9SGC% 'KGBJXU*U\):O<
M:.A?4HK.5[957<V\*<87!W'T7')P.]>%^&]>UO0]-TCQO9>(M=\2Z.I-KKNG
MS&21K9S'O9EW97:O!W<= -V'./:_&WB;_A#O"%]KWV/[9]E\O]QYOE[MTBI]
M[!QC=GIVK&\(?%CPMXMM;<+J$-AJ4FQ7L;J0(PD8X"HQP),GIMYY&0"<4 +\
M']0N]4^%NCW=_=SW=T_G^9-/(9';$T@&6)R> !],5W%<=X,\'ZYX6E(OO&-]
MK5J\3;X+N+)\XN")%<LS*NT8V9(R2W? [&@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@##\:?
M\B)XA_[!ES_Z*:H_!O\ R [G_L*ZE_Z6S5)XT_Y$3Q#_ -@RY_\ 135'X-_Y
M =S_ -A74O\ TMFH Z"BBB@ HHHH **** "O)O%'Q;O+'Q0VF:#8PW5O:/)#
M?/<(5/F*DC;4RR_\\GYP0<=:]9KY>^*VJZ3;_%S4XM8T^XO(+=8#%';2QP$$
MQJS!R8F+@[CU.1D\^@![]K.H1:M\-]0U& ,(;O2))XPPP=KPEAG\#61\*_\
MD7M2_P"PI/\ R6M"[O8]2^%$]]#:BUBN=#:9+<=(@T&0G0=,XZ#I6?\ "O\
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MG$S6\JV\D<<Y0B-Y$+JK8X)4$$C/;(SZBI*CGGAM;>6XN)8X8(D+R22,%5%
MR22>  .] ! )EMXEN)(Y)P@$CQH45FQR0I)(&>V3CU-8WC:*2?P%XBAAC:26
M33+E41%RS$Q,  !U-;,$\-U;Q7%O+'-!*@>.2-@RNI&001P01WK.\37O]F>%
M-8O_ "_,^RV,TVS=C=M0G&>V<4 5_!,4D'@+P[#-&T<L>F6RNCKAE(B4$$'H
M:W:RO#-[_:?A31[_ ,OR_M5C#-LW9V[D!QGOC-:M 'G_ (2_Y*]\1?\ N&_^
MB&KT"O/_  E_R5[XB_\ <-_]$-7H% '@'Q=N/"UI\5X6\765]>V$F@JD*6;
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MI&=V1T=E;&0#C!(!KMO%FLR>'_"FI:I"L+3V\),(GE2.,R'Y4W,[*-NXC/S
MD<#)P#R^I6FIZ?\ ![0K*&.&/5K<:1$B7))C6=9[< /MYVAASCMG% &CH6J:
MOIGA[3+"7P1JL<EK:10LEO/:&-2J $(7N=Q48XW<XZ\U<;7_ +5=6NE:KX8U
M*V@U-WM0UV;62)SY3N48),YP51_X<=CUJ3['XP_Z#NA_^":;_P"2JH:AH?BZ
MZFMKQ=>TG[58^;);I'ITL*2NT3($D/GO\F6!.%)^48H ?I/BB6YT:QGTOP7K
M(T^2WC>U$;62*(BH*87[0-HVXXP,5G^,]=U&;P+XAB?PGK,"/IERK2R2V95
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M(()ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'^"43K"D*MX<!$29VI_HWW1N).!TY)/O4/PK_P"1>U+_ +"D_P#): #XI_\
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M86\D6&(.Y!TR1N]P0>];5 !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XT_Y$3Q#_P!@RY_]
M%-4?@W_D!W/_ &%=2_\ 2V:I/&G_ "(GB'_L&7/_ **:H_!O_(#N?^PKJ7_I
M;-0!\0T444 %%%% !7<>&8&309]8U#Q+=Z-I\EV8$^S)+,TLP0,Q*K(N.".2
M3UKBX)WMY-Z",G&/WD:N/R8$5VWARV;4/#UQ<:SKNG:/HS7(CC,FG)*9;A5S
M\JJA( 5QD\?>'X &AX',D_QCLSH6KMJ%T]O<BVO;V)X\R_99 N]2SG .!U/
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M&05!.3@#(]B:TT%OAMID(UF2RT6"WLI+;49)(XV58VC>%R9%V@DJG!7G.,4
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M&R1FC4[9 =RY/R$<;C7MOA.QN-,\&Z'87D?EW5KI\$,R;@=KK&H89'!P0>E
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M ,(WJGVJ*46_V27S<R6OW=AST7/3TKH?A7_R+VI?]A2?^2UT7BS_ )$W7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB./0 8KTJO-/A]C_ (69X_QCG^SB<$'GRG[]_P <'U .:]+H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH P?&_P#R(/B/_L%W/_HIJ/"'_(%N/^PIJ/\
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M'@\#@@8/&" <H59 #)\5*LWA+5T9@JR6DJ2,W(0,IR_;./F;MG!(PP=3K@@
M<@ #((( 48X(/3&#[@ GJA(7&\8?\B9KI+8_XE]Q\Q_W",'/N .><@ _,%8Z
M=E:06-C;V=G&8H+:-8HD!)**H^7!ZGH?<X) #!U(!,1MW J,<AE(XQP#P3]
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M.IOCE\/XRNS69)=S '99S?+D@9.5' SGCL#U. 9?^%V_#S_H8?\ R2N/_C=
M'H%%>?\ _"[?AY_T,/\ Y)7'_P ;H_X7;\//^AA_\DKC_P"-T >@45Q?A[XH
M>'/%?B!M'T)KJ]D2$SO,L/EQJ@*@GYRK=7'0>M=I0 4444 %%%% !1110 44
M44 %%%% !1110!@^-_\ D0?$?_8+N?\ T4U'A#_D"W'_ &%-1_\ 2R:CQO\
M\B#XC_[!=S_Z*:CPA_R!;C_L*:C_ .EDU #_ !?XBB\)^$M2UR5-XM(MR)SA
MW)"HIQT!8J,]LUYMHOASXE^+M.L_$EYX\_LMKB/[19VEI;;HQ'(H*AQE0>",
M;@Y'7.<UVGQ2L_M_PXU:V_LV^U+?Y/\ HE@VV:3$R'Y3L?IC)^4\ ].H\,@D
M\56MO%;V_AWXHPP1($CCCU>5510,  "UP !VH ]B^''B#Q/=:KKWAKQ8;>XU
M+1FB+7EN %E64%E!  '3&, <=1D9.E\2-?TK0/"X?5]%?68[R=;6"Q6)7$LQ
M5F0$-T&4Z@$@D8!KEO@S;7BWGB*\O]&\1V%U<_9M\VN7!F>XVB0#:QBC/RC
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MBNZHH Y/PIX/N?#^NZ[J]YJ<-Y/JWV?<D-JT*1>4K* -TCDY!'?C'Y=9110
M4444 %>3^(_"VC>+OCK'8:Y9_:[6/PT)E3S7CPXN2 <H0>C'\Z]8KS__ )N%
M_P"Y4_\ ;N@ _P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRO0** //
M_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H
M7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !RO0** //\ _A27P\_Z%[_R=N/_ (Y1
M_P *2^'G_0O?^3MQ_P#'*] HH KV%C;Z9IUM86<?EVMK$L,*;B=J* %&3R<
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MM(Y(XKE6S]P/G. !R&/7M3_B_>>&;3P3L\56=Y<V-Q<K#&;-4,L4NUV5U+$
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M;KNN\K@_BM_R+4/_ &^_^FZ[KO* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KDM2UB34?'J>#-K0VS:7_:5Q/')AY5\WR_)']T
M'J6!SC@8ZUUM>?\ _-PO_<J?^W= '>Q11PQ)%$BQQHH5$08"@= !V%/HHH *
M*** "BBB@ HHHH ***Q_$>@?\)'IT=G_ &OJNE[)1+YVF7/D2-@$;2V#E><X
M]0/2@#8HKS__ (59_P!3[XY_\''_ -A1_P *L_ZGWQS_ .#C_P"PH ] HKS_
M /X59_U/OCG_ ,''_P!A1_PJS_J??'/_ (./_L* /0**\_\ ^%6?]3[XY_\
M!Q_]A1_PJS_J??'/_@X_^PH ] HKS_\ X59_U/OCG_P<?_84?\*L_P"I]\<_
M^#C_ .PH /"7_)7OB+_W#?\ T0U>@5Y?\-]*_L3XC^/M.^WWU_Y/]G?Z3?S>
M;,^87;YFP,XS@>P%>H4 %%%% !1110 4444 %%%% !7C_P (/^2A_$[_ +"H
M_P#1MQ7L%>/_  @_Y*'\3O\ L*C_ -&W% 'L%%%% &#XW_Y$'Q'_ -@NY_\
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M5O\ D6H?^WW_ --UW7>5P?Q6_P"1:A_[??\ TW7==Y0 4444 %%%% !1110
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M +]"NIH \GUKQKXHFT'48I?#TJ1O:R*S?V?=#:"IR<E,#\:WOA;_ ,@75O\
ML*2?^BXZZ;Q+_P BKK'_ %Y3?^@&N9^%O_(%U;_L*2?^BXZ &_%;_D6H?^WW
M_P!-UW7>5P?Q6_Y%J'_M]_\ 3==UWE !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5XOX]\0W_AGXTV%[I2V-S?7&E6UBFGW)D5[
MH273Y$;@;$8%1\SD 9Z-TKVBL;6'TRZN([%[](=6B3[3;K"P:XC&=N\(,L5S
MD'C!Y!H YC_A+?B'_P!$P_\ *_;_ .%'_"6_$/\ Z)A_Y7[?_"NVTZ2[EL(G
MOX4BNB")%0Y7@XR/3(P<<XSC)QFK5 'G_P#PEOQ#_P"B8?\ E?M_\*/^$M^(
M?_1,/_*_;_X5Z!10!Y__ ,);\0_^B8?^5^W_ ,*/^$M^(?\ T3#_ ,K]O_A7
MH%% 'G__  EOQ#_Z)A_Y7[?_  JO?^._'>F:=<W]Y\-/+M;6)IIG_MV [44$
ML<!<G !Z5Z17/^._^2>>)O\ L%77_HIJ -#0M3_MOP]IFK>3Y/VZTBN?*W;M
MF] VW.!G&<9P*\ST#XHZSJOQ4F\,3MHRVB:G=V8A2&<77EQ)(RR;B3'@E #S
MG.?E YKO/ G_ "3SPS_V"K7_ -%+704 %%%% !1110 4444 %9?B74IM&\*Z
MOJENL;3V5E-<1K("5+(A8 X(.,CU%:E% 'C_ ,&-;G\2^(_%NN75Q8RW5]%8
M23)9)*J0L$E381(,[@%&<%EYX)KV"O/_  E_R5[XB_\ <-_]$-7H% !1110
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MOB+_ -PW_P!$-7H% !1110 4444 %%%% !1110 5X_\ "#_DH?Q._P"PJ/\
MT;<5[!7C_P (/^2A_$[_ +"H_P#1MQ0![!1110!@^-_^1!\1_P#8+N?_ $4U
M'A#_ ) MQ_V%-1_]+)J/&_\ R(/B/_L%W/\ Z*:CPA_R!;C_ +"FH_\ I9-0
M!Y=\+?\ A8__  KC2?[!_P"$5_LS]]Y/V_[1YW^N?=NV?+][.,=L5ZOX<_X2
M3^SI/^$H_LK[=YIV?V9YGE^7@8SYG.[.[VQBOG35_$-M?:DNE^#O'/BN64D%
M]1UC7Q:VJ+E<D!@K-U.1P>. U>V?"^RELO#DRW'C%/%%P\P:6XCNC.D#;%S&
M&+,2 <G)QG/04 <!XLDT33OCE<W_ ,0K1GT5[!%TF6:)I8,J%W H@.[YFDX;
MIN!(Y4A?#/\ PC>I_&S3-1^'MO<)IL5I*-8DMXWAMAN1A&NQ@,$L%.,8)4$#
M*L:T=?70=>^('B?2]=\9:SH45H+4+$-<2"WG#P@G9$Z<8P,\MDMGC.*V?"&C
M>%M/U^S_ +)^).I:K,F_R]-DUR*>.7Y&SF)1S@9;VVY[4 >ET5E^(/$>D>%M
M+.I:U>I:6@<1AV!8LQZ *H)8]3@ \ GH#7.3?%[P-!J-O8RZXJ23I&ZLT$@1
M1(JLA9BN%RK@\].<XQ0!;U[_ )*'X0_W+W_T6E>$>+_$E]X;\<:KI^CWNFDW
M>IS/+'9:G?0+'(S#F9O-2(.<C<5)"E2#M KW?7O^2A^$/]R]_P#1:5Y1\1=$
M\=C4]2GL/ WA][+[4[I>V.EP7-Q<(QX+J^YRW/S$*.03G'- '8>![9[?X4^(
M999M)FN+K[3<3MIEZ]T!(T*EA)(SOF7/7#$=#SG)V?A;_P @75O^PI)_Z+CK
M%\ Z3I^C_!W6(+"/5HF>.X>ZCU2W\F19O)"MA>R$*".6ZX)R"!M?"W_D"ZM_
MV%)/_1<= #?BM_R+4/\ V^_^FZ[KO*X/XK?\BU#_ -OO_INNZ[R@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IV>I0WUUJ-O$L
M@>PN!;RE@,%C%'+E>>FV1>N.0?K5RO+]&.J6G[1/B&UGGG33;O2DO8(/.S&Y
M'D1&38#@-E&7)&<#TQ0!ZA1110 4444 %%%% !5>_L;?4].N;"\C\RUNHFAF
M3<1N1@0PR.1D$]*L44 5["QM],TZVL+./R[6UB6&%-Q.U% "C)Y. !UKG_$?
MP[\*^+M1CO\ 7-+^UW4<0A5_M$L>$!) PC =6/YUU%% 'G__  I+X>?]"]_Y
M.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE>@44 >?_P#"DOAY_P!"]_Y.W'_QRN3^
M)/PF\):1X%OKG0-!D&L%XDM%BGGE=V,JA@J%CN.W=V/K7ME<_9X.O33WJO<7
M(D:.WDB0O#;IV7(^ZY'WB>_&<8% '/\ _"DOAY_T+W_D[<?_ !RC_A27P\_Z
M%[_R=N/_ (Y7H%% 'G__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#C
ME>@44 >7_#?1-.\.?$?Q]I.DV_V>Q@_L[RXM[/MW0NQY8DGDD\FO4*\_\)?\
ME>^(O_<-_P#1#5Z!0 4444 %%%% !1110 4444 %>/\ P@_Y*'\3O^PJ/_1M
MQ7L%>/\ P@_Y*'\3O^PJ/_1MQ0![!1110!@^-_\ D0?$?_8+N?\ T4U'A#_D
M"W'_ &%-1_\ 2R:CQO\ \B#XC_[!=S_Z*:F^%$$F@W2$L VIZB,J<$?Z9-T-
M 'SS<0A[ZZ@T:=M<@M)/+FO--\"6,L' R=K9YQZX .,@D8)]D^#L^G7/@^:;
M3]2@OE>[)D:+28]/,3;$_=M''\K$==P)SG&>*Y'PAKOB3P.DW@G3-#TOQ*UC
M/*8YK'5H8I"N[+>9$=S*P9MISC' YP">M^%GA36=%77=;\10PVVL:W=^=-:P
M,ICB52VW[N1DEW/WFXVY.<T 3WWA+PKIOB?6_$WBJ?1IH=6>W2%-4@B"V[1Q
ME2%>0D$L!G  ^[WQ6;H/BOX83>-[#2?#6E:>^J2F81W=EIJ1K"51BW[PA3RH
M8 KD'Z&LWQG\+- \8>.+J]L?%,-MXBS'-/8RB*Y 5$55S#D, 0$)W;@<],&K
M'PQ\.>-O FH/H6H:9IUWHUY,]W+J-G<!?(D*8V["%)!*(,!0!NSD]  ;'Q8T
M6XU'2-)U.TOM,M)M'U&.\!U6X,5L^W.%8]R6V@9(X)Y&:\HN-(FN-*N]!M-?
M\)WVL^+;]KC4[R/4E\N#:X>*-!G)9G9^BGKC'1J]:^*V@:EK^CZ*-,TA=6>R
MU>&[FLGF2-98E5]RDN=N#D#H>O3K7D&K^#=<L/">OP7OP_TS3FO]0-S;ZG/J
MUHGV&,NI6%2Q'& R\%<[NG% 'MFL1"W\=^"X@694CO(PS').(EZGN< \UYAJ
M.B^*[CQ9K]SX5UG3_#&GW5_)8N)M;$BWEV[MN9%4,8IB IV85US@=\>I^(/^
M1_\ !W^_>?\ HFN3O_A#K-QJ-S-9^-?LEK)K;:Y#;_V4DGE7))*MN+Y; P,'
M@XZ4 2^![=K3X5>(K:XL%M-0B-RE^1J*WC3W(A7S)'920C$]4SQCWK9^%O\
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M>?\ IONZ[J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\__P";A?\ N5/_ &[KT"O/_P#FX7_N5/\ V[H ] HHHH **** "BBB
M@ HHHH **** "BBB@ K M"$U^:"_WPW3NTEMY3E(IXQ[#&YP,;@V?4<=-^N#
M^,D\UG\+=6O+:62"ZMWMWAFB8J\;>>@RK#D'!(R/4T =Y1110 4444 >?^$O
M^2O?$7_N&_\ HAJ] KS_ ,)?\E>^(O\ W#?_ $0U>@4 %%%% !1110 4444
M%%%% !7C_P (/^2A_$[_ +"H_P#1MQ7L%>/_  @_Y*'\3O\ L*C_ -&W% 'L
M%%%% &#XW_Y$'Q'_ -@NY_\ 134[PG_R![C_ +">H?\ I7-3?&__ "(/B/\
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MJ",$'N#0!;HHHH **** "BBB@ HHHH *\?\ A!_R4/XG?]A4?^C;BO8*\?\
MA!_R4/XG?]A4?^C;B@#V"BBB@#!\;_\ (@^(_P#L%W/_ **:J&BZU;Z3:75G
M>6FK+,NH7K_N]*N9%*O<R.I#+&5(*L#P>]7_ !O_ ,B#XC_[!=S_ .BFK)T'
MPGX;U.SN[R_\/Z5=W4FIW^^:>RCD=L74H&6(R<  ?A0!L?\ "6:=_P ^VL_^
M"6\_^-4?\)9IW_/MK/\ X);S_P"-5'_P@G@__H5-#_\ !=#_ /$T?\()X/\
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M='_"[?AY_P!##_Y)7'_QN@ _YN%_[E3_ -NZ] KQ#_A:7@W_ (7)_;W]L_\
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MK_MQ_P#2MZ /?Z*** "BBB@ HHHH **** "BBB@ HHHH *\_^-O_ "2'7?\
MMW_]'QUZ!7G_ ,;?^20Z[_V[_P#H^.@#T"BBB@ HHHH **** "BBB@ HHHH
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M?=UW5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5X!\4_\ DX7P5_VX_P#I6]>_UX!\4_\ DX7P5_VX_P#I6] 'O]%%% !1110
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M_P#I6]>_UX!\4_\ DX7P5_VX_P#I6] 'O]%%% !1110 4444 %%%% !1110
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MU-+J;Q$FJ7Y^6)IKA6V_[JCH:[*A %%%%,#'\6?\B;KG_8/N/_1;5SOPM_Y
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M_P!N_P#Z/CH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\  /\
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M +?/_3?=5W%</\4?^1=A_P"WS_TWW5=Q0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>/\ A[_D!^+/^R@)_P"EMK7L%>(0:#XL
M75KJYT87USHEQX@DU"[LXDM"LLT6HN'&^1T=,1P0D ;@6R"5&: /;Z*Y_P#X
M2'5/^A,US_O]9?\ R11_PD.J?]"9KG_?ZR_^2* .@HKG_P#A(=4_Z$S7/^_U
ME_\ )%'_  D.J?\ 0F:Y_P!_K+_Y(H Z"BN?_P"$AU3_ *$S7/\ O]9?_)%'
M_"0ZI_T)FN?]_K+_ .2* .@HKG_^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W
M^LO_ )(H Z"BN?\ ^$AU3_H3-<_[_67_ ,D4?\)#JG_0F:Y_W^LO_DB@#H**
MY_\ X2'5/^A,US_O]9?_ "11_P )#JG_ $)FN?\ ?ZR_^2* .@KS_P"-O_)(
M==_[=_\ T?'70?\ "0ZI_P!"9KG_ '^LO_DBN'^(]EXP\;6=GH]AHNJZ=I$N
M_P#M(/\ 89'DP4:+:/M'9E.?F7KWZ4 >L45YO8>)_B9;Z=;0WGPZ^UW4<2I-
M<?VW;1^:X #/M PN3DX'3-6/^$M^(?\ T3#_ ,K]O_A0!Z!17G__  EOQ#_Z
M)A_Y7[?_  H_X2WXA_\ 1,/_ "OV_P#A0!Z!17E^E?$CQEK?VW^S_AQYWV&[
MDLKC_B>0KLF3&Y?F49QD<C(]Z-*^)'C+6_MO]G_#CSOL-W)97'_$\A79,F-R
M_,HSC(Y&1[T >H45Y_\ \);\0_\ HF'_ )7[?_"L>%?&UI]BU6/PKKDVKKJ%
MQ/=VLWB!/LCP2>=LB4&8K\F^+'[H?ZOM0!ZQ17G_ /PEOQ#_ .B8?^5^W_PH
M_P"$M^(?_1,/_*_;_P"% 'H%%<O8^)/$$EG&U_X%U6"Z.=\<%Y9RHO)QAC,I
M/&/X1Z<]:L?\)#JG_0F:Y_W^LO\ Y(H Z"BN?_X2'5/^A,US_O\ 67_R11_P
MD.J?]"9KG_?ZR_\ DB@#H*\_\ _\C/XB_P"!_P#IRU*KGB'5_%5[HDUOH7AW
M6=/U!WC"73FPD$2[UWG:9R&.S=@'N1R.HS_AQ8:GINJZE;ZR)/[0-E%-,TBQ
MJS&2]OW#$1LR*2&!PI(&<=J /1**** ,/QI_R(GB'_L&7/\ Z*:CPG_R![C_
M +">H?\ I7-1XT_Y$3Q#_P!@RY_]%-1X3_Y ]Q_V$]0_]*YJ -RBBB@ K$OO
M"6AZE=O=7E@LL[_><NPS^1K7FGBMXS)-(J(.I8TL<B2H&1@RGH0:GFC?EOJ.
MSM<Q+?P7X>M+B.>#3426,[E82.<'\ZWJ1F55)8@ =S3(IHYAF-PP]C1S13M?
M45B2BBBJ Q_%G_(FZY_V#[C_ -%M7._"W_D"ZM_V%)/_ $7'72>*%#^$M90]
M&L9Q_P"0VKF_A;_R!=6_["DG_HN.@!WQ1_Y%V'_M\_\ 3?=5W%</\4?^1=A_
M[?/_ $WW5=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %8<_@SPK=7$MQ<>&=&FGE<O)))81,SL3DDDKDDGO6Y10!S_P#P@G@_
M_H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\
M!=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T
M?\()X/\ ^A4T/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\
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M/4\UT-% '/\ _"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\ !=#_ /$UT%%
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M_P"F^ZKN*X?XH_\ (NP_]OG_ *;[JNXH **** "BBB@ HHHH **** "BBB@
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MKMJK*<7'$8=:6<=&A8RDZ=35WOJ%4]3%K]@D-V<1 <GO^'O5RN(\47[7%_\
M958^7%U'J:VS#$1H4&Y*]]+$X2BZU5).QFB5/-/E,PP?E)ZUZ36#X?T6*UMT
MN9D#3N,C(^Z/:MZN3)\#+#0E.7VK:=M_\S;'UXU)J,>AE^)?^15UC_KRF_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO4O_ )/H [ZBN!_X077?^AF7_OO4O_D^C_A!==_Z&9?^^]2_^3Z .^HK@?\
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M^$'U[_H94_/4?_D^@#J/$O\ R*NL?]>4W_H!KG?AC_R M1_[",G_ *"E5Y?
M>M31/%+XBADC=2KHW]HD,#U!'V_D5T/A7P_+X=T^YMYKJ*YDGNGN"T,!B1=P
M VA2[G QW)H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gdzs1tysdsfm000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ JX# 2(  A$! Q$!_\0
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M:9,_?V %0?;-1SV<&B^+=*>PB2".]62&>*,;5;:NY3@<9S0!U%%%% !1110
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MA1112&%%%% !1110 4444 %%%% $%Y:I>VKV\A(1\!L=<9S4R(L:*B*%51@
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M_7X%*A)]3KJ***[C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5K&]:??!.HCNXN)$['T8>H-7:J')*-XH4N9.S"BBBM"0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Q;O7&BU&6TCC0;$!#RY )Y)
M_#@ 'U-:\,GFP1R;2N]0VT]1D=*<RJPPR@CW%+0 4444 %%%% !1110 4444
M %9FHZY!IUPMN+6\N[AEW^5:P%RJ],D]!T[FM.O.?&FH6%CXCF>\NM1A<641
MB2UNVA$I,C C@'D#F@#MM,U>#5!(J17,$T6/,AN83&ZYZ'!Z@X/(S6A6-X72
MQ30HAIM]+?6I=RD\K%F;+$G)('0\5LT 8%S_ &N+J81-(T66VE1_%SM&"/N_
M=!__ %UOCIS41N(%+ S1@J0I!8<$]!]:EH **** "H;JUBO+=H9AE3R"#@J>
MQ![$5-12DE)68TVG=&1&D=S(-/U6))9X\M$[#B5?[P]_45;?2;"0H7M(CL4*
MOR] .U/O;-+V$*6*2(=T<B]4;U%1V-X\K/;7*A+N(?.HZ,.S+[']*YE",9<E
M17OL^_D_,T<FU>+)OL=MO#^2FX2&0''1B,9^N*DAACMXEBB0(B]%'04^BNA1
MBG=(S;;"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% '$_%/5+[2/
M!WVK3KJ6VG^TQKYD9P<'.17B7_">^*_^@]>_]_*]B^,O_(AG_KZC_K7SU7G8
MJ4E4T9]ID-"E/"7G%-W>Z/H_X5ZI?ZOX.-UJ-U+<S_:77S)#DX &!7;UY[\&
M?^1$/_7W)_):]"KMHN]-7/F,QBHXNHHJRNPK%OFU0WTVP2):B(>7Y8#;F#*>
M<<@D9'L.:VJ8\T46?,E1,#)W,!QZUH<01%C$A==KE067.<'TS3Z** "BBB@
M)P,GH*QM,\4Z3K%V;:PGDE?!8-Y#A"!UPQ&#6PV-IR<#'6N \%3JFI01)+JR
MVEQ;R2V27-U')&Z!@"=JJ"AYX'O0!6\>QZ0VO1EKF=]4,(Q:DXA9<G!9MR;?
MKN_"NR\,(L?ARS5(H(E"GY(+@S(/F/1R3G\SCI4/B&XL+-K9IM&_M&YN7\J)
M$A1F. 6Y+=!@&M'2G#Z;"PL&L <_Z,P4%.3V7CGK^- %RL-M =II7^T+B0L"
M-G0,221SP>>,<?G6Y6;/JXMYI8WMV(CY+*P(P!DGZ@$''O0!I4444 9VO_\
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M[\&?^1$/_7W)_):]"KNH_P -'RF9_P"^5/5A61=:,\VI&^6Y^?: $D0$8!!
M]<=3CU-:]4+K4OLLSQ>0[E4#@J>V0"3Z8SG\*U.$M6\(M[:* ,6$:! 3U.!B
MH-2U"WT^V5KBYCMS,_DQ._0R$' _2K:,'174@JPR"#D&H[G_ (]I2"00A(8+
MN(..H'<T <+X*UR_U/65CNM>LK[_ $(^=! X.UU90''RCK\Q/^\!VKOZX'P3
M<7MSJ:37.OV]VWV4Q3V@9E=74KM;RV4,"0&+'U;':N^H K7JW30K]DFCB<.I
M=I$+ H#\PZCG'>N'\'260\1,UO-I[O=VYFW6]B\189!(#%B!C()4#N*] .<'
M'7MFN"\(_:WUJ$R+I02**:*6.U,9,<@9,L-O/S=QT "]Z +_ (_3S;"T0:5'
M?MYCL#*9 D>U"Q)V$') P*TO!LBR^$[%U@2!2&Q''OVCYSTWDG!Z\^M4/'WV
ME=)MWM]1AM LV726X\D2\' W>QYQWQ6KX7>63P[:O->QWDC;RTT;[U/S'@-W
MQ]W\* ->J[V5M(<O A^??R/XO6K%8$E_J?G2*(9%P[;<1Y4X)"KT[CDGGKU%
M &_1110!G:__ ,B]J'_7N_\ *O'J]AU__D7M0_Z]W_E7CU,#M_AW_K=0^D?_
M +-7=UPGP[_UNH?2/_V:N[I %%%% '#>/[2W5+64Y1YI"I8'Y<@<$C],UP#H
MT;E'&&'45Z#\2/\ CQL/^NS?^@UP2S*RA)T+ # 8'YA_C770C*E'F@KI[K]5
M^J^:UO?CKN,Y\LM'W_1_H_Z7K'@__D4]/_W#_P"A&MRN9\*:C;0Z#8VLC-'\
MI\MY%VK)\QZ'IGVKIJY'4C.3<>YUQBXQ284444#"BL/4?%FDZ7?/9W4DJS(
M6"Q$CD9'-0P>-M%N;F*".68R2N$4&%AR3@5?LIM7L1[2%[7.BHHHJ"PHHHH
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M&.?P?8QS1JZ,C95AD'YC5S[#=6/.GS;XA_R[3DE?^ MU'ZBJW@__ )%/3_\
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M>W0 CGI0!<HHHH SM?\ ^1>U#_KW?^5>/5[#K_\ R+VH?]>[_P J\>I@=O\
M#O\ UNH?2/\ ]FKNZX3X=_ZW4/I'_P"S5W=( HHHH XCXD?\>-A_UV;_ -!K
MSRO0_B1_QXV'_79O_0:\\KT\-_#1YN(_B,]>\'_\BGI_^X?_ $(UN5A^#_\
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MSFKE !5+5_\ D"WW_7O)_P"@FKM4M7_Y M]_U[R?^@F@#QD=!79_#S_C^O\
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MR1(L,:RM*L:B1_O,!R?QI]9]O?23:G+;%5")NZ [EQMP3]=QQ]*T* "BBB@
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MNA/O3$=M15/[<_\ SXW7Y+_\533J1$JQFRNM[ L!M7D#&?XO<4AEZN,^(_\
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MO'F^\WU->J_;G_Y\;K\E_P#BJ\^/AO62Q/V!^3_?3_&N7$PE*UD954W:Q?\
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M>@P./:@"S:W$=W;1W,08)*H8;EP<>XJ;OFHX84MX5BC!"(,*"<X%24 %%%%
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9BK(****DH**** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gdzs1tysdsfm000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  E4# 2(  A$! Q$!_\0
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MHY4%BI]G?V_.C[._M^=6Z*.5!8J?9Y/;\Z/L\GM^=6Z*.5!8J?9G]%H^S/\
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M9SQDY.?U- &/JZW-N-'C-TAB:YCCECD4,TAYY!JU;07%X)9!=+&HE90HA4X
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M2;@3V<3 IDIC"]@.GZ5-2BHJX1JM_P##(F\F\_Y_%_[\_P#UZS[BZOH=<L;
M7$92XBE=F\KD;-N._P#M5M5AWW_(XZ/_ ->]S_[)67*A\[_I(TO)N_\ G[7_
M +\__7J*X%Y#;2RB[4E$+ >5Z#ZU>R,XSR:@O_\ D'W/_7)OY4<J#G?])$,"
MWDUO%*;M 70,1Y7J/K4GDWG_ #^+_P!^?_KT^R_X\+?_ *Y+_(5/1RH.=_TD
M95]<W-B(RT^\.6'RQ#C"D^OM1;MJ-U 9DNHEX90IB_B!QUSTK39%?&Y0V.F1
M0B)&@1%55 X51@"CE0<[_I(Y[3=0U:YB(NY8(YENVMV$<9*X&>1DUL^3>?\
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MU^U9'B8$Z/P<8GAS[_.M:^ 1@C(K(H6J4O\ R%K?_KFW]*N#Z8JG+_R%K?\
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M@MX@64@'8.*7(NP_;RLDGL5)=+MI(+:(RH!;DD#'!S[9J#^QHA+Q=+Y1!+9
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MX#NJOX)_Y%:W_P"NLW_HUJGB1AXJNV8( ;5=NWKC/>H/!/\ R*UO_P!=9O\
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MB_2@!:*** "LZ?48Y5,%L^+A\JA8$ ')']#^5:-5?[/MA<+.$^=22.3C)_\
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MDU3.H[FJ&J?ZNV_Z^8_YU?JAJG^KMO\ KYC_ )T@+]%%,EW^2_E_?VG;]>U
M#+JZBL[=IIFP@P.!DU3NQNUC2W .,R<Y_P!CTJ*.WN;V3R=1A$D.P$A@,9]O
M?-5KN,IXPTPK/-M,<F823L&%X([9H 31/^1G\1?]=(?_ $ UT-<[HI \3^(L
MD#]Y#U/^P:Z#>G]Y?SH ;(55'PP4XZUPGB'S6*P1F+<.6PK9QVKO&=""-RGV
MR*X?Q'))9M*HE!#H>,C@9_F:WH?$3/8QH6D>%#*H,HZCK2SC<N,'..5STJ"S
MYPQR&*G() "^V*L2A@X(9=A&/H?4UR55RXG0\_[+,Z1QERL>[!49;L!5BQC
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M?$_P1ZU;$O$-.UDM$A]%%%;&057O_P#D'W/_ %R;^56*KW__ "#[G_KDW\J
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MT^U83=V6@HHHJ "J]_\ \@^Y_P"N3?RJQ5>__P"0?<_]<F_E0 ME_P >%O\
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MJUAW=Z?^$KTVS>V(RLCI-N&#\O(QUH W**** $.<<'%96K68N%5Y8_,5&!
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M32OJ["&VE,/E.'.X9W@'VZ5KLJNI5@"IX(/>F1P11.S)&JLWWB!UH DHHHH
MK7EZEF(RZL0Y(R.W!/\ 2J=FKW5__:"N1&5V-&QSM(]*TWC23&]0V#D9%)'$
MD,82-0JCH!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (U=HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gdzs1tysdsfm000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $G 5L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH QO%EY<6'A;4+JTD:.>./*.H!(.0.,\9K)BU.ZTG3[
MG4)EUBYV(H6*]$2*Q) ^4J.O/>NEU'3[?5=/FL;I6:"9=KA6*G'L1TK/7PQ9
M>4\4MSJ%Q&X *3WCN!@Y& 3Q0!37Q/=O='3QIJ?VD)S%Y?G_ +O 3?NW;<].
M,8ZU2TOQ3J+:3N:R^U3V\3SW9:4(57S' 5>/F.%/ITK>N?#NGW,TD[+,D[RB
M7S8I61@VW;P1T!'!%9U[X?\ #^G:>GVB26VMXT,38N'!E4L6*M@Y<9)_,T)7
M 2/Q;)+<[DT_-A]J2U\_S?F+,H8';CIR!UI7\8)'8V-RUFQ^UVKW"J'Y!4JH
M7IW+CFL:?Q#X>C+1P6-Q(AN5N>&VC>H !'/3 '%0Z?>>$WE(GAO(@8WA59I6
M>.-&()"\_+R!T'%:^QJ6O8GGCW-C4?$6H:;<VLNH6OV:)%F>2.*02"4!%(P<
M @Y..E+!XR:6UF=K%$D3RRI:8K&0_JQ4<CT /M5^W\-:/+&LV'NPX;][+,TA
M<,H7!)/(P!CTH_X1+3#!Y;&Z9@Z.LK7#%T*_=VMG@#/2LBC+_P"$X8V<,XT\
M+NEDBD>24K&K(1QNV]\\;@*L'QG&=5^RQVC/"LR0.ZL2P9@#D #!49&3FK9\
M(Z7Y!B7[2BLSLY6X<%]_W@QSR#4R^&=,2Z2>..6,(5;R4E81EE&%)7."1@?E
M0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5YAXUGN)?$4D4Q/EQ*/*7
MM@CD_G_*O3ZRM:\/V>MQ*)P4E3[DJ?>7_$5M1FH3NR)Q<E9'D=%=;-\/[]&/
MDW<$B]MP*FI;7X?7#2 WEZBIW6)<G\S7?]8IVO<P]G+L6/A[/.T=Y Q)MT*L
MF>BL>H'Z5V]5-/TZVTNT6VM(PD8Y/JQ]2>YJW7FU)*<W)'1%65BJUQ<HQS9E
MD!X*2 D_AQ3HKR&1_+),<G]QQ@__ %_PJQ4<L,<Z;)4#+[U!1)15-'DM)5BF
M<O$YQ'(W4'T/]#5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.LSC_:;_  JH4:JDFQJ$KE# ]_SHP/?\ZV/^$9U/_GI9_P#?;?X4?\(SJ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSW20D)@O*WW8UZG_  'O48M7G8/=D$#E85^Z/KZG]* $\^:[XM?DB[S,.O\
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ME %]=2U1\>7?1O\ ,4.U0<$#)H;4]41/,>]5(]H;<R8R"<=*KLEY&52#3+K
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M[_[]4 =1X?O+B\@F:XDWE6 '&,<5L5A^&HIHK:<302PDN,"1<9XK<H ****
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MIWY%S;FD;VU+?]N:O_S^K_WX6C^W-7_Y_5_[\+53[-=_\^5S_P!^S1]FN_\
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M92;L=%7#5*<7.2T.\DM9'U&&Y%U*D<:,K0 #:Y/0GOD59KS?_A(M9_Z"#?\
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M5Y)L1J#;W?3_ )]9/_B:]-HK>G15-W1QQ@HGFGG_ /3"[_\  63_ .)H\_\
MZ87?_@+)_P#$UZ716Q1YIY__ $PN_P#P%D_^)KH?!VXRZE(8I45GCVF2-DSA
M><9 KJJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *MQ_P ?UI]7_E5J
MLR^6]_M&U,"[HSD%\?ZOCJ?6M.@ HHHH **** "BBB@ HHHH **** "BBB@
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M\FC_ (2NP_YY7?\ WY-<M@^E&#Z5TFAU/_"5V'_/*[_[\FC_ (2NP_YY7?\
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M@''&:9_PFL,%O-+-:3>3;B-&G9U4/(X! QGCKUZ"@#5_X1K2O^?8_P#?QO\
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MCPAIBP")/.11$D?ROC)0Y1NGWAZ_A4I\-6[>7(;R\^U1NSBY\P;_ )AAATP
M0!P!110!-%H%C%HZZ8J,81'Y6\G+XSG[U)%X>LH45%\S"W0NQEOX\#].***
M&W_AVTU"YEFDEG19U5;B*-\+,%Z!N/?MBKEGIL%C;S00[MDLCR-D]VZT44 4
M&\-6@MK**":XMVLX3!%+&PW;#C(.00>@[543PFC:C=-+<3?8I%A40B0GS @'
MW\C/4=CSWHHH D_X0[3]X_>W/E*\CI$'&U2X(;MD]>Y-6/\ A&-/%G/;?O=L
MKH^[=\R,H 4@]CQ110 T^&K=@CF\O/M2NS_:?,&_YA@CI@#'8"M'3=/ATO3X
7;*W+F*($*7.3USR?QHHH M4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gvxjy5si4hmk000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +I 2,# 2(  A$! Q$!_\0
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M@#4HK+&O6IDEC$5V9(EW2+]G8%1Z\BH/^$HT_P N)]ESMEV[,Q$$YX''7]*
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M_G0!O)X?TR:]CB>U!5G56 DDZ9E![\?='Y5N+X4T50H^QMQTS-(>W^]7'?\
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M<?E]?P%0O*RWF S;?*W .< <=C^'O^M(WF[O]6H(/&901Z>E1'S3?LLNU0L
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M $D>#+P^5/).[(4>GMW_ #II55B.%^7=D-CIG_(II 4!6?"G@_+@GKU]>O\
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MLP1A_P ]<G*MG<<_K^'O3BTK*,AL'J%/RXZXIR;6",K#(YW9ZGKQ[T 1JT0
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M0$D 8(Y.>GT%,7+PJOR%=P8MCICK@_B/SIO+*H)RXY)<_+]<^G_UZ3=&4;:
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M.L8<#3YMP. %'/SY/IR?PKT(_3->?^.$W:]:LLWEXL+AB<CY@ ?EY[')'XT
M<7+\N\]< @D<YQZ^F:S@Y (Q@C(R%P?K_GWK2N%+DQH-QWLI_,U2?Y1+E4;
M+')Q@[?U_P#K4 5C(Y)"X5P><C&[CM3!'NG4L&SLX93P1Z_7FII')VAPPR>,
M\D8__72(TJL#L 0 =N._^- ">6?+9R,,#D$$GGGM]*A4MM8;1A3RC'_/:IB?
MFC$:JK.Q+C'W>G7T[TGR(BJL:[6;(VY]S_G\* '+(!M/4  $9/\ GUIN2V2
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M\88<\<XQUZ=JNO%R%7)^8$KU'T'Z?G4: &9G,KL=V<%R1]?0#BI;0(QD4.N
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M!Y[^O]* +S$G< V%4#) Q]>G-$?$ 5E9LL%(QGMV[U MR1#MD@;&.3LYY_\
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MG29>41Y*JP/RGD C_/Z5/+?6KRJR.H!;( /WN> <51:Z0G"L O)('\7'T]:
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M#Z\^G;%4[R(16ZE0!(9&W9R6/&>O>KZKB+]R<J<=AR*A?:%P0%5AM0'!R>O
M^E $.Y4VAXIF) P-IR2.O<4*Q+$O!*5^[CR\9]>_^<4AA!G#>65" YQP23S^
MF/UJPL97@QKOX&<=O2@"C+(ZN,P2!NIPN,X/N:?*'FA"PQS>8K9/.T'@CJ#4
MTL3*R,Z#K@$#D>M2^6RE>BA@0#QC&* (+6'_ $:!P"$ SPHZ=N_/7]*G"(R@
M\%0.<?YZ>_Y5';E4L Q.$V !??':DC1E3!ZD9+*.1ZT *JE[=?FWX7HWT/Z\
M^_2G,I*D@!2IVKQC&/?N:<!((VY;(()!/(XQ_3]:8K1K'EL'J"S9(!SQ0!=B
MW28(0%LD?-UZ''%>M^$U=-+G65E>47<_F.JX#-O.2/:O(?G27+)^[/55'MQC
MOZ<UZYX/,7]CRB"/RH1=2^7'SD+O.,Y[T =!1110 4444 %%%% "$9'3-<1X
M[$'V[33<LP0QW&-N<YVK@\=MV*[<^OI7&>--ZZEI7DJA<)<K\QQ@%%R?R[?2
M@#SVXC7#*5,; _>"]._X?6J01VD96("D'I@#UR,=JT)MI_AVJ#SVQW[?G^)J
MG)N4;SQDYYP,=_\ /- %=E9AM+MPO4'Z4U!Y;! 6".<Y'0?A^-228E"YX5>6
M _ST_P *C9%*@@@9  P.1WH KH)1-,R_,6D ;)^Z-O7\_P"E7"H6958YYPV!
M_GW%5(4E>[NG$N 7Z,.!P,$597.]V[I]TX!^F/ZG_&@"K:O*D*1M;2G8BY!P
M <=<]\TYKB2;>#:29(Y(<5-*SGA 0"1DG^GMS2[E^5?OX'S CM^% %;S9B/]
M0W#?-\XZ_A_/Z4MN)II96*@*[MYJR#E20.OZ58#_ #<*1GGVIRE_M,QB4L),
ML,<8_P 3B@"3(92R\[5Z#)/'K4D@,C$LVS<,@9(P<4R-=]LIVC)'('.._P#D
M4]8W,C*SA04QC P>P^G>@!;@MY4@4XS&WIZ?Y_.EC#;4W*N"@R0<9[>G-,E^
M6PD.#PC'T[$XJ>(LR*OR2;1CKT^GYT ,$;F?)P8PG;.0>YJ38Y&UN^!C'0<C
M_/%218.XD-T/88[4I13'OV$8;U[9/^- %.2-UNY)8U#A]HR< @A<'BH2]Q*K
M PI\ZE<B5>.,=/\ /2M%D87!E"X#'/7C'UJ  *I')W#YNO)SZ=* *$C7*HI-
MJGR?+M\T#/X_C^M1D737"F5!M\\LN&R5XZ?E_.M1U7 PN68=,9!([_Y_^M52
M[9/*@3&=L@)//]TXH 6-CO59&?<"22R^W%!VO(%?=C;\HQ[]14.PB8G=L9FQ
M@D8XZ<U:.QE92%WD X Y';B@!D@D.$.UL9. *<FUG4!P2!MVX[TU@ Z;6*D<
M#)[^I]N*@FBWI\Y)59%)^4'/ISUH 2UC"VZ)(Z.F%P <8'H?UJ<-PF&#!L8'
M3]?P_P ]JKVZ.8U18VP-VTQKQV[CCJ/7O3Y+4!8'C RLA+ (/E'IT]: )G.(
ML#G&<@C!&/\ ]9_*FDH)UP22R\#)QTZ$?Y]J43*S!@%<(<$J>!W_ ,\4[>!Y
M@)ZDD84J%!.30!-;H1<%%^;><*!CGCO7L7A@2"QN1,$\\74GFE 0I8X/&><=
M.OO7D*[1<)B,@#=W]N_%>K^#$ABT5TMI&EMQ.WE.S$LRX')) [YH Z*BBB@
MHHHH **** "N)\<-$M[I0DG,*D7!#JW0X4?KG'XUVU<AXOAGFU#2C! 9S'YY
M=..%*J-Q/8#- 'GTBJJX7!Y.&SGK60F[RRSMU8Y3LWO@^HQ6I*FQ -^3C.0>
M?4'Z]_J:IE<E0IW#:2<#N30!40G:$"$;@2"&)SVYQ^'Y"C:7$3=]P8KZ=N:F
M"$GF0'GDC\?_ *WUJN$.45?WF/F=LGMVQT';\J (8G/VZZ5G"%B!@D\$@?GQ
M5I8Q]H*!@I) Y&<<\G\:@CBCFN+I=N=CJWWN<D#D?RQ4R*6N(CA!AQT/?ZT
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M8;."<=?2M:P\36MU-+%);WMFT2JS+=PE"0Q(!QR<9!Y_PH VPO'*KUSQ_.E
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M"Q>0??48'W<=&SC\,UUU<7\0T@.G6WG$EO,;RAD\OC@<=1UZ\<>U '$7-Y?
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MKF@"B%CPI$$91O2#M^%OBI_"2&+7=<0*57,!"[-N,QCML7^0I#/$ 2+DG;G
M\^+G'_;;ZTWPD0?$FM;#E-L.,LIP-@[JS#]: +?CB(3:;91M<O;*;Q,RHV"H
MPV?P/3\:\R?$D:$1+DJ/O8P.G KTKQ[)#'I%HUQ;R3PB\C#1I&7+=<?*.N#@
M_AZ5YEL=4C+E6!C ) &X''4<^M #71?+96C7  XV\G';_P#7522)A+@KU P5
M[9/\O\*L%D0*68D<'Y%Z=JCQF63C=G#;L\J,]J &L[;]TD8/.", #/\ G-([
MIY:L8P5Y 4+@ _\ ZJD9 4W*/FQT)(+$?K0\>1M9@"#D \=3W- $)8K+;NV
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M-=?7'^/H1-I(S(58%F50<;B$? /J/44 < [DQ#.&4@@ D\9&/ZUFR2D%MK'
M/.W)_/M6I.0T9PY8*<@\_D,5F3?\M$!(&/O YQSZ=.U $>]_F89B<\ A>W'/
MTIJS&/:KMG!XQQD]!FGIQ!(%R<,5&0?7\_YU J(A=O++2$[1D' QDY_(?RH
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M#@'@#TKS>%0,$/\ ,I''([^E>L>% PLP6A$+FTMRRJ!UVGG@=>AH Z.BBB@
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M;R%C'C<"I7&>G4>U %FJ>JASI=QY=N+A]GRPLP <^A)!&#]*B>WU'^V$F6\
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M"5+#(/&/QZTYU8LA!<9 )7<:<K+Y04 LQ7& ,G&/T[5$P+ +]"S$9(.!_G%
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MGA  5]S@D<@^GOG/?_Z[2P,87>G0YV@_+G!Z]?3M4ZL5:([%.W&%..PZX/%
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M1-<.N&6UD=,8)P,*3VZU?E"[@%ZC/(."1Z^W_P!85 @42G:Y+$<?+G)_'VH
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M$9YQGUIAPH &<=O89XY_&G.Z+G+!%52Q9^ .>F?QI@*OM\M2P  ^4C^7X=J
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M.-5D4X&' P/3ZXJ2(W2;B$W?+@+YG.<^N* +:.Y<%\%0,;N>,'C^O%.W"0]
MB@?+\^#QTJC)+<O<) B@$ $_,2 ",^@I;221CYA7#K*R]>.HZ$]* +?F,KJB
M[MP"D$GKSZ_@?SIR$R!-XXR2<]AC'\Z1I),*Z1(=H&!G_>[?6FHK>21$.5Z8
MX_S_ )_$ EE=_LK% =Q/!&?F^HKO_ 1B5MJ3*\@28R*A&5R8]HQVSACS[UY\
MX.'4C(P,Y[?7'X_6NY^'SL][.K6YC*Q.!(V#YO*'MS\N>_\ >H ]&'4TM%%
M!1110 4444 %8?BW#>'9MUN;A?,A!B'._P#>IQ6Y6+XJ623P]*L4XAD,T&V3
M:#M/G)V- 'D$3R"T1L[B$'.!\V!CT_S^-0%#N(8DKGN>@R1WZU9B+?8H"%*G
MRU.WN../RS5)F);#G*@<\8.>>/2@"(J802IQD A2>>W;TI6#K;LZLJ%?FW <
MG@\?I36E99  2% Y/X=/RIK,IC1=K @E</TP>O\ GF@"*2-9 R,N58@< G"_
MYQ3]BQ?(@!PQ90Q(P?8]^:D3)/0!0.W/^>HIC@MA@0-I/7)SSP/SH =*[,&
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M9)2D8 ^3B+/(YYR/R]ZX3RR#(S$[0 #\QR#[&NV\ )'_ &G<,D+I(87\R5D
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M@#_#.* *;3(A1UC4KG.W=U/KQG/T]Z>\@DGC8%@V,C (XP.3QTI9?,W,%"J
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M;S[MV6+<J I&SG). -J@FO&9XM161XFA+R84YC^5'&U5+ L>#C (.#D&@"H
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M.[OTZ5T7@&-UN+.X:0"WFBDV0@<HP'S,3WSC  ^OT /4**** "BBB@ HHHH
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M%1EMDBQAMF3\OKUH<E=P8C<S<G.?;/>HV1@!T5N@.>2.OX4 1JBVMW*KG86
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M6WN )$P<Y8>A]QWI8I 49BX9=H"Y4=/7\10 LR.V3U4X([_E_P#6IAPAX)W
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MK,PVR1%A),%(*J-YZ>U+);@SLTQ=U&2-[<#Z@'&.OZ5((U2,DC_=(7&/\Y-
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M$D$]>?J?>JDX9;5)8HR/+E!^5@#M/#=1[#CZT 6=XD,C)ETP4SG SCCGV/\
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MXZ'\>U0Q222RB3RPB$C#. 6/S#GCC_\ 71- 70^;-(7^551N .HR1_O ?G0
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MX IV!2T4 %%%% !1110 44F1ZTM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%1M]\_\  ?YU)0 4444 %%%% !1110 4444 %%%% !1110 4
D444 %%%% !1110 G/K2T44 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gdzs1tysdsfm000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. CP# 2(  A$! Q$!_\0
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M?\]%_.CSHO\ GHOYT6 ?12*RL,J01[4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %!Z44'I0!C56U&_M]+TVYU"Z++;V
MT9DD*KN(4=<#O5FJ.M::-9T.^TQI3"+J%HC(%R5SWQWK4S*UEXFTJ]BN'-PU
MH;=E69+Y#;LA897(;'!'0]ZF_M_1_M5W;-J=JDMIM\]7E"^7N^[DGCFN?O\
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M\R>"T6-73.2FQ2  > <'GGUJM'X-"ZI:7CZ@?+B,$DUO%;K&DLD*LL;#!^0
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M+N4P6<TJ_>1"1GUJ"UMHX+F50-S;$+.>2QRV2: )/[0LO^?N#_OX*7[?9_\
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M,W?_ #S@_P"^S_A1F[_YYP?]]G_"@">BH,W?_/.#_OL_X49N_P#GG!_WV?\
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M"5RK_O3S\I(_E0 Z A[FS5>3%;DO[9QC^1_*M&HH+>*VCV0H%7J>Y/U/>I:
M"BBB@ KS[XIPK-;:1Y<\OVQ+AI+>W2S>Y$A5<EBBD'*@9S[GUKT&O,OB)I=I
M9ZC9W[3W?G7LS('GUMK.WMR$['!P6 (P!SS0!VWA58$\*:4MK>->0"V39<,"
M#(,=<'D?3M6O61X7BC@\+:9%"8C&ENBKY-QYZ8QVDP-P]ZUZ "BBB@ HHHH
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MB^T:'VNV_P"?B+_OL4?:[;_GXB_[[%2;%_NC\J-B_P!T?E4E$?VNV_Y^(O\
MOL5!>ZM8V%E-=3W,8CB4LV&!)]@/6K>Q?[H_*N;95\1Z_P"6%!TO3),N<<3W
M [>X3^=:TH*3O+9;_P!>9E5FXJT=WM_7D2>'T!:;6-0EB6_O<'87'[B(?=C'
M\S[FMS[7;?\ /Q%_WV*EV+_='Y4FQ?[H_*IJ3<Y<S*IP4(\J(_M=M_S\1?\
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MW7]*R&5=/\<+\H$6IVN.G_+6+_[$_I7J4_>A*'E?[O\ @7/.J^[.,_.WW_\
M!L;GVNV_Y^(O^^Q1]KMO^?B+_OL5)L7^Z/RHV+_='Y5@=!']KMO^?B+_ +[%
M'VNV_P"?B+_OL5)L7^Z/RHV+_='Y4 1_:[;_ )^(O^^Q1]KMO^?B+_OL5)L7
M^Z/RIDSP6\9DF:..,=6<@ ?B:-P;L)]KMO\ GXB_[[%'VNV S]HB_P"^Q6))
MXIL)7,6EVT^J2CC_ $6/* ^[G"C\ZKWEAXCUNRG@F:RTN"5&7RT!FD.1T+<
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M**TG4E4ES3=V1"$:<>6"LBOY5S_S\C_OV*/*N?\ GY'_ '[%6**@LK^5<_\
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M<-OUBV9GQN;ST!.,XZ=.M2)J7AE8[A3K%JQN%VR,9U!/7ICIU-;GVK_IA/\
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M2JS[^%RA"G'U-%K@FUL/FT'2[BWEAFM4D261Y&+<D,QRV#U&2.U:2@*H50
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M0,_6I*@^R1?]-/\ OZW^-'V2+_II_P!_6_QI#)Z*@^R1?]-/^_K?XT?9(O\
MII_W];_&@">BH/LD7_33_OZW^-'V2+_II_W];_&@">BH/LD7_33_ +^M_C1]
MDB_Z:?\ ?UO\: &V;;A/^],F)F'(^[[59JE;/';6]P\LL211R.2Y884?[1/?
MZU;1TD0/&ZNIZ,IR#3>XEL.HHHI#"BBB@ KP'XG>(M:TSQ[?6UAJU[:P>7$W
MEPSLJY*#)P*]^KYO^+G_ "4:^_ZY0_\ H KKP23J:]CDQK:IZ=S"_P"$R\3_
M /0PZI_X%/\ XT?\)EXG_P"AAU3_ ,"G_P :Q**]7DCV/*]I/N;?_"9>)_\
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M_@^?Y5&G@[14_P"77/U/^%6%\,Z.G2QC/U)_QHYUTA_Y-_\ :L?+4_F7W/\
MS15;QQX<7_F)HWLL;G^E0-X_T!?NSSO_ +MN_P#A6NFAZ6GW;&#\5S4ZZ?9)
M]VT@'TC%'.OY/_)O_M0Y*G\Z_P# ?_MCFV^(6D_\L[>^D^D%1GX@0M_J='U%
M_P#MGBNM6"%?NQ(/HHJ0 #H,4^9?R_B_^ +DG_-^'_#G&?\ ":ZA)_J?#E^?
MJAJGJOB'7+K3Y%ET.\M[?@NZG8<>F<\"N_H(!&",@T^?^ZOQ_P#D@5.5]9O\
M/\CS[P3I::C<W&HWD;-Y1"0HQRBCDX![XZGW->@U6L%C6W98U*J)9.".^]L_
MAFK-9ZMN4MW_ %]R-(J,5:.W]?F%%%%,84444 %%%% !1110 4444 %%%% %
M>X!,MJ1'OQ+DG/W/E;G^GXU8JM=;?.L]P8GSOEV]CL;K[=?TJS38D%%%%(84
M444 %%%% !116!J5Y<0>);&W6\V0S!2T)=5SAB./E)).1W'W30 _5XF;P]JJ
M>2$+%\#87W].<>_Z4GA'S_\ A';=IC%L;)B6-2H5.P.><YSUS]31J9C&A:D!
MO3=*5R=V=Q('&T9'/0]JO:*TCZ-;-*[.^WEF))/)P23R3CO3>XEL7Z***0PH
MHHH *^;_ (N?\E&OO^N4/_H KZ0KYR^+X ^(ET1WMXB?^^:[,#_%^1QX[^%\
MSA*5"%=690R@@E2>H]*2MCP_=VUK+>_:DM64VDIC^T0J_P"]"_)C(/.?SKT:
M]1TZ;G%7:Z'EP7-)(ZF/Q?I-KXCN-<%U>W("8L;'R0BVH8J&49RN @9>!SGU
MJ+4O$V@OX5ET.R-R8U+M&7C(!7[09 F.=K;2!OYQ@CH:PI?"E[&D,\MQ:I#,
M ?-R=J$A#@X'!S(!C^E(/"5^9W@WQB=8C-Y;9Y ;;C/3=GMGI7$L7@[*7M/Z
M7^7_  YT_OM5RDMKJNA6OC&PU&#3I8M-@*&2&1A(2P7!;''\7..^.V<#8O/%
MFFBTO%MIKB1_/CN+=9!)EYAY>YG)<AH_D.$;+#CFJ.B6>EZ9J&K6FL2V3RQ$
M0(91E0.=TBY'...!ACG@BJUG+IFGZ_J4:_9);$6\OD/,JS!G"'802.I;M^!Z
M5$L9&4I*$&^5)I])+1Z>>H)225VM7]Q8\5Z]I.MV5N;9)ENXICOX*I("/FD(
M)/S-A>I)P.:I:!K-KI'B+^T(OM5M;QQLR0K*7,CA?D5R N5+X)XZ"EM?"E]J
M$K+'-;B3,)<$$*HEY!! P0!UQTK.@BT];*\6\D=;E#B#RLDLP[$$8V^^<^QK
MHAB*$DX0?-:UTM;7_3KZ&;4^92>G_ .IM/&%M;V^C223O)>VY*3,(WV+$5^;
MY=V#*6)^9<<=<]*Q?%6HZ7JM];W6F12Q P*LL3?=B(X"K[ >G'?UK>M9?#AN
M;>2=M-C<P(&A95>*,!T#G<JC+L@<@')![\BJ$\GAV[T*41B"SO$B/EX 8LJG
MY1TX9B!GJ0#UQ7%3S#W_ .%):I7MW_->:T_!O:<&XVYD<E1117MG"?5/@;_D
M1-#_ .O*+_T$5OU@>!O^1$T/_KRB_P#016_7S]3XV?04_@04445!84444 %%
M%% !1110 4444 %%%% !61XF8C0Y@$E<L0 L0Y]<^P&,Y]JUZ@N[.WOH?)NH
M5EC#!MK#C(Y% &!9P0KH,<44K.CV,DH3!D#$D'< W7GM[U=\+*RZ#"&D63!;
M#K&45AGJ ><'U-+J5O,MO);6$-NQ:V=5B?C.6&?0XP3WZXI_ARQET[1(+>:(
M12C)=0^[!)]<G--B1JT444AA1110 4444 %%%% !1110!!9G="Q\PR?O9!DC
MI\YX_#I^%3U!:9\ELE"?-D^YT^^?U]??-3TWN);!1112&%%%% !1110 4444
M %%%% !1110!7N6Q+:CS"F9<8 ^_\C<?U_"K%5[C/FVN"@_>\[L9/RMT]_Z9
MJQ3$%%%%(84444 %%%% !7.:L\"^+M)$TA1PK>5MV$L3P0=W('NHS[UT=9%W
MIMU<:]:W89#:PCE&DYW=B!M[<]^_M0!#JMP(M&OF;R[E?.*F.64Q<<?*".<C
MMBKNALCZ-;-%;I;HRDK$ARJC)Z>W>H;R&2YTG4(542,SL%6$@''''IGV/7IF
MK&CPO;Z3;Q2*Z,JD;7(R!DXZ<#CMSCIS3>XEL7J***0PHHHH *^=?C$C+\09
MF(P'MHBON,$?TKZ*KSSXH^!9_%%E#J&FJ&U*T4KY9./.CZ[0?4'D?4UTX6HH
M5+LYL5!SIV1XO8V5E>^%;D+%"-6%_#'#(\^TLC*^1@D  $#)]ZZ&RT;2D.D0
MWMC9O-- YEFBG4Q)N";"X,HW,OS,V".N!G%<-=6L]E.T%Y;R6\R'#)*A5A^!
MJ#*>JUZK@WLSRU-+='5V-K:_V3J[6YM+V_BNPD<<LYCC$ #?O4!9=QR !DD@
M=JW=2TKPPD\:S7%M8VXN(3"\%RTC7$1AW2[P"VT[\*&P,9/7%><;E]1^=)E?
M44G2N[W&JME:QW<VD^'X?%&HQ$12V;PWK6[?:AY<;(#Y>TAMQZ ?-U/3(K,T
MNRL)/#<-PD%I<7;73)>&XGV-;PX7:47<,YRW//0"N7RGJM&Y?44U3=MQ>T5]
MCU3^QO#)UQH94LHE2:Y6&WBO"RR0!D$3_P"LQNY?C<N0"<<8.+X>T?1+C5+P
MW*03VB:JEMN,Q\N. B4AMV1D$JJ@G^M<+E,8RM.$NU64285QA@&X8=>?6I5)
MI6N5[5-WY3T&[\*>'YY;V\&HP6D,"0L+:*="2=J&12"3AN6Q@L,\<XJ0^%_#
M5KK,TC7/GV):[41_:8]L01&,8SNW,S8#*>G(!YS7G&4]5HRGJM/V<OYA>TC_
M "GH,?AS2[&-XQ%;:LKWT$=JT<P\TJQ3?Y@5\8PQ4 #.<G@"N)U*"*UU2\MX
M)/,AAG>.-_[RAB ?RJLDGER*\;[''1E."/H:['P3\/\ 4O%-_%)-;RV^DJP,
MUPZE=X_NIGJ3Z]!1_#3E)A_$:C%'O7@I&C\#Z&CC#"RBR/\ @(K=ID<:0Q)%
M&H6-%"JHZ #H*?7AR=VV>W%621G:A=303(L;[05R>!6)JGBNVT7[*=2U!+87
M4HAA+IPSGMP./J:U=6_X^(_]W^M</XT\,R>*/[+M@%^SQ23F=RP!0-"R*P]2
M&(/X4AG2+XI@;7GT-;]#J:0^>UN$^8)QSG&.XXSGFIYM<E@OK:S=Y?.N0YCV
MPDK\HR=S 87KQGKVKRQ/!OB@I)J-Q'9SZS>6-PEV7FPAD9X@B @YQY<?KC)Y
MJI9:'X@M+JST,3/:WS1ZE- %FWK;1R1HL19E^4?.&  Z'I0![/\ ;KS.-Y_[
MY%9.K^-++09((]3O_(><,T:B!G)"XW'Y5. ,CDUYY;^!]5F\J.2P6QTY[VT>
M>P74&ERJ*XFDW9_CW+\HY..:Z?6K/5K?Q+HNJZ/IL=['96MQ;M$URL.-^S;R
MV<CY>: .LM=8DO;2*ZM;E)[>50\<L8!5E/<&IOMUW_?/_?(KQU_ GB2U?18[
M>.UD%GY<C3Q3[/+8SM)*@!_APV!@#(SGL*8GA?4]1AUVSB::Z@TN?^S].5;C
MRMT?F&9MQ;AP,QH0>H7K0![)_:%U_P ]/_'12?VA=?\ /3_QT5D:-!<VNAV%
MO>+$EU% B2K"24# 8(4GG'UJ]0!)=:T]E:RW5S<".&)=SN5S@?@,U#I?B,:S
MIEOJ-C<&2UN%W1LT>TD9(Z$9'(-4+JVU".ZFOK2\EF(A*Q:=(R) S_WB^TL#
M^)'M6?X)TS4M%\*VFEZI%;I-:Y16@F,@=22V>@P<DC'/2@#JO[0NO^>G_CHH
M_M"Z_P">G_CHJM10!2/BW3O^$B72SJ47]J!3&(MI[@-MSC;NP <9SBMA;Z[=
M@JR<GI\HKSK_ (1C5SXHP8H?[-_MS^V1=^>-_P#JMOE;,9SGOTQ7?VW_ !\Q
M_6@"[OU#_GHOZ?X4;]0_YZ+^0_PJ>L?Q%#?WMG'IMC#N6[;9<RM(8UCA'WAN
M )#-]T8'<GM0!H[]0_YZ+^0_PHWZA_ST7]/\*XZS_P"$C33(K22'4;>2VTH+
M ENB%)9E5U(=V!(/RIM''7/T5(?$=E% ]A#=3,L<%FK7*+YA4PN3)(3SA)&7
M(_V3UH [#?J'_/1?R'^%&_4/^>B_I_A7%7W_  E<PU.%3JFU+:YC&R*-5<@J
MD1C/4N5+.>V>.,5->1^(8);A;!+]$<&."9(HVF<I%&(A(6& A9I"21_#CC-
M'7[]0_YZ+^G^%&_4/^>B_I_A6)8+X@.OK+=RR_8F>=6B\M1&JJ$5".-V6;>P
MYZ<8KHJ *<MU>PD;Y!STP!5>XUB6UMI;B>X"0Q*7=ROW0.IZ58O_ /EG^-9E
MV9A93_9X_-F\MMB>9Y>XXZ;OX?KVH ;HOB:UU>UEDTJ]$T<<K+(/+*LCD[B"
MK $=<]*UHKF]F!*2# ]0*X?P5HVI:0NK27\9A2\NA-##+<BYF4;0"9)<?.21
MQUP*[FP_U3_[U #]^H?\]%_3_"C?J'_/1?T_PJ>B@"#=J'_/1?R'^%&_4/\
MGHOZ?X5SVNV<M]XLTL36<LVGP0,Q/V3SXVD9QD'D;2%3KS]ZLB74O%"-';W(
MU&.:>>5HH[:&)I?LRH2N<C ?=(BL>@V_4T =QOU#_GHOZ?X4;]0_YZ+^G^%<
M>;CQ@MXRO%=M)!"^X1QQ_9Y2+<;<'&XLTQ/0@ +C'K90>)K:X@@DN+VZ1;U
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MTWH#_.H_[.L?^?*W_P"_2_X59HIW8K(K?V=8_P#/E;_]^E_PH_LZQ_Y\K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gdzs1tysdsfm000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H ?@# 2(  A$! Q$!_\0
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MN/J1S6Y50ES13$U9V"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4-:_Y UU_N5FZSX0L]7U>+54OM0T^_2'[
M.T]C/Y;219SL;(((!R1W&:TM:_Y UU_N5?H Y3_A7VDMK,FHRW&H2H][]O-F
M\_\ H_VC P^P#DC QDD<57MOAMI=MIEQIXU+5I+>687($DZDQS!_,$JG;DMN
M'5LUV=% &;H>B6N@:<;.U>:0-+)/)),VYY)'8LS$X R23T %:5%% !116#XI
MU26PLH8+241W5S*(U( +*G5F /H!U]2* )-7\10:;(UM!&;F^"AO)4[57/3<
MW\/?U/'2K^EWZ:II=M?1H46>,/M/5<]JX!5(>21G9Y)7WR2.<LS>I_  ?A4V
MDZOJ.F7&FV6$73X[AH7Y!,@E?Y#_ +.TD#WH ]$HKESXQ1]3@C@M@UC).(#<
M,^"23M# ?W=W&2><UTY=0K,6 5>I)Z4 +134=9$5T8,K#(93D$4Z@ HHHH *
M*** "BBB@ JEH_\ R!+#_KWC_P#015VJ6C_\@2P_Z]X__010!=HHHH ****
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M8T >DT5AZ%KPU$FTNE6.^C7<0OW95_O+_4=L_C6Y0 4444 %4M'_ .0)8?\
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M[5+1_P#D"6'_ %[Q_P#H(H NT444 %4]6_Y ][_UP?\ ]!-']K:=G'VV#/\
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M )W$8^7MUKTNN2UKP?>W^HW]QINO2:=#J<2Q7T7V5)O, 4KE"WW#M..X[XH
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M9DMSI\3W$EUIQVE"C2-+NW-Y8?'S="5P-WM1!=:=L:2WT^0;[82KLE.Z7/)
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MM'_Y EA_U[Q_^@BKM4M'_P"0)8?]>\?_ *"* +M%%% !5+6$>71;Y$4L[0.
M!U)P:NT4FKJPT[.YXU+'',"'"NN>AYI@BBBB81JJ[A@ =S7I^IZ99QI]HCM8
MQ,7&65>>]5=$T:QFL4GEM4,I8G<5]Z\Y83W^7FV/1>.]V_*:ULK/HZ*/O&+
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MY@6&\7[UM*)#[J?E8?D3^5=)6]&3=XOH7!] HHHK<L*I:/\ \@2P_P"O>/\
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M !1110 4444 %%%% !1110 4444 %%%% %#6O^0-=?[E7ZH:U_R!KK_<J_0
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MG.,.IQQC^[Z\U-#/86-K;VXNXE15\J/?*,ML'(]R .:H9=HID<B31++&P9'
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gvxjy5si4hmk000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'F H,# 2(  A$! Q$!_\0
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MHW_"]/'_ /T%H?\ P#B_^)H_X7IX_P#^@M#_ . <7_Q-><T4 >C?\+T\?_\
M06A_\ XO_B:/^%Z>/_\ H+0_^ <7_P 37G-% 'HW_"]/'_\ T%H?_ .+_P")
MH_X7IX__ .@M#_X!Q?\ Q-><T4 >C?\ "]/'_P#T%H?_  #B_P#B:/\ A>GC
M_P#Z"T/_ (!Q?_$UYS10!Z-_PO3Q_P#]!:'_ , XO_B:/^%Z>/\ _H+0_P#@
M'%_\37G-% 'HW_"]/'__ $%H?_ .+_XFC_A>GC__ *"T/_@'%_\ $UYS10!Z
M-_PO3Q__ -!:'_P#B_\ B:/^%Z>/_P#H+0_^ <7_ ,37G-% 'HW_  O3Q_\
M]!:'_P  XO\ XFC_ (7IX_\ ^@M#_P" <7_Q-><T4 >C?\+T\?\ _06A_P#
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M_P")H_X7IX__ .@M#_X!Q?\ Q-><T4 >C?\ "]/'_P#T%H?_  #B_P#B:/\
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MH&BBB@ HHHH **** /!_VE_^0?X=_P"NL_\ )*^>*^A_VE_^0?X=_P"NL_\
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ME,80.2 >AS@CIUZ8!I=?\'7^AW^G6R3VVH1ZG&LEE/9L628%MH R 0<\8(H
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M^%'_  ^_Z C_ /@9-_\ %4?\*/\ A]_T!'_\#)O_ (J@#Y#HKZ\_X4?\/O\
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M'W_0$?\ \#)O_BJ /D.BOKS_ (4?\/O^@(__ (&3?_%4?\*/^'W_ $!'_P#
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MP^_Z C_^!DW_ ,51_P */^'W_0$?_P #)O\ XJ@#Y#HKZ\_X4?\ #[_H"/\
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MP^_Z C_^!DW_ ,570^%_ WA[P:;HZ%8FV^U;?.S,[[MN<?>)Q]XT =%1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4455O[^'3H%EF65][B-4B0LS,>@ % %JBLK^W5_Z!NI_^ IJQ8:G#J#S
M1I%/%)#C>DT10C/0\]N#0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1;V1W=%<=_PD.E_]#M_XY#_\11_PD.E_]#M_XY#_ /$4N>/<?)+L=C17'?\
M"0Z7_P!#M_XY#_\ $4?\)#I?_0[?^.0__$4<\>X<DNQV-%<=_P )#I?_ $.W
M_CD/_P 15:+Q-9MJ-S$_C'$"(AC?RHOF)W;AG9SC _.CGCW#DEV.ZHK$LX9]
M0M([JS\23SV\@RDD<4)#<X_N>M4;W5+33KMK6\\8-#<+@-&Z0Y&<8_@[Y'YT
M[H5F=317 VGBW397NA/XWC14F*1';"-R8'/W.>2?RJU_PE&B_P#0]Q_E!_\
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M\>7S6L37'V=)BOSJTY4@]QCR#C\S4D'C1[G4O*N]3%C:B$L)(%,Y9]P&#F$
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MX9&O[DJRMD$><W0UZ9XD4O<:2!%')_I)RK],;&R>AY S7FB@+=ZBJ@ #4+H
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M&MFT%B-T\CJ1-))S@AL=,LS8[D^U0_\ "LO#'_/"^_\ !C<?_%T?\*R\,?\
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M\S2B3(C=)7C16XX#%,;NQ(%6)O$6@0PI>W>AO;S64<+6RS6\:N(G<(C(<X4
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M[KR8\QJF=P))R,#T]: .JHK#T3Q9I?B"=(;"0R.;5+IAQ\@8D!6P>&XZ5N4
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M237S@, U_<D!U*D?OFZ@\BO'SK^#'U_1GKY-_&EZ?JB:BBBOFCZ0**** &[
M6R"5)[BL?0M3N;^]U6*<@I;7!BC^0#@%AV//0=<5M#K7->%O^/\ U[_K^?\
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MNPHH Q=#\-6V@23O!?:G<F8 $7MX\X7&?N[CQUK:HHH **** "BBB@ HHHH
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MC!]*JQ:$+K59-.AO[FZO\R,56(HIVK&YVGS@" )E ''2J7]EZC_T+WBK_P
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M_OS?]^HO_CM5QX"NC>&R%S/]K')B\B/[N <Y\W'?I2>(I]Q/&T7U.2HKM?\
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M<L59 EU84445D4%4M5_X\T_Z^8/_ $<E7:@O;<7-H\;.Z<JX9,9!4A@>01U
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M35\6RWQG;R S6I/EMD2C:"N,9R""* .YHJO!>V]R[)')^\7[T; JP_ \U8H
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M!@,;%!SDCOZT ;=I9QVB';EY7YDE;[SGU/\ AVKQS_F)7G_8QW'_ *.KVNN
M_P"$(N3K#G]XMN^K/?M,)D/RL=VW;MS]['?\: .WN[..[0!LI(G,<J_>0^H/
M].])8W#W%N?- $T;&.0#IN'<>QX/XU9KG;VWUV/5;J2S9_LLNUD$31 @[0#G
M>I/84 )X[M[JZ\(7D5K'+-\T33PP@[Y8!(IE1<=R@88[].]>1>7)=>+=2O\
M2'LVT9;,Q3R6-FUM"3MD,:%3]Z105RPZ $8KUG;XD];G_OY;_P#Q%5KZPUZ^
MMFBFAEG R5CEEA",V"!NPF2.>0* *?PH@SX)TZXW=$DCVX]7SG]*[RN/LO $
M%A:I;VVLZI;QK_RSAE"*#WP .*L?\(8?^AAUK_P('^% '45XW\5/^1JMO^N*
M_P GKO/^$,/_ $,.M?\ @0/\*S]1^&.FZL#]NU"^N6V[0TY1V7W!*\'_ !-5
M"7+),NG/DFI=CR#!]#1@^AKTL?!#PR !YEV<=S*:7_A2/AC^_=?]_#_C77];
M78]#^T5_+^)YHJEF YYI&<,V<C'8>@KU&V^#'AVUNHYXYKK*.C[2P(.U@W<'
MKC!]02*[+_A&M!_Z FG?^ J?X4OK2OL+^T%>_+^)X!X'!/B34<#/[Y?_ $HM
MZ]&\%?\ (DZ+_P!>J5L3_#'0GU"_O+=/LK7I!=8HD C("CY./EY4-_O<UO:=
MX:TK3-,M;""T0Q6T2Q(7&20!C)]S7S&=93/,9<T9<NWX7_S,88I*;E;<YU5\
MF]VJ/DF!8CT8=_Q'\JM8/H:OZSX0T_5UMQF2U,$F\&# W\8PV>HKGQ\)],QS
MJVKL?4W3#^1 KQ9\*59V;JJ_I_P>QHL:ET-'!]#1@^AK/_X5/I?_ $%-6_\
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M%% !1110 4444 %%4;+5[+49I(K65G>,9.Z)E!&2,@D ,,J1D9Z5>H ****
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MLOCAJ?.I7UL>B?\ "Q+'_GDO_?W_ .QJ"[^)EE:6YE6PFN2" (K=PSG) SR
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MH36S13C4@G=PO\V3*G-JRE;Y(****R-@K/F_Y"5G_O7?_H%M6A6?-_R$K/\
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MX!CU--2J/K^)+C!=/P,6QT^R.L7R&SMRJ] 8EP.?I6HNF:?N'^@6O7_GBO\
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M)M=U2-M%TTH@AVJ;5,#*G..*T_\ A%_#_P#T M,_\!(_\*6Q_P"1@U;Z0_\
MH)K5H R?^$7\/_\ 0"TS_P !(_\ "C_A%_#_ /T M,_\!(_\*UJ* ,G_ (1?
MP_\ ] +3/_ 2/_"C_A%_#_\ T M,_P# 2/\ PK6HH R?^$7\/_\ 0"TS_P !
M(_\ "C_A%_#_ /T M,_\!(_\*UJ* ,G_ (1?P_\ ] +3/_ 2/_"C_A%_#_\
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M>U^WD>OE>*I4%+VCM>Q6HJ__ ,(IXO\ ^@;IG_@P;_XU1_PBGB__ *!NF?\
M@P;_ .-5Y/\ 9F+_ )/Q7^9ZW]I87^?\'_D4**O_ /"*>+_^@;IG_@P;_P"-
M4?\ "*>+_P#H&Z9_X,&_^-4?V9B_Y/Q7^8?VEA?Y_P '_D4**O\ _"*>+_\
MH&Z9_P"#!O\ XU45MX=\674;21Z9IP59'C.=0;JK%3_RS]0:/[,Q?\GXK_,/
M[2PO\_X/_(JUGS?\A.R_WKO_ - MJ[6S\ ZG+:1R7NJ0V]PPR\,4'F*GL&)&
M>.^!69J7@'Q#!?V\E@UC?1QF8EI96@;YUB'0*PX\L]^]>IEN!K4*W/46EO\
M(\S,<=1KTN2#UO\ YC8]<FCB2,0QD*H4')[4[^WY_P#GA%^9JI;^&_%=R\ZI
MIFG P2>4V;]NN >/W?3D5-_PB/B__H&Z9_X,&_\ C5>X>(3?\)!/_P \(_S-
M'_"03GK!'^9J'_A$?%__ $#=,_\ !@W_ ,:H_P"$1\7_ /0-TS_P8-_\:H F
M_P"$@G_YXQ_F:3^WY_\ GA%^9J+_ (1'Q?\ ] W3/_!@W_QJHKKPUXLL[.:Y
MDTS33'#&TC!;]LX R<?NZ )+K59+R(1/$BC<&R":R[3_ %2?]<(/_1*5J_\
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M:E--L4.K-A67&2%Q0!J6/_(P:M](?_036K658_\ (P:M](?_ $$UJT %%%%
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M#H/^^:U:* *MEIUGIRNMG;1PB0Y?8N-Q]ZM444 %%%% !1110 4444 %%%%
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MQ] ?\)UH'_/T_P#WY;_"I+?QGHEU<Q6\5RYDE<(@\IADDX':O(>W/6M#0_\
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MGH/YUDRS^)<:C\MP,?Z@1PJ<G/ 7VQU)Z5FJLVKZ%.*/=?\ A,-%_P"?E_\
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MI6)_PJ[PQ_S[3_\ ?]J[*BK5225DSJI8[$TH\E.HTNR9QO\ PJ[PQ_S[3_\
M?]J/^%7>&/\ GVG_ ._[5V5%/VL^YI_:>-_Y^R^]G&_\*N\,?\^T_P#W_:C_
M (5=X8_Y]I_^_P"U=E11[6?</[3QO_/V7WLS=$T.Q\/V)L]/1TA+F0AW+')
M'4_05I445#;;NSCG.523G-W;"L*3PCI$LKRO%+N=BQ_>GJ3FMVBI<5+="3:,
M#_A#='_YY2_]_31_PANC_P#/*7_OZ:WZ*GV<.P<S,#_A#='_ .>4O_?TT?\
M"&Z/_P \I?\ OZ:WZ*/9P[!S,PX?"6DP3QS)'*'C8,N93U!S6Y115**CL#;8
M50U/1[35XXTNU9EC8LNUBO/X5?HIB.>_X0O1O^>4O_?UJ/\ A"]&_P">4O\
MW]:NAHH Y[_A"]&_YY2_]_6H_P"$+T;_ )Y2_P#?UJZ&B@#GO^$+T;_GE+_W
M]:M73=,MM)MF@M%98V8N0S$\_P"15RB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *Y?Q[XQC\$^'#J/V8W5U-*MO:VX./,D;.!GTP":ZBN2^(?
M@P^-O#BV4%U]EOK:=;FTG/19%R!GVP3].M &-HU]\6+C4K)]4TK0;?3Y)5-P
MJ2,98XR><?,1N KA;;XP^,+JPO\ 4%N/"<$5I(Z_9KJ9HYY O/RKNYST'O7;
MZ++\7(]3LH-7MM!EL%E5;F>-CYC)GYF R!G'M7G,'PE\9V]E?V7_  COANY^
MU22,MY=.6FB#<?*01C'4<'F@#H]4^+'B5KW08+&+1--_M+2UO9#JSLB(VYQC
M=D<$*"..]1CXO^)(O"WB:ZEM=(GO-'DMUCN[-FDM9O,?! .>2!Z&M&P^%-Z?
M%'AQ]=BM-6TS3](^R7#3-NW2[G( 4\D#< #[5F:O\)]<$'C33]%MK:#3-3DM
MGL+<3X0%'!8X_AXW4 :&A>.O&NJZCI\1U3P.Z7,B;H(;MC-M."0%W?>QGCUJ
MS)XOOO"Z_9[&WM)FO-7U1O)FW;YF2Y $<6W^-MYZC'%9?A[P7XOTG5=-F/@G
MP?#]GDCWW49?SE P"X._[V,GIUKI;#PA;>)[>ZN)KJ:WFL]5U(6[Q 9CD:Y#
M"0>ZF,?7)H O77Q*TG^T-/\ L=T'L3-)'=LT#[O]6S1^7Q\VY@,$ YJU#\1]
M :X*R7L9CEE1+<Q1R.Q#*AS(-OR?-(%].1WR*QW^$=O-;QQ7&M7$_DLI@+P(
M0@1&6-2.C ;N<]:H:E\,]0LKZQ.BSM,LKQI>2.8XU5%:$D; .A\K/R\@\=#F
M@#LO!'BF+Q5H$-PSC[?%&@O(Q$R!'9<\!NJD=""0?6NEKG_#'A2#PP)Q#=2S
M^=%!$?, &!$FP=/4<UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %106T%JKK;PQQ*[M
M(P10-S,<LQ]R3DFBB@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gdzs1tysdsfm000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #D KH# 2(  A$! Q$!_\0
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MX53\W\)ZYZGODT :8(8 @@@\@CO2U0T3_D :;_UZQ?\ H(J_0 4444 %%%%
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M>HZ9YXZBH+OQ3I%E//#-<.)(2 RB%SDDJ,+@?,?G7('3(H&:RPQ)*TJQ()&
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MU=!6#X/XT +_ '9YA_X^:WJF'PHY\)_N\/1?D%%%%4= 4444 %%%% !1110
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M)H BTG>/#=B8@ID^R1[ QP"=@QFLGP?JVH:JE\UY)%(L4Q12I&0?3C^'T/\
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M00H7D=NB@4 353U;_D#7W_7O)_Z":J2^)])AD\M[E]Q564+"YW%@"%&!RY#
M[1S@]*EN[J&^\.75S;/YD,ML[(P!&?E/8\@^U #]$_Y &G?]>L7_ *"*S_#N
M%U'7H\=+TO\ FHK0T3_D :=_UZQ?^@BLO0YD/BCQ%$KJ2)8F !_V.?UJ);HP
MJ_Q*;\W^3.CHHHJS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM-G-B(IRA+L_ST.CHHHK0Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M527ZKN7D KW![CF@#3T3_D :=_UZQ?\ H(K)N_W?Q!T]O^>MFZ?D2:UM$_Y
M.G?]>L7_ *"*Q=;8Q>-?#\G9O-0_]\X_K6=1V2?FC&NO<^:_]*19USQ')I&I
MVEL+)Y8YC\S^O;"^_P!:Z"N3\86L^H7=A:6R*\GES.%8XY &/Q]/>F^#O$\F
MIR2:;>L#=0+E7)Y<=\^XXKEI5I?69TY:KI]RNOQ/0Q"I0P].=TF]/7>WY,ZZ
MBBBNXY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-%1%5448"J, "K49-*[.*CAJ\X1]I4;6CM9>NK[&%X:S#/K-F3_JK]W4>BN
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M8V@_SK?HCM<>&UBY_P S;_1?@D%<UX^EU.'P==G2!>?:F>)";%"\ZQF11(4
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M>.12K*>X/6LJU)58.#+A-Q>G6Z^_0\GL=1OM1L+V+?#_ *8;:U<C[V<@+C\
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M,U@_$6W6;P_"VX*R7*X).,Y!!'^?2NMC01Q(@Z*H _"H7Q,X:,6L74]%^/\
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M[U.+Q)- 6LOM*Q*@7ET (\P^O('%=-XBT9];TT6\<YB=7#K_ '3]:2ZT<?\
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ML)N9?F:"0L58'^$GVXQ5J\\7C3 D>H:;<0W!/* @J1ZJW>L:>)4(MUER^O\
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M** "BBB@ HHHH ***BN+B"T@::YFCAB7[TDC!5'U)H R?%__ "*E_P#[@_\
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M_H)JY5/5O^0-??\ 7O)_Z": &:)_R -._P"O6+_T$5?JAHG_ " -._Z]8O\
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M2X9FC5I(A9.VQB.1GSN<'C-)KDZ0>%#)*U^$V1AI(9#',F2/F)'3'4]NM4O
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M/5C2:1H<NDK&JZI=S(-QDCD(9&)).1NRR]>@./:MBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS6Q\%^)3]CT
MV]DTJ+2K+5I-4CFB>1YI&,CR(I4J%49<9P3P/>O2J* /&+KP7KF@Z1J.HR0V
MCZD8[,V":;"TG^EPR.RML6-0JL&(/8 D$GK6M/\ #34(IM"?37LXY;*"!)[F
M9BQ=EE,CDQ%&5LLS$$%""<Y->HT4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !61XITN;6_">KZ5;,B3WEI+!&TA(4,RD#..W-:]% 'FMQX.\5:
MKYM[J!T2*\AT];"UMX]TT3IYJ.[.SIP2(P%^4X//-8EQX$U*W?2=(VCS;R]N
MDOFMHV>(:?+()F5I"H (9 H'?><#DU[+10!P>D>"]1TSX@W&MQFRAT^5YW>-
M6,CR&3&,;DS&<C)PY!X  KO*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gvxjy5si4hmk000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &F F\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KC?B3KMYX?T*PN+/41IWGZE!;SW1B63RHF)W-M((XQFNRK
M!\4Z!)X@BTI([A(?L6I07S%DW;Q&22OL3GK0!S?AKQP]MX9U/5O$-\]SIMK?
M"WM=26R:,W4;;0&\L#^\Q7(&#BMU];6\OO#TB7E[IJWDTRBRN++:]SM1CM;<
M,QXVE@>,\>M6/%F@R>(]$6PCG6!A<P3[V7<,1R*^/QVXI^K:(^HZ]H.I+.J+
MID\LK(5R9-\31X![8W9_"@"O#XUTF;Q&F@B/4$OY&<(LEC*B,$^\P<KM*CUS
MCD>M1R>/-#BU9[!GNBL=P+62\%LYMHYR0!&TN-H;) ],G!.:I6'AWQ-;>,[S
M7)M1TJ:&Z98RKVTAEAMU)Q%&V_ Y.2<<DY],90^&<T6M7#Q3:5)IL]^;UC<V
M327"EGWM&#NV$;NC%<C/L* .LNO%FFVOB*/0=EW-J#!'9(+9W6-') =F PJY
M'))IL?C'198;:1+AR;B^;3HX_*;?YZDAE*XR,;223P!S3[30WM_&.HZX9U*7
M=I!;B+;RIC9SG/OO_2N9\.:!%<_$C7_$ BFCL[><Q6L<BD*URR(L\R@CN%5<
M]\-ZT >@US?@N]NK[3-0DNYWF>/5;R)"Y^ZBS,%7Z  "NDKE/ (*Z3J>X$?\
M3F^/(Q_RW>@#7\01ZO+IGEZ-=V]G<&1?,N)HS)Y<>?F*KT9L= >*X[PUXPU:
M;PKKNI/(-92QNC%97'D_9VNE^7.Y ,J0Q(S@9 SBNM\1Z=JNH6<!T;5/[/O+
M>=9E+IOBF SF.1002ISV(/ JGX7\/7NDW>K:EJEY!<:CJDR2S"VB,<*!$"*%
M!).<#DD\T 9FI^(M4_X2O2M'$0@VW<7GM&7/G*T3LQ'RX\L, ,D@Y'3UU?'>
MJWFB>!=8U.PD$=W;6YDB<J&P>.QX-=%6+XMT1_$GA34M&CG6![R$Q"5EW!<]
M\4 <5H?B6[O_  OXDN4\37VHW%OISRQF;2OL?D-L<@J=HW'(]\8]ZZ"Q\6VV
ME>"_#ESJDMS=7]_90F.&"(RSW,GEJS$*HY]2>@K=U+37O_#5YI0E"//9O;"0
MC(!9"N<?C7.S>#]1M[+PW-I6HV\6K:):?9 ]Q"7AG0HJN"H((Y0$$'VYH UD
M\9:$WAR77C>;+&)C'*7C82)(#M,93&X/G VXSS3M'\6:;K*W:Q"ZM[BT4//:
MW=NT,R*02&VL,D'!P16&/ 4S^&[JVFU0?VQ<ZDNK->)#B-+E2I7$9/W $48)
MR>3G-7=+\-:H=4O]9UR_M9]2N;,6,:VD+1Q11 ENC,2Q+-G)/L* -'P[XHT_
MQ1;O<Z9'=FU 5DGFMGB24'/W"P&[&"#7+_$KQ+?Z#J7A^WMM6ETRVO6N!<3P
MV0NG^15*@)@GJ>U=7X6T9_#WA;3-'DF69[.W6$R*N V!UQ69XJ\.ZMJNL:+J
MNC:A:6EWIAGQ]J@:57$BA3P&'0 T &E>*;"S\,Z5>:IJTT\=Y(85O[FT-N&?
M+8WK@"/I@$X!X]:GG\<:);:-IVJR27/V;4I/+L]MK(7F8@E0$ S\P4XXYR/6
MJFL>%]3\3Z%8Z1KFHV[6S2%M3%K$T?VE0<HB9)V#.TD\D[>,9K$U_1]?MK+P
M98QWT=QJ%GJF$O3;%DV+#*%,B@]QA201R<C% '46WC;0Y_#]YK3SR6UM8L4N
MTN8F26!QCY60C.[D8 ZY&*=HOC#2]=O9+&W2\@O8X!<26]W:O"ZH3@$AAWK#
M;P%=WWAW7H-2U.(ZMK%S'=/<6\)$4+Q[/*"H220/+7.3SS5[1/#NN1>*)]>U
MS4K*XGEL%LQ%:6[1H@#EL_,Q)SDT +IOQ%\/ZM>V%O:2792_+);7+VDB0RN
M24#D ;A@\>V.M:-MXJT^\U^?1[:.\EE@<Q2SI;.8(Y H8H9,8#8(/XXZ\5@6
M/@*>TT+PCIQOXV;0;L7#N(R!-PXP!GC[_P"E3'P?J#>.TUY+RSMH5E+R&UA>
M.:YCVX$4OS;' /.XC/ '% &AI^N6EI8Z[?W^MF>UL;Z599)8!$+4*%_=# ^<
M#/#<DYJ;0_%VF:]=R6<"W=O=I&)OL]Y;/!(\1.!(H8#*Y[CIWQ69+X'%UH'B
M+2KB]*C5M0>]CEC3F$DHR<'[V&0'WZ5-H_A[63XC37?$.HVES=6]JUK;165N
MT2*K,&=FW,26.U>.@Q0 :=\1/#^J7UC;6KWA2^9H[:Y>TD2&21<YC#D8W#!X
M]JZ2]D>&PN)8SATB9E..X!KDM.\$3V.@>%]-:^C=M%OOM3R",@2C$HP!GC_6
M?I7774)N+.:$':9(V0$]LC% 'E/P]\::WKFKZ-%)K0UB*\LI)M1C%B(A8. -
MHWJ #DDC!^M=QIGCC1-6L[N^MWN4T^TC:26]FMWCAPI(8!F R1@Y JYX5T9_
M#OA73='DF69[.!8C*J[0V.^*QK/P,B_#27P?>W>]98YD:XB3;C?(S@@$]BP^
MN* -+1/%^F:]>/9P)>6]R(O/2*\M7@:6+./,0,!N7./ID9K,B^)_AN9[<1-?
MNMR&^S2"QEVSNIP8T.WYG]A3/"G@V\T75FU"_.D%TM_(C%C9M&QR02S,[,><
M#Y1@4:/X(GTS3_"EL]['(=#GFE=A&0)=Z2* .>,>8/RH FOO%MAJ7@M]9LM5
MN-,A6Y2!YGM"TL3B54:-HV'!).T^F<UIWWBO3[#7(=':.\GO'57=;:V>40HS
M%59RH^4$@C]>E85UX#N+CPKJ^CB_C#W^KMJ*RF,X0&=9=I&>3A<9J3Q9X.U#
MQ#K-K>V=Y9V30A EXL3B[@P^6".K ,K#C:P(')YH TM:\;Z/H5\]I<_:Y9(8
MQ-=&UM7F6UC.</*5!VC@^^ 3TJ34O%^EZ==6=KBZNY[N'[1&EE;M.1#D#S3M
M!^7+#GWKG/$7P\N=2\1:AJNGS:9_Q,HHX[E=0M6F,112H:/#@'*]58$9'UJS
MXH\#WFL6FFVVG7%A:BS@$,-P;=TGMF& 'B:-AC@?</R]* .YHID*-'#&C2-(
MRJ 7;JQ ZFGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445E^(YY[7P[?36\K0S+$=DB@94^HSD9H U**Q/^$?G_ .AAUC_OY%_\;JO/
M976EWNG2+K.HW"RW0B>.=HRK*5;T0'L.] '1T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#N']CXO^7\5_F?0=%?/4OB1Y(9(QH 0LI4,(QE<CK]RKT7C*WCA1#X*MG*J
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M,5LT<@<M&'.X8(VGY<8Y[^E'MJ?</[(Q?\OXK_,]]HKY^_X263_H7%_[]?\
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M_P ?-Q_O-_Z,>M"KGN)!1114#"BBB@ HHHH *@O?^0?=?]<7_P#034]07O\
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MJW+J ?VA+_SZC_OMO_B:7^T)?^?8?]]M_P#$U?HI<R[!8H?VA+_S[#_OMO\
MXFC^T)?^?8?]]M_\35^BCF78+%#^T)?^?8?]]M_\34%Y?RFQN1]F S$X^^?[
MI_V:UJ@O?^0?=?\ 7%__ $$TXM7V''='F/P]EB3PKJ<;2(KOJ-CM4L 6_>IT
M%>W5\^^"XHG@A=HT9UOHMK%02/FBZ&OH*OK:7P(>;?[[4]?T"BBBK/."BBB@
M HHHH **** "BLVZURRL]5M],<RO=SKO6.*%GVIG;O; ^5<D#)JS>7L=G:27
M!6254&=D*[W/.. .M %FBJUMJ%I=^=]GN(I/)F,$FUONR#JI]^:BU75K;1[3
M[3="8H6V@0PM(QX)/"@G  ))]J +U%8P\5:.U_;6:76Z2Y5&C948I\X)0%L8
M!8 D \G%2:3XATW6Y9H[&9G:(!OFC9=Z$D!UR/F4E6 8<<&@#5KBO&G_ !Y^
M(O\ L#)_Z')7:UYQ\1;B\ADOTMY(5AGTT1S*\99B,RGY2",'CN#UI2V9MAOX
MT/5?F4OAS:/-X35Q+L'VB08^;V]&%=9_9\G_ #\'_P ?_P#BZYWX9?\ (G+_
M -?,G]*[&OE*\FJLCT\;_O,_5E#^SY/^?@_^/_\ Q=']GR?\_!_\?_\ BZOT
M5ESLY;%#^SY/^?@_^/\ _P 73#:@$@WJ ]P7;_XNM*LU-*T^66;SK*!Y0Y)9
MD!)!Y!_SZ4U+N%B.6W58)&^V1MA2=I=N>.GWZL:5+'/:R2Q,K1M,Y4J>.U']
MBZ7_ - ^V_[]BKBHJ*%1551T"C IRDFK D.J*Y,HMI#""90ORX]?QJ6BLT,K
MVC3,DAF$@^<[/, #;<#KCCKFK%%%#=V 4444@"BBB@ HHHH *BN3*+:4P_ZT
M(=GU[5+130%>T:9ED,HD W?)YH ;&!Z>^:L444-W8!1112 **** "BBB@ J.
M8R""0Q?ZS:=GUQQ4E%,"M9M.RR><) ,C;YB@'H,]/?-6:**&[L HHHI %%%%
M !1110 5'-YGD2>5_K-AV?7''ZU)13 JV;3L'\X2@<;?-50>G/3MFK5%%#=V
M 4444@"BBB@ HHHH *;)N\MMGW]IV_7M3J*8%2R:X;?YXE PN/,50<XYZ=NE
M6Z**&[L '6LC0)9)K:8NBKM8(,'.0!C-:XZUC^'O^/6;_KI5Q^!B>YL4445F
M,**** "H+W_D'W7_ %Q?_P!!-3U!>_\ (/NO^N+_ /H)JH[H:W/'_!./LL6<
M9^W18_[ZBKZ KY_\$X^RQ=,_;XO_ $**OH"OKZ7P(,V_WVIZ_H%%%%6><%%%
M% !165<>'K*YN))Y);\/(=Q"7\R+^"AP!^%1_P#",:?_ ,]M2_\ !E<?_%T
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M_P#/!O\ OVO_ ,75J"W6 ,%9V+')+MN/3%2TW)7T0:E#S[__ )X-_P!^U_\
MBZ//O_\ G@W_ '[7_P"+J_12YO("AY]__P \&_[]K_\ %T>??_\ /!O^_:__
M !=7Z*.;R H>??\ _/!O^_:__%T>??\ _/!O^_:__%U?HHYO("AY]_\ \\&_
M[]K_ /%TC75[&C.T)"J,DF-> /\ @=:%->-94:-QE7!5A[&FI+L!FZ9-"J.#
M)M^5>)1L/<]#]:T/M$'_ #WB_P"^Q67I]J)P[R33LV%&?,^HJ[_9T7_/6?\
M[[IR4;ZB5R?[1!_SWB_[[%'VB#_GO%_WV*@_LZ+_ )ZS_P#?=']G1?\ /6?_
M +[J;0[CU%N9X6B 66,DNF &&3\PIFGSPC3K<&:,$1C(+BG#3XP<B6<'VDH_
ML^+_ )ZS_P#?RG>-K!J3_:(/^>\7_?8H^T0?\]XO^^Q4']G1?\]9_P#ONC^S
MHO\ GK/_ -]TK0[AJ3_:(/\ GO%_WV*0W-NJDF>+ &3\XJ'^SHO^>L__ 'W2
M'3864J9)R",']Y1:'<-2O97,-SJ<S0R!QECP/54K4JG;V,-M-O1I2VW;\[EL
M#BKE$VF] 0#K6-X=8-:SX(.)><&MD=:QO#BJMI/M4#,N3@4X_ P>YLT445F,
M**** "H+W_D'W7_7%_\ T$U/4%[_ ,@^Z_ZXO_Z":J.Z&MSS3X=_\BCJO_81
ML?\ T:E>UUXI\._^11U7_L(V/_HU*]KKZZE\"#-O]]J>OZ!1116AYP4444 %
M%%% !1110 4444 %%%% !1110 5YM\2!^]N?E!_T$<^G$U>DUYM\2,>;<\X/
MV$8'KQ-2EL;8;^-#U7YB?#+_ )$Y?^OF3^E=C7'?#+_D3E_Z^9/Z5V-?)8C^
M+(]/&_[Q/U84445B<P4444 0W9Q97!](V_D:H>'76320R_=,KXX]ZOWG_'C<
M?]<F_D:I:#_R#3_UU?\ G6J_AL74TZ***R&4(_\ D+2_C_Z"E'_+M_V]_P#M
M2B/_ )"TOX_^@I1_R[?]O?\ [4K7_@"+]%%%9#*T2(UU<ED4G<O)&?X13;J-
M%>U*HH/GKR%'H:DA_P"/FY_WE_\ 013;O[UK_P!=U_D:TN^870LT445F,*BN
M?^/2?_KFW\C4M17/_'I/_P!<V_D::W!D&F_\>\G_ %U/\A5RJ>F_ZB3_ *ZG
M^0JY53^(2"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !2CJ*2BF
M!F:-(DD<VQ@VPA6QV()XK3JM9_\ +Q_U\/\ TJS53W$@HHI#_6H&+1110 44
M44 %%%% #?XOSIU-_B_.G4V #J*Q_#O_ !Z3?]=:V*K1Z?:0AA#"L6X[CY9*
MY/KQ5*246F+J6:*K[G@8"1B\1. YZJ??U'O5BI:&%%%%( J&Z1I+.XC099HF
M51ZD@U-133L!XGX6N=3TK4IM%?9'&;FW-U"P!(99XAP1W&?I7T+7@B_\E(U3
M_K\B_P#2F&O>Z^LP[;IILUSAWQ"E;=)_@%%%%;GE!1110 4444 %%%% !111
M0 4444 %%%% !7G7Q#M[F=M1>)(S%!IHDE+.00,RC@8YZ^HZ5Z+7 >/+^"U7
M6;>7S/,N=)5(ML;,"0TAY(&!^/O2ELS;#?QH>J_,J?#+_D3E_P"OF3^E=C7'
M?#+_ )$Y?^OF3^E=C7R6(_BR/3QO^\3]6%%%%8G,%%%-DD6--SG _G3 CO/^
M/&X_ZY-_(U2T'_D&G_KJ_P#.K4HGN()(UC6,.A7,AY&1Z#_&F:9:265EY,KJ
M[[V8E1@<FKNE!H74N4445F,H&.Y747DCB4J<_,[8'11VR<\&E6"ZVA'$(7SO
M,)#DG[V[&,5>HJ^9BL%%%%0,K%+A)Y7B6)E<@_,Q!&!CTIKQW4TD.]856.0.
M2KDDX!]O>K=%5S,5@HHHJ1A45S_QZ3_]<V_D:EJ*Y_X])_\ KFW\C36X,@TW
M_42?]=3_ "%7*IZ;_J)/^NI_D*N54_B$@HHHJ!A1110 4444 %%%% !1110
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M1_8]M[?]^8__ (FBT>X:GEJ_\E'U/'(-[%_Z4PU[Y7@,$8B^(>I1KT6[B X
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M+0]/&_[S/U9G_;Y_^?4?]]/_ /$4?;Y_^?4?]]/_ /$5H45ES+L<IG_;Y_\
MGU'_ 'T__P 11]OG_P"?4?\ ?3__ !%:%%',NP&9-?3-!(IMU4%2"2S\<?[E
M3Z=Q%,,YQ,W/Y58N/^/6;_KFW\JQ])>6;4-1B,SJD3J4"XP,CFK2O%V%U-RB
MH!(\3JDV"&.%D P,^A'8TZY,HMI#""90OR@#)S65BC,O+=[N6]MXR \D;*I;
MIDJE:"I<-&J,R1 * =ARWY]JHVDA74)3.[+\S &4!21M3\*U00P!4@@]"#FM
M)MK02$1%C0*@PHJKJ@4Z5=!\A?+.2.N*N53U;_D$7G_7)JB/Q(&5K5;679%+
M9LDN2C$CC<!GU[CFFZM%9VEA(WEA&*GYAG*@#EOP'ZD5-=JT%]:72J6C9Q%(
M!V)!"M^N/Q%5-8S-HNI7753$4C_W >3^)_D*U6LD^@B]I9S!*>>9!U_W%J]7
M-BZGB:.&WO(X6ED^;S%!"@1J<^O-227=];O"9-5MI$>548)& 0#WHE3;8)G0
M4R9S'#(XZJI89]A53SH_^@G_ .@?X5!>S@6%P8]0#.(FVJ=G)Q]*S47<=QEL
MFJW<;2/J21,'*[(X 5'3H3S4QLM2(Q_:YY_Z=EHT8RFWG\S=CSCMWJ 2-J^G
MOFM*JE)IV$EH,B0QPI&6W%5"Y]<4^BBLR@HHHI %%%% !114<YD$$AB&9 AV
M#WQQ3 DHJM9M.RR>=YG##:9%"G&!G@>^:LT-6=@"BBBD 4444 %%%% %6XQ)
M=6\+$;<F4@]]N,#\R#^%6N:KW%E;790W$"2E/N[ATJ.:PMQ!(8K6(RA3L&T<
MMCC]:O1V$6P0>A!^AI:R="@A@BG6!75&*M\ZA23CGI6M2DK.P(***IF]D-[+
M;16S2&)59FW@9W9Z9^E))L9<HJ&*Y25RF&20#)C<8./7W'N*E) !)( '))[4
M68"T56%TTN#;P/*O]\D(I^A/)_*ELKH7MJLXC:/+,NUCTP2/Z4^5VN*Y8HHI
MLFX1ML^_M.WZ]J0QU%5+)KA@_GB3&%QYB!3GOT[=*MX/I0U9V !UK'\/$&UF
MP?\ EK6R <UEZ+&D<#A$"[@A.!U.WK5Q^!BZFG11168PHHHH *;)_JW_ -T_
MRIU-D_U;_P"Z?Y4UN!Y5\/\ _D#ZW_U^V'_H\5[A7A_P_P#^0/K?_7[8?^CQ
M7N%?7T?@16;_ .^3^7Y(****T/-"BBB@ HHHH **** "BBB@ HHHH **** "
MO.OB'<W,#:C'"8?*GTP1RAU);&93\I!XZ=\]:]%KS;XD8\VYR#G[",'TXFI2
MV9MAOXT/5?F)\,O^1.7_ *^9/Z5V-<=\,O\ D3E_Z^9/Z5V-?)8C^+(]/&_[
MQ/U84445B<P4444 1W'_ !ZS?]<V_E6-H?\ R%M6_P!Z/^5;-Q_QZS?]<V_E
M5/2H43[5*!\\LQW'Z  5K%V@Q/<O2()8VC;HPP:;;LTENC-RV,$^XX-25D2>
M'K:2620SW(+L6(#\ G\*F-GNP+-] J037"EP_#8SD9X'0^U/BBO((_*2*W*J
M3M.]AQD]L5D:AH%O#I\\JW%R6C7< 7XR/PI++17N[**X.HW2F1=Q4,<#]:UM
M'EW$;>;[_GE;_P#?QO\ XFH;N&^NK.:W\NW7S$*[M['&?PJC_P (ZW_04N_^
M^C_C1_PCK?\ 04N_^^C_ (U*4%U_ -1NIV^JW%OY5Q):I;NP!$18$8YZXSV[
M5GR'4I=)E@?4+62T\L*[K;N2JD CD#T([5-JFF2:99&Z2_GD96 "N21SD>M-
MT*1EO;B-9HX=\4'+#)/[L=!TS]:VC\-T(B_M.V!C*W4&48L#B4$955ZA?;]:
MCBU( +]JU2*Y*2B12ZRC;@],;<?C[UU,321W9MVE,H,>_+ !EYQSCL?Z&K50
MZJ70=C/6]NG4.MLI5AD'#]/^^:;-=736\BM;JJE""</P,=?NUI5%<_\ 'I/_
M -<V_D:R4E?89G6DUS#&ZK%')\Y)*[R,X''W:G^UW?\ S[+^3_\ Q-/TW_CW
MD_ZZG^0JY1)J^P)&')XBAAE:*5H4D4X92),@_P#?%-_X2>V_YZP?^1/_ (BM
MZJ]U(\:QJC!/,D"%R,[>OZ\8_&FG!Z6%J48-9-S"\L*Q/&GWG DP/_':DEU"
M:(2%HXBL7+E2Y"\9[+Z&J/B)I(=(N(6NDDWJ/E<8<?,.1C^M+!*Z>)-1C6:.
M+>(1N?D_=[#IGZU:@FN:P7%_X2>V_P">L'_D3_XBC_A)[;_GK!_Y$_\ B*U(
MVDBO! TQF#(7RP 9<$>G8Y_2K52W!= U,]+ZYD176W4JPR#B3D?]\TIO+H D
MVRX'L_\ \35^FR_ZI_\ =/\ *HYEV&45OKAL[(8W ."5WD=,_P!WW%+]KN_^
M?9?R?_XFETS_ %,O_73_ -E6KU.32=K 8DOB**"5HI6A213AE(DR/_'*9_PD
M]M_SU@_\B?\ Q%;U5[N1HTC",$,D@0N1G;GO_3\::<'I86I1@UDW4;R0+'(B
M?>8"3 _\=IZZC/(^V***3[P)0N<$8R/N^XJIXA:2#1KF)KI) \?W9  _4=-H
M_F*S[*UDU#5+R#[3+"L3LR^6<==N>]:J$7'F%=G0?:KS_GU'Y/\ _$T?:KS_
M )]1^3__ !-4?^$=;_H)W?\ WT?\:/\ A'6_Z"=W_P!]'_&HM3[CU+WVJ\_Y
M]1^3_P#Q--6]N&(V0QOP#\N\X^OR^QJF/#K9_P"0G=_]]'_&J&DZ8]U)<YO)
MD$+[ %)^;KR>::C!J]PU-W38I(D<.K#A1DJ1D\DXS]:O8/I61_81_P"?^X_[
MZ/\ C3?[ /F;O[0N<8QMR?SZU+4&[W#4V<'TJM%_R$+K_=C_ *U1_L(_\_\
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M>2%7&:DJ&WN8[F,NFX%6VNK##*?0BIJQ=[ZE!39/]4_^Z?Y4DDJQ 9R23A5
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M;T5]EW&R[AG:?/BY'H>O->[UX5'_ ,E0U3_KY3_T?#7NM?687^$C3-OXL/\
M#'\@HHHKH/+"BBB@ HHHH **** "BBB@ HHHH **** "O,/B=<0Q7$T;S*DD
MEFNQ"V"W^N_Q%>GUP_CC_CR\0_\ 8(C_ /1CU,MF;X7^/#U7YF=\,_\ D38_
M^N\G\Z["O/? -MJDOA6-K2\CBB\Z3"L.<Y^E=1]BU[_H)0_]\_\ V-?+5X)U
M):GHXU_[1/U9M45B_8M>_P"@E#_WS_\ 8T?8M>_Z"4/_ 'S_ /8UER+NCFN;
M5(0&&& (/8BL;['KO_02A_[Y_P#L:/L6O?\ 02A_[Y_^QHY%_,@N2BWACU]9
M$C57QMRO'&S/2M6N=L_MD7B-8+N<2MY9?*]/NX]*Z*G45K @HHILDB11M([;
M449)]!68QU%1PSQW"%HFW '!X(P?QJ2@ HHHI %%%% !1113 ***;)(L4;2.
MP5%&6)["@!U%1PSQ7"EHFW '!X(P?QJ2BP!1110!1O=)@OI3))).C%-C>5)M
M##.>?SJ+^PK/S%8-.%5@XB$IV9&,<?@/RK3HJN>25KBL@HHHJ1A1136=41G8
MX51DGT% #J*B@N(KA2T3[@#@\$8_.I:+ %%%% !1110 4444@"BBFLZHC.Q
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M@C_9:IBDY68/8D_M.'_GG)_WTG_Q5)+?PM&T4L,H#K@@L@.#_P "JWY$./\
M4Q_]\"LW288I#<;XD8_N@"R@_P#+-:I<MKBU'PWUO#NVB=BQR2\B$],?WJE_
MM2'_ )YR?]])_P#%46DEK=AL6L:,O4%%/'KQ4\4$.P_N8_O'^ >M)N/5!J49
M-?LXIO*=)MVW=@*#Q^!I/^$BLO[D_P#WQ_\ 7K2\F+'^JC_[X%+Y,7_/*/\
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MC)8(,$[<9_&C^S*0?7<'_P ^7_X%_P  X6'XJ:=;EMNEWC$@#+W"G@=!4O\
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M9%#"R7@'W$**#\W("GO5C1H?"NA2RR6>JVNYT$:^9>J_EQJ25C3)X4%B<>]
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M+F25SNDD;JQ_H/0=JK?V_HW_ $%[#_P)3_&C^W]&_P"@O8?^!*?XT 9GC_\
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MAB*BE!-))+7R"BBBM#B"BBB@"L^G6,LC2265N[L<LS1*2?TIO]E:=_SX6O\
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MN#_KM)_Z%7E9HVH*QZ^'2^H2_P 2_(Z7^SK'_GQM?^_*_P"%']G6/_/C:_\
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M>02V>Y].M4[?PO;W4EQ'%9^*"UO+Y4F=1A&&VJW][GAA7:_\(]+_ -!_6/\
MO['_ /$5%#X5\AYGBUS6%:=_,D/G)\S8"Y^YZ*!^% '+?\(8O_/CXG_\&<'_
M ,72KX+@WKYVD^(;B,')BFU&$JWU^?-=;_PCTO\ T']8_P"_L?\ \11_PCTO
M_0?UC_O['_\ $4 5[74I-/>+3+7PQ=0#RS(D<<D 7:" 3]_KDBII]>O;;RO-
M\/WP\V01IB: _,>G_+2FGPN3<+<'7=8\U4*!O.3A202/N>P_*B7PN9_+\S7=
M8;RW#K^^3AAT/W* +']JZE_T+U[_ -_X/_CE']JZE_T+U[_W_@_^.5'_ ,(]
M+_T']8_[^Q__ !%'_"/2_P#0?UC_ +^Q_P#Q% &5XKDN=3\-WL5SX?O46.,S
M+)YT!V,H)S]_Z@^Q-2:)=>+;[3[4RP6=D%MTW270\YIF.>1L<8^7:3GN3Z5=
MG\,&YMY()M=UAHI5*.OG)R",$?<IT?AIXHDCCU[6%1%"J/-3@#_@% &-XQM/
M%-QX7O+>,6%\)EV/#;V[I)M/=27()''&*X31KGQWH.FK86?A^8PJS,/,M&)R
M3D\YKU;_ (1Z;_H8-8_[^Q__ !%'_"/3?]#!K'_?V/\ ^(K&K0A5^([\-CW0
MI.DX*2;OJ><?\)#\1?\ H7F_\ V_QID7B?X@SPI-#H7F1N RNMFQ# ]QS7I7
M_"/3?]!_6/\ O['_ /$5';^%C:V\=O!KNL)%$H1%\Y#@#H/N5A]0H=C;^TH?
M\^8_C_F>>?\ "1?$7_H7F_\  )O\:/\ A(OB+_T+S?\ @$W^->C_ /"/3?\
M0P:Q_P!_8_\ XBC_ (1Z;_H8-8_[^Q__ !%/ZA0[!_:4/^?,?Q_S/-)?%/C^
M *9M#\L.X1=UFPRQ. .O4T2Z[\0YHC&WA]]I(/%FW8Y]:]%N/"@NEC6?7-8<
M1R+*N9DX93D'[G8U-_PCTW_0P:Q_W]C_ /B*7U"CV#^TH?\ /F/X_P"9YK%K
MWQ#AB6-?#[[5Z9LV_P :=_PD?Q$_Z%]O_ )O\:](_P"$>F_Z&#6/^_L?_P 1
M1_PCTW_0?UC_ +^Q_P#Q%'U"CV#^TH?\^8_C_F>;_P#"1_$3_H7V_P# )O\
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MZU:/C7QD!D^&&Q_U[2UZ1_PCTO\ T']8_P"_L?\ \11_PCTO_0?UC_O['_\
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M,R)/[5U+_H7KW_O_  ?_ !RC^U=2_P"A>O?^_P#!_P#'*C_X1Z7_ *#^L?\
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gdzs1tysdsfm000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ LH# 2(  A$! Q$!_\0
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M+MCSC<<]!GC- %JBH;B[M[6)9;B>.*-V5%9VP"S'"@>Y/2IJ "BBB@ HHHH
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M$32)D>HZ\U,CP?\ "<>'KI/$%]<6<]I-%!<28Q.XD'[LG:,Y]>,[1@UZ%_\
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M>Q)SP,UZ71QSP.>O'6CVB[#Y'W/-- U"]U/7?#,U[,\[PW>I0K*W)**B[<L
M,\'K@9KTNBBIG+F>Q4(\H4445!1-'-CANGK3GB5QN0@'^=5Z<KLAX/X5+CU1
M2ET8C*5.",4E61(D@PPQ]::\'=3^!H4NX./8XWX@JS:#:F2.233TOX6U!(P2
M3;@_-D#DKG&:P=0GT236-+N/#<=N+=8=0+M;0;8S(+<8XQ@\8_E7I1!4\@@T
M@'0 ?0 5M&I96,90NSRE]6U[^QIY[?5;BV6PT.RO$ABB0*\C [@1MZ''08_2
MK^HZU?VNI:OB[>QM'U2TBN+N*)=T$+0;F.<?WL#<<XS7IBP,>N /I4FV*,<X
MYZY[T.M'L-49=SROQ#XIN[,VXTO6+^=X8()8Y961$N5:3!.S9F0XSDY4#@UU
MG@Q5$WB9G7'_ !.YR"1U^5*Z5ILGY5 [9-1$DG)-2Y7C9*Q2C:5[W)FG X45
M$SLW4TVBH22*<FPHHHIB"BBI$A9NO H;L-)L\B\:6,USXA\33"V@DMH;:R:X
MD,1:>*/)RT)Z!@.M:&LZY=V%]JYM[F1+=[^RB$D(5)&B:W+'#D=3@<G/IQ7J
M6(XAVS^IK+U;3+365@%RLJM;R>;#)#*T;QM@C(93GH2*TC6O9-:?\-_D9RHV
MU3U/.T74+^Y\/R?V_+)>?V9?2/>VI20Y#*0@;;CC !XSP:+;4+N?7M&U6^UB
M:TN+SP^71F4>4TP/*E=O3^,CKQZ<5Z)IVFVFDV2VEE%Y<*DM@L6)8G)))Y))
MZFK?IP..G'2G[1=A<C[G+>!=3GU'3+I;JXFNI[>81O<-,LL4AV@DQ,%7Y?8C
M@\5U-   P  !V HK.3N[EQ5E8****0PHHHH **** *WD7'_/Z_\ WZ7_  H\
MBX_Y_7_[]+_A5FBE8=RMY%Q_S^O_ -^E_P */(N/^?U_^_2_X59HHL%RMY%Q
M_P _K_\ ?I?\*/(N/^?U_P#OTO\ A5FBBP7*WD7'_/Z__?I?\*/(N/\ G]?_
M +]+_A5FBBP7*WD7'_/Z_P#WZ7_"CR+C_G]?_OTO^%6:*+!<K>1<?\_K_P#?
MI?\ "CR+C_G]?_OTO^%6:*+!<K>1<?\ /Z__ 'Z7_"CR+C_G]?\ []+_ (59
MHHL%RMY%Q_S^O_WZ7_"CR+C_ )_7_P"_2_X59HHL%RMY%Q_S^O\ ]^E_PH\B
MX_Y_7_[]+_A5FBBP7*WD7'_/Z_\ WZ7_  H\BX_Y_7_[]+_A5FL;Q-JMQH^E
MK<VPC,AE"'S!D8(/^%-1N[(3E979H>1<?\_K_P#?I?\ "CR+C_G]?_OTO^%<
M%_PGFK9QLM/^_9_QH_X3O5_^>=I_W[/^-;?5YF7MXG>^1<?\_K_]^E_PH\BX
M_P"?U_\ OTO^%<%_PG6K_P#/.T_[]G_&C_A.]7_YYVG_ '[/^-'U>8>WB=[Y
M%Q_S^O\ ]^E_PH\BX_Y_7_[]+_A7!GQSK .#%:@^AB/^-)_PG>K?W+3_ +]G
M_&CZO,/;Q.]\BX_Y_7_[]+_A1Y%Q_P _K_\ ?I?\*X+_ (3O5O[EI_W[/^-'
M_"=:O_SSM/\ OV?\:/J\P]O$[WR+C_G]?_OTO^%'D7'_ #^O_P!^E_PK@O\
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MS#V\3O?(N/\ G]?_ +]+_A1Y%Q_S^O\ ]^E_PK@O^$ZU?_GG:?\ ?L_XT?\
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MS$_O"DA(,$9484H,#/3BGU1(WS$_O"CS$_O"G58CA &Y_P J3=AI7*ZLC=7
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M.><X]NG^%79M5)2UAAVK&L$4<S",!VVG)&[J15R+6X5U&:XDDF.Z_%PIQDA
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MYO:OH/RHVCT'Y4YL%F(Z$G%)6AF)M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+10
MFT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+10 @ !R!@CH17?
M^&?%(NXQ8:@X^TA2(I6Z2\=#_M?SK@:ZGPSX8:] U"]0BV7YHH^\I'0_[O\
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M\O\ WS_]>C$G]Y?^^?\ Z]'/+N')'L9'_"*Z(0 ;!2!T'F-Q^M'_  BFA_\
M0/3_ +[;_&M?$G]Y?^^?_KT8D_O+_P!\_P#UZ.>7<.2/8R#X5T0@ V"D#H#(
MW'ZT'PIH9.38*3ZF1O\ &M?$G]Y?^^?_ *]&)/[R_P#?/_UZ.>7<.2/8R/\
MA%-#_P"@>G_?;?XT?\(IH?\ T#T_[[;_ !K7Q)_>7_OG_P"O1B3^\O\ WS_]
M>CGEW#DCV,C_ (130_\ H'I_WVW^-'_"*:'_ - ]/^^V_P :U\2?WE_[Y_\
MKT8D_O+_ -\__7HYY=PY(]C(_P"$4T/_ *!Z?]]M_C1_PBFA_P#0/3_OMO\
M&M?$G]Y?^^?_ *]&)/[R_P#?/_UZ.>7<.2/8R/\ A%-#_P"@>G_?;?XT?\(I
MH?\ T#T_[[;_ !K7Q)_>7_OG_P"O1B3^\O\ WS_]>CGEW#DCV,C_ (130_\
MH'I_WVW^-'_"*:'_ - ]/^^V_P :U\2?WE_[Y_\ KT8D_O+_ -\__7HYY=PY
M(]C(_P"$4T/_ *!Z?]]M_C1_PBFA_P#0/3_OMO\ &M?$G]Y?^^?_ *]&)/[R
M_P#?/_UZ.>7<.2/8R/\ A%-#_P"@>G_?;?XT?\(IH?\ T#T_[[;_ !K7Q)_>
M7_OG_P"O1B3^\O\ WS_]>CGEW#DCV,C_ (130_\ H'I_WVW^-'_"*:'_ - ]
M/^^V_P :U\2?WE_[Y_\ KT8D_O+_ -\__7HYY=PY(]C(_P"$4T/_ *!Z?]]M
M_C1_PBFA_P#0/3_OMO\ &M?$G]Y?^^?_ *]&)/[R_P#?/_UZ.>7<.2/8R1X5
MT,,#_9Z<'/+L?ZUK,,1E5&,+@ <8]*,2?WE_[Y_^O37$A1AN3D'M_P#7I.3>
MXTDMAT881(&^\%&?KBG5%$KK#&-Z'"@9 ]OK3\2?WE_[Y_\ KTACJ*;B3^\O
M_?/_ ->C$G]Y?^^?_KT .HIN)/[R_P#?/_UZ,2?WE_[Y_P#KT .HIN)/[R_]
M\_\ UZ,2?WE_[Y_^O0 ZBFXD_O+_ -\__7HQ)_>7_OG_ .O0 ZI8/]9^%08D
M_O+_ -\__7J2'S/,^\G(_NG_ !I2V*CN.G_UOX5$V=K8ZX.*?.)-XRR=/[I_
MQJ%A(48;DZ'M_P#7H6P2W%B#"&,-]X*,_7%3P?ZS\*K1*ZP1@.APH&0.O%31
M>8)!\R\\?=/^-#V$MRV753@L :3S4_O"J\ZR9#;D]/NG_&HL2?WE_P"^?_KU
M"BFBW)IEWS4_O"CS4_O"J6)/[R_]\_\ UZ,2?WE_[Y_^O3Y$+G9=\U/[PH\U
M/[PJEB3^\O\ WS_]>C$G]Y?^^?\ Z]'(@YV7?-3^\*/-3^\*I8D_O+_WS_\
M7HQ)_>7_ +Y_^O1R(.=EWS4_O"CS4_O"J6)/[R_]\_\ UZ,2?WE_[Y_^O1R(
M.=EWS4_O"D:1=C889QQ5/$G]Y?\ OG_Z](PDVM\R=/[O_P!>CD0<[+<$@$$8
M=_G"C=D]\4_S4_O"L^%76",;T.% R!UXI^)/[R_]\_\ UZ.1#YV7?-3^\*;/
MP@/H:K(LC.!N7_OG_P"O4MQYF -R?]\G_&E:S"]XGD.M?!A[K4Y[G3-5BBAF
MD+^3/$<IDYP".HKK_!'@T^$-.N+:2_-X;AUD9?+VHA']T<GT_(5U&)/[R_\
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M7Z5?KF/'?_( C_Z^%_DU5!)R29,VU%M#/^$^TW_GUN_R7_&C_A/M-_Y];O\
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M:=KDKD\G&&&#]16=*JI-(B/O16(5\8W#/6FJ--["=6HMSO\ _A/M-_Y];O\
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M_P!Y?SH 6BDWK_>7\Z-Z_P!Y?SH 6BDWK_>7\Z-Z_P!Y?SH DC?8WL>M27*
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M@\D* >?:GT )M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O\
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MF@>TRF#)(^/G&>QQU[UZ+2Y..II*:5A-W"BBBF(**** "BBB@ HHHH ****
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M\*J2)\DGDY[YP<]A3[;5+:-(-[MN^Q&V8-&6$9W9SP1D$<<8-=O_ ,(GH?\
MT#U_[[;_ !H_X1/0_P#H'K_WVW^--U8/N"IS.,CUR(3K*\C;UF+AHXRO'DE
M<9)SG'?WK)O+D7-G9)N9I886C<MZ[B1SWX->D_\ ")Z'_P! ]?\ OMO\:/\
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MTE0(ZQ6X4$ [N@]Q4GV/Q'E&.FS&1%V"3[.-Y&TK@GOP<47=MQ65]BF=+B2
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?2*C,>E3X!E;([U)@#I5.5D2H78U$""GT45F:)6/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gvxjy5si4hmk000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +O 0H# 2(  A$! Q$!_\0
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MXTRP!R+&V!]?*7_"FRZ=9&,_Z';9QQF): ,+_A/=+V[OLU[TS_JU_P#BJ/\
MA/=*SCR;O@9.%3C_ ,>^E$=O&;=0(X5Z#A1TV1GT]Z9:00^;'NACW$D\QCUN
M/Z ?D* +=EXAM/$,_P!DMHKE,#<YD4*&4=1P3WQ^&:FU37;/0[J-+A)#NARH
MB4' !],\#FI]&MX8H&9(HU?(^94 XVCT_&KTMK;SE3+!%)@8&] <#TH YS_A
M/M)VAA%>$$9SY8_QI@^(.D$LOV>]#!MN#&O/T^:LO55%OK.K"*)41)(50*,
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M=O/3VXZUEQZ]IKXB^T#=,V,-$^&.1@9(]ZN07\,^H7%F'_>Q??4@D#.._<4
M:@(Q@G<0.GI].U,\Q6565CAL@<]\5&CL<;\[0>A]QG%*5^91M4J!G'7M_DT
M4M8;&G/AF'S+R2?7MSUKG?/90H9FW@[^O3W_ $K?UDXTUG7# E, KQUS7,,[
M*6R#G;USD#D?X&@"?S"1CS&!QD')X]L9[TP2,P;YV+=22Y]?K5:.?SA(FU@4
M.UB%S@^G^34H8,<;<G'7U]OI0 PDNX+R,Q#?=).,9QTJ/<YC.2PVOC<I(Q_D
MU,Z+D#+'(/;/?-,V,R@$@Y!/WL@X]?\ /I0!&ZR.HWR'GG[QQR/7UI(]_">8
M26SD;CU'3O\ 7I3W5ED4;<8/S$]O3'_UZA22*61UMP"T9PY4=_7W_.@"41J
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M,F93&HZD_,3GI_D5F:WC^R=JCAIH<'IQYBYX_P#UUI-\LDB[5.26P.O^/44
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MJ*EM[NVGD8),Q 'W=IQCH?Z?YYKUR1[.*9$D\I9'.$#8RWTK@O%")_PF,P"
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M* $].:Y35!(WC2U;;^Z%M@-VW'S."3QV-=7Z<U@:BI;6D*@%LHO/8;)__K4
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MNTDMD?C71S1+/!)"_P!R12K?0\&JFEZ9;Z18K9VF_P E3E=SEC[\T 7J***
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M@!6/[I=XP2>1W[\?6F\'G&X#N> 0!U_2F%MT9/S8)P,=J>R_N]@S@<9XQ]*
M&M)MW,,\YZCM[UE:SNCOM)NA'(\<,[%Q#&7(!7'Y]*NM?VYU1K')>?8)<<D;
M>,<U,JAL'@; <#&* ,\:LIC!73]4+<$@V>WW_O?6D.IWSC]QHEP5(X,TBIFM
M#:I4C>6.=V :7"QLW+' Z-0!DO'J^HE$NA9VUJ&5RL89W^5@<>F1C':MAFWJ
M=P !!.3W%(!DJ3GDXY[>]5HKN":_GL07,L"#<NS ^;T/]* +RYSN4X]1GKZU
M-'C*E3@C\"O^<5 I(8 KP>/E/ZCWJ9-A=-K853D!NO6@"?PW-8Q:%"LT]N'#
MR%M[+G[[=<UT*%6&Y2"#S\O2L*74--^V/86MO#<:@O!A$0PAQU9B  ,G/7/H
M":U[*W^R6J0;BVP %B/O'N: +%>17$N-8U=0Q4"^E)S_  C->GZ?JL&I2720
M;LVLIAD)Z;AUQ7E=Z5.LZPJ%=HO)!]WWYH C>7*@*3\W?MU_ST_^O41F.""Y
M"J2/E/3CH?QQ4<C$L8B#\RGKP>>V>E5R02#MY/&<8_+UXXH MF:3.6;D#"AC
MC_(ZTQII%^1B2 .I.:C+_> .WDC@Y!JD)1(61<':2I&T';CZF@#2CNR,A2=H
MPN>>W>CSF*%BP ZJ0> /\XK/3 EP68D<<T3+Y1#N3MR!M4]_\.10!?,A48+;
MB01P>F?I_GFF>=C[@R. IW?I4*,&PVXL">*'=2KX& .6VCI0 KNXV/&-\8CY
MR0.>O^>*;:W$IGGD?:@9@44-D\#'Y55AD,T2NF3&<D;5ZYSZ]N?TJP9 N,2I
MM!SP"#QZ4 63+*0,'YB<>W_Z_P#/:D$KL0S'=C(*XQ_G'K5<ML(&#DYQWSR*
M<C>4QC3'/+ CIQV_'/YT 6TE"J=@)8CD?Y_"O1OA^<^$K?@##L.!BO,G&0HQ
MC.#Z9KTWX?8_X1*#&2-YY)Z].: .HHHHH 0G%</X@G@MO&UO+<R!(Q9@%SGC
M+2XZ5W!KC=9S_P )Y:\8;[(/F/0X,F* *C^(M(D?!U!"JX!^]QVSR.*B;7])
M+#;J%OM.<9)S_+ZUMSAG(5<].!GBJ3P2F3&S.W!(]10!E'Q%I6=J:A ,8+$@
MUIM+@)M(96^;(!R1BJ.NNL>@Z@^!_JFPQX&<CI5J';]GA5N&9%X/T''Y=Z '
M;5,ZL4 =1LR0,GVZ?SIUU=6UI'F6XCB+<!G8*/S/U'%!4"15/&.A([Y_^O\
MA6;K&U]5T5',9)N6SDYXVD=/R_R* +":QIF2R7UH5/"GS5].E6!<P2N2D\;
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MJ* (+]V\F ;V"FYBR,'^^OOCZUV(]>]<;J;,(H<9&;B(8]?WJ?X&NR7H?J:
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M#.$0^O)Y/^)J+5]-FU%[-XKGRA;EGR.""1@8/0?CZF@#19P20 3LR,*I&?\
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MUD( +8"D\9_#M5G[7*^L&R$$P5(ED6X_@)SC;TZUF:W\VM^'@#\IN9?P/ET
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MGE,:E@1YG^T/;\Z\DN@[:QK(7&&U&7[Q&#@_YX]Z &JYFW2D\ %3D\>U0NB
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M2S;0,?UQ^/3\JLF))I/,E5#$!P67(R3U^F* '+(F]!B/+<?-@<?6HS,7EDA
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MFP,SYR01S3]GEJ8CAM[E5"]>?7V]J (Y,Y0\+CN2 >?7BC(#+UV@@IMXQ_\
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MI[>]2@(K.V&4$'D-C'^)I-OS@C&-V?F7 /OS^/\ ]:EF 99"OS9.6['/^<4
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MXB[>),*#PHLH^!V'-9VJKK6CM;RW7BB3[/-*8V(T^+Y 59L\ DCY1^==G2$
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MS_*G0H#)DD?,?N[?ITJ))Y<Y6 G@Y(D!'3';OC^5+)+,Q?=$"HYP9  1[>M
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M]J]!'?ZT +6%K@=M0T1HPI87A(!)'_+&3N,_RJYINIK?S7D(@FC-K)Y;-(N
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M YQDXQUZ^G3K0!;=E.'C;<3P.V.<_K[]Z]$^& 0>"H/+4JIE<C(QGFO-/*(
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MKQ5C?P\IF9<'!)(Z_P"'2@!Y)=I&(.<\*1@Y-6[!,:G9!D!5;B$A<]/F&?\
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MD!4(/S>G3CGVJ@<S,B"53Y9[')_2K\\+>:5V#<HXYSDU5V\;@ ?DZG@;@.]
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M'B;76T*VMI42%UFE,;>=*5"@*QSP#S\N,5OA0O05F:C;P3WFF^?&&V3,X#=
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M,!+P2O!YVC@8XH :2[C:[$D @$, 3P/3\:]1^%C;O UN?F_UCXR/I^E>9)(
MZL3G&68GMQS_ "KTWX6C'@J'D']ZW3Z"@#M**** "O)_')9_&[+ELK9Q[1GG
M&YS_ #S7K%>6>-%$GC60E<XM(TXQ_>>@#EW61C(FP,V/F8C[OZU7 ==JEPY8
M%!D<YQ^=6[E2K$99E/8#'XD#Z]/K59@3*G(/4#"]J (%#)*=N<KTX[?Y-) 2
M]PL04?*VW 88YJ>0%I& 4;0>.@X%1P(RS6S,".0VWB@"A:2QK:(%+J<8W!2W
M<U(^Z:V:9HU *\;E.<>G7N.P[TVQ4/!#+R&*A0,G:!ZX[59B"A6X4#)(+=%Y
MH JP1%I;J569O,F9EWC!8?ETZ5/ERI# *B^_!/T]*5AB-41>Q!!XZ\C]*7RU
M?:NUMY&<'D]N<4 -+<*,DF-N1G@<>N.F*LE7\P./NX )88!Y)R"/][]*8.%.
MP LQ^89Y_P \TJ1D2-)&3R%4C/'3'3I0 \@JS$A!D 9P3V_+L*GCW*BL.0_/
MITZ8_P ]JK':SM&V5(.T8Y_"I[8R"/YN,';G'7\* +VGQ[-4L6)88N8N"!C.
M]?UY->W(,#OU[UXE9*YUO3P69%,\;;3VPXKVU>Y]3S^5 "A@>XYZ5@:_?QZ?
M>://<3BWMUNG$KEMH"B-SS[<"I7TM-.AN[BWGN 9YOM$K+@M][+!>.F,\<]A
M3_[)L[_[/++-)>11-YB"0HR-D%<XQ@C!- $7_"8^'P0#J]IG&>9.<?Y-'_"8
MZ",#^U;0,1QE_P!?I537-,L('TLP6%JK2:C$CE(E&Y2ISG'45KC0M(P,Z79'
MC'-NG^% 'GOQ$UC3=;328+"\CN9$NBSI$_(4HPS_ )SV]:XF6V1I&8RR!23E
M?-;!_#K@UZ!\1=.LK+^Q/L5K;VS-=,&,,2J2/+8\X'3(KAEMDADFQ(7#G<V>
M.<]/IUH J?9MQ9E:4+@]921GV-1RV:E,F><\[N&(V\\?A5Q]]P48#!S\H_\
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M_+- '(W"[Y&#NR87@@?I55FRS)P0V=N1VSQQZU->32B1]D+MG@9D XJFDLF
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M1'>C$,%?<<9(&,CH1TKQCSI&C">6$5AT8Y!&.:O0:QJ,4$D$NKWDJLQ(56V
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M';<@!SV8YY%.40/SMRB]=HZ_Y_K284QG:N6.2A4=^O3VQ4B&10XWG!?LO/\
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M9)"5VNJ#:3@GGYNGTZ\5*R8>)BJA1\J\=,K[]/\ /--A!\UD239Q@\=_KUH
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M8&[Y)]NOUI7;RA',5;#@Q'/XD?IQ5_[.CHR[=QVC@CCCH3[4PVT4FGS^;L&
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gcilxvfwaiqx000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +N A\# 2(  A$! Q$!_\0
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MK7^C>%$NM.NGMIS=(A=,9P0<CFJA'FDHHBI-0BY/H=I17S5_PG_BO_H.7/\
MX[_A1_PG_BO_ *#ES_X[_A73]3GW.#^TZ79GTK17S5_PG_BO_H.7/_CO^%'_
M  G_ (K_ .@Y<_\ CO\ A1]3GW#^TZ79GTK17S5_PGWBO_H.7/\ X[_A7O'@
MR\N=0\':7=W<S37$L(9Y&ZL<FLZM"5-79OA\7"O)J*-VBF3$K!(P."%)!_"O
MFYO'WBL.P_MRYX)_N_X4J5%U+V*Q&*C0MS+<^E**^:O^$_\ %?\ T'+G_P =
M_P */^$_\5_]!RY_\=_PK7ZG/N<W]ITNS/I6BOFK_A/_ !7_ -!RY_\ '?\
M"J]]XQ\2ZE;I97&MWGDS3Q(VQ@IP9%Z$"E+"R2;N5#,:<Y**3U/IVBN5_P"$
M+G_Z&WQ)_P"!4?\ \17/>,O#%S8Z1:RIXJ\0N6U"UCP]TN!NE49X0<BN4] ]
M+HKE?^$+G_Z&WQ)_X%1__$5SVJ^&+F'QKX>M1XI\0%9X[HES=+N7:J'CY,<Y
M[@T >ET5RO\ PA<__0V^)/\ P*C_ /B*/^$+G_Z&WQ)_X%1__$4 =517*_\
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M>&-WD)&Z4G8N!GG'KVH>F@EJ=#163H&K/K%C)-)&JM'*8]R?=?&.1[5K4-6
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M%^Z2>-?![I$8HVMKPK&1@J-D?&*%\.@W\1C:F\6KM+>1PE7GMS/<()R%,*\
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M8A4N>[<\\UJTV(Y3Q$VWQMX2;T>[/_D UDW%W::C&]Z2\+W-B;J>))@$EV'
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MUITVTW.O(J:GS)-W]$UY?,\POY7FU"XEDC\MWD)9/[I]*K#_ %]K_P!?4/\
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M@@\$:I+<>+KBYA6,;HC8PJ&^8=P,BNB_X1[Q-C_D=KG_ ,%\'^% '545RO\
MPCWB;_H=KG_P7P?X4?\ ".^)_P#H=KG_ ,%\'^% !X@_Y'GPA_UTN_\ T0:Z
ME55%"HH51T & *\TUK0_$">,/#$<GBZXDEDDN?+E-C"/*Q"2> ,'(XYKHO\
MA'?$_P#T.US_ ."^#_"@!-8 ;XC^&P0"#:7H(/TCKJ@ H    X %>9ZGH?B!
M?'>@1/XNN'F>VNRDWV&$>6!Y>1C&#GW]*Z/_ (1WQ/\ ]#M<_P#@O@_PH 2X
M_P"2JV/_ &!IO_1L==77!:=8:C8?%"V74=8DU-WTB8HSP)%L'FQ\?(.?QKO:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KS[XQ?\B5'_U^1_R:O0:\^^,7_(E1_P#7
MY'_)JUH_Q$<^*_@R]#PBBBBO7/F@HHHH *^E/ '_ "(6C?\ 7N/YFOFNOI3P
M!_R(6C?]>X_F:X\9\"/2RS^(_0Z"X_X]I?\ </\ *ODQOOM_O'^=?6=Q_P >
MTO\ N'^5?)C??;_>/\ZG!]33-/L_/]"Q8-9K=J;]96M_XA$<-78O/H]AHMM.
MLVJK:W)95C2;ICKFN0TV\6PO4N&@28+_  ..#71GQAYBQP'1X&4?<0KZ^@K@
MS/#5ZM:#A&3BM[2277H^M[:EY;6HTZ<N>23>WNMOIU73?0Y6X,37$A@#"(L=
MF\\X[9J,?Z^U_P"OJ'_T8M2W3F2[E<QB,LY.P#&WVJ(?Z^U_Z^H?_1BU[$OX
M;]#S:?\ O"]?U/KBN4^('_(!L_\ L*6?_HY:ZNN4^('_ " ;/_L*6?\ Z.6O
M(/ICJZY76_\ DH?A7_KE>_\ H"5U5<KK?_)0_"O_ %RO?_0$H ZAI$1E5G56
M8X4$\GZ4ZLS44TY[ZSFN[I(IK5B\:F0#.1CD5?EEV6SRJ-VU"PQSGBCI<?6Q
M)17!R>,M5@AM[EH+*6.7<6BC<[T /?T-=S&_F1(^"-P!P>U A]%%% "/]QOI
M7+_#C_DGNB_]</\ V8UU#_<;Z5R_PX_Y)[HO_7#_ -F- !\2/^2>ZQ_UR7_T
M-:/&6$@L9Y')MXY29($DVO+QP!ZXZT?$C_DGNL?]<E_]#6HO%<H>XM?+81W-
MJ^]&W#D%<'@BDQHA\&V=ZMW->+._]GR;\1/(6*G(VCGN!G\Z[2L?PU/-<:7O
MG8,^\C(Q_2MBJ?8E=SE=?_Y'KPA_UTN__1!KJJY77_\ D>O"'_72[_\ 1!KJ
MJ0SE=6_Y*1X:_P"O2]_]IUU5<KJW_)2/#7_7I>_^TZZJ@#E+C_DJMC_V!IO_
M $;'75UREQ_R56Q_[ TW_HV.NKH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/OC%_
MR)4?_7Y'_)J]!KS[XQ?\B5'_ -?D?\FK6C_$1SXK^#+T/"****]<^:"BBB@
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M^][TF,J>(+6VM/!/B2TB99S;1H%FR"?F9<C-='K%]IUUK,NGZE%/_H>V2&2
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$8VJAZ!<'KW!QVKTFN5UO_DH?A7_ *Y7O_H"4 )_PB^N_P#0[:G_ . UO_\
M$4?\(OKO_0[:G_X#6_\ \175TR9S%#)(%+%5+;1U..U#T Y?_A%]=_Z';4__
M  &M_P#XBC_A%]=_Z';4_P#P&M__ (BH='\6:AJ>KPPM9(EJY9"1NW;ASGGL
M*[&@#E/^$7UW_H=M3_\  :W_ /B*/^$7UW_H=M3_ / :W_\ B*ZNB@#E&\,:
MZ%)_X3;5.G_/M;__ !%87@O1=>U+P=IEX?&>J(98MVTPPOCD]V4D_B:]'?[C
M?2N7^''_ "3W1?\ KA_[,: .?\::+KVF^#]2O%\9ZHYBC!VB&%,_,!U501^!
MKT2UC>&TABEF:>1$"M*X +D#J0.,GVKF_B1_R3W6/^N2_P#H:UU Z"@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIMX\ ,HW+GCL/K7I@Z"J9*%HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KS[XQ?\B5'_P!?D?\ )J]!KS[XQ?\ (E1_]?D?\FK6C_$1SXK^
M#+T/"*W?"USH]MJ,KZU#=RVYCPJVI.[.>_(XK"K6T'7I_#]S//!;6\[31&(K
M.NX 'N/>O5DFTTCYVDTIIL[<:OX!QQIVOX]BW_Q5<3XEGTRXU=Y-)BNHK4J,
M+<D[\]^I->Q:6_B:?2X)9[7P[:/(@,<,R-N8=L\UY1XV?4G\33C5;2WMKE0
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M,\<(G(9=T>0#M)P2*X_P]=7#:Y9C,R7#[_MADNO,#^F%[?A72>+8Y!HDTT$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7GWQB_P"1*C_Z_(_Y-7H->??&+_D2H_\ K\C_ )-6M'^(CGQ7
M\&7H>$4H&6 SC)ZTE !) '4UZZW/FCV"YFMO"?\ 9VDV'A--0@N84:2Y9-QD
M+=><&N&\?:19Z-XIFM[%!'"Z+)Y7_/,D<BO2-&F/AK1[;3-6\6I!=RQAHHF4
M'R@W09[UY=XQTR]TKQ)<0W]U]JF?]X)_[X/0UQTOXN_?Y_\ #'JXE?N-NVFF
MGZZF#7TIX _Y$+1O^O<?S-?-=?2G@#_D0M&_Z]Q_,T8SX$1EG\1^AT%Q_P >
MTO\ N'^5?+NCW,5KJR/-:BY4OM"'KG/!'O7U%<?\>TO^X?Y5\HPR"&]24YPD
MNXXZ\&N>G3]I1J0[KT.C'S<*E.2Z/_(],N8?+FGNX-.M5G9#\\DF&Z=Q7EY8
MB0MT;.>*[B_FL+B&2_GT6_ D7)ER0N<=>M<1'$\\ZQ1*6=VPJCO7'D4/9TIR
MGY7OY+:_-+;Y>AIG513E!0\WIY]=EO\ ,] M[[4GT33)E>XN'DD_>-"!]WT/
MO7*^)H6@\3HAG>8FZ@.YSDC,B\'Z5T&C^']6L4*3:F;.,@L8HSN)']*Y/56M
MGUF)K2262+[5!\\OWF/F+DUAEL*2KU?8M-)/X5IJ[J[VTZ6.G%2J.C2]JFG>
M.[[;V6^O6YZ;XAAT9_$%]_9]O=_;_,/FO>([6V[/. /Z5TGB4;? VCC$0Q?V
M/$((3_7)TSSBNX,:$Y**?PKEO'X T"S &/\ B:6?_HY*ZUI&QL]7<X?5X-&;
M6KW^R[>Y%UYI\U]021K<G/.T#FNMO4W>*_!R#RQFTO!\F=H_=Q],\XKM#&A.
M2BG\*Y?6N/B%X4Q_SRO?_0$H7P\H/65R73O"$%M8QQ3W-R9!][RYB%_ 5OS(
MBV4B,K.@C(*YY88Z5-10]58%O<X3PS8:/_::7$.IS2,7:2.TD0CRVQ@Y/? %
M=+XE++H5PR(CN -H>;RN<_WNQK26")6W+$@;U"C-$T$5Q&8YHDE0\E74$?D:
M'JK M'<Y'P#J%]?6UV+V>Y<QN%59X@"OT?\ C'O794BJJ*%50JCH , 4M-NX
MDA'^XWTKS/PC=W1\-:)IZV'VZTDTTO)$< 9\PC/->F/]QOI7+?#A5_X5_HK[
M1N^SXSCG&XTAF7XLC\GX9ZU$-+&GHL:[8P0<_.O/%=Z.@KE_B1_R3W6/^N2_
M^AK74#H* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/O
MC%_R)4?_ %^1_P FKT&O/OC%_P B5'_U^1_R:M:/\1'/BOX,O0\(HHI00&!(
MR >17KK<^:/8K75=/UR33_,\%7MU=) OE2R%1N5>^2>E<]XV\2Z+J0N[>7P_
M=6NKC"^9,P^3'MZ8KM6\3Z0-(BGM-:B2>[BBMX(\@& C[Q]J\T^(FHVFI>+)
M9+.59DCC6-I5Z2,!R:X8+FJ6MW[GL5I<E&ZDF].B_KN<G7TIX _Y$+1O^O<?
MS-?-=?2G@#_D0M&_Z]Q_,U6,^!&.6?Q'Z'07'_'M+_N'^5?*MFKF_5T@>81R
M;F55SD U]57'_'M+_N'^5?-WA&>\@U:?[':"X+*0X+8VC/6N*=5T<-4FDG9=
M7;\>AVXFFJE>E!NUWT5_P.HDG6.2XU)KRXDMY(B%LC&<#CIBO-Q(R3>9&2C!
MLJ1VKUF_<+92/+.;=RAR%&[M7DC?>/?FN/AR2J4IMKLODEY))^NMS3/XN#@K
M]W\]/-M>ATMCXUOH,+=HETF,9888#ZUA:K);W>HQO8(]K')<0[0<,48R+S_6
MJU _U]K_ -?4/_HQ:]>.!H4.>I2CRMK6VWW;'EQQM>LX4ZDKI-;[_?N?1W_"
M.^)_^AVN?_!?!_A7.>--#\00Z-:M<>+KB=#J-JH4V,*X8S* W ['G'M7IM<I
M\0/^0#9_]A2S_P#1RUPGO"_\([XG_P"AVN?_  7P?X5SNK:'X@3QOX<B?Q=<
M/,\=V8Y?L,(,>%3/&,'/OZ5Z97*ZW_R4/PK_ -<KW_T!* #_ (1WQ/\ ]#M<
M_P#@O@_PH_X1WQ/_ -#M<_\ @O@_PKJJ* .5_P"$=\3_ /0[7/\ X+X/\*/^
M$=\3_P#0[7/_ (+X/\*ZJB@#E?\ A'?$_P#T.US_ ."^#_"C_A'?$_\ T.US
M_P""^#_"NJHH Y1O#WB;:?\ BMKGI_T#X/\ "N7\(6&KV_@'2KM_&DMC:-%\
MJM90E4^8\;B,_G7J3_<;Z5YKH^I/8_"W0HQ!<-'-%M>6)%8(-QZYZ?6DQHC\
M;:3K?_"":G<OXREO+;RE)06< #C<.ZC->E6L<L5I#'-.9Y50!Y2H4N<<G X&
M?:O+-:TJSA\!:Y=6,%Y;1K&%8S3!_/)=3D@''']:]7'053)0M%%%(84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>??&+_D2H_\ K\C_ )-7H->?
M?&+_ )$J/_K\C_DU:T?XB.?%?P9>AX12C!(!. 3UI*Z?P+X=MO$>N/!>NRVL
M$1FE"]6 [5ZSDHKF?0^<A!SDHQW9Z>FAVMKH+V5AX?BN(A;12I<; S3N2-PS
M7F?Q"TZRTSQ9-#8QK%&R*[Q*>(V(Y%>EV=O:PZ/!J.D^(;G3_#Z!A+',=S9!
MQA2W(KR;Q;?Z=J6OS7&EK(+8@ -(<LY[L<UQ4;NK]_\ 3/5Q7*J%M.G](PZ^
ME/ '_(A:-_U[C^9KYKKZ4\ ?\B%HW_7N/YFJQGP(RRS^(_0Z"X_X]I?]P_RK
MY;TW5+S2[J:6S^^^5;Y<\9KZDN/^/:7_ '#_ "KY?T;59-*U(NNS;(VQRPSA
M<\FN11YJ%1<BGY/9_F=>+ERU:;YN7?5="\_BW6G1E8+A@0?W5<\3DDGO7J<T
M\RM<7$LMF-+:(^6X'S=*\L;&XX.1FHR:O2JQE[*FH;;?\,M5U,\VHU*?+[2H
MY[[_ )K5Z,2@?Z^U_P"OJ'_T8M% _P!?:_\ 7U#_ .C%KUJGP/T/+H?Q8^J_
M,^N*Y3X@?\@&S_["EG_Z.6NKKE/B!_R ;/\ ["EG_P"CEKQSZ@ZNN5UO_DH?
MA7_KE>_^@)755RNM_P#)0_"O_7*]_P#0$H ZJBBB@ HHHH **** $?[C?2O(
MX[V1?A9H=@MO,PG@^611F,G<PVM^>:]<?[C?2O/?#^GR:I\*]#M(KA(G:/)5
MVV[QEL_X_A28T9M_$Z?#'Q TA"N4C!B4?*N"H_7%>J#H*\NU/39+#X:>(V:2
M%XY-NPQ2;\X91G/]*]1'053)0M%%%(84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>??&+_D2H_^OR/^35Z#7GWQB_Y$J/\ Z_(_Y-6M'^(CGQ7\
M&7H>$5U/@7Q)9>&=5N;F_AFEAF@,6V( GD^YKEJTM"TC^W-4CL!=16SR [7E
M.%)]*]623BT]CYVE*49IQW/0IO&_@:?1DTF32=1-DDGF+'A?O?\ ?5>?^(+C
M2;K5&DT6VEM[,J,1R]<]Z[W4OA&(KJ(6FJ0I"44N)W&XGOCVKC?&&D:?H>NM
M8Z;<FXB1%+,6#8;N,BN>DZ?-[K9VXA5^1^T2LO0P*^E/ '_(A:-_U[C^9KYK
MKZ4\ ?\ (A:-_P!>X_F:G&? BLL_B/T.@N/^/:7_ '#_ "KY1A:-;U&F&8A+
MEQZC/-?5UQ_Q[2_[A_E7S=X3$9U*Y\S[/C8?]<N1UKD]M[&A4FU>W8[,52]M
M6IT[VO<ZV?4=--@TDEY:M:;&"Q#&=I' QZYKS!L%B5&!GBO3)H[7R)2%T[.P
M](?:O,V^\?K7)P]&,:<^6^_7_AD7GSF_9\UNNWR$H'^OM?\ KZA_]&+10/\
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M#H*\SUB"_B^&.NF]#HK1Q[(I)-[+@J"3Z9->F#H*IDH6BBBD,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O/OC%_P B5'_U^1_R:O0:\^^,7_(E
M1_\ 7Y'_ ":M:/\ $1SXK^#+T/"*48) )P,]:2M?P]HB:Y=3PR7\%F(HC(&F
M8 -CL/>O6NEJSYN,7)\JZGI&I6_AG3([**_T;4M6E>V1Q<[F<$$= <_I7G'B
M9]/DUASIEA-8V^T8AE^\#W->NVUQKBVD*#Q?H"JJ *K1ID#'UKR_QT]R_B60
MW=]:WLNQ?WUJH"$8]JY*3]_[^YZF*2]CHNW;\[W.:KZ4\ ?\B%HW_7N/YFOF
MNOI3P!_R(6C?]>X_F:,9\"(RS^(_0Z"X_P"/:7_</\J^:?#*WCZA<K:-"@V,
M99)AE57/6OI:X_X]I?\ </\ *OFGP[J%G87-\M\7$4\31_*.>37GU5-X6HH1
MN]-+7Z]NMMST*KBL32<G9:Z[?B=;*-5%G(ANK%IS&62-4^^@'6O-3G<<]<UW
MO_"0: CI,CSF6*W,"9'&"*X)CEB?4U&14ZD(S52'+MTY3+.JE.:AR3YK7ZW[
M?\$2A?\ CXM?^OJ'_P!&+10/]?:_]?4/_HQ:]NI\#]#QZ'\6/JOS/?O$\)FU
MM(;N9XHQ%O2:.$G=R?D..P]ZD\6A5\':4$(*C4+( A-HQYR=NU5_$-K<IXFN
MG_MN[LH)+/='EOE+Y/"_X>]&O;O^$ T3>CHWVZQRKG+9\Y.M>/'X?Z\SZB6_
M]>1N:G?ZCI^L-Y=S8&"9!Y<-Q)L8,.N/7-4M8D8>./"DL@&X6]ZS!#D?<3I7
M-^+/MT_BJ=[>PD'EQ@;I]H5OE8?*2>G-;;HT7BCP1&X^9+.[!&<](X^]"UC<
M'\5OZZ&L-:U"7PU)J\<5JI7,BQNQ_P!6.Q/9L5NVLXNK2&<*5$B!@#VS7G-W
M-:W^MPV5I9+8?:;AT;[23]X<[A'T(/UKTF-2D2(3DJ "0,9_"GTN#WL.HHHI
M %%%% "/]QOI7G'AOPW#KWP_T!Y'1)(K?Y&*\@[C^E>CO]QOI7G_ (7M-&;X
M:Z-?:P%$<-L1O9B,#<?3K28%3Q%"++P-XGL2X=XDC)<  '++7I8Z"O/O%$6B
MI\-]=?1@FUT0R%<Y)W*1G//0UZ".@JF)"T444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y]\8O\ D2H_^OR/^35Z#7GWQB_Y$J/_ *_(_P"3
M5K1_B(Y\5_!EZ'A%  9@#CD]Z*V?#/ARY\3ZNMA;ND8"EY)'Z(H[UZUTM6?-
MQBY.RW/0KE](\(_V?I$7A0:BMS$C2W++DN6ZX.#7%>.]%M-"\3RVUDNR!T61
M8O\ GGD?=KN=2U#Q'X+\.12Z=JUKJFFJWDK*5#-$WIGO7E%]?7.I7LMY>2M+
M/*<LY[URT4W+F3[_ #^1Z.*E&-/D:UTMMIWUZW*]?2G@#_D0M&_Z]Q_,U\UU
M]*> /^1"T;_KW'\S2QGP(,L_B/T.@N/^/:7_ '#_ "KY,;[[?[Q_G7UG<?\
M'M+_ +A_E7R8WWV_WC_.IP?4TS3[/S_02BBBNX\D*!_K[7_KZA_]&+12IS<V
MG_7U!_Z,6LZOP/T-:'\6/JOS/=/&K-<:U:NKI<P0$ PK( 8WR<D_I^56O$HG
M7P/HXN9A-,+^QWN#D,?.3O37\0Z<+]8;M-.$CS7"RET&Y=GW<_6F:]<O>> =
M&N9 H:2_LF.Q<#_7+T%>/'X3ZF2U(]?L+37]8N)+;4K<S1@(8+@LFQ@"#STP
M<Y_"KUW ;;Q?X,MVD#M':7:%UZ'$<?-9'B%C]OEA\1RKJ5HTA\JWLW561<\#
M:/F8UL7XB_X3'P<(4:.'[+>;5<8*CRX\ @T+X ?Q%?4IMMT;2)UU_GFV:/\
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M"'_0O6/_ '[H_P"%=^$/^A>L?^_= '1?:(?^>T?_ 'T*/M$/_/:/_OH5SO\
MPKOPA_T+UC_W[H_X5WX0_P"A>L?^_= '1?:(?^>T?_?0H\^'_GK'_P!]"N<;
MX>>$ I/_  CUCT_YYUSW@3P/X8U#P1I-U=Z):37$L.7D=<ECD]30!Z)]HA_Y
MZQ_]]"C[1#_SVC_[Z%>=>// _AC3_!&J75IHEI#/'&"DB+@J=P'!KHA\//"&
M/^1>L?\ OW0!T?VB'_GM'_WT*/M$/_/:/_OH5SO_  KOPA_T+UC_ -^Z/^%=
M^$/^A>L?^_= '1>?#_SUC_[Z%'VB'_GM'_WT*\ZUKP1X8@\8>&+:+1+1(;B2
MY$R!>'VPDC/K@\UT?_"N_"'_ $+UC_W[H Z+SX?^>L?_ 'T*/M$/_/:/_OH5
MYUJ?@CPQ%X\T"S31+1;>:VNVEC"G#E?+VDC/;)_.NC_X5WX0_P"A>L?^_= '
M1>?#_P ]8_\ OH4?:(?^>T?_ 'T*\ZF\$>&%^(]G8C1+3[*^E2RM%M.TN)4
M;&>N"1^-='_PKOPA_P!"]8_]^Z .B\^'_GK'_P!]"C[1#_SVC_[Z%>=+X(\,
M?\+)DL?[$M/LHTA9A%M^7?YS#=CUQQ71_P#"N_"'_0O6/_?N@#HO/A_YZQ_]
M]"C[1#_SVC_[Z%>=>%O!'AB[O/$27&B6DBP:J\4092=B".,A1SP,D_G71_\
M"N_"'_0O6/\ W[H Z+[1#_SUC_[Z%'VB'_GM'_WT*\Z\(>"/#%[#K)N=$M)3
M%J]U#'O7.U%;A1["NC_X5WX0_P"A>L?^_= '1?:(?^>L?_?0H^T0_P#/:/\
M[Z%><^"/!'AB_P##[S76B6DL@O;I SJ2=JS. .O8 #\*Z3_A7?A#_H7K'_OW
M0!T7VB'_ )ZQ_P#?0H^T0_\ /:/_ +Z%>=> _!'AC4/!>GW5WHMI-._F;I'7
M).)& Y^@%;UQ\/?"*VTK#P_8Y"$CY/:@#I_M$/\ SVC_ .^A1]HA_P">T?\
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MB'_GM'_WT*/M$/\ SVC_ .^A7._\*[\(?]"]8_\ ?NC_ (5WX0_Z%ZQ_[]T
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M_P!M?_1KUTMU_P >DW_7-OY5S7PW_P"1!TS_ +:_^C7KI;K_ (])O^N;?RH
MY_X>_P#)/=!_Z\T_E6IK_P#R+FJ?]>DO_H!K+^'O_)/=!_Z\T_E6IK__ "+F
MJ?\ 7I+_ .@&@"OX0_Y$O0O^P?!_Z+6F>,O^1(U[_L'S_P#HLU'X;O+:P\!Z
M'/=SQPQ#3[?+R-@#]VM'BNXANO >O202I(GV"<;E.1]PT :.B?\ ( T[_KUB
M_P#015^LBPO[2P\.Z8]W<1P*UO$H,C8R=HK4BECGC62)U=&Z,IR#0 ^N4U#_
M )*?H?\ V#;O_P!"BKJZY34/^2GZ'_V#;O\ ]"BH ZNN5;_DK$?_ & V_P#1
MZU2U67Q/_:DS12^59PR@QE2NU@<  ^PYS5SG_A:T6>O]A-_Z/6A;7#K8Z1[V
MUCE6)[B)9'.U5+C)/I4]>;+IME/K]T;J:YCG%X=BF'.!D'(;W('->DT+X4PZ
MV"N5\$_?\2_]ARX_DE=57*^"?O\ B7_L.7'\DH ZJBBB@#E?B-_R(][_ -=;
M?_T?'3/&L>DR"T?5;Q[:)&93(I!49QPP]\<4_P"(W_(CWO\ UUM__1\=)XGM
MK"._M)KVTB-K*S"XN) 2%P/E'X_TI,:-#PK!%!HW[E)$CDE>0;\ G)SG Z"M
MNL3PH7.BC="(T$KB,@8WIGAL>XK;JI;DHY76O^2B>%O^N%[_ .@QUU5<KK7_
M "43PM_UPO?_ $&.NJI#"O/OC%_R)4?_ %^1_P FKT&O/OC%_P B5'_U^1_R
M:M:/\1'/BOX,O0\(HHHKUSYH**** "OI3P!_R(6C?]>X_F:^:Z^E/ '_ "(6
MC?\ 7N/YFN/&? CTLL_B/T.@N/\ CVE_W#_*OE* 2-?1K$VV0R@(?0YXKZMN
M/^/:7_</\J^7=*U4Z3>2S"WCF+9&)!TYZBN>DYJE/V:N^QTXY1=2FINRUU._
MFNA)#/IT-Y#_ &LD1+GR^^.:\O;(8@]<\UU+^-Y7\P_8+<.ZE2X'//O7+$Y)
M/K7/DN"JX2$XU(VO;L_79+3LN@LWQ=+$<GLY7M?NM.F_7NQ*!_K[7_KZA_\
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ML/4 URY(IQC*-2ZO:R?XNS;?KT+SGDDHN%G:][=.RT2T[=2"@?Z^U_Z^H?\
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M ,B#IG_;7_T:]=+=?\>DW_7-OY5S7PW_ .1!TS_MK_Z->NENO^/2;_KFW\J
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M82@:[<1RZJRQE05A0ME&V\ X/_ J]#L\_8H,N7/EKEB.O'6A:JX/1V)Z***
M"BBB@!'^XWTK@_!GAW3-9\!:'+?6_F.MJ4!#$?+N)QQ7>/\ <;Z5YOI;O'\'
M]'>.\%JRQ@Y)/S?,W''/O^%)C6I9\8V6D:9X'\06FGC;,84>5<DG[ZXY-=^.
M@KRB\,9^&WB4Q7+S(=A)8'[Q9<GGUKU<=!5,E"T444AG*Z__ ,CUX0_ZZ7?_
M *(-=22!U.*Y;7_^1Z\(?]=+O_T0:Y_Q9*!X@G275&"85DA0ME6Q@ X./?\
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M:X_PM);6U^(H=,@M4O(S-"T;$ML!_BSTSU_&NPJY$K=G*_$;_D1[W_KK;_\
MH^.J7C::6POK.ZCOKU?E<_9XB I QDY/?FKOQ&_Y$>]_ZZV__H^.CQD6<V,#
M+(EO(S^9/#")'CX&, ] :A]"HEOP?,)M$+YE+^<X?S7W-NSSR*WZYCP7=HVF
M&R%O)$T+M@O$5WKGAC[FNGJY;DHY76O^2B>%O^N%[_Z#'755RNM?\E$\+?\
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M19'V?+N;.&[&DQK<JZNMBOPX\1&U-QYC(C.L^,J"RD 8[<UZ>.@KS#56L_\
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MMVEE=:3H232R_:#9*$BCA,FX;5)/'3D#\ZZ;PI;&U\/PQL7W;F8AHRF,L3@
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MMD?,!ZUT0^''A#'_ " K;\V_QH^)'_)/=8_ZY+_Z&M=0.@H Y?\ X5QX0_Z
M5M^;?XT?\*X\(?\ 0"MOS;_&NIHH \SUKP)X7@\8>&+:/1H%AN)+D2J"WS;8
M21W]:Z/_ (5QX0_Z 5M^;?XTFO\ _(]>$/\ KI=_^B#754 >9ZGX$\+Q>/-
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MD6:Z-;BWEL+EW3+8+!H\'KVR?SKTRN4U#_DI^A_]@V[_ /0HJ '?\*X\(?\
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MJJY5?^2KR?\ 8#3_ -'M754 <KX-_P"/_P 5?]AF3_T7'755RO@W_C_\5?\
M89D_]%QUU5 '*^!O]1KW_8;N_P#T.NJKE? W^HU[_L-W?_H==50!RGP\_P"1
M8D_["%Y_Z/>NKKE/AY_R+$G_ &$+S_T>]=70!ROPW_Y$'3/^VO\ Z->NENO^
M/2;_ *YM_*N:^&__ "(.F?\ ;7_T:]=+=?\ 'I-_US;^5 '/_#W_ ))[H/\
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M10!RNM?\E$\+?]<+W_T&.NJKE=:_Y*)X6_ZX7O\ Z#'754 %>??&+_D2H_\
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M6WBJZFSY<>MW!; SQA*!G8URGC>'4);>S^QEV42Y>&*3:[^F/7Z5T-IJ5G?
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M==Z.@H 6BBB@#E=?_P"1Z\(?]=+O_P!$&NJKE=?_ .1Z\(?]=+O_ -$&NJH
MX_Q!;I=^/= MY/N2V5\AQ[B.K0T74[JV33KG48'L8BJL8X_G=5Z*>PJ/5O\
MDI'AK_KTO?\ VG7.ZG]KD\>J+-C(HD <6,A211_TT#<,/H*%\20/X6SH9@%^
M*=@HZ#1I@/\ O['5*/5O$MWJX\J/%I%<["%C!5P>V[T&.OO5V?\ Y*I8?]@:
M;_T;'6'"QAUO[3%(D<+WOEFP5F$N?[WICOC%"^-?UV!_"S=7_DJ\G_8#3_T>
MU=57*K_R5>3_ + :?^CVKJJ .5\&_P#'_P"*O^PS)_Z+CKJJXWPVTR?\)BUN
MNZ8:M*4 [GRH\5F6VM:VUS:?9;Z2\< "ZA:$#8Y_AH6KL#T5S;\#?ZC7O^PW
M=_\ H==57*^!?^/;7<C!_MN[R/\ @==50!Y_X?>\C^'MV]BS),-0NR67&57[
M0^2,]\5+HM_JMSKL36=]<7FG%@LGGJ!CY>3ZCFJFC(T_@"XMT$GF-J%VR[5)
M!Q<.<'':NA\+/(SSB2R2V( Y6(IN_,T1W"6Q%\./^1!TW_MK_P"C7KI;K_CT
MF_ZYM_*N:^&__(@Z9_VU_P#1KUTMU_QZ3?\ 7-OY4 >>6 /_  J7P^S-%Y2P
M1&6.5]JR+W4GK4VD7$S^']>CMX(5T[R)B@BD)$7[L_*,TW2(;2X^&7AB&Y\S
M=)'$L>P#J1@YSVQFKUA:QV/AWQ+:B1FECCF#Y  QL.,8]J(]?Z[!+I_7<J:+
M-;G2='M]9D(T]M(M_*B928W.P9)]Z>\8@^''B6"W#_V?%:W"VC2+ABFQO7J,
M]ZT=*U:PTKP'X>>_7<KV, 4; W2->>:36-8AUGX=Z_-##)#LL9T:.08(_=FB
M/4'T-_1/^0!IW_7K%_Z"*OUQ5YJ-]IVG:#)8.\LC6:@V:1[S(-J_-C(Z?UKI
M-$OFU+2HKIV1G;(;8",$'&,>HH6JN#T.#\3RS1>([J2.U2(;E5G(;,F%R#Z>
MPK>N"6^(OAXD$$Z5<G!'^U%6?K,T:^*+F&_#3AMC6ZK/MV#Z8]:M:W,]OXYT
MJ:,?/'H]XZ@\\@Q$4+2 -7F4=0U+3(O$E[_Q+?\ 5NIED$Y5G;CHOY5;U>VD
MOO'MQ:P$"2;PY(B%CCDS#%85C-:ZCK<,EYJD99HHYFN'A/FASUC4XQ@>X-=)
M>FX'Q)8V@5K@>'Y/*#]"WG#&:+6A9@G[^A!I>@ZK9ZS]NFTG3SE(XUQ,?W>T
M8+ 8QDUW%><2MXDNM0M/MJ7$;QNOEQ(F%G!/.\@\8_PKT>GT%U"N&T/SSI/C
M 6RJTW]L7.T-T/"5W->=VEK!=:!XN$Z2NJ:W<.!&Y4YPG<5$MBH[FCX3M_LV
MJ.+<71MV@!=KL882=POM^E/\=E_*L_+M1(RL[K(03LPOMZUG^")M^LR(\,8=
M8  PD9VQGW/'K6MXSE: 6$DCG['YA66,2["Q(XY[\U4NA,>O]=#GM3E>;X47
MC2=1=0@$ X/[^/IGJ*]*R,XR,GH*\_\ $/DGX6W!MXS'$9X-JE]W_+>/O6EX
MRO+&26UTZ2Y@@NF)=)9"^8L#J O6G)ZA%:'7T5SGA471@+'5GU&SP5$DT>U]
MX.#C_9KHZ&K#.5UK_DHGA;_KA>_^@QUU5<KK7_)1/"W_ %PO?_08ZZJD 5Y]
M\8O^1*C_ .OR/^35Z#7GWQB_Y$J/_K\C_DU:T?XB.?%?P9>AXWH&IQZ1JJ7<
MD;2*%*E5..M=AXOTTZCI4=_:2LZQ+N\M/F5P>X]Q_*O/*[7PKXRL=$TO[)>6
MDTC*Q*/'@Y!]<URYM@:WUBGCL*KSB[-=X_U^?D<F78RG[&>$KNT):I]G_7Y'
M(VEG-?7<=M$OSR' SP*] U[4H-+\/?V?*_F3RP")57Z8W?2AOB/82_:8WTUT
MC.!"R!=Q'?=Z?A7'>(-736+]9HXBB(FQ=W4]^:RJT,3F.+I_6:7)"&NZ>OK]
MVAO2K8;!82I[&IS3EIMT,FOI3P!_R(6C?]>X_F:^:Z^E/ '_ "(6C?\ 7N/Y
MFO:QGP(X,L_B/T.@N/\ CVE_W#_*OE&";[/>I-MW>7+NQZX-?5UQ_P >TO\
MN'^5?+NEV-K?W<R75X+55R0Q&<G/2L*4X0I3=3;KN_RU.G'PE.=.,-]3L[;Q
M/:WYN8XH[J1]C.L8&<@CD?05YVW+MQCGI7;:39:3HUQ+<KK$<I,+(%QCJ*XE
MN78^]<V44Z-.=54(M1TW373S2%FM2M.E3==KFN]K>7:XE _U]K_U]0_^C%HH
M7_CXM?\ KZA_]&+7L5/@?H>50_BQ]5^9[_XOA2?64%Q+]CC2WW13B+>96R?W
M?/3_ .O2>)&D;P+H[30^1(;ZQW1_W3YR5#XCCN+779)VO[A1-'@0+.<* 3R
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M''F.&/YBM:N;\$*5T%E?;YJW$HD"#Y VXY"^U=)3EN)'*ZU_R43PM_UPO?\
MT&.NJKE=:_Y*)X6_ZX7O_H,==52&%>??&+_D2H_^OR/^35Z#7GWQB_Y$J/\
MZ_(_Y-6M'^(CGQ7\&7H>$4445ZY\T%%%% !7TIX _P"1"T;_ *]Q_,U\UU]*
M> /^1"T;_KW'\S7'C/@1Z66?Q'Z'07'_ ![2_P"X?Y5\F-]]O]X_SKZSN/\
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M_$%D+/4X/.@#B0+N*_,.AX^M:-%--IW0FDU9G(?\*P\(_P#0*_\ (S_XT?\
M"L/"/_0*_P#(S_XUU]%5[6?=F?U>E_*ON.0_X5AX1_Z!7_D9_P#&C_A6'A'_
M *!7_D9_\:Z^BCVL^[#ZO2_E7W'(?\*P\(_] K_R,_\ C73:?86VEZ?#8V<?
MEV\*[8TR3@?C5FBDYRENRHTX0=XJP4445)84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gdzs1tysdsfm000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #@ JL# 2(  A$! Q$!_\0
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M-<V$4RQC'\1H ]2/QJN 2/[.BX/J:F/Q?U!;-;PZ2@MW8HLF3@D=J\M1%/F
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MAIM-.S&=KX%_Y /B;_KUKF(_NCZ5U'@7_D ^)?\ KUKET^Z/I2 DI_:F"E%
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M-P]J\WT+Q+=Z-I@M[-(U+Y+.1DFC5]?N=951=JF4;,948VCN/>HI864E[VS
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M* *']E0103+;#RY)5VEV)8@?C7"_%V)8/"%I$GW4F"C\!7I->=?&/_D5K?\
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M=;ZOA_:):MV.S#X:6+KQH1=K[OR1F:HTL$"VTX*LK;@.HQZBLP]:U=3C,MC
MY4Y1R-Y/4?W:S#T'<UC.I&JE46[6OY"KT)8>K*E)ZK^E]Z.U\#?\@'Q+_P!>
MM<NGW1]*ZGP/_P @'Q+_ ->M<LGW!]*@R)!2TE+0!+974]E=">WD,<B]&'45
M>@LM0U>22<;G=CDO(>6K*0CS45OXV"_K6_JUU*MP+:/,4<(PH7C/O6LL7]5H
MIQC=MLWPF"J8VO[&$N72[9G;+BRN-DJ-&3E2>Q]:IOPRUT-@RZI VGW4N"JE
MH6/7=Z5@R1X?'3&112Q"QNJ5G&UUZ[,6)P=7!U72J:]GW1LVFB(]@;^ZD(B
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M/ "", 'GFM#3M.FL[FZFENFF\]@0IZ)@8P*[3<T:*** "BBB@ HHHH ****
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M #]AN/\ OV:](T;Q+K$OPSU;4Y;LM>P-^[D89QR.U<*?B7XI0[7U#G_KD*R
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MO))AB>]4_!443:I*67+G"Y]!5OQU(W_"0- W\*[LU-\.M->\O[F4Y"(P'U-
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M\;Y?I7BO)8LW+$YS0!U?P[_Y&.?_ *\IO_0361;W)M;EI0H8Y( _&M?X>?\
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M5A 4D]?7- 'C=WMVG9DJ&XS7:>';:XU2U@:'" -P*XJY_P"/<?6O3_AS"_\
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M143?-)O8&[LL:!_R,FF_]?"UN?%'_D<I?^O:+^58N@?\C)IO_7PO:MOXG?\
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M_P"@FN;<Y9B?NY/'XUTOP_\ ^1@G_P"O.;_T$US;J"6&>Y_G6:W G2/,2XX
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MQG82#MZ8KT5OA%?DC_B9V_'^P:0?"*_'_,4M_P#OAJ //*CDC#[L^G%>D?\
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M,649#=.179_\*@O\D_VI;\_[#59NOA5?7,PD_M* ': ?D/:@#S265Y6W$X]
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M#YESSCI5"Z\5W-G<R6\EI&SQG!*N<&@#JJ*** "BBB@ HHHH **** "BBB@
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/*>X@LYVBD;*G;U% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gdzs1tysdsfm000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R LD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M54ZJ::2M?_@?Y"C1::;93HK0RACW[1C&>16?U.:YVK&S"BBB@04444 %%%%
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M@QCUP:DR?4T 5OMUM_SU/_?#?X4?;K;_ )ZG_OAO\*LY/J:,GU- %;[=;?\
M/4_]\-_A1]NMO^>I_P"^&_PJSD^IHR?4T 5OMUM_SU/_ 'PW^%'VZV_YZG_O
MAO\ "K.3ZFC)]30!6^W6W_/4_P#?#?X4?;K;_GJ?^^&_PJSD^IHR?4T 0Q:E
M;1RAO-.._P C?X5-<W]HX#+*<CK\C?X49/J:MV\GF)L;J!^8IKL",O[=;?\
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MIHX[G5KB9#M*L$9" W^S[9HL,[($,,J00>X.:6N&T:&=K71]/CN]0@!GG2[
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M7FH_\_MI_P"/?X5Z%O'HW_?)HWCT;_ODT>P@'LXGGO\ PKS4?^?VT_\ 'O\
M"C_A7FH_\_MI_P"/?X5Z%O'HW_?)HWCT;_ODT>P@'LXGGO\ PKS4?^?VT_\
M'O\ "C_A7FH_\_MI_P"/?X5Z%O'HW_?)HWCT;_ODT>P@'LXGGO\ PKS4?^?V
MT_\ 'O\ "C_A7FH_\_MI_P"/?X5Z%O'HW_?)HWCT;_ODT>P@'LXGGO\ PKS4
M?^?VT_\ 'O\ "C_A7FH_\_MI_P"/?X5Z%O'HW_?)HWCT;_ODT>P@'LXGGO\
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MM:^%6ESW)+3K=^6[_P![:&&?Q&*TO$<]YJM_HOA>TG:WCN;=);F1>I7;T^F
M3COQ1L/G-C5?&%B+;4(;"Z:34(2(5*Q%P)&. ?0J#U-:5I?NCK873K/>QI'O
M:#!\P-P9-H^ZN[(KGKKX<::FGR+ID]W;W@C(64S'#^S#T/M61X0NUGTN/3+8
MH9[>2.3/D-)+&Q8@G&0-BMC')'7(I:#4G>S/2ZGMH][[CT7^=1Q1-(0O7'5J
MM2.MO$%7KVH2ZEHBNI-S!!T'7ZU7HHI, HHHH$%%%% !1110!SWB:625[73V
MMKIK*8[[J2"$N2@_Y9C']X]?:J%XM_/KN]&NK: F V96"0A4XW+A3M7N#N'2
MNPHHN,Y&6SU :?JMU&;XW#7K($61L_9]X)\L>I&>1SZ5"]A->0M"MO>-ICZE
M#Y*7 8NL>TAS\W(7)[UVE%%PN<+#I^I3-:R7MO*6L+J"TB.TG=&KDM)]"-O/
MM5FRAU-M6G:ZEN5FW7&]/*D*2(0=@W9V =,8&:[&BG<+G!FWOTTVWBE@U(,N
MFQK9+;AALGYSOQT/3[W&*MWUIJC27]R6O3<PR6AA$3ML)PHD(4<$=<UV-%%P
MN9]SH\%Q+<%W8K-.LS+@8^5=N/H13;#2$TV*00S222/"(]SXRQ&X[C[DM6E1
M2 X6.9Y?#&BZ<;:Z:TD0F]D@A+G"L<Q\="6Z^U6KQ;^?7-Z-=6T!\@V96"0A
M5XW+A3M4]CN'2NMAABMU988UC5F+D*, L>2?QI].X7.1EL]0%AJUU&;XW#7K
M($5VS]GW@GRQZD9Y'X5I:#',/[1\L74=BT@^QBZW;U&WYC\W.,^M;E%*X'(Z
M;--8>'#IC:1>M?V\<F[9&55VY^82#N<]N:K6D%^[*I@N#;KJ5K+&&23"K@[B
M-^6QGKFNWHIW"YQMA'J/VZW+)J O0\_V]Y"WE,F#L"_P_P!W&*EL;/4+>RT)
MT-X;F4N]UYSL<-Y1"A@>@SCBNMHI7 Y7PM%?+<[[N6Y$GD8N(I8I #)G[VYB
M03U^[QBGND\'B@_V?'>!;F<?;HI8/W)7;CS%?L<8Z5T]%%P.!8>(;=#LBNW^
MRJ]@HP3YN_=ME]\?)S5VZM-1AUE8#<721Q+ MK,D<D@( &_[IVY)SG=V-=C1
M3N%SDK6#4)/$DGVN6YC)N9 0(Y"CP$$* P.P#&.V0:SK>SO+;1[*V2"\BBCN
M)1>JR2L,\[" I!*_[O&>M=]11<+G&SV-_<0JDD^H2B/269'7?$7F#';D==V,
M<'FFW2:M-J$+32W4.8+<P2)#(^UL#>,*< YZ[ATKM**5PN<G<VS1Z9XFO+UK
MCDSQQ+(YV>60,;5Z<GO6M;Z-;2M87US&QO(8$7=N/4*/\/U.:TIH(KF(Q3QK
M)&2"589!P<C]:DHN 5QOQ$_Y!MC_ -=V_P#0:[*L+Q/H4VO6MO##/'$8I"Y,
M@)SD8[5%1-Q:1,E='E-%=A_PKR^_Y_[7_OEJ/^%>7W_/_:_]\M7)[*?8QY)'
M'T5V'_"O+[_G_M?^^6H_X5Y??\_]K_WRU'LI]@Y)''T5V'_"O+[_ )_[7_OE
MJ/\ A7E]_P _]K_WRU'LI]@Y)''T5V'_  KR^_Y_[7_OEJ/^%>7W_/\ VO\
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M6OB&+Q)IEC'?JJA+BU>/?D 8SM[C'IR,9K,B\22WDBP:=X MVF+9?S8. /\
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M44 -W_[#_E1O_P!A_P J=10 W?\ [#_E1O\ ]A_RIU% #=_^P_Y4;_\ 8?\
M*G44 -W_ .P_Y4;_ /8?\J=10 W?_L/^5&__ &'_ "IU% #=_P#L/^5&_P#V
M'_*G44 -W_[#_E3/,/VC;Y;8V9^[SUJ6F?/Y_?9L_#.: %W_ .P_Y4;_ /8?
M\J=10 W?_L/^5&__ &'_ "IU% #=_P#L/^5&_P#V'_*G44 -W_[#_E1O_P!A
M_P J=10 W?\ [#_E1O\ ]A_RIU% #=_^P_Y4;_\ 8?\ *G44 0R2$&/$;<N
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M9N]@>F?:F]A.2V-W?_L/^5&__8?\JYSQ/XBN]&U31[*UBB;[;+MD:0$X&X#
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M5[PO9W=K>7KS6CVT$L411"FQ=XSNPNX_GWI6 Z6BBB@04444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gdzs1tysdsfm000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #T!&4# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_S[7'Y+_C1_PFMC_P ^UQ^2_P"-4JL$K7&IQ74Z6BN:_P"$UL?^?:X_)?\
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M!^5<7_PG,W_/I'^9H_X3F;_GTC_,T?6*?</:1.TVCT'Y4;1Z#\JXO_A.9O\
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MA_T!;7_OZU'_  O34/\ H"VO_?UJ/J=;L'URCW/;L#&,48'I7B/_  O34/\
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M_LV^_P"?2?\ [X-']FWW_/I-_P!\&@"K15K^S;[_ )])O^^#1_9M]_SZ3?\
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M1:G%'HEY8>6^Z>4.K9R !C@_E21:FD6@/IX1O-,XE#]AC'^%5OL%Y_S[2_\
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M;??\^<__ '[-']FWW_/G/_W[-%T%F5:*M?V;??\ /G/_ -^S1_9M]_SYS_\
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M*U:Z-W=:3?-;"X;[TBY.,^^0: .]HHHH **** "BBB@ HHHH **** "BBB@
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M"/LXB\S9MV]^?T_.@#W:BJNFW8U#2[2]"[1<0I+CTW*#_6K5 !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KFO'&M_V/X?D6-L7-SF*/'4#^(_@/U(KI:\Q\=Z1KFI7\]^UN
M!86J80^8OW1U.,]_\* ,_P"'FN?V?K7V*9L07F%&>@?^'\^GXBO7J\#T71=1
MUB=QIT>^2'#GYPN.?>O<=,>[?3;<WT7EW6P"500?F'?CUZT 6Z*** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5*76=+AD*2ZE9QN.JO.H(_6L_Q)-*WV/3XY&C6Z=O-9
M#AMBC) /;/ ^F:IQ65I#&(XK6%4'  C% &S_ &]H_P#T%K#_ ,"4_P :/[>T
M?_H+6'_@2G^-9/D0?\\(O^_8H\B#_GA%_P!^Q0!K?V]H_P#T%K#_ ,"4_P :
M/[>T?_H+6'_@2G^-9/D0?\\(O^_8H\B#_GA%_P!^Q0!K?V]H_P#T%K#_ ,"4
M_P :X#XFZA97B:;]EO+>?:9-WE2JV/N]<&NI\B#_ )X1?]^Q1]G@_P">$/\
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MT?1].74)V33+[[:DC(-TAR3M/Y]:-6\"QW^M7.J66KW.FS7847*QPQR+(0,
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M *]W_E766_\ Q[1?[@_E0!)1110 4444 %%%% !1110 4444 %%%% !1110
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MY('89I](Q 1B3@ $DT 7?#'_ "+&F_\ 7NO\JUJRO#((\,Z;D?\ +NO\JU:
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M_P# F+_XJC_B;?\ 0"G_ / F+_XJNIHH Y;_ (FW_0"G_P# F+_XJC_B;?\
M0"G_ / F+_XJNIHH Y;_ (FW_0"G_P# F+_XJC_B;?\ 0"G_ / F+_XJNIHH
M Y;R-:N/W46G?9&;@S3S(P0>H"DDG\JZ#3[&+3;"*TA)*QC[S=6/4D^Y.35F
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *H:U_R!;O_KD:OU0UK_D"W?\ UR-14^!ET_C7J8XZ"B@=
M!17*=85DZ?>W$^K:M!(V^.W=1$H &,CI6M6 EMJ]EK%_<VUG!-%<NK O/M(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gdzs1tysdsfm000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! M(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#(\7^,-1\2
MZO<.US*E@LA6WMU8A @/!([D]<FN:HHKWHQ459'@RDY.["BBBJ)"BN\^'VAV
MES;W.I:CI4FHV[W$5C'&L9?87.7DXZ;5QS[U<\/>&DM(O$=K+9:7<W]E?0V\
M+:F<1X9B.N1RPQC\*QE6BFUV-XT)22?<\WHKTB]TO0M(F\4:O;Z6ES'I\\5K
M;VER&\I)&QO8@\E<],_X5BL+'5/!NO:LNEVEK<1W-LB" ';'G(;;D\ ^E-54
M];"=%K2YR-%>AVEEX=M;KPZVHPVD(N=&:1'G4^2UR6(5I<=1U_2L/5] OY_&
M=OI4EG8V5Q>&-8_LF?(8-P)%Y/!Y/X4*JF[ Z+2N<Q1D>M>CVG@6PT[Q!H[W
M-S/+:RW_ -F>&X@56D8#*D*&.8VP1D\CTJU=-I3:'K=]!*C74VJ)9!WTV, #
M&!&%S@#U8<\5+KQOH-4)6U/+J*[K6_#%A!?:MJ.K:@+.V74#9P+9V8PSA Q.
MS=A5&1T)-/7PBVKII671(8]'6[D^R6RB1\N0%P6 9C_>)%5[:-KB]A*]C@J*
M[:;P+9V<FJ27NK216=C!!<;U@#R%9"1M90W#@C'7%6?^$/T33[+Q&+^]N)&L
MX+>>VN(X>523&#MW#).=I!Z=:/;0_K^O,/83. HKT#7O#<.HV4$MGMCO+70K
M2Y%M%$/WX)(=LCN,@^]0Z!H=KI?Q7LM'DD2^CA)6;?&"I?RB67'((!X_"CVT
M;-A[&5TCA:*[0>!H%U:73;O4V@N;?3WO[LK!N2+&"%7GYOE.21WX%-;P79^<
MMTFJR'1SIW]H-<&WQ*%W;=@3.-Q/OBG[: O8S.-HKLCX*LUSJ#:K+_8@L%OO
M/%O^^P6V!-F<;MW?.*T]/\,V.K^"&:VN +.UU*:::_, $OD+$#C;U)R<8SCO
M2=:*U&J$F>=45VT7@#S="2_-W,DLUHUY#NB7R@@R55VW9#L!V! J_H_AO3-+
MAU)+F[%SJ;:#)=-;/;?)$&4%2KD_>'';OQ0ZT>@*A/J>=45TUAX*U![MEU56
MT^UCM7O))2!(?*3&=H!Y/S#KBK;>"[:6U>_M-2EDL'TR:_@:2$*Y,;!61AGC
MD]13=6"ZDJE.VQQU%=[HOA#1O):75+J=Q-H;:B@CC_U1R03PPW%<# /7)]*R
M_!VD:-JM]JT>HRSF&WLIIH65.<+_ !D ]0,';T.:/:QLWV'[&5TNYRU%>D0^
M&M(UOP_X6LUOC:W5T+I;9Q:@F<AR09"#QP ._6LW3_A\]WHD%W+=R17%S!)/
M%^[7R4"YP'<L""V., XJ?;0ZC="?0XFBNK\#Z5::B^L3WWV80VU@Y1[HXC25
MB%0L?;FM*?P<C:9X<T>TDL[K4-2N997O;8EU$*X'7 X')^HINK%2LQ1HR<;H
MX*BO4=4\(:=JFI^&[>RTZ73+>>:X@GWQE)'CBY#G(ZLH)S[UE6TNCZ_I7B-(
M]!LK*TTZT,UI<Q!O-#!L('8GYBU)5DU=+^KV*=!IVO\ UN<'176ZU#ID/@#1
M)[;3$MKJ[GD)F9R\DB1C:23V!8]!QP*FT7P3:ZAH$6JWE_=0QR133%X;8/'$
ML1P0[%AAF["J]K%*[)]E)NR.,HKM?^%?LOAX7\EW*ERUA]O4&)1#MQD1E]V=
MY'/3':B\\$64%I>"#5Y)=0MM/34# ;?:OED#(W9^]SZ>E+VT.X>QF<517;:U
M\/VT?1KJY>\D-U:1QR2J\2K%)NQE8VW9)7/.0,UQ-7"<9J\29PE!VD%%%%40
M:VA>)=4\-WT=U874BJAR\!8^7(.X*]/QZU]/6-TE_I]M>1@A)XEE4'L& (_G
M7R4WW3]*^J/#/_(JZ/\ ]>4/_H KS\=%63/0P,G=HU****\\] \(^)_C#4+S
MQ%<Z/;7,L%C9GRV2-BOFOC)+$=0,X ]J\[K>\;?\CSKG_7V]8->Y2BHP21X=
M63E-MA1116AF%%%=GX!TFWN&O]5OM+?4K6T$<2VR1ERSR. 3@#^%=Q_*IG)1
M5V5"#G*R.,HKTK3/#$&FZQXMM);/3YY;'RS9G4CB%5=^"QR,94@?6GWNB:)I
M^J^(M1&EQR#2+2 M8MN$)N'X) /)0<'T-9>WC>R_K;_,U^KRM=L\RHKLK9K#
M6_#GB?43I%C:7%M;V_EBW4A58R$,R@D[21@''I5VPLO#UM8^#;K58((X;J*[
M,\CJ=KN'Q&9,<E0:IU;=/ZM<2HWV?]7L<!174^(]-:V\26,>HVUA:6MPJ$3:
M4NZ*:,MCS%!/7MCCI6OJO@_0?^$EUV"#49[*QTN%9I@8"^S) *K\V6X.0?4X
MH]K'2XO8RUL>?T5W.F_#Y-1TR&[6^F3[8LKVKF%1&J(3M,K%LJ6QV!Q52T\&
M1WOA>XU2.:^CF@M&NCYUJ$@<+U5'W98^^,4>VAW#V,^QR-%>A7O@W0KK6-%T
M_3KZ>W:ZTP74KR0DC 1FWGYN"2.5'3M4-KX$T>^_LS[+K\['58Y#9![/:2\>
M=V_YOE7CCOS1[>%A^PF<'17:Z;\/VO=#M[V6[DBGNH))XOW:^2@7. [E@06Q
MQ@'%)'X(LI;*#;J\@U&XTO\ M**W-O\ )M R5+Y]CCCM1[:'<7L9]CBZ*ZSQ
M9HVBZ=9Z"^F2S^=>6<<TBR1X#AL_/G<<'/&T<5>E\ V?_"33:)::M-<2VD4D
M]X1; ;% 4JJ?-\S'<!U %/VL;7#V,KV.%HKNE^'\)U=K8WUPR&R%W' D2?:G
MRVTIL+[=PQD\]*SX?",4W]CG[7,@U'4I+$B2':T85@-Q&>O/([4>VAW#V,SE
M:*]2TGPWH]U'X<TW4(RZ&ZU&)FC3:TQC/R[F!!  !/?ICO6)H_@2VUBU-Y%?
MW7V.:Z-O;2"W7(P!F24%AM7)QQDU/MX]2G0ET.(HKT/PMX4L++6-#GU:_4W%
MW=RK;VRP>;%*L;%3N;/&3TX/:L'2;,3P>*G"V^+>U=P)(0Y'[P#Y#GY3[BG[
M5-NPO8RLKG-45VFL^"++3K?5EMM7DGO=,CBGFA:WVKL?&,-G[PSGTK&TE_#8
ML&BU:&_-U+(0+BW88@0 ;2%/WR3G(...E4JB:NB72:=I:&)17?>$IM'O=8N[
M8:#8OHMJLMU+<WB%YTA X!.<9)Q^9J]I%CHTC>';271;61/$+7$DTC EX%W$
M(L9S\NT8J)5K/5%QH<RNF>9T5Z+::-X?UG3(;2V1-]JT'GO#$PGW?,LB%CPS
M2-L" =.3P :YJ_TJXN?%]M9W5I%IRWTT:Q);E71(V;:"I!PV/7/)!S51JINQ
M,J32N<_17;0^![.YU?4;2TU&YNH=,3_2VBM@',F\J$C#, >G4D=#4=QX)L].
MDU274M7>*PL_)5)8H-\CM*,@%<\8YSS]*7MH![&9QM%=]XX\/6PO]:U&W=(8
M[.6T@6&.,*K;XE);V]:K7_@G3]'FU*34]7FBL;6Z2TCDBM@[R2-&'R5W#  /
MK0JT6D_Z_K4;HR3:.*HKT*U\/Z(D7@V:SF9KW4)B'\^WWQRX?!+*6P .@'?J
M<52M_!UE<RVGV_5&M;G5KJ:.RCAMMR#:Y7+\C:"W  SBCVT0]A(XJBNXT_P%
M:7*:9#=:P\&H:CYZ0PK;[E#Q,RG+9^[\OIGFN((*L5/4'!JXSC)V1$H2BKL2
MBBBJ("KFFZMJ&CW27.G7DUM*IR"C$ ^Q'0CV-4Z*32>C&FUJCW*S^,.E-96Y
MNH)!<F-3*$Z!\<X]LYHKPVBN;ZG2.GZY5"BBBNHY0HHK8T+3H[^#5WDMC/\
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MZRMMX9OM',!9KJYBG$N[A=F>,>^:Z_\ X4QXC_Y^]-_[^/\ _$T?\*8\1_\
M/WIO_?Q__B:E5*"5KE.%=N]BA?>.+#5YM0CU32)I+&YNX[R..*Y"/'(J!""V
MWD$"JNI>-Y-5MYEN+,"6754U#*OPJH@0)C'H!S^E;/\ PICQ'_S]Z;_W\?\
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M>(_^?O3?^_C_ /Q-'_"F/$?_ #]Z;_W\?_XFA2P_<+8CL9GA;6-/35/$MYJ
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MD'V5HT9V0+AOWFW(R<FKO_"F/$?_ #]Z;_W\?_XFC_A3'B/_ )^]-_[^/_\
M$T^>AR\K=PY:_-=*QEQ^/KC38=-M=%M(K:SLRSE)D25G9G+$[BN5XXXJ:R\?
MQ:?-K36^EG9>3M=6BM+_ ,>DS(REAQS][VJ]_P *8\1_\_>F_P#?Q_\ XFC_
M (4QXC_Y^]-_[^/_ /$T<V'[ARXCL96@^,[?2-,T^WFL;EYM.G>>%[>Z\I96
M;M*,'=Z?3BLW1O$4=AJ&IRWED+BUU.&2*XAB?RR S;LH><8-=/\ \*8\1_\
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M\UQ7_"F/$?\ S]Z;_P!_'_\ B:]>EB*?(KNQY-7#U.=V5SSJBO1?^%,>(_\
MG[TW_OX__P 31_PICQ'_ ,_>F_\ ?Q__ (FK^L4OYC/ZO5_E/.J*]%_X4QXC
M_P"?O3?^_C__ !-'_"F/$?\ S]Z;_P!_'_\ B:/K%+^8/J]7^4\ZK5\-78T_
MQ)I]Z?*Q;S"4B63RU..V[!Q78?\ "F/$?_/WIO\ W\?_ .)H_P"%,>(_^?O3
M?^_C_P#Q-)UZ35N8<:%5._*10:TL-QH4IETP_P!EW5Q<$?;Q^\\UMV/N\8_6
MLW0I5T?79[^2ZTN>"XCEBFA%\%)23KAL=16O_P *8\1_\_>F_P#?Q_\ XFC_
M (4QXC_Y^]-_[^/_ /$UGST;6YC7EJWORBMKEI'#';VB:;#;Q:7/IT:-J8<@
M2$$.3MYQCD>_:J^@ZNNBV^DQ&;3)O[/N9YR1?A?,\Q-F/N\8ZU/_ ,*8\1_\
M_>F_]_'_ /B:/^%,>(_^?O3?^_C_ /Q-+FHVMS#M6O?E(=%UM]%M=)ACGTM_
ML,EP9#]O"^8LH ('R_*1CKS6;XA(UF:W:+5XRD*D#[=J@F;).>,* !_.MC_A
M3'B/_G[TW_OX_P#\31_PICQ'_P _>F_]_'_^)IJ=)/F4A.-5JSB.N]=L[I[Z
M[VZ>FHZE;K:WLPU,%#&-H;8NWAF"@<DXJR_BJ"XO+2XNH-(?[%(ZV@2_4>3
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MKRSO!Y94!> B@,, <'I7J5%5]8D3]7B<18WD&BKXBO/]*N'O9WN88X[&?/W
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MNNT@QMSMVDG.<9X'UI^@Z%+I=[=74GV2$3(D8MK*,QQ#:6._!/WCNQQV ZT
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MD1WJ7N)$E2)1C^ ;V/7MR<=* .UHKDIO&S6LL<-SI;PND[073M,/*@(V$?O
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ME=E7D'B[_D:;[_>'_H(KHPT(SDU(Y\1.4(IQ-_\ X61+_P! U/\ OZ?\*/\
MA9$O_0-3_OZ?\*X6BNWZO2[')[>IW/4_#?BQ]>OI+=K180D1?<'SGD#'3WKI
MZ\U^'?\ R&[C_KW/_H2UZ57!B(J,[1.VA)RA=A1116)L%%%9=UXBTFRN7M[B
M\5)4.&4JQQ^E-1;V0G)+<U**Q?\ A+-#_P"@@G_?#?X4?\)9H?\ T$$_[X;_
M  JO9S[,GVD.YM45GV.MZ;J4S0V=TLLBKN*A2../4>XK0J6FM&4FGJ@HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **JC4[ V\MP+ZV,,+;99/-7:A]&.< _6G
MF]M1-#";F$2S#=$GF#,@ZY4=Q]* )Z*** "H(K2&"YGN(TQ).07/K@5/118
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M[1DY^7:IP .#NP.]>DT5)1@>*K:X71]0U&VU.]M9;:SD=$A90A95+ D%36W
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M=%5X[VWD?8) LG]QQM;\C5BM4TRPHHHH **** "BBB@ HHHH **** "BBB@
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M:BL=4L-3#FPO(+D1D!S"X8#/3I2&6Z*** "O(/%W_(T7W^\/Y"O7Z\@\7?\
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MB*-(1F5F< (.OS>GXTTZA9!K=3=P9N1F >8/WO?Y>?F_"I**/BC_ )%+6O\
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M9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7FNJ3>*O[4O$=]9^RK-(6&G^1E1G]QLS\VW'W\]\=LU
MZ57FLNCZ1;W>L2'Q)I-MJ<MU+)!=&X7S0'R&AF4G#*.F.V,\$5O1:3=S"M=I
M6.]TA[N31K)[]HVO&@0SF,@J7P-V,<8SZ5=K+\-6OV'PQI=IYT4_DVL<?FPM
MN1\*!E3W!K4K&6[-H[(YVZMYQXUM+N'2I&A6UEAFNE\L!F8QE<_-N( 0CIQD
M4>&;34+*26!TNH=+CAC2WAO)(WD5AD-@H3\F-H&23P:Z*BD,.U1[),_ZX_\
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M]*KS7X=_\ANX_P"O<_\ H2UZ57F8K^(>CAOX84445SG0%%%% !1110 4444
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M7HI/E?0:<EU,N.VU<-_Q^PHG]UD,I_/Y:Y+QQ;Z@+6U^U7"SC>V B;1V[?\
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MSAO!WAR6RO9+F_A=9 A"(T?R]1SGUKN>G2BBJJ5'.5V3""@K(****@L****
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M5/\ P('^%9]QX%TN[G:>XN+^25OO.T_)_2NGKG+;QIIMW<-;QI-YR:BVGNA
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M8&T,N.#SW) 'O34FMA-)[F1_PKS1?^>E[_W_ /\ ZU'_  KS1?\ GI>_]_\
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M"(9XED0,,$ CH1ZB@#/_ +#O/^AEU?\ *W_^-4?V'>?]#+J_Y6__ ,:K:HH
MY36K'4=.L8YH?$FJ;FN8(CN6W(P\JH?^677#&M'^P[S_ *&75_RM_P#XU2:U
MK-WIMY9P1Z4+N*YE2)&$ZJV\DDX4CD*H+$YZ UMT 8O]AWG_ $,NK_E;_P#Q
MJC^P[S_H9=7_ "M__C5;55[Z[6QLIKIHIIA&N[RX$+NWL .IH YN[LM2@U_3
M;%/$FJ>5<QS,^5M\Y3;C'[K_ &C6E_8=Y_T,NK_E;_\ QJH9O%5I%9:)<M;2
MM-JK0B*)0"T2R;068] HW*"?4@#K704 8O\ 8=Y_T,NK_E;_ /QJC^P[S_H9
M=7_*W_\ C5;59&O:U-HML;A-.ENH8XWFG=9%18T7D\L>6/8=\'D4 95G9ZE<
M:[JED_B35/*M5A,>%M\_.I)S^Z]JTO[#O/\ H9=7_*W_ /C526VMPW&OMIB6
MEPC_ &47/GO'M1@2!M&>21D9[#IUS6M0!B_V'>?]#+J_Y6__ ,:H_L.\_P"A
MEU?\K?\ ^-5M5BWVO26&K06LNFS_ &6:58%NMZ_-(RE@%3.XCCD]O3 )H S]
M%L=1U"P>>;Q)JFY;FXB&U;<#"2N@_P"677"BM#^P[S_H9=7_ "M__C50^%_%
M%OXD2X\BW\GR0CG$BR##Y(!*_=<8^93R,CUKH* ,7^P[S_H9=7_*W_\ C54]
M8T[4+#1+^\B\2:KYEO;22IN6W(RJDC/[KIQ735R=UXVBM3J4=SILD;VD:R!'
ME3YE:3RUW\_N]Q((!ZKSV(H NVND7T]G!*WB35MSQJQPMOC)&?\ GE4O]AWG
M_0RZO^5O_P#&JN:/J U32X;P+"HDS@0S"5>"1PPX/3\.E7J ,7^P[S_H9=7_
M "M__C59FLV>I:>+ P^)-4_TB]B@?<MN?E8G./W76NK=UC1G=@J*,LS'  ]3
M7+_\)@+G29M2M-'N9[>"6;>TCI$%2+!W_,>-P.5'IUQ0!H?V'>?]#+J_Y6__
M ,:H_L.\_P"AEU?\K?\ ^-5JV\ZW-M%<(&"2H'4,,'!&>1V-2T 8O]AWG_0R
MZO\ E;__ !JLY[+4E\2V^G#Q)JGDR6<DY^6WW;E=%'/E=,,:WM5U.#1],GOK
M@.R1+D)&,O(W95'=B< ?6L2'QC#/<VY&GRB!DMA-.9$_<O. 43&<MU7)'KWP
M< %[^P[S_H9=7_*W_P#C5']AWG_0RZO^5O\ _&JVJ* ,7^P[S_H9=7_*W_\
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MJ9D$[#(CW?,1]/PJ:@#G&T?59O&-OJ<TEJ+2V$BQLA;>R,H&PH?E!#<[P<D
M#%='110 4444 %8>N^&K?7[FW>YE(CB@FB*!>3YFW# ]BI4$>];E% '&1?#V
MS%E]GN9X[EETW[!')+; F-MSMYHR3@_/^G6M'3O!^GV>IRZA<1PW=RPA\J22
M$;HO+C5.#SUVY]LUT5% '.:OX/M=5UBWU075U!<131R/LE;:ZIG"XS@?>//N
M?6NCHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,S5])?43:S6]VUI
M>6KEX9E0/C<I5@5/!!!_,"K.FV$.EZ;;6%ON\JWC6-2QR2 .I]ZM44 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /*];BLVU+QA:7.B7%Y?7K*MBZ6+/\ -Y*@$28PN&YZ]JGFN-:A
M\1Z;;%]5#Q7%M;71W2-#)&8\.X 78%+=R2V>>!7IM'48K?V^EK&'L=;W.'\&
MS:O=ZQ=0ZA<3M'H\9L"6<D7$N\GS#ZGRQ'U_O&NXJIIVEV6D6IMK"W2"(N7*
MK_$QZDD\D^YJW6=22E*Z-*<7&-F%%%%06%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gdzs1tysdsfm000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #? 7(# 2(  A$! Q$!_\0
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MUVX/D)\L*GLOK]3UK5 "@ =!7/.5V:)6$5%0848%/%)2BH&+2BBEI@%+113
M44M(*=3$*O6I5J)>M3+5(3)5J9:A6IEK1$DE%%%4(**** "BBB@ HHHH *R-
M?TZ\U&VCCLY_*8;]QWE<Y0@<CW(K7HIIV=Q-75C#_LF\CT^2UAGV_P"F"6+,
MC';'N!VYZ^O'O64_A2_\J-8KM4ECBPDIE=BDIB*,P)]3C^==C15*I)$NG%G*
M6N@:E$\!ED62,$X1[EOW&6!)&T -D9&#C'TS56#PMK$,:1QWHA"0"--DQP@"
M;=N-N<$_-G(QGU%=K13]K(7LHG-0>'YCI,UI*D4:RWZ7)C65F"QAD)7<0#G"
MFH/["UI4,"72>6>0YG?* +(H4<<_>3G/;Z5UE%'M&/V:.4?PW?Q)(;2<!R2%
M#SR8V&)01U_OAF_&DL?#NIPE))[D&2*1##B9\(OG%F&.GW#M_2NLHH]I*PO9
MQN<Q?^'KZ:XO;BSNA!-<2,=XD8?(8U4#'3[R]?QJE%H>K+?1Q!G&R-729KAB
ML)\PDJ   QVC&.,9]*[2BA57:P.FKW.)3POK!+227$*R@DQ$3.?*8QLK,.,\
MDCW_ !J[#H>HK<Q2-Y8MPY*V_P!JDQ;C*Y((Y<D!N#C&[TS74T4.K)@J44<1
M'X<U2YMH[GSV%R4DB#RLRN(@Z;%P0<;D0Y]VJ]8Z'JMMJ5E.UP&CC&)!),S8
M7+?*!@<\@9Z<=.!74T4.K)@J204445F:!1110!SEZ1!?^;*FY8Y][9 R%(P#
MZ\5!I.I66E6\]M?SI;RI*69I#@.#T(/?-;]Y9"XPZ$"0#!R/E<>C>HK%N].>
M6)8;BR:1(\;5\M91P1CD\^IK+$4)59*<-]M0H5(TN:-1-Q?;<AN[J*^EFEMU
M,B31I!&<$;W#$Y'^[GKZFK=O87UP]Q-;ZQ/;1M)PB0HPR!R3O4G]:ECL+B=A
MO7RU"[-S 9QSD!1P,@_I6Q%&D,2QH,*HP!54:?LJ?*]WN3*7M*G,E9+8QB^O
MZ:-SB#5H!]X1KY,X'L"=K?3Y:I:QKMOJ&EQP6,I+7#F.52"KQA?O*RGE3T&#
MZUU->8>*-$O=<\91ZCIE^MI-82Q@QM'\ER$.2KD<]V ZT3=D:16IU-I ((%4
M#'%6*BDGC1]O)/7:!D@>M$4Z2G #*< X88Z]*PY7:Y7,KV):444HI(8M+0*6
MJ *7% I:8@%.I!2TP%7K4JU&O6I5!JD)DJU,M0CWIBW]O_"SN/5(V8?F!5)I
M$MERBJOV^'^[-_WY?_"C[?#_ '9O^_+_ .%5S(FZ+5%5?M\/]V;_ +\O_A1]
MOA_NS?\ ?E_\*.9!=%JBJOV^'^[-_P!^7_PH^WP_W9O^_+_X4<R"Z+5%5?M\
M/]V;_OR_^%20W4-P2(W!9>JD8(_ \T70[DU%%%, K.U5+PF%[-Y X$@*J1M)
MV-M)_P"!8K1HH YJV&I?:K?'V[R?,!B\T_P9^?S/PZ9KI#G''6EHH 9^]_V/
MUK#\0>(GT%H UNLWFACPV,8Q_C6_7"?$/[]A]'_I0 ?\+#??_P @]=N/^>G/
M\JVM \2OKLTT:VRP^6N[);.:\NKL_A[_ ,?=Y_US'\Z8CO/WO^Q^M'[W_8_6
MGT4AC/WO^Q^M'[W_ &/UI]% #/WO^Q^M.7=CYL9]J6B@ HHHH **** "BBB@
M HHHH *X>P=GDGD5L//,Y4YY ))R/I78WTWV>PN)O^><3-^0KE-&@V6L;$G(
M7&.WUK*HU=%16@V9_NPP('D:811Q[L*SD9+$CG&.HJ>YL+FT\N6=X0[959+=
M2@5L$@$$D$$ C/!%0WEO(KEEW@F02I*F-R.!UQT*XX(H9;ZYO8Y[JZ694C*J
MOE^7&C,/O'N3CCT&:Y9JISWC?R[>?]/<UA[)T[2M?7H[^5B]#<AK-9L9R!A5
M.3].>IJT*SEN;875K:O,J;@?(20\RD<87/<?F:N7-S':P^9(3UPJCJQ]!6\D
MD]#.%VB4D*I9B HZDG %4GU6'.((WG/JHPOYFJGESW[A[C[N<K$/NK]?4UI0
MV0P.*195^WWK?=MH5'^TY-.%_>K]ZVA8?[+D5I+: #I3OLJ^E,5T9XU3'W[2
M=3_LX;^M!U-V_P!5:2$^LC!1_6KYLU]*46BCM0&AF!KZ<_/+Y:_W8AC]3S4\
M=JP.?,DSZ[S6BL %2B(4T)LI1QR3W,=M*Y>':9&!ZMC  /MD_I6P!@8'2J,:
M[=33_KBW_H2U>K6)GU.0&M:EY418E5)N\394[]@?:,=L8'Y4RRUR\CB^TW%T
MSV]O)$T^[:W[MU()++QPV#CJ!UKJ;J2RL;1[BZ:""WB!9I),*J@]3D]*Q]4\
M1:-I.G)(@@N()<GR[=D.X8SG'>HE[NK9+5NHZ74+NW\-1W$LC"\NF CPF2A<
M\  ==J_RK)N-<U!K.W:*>4310S>?M51AT91N<,,XP<D#GFN)U;XO7IORMG%;
MK%$08PH#!B?5CTP#CCWKI8_B)%9:8+O5-/@:61@@-NPPY;&1SUX_/%0ZL;VN
M3<Z#^T+B9M1D.I".:#<D-J@7#@1Y#8(R<GD8]*CFU6ZN%"V=]%G[%$[,74#>
M6Y&X\!B,@9K/D^)/AB&;>UO<AD7;'(+89;V7O4VB>-M#U>Z_L]K$VC3L-JR(
MI60^^.,_6JYH[7'?S.FTBZ6]TJ"=6E8,#S+C=P2.<<'IU'6GW\?[AKA>)H07
M1OIU'T/2K2JJJ%4 *!@ #@5#>_\ 'C<?]<F_E6K6A70F4[E##N,TM,B_U*?[
MHI],85%=3?9[2:?C]W&S\].!FI:* .;L-?N[FX@BE6W#%Q'(B_>;.[E<$C P
M,]>O:NC)P,TQ+>&/9LAC78"%PH&T'KCTJ2@!GF?[#_E7#?$%MSV'!'#]1]*[
MRN$^(?W[#Z/_ $H XBNR^'[8N[S@G]V.@]ZXVNS^'O\ Q]WG_7,?SIB.\\S_
M &'_ "H\S_8?\J?12&,\S_8?\J/,_P!A_P J?10 SS/]A_RIRG(S@CZTM% !
M1110 4444 %%%% !1110!D^)9?+T&X'>3;&/Q(!_3-9UDFRU0>U3>*G)ALH!
M_'-N/T _^N*(QMB4>U<]5^\:1V!T61"CJ&4]0>]-%K#G)C!Z]3D<U)3A4)M;
M#:3W(KRWMKNTDAO(TDMR,NK]!COGL1V(Y%<]I,MQ>7LUM>2/+); &!Y/O/ V
M=KG_ &N"&/J/>M;5)"YBLU_Y:?-)_NCM^)K(FT.^/C;1]6CU-HM.CBD2ZM6D
M"AB!E".Y!;&1TRH/<TUYC.KMK8 #BKBJ%%->2*WBWRR1QI_>=@H_,T07$%R"
M;>>*8#KY;AL?E5$W)**** %HHHH 4=:<*:.M.%4A$8_Y"<?_ %Q;_P!"6K=5
M!_R$X_\ KBW_ *$M6ZTB0>;_ !$UBZ:\ATF**.:SV^9,% <EP> WIC&:\^U7
M0XXX()].G%M=9);YMGF'KDXZ&O7=?\'+?2O=Z>XBN&+-(CDE9"?3T/\ C6)#
M\.[N^C4:A=+;QAP6C0;RZ_7H/UKCG"HZFQDU*YXMJ?AK4[*T:1XG$SHTBB(;
MQD8W;ST48[YK&T&_NK5DN1&LA5<1K,N]#DY+ $\,.@/I7OMY\,YH-*86DJ75
MP)RY@E=A%+%C&PJ3C.<')]*\_D^'7B6ZUG[,FA?99)&+-*"H@ ]B,@8Z8JTI
M6M)#UV9F?V]I=WJT7EVCVR%@)))&&,G@D#L.O2N@T[1)]3\51:1'=(J%\M(5
MRRJ!GCISBO2_#_PYTC3=#>RU.TM;^6<#SFDCR!@=%)Y'Z5I:#X'T+PW>376G
MVSB63&#+(9/+ &,)GI35!Z,.0V--L(],TZ"RB>1XX4V*TC98CW-/O?\ CQN/
M^N3?RJ>H+W_CQN/^N3?RKI>B+Z$D7^I3_=%/ID7^I3_=%/IC"F32I!#)-(<)
M&I9CZ <FGTV2-)HGBD4,CJ593W!ZT 9=OKT%R\"K%)ME(&\,I"$YV@X/4[3]
M.]:W3K6=!HEG;S),@D+J=Q+2$[CV+>I&>*T: &[T_O+^=<-\0F!>PP0>'Z'Z
M5W6U?[H_*N%^(0 >PP .'_I0!Q%=G\/B!=WF2!^['\ZXRNS^'P!N[S('^K'\
MZ8CO=Z?WE_.C>G]Y?SI=J_W1^5&U?[H_*D,3>G]Y?SHWI_>7\Z7:O]T?E1M7
M^Z/RH 3>G]Y?SI001D$&C:O]T?E2@ =!0 4444 %%%% !1110 4444 <OK[>
M;KUI%G_5Q%L?[Q_^QJSVJC=D3>*;D_\ /-43],_UJ]7+/XC5;!3A3:;+)Y-O
M++_<0M^0I(9G0?Z3J,\W4;]B_1>/YYJQI%A;WUL]W=()I9'(.XGY<=A4%ABU
ML#,VW]W$7.Y@H) SR3TY[U.=!EDM86@U"ZL9WV-.8W#;CU89X]QG]*B<6[.U
MS6G)*\6[7ZDT.B:8-2F$EE#.4B0HTZB0QYSP-W0<9X]:L3^'])N"&;3X$D!^
M66!?*D4^S+@C\ZM6EI%9P^7%NY.69CDL?<UF6MJ-6EO+FX^V6[,3;& 3%=JC
MHV!W.<Y]"*?,XI)$\JFW)O0S]-_X2RS\7R6M]&MUX?>$I;W0D5I8W!R#*, \
MC(R!V&>YKJL'-<_I]L+V]\N<SXT]/)MW$Q'GJ<@N<')Z8^H-,BL83J,>E.LC
M6-NYFAD,QRTN<["<Y.,D_CCM4^V;L[;E^PBFTY;:[?\ !]/Z1TG ZD"C(SC(
MR.HKF[RQMHKU[ 1YT^[<27I,A_=MCY1G/ ; _+WJW);1V6L6[Z;#$9Y@$N5+
MGB$'[WU!/'KFFJKOL#HQMH]U?_A]=.OX=S:'6G"L^ZUC3[*4Q7%TJ2#DI@DU
M7A\2V-U<I;VB7$\K' "QX'U)/05MS13M<Y')=S3R!J2$G $#DG_@2UQ6J^)]
M1N9F>U>2WM-Q6-E7!?W)_I7877^O?_KUD_F*\[%S ZQE_-_U/E%  57Y<;AS
M^/YU%:32LF8U&UH/_MW5O^@A<?\ ?5!US5E.#J%P"1GEJ;=W4-U& I:-8]Q1
M-@YR>.GXTHO8/*$9A.TKAL*,D[5 .?J"?QKFN^YE=]Q?[=U7_H(S_P#?5!US
M5@ 3J%P,\CYNM2/J%OY@>%'1E96)V+E\=CZ4U]0@<L7B9VQ\K%5!SD\G_@)_
M,"G=_P P7?<;_;NJXS_:-Q_WU1_;NJ_]!&?_ +ZJ8ZE;;@HB<QAE8J5'S$!A
MD_F/RJH\L!O$G.=I;+JBXP!T_$]:&WW"[[DR>(-61PPU"8D=F((_*NSTO6&U
M?0[EI4"3QQL'QT8$'##V//Y5QS:A;&0_Z/F,G<5*@9/R_P"#?G6]X>N%N(=3
M92Q"6RH2RA<_?/0<=ZUI2?-:Y<&[VN==%_J4_P!T4^F1?ZE/]T4^NXW"BBF3
M1F6"2,2/&74KO0_,N>X]Z (5U"S>9(EN8FDD+!%# DE20?R(/Y&K-8=GX>:T
MFC(N_,B63S"&C ;@L5 (P,?.<\<UMD9&* %KA/B']^P^C_TKN/+']Y_^^C7#
M?$)=KV')/#]3]* .)KL_A[_Q]WG_ %S'\ZXRNR^'Z[KN\Y(_=CH?>F(] HIG
MEC^\_P#WT:/+']Y_^^C2&/HIGEC^\_\ WT:/+']Y_P#OHT /HIGEC^\__?1I
MP&T8R3]30 M%%% !1110 44CNL:,[L%51DD]A5!]6B',44LJ\_,HXX&::BWL
M2Y);FA15.+4H'D\N0/"Y) $@QG'7GI5RAIK<::>QQ]N1)K>H2>LS#\N/Z5HU
ME:4=T]TY_BF<_P#CQK5KB>YN%5=4.-,F']["_F0*M53U7_CR4>LR#]:8(CN
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M!:6>GHR7EG!$IDB55D0?>C/('TJR(HPVX1H&QC(49QZ?2G*JHH55"J!@ #
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MYV=%<1_;7B@3Q^9IUSBVO&-V$@&UX1L3"$\D$F208R?E K8\2ZW]@B-G;/\
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MW$84*C[02"O/ XX7WK1^P:]Y;)_9S_,#\P<9'+>_^T:H?\(WK'_/A)_WTO\
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)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gvxjy5si4hmk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )' >T# 2(  A$! Q$!_\0
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MJ*,CU%<I_P *R\%_]"]:?^/?XU,?A[X2:R6R.AVQMDD,JQ_-@.0 3U] /RH
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M<'GU /X4 =+D>HHR/45S[^!O#+Z3'I3:/;FQCE,R0<[0Y&"W7K53_A67@O\
MZ%ZT_P#'O\: .KR/449'J*YRQ\ >%=-OH;VRT6VAN86W1R+NRI]1S5A/!WAZ
M.#4(4TJ!8]1(:[49Q,0<\\^I- &WD>HKS*'_ ))1X6_Z_++_ -'"NB_X5EX+
M_P"A>M/_ ![_ !KEK"SMK+X2^&4MHEB5[^TD8+W8SC)H ?\ "C!^#=HI_BGG
M'_D9J]$Z:T3_ 'H /R)_QKSOX2_\DCTQ>[7<P'_?YJ]$DXUJ#_:A;/X$?XT
M><_!_P#X]M0_["E__P"A15ZI7E?P?_X]M0_["E__ .A15ZI0 4444 %%%% !
M1110 4444 %%%% !1110!0OOW5[97 X <QL?9A_CBK]4]4C+Z=,0,L@\Q1[J
M<C^5689!+"D@_B4&@!]%%% !7CEA=:^? WA^"72[-=*&I6FV[6\)E(^U+@^7
MLQR<#[U>QUY;:75N?AAX=@%Q$9AJ-GF,.-W_ !]KVZT >I4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJP Z=A0!T=%<E_PKO1_^?W7/_!Q<_P#Q=6XO!NG0Z7<:<MSJA@G=7=FU&8R
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M%<S:_#[PM8S^?;:2D<FUDW"60\,"I'+>A- ^'OA86)LO[)3[.91*4\Z3[X!
M/WL]": .FHKDO^%9>#O^@*G_ '^D_P#BJ?'\-O",4J21Z,BNC!E/G2<$=/XJ
M .IID\\5K;R3SR+%#$I>21SA54#))/8"LP>&-'&IW>I?8E^V7D1BGEWM\Z$
M$8S@< =*Y_4_A5X5N]*N[6UTV.WGFA>..8R2-Y;$$!L;N<'G% '6Z?J=CJUH
MMWIUW!=VS$@2P2!U)'7D59KS[P]\(_#^G:7Y&J65M>7)E=S)")(D )X4+O.
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M!Y;\&SNLKUL8SJ=\?_'HJ]6KR?X+N9--NW.,MJ-\3C_>BKUB@ HHHH ****
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MN2>Y[F@"WJWB_0=#U".PU+48[>ZE572-D8\,VT'(&!DC'-;=>::S\((M2O\
MSX/%&N6\#QI'<0O=/-YP5BP!9FSCG@=CS72P>"+*&.X0:KKS>?'Y;&359F*C
M(.5);Y3QU';/K0!TU%<\W@^S?28]..HZR(TE,HE&I2B4DC&"^=Q7VSBJG_"O
M]/\ ^@QXC_\ !S/_ /%4 =917-V/@JRL+Z&[CU/7)7B;<$GU2:1&^JLV"/K4
MZ^%;5(-0B&H:L1?$%V-_*6CY)_=G/R=?X<<<4 ;M>8P_\DI\+?\ 7Y9?^CA7
M1?\ "O\ 3_\ H,>(_P#P<S__ !5<M86J6GPE\,HDDKAK^T<F60N03.. 3T'M
M0!)\!L_\*]Y[7<H'TW&O3+KFTFQ_SS;^5<!\%DV_#RW. -TCG([\UZ#,"8)
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M2/2JH^&GA$$$:4^0?^?N;_XN@#I[67S[6*7NZ GZXKSFT!_X53X<Q_T$;/\
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MD/A[319V3J\8NY"K/!*/[ZDX(^F:Z*W\(2WEO93:U=O+>QK^_P#)D8Q2'.>
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M2Q>5YK_(&##!96.%P 3[\5-8_"W1+/Q3+KK-)/+(,&*4*R'C'(QSTKMTC2-
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M!IMO9VD0/DH$$KJ-[ >IK6HHH **** .6O[=AXDO;7:AAU*P.U<8+3)D=?\
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MBBB@!KJ'1D/1A@U3TEC]A6(\&%C%CV!P/TQ5ZL^V_<ZM=P]I LP^O0_R'YT
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MB  /%&E@#_EC%T_Z_K6O2: *D&G6L+I*(@TR((Q*W+8'O5NBFNP2-G;HHR:
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MC\35+0/!5O:Z/8V^K;KJ:TW>7NE8A 6) Z_-@''.>E=3#;PVR;((HXD_NHH
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M"9?KT;^E:%9]\?)OK.XZ N8G/LW3]<4 :%%%% !1110 4444 %%%% !1110
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MNAM[9/*@8-_>4DDD#OGUK> Q10!4L-+LM,MA;V5ND,0.0J^OXU;HHH ****
M"BBB@ HICR(A 9U4DX&3UK._MI+A[R&PA>XGM@<C[J%@<;=WK^% &I56\U&S
MT^,27=S% A( ,C8R36+]B\1ZHI^VWL>F0NN&@M/GD'N)>,?]\U;L/"^EV$RW
M A,]V%VFYG.^1OJ: )EU62;4+BRAL+K]TF[SY(RL3DC("MWKBX/"WBZ^\927
M>J:HT&F;BW^B38:12.(B"#A0>_>O1\44 9NGZ!I>EJ1:6<:$G+,1N)/KDUI4
M44 %%%% !1110 451U35[+1K3[3?3K#$6V@L>6/H/>L@>-M+ND0Z4EQJCL0"
MMG'NV9[L>PH Z6H;F[M[.%IKF9(HUY+.V *S736K^&UD66+3OF)GBV>:S+V
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M75);*'39A&D>X7DA41,W9>N[]*9I_AK2=-"&*U$DJ?=GN"9I1_P-LG]:U\4
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MQWU_&UQ-& $#.0JG&"0 >_OFMBB@".*&*!-D4:1KZ(H J2BB@ HHHH ****
M"BJ&I:UIVD(CW]W%!YAP@9N7/H/4UDC7M6U(@:5HLR1EBK3WW[G:!T95P=X/
MU% '2US-]XWTRQU9M/>*[DD5_++10%P9,!M@QU.#TJY9Z3?N9'U;4?M7F(4,
M$2>7%@^V2<^^:9:^#]!LK^&]M]-B2>#_ %3#/R'U'O0!7_M'Q%J3E;#38["
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MHVG:66:RLX87?EY%0;G/JQZD_6K] 'GD/PWFE\7?VUJFIF[^]O 39YH92-A
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MUB97+VTD>IQ +C8G!VC'7F)_^^J[.SN%N[*"Y3[LT:R#\1F@":BBB@ HHHH
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MMS'!&HR2YK&D\375ZA&A:3/>$C*3S'RH&^C\G]* .@FFBMX6EF=8XT&69C@
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M[7DA:XUG6;?2+/:-T5L?WB'O^]/!'_ :HV3Z:+IWT+0KC4[ID!-_<?+%*/\
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MH#5-!L;WS%D,T"LSKT+8^;'XYK1K+\-O')X<T\Q(B*(%4H@PJL.& _$&M2@
MHHHH **** .?\+@VJ:AIC"-?LEVXC1/X8FY3\<9KH*PE!M/&C87$=]:@LWK(
MAP!_WSFMV@ HHHH **** "HKF+S[:2+^^A7]*EJM?77V2U:0#+_=1?[S'H*
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MYJ1U"[8X>*5VG)(':%<A?P%21>(?$&JHD?A[P\+6UQA;G43Y<>/]E%RWY@4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BLF_\ $FE:<[12W0DG7K! #++_ -\+DU1_M/Q!J3.NG:7'9Q<%+F^;
M(<=_D4A@?K0!T98*"20 .23VK%NO%>E02"&&9KR8DJ$M$,N#Z$KD+^.*K_\
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MUA;.R)!B^QQ8F]PS-N!S[ 444 3V7AC2K)S*ML)9F.6EF)<D^O/ /T%:^,#
M' HHH YR[\+_ &KP[J&D+<^6EQ,TD;JO,>YMQ'ODEOSK8TJT>PTNWM))%<PK
ML#*,# Z#'L,"BB@"Y2$!@00"#U!HHH HQV#6MUOM9=D#',D)&1]5]#5^BB@
MHHHH **** "BBB@ JM%;;+V>X+ F0*H&.@'_ -?-%% %FBBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gdzs1tysdsfm000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #] <L# 2(  A$! Q$!_\0
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M68VBGQ/>&S2S%]M\F/G]YMV=.F/QKT-98VV[9%.X97!Z_2J!T.R_M]];"/\
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MHY!_7U_*8W@K_D6HO^NC_P ZZ&FQQI$FR-%1?11@4ZK6B//J2YYN7<****9
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M:.HINYO[A_,4;F_N'\Q0 ZBF[F_N'\Q1N;^X?S% #J*;N;^X?S%&YO[A_,4
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MAA(RE?HR)8IJ-NIRJL&4$=#5JUTZ\O5+6T!=1P6)P/SJI!);0Z5-!/!+]N!
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M[$M]E&%S\[]_]HU:JM8_\>H_WW_]"- $^6_N_K7*:MG^TYLC'3^5=;7):O\
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MMK\RDMMS&W*XO?8B=/*6WD9T=91DHC?,H!Z'TJQJ,R2:-9RQVR0 W3H O)(
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M1Z@5W'GP[6;S4VJ,D[A@5Q_V7A_/[S?ZW5(;**2VLHH64%D7!(-6,M_<_6G
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MM[=*GOO!6KQ7MU#HT2Q1367DO<SR*<L ,>60=Z;N0>W-=9_PDA_Y]1_W\_\
MK4?\)*?^?4?]_/\ ZU '*7OA?69IM,O](TF'2KBPC<+!YZE2S%0V2IYRN>:Z
M?P5H=SX>T%M/NCN9;B1E;=N+*3P3[GK4G_"2G_GU'_?S_P"M1_PDI_Y]1_W\
M_P#K4 ;]%8'_  DI_P"?4?\ ?S_ZU'_"2G_GU'_?S_ZU &_16!_PDI_Y]1_W
M\_\ K4?\)*?^?4?]_/\ ZU &EJ^E6VMZ1=Z7>!S;749BDV'!P?0USFL>'[@:
MMI,L.FKJFFVEL;<6LDH7RVRNV3YN&( (]?2M'_A)3_SZC_OY_P#6H_X24_\
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M 9XX_B%=W10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>gvxjy5si4hmk000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHKSKXSZGJ&B^"H]1TR]FM;I+N.,-&V,JV<@COT% '
MHM%><^&+:]U_[1>6FL:C%:+ ]HT5P&#"<8Q(N>P]*YKPSJ/B6_\ %%YX*UK6
M9H=5M;@W#7J2#]];X&%5>Q.<^PH ]KHKQQO$&H6OQCO="N-4OO[(BM@ZQ1HT
MA#D#!)&3CW-9ECXK\0S_  K\0^(?[8N/MUE=M%;L5& @88!'X^] 'NU%>&:K
MXOURQU#P)&^JW:P:M8B>_$4>]V;&20H&>_04VZ\;>)S\(]5U[^TU%Y::EY-K
M*H4/Y)8+B1>S<GKS0![K17CGB:^\4:-\.3XE37YEF>* 1P[!\I)^8GZUWWA&
MUU=;0WFHZLUY#=P0O"C+@PG;\_/?)H Z6BO&=$UGQ3JT'C66/79(Y=&N)%M,
MQJP(4$[3G@YQCUKM/ 7CFW\4>%K"]OYK6VOY@5:$R!2Y!QE0>>: .RHKS[PY
MKVM77Q4\0:-?7@FLK2&-H46,*$S].OXUZ#0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%<?<OR?4WLGY]:1O@YX188:&^(]#>2?XT =L;ZS!P;J '_KH*/M]G_S]P?\
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M^N8_G6G\/./AYH'&/]"CX_"LSXP?\DPUCG'[L=_>M7X?*4^'V@J<9%FG3Z4
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M02/Q% $'AZV-OH\1<#S9B99&'\18Y!_+%:E(JA$5%&%48 I: "BBB@ HHHH
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M2]4J<I@/'C_:)^;/T%=I10!Y-H\NG:;XNL9%TZ*W_M"X,6RRB*(6'*LP;#$
M[N<8YKUFN>U.")_&>A3/#N=(K@*^S.W(7OVKH"0JEF(  R2>U "TC,%4L>@&
M:\UT&\\4Z]<ZGK]M/OL9+J2VLK5&5=J(2N\EN""1GCFM*X\0:K)#<:5=6P2X
ME4Q+/S$JMCIEN&/TH L>%DDOM9N]29F>$DM&Q PK/]Y0?;:/SKL:Q/"EHMIH
M$)52C3DS.A&-K'J /3BMN@ HHHH **** "BBB@ HHHH I:MJ(TO3WN?*:5P0
MJ1+U=CT ]Z33=3345F'DR030MMDBDZJ>W2I[NS@OH/)N$WIG/7&#ZU#INEVN
ME6[0VJL%9R[%V+,23GDGF@"[1110 4444 %%%% !111T&30!R?BUY+LS62$B
M*"TEN)&&#M8+\F?KS5?X3D'X9Z+M+']S_%]?Y5893<:7XCU)QAI4DB0D=8T4
M[3^IJI\(G+_#'1RQSB,C/XT =O1110 4444 >=?'#_DEFH_[\?\ Z$*ZKP?_
M ,B=I'_7JG\JY7XX?\DLU'_?C_\ 0A76>$UV>$M)7GBUC'(]J -FBBB@ HHH
MH **** "BBB@ HHHH *@O/\ CRG_ .N9_E4]5+F:.6UNT1PS1H0X'53C/- &
M?X659/"EBCJ&5HR"K#((R:L2Z#8/+YT49MI\8$D!VD#V'3]*@\*,!X5L6)X$
M9)/XFI)_$^AVP0S:I;)YFW8"_+;LXQ]<&@"GJ2:WI-DTVGS/?E2/W$J;G;)&
M<$8QWJ*+6/MEC'-K6@3V^\'.4$@09(Y(Z?X&K-AXST#4K&_O+;4(VM[#/VER
M"/+QUS5BU\2Z'?3)!;ZI:R2R1B18_,&2IZ<?C0!3L;32[F$OHNI20QN=P6&7
M*LWJ0>?P]JF)\0V3[52VU!&(P2WDLGKGKG/6N/\ BI=6+^ +W5M*FC-U;2;(
M[J \HPZ@$5G0ZUJ^@^!]!U:+6A(\UA&\UO=9=Y6..4ST/;F@#T6'Q%:EREU#
M<63@[<7,>T,<XX/<>].UG44BT.>:VE5Y& 2/:<Y8]!]:YJV^($6Y+76-/D@N
MI%!6(C'RD9R2V%!]LU>A@\*:LK_8KI(AOR_D2F,,WUZ$]>E %WPG#ML)I2/F
M:0Q@XQE$X7^=:&MWGV'2+B9?]85V1C.,N>%&>W)'-84_AO5;>P@M]*UAUA@4
M+#$?E 7U+#EOQKG]3NO%]E=6L.JQ1WFFP2^=<7'E;0V!E%7;DD[L<D4 =#;J
M+?485DBVQZ59ERV[(\Q\[ESTR,9_&HK6%I)-+MY@3N9]2N';G#?W?H<_I7.Q
M>,M,U6%]/O#/I]UJ=VK-;W";F:'HW3H..^*Z ZE;W=OJMYI\\4SR2+86RQN'
M.1P0!T&1S^% !F2_M8U*%VU6]):16X2.,Y4_B% _&IKZ1C#J5Q &,T\B6,1)
MQL![^_)/>I&>/3[BZ,>%ATNT6WA0G"F1@"N!Z]%S[U':1?9;K3K29BL5A;->
M7((P"SD]O4')H 9?)#''JEQ>10S6=E:K;1K*H'S?Q?,<GN*Q#X%TVVF$=M*]
MA':V;3W)MY"FZ8XY<]2,9K:MC)-#I=LRLDUY<-?3DC "CJ#[G(_(TDT[WEK<
M&(-%/JMX((W0Y^2,_>/U4$?4T <JFB^)MNG(EQ::MYT1F$<R^68X_P"$[EZG
MH,FNFM3XCMK/>()X6CP,']\K =<1\$>QS6[ID22ZU?7?EJ/*5;:)@/X!R1^=
M;- '*V7BN;=Y-W;;YE!+)%_K"!_L'H?;-,M[C0$N)+N*YEC>S62Y-FY"A"0=
MQ(QUZ]ZZ6ZL;6]C\NYMXY4SG##O7*>)-+TVR@AA5#LD+$0NV8555+,2ON 10
M!D?"J8:U/KGB&0N9+BZ,:JZ[3&HZ#'K@CG->E5B>$["'3_#EK'#$(@X,A ']
MXY'Z8K;H *\_UWQ-J5MXUATZRU"VA<O$@L+A.9D)^>4-G@ 5Z!7D$4$WB;XF
MZKJ4-M97MO:1_9H8[Q]GS'AP,9ST_6@#UY6#+E6##U!H9E5=S$ #N37'M)9V
M&5NH=1TD+D+Y1+0LW<@+G(^HKFOB!KM]8:):64MW:ZI:ZE<QPN4_=2("<@;1
MV. #GIF@#U4$,,J00>A%+6'X2LKO3_#T,%ZACFWNWEEMWE@L2%SWP*W* "BB
MB@ Z#)I 01D'(JEK%V]CI-S<1 F9$/EJ!DLW8 >M>6>$M5UZZ\7:QIUQJ\EA
MIEE@6OVV,*^X_7Y7'4=<T >PT5P'BCQ5XI\)):2QZ-'K5E(X62ZB?8R GJ5Z
M=/?%=W!+YT$<NW;O4-C(.,]N* ,_7;&>[LEELB!?6SB6WR<!F'\+>QKG/%GB
M^.#X>:G?VQ:*]$?D"%QAXY6^4 CUY[5V]96J^&M'UIHVU"PBG9)%D4L.=PZ&
M@"#P?I T+PCI>G[<216Z^9GJ7(RQ/XDUC^,&_M+5++25*E"1YJ8R?G.%;'^R
M1FNTKA]%5-5\:3WS*#]G#/&<DX#?+@\8XVYQ[T :&H>))-+N)[>VMX)[>PCC
M%P3,$9=W P._2NG1MR*V",CH>U4+O0],OKC[1<6<3S<?O-OS<<CFM"@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "J6KWGV#2;FY! 9$.SW;L*
MNUAZX?M-_I>F[OEFF,D@4\X0;L'V/OUH P_&-VOAOX47S/\ -(+0QJ ,;G;_
M /6:G^%1S\,]#)SG[.,Y&*R?B0W]IW]AH:L/)A@FU&<8R!Y:X4-['<:UOA6X
M?X::(5;=B #I0!V-%%% !1110!YQ\<@3\+-0 ./WL6>>VX5V/AA=OA;2UQC%
MLG'X5QOQT;;\*[_G&98AUZ_.*[7PZK+X<TU6.2+9.V/X10!IT444 %%%% !1
M110 4444 %%%% !7/68Q>>(\#K(O_HL5T-<]9@BZ\1G&,RC_ -%B@"7PP@E\
M(V<>>'B89^I->9^)/"DGA*WT75+@0ZG+;7T-O'#L"[XPKJ@Y[Y;)[<5Z?X3_
M .17L.<_(?\ T(U8UK0M,\0V'V+5K1+JVW!_+8D<CH>"#0!\Y3W?B?P?-KNB
MWVBP[]6A9G/GJ74.=JX(//..*W?#.CS>)CJ&EG2K?3KR\TB![6Z<!BFQBF_*
M\@G%>D:A\+/!KVL\R^'XYKE8V,9::5F+8XY+>M<WX;\ ZII$*:EH4]O!/.@1
MG20N N>5&<X /8=Z -#XK:?;:5\(;FRMX8XHH@J[8UV@G!R?SYK-N=.TZ;P/
MX$N+Z"<PB*W6>:-698XU3?\ ,!QC<!U&*T/$7@KQAXETA]+N=;C6"5E\QBH/
M'?BNE6:+P3X;T?2)4^U(D!M_,)"@[(RW(/J%/% '(7]SJ?B7QK=06MQIEYHB
MVX?YF23:N./D;CKG)JI!H,$/A6P,EF5OKK4EMK,JY*HF20X7I@?-5;Q!XLTB
M6Q-^?!]N3#*(C()POS^6)%'RXR,,.M6TU"72-;T'4O,N]0@?2KB\CLIID5+?
M 4G:<?@,T =S=^&]3CO(7T;5FLH#@3*^93CU3=D _7BKROK]D^)(K>_@Q@&,
M[)<^IS\N/I6!8?$6;4+K3[*+P_<F]U"!;N%!,I3R"<;V?&!CTQ7=4 <M--H%
MY<LNI6 LKL B1Y8]F!CD>8.",>]9<WPWTF62*ZT:Y>U2-_-2&&0K$\G8DKS^
M5=%XBUB'38H+<6)U"\NF*V]HN,N1U)SP .YKB=:;4+6YBN=2M'T%)D:-;BTG
M\U%;&0"!@+T^\1B@!T^E>-=+BDA_<:G!),9IC-@(J@Y 7;\Y/'>HIO&;BRN4
MU:QNK7[9<+&QV' AP =H'S=/7GFI?ASXG\1:RNH6%W<PW4]DD3K+(NTR!TS@
MXX!SWKL9KX-(8-3T68,R@F2-/-3'NPZ4 8IU:TD&J7UE=+),L*6UK;9!<8]%
M^]DYZ>U7UC2QN6;:@32[+&">/-;D8)]N/QJE<>$/"WB")9;&58B'$WF6LFTL
M?<]<=:QKSP/XGLHS'I&KM-#+(&>&1@(PJ\@'.6)SCG/2@#O/#\4T6B6YN5VS
M2#S77T+<X_6M.N6TCQ+-;PFW\2;+2Y5PBRF,QQR9X&W/O^=;%OK^DW5Z]G!J
M%O)<I]Z(.-PH T:XSQ EU=^+K.R%I.T4T0"3A<Q1[6W,6(Z$C*^]=D"",@@_
M2EH 15"J%484#  [4M%% &7XCU2+1O#M_J$L@C6&%B&/0'&!^N*\[^&NF7$G
MA%-4FT^&\.I.]P\L4FV4,25.">W'&*T/C#-/-H=CHT+(BZC<B*4R'Y2IZ#W^
M;!Q6I!8C3K"W@N-$N$\B)8DN-/DWG=@#=L'3U[T 2K<Q6SM';ZM<Z=Y?S-%>
MIN0G_?;M]#7%7%O/XD^,>FV=Q:V?DZ?#]HF>V!\N?/4^Y#8ZUVL$S30O'#JL
M%]&JEG@U&(&5>N5[8'3K7/\ PELA>W&N>*&15%_=,ENBR!Q$@/S*/3D#B@#T
M^D8[49L9P,XI:* ."T'Q7JE]X@@L3)9S)<%Y7MVRMQ:Q@X&X>_O7>U"MI;)<
MM<K;Q+.PPTH0;B/3/6IJ ,/6#]KUC2]/P=OF&XD(.,;.5_,UPWQ;$5]HUY'*
M0VUXK6V*\[9I#S@#JPQ^%=SI?^E:SJ5^P#)&P@A?U4#)QVZDC\*X%L^(_B#H
M-@RYBMVDUBX3/R@L<1C]#P: /-%M?B!X8U%=-T_5;JZAE<0>5,A(8=,*DG4?
M2O8(/&>I>'UM;#5]-=!&@0MY9  'R@EQ^[7Z5Z$\,4CJ[Q(SI]UBH)7Z4LD:
M31M'*BNC#!5AD'\* .<'C?2FLI+@2J BD[R<Q9]/,'RC/UHL)_$$MJ+Z*6RN
MHIR7\G=S&/[JLO#?4UB?$'X>6_B#1!#I=E''/YRM(D4GE;T_B _A!/J0:\>M
MO!GB'P_XNTS2+76=0L9;ERSQD,5BB499@V=K<#L!VH ][U?Q2NF6+)?036=U
M,/*@& X:0] "./2G^";7R=!$^6S=2-*P;J#T/Z@UQ/CCPUJGB'P-I:G7)$6.
MZ4DR)N:X5G CR5Q@X->GZ;9IIVF6UG&BHL,:H%7H,#F@"U1110 4444 %%%%
M !1110 445QOB#3]7N=3GE@AN29$6&UEAG"B'N7(]^G- '944V,,(D#$E@H!
M)[FG4 %%%% !1110 4444 %8>GLU[XFU"[#XBMU6U"Y!R1\Q/'UQBM>ZF^SV
MDTQ!/EH6P!UP*YU;M?#7@>YU*X959(I+EBV 6)R0"?7H* .=@4:M+XVUZ4_N
M?*?3X#CD+&IR1[$M6I\)O^29Z-R#^Z/08[FDL-.?2_A/)!-F.=K*269NY=@2
M2?SIWPG(/PST7'_/'T]S0!VE%%% !1110!YI\>3CX5WG7FXA''^^*[S0_P#D
M V'_ %[I_(5P/Q[./A9=<];F'_T*N^T/_D Z?_U[I_Z"* +]%%% !1110 44
M44 %%%% !1110 5@6@*S^(,N&)D!X&,?NQQ6_6!9DYUUF(QYA]L?+0!-X4!7
MPQ8 ]=A_F:V:R?#*-'X<LD88(3^IK6H *YR&9O#FH26]SQI5P^Z"?M"YZHWH
M">0?>NCIDL4<\313(KQN,,K#((H 5'21 \;*RL,AE.0:I:GHVFZU'%'J5G%<
MI$_F1B09VMTR/P)_.N%^*MM_87P]O;K2;BXL9(]JQB"8QJ@] !T_^O3;/5?&
M47@[0Y])M!?[]+@>1Y"-[2$C/)ZG&: .$^)ECI,>L:_!-+?VUP%CEL[>U1O*
MD8J%)( QG'O7"6)MUNXT>]U^&&(^4&:-OFB<?.. =N".V<U[]>7_ ,0510+>
M&)U5-[I&KHVYSG'?Y4Q^-3Z3?>.SX=U*>_M86U 1!K./8!ELG@XXZ8H K_#/
M3XO^$*TG6;B%SJ%M9R6\;R@AA%NR%P>W K$T[XD^)+A=&OYX=-_L_4K]K18T
MD_>KABN2/P-:UEJWQ$EMI#=:7;F9K@J8, !(1_$#W)["L:?2/$-MJ4KV&@V:
MK!*);1'M5R6/)YZ CUH [3Q3=2Z'KFGZ_+ TNFP121W3H,F#(^5\=QV-8&K^
M)QXJ\%W&F:>ZWFHWD3>9Y49"6J=<L3[#'UJW_;EU>6,-EXBGM[8H5-W"$<R2
M'/*  88>N,X'6K6M^,=/AMY['2(XI6DA?,Q4B%0%[D=1[C@=Z .?^&< T2YU
MC4M3DCMX9X;41EVY(\L=J](_MO3MJM]I&&&5^1N?TKS#X>RV?_"636=_)]ME
M-I:RVDS@;4<1<HH'1@,GZ"O6KF>&U@>XN'5(XQDNW84 </K5]HBZ\[36UTTD
M6(TC1PL<SXSMQG@^YQUJ70=0.IWTD6EWE] 5A679=$2QJ"1A0.JFN/\ $>HR
MW>KS3'5]-TU;V010P7L"N[KV=SU5?0'%,O['QE8ZE%=1ZCHMFCH$>2T=%::(
M?\M ">1V^IH ]0FN]2MU O-+%W'G&;?#'IUVFLN[TKPEK;[)H8[>[P1N7,4B
M'OSZU@V.O:K<20BUUVWN8([B,.DA6)V3=S@GEACK[\5L>&GN;^-8O$-_IUSY
MBYBM-Z.X82-\V1UXV_E0!7N?!&JV%N7\+^([JWQDQ6\S[X0??UK8TO5]5L=/
M1/$MJ%ND_P!==6RY@QZCO^E7IM!08:RN[BTD'38VY1_P$\5RGQ \7:GX&T)9
MYTBOX[EC;H5&V3>0<''2@#L]/UK3=4B$EE>13*3@8.#GZ'FK]>3>'->T"]OX
M;G5K*XTB2.V1(Q>PM&2W5G\SISQU/%=U;V+M%]HT36O,B89 9Q,C'_>YP/I0
M!?U?1;#7+3[/?VZ2JIRA(Y1O[P/8UPU_<R>&-7L-/OKM+6WN6<?;8IR& 5?D
MWQX/4\?7-=:VHZU9C%UI:W0!^_:.,8]<,<]*CEO?#FJR?Z7Y'F;?+!NDV'![
M#=C]* .*^(.I7-OX1N&^T6%\EX1;P3J/+D1GX' ^G7WKM/ VF+I'@S3+41+$
M_DJ\JKTWD9;]:XSQ'\.K_4==T2&V,$V@Q7!DN,\2A3R 3_$!V[UZFJA5"J
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M*G$LK$Q/'GC'I0!V-<O=7@76]3U!H]ZZ;;"*$,.&D8;AM/3)X'XUEQ:Y??\
M"1Z?INA:C#J5C<VKW!>9MS*%('WQZYZ8KD-<C\7_ /";:='-!>Z;HIF\Z^F@
M_?0,P8NHZ9[!<T ;_B?P)-XLM87UBR>223:\OV*X\LH<=PQPQ'T^E<%9_"+4
MH=9@_LO5;F>P@D\W[+< Q2IMZ ;OE/)Z@8KZ#M+NWOK6.YM95EAD&4=>AJ7
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ML%RWTR.* ,+4_$'BGPS%::AK#Z?<:=-*D+K;0L)$+=#R3D5WL4J3PI+&VY'
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MJW7.>"/$EAXH\,6U[IQ<PQ@0-O7'S*!FNCH **** &[$QC:OY4N!G.!FEHH
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MS$H_L1WKIK2TM[&TBM;6%(;>%0D<:# 4#H!6%?>+8=(TVYOM8L[FQAME#.Q
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M][8'IBN?TJTQ\-/$&IR!Q/>0S%B_&5&<'\C70?"U0OPUT/!)S;*: .PHHHH
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M[,*@_=?\*=D^SQLL7]FOM5VR0,'O4GPH)/PST7..(<#!SWH [.BBB@ HHHH
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MRP</M Z$MG/>MFB@#&.A3_\ 0<U,?\#7_P")H&A7 .?[=U,_\#3_ .)K9HH
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M (1VXU)9[WP9=W%U=2E/,\I&+,!W^?B@#%^&.FVFD_$SQO8V07[/;BV2/ '
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M<7\/=/AO-*MI[*ZF\N#4'ED6[V[R=N"!MZX[9]*ZOQYSX.O5&=S&-5([$R*
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M%P>>].AU2\UWPOIZ6^N6O[L@7+1R2JTF?N%6 W9ZY&.: -K6)/%.JZ3<V/\
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M73],N@MW<(+FZ2:7RMI&2!AL9)_#@UPW@_2+?5=/FL+G5S;WDTKV@D<Y8':
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MUM;Z)IZR7]S?2 1BV&2C*0X)![?+6-?W7C&[>">XTN\/V9BZ_N1C.,'()Z4
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M[HL 'A6_A%>??$7XC-%.UO8Z7!>6U@\,\CW#81BV1L9>O'4_A5G3O$VN>&-
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M6JP32*- GD N&@ 2)R5PV S>Q]J?8^.?$$LEV;GPU+Y=L67$2G=*0,Y7/&*
M.I\58_X1/5MV,?99,[NGW37/?"+/_"LM(![(P''N:W=>:6;P9?M*H21[1BP'
M\.5Z5A?"(8^&FDC_ &6_G0!W%%%% !1110!Y/\9"?[;\#*,\ZKGCVVUZN/NC
MZ5Y5\8#_ ,3_ ,#<D?\ $S;I]%KU5?NCZ4 +1110 4444 %%%% !1110 444
M4 %>>NY'P@U]N&/EWW4_[;BO0J\]./\ A4&O_P#7*_ZG_;DH YGX6:Q8V/@#
M3X)/$=M9R#<S0N.1DUZ7HVJ6UVETT>M07@3J5&!']:XWX+W5DOPTT];F>U#A
MG #NN0,U<\5:A:I?';=6)C_=[$DD&P1_\M&&W^(<8H TCJ;N6\OQ3:;3T_=Y
MK4BO&/A]Y_[9@=@?^/O9\@_"FZ!<6G]CQ>?<V[\GRW=UW-'GY"??&*U1=V.W
M8+BVV_W0ZXH Y5=1N\KGQ58'D9 AZ_K4WB3Q+9:7<6MK+XELM.N'C#;94+&0
M=F]AFNC\_3S_ ,M;7_OI:\^U_P#LNY\:ZYLG$M\?#4RK&54QXW<$-G[V>U %
M34/%%MJDVGV5OXML;^9M1@!M88RKN!(,X]0/Z5<\<WUUIP\675G<-;W$>G6N
MR13RN9&!_2N<FCTZ"X^&RR2+#J,<: 0A%V'*@,7;L0.G')KO)8-,U;Q;KMC?
MM!-:3V%NLD;N,,-SG% '+^-'NM.M;=+>\N91-LW1-(&$I#+C&/4_S_"JND>*
M?%'_  D.EPO;2/\ :[AUD). J X*$8_A['VK;UWP=X2T30[F]TJRM8KM6B"N
MLN2,RITR37HH@A5]XB0-ZA1F@"2O/-9FU";QA+:W$:"R*%6<-\R*1\I7TR>M
M>A$@ DG '4URDWBS29[D"33[F2,OL%QY:E2,XW#G.W/M0!Y]X*_X2;[+K]OH
M45K>B6Y,=Q+=SD&-MF-J^H [UYA\1H-3M_'-C;ZY'%!/%%$/]&;?\N>"!Z^U
M==<>+]6T;Q7K6DZ7>&)+^ZE)6/3Q(H4?+E6W=,=3S6)\1_#>JQZOX?EGOWU2
M\U.-(TCA@$3+AN%7GDGUH [)U\>WR6IFN-8$5M*DT0%@.<#CCUYZ5C:;=K?^
M.7OM8UF]E*!HKHO"8FB>/( *CL. <8ZUL:M#%82Z,LEKX_BEDO8D59KE2&QG
MY5PW7CCIQFJ>F:5K(\576H6FG(LUW?3/';7X'FA<Y^<>IQTS0!ZIX*?2[Q[G
M4+:[-Q>3JOFD!E3:.!L4]!_6N8\96$[>.4,5]<1!D28FV0NX S\A / /;\:[
M#PK#JA:2ZU&QCLRZXV* "><\J.!BJ6LZ/(OB/[;-9W-[:NF56W4%DD]\D<>@
M^M '@7B*3SM=U.RF,BO)-;8:&$O@#/WQG[WJ.]=+XJU/4VU'0-/O=1NKFU$Y
M*I/IYMPI5>,>OZ5C^+5M](\3ZK;7U[]CGNKFUN,A-CHI!W-@9P1Z9J/5+K3+
MCQ)%;6_BJZUR.&Z0VC3N<89/FX(Z@\4 .LIO"6@?VAIGBE;IKZ2=G<VR[P4;
MD<]B:Z'Q-\5_#>K+%!I]M=[4L9+2..2/&6<H%'Y#-7OA[/HL_B?Q=<AH[E$B
MC,1G42?, <XSUYXQ47Q%O[6Y\!V\4VDVUIJKW<+L]L@"%0W7/Y<<XH [[P_X
M=U>W\6QZJY3^SWLXTY;#E@.Z]:[ZH+//V&WSU\M?Y5/0 454U+4;72-.GO[V
M416\"[G8]A7(ZC\2+;3KW3[*XT^Y@N[Z-Y4BF7YHU4@9<+DKGJ* .VE3S(7C
M!QN4C/I6!8:5KNFV$5G!?V1CBR%+6[9P23S\WO6;%\1;%_#^G:L;6?9?7_V!
M%"\[]Y3=Z[>*Z#6M<AT:.'=#-<W%PVR&W@7+R$=<9]* (_(\0_\ /]8_]^&_
MQJ"]T[7KVQN;22_LE2>)HB5A;(##'K[UEZK\1].TA+?[1;3&26ZCM6C4@F-W
M['![=ZFU_P >6V@>(+?2)],O99)U#),BC81D XYSQF@#IK*W^R6%O;;R_DQ+
M'N/? QFH-8TJVUS2KC3KQ=T$ZX;U'>N$G^,NBPZE>60MKAI+641E0!ER?[OK
M73>$O%]MXNM'N;6WFA10#B5"IYSZC';M0!P_Q*T9=#\.6NI278F%E/&8X9"%
M1L$=?P&.X]JXK7/BKIFN^4TV@PQRQ$A'BG4'G/J,$=Z](^-BA_ \2,,JU[""
M/4;JX[6)]/MK?5C;6"-<13PJD895"+QD*3CD\\4 5_V?1NO_ !:L9#[DCVD'
M.<E^_P#]>O1+.TDM;/P7;74,D<L+8,;#E6"'J*\^_9V;_B;^*F8;!F(D9Z?,
M_>O6=:F277/#\D++(CSMAE/!&T]#0!TM%%% '#^$4QX_\9OM(W30<D'G"M7<
M5SFA:]+J7BCQ!ICQ1HNGO&J,HY8,">:Z.@ KD_B;D_#;70 3FVZ 9[BNLK#\
M8:O+H/A'4M4AC222VAWJCC@G(H U+#C3;4'/^I3K]!5BHK60S6D,I !>-6('
M;(J6@ KA-6)/QG\/@*Y TVXR<94<K^5=W7,WVOSV_P 0=,T(0QF&ZM)9VD/W
M@5(P/UH Z:BBJNI79L=,N;L)O,,32;2<9P,T 6"BDY*@GW%8^NW2I$NGVRHU
M[=_(B8Z+_$3Z#&>:YSP;XNUWQQI#7]O9V-C;&5XA,)C*P9?]G '?UKI['2;3
M2I);^YG\V[E_UMU.P!_W1_=7T% &E;PK;VT4"?<C0(N?0#%25GS:[I%NLC2Z
ME:((R ^9EX)Z=_>IDU.QD<K'>0.0F\[9 <+ZGT% %JL#6.?$V@#=@B24X]?W
M9K2CU?3I;EK:.^MVF7&4$@SST_.LS6F5?$_AT$'+2S 8'_3,T 8NJ1:U)XDO
MCHG^M!A,HWA-R<Y )%-@L/'$;)YMUYFQCYN)D42YZ%>/E [@YS6WIW_(Y:M_
MUQCKH: /.]'TCQY9[FOK^.XD-T#]\;6CSSGCKCI7HE%% &)XQ./!NL?]>K_R
MK)^%BJOPUT4+C_4#./6M?Q?QX/U?G'^B2<_A6)\)2#\,M&P2?W1'/U- ':T4
M44 %%%% 'E'QB_Y#W@7K_P A,]/^ UZL/NCZ5Y3\83C7_ O./^)FW_LM>K+]
MT?2@!:*YOQ3IVMZB(X]+N1#$%/F+NVESZ9[5B?V!XICMM6MX;G:LUU;O:,9L
MF.)5 D'XD'\Z ._HKD](T/7;&21YM3DFQ:[8HYF!5923D\#)XQ^=95SH7C:X
M2V6'4XH&53YKN=Q=CP2<>W2@#T&BO.KOP[XW>;3T75XGCB;;<,#M#H!\N!UR
M>];FH:1K=UKUF\%_+;Z>ENRR^6RY#[?E(!]Z .IHKS[3O#_C1&\V]U??(ZQJ
MWS#@Y^8\<8P!P.:ZF>WUXW3O;WMHL))VH\1) ]^: -BBL;R?$0.?MFGG_MBW
M^-"P^(ADFZT\Y[>4_P#C0!LUP=F0?AK?AQE'FNE(/<&5\YKI1'XA[W.G?A$_
M^-<7;QZROP^O?](T_P KSKC</+8G_6MGG/UH ZVQ\*^'A808T/3E!C4D"V3T
M^E65\,:$GW=(LEZ=(%_PJI;1>)?L<6RYTL#REVYA?CCO\U.:+Q5M 6[TD'N3
M!)_\50!;'AW1E8L-+M,DY)\H4?\ ".Z-N+?V9:@GKB,"L_R/&/\ S^Z-_P"
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MXDO[A0+:^DB: @Y)"@YS^==37%^$=<EUCQ9XG1;XW-E;R0BW"X**"#G!KM*
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MB31Y+F<(9(YF3<@PK#/!'X5TU>.^"([@>*Y]#L?%2WEH=/\ MS26\2+Y<K.
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M 68K*PYW&@#D=$AO=:^&^IZG)/'!$-;>YDM_*RVX2+QOS[U['XB_Y%G5L_\
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M?0-"T^.65&DGM6PX4,"?TKHM/^'RVVJVL\\ZM;VF5B1&8&1>H#Y.#SS7<T4
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M]DUU;2ZA"]LZ26<)*L@SQ+NZ* >M2GQ;:Z3\/6M)O$FG2:_#9':(IU9M^,J
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MUQQ795YM\)=2L[;P5+'+<(KI?W1=>Z_O">?PYKT2WN(;J!)X)%DB<95E/!%
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MU>GUPO@/0!X7O[S1EN6N([:"-8G9<$+DG'Y_SKNJ "BBB@#&\6_\BCJW./\
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MG<1QGKP.M;9\2:&HRVKV('J;A?\ &@"B?!>F,P8RWF1T_?GBI#X4M2,?;M2
M'0"Z(J]/JL8TY+RQ07\;.JCR)%P03@G/3BLQO%+?\)0^B_8)4P,+<2<([8R
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MWI=O>RW=R]W#'&93M4!XXNTOH0?3K0!U UX]].O <XQLJRVJ(NG+>-;SA6;
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MKG^Q?^%A6 DBD.M"RD,+@G:(LC=D=.I%:-MXCT6\T^:_MM4M)K. $RSI*"B
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MXRO[G2]3L-0MH893:P3S.DKE<HJ$G!'>@#3TP?\ %5:L2.=J#.>U;]</\/\
M7&\2"ZUA[<0?;$26-5).%Z<GUS7<4 %%%% &'XRX\%ZS_P!><G_H)JA\,_\
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M<TZ:[T,.)V,FDB0CSVP30!Z)Y6GEE.VWW'D=.<4L=I8LN8X86'3*@&O/-/\
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MC@:#S(G:7;.FY''F,2"*UYHM0'Q$\.1:@MKY1L[P)' F%'$?!!_"M/X=F-O
M]B\49BC<R,J%=I4&1B!BF:OG_A97AGT%K>=_:.@#IHK2W@;='"JMC:&QR!Z9
M]*HCQ'HIU#[ -3M3=;MGE"0;MWI]:/$>K6VAZ!>7]W/Y$<<9 ?N&/ Q^)%>/
M)XGLK>*=9/M)M)+=3;Q&V9F6YSDR$XS][YLYH [/Q+XN1?$T-C9Z3JFI3:=)
MNN8K: NBAA\KGW7K^-85GXQGTJXTZ^U[1M;A2T1X9+J2T<*PD8;<DGH..M3^
M%=<^TZOXKUBQG^UG[% ZRHGWV52#Q]0:R_%OB+5[SP&EE<QQ7BW3+++=1/\
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M'6]*&I^&&;4;?*6]T&/F#"GY>OZ_E6UX2U?36LGA6_@>:2ZD( D!+$FO-_\
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MM2,9Z$,.P%=+:VTDEE&NI"*:XP=Y"\#/84 5/#FK_P!K:1!--+ ;O:?.2(\
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M;=!G.%L5']* ,>*;39=/CN]"G\376L3(PN8VD=T5MIWK(&^4<]A7.?"01_\
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MI<V\D$HS'(A1AZ@C!K%B\,>1#'#%K6JI'&H1$$XPH P!]VMZB@#%'A^0$?\
M$[U4X]9EY_\ ':D&B.!C^U]3]/\ 6C_XFM:B@#*_L63(/]K:CQ_TU'/Z4_\
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MP0>]<K9ZOI_A>>XTK4[Y(463?:F0'YD;G ]@3C\*ZND*J3DJ"?<4 <O:>/\
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M?P5;V5O;QQ07&K6YD0=&);G/Y5Z77GWQBC:;P=:PQS&&234[95D7&5.[@\T
M+\/HDM_AE<11H%1/M 4#ICFNH\*<>$='_P"O.+_T$5R_P_1H_AG<HTQE93<
MR,.6//-=3X5Q_P (EI&.GV.+_P!!% &O1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !111VH **!TYHH QO%O/A#5QG
M'^BR=/I6#\(\?\*ST?!SF,G]370>*AN\)ZL,9S:R=\?PFN?^$?\ R3+1^!S&
M>G?DT =O1110 4444 >87XS^T;I/^SHDA^GS-7I]>8:AS^T;I/RYQHLG/I\S
M?Y_&O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *84S(&)X
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M->FT %%%% !1110 4444 %%%% !2,RHI9F"J.I)P*6F2Q)/$T4J[D888'O0
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MIT5E_P#"/V'/RS<G)_?O_C2'PYIQQ\DW'3]^_P#C0!JT5C_\(SIFTKLGP?\
MIXD_QI#X6TLG[EQ_X$R?_%4 ;-%8G_")Z3G.RYSG/_'U)_\ %4?\(GI. /+N
M.!C_ (^I/_BJ -NLOQ'9S:AX:U*SMUW336[H@SC)(J#_ (1/2?[ES_X%2_\
MQ5'_  B>DCHES_X%2_\ Q5 'C_A[3O&.A:#::9+\+-/OG@7:UQ+<1[I.O)Z\
M\UI+)XM[_!_2OPGBKT[_ (1/2O[MS_X%2_\ Q5'_  B>E?W;G_P+D_\ BJ /
M,]_BHMAO@_I6W'_/>+K2AO% X/P?TO'?%Q%7I?\ PB>E?W;G_P "I.?_ !ZC
M_A$]*_N7/_@5+_\ %4 >9Y\2C/\ Q9_3,=_WT5(%\2$?-\'=+STP)HB*]-_X
M132O[ES_ .!<O_Q5'_"*:5_=N?\ P+E_^*H \Q\KQ!G/_"G-,XZ?OXJ/)\0
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MKU3M0 5D^)=0GTOP]>7ELF^>-,QKD D]ASQ6J"",BHKLVZVLC76P0*-SE^@
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ME"&@0I$=O**>H'UJQ;6L%G L%M"D42_=1!@"@":BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH CGA2XB,<F=I(/!(Z'-2444
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M/^%C>#<X_P"$CL/^_M+_ ,+%\''_ )F*P_[^4 <C_P (3\4?^BC1_P#@&O\
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M+\V_PH Y,_"WQFV=WQ"NSW_U??\ .G#X5^+@K8^(%[N(Q]S_ .O75?\ "U?
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M-N2?K6G(L2Z=';O,BB1!$C9X8D<8H PK>W\%W;)Y-AIS,\OD)FU W-@G X]
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MJCKG=S]*2*^U.ZM;*UFO_+EFEF\VYC4* $Z* >F?Z5T::-IL>H?;TLH1=_\
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MBVU.RM8;BX:2"!8IB0#NX[5C_'C_ ))==#KFY@P!W^>H?C,%/PKMU9M@-S;
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M<X^M;\=W;2HKQW$3HQPK*X(/TKS?5_"NJ[-06QMVBM&*[+6)553^Y92<]>I
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M?1S06V^<E<8E&,H!^/6LZ3XFZ[>?#:\U^R5(;LZI]F@25?N1EL*#[@5P&O\
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MBBB@ H[444 >$P^++?P7\9O&%UJ%C?RP7GE)&;> ODJJ]_QKI_\ A>&B9_Y
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M=N)+R5C)YA9XV8[@,9/U&/TKU3^PM'QC^RK'_P !T_PH&A:0.FE6/_@.G^%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>gdzs1tysdsfm000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N C(# 2(  A$! Q$!_\0
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M_A7GM]J9OC.&N5658RT:MUE(_A'^US^E=1D>H>&KNYOM)%Q<-D,Y$9[E1_\
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M:A:B^L(DLBP65C#L<@[_ )L;SMQM3CG.ZM&_\0+8WKVYMF?;CY@^,Y&:K?\
M"5I_SYM_W\'^%<4\PPT).,I:KR?^1NL-5:ND3>'VU@W>K#4_.-N+@&R:954[
M,<C YP#W/KQ6Y5'2]2&IPR2"(Q[&VX+9SQFKU=5.I&I%3@[IF4HN+LPHHHJR
M3B_MGC"VO+HQ6<MTKZDR!94 2.TR<.A!&3C''.?PJ6SU+QE)<V_VC3(8X/,7
MSLQ8;:60,!\YP%#2$-SN"#@9K0F\3K#/)%]D8[&*YW]<'Z4S_A*T_P"?-O\
MOX/\*X7F6%3LY_@_\C=8:J^A)ICZ^?$NKC4H0FF;4^PE'5EX+ ]!G<1M)ST[
M5LFLFR\0+>WD=N+9DWY^8OG'&:UC6D*].M'FINZ)E3E!VD,-,-/-,-9R*B1F
ML/6;O[/!<3#K&N%^O_ZZW#7'^)I#_9^!_', ?U-<&)=D=%-:G.AX[/3+S5+K
M)@M(FE?_ &B!G'XGC\:YG58+VWO;";Q#JVK0I/:?:1%8RL@GF)&+6(+PI&1R
M<D]>U=5XJMO*\!W#*F]8&BN)4_OHDBLP/M@&N?\ &-YJOB!O#\LMC'9:+=:D
MB0><S><V\861@IPG!)4 YS@UI@Z:45/JR:TKNW8S]1O?%'P[N+.XN]5AO+6^
M;?/I5Q<O(T'.>IRQ _O#C/8UZIX4\56GBBUF:)/)N;<J)H?,$@ 895E8<,IY
MP?8@UYQ+?ZS\-]4U6?6M(76M.O7P-4D?]XRXP(W8@]AC:0!GZUJ>&K[3/!LU
MQIFEZ6EY=ZBT<VE&W8;KN&0D['DY \HA@3Z8KKFN:)BG9GJ36<$V/.0R*.0K
ML2H_#.*SI[007,<<C220$YB#R,0I';&<?2G:!K]OKD$RB*2UOK5_+N[*?B2!
M_?U!ZAAP16A>P^=9R*/O*-RGT(Y%<=:,FK]5_5C:#5_(J"!&W;@QWL&;+'YB
M.F?6K@174JP#*PP01P:K0.)(T<?Q &KB5$'?4J6@DD"FU,:*%"K\H X&*70[
MC9>-"3\LB[A]1Q_A5A!FLNV8Q:E;X[2E3^7_ -:NBF^6M%]]#.6L&CKZ***]
M4Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,G5+*TNI=US!'(0I7+C.!P>/2N>8Z(KF=[>5EE@$H!C8J$R1GZDM^M=1>@,
MQ4]#D'\A6(FBPFVCBN&,A6&.%L<!E1MP&/?O652#;]U(N+[LCBET<7MO,BA+
MF4R%"5((*YW9[#^+K[TL$>DW3K&ELV&0S)N5E5ESR5SV.>G0YH7P]9 *"TS;
M %7+]% (VXZ8^8^_-68; Q7$3F=Y%B@:)=X&[DCT]E%2HSZI#;71D$2Z/-"D
M@$*KL64*[X(&<@D9]3W]:46>C(0^VW! "@F3L",=_I^E,7P]:(H59)AMP4Y'
MRL-OS=.ORC@\4LN@6TTDCO-/N<YX(^4D@DCC@Y _I1RRM\*"Z[C=4L[>"RW0
MQ!&:6,$@GD;\_P R:VWFC@B5I&V@\9Q67K'_ "#U_P"NL?\ Z$*UUY1<CM6S
M5E:)%]=2O_:-I_SU_0T?VC:?\]?T-6<#T'Y48'H/RK.U7NON_P""5>/;^ON.
M/\131SZBC1MN41 9Q[FLBMKQ1@:HG0?N1_,UB9'J*^1QU_K$[]SV*'\-6 ]#
M7=V^H6HMH09>0B@\'TKA"1@\BO1+8#[+#P/]6O;VKT,FYG*?*^QS8VUHW(O[
M1M/^>OZ&C^T;3_GK^AJS@>@_*C ]!^5>]:KW7W?\$X+Q[?U]QCZU>V\ND3HD
MF6.,#!]17.Z1(L6K6SN<*K<G\#74Z\ -%N. .!V]Q7,:)@ZU:CC[_P#0UX6/
MYOKM.[UT_/U._#V]A*WG^1U_]HVG_/7]#1_:-I_SU_0U9P/0?E1@>@_*O=M5
M[K[O^"<%X]OZ^XK?VC:?\]?T-']HVG_/7]#5G ]!^5&!Z#\J+5>Z^[_@A>/;
M^ON*W]HVG_/7]#1_:-I_SU_0U9P/0?E1@>@_*BU7NON_X(7CV_K[CB-<D275
MYG0Y4A<'\*SZTO$&!K4_0<+_ "%9F1ZBOCL5?V\[]W^9[-+^''T.E\-W4,%I
M.LK[29 1Q[5M?VC:?\]?T-97A7!LKCH?WH_E6]@>@_*OI< JGU:%FON\_4\S
M$<OM7=%;^T;3_GK^AI1J-IG_ %OZ&K&!Z#\J4 9' _*NRU7NON_X)A>/;^ON
M//;M@U[.PY!D8C\ZAJ:](^WW'(_UK?SJ#(]17Q-3XV>['9%_1I%BU:!W.%!.
M3^!KK#?VW_/7]#7*Z'@ZS;]#R?Y&NS('H/RKW<JYO8/E?7]%YG!B[<ZOV&&F
M&GFF&O0D<T2,UR'B1#]B4_W)QG]:Z\U@ZU:&XM[F$#YG7<OUZBN#$JZ.BD]2
MM$J2VX1T5XV7:RL,A@>H-><>(H[C1M&3PW?6VH2:(E_%)%>6L)D9;3))3<,[
M71L8]1TKOM*N!/9H?XEX(J76=4.BZ!?ZFL1E-K THC!QN('3Z5IAY^ZK$U(Z
MLX[P1?/XQGCOM9OH9X='F-M:0NNPW$N.)W4]6V\ 8X.36MK&C6G@S4O^$OTF
MVB1 5AOK,* '21PI:+^X^2.!PW-<AXI\'?V;;V'BZ\*:K.[K_:T<G"RK)@ P
M@8*E<X7'/0^M:FDZI-XBU?3?"Z71O;*QNTOX]2G5D>>"+D1%6 W2*S $],#/
M6NIJ_O1V,K]'N=KXML)[,?\ "4Z4N-4TV(F5 .+NW'+Q-[@9*GL1726MW!>V
M$-[;OOMYXA+&WJK#(_0U3UK4X-(T#4-2N?\ 56\#NPQG/& /Q) _&LW0+2?1
M? 6D:;< K=K:)$RDY*L1DC\,G\JPG+EI\SZ%I7E9&A8_\></^[5]#5.(!%51
MT48%64-<U+1)&L]67$-8Z$MJ%MC^*8G]#_C6A++Y<#-WQ@54TJ(SZU$.=L*;
MC]3_ )%=-/WJT5VU,I:0;.NHHHKUCD"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH HW?W_Q_H*K5<N[+[5MQ-)'C^XQ&:J_V
M,?\ G]N?^_AH ;13O[&/_/[<_P#?PT?V,?\ G]N?^_AI@-HIW]C'_G]N?^_A
MH_L8X_X_;G_OX: ,[6?^/ ?]=H__ $*M=/N+]*HMX<9V'F:C<N@8-L=LCBM,
M6L@&/./'M2 CHJ3[-)_SV/Y4?9I/^>Q_*@"N\$,K;I(8W;IEE!-020VD<L49
MM8B9"0#Y:\8J_P#9I/\ GL?RJM<6S?:[7,I)RV#CI6-5)*]NJ_,N#;=A/L=K
M_P ^T/\ W[%3    # '05)]FD_Y['\J/LTG_ #V/Y5JHI;(EMO<CHJ3[-)_S
MV/Y4?9I/^>Q_*F(A=%D4JZJRGJ&&13%MK=&#)!$K#H0@!%6?LTG_ #V/Y4?9
MI/\ GL?RI.*;NT.[(Z*D^S2?\]C^5'V:3_GL?RIB(Z*D^S2?\]C^5'V:3_GL
M?RH CHJ3[-)_SV/Y4?9I/^>Q_*@"L]M!(Q9X(F8]2R FD^QVO_/M#_W[%6OL
MTG_/8_E1]FD_Y['\JGDB^@^9]R".*.($1QH@/)"J!3ZD^S2?\]C^5'V:3_GL
M?RII):(1'14GV:3_ )['\J/LTG_/8_E3 JFTMB23;PDGDDQBC[':_P#/M#_W
M[%6OLTG_ #V/Y4?9I/\ GL?RJ>2/8?,^Y4%M!&VY((E8="J $4XU9^RR?\]C
M^5)]D?\ YZG\JET^P^;N5#3#5W[$W_/4_E1]A/\ ST_2LI49,M32,XU3O8\J
M''5>M;GV#_II^E(=.!&"^0?:L9X24E:Y:K)'F]XCZ5J/VB,?Z/,<D#^%NXK2
M'V74[.2"15E@F0I)&W1E(P0:V=6T8)$R.OF0OQGT_P#KUQL]I<Z9+N5F,6?E
M<?U]Z\N2J8>;3.I.-2-R>P\&:=:7=M/)=:C>K:'=:P7ET98H". 54]P.A.<5
MH>(M(N-4M[6ZT^5(=6T^7S[.63[I.,-&W^RXX/X'M5*'5K@#!*GZBK0U.Y<8
M#JO^ZM:_6UO9_@1['H47BU3Q'<V\OB*R&E:3:2+*-/\ -662\F7D%BO'EJ>0
M.I(R:WVDDN9S<2C!QA$_NC_&J$;9?>Q+/_>8Y-7(VS6-2K*IOHNQI&"B6$:I
MT:J@.*>7.T\X]3Z41E8&AUU<*%)8_(G)]S6OX<LVBMFN91B6<[OPK)TVQ;5;
MI6((M(CG)_C-=@JA5"J, # %>QA*+@N>6[..M--\JV0M%%%=A@%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !52Y_X_;3ZM_2K=5+G_C]M/JW]*RK?!\U^:+AO]_Y%NBB
MBM2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!KHLB%' *D8(-8&H:.R;FB7S(SU7J1_C70T5E5HPJJTD7"<H.Z/.9
MM'B9B828V'51R/RZBH/[/N$/&UA[&O0[G3K6ZYDB&[^\.#6=)X?RV8KIQ[-@
MC]:\V>72O[C.F.)75'));SCJF/QJW'$_?'X5M_V!=9_X^DQ_N#_"GIX:+?Z^
M\D9?0<5,<OJ=6AO$1,1Y4B^5FRW95Y)J[9:-<Z@P>Y4PVW79W;ZUOVFD6=GS
M%"N[U(YJ]7=1P<*;N]683K2EIL1PPQV\2Q1*%51@ 5)11768A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %9\T\<EW;L&X1G#9[8 K0K,O=-,]Y'(G"L?G]JY\1
MS\ON*^J_,TI\M]30BD66,.N=I]13Z15"*%484# %+6ZO;4S?D%%%%, HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)#97;G!Z@=<>F>:N,U)V,Y4W%7+U%%%60%%%% !1110 4444 %%%% !1110
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MO-+U:VO'=)1NN1*K2%A&'?<K1C'!/1J .MHHHH **** "BBB@ HHHH ****
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MD.(W(]#GD4S3?^1ZUS_KC!_Z#3=:3RM:\-QYSMG<9_X"*=IO_(]:Y_UQ@_\
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M),UKV-A/!=+)(%"@$<-FM;_@2_\ ?0H_X$O_ 'T*FG!0CRH=2;J2YF)12_\
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M62/B5H]J#'(.?PKIK;3K&S&+:T@B]TC -6J]!.SN<!\O:W;V"/%=7(N'./+
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M?6C#5?:T[RW6C]3DS7!+"8AJ&L):Q?DS9MCQN/?I61XSO1#HBVP/SW$@&/\
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M_/,?E1]GA_YYBI:* (OL\/\ SS'Y4?9X?^>8_*I:* (OL\/_ #S'Y4?9X?\
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MMBS25+.%9Y&DFVC>S8R3WZ<5/10 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>gdzs1tysdsfm000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 FL# 2(  A$! Q$!_\0
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MFYU&ZLKH7"I<RY9UQM90>W'-6#K.IZE<6UOIVFW5H/,#7,]W&%5$'50,G)-
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M)5DB.<.IR#C@UG3Z9ID>JP7H"PWOEO&@0A?-&.01_%CK[51\$\>#K8>C2_\
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M& ^.0*L4 97V*UM;JTMH[=-C.TI)R3N4<'-:"VT2W+7 0>:ZA2W? [56N?\
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M^CO8[2*51%=R.RL1S%L/S >N<C]:8=5NHY+IH+G[9&B["0HPLF>P'.T#K[T
M2MHE_.8HIKSR88H_++PNP+KC ^4\"F#1M1AMG@MKJ.:WFFWN&PI*;0 H*CC.
M.:T-'NY+[PY%<3/OD:-MS;<9//:H8]82TMHH1;32^5;))(R8PJD>Y]C0!KPJ
M4@C0JJ;5 VKT'L*DK)D\0VL6V22*=+<CB=DPN=N['Y5/::I'>V\TL<,H,0SL
M(&6XR,8H N++&[,J.K,APP!R5/O3&N[9%5FN(E5FVJ2X&3Z#WKE[>QUJTD9X
MTB\R_0F5AD;'SG+>^#CCTJO#IUY;VQCN-.=U,<L,2(-^QBV0QST^M ';45!$
M?LUG")W&Y4568GJ<5*CJZ[D8,I[@T 16^Y7EC/FMM;(=^ASV'TJ>J[KMO8Y
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M* *5O_R%K[_=B_DU+9?Z^^_Z[_\ LBTEO_R%KW_<B_\ 9J6R_P!???\ 7?\
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MQ0!U>CWS:AIT<SX\P$JX']X5?KFO"EU]L-Y+ /\ 0]P"''#-W(KI: "BBB@
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M9[@DF$R'/E =,>]=GX=OI-1TL32$MB1D5S_$ >#0!I000VT*PP1I'&@PJ(,
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MV\N[2+AX6E;E5/&?7%1Z=X#O5D$]S=2/*ISM8\9^E*R!2:.<?36N9]':2#R
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MP.HQWJTDC)MMW9);Z1>:C9VMQ-(O[L*0OKCM6S>V:ZAIJK;D*T9W#/ R*PM
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M6 ^A]:ZNWNXKB_M[J+/DW,109&#N4]_UK5I6*4G:QYCIOA_7+V)(WM[>VB9
MKW(<-N4>@ZY^N*[32[JTMM)6.QMKAK:!0L;*G^L]Q5\Z?$)C+"SPLQRP1L*W
MU'2LN+2[J(WC+;0+%,H'V99FVL<G+9Q\N?0"A12V'*<I;EQM=M5MH;G9,8),
M9D\LX3)Q\WIS6G7-+I.IQVMG9;();.)B[Q^:5[Y5,X.0/UKI1TYID!1110 4
M444 %<OK/AO >ZTRXEMKEGR8U8;&)Z\'H:Z5I,':HW-CI4#NMNRRS,3D8)["
M@#C+G[3HVB+;:IMN+B:4H&CX4H?7T-5IOA]IP"WD, AC? >%&.T@^E:_BV[M
M(?LEP9$8+* Z'HP-;<+Z?<PH(B74 ;4W'C'3B@#A8/ D>GW"S174B>4^Y'49
M/7H3Z8KL;J=Y(([:PE$DNW)(.<5874;:UMS&XV,N?E-87AN6&3Q#J$\$N(WP
M-G8GVH V=-MRKEKLG[4HYYZCVJ\ZLS;(9,C^($TV55COHKC=]X;#27$\-O.D
M@8 L<-CO0!R6M2W^FO<1)I[SV9.]#$?FC/?/>N4L/$%J+IQ?WD\$A'RQR#:<
M?C7H^L:S:6\!VJ99O[J+DFO/?$NH:=XBQ!:6J)<QJ7;SH^$'^>U %'3V@UWQ
M39PV/,<$I:>3/WL]!FO2=9FT[1[?>I5)5& !U->3Z?K-YX?E\R&.SEC3.3N5
M''X4Z[>\\:*;VZDCMH<8B#N?SP.M ';>%M737I9],O"HVN6V$@[@34OB30]#
MTU69K5@[1X5P3MSGH1WKA= U"PL(Y+1E*:A;']U<PJ2#]1Z5!?\ BO4]5O\
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MR5#*.K'V-=%=^$=&NH8XUM1;&,85[<[&QZ9'7\:VHHDAB6*) D:#"J!P!3Z
M.:T/POHNFW5XMOI\(*R !G7<3P#WK9O;S[$;1%C#":81#MMX)_I3;+_C]O\
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MI1ER%R>?Y5<MBAMHS'NV;?EW=<4)W"4;$M%%%,@**** "BBB@!"RK]Y@/J:
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5%D/HHHH&%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>gcilxvfwaiqx000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D DT# 2(  A$! Q$!_\0
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MJ@#T"BO/T^,'AQ[>XD/RR0S+$86U"QW.2%.5/VC:R_.,L#@8;/0T?\+<T/\
MY]__ "KZ9_\ )5 'H%%>>O\ &#0HU#-;L02%^75=-;J<=KKISU[=33O^%N:'
M_P ^_P#Y5],_^2J /0**\YG^,WA^V:$/:RGSI!&OEZCI[X)!/S;;D[1Q]XX'
M3GD5-_PMS0_^??\ \J^F?_)5 'H%%>?I\7O#WVJWAE3R1,Y02'4M/=%(4M\Q
M2Y.T?*1D\9('4BJ]C\:?#VH6<=U#:SI&^<">_P!/A<8)'*/<AAT[CGKTH ](
MHKS_ /X6YH?_ #[_ /E7TS_Y*J.#XQ:#<V\4Z6T@21 ZB34].1@",\JUT"I]
MB 1WH ]$HKSV3XP:%%&TC6[%5!8A=5TUCQZ 762?84V#XQ:#<V\4Z6T@21 Z
MB34].1@",\JUT"I]B 1WH ]$HKSV3XP:%%&TC6[%5!8A=5TUCQZ 762?85&G
MQH\-2R01PQ2NTMLES\U[91A V?D8O.H#C'*=1QF@#T:BO/\ _A;FA_\ /O\
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MGNJ["@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Y_QW_P D\\3?]@JZ_P#135H:#_R+
MNF<8_P!$BX_X *S_ !W_ ,D\\3?]@JZ_]%-5_0?^1=TS_KTBZ?[@H T:***
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M"71I8F93Y^&:<Q[<%63 W=P*]9H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\?:G"
MOA;6M(C@OKB_N],G2&*TL9I\ET95R8T(7)R/F(Z&MS0?^1=TS_KTB[Y_@%8/
MB&WT%]>,FOZ$VI1FUC6W8Z/)?!"&DW@%(WVGE.N,\=<5PMA;>)],TZVL+/X@
MZY':VL2PPI_P@DQVHH 49,>3@ =: /:**\?\WQA_T477/_"#F_\ C='F^,/^
MBBZY_P"$'-_\;H ]@HKQ_P WQA_T477/_"#F_P#C='F^,/\ HHNN?^$'-_\
M&Z /1?$'BBQ\-/9G4%E6WN'*R7*KF.W' #R'^%2Q5<] 6YP*Y:XF^S>)[B^,
M%U-;VWBA9)C:VTEPR*=(5 VV-6;&YU&<=Q3_ (:V/B/4= FU;QI=RW5UJ4/D
M-87=@L!MXT>12K  ;@X(/*CC'6N'O?"=GIFK?$6TNO#EW>^?9Q1Z%*-(FN0C
M?9W 2*0(P3:3&N<C[HZ8X /<;"^M]3TZVO[.3S+6ZB6:%]I&Y& *G!Y&01UJ
MQ6'X,@FM? OAZWN(I(9XM,MDDCD4JR,(E!!!Y!![5N4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_JW_ "5[3/\ MT_]
M$:K7H%>?ZM_R5[3/^W3_ -$:K7H% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^"J[_P#C51Q?%?P;/O\ )U&ZD\MRC[-,NCM8=0<1\'VH [2BN/\ ^%G^$_\
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M^#X0IEU"[0,P52VEW0R3T _=]320?%?P==0K-;ZC=S1-]UX],NF4\XX(C]:
M.THKC_\ A9_A/_G[OO\ P57?_P :H_X6?X3_ .?N^_\ !5=__&J .PHKC_\
MA9_A/_G[OO\ P57?_P :J]H_CGP]KNHBPL+R4W3(9%CGM)H-P&,X,B*">1P.
M>] '145GZKKFG:+I1U.^N=EF"@#HC2%BQ 7:J ELDCH#7-Q_%?P;,S+%J-T[
M)]X+IET2.2.?W?JK#\#Z4 =I17'_ /"S_"?_ #]WW_@JN_\ XU1_PL_PG_S]
MWW_@JN__ (U0!V%%<?\ \+/\)_\ /W??^"J[_P#C5'_"S_"?_/W??^"J[_\
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M^HHH **** "BBB@ K)\4VZ7GA#6K:0L(YK">-BO4 QL#CWK6K.UXX\.ZF?\
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M?E2!!+M)RI8$>>_1@.F<XK8HH P_&<$UUX%\0V]O%)-/+IERD<<:EF=C$P
M'))/:N=MI8O$MC8>&M0TJYDL%14N?-L[N%)%2,XR9(4 ^<(1ALY QTR.^HH
M\CO$U'3_ (Q> =%OI)[R.TCOWM]0E',T;PL C'&#(@0 D=0RDX)KU>YMH+RU
MEM;F))H)D*21NN5=2,$$>E<)XM_Y*]\.O^XE_P"B%KT"@#G-"\,3:/?+YFHR
M7=E:1O%I\<H)>"-RI9&8GYPNQ0K'D D'/6M75-.;4H8ECOKFQEBD\R.>V$9=
M3@J>)%92"&/45>HH S]%TE-$TP64=S/<_O99GFGV[W>21I&)VJJ_><] *T**
M* "N?\"?\D\\,_\ 8*M?_12UT%<_X$_Y)YX9_P"P5:_^BEH Z"BBB@#ROX"Z
M'#9> ;?65NKN6?44*/'+(&CA6*:8*(QC*@EV8C)Y)/&:]4KS_P""7_)(="_[
M>/\ T?)7H% !1110 4444 >9^-_"]IJ/Q4\$ZC+<7:R/<%6CC<",_9TDGC.,
M==Q(/L3C!YKT+4=/MM6TZXL+R,26]PA21?8]P>Q'4'L>:YGQ/_R/O@;C_EZN
M_P#TEDKL* ,+0-*U>R<OK.JQZC)%$(()$@\LE<DEWY/SM\H../D![\;M%% !
M1110!R/Q-TQ-2\ :K(;FYMY=/@?4+>6W?8ZRPJ70YQD<@=,'T(IWPQTV'2OA
MEX=MX&D9'LDN"7()W2_O6' ' 9SCVQUZU<\=_P#)//$W_8*NO_134>!/^2>>
M&?\ L%6O_HI: .@HHHH *H:QHNG:_I[6.J6JW%N6#A22I5AR&5@05(]00:OT
M4 <YI7AR[@U2&]U*_6X2RB^SV%O$A5(EQM,C9)W2D<9X !( Y)+] \(V?AW5
MM8U&VO+Z>35)?-DCN90R0_O))-L8"C:NZ9SCGKZYST%% !1110 4444 <?\
M%3_DEWB'_KU/\Q5F:QTGQ5>L9)M0B>)46YLG#P"9 Q9-Z, 67.[E>#R#GI5;
MXJ?\DN\0_P#7J>WN*\WC^,=[X@UW1 O@RXL+@ZA!;17S71*H)G :,YB (=5;
M@GJH8<J" #WBBBB@ HHHH **** "BBB@ K.UXX\.ZF?^G27I_N&M&L[7CCP[
MJ9_Z=)>G^X: ,#P!Q#K0_P"GNV_](+2NPKC_  !Q#K0_Z>[;_P!(+2NPH *\
M?_9Q_P"2>:A_V%9/_145>P5X_P#LX_\ )/-0_P"PK)_Z*BH ]@HHHH \_P!6
M_P"2O:9_VZ?^B-5KT"O/]6_Y*]IG_;I_Z(U6O0* "O/_ (I_\R5_V-=C_P"S
MUZ!7G_Q3_P"9*_[&NQ_]GH ] HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#S_Q;_R5[X=?]Q+_ -$+7H%<!XQ!B^*7P]O)%*6L<E_"\S#"
M*\D "*6Z L00!WP<5W] !1110 4444 %<_X$_P"2>>&?^P5:_P#HI:Z"N?\
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M=!UFX\&6^EZWIM].OBBQ=H[6Z25@N7&2%).,D<^XH ]4HHHH **** "BBB@
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M_H5-#_\ !=#_ /$U1\!L776V)R3>6YSZ_P"@6E==0!S_ /P@G@__ *%30_\
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MUX3@\,[O*U&^O?\ 1+>RC^U^5^ZAAW[%&Q%S_K&Y.2>.:Z"B@ HHHH ****
M"L>;P]%+XHBUX7MVDJ1)$ULNSRI-@E"ELJ6R//?HP'3(.*V** "BBB@#S?QW
M86>I_%+X>V=_:07=K)_:6^&>,2(V(%(RIX." ?PKLK#PMX>TFZ%UIV@Z79W
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MO/\ XI_\R5_V-=C_ .ST >@4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"B-5KT"O/]6_Y*]IG_ &Z?^B-5KT"@ KS_ .*?_,E?]C78_P#L]>@5Y_\
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M0*\_^*?_ #)7_8UV/_L] 'H%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >?^+?^2O?#K_N)?\ HA:] KS_ ,6_\E>^'7_<2_\ 1"UZ!0 4
M444 <_X[_P"2>>)O^P5=?^BFK0T+_D7M,_Z](O\ T 5G^._^2>>)O^P5=?\
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MQW'/J=H\36]T=%C5HO+9F4 +(%(W.2<@YP/2MS_A$OB'_P!%/_\ *!;_ .-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>gdzs1tysdsfm000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& FL# 2(  A$! Q$!_\0
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M7._\+1A_Z!K_ /?8J-3!RL=G_8NE?] VT_[\K_A1_8NE?] VT_[\K_A7&?\
M"T8?^@:__?8H_P"%HP_] U_^^Q3LPYD=G_8NE?\ 0-M/^_*_X4?V+I7_ $#;
M3_ORO^%<9_PM&'_H&O\ ]]BC_A:,/_0-?_OL468<R.S_ +%TK_H&VG_?E?\
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M &+I7_0-M/\ ORO^%']BZ5_T#;3_ +\K_A7&?\+1A_Z!K_\ ?8H_X6C#_P!
MU_\ OL468<R.S_L72O\ H&VG_?E?\*/[%TK_ *!MI_WY7_"N,_X6C#_T#7_[
M[%'_  M&'_H&O_WV*+,.9'27FD:8-7TQ1I]J%;SLCREY^0>U7/[&TO\ Z!MI
M_P!^5_PJJMZM]-HE[CRUE29\$_=&P5B:K\0(--U*:T%FTPC(Q(KC#?2M864=
M2KV6ITO]C:7_ - VT_[\K_A1_8VE_P#0-M/^_*_X5QW_  L^'_H&O_WV*/\
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M VT_[\K_ (5S'_"R]+_Y];G\A_C1_P ++TO_ )];G\A_C2NA<R[G3_V-I?\
MT#;3_ORO^%']C:7_ - VT_[\K_A7,?\ "R]+_P"?6Y_(?XT?\++TO_GUN?R'
M^-%T',NYT_\ 8VE_] VT_P"_*_X4?V-I?_0-M/\ ORO^%<Q_PLO2_P#GUN?R
M'^-'_"R]+_Y];G\A_C1=!S+N=/\ V-I?_0-M/^_*_P"%']C:7_T#;3_ORO\
MA7,?\++TO_GUN?R'^-'_  LO2_\ GUN?R'^-%T',NYT_]C:7_P! VT_[\K_A
M1_8VE_\ 0-M/^_*_X5S'_"R]+_Y];G\A_C1_PLO2_P#GUN?R'^-%T',NYT_]
MC:7_ - VT_[\K_A7FGBJQM(_$MXD=K"J@K@*@ 'RBNTT7QI8ZWJ LX()DD*E
M@7 QQ7)>+?\ D:+WZK_Z *':Q<7<Z/7?^290_P#7M%_2O)Z]=U6VEN_AQ!#
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M,&>+P]#>20+H$4R0LJ3316J%8V/0'N>O8''>K#VWA&-IE>'1U,) E!6,;">
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M.V%O#Y<UZL6[RG!9!C$.2>O&#GF@#0M=)\-WT/G6EAIL\><;XXD89^H%3?\
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M,G^%(?"OA[!_XD>G?^ R?X5:M=8T^\P(+E&8OLVG(.[&0,'GD<U=/W3]* .
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M** .5UNSM;;7M$:"WBB)DE!*(!G]V?2O._%O_(T7OU7_ - %>E^(?^0YH?\
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MNOF1HY =1,K 8VC^ ;>2>O84V;PIJD;[[>>.,)'*J.KDM&I:0J%7;D$!@.&
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M1R>%M46Z@-O);+#!,'CPY!1?-+E1\IXVD#@CWR*Z^UCDAM(8II3+*B!7D/\
M$V.3^-34 <4/"-Y!';"-;6>-+>-9[:21E2:4;@7)P<GE?R]A5S2/#M_8Z^]]
M/<!XR9""),DAL;4(*YPN.,L?PKJ:* "O/KK_ ) 7B?\ Z_)__9*]!KSZ[_Y
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MYD;O!K$OEL'59;IW7(Z'!DP:FO/%6@7URMS+;:HDRILWPS&(E<YP=KC/-%%
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M$K!V<MU)8MGM110(@&N^&0,"SU, ?]-S_P#%T?V]X:_Y\]3_ ._Y_P#BZ**
M#^WO#7_/GJ?_ '_/_P 71_;WAK_GSU/_ +_G_P"+HHH /[=\,_\ /GJ?_?X_
M_%T?V]X:_P"?/4_^_P"?_BZ** #^WO#7_/GJ?_?\_P#Q=']O>&O^?/4_^_Y_
M^+HHH /[>\-?\^>I_P#?\_\ Q=']O>&O^?/4_P#O^?\ XNBB@ _M[PU_SYZG
M_P!_S_\ %TCZWX7D0I)8:BZ'JK2D@_4;Z** +=]XNT'45C%U97K^4^]"I"E3
M@C((;T)JK_;WAK_GSU/_ +_G_P"+HHH /[>\-?\ /GJ?_?\ /_Q=']O>&O\
MGSU/_O\ G_XNBB@ _M[PU_SYZG_W_/\ \71_;WAK_GSU/_O^?_BZ** #^WO#
M7_/GJ?\ W_/_ ,71_;WAK_GSU/\ [_G_ .+HHH /[>\-?\^>I_\ ?\__ !='
M]O>&O^?/4_\ O^?_ (NBB@ _M[PU_P ^>I_]_P __%T?V]X:_P"?/4_^_P"?
M_BZ** )+?Q)X<M;I+F*QO_.3.QG?=MSP<9>N/\1^);.[U^ZGCBG"N5P& S]T
)#UHHI/8:/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>gvxjy5si4hmk000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )1 DT# 2(  A$! Q$!_\0
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M14D.'W)'+W53VK'\#^&])U[XB>,IM3M1<M!>MY0<DJN3U^O% 'M?49%%(
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MTRZ#"-O)D>*/R_O%QT*UEVPN!XH3[6,7 %H),'OAJ .]HHHH **** "BBB@
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MK](O_0: -:BBB@ HHHH *R[$_P#$\U3G_GE_(UJ5E6'_ "'-5Z_\LO\ T$T
M:M%%% !1110 4444 %%%% !1110 R7_5/GIM-9/AS/\ 9L>?[O\ 4UK2_P"J
M?_=/:LKP[_R#8_\ =_J: -BBJ37DGVN:".,-Y2AB2<=:L6TIGMTE(QN&<>E
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M)Y<I'FG/\8^IXKHM&BDBL )%=078QJYY53T% &@,$9'2EHHH **** "BBB@
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MS^]-/T';]C7:. H SSQ]: +ILHS=27 9P\BA6PW&!4L,2P1+&@.U1@9J2B@
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MRL?NGLIK5[<U6O[=;NSE@9<Y7*DCH1TJ'2;G[3I\+LVZ091SG^(=: +]%%%
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M.2:6&^MYBJJX#%=VT]J +-%)DX^Z:,G^Z: %HJ.6>.!"\K;%'4FJB:O:O<)
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M'/XUOZ(S/I>20W[QL$<B@#0ZGOS_ )_K1SVS_G%+_G_/^?\ ZZ#_ #_G_/\
MB *.W^?\_P#UQ[4F/\C_ #[_ .>*7M_G_/?_ #W/U_K_ )_K^8 F"<>Y&?\
M/XFE]".O^?\ /^>0'D?Y_P __7_,!X'^?3_"@ _3_/\ ^K\J/\_Y_P __7/\
M_P"?\_\ UC_/^?U_SF@ /^?\_P"?\0]_\_Y[_P">IGU_']/\*/K_ )_SD_G^
M0 ASG_/^?_U^]'&/\_Y]/\XJ*XG6W$9968R/L 4=_P#.:(I_-=U*,I7GYAUH
M E_S_G_/]*.>V?\ /^101SSG_/\ G^='^?\ /Z_YZ %6[Y>U![SC _"K??\
MS_G_ #^='4)!"UJ[(S*LP8[!G&,]:6+5K&9]B7*;L_=8$4 7/;]*7G_/^?\
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M1I*\8DG569#@XQ0M@Q'%Y<X[9?\ ^M0!>_R/\_E^=+@^AJA]A;_G[NO^^_\
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M21U*M-,TN#Z$\5IT %9FIA8Y[&<L5V3 %NV"#UK3K/UR,2Z1.N[;T(.?0@T
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M6>HQ"0SR(LC'F0-NW^^,<5H&.Y4%OM .!T*"@"S14-K(TMLCMU(J:@ HHHH
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M!?6O_/9?\_Y_SW7[=:\8G3_/^?\ /=WV:'',*8]"/\^G^>R_98 ?]2GO\O\
MG_/Z $?VVU_Y[K^7^?\ )I?MUK_SW4G^?^?ZT\6T _Y8I[_+_GT_SV3[-!_S
MQC_[Y_SZ?Y[ #!?VA_Y;H?Z]/\_C1]MM1C_2$SG SQ_G_P"O3A:0 G]RGY5C
M:K$C:Q86ZJ%4Y<@#K[T ;0N(0?\ 6C^7^>M+]HAQGS5_S_G^5.\N/O&O3ICV
MH\N/&-@_*@!IGB_YZK_G_/Z4GVB+^^*<88^,QI^(I/(CQD1K^7^?;\Z &B>+
M&-XI?M$77>/SH\F+_GFOY4HAB_YYK^7^?\_J 9NI2H64QE6D6,X /;(_^M6L
M/YXQ^59.JHD8#Q1;G6,Y"\'!85K'D^VWM]*  GG_ #_G_P#7^90>3_G_ #_G
MZTGT_P _Y_S[@"]O\_Y__5]*3@4O3GT_S_2C^G^?Z?Y[@!WR?\_YY_+ZT#C'
M'^>/\/YT?I_G_/Y>U'Z?T_SS^7M0 WMCM@?Y_E2.#Y<I_P!AL_E3_3COG'^?
MQ_*F2<0R>R'^1H \\^$PQJ'B/G.ZY4\?2ND\[R/$/B64<XAMUZ]RI']:YGX1
MX:^\1,.0;A?F]>#6[(OVGQ?JUMM++)+:K*!V782#^= '5:= ;73X+<G)CC"Y
M]:M4@XXQP.E+0 5',N^"1/[RD?I4E(>WUXH \U VQR(A)\J%HCN'.5D6NUTC
M_C[U#_KJ*Y"\ 35M5B5-L<:;]V.#ND4FNOT?_C[U$?\ 3;M]* -:BBB@ HHH
MH **** "BBB@ HHHH IZJ<:7<'T6F:4,02CTE/\ 2GZM_P @JY_W*33!B*7
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M )S^OUI/\GC\/\_7\@ Z>V/\_P!/T_,Q^G^?Z4=L_P"?\_Y[<(>N!]/\_I0
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MUK+U'3VN=5L9O,4+$V2&/\JUL?Y_.H)_^/NW]LT 3_X?Y_S_ ) :4]Q_GO\
MY_SP=_QH :1G_/\ GZ48]_Q_S_GFEZ_Y_P ^_P#DTASGWS0 8_S_ )_"CCIV
MH X]O\_Y_P \K_G_ #_G^= %2ZPL]F6*C,XZ\=C5L<G .?\ /^?\\4R6"*=5
M\Q%;;DC(Z'M5:33]^2DTD+YZH>/RH MGD]:7%4HYYX)4@O,-O.U)UX!/H1V-
M71T^O^?ZT &/>DQCOU&*7&?3_/\ G_/8[G'^>O\ ]:@ X_\ U?Y]_P"5&/\
M(_S]?TH/.<?A_G\O\XHQV'X?Y_S_ (@"?7_/^?\ "F3?ZB;UV-S^'^?\]7Y'
M7MU_K_G_ #ELO_'O+U_U;?R- 'FWPDF2!]?,K_\ +RN#CV-='I&FVLOC+Q&T
M4UPN[[.YVR$#)0U@_"'_ %NO_P#7PO\ 6NPTK_D<O$!X^[;?^@&@#0_LB/\
MY^KO_O\ &C^R(_\ GZN_^_QK0HH SO['B/\ R]7?_?XTAT:(];J\_P"_QK2I
M#]<4 >?W<"+=W41WN!$XW2-N/^L7O^%=9I Q=7_O+7,W8/\ :5P0/^6;\_\
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M_JHP: $[>V/\_P"?:D(Y/'.>WUI?\_R_^M1],<?Y_P __KH 0>W?_/\ G_\
M51_^NEQ_A_G_ #_*D_S_ "_S^% "YQ_G_/\ G]4R?_U_Y^M4M1U.'345YHIF
M5ADF-<[1ZFJ?_"2V799"?8&@#5N(O.MI$)Y(XSZC_P"O3;*X^TV:2'&_I(!T
M##J*R_\ A)[%,$QRC'8*<TFD:G9_9YF\XQAYF8*ZG(% &YD@_C_G_/\ D'?Z
M_P"?\_\ ZZI_VI8GDW*Y[C!H_M2PYS=*,^Q_PH N<_Y_&@G^O]?\*I-JVG
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M?/WV[\_X51O/^/NSX_C]/:KQ^]GU- "?0^G^?\^WI3AG'^?\^GY4T#_/^?\
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M#1[K/393[ DP'/K_ $%1:X<:)=G_ &*ET_'D''KZ>U %NBBB@ HHHH ****
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MV!6WF2>/LDYP0.G7O4\4\OG"&:W\LG[I5LBK/OGW_P _Y_K4$G_'[;C'56%
M$]'^?\_Y_P#K'^?\_P"?Z4=\T )_G_/Z_P"1PM![?Y_S_G\$_P _Y_S_ /6
M#C_/^?\ /- Z_P"/^?\ /-'3_/\ GV_ST.@_S_G_ #^0!5NA_I-F<<>;^N*M
M=\'K6=?321W]NJ$;=C,01W!X_K6B<DY/7% !Q12=Z6@ S@Y]_P#/\J!_G_/^
M?Y4=_K2X /X^E  ,4<4E%  >E1S_ /'M-CM&Q'MQ4E13Y\B8#_GDW\C0!Y]\
M'<&WUHCI]H7G\#FNZL#_ ,3?4S_M1_R-<-\'0%L]849P+A?Y&NYL/^0KJ?\
MOI_6@#4K.UZ,2Z+<1D9!V_\ H0K1K-UB?R+->,[I N/QH ;I"^7+>IMVXFS]
M<]ZU*S+$XUC4H^,*8R/;*YK2].* .8<XT#4#G_E];_T,5IZ)_J[L_P#3S)S^
M-9DW_(O7V?\ G];_ -#%:FBC$5R?6YD[>] &I1110 4444 %%%% !1110 44
M44 9^M_\@6[_ -RIK#'V?(Z'G]*BUHXT:Z/_ $SI^FC%MWH N4444 %%%% !
M1110 4444 %17'_'N_4\=JEJ&[_X])?]V@ M?^/6/_=J:HK;_CVB_P!T5+0
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M2Z>P>PB9?NLN1_G\JK:FDC7MBRL0JL2P]?E-3:/_ ,@JV';8.U %SI_G_/\
MG]%^G^?\_P"?8]/\_P"?\^U _P _Y_S_ "H 7M_GC_/]*0?Y_3_#_/9?\\?Y
M_P _R/\ /^?\^E !C'^?\_Y_0/7/^?\ /'^<44AX/T_S_3_/% !_G_/^?Y5!
M))&M];JSJ&8$ $]>:GKG=2$9\4Z>9 "1*FPGJ#@T =$1EL_Y_P _X&CO2GDG
MW-)0 $],T=L?Y[4'W[>_TI.U "_7\:0_Y_S_ )_P/I_G_/\ GM2_Y_S^GY4
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M110 57O>+*7_ '?7%6*K7_%C-SCY?6@"2V_X]H\?W14M16W_ !ZQ_P"Z*EH
M*R];NKBWCLTMY5B:>Y6)G*YP#GI6I4<UO#<*JS1K(%;< PS@^M %33FF,3K/
M,LK)*R[P,9].*OU''!%$N(T5 3D@#O4E 'C^@!7^*^O8&,32<]1GBO5CU^@
M_2O*O#ZL?BMKNUL'SY.O/I7JIY;@$ ]: *=WQJ%GQR2<5>X+L>O/^?\ /_ZC
M1N_^0C9MV&['N:OG[QY/7O\ Y_S_ # $_P _Y_S_ /7.?7_/^?\ /J#G\?\
M/^?\Y7_/^?\ /_UP!!QS^/\ 6E[8H_R/\_Y_Q3'?/X#_ #_G\: $;H?Q_E45
MIQ90^R_X_P"?\BICT/T/\C45GC[)#C^Z/\_K0!,.OI_G_/\ G%49C<_O)([M
M(U7HA0'I5YO?_/7_ #_^JHV@B8DM&I)ZDCK_ )_I0!G3N7-B[=3R>/8U9TUA
M+IELP7;\F<'W-0ZA\ES:A0  QR.>!@__ %JFTDN^DVI(/,?/'O\ _7H M8Y_
MS_G_ #[TO? []._^?\^II=K$$D'W_P _Y_P3!SG:<C_9_P _Y_0 4G&?\^O^
M%'?_ #_GM_.C:^<X/^?\BC!'\)_ 4 'H/\_Y_P ?>D8;EQ_GM0,GL?R_S_G]
M09.#@G_/^?\ (H 0=<_Y_P _Y]*Q-0@C?7;*0YWK.A&#QT-;F#_G_/\ G^6)
M?^;_ &]9[!B/SDW'\.E &YTSG_/^<4=Z#[=,_P"?Z44 4K^:9)K:&*58_-;#
M,R[N*=:>:&ECEE60H1AE4#&>U33VT-QM$L8?:<CU!_SFB*&.!2(U"YZX[_Y_
MK[T /Z?Y^E &1D#K_G_/X4?Y_P _Y[^]'(X R,\_2@#&UB,S:E:1@D;HVS@]
M1D<5?_LRU88:-6Z8S4.H?\A"V ;GRFXQP>:T?I_G_/'YB@"E_9=D.5MD##H1
M2_V=;G@H",^G^?;\ZN=1ZT8ZX[_Y_K_GN 5/[+M&X*=<?Y_7]:#I]J  $]JM
M^_J<_P!?Z_Y[AYZ_Y_S_ )]P"G_9ML>L>>/\_P OYT?V;;#($?Z_Y]ZMKT8D
M=#],4O\ G_/^?_K %,Z=;'CR^_J:BGT^V%M<?(>(FSS[&M''^?\ /^?UQ%<8
M^S3D_P#/)NIZ<'_/^30!Y]\&@%T[50N2//7DGV-=UIO_ "$=0_WQ_*N*^$ (
ML-5XX\]<'\#7::9@ZCJ!']\?RH U:R=25GU/35&<+*7( XZ5K50EN,:S;VI"
MG?&SY(Y&/3\Z *P)7Q0P ^_;[LX]#BM?/2LN:11XGMDQ\QM7.?8$5J'@ =J
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M<../I5G3!MTNT0=!'QGKUH N=_Q_S_3_ #BC/^?\_P">/R04XX]O\_Y_0^E
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M9Q,!E8AG&* *_P#;<?0QC/MN_P *!K4:*28P._\ %_A6H/H/RH)QV_0?Y_\
MUT 9?]M)C)C7\-W^%-;6XV.55<8.?O>GTK6^HZ\]/K2XX8G'"'M_GWH Q?#S
M!VN9!(L@=@VY?3TK:'0?AT_#_/Y5BZ!S/>G84)<>V:VP<<^G^?Z?YQ0 A%)_
MG_/^?_K.QC\/\_TI* %_"DI<4C<X^E "#./\_P"?\_DOU'^?\G_/;.U)PMU:
MK)*T<+DAMI//Y5)8R+(9A'(SQ@C:6.<_C0!<_P _Y_S_ /6,#'3_ #_G_/H8
M_#_/^?\ .:=^G^?_ *WZ?D (<\_Y]?\ /YT$]<$=?\?\_G65J^J7-A)#':V7
MVF64G +;54=R?\]JH#6]5YW:7;#)[3T =!.HE@=3W4X_S^516=P;BT20XW8V
MN!V8=16-_;FI \:;;Y_Z[U-IFH)#;R))!LD>1I&5'! S[T ;@SC_ #_G_(_$
M/M_G_/\ A^.9_;=OG_52_7*_X_Y_.G_VQ;@9*2#ZD4 :'^?\_P"?Z4@]>_T_
MSZU0&KP'I')^E(-6@)QY; XSR5_QH T!_G_/^?YU%=Y^P7/_ %Q;_P!!/^%5
M/[:MO[DF/J*AO=7@.GW2!'RT+J.1_=^M '*_!XYTC43Z3@9_"NST@DWNI=?]
M</ZUQ?P:_P"0#?8_Y[#^1KM-(_X^]0_Z[?Y_G0!K5DZ;\VL:G(,\L@_0UK5E
MZ0=[7DN" ;AE^N.* $UM3BS=2 4N%;)K3/89S@UF>(]0MM(T2XU.[ ^SVJ^9
M)],UE:-XTAU?1[S5!IMY;06T?FCS4 \U",@K^%  G_(&N1@_\A%QC_@5:GA_
M_CTN?^OJ7^=<='XFM!\-IO$_DRFU%TUP8^C;=V,?6M32_%FGVD&D)<+(LFN3
M/):J%Z GC/I0!V=%<%??%OP_IVK3Z;/!J'VB&4Q$+;D[B#C(]15C6/B?HFBZ
MK_9UQ#?27'DI,5@@+X5AD9Q0!VM%06ERMY9PW**P25 ZAA@@'U%9">,-(D\3
MMX>65OMZKN*E3@_0T ;U%<MX@^(.@^&M26POII/M! 9Q&A;RE/0MCH*LZYXS
MT;0-)M]1NK@O#<X,"PKN>7/]T=30!T%%9VAZYI_B+2X]0TV<2P2<9Q@J1U!'
MJ#6C0!0N-6M[>5HI"0PJ/^W+3GD\58DTVSFD:22UA=F.2S+DFD_LNQS_ ,><
M'_? _P ^E &=?ZE#=VK01 M(Y  XY_SS5^UN8HK6)'<*P09X-8_B6S@MK"W:
M""-'^TH 47![UMV2*UE#D _(.U #_MEN3CS._!QTJM>:Q;6,:2NQ=7<( HYR
M>E7O+3^X/RJ"[LH+J$)/&K*I! QT/K0 [[7#C_6X_"C[7!_SUS[U+Y:XQM'3
MN*7RTS]Q?RH A^UP_P#/4?I2_:H/^>HJ3RU_NK_WS1Y:_P!U?RH C^UP?\]5
MY]JR;6XNK995Q:'=(SYWD$CU^M;1BC_YYJ?PI/(B_P">2>W% &=_:%W_ '+8
M_1S56]UZXLGMP;9)3/((D2)\MDUM?9X?^>2?@N*KW6E6=V8C)'M:)PZ,AP0:
M +,#M+ CLI1F&2I['TJ2F11^5&$!) Z$]:?0 4444 )@<>W2CO2T=\T >*>'
MM?T[0_'WB=]1N!$C7#["?7_(KK1X^\-,>+],_C_A6Y<^!_#UW<RW$VG1M+*V
MYVZ;CZ_6H?\ A7OAG_H&)^= &/)\0/#14XU 9/?!/^>U4+3XFV$"21!(O+C9
MOG9R,^E=0?A]X9(Q_9J"DA^'GAF!]RZ<C9[.<B@##'Q1TO&7:W7_ (&?\_\
MZZ#\4-,/0V[#U$AKIO\ A"_#G_0)MO\ OBD/@KPX?^83;_@E &#I?Q \/1V;
M>??*CERP4 \ _A74:7JMIK5G]LT^42P;BN>G(KG/%OA+0K3PGJ=Q;Z;!'-'
M61U7!!K$^$#M_8S)G"%Y'"X]QS0!Z7_G_/\ GL?:C]/\_P"?R/I1_D?Y_+_.
M*/I_G_/'^<4 ,GFC@C+RG:GKZ?A^/\ZK&_L&(8R@L3PQCI-4&;/CNP_S^M7>
MP]<#L/\ /^?S .>O[R&?6M.$3[MJ.2<$=N*UK!M^GV[[2N8P?UYJMJ$8;5;*
M3>=R(Y!JW8$&QM67D>6.: + X&/3_/\ 3_/90 2,]/\ /^?\\% _R?R_S_\
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M3J9)G80* '#@ 4M(.@QQ2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY"_H:U* "JE@,1R\@_O6Z?6K=4]._P!3+_UV:@##@^:SBZY.HOC/^]6GH/\
MQ[7)];J3^=9=M_QZ08Q_R$G'ZFM70O\ CTN/^OF3^= &I1110 4444 %%%%
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MHPW(5G"^O:M3H,"@ JK9J%23'&9&./QJU5/3SF*8\\3/F@#"MO\ CTM^,_\
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MY^Q7X^J4H^*^B_\ /E>_]\?Y_P BNU_LW2S_ ,NEK_WP*;_96DGK9VO'^PM
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M7\JFHH A^R6__/%/RH^R0?\ /)?RJ:B@"'[);_\ /%/RI?LL&/\ 5)^52T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>gcilxvfwaiqx000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +# :$# 2(  A$! Q$!_\0
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MJ.XD,5O(X9%*KG=(<*/K[4 245S'_"03?]!7P_\ ]_V_QH_X2"?_ *"N@?\
M?]O\: .GHKGFU6_6Y2W:]T03OC;&96W-GI@>]4H?$OB1WN(U\)2W0AG>'SX+
MV%4?:<9 =@P_&@#KJ*Y;_A(?$W_0D7?_ (,+;_XNC_A(?$W_ $)%W_X,+;_X
MN@#J:*Y;_A(O$H&3X(N__!A;?_%TU/$OB.5=T?@NY=?5=1MB/_0Z .KHKEO^
M$A\3?]"1=_\ @PMO_BZ/^$A\3?\ 0D7?_@PMO_BZ .IHKE6\1^)41F/@>\(
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MA;?_ != '4T5RW_"0^)O^A(N_P#P86W_ ,71_P )#XF_Z$B[_P#!A;?_ !=
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M ) -O_O2?^AM6K0!E_\ ".:-_P! RU_[]BC_ (1S1O\ H&6O_?L5J44 9?\
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M444 <M>_\@K7_P#K^7^45=37+7O_ ""M?_Z_E_E%74T %%%% !1110 4444
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M;_[TG_H;5JUE>'/^0#;_ .])_P"AM6K0 4444 %%%% !1110 4444 <M>_\
M(*U__K^7^45=37+7O_(*U_\ Z_E_E%74T %%%% !1110 4444 %5=1&=-N1A
MS^[/"9ST[8JU5>^M1?6$]JQ4"5"A+(' S_LG@_0T <5\/&UO[/++J;-'9DL(
M8Y8S$WWC@[3SC;CFNFOY%.N:258-@S=#_L5QG_"H;3_G\T[_ ,$%E_\ &ZN:
M=\-Y]'G:?3-;@LIF7:9+;1;2-B/3(2@"_+XY>&T2XDT6ZV>6CR,KJ5CW@%03
MTR0177 Y /K7A<>AW6F^*Y=/N]?U/4+8Z;=2B*64I&&@8QQDJO!P%!Y'6O<T
M^XOTH =1110!S'BC_CZM_P#K@W_HZ"C4?^1JA_ZZ6O\ *XH\4?\ 'U;_ /7!
MO_1T%&H_\C5#_P!=+7^5Q0!T]%%% !1110 4444 %%%% !1110 5F7&NV-MJ
M(L9&?S<J&(0E4W?=W'H,UIUF7&@:?<ZF-0EB<W VYQ(0K;?N[EZ''O0!IT44
M4 %%%% !1110 444QYHHW1'D56D.$4G!;Z4 /HHHH S;[7+'3KE8+B1@Q 9F
M"DK&I. 6/\(SZUI=1D5G7VB6&HW*7%S$S.H"D!R%< Y 8#AAGL:T>@P* "N9
M\5?\AGPC_P!A@_\ I+<5TU<SXJ_Y#/A'_L,'_P!);B@#1\.?\@&W_P!Z3_T-
MJU:RO#G_ " ;?_>D_P#0VK5H **** "BBB@ HHHH *R]=NM0M[:WCTO[*+NX
MG$2-=*QC7Y68DA2#_#6I5'4[2>Z2W>V:-9K>82J),[3\K+@XY_BH Y2VNKF;
MP_K*WTUO+=O<I,QMH)(X]I94&-Y)/,;<UW-<9]E\C1=:,D:),ERD)\N5V4J&
M5QC=TYD;@<5V= !1110 4444 %%%% !1110 4444 >1ZI_R/S_\ 8(U/_P!'
M/7K2?<7Z5Y+JG_(_/_V"-3_]'/7K2?<7Z4 .HHHH Y;Q:YCECD$4TNRV=BD$
M32.0)H"<*H)/X"H4FG\0:F]_I<$T2PM ?^)C:S6V[;YNX .H)^^O.,4_Q?;0
MW-Q;+/&'5868 ]CYT(_D36P?#FCGKI\/Y4 )NU__ )Y:;_W\D_\ B:-VO_\
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ME>O)]Q?I7DNJ?\C\_P#V"-3_ /1SUZTGW%^E #J*** .8\4?\?5O_P!<&_\
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M@93]F'[U=K_,W(R#Z^PK0HH BMK:&SMTM[>,1Q(,*HZ"I:** "BBB@ HHHH
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M^T+\@'6C0C;^=8@&Y\[RQP3\F?(BSVZ8Q^.:Z.XM+:[55N;>*8*<@2(&Q^=
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M/_9S]2:N_P!K>-_33/\ P577_P 77=T4 >>WMWXTOK&>TD_LT)-&8V(TJZR
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M:[9+G3@DD86(&2ZR&]\28Q],&J\>A^*@UJ6N]+PAS+B6\Y&<\?O?3US7944
M<;_8GBK^S'A^UZ7]I,X<-YMYMV;2,?ZW=G..^/;-69](\1/<:FT5SIXCF4"V
M#27.5.Y3\V),#@'[N.W;(/4T4 <[#IFNI<::TEQ8F.&!EN0KW&6?!P5S)@C)
M'WLGWZ5F'0O%ODS*+S2M[."A\V\P%YSG][G/(Z<?I7:T4 >:WNG:]82:JL;:
M,7F:WGNIFBF:1T)"J@8MG@HY&<CY_K7I5<OKG_'QJW_7K:_^C7KJ* "BBB@
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M:V?S'_=VQ4IC/7CC-:U8/A"2TET(-91210^=(-LC[SG//-;U !1110 4444
M%(?NGZ4M(>AH \-MH-*N-?\ M3-JDGV=K,R6UO8WK)&%0&0,J1E'WX)!)P0:
M]A\/QO%X?L$D1D=8%!5P01QT(/2LGPHLZZAJGG6]A$ICM-IM2A9OW"YW;2>
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ME/&@RS1L /4D5P&B^&;EM+\.V<VF7EA<6FGB&XGWQ[4D$*KD88D\@]J]%HH
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M=-ILNHZL+"WFB=8[/S6DD#!OW"[ ,=,+@'WKKJS;72],T@R#3[&WLWNGW/\
M9X@GF/\ WFQU/N:T(PXC42,&<#YB!U- #J*** "BBB@ HHHH **** "BBB@
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M6/RU#=."<_C7TG0 4444 %%%% !1110 4444 %%%% 'D>J?\C\__ &"-3_\
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MR3-*_F@NX8#=S@>U+J-Q#'_PE$;S1K(UL,*S@$_NCVIO@6!+?3IPB; S*V,
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M)K">.$*9&0A0W0GWKG=&MKR'7X%N8(4:/3(Q(#(7=6+N2%/3:.GX4[[->?\
M/KK_ /X'1?\ Q=1#3K@737 L]>\UD$9/VZ+H"2/X_<U1D<%XK_Y++<_]>5O_
M .A5[57G6I^%K8W-WK4NE:RU\8 GG27L9VA>1QOJ_=VVN_VGIWV6VUK[%OD^
MV[KV+=MV'9M^?^]C\*74T?\ #7J_T.VHKG/L]UO'^CZUCR\?\?D>,X_WNOOZ
MU'>V^H_V4!:V^L_:0DFP?;(\AOX=QW8(STIF9-KZEK^ ^0TG[H<@GC]_#_\
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M#,T$@>Y6-ED7JI#,#QF@#MJ*X634UCGEA^S>)W>)MC^7)O /ID$CO2?VH/\
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MD5QHUS=R(7)4RACAL=,U[&GW%^E>;>+?^2EQ_P#8N77\S7I*?<7Z4 .HHHH
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MC_TH@KIZYCQ)_P A*W_ZXC_TH@KIZ "BBB@ HHJ*YN([2UDN)FVQQJ68^@%
M$M%97]M_]0O4_P#P'_\ KTR7Q D$+RRZ;J21HI9F,'  ZGK0!L45E?VYD9&E
MZG_X#_\ UZ9+XAC@3?+IVHHN0N3!W)P!U[D@4 ;%%97]M_\ 4+U/_P !_P#Z
M]07GBBVT^U:ZO++4(($(#2/!@ D@#OW) _&@#<HK*_MO_J%ZG_X#_P#UZ1M?
MCC7?-87\,8^]))!A5]R<T :U4M3U6STBV$]Y.D:LP1%) +L>BKZDU=K,U?P]
MI.O?9_[4LH[G[,Y>'>3\C$8R,'K0!%8A3>/J%[>0^>Z[4A60;8E]/<^IK8KS
M;XC^'-)T;X?:S?:?9K!=1VY"2!V)7/!QD]?>O18/^/>/_<'\J )**** "BBB
M@ HHHH **** "BBB@ HHHH \0^+'_)6_!GU_]FKV^O$/BQ_R5OP9]?\ V:O;
MZ "BBB@ HHHH **** "BBB@ HHHH \T\6@GXEQX!/_%.773ZFO24^XOTKE_^
M:KC_ + 9_P#1]=50 4444 <WX]U9-#\%:AJDD+3+:^7(8U;!;$B\9JSX0NA?
M^%;"]5"BW*M,$)R5#,6Q^M87Q@_Y)1K_ /UR3_T8E:?P^_Y)_H?_ %ZK0!TM
M%%% %34["+5=)O-.G_U5U \+_1E(/\ZJ^&;^74_#=A=7'_'T8O+N!Z3)\D@_
M!U85JUS^@_Z%KNO:4>%$ZWT(]$F!W?\ D5)3^- '04444 <QXD_Y"5O_ -<1
M_P"E$%=!>RO!87$T8R\<3,H]P,US_B3_ )"5O_UQ'_I1!73T </+XBFAN] 6
MVUD7DE]>I!<6Y2/Y%:-V)&U01@J!UKM(':2,,Z[34E% !67XDX\-:B?2W?\
ME6I6;XA5G\/:@JJ68P-@ =>* .7_ .$KL_\ H/:I_P" ,?\ \15/5?$UK/I%
M["FMZH[O ZJILD^8E3Q]RNT_X2'1O^@K9_\ ?Y?\:H:UKNDS:%J$46I6KR/;
M2*JK*"22IP!0!S$_C-##;Q6.NWBR/)M9[BQ4X4*3P HR<@5%<>+(KJQ83:M>
M221W4>Z.*T4(P612?X<C@'C.:ZV>]\.W<,"R:G;QF([U:&Z\M@VTCJI!Z$U5
MO]0T2#1S;VFHV[DW$4C9GWLQ\U"223D\#K[4 /\ ^$]T3^]=?^ [5S_C;Q;I
MFJ>$[NTM!=/,[PE5\AAG;*C'] :[7_A(=&_Z"MG_ -_E_P :YOQYJVG7W@Z\
MM[2^MYYFD@*QQR!F($R$\#T )_"@!][X_LOM,$-E*%W!R[3VSGIC& ,$]35*
MY\=:?J>ARV<A<WDP9 8X6$9(? Y/3@#/I717M]X>OI(I)=6A22'<$>&\\L@'
M&>5(]!5+4+G1%\/SV5A>6\TI4B-1,))&+-D\YR2230!U=4-7UBUT6UBN+H2E
M99X[=%B0NS.[!5&![FK]<OXY_P"/#1_^PW8?^CUH Q/BAJBW7PVUN(6=[$3;
MGYI;<JH^I-=_!_Q[Q?[@_E7'?%K_ ))?KG_7#^HKL8/^/>+_ '!_*@"2BBB@
M HHHH *@N[RVL8?.NIXX8\A=SM@9/05/7'_$.1H=.T613AEUJT(.,_QT =);
M:MI]X<6UY#*=VW".#SUQ5RO+/#LTD_BW6II;DO,=1M_-959=ZBVCP2/KTS7;
M^%)WGT<EYGFVS.JNXP2 >#2U W****8!1110!XA\6/\ DK?@SZ_^S5[?7B'Q
M8_Y*WX,^O_LU>WT %%%% !1110 4444 %%%% !1110!P^IZG'IGQ2622-W!T
M"5\+C^"7<?T%=N#D ^M>:^+?^2EQ_P#8N77\S7I*?<7Z4 .HHHH Y'XGZ?<Z
MK\.-8L+*,27,Z1I&A8+D^8O<\"KW@>WEM/!6E6LZ[9H(?*D4'.&4D$9^HJ[X
M@_Y TG_76+_T8M'A_P#Y T?_ %UE_P#1C4 :=%%% !7/ZG_H/B_1;[I'=K+I
M\OU(\V,GZ>6X'^_705A^+X))/#-U/ A:XLMM["HZL\+"0*/KMV_C0!N45'!/
M'<V\5Q"P>*5 Z,.X(R#4E ',>)/^0E;_ /7$?^E$%=/7,>)/^0E;_P#7$?\
MI1!73T %%%% !1110 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]
M!^5+10 FT>@_*C:/0?E2T4 %<OXY_P"/#1_^PW8?^CUKJ*Y?QS_QX:/_ -AN
MP_\ 1ZT 4OBU_P DOUS_ *X?U%=C!_Q[Q?[@_E7'?%K_ ))?KG_7#^HKL8/^
M/>+_ '!_*@"2BBB@ HHHH *R?$&AC7;:TB-RUNUM=Q7:.J!LLAR 0>QK6HH
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MN5\1:9H[R:W=7%E.][]JRDR7$HZ;/E #;>F:[7P<XD\.0L,@;C\K9ROL<]Z
M,'5O'X@N[2%+>^LEE60LT]H"6V[<  L/4Y_"K&A>/!J,-LCZ=?RM([I]H2WQ
M&<.0#U/8<UV$D$,Q4RQ1R%>FY0<4Z...) D:*BCHJC % #JY?QS_ ,>&C_\
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M@_\ B:AO-5U:SLI[I]&B*PQM(0+P9( S_=H VZ*RA>ZP5!_LB'D9_P"/P?\
MQ-07FK:M9V_G/HT1&]$P+P=68*/X?>@#'U?0M4F@U;[-I]M)-/,9()FNV4@?
M*>5VXS\IK>\-V,^GZ)#!<@BXY:3+;N3[T[[9K'_0(A_\#!_\36=K?B/4]#TB
M;49]%C>.)D4JMX,G<ZH/X?5J=P.EHK+-YK&?^01#_P"!@_\ B:ANM6U.RM9+
MF?28Q%&,L5NP3CZ;:0&U7+^.?^/#1_\ L-V'_H]:ZBN7\<_\>&C_ /8;L/\
MT>M %+XM?\DOUS_KA_45V,'_ ![Q?[@_E7'?%K_DE^N?]</ZBNQ@_P"/>+_<
M'\J )**** "BBB@ HHHH 1ONGZ5YE(EOML(7TZV>(V5NY<I@[V*C=D=AGI7I
MK?=/TKSV739?L>DZE+)_H8MK:,H&P2V5Q0!'JMO9R1W$+6<,8-]+$6B0;E C
M;!''Z5N?#S/_  BRDH$8SR%AMV\Y]*9IJB.\NC+$)&?4VV# ^7KSSGMZ8K9T
M/[NH?]?TO\Q1H&IJT444 >(?%C_DK?@SZ_\ LU>WUXA\6/\ DK?@SZ_^S5[?
M0 4444 %%%% !1110 4R4N(F*%0^."_0?6GU7OK.._L9[289CF0HW&>#]: ,
M[SM8_P"?W2?^^'_^+H\[6/\ G]TG_OA__BZY'_A2WAC_ )XI_P" \?\ \31_
MPI;PQ_SQ3_P'C_\ B: )?$&FSMKBZS=7EM),=,NK18[=2!MV,^>23GC%>@)]
MQ?I7CNB>&-'TO3[J\MK"W2\BN=4L_M"1A6,<?F*HXXZ 5[$GW%^E #J*** ,
MSQ!_R!I/^NL7_HQ:/#__ "!H_P#KK+_Z,:CQ!_R!I/\ KK%_Z,6J&C:UI=KI
MJP3ZC:Q2K+*&1Y0"/WC=J .BHJ"SO;74;5+JRN(KBW<D++$X93@D'!'H01^%
M3T %%%% !7/^'/\ 0]0US23P(+PW,(_Z9S_O,_\ ?SSA^%=!7/WO^@^-M,N^
MD>H6\EC(?61,RQ?^.B?\Z ,OQU=S67E3P",R[(D7S =OS7=NO..>]=!IUU?O
MJ=[:7IMF$,<3HT",OWM^<Y)_NBN8^([!+:-R&(7[.<*,D_Z;;=!W-;-O=->Z
MEKAMH[B.46D*IYL31G=^]QC- '145P\D%Z]WH L/[:66.]1KXS23",Q"-PV=
MQP1N*UVL2ND85VW,.] #ZRO$N?\ A&=2QU^SOC\JU:H:W;2WNB7MM"@>66%E
M52< DCI0!YYYOC3_ *%NT_\ "BE_^*JIJDGC Z1>"3P]:I&8'W-_PD$C8&#D
MXW<_2M+^P;?_ *(_I?\ WW9U!>>&X[BQN(8?A'ID4LD;*D@DM!L)& >/2@#*
MU.]\;06UJLFGVNGQ/-@RC72=WR-A26)P._X"HVNO&5SI+M-I5M<J;I LYUQA
MG]XN  I"XSWQ[UT0T6,0>3_PJ/3O+R&*^;9X) QGZU!J.@&^C8CX4:<)FD1F
ME,MID@,"1GKR 1^- #3+XTS_ ,BW:?\ A12__%5C>+9?%I\*7B76@VL-N7AW
MR+K;RD'S5QP6[GC]>U=!_8-O_P!$?TO_ +[LZH:YX8GU#0KBPT_X7:?92RO&
M_F+-:C&UP3TYZ;A_P(T 5M:U#QK%?6XELK735D60-_Q/>'QMQDMG:1[8SDU'
M8W/BZXTA'O-.@ELRS"2\_MAG;:'/.P'#8X XYZUT)TO=)(Y^$VGEI%V.?-M,
MLO'!]N!Q[5"?#PEPEO\ "_3M.F)&R\22UW0G/WAMYX]J /3*S-<T:/7+2"![
MB6 P745TDD04D/&X9>H(QD5IT4 >>?%&RNX?AMK;RZI<7""W.8WCC /_ 'RH
M-=_!_P >\7^X/Y5QWQ:_Y)?KG_7#^HKL8/\ CWB_W!_*@"2BBB@ HHK,L=?T
M_4;QK6VE9IE!8@H1P&*G]0: -.BBB@!&^Z?I7)W3!? &G$HC_);8#],Y6NL;
M[I^E<NZ1R>!M,$D;OA+<J%QD,"I!Y]#0!6V1G4HBQ8L-5.T*W^R>N[/;L,5N
MZ']W4/\ K^E_F*YW9"-3MMD<CD:Q(7>1Q][:W3V'I71:']W4/^OZ7^8H U:*
M** /$/BQ_P E;\&?7_V:O;Z\0^+'_)6_!GU_]FKV^@ HHHH **** "BBB@ H
MHHH **** /,[7_D"ZA_V%-9_]"FKTI/N+]*\UM?^0+J'_84UG_T*:O2D^XOT
MH =1110!'/;PW4#07$22Q/PR.,@_A6!JNDZ1!:2);:3;/<N-JB.W#%,_Q$ =
MJZ.LN99-+N);M &LW^:9>\9[L/;'4>U $7A305\,^&K32$N9+D0;R9I$"LY=
MV<Y Z<L:V:@L[VUU&SCN[&YAN;:49CFA<.C#IP1P:GH **** "L#QBC+X=EO
MXU)ETV1+]0!R1$P9P/J@=?\ @5;]-DC26-HY%#(X*LIZ$'J* .$^(<L?V.";
MS%\K%N^_/&W[;:G.?3%='IEY;7GB+5&MKB*=5@MP3$X8#F3TKS_5OG\)6NG7
M/[Q[!X]/E#\[A'?VR G_ 'D"M_P*N^TFPL]/\0:HEG;10*T-N6$:X!.9* -R
MBBB@ HHHH **** "BBB@ HIDDB0Q/+(<(BEF/H!6+:>,-&OK+[9:RW4MN-V7
M6SFP,=?X?:@#=HK&/BC3 D+DW>V<@1G[%-\Q(R,?+Z42^*-+@N+6"9KJ)[J8
M00F2SE56<]%W%<#.#UH V:*** .*^+7_ "2_7/\ KA_45V,'_'O%_N#^5<=\
M6O\ DE^N?]</ZBNQ@_X]XO\ <'\J )***B=G+&./ 8#)8]J ):X#PQG_ (2L
ML9U8&.X CS@C$@_/K6Y9ZC=MXYU?2R[/##8VDT0(X5F:8,<^^U>/:ECAC@\:
MHJ$AC9$LHX'W^N/?F@#HJ*** $;[I^E<K.47P#IY=-W[NWVC&?FRN/UKJF^Z
M?I6#9V+ZAX1TN!)?*_=0.QQG*C!(_$<4 1ZO MI?Z3]F!B$]]NF*@_,=IZGM
M5[0_NZA_U_2_S%1ZW'&U[I#2%QLNOE"C@G:1R>U2:']W4/\ K^E_F* -6BBB
M@#Q#XL?\E;\&?7_V:O;Z\0^+'_)6_!GU_P#9J]OH **** "BBB@ HHHH *9-
M-';PO-*VV-!N9O04^HKE96MI%A"&4J=OF#Y<^_M0!B?\)OX<_P"@HG_?M_\
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M-TBXDMKRSMX3@0LP:-I3R&D7 _>#U[U7^V^,3?+?'P_=_:1&8]WEV^ N<_\
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M]NMG$3';+ A/S%8P!GWP*L4 %%%% !1110!F>(=.?5O#U_8Q-MFFA80O_<D
MRC?@P!_"I=&U%-7T2QU)%VK=0)+M_NE@"1]1T_"KU<_X7_T235](/'V*^=HA
M_P!,IOWRX]@791_N4 7]9UW3/#]HEUJETMM#)((D8J6W.02   3G /Y50T[Q
M;IVM7*#2ITNH!)Y4K@,I1\9P0P!Z8/X]JH>/))(3X;DB1WD76$*JG4GR9N!7
M,^%II[KQCJ$URDD<YU7,B2$;ES:P<<8]/3TH ]5HHHH **** "BBB@ HHHH
M**** "L9K5+B_O6:"*<Q3(P210<YC .,]ZV:HV?_ "$=1_ZZ)_Z *3W1I#X9
M>GZH(;/3)55XK2UY&1B)<_RJ]7GGQHGFT_X9:E=V4LEK<K)#B:!BC\R*#R.>
M]>@0DF",GGY1_*F9CZ*SM1UA-.N+> VMU.\^X@PQ[E0 9)8]AV^IHTK5X]6^
MU".VN83;2^4_GQ[=QQG*^HYZT :-%4M3U)-+@CE>WN9_,E$2I;Q[VR<\X]..
MM5['7(K[4Y; 6EU'+'$LI=X\1D$D !NYRIXH S=?\>Z)X;U=-,U W7VEX5G
MAMVD&TLRC)'3E33H+FT\;:)%>V22PQ^;(L-PQV2Q.CE"0!GC*GJ<'N*B4D?$
MC5\'_F!VO_HZYKC_ (82>*KOPF\>F7NC06EO>W,:+<V4LDAS*S$EEE4=6/:@
M#UD=.3FEK*T&\O+C3A_:<MJUZLTL3&V0QHVQR,A69CT [FM6@ HHK!U6\U>>
M_M[/0KK3HV>%YGDNH7F4@$# ".O][KD]* -N4Q!,2E K?+ACP?:L^T>2UO/L
M0;SH""Z,#DQCT/J/2O)/B?JOB&RU?PCH^K7-A,+K58IUDL8)(<!&"E6#2-N!
M\SVZ5[8J(@PBJH/H,4 .KF;8G_A+I/\ KO-_Z)@KIJYBV_Y&^3_KO/\ ^B8*
M -K2O^/(_P#7:7_T8U7:I:5_QY'_ *[2_P#HQJNTH[(TK?Q)>K"BBBF9A111
M0 445'<.\=O(Z#+JN0-I/Z#DT 245S']M:Q_S[#_ , +BC^VM8_Y]A_X 7%
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M_P#A7^N_]#Q>_P#@!;?_ !%'_"O]=_Z'B]_\ +;_ .(KT"B@#S__ (5_KO\
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MJ 7)'Z&KE%%"5E8F<N:3EW"BBBF2%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7/>+O]&L;+5QUTR\CN&/I&<QRG\(Y'/X5T-5[^
MRAU+3KJQN!NAN87AD'JK @_H: +%%8_A6]FO_#-C+<G-U&A@N3_TVC)CD_\
M'E:MB@ HHHH **** "BBB@ HHHH *Y>;_BK-8:V'.AZ?-^_/:[N%/^K]T0\M
MZL /X6!L:[?7-W=IX?TJ5HKR=-]S<IUM(,X+?[[8*H/7+=%.=BQL;;3;&"RL
MXEBMX$"1HO8#_/6@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ'TCU2R69?3S86VO^)62/_OBNAKGO%7^BC2M7''V"^C,A_Z92YA?/L/,#?\
M * .AHHHH ***JZCJ%MI6G3WUY)Y=O NYVQD^P ZDDX  Y)(% %/7M8?3+>*
M&TB6XU.[?RK.W)P'?&2S>B*/F8^@QU(!DT32$T:P\GS6N+F5S-=7+C#3RG[S
M'T[ #L  .!5+0=/NI;B77M6C*:C=)LC@)S]D@SD1#_:/5SW;CHHK?H ****
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MG_MGC#_H!:'_ .#F;_Y%H^V>,/\ H!:'_P"#F;_Y%H Z"BN?^V>,/^@%H?\
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MP_Z 6A_^#F;_ .1: .@HKG_MGC#_ * 6A_\ @YF_^1:/MGC#_H!:'_X.9O\
MY%H Z"BN?^V>,/\ H!:'_P"#F;_Y%H^V>,/^@%H?_@YF_P#D6@#H**Y_[9XP
M_P"@%H?_ (.9O_D6C[9XP_Z 6A_^#F;_ .1: .@HKG_MGC#_ * 6A_\ @YF_
M^1:/MGC#_H!:'_X.9O\ Y%H Z"BN?^V>,/\ H!:'_P"#F;_Y%H^V>,/^@%H?
M_@YF_P#D6@#H**Y>[USQ)IBV\]_HFE+:R7=O;.T&JR2.OFRI$&"FW4'!<'&1
MTKJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MG_'?_)//$W_8*NO_ $4U=!7/^._^2>>)O^P5=?\ HIJ .@HHHH **** "BBB
M@#F/#'B:_P!>U76K*ZTRVM%TNX^S-)%>-,9'P&X!C7 P>N>O;O4\?BW3UU75
M+6]N].M+>SFB@CG?4(B99'4DJR9S&P(( ;EL$BN:M?#WC6P?Q.;2+18I-;N&
MFCG&HS;K7*!,@>1\S#&1R.:H>)/A]XAUB^\5R0KI+0:U=6,L:S7,@VI;@ A@
M(B,M@<<XR>N.0#T&U\1:'?300VFLZ?<2W&[R4AND=I-OWMH!YQWQTK'MO'^C
MBU@FU&\L+3[5?R6=IY=_%.LP4X#[E.%&,$@_=W 'DC/*:=\/O$EIXHAU)H]&
M6$:_/JLC1W<GF>5(@3RP/) )4;CU .<<9S4NG> /$-G+IUVXTHW%IKMQJ3(M
MS)M>*4-\N[RL[E+=,8/J* /1$UG2Y+JZMDU*S:XLUW7,2SJ7A'7+C.5'UK$\
M.>,X?$7B/6=,MH[62WT]89(KVUNQ,EPLF[T4 $;<'!//?BN1'PJOGL=>LIKF
M#?>"Z%K?F[G=PLSARC0G]VGS ;F7); X!K?\(>&=:TKQ9K.L:G#ID4>HVUM&
M([.=Y"KPJ5R=T:Y!!S[8QSUH FD\9ZA?:OK-AX<T2+4?['^2YDGO#;AY<$^7
M&!&^X\8).T9_.K^F>.?#NI>&['7CJ=O965[E8C>RI"=X)!0Y.-P(/ )_*LF/
MPUK_ (=UG7[OPW_9MQ#K+_:?+OIWB-M<8P6&U'WJ3SCY>F,UDVGPPN-!AT"+
M36L-4@L+6XM;NVU/<D<XF.YG "N =P'RD$$<9[T =_-KND6U^UA/JMC%>+&9
M6MWN$60( 26*DYP "<],"H$\4^'I%9H]>TMU6 W!*WD9 B!P9.OW<\9Z5S^E
M>$-0TWQ/J=S+'I5U97ES]KCN9%;[1:N8O+947! &  "'&!D8-<;;>!M<\*Z5
M->:E/I7V'3O#EYIQ>.X?>VYFD5\,@ R2%VYXZY.<4 >JVGB30K^WNKBSUK3K
MF&T3S+B2&Z1UA7!.YR#A1@$Y/H::OBCP^UI#=KKNF&VGE\F*87<>R23^XIS@
MM[#FO+?"OA;6->\'1:M9R:*K3^&X-+LT<_:(G97+,\RE-H92-NW#X.<^E7(_
MAMXA&FR64ITN2.7Q%%K#"2\ED_=@#=&2T>6/&-QQGK@=* /26\1:(FDIJKZS
MIZZ;(VU+PW2"%CDC ?."<@CKV-1/XK\.QF</K^E*;=%DF#7D8\M6( 9N> 2R
M@$_WAZUPEGX \16]GITDATF:YL-6NKP6CW$A@GBG# JS>7D,-S ?*P_/%:<&
MD6%U\0+/[#<06]UIEBMKJUG:Q%(M@\N2!0",  G@CJ R\8(H W?%/BA?#KZ;
M ([5IM0G:&-[VZ^S0(0I;YI-K8)Q@#')-2)XNTNVM(I-=N;70[F0R8M=0NHX
MY JN4#=<$' .1D<CDTGB?2;K5[>.W2RTO4+/:_GV6HY5)2=NTAPK%"OS'.#Z
M8YW+YEJ&E7/ACQ%\/-%CFT^>^B34Q'!=7;"*,2J D8<JSE0#L4E<MMQ@9X /
M6[KQ!HME]E^UZO86_P!L&;;S;E$\\<?<R?FZCIZBI'UC3(]5CTJ34;1-1E7?
M':-.HF=<$Y"9R1@'MV->5ZW\*_$5YX7T[0[*\TLI;Z4MJ]Q*SQR^:)1)]Y4+
M-%Q@(2!DAB"57'3P>$-43Q1J][,FF36NJ/'<">1F:XL95B,;"/*X;C 5LH0"
M>#TH Z^QU73M3,PL+^UNS _ES""99/+;^ZV#P?8U;KB/A[X,NO"=J8[U;=KA
M8$MOM$5Y/,9D1F*DK)\L0&X_(H(R3SVKMZ "BBB@ HHHH Y_QE_R [;_ +"N
MF_\ I;#705S_ (R_Y =M_P!A73?_ $MAKH* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K#\9P377@7Q#;V\4DT\NF7*1QQJ69V
M,3   <DD]JW** .?_P"$RTO_ )]=<_\ !#>__&:/^$RTO_GUUS_P0WO_ ,9K
MH** .?\ ^$RTO_GUUS_P0WO_ ,9H_P"$RTO_ )]=<_\ !#>__&:Z"B@#G_\
MA,M+_P"?77/_  0WO_QFC_A,M+_Y]=<_\$-[_P#&:Z"B@#G_ /A,M+_Y]=<_
M\$-[_P#&:/\ A,M+_P"?77/_  0WO_QFN@HH Y__ (3+2_\ GUUS_P $-[_\
M9H_X3+2_^?77/_!#>_\ QFN@HH Y_P#X3+2_^?77/_!#>_\ QFC_ (3+2_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>gdzs1tysdsfm000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "> LL# 2(  A$! Q$!_\0
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MN?:F3GKS0]])+Y?F>%YW\KB/<J';]/2G_P#":Z#_ ,_A_P"_3?X4?\)KH/\
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M_P"$WT#_ )_#_P!^F_PH_P"$WT#_ )_#_P!^F_PH]A5\_N#GC_,2_P!N7_\
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M6>M:9#J-A*9;6<$QN5(S@D=#[BKE.S6C-D[H****!A1110 4444 %<9\1?\
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M&)DR IR">/0T <=)')$^R6-XW'\+J0:;6KXCWGQ!=&2:.9B02T?0<=/J*RJ
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MY_\ KT?\*X_ZBA_[\_\ UZ[RB@#@_P#A7'_44/\ WY_^O1_PKC_J*'_OS_\
M7KO*R[J_MKR6XTNRU>*VU*-=S!-CR1#CDJW]?6@#E_\ A7'_ %%#_P!^?_KT
M?\*X_P"HH?\ OS_]>M#P'J6IZQ87]_>WOVNS:[>.QD:%8V:)/E+G;P<L#CV%
M=90!YY>>!([*W,TNIN1D *L'+$] .:S_ /A%)/\ GI)_X[_C7?:__P ><'_7
MPE<AKNJS'3KR#0KA)]6@9-T$(621%W ,=I[XSUK"<I<UDSHA"/+=HH?\(I)_
MSTD_\=_QI/\ A%'_ .>DG_CO^-:N@ZI!>:;<2M?3S-:RO'<-=0+"\1')5E'
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MK;_J*G_OS_\ 7KOJ*/K-7N'U>GV.!_X5M_U%3_WY_P#KT?\ "MO^HJ?^_/\
M]>N^K.UZ[O+#P_J%WI]M]IO(8'>&'&=[ <#WH^LU>X?5Z?8Y+_A6W_45/_?G
M_P"O1_PK;_J*G_OS_P#7K$C\>ZPAFL([Y+N68V2PW<EIY1@:9RK@IQNVXX_7
M-=IX1U:^OI-9L-1E6XFTR^:V%PJ!/-7:K D#@'G'%'UFKW#ZO3[&-_PK;_J*
MG_OS_P#7H_X5M_U%3_WY_P#KUWU%'UFKW#ZO3[' _P#"MO\ J*'_ +\__7H_
MX5M_U%#_ -^?_KUWU%'UFKW#ZO3[' _\*V_ZBI_[\_\ UZ/^%;?]14_]^?\
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MM'M$D1D(\W&><?[.>/6I=)MKNWEOFN8HD$\YF39)NZ@#!X'I3Z[#ZFE4$O\
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M29GDEMK&6.5 ZJ?,"9PK#&".<&J \!:=Y]I+Y\[?9E\M%=$<>6'+J@R.-I.
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MZ&NDHH **** %TG_ )&.[_Z](O\ T)ZZ&N>TCGQ'>'TM8@?;YGKH: "BBB@
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M ,D_^*H\^\_Z U_^2?\ Q5 &3KVAW6IZE8W%DUO:M;LN+H.ZS(H;+( /E96
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MC_A'7_Z#%_\ ^0__ (FMRB@##_X1U_\ H,7_ /Y#_P#B:/\ A'7_ .@Q?_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>gvxjy5si4hmk000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> 6D# 2(  A$! Q$!_\0
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M;U_E[=JF\]E($D+J#W4;A^G/Z4 3T5''/%*,QR*V!D@'G\J>K*ZAE(*D9!%
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MU58G,:9;T+-R?\^]27!W%(MP&Y@3GT')_EBBU!,9D.<R,7Y[>GZ8H GHHHH
M**** "BBB@"*+^$\8P>@XZU+4,42(V4R,CE0>,^M34 ->-)!AT5A[BLK5/.L
MS8_9)V@\V[2-QY9D#*<Y'^S]>@JY<17DDG^C7,<*!2#NBWDG\Q@?YXJI/IFH
M74]JTNK%(X)UF9(8=ADQGY6.X_*<\C':@!#?6L[D,T,Q#^7D HV[CC/Y'KZ5
M)'+Y<DD/G2PD'<!<#<,$] ?8^_>M'RXQ_ OWMW3OZ_6J\UBD]];7;2SJUN'
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MIFIZJ7$GSE@,F)"0!S\S<#_/O0!);C<9).S/\O'8<?XU/3(HQ%$D8Z* *?0
M4444 %%%% !1110!DVA'_"1ZBN0<00<>GWZU=J_W1Z=*@AM+:"62:&WACEE.
M9)$0!G^I[_\ UZL4 )M7^Z/RHV+G.T?E2T4 1.B!0 B]>F*9<7%O8Q>;,Z11
MDX+$8'XU*XR >>"#BL2[TR675KZ:4^99RP1".&YEW0>8&8L?+[<!/KDT 9VN
MIM\;^'9DC#)'#=O)$DN'8%5!(B_Y:<D<]L_[5=-8LKV<;I'-$K_,(YEPR9YQ
MCM]*P;H/)J6CS6CR3)!"WF^2JJFWY#@@?.&(!VJ, \YZ"MVP>:6!I91(H=R4
MCE0*R+TP<$^A/XT 4[NUNFDO)P5W?*MN68X5,#=D#_@57K:&/[)"/+3&P#[O
MM44DEREVT9MI)(I" LB%<1C'.[)SU]!_*K<:[8U4=@!0!6N(?,=(E1-C9$HS
M@E<>WOBG6$4D%MY4G\#L$R^[Y,_+R>>F.N:9=3F*X0+!),P0MLC(!(! [D#O
MGKVJ2R%QY&;GAV=B%P/D7/"\=<#O0 7GF>1NB+ED(<H@&YP.2HR0.>E9-D9E
MU&P,D31BX@>01-_RP^6/]WC'&#FMFX0/"<QJ^/F"L<#(Y'ZUSFGR7<D6DWEV
MQ$\UJ\GEE@63*Q9 (&#R">G\6* -+5B);JTM3MVEO-DW XPO3D=.2/R-2\RK
M]W>,YS_K0/Y,*=:!YM1N;ED=5 6*,,A4E1SGD>I-37D:?9Y)1%OD"DKM!W$X
MQVYH S=(M8IY;R] V^8_E1M'(V-J<?SS^5)!'<RSW5RKF6-WV+YB!OE QV/<
M\]/6I89OL>DK!&MP\R18#-!)\SXZDX]:T+*#[-9Q0X^ZO/U[_K0!B7.+2RG:
M*)[=CD#R9/EWGC[K#CGVI-MW=:>(M)N+8M9R% I!3YP,8)P1CYL]/3I6CJ,F
M+JU5HY6B5C(Q2)GP1T^[D]:CTZ&*6;4#)&&/VQB"1R/E2@"Q;7,<,0@E\Q7B
M 5F=>I]>/7FG2V&GWP622VMYB.5?:"1]#4@M3$28967/4-\P/Y\_K44L!)W2
M6X+'CS(&PP]^U &)J_A WD*BSOY(Y$DWH+K,Z+D<@9(8?F?I5*.RUJS<V,B1
MF'S%<7(N-S!<C((//S,B* .,$UTIG\A#MN"S*N1%,,,WL"<<_P"-1;;S[=OG
MA_<$J2%._& ?Q^]SWH OPJ(E6($GRU"]/\_Y-357MIXG4E9@Y8E@.^/IUZ5/
MG_.* %HHHH **** &2<H5X^88QG%.  &  /I49!:9#M!"C.[/>I: $W?-C';
MK2T44 %%%% !61:S/>7TR^2%ACGSYF_._:!C\B:T;EVC@9DV[^B9_O'@52T:
M!X;7;, )5)5RO=LY)'MD_I0!IT444 %%%% !1110 4444 01A8=P6.098L>_
M)_&HI[[R;BUB^RW4GVB0IOCCRL?RDY<]AQC/J11=ZC;:>@>Y9U786^6-GX&,
M_=!]13/[7LC)Y6^3<9#%CR'QN W'MZ=^E %X=!2U175[1U!1I3D(1^Y?^,X7
MM_\ J[XJ*]U)UM'>R17N K,JSK(JD*<'E5)^@QSVH T) Q "@'+#=GTK.\0-
M"NCRFXW^4",E$#D<\':0<\]L5F?VUK=I/ -0L+,PO.ENQM99G=2Y #?-& 5&
M<DY['N*W+QP84BS('D?8IC;!!P3D'\#UZ]* .=NHK>#5[.><6Z1LDSAF5CB,
M"/*[C\J \94\GC!X-=)8):I9HMDL*VV,QB$ +CVQ6#J40&M>'K>6=HF1)6VB
M[*B1E\OY2O\ RTZ]^GXUTD9SOX(^8CE<4 9>H.;6[W>2MPUT4B56G5 @!]"?
M4_P@G]*UZI7%A%//)*\43L\8C!8'<HR>A_'L!_@"^VOY7V6YW!<@;1R!^/N*
M *6KW1L]3LYO($R[&5E,JH1EE&1N(4X]"<^E:-C"]O9I$Y!*DXVDD 9) Y]!
MBJ9C^WZG#-)9-Y*P.I\]1C)9"..?0]JOVD)@M4B.,CJ%Z#G.![4 -O!,8E,&
MTLK996. PYXSV]?PK T:%_L^ABX+;WM9&"JV0H(0XW<>W^>O3-]T\9XZ>M8K
MRD7VCRM!Y3?99"81QLR(^/PZ=J -NBBB@ HK.CU'?K<FF^5C9#YHDWYSR!C'
MXBK<UPD2ON5R5 .%')SP,>^: )N^*J6,<4;WGE3>86G+./[C8'R_EC\Z@>XO
M1>VL6V-5E)+YY*@+TZ]<]\8J:QDCDDO/+A\LK<%7.<[VVKS_ "'X4 7****
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M )Q31:2;YB;RX82@@*=F(\_W<+G\\U!'I<T:!1JU\0.F1%_\10!H]\50 /\
M;['/'V48X_VC4D=E*CJS7]U( >5<1X;V.%K.ATFXC\5W5\]Y<26TL \N)ONQ
M/T.#WX ."#B@#;R/449'J*J_8I=N/[0NNG7$?'_CM/6VD64.;N=E'\!VX_\
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MF/WQR#R?8Y[]*NM=Q#4$LV8^;(C2*,<;5(!_]"% %HXVC@#I3J:3QG/<4Z@
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M%<ZK&.+@19^5N"/^6GKM'IG^&@#I:*** "D(R1P#SWI:0]1]: % P,"BBB@
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MCK77]J@CNHY+J:W ;?"%+9''S XQ^53T %(1G%+4<DBQE=V.6 'U- $E%%%
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M_OX*3[=:\9N8>>G[P5B?\(!X.SG_ (1;1O\ P!C_ ,*/^$ \'?\ 0JZ+_P"
M,?\ A0!MK>6TC*B7$3.3P%D!S4XK$L_!GAC3[N.[LO#VEVUS$=T<T-HBNA]0
M0..M:TQF! @2-CU.]L#VZ ^U $U(W;C/-5"=0W#]Q:;>_P"];ID9_A],_I5O
MTQZ\F@!:*** "L+6W$>N^'F8X7[5+DYZ?Z/(:W:Q-<WQZKH5SY+O#%>E9'0
M[-\3HI/MN8#/O0!L1,KH&4JRDG!!SWI]9TUA,97EMKCRF9A\NTX&/\:8)]1M
M5'FP+*. =@Y[>G8<\D4 :E%4(]6MW!+DQ#/!D&!C'7_]>*N)(CIN5E*]<@T
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M4?#,!GH">:DIC11N<M&C$>J@T -^TP?\]4_[ZIQ()4JP()[4W[-!_P \(_\
MO@4\J $50  > .E #J*** "L_6/^/2'_ *^[?_T:M7]QW[=O&,YS_G_)JAK&
M?LD./^?NW_\ 1JT 7E[\8Y-.IJ]\>IS3J (9[6"Y0K-&&!]:J2:2A;=#(\3;
MBP.2<$YSWSWK1I",]\4 9T":E;R*)66=#M#$ 9'J>W]:TJ** "BBB@ HHHH
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M0E^&!$EJ!E-P\MNG\??J>WIWS5>0ZH/D2YL%?RF(+0O@-NXR-_3:>1Z\\=*
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M]W'.>G7FNEN+2]FP%O(E3.2K6^[/0C^+L1FI/(O=A'VQ-V.#Y/?CW^OYCTY
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M?II=S_\ &ZOC25'_ "^WW'_3P:/[)7&#>WW_ ($&@"C_ ,)AI/IJ7_@JNO\
MXW7-Z3KUK:^-_$M]/;ZDEK>+:"WD.EW/[S8C!L#9G@D=?6NQ_LA/^?V^_P#
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M_P#U4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BD4;1CL.!DYI: "BBB@ HHHH **** "BBB@ HHHH **** $/UQ5-)[
M,S2.LJ^85(8JQZ(3G\B35VB@!BLK9"L3ZBF1LK1*<,H.<#T[5-10 S</1ORH
MR/1C]13Z* &9&?XOUHX(Q\XS]>*?10!$ZHP(.\Y(/4TL1'(&[Y>,GO[U)1B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>gvxjy5si4hmk000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &- F # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **3<H."PSZ9I>HR* "BDR,XR,
M^E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%0_:81((RX#,<+GO]* )J*.U% !112!E;H0?H: %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,2?G7+H'/_ ![#O]:U
M++_CSBS_ ':RY<?\)!<Y_P"?;M6CIK^9IT#>JT 4]0P=9T]<?,=V#Z5J@Y[@
MX/:L75E+:QIV&V$;^OI6T,]Z %I">>AI:P+I9;OQ,+8W5Q%"L&[;#)MR?4T
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M\\_2KE)@<^] %47QQ\]M.G/=:FAG2=24SP<$$8J7O10 4444 %%%% !1110
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MO5B/5]/CU6T5KJ,&..Y60$YV$XP#Z'_"J_\ :VGG1KU?M<9+6D0'!Z[CD=*
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M?UK5AOGFC2=(,Q'.2.H/3I7.Z]JNG7&HZ3)'>1LL%R/,;=P!CO6_HFUM-61
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MR4@C(Y_E7J-<1X/Q_P )GXM'.?M2]?I0!*OPQ\.JI4+=<]?WYI__  K7P]M
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M]11:!XJ6&,)K=@%'(7[%TS^/^>*F^(\PA\*\J&W7,:X)]ZZN'_41_P"Z/Y4
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M- &7;3K=:@LRHZ*\O < $_A_G^M=!5:*PM()!)%;QJPZ$"K- !1110 4444
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M@*;"@3 *^E=[2 @]* .$C\(>);:UAM[7Q(\447"H$Z#T_P ^M/;PIXI+ ?\
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M6L37MI#/<,Q\R-6:/H.F:S?'@SX&U@9Q_HY_F*V--.=,M,]?)3^0H LJ J@
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M/&$E6P ;;TSGG\/RK*\0(+V<I?:>LLD4PACV7)&YO3..E=!X3LY[O63K'DI
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M@DP3C<1UJ\]A=:I'$E^5A@4JQ@3YBV.Q/IGM]*V:0# H %&% P!CL.U+110
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M( Q@D*KC)/2@#:HJ&WN8[F+S(V#)DC/I4U !1110!QWQ-#OX)N5CY8R1C'_
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M_$ @?-^Y_P#UUW(Z<]1UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q[S_D8;3_KA+FI]"XT6TXY*>GO4%V,^(+0]<02U
M/H>?[%M/^N= %+7PWGVQYVX;./PK<3_5KCT%87B!<W-J<CA6_I6['_JU^@H
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M52QQP.YQ5=KRT9=K3QX/49'- %C</4<],4M9MA)MGN(8Y#+"I5E/7;GM6C0
MM<MJI*^.]&"D9:"7(QSV_P Y^E=1D^E<MJ^/^$\T,G[QAE&TC_/K0!U5%%%
M!1110 5P@/\ Q>9@".=.Y%=W7" X^,[#'73L_2@#NZ*** ,[7<?V%?Y.!Y#<
M_A69X".? VCY'_+ 8X]S6GK_ /R+]_SC]PW\JS? 8V^!=('I!_4T ='1110
M4444 %<Q)SX]Z#B!>WUKIZYLD'QRZX&1;H<_C0!TE%%% !1110 4444 %%%%
M !1110 4444 17./LLV>FP_RK@Y[1(_#OA>02RD_VA!\AD^7JW;_ #UKO+C'
MV:7)P-AR?PKSZ2]EET#PO +"=4&H0?O6 V]6]Z /1<'U-'XU'Y\8&2P_ TGV
MF,<%AGZCW_PH XC4MI\?8/)$)X_+_P"M7>#[HSZ5PFHX/CD.HW*83ANW!Z?X
MUW:\*![>F* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,>]Q_PD5GZ_9Y<?I5C1/\ D"VG^Y5:]/\ Q4=F/6WE/\JLZ'C^
MQ;3:<C90!4U[E[?/'WNOX5LKRN?7WK%U['FP''\)K:C.47Z#M[4 .K!O0?\
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MP=AQ^5<@@SX6\-!AG-Y#P?\ @5=?/Q;RD?W#_*N0CX\+^&CZ7L/\VH ZX6T
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M<7Z5CZX2&@ .,DX)-;"_='L/2@!:P;\X\9Z./6"?^0K>K"OAGQEI!XR()_\
MV6@"_IO6\/\ T\O5ZN;CUF6TN;R)-.N)O])?#QC(-3IK\[L%_LN['."2G% &
M[16#_P )!,)-ITN\P/XMHY_R*5=?N"!G2;L9_P!GZ_\ UJ ,_P")IQ\/-8X/
M,0&1_O"NDL,_V=:?]<5_D*Y?Q)JDEYHTL#6$T:,0&:5?EQGH:ZBPYT^WR.1&
M.W3B@"PV=C8ZXK$TG69]2U&2%H8PD2 L5)RC<\<BMRDQR3ZT 9OB&,3>';^,
MD@-"PR*YO2?%'V/1K*$6$\A6(98*?F//-=L1D$>M(53J5!_"@#GK?Q%=7()@
MTFY<#FI6UC4N,:'<-V.2*U8W\Z[9H_\ 5IE6/]X__6JS0!SQUO5>"= N3ST#
M#C]:R+JZNKOQOH0N+&6VVI+@L<YX%=Q7+ZS_ ,CQH/J4F_3% %FUUFZFUU[(
MP@1I(ZG(.0%Q@^^<UO 8[48I: "BBB@ KA&4#XSQG/S'33P/3-=W7#-S\9(S
MW&G,/U% '<UG:E?FQFM?W8D6601D=QGO6C33&K.K%<LO0^E %+6E#:'?*QRI
M@<'MVK'^'I!\!Z25S_JOZFMG6,?V/>9X'DMSGVK&^'JE/ FDKD']QG_QXT =
M/1110 4444 9FMW-Y;6(DLD+N955MHR=IZX%8JB1O&D<D@'F&WCWC'(//_UJ
MZS [C.:XS5I;V'Q=(=-ACFNC'$ LAPNWG)S0!VE%<P9_%^<M;:<BCDGS#T_+
M_.*SD\0>*' 9;&TP>F6(#?3CI0!W%'45Q=OK7BR[N1!%ID*G;DRN2(Q]3US5
MP/XR/!@TT>_F'_"@!G@3_CUUK@C_ (F]QU_X#70:FUPFF7#VBLUPJ915&236
M;X6TV[TRPGCO1$+B6=IF$9R/FK=H R]#DOI;>9K]9%<2D1^8H!*\<\5J4@&.
ME+0 4444 %%%% $=Q_Q[2_[A_E7'I_R*OAL]/]-AS^;5V$__ ![RY_N'^5<>
M,_\ ")^',#_E]A[9[M0!U]SM^S2;NF.:S](C6%)(UZ+@\=_ZU:U-BNFW# X(
M3BH-/79<R+W\M#@_2@#F=3&?$EMCN\X(_+_/-=NOW1]*XC4,GQ):@=I)_<]J
M[9.(U^@H =1110 4444 %%%% !1110!4U*W^TV,D8P'QE&_NL.AJEX<O$N=*
M78NW:<*OH.W]:UST/&?K7/6<7]GZ[-;*,0RDMQVST&/SH R/'H9I(44$LUK.
MNT=\[>GO7GKWB_,TQFENDC\N&*$A5ME7&6]"Q[UZ+XY)\^V<?>6UG('O@5YM
M<7D$B^6MM&)%R 4&P1'/ZL: (%MS?0WWV%GE@+_:+Q%R?LP8<MG'S'C]:I:K
M;$S7$%L)B(X% R& =#CGIP!UQ7>:*=0&G:O8K+#8+''))(L*A\O@'[W:O/8=
M5O+RT:<ZI<RRB(B1?,/'/2@#U_P39)>:'IAM]6EEALF=9=G G)Q@GZ5W!4$=
M 3ZD5S'P^A6'PE;XC"%B2>.3]:ZF@"$6L"YV1(I8\D"I1T'&/I2T4 %%%% !
M1110!C7W/B6P'_3";KVZ59T08TF'W!-5;_'_  DECZ_9YNWTJSH04:1#M! Y
MZF@"'68O-DMU)]?Z5K+]Q<>E96KH)7@!Z\X'K6JOW%^E "U@7_/C71_:WG/_
M *#6_6#?C_BL]'.,X@GY].%H T--/_'W[W+FKU4M.^]=_P#7PU7: "BBB@#F
M_'MV+#P=?7A3S!"%;9G&[D#&?QK:L#G3[4D<M&K8],BN;^)H!^'6L[C@>2.?
MQ%='IO.EV?\ UQ3I_NB@"W112!E)P#SC)'I0!2UBX>TT>[N(WV/'&65L9P:A
MT8R7NAVD]Q*[R2Q*SMTS2>)0&\-:B"<?N&YI?#8QX<T\?],10!IJH50JC '0
M4M%% !7+:VH;QOX?R"?DF_DM=37+:UN_X3KP_CH8YOPX% '4T4T2(7V!U+#M
MGFE!!Z4 +111VH *X5P3\9XB'X&FME<>X_SVKK_MGF7+0P+O9#B0]E_^O63%
MX<F_X3#_ (2":]W$6Y@6 1C 'UH Z&BBDS]?RH I:S_R!;W_ *X/S^%8WP^3
MRO >CJ.<0?CU/%=#<0+=6\L#Y"R*5.,].]<K#\/[6WMEAAU348D0%45)R% [
M<4 =?EO[OZTM<O:^$'L-1AN[76;]@GWH9Y-ZO_A6VEVZ3+#<IL8_<<=": +M
M%(!@8I: "N5F4#QYOZL84_K73O+'&I9W5%'4L< 5R\[C_A/% [Q)S^?^?QH
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M%X4T72KKP];RSPAY#D;F;);G&<]_K5'7=!TJ7Q=HFF&!7LYUD>2'.59AC!-
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M10!C7W_(R6/3_CWFR?RJSHF?[*A![9X].:KWN#XBL!SDP3#I]*L:-QIL8_\
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FD^E6DMR)WC)D!)SGUZ_RJX!@8]/:EHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>gvxjy5si4hmk000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &3 F\# 2(  A$! Q$!_\0
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M9[_*V[^50Y-.SE^ 7-07I=@ (<GI_G%3?OS_ ,LX_P#OG_ZU8R7PE<K$ID8
M,=BDX!Z'/3G!K0M]7E4+'/"1D[0Q9<_B-V>W7%',[7YOP%<LE)N\2?\ ?/\
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M+_O@4OV2V_Y]XO\ O@5F+X@@/4$5,NMVK?Q8HN!=^R6^,>1%_P!\"C[+;_\
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M9C_95T!COF0_K3C*Z,JM)TI<K=^NAMZ3:0R)';2&2*41)<0/$Y5BKHH;GO\
M,.?J*NZ):QV[:G;("T:W./G.2<QIG/KUK.CU?1+C2;%'U)8;B&)-DB@AHVV@
M'M^!!ZU5L?%$5G/?F1X;GS)PP>-O+W?(HR W;CUZYJC(Z :#9!<'SCM $9,K
M$Q '("'M7,>)[2*+2]3\EI)%@53))(Y8F5WCXS[*H_,5I/XHBNQL6\MK%&^\
MY8R2#Z #:#[DGZ5G^(]3T8>#[NRL+D2.VPA0&9G.]22>,D]30!UFG];O_KX;
M^0J[5+3^MW_U\-_(5=H #TKCM:_=ZFCMPH<&NQK(UC2A>QD@<XI 8-PFZ(X'
MS+R*J=:FMT:VE:W?ZCZUDZWJ"Z3 [8R1RH'4YZ >]<6+I.5I(B2.>\7AH]0L
M6(#1DLV#T)XK'U"X\KS/L2OYY0E(PORGCC/^(J:\EU'6[5Y7G"Q@G9&!\R,.
MGU^OO67;S722F.9,LS!5D0?Q'^$=^F:JE&T+/H92WNBQ=G;H/FR2)YKJ%9 I
MRISVSP<UVWPLLR-/\QAG]])M..HX%<->V%]JUU%'$CQKN(1W3:#[X]>GM7L_
M@[2H]-T^*WBR8XE"@GJ?4_B:WII%TT[W,?Q.GE7D$F,[+A3^=9<2_OW0C@@@
MC\:V_&<>(97Z;"KY^AK%!'VS<#PQ)'X\UE4TJQ9H]S7\,R%M$C5F=G5V!+XR
M><CI[$5K(2^?G0?,5P<YK%\.M&MM- H.Y)\D[?8CK_P&MK=LR!*RC.<!L5Z4
M6W$XYI*;&VTBW<7F1M+C<5Y@*G(..A[<=:SM8W2Z!J(9&)6!F 88Y'/\Q6ED
M.<YD<_4FHYXUDM;B (5+QLN"N,Y!%%F*ZZ(99S27%G#--%Y,DB!C'N#;<^_>
MK.F&3^W)4C8*TEF=K$9 96X.._WJRM FGN-"LY+F-4D,2CY7W!@!@'/OZ5;L
M9$D\4V;QK*QA6:&5EA8JI*JP!;&!T%>73TJ'NU6G3+>JI)#J>G^?(CSO:NCN
MJ[=[*4)('8<FH)H5N(7@9G59!M+1MM89]#V-7/$-O<7%SI]S:VTTQMVDWJNU
M?E9#U+$=P*H02K=V4<N"JS1AL;N1D>H[^XIUDU*Y.':<;%'0H0_AZU@W;O)W
MQ9)_NLRUJ2QK/&8Y8H&0XRK1[@<=.M9.B1BUT^ZM8PP6VO)$&]B21D')/?AJ
MUD,7E*S>4&*Y;[S8KTHM.*9X\TU)KS',=PP\@QZ8 K!\9+._A>_6%5(PC/N[
M -Z=ZW%F@N+7?;NLD;IE'CC&&]"#4&H0M/IMQ&,[GA92H&=W?'Z4VKIHA:-'
ME\,;?9H7@C;YXAA4&2W':N]Q+')IK7! D\@K)G^]\I_QJKING*+&*YAMA" J
MK(3PX!S@8Z@FK5T$>.R9E!V3,F#R.0:X*,7%.YUQ5CM[:]MA:H7N8AQ_?%3+
M>0/(J(Y8MTPI(_/&*JZ4\26"$^6@Q["K9O;4,JFXBRW0!QS6Y9/1110 UW2-
M=SNJCIECBH3?6H)'VB,D=E.?Y5,ZHPPZ@CKR*89X$.#+&I]"P% 'G?CVUAU&
MU9H]_FQ,LD3[&4!@>YQTKS@O'-(1E6>->$88Z=<CN*]<\62P7%O.L<R-NB9<
MCYAT]J\U\*V]O=ZE<07,*RHT9.'&>A!Z_C_(5A5ERJYE4C=E9Y_+)6V_=R-@
M.B<[\_TP?PK3TVW72XE-S+ SOE\I(,?-P$SG&:G\5K%I]C##9Q1P"=R9#$H!
M;&,9]N?Y5DV7A6ZO[".:.2,^:I)W.W<]QCVY]:QC>K'38F,=3>DO+>7RXS#$
M';?C!R=Q/!&.V:PIHROBZ/>5#FXCW; , _+QD?Y-3CP1J"Y"O&N<])#W_P"
MUHZ5X.G34(9IL;D=7)W;F)7L#Z9_SS54Z+A*Y?*[GIM@VW1)V]$-;,__ ![2
M_P"X?Y52L+(#3C!)G#K@XJ^Z!XV0]&&#BNM&AQWQ'_Y)O>_[D7_H2UU&E_\
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M7.<UV47>FCSL3%*LQ=GDQ83R450<*IX&.<<"E'SH.V13([H3F413%S&_ER;
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MY'_;%JGBD$J[@KK[,I!_6N@U']***1F"C)H Y'XG_P#)/]2_[9_^ABNDTO\
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MIRNZQ,RH9& R%!Y-? YGQ%.LJF$=-6O:]^S(]Z2U9G)<:R4R^FVRMZ+=9_\
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M1^56=,NFL]0#9^63K]1_];^5)K\0VW.H1@F33[MC* .3"RKO^N.&_P" FJK
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MV4L4CE$<;68'& ?>K-4M7V_V1=[@"OE'.>E 'BT<S", 03-CC/R\_K3O/?\
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M\16EL@^\\=OG;^E=)?221O 4?:C,0WY<?UHT#P_9:IH%K=ZK)=SS.I$HDNY
MNX,0?E! [=*F4$MV_O+IXJ4G[L(K_MU?J9\?@751F>]\;:BF[@[3L&/;+<?E
M3I?AEI-Q%YVHZWJ5X%!97FN!M7WZ5SEU9::OB35K.==0GRY\E;69MIAP/EW;
ML9SGKFNK\,6-U)X.L[6>SGA/V=H6212& Y'?VK'V<3I^N5NCMZ)+]#FQX?\
M!/VN2&-);DIC#++),),C.05'X5=ATCPS%)"HT"5%DD$:2SVDBH6/3EOI7=^&
M91-X7TMP<_Z+&I^H4 _RJGXK*RZ$L\,BL(;J%B0<CB0 _P S6D5%=$8SKUY7
M;J/[S*73=,M641Z?9H3W\I1_3WJX(Q$&*>2@ /"CT^@I&C#[2>J],C-);W(N
MK9)TEE".,C<NP_B,#%;\MMCSW4<OB;9B>,U$_A#40P)/DAT[X(8'^50Z):VI
MMK.X6)<R0*3Z9(!Z5JZW")M!O85Q\UNZC/\ NFN3\/Z_:6^BZ:)"Y*1A'('
M(R/\*X,4K5HL[Z3OA/27YK_@'0ZH&$]FRH6)9EX/MG^E=-8QW<MLF($ QU:7
M^@'_ .OZ\US5_/')9VMU$^^/S5(*\Y!!''YUTNE:B19JHMY3C^(E0/YYK8DM
M+973/&TI@ 1PY W-T]SC\_YUIUF2:E<)&S_95&T9(:7\^@_STK2!R ?6F M,
ME9U0F./S&[+G%/IDC%$+!68@?=7&3^= $.^]8#$$*^NZ0G^0KC?&D$SV5UYC
M1A3"Q.Q3GCGKFNQ^T7!'RVC#/]^11_+-<3\0[^XL]+=_*AR5QMWDDD\ =*3
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MFRN^/IN)Q4-EX2\/W,=QYNEV[$3.@.#D <#O6S:W+Z@[&6RN;9(\86=0-Y_
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MJ:/X3Z]<6<ZS7%E;R$$*N]GW<>H Q7:JT+;GK+$TN7<Z+PQ(C>'K-0ZEE3!
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M.0"1_*NN^J?F=]#6-2/>+_S.Y4%W8?/@8QM [U"_F!Y4\EU50I61IE^8D\C
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M?ZU4[VL@O9V%DBBACQ&J(B3-ED7.]LX ]^!G\JJ7UD998_-G\@LPC;(QD-@
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MS%!PK!^I8=?H/0]Z^@=+_P"019?]>Z?^@BO"-=NKB?1YDBLQ%:JF6?9N_BX
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MW1;/2OW+BW6RM%,<P+<EIQR6P%.T[>IX.,UU$'H%%8FC:@UQ.UN]XL\@\PE
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MV<P8#.W=YHQGMGK7!7#%[:7>HR5;I\HZ5WG@O/V+1\0Y'V.;,F3Q^]Z8Z?\
MZJ[<(M&:TSLS7F_@NSC@\3R7\MEIB2W\<GV=K&9ML<2E3M\O8,,0P8LQR<C
MQ7I%>;>!K>RC\37$41O+F2V1P+F&Z^T60SM!4,5&U\*HV\X ZUV&AN:3<S"]
MU*1#;O\ 9UD"DX3<2V1N89/8]N,UM:%?RZC8--.T9E$KHXCQM4@] 03FL73Y
M$D.I6RSO"_ERYN/D78=QSRH##&1R3_*M?P\ FG-"LT<R12%%DC^Z1@'^OYT
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MJ[+SI%%);+'+YC+(AC9.!]\8R.N:[H]37%:1I8BO([R]1E,;;HX5.><=6/\
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M 1Y0.0&^?[LF&."-X&,"N^HI>WD'U>!S']G:M]A6U6VBW26ZPM-/()?+51,
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M+<6<ZA9HMX!R RYP:@CTK2+B0NEI'D8R-N.G2MHXJ27O"NS$C^(RL,O"R_\
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MMX1&L:[<[B N 3[^OU.:Y:F+BM(ZDN19;5-4NR[Q;=/BE.<\23[<<#/W5_\
M'NO6HH+=+<NZ%VE=@[R2.7=V'<D]?2I:/YUR2K3D[MDW)[K+PQSQ]4(85UFD
MW0NK)&!Y KE+8AXWA;IV^AK6\,%U:>(YPC$5Z=.7-:2ZE(O>(+=7T\W2VD=Q
M-;$2(LAP,9!;N >!G!.,@5%X5U275M&$\\JRS)(T;NJ[02.>GXUM8!&#S7':
M.TFB>+[_ $MXYF@NR)H7QD*?]T#"KCC/ ^2M1G8.H92#WKB=<M#!.S <=:[B
MLC7+3SK8N!DBDP.$:6:VFAGMPAD5]OSYQAN,<>IQ736T\<RQW'EETD0%01T/
M^?Y5S<L0(DA?.""I/?!J_H=R[V\L+?ZQ<N![DD,/^^@?P(K6F^AA6CIS(VII
M9)(VR JXSM!Y/XFJ\$@O+0>="T9D3YXF()7/49'!_"I@8\*QQ\PR"_S-T[+V
MIFPFX\T;N1R6/)_#MVK5>1@UW.>99++4+:XD#-&K&SN"PR-K'Y6Y[;L?]]&N
MBZ?A4=Y;Q7]G/9R-Q*A4X/*^A_ X-4=.U(2V=JMSE;IV:%U"D_O$^]GTZ9Y]
M:X<7"S4D>E@*MXN#Z%S1M3M=*B?1[PL=EP/LJJA;]W(?ER1P &++D\<"M3Q+
M)<VVA3SPNL449!G"QAR8LX?&> <$GOTK+N[9;RSFM7)"RH4)'49[UI:,]MJ.
MG)>7B(U\T/V.[ ;=RI(92 <#)R?QI4I\RL76I\CNC/MXE@MHH5=I%C0*'=LE
M@!U)[UDRK-I^NQ7LLJO%=L;=L)MV=XP?4_>&?<5:CBO=)^QVURL?V-F:WAEW
M%G8C)CW<8&5!X]1[T:O82ZC:>3%.8R,L!M!W..4Y[88 \5C%NE--F\U&M2:1
M>&Y+EB?ND<,%RWX>E2$LV?E"YSDL=QY_05FV6KQW-A#(%/G.F6B4%F4C@C:.
M1@Y&3@4^-KW46VVL;%<]4PV/JWW!^;GVKTW**U/%4)O0;J^Q;6.=9 KP.,/G
MID@?SP?^ UU^GWJWUI'*!M<K\Z8^ZW0C\""/PK'L_#!WB:[G/F#IY3$L/^!G
MD?\   E:]I!;V+&U@1(TQO51UYZ^YYYS[UE*5W<Z:<>56$U;38=8TFZT^X'[
MJXC*$^GH1[@X/X5Q]K+;WNE^5J-O:QS6S?9;F-E5%W(,,P&TA\G:0I[,*[VN
M)\3)>:5K'F6/E>3K($$RR(67SE'!P.<LF1Q_=%26;,%EIM_:>3)IFFS,$431
MB-" ?3ICM^E<[J]Y;Z??7$4_A^T\Z%T%O<>2-BQO\N6?& <_UJ+0]6FL+PVT
MTMS<:BN;<0-&=D:*>, #/08SZ^M=/JTT.IV%S8M9W4T9 64Q*"4;A@,9&2,C
M.* ,6TL[?4YMD=C81W4,1'VD19$I[A. /3)_(4ILK!)[:\N($BN-H4[49 RY
M^90G+N?H !5[2O#TMJ"80UD&^]([^=<-VZG*IQZ _6KUQ<Z'X9B:XO+F&V9O
MO2S/NDD_$Y8_2EMN-)R=D9L_AR+5IO-%BUDN,>;+.YE(]D#8'XG\*G7P1I*Q
M(@EU#<C;@YO9"<_B<?I7/:AX]O=87RO#&DW4RJP87DQ\J/(.<>X/H2,UFP:9
MJGB*T34]7\2W>'7>L5H?*2/U'UI)N7PJYO*@J:O6DH^6[^Y?J=OJ?A&TU729
MM.NKV_>*5U<N\VYAMZ $CI6#)\++.2$0_P!N:OY2D%8VF#*,=.,8XKF[_2;[
M0H8]5T[4=6FN;1TG:WN92P>/.#P.OTKH&^*M@[1-#IVI^7N^?_1\Y&#G!SZX
M_6IDE?WT=%-5E!?5Y<T?39_,F_X5D!T\3:R/^VHH_P"%;3 ?)XJU<?5P:SAX
MO\5:];[-$L5MH<E6OKI0"><?*O\ ^OFI?L/C,#CQ<#];5?\ "I5*+VB4\16A
MI4JI/MO^29;/PZU$?<\8ZF/JH/\ 6D_X5_K2_=\9WOXPC_&JAM?&ZJ2OBN$X
M'0VJ\_I5:PF\;7ULLR>)K=#DJR-;#*,#@J>.H_K1[%?RB6+EO[:/W?\ VIJ'
MP)XA'W?&5S^-N/\ &F?\(1XI'W?&+'_>MA_C6;>WOCC3[6>X37[6Z:W3S&A6
MV + =0#CTKHQ\2/#YTF*Z%_;_:'C#M;L^&4\97IUI>S@G9JQ?ML0X\U-J2\D
MO\C/_P"$/\8+]WQ5 W^]:BFGPGXV'3Q)9'ZVW_UJEO\ XF6OFR6VBVS:K=$_
MNE@!V8P/F8X]<C'MUJK'JGQ!DB27S-&3> P1E8%<]C[T>S@]E</;5XJ]1QCZ
MI+\+$MEX*\1-XCTW4M6U6RNH[-F(1(BI((P>WTK4U7PUKNJ1Q1S:M:E8G+)N
MMS^'0^GO61_:7Q"[-HI_!J@LO%GC>:6YA%CI$TEL0)5:0H0#T(&>GO5J*BK6
M9A54J[NYQ=O-(QI+;Q"VOW^D:?:6U_)9!?-D5O+'S#(^\:G_ +&\:?\ 0OP?
M^!2_XU?\+7'B"RO-5U:72;:274Y5E(-T5V@9&!A6X^M=?'KVH&-3)I4:N1\P
M6[! _P#':SCA5)7L15KT*4N2,8NUM==[:]3@?[&\:?\ 0OP_^!2_XU$\GB72
M5DN;OPU.(8E+2,DH("CJ:[P>)]2)D4>'Y2RL5 ^TI\^!G*^H_K6Y9W5OJVF1
M7,8WV]Q'G:P['J"/7J#1+"1L3'$4I;TU^/\ F<AH-K)XAM$O(6-O:. 5=URS
MC_9'3&<C)].E/UO2(M,FBN(0WEMB.5W.6/\ =)/UX_&H/!CMX<\2:GX1G)\H
M,;JP9OXHSU7\/Z&M7Q7>7"D6*Q+Y<R$Y"[G;U SPN..3ZT4J<(1NB*U)4YV6
MVZ]"I_;D5E:JB81CP!C))]AU-9LDU[>MN8F!#W;ES^'0?K5CRK2,*;>W9'(^
M>21]SL?<^E)7+6Q3O:!@Y=C+U33EDTBYCA'[UDR7.69L>_6N3L1+)9_9IW:.
M1@$52<$=P1Z?45Z!6!J>EV*W'VI)/*D7[R\%,9R<@],^M94JG21F]3!UB!5T
MYGFNBX4-#'"JC<6 S_DUVGA#4#I>CV4<[)Y@A7<"XXKCYM0LK5;B>VC-]=(%
M#.<>6O< #N!3/[;N8[@1^7:2I(N])#;@ACUVXSQ773G**V'%J)ZE8^)(ELXE
M&WH>C#U-/M/$"K"WR$YD<_\ CQKR=?$$[1QR-:VD:N^QU\G_ %)_KV]*<_B"
MZC6=#:6C-"?N[,;P>X/;]:U]K+L5[1'J(UQ&BNU"'+S,?T%<9<:#<WVK37-K
M:R/N97=50X?C'7IQ6#_:\J3JBQ6CJZ;UDV$!C_=QGK4/_"0W+1PNJI$DC;9/
M+CYB^GKV[5,Y<ZLT)SBT=/\ \(S/= K?6+H@).S>BY_-JU;/7ETN-8I;B,2A
M0'53NP<>U<%+?:K*ES$2PGB 90L(YC_O=.O!YI?LTMQ=Q(R_N+NW+)]H?/E@
M<EO8<]>]3"U/82FEL=#XE\7R7NER1V%PQD9@N=P7J>HSS^E<G%8/:-'-,0Z%
M<ET4LRYZ'\ZO1:%>7NG6QB1C<PN=F]"JB->F<\Y.!@>AYJI(TDR(K,ZJG4*>
MA_N^Q_E5\_-H1*3;N6+>2&X*F!E6,EE^4<=>X'<UH07P_LQ["<".6.?Y/-/S
M;",\?3&*S;65=,L1%:_Z@_,T+]$)[_7GKZUIZ?I=U?:8;LH5?S0T08<LH&,_
MCDUA424=1)W8]@([=O+V[2C!B/X>/Y5WG@P1_8M').)!9S #:>1YO//3L*\^
MNHS):3)*I1MI!P26S@^O2O0_!03^SM(.%,@M)?FYR!YOY?UK3"]36F=C7G/@
MI2WB_5+H&>&*7<JI/I0@DG(;+2-($ VYZ+DD\L:]&KSWPKD^-;J6;4Y-79X6
M$=Q/%-$\ #9*!"HCP<@97!^4<'K76:&S )KN[U"UCBMDD,4BJROPF7^Z>N">
M23CTZ8Q6SI%D]A:-"R1QKO)2.-RX13CC) /7)_&J6DV5Y!JDTLZ*(&#B)0>(
MP7S@<_Q=?P'3I6[0!BP_ZZ\_Z^&_D*FJA/J-EIINY;VYC@4W+;=QY;@< =2?
MH*QIO$]U>,8],M?*3_GXNER?P0?^S$?2LYSC'63"YTLTT5O"TT\J11+]YY&"
MJ/J36!=>*XB-NFVYN2WW9Y<QQ?AQN?\ X",>]8[6;W4BSW\\EQ.#E6D8-M_W
M1C:OX#/O5L(H<N% 9NI[G\:XYXO^5$N17N$O=3+#4KII(^T2?)%_WP/O?\")
M^E31Q)$BA% "KM!P.!Z4^BN24Y2=VQ,#112%@#@]>P'6I2;V 6D)"C)(Q5JW
MTZ[NC\L91?4C)K:L_#R1D/*<MZGD_P#UJZJ>$G+66@[&':6UW<3+]GCQV+..
MWTKK-+T\6%OM)W.W+,>YJU#;Q6Z[8U ]ZEKT*=-0C9%!2;1N+8&3U-+15@%,
ME021LI[BGT4 >?ZO;&VNR<8&<'^G^?>LZWF^QZDDO16Y;Z<!O_9#_P !-=?X
MBLA)$7 ZC!KC)@6A)*[FC.2OKC@C\1D?C0G9BDKJQU8 #%455XR23@4DPE6+
M=&@F;< 0[^6F,X//7('/O5/2;@7EA%.DJN4W1^8 "&P<9_' -7MN6W,2S>K'
M-=.K.'2)&4S.K1G*@<A5VK_G'\JST_T+Q!+%TAOT\U/^NJ8##\5VG\#5RXYG
M'FB8P[>!%_$V>A]*S=5?;I\+AR;V"43V\1Y=\'E !U)4D?C6=6"E!Q-J%1PJ
M*1J7$"75M+;R9V2H4;!(.",=15_PQ(EQHD.RVBBFB)AG55 42*<,<#UP#^-<
M]<:PJRK"NV%V8*%D&^0$G R@.%Y/\;+6QIOAJXCNA=W$[Q,9EG91(69F  YQ
MA%R  0%)/K7%0C)7N>E7G&6S)O%P7^Q_(<N9YG'V=^BQRK\RD^V5]R>@JA;Z
M9JFI#=(?*C/7.8E]^/\ 6-^)2NRJA=W/V)LF2WB20Y#SRA0#_6MG%-W9@IR2
MLF5;+PU86L061!, =VPJ%C!]=@X)]VR?>KWVR(?N[=#,1QMB'RC\>@KG[G7K
M:3B%9=2;U/[J <_^/?DU9UQ>7]ZNRXNBD7_/"US&GY_>/YX]JRJ8BG#=D-HW
MK[68+=S%<7>)?^?:S&^3\3V_3ZUE#6G$I==(B6(CH9_WQ]RV"/PS^-9\<4<,
M>R)%1!_"HP*?7'/&3;]W0GF9OV>KK>EX+1YXKI4+B"X3[P!YPPR#U'0]ZEU>
MQAU?1)8('(N)%66"3JR2+AD;VP0/UKF6EDM98;V$$R6S^8%S]Y>C+^*D_CBN
MSL98]Y6$AH9E^T0L.A5NOZG/XUV8>M[6-WN4G<QK9-6O+R..\BCL-Z9NA:-A
MB^!@"0X+=#G:!CUK8MI],M+@:7;SVZ3@%_LXD&\Y/)(SDUQ/C74M<;Q59Z'!
M>+IUG=Q$Q7,49:1S_$H/8_3'7K5)? >DM: (UREUNWB]\TF;=ZYZ?A^M:KFD
M_=6QTNG2IQC*M*W-M97^\ZS4O&6G:%>3Q:G<QH@^:,!?FQ@<8&2V3NYXZ8]S
MP.@:?::Q/J&LWMLTDLU\P@EO%9@D9Y!VGCC-:/\ PB5IH]BM_!$;K4;=A/))
M*2YF ^^N#ZC./<"NICFBGMTFC8-#(@96[%2.*TC2;=YF4\93IP<*%[O=[?<O
M^"58A&95CMII98P")'*X3V"^F/:J5F$LM2N[-VQ'/FXB0GC.<2+]<D,/J:U]
MX7: N%/ [?IZ5GZW;R2:>9+= ;FVD%S ?5A]Y?\ @2Y'XUM;30\].[U+L4#I
M)&7EWB)-L?RX(^I[U.ORC"\#T'%06ERM[:0W$ +I(@<'H ".YITRN82ZL6QU
M(X4#^M.Z1-FS.@']GZ[-!SY%_F>/)X64#YU_$8;\ZT]V9ECW!-W<_P!!_GK5
M+4K:6\T[,.%NX2)H#_TT7H/H>1]#4UM/'J-G!=Q#Y77< W\/J#[@_J* TW9=
MFMTCA,BY+KR6)Y([BL/!T_7<#/D7WS*/251R/^!*/S6M<DNP#%I7],=/P[52
MU?2_[6TV:U)(E(W1>6<%'4Y!W#ISZ=LTGHBEJ] N'AMF5"))2V7BMXTW')ZG
MZ?7 YJM8>'=,@LH5ETNT\[8OF9C5OFQSS5C19H)=&@:WC$4:KM,8.=C X8?4
M'-74<2]&QST'+?EVH:B]6$9U(Z1;1D"W@T;6HGMX8X;:^ A=44*%E&2AX]1D
M?4"ME6\MW/E!RW0GM5;4+..\L9K0GRW<?*5^9U8'*G/;! -16-T^H:8LCJ%N
M!E)D/19%.&'TS^AH5M@DVW=N[+B[CN*@')R2.%7\:R[M5TW5H-0R/(NB+6X;
M&%5L_NS^9*_\"%:<9<QJK#<PXW/TQ]*BO+5-1M9K67=)YBE2?[GH1V&#@_A1
MJ+0L<[E4#+,< 9Q4OV8;"9Y,#T4X _&LO2[J2\L0)F NX',4V.TB]_H>#]#5
MTDN_),L@YQZ?T%/<2T!<E00WS*>&QZ=Z70;@V.K3:>YQ#=EKB = L@_UB#ZY
M#CZM2A"V06)XY5#T^K?X50FACU%?*%RT<UO(I:2!L/&X'!!]U)'T-3)<R+A)
MP=V5OB.T5F^G:Q:3(-7TZ7S$A!R\D/\ $"!V]SQUKH+MH?$/AVWU*Q^<E!/#
MCJ>/F7ZXR/J!6;;V,=G;RQV\40:12)'<%VF)_OL>37*Z#J%YH5]<>&TG:&TE
M)N;1L?/M/WD!/3!!]\@UR5XJFFY;,]*G46(HN*WA^77[C;5@RAE.01D5'/=0
MVR%I944#U8"L;5=7GLK@V=G"N$3<\CG@$\@>N3US7(/<7MY;)?N7D-O)^]+'
M* L<# _$"O+A0<M>AQMI'1:CXI4!?LV3&TGE^;_ /4YZG'M7/S37FIB\1G+-
M ?.&&PBJO/3...O.<UHVOA>:<7T7+0R$"&8DJJM_$P'4XZ#UKJ;?1K6&3S91
MYTH18P6& %7H .GOSGFMN:G3VW#5G-:=H\UY<K="+S(I[;,H?**'/0>IQU/Y
M5N6GAV.VBM5-U(\ENA56*C SU('8^];=)6$J\GL"2,?_ (1V#R/(\^0QF7SC
ME02[;MWSG^+FG/H2/+-(;A]TR"-F"@,JC/RJ?X1S6M14^UGW'9&0N@Q(UN5E
M&+=2L2&,;5X W ?WN.M">'K=8A$TTK)YOG'IEGSNRQ_BY[&M>BE[6?<+(S_[
M%LR9=XD<38\X,W$F/7_ <5:CL[:+[D"9X&2,G Z<GTJ:BDY2?4 K,U#0K/4)
M?.<-%/MV^9&<9]R.A/UK3HI1DXNZ R+;PUIL$HE97G90 HF;(7'3CI^=:]%%
M.4I2W8&9JVF+>02RK(8Y%C;G&0>#UKH/!80V6D$EO,%E-@9XQYO/]*SKG_CU
MF_ZYM_(UH>"POV72&+'=]BF 7;_TV]?Z5WX)NS*B=I7G/@&TNUU)[NX>"6&:
M(O&R:F\I#'&YC$0,,Q&2<\=!WKT:LK2?#>D:*J?8;"WCF52AN!$HE8'D[F R
M<UW%FK1110!Y]?6=N/$.HW7E*9VE*ESR<;5X^E)VP.,5/?\ _(6O_P#KN?\
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MS)$A!]2I(R/\^E=#;M<\M13=@%O*'VB)D!XW;<D_Y]ZD$$D>&$3ANQ(W/_\
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MN/E'T7I^>:T:TIX/K-F/*V[LR[?1(5PUTQN&_ND80?\  >_XYK3 "@   #@
M#@5#<W<%G&))WV@G"@ DL?0 =363/K%S-E;:,0)_?D 9_P N@_'-=+E3HJVP
M]$7M82)M-<RR)&5^>-G./F'0?CT_&L%6#(K8(W '!'(H*[Y/-D9I)?[\AR?_
M *WX4M>=7JJH[I&;=PHHHK 04444 %%%% !1110 4444 %%%% $=Q_QZ3_\
M7-OY&IM#=1X4MD\U@QTRZ/EXX(W]?K_C4-Q_QZS_ /7-OY&I="A4^%K:;YMR
MZ7=*/E^7!<]_7@5Z&!V9<2UJZZCK&F66A:5=1VT[62322R+N7&!M5@.QP<U:
M\+>(K>69M"O; :3K4"9DLB<K*H_Y:1-_RT3WZCO2Z6PMM>M!( !<Z=&(V/<@
M#(_E^=7=?T33_$3V]K<0DRVT@F2YC8I);G_88<@GT].O:N\HFO["#70T,R V
M\9QY@'+/['T'ZGZ5S>JW4[>#-8T^[<R7%D\<9D/5U+KM)]^H_"NNAE:U*6TZ
MJJ_=CD485O0'T/\ /MZ5QVOR"ZT[Q+<H/W2M!"&'1F#KG^GYT =CI_6[_P"O
MAOY"K$UQ' FZ1@*YZ76FLY[R"*/=(+ALD\ <"LBXN9[IRT\A;/\ #T KGJ8B
M$-.HFS<N_$:@E;==Q]:QIK^ZN&W/*1[+5?M[45Q3Q,Y;:";9:M]0NK=@1(S#
MN">:ZW3[U+VW#J><<UQ%:6B7)AO=F?E;G_&ML-7DY<D@3.PK-UR!KC375!DX
MK2I" 1@UWE'GJL"N3P1U![&I+>WGNVVV\98'^,]/_KUU,WA^TFG,I4;B?2M&
M"WCMT"HH&*XXX.*=V*QQ%W92V$J+(Q;>,$^A]JAKJO$%E]HLRZCYUY!_E7**
MVY01WYK#%4E"2:V$T+5FT?[T9[?,/\_YZU6I5?RW5_[IY^G>LZ$^2:8D:^E7
M!M+PI_ 3G\#_ /7KJAR*XJ8[0LR_P')Q_=/7_&NHTVX-Q:C<?F7@UZQ9=HHH
MI@5[FSBN5PZ@UF-X>@+9S6W118"A;Z5;P<A03ZFI;JZBLHP6&2?NJ.]2S7$<
M*Y=@*XCQ=XGBL86N0NY8D]<9)/'-(#>DUV16Z1(#T#&K%GK2W$BHZJ >-ZMD
M9KP47FH:M/ON?,EPS21I*3MYZA<]L?RJRDL]E,@@>2VFWD^9 ^ Q[#'0\#N*
MCGL[$<Z/H>L[62PL)-N<XJAX0UMM:T1))MOVJ$^5,%Z$XR#^(P:V;N(36[KZ
MBKW1:/ ;M'>]UA);=7F#$%F;^ ?= ]_4#US5BUTU;N#3Y]/58Y$E7RTC!#*N
M?FW-U  SUZUT%_HK6_B"5PHEANB6,<CD 2@?^@E1T]JT=+L%TS3H[56W8)8D
M# R3G@=ASQ7#7J\CTW,6GS$J7%UIS^8KM- .2<?.@]_[P_7ZUUVD:NMY&H+
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M=INBV8T[302B$L[?>+,>I+=,^U:]:I61O%65CEO$>DF5#)&2K9#!@/NL.AK
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M8_\ ?U__ (FK^K5>P<K,[M2UH?\ ".ZQZV/_ ']?_P")H_X1W5_6Q_[^O_\
M$T?5JO8.5F=16C_PCNK^MC_W]?\ ^)H_X1W6/6Q_[^O_ /$T?5JO8.5F=16C
M_P ([J_K8_\ ?U__ (FC_A'=7];'_OZ__P 31]6J]@Y69U%.N;>[L+Y;6Z6#
M<\1D5HG)'!Q@Y ]:;64HN#M(-B.X_P"/2?\ ZYM_(U-H;1?\(I;(8B9CIET1
M)G@+O.1CW./RJ&X_X])_^N;?R-/T,_\ %-VJ[O\ F%71V_\  SS7=@=F5$8U
MK=7#1I!#J,<3-$);BUU-$ !1/X&^[CT'IZFMJRGU73EU&WM]*FO8HCOMIIKY
M&>Y)(SU^Z.O7T]ZF@\*:#J-E;W-YI5M-/+ F^1EY;Y1U_(?E6A8>'-'TRZ%S
M9:?#!,%*;T'.TX)'Z"N\HX2Y\+ZA+8S3IIVMK<3W#*UNNL@8C(R&W8(Z\8[5
M>N+2[M?AYJB7UK<P2M,AVW,ZS,1NC&=P XX_2O0:Y_QO_P B???]L_\ T8M
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MA?\ _(-NO^N+_P C75WOARPU K=W#3*X56)C8+RHX.<9KE+_ /Y!UU_UQ?\
MD:]" !LP&.%,?)].*,#LPB<_IFK6=M;[X(=3ECF_>*9$7OELCIC))/XUKVFK
M6MW;-/DPJLAB(FPA##M7+VBVZ64"1:LSQ+&JHW]FR?,H'!Z^E:EAI>F:AI,L
M-Q+]KB:XD9RR-%AB,%<$YQBNR//?WD:R]G;W7J;7]HV6,_:[?'KYJ_XU8!#
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MJ,<*0RY.>J]*[30[&YL=)MX-0N%NKU%Q+<8YD.2<USFDQL9;38D[94;I,$;
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M_P */^$CU7_GY'_?I/\ "BB@ _X2/5?^?D?]^D_PH_X2/5?^?D?]^D_PHHH
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MVN:C]GA?SERJJP_=)U&/:MC_ (6)XJ_Z"O\ Y+Q?_$T44 '_  L7Q5_T%?\
BR7B_^)JCJ_CKQ)?:7-;7&I;XGV[E\B,9PP/4+[444#/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>gcilxvfwaiqx000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &8 F8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA\Q% *A%<EU7'; ;'OBMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6_\ [4\+_:HUM8QJCXELG:>0'[)<]$,7USP<?J-'<I^(VW(W#2<D \@&;O\
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MJMM^^7/0=!TKLJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXOT/4/#-_:VMU)+-E%"?9I1G#*QQE>>.X_I6T/'GALS/"-1;>BAF'V>7 !)
MYVX_A- ')>'(-+LO'NVTT:6UNI[V]#SM;6@C9%9^%9,S+GY2 V 0">:T=5\-
MK?:7J=Q#]B!O]2_>Q36,,BM()A"I.]3_  C)R"<DD'G%95KK>B)KNE:C;:A-
M,6U&[\TFV8HD<CL%)<!<#)4 MG[V!Z5K2^,M!AT)C+?,FW4?..ZWD^Y]KWAA
M\O(*X(]01CJ* +6D^$-7TN*Y2SU'2M)65A\FEZ3'&IP@&XYZMNW'N.<5/I]I
MXJGTW3KV/Q'!,TL<4DL<]BH5E*Y;E2#GGVZ=JUI?%&CPV(O7NS]G/1A$Y)_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV 3:##< Y'S=.W/I7GWBK4]0OO'UG-')9:;I?E6=O=P:K;1"YD5YY%+1!U/
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M $+Q!);_ -IM>6%['-=.)H$643!HAG<F%(()XVCI73T %%%% !1110 4444
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M2"#T/M6+X?T=K[3V9[;2F6.3;'-<:5\TRE58/G$0/WL9" <5TNH_\?VD<_\
M+VW_ *(EHT'_ )%W3/\ KTBZ?[@H S_^$:7_ )]M"_\ !5_]LH_X1I?^?;0O
M_!5_]LKH:* .>_X1I?\ GVT+_P %7_VRN>U*QGM]2#1Z99M%9>?YL4.CL4NL
MPJT6/W;DX<L#M=??/2O0J* .>_X1I?\ GVT+_P %7_VRC_A&E_Y]M"_\%7_V
MRNAHH XSP]IC:UX9TK59+/0(Y+VSAN61=*R%+H&P/WG09K2_X1I?^?;0O_!5
M_P#;*L^'/LUOID>F6C(]O8(D$#1OO5H0,1G=SD[1@^X)Z$5L4 <]_P (TO\
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MXGRGEIDD^7UW^9CVV]^3[K10!X__ ,,X^#_^@EKG_?\ A_\ C5'_  SCX/\
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M2RELG)PV.N*[*_U?7-2^%6EW^AO<7NJWL=IF>T6-'^9D\UL-E%.-PYX4GVH
M35OA;I=]#Y5E<'3HWTQM-F6&!,2H65@S8 ^8%<_CVYSJVG@FSL?B)>^,()G6
M>]L_LLUOM&TG*'?GUP@&/QKA]2\0>()?!*7VD:MJZ7&G1WBWEN\%O+>M<QL
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MZT:SM%_X\9/^ONY_]'O6C0 4444 %%%% !7/^%?^8W_V%I^O_ :Z"N?\*_\
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M-.77YM7LM?\ $.G23>2)(+*]6*)EB4(BD!,E0HQR3U/K7=T4 %%%% !1110
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MT/1-);P_IK-I=D6-K$23;IG.P>U.O(FUG6!9,TD%K9,LK,DC1RRR$<!2""$
M;DCJ3MS@,#M111P0I#$@2.-0J*.@ X H I_V'I'_ $"K'_P'3_"C^P](_P"@
M58_^ Z?X5?HH H?V'I'_ $"K'_P'3_"D_L+1]Z/_ &58[D=9$/V=,JRG*L..
M"#R#V-:%% !1110 4UT26-HY$5T8%65AD$'J"*=10!G_ -A:/C']E6./^O=/
M\*/["T?_ *!5C_X#I_A6A10!0_L/2/\ H%6/_@.G^%)_86D?] JQ_P# =/\
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M,?./]+MO_1Z50\$?\B?8_P#;3K_UT:@#H**** "BBB@ HHHH **** "BBB@
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M[G_T>]&O?\B[J?\ UZ2]?]PTNC?\>,G_ %]W/;_IL] &A1110 4444 %%%%
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M^1=U/G'^B2]/]PUR^BQ7-CXHU#4+V%DA+7$*+!8W!=LW!8,QV$-D8Y!Z ?@
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MRTL,FV28M#L=7;&2K*V.,$!5P1M%7AX.T^'Q%)KEC+-8WCVB61^SI%M$2'(
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MK#UT+\IJJWNF^)M3@,-Y_9!4*^WRFD4AFC:/)R#D .3CO[5U5% '*W$?C]I
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MNI?^ELU=!7/^#?\ D!W/_85U+_TMFH Z"BBFR2)%&TDCJD: LS,<!0.I)]*
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MV6?Q%Y\*6[M)$UBBB10IRN1R,CC(Z5MZ+_QXR<8_TNY_]'O0!HT444 %%%%
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MP.2.M9_A_P >:7YNJVEW/;)';7\ZPS6\K3B4&1VY"K\I (XR>O6@#NZ*Y_\
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MR-MV9T;:'&)%Q]XCH?KV]QCT%34 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2$ @@C(/4&EHH S_["TC_H%6/7/_'NG^%'
M]A:0.FE6/_@.G^%:%% %#^P](_Z!5CQ_T[I_A2?V%I&,?V58],?\>Z?X5H44
M 5K73K*Q>1[2SM[=I  YBB5"P&<9P.<9/YFK-%% #)H8KB"2">-)89%*/&ZA
ME92,$$'J"*KV^EZ?9S>=;6%K!+M*[XH55MI()&0.F0/RJW10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2?-N'(VXY&.<_P"<TM% "?-N
M'(VXY&.<_P"<TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>gdzs1tysdsfm000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $B M # 2(  A$! Q$!_\0
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MJ\*G&R3=N^@ .?PK#_X7GX4_Y]]5_P# =?\ XJC_ (7IX4_Y]]5_\!U_^*H
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MHW_07L/_  )3_&C_ (2#1?\ H+V'_@2G^- #=9L;J\^Q26AA$MM<";$I(5L
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M^E,CLX)DCW8W8'0]./K70(H1%0=%&!6%_P )MX6_Z&+3/_ I/\:/^$V\+?\
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M6?;_ (/^16%H6@W);D 0B4EAC"&G0(Z*A(QA>OXT^7&.#\Q0_G4C.) "  H
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M[/)J4HB550[ QY=LXQC_ #TJ72C:-/)%>Q;XI4*9[J3WS5!7=EPS,0H  )X
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M5B90[(2W?FFDLES T1(E;'.?PK3\1V937[^+&7\S>/QYJ+3DA_M.Q6Y7<OF
M.!Z=Z]VA.K/'NNU[CIJW;H_\SIC)SRU5;:<ESI?%.BC3M!AGMY/E= LJ@=SS
MDUS%N@*K&."<9]LUWGCR=ET(H4B6.2Y"0B/.?+ X+>IZGVS7"PAMR>6K.Q(P
M%&37+P]CL3C<NA7JJS<I7]%>WZ&.01>'HU92FI6ZIW6U]_)Z/T/6M,MXK6VD
MLK>)HXK%40R.0JL2N<CUYKS76]3:>*:P9EE,L^_=G.SGFO7;^*:Z\/E8L@."
MA;^[Q@']:\,>SGM-3FM9(':Z5R-J#<6]Q7SG 566(>*J8B=ZBGJK[6Z_?<\C
M!8? UL9&<5R)0A)W;]YVO*5WY]M!T9VJ[X'RGCW KUBZU&SL]*M)+\L6D\LJ
MH4-@[<[L>W]:\GD0K%(HRKD]#P0:[+Q&S_9-*5R?^/<$CWP*?&=*:RVC&;U<
MW?\ %_U_F?5++:.89W@\/5;M:;=FT]KJS6JU.RO-2AM=+DNFCW(L8E62,<NI
M''YY'6O&YU\R)DX#-R!79Z_?S6?@O24CQLN1Y<A/H&)'\JXV16,B,I( //IB
MMN"Z%3"96JZ]YU)MOTNU^:N<F59='"U\5!:I3<%M\,;I7M;7S'KI=K+9VQAN
M%:YDZJ#^A%%[H=]HUQ#]L"CS!\H4YJUX?A63Q5IP5 <2Y;CVKL/&<,@T'?>J
MHG^V9@( _P!6>G3VS7T&89S+"YA0P'*Y>V4M>UCS[5\+C/9JHG%.-T]WS-I6
M].IYQ)_JV^AKW_2?^1X\&_\ 8#DKP)Q^[;Z&O?=)_P"1X\&_]@.2OSH]8\*U
M9O\ B9WG_7=\\?[1K1BB\K3;$[BWF0E^O3YV&/TJJ]B=3\275L&V1K)+)(W]
MU022:NR,A*K$&$2*$C#')"CI7T_'&+IQP=+")^\VI6\DFOS?X'U/"M.5;,95
M$O=A'5^;V7W7?](96?J]S.TNQ^(TC55[5H5:>VFU?1Y;&.*-I(#YR/CYST4+
M].:^;X0QU/"9BE4C?G]V_;7<]7CC"RJY>JRM:F[N_;;3[RI#(9K&VF8Y9DPQ
MQQP<?TI:>UG-IT,5C.ZM)"#D*<A23G&?7FF5Y.=.E+,:TJ+3BY.UMCV.''-Y
M50<_Y=/3I^%B#5HA)?!PWR);1;0?Q_J#4?:K-U:J-/-U&ZEBXCD0]1U*GZ'D
M?A5;^'CTK[&HHXK X>I3MI%1^:6J\MC\WQ>&E1Q-:G+I.6_9ZK[[CE%5%!W-
MSQOXJV.E4P<.W^_7E4YJ,G)'(G9EOZFD/0_2G&F^OTKIJU75OIK_ %_7D7*7
M,9UKD2CZ$_K5UCWJC:X\\8XR/ZU=;K7%)\LM&9O1C2:6U_X_[7_KLG_H0I#3
MK4?Z?:_]=D_]"%.=1S!NY]#Z%_R5C7/^P9:UWE<)H7_)6-<_[!MM_*N[K$DY
MS5VV^(K?_KSD_P#0TJ+3;]+;6;X-#<2;H8>8H6<#F3K@<4:^VWQ!:_\ 7I)_
MZ&E2>'&W:IJ1_P"F4'\Y*^3C'_C(9/\ N_\ MJ#VOV#0N+J\CNKY$5Q&MLC0
M/Y!<"0EP>G+8PIQ5NP>>33[=[E66<Q@R!@ 0V.>G%6:*^L **** "BBB@ HH
MHH **** "BBB@ K&G/VCQ;:PM]RVM7G4?[3,%!_ 9_.MFLVXM)AK]G?0IN0Q
M/!/SC"G#*??D8_&@#F=,=YOLCVCWCZA]L;SVRYC\H.<[L_+C;CISFF-<-$US
M<@7R2QZBP-V78PI'YF"&&>F..E=AIU@FFV8MHW9U#LV6Z_,Q8_SK/;PX&6XA
M;4+C[)/,TLD "@$L<D;L9Q^- %.\VVNL2SZH+L6[R(;:ZBE81Q#CY6 /'/<@
M@YJ_8?N/$>J6Z_ZN1([@#T8@JWY[12W.A?:V=)K^Z:SD8,UKE=IQSC.,A>.F
M:ELK29=7U"]G7;YI2*(9!^11U_$D_E0!I5\W_%7_ )*-J7TB_P#1:U](5\W_
M !4'_%QM2^D7_HM: ./4';GT-%6880;6:5B!@!!QW-5WP.:^UR7.J?LHX>MH
MTGKTLOUM^1Z6&Q*Y5"70:S*B[F. .]+2SQ*SK&V "#R>QJ,+Y2JG.U1CGK7=
MA\\I5I.>T-%YIM]?+S\C6&)C+7H/J.0KYD8/<T\9SCT//'6A+;S-TA(RAR03
MUK/-,UA&'+2U:FD[[75GU]+?>36KI1LNXM%!X&32*,]/K7;'.<&Z<JG-I&U_
MG^?R-/K%.U[[!P3C/([4&F^2 WF<@DYIV?GVGTW<>E30S>C)J-5I<S?+K>Z[
M^7S"->+T?786C\:3[RXSMR.#3$MI8WC.&VA2IS_%653.Z7M(*DN:#WE?1??]
M[VTVN)XF-U;5=R2@<FGLA#*N"6;@ 4I3Y<@\U57/<'"DJBE>[:^[OY;?>$L5
M34;W(''M7T#I/_)68?\ L74_]&BO!9A$44H<-T9?ZU[UI7_)68?^Q=3_ -&B
MOSJ<G*3D^IY#=W<X+XL?\C]-_P!>T7\C7%J"37:?%@?\5]-_U[1?R-<:M2(;
M:@;7^M/N(PT8SP<]:2W;*M_O'M3YON#_ 'A7J8W$5*6/E5CI)/\ 0WJSE&JY
M+<@:)!$PQVZTRUB0(25!R>]3'E6^E$>WRUV],<_7O5QQU=X*I>;;<H_D_P#)
M?</VDG3=WU%$42G(3D>](L*+SC+=S3^U%<4L=B91<93;OY_KV\MC)U9M6;*_
ME*UU]T;1VJ66 22*V0 .OO21C][(W;.*ES7=7S'$TJL'&;O&*7?=7?SU_!&L
MZLXR5GLA< #: ,>E1BW\@HP;=YB$_=(VG.,9[_A3LU*]Q)):10LP\N!VV+M_
MO<DY_"N"E4J<E1)Z-:_^!+]3*,G9K^MRFT2!P23\S8  HG11']W'.!2ORT?^
M^*?.O[M<]V%=^$Q^(K8JBJDW:+7W+T^XUIU9RG'F>PQ(@(\8ZCF@QJ@VJ2P]
M<8JQMXSZ5&XK@J8NM54E*6DG=^IDZDI)I]3V+PS_ *_P!_UZW7_HM:\N^('_
M "476_\ KY'_ * M>H^&?]?X!_Z];K_T6M>7?$'/_"Q-<_Z^!_Z"M94JGLZD
M9[V:?W$Q=FF:VA:%IFH>&\7#QS&8[CN4!HG4D$ ]3V_R:ZO3[,Z5IT<-M&HA
MA 4Y'&[KGZUY%8W<]GJ5O-&["%'!D7/&,C)KUK5_$,&G:*)9&5HQAHPAR9"?
M;\>W:N_BK!8J<:.#HN4XXBIS._V5O;RM^A\GFV%Q<,;.K.H[VO"VC<M(I+N[
M.\NN[,+6]$M=1NB39-]JD3)N0VP+CA5R>,D\$>E36GA'3UN8KV6VCCG"C='%
M_JR1W -<5J?BZ^U:(V[KY$8</N0?,<=.?8\_A70>"O$<UQ/-IU[*7F)S"YZ'
MU_2O4CE.:9=AIXC$8F4E!2]U=(Z?BK?UJ98_#XZ&54XTZ:@H[V<G)]V[NR3[
M):66ITNJ:9;ZSIQM[I< DB-AU4UF:5X?M-)U6-HBD02/*YE#/,I&"3_=&[K^
M%+K^NR6.EQ.D!@GDE(B1W[ D;C[''ZUP=_K%[J\L=S/+LD4%8S$<;0:X<MR_
M$YIE=-SKRA1=^;NW?\KHK)\LS+#U*V&T5N:.NJ3V;2V=]M;VWW1[(+N6"-HH
MR&1SD<G@^U9UQI]O(LTR*8KAHBBW"CE#CBN,T;7M0N+1=.CO3!>ALQ3,P'F>
MJD_PGT]>E+XJUY+IEM;2>3=$2LFP8B<]_?'^->=0X=K1S;$8."<(5%=S6MT_
MPU;?W.XHY)F5%X:2J*4X2=H6ORI---K9QD_ETZ.U*VM=/N=<F_M!S+%N6)I(
MG&WSNY/<C@Y/KS5KQ+?"ZU+R(\>1:KY<>._J?\]@*S_#U]96VLK+J2+Y)(*%
M1M6-A]WC^Z/\*U_$FBQV)CO+1F>WE."#R4/U[@^M8<64<;0Q4*53F=",4H/=
M7LD[OOZ]]#]4X;J9=3S*'UBZQ4HNR^SO=J'1.RV73\32+B"XT.]M;Z"&>&U7
MSXEE;')XVCUR<<?6LJUT@3ZH72V-Q9A5D:$ @J'.,8'. 0?PQ71:#IEG:Z3/
MJ.J(DD3Q%O*?/RQC^+CG/'%<O!XB>UUN34[&(")OW8AW<>7P #[X -=/"M+-
MJU&O##2<:?*^5O;F;Z=>^IY^>8C+GF&(^HP<ZJ:=35J+LDG%/^9]6MG<ZW2/
M!D.BZP]]]I>6->(E;J#GO5G7-'77/LL,TKK&C-)L0X+>V>WIFKFDZJ^I*Z_9
M@TD/!@!QEL$A?QXJEK>MR6$\,-O;(U]Y!E>%6XC&.1D]@:Z?K.85L[CAYR_>
MPINTK*R;5K^A^1JECJC^O2DKJ7+OKM>_I;=]V>=ZK:FVGFA\J2(+T64@L![F
MO;M)_P"1X\'?]@22O#KR]DU&6:ZE93+)\S;?I7N.E?\ (\>#O^P))5YRIQQ"
MA47O**3>W,TM9?,_2ZDG*SDK.RTW_'K;:_4\8B-Q%XLG:WMVN2\LL;Q)U93G
M=C\*M7MNMK<F-9-ZXR#@@_0Y[U1N))(M4NI(Y'1UGDPRM@CYCWJNSW"RB9)Y
M!(!C)8GCTY[5WYI@J6>RIRC-4Y1C;5:M]KWZ=K7/9RC,99?6G4@N:,DO=O;5
M==GK;S7FMK:"(TCA$4LQ.  ,DUT.B7=EH]J)I[B-;J]^2,'^!<XW?]]?RK$D
MOY+"QAN[+R3<7:,I;'-N0<':/4]CV%2:C>V6L0Z7:_NH"+<0W$SY&PA@V<_G
M^=>-EO"]:-6%3%Q?(W).VZY;V?HVM.^G<?$G$$LSPKPN%BU3=KR[VNY1:Z).
MR?=IKLW7GCDBN)(Y@1(K$-D]ZCJY<WND/+:6*7-R_EKY0NI8@-W]T-\W0>OI
M2Q06EH7FU27RXHR0(E.7E([#V]Z\.ODF-IUHTHTY/GORZ6;2\NGG?;J?5X;B
MG!/!NM7ERR@ES1L]WLHW2O>VEMNMC/NX'_L\W)XC60+UZG!-5_X1]*TM>M)E
ML]-E6;_1)H"\: 8P2<GCOQMY_#M69T'X5[L/]GP%*C?5WD_)W:M^'YV/BLTS
M)8_$3K1MRW:5NT7;[VTWY;#UZ"J /[Z3_>J\#P.:K>1^\=L\%JX[NYY99IIQ
M@_2G$TP]#6M.M.GK$I2:V,ZS.9ESW4_SK2Q5.UA*7 !.3L)S^-:.WBLV[DD!
M6G6RXO[;_KLG_H0J1EQ_2BW7_3[?_KLG_H0J0/H#0O\ DJ^N?]@VVKNZX30O
M^2KZY_V#;:N[H Y'Q.VW7[/_ *]9/_0TI/#%O!/K5]<O$K3110A'(Y7/F9Q4
M7BYMNNV/_7K)_P"A)2^$1/)J]^Z3JL*QP[XS'DM]_'.>/RKYF,?^%UO^[^B/
M/]K_ +9R>7Z'9T445],>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\X?%3_DHNI?2+_T6M?1]?-WQ5./B-J7TB_]%+0!R(J14,@VK&7;K@#)
M&*A![U+&Y#95BON#6^%J*G6C-[7_ .'+A+EDF,N&S(GT--9VD8%F+'/4FFW&
M5E0,"" >"/I0ARWX5O@Z'^VPI-[2_)E4X_O5'S'AL'/<&I'D:61I'.68Y)JL
M&IP;C%<E6HZDW.6[=_O,Y-MML>W)QGK2+P2/PIO4XISYW'< "#C KHB^7"R_
MO27X)_YHM:4WYL?O.W:2< Y SP*GMW6*UNY"FYGC$*''W<D$G]/UJGNJVKNN
MD2X$>QIU#$GYNAZ>U<\+7U[/\B$52:47$KS1QO*[(%)"DY Z5&6XIJ-_I*]/
MNG^E0(THGEBE6:$@,H8<^XP:B;K@#I3HWB\J0ON\P#$>.GOG\*CW#DFMZJ2I
MPTMHW?OJU^%OS*ELA), Y'3/>O>])_Y*Q#_V+J?^C:\ E<$\=*]^TG_DK,/_
M &+B?^C16!)PGQ7_ .1^F_Z]HOY&N,'2NR^+!_XKZ;_KVB_D:XQ30!,4CC(\
MN0MN 9LC&">U,G;]VO\ O"GL (XWWDLX(*XZ8.*AG/RK_O"M:TG.?,W>]OR*
MD[NXE-C. 1C&#T]*3-2S1+!Y85BQDC$ASV)[5=.I%49P?6S7JK_HV--<K0"A
MC3 U2VZF6ZBC&/F<#DXKG(&+M ^4$9Y.1SFES1(097VDE=QVDGG':F;JUKU/
M:593[LJ3O)L>35MG+Z,JY3]W.?\ >.1_*J.:FB5)+6?(_>1X=2/3."/UJ(VZ
MB17)_>1_[_\ 2K$CE8B0 W08(S54G]Y'_O5IV!5KD*PRI5N#]#BKH5%3JQG)
M72:8XNTDV0-UQCGO3'P.1Z<TH;)R:9(P P/2LB3V/PU_Q\> ?^O6Z_\ 1:UY
M=\0<_P#"P]<_Z^!_Z"M>H>&?]?X _P"O2Z_]%K7EOQ"/_%P]<_Z^!_Z"M &#
MDG)/>GC>0JR.[+&-J*Q^Z/0>E1Q_,RJ.YQ5N^"IJ%RJD%1(<$'->EA\QKT:5
M3ED[R:U^\T4[+FZ]'V*EP1^[QQDG^5,@<P,C1,5=6#*PZ@CH:+@G=']3_*FI
MRXK;+<PQ4:L:,9:2DK^?3J53G*4E%ZW+5U?7-_/Y]W,9IB N\@#@=N*KA0&W
M#C/7'>F;N:<&J*^:XASE&#M"SBHK1*/HOS)4N1<D-(K1+L*Y!4J>AXI4.$ ]
M!32<D?6BM/[1Q*P*BIOXK?*RT+]I-0O<&C21@S@G'3FK]AJMYIDC26L@.X;7
MCE^9''HP[U0W4H.6 K?!YO7K5(X?$VG"32::TML3%QJ2Y:B3O]_W[EB[O)[V
MXDN+J5I)9!ACG''ICT]JIIM65550 ^<X^E/8]?K40/\ I$7_  +^59XO.<5S
M^SI/DC'1*.FBV_('/D=J:44NQH:5?7FB7)EM'4%^&1AE7'N*2ZE>[N'GN'\R
M60[F+5&/F;.>@I<[F/0<5OF>;5I*$HVA.45S-;^2OO:VOS(E2I0J>UA%*;6K
MZVZ#)1M1L8P5[5[GI7_(\>#_ /L"25X7<, C#VS7N>E?\CSX._[ DE>!4JU*
MKYJDFWYNXG)O=GB5W_R$+KT\^3_T(TT4MV?^)C=_]=Y/_0C2*>].%64=OZ_X
M U)H%3";<<AV./3.*9( &]B*>KY>0=PPY_"HIF/G 9XV_P!:^@Q&;5H5/E'O
MUBGW[OU]2J-648V\W^;8QU&-QQQSS4US<3:E<->715IY,$D#   P,#Z57DRZ
M;5ZL<4\&MI9S4A0C4T<FVEI9I:-_)O\ (;E%U%4:NTK+Y[_DB=I9) @DD9Q&
MNQ 3G:OH*C)I-U(37SN(Q#K3<I?TC-M=%8?FC-,SWI<USB'9II:D)I"<"D L
M)_TH_P"Y_6KG4XQS5"(_Z23_ +']:OA_E[<#(H :<$X[4MN,7]OSG]\G(_WA
M35.23FEA8?VA;@?\]D_]"% 'OVA?\E6US_L&VW\J[NN$T+_DJ^N?]@VV_E7=
MT <-XV;;KFG_ /7M+_Z$E+X)N&&J:C&(96#I#F1<;5^_UYS^0J#Q\VW6M._Z
M]Y?_ $)*E\ 2I]LU12ZAF$.%)Y/WZ^>4?^%EOR_1'SZJ_P#"PX>7Z'=4445]
M"?0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-7Q8/_%R-3_W
M8O\ T4M?2M?-'Q9W?\+(U,[6(Q",XXSY2<4 <B'I=_!JN"V"=K8!P3CH?3ZT
MI)4D,"".H(P10!8U^Z$-Y!+MR)(5./\ @(_PJK9W7VB*XE5,+$%R2?[QP*FU
M2,3?9EFC.4@7AL@BF+:+!I#[8G1I+@%L@@JJKG)]LM6E*K*E-3CNAQDXNZ%W
M4NZHF5E.#O!(SSQQZTG_  )JS$6[=?-G1,,V3T7J:CW>^:DTY6^UABKD")Y
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MT4JLRR [>,>I/^33MU5H[;[/8P!7RTDS.3CJ ,?S-29;_9J:L^90CV7YMO\
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M)!XCT]WDE34YK=U5I8E:%RL>5C41';R5!4MA?E.<>M9>IW5GKD5K%8F&.>)
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MFF+';)L8!2N1QP37N2? [PRARL]_T(_UWK^%26OP6T"RG$]K>:C%* 0&$P.
M>O44 >0:?H]C/I"7!M6FD^RB:(B1O]*F_>9@X/;:O"X;FE?P]:27,21*T,)U
M)H99WE^1(Q"LC+D]"IWC/7CU%>NW'P4\/7=PT]Q=ZC)*QRSF89)_ 5%_PHSP
MQ_SWU#_O_P#_ %J /%O%-I;6^I0/:&,VUQ;1S1"*7S%4$8VAOXL$$9/7&:SK
M3$=I>2CKL6//^\?\!7OA^!_ADQJAGO\ :I)'[[U_"E'P0\-")XA/?[7()_?>
MG3M[T ?/.^FE^*^A?^%%^%_^>]__ -__ /ZU'_"BO"__ #WU#_O_ /\ UJ /
MG61_W;?2OH;2#_Q7O@H?]0&3^E./P(\+$$&?4.?^F_\ ]:NRM?".GVNIZ7J(
M:9KG3;5K2$E_E,9]1W/O0!\]6EA8RI]MOH;1((KR\>:2>1E$P4J$0[23C<Y^
MZ,\>U2KH5O:EHY;.&YB,T@M;E)21+@,4#G(&&.U0@ .<G(KT>?X4^'9;J:;_
M (1K6=SR,Q(O(><DG_GK3/\ A4OAS.?^$:UK_P "X?\ X[0!YR^G6*6[R-:$
MQ1:A"DB12$X+PY9 ,YPLAP><]LU%<Z5:.9Q8V\,\B7EK"2LC1Q[W1O,C 8Y5
M=X'.21TS7I@^$_AW_H6]:'&/^/N'I_W]H_X5-X=_Z%O6?3_C[A_^.U3E=)=@
M.$FT?3&,-O<VL=I$JL+F<,4^SDA2C(&8[0Y+<-G..U5I=(TN%IGEME\G+-.N
M[9+:QK&2G&\@,[#J<@[AP*]&;X4^'WV[O#FL_*NU?]+AX'_?VFCX3>' 1CPW
MK/'3_2X?_CM2!YS/IWAW?<*\ZP70L))5@6.0*C#<5)R2=^T+\N<$G/M3TT[0
M6A1+%$N?,M%D^TSHVV'#2!GD7>I7.%Z XQTYY]$_X5/X=QC_ (1S6O\ P+A_
M^.TG_"IO#IZ^&]:]?^/N'_X[0!X]K5O%;Z?82I:);7$B/OC5MVX#&UNIR#D_
M-QG!X&.>@31],*_)902/YB+;J93^_@/E[YC\W)7<_(P!CH<5Z59_#72=.=GL
MM&\06S.,,8KZ)2WUQ+5=_A1X>D=G?P[K3,YW,3>0DD^I_>T >8V^EZ8LUC=3
MB!+%;>>:1KB=MMQMF*)DKR,@IT'3FN?U2TCLM5NK5)5FCBE*I(K9#KU4_B"*
M]N_X5-X=SG_A'-:S_P!?</\ \=H_X5/X>'_,NZU_X%P__': /!P0HP.!1OKW
MC_A4_A[_ *%W6O\ P,A_^.T?\*G\/?\ 0NZU_P"!D/\ \=H \%+U):/_ ,3"
MU_Z[Q_\ H0KW7_A4WAW_ *%S6O\ P,A_^.TZ+X3^'DGC=?#VM*RN&#&[B(!!
MZ_ZV@#9T'_DKVO#_ *AEK7?UBV6BVMKXFN]32TG6ZFMHX9+EI!Y<@7H N[((
M^@_&MJ@#@_'0SK>G_P#7M+_Z$E.\#22IJ6H1K;L\;+%ND# !/O\ ;J?PH\;C
M.MZ?_P!>TO\ Z$E/\$3P1ZEJ,#S1K-(D)2,L S8WYP.]8>R_>\Y\K%_\9"_\
M/_MJ.WHHHK<^J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\L\
M8_&(^$_$]UHW]BBY\@(?--ULW;D#=-I]:]3KY9^+7S?%?6@><+!U[?NDH [<
M?M"<9_X1U?\ P-'_ ,13O^&@>1_Q3J\]/]-_^QKQ8*/[H_*G!1GH/RH ]J'Q
M])./^$='_@9_]C1_POT_]"Z/_ S_ .QKQ@(,]!^5&P?W1^5 'LW_  OX_P#0
MN?\ DY_]A1_PO\_]"Y_Y.?\ V%>->6I_A'Y4>6O]U?RH ]D_X7^?^A<_\G/_
M +"C_AH _P#0N?\ DY_]A7CGE)_<7\J3RD/\"_E0![)_PO\ /_0N?^3G_P!A
M2_\ "_C_ -"Y_P"3G_V%>,B&/^XOY4AAC_N+^5 'M'_"_6_Z%S_R;_\ L*3_
M (7\W_0N?^3G_P!A7BYB3^XOY4TPQG^!?RH ]J_X7ZW_ $+G_DY_]A2_\+];
M_H7/_)S_ .PKQ(PQ_P!Q?RIIA3'W%_*@#VP_M ./^9;_ /)S_P"PKTZQ\2?;
M?%4FBBUV*NG17PF+YSO9EVXQVQUS7R#L"S1[?ER?X5SFOIS0O^2L3C_J6[7_
M -&O0!B>,OBUJOAKQC=Z+;:;930P*A621V#'*AN<<=ZQ_P#A>6M?] ?3_P#O
MMZYOXK(J_$S4Y#P2L0)_[9K7(AX_[Z_G0!ZG_P +QUK_ *!&G_\ ?;T?\+PU
MK_H$6'_?;UY<&0_Q+^=.WIG&]?P- 'J'_"\-:_Z!%A_WV]+_ ,+OUK_H$6'_
M 'V]>7AX_P#GHOYT;D_OK^= 'J'_  N_6O\ H$6'_?;T?\+OUK_H$6'_ 'V]
M>8;T_OK^=+O3^^OYT >G?\+OUK_H$6'_ 'V]'_"[]:_Z!%A_WV]>8[T_OK^=
M)O3^^OYT >G?\+OUK_H$6'_?;T?\+PUK_H$6'_?;UYAN3^^OYT%D'\:_G0!Z
M=_PO'6O^@18?]]O2?\+QUK_H#Z?_ -]O7F!=/[Z_G2;D_OK^= 'I_P#PO+6_
M^@/I_P#WV],?XZZXJY&CZ=GWD>O,2R?WU_.HWVL, @\]!0!]+VGC.[N=?\,:
M>;2%8]7L9+F5MQW1LJ@X7VY[UQ/BSXTZKX>\5ZEI$.F6$D5I+Y:/([AF^4'G
M'UK4TE ?&/P_;N-'N,?]\BO&_B'S\6/$?M./_05H [D?M :T1_R!]-_[^/3O
M^%^ZSP?[(T[!_P"FCUY.*=B@#UH?'G6<_P#((TWG_IH](?CUK(ZZ3IO_ ']>
MO*-H]!^5+L'H/RH ]4_X7YK'_0(TW_OZ_P#C1_POW6/^@3IO_?U_\:\KV+_=
M'Y4>6O\ <7\J /4_^%_:S_T"--_[^/\ XT?\+]UG_H$:=_W\>O+?*3^XOY4G
ME)_<7\J /5?^%^:U_P! ?3_^_CTO_"^M:_Z ^G_]]O7E/DQ_\\U_*D\F/_GF
MOY4 >L?\+XUO_H#Z?_WV])_POG6_^@-I_P#WV]>3&&/^XOY4GDQ_W%_*@#UO
M_A?&MX_Y VG_ /?;T?\ "^-;_P"@-I__ 'V]>1^4@_A'Y4TQKZ4 >M/\>]=5
M"1HVG<#/WWKTRS\975UXG\/Z6;6%8M3TUKR1]QW(P[#VKY4F  &&*9/4#-?0
MFE_\E(\#_P#8 E_I0!DW'[09@NIH?^$<#>7(R9%YUP2,_<]J9_PT.?\ H6__
M ";/_P 17BC_ /(9U+C_ )>)/_0S4PH ]F'[0O.#X= ]_MG_ -A3A^T&#_S+
MR_\ @9_]A7C0!I: /9/^&@\]/#J_^!G_ -A1_P -!G_H7%_\#/\ ["O'<48H
M ]B_X:#;_H7%_P# S_["C_AH-O\ H7%_\#?_ +"O'<4NWVH ]@_X:#/_ $+B
M_P#@;_\ 84O_  T&?^A=7_P-_P#L*\>VCT%)M'H/RH ]B_X:#_ZEU?\ P-'_
M ,31_P -!_\ 4O+_ .!H_P#B:\<V#T'Y4A0>@_*@#V3_ (:#_P"I=7_P-'_Q
M-+_PT%_U+R_^!H_^)KQ@H/[H_*FE1_='Y4 >T_\ #01_Z%U?_ W_ .QI\'Q_
M,US##_PCH_>2*A(O,XR0,_=KQ$H/0?E3[-0-3LOO#_2(_NC_ &A^E 'UK8>*
M/MWC34?#XM-@L[6*X\_S,[]_;;CC'UKH:\Y\/?\ ):_$7_8)M*]&H X?QH,Z
MY8?]>TO_ *$E3>"47[=J9(&0D.#CI]^H_&/_ "'+'_KVE_\ 0DI?!\&_5K^8
M32J(TB_=JPVMG?U&*Z72_<<Y\E%_\9%+_#_[:CM:***YCZT**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KY:^+ _P"+L:WQ_#!_Z*6OJ6OF'XOK
M(OQ+U.1$+@I"-HZC]VM '%@4X"JOVQU.#;/D9SSTJ8SNB*[6TA5O2@"<#UI=
MM5#?A#\T#CC=UI5U -C$$G(![=Z +>*,5#+=>0<-#)P.HIAU*,!B8I,)@'IW
MH M8HQ4 OE8D""7(.#P*1KY%8*89<DX''>@"QCBFXJM_:4148BE^9B@&!U%.
M2]23I%+^5 $V*:1FH&OT5N8I<\GH*:-0B;:1'(=P+#@=!0!.132*C6[1\XBD
MX]JC-['_ ,\I/RH <01/#@G[QZ"OIG0L?\+6FXY_X1RVY_[:O7S3#F617",J
MKD'-?3FAC_BY4I_ZE^V_]&/0!Y7\4$#?$75,@$;8NO\ US6N(DA3[8B!  <9
M&/K7=?$[_DHNI^XB_P#1:US5GI4FIW\?EOL*$;B>@H NV_AT3>!9-6"JQBN]
MC+CHI7@_F#7-7,:J80@497/'^[7M"Z2UKX;ETS:AMG4%QMQN('7->3:CIWV5
MSF0MY9P!CKZ'\J ,F.(%(P0.&;/Z5UVL^'+>R\*:%J,05S<PN9SCE7#8 _*L
MWP_H<NJ7<(Z0[OG)X'/;]*]2U_0);KPU'8(B[(8SY0' !/\ ]>@#Q,(I9AM&
M G'YU-:P+*4!"9\O/S?0U)/;26D\T,ZLLB#:5(QCFNF\(^%+C4[N*X>)_LL>
M"21C=Z8H J^+=!MM)GB%N5>%X%=6/5B=W^ KF71<7!VC((Q^E>G>/M(D:SBF
M._9"@C48& /\DUYR\*[YD+'YL'- &EX<L;>ZUJV$H3:)X\J?XLN 0/PJ7QA8
M6UMXEN3;;/*-QA47LH QQ[UN^!]!>XO/M\B2;(^8VQ@$]S53QAHQM;_S@[;'
M?(##)7OU[C-/2P'%1)^\!(X\S^AKHO#VCQZGJ3P[!A87<_+GHA./Q(Q6.D*^
M<4#$;7X.*]!\%Z68Q)>*7)<%>#P%(Q_GZT@//[JW$$C*T>U@Q!'IQTJ[)#%$
MAV(JY'85M^)]!>*^:XPZQ,V2V,\]/PK'F(V$8[4 >RZ0/^*L\!G_ *A$_P#Z
M"*\9^(:G_A:WB(E2 9Q@^ORK7L^D?\C7X$_[!,__ *"*\C^)44A^(VN21@,P
MN,;3_NK0!S IX%53/<(^PVXW#J,^V:L_Z0ELEP;?*,>F: '@4N*J->NA -N1
MG/&[TH6_9@I%LW(S]Z@"YBC%5VNV09-NWYTW^T?E=C WR*&//8T 6]M&*K+?
M%B0+=^/>E>^\O[T#T 6,4F*K?V@F2#%("'V$<=:5;U'.!%)0!-CFD(J$WJ!P
MIBDR3@<4Q;^)PI"R?-G''IUH G(IA%-%W&QX23_OFHS>1?W7]?NT ),"-F,@
M[NP]C7T'I@/_  L?P.=IQ_8,O/Y5X I$W*J<)G.?H:^AM)'_ !7?@P^FAR4
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M9,]JCVS6#2N^6#>8%8DE<=.I/.?PJIIGAU]/G@!MM.=(3Q<;6\TCL<= ??-
M%?3=0NY)-%\RYD82S78DR?O!=V,_3%;NFZH-37S([6>.%EW1RN%VN/;!./H:
MSK/0;FU.FGSHB;22X=NO/F9QCZ9YJ;2M*NK349KJ7[- DD>TP6I;8[9SO(/0
M]N/6@#:KYL^*W_)1]3^D7_HI:^DZ^;?BM_R4?4OI%_Z+6@#$\/WEO9?:VN[?
MSX2H5D#8)SD5L27'A9/#T:P--+>K,Z!98 K+&Z]2PR&*G!'0]17,V5I+=FX\
MK&(XB[9]!S45?9\.8:%3#N7,TU+5)^6GYO8]'!P4H7OU(-31742Q[@B?+M9L
M]>_Y_P Z[#P!;"XN+I)%+Q.FTJ#@YQD8-<5?[L)C[O.?Z5UGA/2=3U2.Z&GS
M_9P O[QB0,CK@CO7E9M&*S.<$[)V3;\TM3#$)*LT>O>$-)\/-IBHDBW=W&=S
MR7.UI%;TYZ#GZ\\UX[\2-R>((;=K,6[PQ[2@(*X#':?R[5ES7EU,81+<2/Y"
M".++?<4'@#TJ'6=0N-5N;>2Z??)'"L6\]6 )P3ZGWK;.,IJ8:G[=SYDW]WIT
MM\M"L1AW"/->YLV]I>:Y]FL8(4@AA81K+("J!FQ]]L8!/O71S>'Y_#D+:?'-
M'?W,L1DNX$8&./;QP>I(!Z8[^U85SJ5Q9Z99/:2,B74$@F'.&)."3[X'!]JR
M-/OYM.O5N82-P!!SW!X(KV:6%EBL"HTK*%M(]WYO=:ZZ'1&#J4K1V[%#3+5I
M]9@ME*H3=D*93A<C.,G\*]&ATCPI8Z2FIWVJFZNHI,31!=[.QZ!5) 9!@Y.>
M<GH>GFDC.][,23N-TK*<>K C^=;^MV5[I4T=A=']VH\V/@8.[J1WQD=Z\?(*
M;G4G1YW!Z>K6MU_7KT.?"QNW&]CLO%6HV7B3P-'JEA''9R67[F6"+& IR -O
M4# ![CGKQ7FWA>RN+^<VUO,$D,;-EB0-H//0'VK;T211:ZA$REE>$EP?N[0#
MU[]<51\!V,FH:K]FADV2-93!3V.< 9KFQD%@,RM#9;7Z7[]]V147LJVAU4#>
M'?#NLP37,8U$/;(90K1O"';J5!&2H'T(/UK)\;R6[ZG&]F)$M;A%GB208*9'
M/';/6L2>"6UN)()XVCEC8JZ,.01U%.U%Y)H[*61RY\HH"?120!7I\0X10H0K
M<W,]K^6^GW&^+IVBI7N9S5]):'_R4B7_ + %M_Z,>OFUNOXU]):'_P E'E_[
M %M_Z,>OD#SSRWXG?\E$U/\ W8O_ $6M3^ 8O.-X@7YN"#4/Q._Y*)J?^[%_
MZ+6M?X;(BQ3S Y;?AA0!Z/I]L?+C0=N:XCXN60.C)*%Y27(/_ 37I5HT:KE<
M' YKB_BDJS^%6_W^/K@T 5? EI(OAC3FB.2 -P]17<SQ-);_ #YR>,8ZFLOP
ME:K8Z381D<>2@/Y"NJG5#"0 ,Y_6@#YD\861L/$FI0D8W8<#ZUZEX9NK/3O#
MV@[F9%NW6!'/0/MR ?KC KF_BY9P1ZU9RC"O,@1R/3->I:/IME#I=E$8(I(D
M*M$'0$(1T(]#[U4'%2]]:#5KZDM_:-)$"W"D$$?A7@/CBW6T\27"(N%\H8]^
MM?2=U&CPG(Z#BO&?B;I%O+X@TN&(A99P48CKMSFI$==X9M'TS0-,39E6B56
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M9(V&PY_@[@U[+-IEM<6VQ?G3@LIZD5X_\,XCYUPY^Z[ 8]<5[%#E8,Q\$\T
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M "KZ&D4K"HR"?Y5\]>/@W_"6WI8$$I&>O7)ZB@#I?A[IUI<0O<3[25EQ('.
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M*N[KY@ZCP[]H%=UUX?\ ]R?^<=7/V?UVZ=KO_7:+_P!!:H?CRNZ\T'_KG/\
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M"\8'%=EJ7AOQ1J44<I\-303!8XW2% %8(FT,!GCC Q[5F?\ "$>*O^@#>_\
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M\?\ Z$*E.B:S_P! C4/_  %?_"I+31=8%_:DZ1J  F0DFU?@;A[4 ?0^@_\
M)7=>_P"P9:UWU<)H=M<)\6-<N'MYE@DTRV6.5D(1R.H#="17=T <SXAEMX=0
M\RZMWN(1:C=$G5OW\>/KSV[]*S-*N_"ZW3^7:307,DA9HGR<$EHP.N!PW3MN
M%=1>6%Q+J$=Y;3PHRQ&,K-"7!RP8$888((J'^SKXRM*7TOS&&"_V%LG\?,H
MSD;0+6.>PL8V@.FR?:GC7=$FX<<L>".:S-1315DC%Q9W,DETBAXWN0,&0DA&
MYZ%EW,>QP>^*ZB6VU2:)HY;C3I(V&&5[-B"/<>941TN\*A2=**A2H'V$XP<9
M'W^G _*@#GM U3P_:WUNNE6MR'GQ [,-H4\<^AR< D>G'OU&C?\ 'I/_ -?=
MQ_Z-:HAI]^L@D#Z6'#;@PLFR#C&<^9UQQ5O3K1[.U,<DJR2-(\C,J;1EF+<#
M)]?6@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>gcilxvfwaiqx000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +3 B8# 2(  A$! Q$!_\0
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M:@#A?^$^O?\ H%/_ -\/1_PGU[_T"G_[X>N\VCT'Y4;1Z#\J .#_ .$^O?\
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M_"P;_P#Z!#_]^WKO]H]!^5&T>@_*@#@/^%@W_P#T"'_[]O1_PL&__P"@0_\
MW[>N_P!H]!^5&T>@_*@#@/\ A8-__P! A_\ OV]'_"P;_P#Z!#_]^WKO]H]!
M^5&T>@_*@#@/^%@W_P#T"'_[]O1_PL&__P"@0_\ W[>N_P!H]!^5&T>@_*@#
M@/\ A8-__P! A_\ OV]'_"P;_P#Z!#_]^WKO]H]!^5&T>@_*@#@/^%@W_P#T
M"'_[]O1_PL&__P"@0_\ W[>N_P!H]!^5&T>@_*@#@/\ A8-__P! A_\ OV]'
M_"P;_P#Z!#_]^WKO]H]!^5&T>@_*@#@/^%@W_P#T"'_[]O1_PL&__P"@0_\
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M%JW'G 'WXJ43Q-]V1#^-*T4;_>C4_457FT^WDB8+$JL1P1VH MT511;^*-4
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M** "BBB@ HHHH S/$/\ R+NH?]<'_E6!\.?^0/<_]=1_Z"*W_$/_ "+NH?\
M7!_Y5@?#G_D#W/\ UU'_ *"* .RHHHH **** "BBB@ HHHH JZE_R"KS_K@_
M_H)KDOAO_P @V;_KE#_Z":ZW4O\ D%7G_7!__037)?#?_D&S?]<H?_030!V]
M%%% ' ?$#_D*:=_UR?\ F*[V/_5K]!7!?$#_ )"FG?\ 7)_YBN]C_P!6OT%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_A)-#_Z"]C_ .!"_P"- &I167_PDFA_]!>Q_P# A?\ &C_A)-#_ .@O8_\
M@0O^- &I167_ ,))H?\ T%['_P "%_QH_P"$DT/_ *"]C_X$+_C0!J5XI\4?
M$VI6'BZQMVO9-/M8GS&T1SYO!ZCZXXKUN'7=)N9EA@U.TDE<X5$F4DGV&:\?
M^(>C:E_PF-SJ\.E:I-##&#YT<2/& !DD;CVH ]%\-ZEJ>J^ #=ZO;^1=M;R
MKZC;P?QJG\-_^0;-_P!<H?\ T$T_P=JTNM?#IKV:>29FBE&^0 ' 'H.*9\-_
M^0;-_P!<H?\ T$T =O1110!P'Q _Y"FG?]<G_F*[V/\ U:_05P7Q _Y"FG?]
M<G_F*[V/_5K]!0 ZBBB@#S?PYHNGZOXW\77%Y:"=!=1B-VR!]WG!KK?^$/T#
M_H&1?]]-_C7,>'[S5-.\4>)H(=.N;NQ%TIAVN J';\P&?>NE_MO4O^A>NO\
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M:M+Z*\TZ*]4,D4D?F?.,$#&>:Y:]\7S-K&E2Z7+8SZ!-*8+J[,G*29P%'J:
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M4, ;X###!_U= 'H]<-IW_)4+_P#ZY_TKN:X;3O\ DJ%__P!<_P"E '<T444
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MA(PBY//'2N6\4?\ (4^'O_7ZO_HJNP\1?\B[J'_7%JX_Q3_R%?A[_P!?J_\
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M0(/!L1QW8$G^5 'HVJ7VD:E:" :_;VV'5]\-T@;@YQUZ&KG]O:/_ -!:Q_\
M A/\:\LDD\!1!2?!,1W,%^5"<?I3_P#B@_\ H2X/^^3_ (4 >B:C?:1?BWQK
M]O!Y,HD_=72#?CL>>E<E\0O%DUO=Z-:Z)X@MK47,D@GE1EDV@+D9].:PKBY\
M VWE[O ZOO8*-D9./<\=*M0S^![>3?#X.A1L$9"GH?PH XJP\::MXA@2QU#Q
MDJ_:7\IH(HAO8[L8_P#KUZIXRA^SZ_X#ASGR]1V9]<1XKFVO_ VF8O8O!BB2
M$AE,2$L#VQQ4NI^*9/$_C'P@L6EW,,46H&3S&4D8VXYXXH ]=KAM._Y*A?\
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M %RA_P#030!V]%%% 'GWQ#_Y"6G_ /7)_P#T):[^/_5K]!7 ?$/_ )"6G_\
M7)__ $):[^/_ %:_04 .HHHH YG1;NR@U#6DN+BWC?[:QQ(Z@]!ZUL_VEI?_
M #^V?_?U?\:P;GP5X<UW4;J[U+2H;B<O@NV03^1IG_"L/!G_ $ ;?\V_QH Z
M'^TM+_Y_;/\ [^K_ (T?VEI?_/[9_P#?U?\ &N>_X5AX,_Z -O\ FW^-'_"L
M/!G_ $ ;?\V_QH Z'^TM+_Y_;/\ [^K_ (T?VEI?_/[9_P#?U?\ &N>_X5AX
M,_Z -O\ FW^-'_"L/!G_ $ ;?\V_QH Z'^TM+_Y_;/\ [^K_ (T?VGI@Z7UI
MQ_TU7_&N>_X5AX,_Z -O^;?XT?\ "L/!G_0!M_S;_&@#H_[5T[_G_M?^_P O
M^-<;I,T4_P 3;Z2&1)$,?#(P(Z>U7_\ A6'@S_H V_YM_C6GHWA#0?#\[3Z5
MIT5M(PP60GI^)H VZ*** "BBB@#/DCN;>6>:+RRK?,0W7BKD$AE@CD(P67-4
MW-U<S7$22HD:_+RN3S5R&/RH$CSG:,9H DHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#,\0_\ (NZA_P!<'_E7G_A_PN==LVN%DAAV[4/RMEOE')P17H'B
M'_D7=0_ZX/\ RK#^'O\ R!9?^N@_]!% %+_A7C_\_<7_ 'R__P 51_PKQ_\
MG[B_[Y?_ .*KO** .!;X=RD\7T0_X __ ,52?\*YF_Z"$7_?#_\ Q5=_7/\
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M_D):?_UR?_T):[^/_5K]!7 ?$/\ Y"6G_P#7)_\ T):[^/\ U:_04 .HHHH
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M-I;6%E*\,)MNDB[<[C4GPS_Y!UQ_N0_R- '=4444 >??$/\ Y"6G_P#7)_\
MT):[^/\ U:_05P'Q$XU#3CZHX_5:[^/_ %:_04 .HHHH IV7^MN?^NE7*IV7
M^MN?^NE7* *9OF,CK';2.$."11]LF_Y\Y?THL?OW/_70U<H I_;)O^?.7]*/
MMDW_ #YR_I5RB@"DU^Z;3):R(I(&35VH;FW^TP^7N*\@@BJR^?#?PQO.TBNK
M9!'I0!?HHHH **** "BBB@"G:_\ 'W=?[PJY5.U_X^[K_>%7* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,SQ#_R+NH?]<'_ )5A?#O_ ) T_P#UT'_H
M(K=\0_\ (NZA_P!<'_E6%\._^0-/_P!=!_Z"* -_7II[?P_J,]J0L\=M(R$]
MB%/->%^%?"'A#6]"@U7Q1XIDEU.['F.HO=FS/8BO=M<D2+0=0>1D5!;ODR?=
M^Z>OM7S7IW@'6=70/8:;X5N 1GY+D$_EF@#N_AM<G2/B5J7AG3=8?4=$6V$T
M)=]^T^@->F>+-0U;3M"DET33UOKXD*D3'CGN:X#X9>!->\->(9;S4])TJTA:
M$H'M'RQ/I]*Z'XMZMJ.D>!+F?3G>*1W5'F3K&I/)H X_3_A ^O7TNO>,]21;
MB7K!8,(U3V+#O7HWA'P9I/@^VN(])>X>.Y8.QFF,G08X-<UH.A^'KKX8G2VU
MYIK:X4RS71N,.'/)Y[<]JI?!G5+R8:UI#WK7]AI\^RUNF.<KZ>] '8>*_P#D
M(^'?^PDG\C61XCED76I@OP_;5A@?Z6/+^?\ /FM?Q7_R$?#O_823^1KC_&7Q
M5U+P]K]Y8V6G64L-HT:.9[C8S,_3 ]!WH T_ FEWVG:/XDFO-*;3%NYWFAMF
MQ\J[/;BK/PS_ .0=<?[D/\C5SPWJ^K:SH&I7&JBP#!6$:V4PE51M/4^M4_AG
M_P @ZX_W(?Y&@#NJ*** //OB+_Q_:;_N/_-:[^/_ %:_05P'Q%_X_M-_W'_F
MM=_'_JU^@H =1110!4:P4R,ZRR)N.2%-)]@_Z>)O^^JN44 0V]NMLC*I8[CD
MDFIJ** "BBB@ JO<6JW#(Q9E9.A4U8HH I_8/^GB;_OJC[!_T\3?]]5<HH I
M_8/^GB;_ +ZH^P?]/$W_ 'U5RB@"G]@_Z>)O^^J/L'_3Q-_WU5RB@""WMEM]
MVUF8L<DL:GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$/\ R+NH
M?]<'_E6%\._^0-/_ -=!_P"@BMWQ#_R+NH?]<'_E6%\._P#D#3_]=!_Z"* .
MFU)[./3+E[_9]D6,F;>,C;WS7SMK0\):E=N/ NBZS+?EB5ELMT<>[W]J^BM1
MA-QIMU"NS<\3*ID&5!QQGVKYNN?&^O\ AZ[ET]/%^EHT1VL+:RRN?J* /2?A
M?IOQ!L[EF\4W'_$O\K]U%(X:0-[UV/C.6[B\-7 L]%_MB1QM-IG[X/6N/^%^
MK^(=>N)+V^\2V.IV(CQY,,>UT;MD5V'C./7YO#D\?AMT346P%9ST'>@#YMUU
M8M!97U'P1<Z="[?ZC[:0K?\  0:]K^#M\+SPU-Y/AS^QK1''D]3YV1RV3UKS
MBQ^'GCK3M3DU?5;+3M2N,[A+?SY5/SXKUKX>Z[JNL6]]%JC:;YEK(J*E@^Y5
M&.AQQ0!>\5_\A'P[_P!A)/Y&O)/'VNZ?;^,M9LKBPCN+X36Y@Q;>8?+S^\R?
MI7K?BO\ Y"/AW_L))_(UX7\;5N7\:M_9VUK@ ;Q:1MYHX_B(H ]3^'MQ'<Z)
MXDDMK(VEB;A_LJ& Q'9L]*N_#/\ Y!UQ_N0_R-9GPNBN8? EVMU%J:/Y;'_3
MCG/R_P /M6G\,_\ D'7'^Y#_ "- '=4444 >??$7_C^TW_<?^:UW\?\ JU^@
MK@/B+_Q_:;_N/_-:[^/_ %:_04 .HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KD/!VI7E]KWBR&YN'ECM=1\J!6/"+M!P*Z^O+/#WB.TT
M?Q/XRM0PFU&?5/\ 1[53\TAV#]* /4#-$LJQ-(HD895">2/I2)/%)(\:2(SQ
MG#J#DK]:Y5=#NH;.?6;V0S:R1O4KTB'9%'I_.GW&@W5K'#K&E-MU,(#<1D_+
M<CJ0??T- $OB+Q3-HNJ6EE#9?:#/MS\V#EGV@ ?K735YE?:[:ZUXST9H6VSQ
M/"L\+?>B;S#P:]-H **** "N4\2>++C0M06V2S6163<K,2-Q[@>]=77#>/\
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MQ0!-14/VNV_Y^(O^^Q1]KMO^?B+_ +[% $U%0_:[;_GXB_[[%'VNV_Y^(O\
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M ) EA_U[1_\ H(J[0 4444 9VO?\B_J'_7!_Y5@?#O\ Y <O_70?R%;^O?\
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M_P ?VF_[C_S6N_C_ -6OT%<!\1?^/[3?]Q_YK7?Q_P"K7Z"@!U%%% !1110
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M_P!>T?\ Z"*NU2T?_D"6'_7M'_Z"*NT %%%% &=KW_(OZA_UP?\ E6!\._\
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M_P#(-NO^N+_R-<;\,_\ D'7'^Y#_ "- '=4444 >??$7_C^TW_<?^:UW\?\
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M\?VF_P"X_P#-:[^/_5K]!7 ?$7_C^TW_ ''_ )K7?Q_ZM?H* '4444 %%%%
M!1110 5\W_$K_DX32_\ MVKZ0KYO^)7_ "<)I?\ V[4 ?2%%%% !1110 444
M4 %%%% !1110 4444 %%%% 'E/CW_DLG@3_??^M>K5YGX_LI!XY\/:TD4DAT
MY3(L8&!)EL$9QP<<UI?\+"N/^@#+_P!_A_A0!W5%<+_PL*X_Z ,O_?X?X4?\
M+"N/^@#+_P!_A_A0!W5<-X__ .0AHG_71_Z4G_"PKC_H R_]_A_A6-K.MW/B
M/4--_P")9);B"0_Q;RQ;'H* /4Z*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N2\9_P"NL?\ KC=?^BJZVN2\9_ZZQ_ZXW7_HJ@#H
M-'_Y EA_U[1_^@BKM4M'_P"0)8?]>T?_ *"*NT %%%% &=KW_(OZA_UP?^58
M'P[_ .0'+_UT'\A6_KW_ "+^H?\ 7!_Y5@?#P@:',3T$@_D* .PHJO9W]IJ$
M;/9W,4Z(Q5C&V0".U6* .&\8^/[WPMJ(MX?#5]J$/E[S/"0%'MS6'X2^-">+
M/$,.DP^'[N(N2'E+AE3'KBLCXVF^^U0QMXGCL;-X\K8JK%Y2.IPO6JGPGUN9
MM3MM-M+_ $B"+DO;_8FBGD [@GK0![O1110!S?BC_D(^'O\ L(+_ "->*_$F
MQN;OQ;K\L5A:7$:W-I&99G(="QP%'L>]>U>*/^0CX>_[""_R->/?$32UUWQ[
MJ=I8SPV,D?E27$US>^6LC#D +_6@#T/P'=&30=>LGTFRTV6QD>!X[0DJQ"=<
MFK'PS_Y!UQ_N0_R-8WPJ>$^%M?B6)EN(YG%Q)]H\Y9&V]0U;/PS_ .0=<?[D
M/\C0!W5%%% 'GWQ%_P"/[3?]Q_YK7?Q_ZM?H*X#XB_\ ']IO^X_\UKOX_P#5
MK]!0 ZBBB@ HHHH **** "OF_P")7_)PFE_]NU?2%?-_Q*_Y.$TO_MVH ^D*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KDO&?^NL?^N-U_
MZ*KK:Y+QG_KK'_KC=?\ HJ@#H-'_ .0)8?\ 7M'_ .@BKM4M'_Y EA_U[1_^
M@BKM !1110!G:]_R+^H?]<'_ )5S?@'+>'+H#^]C_P =KI->_P"1?U#_ *X/
M_*N<^'N/[ N=PRN_D?\  : /./ FE:E96>HK)XP70]U[(PM\QMN!)^;DUZGX
M1CGC^T^=XI&N9QC 7]W_ -\U\Y>+8_#^I:[+9:7H%UIL'GMYU\\;NQYYPH]:
M]H^#]AX8T^PNXM :]DF^7[1+=0F/<>V : ,[QY'=^'_B+9^*9M';5M-%OY+(
MF"T1SU K.ANI_'_Q T:]TC0IM)M=-<O/=2H$9Q_=Q6A\2-7\.V7CNS@\3+<"
MS:R+*\#/NW;NF%-'@W5_AO<^*+2+0WU$Z@Q/E><9-O3ODXH ]?HK!\6^*K/P
MAHW]HW<4LP,BQI%$,L['H!7':K\9+;3[_P"SPZ)>W"P0K->E,9MU/3/O0!U?
MBC_D(^'O^P@O\C7BWQAM-_BZ=K'2[^>Y8+YL_D;HE'MQS7KFKZC#JR>$]0MM
MWDW%]'(FX8."IKC_ (B:%XH\1:S=1>'_ !5"@B0!].\WRV&: +GPFM[:U\%Z
MG%#<S3288RB2V,(5MIZ ]:V_AG_R#KC_ '(?Y&LCX6Q&T\)ZM83P*E[; I<2
M+<>:)6VGG-;'PV7987*^B0_R- '<T444 >??$7_C^TW_ ''_ )K7?Q_ZM?H*
MX#XB_P#']IO^X_\ -:[^/_5K]!0 ZBBB@ HHHH **** "OF_XE?\G":7_P!N
MU?2%?-_Q*_Y.$TO_ +=J /I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *Y+QG_ *ZQ_P"N-U_Z*KK:Y+QG_KK'_KC=?^BJ .@T?_D"6'_7
MM'_Z"*NU2T?_ ) EA_U[1_\ H(J[0 4444 9VO?\B_J'_7!_Y5SGP\V_V!<[
MON[^?IMKH]>_Y%_4/^N#_P JYWX>*&T&Y5NADP?^^10!Y/<Z7_PDNIZ@?"?A
MV[NK>WG97N9K]U5SGG KO_A/-IH_M.SBT^ZT_4X&"W5O<3-)]",UQ5MJ]SX/
M\67VA^&/$.G/;W,Y8178/[N5CR W?FO2O G@[4M"N]1U;6[Y;O5-08&4H,*@
M'84 0^+-0\':%XFCUG7KV,WB6WDI:L@?*D]0M9OACQ]8>(_$$4&@^%&%LDA2
M:],*IY7IT&:B^(NG?#[5-?AMO$MQ)9ZDT?[NX!*C'UZ5%X%\%WWAO63<:#XI
MM[_1[E]\\#89B,<'/K0!T'Q6M=,N/"'F:GJ3:>()TDAN%7<0X/ QWKQ)M4TB
M*UFLK3Q'=7$NIS_\36]-J<I%C@>PS7O/Q"\/7WB/0K>WT\6YF@NH[C;<'Y&"
MG.#7COB2VOM)L?$$-[>^'+?^V-ID6%\M&!QA0* /6+VVMK.Q\'6]D^^VCNXA
M&V>HVGFN&\;>'M.UOQIJ5Y>ZO_9T5J8H&-K&1*SR<+N;N,UUMM%Y/ASP+&'#
MA;B(;@.ORFN;\<:9X9D\47WV[7M7LYIVCDFAMK<LA9?NG..HH W/AQIHT3P]
MKVDB6"<V4KQ--'&59SMS\WJ:U/AS_P >=U_N0_\ H)K$^%X)T/Q3()[FXCDN
MG9+BY0J\HV?>(K;^'/\ QYW7^Y#_ .@F@#MZ*** //OB+_Q_:;_N/_-:[^/_
M %:_05P'Q%_X_M-_W'_FM=_'_JU^@H =1110 4444 %%%% !7S?\2O\ DX32
M_P#MVKZ0KYO^)7_)PFE_]NU 'TA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<EXS_UUC_UQNO_ $576UR7C/\ UUC_ -<;K_T50!T&C_\
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M\8:SXK\2>%;_ $BW\%:C;RW,>Q93,F%Y]J .BU&[^WVWA&[%N;;S;V-O)/\
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MUZ'110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7%_Y&N0^'/_ !YW7^Y#_P"@FNMU+_D%7G_7!_\ T$UR'PV_Y!]Q_P!<X/\
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M **** "BBB@ KYO^)7_)PFE_]NU?2%?-_P 2O^3A-+_[=J /I"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_Y!LW_7*'_T$UUNI?\ (*O/^N#_ /H)KDOAO_R#9O\ KE#_ .@F@#MZ***
M.#\?_P#']8?[C?S%=U'_ *M?H*X7Q_\ \?UA_N-_,5W4?^K7Z"@!U%%% !11
M10 4444 %?-_Q*_Y.$TO_MVKZ0KYO^)7_)PFE_\ ;M0!](4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_07U?_P)'^%'_"*1?]!?5_\ P)'^% $W_"6:%_T$$_[X;_"C_A+-"_Z""?\
M?#?X5#_PBD7_ $%]7_\  D?X4?\ "*1?]!?5_P#P)'^% $W_  EFA?\ 003_
M +X;_"C_ (2S0O\ H()_WPW^%0_\(I%_T%]7_P# D?X4?\(I%_T%]7_\"1_A
M0!-_PEFA?]!!/^^&_P */^$LT+_H()_WPW^%8OB/PMJ$?A^\;1-5U5M1"?N
MUP""<_2L[2?#VNW.O_Z;?:O!IHM%X:X&XS?Q=NE '5_\)9H7_003_OAO\*/^
M$LT+_H()_P!\-_A4/_"*1?\ 07U?_P "1_A1_P (I%_T%]7_ / D?X4 3?\
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M2/\ "@";_A+-"_Z""?\ ?#?X4?\ "6:%_P!!!/\ OAO\*A_X12+_ *"^K_\
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M[*6K.OZU>"4EL<[YUW%SND'UK E$M[JIX+LS<X%>B-&C##*"*@M["WMG9XT
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M?\(%JG_/_9_]^Y/_ (JC_A M4_Y_[/\ []R?_%4 >@T5Y]_P@6J?\_\ 9_\
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M0SI+-'(9"H41IM5548 Q0!NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>gvxjy5si4hmk000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )' BX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD'A[28M-MKBZG@BX0W,OF,H],^E:= '&GX4>!B/^1<LQ_P !/^-(?A/X&/\
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ME 'F_P#PHGP#_P! N?\ \"Y/\:0_ CP"1C^S;@>_VN3_ !KTFB@#Q[Q-\(_
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MNZ!IMP5NA ],<UEV/A[X57/B2:QDM[T6)$7V:[6:0I(TF<!CT7D8'K7I-_\
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M=\*S9ZC:F;7))],M9Q<167V=5'F;=N2V?85Z-0 4444 %%%% !1110 4444
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M)9_%K2A:6?VR&=II=L;R0Q_N_-()VKDY/ ZTM[\5;$RZ;!8Q[9KK[-*WVI2
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M0V\<KWD*17DMJQ 22-V(*>Q7]:CA^*WB:>!9V:RAELUA#6K0MOU%V?:_E^@
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M.555ZDMT'XTS2/$^F:YJ6HV-A*TDNGR".=L?+N/H>] &S1110 4444 %%%%
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M'<WP0^3%*^U6;MD]A5VB@#Q:T\'^+HFM-3GT-)=6751J%VXOHQYV.BCL%4#
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MM'!YQCA(;<VWO@XZ4 =716+X3U:/6_#5I?QWWVT.I#3^5Y>Y@<'Y>QR.E;5
M!1110 445YUXQ^(I\.^-](T>*:S%JQ1M0,C?.B.P5=H_4^PH ]%HKR/5/BY)
M!XCTZ6*RN(M! NO/D=!NN/*!Y3G@!ACMU]JUH?B[97$#>1HNHSW22,K01!6(
M55#ELYP1@G\C0!Z-17F-K\55DOKAH;2XU&"1PMM!:V^UU^7<=S,V#QZ5/%\9
M] GU*PM(K:[9;EHE>4J L+.< ,.I]\"@#T>BBB@ HHHH **** "BBB@ HHJK
MJ)OAI\QTP6YO-O[H7&=F??'.* +5%>/VWQ/\47DDFFV^GZ/)J$,TX>Z\U_LS
MQQ)EMO?(. 3G%;'A7XP:7XCN]-TYK&ZCU"Z&QQ&NZ-9 "6&<YQ@9SB@#TBBB
MB@ HHHH YWQKX=E\3>'7L[:5([J.1)X#)G89$8$!L=1Q7)^(/"'BSQ-<6MWJ
M,.B/)!')"+=I)&B =<>:,KPX[<?B*[+Q;J6I:/X<N]1TN*UDFMD,K)<EMI4<
MGIWKD].^*!MM*L[GQ!:8GNX4N1'IT32"")C@&3)XH QK7X/7-MHE[9-_9L]U
M-=V\BW<J$N8TQN!..,]@/QJ3_A55]'JLT<=KI*Z?_:4M[#,FY)5C92/)P%X7
MG'!XK=U'XJ:3Y=W;Z8[MJ%K(BRQSP/MC4R*N6(]=PQ]16WH'C?3O$FH36NG6
MU\\<1(^UF B!\<':_?G(_"@#SJ'X/:I,D45T^GPV\44ZP)%@F$L 8\D(-Y##
M[QP<>M0W7P;UB>WL7N9+2^N9(Y#J DN"O[YW#%XV*$]% Z U[A10!%;QF*VB
MC9BS(@4ECDG ]>]2T44 %%%% !1110 4444 %%%% !117(>)?%6IV/B;3_#V
MAV%O>7]S!)<R&>4JL4:X )QSR>!0!U]%><Z?\7](?387U*VN8KX)(UQ#:QF9
M8A&Y1VW#^'(//I5L_%WPH+B6+S[EA&C.'6'*OM&2%YY- '=T5RUOXWL-4\,Z
MEJ^EAV-BC-)%.A1L@9P0>A-59?B+IVFZ'HFH:M#-"=3MHY_W499(]Z@XS[$C
M\Z .SHKA?#GQ'LM2U'^R[])8;R6ZFAMG\O\ =RJAXPW][':NZH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM7T6TUJ&.*Z:=1&VY3#
M,T9_,=JT:X/XG>(-8T:STBUT0A;C4;T0,P=%?;@DA"YVACC@G- '7:1I%CH6
MEP:;IT"P6L(PB#]2?4D]ZO5SW@C6$UWPM;7J/=N=SQN;LJ9-RL5.2H"GD=0*
MZ&@ HHHH *YC4/A_X;U6?49[_3UN)M09&FDD.64J,+M/5<>U=/7CGC/QOX@T
M;Q_<0V]ZT6DV3V@G/DJT2+(3N\SJ_(Z;?TH ZY_A7X6E/[^VGF0"4+'),2J>
M9]\@>IZU>M/ .A6B1*(I9/*22-2[\[738PX _AXKSWQ1\6-9?PG$^E64-K=7
MD5P?/$N[R0DACRO')[YZ?RK,TKQ]XE\/ZY?0ZE#)?21E+*&W-R75&5-S%L)E
MF/'YT >HV'P[\.:;+%);VK@Q9V!I"0#MVY_*HK3X:>';#4K>_M(98IH0H.'R
M'VG(W9';VQVJMX8\=:CXD\0+IW]B?8XX[..YN6GEQ)&7^ZH3&2#ZG%<3!\2_
M$4?B>ZTV]=5MKG5UM;*9(UX590KIGL=ISS[T >WT5YQX4\3:K+\1+_P[J5S.
M8X;-98ENH%225MQ!==F1LQCK@YKT>@ HHHH **** "BBB@ JEJVFQZOID]A-
M-<0QSKM9[>0QN![,.E7:Q_%'B&V\+^'KK5KH,4A7Y549+L>@'(ZF@#GE^%>B
MI;6T,=_JR?95>.!UN0&C1QAU'R\AN^<FL+P_\+-3\/\ C@:K9W]M#8+,2"K,
MTK0$']T01C.<$MFN?TGXXWT&E,=1M8;V_GN9#"L+A$2)=OR\]6YX]:U_$7Q9
MNET?4K:WM!8Z@+-Y89HYEG,3J1PR@<'GOT[T >OT5YSIFK^()/'UC9KJ$UY;
MS6:3W]JUJ$CM%* HRR=68MD$?RKT:@ HHHH JZGI\&K:9<Z?<[O(N(S')L;!
MP>N#VKEY_AIHDT5O&EQJ, BLUL6,5S@S0 YV/D'/UJYX[\077AWP]Y]B(_ML
M\R6\#2KE%9F !89Z"L._\6ZSX1G_ +.U'9KMXT3W6ZVC6W$4"#YBP+')^E %
MN3X5^'Y;J[N3-J(FO&4W#"Y/[P*RLH/'1=H ]JU/#7@ZT\*M*FGWM\;1F9DM
M))0T4>XY.!C/7W[UR*_&%KF8?V?X8O+FWEE\B"4SQIOEV;PI!/'&>OI5"/XL
MWO\ PD$E^MA-/H']G6\\T8**]H7?:6/=ADXQ0![!17F<_P 9+"&SM;A=&OW^
MT03SA0!PL1P><]^#GIBLN\^+6J227_E::MK9Q::EXMTCQW'EDL%QPX5@2<#!
M!!(S0![!17B]W\5-8L]#U2.YM9([I[B:*QOP$\H%2OR,N[((#=?YXKI?#?Q4
ML-:UVUT0VTIFF4QBX#(0TJ#+@HI)0>A/6@#T.BBB@ HHKCO%7B#5+?Q-H?AS
M1Y+>WNM1\R1[FXB,BQQH,G"@C+'ZB@#L:*\D'Q&UCPW<>(4\0&VOVL)XH4^S
M,D RT9=L!VRW ' R<YJ]+\9]/6"ZN(M&OGB@MHI_F>-'8/MQA2V=HW<MC'%
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M$*:8ABO$O-0N=]HJMYUL  P8GH$Y->RT %%%% !1110 4444 %%%% !1110
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M9&/R- %_0_&VBZ_]L-K.T:VA02-<+Y?+@D##<YX/%;C7ELKLC7$0= "REQD
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MO'(-KAE.#QZ>]:E>1Z#X!UZR\56-^UI;6CPW,T]SJ"3^8]RC 8C*_7/->N4
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M%[CWKH:\OT7X;ZM9^(=/N;RYL3:V-U-=++$&\^4R #:Q/&T8Z>]>H4 %%%%
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M'[1,9B%E=DVLV/<'%=78^';'3]36_@\WSELTLAN?*B-.G'K[T :U%%% '/\
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MGGR+FTF,4B@]1GT/I0!Q]K\3[C1Y=;_X2RV5?[/N8K?_ (EZ[U5F0L?O$'&
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M;>QM8[6TAC@MXAM2.-0JJ/0 =* )J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#DOB-J]]HOA0W.G3R0W#W,40>*$2N S8.%/4UR$/CC4]!U#4Y;
M^>>^2.TM?+M[P+;2;V+Y^7'4XZ9KU*_TVSU2!8+ZVCN(DD654D&0&4Y!_ U0
MU3PGH.M232:EI5M=22A [2)DG;G;],9/YT <))\8V>PM+ZR\/RW%M+##+*3<
M*AB,LCQJN".3N0^V*=)\7YQ:.T7AUY+JWCN)+N$72_N1"P#\X^;A@>/I79)X
M(\-QV2V::5 L"JBA ".$<NH_!B33QX,\.A[EQI-OONEE29MO+B3&\'ZX% ')
M7'Q5DM]+N+F315CN;>7;);/>(&V[-X(/<X/3UK$TGXGZA/-J=U+:R2:9=SQQ
M6]P' ^R.\60I7JP!!Y%>A7O@+POJ.[[7H]O*6<.2<Y)V[?Y ?E4=O\//"EI<
M13P:- DD0PA!.!^&<4 <=X5^*YN'TW2KNSN;N9G2">\7&=[#(;8!G'(!/0=Z
MD\0^.-4MM8UJ7^T5TW1])N(K5BEB;F1F*AF=L$!4Y '4YSQ780> O#-MJ$-]
M!I:1W$)4JRNPY'3(S@X_I3M8\#>'->OGO-2TU)IW54D8.R[P#D!@" <>] '*
MS?%V*WU&\LQH\]UY$!EC>VF20R8QG(!R@Y'7\<5W'AW6/[>T*VU+RTC,RY*)
M*L@4^FX<5E/\.?"KW%U/_9:I-=#$KI*ZD],XP>.@Z5N:5I%AH>GI8:;;);VR
M$E8TZ9)R: +M%%% !1110 4444 %<-XDUC7+CQI;>&M'OK?3RUC)>O<2Q>86
MVE0% R!U/7/0&NYK&USPKHOB1H'U6Q6>2WSY3[BK+GJ,@@X/I0!Y]I_Q?NO[
M/A6?17O;B&W:XO+B"54B6-'*,Z[NIXSC]:E3XV6D@FN(]#O)++!$$J,I+L,#
M##/RC)&">*W[OX7Z!>Z]:W\T"FTMK,6L=DJ[4 # @G'7Z=\UH-\/O"S7$\QT
MF+,_^L3<VP_\!SC]* *-KXTN-7\(:]?6]BUCJ.FI(IAF8. X3<O(."#]:SK_
M .)4NBZ)H-Q<6*WDU]80W,VR=(V4L%SA"<D9/:NR@\/:3;17T<5E&B7YS<@?
M\M.,<_A6$?A=X..PMHZ$H-JDRN<#.<=>F>U &%X7^(-TVJI8:I"\UM?:C<P6
M=]O&"5PPCV#YN >#BO3:Y^Q\$^'=-UC^U;/3(HKS)(<$X4D8)"YP"1WKH* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ6IZMIVC6A
MNM3O;>SMP0OF3R!%R>@R: +M%9+^)]"CU*'37U:S6]F"F.W,H#ON&1@>XK6H
M **** "BBL^ZU[2;*]2RNM2M8;I\;8GE 8YX'% &A1110 4444 %%0I=V\EU
M+:I,C7$(5I(PWS(#TR.V<&FWE]:Z=;-<WMQ%;P*0#)*P51GW- %BBH+:\MKR
M-9+:XBF1UW*48'(]?I2F[MUNUM3,@N&4NL>[YB!U./2@":BBB@ HHHH ***1
MF5$+.P50,DDX H 6BH(KVUG$9BN(I!+GRRK@[\=<>M3T %%%% !1110!R_Q!
MUUM!\(W4T$KI>3E;>V\H OO<@94=R,DUYAIOQ;UC3= TS35MS?:O&T\=R;T$
M.WEM@ X(VL<CD].:]LOK:PF$4U_%;L(&WQO,!^[;U!/0^]9CZ7X6UF[FB>RT
MR\N RSR@QHYR1PQ^H% ' WOQ0\1127$D>FZ;;V_VZ'3X1=2-OCFD17/F%3M
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M2.:2SF$JPS/ Y Z.IP15N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDB@#U:BD!R 2,>U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW2ZS(SJH8.T>,JASC.>M>KURX\!:-]GUZ-A*TFMR.]S,2/,&X ;5..%XZ>]
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M!< ,8HPN0!@9QZ"K- !1110!P_Q$U>[LGT+3X+V33X-1OTM[F[3 *(03@$\
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MK0].U!]0LM(LK>\D!#3Q0*KG/7D#/-:E !1110 4444 %%%% !1110 4444
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M)T/Q#8:_;236<GW)I(BC$;OD;:3CTK6H **** "BBB@ HHHH **** "BBB@
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M*$MU,84B&W.YC@G'X5G6_P 2;>W359]5@?[-9W/E++8Q/.FS:&,C,!@+SUH
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MZ;.'4;.2[7.84G4N,=?E!S5ZO'O!]FVF?$0QZ1:O<65U+<37DUWI?DRVQ."
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MD_Z*%>0E?G$>X8+9'0_A5*/5M0OKVY>\O[FY>34HG%K=6Q5D4PD[U ^Z,G&
M?2@#Z'%W;M%'*)XC'*<(V\88^WK4U?-5OKFK3V'A_26NDU"SM;RRG5%MBIAD
MWR@Q.1U. #SZUZ%\+?%_B/Q+JU^FK7$$D$<0<QA CQ/N(P /X<#OSG- 'J=%
M%% !2,RH,LP49QDFEKRGQK_8\_Q'BM_&-Q)%H@TW=9#>Z1F8MARQ7^(#&,T
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M\/MK%MJ&G):1NDJ!K=P6R"&_A.1DC]: .TL]/T=M3DUVTB@:[O(D5KE&SYB
M?+CG'3TJ^J0H6*K&I)RV .OO7SK;^&/$-OKEYX>L;6:75+2QL1'<176R.S?
M+-@D;@<$<"K-G\/_ !A]BN8+F#4S=R31B=EN$1)5\W<S;]Y)POM[4 >^7M[:
M:=837MW-'#:Q*7DD<X4#U-/0VTB1N@C(8;T.!W[BO-T\+:W'\,?%6A_9I7GN
M+FX_L^!Y0Q,+;=@W$\#KU-<YXAT7QSKVLZ3<6WAZ;3TMHX K_:(RP=&&[<5?
MY5P.P.: /8M(U>PUJS:ZT^42PB5XRVW'S*=K=?<5?KR+P;X2UW3?&5M=-I4F
MFVL371N)&N!(MP';*84-QQZBO7: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $  & ,"EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *:T<;D%D5B.A(SBG44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !115>SEN98G-U;"!Q(RJH<-N4'AN/7TH
M L4444 )M4.7"C<1@G')I:** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>gvxjy5si4hmk000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvxjy5si4hmk000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S 7 # 2(  A$! Q$!_\0
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M'H0?I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2*T$XX,<O!_"K]5[JQM[Q=L\8;'1NX^AJAY6HZ;_ *IC=VP_@;[ZCV]?\\4
M:]%5+/4K>]&(V*R#K&XPP_QJW0 4444 %%%% !1110 4444 %%%% %/58Y)=
M,GCBSO8 #'7J,UG6UW?6ULD\D1:!QG:6+;!]>H_'(]Q6O=)+);LL#JLN05+=
M."#@_7I3H$,<$:-C<J@';TSWQ0!5TS5['5[;S[*=9!_$O1D/HPZ@U>K(U+P[
M9W\XNXVDL[Y?NW5L=K_0]F'L:II?ZY83QV-_#%<^<2D-]#A0, DF1">, $\<
M4 ='15'2;U=0T^.X2>.=6)Q)&1@C/&<=#CJ*O4 %%%% !1110 4444 %%%%
M!6/J!-Y>P6RX*1S*S*>CD<D'V48/U(%7=2OH].L);F0CY1A03]YCT'YU%I>G
MK:PB64![N09EDZY).2/I0!H4444 %%%% !1110 4444 %%%% !1110 4444
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MM0!>DGCB.&.6QG:!DX]<>E5+R"&YO[5)HTD0I(<,,_W:L*HD,Q"[2WRAB<Y
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M]E7H"2>E "WUK+=Z]!&)[J&$6KL3$< MN7&>",XS[U)_8O\ U$;_ /[^+_\
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M&" @VAMV>HYSC;Q]30!=HHHH ***0T +14<$1AB6,R/)C^)SEC]:DH ****
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M]?\ &C^V-,_Z"5G_ -_U_P : LR[15'^V-,_Z"5G_P!_U_QH_MG3/^@E9_\
M?]?\: LR]15+^V-,_P"@E9_]_P!?\:/[8TS_ *"5G_W_ %_QH"S+M%4O[8TS
M_H)6?_?]?\:/[8TS_H)6?_?]?\: LR[6*"OVN^R.5ESGVVKG_/M5W^V-,_Z"
M5G_W_7_&LZVF2XGOGC>.2-I\J\;AE8!%[]CD4!9D\#1F\M@C*2&/<<_*:UZC
MB51&A"@':.@I['"D^@H$+5+S!#J<AD#*LB1HC$<,V7X'O4D+7,L$<FZ(;U#8
MVGC(^M1QK))JC><5;R8U*!00 6)R?KP/UH NT444 %%%% !1110 4444 %%%
M% !1110 5CZ;_P C%K?^]!_Z!6Q6))I^JQ:M>7=C<VBI<["5FC9B-JX[$4 ;
M3*K*5905/4$=:S]$).G9,9C_ 'L@VDCC#D=OI4'E>(O^?K3?^_#_ /Q53:&)
M%TW;*X=Q+(695P"2Y/3\: +EV"UG. S*3&V&7J..HJ+2TV:5:@LS$Q*S,QR2
M2,DG\34MV ;.<$9!C;/Y5'IN!I5F!T\A,?\ ?(H M5!>KNLIE]4(J5W2-"\C
MJBCJ6.!4)N;:52BW$3%N  X.: 'Q2QR/,$^]&^Q_K@'^1%2U'$(\R&/&6?+X
M]< ?T%49WU".\E<!WMQCRXXHU)/ R22P[YH TJHZO</::;)/']Y"OY;AG]*M
MQ%FB0N,,0"1CH:I:W<K::3-*Z@KPI!]SBACBKNQR7AKP/X;U+PW87UYI,,UQ
M<Q"621F;+%N<GGWK3;X;^$696_L:(8["1P#]>:T?",1A\'Z/&QR19Q?^@BMF
MLXPCRK0[*^*KJK*TW:[ZL\]U+P/X:@\3Z':QZ3"L%P+CS4#-AMJ KW[&MK_A
M77A'_H"0?]]-_C4^K_\ (Y>&_I=?^@"MXNPG$?E,5*DF3(P#D<=<Y_#M5<D>
MQE];Q'\[^]G-?\*Z\(_] 2#_ +Z;_&C_ (5UX1_Z D'_ 'TW^-=112]G#L'U
MO$?SO[V<O_PKKPC_ - 2#_OIO\:SM?\  7A>T\.ZG<6VC0I<16DKQ,I8D,$)
M!'/7-=S6=K<WV339KYU+P6D;W$D2_>D"*6 'XCO1[.'8/K>(_G?WLX76_!7A
MVTM?#[1:3%&]SJ$$,_+?,K*Q8'GU%=!)\.?"NS]WHEL&SW9O\:C\6W32:=X;
MNQ"T;OJEO((Y",J2K'!QD<>U=%=W;VUG<RN%1H(S(6/*[0,D_A@\4>SAV#ZW
MB/YW][.#T/P5X>GU37H;S28'6UNU2%<M\JF-3@<^^:T+WX9Z'+-FTTRU2/;C
M!D<<\^F?:L*V\5:#'=:\UU*TSWKJ]O<&W)!'E*H)...1^E>GV5[;:C917EG,
MLUO,NZ.1>C"CV<.P?6\1_._O9YUXB^'-D+O1X](TVRC#R[+DR2, 0-KYQSGY
M4D&,C[U=)_PKKPC_ - 2#_OIO\:T]6=Q>:>BHV"\I\P$84B)\=\\Y_2M*$,(
M(PV=P49SZXH]G#L'UO$?SO[V<U_PKKPC_P! 2#_OIO\ &C_A77A'_H"0?]]-
M_C7444>SAV#ZWB/YW][.3G^'OA6.%FCT""1QT7<W^-4?"%K:6%OJT%MA(H=1
MF"QJ"-O"XP#TXKNJ\]\.R:Q>WFN"Q@L52/49"S7,C$[B<X^4$<#'>ERJ+32-
M%6G5IRC4G?;=G9C4%3]WLY0<_,.G<T]KW,9_=G)'8^V:PS9^+<DH^BKDY_Y;
M56O(?&%M97$[2Z&4B1I"!'+G@9..:?/Y&:P]W927W_\  .KL_P#CR@_ZYK_*
MHX_^0G<?]<H_YM6=H=SJ-_H&G7>^U3S[:.3;Y;'&5!Q]ZKT*7,=\6F D\U "
M\:[53;G&<G.3N/3TJD[JYA*+BW%]"[1113$%%%% !14<,C21*SQ-$QZHQ!(_
M(D5)0 4444 %%,9V61%$;,K9RP(POU[_ )4^@ HHHH ***CAD:6%7>)XF/5'
M()'Y$B@"2J&D?\>;?]=7_G5^J&D?\>;?]=7_ )T 6;L[;*<A68B-L*O4\=!4
M6E/OTFU)5E(B52K#D$#!!_$5-<?\>\G^Z:ATWBQ3_>;_ -"- $>KHLUD(6C$
MAE<*JD @G!QG-5]/L?LJ@-81J=WWE"<<G_$5;OO]99_]? _]!:KE $-O%Y7F
M_P"W(6_.IJAMM_EMY@P?,?'TW''Z8J:@ K%\6W$%KX8OI;DA8A&06(X!(POZ
MX'XULLP52Q. .2:YKQE'->>"M7W$1(;5V"[<L< D9]#G%*6S-:*3JQ3[HU=
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MPFFMHNFO,\#3J4OV VJRJ>L?7+"MV*ZU(W21S:8J1,H)E2X#;3CD$$ ]>XH
M@?PWI[VC6I$_DM%Y)03-C9Z?UJ[INGVVDZ=!86<?EV\";$7.>/KW-1:=?75W
MYXNM.EL6C?"B21'WK_>&TG ^M8=CX]L=0U!+.+3=4!:X^SF5H!L5L]R&/'0_
M0T =+/;17#1F1<F,DK^(*G]":FK(U+Q'8Z3J5G8W7G"6\8+$RQ$IDG: 3VY-
M:] !1110 C,$1F.< 9X%<3\*K>5/!GVRXCDCGU"]N+R19 0P+2'J#T. *[>B
M@ JEK'_($O\ _KVD_P#035VJ6L?\@2__ .O:3_T$TGL73^->I3\)?\B=HO\
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M_P"@FK/GQ?\ /5/^^A5+5YHCHM^!(G_'M)_$/[II-Z%TT^=>I7\)?\B=HO\
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'<HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>gcilxvfwaiqx000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcilxvfwaiqx000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $W G # 2(  A$! Q$!_\0
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M^%.^TW7_ #]2_P#CO^%0@4M'+'L'-+N2BXN?^?J7_P =_P *=YUS_P _4O\
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M&W6DQ1RKL'/+N2?:[K_GYE_\=_PH^U7?_/U+^2_X4S'-*:.5=A\TAQNKL?\
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MQ+?;\Z\$\'., _SKI?'6N:6]U;WFF),652SH$:,,"3\V?7V(KB9?$,<DC/)
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M49/O0349--"'9/K1D^M,W4FZJ$/R?6EW'UJ/=2YH D5CCK07/K3%/O0<>M(
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MT!8__ F3_&E^W:=_T!8__ F2@#/HQ6C]NT[_ * T?_@3)1]MT[_H"Q_^!,E
M&=CBE R*T/MNG?\ 0%C_ / F3_&@7VG?] 6/_P "9/\ &@#/VCT_2C:/3]*T
M?MVG?] :/_P)D_QH^VZ=_P! 6+_P)D_QH SMHQT%+M'H*T?MNG8_Y T7_@3)
M_C2_;=._Z T7_@3)_C0!G;1Z4;1_DUI?;=/_ .@-'_X%24?;=._Z Z?^!4E
M&=C'K3N?5OSK0^VZ?Q_Q)D_\"9*7[;I__0'7_P "9* ,\9]33N?[QJ_]MT__
M * Z?^!+TOVVP_Z \7_@1)_C0!G@MG@TOS'K@_45?^VZ?_T"(_\ P)D_QIWV
MW3_^@1'_ .!+T 44EECSL?;DY.*LIJE]%]V=OQJ7[98?] A/_ AZ0WEA_P!
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M-39.>U# 3M2=Z=FD4Y;%("];_P#(.D_&J8YX S5VW/\ Q+Y/QJG'U- !M/\
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MXC.+<@+U2Y4YYKFA]IMA_I7AJXDV\%I$(S_WRM-N/$]Q!&(K/3(K' [ID_\
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MK;^H'YT<@=OSIWD%D8@\+Z'C/]G0GZ*:7_A%=#_Z!T/_ 'R:V3ZC /J#1YA
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MV22PN@Q.?J*NC5,\G6M0&>TEM%)_A6$9$]:-Z^M2X(KF-%7L< M:2C_MX/\
MA41N;4/B.RG8>HN3_A42HIX[U.N$0 >O-:F8\7=L,?\ $OF_[_G_  J5+FV8
M@&PF'_;4_P"%,#X.*?YG'8TK@3K/9!>+2;_OX?\ "D,UN/NV$A^L^/Z55DE*
MIN)YZ"FB4[<%J +)N82/^0>?KY_/\J<MS;@<V4G_ '^_^M5!9CG -/WL.<$Y
MI@71?6P./L4PS_TV_P#K5(FH0Y_X\Y1C_IM_]:L]F9AMP1GH:<)7Z-U'7-(+
MFP+VV[VTH_[:C_"FO?VP./LTWU\W_P"M5!6/6E;GJ: )FU6R0X:UG./23/\
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M]&?GC_6__6I?M%H#@0/]/-_^M48/3G]:8V#]X?GS0!8-Q;%O^/>0'O\ O?\
MZU.^T0!>8'_[^_\ UJI%AT'\Z4>8&^^"/?F@"PTL7/[AP/\ KL?\*JO<01MA
M[><#L1.QS^E!#8.6 X[&H^D>R0EAZCK0!9V6I Q!,<CO.>?TJ%W@3AK60GT\
M\_X57C#1/E)"5[@BK*21L/FR#W!I@"R6V.+5^/\ IO\ _6I?-MQUM9/^_P"?
M\*:T4)!SCZBFE(ATR*+@2>=;?\^TG_?_ /\ K4&YM1UMG_[_ '_UJ@9?1N/<
M4SH>J_EB@"UYMF1_QZN?^V__ -:F%K#O:2?]_O\ ZU5"W.2I_ TFY>Y(^HI@
M6B^G_P#/I(3_ -=O_K4PMIYX^PN?K-_]:JQDC(X:CY#GYS0(DQIZ\K9./K/_
M /6I!/9CK8,?I<?_ %J:=N.V?I4;H.JG!H E^U6/_/C*/K.?\*7[19'I8R'_
M +>/_K54('^- B'4$CZT 6S+9#DV,O\ X$'_  IOFZ>>MC)_W_/^%0;0.III
M ['Z<4 6/-L!TLY1]+@_X4X75F/^723\;C_ZU46![\TU@<?='X47 T#>67>S
M;_O^?\*3[=9X_P"/!R/^OC_ZU9?.2>:7<,=30!H_;;$\'3F_[_\ _P!:C[38
M=?L$@^EP?\*S201VH!]\47 T_M5AC_CRE'_;<_X4TW=GVLW/_;P1_2LTD]J3
M+9H T?M=G_T#Y/\ P)_^M3OM=CCFPD_\"#_A6=N_'\*7<* +_P!ML#_RXO\
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M)^;G-6/[+U#H+&;_ +YI5TO4<<V4H_X#0! &+<# IZJQXS4G]FZE_P ^<O\
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M)L)/4UH_V3? Y^Q3_P#?-+_9U^!_R#Y_^^: ,_#]O6E(?J2!5YM.U'M83?\
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M8H <I'8#GO32XZ'FE/; X]*B8-C.!^=("120>!QW]JD4_E^E5\E1U/)Z4\3
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M(TKO)??3:G^-("D2I/3(SS33C@@_4>U7Q_9/(#7OTV)_C1C2<9#WW_?*?XT
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M_P :+ 4CG!R?KSQ2@@#&!M%6@NF*JKYE\2./NIS[]::ITK<V&OLC_83_ !H
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M0 \8QG@?RIB2+*GRCS 3T_I0,D6*!$638<@XR>"?0U(T*,&X!'3-0O-O7!
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ML1D9_P XI>-W7M2]2#@G!SBF F!C(P,=:0G/7C!I6QNQRON.]-;KU[\<4 '
M&?PQVH#!3TQQUI.<X.<COF@$'J: %Y/09P:<6 ZYZ\^]#$C/>F9))RW ZXH
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M,2V57IUS4 G 7[I!7K[TIG5E4XQ@8)SUH G\Q@<@G&,8/:E5AM ^8 #+'M4
ME7D \D#.:=NYP""/YT 3$G (.6/8BEZ C)#8QCUIF[OC!]<T;LG."3WQ2 <&
M)/(Y SFA<$XP0<=>U,Y! /UI58 =Q]!3 EVY&[>QS3"Q)X/OB@/N ST'!P:0
M<G/4?RH 56+'!&/QI1R3@X]?:F[QR3QGVII?/RG &:  D$GKC/04Y>W8^E1A
M2,\@X.<XHR&(^?'/Z4P'DD'DCITI'(YP<#K]:0_>!)S@8%(>#G\Z0 6/K3<]
MN WK2$D8XR":3(WG'I3 4M@8ZFF@X)R!S[TN3]*9N R<\>U #NK=.0<?6E9B
M0"<<#'2H\@GKC'I3NIQQ0!*65^F%X[5$R[3BFIW/YT$Y[\>M !Z@C@T'MC/H
M<F@CGKFD_#KZ4 .!-.WX' '3K49.,']*3@<\'/MTH <&XYQTS1@XYI,@#K3\
MY'';DT 1T9P:4G-)SG'?I0!(O]::_7D_K2*<=33FRP['TH 9MYS[<4*<&F D
M=3R.M+D<<T 3,=H!/4<TF[<1D$^@HHH$(_.#P.>:<1M R>>M%% "'@@YZ?PX
MI_0D\=.:**0#D)ZKP.E/4-N(&-WI110,79QDY [$=ZBF4 9R>1G\*** (UQM
M8L.,X//6GKM2-@<X8C:1V]:**8@/+Y' /ZT#EFPW0_-ZCBBB@8;6!RIP0<TD
MCX7/S G^=%% #<$1]22>Y[TR0$$@J 1U/K[444A V[:B_=W#..QI)'&X#^+I
M]T<_3THHI@.R/**NWW.JXZY]Z>L@0!01G[HR*** &EMD;+LR3^&#0L;)'&R.
M0?XL=:**0#D#")6#.,CN1DCWH,9\M5& Z G&3@T44P)K4G>1U (&/7WI7R$=
M(^=I[FBBD,>Z*@RK% .&ZXS^'M_.E>/S,; =[KEL' &1VHHH AE"B)< L!SQ
MP,?C[U!(P7(V\CE<BBB@!R[0B;>68=^U#RM*PW9^4!>N1@=OI113$/C?S$)(
M7Y0#DCF@X*X"XX(!SUHHI#(Y-P5FP&^GI4._!W!N-O ]S113$+L?&>/E.:7<
M< A@%Z].U%%(!,#?M!^GO3]YW'>1N]J**8"G*,0<#::'4;=K<8Z8%%%(8"'S
M!P<GOQ2>41@<$=CGGBBB@!Y+#'S'!YP>U*9#C<0,+QQ110 JR!W4 ]?44XR$
M9]NH':BB@ 0C#8S@9S2[\G&,8%%% "EO?H*:3G@@ FBBF F020&)/J:7."3Z
M^U%% "Y  /7W I"X&!CG//O110 C?_JIG?WZ444"$SQG%-SD<#G-%%-  '>E
M%%% (.G'84UFY&":** #/&#TIH)SU[X HHI *?K]:7=TY_2BB@8$Y'XXI.>!
F^M%% "GN:0G HHH0" CC%.'S9&:** (Y!@Y]::3TQUS110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>gdzs1tysdsfm000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) M # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3]H;# ,/G4<@J.<D=>E>AT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M))D9NI1$G[HM_#Q\V.K=NAJ#2]5UBZMS>R7<8+6]P\\#7*$QLJDJ$C"@H5(
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M4#I33:VYF,Q@B,IQE]@W''3GVJ6B@",6\(G,XAC$S#!D"C<1Z9ZTHAB 4"-
M%.Y1M'!]1[\G\Z?10!$EO!'*\J0QK))]]U4 M]3WJ1$6- B*%4#  & *6B@"
M);:W65Y5@B$D@P[A!EOJ>])':V\4:QQV\2(K;@JH  ?7'K4U% $1M;=C&3!$
M3&2R$H/E)[CT-2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %74_^05>?]<'_ /036%X=_P"1;T[_ *X"
MMW4_^05>?]<'_P#036'X=!/AO3N#_J!64OC(>X:Z]TFF$V=Q'!,9$&7D$>Y<
M_,JL00K$="17-S:U=W;64-G=7$%N]G)*LL]S'%(\BR%2"Y4JP7'0=00>17:2
M0I-&4EB61&ZJZA@?P-(]M#)&J26\3HG*JT8(7Z ]*8SC+O4-0LVU";?$MU*N
MG1W$T;@)&&#!F#$$ >A(P,YJPE]J"?9;6[U%8;6XO'C^UI<)(Z*(]PC:3 4,
M6R,XSCCK76F)3N!B4[QALK]X>A]:9]EA\CR!;Q>0>/*\L;/RQBBX'*3A(/$D
MUQ'JD\C#16>%VF4B4JS>@PV.O'?FF_VG/-;W+7.LR6#VVGP36X4HOG,T>XN0
M1\XW?+M']:Z[[-#A,V\6(QA/W8^0>@]*&MHG,9>WC8Q_ZO=&#L^GI^%%P./N
MM0U5[76+UKZ>TEL;&WN5MD"[5D,9=PV1D@D8Q6YKM]+;:=:R1S?9DGN(HIKC
M _<(W5N>!V&3P,YK6,2-NW1*=_#94'=]?6E9 R%&0,I&"I&01Z8H P%\R37]
M.L8-8N9;4P32R,)%=I&61  6 Z#<1^E9%E+)=ZIX>O;F\F\U[>\  D"K(RR#
M"].X&".^!79QV\<(4101QA1A0B!<#OC'2@V\15 8(R$;<@*#"GU'H: .(L-7
MUB?2Y;]KU,M83S31FY1C'(%RNR,*"FT\$$GWYK2GU"?25M9+F]N9XSI<]U,<
M*6+#R\%1C  W' Z<\UTHMH0TCBWB#2?ZQA&,O_O'O^-.\I21F,9 VCY>@]/I
M1<#G/#6H7-QJFIV<]R)T@2"1/](6<H7#9!=5 _A!QV]:Z2F16\4 Q#!'$.F(
MT"_RJ3!]#0 E%+@^AHP?0T"$HI<'T-&#Z'\J $HI<'T-&#Z&@#%US_C]T/\
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MS]J=97\&H6@NH!((&&5>6,IN7KN&?X2.AJ&/6],FL;J^AO(Y;6U)$TL>652
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M;/-.J(SAHX'*N%Z[&QAC]"<UHM@HP(R,<CUKA!+<6EG>:9I#WEQIHT^XQ'-
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M HHHH **** *NI_\@J\_ZX/_ .@FL+P[_P BWIW_ %P%;NI_\@J\_P"N#_\
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M %%%% %74_\ D%7G_7!__036%X=_Y%O3O^N K=U/_D%7G_7!_P#T$UA>'?\
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M1110!5FT^WN+Z"\E#O)!GRE+G8I((W;>F[!(S[U:HHH **** "BBB@ HHHH
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MS5^B@"FVEVC-*Q63,OW_ -\_KGCGCIVH&EVBR1N%DW1KM7]\_3GWYZ]ZN44
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MIVJY10!372[1&B8+)F+[G[Y_7////7O3/['LO)\K9+LW;O\ 7R9S]=V:OT4
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MAA+.3G 8$87KSR<TFD^!-3L--\+0NUD9=+FN)+@AB0X<G ''/;.<5HZ=+O\
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M+KI]\Y-JQQ'(?^69_P /Y59^)'^OT_\ W7_F*D\'^$\>7J>H1_[4,3#\F/\
M2N].'L%S'"U+V[Y3O****X#N"N8T[Q3<7 TV:\LH8;;40_DO',79"JLQW J.
M,*>1G]:Z>N:T7PM%IFAK$\,)U+[.\33!BP!;/0GH.F< 4 :"^)=(:TCNDO T
M,K;8BL;$R'&?E &6X],TLGB+28X;:8WJ%+H,8-@+&3;]X  9R,\CK^59\>C7
M]C%H<]LMO-<:?9FUDA=RJL"J9*M@X(*#MR">E9GV"_TO7=(*);3WDS7US)&7
M*H"Y0D*V">,CDCGGIF@#I/\ A(-**VC+>(_VL$P! 6,F" < #L2,^G?I4::_
M9P6,4][=0AI7D5/(#/NV,0<#&>,<G&!5/2M!NK/4+.[N&@9D6[>;9G"R32*^
M%R.@P1G_ !J@OA>_MWLKA2LLD*W$4D27<D'RR2F12'09]B",?E0!LIXEL9-<
M_LQ"S9M5N5G528V4Y[@8Q@9SG';K4H\1Z2;:XN3>*D5OM,ID5DVACA3@@'!/
M0]*RF\/W]I/G2C;VR-I?V)2)&/V=P696&0=PRW?!XJB/"NI3&_>1((S<Q6J!
M6NI)R3'*78LS#N#QB@#I4U[3'MKJX%T%CM%#3ET92@(R"01GD5#XAUQ]#M;2
M=+-[KSKA8F1#A@NUF9@,<D!3QWK+U>S6^\8V=M!(C)-&KZC&.2$B8/%GTRS8
MYZC/I6SJVGS7T^EO$4 M;T3R;CU4(Z\>^6% %>X\2VMO=D'#V8TYK_[0C9RH
M(& .^0<U9TB_N=0B>6>&VB7C"17'FLA[J^  "..A-<_/X,FDOM2A2>--+N;"
M2WMUYW0.[AB,=T!&1SQG'3%:6C:/<VVK27\]O9V>;9+?R+0DJY4D[SP/7 &.
M!GF@#2;6+!-1^P&?-UD HJ,VTD9 8@84D>I%,M->TN^NOLUM=I)*0Q48(#[>
MNTD8;'L35&WTS4+2ZU&W18)+*_G>8S^:5ECW* 1C:0<8X.1Q]*KV.B:EC1K:
M\%JEOI(^66%V+38C,:\8&P88D\GGI0!O7NH6NG1I)=2[ [;$ 4LS'K@ 9).
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M^]BW<]\<<<_A0-3MS)&@6?,B[A^X?&.>IQQTZ&D,N450_M>U\KS-MSM+;?\
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M;2&10BYW,3P,=<FE1TE17C971AD,IR"* '44R6:*")I9I$CC7[SNP 'XFGT
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M2]N[621U53*$0,F<#&[!/3&<53@NI-5OO#VH7%_(RK<7Q!C5"K*C.!_"<_*
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M4#YP(#ECST.[CMZTSR=4\G'VVV\S=G=]G.,>F-U %^BJ;1:@7E*W< 4C]V#
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M3C<:FMZ]Q;R6C1B3 CR-Q5APH[?CBI=8UC4U\=HUK+J-NT6IPP/"TDK))$<
MMMQY:H?J3WKUFV@6UM8;=&=EB0(&D8LQ &,DGDGWJ6K5=+[/]:?Y$.@W]K^M
M?\SR'36OK;4(HX&NH8YO%ERLHC+*'C(7KCJ*J:=IMQIVE^*/L-QJ<.K:;J+7
M:1/+(%EA5@<GLQ8!L]S@5[36;KFBQ:]I_P!BGNKN"%FR_P!FEV&1<$%6..5.
M>136(UU0GA]-&8_@6:ZU+3KS7+J2;;J5T\MO%(Y(BA!VH .@Z$\=<UU516MK
M#96D-K;1K'!"@CC1>BJ!@"I:YYRYI-HZ(1Y8I,****DH**** "BBB@ HHHH
M**** //_ (D?Z_3_ /=?^8K$\*Z/>ZEJD<MN[P1P,&><?P^P]Z[#Q5HD^N:M
MIT$>5B57,LF.%&1^OM716%C;Z;9QVML@2-!^)/J?>NQ5E"DHK<Y/8N=5R>Q9
MHHHKC.LK:C'/-IEW%:OLN'A=8FSC:Q4X/YUA:+JMI'H-KIMHOD:C%;>6MG(A
M#)(J]&&.F1][H?7FNFHH X33;AFDTLV=W?2WK0R'54F=SM_=G.Y3PC"3: !C
MC..*;;1W=M9:04U&^BDO]'E-S/*[R[) D95]IZ,"QZ8XKO:* .(TV\F=-.CB
M$J*FI&.26*>2:.<?9W.Y2_)7.,@\;AWK+F NO#-];3F6\-M):RR7T<\S)-^]
M&XE2?D<*"64<#(/88]+HH \_N9+V;79H8=1%L%>#^SF>28[HMJG*J/EDR=P;
M=D^N.*GVW4;/J N;TSKK_DJIE?8(6D"E=O3;@D]/QKN:* .8\'V]M:?VM;Q[
MUN$OYC(CNY(4R,4.&/<'.1UK#TYT1XTM;B]&K?VQ)F'<X40F=M^4^[LV9.[U
MQSFO0Z* //+&]GU+Q#"@,R17D5TES:^;,S(1C:').%;K@*!@=R*;I$EK!I6@
MV]W/<6^E"R(G*RR*/M0"#8[ Y7 W87(&1["O1:* . U&%XD\2:E:37BRV[VS
MVQ21P#B*/DC^+(X.<UT6NV^H7FD:O;R1P/;/:RB)8F?S6;;\H/X^E;M% ' V
MLU@$L([N[NH=(_LY3 T<TJAI\GS 6!SN'RX4GN<#TZ'1'UU]*TQKH0DF)?M!
MGW"7J>P&,[<9SWS6[10!YWH;A(]+2RGO#J?V^03P%GVB#>^[*GY0N,$'UQS4
M=I<W&JWLT2F7R[S3;AIK42S,R2 IM5RQP'&6&% _$8KTBB@#S[3IK)+31X;N
MYN8=(&G#!2610;D8#JS Y! Z+G'7CBI+J"6"/7-3MY;M;B'5(/)"R,%*D0!L
MKT;()!R#^E=[10!SGBV=8/['\VYGM[=[X+.T+LI*>7(<$KSMR!FN?N+F\6W0
M6]Q/_8;:BZI-<22@&/RAM!<?/Y?F;\'/8#.*[F[L(KR>TED+AK6;SH]IQEMK
M+S[88U:H XS3K6YN=1TFWN[^XN(!:7,NZ*215?\ >IY88G!;:#C)ZXS5&T@C
ML+:S29[JWTN2_O!=.LL@Y$CB(,V<JIYY&,D#/6O0:* .%LTNKV]TRWDN+XZ<
M]W=>23(ZM+ $&S<W4C=G!/) %->WN9)(9C=Z@'FUV6W?;.X'D9?Y,9P%^4<C
MGT-=Y10!P$E[+!;R:=,TPMQJ5Q%'<3S3!8T4!E4E#N;.X[03_#UX%)HRWFLK
MIZZA=7^#H[.^V5XBT@DP&.,'< ._XUZ!10!PFFWWVI[&3Q!=742OI]L]MAWC
M624@^83MQE\[>#V/3DT:1)J5QX@4W%\L-XEY+YT#/*6:(%MJA/N!=NTAA^>2
M:[NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZG_R"KS_ *X/_P"@
MFL+P[_R+>G?]<!6[J?\ R"KS_K@__H)K"\._\BWIW_7 5E+XR'N6K^^@TVQE
MO+DL(8@"VQ=QY( P._)%,LM2M[Z6:&,31SP8\R&>,QNH/0X/8X/(]*I^*8)K
MKPS>PVZ.\SA-H1=Q^^ISCOCK5/5]"9H&D>6>^N;F\M5FDVA?W229P N,* 6)
M^IIC.D]/?I[T5R&I:=&MQJT,VESS/)$J:4T$1*Q )@*I'$9#Y))QQBJ=W;":
M[UV"YLKB\U,P6Z02Q(659O)'(8<(=V&W'''Y46 [>>7R8'E$<DNT9\N,99O8
M#UJ3T]ZY"_TF:2W\33R6SS7KP1QP2!22Q\E0VSZG.<4VZTV[N/$=VUP\\<C7
M44EI/'9&0K$H7A9 V$&0P8$=SUS0!U<%U!=&;R)%?R9&BDQ_"PZC]:FKBS9_
M8DU2WBTD+YVJ%Y9/L1D40,,JP5<>8 1C;SC.2*31]+FF;2([ZSG:W@N+XA)X
MMH521Y>Y>@'H.GY46 [6BN6TFUE&O-IK!OLFC.\T+$\,9N8Q_P  4N/Q%-U9
M+)_%5P+_ $^XO8_[,0(D432 ,7?L.A/9NWJ* .C2\B?49K$!O.AB25LCC:Q8
M#G_@)IT]U!:F$32JGGR"*//\3'.!^AKD1;:K:VLHN+1[F9M/LH)V9#*.'?><
M YD*@@D \U5BTQS9*USITTUM;:V)41[/!$!09*Q#.%W'H*+ =G!J$5S?W-I%
M'*QMB%EEVC8&P#MSG)."#TQ[U;_K7'3:1Y3ZE+%IK?9Y-4C>X2&+#S6WEKN
M Y8;^2!UP:1],:Y9UM[*>+29=2M7CMS&T>  ?-;9U5"<>F<'UHL!V77IWHKB
M]5T/S$UZ6*QD\Y9K46;1@@JH$8;R\=!C<#BM2R6'1M?U"VCMGAM+J:!;5(T^
M0N8V+D=L87)Q0!T%%%% @HHHH QM<_X_=#_["*?RKK:Y+7/^/W0_^PBG\JZV
MB&[''=A17-:3I6N6VJ7,UUJ&87S@'Y]Q[$#^''_UJUOLNH^6J_VDN\,26^SC
MD<<8S]?SK0HOT52:WOR9MNH*-Q_=_N =G/UYXXH%O?>8A-^I4+AE\@?,?7.>
M/I0!=HJA]EU'RE7^TEWAB2WV<<CCC&?K^=.:WOR9MNH*-Q_=_N =G/UYXXH
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MKG_'[H?_ &$4_E76UR6N?\?NA_\ 813^5=;1#=CCNPHIDTHA@DE()"*6('?
MKC='^(MOJ4^G+<:5=V=OJ1<6MS(RLCE>H.#D=.];QA*2NA2G&+LSM:*S8_$&
MC2P2SQZM8O#"H>21;A2J YP2<\9P:D76=+?3FU%=1M#9+UN!,OEC_@6<5/*^
MQ7,NY>HKG-,\8Z=J%WJ4;36\-O:3QPQW)G4I.77(VGI^&36P=4T\&Z!O;<&T
MQ]HS*!Y.>F[^[^--PDG9H2G%JZ9;HKG+SQUX=LY[")M3MY!>L5CDBE5D7'4L
MV>!GCZUM7VHV.F0>??WD%K"3@/-($!/IDT.$EN@4XO9EFBJ/]LZ9B4_VA:XB
MB$TA\Y?DC(R&//"D=ZCF\1:+;@&?5K&+*+(-]PHRK?=/)Z'M2Y7V'S+N:5%9
MUSK^CV3;;K5;*%M@DQ).J_*3@-R>A]:SKCQ?96OB8:5/Y4=N; 7WVYI@(]I?
M:!Z<\<YIJ$GLA.<5NSHJ*KK?V;W:VB74+7#1><(@X+%,XW8],]ZL5)5PHHHH
M **** ,R_P!;M]-U*UM;DA$N%.V0G@,".#[<]:TZ\_\ B1_K]/\ ]U_YBI/"
M'BSB/3=1D_V896/_ (Z?Z5T.@W34XG.JUJCA([RBBBN<Z HILC^7&SD9V@G%
M90U^(Z'IVJ?9Y-E\T"K'D93S64#/TW4 :]%9_P#:]M#;RSWMQ:V\:3M"&\\$
M$@XP3QAO5>U5[CQ)I\%S9K]H@:UN5E/VD3+L4QXR,]#R<=>U &Q14!O;1;+[
M:;F'[+LW^=O&S;ZYZ8]ZBO-0CMF2-9(#,S)^[DF"':S!=WYG@=SQ0!<HJJ-2
ML6O6LEO(&NU&3")!O'X=:I6WB*QDT:RU"ZFAL_M<8D2.64 ].@)QF@#7HK/T
M_5HKS0;;5IMMM#- L[>8XQ&",\GV]:3^W]' S_:EGC?Y>?/7[WIUH T:*JR:
ME8PWB6<EY ES)]R%I &;Z#K34U;3I+S[)'?6S7.6'E"4%LKU&/48- %RBJO]
MHV1ABF%W 8Y=WEMY@P^ 2<>N "?P-96E^*]/O].;4)I[6UMC*T<3/<#+8_O#
MC:<<XR>#0!OT54N-4L+3R?M-[;Q>=_J]\@&_Z>O454L/$FEZC)<QPW48:WN/
MLS!V W/VQSSD\#Z&@#6HJK-J=A;B0S7MO&(W\MR\@&UMN[:??'./2H5U>U59
MI+BYM885E$:2&X!#90,,]-IP<X].>] &A15)M7TY+%;YK^V%JYPLQE&PGT!]
M:GMKNVO(?.M9XIXLD;XW##(Z\B@":BJ5OK&FW<WDVVH6LTNW?LCE5CM]< ]*
M;_;>E?9FN?[1M3 I"F3S5V@D9 SGJ: +]%5'U33X[)+U[VW6U?[LQD&QOH>]
M(VK:<CVZ-?VRM< -"#*,R ]"/7- %RBJG]IV'VJ2V^VV_GQ*6DC\P;D ZDCM
M4EI>VM_"9;.XBGC!VEHW##/IQ0!/1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %74_^05>?]<'_ /036%X=_P"1;T[_ *X"MW4_^05>?]<'
M_P#036%X=_Y%O3O^N K*7QD/<NW5I#?6[6\Z%XV*DJ"1R"&'3W I$O8IM2N+
M)=YGAC21^.,/G&#_ ,!-4?$4=Q+HDJ6Z2R9DC,L<)^=X@X\Q5]RN>E<S<6,C
MOKC:-I]S;6LJ6?RB!D\U%=O-"(2#]WJ.">?6F,[NEYKC%LI].M/[7L(Y[AK:
M[$J6D=FT *,FR14C))P>&^JFJ]YHEU"]K;WADDMS9$&1;1[D"Y=RTC85@58Y
M&UO;J*+ =G#>137MU:)N\VVV&3(X^8$C'KP*L<_G7&W5A>K-=B2.ZN;<26/V
MDA2'N(E0A^!UYP6 ]Q5>^MTCBD:*SN8])EU.T\JV5&1FP#YA5."%/''&<'CF
MBP'=<T<UQ?\ 9IN)@L%E/'I,FJP/' R,@"B-A(VT\JA;'!QGGUI8='^R-Y\%
ME*LL.N@0D!LI;%AD+Z1X+<=*+ =ES2.PCC9W.U5!9B>P'-<7I&FW8OUENWF3
M4(Y)VG(LV'G [@ 9MVUE(*D #C &!S2V6AF&TT:-+%PUQI<T-[O!.]MB%1)G
MONSC/O18#L()X[JWBN('#PRH'1A_$I&0:EYKG]&5K/P3$MII["YAM,&U:,Q%
MY@G([=3W[^M<ZMA=26VK0PV]R+>>WM"!':-;J9!-\^U2<Y"]6Z\46 [J]L8=
M0MC;W =H6/S(KE0X]#CJ/4=Z2"\AGN[JUCW"2T*"3Y<#YEW#'X5S&H:;):WV
MH06MG-_9)GM)9H8%.)$^<2[0.O1"P'4#WJ_X;MXX-3UN2WLI;6TEFA:%9(S&
M& C )4'H,]N/I0!T/-)_2N*DM+Z-M7ATZVFEEFCE?[6\+13J3("8MYX?*[MI
M'3 JU=I9&SMX=.TAX;*2?_2&DT^1]A"':?*X+$GY<G(!ZYHL!T%QJ$5O=_93
M'-).8'G5(TR652 0/?+# JV,E0<$9'0]:X"&RU)M C62VNC,NCWL(#QD."91
ML7'8[1P/05<U+29)8?$%V+29[Q/L[6;@-N#+&F2GOG(./3!HL!V>**X37H$2
M#4WO+&Y?46U"-H+D1MM$)D39M?H% R"OKVYKO'^^WUH Q=<_X_=#_P"PBG\J
MZVN2US_C]T/_ +"*?RKK:(;L([LANXVELYXT&6>-E ]R*X;PAX!72]#M)]2C
MF?5X(I5CCDN2\<)8MR@SM&017?T5O&I*,7%=12IQE)2?0\QB\":A;^!M%MX]
M/M&U&QNQ<W5J[*%N@&;"LXR#P1UR*AG\$ZW-9W-\NG6<4DNJPWPT<3#RBB*0
M5+8VY.<GMQ^%>J45I]8F9_5X'E4G@S79M/UF1-,M+6>;48+VWM(IAL(3.5S@
M8//H.<TZ[\'^(M4_MVZN+&VAEN[VUNTM&N \<ZQA@T;,/J.HQG\Z]3HI_69_
MU\O\A?5H?U\_\SSS4] U6^;0]3A\,V$$UE=.TVGK/'AD8  [MN.Q.,>E:GCS
M1;W5[6R.GZ=]IN[=V>*47"1^2V!@E74JZGN/:NOHJ/;.Z?8OV*LUW/+]0\+>
M*%:^\BQLKEM2TB.TF9)A$L,BC!VKCD<<8P/I67+I.H'Q-+IL6C6FH7B>'H+9
MXYY540MM"EU)!!P?3'L:]DJ%;.V6\:[6WB%RZA&F"#>5'8GKBM%B&MT9O#KH
MSQ]M#O[/Q5%I$6F6FKW4'AY(62>0*J$N064L.<9QV.*V;'P5<V%U;KJ\D(TQ
M/#[:?<7#2@!9&D+8&><#(P?85Z.+.V%X;P6\0NF3RS-L&\KG.W/7&>U+<VUO
M>6[V]U!'/!(,/'*H96'N#UH>(DP6'BC@OA;9W,UC<ZS?.LLDBI96\@Z&&$;0
M1_O'/Y5Z%3(HHX(DBAC2.-!M5$7 4>@ I]8U)\\G(VIPY(J(4445!84444 >
M?_$C_7Z?_NO_ #%0>$/"GVTIJ-^G^C#F.,_\M/<^W\ZZ[5= BUC4[.>Y(-O;
MJV8_[Y)&!].*V  JA5 "@8 ':NGV_+34([G/['FJ.4A:***YCH&3*7@D5>I4
M@?E7'P^$Y(/#NB1+%+]NMI+1IE:[=D78RE\ MMX .,#Z5V=% '')I=_8:I!?
M&UCGV7EXX@\U58K*05D7)QD $$9SAC4'AG3Y;IM+O_LT(@ANM0?Y&!5-\IV[
M/4<'D?UKL+NQM+^,1WEK#<(IR%E0, ?QJ:.-(HUCC1411A548 'H!0!C:+I!
MA\,-I=_$H5S.KQ@@CRWD<@<?[+"L#1]-OM1T<7KE9YS=VT2/NX>WMY1\X)_O
M8=_?(KMYH8KB%X9HUDB<;61QD,/0BE1$BC6.-%1% 5548  [ 4 <AIGAV[M]
M21;N.ZD2"]ENHYUN$\HEBQ!VXW[L/M(/'OVIFG:/JFEQVK-IL=VS:6EFZ>:H
M\EU+$YSU5MPSC)^4<&NTHH YG^QKS_A6ZZ*8E-Z-.%N8]PQOV8QGIBF:GH$]
MQ=:\\-K"5N](6T@^Z,N/,^7V'*?Y%=310!Q.HZ/KEW=QHT4CQ1W5I)&RW"+&
MJ(4+[E^\SY5NO&,8Z8JW_8-VMO $MXQ*NN/>N0PSY9D<[L^NTCCKVKJZ* .-
MTO2-6MI]"M);)1;Z;<3M)<^<I#JR2!2J]>=PSG&/>FC2-;@TC3K-87:-(IEF
MCMYTC?>S93+G^#&<[>>G6NTHH X_1=+U313:22:<MVS:;;6K[94!@:,$,.>J
MG=GCN.G2DGT;4U^V".T$FS5TU&$^:H$R?+E1GHPP>O'3FNQHH X^/1M1NK]K
MJYL4B5]92\\MI58K&L 0$XXSN XJQ+HEW+JIF:!&A_ME+P98?<%OLW8]=W;\
M:ZBB@#C%TF_L-96_%K',B:A<RI;B559ED1,2+DXR"&R#@X8UH>#,G1;F0QI&
MLE_<NJQG*X,K?=/<>];=W8VE_$(KRVAN(P<A94# 'UYJ6...&)8HD5(T&U44
M8 'H!0!P_AJRO+S1_#873X[>"R4S_:!(I\S,;* H'(W;\MG'3O5ZUT6^T_3_
M  T\=FDSZ; 8YK574'<R %E)^4D$'N.&/-=5##%;PI##&D<:#"H@P%'H!3Z
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M_P!!*T_[_+1_;.E?]!*T_P"_RUXO11]8?8/:,]H_MG2O^@E:?]_EH_MG2O\
MH)6G_?Y:\7HH^L/L'M&>T?VSI7_02M/^_P M']LZ5_T$K3_O\M>+T4?6'V#V
MC/:/[9TK_H)6G_?Y:/[9TK_H)6G_ '^6O%Z*/K#[![1GM']LZ5_T$K3_ +_+
M1_;.E?\ 02M/^_RUXO11]8?8/:,]G.MZ4HR=2M,#_IJ#5-M;FU)C;:! US(>
M#=.I$,7OD]3[5Y?IO_(1@_WJ]UT[_D'P?[M:4Y.IY%Q;D5M$T>/1[-HPYFN)
46WSSMUD;U^E:=%%=*22LC5*Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>gdzs1tysdsfm000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gdzs1tysdsfm000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Q LH# 2(  A$! Q$!_\0
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M72M,>8$><WRQ#U;_ .M4RDHKF948N4E%&?JWBV#3[MK:* S.G#G=@ ^E9_\
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M]65BN##+?N=TS?,!W /5\?R_/M5"G)-+44&F]#1T34VTK4XY\GRF^64>J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC'FN,HWF;LYZD]L8%>CRVEM--'--;0R31_ZN1XPS)]">12/9VLD_GR6L#S8
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M_P!.]Q_W[H^T_P#3O<?]^ZGJI?ZE;::L;7!<"0D+M7/2DVDKL:BY.R)/M/\
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M '[H^T_].]Q_W[K-_P"$GTS^]-_W[H_X2?3/[TW_ '[H]K3[A["KV9I?:?\
MIWN/^_='VG_IWN/^_=9O_"3Z9_>F_P"_='_"3Z9_>F_[]T>UI]P]A5[,T6NP
MJEF@N  ,D^72_:O^G>X_[]UER>)=,>-E)G(8$8\O%.'B?3,#YIO^_='M:?<7
ML*O9FE]I_P"G>X_[]T?:?^G>X_[]UF_\)/IG]Z;_ +]T?\)/IG]Z;_OW1[6G
MW'["KV9I?:?^G>X_[]T?:?\ IWN/^_=9O_"3Z9_>F_[]T?\ "3Z9_>F_[]T>
MUI]P]A5[,TOM/_3O<?\ ?NC[3_T[W'_?NLW_ (2?3/[TW_?NK-EK5C?S>3#(
MPDQD*ZXS]*:JP;LF)T:B5VBS]I_Z=[C_ +]T?:?^G>X_[]U/15F9!]I_Z=[C
M_OW1]I_Z=[C_ +]U/10!!]I_Z=[C_OW2&[ *@P7&6.!^[ZU8J.3;YL.0<[CM
MQVX- #/M/_3O<?\ ?NC[3_T[W'_?NIZ9+-%;QF2>6.*,=6D8*/S- B/[3_T[
MW'_?NC[3_P!.]Q_W[J2*:*XC\R"6.6,_Q1L&'YBGT 0?:?\ IWN/^_='VG_I
MWN/^_=3,ZH,LP4>YI$D21=R,&! .0?49'Z4 1?:?^G>X_P"_='VG_IWN/^_=
M%Y>06%JUS<,RQ+C.U"QY] .32VMW!>PB6WD$B'O@C'U!Y%/E=N:V@N97Y;ZB
M?:?^G>X_[]T?:?\ IWN/^_=3T4BB#[3_ -.]Q_W[IT<WF-M\J5?=UP*EHH *
M*** "BBB@#.U_5#HGA^^U00B8VL1D$9;&[VS7.3^.+JTM-1%QIMNM[9/; A+
MK="RS'"DOMR".XQ71>(-+;6_#]]I:S"%KJ(QB0KD+TYQ6?J?A*TN/#9TG38[
M6PS+%,6$.59D8'Y@,9SCUIJPG?H5$\;,=&GNFT]9;M+X:?!';3AXKB4XP4DP
M/EYY..,5:U#7M6TG1&GO-)@;4GN%@M;6"Y+K.6Y^]@$8 ;/':J7_  @[O:7C
M/J*1:A->17L4EM;A(8)(QA=L>3D$9SSS5F?PSJ.K7EE/K>KB5;0NZ)8QM;D.
MP !#!B>!N_[ZHT%J1W?C%_L&@W-A;VKG5E=@;JX\I(MJ;B"V#SG(_"HD\:W5
M[9:>VFZ2KWEU;373PSS[%2.([3A@#NW'[O'O26_@*&,V5O<7$=UIMG=7$T=M
M-'N)CE7&PDGD@Y.:$\':C;VUC]EUF,7=I;S62S30%PUNYRH(S]Y0!@]#1H'O
M%I?%SSS>'6M]-8V>L;<7$D@'EDJ6VA1R2,<G@5$?&3C7/LWV.$6(U$:893/^
M^$I&=WEX^YGCKGO2W/A2^5="@TW4+:&VT8*85GMV=G<*5)8AAP0>GK4UQX5-
M]XEAU.[:P$,$XG00VFV>1E'RAY,\@'G@<X%&@:EK2=<N-0UW5--N-/-I]B$;
M*6D#,ZOG!(' Z9QD]:IZCXL_LV^UMI(1)9Z7#"-J?ZR6>4\(#T QM_.I]-T7
M5+3Q-?:M<W]I+'>(J/%';LK )D)@ECZ\^OM5"]\,R:EJWB*TG$L=GJ<5O/%=
M)@^7-'QC'J,*?I1H&I->>(-?TZWM1=Z+9)=7EW';0*MX63YPQ^8[<@C'H1S4
MB^*+O[#JROH[#5-,QYUJLX*%2I8.'./EP#VSQTJ.]\/Z_J-O:F[UNR>ZM+N.
MY@=;,JF4##YANR2<^H'%2)X;OHK'56&I0RZKJA N+F2W_=J@7:%5 >  3CD\
MT:!J17'BV?[#HC6EE;M>:I;-<JMQ<>7%&JJ&(W8R3S@<5+I7BEM4U'20(5CM
M-4T][F$'[Z2(P#J3T(P>/I4+>%]1?PW8:3)<Z3.;1?+66XL#( H "E06X<<\
M]#3K/P^UCXAT.&WCD_L_2-.DC69\?O)'(&/K@$GZBC0-3J:***105S?B[_4V
M?^\W\A725S_BJ":>*U$43R89L[%)QP*QK_PV;X9VJHQK"UMKC391* L\DPBA
ME)X5MI(!]B1C\:DAL(V-O&\2I(UI,S[SMPZE@"?3&*J>1??8VMOL<VPR"0GR
MVSD C^M6I9]4F='DLY"ZP- 3Y3?,#G)/OS7$K6U1Z$KWT?\ 5AUIIL02V\_R
M93)>I&3'(&^4@Y!Q6.W#L!V)K1MAJ%JL:I92D).LXS$WW@,?E4=Q;W,Y!33'
MAZY\M'Y_/-*2NM$5%VD[L=_9;&Q%TKL0"@8-$5'S''!/7!I9=)(=XX+A9I8Y
MQ ZA2N&)(!!/49%3RSZA*D@.G,K2!-[B-\MLQCV'3M40;4UDFD6TE5Y9EF)$
M3<,"2,?G3M'L2I3[_P!?U<22VMXM+N6CF69TG1-VPJ1PV<9Z@X_2G:19Q3^9
M+<1/)%N6$;03AF_BX]!S1/\ ;);>2!-,,*22"1MD;\L,^O;GI4>S4A:QVZ6]
MQ&B,S91&!8G'7\J-$[V'JXM7W&R6H@TZ?S4Q<170B)]/E.1^8IEU$D=G8NJ@
M-)&Q<^I#D?R%76FOI!()]+,PD97;=&XRRKMSP>I'6HV^U/:I ^E%O+5E1RCY
M4$D^N.])Q70%)]?ZT*4-E=7";X;>210<$J,\U/I]MNUFWMKF+K)M>-N.W0U#
M]@O/^?2?_OV:EMH+ZUN8YTLYBT9R T;8J8JS6A4G=.S-!+2!RHG@@M[@Q3%T
M5MRJH7*L1DX.<_E5#^SU,L 2=I(IT+HR0DMP2"-OKD>M-M[>^MF=DLYOFC:,
MYB;HPP:L0MJ$42Q&PD>,1-$5,;#*EMW4<]:O1[HC5;,1M':.2X$DQ"PJC$K$
M68AAD';V [^E)%HTTEFLX9@6C,JCRR5*C/5N@)P<"IEFOUNUNO[,;SD51&0C
M@)M&!P.H]C43?;9+=8I=.=V12B2&-P0,YZ#@XR<46CV#FGW_ "*VG"%K^!)X
M3*CNJ[=VT<D#G_"HW11?-'CY1,5Q[;L5+#:WL,\<JVDQ:-@P!C;&0<T&TO6G
M,OV2;<7W_P"K/7.:BSM:QI=7O<OR16MQJ-Y8BTBA,?F^5)&6!&P$\Y)!!Q54
M:9_H(N_-<1@IOS"0 &.,J3][%33RW\WGE-,\AY\^:\<3[F!ZC)S@'VHGEU">
M&5#IS*TRH)'$;Y.W&/8=.U:-1>Z,DY*UG^(DNEPMJUQ:P32[(VP,0EB.>^.P
M]:AL[0#78K.X57 G\MQG@X.#5EI[YVE9M+)\UUD8>6^-XS\WZ].E0@:@-3^W
M_8I3+YOF[?*;;G.?RI-1O=+J-.5FF^@DMJ;FY$*+:1R["8TMVW"0_P!W.3@^
ME(=.A2.266]58XY1$Q5"V6QDX]0.1FGC[7')YEOI;02;2H9$<E<]QG//^-6-
MT[V4OFZ:9))+@2-&8G ^[C=QZGJ/>CE3#F:V?Y$4>@SM(ZLY&)?*1DC+AC@'
M)QT'(Y]ZJR626\*M<W CD<$K&J%N <9)[=#5HRZA+O%QI[SAI#(-T;KM)&#C
M&., <>U1,EY):K#+IKNR*5CD,;AE&<XXX/4XS0U'HAJ4NK_(FFT=&OKF.VDD
M:& +N(B+,">@ '7N<U#)I?V:1A=7"QJ)?+0["=YP#G'88(_.IFEOI))&DTUF
M655$J[' 8KT;V/TIB&\5#&VEEXQ)YD:M&^(V]O4<#@^E-J/1?F).?5_D5=21
M(M5NHT4*B3, HZ 9J]';0W?V-)K=+:2:?Y5CR"T6,DG)]>A[\U5FAOI[Q[E[
M*4L\GF,OE-C.<X^E6)7OI+D72::\5P)!)YBHY.?H21BDK7;L-WLDF1.8);..
M\6SC5EG,1B7=M<%<KGG.1^M3O;P+(9)+>-9H;4RS0*3MW[L*#SQP02,TB37T
M<L3Q:88TC9G$:QO@LPP3ZY]/2HU%W'+OBTID5D*2)L<AP>N<G/Y4]/Z0M?Z9
M!?1QA;6>.,1^?%O9%Z!@Q4X]N,U3J]<PWURZDV4J*BA$18VPJCM4/V"\_P"?
M2?\ []FLY)MZ(TBTEJRO15C[!>?\^D__ '[-'V"\_P"?2?\ []FIY7V*YH]R
MO15C[!>?\^D__?LT?8+S_GTG_P"_9HY7V#FCW*]%6/L%Y_SZ3_\ ?LT?8+S_
M )])_P#OV:.5]@YH]RO15C[!>?\ /I/_ -^S1]@O/^?2?_OV:.5]@YH]RO15
MC[#>?\^D_P#W[-'V"\_Y])_^_9HY7V#FCW*]%6/L%Y_SZ3_]^S1]@O/^?2?_
M +]FCE?8.:/<KT58^P7G_/I/_P!^S1]@O/\ GTG_ ._9HY7V#FCW*]*K%6#*
M2&!R"#R*G^P7G_/I/_W[-6;'1;R\N!&T3PH.6=U(P/;U--0DW9(3G%*[9T>@
MZP^H1M#.A,T8R9 .&'OZ&MFH+.SAL;=8($VJ.I[L?4U/7J04E&TMSQJCBY-Q
M5D%%%%60%1R$"6$%0<L<$]N#4E1R%A)$ ."QSQ[&@!E[=QZ?I]S>S9\JWB:5
M\>BC->%2W^O?$6SN;;)>2&Z^U;6.V*.(KMQGH-N,XZG)ZFO<=4LEU+2;RQ8[
M1<P/%GTW C->(>.EN_#":/X>M':WAM[9+EVB.WSK@D[G)'7!&!Z5WX*S=E\1
MP8VZ5W\)FVGBRX\-WMBFBW#/9V9;?D%4NV8@N2/3@ =P #UKZ%M;J*\L8+R(
MGRIHEE7/H1D5Y%#"/B!INJ"PO5>]$4933Y(1&D7S#YPV<%A\P)&,YYKUFPLU
ML=/M+!#NCM84CSZ[0!_]>EC'%VTM+J/!J2OK>/0S_$NEW>JZ++;VLK1S/SP?
MR&/Z]N:C\-:;=Z#H31WTDDS1[F(0%CU/ '<^GKQTK7EL;:8'=#'D]RN:RKS0
MUV%HTC8^BQ-G])!6<*J=/V+=E>^Q<Z353VT5=VMN<MJUQJ6LWXFET^]2&,D0
MQM8S@H/<HPR:N6,E[;X_=W:CWBO1_,FJFH64\&<V\RX]+>Z_]EE-3Z18?9+&
M37]06X>WMQOA@B>?<Y!QDH[=/_UUZ4G#V:2VV2/-BI^U;>^[9TEMJTH4+(G'
MJ8I\_JE:45Y#*!AFSZ%&'\Q7/Q^-X9I8(H[)V>52QQ.A50&QG(Z]#Z=*CMO'
MUG<!)'M)HK=F ,QD5E7*LP!QWPIX]Q7GSPM5W:A^*/0ABJ2LG/\ !G645RQ\
M;1BX2W_LV<7#/LV-(HP0JD@G_@0'US5O1O%$.M:C-:0VLB^4K,9-ZL!AMO('
M(SV]:SEA:T8\S6GR-8XJC*7*GK\S>HHHKG.@**** "BD*JQR5!^HI/+3^XOY
M4 .HIOEI_<7\J/+3^XOY4 .HIOEI_<7\J/+3^XOY4 .HIOEI_<7\J/+3^XOY
M4 .HIOEI_<7\J/+3^XOY4 .HIOEI_<7\J/+3^XOY4 .HIOEI_<7\J/+3^XOY
M4 .HIOEI_<7\J/+3^XOY4 .HS3?+3^XOY4>6G]Q?RH =GWHS[TWRT_N+^5'E
MI_<7\J '9]Z,^]-\M/[B_E1Y:?W%_*@!V?>C/O3?+3^XOY4>6G]Q?RH =GWH
MS[TWRT_N+^5'EI_<7\J '9]Z,^]-\M/[B_E1Y:?W%_*@!V?>C/O3?+3^XOY4
M>6G]Q?RH =GWHS[TWRT_N+^5'EI_<7\J '9]Z,^]-\M/[B_E1Y:?W%_*@!V?
M>C/O3?+3^XOY4>6G]Q?RH =GWHS[TWRT_N+^5'EI_<7\J '9]Z,^]-\M/[B_
ME1Y:?W%_*@!V?>C/O3?+3^XOY4>6G]Q?RH =GWHS[TWRT_N+^5'EI_<7\J '
M9]Z,^]-\M/[B_E1Y:?W%_*@!V?>C/O3?+3^XOY4>6G]Q?RH 2+> ^\G[YQD]
MNU/S[U##$H$F0IS(QX[>U2>6G]Q?RH =GWHS[TWRT_N+^5'EI_<7\J '9]Z,
M^]-\M/[B_E1Y:?W%_*@!V?>C/O3?+3^XOY4>6G]Q?RH =GWHS[TWRT_N+^5'
MEI_<7\J '9]Z,^]-\M/[B_E1Y:?W%_*@!)=YAD"$[]IVX/>G@G R>U0S1*8)
M  H)4X)XQQ3Q&F!\B]/2@!^?>C/O3?+3^XOY4>6G]Q?RH =GWHS[TWRT_N+^
M5'EI_<7\J '9]Z,TWRT_N+^5'EI_<7\J '44WRT_N+^5'EI_<7\J '44WRT_
MN+^5'EI_<7\J '5&^_S(MN=NX[OI@_UIWEI_<7\JCDB4RPD!1ACD>O!H FJC
MJ6C:7K,:IJ5A;W2I]WS4R5^AZBKGEI_<7\J/+3^XOY4TVG=":35F4]-T;2]'
MC9--L+>U#?>\I "WU/4U>XIOEI_<7\J/+3^XOY4-MN[!))60ZBF^6G]Q?RH\
MM/[B_E2&5;W2=/U+;]MLX9BI!#,O(_'K4EY96]_;&WN4+19! 5BI!'0@CD8J
M;RT_N+^5'EI_<7\JKGEIKL3R1UTW,I/"^C1MN2T*L5V$K*XW#G.>>>IZ^M2'
MP_I) !L8R T;8).,QC"?D*T?+3^XOY4>6G]Q?RJG6J/>3^\A4::VBON,UO#N
ME-=?:OLQ$^]G+K*ZDECDYP>YJ>STFPL)%>UMUB98A"""?N DX_,FK?EI_<7\
MJ4(H.0H!]A2=6;5G)C5*"=U%"T445!H%%%% $5S<P65K)<W4R0P1+NDD<X51
MZFJ*>(]$DL)+]-5M&M(F"22B081CT!]":J>-H);GP1K$$$3RRO;$)'&I+,<C
M@ 5S6O>&KVVT"^OWF>[U&[FLBXM+7'EI$XQM3)+$<DY]*:2$VSMHM9TR?3I-
M0BU"V>RCSOG$@V+CKD]JA3Q%HTFERZFFIVK6,)VR3A_E0\<'T/(_.N";3=3F
MTR_N#87=[:C6H+Y_-M_*GO(P/G_=<#Y3C P,XZ5KZU/-XGFTZSTS1IFM6N#<
MW7VZ%K:.41J H)P3U;T_A]*+"NSJKW6]+TV"">]U"WMXIQF%W? DXSQZ\'-1
MW7B/1+&WM[BZU:SBAN1F&1I1B0>H]1[UPMII^O30^&M.VRVE[I=S=VQNF@\V
M-5$?[MN1@J00N?:DD::#P'IVA)HM[#)="6"]G^R-,;==Y\PJ ,DL>5Z#G/:B
MP79W]UKFE6-Q;P76HVT,MP 84>0 N#P"/8^M32ZC90:A!I\UU$EY<*6A@9L,
MX'4@5YWJ]C+MU>SM-+OI8]5TVSM]-8V[?)LX*N?X".&.<4:S8:]=:E?Z];:<
M)#IUQ"MJ[LPF9(/O[$Q\P<LW?FBP<S/0[_4+73+=9[N38CRI$N%)+.QPH 'J
M:AEUW28-3&F2ZE:I?'@0&0;L]<?7VK)\42!KOPM<,"+;^U8F<,,8+(VS/XG\
MZS=!9M)?4M(O])O'O[B_FF6X6U+QRJQ)1_,Z# XYY&*+#OJ=-I_B#1M5F,.G
MZI:W,H&XI'("V/7'I2V6OZ/J,L\5EJ=K</;@M*(Y =@'4GV]ZX70[:YO+'P?
M91Z3>P7.DR>;>7,UN8A&@# H&/WMV0,"HY8KCQ$^OW*:7>V=]-ITEEI]L;-H
MT6(<G<^,;W/0=AQ187,SN1XGT1[&2]BU*":VBD2.22([@C,0%SCH"3UZ5K=#
MBO,-24W.D>)M36QN+2T.BP6:+/"8B\RD]%/H2!G\J]*M@ZVD"R_ZP1*'SZX&
M?UH:&G<EHHHI#"L3Q%J%S81VYMI-A=F#?*#G 'K6W7-^+O\ 4V?^\W\A65=M
M4VT;8=)U4F9Z:QK3VLERLN88V"NP1?E)Z=J4:MK;*K"7(>-I5^1>57.3^AJ&
MRN_LFELV X-R!)$3]]"A!'^>^*N_Z/;S6ZI(D\*V$VW+8W EB ?0\UQQ<FOB
M9WR44[<J^[R((=7UN=5,4NX-((A\B\L>@J$^(=4!(-R./]A?\*LV%Q \=KLA
MCM]NH1D@.3D;3SR:S9["YB,C21A54%R=X/&<=CZD4FYI738XQIN33BE]Q>M]
M8UJZ<I#-N(&YCL4!1ZDG@"G2ZKK<2R,TZ%8]I9E",/FZ<CZ54LU-QIMS:1,H
MG:1) I8#S% .0,]P2#BI;>RG%C?6NQ1.3$P3>N<9/O0I3:W8.---Z+[AS:YK
M"PI,9\1N2%.Q>2,9[>XI@\0:JS!5N,DG  C7G]*'LYY-(@1$4M#++Y@WK\OW
M??VJB(YK>[C0828%67D<$X(_I2<JBZLJ,*;Z(V'U#7DECB,R&21]@0&,G=Z'
M'3\:@CUO6)?,V3Y\M2[?(O '4]*L1PHFH6-U/%':W370#HK@JXZE\9^7G\.:
MK6EE<12W<4B*KRVSB,%U^8Y'O5OGOHV9I4[:I#?^$AU3_GY'_?"_X4?\)#JG
M_/R/^^%_PJB8A;W'EW2/P.51AGVYY%$QMB!Y"3*>_F.#_("LN>?<U]G3_E1L
M'4-?%M]H\P&/9YG 0G;ZXZXJ&?6]7MIVADN5#J 2 BGJ,^GO3;F[BMX;<QQ;
MKDV0C\POPH((/R^N/4]ZFO9DGDOX6,/EI#&T9P,AOD&<]3P3FM')VTDS-1C?
M6*^XK_\ "1:I_P _(_[X7_"D_P"$BU3_ )^1_P!\+_A6A<1)'%&&B2X>*Z01
MAC&HE3!SC;T4X'6FK'&MS.S,9+DPJT2;8Q(GS'<,?=+8_'!IVJ?S,5Z?\J*7
M_"0ZI_S\C_OVO^%37&KZW:^7Y\AC,B[E#1J#C..F*S]19&OY3'%Y0XRF1P<#
M/3CKSQ3[Q@UGI_S;F$3[N<G.]NM9\\M=7H:>SAI[JU\C1@U#7KB%98I4*N2%
MSY8+$=< \FJSZ_JT;LDDY1E.&5HU!!_*D^R27FD68B\OY'EWEI%4+DC&<FK4
MTIN&N)-/,<MT'C1G8*2R! "PW=BPY_"KO*V[(M"_PK^GU*O_  D6J?\ /R/^
M^%_PITFOZK&P!ND.0#\JJ>M662)UO4MQ'%%N8F=0C(2$&4YY SG!'K4,LJ6]
MM<R0K")1%;;#M4D':=V/?UH?.OM E![11%_PD6J?\_(_[X7_  H7Q!JK,%%P
M"2<#Y%_PJS,HW7;6*P?:"\;$87 0IDX!XQNZU3U)5CU^15"*HD3A!A1P.GM2
M;FE?F8XJG)VY46[K5-;LSB>XC!R5PIC8@^^.E5_^$BU3_GY'_?"_X5:NHF&M
M&3[);QQ-,^YS)N61.<D\G'&3QWI5C'EWALDB95BB^S%@I;:6.2<_Q]<Y_P *
MI\]]),E>SLKQ7X%3_A(M4_Y^1_WPO^%'_"1:I_S\C_OA?\*O*(-\S(BM>A8M
MXA$9YP=^ WR]<9Q5>3+0R/IT,2$S2><AV,R+Q@<_P]>E)\Z^TQKV;?PHB;7]
M63&Z?;D!AF->0>_2F_\ "1:GC/VD?]\+_A5]9!<36TDVUQ]B'D;0@S(, CGC
M(&< U%)\YN&M8%2^"Q@K)L+$<[F ^Z#]W-'O_P S!>SZQ1!+K&K6LAC:X 9@
M)#A5/W@#Z>]68[[Q!+&KI(#O&44A SCU"GDUGZT0VHO@H?W<8S&?ESL&<5;N
M+66]U!;ZW=/LN$;S=X A  &#W&,4<TKM78<L.5.R5_((M7UR:&6:.0F*(9=_
M+7"_IU]J9%KFKS2"..X!8^JJ/U-,6XCFN]5E0[8I(I60$XZL.WK5.RM?METL
M.\(""23CH!GC/>I<Y72392A"S;BON-7^TM=\]8?-&YDW@@)M*_WMW3'O1_:6
MN^<T1F164!B6V!<'H<G@YII64F:T,0AW6OEVT9D4D@.&()!QD\TALEN7BC?$
MAM+9%DC1U!=B2=H).. >3VJ[RZ-D6AU2^[^O0>FHZ])+)$) 'B8*^]44 GH,
MGN:KMK^K([(\^UE."#&N0?RJ29+F^@N(65%NOM(E= X "E< CGH/ZU0U*5)]
M3N98SE&D)!]?>IE*25TV5"$&[.*+7_"0ZI_S\C_OA?\ "C_A(=4_Y^1_WPO^
M%9=%9^TGW9K[*G_*ON-3_A(=4_Y^1_WPO^%'_"0ZI_S\C_OA?\*RZ*/:3[L/
M94_Y5]QIMX@U-E*M< J1@C8O/Z5UFEZG#J5MN3Y95&'CSR/_ *U<!6CHD%Y-
MJ*-9ML*<O(>@'OZY]*UHUIJ5MS"O0@XW6ECO****]$\L**** "BBB@ HHHH
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M/,\6_>HCCP=X.3C(."I)P?K7ME<^+A3C).GLSHPLZDHM5-T%%%%<IU!1110
M4444 %%%% !12$,3PV/PI-K_ //3_P =% #J7)/4TS:__/3_ ,=%&U_^>G_C
MHH =DTN3ZTS:_P#ST_\ '11M?_GI_P".B@!V313=K_\ /3_QT4;7_P">G_CH
MH CN;6WO8?)NH4FCW*^UQD;E.0?J",U/D^M,VO\ \]/_ !T4;7_YZ?\ CHH
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MJMK_ //3_P =%&U_^>G_ (Z*/JU/L'UNKW.5_P"$1N?^?N'_ +Y-'_"(W/\
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MWFEM_ ^LRPRO%(EL2KHQ!7D=".E<=J%OJ]CX9U&8B^M+"XN+);6VN+TM*"7
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MX;2F<@]_8^AJ*"RM;M8)(UEB4R.DB[]Q8*N[(XX)Z4>TJ]P]E0[&I_PET?\
MSY/_ -_!_A1_PER?\^,G_?P?X5AW$5N=.@NH(GB,DKH59]PP .AQ[U;2?R=!
MMQ]KF@+O+A8UR'^[UY%"K5+ZL;H4K*T?S-'_ (2Z/_GR?_OX/\*/^$NC_P"?
M)_\ OX/\*RUL+<VMK<;9-MPZ1!,_<.<,Q/H<<?CZ5(FFVMW<2P0K+"8;E82[
MMNW DCIC@\4>TK=Q>RH=B\OBU1NW6CMEB1^\' ].E._X2Z/_ )\G_P"_@_PK
M-^PV$K@Q2@^6LCR112;R549') P3T-11-9OIE\ZVF"#&%)ESMR2.N*/:U>X_
M8T?Y?Z^\U_\ A+H_^?)_^_@_PH_X2U,9^PR8Z9WC_"J,NE60N19+<*+@2I'D
M.6+Y.&RN./4<U!(8&T6X^SPR1J+I%.]]V<*WMP:'4JK=B5*B]HFK_P )<G_/
MB_\ W\'^%'_"71_\^3_]_!_A6-ILDT),WV@P6J.IE8?Q'LH'<GGCIZU<M[AD
M^P-;+L2ZNW\Q!T8;@ I]0%/3WHC6J-;_ (!*A23^'\67?^$NCQG[$^/^N@_P
MH_X2Z/&?L3_]_!_A69',UG%,9)O]#82QP09_UN<C./0'G)].*FWL&^R9_P!$
M_L_?M[9V;MWUW=_PIJK4[_@#HTOY?Q9=_P"$NC_Y\G_[^#_"C_A+H_\ GR?_
M +^#_"N6HK/ZQ4[FGU6EV.I_X2Z/_GR?_OX/\*/^$NC_ .?)_P#OX/\ "N6H
MH^L5.X?5:78ZH>+(I,H;>2+((#[@=I[<5T2D,BL""" 01WKS.M[P]JTL,Z6+
MJTD+G"8&2A_PK6CB&W:9A7PJ2YH'7T445VG %%%% !1110 4444 %%%% !3'
MW^9%MSMW'=CTP?ZT^HY QEB(/ 8YY]C0!)1110 4444 %<_KWC70_#GD"_N6
M9I]Q18$\PX4X)..!SQ^!J#X@:O/HG@N^NK5BD[[84<=4W'!(]\9KR?3_  ZV
MHZ+ILFKN\#*'%C:JX$]]&27VH#]WYB<,>N[@$XSUX?#QG'GF]#DKXB4)<D%J
M>VZ3K^F:W!#)8W(8RQ><L3C;)LW%=VT\XR",UI5\WW-SKVB:Y;:Y+:2630NJ
M0H/NQJHXB/I\O8\GDU]&Q2":&.51A9$#@>F1FIQ.'5*S3NF5AJ[JW35FA]%%
M%<QTA1110 4444 %%%% $5Q;P7=O);W,*302#:\<BY5AZ$4VZLK6^M3:W=M%
M/;G&8I$#*<=./:IB2#PI/TQ2;F_YYM^8H JQ:3IL%@]C%I]JEF^=\"Q*$;ZC
M&#3;+1=*TUT>QTZUMG0,JM%$%(!QD9'K@?E5S<W_ #S;\Q1N;_GFWYB@"NNF
M6"7(N4LH%G$C3"01C=O889L^I'!-5IO#FAW"*LVCV,BJ690T"D L<L1]3R:T
M=S?\\V_,4;F_YYM^8H HOH6D2-:L^EV;-:*%MRT*GR@.@7T IZ:1IL>H2Z@E
MA;+>2@B2X$8WMGKD^]6]S?\ /-OS%&YO^>;?F* *YTVQ-C%9&S@^R0E6C@\L
M;$*G((';!YJ*]TJ*]U/3]0:1TFLC)C:!B177#(WMT/X5=W-_SS;\Q1N;_GFW
MYB@"G8Z+I6ER-)8:;:6LC##-#"%)'ID5&OAW1$>=UTBQ5K@8F(@4>8,YP>/4
M UH;F_YYM^8HW-_SS;\Q0&A7ETRPF-R9;*W<W2JMP6C!\T#H&]0*<MC:+#<0
MK:PB*Y):= @Q*2,$L.^1Q4VYO^>;?F*-S?\ /-OS% %"PT:WT_4+V\B)WW*Q
MQA, +%'&N%1<=NI_&M&F[F_YYM^8HW-_SS;\Q0 ZN;\79,-I@?Q-_(5T6YO^
M>;?F*-S?\\S^8J*D.>+B72GR34CS</*(_+!8)NWX_P!KUIQGG8N6DD)=P[$_
MQ,.A/OR:]&W'_GF?THW'_GF?TKF^JO\ F.OZZOY?Z^X\X::=PX9W(D?>X/\
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MYM^8HW-_SS;\Q61J.HINYO\ GFWYBE!)/*D?B* %HHHH **4@@X-)0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%.V-Z&@"2X3:^>
MQJ&M)T#K@U2D@9#QR*J2L3&5R*BE((Z@BDJ2@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBGK$['&* $1=S@8S6@$  !&?>F10B,>]2UI%6,I2N%(
M>AHHJB2A-]\U'116+-UL%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 H
2ZUH1_<HHJH$3V'T445H9G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>57
<FILENAME>dtil-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-10T02:29:53.6244110+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 110b6502c8774be1969d6e34eb8cea58 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:dtil="http://precisionbiosciences.com/20191231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="dtil-20191231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217GBP">
    <xbrli:measure>iso4217:GBP</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_dtilSegment">
    <xbrli:measure>dtil:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001357874_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20200302">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20190628">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-06-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:PrecisionPlantSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:PrecisionPlantSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:PrecisionPlantSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidatedEntitiesAxis_srtSubsidiaryIssuerMember_srtOwnershipAxis_dtilEloLifeSystemsAustraliaPtyLtdMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:EloLifeSystemsAustraliaPtyLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiaryIssuerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidatedEntitiesAxis_srtSubsidiaryIssuerMember_srtOwnershipAxis_dtilEloLifeSystemsAustraliaPtyLtdMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:EloLifeSystemsAustraliaPtyLtdMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiaryIssuerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtOwnershipAxis_dtilPrecisionBioSciencesUKLimitedMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:PrecisionBioSciencesUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtOwnershipAxis_dtilPrecisionBioSciencesUKLimitedMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dtil:PrecisionBioSciencesUKLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20190315_20190315">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-15</xbrli:startDate>
      <xbrli:endDate>2019-03-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_dtilSeriesAAndSeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dtil:SeriesAAndSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_dtilSeriesAAndSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dtil:SeriesAAndSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_dtilDevelopmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dtil:DevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_dtilDevelopmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dtil:DevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilLaboratoryEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dtil:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilLaboratoryEquipmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dtil:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapGeographicDistributionAxis_dtilDurhamMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">dtil:DurhamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtStatementGeographicalAxis_stprNC_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilManufacturingCenterForAdvancedTherapeuticsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dtil:ManufacturingCenterForAdvancedTherapeuticsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapGeographicDistributionAxis_dtilDurhamMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">dtil:DurhamMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilPropertyEquipmentLeaseholdImprovementsAndSoftwareMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dtil:PropertyEquipmentLeaseholdImprovementsAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilPropertyEquipmentLeaseholdImprovementsAndSoftwareMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dtil:PropertyEquipmentLeaseholdImprovementsAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20180901_20180930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandSixStockIncentivePlanMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandSixStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandSixStockIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandSixStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandFifteenStockIncentivePlanMember_20150430">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandFifteenStockIncentivePlanMember_20180531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandFifteenStockIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_20190312">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_20190311_20190312">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-11</xbrli:startDate>
      <xbrli:endDate>2019-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_20191230_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-30</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190312">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190311_20190312">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-03-11</xbrli:startDate>
      <xbrli:endDate>2019-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20191230_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dtil:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-30</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementNonemployeeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementNonemployeeMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFiveMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFiveMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSixMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeEightMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeNineMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTenMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeTenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeElevenMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeElevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSixMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeEightMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeNineMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTenMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeTenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeElevenMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dtil:PriceRangeElevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_20110101_20110131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dtilOutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dtil:OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dtilOutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dtil:OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:PacificWesternLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20190501_20190531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:PacificWesternLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-01</xbrli:startDate>
      <xbrli:endDate>2019-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapDebtInstrumentAxis_dtilRevolvingLineIfDailyBalanceIsMaintainedMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dtil:RevolvingLineIfDailyBalanceIsMaintainedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:PacificWesternLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:PacificWesternLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapDebtInstrumentAxis_dtilRevolvingLineIfDailyBalanceIsNotMaintainedMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dtil:RevolvingLineIfDailyBalanceIsNotMaintainedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:PacificWesternLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:PacificWesternLoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_dtilOrphanDrugTaxCreditCarryforwardMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dtil:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_dtilOrphanDrugTaxCreditCarryforwardMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dtil:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_dtilOrphanDrugTaxCreditCarryforwardMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dtil:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-23</xbrli:startDate>
      <xbrli:endDate>2016-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-23</xbrli:startDate>
      <xbrli:endDate>2016-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2019-01-01_20160224">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
          <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
        </xbrldi:typedMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapBalanceSheetLocationAxis_dtilCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dtil:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapBalanceSheetLocationAxis_dtilCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:DevelopmentAndCommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:ServierMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dtil:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180910">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-09</xbrli:startDate>
      <xbrli:endDate>2018-09-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-09</xbrli:startDate>
      <xbrli:endDate>2018-09-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:GileadSciencesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:SponsoredResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:SponsoredResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dtil:SponsoredResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dtil:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dtil:TherapeuticsSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dtil:TherapeuticsSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dtil:FoodSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dtil:FoodSegmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001357874_20190101_20191231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001357874_20190101_20191231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001357874_20190101_20191231">2019-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000003" contextRef="C_0001357874_20190101_20191231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="F_000004" contextRef="C_0001357874_20190101_20191231">2019</dei:DocumentFiscalYearFocus>
  <dei:EntityRegistrantName id="F_000005" contextRef="C_0001357874_20190101_20191231">PRECISION BIOSCIENCES INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000006" contextRef="C_0001357874_20190101_20191231">0001357874</dei:EntityCentralIndexKey>
  <dei:TradingSymbol id="F_000007" contextRef="C_0001357874_20190101_20191231">DTIL</dei:TradingSymbol>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001357874_20190101_20191231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001357874_20190101_20191231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000010" contextRef="C_0001357874_20190101_20191231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000011" contextRef="C_0001357874_20190101_20191231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityCommonStockSharesOutstanding id="F_000012" contextRef="C_0001357874_20200302" decimals="INF" unitRef="U_xbrlishares">51399847</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus id="F_000013" contextRef="C_0001357874_20190101_20191231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000014" contextRef="C_0001357874_20190101_20191231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityShellCompany id="F_000015" contextRef="C_0001357874_20190101_20191231">false</dei:EntityShellCompany>
  <dei:EntityExTransitionPeriod id="F_000016" contextRef="C_0001357874_20190101_20191231">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber id="F_000017" contextRef="C_0001357874_20190101_20191231">001-38841</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000018" contextRef="C_0001357874_20190101_20191231">20-4206017</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000019" contextRef="C_0001357874_20190101_20191231">302 East Pettigrew St.</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000020" contextRef="C_0001357874_20190101_20191231">Suite A-100</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000021" contextRef="C_0001357874_20190101_20191231">Durham</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000022" contextRef="C_0001357874_20190101_20191231">NC</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000023" contextRef="C_0001357874_20190101_20191231">27701</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000024" contextRef="C_0001357874_20190101_20191231">(919)</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000025" contextRef="C_0001357874_20190101_20191231">314-5512</dei:LocalPhoneNumber>
  <dei:Security12bTitle id="F_000026" contextRef="C_0001357874_20190101_20191231">Common Stock, par value $0.000005 per share</dei:Security12bTitle>
  <dei:SecurityExchangeName id="F_000027" contextRef="C_0001357874_20190101_20191231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityIncorporationStateCountryCode id="F_000028" contextRef="C_0001357874_20190101_20191231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:DocumentAnnualReport id="F_000029" contextRef="C_0001357874_20190101_20191231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000030" contextRef="C_0001357874_20190101_20191231">false</dei:DocumentTransitionReport>
  <dei:EntityVoluntaryFilers id="F_000031" contextRef="C_0001357874_20190101_20191231">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="F_000032" contextRef="C_0001357874_20190101_20191231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityPublicFloat id="F_000033" contextRef="C_0001357874_20190628" decimals="-5" unitRef="U_iso4217USD">589000000</dei:EntityPublicFloat>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000034" contextRef="C_0001357874_20190101_20191231">&lt;p&gt;None&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">180886000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">103193000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="F_000037" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">965000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000038" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">523000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000039" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">9497000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000040" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">8913000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000041" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">2324000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000042" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">3046000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000043" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">193672000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000044" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">115675000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000045" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">39571000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000046" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">21147000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000047" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1432000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="F_000048" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">1466000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OtherAssetsNoncurrent id="F_000049" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">558000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000050" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">312000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000051" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">235233000</us-gaap:Assets>
  <us-gaap:Assets id="F_000052" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">138600000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000053" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">2037000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000054" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">2218000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000055" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">4425000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000056" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">965000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <dtil:AccruedClinicalAndResearchAndDevelopmentExpenses id="F_000057" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">2400000</dtil:AccruedClinicalAndResearchAndDevelopmentExpenses>
  <dtil:AccruedClinicalAndResearchAndDevelopmentExpenses id="F_000058" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">1569000</dtil:AccruedClinicalAndResearchAndDevelopmentExpenses>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000059" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1584000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000060" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">887000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000061" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">16486000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000062" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">8436000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000063" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">26932000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000064" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">14075000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000065" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">65895000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent id="F_000066" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">82807000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000067" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">4092000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="F_000068" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">1758000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:Liabilities id="F_000069" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">96919000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000070" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">98640000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000071" xsi:nil="true" contextRef="C_0001357874_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000072" xsi:nil="true" contextRef="C_0001357874_20181231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000073" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000074" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000075" xsi:nil="true" contextRef="C_0001357874_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000076" xsi:nil="true" contextRef="C_0001357874_20181231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000077" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">316333000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000078" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">126094000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000079" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">-177067000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000080" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">-85187000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:TreasuryStockValue id="F_000081" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">952000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue id="F_000082" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">952000</us-gaap:TreasuryStockValue>
  <us-gaap:StockholdersEquity id="F_000083" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">138314000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000084" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">39960000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000085" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">235233000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000086" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">138600000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000087" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="4" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000088" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="4" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000089" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">25650000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000090" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000091" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">25650000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000092" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000093" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">25650000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000094" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="4" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000095" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="4" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000096" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">21956100</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000097" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000098" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">21956095</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000099" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000100" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">21956095</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000101" contextRef="C_0001357874_20191231" decimals="4" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000102" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000103" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000104" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000105" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000106" contextRef="C_0001357874_20191231" decimals="6" unitRef="U_iso4217USD_xbrlishares">0.000005</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000107" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000108" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">51965708</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000109" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">16717117</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000110" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">51155236</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000111" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">15906645</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000112" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000113" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">10883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000114" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">82416000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000115" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">45122000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000116" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">27026000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000117" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">13673000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000118" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">109442000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000119" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">58795000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000120" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-87204000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000121" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-47912000</us-gaap:OperatingIncomeLoss>
  <dtil:ChangeInFairValueOfConvertibleNotePayable id="F_000122" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9758000</dtil:ChangeInFairValueOfConvertibleNotePayable>
  <us-gaap:InterestExpense id="F_000123" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">182000</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="F_000124" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4267000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000125" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1875000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000126" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-5673000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000127" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1875000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000128" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-92877000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000129" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-46037000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000130" contextRef="C_0001357874_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.21</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000131" contextRef="C_0001357874_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.92</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000132" contextRef="C_0001357874_20190101_20191231" decimals="0" unitRef="U_xbrlishares">41991162</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000133" contextRef="C_0001357874_20180101_20181231" decimals="0" unitRef="U_xbrlishares">15775541</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding id="F_000134" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">25650000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000135" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000136" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">16496801</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000137" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">13691000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000138" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-39111000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000139" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">-952000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000140" contextRef="C_0001357874_20171231" decimals="-3" unitRef="U_iso4217USD">-26369000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000141" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">21956095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000142" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000143" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">109740000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000144" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">109742000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000145" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">220316</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000146" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">171000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000147" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">171000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000148" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2492000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000149" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000150" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000151" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-46037000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000152" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">25650000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000153" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000154" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">21956095</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000155" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000156" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">16717117</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000157" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">126094000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000158" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-85187000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000159" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">-952000</us-gaap:StockholdersEquity>
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption id="F_000160" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">997000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption id="F_000161" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">997000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares id="F_000162" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-25650000</dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares>
  <dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering id="F_000163" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-3000</dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
  <dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares id="F_000164" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-21956095</dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares>
  <dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering id="F_000165" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-2000</dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
  <dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares id="F_000166" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">22301190</dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares>
  <dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering id="F_000167" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5000</dtil:ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000168" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2921461</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000169" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49490000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000170" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49490000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <dtil:IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares id="F_000171" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">9085000</dtil:IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares>
  <dtil:IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost id="F_000172" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">130543000</dtil:IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost>
  <dtil:IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost id="F_000173" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">130543000</dtil:IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000174" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">940940</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000175" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000176" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000177" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000178" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000179" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-92877000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000180" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">51965708</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000181" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">316333000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000182" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-177067000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000183" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">-952000</us-gaap:StockholdersEquity>
  <us-gaap:ProfitLoss id="F_000184" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-92877000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000185" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-46037000</us-gaap:ProfitLoss>
  <us-gaap:DepreciationAndAmortization id="F_000186" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5317000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000187" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2354000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000188" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8940000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000189" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2453000</us-gaap:ShareBasedCompensation>
  <us-gaap:GainsLossesOnSalesOfAssets id="F_000190" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-22000</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:GainsLossesOnSalesOfAssets id="F_000191" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-14000</us-gaap:GainsLossesOnSalesOfAssets>
  <dtil:NonCashInterestExpense id="F_000192" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">182000</dtil:NonCashInterestExpense>
  <dtil:ChangeInFairValueOfConvertibleNotesPayable id="F_000193" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9758000</dtil:ChangeInFairValueOfConvertibleNotesPayable>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="F_000194" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">584000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="F_000195" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">7476000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000196" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">441000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000197" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">523000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <dtil:IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets id="F_000198" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1032000</dtil:IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets>
  <dtil:IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets id="F_000199" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">448000</dtil:IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000200" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">667000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000201" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-673000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <dtil:IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities id="F_000202" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4835000</dtil:IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities>
  <dtil:IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities id="F_000203" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1790000</dtil:IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000204" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-7866000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000205" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-3177000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000206" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-71015000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000207" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-51723000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireOtherInvestments id="F_000208" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1400000</us-gaap:PaymentsToAcquireOtherInvestments>
  <us-gaap:PaymentsToAcquireProductiveAssets id="F_000209" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">24666000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets id="F_000210" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">14278000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:ProceedsFromSaleOfProductiveAssets id="F_000211" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:ProceedsFromSaleOfProductiveAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000212" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-24666000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000213" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-15663000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000214" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1261000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000215" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">171000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000216" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">109742000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000217" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2622000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000218" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2136000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromConvertibleDebt id="F_000219" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">39550000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000220" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">135185000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000221" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">173374000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000222" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">107777000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000223" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">77693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000224" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">40391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000225" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">103193000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000226" contextRef="C_0001357874_20171231" decimals="-3" unitRef="U_iso4217USD">62802000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000227" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">180886000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <dtil:CommonStockIssuedOnConversionOfConvertibleNotes id="F_000228" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">49490000</dtil:CommonStockIssuedOnConversionOfConvertibleNotes>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 id="F_000229" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">401000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 id="F_000230" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1340000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction id="F_000231" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">168000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction id="F_000232" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">406000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="F_000233" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 1:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Business&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Precision BioSciences, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is focused on utilizing its proprietary genome editing platform to help overcome cancers, cure genetic diseases and enable the development of safer, more productive food sources.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc.&amp;#160;&amp;#160;Elo Life Systems Australia Pty Ltd was incorporated on May 29, 2018 as a 100% owned subsidiary of Elo Life Systems, Inc.&amp;#160;&amp;#160;The Company&amp;#8217;s 100% owned subsidiary, Precision BioSciences UK Limited, was incorporated on June 17, 2019.&amp;#160;&amp;#160;The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company&amp;#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 1, 2019, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) in which the Company issued and sold 9,085,000 shares of its common stock at a public offering price of $16.00 per share and received approximately $130.5 million in net proceeds, after deducting underwriting discounts and commission of approximately $10.2 million and issuance costs of approximately $4.6 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the IPO, on March 15, 2019 the Company effected a reverse split of shares of the Company&amp;#8217;s common stock on a 1-for-2.134686 basis (the &amp;#8220;Reverse Stock Split&amp;#8221;) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company&amp;#8217;s Series A and Series B preferred stock.&amp;#160;&amp;#160;Accordingly, all common shares, stock option shares, and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this Reverse Stock Split and adjustment of the preferred stock conversion ratios.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized common shares were not affected by the Reverse Stock Split.&amp;#160;&amp;#160;Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 22,301,190 shares of common stock at the applicable ratio then in effect and the outstanding convertible notes payable, including accrued interest, were settled into 2,921,461 shares of common stock. Subsequent to the closing of the IPO, there were no shares of Series A or Series B convertible preferred stock or convertible notes payable outstanding.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ from those estimates. Significant estimates include recording revenue for performance obligations recognized over time, determination of the fair value of share-based compensation grants and estimating services expended by third-party service providers used to recognize research and development expense. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These financial statements have been prepared in accordance with GAAP. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. During the year ended December&amp;#160;31, 2019, the Company incurred a net loss of $92.9&amp;#160;million and, as of December&amp;#160;31, 2019, has an accumulated deficit of $177.1 million. The Company has financed operations primarily through its IPO, private placements of convertible preferred stock and convertible debt and with proceeds from its development and commercial license agreement with Les Laboratoires Servier, (&amp;#8220;Servier&amp;#8221;) and Gilead Sciences, Inc. (&amp;#8220;Gilead&amp;#8221;) (see Note 12). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management believes that existing cash and cash equivalents will allow the Company to continue its operations into 2021. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain reclassifications have been made to the presentation of amounts in our Consolidated Balance Sheet as of December&amp;#160;31, 2019 to conform to the prior year presentation. Specifically, certain current liabilities were reclassified from accrued expenses and other current liabilities and are now presented separately on our Consolidated Balance Sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&amp;#160;31, 2019 and December 31, 2018, the Company held cash equivalents composed of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. All of the Company&amp;#8217;s cash and cash equivalents are held at financial institutions that management believes to be of high credit quality. The Company may maintain cash deposits in financial institutions in excess of government insured limits. The Company regularly invests excess cash deposits in money market funds and repurchase agreements. The Company believes that the credit risk arising from the holdings of these financial instruments is mitigated by the fact that these securities are of short duration, government backed and of high credit rating. The Company has not experienced any losses on cash and cash equivalents to date. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from two development and license agreements accounted for 60% and 33% of revenue during 2019 and 34% and 53% of revenue during 2018, as well as 2% and 98% of deferred revenue as of December&amp;#160;31, 2019. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Equity Offering Costs &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes incremental legal, professional accounting and other third-party fees directly associated with the Company&amp;#8217;s planned equity offerings as other current assets until the equity offering is consummated. After consummation, these costs are recorded in stockholders&amp;#8217; equity (deficit) as a reduction of additional paid-in capital. If the equity offering is not completed, any costs deferred will be expensed immediately. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, Equipment and Software &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and software are stated at cost, net of depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The depreciation and amortization periods for the Company&amp;#8217;s significant property, equipment and software categories are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;"&gt;
&lt;tr&gt;
&lt;td style="width:307.45pt;"&gt;&lt;/td&gt;
&lt;td style="width:232.55pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 to 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser&amp;#160;of&amp;#160;remaining&amp;#160;lease&amp;#160;term&amp;#160;or&amp;#160;useful&amp;#160;life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repairs and maintenance are charged to operations as incurred, and expenditures for additions and improvements that extend the useful life of the asset are capitalized. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets primarily include licenses and patents. The Company capitalizes license fees paid to acquire access to proprietary technology if the technology is expected to have alternative future use in multiple research and development projects. The cost of licensed technology rights is amortized using the straight-line method over the estimated useful life of the technology. If the access to use the technology rights is one year or less, the cost is recorded as a prepaid expense and amortized over the period identified in the agreement. Amortization expense for licensed technology and capitalized patent costs is included in research and development expenses within the accompanying consolidated statement of operations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets, such as property, equipment and software and intangible assets, subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is assessed when future undiscounted cash flows are less than the assets&amp;#8217; carrying value and recognized when the carrying value of the asset exceeds fair value. Fair value is calculated by estimating the discounted future cash flows expected to be generated by the asset as well as other valuation techniques. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value of the asset. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition for Contracts with Customers&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s revenues are generated primarily through collaborative research, license, development and commercialization agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January 1, 2019, the Company adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;), using the modified retrospective transition method. Under this method, results for reporting periods beginning on January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, &lt;font style="font-style:italic;"&gt;Revenue Recognition&lt;/font&gt; (&amp;#8220;ASC 605&amp;#8221;). The Company applied the modified retrospective transition method to contracts that were not completed as of January 1, 2019. For the year ended December 31, 2019, the Company reduced revenue recognition by $1.4 million for changes in total estimated time to be incurred in the future to satisfy the performance obligation. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer&amp;#8217;s discretion are generally considered options.&amp;#160;&amp;#160;The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue.&amp;#160;&amp;#160;Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue &amp;#8211; noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the other current assets line item in the accompanying consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone Payments &lt;font style="font-style:normal;"&gt;&amp;#8211;&lt;/font&gt; &lt;font style="font-style:normal;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&amp;#8217;s or the licensee&amp;#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalties &lt;font style="font-style:normal;"&gt;&amp;#8211;&lt;/font&gt; &lt;font style="font-style:normal;"&gt;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation linked to some or all of the royalty has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Significant Financing Component &lt;font style="font-style:normal;"&gt;&amp;#8211; In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.&amp;#160;&amp;#160;The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&amp;#160;&amp;#160;The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements &lt;font style="font-style:normal;"&gt;&amp;#8211; The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company&amp;#8217;s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzes its collaboration arrangements to assess whether the collaboration agreements are within the scope of accounting standards codification (&amp;#8220;ASC&amp;#8221;) ASC 808, &lt;font style="font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt; (&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&amp;#160;&amp;#160;For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For additional discussion of accounting for collaboration revenues, see Note 12, &amp;#8220;Collaboration and license agreements.&amp;#8221;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities including salaries, benefits, share-based compensation, allocations for rent and facility costs, depreciation, preclinical manufacturing expenses, costs of services provided by contract research organizations (&amp;#8220;CROs&amp;#8221;) in connection with preclinical trials and contract manufacturing organizations (&amp;#8220;CMOs&amp;#8221;) engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to estimate accrued research and development expenses resulting from its obligations under contracts with CROs, CMOs, research organizations, service providers, vendors and consultants in connection with research and development activities. The financial terms of these contracts are subject to negotiations and vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&amp;#8217;s objective is to reflect the appropriate research and development expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. There may be instances in which payments made to the Company&amp;#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&amp;#8217;s estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&amp;#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to prior estimates of accrued research and development expenses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common Stock Valuation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the IPO, due to the absence of an active market for the Company&amp;#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted prior to the IPO, the Company considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock was determined based upon a variety of factors, including the illiquid nature of the common stock, the Company&amp;#8217;s financial position and historical financial performance, the status of technological developments within the Company&amp;#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&amp;#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&amp;#160;31, 2019 and December 31, 2018, there was no difference between net loss and comprehensive loss in the accompanying consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&amp;#160;31, 2019 and December 31, 2018 since all potential shares of common stock are anti-dilutive as a result of the net loss. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for all share-based compensation, including stock options and the employee stock purchase plan at fair value and recognizes compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each equity grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&amp;#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the Company&amp;#8217;s expected dividend yield. As the Company has limited trading history, expected volatility is estimated based on the historical volatility of publicly traded peer companies and the Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of our traded share price. The expected term of the options has been determined utilizing a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date.&amp;nbsp;&amp;nbsp;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are determined based on the temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than the enactment of changes in the tax law or rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounting Standards Updates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an &amp;#8220;emerging growth company,&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section&amp;#160;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The JOBS Act also exempts the Company from having to provide an auditor attestation of internal controls over financial reporting under Sarbanes-Oxley Act Section&amp;#160;404(b). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will remain an &amp;#8220;emerging growth company&amp;#8221; until the earliest of (i)&amp;#160;December 31, 2024, (ii) the last day of the fiscal year in which it has total annual gross revenues of $1.07&amp;#160;billion or more, (iii)&amp;#160;the date on which it has issued more than $1.0&amp;#160;billion in nonconvertible debt during the previous three years or (iv)&amp;#160;the date on which it is deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;), which generally is when it has more than $700&amp;#160;million in market value of its stock held by non-affiliates, has been a public company for at least 12 months and have filed one annual report on Form 10-K. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company&amp;#8217;s collaboration agreements under prior revenue recognition guidance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - noncurrent liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,807&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(84,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet as of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - noncurrent liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(177,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidated Statement of Operations&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the Years Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(95,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Cash Flows for the Years Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption&amp;#160;of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(95,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="eolPage14"&gt;&lt;/a&gt;During the year ended December 31, 2019, the Company recorded $9.4 million in revenue that was included in deferred revenue as of December 31, 2018.&amp;#160;&amp;#160;The most significant change to the Company&amp;#8217;s revenue recognition as a result of the adoption of ASC 606 relates to the accounting for certain option fees and milestone payments in determining the transaction price (step (iii)), and the revenue recognition pattern (step (v)) related to the Company&amp;#8217;s development and commercial license agreement with Servier. Under ASC 605, the option fees payable by the Company to exercise the 50/50 co-development and co-promotion option was accounted for as a reduction in the arrangement consideration, and certain development milestones that may be earned for early-stage pre-IND development milestones were included in the arrangement consideration as the early-stage pre-IND development milestones were deemed to be non-substantive. Under ASC 606, the option fees were not accounted for as a reduction in the transaction price as the option fees are contingent upon Servier&amp;#8217;s&lt;a name="eolPage14"&gt;&lt;/a&gt; exercise of its commercial &lt;a name="eolPage14"&gt;&lt;/a&gt;(customer) options on licensed product candidates, and the milestone payments were excluded from the transaction price based on the assessment of the most likely amount and application of the variable consideration constraint, since the milestones relate to successful achievement of certain developmental goals, which may not be achieved. In addition, under ASC 605, the Company recognized revenue on a straight&amp;#8209;line basis over the period the Company expected to complete its obligations. Under ASC 606, the Company recognizes revenue based on the proportional performance of the services related to the performance obligation expected. For further discussion of the adoption of ASC 606 see Note 12, &amp;#8220;Collaboration and license agreements.&amp;#8221;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="DTIL_10Q_20190930_HTM_LD_TABLE_29"&gt;&lt;/a&gt;In June 2018, the FASB issued ASU 2018-07,&amp;#160;&lt;font style="font-style:italic;"&gt;Compensation-Stock Compensation Improvements to Nonemployee Share-Based Payment Accounting&amp;#160;&lt;/font&gt;(&amp;#8220;ASU 2018-07&amp;#8221;). ASU 2018-07 substantially aligns accounting for share-based payments to employees and non-employees. This ASU became effective for annual periods beginning after December 15, 2018 including interim periods within that period, and early adoption is permitted.&amp;nbsp;&amp;nbsp;The Company adopted ASU 2018-07 effective January 1, 2019.&amp;nbsp;&amp;nbsp;The adoption of the standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13,&amp;#160;&lt;font style="font-style:italic;"&gt;Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen&lt;/font&gt;t (&amp;#8220;ASU 2018-13&amp;#8221;). ASU 2018-13 is intended to improve the effectiveness of disclosures in the notes to financial statements related to fair value measurements in Topic 820. This ASU will become effective for annual periods beginning after December 15, 2019, including interim periods within that period, and early adoption is permitted.&amp;#160;The adoption of this standard is not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;font style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808)&amp;#8212;Clarifying the Interaction between Topic 808 and ASC 606&lt;/font&gt; (&amp;#8220;ASU 2018-18&amp;#8221;). The amendments in ASU 2018-18 make targeted improvements to GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASU 2018-18 was aligned with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606.&amp;#160;&amp;#160;ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of ASC 606. The Company adopted this guidance effective January 1, 2019 with its initial application of ASC 606. The adoption of the standard did not have an impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2019, the FASB issued ASU 2019-10, &lt;font style="font-style:italic;"&gt;Financial Instruments &amp;#8212; Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) &lt;/font&gt;(&amp;#8220;ASU 2019-10&amp;#8221;)&lt;font style="font-style:italic;"&gt;,&lt;/font&gt; which provides a one-year deferral of the effective dates of ASU No.&amp;#160;2016-02, &lt;font style="font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt; (&amp;#8220;ASU 2016-02&amp;#8221;), issued in February 2016.&amp;nbsp;&amp;nbsp;ASU 2016-02 was issued in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term.&amp;nbsp;&amp;nbsp;ASU 2019-10 is effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and expects to have an increase in total assets and total liabilities as a result of adopting the lease standard.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accounting standards updates issued, but not effective until after December 31, 2019, are not expected to have a material effect on the Company&amp;#8217;s consolidated financial position, statements of operations or cash flows.&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; &lt;/sup&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000234" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;PROPERTY, EQUIPMENT AND SOFTWARE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and software consisted of the following as of December&amp;#160;31 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,057&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,602&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property, equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,220&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,649&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and software - net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,571&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, we completed construction and opened our Manufacturing Center for Advanced Therapeutics, or MCAT, a manufacturing facility supporting our therapeutic product development platform, in a leased facility in Research Triangle Park.&amp;#160; Of the $8.6 million construction-in-progress (CIP) balance as of December 31, 2018, $2.5 million related to the MCAT and $4.4 million related to our other leased facilities in Durham was recognized as leasehold improvements in the year ending December 31, 2019. &amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense, including amortization of leasehold improvements and software, was $5.3 million and $2.3 million for the years ended December&amp;#160;31, 2019 and December 31, 2018, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:IntangibleAssetsDisclosureTextBlock id="F_000235" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;INTANGIBLE ASSETS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net, consisted of the following as of December&amp;#160;31 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,831&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,831&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: impairments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense of the intangible assets was $0.1 million for the years ended December&amp;#160;31, 2019 and December 31, 2018. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the Company entered into a license agreement to obtain the rights to intellectual property for the production of biological materials for use in its development programs. The Company paid the licensor a one-time, non-refundable license fee of $1.4&amp;#160;million for rights to a cell line that can be used on up to four product candidates. The intellectual property rights are being amortized on a straight-line basis over a period of 216 to 257 months depending on the date the company adds product candidates to the agreement. Amortization expense will be approximately $0.1 million for each of the next five years with the remaining $0.9 million amortized to expense in 2025 and beyond. &lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000236" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital Structure&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the IPO, all of the Company&amp;#8217;s outstanding shares of the Series A and Series B convertible preferred stock automatically converted into 22,301,190 shares of common stock and the Company&amp;#8217;s outstanding convertible notes payable, including accrued interest, converted into 2,921,461 shares of common stock at the applicable conversion ratio. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 1, 2019, the Company filed an amendment to its amended and restated certificate of incorporation pursuant to which, among other things, the Company increased its authorized shares to 210,000,000 shares of capital stock, of which 200,000,000 shares were designated as $0.000005 par value common stock and 10,000,000 shares were designated as $0.0001 par value preferred stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000237" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:-13.33%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of its equity incentive award plans, the Company&amp;#8217;s board of directors may grant equity or equity-based awards to employees, directors and other service providers. The Company granted stock options under the 2006 Stock Incentive Plan (&amp;#8220;2006 Plan&amp;#8221;) until April 2015 when the 2015 Stock Incentive Plan (&amp;#8220;2015 Plan&amp;#8221;) was adopted. The 2006 Plan expired in 2016 and there are no remaining shares available to be granted under the 2006 Plan. There were 1,385,203 stock options outstanding under the 2006 Plan as of December 31, 2019.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption of the 2015 Plan, there were 5,270,095 shares of common stock reserved for issuance. In May 2018, the Company amended the 2015 Plan to increase the number of shares reserved for issuance to 8,211,980. The 2015 Plan had 5,462,954 stock options outstanding as of December 31, 2019. The Company&amp;#8217;s board of directors determined the terms of stock options granted under the 2015 Plan, including option exercise prices and vesting.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 12, 2019, the Company&amp;#8217;s board of directors adopted, and, on or about March 14, 2019 the Company&amp;#8217;s stockholders approved, the Precision BioSciences, Inc. 2019 Incentive Award Plan (&amp;#8220;2019 Plan&amp;#8221;) and the 2019 Employee Stock Purchase Plan (&amp;#8220;2019 ESPP&amp;#8221;), both of which became effective on March 27, 2019. On March 27, 2019, the Company ceased granting new awards under the 2015 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other share-based awards initially equal to 4,750,000 shares of common stock.&amp;#160;&amp;#160;The 2019 Plan provides for an annual increase to the number of shares of common stock available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the board of directors.&amp;nbsp;&amp;nbsp;The number of shares available for issuance under the 2019 Plan was increased by 2,046,209 on January 1, 2020 pursuant to this provision. Any shares that are subject to awards outstanding under the Company&amp;#8217;s 2006 Plan and 2015 Plan as of the effective date of the 2019 Plan that expire, lapse, or are terminated, exchanged for cash, surrendered, repurchased, or canceled without having been fully exercised or forfeited, to the extent so unused, will become available for award grants under the 2019 Plan.&amp;#160;&amp;#160;The 2019 Plan had 2,070,959 stock options outstanding as of December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Up to 525,000 shares of the Company&amp;#8217;s common stock were initially reserved for issuance under the 2019 ESPP.&amp;nbsp;&amp;nbsp;The 2019 ESPP provides for an annual increase to the number of shares available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors.&amp;nbsp;&amp;nbsp;The number of shares available for issuance under the 2019 ESPP was increased by 511,552 shares on January 1, 2020 pursuant to this provision. No more than 5,250,000 shares of our common stock may be issued under our 2019 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date.&amp;#160;&amp;#160;The first ESPP offering period commenced on October 21, 2019 and ended on February 29, 2020;&amp;#160;44,197 shares were issued with respect to this offering period.&amp;nbsp;&amp;nbsp;The next ESPP offering period commenced on March 1, 2020 and will end on August 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,431&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonemployee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense related to stock options is included in the following line items in the consolidated statements of operations (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,639&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,301&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Determining the appropriate fair value model to measure the fair value of the stock option grants on the date of grant and the related assumptions requires judgment. The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average expected stock price volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term of options (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value per option&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term represents the average time that stock options that vest are expected to be outstanding.&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;The Company does not have sufficient history of exercising stock options to estimate the expected term of employee stock options and thus utilizes a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date. The risk-free rate is based on the United States Treasury yield curve during the expected life of the option.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity in the Company&amp;#8217;s stock option plans for the years ended December 31, 2019 and December 31, 2018:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of January 1, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,416,025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,160,097&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(220,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(592,350&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,763,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,647,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(940,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(550,644&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,919,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The intrinsic value of stock options exercised was $10.6 million and $2.7 million during the years ended December 31, 2019 and December 31, 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There was approximately $29.0 million of total unrecognized compensation cost related to unvested stock options as of December 31, 2019, which is expected to be recognized over a weighted-average period of 2.9 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes certain information about stock options granted under the stock option plans which are vested or expected to vest as of December&amp;#160;31, 2019 and December 31, 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,919,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currently exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,082,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,763,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currently exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes certain information about stock options outstanding under the stock option plans for the years ending December 31, 2019 and December 31, 2018, respectively: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&amp;#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.01 - $0.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,385,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,385,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.41 - $1.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,310,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,721,811&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$7.74 - $9.46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,266,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,644&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$10.17 - $13.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,891,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;844,005&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$14.91 - $16.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,919,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,082,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&amp;#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.01 - $0.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,440,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,166,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.18 - $1.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,846,255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,376&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;289,408&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,708&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,070,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;428,626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,763,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000238" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;RETIREMENT PLAN&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2011, the Company established a defined contribution 401(k) retirement savings plan (the &amp;#8220;Retirement Plan&amp;#8221;) to all full-time employees. Employee contributions to the Retirement Plan can be 100% of annual compensation up to the prescribed annual maximum under the Internal Revenue Code. Administrative fees of less than $0.1&amp;#160;million were paid by the Company for the years ended December&amp;#160;31, 2019 and December 31, 2018. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Retirement Plan includes a safe-harbor matching employer contribution equal to 100% of participants&amp;#8217; deferral contributions up to 4%. The Company made contributions of $0.6&amp;#160;million and $0.4&amp;#160;million to the Retirement Plan during the years ended December&amp;#160;31, 2019 and December 31, 2018, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000239" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Litigation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to various legal matters and claims in the ordinary course of business. Although the results of legal proceedings and claims cannot be predicted with certainty, in the opinion of management, there are currently no such known matters that will have a material effect on the consolidated financial condition, results of operations or cash flows of the Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office and laboratory space under long-term operating leases.&amp;#160;&amp;#160;These leases provide tenant improvement allowances and rent abatements as incentives for the Company to either enter into the initial lease agreement or expand within existing premises already under lease and represent all of the Company&amp;#8217;s lease obligations as of December 31, 2019.&amp;nbsp;&amp;nbsp;These leases include the following: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:12pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and laboratory space at 302 East Pettigrew Street, Durham, North Carolina, which is the Company&amp;#8217;s corporate headquarters. The property is leased through July 2024 with the option to extend. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:12pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and office space at 3054 Cornwallis Road Durham, North Carolina. The property is leased through April 2026 with the option to extend.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:12pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory space at 20 TW Alexander Drive, Research Triangle Park, North Carolina. In December 2019, the Company expanded the amount of spaced leased at this site and extended to lease to August 2027. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a schedule of future minimum lease payments for all leases as of December 31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,706&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,196&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,611&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and beyond&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,966&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supply Agreements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into contracts in the normal course of business with CMOs for the manufacture of clinical trial materials and CROs for clinical trial services. These agreements provide for termination at the request of either party with less than one-year notice and are, therefore, cancelable contracts and, if canceled, are not anticipated to have a material effect on the consolidated financial condition, results of operations, or cash flows of the Company.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000240" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;NET LOSS PER SHARE&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,015,814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,285,376&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding share-based compensation awards converted to common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,032,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,796,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,032,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,097,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000241" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;DEBT&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:-13.33%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2019, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $39.6 million of convertible notes payable (the &amp;#8220;2019 Notes&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Notes accrued interest at a rate of 6% per annum.&amp;#160;&amp;#160;The 2019 Notes were settled in 2,921,461 shares of common stock in connection with the closing of the Company&amp;#8217;s IPO (see Note 1) at a settlement price of $13.60 per share (equal to 85% of the IPO price per share).&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On issuance, the Company elected to account for the 2019 Notes at fair value with any changes in fair value being recognized through the consolidated statements of operations until the 2019 Notes were settled. The fair value of the 2019 Notes was determined to be $39.6 million on issuance and $49.4 million as of April 1, 2019, the settlement date. For the year ended December 31, 2019, the Company recognized $9.8 million of expense as changes in fair value and $0.2 million of interest expense.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revolving Line&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into a loan and security agreement with Pacific Western Bank (the &amp;#8220;Pacific Western Loan Agreement&amp;#8221;) pursuant to which the Company may request advances on a revolving line of credit of up to an aggregate principal of $50.0 million (the &amp;#8220;Revolving Line&amp;#8221;). The maturity date of the Revolving Line is May 15, 2022.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Revolving Line bears interest at an annual rate equal to the greater of (i) 1.25% below the prime rate then in effect, or (ii) 4.25% at all times when the Company maintains a daily balance of cash in its demand deposit accounts at Pacific Western Bank of at least $25.0 million, and the greater of (i) 0.25% above the prime rate then in effect; or (ii) 5.75% at all times when the Company does not maintain a daily balance of cash in demand deposit accounts at Pacific Western Bank of at least $25.0 million.&amp;#160;&amp;#160;The Pacific Western Loan Agreement requires that the Company pay a quarterly fee in an amount equal to 0.50% per annum of the unused portion of the Revolving Line. The unused fee shall be waived for any quarter the Company maintains a daily balance in its demand deposit accounts of at least $25.0 million. If the Revolving Line is terminated prior to the maturity date, the Company is required to pay an early termination fee equal to 1.0% of the Revolving Line. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company granted Pacific Western Bank a security interest in substantially all of its assets, excluding any of the intellectual property now or hereafter owned, but including any rights to payment from the sale or licensing of any such intellectual property. The Company is prohibited from paying cash dividends without the prior written consent of Pacific Western Bank. The Pacific Western Loan Agreement includes customary representations, warranties and covenants (affirmative and negative) and was amended in December 2019 to allow the Company to maintain a bank account with a non-affiliated bank in the United Kingdom provided that the account balance does not exceed 1.5 million GBP or its U.S. dollar equivalent at any time.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no borrowings, and the Company was in compliance with its financial covenants, under the Pacific Western Loan Agreement as of December 31, 2019.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000242" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;INCOME TAXES&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded no income tax expense due to the operating losses incurred for the years ended December&amp;#160;31, 2019 and December 31, 2018. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and deferred tax liabilities are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contribution carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets, noncurrent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax liability:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities, noncurrent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019 and December 31, 2018, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. The net increase in the valuation allowance for the year ended December&amp;#160;31, 2019 of $25.0&amp;#160;million is comprised of an increase in deferred tax assets, primarily related to deferred revenue and net operating loss carryforwards, for the year. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reasons for the difference between actual income tax benefit for the years ended December&amp;#160;31, 2019 and December 31, 2018 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of Pre-Tax&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of Pre-Tax&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,505&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,668&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,827&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D and orphan drug credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,810&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(639&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,272&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax (benefit) expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019, the Company had federal, state, and foreign net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards of approximately $101.3 million, $101.7 million, and $0.4 million respectively. At December&amp;#160;31, 2018, the Company had federal and state NOL carryforwards of approximately $40 million and $39.8 million, respectively. Federal NOL carryforwards of $19.7 million begin to expire in 2030 while the remaining federal NOL carryforward of $81.6 million carries forward indefinitely. The state NOL carryforwards begin to expire in 2025. The foreign NOLs carryforward indefinitely. At December&amp;#160;31, 2019, the Company had federal and state research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) tax credits of $7.2 million and an amount less than $0.1 million, which begin to expire in 2027 and 2030, respectively. At December&amp;#160;31, 2018, the Company had federal and state tax R&amp;amp;D credits of $3.6 million and an amount less than $0.1 million which begin to expire in 2027 and 2030, respectively. At December 31, 2019 and December 31, 2018, the Company had federal Orphan Drug credits of $1.8 million and $0.7 million, respectively, which begin to expire in 2038. At December&amp;#160;31, 2019 and December 31, 2018, the Company had federal contribution carryforwards of $0.1 million and an amount less than $0.1 million, respectively, which begin to expire in 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incorporated a subsidiary in Australia in 2018. However, the subsidiary has had minimal losses since inception. As such, there are no undistributed earnings as of December 31, 2019.&amp;nbsp;&amp;nbsp;The Company incorporated a subsidiary in the United Kingdom in 2019. However, the subsidiary has had minimal activity since inception. As such, there are no undistributed earnings as of December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s ability to utilize its NOL and R&amp;amp;D credit carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section&amp;#160;382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &amp;#8220;ownership change,&amp;#8221; as defined by Section&amp;#160;382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed a study to assess whether one or more ownership changes have occurred since the Company became a loss corporation under the definition of Section&amp;#160;382. If the Company has experienced an ownership change, utilization of the NOL or R&amp;amp;D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of the Company&amp;#8217;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL or R&amp;amp;D credit carryforwards before utilization. Until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any possible limitation will have an impact on the results of operations of the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reflects in the accompanying consolidated financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only if it is considered &amp;#8216;more-likely-than-not&amp;#8217; that the position taken will be sustained by the appropriate taxing authority. As of December&amp;#160;31, 2019 and December 31, 2018, the Company had no unrecognized income tax benefits. The Company&amp;#8217;s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations. As of December&amp;#160;31, 2019 and December 31, 2018, the Company had no such accruals. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&amp;#8220;GILTI&amp;#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognized deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. The Company does not have a GILTI inclusion in years ends December 31, 2019 or December 31, 2018 and therefore, no GILTI tax has been recorded for the years then ended.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock id="F_000243" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, including accounts receivable, accounts payable, and accrued expenses and other current liabilities, approximate their respective fair values due to their short-term nature. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis and to minimize the use of unobservable inputs when determining their fair value. The three tiers are defined as follows:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Inputs, other than quoted prices in active markets, that are observable either directly or indirectly&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs for which there is little or no market date, which require the Company to develop its own assumptions&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets. Investments in repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019 and December 31, 2018, the Company held cash equivalents which are composed of money market funds and repurchase agreements that were purchased through repurchase intermediary banks and collateralized by deposits in the form of government securities and obligations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following represents assets measured at fair value on a recurring basis by the Company (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000244" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;COLLABORATION AND LICENSE AGREEMENTS&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development and Commercial License Agreement with Servier&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 24, 2016, the Company entered into a development and commercial license agreement, as subsequently amended, with predecessor entities to Servier. This agreement establishes a collaboration between the Company and Servier to develop allogeneic chimeric antigen receptor T (&amp;#8220;CAR T&amp;#8221;) cell therapies for up to six unique antigen targets selected by Servier. Servier selected one target at the agreement&amp;#8217;s inception. Servier is required to make a milestone payment to the Company upon achievement of an early-stage pre- investigational new drug application (&amp;#8220;IND&amp;#8221;) development milestone event completed for each of the remaining five targets selected, if any. The Company granted Servier a development license and will perform early-stage R&amp;amp;D on the selected targets and develop the resulting therapeutic product candidates through Phase 1 clinical trials and manufacture clinical trial material for use in Phase 2 clinical trials. Also, the Company and Servier have formed a joint steering committee (&amp;#8220;JSC&amp;#8221;) to provide high-level oversight and decision making regarding the activities covered under the agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company received an upfront payment of $105.0 million under the agreement. At the Phase 2 readiness stage for any product candidate, Servier may exercise a commercial option, subject to payment of commercial option exercise fees, to proceed with development and commercialization of the product candidate and perform late-stage R&amp;amp;D, including Phase 2 and Phase 3 clinical trials and obtaining regulatory approvals. The Company has the ability to receive total payments, in the aggregate across all six targets that may be selected by Servier, of up to approximately $1.6 billion, including the upfront payment of $105.0 million and up to $1.5 billion in milestone payments, consisting of up to $401.3 million in development milestone payments and up to $1.1 billion in commercial milestone payments. The Company is also entitled to receive tiered royalties ranging from the mid-single digit percentages to the sub-teen percentages on worldwide net sales of any products developed, subject to customary potential reductions. The Company also has the right to opt in and participate in the development and commercialization of any products resulting from the collaboration through a 50/50 codevelopment and co-promotion option in the United States. This will require the Company to pay a codevelopment and co-promotion option fee on each licensed product for which the Company elects to participate. This option is exercisable at the Phase 2 readiness stage and only after Servier exercises its commercial option.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded that the promises in the agreement represent transactions with a customer. The Company has determined that the promises associated with the research and development activities for each of the six targets are not distinct because they are all based on the ARCUS proprietary genome editing platform. The Company has concluded that the agreement with Servier contains the following promises: (i) a development license; (ii) performance of early-stage R&amp;amp;D services, (iii) the manufacture of clinical trial material for use in Phase 2 clinical trials, and (iv) JSC participation. The Company determined that the license, manufacture of clinical trial material, and R&amp;amp;D services were not distinct from each other, as the license, pre-clinical and clinical supply, and R&amp;amp;D services are highly interdependent upon one another. Participation on the JSC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;amp;D services. As such, the Company determined that these promises should be combined into a single performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the agreement with Servier, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of $105.0 million constituted the entire consideration to be included in the transaction price as of the outset of the arrangement.&amp;#160;&amp;#160;As such, this amount was allocated to the single performance obligation. The commercial option exercise fees that may be received are excluded from the transaction price until each customer option is exercised as it was determined that the options are not material rights. The potential development milestone payments that the Company is eligible to receive prior to the exercise of the options as well as commercial milestones, were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain developmental goals, which might not be achieved. None of the future royalty payments were included in the transaction price, as the potential payments represent sales-based consideration. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue from the upfront payment of $105.0 million based on an input method in the form of research effort relative to expected research effort at the completion of the performance obligation, which is based on the actual time of R&amp;amp;D activities performed relative to expected time to be incurred in the future to satisfy the performance obligation. Management evaluates and adjusts the total expected research effort for the performance obligation on a quarterly basis based upon actual research accomplishments and the probability of continuing research efforts in the future. The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The remaining performance obligation associated with the $105.0 million upfront payment is expected to be satisfied over a four year period as of December 31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2019 and December 31, 2018, the Company recognized revenue under the agreement with Servier of approximately $7.3 million and $5.8 million, respectively. Deferred revenue related to the agreement with Servier amounted to $80.9 million and $88.6 million as of December 31, 2019 and December&amp;#160;31, 2018, respectively, of which $15.0 million and $5.8 million, respectively is included in current liabilities. No development or sales-based milestone payments were received during the year ended December 31, 2019 and December 31, 2018.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement with Gilead&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 10, 2018, the Company and Gilead Sciences, Inc. (&amp;#8220;Gilead&amp;#8221;) entered into a collaboration and license agreement to develop genome editing tools to target viral DNA associated with Hepatitis B. Pursuant to the terms of the agreement, Gilead will receive an exclusive license to exploit the resulting synthetic nucleases and products that use them to treat Hepatitis B in humans (&amp;#8220;development license&amp;#8221;), and the Company is entitled to receive up to $40.0 million in research funding for early-stage R&amp;amp;D services, paid in semi-annual increments, over an initial three year term and development and commercial milestone payments of up to an aggregate of $445.0 million, consisting of up to $105.0 million in development milestone payments and up to $340.0 million in commercial milestone payments. The Company is also entitled to receive tiered royalties ranging from the high single digit percentages to the mid-teen percentages on worldwide net sales of the products developed through the term of the agreement, subject to customary potential reductions. Gilead is responsible for obtaining regulatory approvals and, upon completion of the collaboration, will assume sole responsibility for the development and commercialization of such gene editing therapies and products. The Company will provide technology transfer of its development know-how prior to Gilead assuming responsibility. Also, the Company and Gilead will negotiate a separate supply agreement for the Company to manufacture specifically identified products for Gilead to use in clinical trials at price based on the Company&amp;#8217;s costs. The Company and Gilead have formed a joint steering committee (&amp;#8220;JSC&amp;#8221;) and a joint research and development committee (&amp;#8220;JRDC&amp;#8221;) that collectively will provide oversight, decision making and implementation guidance regarding the collaboration activities covered under the agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded that the promises in the agreement represent transactions with a customer. The Company has concluded that the agreement with Gilead contains the following promises: (i) a development license; (ii) performance of early-stage R&amp;amp;D services, including technology transfer services, iii) JSC and JRDC participation, and (iv) regulatory responsibilities related to non-clinical and chemistry, manufacturing and control (&amp;#8220;CMC&amp;#8221;) reports. The Company determined that the license and R&amp;amp;D services were not distinct from each other, as the license and R&amp;amp;D services are highly interdependent upon one another. Participation on the JSC and JRDC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;amp;D services. The regulatory responsibilities related to non-clinical and CMC filings do not represent separate performance obligations based on their dependence on the research and development efforts. As such, the Company determined that these promises should be combined into a single performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the agreement with Gilead, in order to evaluate the appropriate transaction price, the Company determined that the $40.0 million research funding for early-stage R&amp;amp;D services, paid in semi-annual increments over an initial three-year term, constituted the entire consideration to be included in the transaction price as of the outset of the arrangement. As such, this amount was allocated to the single performance obligation. The potential development and commercial milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain developmental goals, which might not be achieved. None of the future royalty payments were included in the transaction price, as the potential payments represent sales-based consideration.&amp;#160;&amp;#160;The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue associated with the combined performance obligation is being recognized as revenue on a straight-line basis as the R&amp;amp;D services are provided over the initial three-year term.&amp;#160;&amp;#160;The transfer of control occurs over this time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2019 and December 31, 2018, the Company recognized revenue under the agreement with Gilead of approximately $13.3 million and $3.7 million, respectively. Deferred revenue related to the agreement with Gilead amounted to $1.5 million and $2.3 million as of December 31, 2019 and December&amp;#160;31, 2018, respectively, all of which is included in current liabilities. No development or sales-based milestone payments were received during the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research, Collaboration and License Agreement with the Trustees of the University of Pennsylvania&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;1, 2018, the Company entered into a Research, Collaboration and License Agreement with the University of Pennsylvania (&amp;#8220;Penn&amp;#8221;) to collaborate on the preclinical development for gene editing products involving the delivery of an ARCUS nuclease. The Company will provide semi-annual research funding payments of up to $5.0&amp;#160;million for a three-year term to fund the cost of research programs as specified in a mutually agreed-upon research budget and be responsible for&amp;#160;post-IND&amp;#160;enabling study development activities. The research funding payments will be expensed as incurred; however, if payments made by the Company exceed the costs incurred by Penn in the six-month period, the excess amount will be credited to the Company in the next semi-annual period.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the research funding payments, if the Company elects to use certain Penn technology, the Company will be required to make development and sales milestone payments totaling up to $16.1&amp;#160;million per product in any one year, assuming the maximum development and sales milestones are met in any one year. An additional $12.3&amp;#160;million per product in sales milestone payments could be payable in other years if other sales thresholds are achieved, thus totaling $28.4&amp;#160;million in aggregate milestone payments per product. Low single-digit royalty percentages are also payable on net sales of certain products.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Penn provided the Company a&amp;#160;non-exclusive&amp;#160;license for patent rights and&amp;#160;know-how&amp;#160;to be used in exchange for an upfront payment of $0.3&amp;#160;million. Once the Company has paid $15.0&amp;#160;million in research funding, it then has the option to pay a $1.0&amp;#160;million option fee to obtain a license for additional patent rights.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, both parties agreed to adjust the activities conducted under the agreement to focus exclusively on the collaboration&amp;#8217;s program to edit the PCSK9 gene to reduce levels of LDL-C in the blood, commonly known as &amp;#8220;bad cholesterol&amp;#8221;. The agreement&amp;#8217;s termination provisions allow the Company to terminate the agreement by providing written notice at least 60 days prior to the due date of the next semi-annual research funding payment. In this event, the Company would not make termination payments to Penn other than for&amp;#160;non-cancelable&amp;#160;costs and reasonable wind-down costs. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock id="F_000245" contextRef="C_0001357874_20190101_20191231">
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:13.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/font&gt;&lt;font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;"&gt;SEGMENT REPORTING&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has developed a genome editing platform and performed related research for human therapeutic and agricultural applications. The Company&amp;#8217;s Chief Operating Decision Maker (&amp;#8220;CODM&amp;#8221;) evaluates the Company&amp;#8217;s financial performance based on two reportable segments: Therapeutics and Food. The Therapeutics segment is focused on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment is focused on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies. The CODM reviews segment performance and allocates resources based upon segment revenue and segment operating loss of the Therapeutics and Food reportable segments.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are directly attributable to the reportable segment (including directly attributable research and development and property, equipment, and software expenditures).&amp;#160;&amp;#160;For the year ended December 31, 2018, the Company allocated centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies to the Therapeutics and Food segments based on headcount.&amp;#160;&amp;#160;In January 2019, the Food segment moved into a new leased facility in Durham, North Carolina. The Company has determined that the Food segment is no longer deriving benefit from the Company&amp;#8217;s centralized research and development expenditures, thus all these expenditures are allocated to the Therapeutics segment for the year ended December 31, 2019. The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation, laboratory supplies, purchases of property, equipment, and software and procuring services from CROs, CMOs, and research organizations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain cost items are not allocated to the Company&amp;#8217;s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company&amp;#8217;s executive, business development, finance, operations, human resources and legal functions. The Company does not allocate non-cash income statement amounts to its reportable segments, such as share based compensation, depreciation and amortization, intangible asset impairment charges, non-cash interest expense and losses on the disposal of assets. When reconciling segment operating loss to consolidated loss from operations, the Company makes an adjustment to convert the cash expenditures to the accrual basis to reflect GAAP.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="eolPage22"&gt;&lt;/a&gt;&lt;a name="eolPage22"&gt;&lt;/a&gt;All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Presented below is the financial information with respect to the Company&amp;#8217;s reportable segments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total segment revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment operational cash expenditures:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,984&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total segment operational cash expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of centralized research and development operational cash expenditures:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total allocation of centralized research and development operational&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; cash expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment operating loss:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,666&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total segment operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,793&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Adjustments to reconcile segment operating loss to consolidated loss from operations:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate general and administrative cash expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income received&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,267&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss on disposal of assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments to reconcile cash expenditures to GAAP expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consolidated loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(87,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,912&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:NatureOfOperations id="F_000246" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description of Business&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Precision BioSciences, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is focused on utilizing its proprietary genome editing platform to help overcome cancers, cure genetic diseases and enable the development of safer, more productive food sources.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc.&amp;#160;&amp;#160;Elo Life Systems Australia Pty Ltd was incorporated on May 29, 2018 as a 100% owned subsidiary of Elo Life Systems, Inc.&amp;#160;&amp;#160;The Company&amp;#8217;s 100% owned subsidiary, Precision BioSciences UK Limited, was incorporated on June 17, 2019.&amp;#160;&amp;#160;The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company&amp;#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 1, 2019, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) in which the Company issued and sold 9,085,000 shares of its common stock at a public offering price of $16.00 per share and received approximately $130.5 million in net proceeds, after deducting underwriting discounts and commission of approximately $10.2 million and issuance costs of approximately $4.6 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the IPO, on March 15, 2019 the Company effected a reverse split of shares of the Company&amp;#8217;s common stock on a 1-for-2.134686 basis (the &amp;#8220;Reverse Stock Split&amp;#8221;) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company&amp;#8217;s Series A and Series B preferred stock.&amp;#160;&amp;#160;Accordingly, all common shares, stock option shares, and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this Reverse Stock Split and adjustment of the preferred stock conversion ratios.&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized common shares were not affected by the Reverse Stock Split.&amp;#160;&amp;#160;Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 22,301,190 shares of common stock at the applicable ratio then in effect and the outstanding convertible notes payable, including accrued interest, were settled into 2,921,461 shares of common stock. Subsequent to the closing of the IPO, there were no shares of Series A or Series B convertible preferred stock or convertible notes payable outstanding.&lt;/p&gt;</us-gaap:NatureOfOperations>
  <us-gaap:UseOfEstimates id="F_000247" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ from those estimates. Significant estimates include recording revenue for performance obligations recognized over time, determination of the fair value of share-based compensation grants and estimating services expended by third-party service providers used to recognize research and development expense. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000248" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These financial statements have been prepared in accordance with GAAP. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. During the year ended December&amp;#160;31, 2019, the Company incurred a net loss of $92.9&amp;#160;million and, as of December&amp;#160;31, 2019, has an accumulated deficit of $177.1 million. The Company has financed operations primarily through its IPO, private placements of convertible preferred stock and convertible debt and with proceeds from its development and commercial license agreement with Les Laboratoires Servier, (&amp;#8220;Servier&amp;#8221;) and Gilead Sciences, Inc. (&amp;#8220;Gilead&amp;#8221;) (see Note 12). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management believes that existing cash and cash equivalents will allow the Company to continue its operations into 2021. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription id="F_000249" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassifications&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain reclassifications have been made to the presentation of amounts in our Consolidated Balance Sheet as of December&amp;#160;31, 2019 to conform to the prior year presentation. Specifically, certain current liabilities were reclassified from accrued expenses and other current liabilities and are now presented separately on our Consolidated Balance Sheets.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000250" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&amp;#160;31, 2019 and December 31, 2018, the Company held cash equivalents composed of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000251" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. All of the Company&amp;#8217;s cash and cash equivalents are held at financial institutions that management believes to be of high credit quality. The Company may maintain cash deposits in financial institutions in excess of government insured limits. The Company regularly invests excess cash deposits in money market funds and repurchase agreements. The Company believes that the credit risk arising from the holdings of these financial instruments is mitigated by the fact that these securities are of short duration, government backed and of high credit rating. The Company has not experienced any losses on cash and cash equivalents to date. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue from two development and license agreements accounted for 60% and 33% of revenue during 2019 and 34% and 53% of revenue during 2018, as well as 2% and 98% of deferred revenue as of December&amp;#160;31, 2019. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:DeferredChargesPolicyTextBlock id="F_000252" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Equity Offering Costs &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes incremental legal, professional accounting and other third-party fees directly associated with the Company&amp;#8217;s planned equity offerings as other current assets until the equity offering is consummated. After consummation, these costs are recorded in stockholders&amp;#8217; equity (deficit) as a reduction of additional paid-in capital. If the equity offering is not completed, any costs deferred will be expensed immediately. &lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000253" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, Equipment and Software &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and software are stated at cost, net of depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The depreciation and amortization periods for the Company&amp;#8217;s significant property, equipment and software categories are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;"&gt;
&lt;tr&gt;
&lt;td style="width:307.45pt;"&gt;&lt;/td&gt;
&lt;td style="width:232.55pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 to 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser&amp;#160;of&amp;#160;remaining&amp;#160;lease&amp;#160;term&amp;#160;or&amp;#160;useful&amp;#160;life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repairs and maintenance are charged to operations as incurred, and expenditures for additions and improvements that extend the useful life of the asset are capitalized. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy id="F_000254" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets primarily include licenses and patents. The Company capitalizes license fees paid to acquire access to proprietary technology if the technology is expected to have alternative future use in multiple research and development projects. The cost of licensed technology rights is amortized using the straight-line method over the estimated useful life of the technology. If the access to use the technology rights is one year or less, the cost is recorded as a prepaid expense and amortized over the period identified in the agreement. Amortization expense for licensed technology and capitalized patent costs is included in research and development expenses within the accompanying consolidated statement of operations. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock id="F_000255" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets, such as property, equipment and software and intangible assets, subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is assessed when future undiscounted cash flows are less than the assets&amp;#8217; carrying value and recognized when the carrying value of the asset exceeds fair value. Fair value is calculated by estimating the discounted future cash flows expected to be generated by the asset as well as other valuation techniques. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value of the asset. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
  <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock id="F_000256" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition for Contracts with Customers&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s revenues are generated primarily through collaborative research, license, development and commercialization agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January 1, 2019, the Company adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;), using the modified retrospective transition method. Under this method, results for reporting periods beginning on January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, &lt;font style="font-style:italic;"&gt;Revenue Recognition&lt;/font&gt; (&amp;#8220;ASC 605&amp;#8221;). The Company applied the modified retrospective transition method to contracts that were not completed as of January 1, 2019. For the year ended December 31, 2019, the Company reduced revenue recognition by $1.4 million for changes in total estimated time to be incurred in the future to satisfy the performance obligation. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer&amp;#8217;s discretion are generally considered options.&amp;#160;&amp;#160;The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue.&amp;#160;&amp;#160;Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue &amp;#8211; noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the other current assets line item in the accompanying consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone Payments &lt;font style="font-style:normal;"&gt;&amp;#8211;&lt;/font&gt; &lt;font style="font-style:normal;"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&amp;#8217;s or the licensee&amp;#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalties &lt;font style="font-style:normal;"&gt;&amp;#8211;&lt;/font&gt; &lt;font style="font-style:normal;"&gt;For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation linked to some or all of the royalty has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Significant Financing Component &lt;font style="font-style:normal;"&gt;&amp;#8211; In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.&amp;#160;&amp;#160;The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&amp;#160;&amp;#160;The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements &lt;font style="font-style:normal;"&gt;&amp;#8211; The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company&amp;#8217;s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company analyzes its collaboration arrangements to assess whether the collaboration agreements are within the scope of accounting standards codification (&amp;#8220;ASC&amp;#8221;) ASC 808, &lt;font style="font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt; (&amp;#8220;ASC 808&amp;#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&amp;#160;&amp;#160;For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For additional discussion of accounting for collaboration revenues, see Note 12, &amp;#8220;Collaboration and license agreements.&amp;#8221;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000257" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities including salaries, benefits, share-based compensation, allocations for rent and facility costs, depreciation, preclinical manufacturing expenses, costs of services provided by contract research organizations (&amp;#8220;CROs&amp;#8221;) in connection with preclinical trials and contract manufacturing organizations (&amp;#8220;CMOs&amp;#8221;) engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to estimate accrued research and development expenses resulting from its obligations under contracts with CROs, CMOs, research organizations, service providers, vendors and consultants in connection with research and development activities. The financial terms of these contracts are subject to negotiations and vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&amp;#8217;s objective is to reflect the appropriate research and development expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. There may be instances in which payments made to the Company&amp;#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&amp;#8217;s estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&amp;#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to prior estimates of accrued research and development expenses. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <dtil:CommonStockValuationPolicyPolicyTextBlock id="F_000258" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common Stock Valuation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the IPO, due to the absence of an active market for the Company&amp;#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted prior to the IPO, the Company considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock was determined based upon a variety of factors, including the illiquid nature of the common stock, the Company&amp;#8217;s financial position and historical financial performance, the status of technological developments within the Company&amp;#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&amp;#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. &lt;/p&gt;</dtil:CommonStockValuationPolicyPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000259" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&amp;#160;31, 2019 and December 31, 2018, there was no difference between net loss and comprehensive loss in the accompanying consolidated financial statements. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000260" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&amp;#160;31, 2019 and December 31, 2018 since all potential shares of common stock are anti-dilutive as a result of the net loss. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000261" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for all share-based compensation, including stock options and the employee stock purchase plan at fair value and recognizes compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each equity grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&amp;#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the Company&amp;#8217;s expected dividend yield. As the Company has limited trading history, expected volatility is estimated based on the historical volatility of publicly traded peer companies and the Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of our traded share price. The expected term of the options has been determined utilizing a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date.&amp;nbsp;&amp;nbsp;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000262" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are determined based on the temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than the enactment of changes in the tax law or rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000263" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounting Standards Updates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an &amp;#8220;emerging growth company,&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section&amp;#160;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The JOBS Act also exempts the Company from having to provide an auditor attestation of internal controls over financial reporting under Sarbanes-Oxley Act Section&amp;#160;404(b). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will remain an &amp;#8220;emerging growth company&amp;#8221; until the earliest of (i)&amp;#160;December 31, 2024, (ii) the last day of the fiscal year in which it has total annual gross revenues of $1.07&amp;#160;billion or more, (iii)&amp;#160;the date on which it has issued more than $1.0&amp;#160;billion in nonconvertible debt during the previous three years or (iv)&amp;#160;the date on which it is deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;), which generally is when it has more than $700&amp;#160;million in market value of its stock held by non-affiliates, has been a public company for at least 12 months and have filed one annual report on Form 10-K. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company&amp;#8217;s collaboration agreements under prior revenue recognition guidance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - noncurrent liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,807&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(84,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet as of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - noncurrent liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(177,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidated Statement of Operations&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the Years Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(95,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Cash Flows for the Years Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption&amp;#160;of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(95,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="eolPage14"&gt;&lt;/a&gt;During the year ended December 31, 2019, the Company recorded $9.4 million in revenue that was included in deferred revenue as of December 31, 2018.&amp;#160;&amp;#160;The most significant change to the Company&amp;#8217;s revenue recognition as a result of the adoption of ASC 606 relates to the accounting for certain option fees and milestone payments in determining the transaction price (step (iii)), and the revenue recognition pattern (step (v)) related to the Company&amp;#8217;s development and commercial license agreement with Servier. Under ASC 605, the option fees payable by the Company to exercise the 50/50 co-development and co-promotion option was accounted for as a reduction in the arrangement consideration, and certain development milestones that may be earned for early-stage pre-IND development milestones were included in the arrangement consideration as the early-stage pre-IND development milestones were deemed to be non-substantive. Under ASC 606, the option fees were not accounted for as a reduction in the transaction price as the option fees are contingent upon Servier&amp;#8217;s&lt;a name="eolPage14"&gt;&lt;/a&gt; exercise of its commercial &lt;a name="eolPage14"&gt;&lt;/a&gt;(customer) options on licensed product candidates, and the milestone payments were excluded from the transaction price based on the assessment of the most likely amount and application of the variable consideration constraint, since the milestones relate to successful achievement of certain developmental goals, which may not be achieved. In addition, under ASC 605, the Company recognized revenue on a straight&amp;#8209;line basis over the period the Company expected to complete its obligations. Under ASC 606, the Company recognizes revenue based on the proportional performance of the services related to the performance obligation expected. For further discussion of the adoption of ASC 606 see Note 12, &amp;#8220;Collaboration and license agreements.&amp;#8221;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="DTIL_10Q_20190930_HTM_LD_TABLE_29"&gt;&lt;/a&gt;In June 2018, the FASB issued ASU 2018-07,&amp;#160;&lt;font style="font-style:italic;"&gt;Compensation-Stock Compensation Improvements to Nonemployee Share-Based Payment Accounting&amp;#160;&lt;/font&gt;(&amp;#8220;ASU 2018-07&amp;#8221;). ASU 2018-07 substantially aligns accounting for share-based payments to employees and non-employees. This ASU became effective for annual periods beginning after December 15, 2018 including interim periods within that period, and early adoption is permitted.&amp;nbsp;&amp;nbsp;The Company adopted ASU 2018-07 effective January 1, 2019.&amp;nbsp;&amp;nbsp;The adoption of the standard did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13,&amp;#160;&lt;font style="font-style:italic;"&gt;Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen&lt;/font&gt;t (&amp;#8220;ASU 2018-13&amp;#8221;). ASU 2018-13 is intended to improve the effectiveness of disclosures in the notes to financial statements related to fair value measurements in Topic 820. This ASU will become effective for annual periods beginning after December 15, 2019, including interim periods within that period, and early adoption is permitted.&amp;#160;The adoption of this standard is not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;font style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808)&amp;#8212;Clarifying the Interaction between Topic 808 and ASC 606&lt;/font&gt; (&amp;#8220;ASU 2018-18&amp;#8221;). The amendments in ASU 2018-18 make targeted improvements to GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASU 2018-18 was aligned with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606.&amp;#160;&amp;#160;ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of ASC 606. The Company adopted this guidance effective January 1, 2019 with its initial application of ASC 606. The adoption of the standard did not have an impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2019, the FASB issued ASU 2019-10, &lt;font style="font-style:italic;"&gt;Financial Instruments &amp;#8212; Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) &lt;/font&gt;(&amp;#8220;ASU 2019-10&amp;#8221;)&lt;font style="font-style:italic;"&gt;,&lt;/font&gt; which provides a one-year deferral of the effective dates of ASU No.&amp;#160;2016-02, &lt;font style="font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt; (&amp;#8220;ASU 2016-02&amp;#8221;), issued in February 2016.&amp;nbsp;&amp;nbsp;ASU 2016-02 was issued in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term.&amp;nbsp;&amp;nbsp;ASU 2019-10 is effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and expects to have an increase in total assets and total liabilities as a result of adopting the lease standard.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accounting standards updates issued, but not effective until after December 31, 2019, are not expected to have a material effect on the Company&amp;#8217;s consolidated financial position, statements of operations or cash flows.&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; &lt;/sup&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <dtil:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock id="F_000264" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The depreciation and amortization periods for the Company&amp;#8217;s significant property, equipment and software categories are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;"&gt;
&lt;tr&gt;
&lt;td style="width:307.45pt;"&gt;&lt;/td&gt;
&lt;td style="width:232.55pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 to 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser&amp;#160;of&amp;#160;remaining&amp;#160;lease&amp;#160;term&amp;#160;or&amp;#160;useful&amp;#160;life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</dtil:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
  <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock id="F_000265" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet as of January 1, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;407&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - noncurrent liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,807&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(84,190&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,187&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet as of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue - noncurrent liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,322&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(177,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,410&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180,477&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consolidated Statement of Operations&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for the Years Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(95,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share - basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impact of ASC 606 Adoption on Consolidated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Cash Flows for the Years Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&amp;#160;reported&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;under ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances&amp;#160;without&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption&amp;#160;of ASC 606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(95,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,866&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000266" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and software consisted of the following as of December&amp;#160;31 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;697&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,251&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,057&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,602&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,373&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property, equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,220&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,631&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,649&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, equipment and software - net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,571&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock id="F_000267" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net, consisted of the following as of December&amp;#160;31 (in thousands): &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,831&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,831&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: impairments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000268" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,431&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonemployee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock id="F_000269" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense related to stock options is included in the following line items in the consolidated statements of operations (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,639&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,817&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,301&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000270" contextRef="C_0001357874_20190101_20191231">The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average expected stock price volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.95&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term of options (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.61&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average fair value per option&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000271" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity in the Company&amp;#8217;s stock option plans for the years ended December 31, 2019 and December 31, 2018:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Option&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of January 1, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,416,025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,160,097&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(220,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(592,350&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,763,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,647,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(940,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(550,644&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,919,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock id="F_000272" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes certain information about stock options granted under the stock option plans which are vested or expected to vest as of December&amp;#160;31, 2019 and December 31, 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,919,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currently exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,082,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.08&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected to be exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,763,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currently exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="F_000273" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes certain information about stock options outstanding under the stock option plans for the years ending December 31, 2019 and December 31, 2018, respectively: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&amp;#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.01 - $0.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,385,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,385,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.41 - $1.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,310,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,721,811&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$7.74 - $9.46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,266,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,644&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$10.17 - $13.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,891,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;844,005&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$14.91 - $16.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,919,116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,082,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&amp;#160;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.01 - $0.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,397,203&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,440,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,166,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.18 - $1.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,846,255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291,023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,376&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;289,408&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,708&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,070,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.78&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,193&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;428,626&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,763,464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000274" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is a schedule of future minimum lease payments for all leases as of December 31, 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,706&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,196&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,611&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and beyond&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,966&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000275" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,015,814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,285,376&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding share-based compensation awards converted to common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,032,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,796,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,032,359&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,097,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000276" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and deferred tax liabilities are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contribution carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;573&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,734&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,736&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets, noncurrent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent deferred tax liability:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities, noncurrent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;586&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000277" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reasons for the difference between actual income tax benefit for the years ended December&amp;#160;31, 2019 and December 31, 2018 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of Pre-Tax&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of Pre-Tax&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Earnings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,505&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,668&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,827&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D and orphan drug credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,810&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(639&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,272&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax (benefit) expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock id="F_000278" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following represents assets measured at fair value on a recurring basis by the Company (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,395&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;95,281&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock id="F_000279" contextRef="C_0001357874_20190101_20191231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Presented below is the financial information with respect to the Company&amp;#8217;s reportable segments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,523&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,606&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total segment revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment operational cash expenditures:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,984&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total segment operational cash expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allocation of centralized research and development operational cash expenditures:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,605&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total allocation of centralized research and development operational&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; cash expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment operating loss:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapeutics&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,127&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Food&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,378&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,666&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total segment operating loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,793&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Adjustments to reconcile segment operating loss to consolidated loss from operations:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate general and administrative cash expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,569&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income received&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,267&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,453&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss on disposal of assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustments to reconcile cash expenditures to GAAP expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,716&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total consolidated loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(87,204&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,912&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000280" contextRef="C_0001357874_20190101_20191231">2006-01-26</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:MinorityInterestOwnershipPercentageByParent id="F_000281" contextRef="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <dei:EntityIncorporationDateOfIncorporation id="F_000282" contextRef="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20190101_20191231">2012-01-04</dei:EntityIncorporationDateOfIncorporation>
  <dtil:AmendedDateOfIncorporation id="F_000283" contextRef="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20190101_20191231">2018-01-16</dtil:AmendedDateOfIncorporation>
  <dtil:AmendedNameOfIncorporation id="F_000284" contextRef="C_0001357874_srtOwnershipAxis_dtilPrecisionPlantSciencesIncMember_20180101_20181231">Elo Life Systems, Inc.</dtil:AmendedNameOfIncorporation>
  <us-gaap:MinorityInterestOwnershipPercentageByParent id="F_000285" contextRef="C_0001357874_srtConsolidatedEntitiesAxis_srtSubsidiaryIssuerMember_srtOwnershipAxis_dtilEloLifeSystemsAustraliaPtyLtdMember_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <dei:EntityIncorporationDateOfIncorporation id="F_000286" contextRef="C_0001357874_srtConsolidatedEntitiesAxis_srtSubsidiaryIssuerMember_srtOwnershipAxis_dtilEloLifeSystemsAustraliaPtyLtdMember_20190101_20191231">2018-05-29</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:MinorityInterestOwnershipPercentageByParent id="F_000287" contextRef="C_0001357874_srtOwnershipAxis_dtilPrecisionBioSciencesUKLimitedMember_20191231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <dei:EntityIncorporationDateOfIncorporation id="F_000288" contextRef="C_0001357874_srtOwnershipAxis_dtilPrecisionBioSciencesUKLimitedMember_20190101_20191231">2019-06-17</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000289" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401" decimals="INF" unitRef="U_xbrlishares">9085000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare id="F_000290" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401" decimals="2" unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SaleOfStockPricePerShare>
  <dtil:ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts id="F_000291" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401" decimals="-5" unitRef="U_iso4217USD">130500000</dtil:ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts>
  <dtil:UnderwritingDiscountsAndCommission id="F_000292" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401" decimals="-5" unitRef="U_iso4217USD">10200000</dtil:UnderwritingDiscountsAndCommission>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000293" contextRef="C_0001357874_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401" decimals="-5" unitRef="U_iso4217USD">4600000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000294" contextRef="C_0001357874_20190315_20190315">1-for-2.134686</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000295" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_dtilSeriesAAndSeriesBConvertiblePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401" decimals="INF" unitRef="U_xbrlishares">22301190</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:PreferredStockSharesOutstanding id="F_000296" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_dtilSeriesAAndSeriesBConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000297" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190401_20190401" decimals="INF" unitRef="U_xbrlishares">2921461</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <dtil:PercentageOfRevenue id="F_000298" contextRef="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_dtilDevelopmentMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.60</dtil:PercentageOfRevenue>
  <dtil:PercentageOfRevenue id="F_000299" contextRef="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_dtilDevelopmentMember_20181231" decimals="INF" unitRef="U_xbrlipure">0.34</dtil:PercentageOfRevenue>
  <dtil:PercentageOfRevenue id="F_000300" contextRef="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.33</dtil:PercentageOfRevenue>
  <dtil:PercentageOfRevenue id="F_000301" contextRef="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20181231" decimals="INF" unitRef="U_xbrlipure">0.53</dtil:PercentageOfRevenue>
  <dtil:PercentageOfDeferredRevenue id="F_000302" contextRef="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_dtilDevelopmentMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.02</dtil:PercentageOfDeferredRevenue>
  <dtil:PercentageOfDeferredRevenue id="F_000303" contextRef="C_0001357874_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.98</dtil:PercentageOfDeferredRevenue>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000304" contextRef="C_0001357874_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000305" contextRef="C_0001357874_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20190101_20191231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000306" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20190101_20191231">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000307" contextRef="C_0001357874_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20190101_20191231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000308" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20190101_20191231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000309" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20190101_20191231">Lesser of remaining lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized id="F_000310" contextRef="C_0001357874_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">-1400000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
  <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement id="F_000311" contextRef="C_0001357874_20190101_20191231">The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
  <us-gaap:Revenues id="F_000312" contextRef="C_0001357874_20190101_20191231" decimals="-7" unitRef="U_iso4217USD">1070000000</us-gaap:Revenues>
  <dtil:IssuanceOfNonconvertibleDebt id="F_000313" contextRef="C_0001357874_20190101_20191231" decimals="-8" unitRef="U_iso4217USD">1000000000</dtil:IssuanceOfNonconvertibleDebt>
  <dtil:CommonStockNotHeldByNonAffiliates id="F_000314" contextRef="C_0001357874_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">700000000</dtil:CommonStockNotHeldByNonAffiliates>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000315" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101" decimals="-3" unitRef="U_iso4217USD">-997000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent id="F_000316" contextRef="C_0001357874_20190101" decimals="-3" unitRef="U_iso4217USD">8029000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000317" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101" decimals="-3" unitRef="U_iso4217USD">407000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000318" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101" decimals="-3" unitRef="U_iso4217USD">8436000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000319" contextRef="C_0001357874_20190101" decimals="-3" unitRef="U_iso4217USD">82217000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000320" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101" decimals="-3" unitRef="U_iso4217USD">590000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000321" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101" decimals="-3" unitRef="U_iso4217USD">82807000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000322" contextRef="C_0001357874_20190101" decimals="-3" unitRef="U_iso4217USD">-84190000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000323" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101" decimals="-3" unitRef="U_iso4217USD">-85187000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent id="F_000324" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">16486000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000325" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20191231" decimals="-3" unitRef="U_iso4217USD">-8017000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000326" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20191231" decimals="-3" unitRef="U_iso4217USD">8469000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000327" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">65895000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000328" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20191231" decimals="-3" unitRef="U_iso4217USD">11427000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000329" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20191231" decimals="-3" unitRef="U_iso4217USD">77322000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000330" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20191231" decimals="-3" unitRef="U_iso4217USD">-3410000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000331" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20191231" decimals="-3" unitRef="U_iso4217USD">-180477000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000332" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-2413000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000333" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">19825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:NetIncomeLoss id="F_000334" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-2413000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000335" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-95290000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000336" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000337" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ProfitLoss id="F_000338" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-2413000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000339" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-95290000</us-gaap:ProfitLoss>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000340" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2413000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="F_000341" contextRef="C_0001357874_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapCalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-5453000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000342" contextRef="C_0001357874_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">9400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000343" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" unitRef="U_iso4217USD">697000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000344" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20181231" decimals="-3" unitRef="U_iso4217USD">8600000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000345" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">25969000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000346" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20181231" decimals="-3" unitRef="U_iso4217USD">5733000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000347" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20191231" decimals="-3" unitRef="U_iso4217USD">328000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000348" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20181231" decimals="-3" unitRef="U_iso4217USD">278000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000349" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilLaboratoryEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">19251000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000350" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilLaboratoryEquipmentMember_20181231" decimals="-3" unitRef="U_iso4217USD">10057000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000351" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1602000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000352" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20181231" decimals="-3" unitRef="U_iso4217USD">839000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000353" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">2373000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000354" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20181231" decimals="-3" unitRef="U_iso4217USD">1124000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000355" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">50220000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000356" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">26631000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000357" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">10649000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000358" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">5484000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ConstructionInProgressGross id="F_000359" contextRef="C_0001357874_us-gaapGeographicDistributionAxis_dtilDurhamMember_20181231" decimals="-5" unitRef="U_iso4217USD">8600000</us-gaap:ConstructionInProgressGross>
  <us-gaap:ConstructionInProgressGross id="F_000360" contextRef="C_0001357874_srtStatementGeographicalAxis_stprNC_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilManufacturingCenterForAdvancedTherapeuticsMember_20191231" decimals="-5" unitRef="U_iso4217USD">2500000</us-gaap:ConstructionInProgressGross>
  <us-gaap:LeaseholdImprovementsGross id="F_000361" contextRef="C_0001357874_us-gaapGeographicDistributionAxis_dtilDurhamMember_20191231" decimals="-5" unitRef="U_iso4217USD">4400000</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:DepreciationAndAmortization id="F_000362" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilPropertyEquipmentLeaseholdImprovementsAndSoftwareMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">5300000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000363" contextRef="C_0001357874_us-gaapPropertyPlantAndEquipmentByTypeAxis_dtilPropertyEquipmentLeaseholdImprovementsAndSoftwareMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:DepreciationAndAmortization>
  <us-gaap:FiniteLivedLicenseAgreementsGross id="F_000364" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1831000</us-gaap:FiniteLivedLicenseAgreementsGross>
  <us-gaap:FiniteLivedLicenseAgreementsGross id="F_000365" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">1831000</us-gaap:FiniteLivedLicenseAgreementsGross>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000366" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">281000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="F_000367" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">247000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <dtil:FiniteLivedIntangibleAssetsImpairment id="F_000368" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">118000</dtil:FiniteLivedIntangibleAssetsImpairment>
  <dtil:FiniteLivedIntangibleAssetsImpairment id="F_000369" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">118000</dtil:FiniteLivedIntangibleAssetsImpairment>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000370" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1432000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000371" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">1466000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000372" contextRef="C_0001357874_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000373" contextRef="C_0001357874_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfIntangibleAssets>
  <dtil:PaymentOfNonRefundableLicenseFees id="F_000374" contextRef="C_0001357874_20180901_20180930" decimals="-5" unitRef="U_iso4217USD">1400000</dtil:PaymentOfNonRefundableLicenseFees>
  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 id="F_000375" contextRef="C_0001357874_srtRangeAxis_srtMinimumMember_20190101_20191231">P216M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 id="F_000376" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_20190101_20191231">P257M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths id="F_000377" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo id="F_000378" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree id="F_000379" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour id="F_000380" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive id="F_000381" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive id="F_000382" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
  <dtil:CommonAndPreferredStocksSharesAuthorized id="F_000383" contextRef="C_0001357874_20190401" decimals="INF" unitRef="U_xbrlishares">210000000</dtil:CommonAndPreferredStocksSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000384" contextRef="C_0001357874_20190401" decimals="INF" unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000385" contextRef="C_0001357874_20190401" decimals="6" unitRef="U_iso4217USD_xbrlishares">0.000005</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000386" contextRef="C_0001357874_20190401" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000387" contextRef="C_0001357874_20190401" decimals="4" unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000388" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandSixStockIncentivePlanMember_20161231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000389" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandSixStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">1385203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000390" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandFifteenStockIncentivePlanMember_20150430" decimals="INF" unitRef="U_xbrlishares">5270095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000391" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandFifteenStockIncentivePlanMember_20180531" decimals="INF" unitRef="U_xbrlishares">8211980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000392" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandFifteenStockIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">5462954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000393" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_20190312" decimals="INF" unitRef="U_xbrlishares">4750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000394" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200101" decimals="INF" unitRef="U_xbrlishares">2046209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <dtil:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock id="F_000395" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_20190311_20190312" decimals="INF" unitRef="U_xbrlipure">0.04</dtil:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000396" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenIncentiveAwardPlanMember_20191230_20191231" decimals="INF" unitRef="U_xbrlishares">2070959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000397" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190312" decimals="INF" unitRef="U_xbrlishares">525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000398" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20200101" decimals="INF" unitRef="U_xbrlishares">511552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <dtil:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock id="F_000399" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190311_20190312" decimals="INF" unitRef="U_xbrlipure">0.01</dtil:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock>
  <dtil:MaximumSharesAllowedToBeIssuedUnderESPP id="F_000400" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190312" decimals="INF" unitRef="U_xbrlishares">5250000</dtil:MaximumSharesAllowedToBeIssuedUnderESPP>
  <dtil:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage id="F_000401" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190311_20190312" decimals="2" unitRef="U_xbrlipure">0.85</dtil:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage>
  <dtil:OfferingPeriodCommencedDate id="F_000402" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190311_20190312">2019-10-21</dtil:OfferingPeriodCommencedDate>
  <dtil:OfferingPeriodCommencedDate id="F_000403" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20191230_20191231">2020-03-01</dtil:OfferingPeriodCommencedDate>
  <dtil:OfferingPeriodEndDate id="F_000404" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190311_20190312">2020-02-29</dtil:OfferingPeriodEndDate>
  <dtil:OfferingPeriodEndDate id="F_000405" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20191230_20191231">2020-08-31</dtil:OfferingPeriodEndDate>
  <us-gaap:CommonStockSharesIssued id="F_000406" contextRef="C_0001357874_us-gaapPlanNameAxis_dtilTwoThousandNineteenEmployeeStockPurchasePlanMember_20190312" decimals="0" unitRef="U_xbrlishares">44197</us-gaap:CommonStockSharesIssued>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000407" contextRef="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8354000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000408" contextRef="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2431000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000409" contextRef="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementNonemployeeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">586000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000410" contextRef="C_0001357874_srtTitleOfIndividualAxis_us-gaapShareBasedPaymentArrangementNonemployeeMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000411" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8940000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000412" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2453000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000413" contextRef="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5639000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000414" contextRef="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1817000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000415" contextRef="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3301000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000416" contextRef="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">636000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000417" contextRef="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8940000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000418" contextRef="C_0001357874_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2453000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000419" contextRef="C_0001357874_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000420" contextRef="C_0001357874_20180101_20181231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000421" contextRef="C_0001357874_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.6825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000422" contextRef="C_0001357874_20180101_20181231" decimals="4" unitRef="U_xbrlipure">0.6844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000423" contextRef="C_0001357874_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000424" contextRef="C_0001357874_20180101_20181231" decimals="4" unitRef="U_xbrlipure">0.0295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000425" contextRef="C_0001357874_20190101_20191231">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000426" contextRef="C_0001357874_20180101_20181231">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <dtil:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption id="F_000427" contextRef="C_0001357874_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.62</dtil:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption>
  <dtil:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption id="F_000428" contextRef="C_0001357874_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.37</dtil:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000429" contextRef="C_0001357874_20171231" decimals="INF" unitRef="U_xbrlishares">5416025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000430" contextRef="C_0001357874_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">3160097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000431" contextRef="C_0001357874_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">220308</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000432" contextRef="C_0001357874_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">592350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000433" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">7763464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000434" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2647236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000435" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">940940</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000436" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">550644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000437" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">8919116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000438" contextRef="C_0001357874_20171231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000439" contextRef="C_0001357874_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">11.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000440" contextRef="C_0001357874_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="F_000441" contextRef="C_0001357874_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000442" contextRef="C_0001357874_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000443" contextRef="C_0001357874_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">11.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000444" contextRef="C_0001357874_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="F_000445" contextRef="C_0001357874_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000446" contextRef="C_0001357874_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000447" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">10600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000448" contextRef="C_0001357874_20181231" decimals="-5" unitRef="U_iso4217USD">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000449" contextRef="C_0001357874_20191231" decimals="-5" unitRef="U_iso4217USD">29000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000450" contextRef="C_0001357874_20190101_20191231">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000451" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">8919116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000452" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">4082663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000453" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">7763464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000454" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">3418993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_000455" contextRef="C_0001357874_20190101_20191231">P7Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000456" contextRef="C_0001357874_20190101_20191231">P5Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_000457" contextRef="C_0001357874_20180101_20181231">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000458" contextRef="C_0001357874_20180101_20181231">P5Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000459" contextRef="C_0001357874_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000460" contextRef="C_0001357874_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000461" contextRef="C_0001357874_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000462" contextRef="C_0001357874_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000463" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000464" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000465" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">7.74</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000466" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">10.17</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000467" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFiveMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">14.91</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000468" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000469" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000470" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">9.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000471" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">13.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000472" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFiveMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000473" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20191231" decimals="INF" unitRef="U_xbrlishares">1385203</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000474" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20191231" decimals="INF" unitRef="U_xbrlishares">2310993</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000475" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20191231" decimals="INF" unitRef="U_xbrlishares">1266454</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000476" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20191231" decimals="INF" unitRef="U_xbrlishares">3891922</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000477" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFiveMember_20191231" decimals="INF" unitRef="U_xbrlishares">64544</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000478" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">8919116</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000479" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20190101_20191231">P1Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000480" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20190101_20191231">P6Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000481" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20190101_20191231">P9Y5M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000482" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20190101_20191231">P8Y11M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000483" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFiveMember_20190101_20191231">P9Y7M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000484" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20191231" decimals="INF" unitRef="U_xbrlishares">1385203</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000485" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTwoMember_20191231" decimals="INF" unitRef="U_xbrlishares">1721811</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000486" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeThreeMember_20191231" decimals="INF" unitRef="U_xbrlishares">131644</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000487" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeFourMember_20191231" decimals="INF" unitRef="U_xbrlishares">844005</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000488" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_xbrlishares">4082663</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000489" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSixMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000490" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeEightMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">8.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000491" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeNineMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">10.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000492" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTenMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">11.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000493" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeElevenMember_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">13.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000494" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000495" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000496" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000497" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20180101_20181231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000498" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20181231" decimals="INF" unitRef="U_xbrlishares">1397203</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000499" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSixMember_20181231" decimals="INF" unitRef="U_xbrlishares">1440920</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000500" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20181231" decimals="INF" unitRef="U_xbrlishares">1846255</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000501" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeEightMember_20181231" decimals="INF" unitRef="U_xbrlishares">291023</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000502" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeNineMember_20181231" decimals="INF" unitRef="U_xbrlishares">289408</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000503" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTenMember_20181231" decimals="INF" unitRef="U_xbrlishares">2070029</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000504" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeElevenMember_20181231" decimals="INF" unitRef="U_xbrlishares">428626</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000505" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">7763464</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000506" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20180101_20181231">P2Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000507" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSixMember_20180101_20181231">P6Y7M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000508" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20180101_20181231">P8Y2M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000509" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeEightMember_20180101_20181231">P9Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000510" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeNineMember_20180101_20181231">P9Y6M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000511" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTenMember_20180101_20181231">P9Y9M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000512" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeElevenMember_20180101_20181231">P9Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000513" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeOneMember_20181231" decimals="INF" unitRef="U_xbrlishares">1397203</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000514" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSixMember_20181231" decimals="INF" unitRef="U_xbrlishares">1166591</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000515" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeSevenMember_20181231" decimals="INF" unitRef="U_xbrlishares">748922</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000516" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeEightMember_20181231" decimals="INF" unitRef="U_xbrlishares">33376</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000517" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeNineMember_20181231" decimals="INF" unitRef="U_xbrlishares">5708</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000518" contextRef="C_0001357874_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_dtilPriceRangeTenMember_20181231" decimals="INF" unitRef="U_xbrlishares">67193</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000519" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_xbrlishares">3418993</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000520" contextRef="C_0001357874_20110101_20110131" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanAdministrativeExpenses id="F_000521" contextRef="C_0001357874_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
  <us-gaap:DefinedContributionPlanAdministrativeExpenses id="F_000522" contextRef="C_0001357874_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:DefinedContributionPlanAdministrativeExpenses>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000523" contextRef="C_0001357874_20110101_20110131" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000524" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000525" contextRef="C_0001357874_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000526" contextRef="C_0001357874_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000527" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">2706000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000528" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">3099000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000529" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">3196000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000530" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">3288000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="F_000531" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">2611000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="F_000532" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">3066000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000533" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">17966000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <dtil:AgreementTerminationNoticePeriod id="F_000534" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_20190101_20191231">P1Y</dtil:AgreementTerminationNoticePeriod>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000535" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">12015814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000536" contextRef="C_0001357874_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">10285376</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000537" contextRef="C_0001357874_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dtilOutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">4032359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000538" contextRef="C_0001357874_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dtilOutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">4796377</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000539" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">4032359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000540" contextRef="C_0001357874_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">27097567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtInstrumentFaceAmount id="F_000541" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190331" decimals="-5" unitRef="U_iso4217USD">39600000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000542" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2921461</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="F_000543" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20191231" decimals="INF" unitRef="U_xbrlipure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <dtil:PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare id="F_000544" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.85</dtil:PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000545" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">13.60</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:LongTermDebtFairValue id="F_000546" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190401" decimals="-5" unitRef="U_iso4217USD">49400000</us-gaap:LongTermDebtFairValue>
  <dtil:ChangeInFairValueOfConvertibleNotePayable id="F_000547" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">9800000</dtil:ChangeInFairValueOfConvertibleNotePayable>
  <us-gaap:InterestExpenseDebt id="F_000548" contextRef="C_0001357874_us-gaapShortTermDebtTypeAxis_us-gaapConvertibleNotesPayableMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:InterestExpenseDebt>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000549" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20190531" decimals="-5" unitRef="U_iso4217USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityExpirationDate1 id="F_000550" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20190501_20190531">2022-05-15</us-gaap:LineOfCreditFacilityExpirationDate1>
  <dtil:DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate id="F_000551" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapDebtInstrumentAxis_dtilRevolvingLineIfDailyBalanceIsMaintainedMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0125</dtil:DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod id="F_000552" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapDebtInstrumentAxis_dtilRevolvingLineIfDailyBalanceIsMaintainedMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0425</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:CompensatingBalanceAmount id="F_000553" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">25000000</us-gaap:CompensatingBalanceAmount>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000554" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapDebtInstrumentAxis_dtilRevolvingLineIfDailyBalanceIsNotMaintainedMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod id="F_000555" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapDebtInstrumentAxis_dtilRevolvingLineIfDailyBalanceIsNotMaintainedMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0575</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage id="F_000556" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0050</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <dtil:MaximumAmountToMaintainWithNonAffiliatedBank id="F_000557" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20191231" decimals="INF" unitRef="U_iso4217GBP">1500000</dtil:MaximumAmountToMaintainWithNonAffiliatedBank>
  <us-gaap:LineOfCredit id="F_000558" contextRef="C_0001357874_us-gaapCreditFacilityAxis_us-gaapRevolvingCreditFacilityMember_us-gaapTypeOfArrangementAxis_dtilPacificWesternLoanAgreementMember_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:LineOfCredit>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000559" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">23358000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000560" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">9185000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards id="F_000561" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards id="F_000562" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent id="F_000563" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1099000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent id="F_000564" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">449000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000565" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">13172000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000566" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">9454000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOther id="F_000567" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">2444000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000568" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">573000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000569" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">9090000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000570" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">3632000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000571" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">47734000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000572" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">22736000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent id="F_000573" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1463000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent id="F_000574" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">586000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000575" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1463000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000576" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">586000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent id="F_000577" contextRef="C_0001357874_20191231" decimals="-3" unitRef="U_iso4217USD">1463000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent id="F_000578" contextRef="C_0001357874_20181231" decimals="-3" unitRef="U_iso4217USD">586000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000579" contextRef="C_0001357874_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">25000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000580" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19505000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000581" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-9668000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000582" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1827000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000583" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-909000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense id="F_000584" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1784000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense id="F_000585" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">270000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment id="F_000586" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4810000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment id="F_000587" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1934000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000588" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-639000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000589" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-31000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000590" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">24997000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000591" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">12272000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000592" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000593" contextRef="C_0001357874_20180101_20181231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000594" contextRef="C_0001357874_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000595" contextRef="C_0001357874_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="F_000596" contextRef="C_0001357874_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="F_000597" contextRef="C_0001357874_20180101_20181231" decimals="3" unitRef="U_xbrlipure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="F_000598" contextRef="C_0001357874_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment id="F_000599" contextRef="C_0001357874_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther id="F_000600" contextRef="C_0001357874_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther id="F_000601" contextRef="C_0001357874_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000602" contextRef="C_0001357874_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000603" contextRef="C_0001357874_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.267</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:OperatingLossCarryforwards id="F_000604" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">101300000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000605" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20181231" decimals="-6" unitRef="U_iso4217USD">40000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000606" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20191231" decimals="-5" unitRef="U_iso4217USD">101700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000607" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20181231" decimals="-5" unitRef="U_iso4217USD">39800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000608" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:OperatingLossCarryforwards>
  <dtil:OperatingLossCarryForwardsSubjectToExpiration id="F_000609" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">19700000</dtil:OperatingLossCarryForwardsSubjectToExpiration>
  <dtil:NetOperatingLossCarryForwardSubjectToExpirationBeginYear id="F_000610" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2030</dtil:NetOperatingLossCarryForwardSubjectToExpirationBeginYear>
  <dtil:NetOperatingLossCarryforwardsNotSubjectToExpiration id="F_000611" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">81600000</dtil:NetOperatingLossCarryforwardsNotSubjectToExpiration>
  <dtil:OperatingLossCarryforwardsExpirationYear id="F_000612" contextRef="C_0001357874_20190101_20191231">2025</dtil:OperatingLossCarryforwardsExpirationYear>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000613" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" unitRef="U_iso4217USD">7200000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000614" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20181231" decimals="-5" unitRef="U_iso4217USD">3600000</us-gaap:TaxCreditCarryforwardAmount>
  <dtil:TaxCreditCarryForwardsExpirationBeginningYear id="F_000615" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">2027</dtil:TaxCreditCarryForwardsExpirationBeginningYear>
  <dtil:TaxCreditCarryForwardsExpirationBeginningYear id="F_000616" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231">2027</dtil:TaxCreditCarryForwardsExpirationBeginningYear>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000617" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20191231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000618" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20181231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:TaxCreditCarryforwardAmount>
  <dtil:TaxCreditCarryForwardsExpirationBeginningYear id="F_000619" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20190101_20191231">2030</dtil:TaxCreditCarryForwardsExpirationBeginningYear>
  <dtil:TaxCreditCarryForwardsExpirationBeginningYear id="F_000620" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20180101_20181231">2030</dtil:TaxCreditCarryForwardsExpirationBeginningYear>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000621" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_dtilOrphanDrugTaxCreditCarryforwardMember_20191231" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000622" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_dtilOrphanDrugTaxCreditCarryforwardMember_20181231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:TaxCreditCarryforwardAmount>
  <dtil:TaxCreditCarryForwardsExpirationBeginningYear id="F_000623" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_dtilOrphanDrugTaxCreditCarryforwardMember_20190101_20191231">2038</dtil:TaxCreditCarryForwardsExpirationBeginningYear>
  <dtil:FederalContributionCarryforwards id="F_000624" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20181231" decimals="-5" unitRef="U_iso4217USD">100000</dtil:FederalContributionCarryforwards>
  <dtil:FederalContributionCarryforwards id="F_000625" contextRef="C_0001357874_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" unitRef="U_iso4217USD">100000</dtil:FederalContributionCarryforwards>
  <dtil:FederalContributionCarryforwardsExpirationBeginningYear id="F_000626" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20190101_20191231">2020</dtil:FederalContributionCarryforwardsExpirationBeginningYear>
  <dtil:FederalContributionCarryforwardsExpirationBeginningYear id="F_000627" contextRef="C_0001357874_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20180101_20181231">2020</dtil:FederalContributionCarryforwardsExpirationBeginningYear>
  <us-gaap:UndistributedEarnings id="F_000628" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UndistributedEarnings>
  <dtil:OwnershipPercentageChangeInOutstandingCommonStockPeriod id="F_000629" contextRef="C_0001357874_20190101_20191231">P3Y</dtil:OwnershipPercentageChangeInOutstandingCommonStockPeriod>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="F_000630" contextRef="C_0001357874_20191231" decimals="2" unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent id="F_000631" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:UnrecognizedTaxBenefits id="F_000632" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000633" contextRef="C_0001357874_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000634" contextRef="C_0001357874_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <dtil:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense id="F_000635" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</dtil:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense>
  <dtil:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense id="F_000636" contextRef="C_0001357874_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</dtil:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense>
  <us-gaap:AssetsFairValueDisclosure id="F_000637" contextRef="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">3395000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000638" contextRef="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">3395000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000639" contextRef="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">173000000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000640" contextRef="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">173000000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000641" contextRef="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">176395000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000642" contextRef="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">3395000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000643" contextRef="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">173000000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000644" contextRef="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">781000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000645" contextRef="C_0001357874_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">781000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000646" contextRef="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20181231" decimals="-3" unitRef="U_iso4217USD">94500000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000647" contextRef="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20181231" decimals="-3" unitRef="U_iso4217USD">94500000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000648" contextRef="C_0001357874_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">95281000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000649" contextRef="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">781000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000650" contextRef="C_0001357874_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20181231" decimals="-3" unitRef="U_iso4217USD">94500000</us-gaap:AssetsFairValueDisclosure>
  <dtil:UpfrontPayment id="F_000651" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224" decimals="-5" unitRef="U_iso4217USD">105000000</dtil:UpfrontPayment>
  <dtil:AggregatePaymentOnCollaborationAgreementToBeReceived id="F_000652" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224" decimals="INF" unitRef="U_iso4217USD">1600000000</dtil:AggregatePaymentOnCollaborationAgreementToBeReceived>
  <dtil:AggregateMilestonePayments id="F_000653" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224" decimals="INF" unitRef="U_iso4217USD">1500000000</dtil:AggregateMilestonePayments>
  <dtil:DevelopmentMilestonePayments id="F_000654" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224" decimals="INF" unitRef="U_iso4217USD">401300000</dtil:DevelopmentMilestonePayments>
  <dtil:CommercialMilestonePayments id="F_000655" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20160223_20160224" decimals="INF" unitRef="U_iso4217USD">1100000000</dtil:CommercialMilestonePayments>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000656" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2019-01-01_20160224" decimals="-5" unitRef="U_iso4217USD">105000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 id="F_000657" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2019-01-01_20160224">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000658" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">7300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized id="F_000659" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">5800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiability id="F_000660" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">80900000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability id="F_000661" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20181231" decimals="-5" unitRef="U_iso4217USD">88600000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000662" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapBalanceSheetLocationAxis_dtilCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">15000000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000663" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapBalanceSheetLocationAxis_dtilCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20181231" decimals="-5" unitRef="U_iso4217USD">5800000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ProceedsFromCollaborators id="F_000664" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="F_000665" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilServierMember_us-gaapTypeOfArrangementAxis_dtilDevelopmentAndCommercialLicenseAgreementMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromCollaborators>
  <dtil:ReceivableFromResearchFunding id="F_000666" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180910" decimals="-5" unitRef="U_iso4217USD">40000000</dtil:ReceivableFromResearchFunding>
  <dtil:ResearchFundingPaymentTerm id="F_000667" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910">P3Y</dtil:ResearchFundingPaymentTerm>
  <dtil:DevelopmentAndCommercialMilestonePayments id="F_000668" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910" decimals="-5" unitRef="U_iso4217USD">445000000</dtil:DevelopmentAndCommercialMilestonePayments>
  <dtil:DevelopmentMilestonePayments id="F_000669" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910" decimals="-5" unitRef="U_iso4217USD">105000000</dtil:DevelopmentMilestonePayments>
  <dtil:CommercialMilestonePayments id="F_000670" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910" decimals="-5" unitRef="U_iso4217USD">340000000</dtil:CommercialMilestonePayments>
  <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment id="F_000671" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180909_20180910" decimals="-5" unitRef="U_iso4217USD">40000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
  <dtil:ResearchFundingPaymentTerm id="F_000672" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20190101_20191231">P3Y</dtil:ResearchFundingPaymentTerm>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000673" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">13300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000674" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">3700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000675" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20191231" decimals="-5" unitRef="U_iso4217USD">1500000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent id="F_000676" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20181231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ProceedsFromCollaborators id="F_000677" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_dtilCollaborationAndLicenseAgreementMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:ProceedsFromCollaborators>
  <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment id="F_000678" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
  <dtil:ResearchFundingPaymentTerm id="F_000679" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131">P3Y</dtil:ResearchFundingPaymentTerm>
  <dtil:SalesMilestonePaymentsToCollaborators id="F_000680" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">16100000</dtil:SalesMilestonePaymentsToCollaborators>
  <dtil:SalesMilestonePaymentsToCollaborators id="F_000681" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">12300000</dtil:SalesMilestonePaymentsToCollaborators>
  <dtil:AggregateMilestonePayments id="F_000682" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">28400000</dtil:AggregateMilestonePayments>
  <dtil:UpfrontPayment id="F_000683" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180101_20180131" decimals="-5" unitRef="U_iso4217USD">300000</dtil:UpfrontPayment>
  <dtil:PaymentToCollaboratorForResearchFunding id="F_000684" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180131" decimals="-5" unitRef="U_iso4217USD">15000000</dtil:PaymentToCollaboratorForResearchFunding>
  <dtil:OptionToPayLicenseFee id="F_000685" contextRef="C_0001357874_srtCounterpartyNameAxis_dtilUniversityOfPennsylvaniaMember_us-gaapTypeOfArrangementAxis_dtilSponsoredResearchCollaborationAndLicenseAgreementMember_20180131" decimals="-5" unitRef="U_iso4217USD">1000000</dtil:OptionToPayLicenseFee>
  <us-gaap:NumberOfReportableSegments id="F_000686" contextRef="C_0001357874_20190101_20191231" decimals="INF" unitRef="U_dtilSegment">2</us-gaap:NumberOfReportableSegments>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000687" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">20632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000688" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000689" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1606000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000690" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000691" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">22238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000692" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">10883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:OperatingCostsAndExpenses id="F_000693" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">45941000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:OperatingCostsAndExpenses id="F_000694" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">35045000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:OperatingCostsAndExpenses id="F_000695" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">6984000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:OperatingCostsAndExpenses id="F_000696" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9125000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:OperatingCostsAndExpenses id="F_000697" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">52925000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:OperatingCostsAndExpenses id="F_000698" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">44170000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000699" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">24118000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000700" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">11605000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000701" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2901000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000702" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">24118000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000703" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">14506000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingIncomeLoss id="F_000704" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-49427000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000705" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilTherapeuticsSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-37127000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000706" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-5378000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000707" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_dtilFoodSegmentMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-10666000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000708" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-54805000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000709" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-47793000</us-gaap:OperatingIncomeLoss>
  <dtil:CorporateGeneralAndAdministrativeCashExpenditures id="F_000710" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">32569000</dtil:CorporateGeneralAndAdministrativeCashExpenditures>
  <dtil:CorporateGeneralAndAdministrativeCashExpenditures id="F_000711" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">15892000</dtil:CorporateGeneralAndAdministrativeCashExpenditures>
  <us-gaap:InvestmentIncomeInterest id="F_000712" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4267000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000713" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1875000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:DepreciationAndAmortization id="F_000714" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5317000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000715" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2354000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000716" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8940000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000717" contextRef="C_0001357874_srtConsolidationItemsAxis_us-gaapMaterialReconcilingItemsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2453000</us-gaap:ShareBasedCompensation>
  <dtil:AdjustmentsToReconcileCashExpendituresToGAAPExpenses id="F_000718" contextRef="C_0001357874_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">18716000</dtil:AdjustmentsToReconcileCashExpendituresToGAAPExpenses>
  <dtil:AdjustmentsToReconcileCashExpendituresToGAAPExpenses id="F_000719" contextRef="C_0001357874_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">22469000</dtil:AdjustmentsToReconcileCashExpendituresToGAAPExpenses>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>58
<FILENAME>dtil-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-10T02:29:53.6244110+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 110b6502c8774be1969d6e34eb8cea58 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:dtil="http://precisionbiosciences.com/20191231" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://precisionbiosciences.com/20191231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://precisionbiosciences.com/20191231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dtil-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dtil-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dtil-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dtil-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftware" id="Role_DisclosurePropertyEquipmentAndSoftware">
        <link:definition>100070 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100080 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100090 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100100 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>100110 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100130 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100140 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100160 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100170 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReporting" id="Role_DisclosureSegmentReporting">
        <link:definition>100180 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareTables" id="Role_DisclosurePropertyEquipmentAndSoftwareTables">
        <link:definition>100210 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100220 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100230 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100240 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100250 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingTables" id="Role_DisclosureSegmentReportingTables">
        <link:definition>100280 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails">
        <link:definition>100300 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization Periods of Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails">
        <link:definition>100310 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails">
        <link:definition>100320 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails" id="Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails">
        <link:definition>100330 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of of Cash Flows (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>100340 - Disclosure - Property, Equipment and Software - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails" id="Role_DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Property, Equipment and Software - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails" id="Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails">
        <link:definition>100360 - Disclosure - Intangible Assets - Schedule of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Stockholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails">
        <link:definition>100400 - Disclosure - Share-Based Compensation - Schedule of Employee and Nonemployee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100410 - Disclosure - Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureShareBasedCompensationScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100420 - Disclosure - Share-Based Compensation - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfActivityOfOptionPlansDetails" id="Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionPlansDetails">
        <link:definition>100430 - Disclosure - Share-Based Compensation - Summary of Activity of Option Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionsGrantedUnderStockOptionPlansAreVestedOrExpectedToVestDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionsGrantedUnderStockOptionPlansAreVestedOrExpectedToVestDetails">
        <link:definition>100440 - Disclosure - Share-Based Compensation - Summary of Stock Options Granted under the Stock Option Plans are Vested or Expected to Vest (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails">
        <link:definition>100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Outstanding under the Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100490 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100540 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1">
        <link:definition>100560 - Disclosure - Collaboration and License Agreements - Additional Information (Details 1 )</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1Default" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1Default">
        <link:definition>100560 - Disclosure - Collaboration and License Agreements - Additional Information (Details 1 )</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="Role_DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" id="Role_DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails">
        <link:definition>100580 - Disclosure - Segment Reporting - Financial Information with Respect to Company&apos;s Reportable Segments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" name="AccruedClinicalAndResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_ChangeInFairValueOfConvertibleNotePayable" name="ChangeInFairValueOfConvertibleNotePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" name="ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" name="ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" name="IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" name="IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_ChangeInFairValueOfConvertibleNotesPayable" name="ChangeInFairValueOfConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" name="IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_CommonStockIssuedOnConversionOfConvertibleNotes" name="CommonStockIssuedOnConversionOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_CommonStockValuationPolicyPolicyTextBlock" name="CommonStockValuationPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PrecisionPlantSciencesIncMember" name="PrecisionPlantSciencesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_EloLifeSystemsAustraliaPtyLtdMember" name="EloLifeSystemsAustraliaPtyLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PrecisionBioSciencesUKLimitedMember" name="PrecisionBioSciencesUKLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" name="SeriesAAndSeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_DevelopmentMember" name="DevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_AmendedDateOfIncorporation" name="AmendedDateOfIncorporation" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_AmendedNameOfIncorporation" name="AmendedNameOfIncorporation" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_UnderwritingDiscountsAndCommission" name="UnderwritingDiscountsAndCommission" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_PercentageOfRevenue" name="PercentageOfRevenue" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="dtil_PercentageOfDeferredRevenue" name="PercentageOfDeferredRevenue" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="dtil_IssuanceOfNonconvertibleDebt" name="IssuanceOfNonconvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_CommonStockNotHeldByNonAffiliates" name="CommonStockNotHeldByNonAffiliates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" name="ManufacturingCenterForAdvancedTherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_DurhamMember" name="DurhamMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" name="PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_FiniteLivedIntangibleAssetsImpairment" name="FiniteLivedIntangibleAssetsImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_PaymentOfNonRefundableLicenseFees" name="PaymentOfNonRefundableLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_CommonAndPreferredStocksSharesAuthorized" name="CommonAndPreferredStocksSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="dtil_TwoThousandSixStockIncentivePlanMember" name="TwoThousandSixStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_TwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFifteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" name="AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" name="MaximumSharesAllowedToBeIssuedUnderESPP" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_OfferingPeriodCommencedDate" name="OfferingPeriodCommencedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_OfferingPeriodEndDate" name="OfferingPeriodEndDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_PriceRangeOneMember" name="PriceRangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeTwoMember" name="PriceRangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeThreeMember" name="PriceRangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeFourMember" name="PriceRangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeFiveMember" name="PriceRangeFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeSixMember" name="PriceRangeSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeSevenMember" name="PriceRangeSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeEightMember" name="PriceRangeEightMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeNineMember" name="PriceRangeNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeTenMember" name="PriceRangeTenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PriceRangeElevenMember" name="PriceRangeElevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" name="OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" name="RevolvingLineIfDailyBalanceIsMaintainedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" name="RevolvingLineIfDailyBalanceIsNotMaintainedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PacificWesternLoanAgreementMember" name="PacificWesternLoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" name="PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" name="DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" name="MaximumAmountToMaintainWithNonAffiliatedBank" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_OrphanDrugTaxCreditCarryforwardMember" name="OrphanDrugTaxCreditCarryforwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_FederalContributionCarryforwards" name="FederalContributionCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_FederalContributionCarryforwardsExpirationBeginningYear" name="FederalContributionCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_OperatingLossCarryForwardsSubjectToExpiration" name="OperatingLossCarryForwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" name="NetOperatingLossCarryForwardSubjectToExpirationBeginYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" name="NetOperatingLossCarryforwardsNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_TaxCreditCarryForwardsExpirationBeginningYear" name="TaxCreditCarryForwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" name="OwnershipPercentageChangeInOutstandingCommonStockPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" name="TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" name="AggregatePaymentOnCollaborationAgreementToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_AggregateMilestonePayments" name="AggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_DevelopmentMilestonePayments" name="DevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_DevelopmentAndCommercialLicenseAgreementMember" name="DevelopmentAndCommercialLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_ServierMember" name="ServierMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_GileadSciencesIncMember" name="GileadSciencesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" name="SponsoredResearchCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_UniversityOfPennsylvaniaMember" name="UniversityOfPennsylvaniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_ReceivableFromResearchFunding" name="ReceivableFromResearchFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_ResearchFundingPaymentTerm" name="ResearchFundingPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="dtil_DevelopmentAndCommercialMilestonePayments" name="DevelopmentAndCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_SalesMilestonePaymentsToCollaborators" name="SalesMilestonePaymentsToCollaborators" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_PaymentToCollaboratorForResearchFunding" name="PaymentToCollaboratorForResearchFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_OptionToPayLicenseFee" name="OptionToPayLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="dtil_CorporateGeneralAndAdministrativeCashExpenditures" name="CorporateGeneralAndAdministrativeCashExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" name="AdjustmentsToReconcileCashExpendituresToGAAPExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" name="AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_TherapeuticsSegmentMember" name="TherapeuticsSegmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="dtil_FoodSegmentMember" name="FoodSegmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>59
<FILENAME>dtil-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-10T02:29:53.6244110+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 110b6502c8774be1969d6e34eb8cea58 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="dtil-20191231.xsd#TemplateLink" roleURI="http://precisionbiosciences.com/20191231/role/TemplateLink" />
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotePayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="dtil_ChangeInFairValueOfConvertibleNotePayable" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" xlink:type="locator" xlink:label="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotesPayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotesPayable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NonCashInterestExpense" xlink:type="locator" xlink:label="dtil_NonCashInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dtil_NonCashInterestExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dtil_ChangeInFairValueOfConvertibleNotesPayable" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10230.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FiniteLivedIntangibleAssetsImpairment" xlink:type="locator" xlink:label="dtil_FiniteLivedIntangibleAssetsImpairment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="dtil_FiniteLivedIntangibleAssetsImpairment" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10090.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingCostsAndExpenses" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>60
<FILENAME>dtil-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-10T02:29:53.6244110+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 110b6502c8774be1969d6e34eb8cea58 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="dtil-20191231.xsd#TemplateLink" roleURI="http://precisionbiosciences.com/20191231/role/TemplateLink" />
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10270.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" xlink:type="locator" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" xlink:type="locator" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:type="locator" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:type="locator" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockNotHeldByNonAffiliates" xlink:type="locator" xlink:label="dtil_CommonStockNotHeldByNonAffiliates" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfNonconvertibleDebt" xlink:type="locator" xlink:label="dtil_IssuanceOfNonconvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfDeferredRevenue" xlink:type="locator" xlink:label="dtil_PercentageOfDeferredRevenue" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfRevenue" xlink:type="locator" xlink:label="dtil_PercentageOfRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UnderwritingDiscountsAndCommission" xlink:type="locator" xlink:label="dtil_UnderwritingDiscountsAndCommission" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AmendedNameOfIncorporation" xlink:type="locator" xlink:label="dtil_AmendedNameOfIncorporation" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AmendedDateOfIncorporation" xlink:type="locator" xlink:label="dtil_AmendedDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentMember" xlink:type="locator" xlink:label="dtil_DevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SubsidiaryIssuerMember" xlink:type="locator" xlink:label="srt_SubsidiaryIssuerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PrecisionBioSciencesUKLimitedMember" xlink:type="locator" xlink:label="dtil_PrecisionBioSciencesUKLimitedMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_EloLifeSystemsAustraliaPtyLtdMember" xlink:type="locator" xlink:label="dtil_EloLifeSystemsAustraliaPtyLtdMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PrecisionPlantSciencesIncMember" xlink:type="locator" xlink:label="dtil_PrecisionPlantSciencesIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dtil_PrecisionPlantSciencesIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dtil_EloLifeSystemsAustraliaPtyLtdMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dtil_PrecisionBioSciencesUKLimitedMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiaryIssuerMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dtil_DevelopmentMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_AmendedDateOfIncorporation" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_AmendedNameOfIncorporation" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_UnderwritingDiscountsAndCommission" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_PercentageOfRevenue" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_PercentageOfDeferredRevenue" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_IssuanceOfNonconvertibleDebt" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_CommonStockNotHeldByNonAffiliates" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12230.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_ProfitLoss" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dtil_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dtil_LaboratoryEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" xlink:type="locator" xlink:label="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC" xlink:type="locator" xlink:label="stpr_NC" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DurhamMember" xlink:type="locator" xlink:label="dtil_DurhamMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ManufacturingCenterForAdvancedTherapeuticsMember" xlink:type="locator" xlink:label="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="dtil_DurhamMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementGeographicalAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NC" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PaymentOfNonRefundableLicenseFees" xlink:type="locator" xlink:label="dtil_PaymentOfNonRefundableLicenseFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_PaymentOfNonRefundableLicenseFees" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonAndPreferredStocksSharesAuthorized" xlink:type="locator" xlink:label="dtil_CommonAndPreferredStocksSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dtil_CommonAndPreferredStocksSharesAuthorized" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OfferingPeriodEndDate" xlink:type="locator" xlink:label="dtil_OfferingPeriodEndDate" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OfferingPeriodCommencedDate" xlink:type="locator" xlink:label="dtil_OfferingPeriodCommencedDate" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:type="locator" xlink:label="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandFifteenStockIncentivePlanMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandSixStockIncentivePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandSixStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandSixStockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandFifteenStockIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandNineteenIncentiveAwardPlanMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_OfferingPeriodCommencedDate" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_OfferingPeriodEndDate" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11650.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeElevenMember" xlink:type="locator" xlink:label="dtil_PriceRangeElevenMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeTenMember" xlink:type="locator" xlink:label="dtil_PriceRangeTenMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeNineMember" xlink:type="locator" xlink:label="dtil_PriceRangeNineMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeEightMember" xlink:type="locator" xlink:label="dtil_PriceRangeEightMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeSevenMember" xlink:type="locator" xlink:label="dtil_PriceRangeSevenMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeSixMember" xlink:type="locator" xlink:label="dtil_PriceRangeSixMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeFiveMember" xlink:type="locator" xlink:label="dtil_PriceRangeFiveMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeFourMember" xlink:type="locator" xlink:label="dtil_PriceRangeFourMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeThreeMember" xlink:type="locator" xlink:label="dtil_PriceRangeThreeMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeTwoMember" xlink:type="locator" xlink:label="dtil_PriceRangeTwoMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeOneMember" xlink:type="locator" xlink:label="dtil_PriceRangeOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeOneMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeTwoMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeThreeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeFourMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeFiveMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeSixMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeSevenMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeEightMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeNineMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeTenMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeElevenMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="dtil_AgreementTerminationNoticePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommitmentAndContingenciesTable" xlink:type="locator" xlink:label="dtil_CommitmentAndContingenciesTable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="dtil_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dtil_CommitmentsAndContingenciesLineItems" xlink:to="dtil_CommitmentAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_CommitmentsAndContingenciesLineItems" xlink:to="dtil_AgreementTerminationNoticePeriod" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" xlink:type="locator" xlink:label="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_MaximumAmountToMaintainWithNonAffiliatedBank" xlink:type="locator" xlink:label="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:type="locator" xlink:label="us-gaap_CompensatingBalanceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" xlink:type="locator" xlink:label="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotePayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" xlink:type="locator" xlink:label="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PacificWesternLoanAgreementMember" xlink:type="locator" xlink:label="dtil_PacificWesternLoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" xlink:type="locator" xlink:label="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" xlink:type="locator" xlink:label="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_PacificWesternLoanAgreementMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_ChangeInFairValueOfConvertibleNotePayable" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CompensatingBalanceAmount" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="11750.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" xlink:type="locator" xlink:label="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" xlink:type="locator" xlink:label="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarnings" xlink:type="locator" xlink:label="us-gaap_UndistributedEarnings" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FederalContributionCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="dtil_FederalContributionCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FederalContributionCarryforwards" xlink:type="locator" xlink:label="dtil_FederalContributionCarryforwards" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TaxCreditCarryForwardsExpirationBeginningYear" xlink:type="locator" xlink:label="dtil_TaxCreditCarryForwardsExpirationBeginningYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="dtil_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" xlink:type="locator" xlink:label="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OperatingLossCarryForwardsSubjectToExpiration" xlink:type="locator" xlink:label="dtil_OperatingLossCarryForwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OrphanDrugTaxCreditCarryforwardMember" xlink:type="locator" xlink:label="dtil_OrphanDrugTaxCreditCarryforwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="dtil_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="dtil_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dtil_OrphanDrugTaxCreditCarryforwardMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_OperatingLossCarryForwardsSubjectToExpiration" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_OperatingLossCarryforwardsExpirationYear" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_TaxCreditCarryForwardsExpirationBeginningYear" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_FederalContributionCarryforwards" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_FederalContributionCarryforwardsExpirationBeginningYear" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UndistributedEarnings" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" order="11960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_RepurchaseAgreementsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OptionToPayLicenseFee" xlink:type="locator" xlink:label="dtil_OptionToPayLicenseFee" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PaymentToCollaboratorForResearchFunding" xlink:type="locator" xlink:label="dtil_PaymentToCollaboratorForResearchFunding" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SalesMilestonePaymentsToCollaborators" xlink:type="locator" xlink:label="dtil_SalesMilestonePaymentsToCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentAndCommercialMilestonePayments" xlink:type="locator" xlink:label="dtil_DevelopmentAndCommercialMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ResearchFundingPaymentTerm" xlink:type="locator" xlink:label="dtil_ResearchFundingPaymentTerm" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ReceivableFromResearchFunding" xlink:type="locator" xlink:label="dtil_ReceivableFromResearchFunding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommercialMilestonePayments" xlink:type="locator" xlink:label="dtil_CommercialMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentMilestonePayments" xlink:type="locator" xlink:label="dtil_DevelopmentMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AggregateMilestonePayments" xlink:type="locator" xlink:label="dtil_AggregateMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" xlink:type="locator" xlink:label="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UpfrontPayment" xlink:type="locator" xlink:label="dtil_UpfrontPayment" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UniversityOfPennsylvaniaMember" xlink:type="locator" xlink:label="dtil_UniversityOfPennsylvaniaMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_GileadSciencesIncMember" xlink:type="locator" xlink:label="dtil_GileadSciencesIncMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="dtil_CurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ServierMember" xlink:type="locator" xlink:label="dtil_ServierMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentAndCommercialLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_DevelopmentAndCommercialLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_DevelopmentAndCommercialLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_ServierMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="dtil_CurrentLiabilitiesMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_CollaborationAndLicenseAgreementMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_GileadSciencesIncMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_UniversityOfPennsylvaniaMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_UpfrontPayment" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_AggregateMilestonePayments" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_DevelopmentMilestonePayments" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_CommercialMilestonePayments" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_ReceivableFromResearchFunding" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_ResearchFundingPaymentTerm" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_DevelopmentAndCommercialMilestonePayments" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_SalesMilestonePaymentsToCollaborators" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_PaymentToCollaboratorForResearchFunding" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_OptionToPayLicenseFee" order="12490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1" xlink:href="dtil-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ServierMember" xlink:type="locator" xlink:label="dtil_ServierMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_ServierMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1Default" xlink:href="dtil-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1Default" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1Default">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ServierMember" xlink:type="locator" xlink:label="dtil_ServierMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_ServierMember" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10070.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" xlink:type="locator" xlink:label="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CorporateGeneralAndAdministrativeCashExpenditures" xlink:type="locator" xlink:label="dtil_CorporateGeneralAndAdministrativeCashExpenditures" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:type="locator" xlink:label="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FoodSegmentMember" xlink:type="locator" xlink:label="dtil_FoodSegmentMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TherapeuticsSegmentMember" xlink:type="locator" xlink:label="dtil_TherapeuticsSegmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_MaterialReconcilingItemsMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_2" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="dtil_TherapeuticsSegmentMember" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="dtil_FoodSegmentMember" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="dtil_CorporateGeneralAndAdministrativeCashExpenditures" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" order="11430.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>61
<FILENAME>dtil-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-10T02:29:53.6244110+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 110b6502c8774be1969d6e34eb8cea58 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" />
    <link:label xml:lang="en-US" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" xlink:to="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment, and software&#8212;net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets&#8212;net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Research And Development Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue&#8212;noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent&#8212;noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock; $0.000005 par value&#8212; 200,000,000 shares authorized, 51,965,708 shares issued and 51,155,236 shares outstanding as of December 31, 2019; 16,717,117 shares issued and 15,906,645 shares outstanding as of December 31, 2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotePayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable" />
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of convertible note payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ChangeInFairValueOfConvertibleNotePayable" xlink:to="dtil_ChangeInFairValueOfConvertibleNotePayable_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Convertible Note Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders- basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding- basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:type="locator" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" />
    <link:label xml:lang="en-US" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock upon initial public offering shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:to="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:type="locator" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock upon initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:to="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" xlink:type="locator" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" />
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in initial public offering net of underwriting discounts and issuance cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" xlink:to="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" xlink:type="locator" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" />
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock In initial public offering net of underwriting discounts and issuance cost shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" xlink:to="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Adjustment to beginning accumulated deficit from adoption of ASU 2014-09</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Of New Accounting Principle In Period Of Adoption</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock Upon Initial Public Offering Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon conversion of convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon conversion of convertible notes, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net of discounts and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net of discounts and issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Issuance Cost Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option exercises, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NonCashInterestExpense" xlink:type="locator" xlink:label="dtil_NonCashInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="dtil_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_NonCashInterestExpense" xlink:to="dtil_NonCashInterestExpense_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotesPayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of convertible notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ChangeInFairValueOfConvertibleNotesPayable" xlink:to="dtil_ChangeInFairValueOfConvertibleNotesPayable_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" xlink:type="locator" xlink:label="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in other assets and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" xlink:to="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued other expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" xlink:to="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockIssuedOnConversionOfConvertibleNotes" xlink:type="locator" xlink:label="dtil_CommonStockIssuedOnConversionOfConvertibleNotes" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockIssuedOnConversionOfConvertibleNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued on conversion of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommonStockIssuedOnConversionOfConvertibleNotes" xlink:to="dtil_CommonStockIssuedOnConversionOfConvertibleNotes_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property, equipment, and software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Sales Of Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Convertible Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Assets And Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Other Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of license rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property, equipment and software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from disposal of property, equipment, and software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from IPO, net of underwriting discounts and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents&#8212;beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents &#8212;end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash financing and investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockIssuedOnConversionOfConvertibleNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued on conversion of convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockIssuedOnConversionOfConvertibleNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued On Conversion Of Convertible Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment and software additions included in accounts payable, accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Fixed Assets Acquired1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable, accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PROPERTY, EQUIPMENT AND SOFTWARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHARE-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COLLABORATION AND LICENSE AGREEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEGMENT REPORTING</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Reclassification Adjustment Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Equity Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Equipment and Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition for Contracts with Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockValuationPolicyPolicyTextBlock" xlink:type="locator" xlink:label="dtil_CommonStockValuationPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockValuationPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for determining the fair value of the entity&apos;s common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommonStockValuationPolicyPolicyTextBlock" xlink:to="dtil_CommonStockValuationPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockValuationPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Valuation</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockValuationPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Valuation Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Updates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation and amortization periods for property, equipment and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation and Amortization Periods for Property, Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Impact of Adopting Topic 606 on Condensed Financial Statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of New Accounting Pronouncements And Changes In Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Equipment and Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity of Option Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Granted under the Stock Option Plans are Vested or Expected to Vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Outstanding under the Stock Option Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Information with Respect to Company&apos;s Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Segment Reporting Information By Segment [Text Block]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business and summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PrecisionPlantSciencesIncMember" xlink:type="locator" xlink:label="dtil_PrecisionPlantSciencesIncMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PrecisionPlantSciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Precision PlantSciences, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PrecisionPlantSciencesIncMember" xlink:to="dtil_PrecisionPlantSciencesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PrecisionPlantSciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Precision PlantSciences, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PrecisionPlantSciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Precision Plant Sciences Inc [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_EloLifeSystemsAustraliaPtyLtdMember" xlink:type="locator" xlink:label="dtil_EloLifeSystemsAustraliaPtyLtdMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_EloLifeSystemsAustraliaPtyLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Elo life systems australia pty ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_EloLifeSystemsAustraliaPtyLtdMember" xlink:to="dtil_EloLifeSystemsAustraliaPtyLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_EloLifeSystemsAustraliaPtyLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Elo Life Systems Australia Pty Ltd</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_EloLifeSystemsAustraliaPtyLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Elo Life Systems Australia Pty Ltd [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PrecisionBioSciencesUKLimitedMember" xlink:type="locator" xlink:label="dtil_PrecisionBioSciencesUKLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PrecisionBioSciencesUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Precision Bio Sciences UK Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PrecisionBioSciencesUKLimitedMember" xlink:to="dtil_PrecisionBioSciencesUKLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PrecisionBioSciencesUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Precision BioSciences UK Limited</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PrecisionBioSciencesUKLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Precision Bio Sciences U K Limited [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SubsidiaryIssuerMember" xlink:type="locator" xlink:label="srt_SubsidiaryIssuerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiaryIssuerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiaryIssuerMember" xlink:to="srt_SubsidiaryIssuerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SubsidiaryIssuerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Issuer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering ("IPO")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A and Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:to="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A And Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes Payable (2019 Notes)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentMember" xlink:type="locator" xlink:label="dtil_DevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DevelopmentMember" xlink:to="dtil_DevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Member</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for New Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2014-09</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AmendedDateOfIncorporation" xlink:type="locator" xlink:label="dtil_AmendedDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dtil_AmendedDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended date of incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AmendedDateOfIncorporation" xlink:to="dtil_AmendedDateOfIncorporation_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AmendedNameOfIncorporation" xlink:type="locator" xlink:label="dtil_AmendedNameOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dtil_AmendedNameOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended name of Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AmendedNameOfIncorporation" xlink:to="dtil_AmendedNameOfIncorporation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage owned in subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AmendedDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended date of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AmendedDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Date Of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AmendedNameOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended name of incorporation</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AmendedNameOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Name Of Incorporation</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity&apos;s first offering of stock to the public net of underwriting discounts, commissions and issuance cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" xlink:to="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UnderwritingDiscountsAndCommission" xlink:type="locator" xlink:label="dtil_UnderwritingDiscountsAndCommission" />
    <link:label xml:lang="en-US" xlink:label="dtil_UnderwritingDiscountsAndCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commission.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_UnderwritingDiscountsAndCommission" xlink:to="dtil_UnderwritingDiscountsAndCommission_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued and sold, public offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance, net of underwriting discounts, commissions and issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_UnderwritingDiscountsAndCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discount and commission</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_UnderwritingDiscountsAndCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commission</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity, reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net income loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Retained earnings accumulated deficit</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfRevenue" xlink:type="locator" xlink:label="dtil_PercentageOfRevenue" />
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PercentageOfRevenue" xlink:to="dtil_PercentageOfRevenue_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfDeferredRevenue" xlink:type="locator" xlink:label="dtil_PercentageOfDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PercentageOfDeferredRevenue" xlink:to="dtil_PercentageOfDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and office equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software Intangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property plant and equipment useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition for changes in total estimated time to be incurred in the future to satisfy the performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefits recognized,likelihood upon ultimate settlement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Likelihood Of Unfavorable Settlement</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfNonconvertibleDebt" xlink:type="locator" xlink:label="dtil_IssuanceOfNonconvertibleDebt" />
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfNonconvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of nonconvertible debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IssuanceOfNonconvertibleDebt" xlink:to="dtil_IssuanceOfNonconvertibleDebt_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockNotHeldByNonAffiliates" xlink:type="locator" xlink:label="dtil_CommonStockNotHeldByNonAffiliates" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockNotHeldByNonAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock not held by non-affiliates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommonStockNotHeldByNonAffiliates" xlink:to="dtil_CommonStockNotHeldByNonAffiliates_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual gross revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfNonconvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued nonconvertible debt</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IssuanceOfNonconvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Nonconvertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockNotHeldByNonAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market value of common stock not held by non-affiliates</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommonStockNotHeldByNonAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Not Held By Non Affiliates</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transition adjustment to opening balance of accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balances without adoption of ASC 606</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Calculated Under Revenue Guidance In Effect Before Topic606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue - current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue - noncurrent liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recorded included in deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dtil_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_LaboratoryEquipmentMember" xlink:to="dtil_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Office Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property, equipment and software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, equipment and software - net</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ManufacturingCenterForAdvancedTherapeuticsMember" xlink:type="locator" xlink:label="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_ManufacturingCenterForAdvancedTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing Center for Advanced Therapeutics.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" xlink:to="dtil_ManufacturingCenterForAdvancedTherapeuticsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_ManufacturingCenterForAdvancedTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MCAT</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ManufacturingCenterForAdvancedTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Center For Advanced Therapeutics [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DurhamMember" xlink:type="locator" xlink:label="dtil_DurhamMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_DurhamMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Durhamas.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DurhamMember" xlink:to="dtil_DurhamMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_DurhamMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased Facilities in Durham</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DurhamMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Durham [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC" xlink:type="locator" xlink:label="stpr_NC" />
    <link:label xml:lang="en-US" xlink:label="stpr_NC_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North Carolina</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NC" xlink:to="stpr_NC_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_NC_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">NORTH CAROLINA</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" xlink:type="locator" xlink:label="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property, Equipment, Leasehold Improvements and Software [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" xlink:to="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Equipment, Leasehold Improvements and Software</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Equipment Leasehold Improvements And Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Gross</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FiniteLivedIntangibleAssetsImpairment" xlink:type="locator" xlink:label="dtil_FiniteLivedIntangibleAssetsImpairment" />
    <link:label xml:lang="en-US" xlink:label="dtil_FiniteLivedIntangibleAssetsImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible assets impairment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_FiniteLivedIntangibleAssetsImpairment" xlink:to="dtil_FiniteLivedIntangibleAssetsImpairment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived License Agreements Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FiniteLivedIntangibleAssetsImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: impairments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FiniteLivedIntangibleAssetsImpairment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PaymentOfNonRefundableLicenseFees" xlink:type="locator" xlink:label="dtil_PaymentOfNonRefundableLicenseFees" />
    <link:label xml:lang="en-US" xlink:label="dtil_PaymentOfNonRefundableLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of non-refundable license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PaymentOfNonRefundableLicenseFees" xlink:to="dtil_PaymentOfNonRefundableLicenseFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PaymentOfNonRefundableLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of non- refundable license fees</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PaymentOfNonRefundableLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Non Refundable License Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intellectual property rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Remaining Amortization Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense 2025 and beyond</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Common stock issued upon conversion of convertible preferred stock or convertible notes payable</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonAndPreferredStocksSharesAuthorized" xlink:type="locator" xlink:label="dtil_CommonAndPreferredStocksSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommonAndPreferredStocksSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of of common and preferred stock shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommonAndPreferredStocksSharesAuthorized" xlink:to="dtil_CommonAndPreferredStocksSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommonAndPreferredStocksSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and prferred stocks, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommonAndPreferredStocksSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common And Preferred Stocks Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandSixStockIncentivePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandSixStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandSixStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand six stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TwoThousandSixStockIncentivePlanMember" xlink:to="dtil_TwoThousandSixStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandSixStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandSixStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandFifteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TwoThousandFifteenStockIncentivePlanMember" xlink:to="dtil_TwoThousandFifteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="dtil_TwoThousandNineteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining shares available to be granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:to="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowed Annual Percentage Increase In Shares Authorized As Percentage Of Outstanding Shares Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:type="locator" xlink:label="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" />
    <link:label xml:lang="en-US" xlink:label="dtil_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum shares allowed to be issued under ESPP.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:to="dtil_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:label xml:lang="en-US" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award purchase price of common stock through payroll deductions percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:to="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OfferingPeriodCommencedDate" xlink:type="locator" xlink:label="dtil_OfferingPeriodCommencedDate" />
    <link:label xml:lang="en-US" xlink:label="dtil_OfferingPeriodCommencedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering period commenced date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OfferingPeriodCommencedDate" xlink:to="dtil_OfferingPeriodCommencedDate_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OfferingPeriodEndDate" xlink:type="locator" xlink:label="dtil_OfferingPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dtil_OfferingPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering period end date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OfferingPeriodEndDate" xlink:to="dtil_OfferingPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares allowed to be issued under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Shares Allowed To Be Issued Under E S P P</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock through payroll deductions expressed in percentage of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Through Payroll Deductions Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OfferingPeriodCommencedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period commenced date</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OfferingPeriodCommencedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period Commenced Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OfferingPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period end date</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OfferingPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Payment Arrangement Employee [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonemployee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Payment Arrangement Nonemployee [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" xlink:type="locator" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" />
    <link:label xml:lang="en-US" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions weighted average fair value per option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" xlink:to="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average expected stock price volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term of options (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average fair value per option</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Fair Value Per Option</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding Option Shares, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Option, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Option, Forfeited/canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding Option Shares, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Outstanding at Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Forfeited/canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Outstanding at Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value of Stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period for recognition of compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be exercisable, Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currently exercisable, Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be exercisable, Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currently exercisable, Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be exercisable, Weighted- Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currently exercisable, Weighted- Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeOneMember" xlink:type="locator" xlink:label="dtil_PriceRangeOneMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeOneMember" xlink:to="dtil_PriceRangeOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$0.01 - $0.04</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range One [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeTwoMember" xlink:type="locator" xlink:label="dtil_PriceRangeTwoMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeTwoMember" xlink:to="dtil_PriceRangeTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$0.41 - $1.20</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Two [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeThreeMember" xlink:type="locator" xlink:label="dtil_PriceRangeThreeMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeThreeMember" xlink:to="dtil_PriceRangeThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$7.74 - $9.46</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Three [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeFourMember" xlink:type="locator" xlink:label="dtil_PriceRangeFourMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeFourMember" xlink:to="dtil_PriceRangeFourMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$10.17 - $13.80</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Four [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeFiveMember" xlink:type="locator" xlink:label="dtil_PriceRangeFiveMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeFiveMember" xlink:to="dtil_PriceRangeFiveMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$14.91 - $16.00</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Five [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeSixMember" xlink:type="locator" xlink:label="dtil_PriceRangeSixMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range six.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeSixMember" xlink:to="dtil_PriceRangeSixMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$ 0.41</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Six [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeSevenMember" xlink:type="locator" xlink:label="dtil_PriceRangeSevenMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range seven.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeSevenMember" xlink:to="dtil_PriceRangeSevenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$1.18 - $1.20</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Seven [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeEightMember" xlink:type="locator" xlink:label="dtil_PriceRangeEightMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range eight.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeEightMember" xlink:to="dtil_PriceRangeEightMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$ 8.99</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Eight [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeNineMember" xlink:type="locator" xlink:label="dtil_PriceRangeNineMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeNineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range nine.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeNineMember" xlink:to="dtil_PriceRangeNineMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeNineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$ 10.17</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeNineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Nine [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeTenMember" xlink:type="locator" xlink:label="dtil_PriceRangeTenMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeTenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range ten.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeTenMember" xlink:to="dtil_PriceRangeTenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeTenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$ 11.98</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeTenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Ten [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeElevenMember" xlink:type="locator" xlink:label="dtil_PriceRangeElevenMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeElevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price range eleven.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PriceRangeElevenMember" xlink:to="dtil_PriceRangeElevenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeElevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$ 13.20</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PriceRangeElevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Range Eleven [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price, lower limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price, upper limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted- Average Remaining Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, Administrative fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Administrative Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, Employer matching contribution percentage of match</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, Employer matching contribution, percent of employees&apos; gross pay</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Company made contribution to the retirement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 and beyond</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="dtil_AgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="dtil_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AgreementTerminationNoticePeriod" xlink:to="dtil_AgreementTerminationNoticePeriod_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="dtil_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommitmentsAndContingenciesLineItems" xlink:to="dtil_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommitmentAndContingenciesTable" xlink:type="locator" xlink:label="dtil_CommitmentAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommitmentAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommitmentAndContingenciesTable" xlink:to="dtil_CommitmentAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommitmentAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommitmentAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" xlink:type="locator" xlink:label="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding share-based compensation awards converted to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" xlink:to="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Share Based Compensation Awards Converted to Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Share Based Compensation Awards Converted To Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving Line [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" xlink:type="locator" xlink:label="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Member stands for revelving line if the company maintains a daily demand deposit balance requirment for the loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" xlink:to="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving Line If Daily Balance Is Maintained [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Line If Daily Balance Is Maintained [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" xlink:type="locator" xlink:label="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Member stands for revelving line if the company does not maintain a daily demand deposit balance requirment for the loan..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" xlink:to="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving Line If Daily Balance Is Not Maintained [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Line If Daily Balance Is Not Maintained [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PacificWesternLoanAgreementMember" xlink:type="locator" xlink:label="dtil_PacificWesternLoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_PacificWesternLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pacific western loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PacificWesternLoanAgreementMember" xlink:to="dtil_PacificWesternLoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_PacificWesternLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pacific Western Loan Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PacificWesternLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pacific Western Loan Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" xlink:type="locator" xlink:label="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of settlement price equal on intial public offering price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" xlink:to="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock issued upon settlement convertible promissory notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes accrued interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement price equal on IPO price per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Settlement Price Equal On Intial Public Offering Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of convertible note payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" xlink:type="locator" xlink:label="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" />
    <link:label xml:lang="en-US" xlink:label="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage points to be deducted from the reference rate to compute the variable rate on the debt instrument..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" xlink:to="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_MaximumAmountToMaintainWithNonAffiliatedBank" xlink:type="locator" xlink:label="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" />
    <link:label xml:lang="en-US" xlink:label="dtil_MaximumAmountToMaintainWithNonAffiliatedBank_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount to maintain with non affiliated bank.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" xlink:to="dtil_MaximumAmountToMaintainWithNonAffiliatedBank_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis point deducted from the prime rate</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread To Be Deducted From Reference Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate during period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Rate During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:type="locator" xlink:label="us-gaap_CompensatingBalanceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensatingBalanceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required daily balance of cash in demand deposits accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensatingBalanceAmount" xlink:to="us-gaap_CompensatingBalanceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensatingBalanceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensating Balance Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis point added to the prime rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving line, fee percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Commitment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_MaximumAmountToMaintainWithNonAffiliatedBank_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount to maintain with non-affiliated bank</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_MaximumAmountToMaintainWithNonAffiliatedBank_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount To Maintain With Non Affiliated Bank</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Charitable Contribution Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent deferred tax liability:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax liabilities, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="dtil_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="dtil_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="dtil_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="dtil_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="dtil_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OrphanDrugTaxCreditCarryforwardMember" xlink:type="locator" xlink:label="dtil_OrphanDrugTaxCreditCarryforwardMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_OrphanDrugTaxCreditCarryforwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan drug tax credit carryforward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OrphanDrugTaxCreditCarryforwardMember" xlink:to="dtil_OrphanDrugTaxCreditCarryforwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_OrphanDrugTaxCreditCarryforwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Tax Credit Carry forward</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OrphanDrugTaxCreditCarryforwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance of net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of income taxes amount, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense at statutory rate, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal tax benefit, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expenses, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">R&amp;D and orphan drug credits, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax (benefit) expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of income taxes rate, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense at statutory rate, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal tax benefit, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expenses, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D and orphan drug credits, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductions Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowance, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FederalContributionCarryforwards" xlink:type="locator" xlink:label="dtil_FederalContributionCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="dtil_FederalContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal contribution carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_FederalContributionCarryforwards" xlink:to="dtil_FederalContributionCarryforwards_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FederalContributionCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="dtil_FederalContributionCarryforwardsExpirationBeginningYear" />
    <link:label xml:lang="en-US" xlink:label="dtil_FederalContributionCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal contribution carryforwards expiration beginning year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_FederalContributionCarryforwardsExpirationBeginningYear" xlink:to="dtil_FederalContributionCarryforwardsExpirationBeginningYear_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="dtil_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="dtil_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OperatingLossCarryforwardsExpirationYear" xlink:to="dtil_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OperatingLossCarryForwardsSubjectToExpiration" xlink:type="locator" xlink:label="dtil_OperatingLossCarryForwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="dtil_OperatingLossCarryForwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OperatingLossCarryForwardsSubjectToExpiration" xlink:to="dtil_OperatingLossCarryForwardsSubjectToExpiration_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" xlink:type="locator" xlink:label="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" />
    <link:label xml:lang="en-US" xlink:label="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carry forward subject to expiration begin year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" xlink:to="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards, not subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TaxCreditCarryForwardsExpirationBeginningYear" xlink:type="locator" xlink:label="dtil_TaxCreditCarryForwardsExpirationBeginningYear" />
    <link:label xml:lang="en-US" xlink:label="dtil_TaxCreditCarryForwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forwards expiration beginning year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TaxCreditCarryForwardsExpirationBeginningYear" xlink:to="dtil_TaxCreditCarryForwardsExpirationBeginningYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OperatingLossCarryForwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OperatingLossCarryForwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forward subject to expiration begin year</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carry Forward Subject To Expiration Begin Year</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating loss carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TaxCreditCarryForwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TaxCreditCarryForwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FederalContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal contribution carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FederalContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Contribution Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FederalContributionCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal contribution expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FederalContributionCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Contribution Carryforwards Expiration Beginning Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarnings" xlink:type="locator" xlink:label="us-gaap_UndistributedEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undistributed earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarnings" xlink:to="us-gaap_UndistributedEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UndistributedEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" xlink:type="locator" xlink:label="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" />
    <link:label xml:lang="en-US" xlink:label="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership percentage change in outstanding common stock period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" xlink:to="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage change in outstanding common stock period</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage Change In Outstanding Common Stock Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage in outstanding common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" xlink:type="locator" xlink:label="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" />
    <link:label xml:lang="en-US" xlink:label="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act of 2017 global intangible low taxed income tax expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" xlink:to="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GILTI tax expense</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Global Intangible Low Taxed Income Tax Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementsMember" xlink:to="us-gaap_RepurchaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UpfrontPayment" xlink:type="locator" xlink:label="dtil_UpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="dtil_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_UpfrontPayment" xlink:to="dtil_UpfrontPayment_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" xlink:type="locator" xlink:label="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate payment on collaboration agreement to be received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" xlink:to="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AggregateMilestonePayments" xlink:type="locator" xlink:label="dtil_AggregateMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="dtil_AggregateMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AggregateMilestonePayments" xlink:to="dtil_AggregateMilestonePayments_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentMilestonePayments" xlink:type="locator" xlink:label="dtil_DevelopmentMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DevelopmentMilestonePayments" xlink:to="dtil_DevelopmentMilestonePayments_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommercialMilestonePayments" xlink:type="locator" xlink:label="dtil_CommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="dtil_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CommercialMilestonePayments" xlink:to="dtil_CommercialMilestonePayments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentAndCommercialLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_DevelopmentAndCommercialLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentAndCommercialLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and commercial license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DevelopmentAndCommercialLicenseAgreementMember" xlink:to="dtil_DevelopmentAndCommercialLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentAndCommercialLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Commercial License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentAndCommercialLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Commercial License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ServierMember" xlink:type="locator" xlink:label="dtil_ServierMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_ServierMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Servier</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ServierMember" xlink:to="dtil_ServierMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_ServierMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Servier</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ServierMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Servier [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="dtil_CurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CurrentLiabilitiesMember" xlink:to="dtil_CurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Liabilities [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_CollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CollaborationAndLicenseAgreementMember" xlink:to="dtil_CollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_GileadSciencesIncMember" xlink:type="locator" xlink:label="dtil_GileadSciencesIncMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_GileadSciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gilead Sciences, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_GileadSciencesIncMember" xlink:to="dtil_GileadSciencesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_GileadSciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gilead</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_GileadSciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gilead Sciences Inc [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored research, collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" xlink:to="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research, Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UniversityOfPennsylvaniaMember" xlink:type="locator" xlink:label="dtil_UniversityOfPennsylvaniaMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_UniversityOfPennsylvaniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Pennsylvania.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_UniversityOfPennsylvaniaMember" xlink:to="dtil_UniversityOfPennsylvaniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_UniversityOfPennsylvaniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Pennsylvania</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_UniversityOfPennsylvaniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of Pennsylvania [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements [Line items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_UpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total payments to be received</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Payment On Collaboration Agreement To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AggregateMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AggregateMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from upfront payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated period performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue related to agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development or sales-based milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ReceivableFromResearchFunding" xlink:type="locator" xlink:label="dtil_ReceivableFromResearchFunding" />
    <link:label xml:lang="en-US" xlink:label="dtil_ReceivableFromResearchFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivable from research funding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ReceivableFromResearchFunding" xlink:to="dtil_ReceivableFromResearchFunding_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ResearchFundingPaymentTerm" xlink:type="locator" xlink:label="dtil_ResearchFundingPaymentTerm" />
    <link:label xml:lang="en-US" xlink:label="dtil_ResearchFundingPaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research funding payment term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_ResearchFundingPaymentTerm" xlink:to="dtil_ResearchFundingPaymentTerm_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentAndCommercialMilestonePayments" xlink:type="locator" xlink:label="dtil_DevelopmentAndCommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_DevelopmentAndCommercialMilestonePayments" xlink:to="dtil_DevelopmentAndCommercialMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_ReceivableFromResearchFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from research funding</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ReceivableFromResearchFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivable From Research Funding</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ResearchFundingPaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research funding payment term</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_ResearchFundingPaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Funding Payment Term</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_DevelopmentAndCommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Commercial Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Semi-annual research funding payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire In Process Research And Development</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SalesMilestonePaymentsToCollaborators" xlink:type="locator" xlink:label="dtil_SalesMilestonePaymentsToCollaborators" />
    <link:label xml:lang="en-US" xlink:label="dtil_SalesMilestonePaymentsToCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone payments to collaborators.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_SalesMilestonePaymentsToCollaborators" xlink:to="dtil_SalesMilestonePaymentsToCollaborators_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PaymentToCollaboratorForResearchFunding" xlink:type="locator" xlink:label="dtil_PaymentToCollaboratorForResearchFunding" />
    <link:label xml:lang="en-US" xlink:label="dtil_PaymentToCollaboratorForResearchFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment to collaborator for research funding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_PaymentToCollaboratorForResearchFunding" xlink:to="dtil_PaymentToCollaboratorForResearchFunding_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OptionToPayLicenseFee" xlink:type="locator" xlink:label="dtil_OptionToPayLicenseFee" />
    <link:label xml:lang="en-US" xlink:label="dtil_OptionToPayLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to pay license fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_OptionToPayLicenseFee" xlink:to="dtil_OptionToPayLicenseFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_SalesMilestonePaymentsToCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development or sales-based milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_SalesMilestonePaymentsToCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Payments To Collaborators</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PaymentToCollaboratorForResearchFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to collaborator for research funding</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_PaymentToCollaboratorForResearchFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Collaborator For Research Funding</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OptionToPayLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to pay license fee for additional patent rights</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_OptionToPayLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option To Pay License Fee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reportable Segments</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CorporateGeneralAndAdministrativeCashExpenditures" xlink:type="locator" xlink:label="dtil_CorporateGeneralAndAdministrativeCashExpenditures" />
    <link:label xml:lang="en-US" xlink:label="dtil_CorporateGeneralAndAdministrativeCashExpenditures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate general and administrative cash expenditures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_CorporateGeneralAndAdministrativeCashExpenditures" xlink:to="dtil_CorporateGeneralAndAdministrativeCashExpenditures_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" xlink:type="locator" xlink:label="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" />
    <link:label xml:lang="en-US" xlink:label="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to reconcile cash expenditures to GAAP expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" xlink:to="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses_lbl" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:type="locator" xlink:label="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to reconcile segment operating loss to consolidated loss from operations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MaterialReconcilingItemsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reconciling Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaterialReconcilingItemsMember" xlink:to="us-gaap_MaterialReconcilingItemsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MaterialReconcilingItemsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Material Reconciling Items [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Business Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment [Domain]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TherapeuticsSegmentMember" xlink:type="locator" xlink:label="dtil_TherapeuticsSegmentMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_TherapeuticsSegmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Therapeutics segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_TherapeuticsSegmentMember" xlink:to="dtil_TherapeuticsSegmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_TherapeuticsSegmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Therapeutics</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_TherapeuticsSegmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Therapeutics Segment [Member]</link:label>
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FoodSegmentMember" xlink:type="locator" xlink:label="dtil_FoodSegmentMember" />
    <link:label xml:lang="en-US" xlink:label="dtil_FoodSegmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Food Segment [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dtil_FoodSegmentMember" xlink:to="dtil_FoodSegmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="dtil_FoodSegmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Food</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_FoodSegmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Food Segment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total segment operational cash expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total allocation of centralized research and development operational cash expenditures</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile segment operating loss to consolidated loss from operations:</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Segment Operating Loss To Consolidated Loss From Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CorporateGeneralAndAdministrativeCashExpenditures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Corporate general and administrative cash expenditures</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_CorporateGeneralAndAdministrativeCashExpenditures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate General And Administrative Cash Expenditures</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest income received</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of assets</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile cash expenditures to GAAP expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Cash Expenditures To G A A P Expenses</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>62
<FILENAME>dtil-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-03-10T02:29:53.6254104+00:00 -->
<!-- Version            : 5.0.1.369 -->
<!-- Package ID         : 110b6502c8774be1969d6e34eb8cea58 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/role/TemplateLink" xlink:href="dtil-20191231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="dtil-20191231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="dtil_AccruedClinicalAndResearchAndDevelopmentExpenses" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotePayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="dtil_ChangeInFairValueOfConvertibleNotePayable" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" xlink:type="locator" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" xlink:type="locator" xlink:label="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" xlink:type="locator" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" xlink:type="locator" xlink:label="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="dtil-20191231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockIssuedOnConversionOfConvertibleNotes" xlink:type="locator" xlink:label="dtil_CommonStockIssuedOnConversionOfConvertibleNotes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" xlink:type="locator" xlink:label="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotesPayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotesPayable" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NonCashInterestExpense" xlink:type="locator" xlink:label="dtil_NonCashInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProfitLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="dtil_NonCashInterestExpense" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="dtil_ChangeInFairValueOfConvertibleNotesPayable" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="dtil_CommonStockIssuedOnConversionOfConvertibleNotes" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftware" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftware" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftware">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssets" xlink:href="dtil-20191231.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="dtil-20191231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlan" xlink:href="dtil-20191231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="dtil-20191231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="dtil-20191231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebt" xlink:href="dtil-20191231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="dtil-20191231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="dtil-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReporting" xlink:href="dtil-20191231.xsd#Role_DisclosureSegmentReporting" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReporting">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockValuationPolicyPolicyTextBlock" xlink:type="locator" xlink:label="dtil_CommonStockValuationPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dtil_CommonStockValuationPolicyPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareTables" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftwareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="dtil-20191231.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="dtil-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="dtil-20191231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="dtil-20191231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="dtil-20191231.xsd#Role_DisclosureSegmentReportingTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_li0l2" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonStockNotHeldByNonAffiliates" xlink:type="locator" xlink:label="dtil_CommonStockNotHeldByNonAffiliates" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IssuanceOfNonconvertibleDebt" xlink:type="locator" xlink:label="dtil_IssuanceOfNonconvertibleDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfDeferredRevenue" xlink:type="locator" xlink:label="dtil_PercentageOfDeferredRevenue" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfRevenue" xlink:type="locator" xlink:label="dtil_PercentageOfRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UnderwritingDiscountsAndCommission" xlink:type="locator" xlink:label="dtil_UnderwritingDiscountsAndCommission" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AmendedNameOfIncorporation" xlink:type="locator" xlink:label="dtil_AmendedNameOfIncorporation" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AmendedDateOfIncorporation" xlink:type="locator" xlink:label="dtil_AmendedDateOfIncorporation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentMember" xlink:type="locator" xlink:label="dtil_DevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SubsidiaryIssuerMember" xlink:type="locator" xlink:label="srt_SubsidiaryIssuerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PrecisionBioSciencesUKLimitedMember" xlink:type="locator" xlink:label="dtil_PrecisionBioSciencesUKLimitedMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_EloLifeSystemsAustraliaPtyLtdMember" xlink:type="locator" xlink:label="dtil_EloLifeSystemsAustraliaPtyLtdMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PrecisionPlantSciencesIncMember" xlink:type="locator" xlink:label="dtil_PrecisionPlantSciencesIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="dtil_PrecisionPlantSciencesIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="dtil_EloLifeSystemsAustraliaPtyLtdMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="dtil_PrecisionBioSciencesUKLimitedMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiaryIssuerMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dtil_DevelopmentMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_AmendedDateOfIncorporation" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_AmendedNameOfIncorporation" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_UnderwritingDiscountsAndCommission" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_PercentageOfRevenue" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_PercentageOfDeferredRevenue" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_IssuanceOfNonconvertibleDebt" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dtil_CommonStockNotHeldByNonAffiliates" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_li0l2" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:type="locator" xlink:label="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="locator" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_ProfitLoss" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="dtil_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dtil_LaboratoryEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" xlink:type="locator" xlink:label="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC" xlink:type="locator" xlink:label="stpr_NC" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DurhamMember" xlink:type="locator" xlink:label="dtil_DurhamMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ManufacturingCenterForAdvancedTherapeuticsMember" xlink:type="locator" xlink:label="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dtil_ManufacturingCenterForAdvancedTherapeuticsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="dtil_DurhamMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NC" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FiniteLivedIntangibleAssetsImpairment" xlink:type="locator" xlink:label="dtil_FiniteLivedIntangibleAssetsImpairment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="dtil_FiniteLivedIntangibleAssetsImpairment" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PaymentOfNonRefundableLicenseFees" xlink:type="locator" xlink:label="dtil_PaymentOfNonRefundableLicenseFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dtil_PaymentOfNonRefundableLicenseFees" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommonAndPreferredStocksSharesAuthorized" xlink:type="locator" xlink:label="dtil_CommonAndPreferredStocksSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dtil_SeriesAAndSeriesBConvertiblePreferredStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="dtil_CommonAndPreferredStocksSharesAuthorized" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OfferingPeriodEndDate" xlink:type="locator" xlink:label="dtil_OfferingPeriodEndDate" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OfferingPeriodCommencedDate" xlink:type="locator" xlink:label="dtil_OfferingPeriodCommencedDate" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:type="locator" xlink:label="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandFifteenStockIncentivePlanMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TwoThousandSixStockIncentivePlanMember" xlink:type="locator" xlink:label="dtil_TwoThousandSixStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandSixStockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandFifteenStockIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandNineteenIncentiveAwardPlanMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_MaximumSharesAllowedToBeIssuedUnderESPP" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_OfferingPeriodCommencedDate" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="dtil_OfferingPeriodEndDate" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" xlink:type="locator" xlink:label="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfActivityOfOptionPlansDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationSummaryOfActivityOfOptionPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfActivityOfOptionPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionsGrantedUnderStockOptionPlansAreVestedOrExpectedToVestDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionsGrantedUnderStockOptionPlansAreVestedOrExpectedToVestDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionsGrantedUnderStockOptionPlansAreVestedOrExpectedToVestDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeElevenMember" xlink:type="locator" xlink:label="dtil_PriceRangeElevenMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeTenMember" xlink:type="locator" xlink:label="dtil_PriceRangeTenMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeNineMember" xlink:type="locator" xlink:label="dtil_PriceRangeNineMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeEightMember" xlink:type="locator" xlink:label="dtil_PriceRangeEightMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeSevenMember" xlink:type="locator" xlink:label="dtil_PriceRangeSevenMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeSixMember" xlink:type="locator" xlink:label="dtil_PriceRangeSixMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeFiveMember" xlink:type="locator" xlink:label="dtil_PriceRangeFiveMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeFourMember" xlink:type="locator" xlink:label="dtil_PriceRangeFourMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeThreeMember" xlink:type="locator" xlink:label="dtil_PriceRangeThreeMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeTwoMember" xlink:type="locator" xlink:label="dtil_PriceRangeTwoMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PriceRangeOneMember" xlink:type="locator" xlink:label="dtil_PriceRangeOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeTwoMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeThreeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeFourMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeFiveMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeSixMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeSevenMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeEightMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeNineMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeTenMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dtil_PriceRangeElevenMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="dtil_AgreementTerminationNoticePeriod" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="dtil_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommitmentAndContingenciesTable" xlink:type="locator" xlink:label="dtil_CommitmentAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="dtil_CommitmentAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_CommitmentAndContingenciesTable" xlink:to="dtil_CommitmentsAndContingenciesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_CommitmentsAndContingenciesLineItems" xlink:to="dtil_AgreementTerminationNoticePeriod" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" xlink:type="locator" xlink:label="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_MaximumAmountToMaintainWithNonAffiliatedBank" xlink:type="locator" xlink:label="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:type="locator" xlink:label="us-gaap_CompensatingBalanceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" xlink:type="locator" xlink:label="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ChangeInFairValueOfConvertibleNotePayable" xlink:type="locator" xlink:label="dtil_ChangeInFairValueOfConvertibleNotePayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:type="locator" xlink:label="us-gaap_LongTermDebtFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" xlink:type="locator" xlink:label="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PacificWesternLoanAgreementMember" xlink:type="locator" xlink:label="dtil_PacificWesternLoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" xlink:type="locator" xlink:label="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" xlink:type="locator" xlink:label="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:type="locator" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dtil_RevolvingLineIfDailyBalanceIsMaintainedMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_PacificWesternLoanAgreementMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_ChangeInFairValueOfConvertibleNotePayable" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CompensatingBalanceAmount" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="dtil_MaximumAmountToMaintainWithNonAffiliatedBank" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" xlink:type="locator" xlink:label="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" xlink:type="locator" xlink:label="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarnings" xlink:type="locator" xlink:label="us-gaap_UndistributedEarnings" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FederalContributionCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="dtil_FederalContributionCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FederalContributionCarryforwards" xlink:type="locator" xlink:label="dtil_FederalContributionCarryforwards" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TaxCreditCarryForwardsExpirationBeginningYear" xlink:type="locator" xlink:label="dtil_TaxCreditCarryForwardsExpirationBeginningYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="dtil_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" xlink:type="locator" xlink:label="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OperatingLossCarryForwardsSubjectToExpiration" xlink:type="locator" xlink:label="dtil_OperatingLossCarryForwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="dtil_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OrphanDrugTaxCreditCarryforwardMember" xlink:type="locator" xlink:label="dtil_OrphanDrugTaxCreditCarryforwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="dtil_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="dtil_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dtil_OrphanDrugTaxCreditCarryforwardMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureTable" xlink:to="dtil_IncomeTaxDisclosureLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_OperatingLossCarryForwardsSubjectToExpiration" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_OperatingLossCarryforwardsExpirationYear" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_TaxCreditCarryForwardsExpirationBeginningYear" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_FederalContributionCarryforwards" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_FederalContributionCarryforwardsExpirationBeginningYear" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UndistributedEarnings" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_IncomeTaxDisclosureLineItems" xlink:to="dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_RepurchaseAgreementsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_OptionToPayLicenseFee" xlink:type="locator" xlink:label="dtil_OptionToPayLicenseFee" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_PaymentToCollaboratorForResearchFunding" xlink:type="locator" xlink:label="dtil_PaymentToCollaboratorForResearchFunding" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SalesMilestonePaymentsToCollaborators" xlink:type="locator" xlink:label="dtil_SalesMilestonePaymentsToCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentAndCommercialMilestonePayments" xlink:type="locator" xlink:label="dtil_DevelopmentAndCommercialMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ResearchFundingPaymentTerm" xlink:type="locator" xlink:label="dtil_ResearchFundingPaymentTerm" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ReceivableFromResearchFunding" xlink:type="locator" xlink:label="dtil_ReceivableFromResearchFunding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CommercialMilestonePayments" xlink:type="locator" xlink:label="dtil_CommercialMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentMilestonePayments" xlink:type="locator" xlink:label="dtil_DevelopmentMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AggregateMilestonePayments" xlink:type="locator" xlink:label="dtil_AggregateMilestonePayments" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" xlink:type="locator" xlink:label="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UpfrontPayment" xlink:type="locator" xlink:label="dtil_UpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_UniversityOfPennsylvaniaMember" xlink:type="locator" xlink:label="dtil_UniversityOfPennsylvaniaMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_GileadSciencesIncMember" xlink:type="locator" xlink:label="dtil_GileadSciencesIncMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CurrentLiabilitiesMember" xlink:type="locator" xlink:label="dtil_CurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ServierMember" xlink:type="locator" xlink:label="dtil_ServierMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_DevelopmentAndCommercialLicenseAgreementMember" xlink:type="locator" xlink:label="dtil_DevelopmentAndCommercialLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_DevelopmentAndCommercialLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_ServierMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="dtil_CurrentLiabilitiesMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_CollaborationAndLicenseAgreementMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_GileadSciencesIncMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dtil_SponsoredResearchCollaborationAndLicenseAgreementMember" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_UniversityOfPennsylvaniaMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_UpfrontPayment" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_AggregatePaymentOnCollaborationAgreementToBeReceived" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_AggregateMilestonePayments" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_DevelopmentMilestonePayments" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_CommercialMilestonePayments" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_ReceivableFromResearchFunding" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_ResearchFundingPaymentTerm" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_DevelopmentAndCommercialMilestonePayments" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_SalesMilestonePaymentsToCollaborators" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_PaymentToCollaboratorForResearchFunding" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dtil_OptionToPayLicenseFee" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1" xlink:href="dtil-20191231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_ServierMember" xlink:type="locator" xlink:label="dtil_ServierMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dtil_ServierMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" xlink:href="dtil-20191231.xsd#Role_DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails">
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" xlink:type="locator" xlink:label="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_CorporateGeneralAndAdministrativeCashExpenditures" xlink:type="locator" xlink:label="dtil_CorporateGeneralAndAdministrativeCashExpenditures" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:type="locator" xlink:label="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_FoodSegmentMember" xlink:type="locator" xlink:label="dtil_FoodSegmentMember" />
    <link:loc xlink:href="dtil-20191231.xsd#dtil_TherapeuticsSegmentMember" xlink:type="locator" xlink:label="dtil_TherapeuticsSegmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:type="locator" xlink:label="us-gaap_MaterialReconcilingItemsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_MaterialReconcilingItemsMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="dtil_TherapeuticsSegmentMember" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="dtil_FoodSegmentMember" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="dtil_CorporateGeneralAndAdministrativeCashExpenditures" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract" xlink:to="us-gaap_GainsLossesOnSalesOfAssets" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780530832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,358</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,185</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,172</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">573</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,736</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, noncurrent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax liability:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities, noncurrent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reasons for the difference between actual income tax benefit for the years ended December&#160;31, 2019 and December 31, 2018 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Pre-Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Pre-Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense at statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,505</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,668</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal tax benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,827</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(909</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and orphan drug credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,810</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,934</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(639</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,272</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (benefit) expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615791120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net, consisted of the following as of December&#160;31 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,831</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,831</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(281</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: impairments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,466</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778075280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,940<span></span>
</td>
<td class="nump">$ 2,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5,639<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,301<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792365904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Outstanding under the Stock Option Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="nump">8,919,116<span></span>
</td>
<td class="nump">7,763,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="nump">4,082,663<span></span>
</td>
<td class="nump">3,418,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeOneMember', window );">$0.01 - $0.04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="nump">1,385,203<span></span>
</td>
<td class="nump">1,397,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="nump">1,385,203<span></span>
</td>
<td class="nump">1,397,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeTwoMember', window );">$0.41 - $1.20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="nump">2,310,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">6 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="nump">1,721,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeThreeMember', window );">$7.74 - $9.46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit</a></td>
<td class="nump">$ 7.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit</a></td>
<td class="nump">$ 9.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="nump">1,266,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">9 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="nump">131,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeFourMember', window );">$10.17 - $13.80</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit</a></td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit</a></td>
<td class="nump">$ 13.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="nump">3,891,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">8 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="nump">844,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeFiveMember', window );">$14.91 - $16.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit</a></td>
<td class="nump">$ 14.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="nump">64,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">9 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeSixMember', window );">$ 0.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,440,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeSevenMember', window );">$1.18 - $1.20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,846,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeEightMember', window );">$ 8.99</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeNineMember', window );">$ 10.17</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeTenMember', window );">$ 11.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,070,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeElevenMember', window );">$ 13.20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dtil_PriceRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6647645264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details 1 ) - Servier - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-01-01<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 24, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue from upfront payment</a></td>
<td class="nump">$ 105.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Estimated period performance obligation</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dtil_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dtil_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787939312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance of net deferred tax assets</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_OperatingLossCarryforwardsExpirationYear', window );">Net Operating loss carry forwards expiration year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarnings', window );">Undistributed earnings</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod', window );">Ownership percentage change in outstanding common stock period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage in outstanding common stock</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense', window );">GILTI tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">101,300,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_OperatingLossCarryForwardsSubjectToExpiration', window );">Net operating loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear', window );">Net operating loss carry forward subject to expiration begin year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not subject to expiration</a></td>
<td class="nump">$ 81,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_FederalContributionCarryforwards', window );">Federal contribution carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_FederalContributionCarryforwardsExpirationBeginningYear', window );">Federal contribution expiration beginning year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_FederalContributionCarryforwards', window );">Federal contribution carryforwards</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_TaxCreditCarryForwardsExpirationBeginningYear', window );">Tax credit carry forwards expiration beginning year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Orphan Drug Tax Credit Carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_TaxCreditCarryForwardsExpirationBeginningYear', window );">Tax credit carry forwards expiration beginning year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 101,700,000<span></span>
</td>
<td class="nump">$ 39,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_TaxCreditCarryForwardsExpirationBeginningYear', window );">Tax credit carry forwards expiration beginning year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_FederalContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_FederalContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_FederalContributionCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal contribution carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_FederalContributionCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carry forward subject to expiration begin year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_NetOperatingLossCarryForwardSubjectToExpirationBeginYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards, not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_NetOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_OperatingLossCarryForwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_OperatingLossCarryForwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage change in outstanding common stock period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_OwnershipPercentageChangeInOutstandingCommonStockPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_TaxCreditCarryForwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_TaxCreditCarryForwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act of 2017 global intangible low taxed income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780132-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2814-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2793-109256<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dtil_OrphanDrugTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dtil_OrphanDrugTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775805264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.000005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">51,965,708<span></span>
</td>
<td class="nump">16,717,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">51,155,236<span></span>
</td>
<td class="nump">15,906,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,650,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,956,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,956,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,956,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780544832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc. (the &#8220;Company&#8221;) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is focused on utilizing its proprietary genome editing platform to help overcome cancers, cure genetic diseases and enable the development of safer, more productive food sources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc.&#160;&#160;Elo Life Systems Australia Pty Ltd was incorporated on May 29, 2018 as a 100% owned subsidiary of Elo Life Systems, Inc.&#160;&#160;The Company&#8217;s 100% owned subsidiary, Precision BioSciences UK Limited, was incorporated on June 17, 2019.&#160;&#160;The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company&#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, the Company completed its initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold 9,085,000 shares of its common stock at a public offering price of $16.00 per share and received approximately $130.5 million in net proceeds, after deducting underwriting discounts and commission of approximately $10.2 million and issuance costs of approximately $4.6 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO, on March 15, 2019 the Company effected a reverse split of shares of the Company&#8217;s common stock on a 1-for-2.134686 basis (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company&#8217;s Series A and Series B preferred stock.&#160;&#160;Accordingly, all common shares, stock option shares, and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this Reverse Stock Split and adjustment of the preferred stock conversion ratios.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized common shares were not affected by the Reverse Stock Split.&#160;&#160;Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 22,301,190 shares of common stock at the applicable ratio then in effect and the outstanding convertible notes payable, including accrued interest, were settled into 2,921,461 shares of common stock. Subsequent to the closing of the IPO, there were no shares of Series A or Series B convertible preferred stock or convertible notes payable outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ from those estimates. Significant estimates include recording revenue for performance obligations recognized over time, determination of the fair value of share-based compensation grants and estimating services expended by third-party service providers used to recognize research and development expense. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements have been prepared in accordance with GAAP. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. During the year ended December&#160;31, 2019, the Company incurred a net loss of $92.9&#160;million and, as of December&#160;31, 2019, has an accumulated deficit of $177.1 million. The Company has financed operations primarily through its IPO, private placements of convertible preferred stock and convertible debt and with proceeds from its development and commercial license agreement with Les Laboratoires Servier, (&#8220;Servier&#8221;) and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) (see Note 12). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that existing cash and cash equivalents will allow the Company to continue its operations into 2021. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the presentation of amounts in our Consolidated Balance Sheet as of December&#160;31, 2019 to conform to the prior year presentation. Specifically, certain current liabilities were reclassified from accrued expenses and other current liabilities and are now presented separately on our Consolidated Balance Sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2019 and December 31, 2018, the Company held cash equivalents composed of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. All of the Company&#8217;s cash and cash equivalents are held at financial institutions that management believes to be of high credit quality. The Company may maintain cash deposits in financial institutions in excess of government insured limits. The Company regularly invests excess cash deposits in money market funds and repurchase agreements. The Company believes that the credit risk arising from the holdings of these financial instruments is mitigated by the fact that these securities are of short duration, government backed and of high credit rating. The Company has not experienced any losses on cash and cash equivalents to date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from two development and license agreements accounted for 60% and 33% of revenue during 2019 and 34% and 53% of revenue during 2018, as well as 2% and 98% of deferred revenue as of December&#160;31, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Equity Offering Costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes incremental legal, professional accounting and other third-party fees directly associated with the Company&#8217;s planned equity offerings as other current assets until the equity offering is consummated. After consummation, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital. If the equity offering is not completed, any costs deferred will be expensed immediately. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, Equipment and Software </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software are stated at cost, net of depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciation and amortization periods for the Company&#8217;s significant property, equipment and software categories are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:307.45pt;"></td>
<td style="width:232.55pt;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 to 7 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser&#160;of&#160;remaining&#160;lease&#160;term&#160;or&#160;useful&#160;life</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repairs and maintenance are charged to operations as incurred, and expenditures for additions and improvements that extend the useful life of the asset are capitalized. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets primarily include licenses and patents. The Company capitalizes license fees paid to acquire access to proprietary technology if the technology is expected to have alternative future use in multiple research and development projects. The cost of licensed technology rights is amortized using the straight-line method over the estimated useful life of the technology. If the access to use the technology rights is one year or less, the cost is recorded as a prepaid expense and amortized over the period identified in the agreement. Amortization expense for licensed technology and capitalized patent costs is included in research and development expenses within the accompanying consolidated statement of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, such as property, equipment and software and intangible assets, subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is assessed when future undiscounted cash flows are less than the assets&#8217; carrying value and recognized when the carrying value of the asset exceeds fair value. Fair value is calculated by estimating the discounted future cash flows expected to be generated by the asset as well as other valuation techniques. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value of the asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition for Contracts with Customers</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenues are generated primarily through collaborative research, license, development and commercialization agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;), using the modified retrospective transition method. Under this method, results for reporting periods beginning on January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, <font style="font-style:italic;">Revenue Recognition</font> (&#8220;ASC 605&#8221;). The Company applied the modified retrospective transition method to contracts that were not completed as of January 1, 2019. For the year ended December 31, 2019, the Company reduced revenue recognition by $1.4 million for changes in total estimated time to be incurred in the future to satisfy the performance obligation. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options.&#160;&#160;The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue.&#160;&#160;Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue &#8211; noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the other current assets line item in the accompanying consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments <font style="font-style:normal;">&#8211;</font> <font style="font-style:normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties <font style="font-style:normal;">&#8211;</font> <font style="font-style:normal;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation linked to some or all of the royalty has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Significant Financing Component <font style="font-style:normal;">&#8211; In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.&#160;&#160;The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&#160;&#160;The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements <font style="font-style:normal;">&#8211; The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company&#8217;s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaboration arrangements to assess whether the collaboration agreements are within the scope of accounting standards codification (&#8220;ASC&#8221;) ASC 808, <font style="font-style:italic;">Collaborative Arrangements</font> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&#160;&#160;For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional discussion of accounting for collaboration revenues, see Note 12, &#8220;Collaboration and license agreements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities including salaries, benefits, share-based compensation, allocations for rent and facility costs, depreciation, preclinical manufacturing expenses, costs of services provided by contract research organizations (&#8220;CROs&#8221;) in connection with preclinical trials and contract manufacturing organizations (&#8220;CMOs&#8221;) engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate accrued research and development expenses resulting from its obligations under contracts with CROs, CMOs, research organizations, service providers, vendors and consultants in connection with research and development activities. The financial terms of these contracts are subject to negotiations and vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate research and development expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#8217;s estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to prior estimates of accrued research and development expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Valuation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted prior to the IPO, the Company considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock was determined based upon a variety of factors, including the illiquid nature of the common stock, the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2019 and December 31, 2018, there was no difference between net loss and comprehensive loss in the accompanying consolidated financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2019 and December 31, 2018 since all potential shares of common stock are anti-dilutive as a result of the net loss. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-Based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all share-based compensation, including stock options and the employee stock purchase plan at fair value and recognizes compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each equity grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the Company&#8217;s expected dividend yield. As the Company has limited trading history, expected volatility is estimated based on the historical volatility of publicly traded peer companies and the Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of our traded share price. The expected term of the options has been determined utilizing a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date.&nbsp;&nbsp;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined based on the temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than the enactment of changes in the tax law or rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting Standards Updates</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section&#160;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The JOBS Act also exempts the Company from having to provide an auditor attestation of internal controls over financial reporting under Sarbanes-Oxley Act Section&#160;404(b). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will remain an &#8220;emerging growth company&#8221; until the earliest of (i)&#160;December 31, 2024, (ii) the last day of the fiscal year in which it has total annual gross revenues of $1.07&#160;billion or more, (iii)&#160;the date on which it has issued more than $1.0&#160;billion in nonconvertible debt during the previous three years or (iv)&#160;the date on which it is deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), which generally is when it has more than $700&#160;million in market value of its stock held by non-affiliates, has been a public company for at least 12 months and have filed one annual report on Form 10-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company&#8217;s collaboration agreements under prior revenue recognition guidance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,807</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,190</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(997</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,187</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,486</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,895</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,067</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,477</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statement of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Cash Flows for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption&#160;of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,866</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,453</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="eolPage14"></a>During the year ended December 31, 2019, the Company recorded $9.4 million in revenue that was included in deferred revenue as of December 31, 2018.&#160;&#160;The most significant change to the Company&#8217;s revenue recognition as a result of the adoption of ASC 606 relates to the accounting for certain option fees and milestone payments in determining the transaction price (step (iii)), and the revenue recognition pattern (step (v)) related to the Company&#8217;s development and commercial license agreement with Servier. Under ASC 605, the option fees payable by the Company to exercise the 50/50 co-development and co-promotion option was accounted for as a reduction in the arrangement consideration, and certain development milestones that may be earned for early-stage pre-IND development milestones were included in the arrangement consideration as the early-stage pre-IND development milestones were deemed to be non-substantive. Under ASC 606, the option fees were not accounted for as a reduction in the transaction price as the option fees are contingent upon Servier&#8217;s<a name="eolPage14"></a> exercise of its commercial <a name="eolPage14"></a>(customer) options on licensed product candidates, and the milestone payments were excluded from the transaction price based on the assessment of the most likely amount and application of the variable consideration constraint, since the milestones relate to successful achievement of certain developmental goals, which may not be achieved. In addition, under ASC 605, the Company recognized revenue on a straight&#8209;line basis over the period the Company expected to complete its obligations. Under ASC 606, the Company recognizes revenue based on the proportional performance of the services related to the performance obligation expected. For further discussion of the adoption of ASC 606 see Note 12, &#8220;Collaboration and license agreements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DTIL_10Q_20190930_HTM_LD_TABLE_29"></a>In June 2018, the FASB issued ASU 2018-07,&#160;<font style="font-style:italic;">Compensation-Stock Compensation Improvements to Nonemployee Share-Based Payment Accounting&#160;</font>(&#8220;ASU 2018-07&#8221;). ASU 2018-07 substantially aligns accounting for share-based payments to employees and non-employees. This ASU became effective for annual periods beginning after December 15, 2018 including interim periods within that period, and early adoption is permitted.&nbsp;&nbsp;The Company adopted ASU 2018-07 effective January 1, 2019.&nbsp;&nbsp;The adoption of the standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13,&#160;<font style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen</font>t (&#8220;ASU 2018-13&#8221;). ASU 2018-13 is intended to improve the effectiveness of disclosures in the notes to financial statements related to fair value measurements in Topic 820. This ASU will become effective for annual periods beginning after December 15, 2019, including interim periods within that period, and early adoption is permitted.&#160;The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18, <font style="font-style:italic;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and ASC 606</font> (&#8220;ASU 2018-18&#8221;). The amendments in ASU 2018-18 make targeted improvements to GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASU 2018-18 was aligned with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606.&#160;&#160;ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of ASC 606. The Company adopted this guidance effective January 1, 2019 with its initial application of ASC 606. The adoption of the standard did not have an impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the FASB issued ASU 2019-10, <font style="font-style:italic;">Financial Instruments &#8212; Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) </font>(&#8220;ASU 2019-10&#8221;)<font style="font-style:italic;">,</font> which provides a one-year deferral of the effective dates of ASU No.&#160;2016-02, <font style="font-style:italic;">Leases (Topic 842)</font> (&#8220;ASU 2016-02&#8221;), issued in February 2016.&nbsp;&nbsp;ASU 2016-02 was issued in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term.&nbsp;&nbsp;ASU 2019-10 is effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and expects to have an increase in total assets and total liabilities as a result of adopting the lease standard.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards updates issued, but not effective until after December 31, 2019, are not expected to have a material effect on the Company&#8217;s consolidated financial position, statements of operations or cash flows.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778354464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current liabilities</a></td>
<td class="nump">$ 16,486<span></span>
</td>
<td class="nump">$ 8,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - noncurrent liabilities</a></td>
<td class="nump">65,895<span></span>
</td>
<td class="nump">82,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(177,067)<span></span>
</td>
<td class="num">(84,190)<span></span>
</td>
<td class="num">$ (85,187)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current liabilities</a></td>
<td class="num">(8,017)<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - noncurrent liabilities</a></td>
<td class="nump">11,427<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,410)<span></span>
</td>
<td class="num">(997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Balances without adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current liabilities</a></td>
<td class="nump">8,469<span></span>
</td>
<td class="nump">8,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue - noncurrent liabilities</a></td>
<td class="nump">77,322<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (180,477)<span></span>
</td>
<td class="num">$ (85,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777640320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 5,317<span></span>
</td>
<td class="nump">$ 2,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=dtil_DurhamMember', window );">Leased Facilities in Durham</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_ManufacturingCenterForAdvancedTherapeuticsMember', window );">MCAT | North Carolina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember', window );">Property, Equipment, Leasehold Improvements and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=dtil_DurhamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=dtil_DurhamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_ManufacturingCenterForAdvancedTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_ManufacturingCenterForAdvancedTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_PropertyEquipmentLeaseholdImprovementsAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780476512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">SEGMENT REPORTING</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has developed a genome editing platform and performed related research for human therapeutic and agricultural applications. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) evaluates the Company&#8217;s financial performance based on two reportable segments: Therapeutics and Food. The Therapeutics segment is focused on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment is focused on applying ARCUS to develop food and nutrition products through collaboration agreements with consumer-facing companies. The CODM reviews segment performance and allocates resources based upon segment revenue and segment operating loss of the Therapeutics and Food reportable segments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment operating loss is derived by deducting operational cash expenditures, net, from GAAP revenue. Operational cash expenditures are cash disbursements made that are directly attributable to the reportable segment (including directly attributable research and development and property, equipment, and software expenditures).&#160;&#160;For the year ended December 31, 2018, the Company allocated centralized research and development expenditures for early stage research, nuclease development and the purchase of general laboratory supplies to the Therapeutics and Food segments based on headcount.&#160;&#160;In January 2019, the Food segment moved into a new leased facility in Durham, North Carolina. The Company has determined that the Food segment is no longer deriving benefit from the Company&#8217;s centralized research and development expenditures, thus all these expenditures are allocated to the Therapeutics segment for the year ended December 31, 2019. The reportable segment and centralized research and development operational cash expenditures include cash disbursements for compensation, laboratory supplies, purchases of property, equipment, and software and procuring services from CROs, CMOs, and research organizations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain cost items are not allocated to the Company&#8217;s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company&#8217;s executive, business development, finance, operations, human resources and legal functions. The Company does not allocate non-cash income statement amounts to its reportable segments, such as share based compensation, depreciation and amortization, intangible asset impairment charges, non-cash interest expense and losses on the disposal of assets. When reconciling segment operating loss to consolidated loss from operations, the Company makes an adjustment to convert the cash expenditures to the accrual basis to reflect GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="eolPage22"></a><a name="eolPage22"></a>All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.<font style="font-size:12pt;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presented below is the financial information with respect to the Company&#8217;s reportable segments</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,632</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,523</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,606</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,360</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operational cash expenditures:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,984</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,125</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operational cash expenditures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,170</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation of centralized research and development operational cash expenditures:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,605</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total allocation of centralized research and development operational</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash expenditures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operating loss:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,378</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,666</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operating loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,805</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,793</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile segment operating loss to consolidated loss from operations:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate general and administrative cash expenditures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,892</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income received</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,267</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,317</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,354</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile cash expenditures to GAAP expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,716</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total consolidated loss from operations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,912</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780577504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">DEBT</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:-13.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2019, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of $39.6 million of convertible notes payable (the &#8220;2019 Notes&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Notes accrued interest at a rate of 6% per annum.&#160;&#160;The 2019 Notes were settled in 2,921,461 shares of common stock in connection with the closing of the Company&#8217;s IPO (see Note 1) at a settlement price of $13.60 per share (equal to 85% of the IPO price per share).&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On issuance, the Company elected to account for the 2019 Notes at fair value with any changes in fair value being recognized through the consolidated statements of operations until the 2019 Notes were settled. The fair value of the 2019 Notes was determined to be $39.6 million on issuance and $49.4 million as of April 1, 2019, the settlement date. For the year ended December 31, 2019, the Company recognized $9.8 million of expense as changes in fair value and $0.2 million of interest expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revolving Line</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a loan and security agreement with Pacific Western Bank (the &#8220;Pacific Western Loan Agreement&#8221;) pursuant to which the Company may request advances on a revolving line of credit of up to an aggregate principal of $50.0 million (the &#8220;Revolving Line&#8221;). The maturity date of the Revolving Line is May 15, 2022.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Revolving Line bears interest at an annual rate equal to the greater of (i) 1.25% below the prime rate then in effect, or (ii) 4.25% at all times when the Company maintains a daily balance of cash in its demand deposit accounts at Pacific Western Bank of at least $25.0 million, and the greater of (i) 0.25% above the prime rate then in effect; or (ii) 5.75% at all times when the Company does not maintain a daily balance of cash in demand deposit accounts at Pacific Western Bank of at least $25.0 million.&#160;&#160;The Pacific Western Loan Agreement requires that the Company pay a quarterly fee in an amount equal to 0.50% per annum of the unused portion of the Revolving Line. The unused fee shall be waived for any quarter the Company maintains a daily balance in its demand deposit accounts of at least $25.0 million. If the Revolving Line is terminated prior to the maturity date, the Company is required to pay an early termination fee equal to 1.0% of the Revolving Line. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted Pacific Western Bank a security interest in substantially all of its assets, excluding any of the intellectual property now or hereafter owned, but including any rights to payment from the sale or licensing of any such intellectual property. The Company is prohibited from paying cash dividends without the prior written consent of Pacific Western Bank. The Pacific Western Loan Agreement includes customary representations, warranties and covenants (affirmative and negative) and was amended in December 2019 to allow the Company to maintain a bank account with a non-affiliated bank in the United Kingdom provided that the account balance does not exceed 1.5 million GBP or its U.S. dollar equivalent at any time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no borrowings, and the Company was in compliance with its financial covenants, under the Pacific Western Loan Agreement as of December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780527712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">SHARE-BASED COMPENSATION</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:-13.33%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of its equity incentive award plans, the Company&#8217;s board of directors may grant equity or equity-based awards to employees, directors and other service providers. The Company granted stock options under the 2006 Stock Incentive Plan (&#8220;2006 Plan&#8221;) until April 2015 when the 2015 Stock Incentive Plan (&#8220;2015 Plan&#8221;) was adopted. The 2006 Plan expired in 2016 and there are no remaining shares available to be granted under the 2006 Plan. There were 1,385,203 stock options outstanding under the 2006 Plan as of December 31, 2019.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of the 2015 Plan, there were 5,270,095 shares of common stock reserved for issuance. In May 2018, the Company amended the 2015 Plan to increase the number of shares reserved for issuance to 8,211,980. The 2015 Plan had 5,462,954 stock options outstanding as of December 31, 2019. The Company&#8217;s board of directors determined the terms of stock options granted under the 2015 Plan, including option exercise prices and vesting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2019, the Company&#8217;s board of directors adopted, and, on or about March 14, 2019 the Company&#8217;s stockholders approved, the Precision BioSciences, Inc. 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) and the 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;), both of which became effective on March 27, 2019. On March 27, 2019, the Company ceased granting new awards under the 2015 Plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units and other share-based awards initially equal to 4,750,000 shares of common stock.&#160;&#160;The 2019 Plan provides for an annual increase to the number of shares of common stock available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the board of directors.&nbsp;&nbsp;The number of shares available for issuance under the 2019 Plan was increased by 2,046,209 on January 1, 2020 pursuant to this provision. Any shares that are subject to awards outstanding under the Company&#8217;s 2006 Plan and 2015 Plan as of the effective date of the 2019 Plan that expire, lapse, or are terminated, exchanged for cash, surrendered, repurchased, or canceled without having been fully exercised or forfeited, to the extent so unused, will become available for award grants under the 2019 Plan.&#160;&#160;The 2019 Plan had 2,070,959 stock options outstanding as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Up to 525,000 shares of the Company&#8217;s common stock were initially reserved for issuance under the 2019 ESPP.&nbsp;&nbsp;The 2019 ESPP provides for an annual increase to the number of shares available for issuance on the first day of each calendar year beginning January 1, 2020 and ending on and including January 1, 2029 by an amount equal to the lesser of (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by our board of directors.&nbsp;&nbsp;The number of shares available for issuance under the 2019 ESPP was increased by 511,552 shares on January 1, 2020 pursuant to this provision. No more than 5,250,000 shares of our common stock may be issued under our 2019 ESPP. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date.&#160;&#160;The first ESPP offering period commenced on October 21, 2019 and ended on February 29, 2020;&#160;44,197 shares were issued with respect to this offering period.&nbsp;&nbsp;The next ESPP offering period commenced on March 1, 2020 and will end on August 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,431</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonemployee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense related to stock options is included in the following line items in the consolidated statements of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,639</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,817</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the appropriate fair value model to measure the fair value of the stock option grants on the date of grant and the related assumptions requires judgment. The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average expected stock price volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.25</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term of options (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.61</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value per option</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term represents the average time that stock options that vest are expected to be outstanding.<font style="font-size:12pt;"> </font>The Company does not have sufficient history of exercising stock options to estimate the expected term of employee stock options and thus utilizes a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date. The risk-free rate is based on the United States Treasury yield curve during the expected life of the option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity in the Company&#8217;s stock option plans for the years ended December 31, 2019 and December 31, 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,416,025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,160,097</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.66</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(220,308</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.78</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(592,350</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,647,236</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(940,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(550,644</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of stock options exercised was $10.6 million and $2.7 million during the years ended December 31, 2019 and December 31, 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was approximately $29.0 million of total unrecognized compensation cost related to unvested stock options as of December 31, 2019, which is expected to be recognized over a weighted-average period of 2.9 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information about stock options granted under the stock option plans which are vested or expected to vest as of December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be exercisable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.19</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,082,663</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.08</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be exercisable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information about stock options outstanding under the stock option plans for the years ending December 31, 2019 and December 31, 2018, respectively: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.01 - $0.04</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.41 - $1.20</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721,811</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.74 - $9.46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266,454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.44</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,644</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.17 - $13.80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,891,922</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.96</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">844,005</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14.91 - $16.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,544</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,082,663</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.01 - $0.04</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440,920</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,166,591</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.18 - $1.20</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846,255</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748,922</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,376</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,408</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,708</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.98</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,070,029</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.78</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,193</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.20</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428,626</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787586272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 180,886<span></span>
</td>
<td class="nump">$ 103,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">9,497<span></span>
</td>
<td class="nump">8,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,324<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">193,672<span></span>
</td>
<td class="nump">115,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment, and software&#8212;net</a></td>
<td class="nump">39,571<span></span>
</td>
<td class="nump">21,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets&#8212;net</a></td>
<td class="nump">1,432<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">235,233<span></span>
</td>
<td class="nump">138,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">2,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,425<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AccruedClinicalAndResearchAndDevelopmentExpenses', window );">Accrued clinical and research and development expenses</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued other expenses and other current liabilities</a></td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,486<span></span>
</td>
<td class="nump">8,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,932<span></span>
</td>
<td class="nump">14,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue&#8212;noncurrent</a></td>
<td class="nump">65,895<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent&#8212;noncurrent</a></td>
<td class="nump">4,092<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">96,919<span></span>
</td>
<td class="nump">98,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">316,333<span></span>
</td>
<td class="nump">126,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(177,067)<span></span>
</td>
<td class="num">(85,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(952)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">138,314<span></span>
</td>
<td class="nump">39,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 235,233<span></span>
</td>
<td class="nump">138,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AccruedClinicalAndResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AccruedClinicalAndResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775940192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (92,877)<span></span>
</td>
<td class="num">$ (46,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,317<span></span>
</td>
<td class="nump">2,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Loss on disposal of property, equipment, and software</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ChangeInFairValueOfConvertibleNotesPayable', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">9,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(584)<span></span>
</td>
<td class="num">(7,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets', window );">Other assets and other current assets</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">667<span></span>
</td>
<td class="num">(673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities', window );">Accrued other expenses and other current liabilities</a></td>
<td class="nump">4,835<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(7,866)<span></span>
</td>
<td class="num">(3,177)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(71,015)<span></span>
</td>
<td class="num">(51,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Acquisition of license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property, equipment and software</a></td>
<td class="num">(24,666)<span></span>
</td>
<td class="num">(14,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of property, equipment, and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(24,666)<span></span>
</td>
<td class="num">(15,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Deferred offering costs</a></td>
<td class="num">(2,622)<span></span>
</td>
<td class="num">(2,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of convertible notes payable</a></td>
<td class="nump">39,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from IPO, net of underwriting discounts and commissions</a></td>
<td class="nump">135,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">173,374<span></span>
</td>
<td class="nump">107,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">77,693<span></span>
</td>
<td class="nump">40,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;beginning of period</a></td>
<td class="nump">103,193<span></span>
</td>
<td class="nump">62,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents &#8212;end of period</a></td>
<td class="nump">180,886<span></span>
</td>
<td class="nump">103,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommonStockIssuedOnConversionOfConvertibleNotes', window );">Common stock issued on conversion of convertible notes payable</a></td>
<td class="nump">49,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Property, equipment and software additions included in accounts payable, accrued expenses and other current liabilities</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs included in accounts payable, accrued expenses and other current liabilities</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ChangeInFairValueOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ChangeInFairValueOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CommonStockIssuedOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued on conversion of convertible notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CommonStockIssuedOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued other expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_IncreaseDecreaseInAccruedOtherExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in other assets and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_IncreaseDecreaseInOtherAssetsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778740016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2018</div></th>
<th class="th"><div>Feb. 24, 2016</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recorded included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,486,000<span></span>
</td>
<td class="nump">$ 8,436,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,238,000<span></span>
</td>
<td class="nump">10,883,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_DevelopmentAndCommercialLicenseAgreementMember', window );">Development and Commercial License Agreement | Servier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recorded included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue related to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,900,000<span></span>
</td>
<td class="nump">88,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Development or sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_DevelopmentAndCommercialLicenseAgreementMember', window );">Development and Commercial License Agreement | Servier | Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_DevelopmentAndCommercialLicenseAgreementMember', window );">Development and Commercial License Agreement | Servier | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AggregatePaymentOnCollaborationAgreementToBeReceived', window );">Total payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AggregateMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Development or sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ResearchFundingPaymentTerm', window );">Research funding payment term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,300,000<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Gilead | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DevelopmentMilestonePayments', window );">Development milestone payments</a></td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="nump">340,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ReceivableFromResearchFunding', window );">Receivable from research funding</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DevelopmentAndCommercialMilestonePayments', window );">Development and commercial milestone payments</a></td>
<td class="nump">445,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Semi-annual research funding payments</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_SponsoredResearchCollaborationAndLicenseAgreementMember', window );">Research, Collaboration and License Agreement | University of Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AggregateMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ResearchFundingPaymentTerm', window );">Research funding payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_SalesMilestonePaymentsToCollaborators', window );">Development or sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PaymentToCollaboratorForResearchFunding', window );">Payments to collaborator for research funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_OptionToPayLicenseFee', window );">Option to pay license fee for additional patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dtil_SponsoredResearchCollaborationAndLicenseAgreementMember', window );">Research, Collaboration and License Agreement | University of Pennsylvania | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and License Agreements [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Semi-annual research funding payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_SalesMilestonePaymentsToCollaborators', window );">Development or sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AggregatePaymentOnCollaborationAgreementToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate payment on collaboration agreement to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AggregatePaymentOnCollaborationAgreementToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_DevelopmentAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_DevelopmentAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_DevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_DevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_OptionToPayLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to pay license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_OptionToPayLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_PaymentToCollaboratorForResearchFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment to collaborator for research funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_PaymentToCollaboratorForResearchFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ReceivableFromResearchFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from research funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ReceivableFromResearchFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ResearchFundingPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research funding payment term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ResearchFundingPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_SalesMilestonePaymentsToCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments to collaborators.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_SalesMilestonePaymentsToCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dtil_DevelopmentAndCommercialLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dtil_DevelopmentAndCommercialLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dtil_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dtil_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=dtil_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=dtil_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dtil_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dtil_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dtil_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dtil_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dtil_SponsoredResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dtil_SponsoredResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dtil_UniversityOfPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dtil_UniversityOfPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6959015232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Noncurrent deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 23,358<span></span>
</td>
<td class="nump">$ 9,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Contribution carryforwards</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">13,172<span></span>
</td>
<td class="nump">9,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">9,090<span></span>
</td>
<td class="nump">3,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(47,734)<span></span>
</td>
<td class="num">(22,736)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Total deferred tax assets, noncurrent</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Noncurrent deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Total deferred tax liabilities, noncurrent</a></td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31958-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790663120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of Operations (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 22,238<span></span>
</td>
<td class="nump">$ 10,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (92,877)<span></span>
</td>
<td class="num">$ (46,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders- basic and diluted</a></td>
<td class="num">$ (2.21)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="num">$ (2,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders- basic and diluted</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Balances without adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 19,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (95,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders- basic and diluted</a></td>
<td class="num">$ (2.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6646820496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">License cost</a></td>
<td class="nump">$ 1,831<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_FiniteLivedIntangibleAssetsImpairment', window );">Less: impairments</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 1,432<span></span>
</td>
<td class="nump">$ 1,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780541024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">NET LOSS PER SHARE</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,015,814</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,285,376</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding share-based compensation awards converted to common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,032,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,796,377</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,032,359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,097,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6959620000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCKHOLDERS&#8217; EQUITY</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Capital Structure</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all of the Company&#8217;s outstanding shares of the Series A and Series B convertible preferred stock automatically converted into 22,301,190 shares of common stock and the Company&#8217;s outstanding convertible notes payable, including accrued interest, converted into 2,921,461 shares of common stock at the applicable conversion ratio. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, the Company filed an amendment to its amended and restated certificate of incorporation pursuant to which, among other things, the Company increased its authorized shares to 210,000,000 shares of capital stock, of which 200,000,000 shares were designated as $0.000005 par value common stock and 10,000,000 shares were designated as $0.0001 par value preferred stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780597440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AND LICENSE AGREEMENTS</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COLLABORATION AND LICENSE AGREEMENTS</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Development and Commercial License Agreement with Servier</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 24, 2016, the Company entered into a development and commercial license agreement, as subsequently amended, with predecessor entities to Servier. This agreement establishes a collaboration between the Company and Servier to develop allogeneic chimeric antigen receptor T (&#8220;CAR T&#8221;) cell therapies for up to six unique antigen targets selected by Servier. Servier selected one target at the agreement&#8217;s inception. Servier is required to make a milestone payment to the Company upon achievement of an early-stage pre- investigational new drug application (&#8220;IND&#8221;) development milestone event completed for each of the remaining five targets selected, if any. The Company granted Servier a development license and will perform early-stage R&amp;D on the selected targets and develop the resulting therapeutic product candidates through Phase 1 clinical trials and manufacture clinical trial material for use in Phase 2 clinical trials. Also, the Company and Servier have formed a joint steering committee (&#8220;JSC&#8221;) to provide high-level oversight and decision making regarding the activities covered under the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $105.0 million under the agreement. At the Phase 2 readiness stage for any product candidate, Servier may exercise a commercial option, subject to payment of commercial option exercise fees, to proceed with development and commercialization of the product candidate and perform late-stage R&amp;D, including Phase 2 and Phase 3 clinical trials and obtaining regulatory approvals. The Company has the ability to receive total payments, in the aggregate across all six targets that may be selected by Servier, of up to approximately $1.6 billion, including the upfront payment of $105.0 million and up to $1.5 billion in milestone payments, consisting of up to $401.3 million in development milestone payments and up to $1.1 billion in commercial milestone payments. The Company is also entitled to receive tiered royalties ranging from the mid-single digit percentages to the sub-teen percentages on worldwide net sales of any products developed, subject to customary potential reductions. The Company also has the right to opt in and participate in the development and commercialization of any products resulting from the collaboration through a 50/50 codevelopment and co-promotion option in the United States. This will require the Company to pay a codevelopment and co-promotion option fee on each licensed product for which the Company elects to participate. This option is exercisable at the Phase 2 readiness stage and only after Servier exercises its commercial option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the promises in the agreement represent transactions with a customer. The Company has determined that the promises associated with the research and development activities for each of the six targets are not distinct because they are all based on the ARCUS proprietary genome editing platform. The Company has concluded that the agreement with Servier contains the following promises: (i) a development license; (ii) performance of early-stage R&amp;D services, (iii) the manufacture of clinical trial material for use in Phase 2 clinical trials, and (iv) JSC participation. The Company determined that the license, manufacture of clinical trial material, and R&amp;D services were not distinct from each other, as the license, pre-clinical and clinical supply, and R&amp;D services are highly interdependent upon one another. Participation on the JSC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;D services. As such, the Company determined that these promises should be combined into a single performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement with Servier, in order to evaluate the appropriate transaction price, the Company determined that the upfront amount of $105.0 million constituted the entire consideration to be included in the transaction price as of the outset of the arrangement.&#160;&#160;As such, this amount was allocated to the single performance obligation. The commercial option exercise fees that may be received are excluded from the transaction price until each customer option is exercised as it was determined that the options are not material rights. The potential development milestone payments that the Company is eligible to receive prior to the exercise of the options as well as commercial milestones, were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain developmental goals, which might not be achieved. None of the future royalty payments were included in the transaction price, as the potential payments represent sales-based consideration. The Company will reevaluate the transaction price, including all constrained amounts, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue from the upfront payment of $105.0 million based on an input method in the form of research effort relative to expected research effort at the completion of the performance obligation, which is based on the actual time of R&amp;D activities performed relative to expected time to be incurred in the future to satisfy the performance obligation. Management evaluates and adjusts the total expected research effort for the performance obligation on a quarterly basis based upon actual research accomplishments and the probability of continuing research efforts in the future. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation. The remaining performance obligation associated with the $105.0 million upfront payment is expected to be satisfied over a four year period as of December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2019 and December 31, 2018, the Company recognized revenue under the agreement with Servier of approximately $7.3 million and $5.8 million, respectively. Deferred revenue related to the agreement with Servier amounted to $80.9 million and $88.6 million as of December 31, 2019 and December&#160;31, 2018, respectively, of which $15.0 million and $5.8 million, respectively is included in current liabilities. No development or sales-based milestone payments were received during the year ended December 31, 2019 and December 31, 2018.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Gilead</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 10, 2018, the Company and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) entered into a collaboration and license agreement to develop genome editing tools to target viral DNA associated with Hepatitis B. Pursuant to the terms of the agreement, Gilead will receive an exclusive license to exploit the resulting synthetic nucleases and products that use them to treat Hepatitis B in humans (&#8220;development license&#8221;), and the Company is entitled to receive up to $40.0 million in research funding for early-stage R&amp;D services, paid in semi-annual increments, over an initial three year term and development and commercial milestone payments of up to an aggregate of $445.0 million, consisting of up to $105.0 million in development milestone payments and up to $340.0 million in commercial milestone payments. The Company is also entitled to receive tiered royalties ranging from the high single digit percentages to the mid-teen percentages on worldwide net sales of the products developed through the term of the agreement, subject to customary potential reductions. Gilead is responsible for obtaining regulatory approvals and, upon completion of the collaboration, will assume sole responsibility for the development and commercialization of such gene editing therapies and products. The Company will provide technology transfer of its development know-how prior to Gilead assuming responsibility. Also, the Company and Gilead will negotiate a separate supply agreement for the Company to manufacture specifically identified products for Gilead to use in clinical trials at price based on the Company&#8217;s costs. The Company and Gilead have formed a joint steering committee (&#8220;JSC&#8221;) and a joint research and development committee (&#8220;JRDC&#8221;) that collectively will provide oversight, decision making and implementation guidance regarding the collaboration activities covered under the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the promises in the agreement represent transactions with a customer. The Company has concluded that the agreement with Gilead contains the following promises: (i) a development license; (ii) performance of early-stage R&amp;D services, including technology transfer services, iii) JSC and JRDC participation, and (iv) regulatory responsibilities related to non-clinical and chemistry, manufacturing and control (&#8220;CMC&#8221;) reports. The Company determined that the license and R&amp;D services were not distinct from each other, as the license and R&amp;D services are highly interdependent upon one another. Participation on the JSC and JRDC to oversee the research and development activities are combined into the single performance obligation as these activities are highly interdependent with the other R&amp;D services. The regulatory responsibilities related to non-clinical and CMC filings do not represent separate performance obligations based on their dependence on the research and development efforts. As such, the Company determined that these promises should be combined into a single performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement with Gilead, in order to evaluate the appropriate transaction price, the Company determined that the $40.0 million research funding for early-stage R&amp;D services, paid in semi-annual increments over an initial three-year term, constituted the entire consideration to be included in the transaction price as of the outset of the arrangement. As such, this amount was allocated to the single performance obligation. The potential development and commercial milestone payments that the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement, since the milestones relate to successful achievement of certain developmental goals, which might not be achieved. None of the future royalty payments were included in the transaction price, as the potential payments represent sales-based consideration.&#160;&#160;The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with the combined performance obligation is being recognized as revenue on a straight-line basis as the R&amp;D services are provided over the initial three-year term.&#160;&#160;The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2019 and December 31, 2018, the Company recognized revenue under the agreement with Gilead of approximately $13.3 million and $3.7 million, respectively. Deferred revenue related to the agreement with Gilead amounted to $1.5 million and $2.3 million as of December 31, 2019 and December&#160;31, 2018, respectively, all of which is included in current liabilities. No development or sales-based milestone payments were received during the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research, Collaboration and License Agreement with the Trustees of the University of Pennsylvania</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;1, 2018, the Company entered into a Research, Collaboration and License Agreement with the University of Pennsylvania (&#8220;Penn&#8221;) to collaborate on the preclinical development for gene editing products involving the delivery of an ARCUS nuclease. The Company will provide semi-annual research funding payments of up to $5.0&#160;million for a three-year term to fund the cost of research programs as specified in a mutually agreed-upon research budget and be responsible for&#160;post-IND&#160;enabling study development activities. The research funding payments will be expensed as incurred; however, if payments made by the Company exceed the costs incurred by Penn in the six-month period, the excess amount will be credited to the Company in the next semi-annual period.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the research funding payments, if the Company elects to use certain Penn technology, the Company will be required to make development and sales milestone payments totaling up to $16.1&#160;million per product in any one year, assuming the maximum development and sales milestones are met in any one year. An additional $12.3&#160;million per product in sales milestone payments could be payable in other years if other sales thresholds are achieved, thus totaling $28.4&#160;million in aggregate milestone payments per product. Low single-digit royalty percentages are also payable on net sales of certain products.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penn provided the Company a&#160;non-exclusive&#160;license for patent rights and&#160;know-how&#160;to be used in exchange for an upfront payment of $0.3&#160;million. Once the Company has paid $15.0&#160;million in research funding, it then has the option to pay a $1.0&#160;million option fee to obtain a license for additional patent rights.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, both parties agreed to adjust the activities conducted under the agreement to focus exclusively on the collaboration&#8217;s program to edit the PCSK9 gene to reduce levels of LDL-C in the blood, commonly known as &#8220;bad cholesterol&#8221;. The agreement&#8217;s termination provisions allow the Company to terminate the agreement by providing written notice at least 60 days prior to the due date of the next semi-annual research funding payment. In this event, the Company would not make termination payments to Penn other than for&#160;non-cancelable&#160;costs and reasonable wind-down costs. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6592231424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,015,814</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,285,376</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding share-based compensation awards converted to common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,032,359</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,796,377</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,032,359</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,097,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6959575824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment and Software</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software consisted of the following as of December&#160;31 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,600</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,969</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,733</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,251</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,057</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, equipment and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,220</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,649</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software - net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,571</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,147</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6775717840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Estimated dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Weighted-average expected stock price volatility</a></td>
<td class="nump">68.25%<span></span>
</td>
<td class="nump">68.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption', window );">Weighted-average fair value per option</a></td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="nump">$ 7.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions weighted average fair value per option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValuePerOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779151152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAdministrativeExpenses', window );">Defined contribution plan, Administrative fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, Employer matching contribution percentage of match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Company made contribution to the retirement plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, Employer matching contribution, percent of employees' gross pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of administrative expense incurred by defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778126304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791835600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 22,238<span></span>
</td>
<td class="nump">$ 10,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">82,416<span></span>
</td>
<td class="nump">45,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,026<span></span>
</td>
<td class="nump">13,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">109,442<span></span>
</td>
<td class="nump">58,795<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87,204)<span></span>
</td>
<td class="num">(47,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible notes payable</a></td>
<td class="num">(9,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,267<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(5,673)<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and net loss attributable to common stockholders</a></td>
<td class="num">$ (92,877)<span></span>
</td>
<td class="num">$ (46,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders- basic and diluted</a></td>
<td class="num">$ (2.21)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding- basic and diluted</a></td>
<td class="nump">41,991,162<span></span>
</td>
<td class="nump">15,775,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ChangeInFairValueOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ChangeInFairValueOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779452256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of income taxes amount, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at statutory rate, Amount</a></td>
<td class="num">$ (19,505)<span></span>
</td>
<td class="num">$ (9,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit, Amount</a></td>
<td class="num">(1,827)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses, Amount</a></td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D and orphan drug credits, Amount</a></td>
<td class="num">(4,810)<span></span>
</td>
<td class="num">(1,934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, Amount</a></td>
<td class="num">(639)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Amount</a></td>
<td class="nump">$ 24,997<span></span>
</td>
<td class="nump">$ 12,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income taxes rate, Percentage</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at statutory rate, Percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit, Percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses, Percentage</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D and orphan drug credits, Percentage</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Other, Percentage</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percentage</a></td>
<td class="num">(26.90%)<span></span>
</td>
<td class="num">(26.70%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6718086752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, EQUIPMENT AND SOFTWARE</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">PROPERTY, EQUIPMENT AND SOFTWARE</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software consisted of the following as of December&#160;31 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,600</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,969</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,733</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,251</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,057</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,124</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, equipment and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,220</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,631</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,649</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,484</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software - net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,571</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,147</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, we completed construction and opened our Manufacturing Center for Advanced Therapeutics, or MCAT, a manufacturing facility supporting our therapeutic product development platform, in a leased facility in Research Triangle Park.&#160; Of the $8.6 million construction-in-progress (CIP) balance as of December 31, 2018, $2.5 million related to the MCAT and $4.4 million related to our other leased facilities in Durham was recognized as leasehold improvements in the year ending December 31, 2019. &nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense, including amortization of leasehold improvements and software, was $5.3 million and $2.3 million for the years ended December&#160;31, 2019 and December 31, 2018, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778018368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">4,032,359<span></span>
</td>
<td class="nump">27,097,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,015,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,285,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember', window );">Outstanding Share Based Compensation Awards Converted to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">4,032,359<span></span>
</td>
<td class="nump">4,796,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dtil_OutstandingShareBasedCompensationAwardsConvertedToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649569760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded no income tax expense due to the operating losses incurred for the years ended December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets and deferred tax liabilities are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,358</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,185</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contribution carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,172</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,444</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">573</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,090</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,734</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,736</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets, noncurrent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent deferred tax liability:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities, noncurrent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,463</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019 and December 31, 2018, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. The net increase in the valuation allowance for the year ended December&#160;31, 2019 of $25.0&#160;million is comprised of an increase in deferred tax assets, primarily related to deferred revenue and net operating loss carryforwards, for the year. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reasons for the difference between actual income tax benefit for the years ended December&#160;31, 2019 and December 31, 2018 and the amount computed by applying the statutory federal income tax rate to losses before income tax benefit are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Pre-Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of Pre-Tax</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Earnings</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense at statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,505</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,668</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal tax benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,827</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(909</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D and orphan drug credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,810</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,934</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(639</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.9</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,272</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (benefit) expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, the Company had federal, state, and foreign net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $101.3 million, $101.7 million, and $0.4 million respectively. At December&#160;31, 2018, the Company had federal and state NOL carryforwards of approximately $40 million and $39.8 million, respectively. Federal NOL carryforwards of $19.7 million begin to expire in 2030 while the remaining federal NOL carryforward of $81.6 million carries forward indefinitely. The state NOL carryforwards begin to expire in 2025. The foreign NOLs carryforward indefinitely. At December&#160;31, 2019, the Company had federal and state research and development (&#8220;R&amp;D&#8221;) tax credits of $7.2 million and an amount less than $0.1 million, which begin to expire in 2027 and 2030, respectively. At December&#160;31, 2018, the Company had federal and state tax R&amp;D credits of $3.6 million and an amount less than $0.1 million which begin to expire in 2027 and 2030, respectively. At December 31, 2019 and December 31, 2018, the Company had federal Orphan Drug credits of $1.8 million and $0.7 million, respectively, which begin to expire in 2038. At December&#160;31, 2019 and December 31, 2018, the Company had federal contribution carryforwards of $0.1 million and an amount less than $0.1 million, respectively, which begin to expire in 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incorporated a subsidiary in Australia in 2018. However, the subsidiary has had minimal losses since inception. As such, there are no undistributed earnings as of December 31, 2019.&nbsp;&nbsp;The Company incorporated a subsidiary in the United Kingdom in 2019. However, the subsidiary has had minimal activity since inception. As such, there are no undistributed earnings as of December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ability to utilize its NOL and R&amp;D credit carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change,&#8221; as defined by Section&#160;382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed a study to assess whether one or more ownership changes have occurred since the Company became a loss corporation under the definition of Section&#160;382. If the Company has experienced an ownership change, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any possible limitation will have an impact on the results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reflects in the accompanying consolidated financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only if it is considered &#8216;more-likely-than-not&#8217; that the position taken will be sustained by the appropriate taxing authority. As of December&#160;31, 2019 and December 31, 2018, the Company had no unrecognized income tax benefits. The Company&#8217;s policy for recording interest and penalties relating to uncertain income tax positions is to record them as a component of income tax expense in the accompanying consolidated statements of operations. As of December&#160;31, 2019 and December 31, 2018, the Company had no such accruals. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognized deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. The Company does not have a GILTI inclusion in years ends December 31, 2019 or December 31, 2018 and therefore, no GILTI tax has been recorded for the years then ended.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6718085952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract', window );"><strong>Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">RETIREMENT PLAN</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2011, the Company established a defined contribution 401(k) retirement savings plan (the &#8220;Retirement Plan&#8221;) to all full-time employees. Employee contributions to the Retirement Plan can be 100% of annual compensation up to the prescribed annual maximum under the Internal Revenue Code. Administrative fees of less than $0.1&#160;million were paid by the Company for the years ended December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Retirement Plan includes a safe-harbor matching employer contribution equal to 100% of participants&#8217; deferral contributions up to 4%. The Company made contributions of $0.6&#160;million and $0.4&#160;million to the Retirement Plan during the years ended December&#160;31, 2019 and December 31, 2018, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlansAndDefinedBenefitPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792252896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization Periods of Property, Equipment and Software (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
<td class="text">Lesser of remaining lease term or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>392</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftware</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization Periods of Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationPeriodsOfPropertyEquipmentAndSoftwareDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization Periods of Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOperationsDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesSummaryOfImpactOfAdoptingTopic606OnCondensedFinancialStatementsCondensedConsolidatedStatementOfOfCashFlowsDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Property, Equipment and Software - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Equipment and Software - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Property, Equipment and Software - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Software - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Intangible Assets - Schedule of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Share-Based Compensation - Schedule of Employee and Nonemployee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfEmployeeAndNonemployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Employee and Nonemployee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Share-Based Compensation - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Share-Based Compensation - Summary of Activity of Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfActivityOfOptionPlansDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Activity of Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Share-Based Compensation - Summary of Stock Options Granted under the Stock Option Plans are Vested or Expected to Vest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionsGrantedUnderStockOptionPlansAreVestedOrExpectedToVestDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Options Granted under the Stock Option Plans are Vested or Expected to Vest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Outstanding under the Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionOutstandingUnderStockOptionPlansDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Outstanding under the Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Schedule of Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateAndIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate and Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Collaboration and License Agreements - Additional Information (Details 1 )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails1</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details 1 )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dtil-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Segment Reporting - Financial Information with Respect to Company's Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20191231/taxonomy/role/DisclosureSegmentReportingFinancialInformationWithRespectToCompanySReportableSegmentsDetails</Role>
      <ShortName>Segment Reporting - Financial Information with Respect to Company's Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dtil-20191231.xml</File>
    <File>dtil-20191231.xsd</File>
    <File>dtil-20191231_cal.xml</File>
    <File>dtil-20191231_def.xml</File>
    <File>dtil-20191231_lab.xml</File>
    <File>dtil-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790751088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Software - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">$ 50,220<span></span>
</td>
<td class="nump">$ 26,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="nump">10,649<span></span>
</td>
<td class="nump">5,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software - net</a></td>
<td class="nump">39,571<span></span>
</td>
<td class="nump">21,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">25,969<span></span>
</td>
<td class="nump">5,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">19,251<span></span>
</td>
<td class="nump">10,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">$ 2,373<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dtil_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790583056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommonAndPreferredStocksSharesAuthorized', window );">Common and prferred stocks, shares authorized</a></td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.000005<span></span>
</td>
<td class="nump">$ 0.000005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible preferred stock or convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Series A and Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Common Stock | Convertible Notes Payable (2019 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible preferred stock or convertible notes payable</a></td>
<td class="nump">2,921,461<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Common Stock | Series A and Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible preferred stock or convertible notes payable</a></td>
<td class="nump">22,301,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CommonAndPreferredStocksSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of of common and preferred stock shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CommonAndPreferredStocksSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dtil_SeriesAAndSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dtil_SeriesAAndSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606688256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following represents assets measured at fair value on a recurring basis by the Company (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,281</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780603088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded employee and nonemployee share-based compensation expense as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,431</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonemployee</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense related to stock options is included in the following line items in the consolidated statements of operations (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,639</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,817</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,301</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model</a></td>
<td class="text">The fair value of each stock option grant is estimated using a Black-Scholes option-pricing model on the date of grant as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated dividend yield</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average expected stock price volatility</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.25</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.95</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term of options (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.61</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average fair value per option</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity of Option Plans</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity in the Company&#8217;s stock option plans for the years ended December 31, 2019 and December 31, 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of January 1, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,416,025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,160,097</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.66</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(220,308</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.78</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(592,350</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,647,236</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(940,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(550,644</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Summary of Stock Options Granted under the Stock Option Plans are Vested or Expected to Vest</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information about stock options granted under the stock option plans which are vested or expected to vest as of December&#160;31, 2019 and December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be exercisable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.19</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.02</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,082,663</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.08</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected to be exercisable</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Stock Options Outstanding under the Stock Option Plans</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes certain information about stock options outstanding under the stock option plans for the years ending December 31, 2019 and December 31, 2018, respectively: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="12" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.01 - $0.04</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.41 - $1.20</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,721,811</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.74 - $9.46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266,454</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.44</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,644</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.17 - $13.80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,891,922</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.96</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">844,005</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14.91 - $16.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,544</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,919,116</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,082,663</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-&#160;Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.01 - $0.04</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397,203</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,440,920</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,166,591</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.18 - $1.20</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846,255</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748,922</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291,023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,376</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,408</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,708</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.98</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,070,029</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.78</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,193</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.20</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428,626</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,763,464</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787749248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc. (the &#8220;Company&#8221;) was incorporated on January 26, 2006 under the laws of the State of Delaware and is based in Durham, North Carolina. The Company is focused on utilizing its proprietary genome editing platform to help overcome cancers, cure genetic diseases and enable the development of safer, more productive food sources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 100% owned subsidiary, Precision PlantSciences, Inc., was incorporated on January 4, 2012. Precision PlantSciences, Inc. amended its certificate of incorporation on January 16, 2018 to change its name to Elo Life Systems, Inc.&#160;&#160;Elo Life Systems Australia Pty Ltd was incorporated on May 29, 2018 as a 100% owned subsidiary of Elo Life Systems, Inc.&#160;&#160;The Company&#8217;s 100% owned subsidiary, Precision BioSciences UK Limited, was incorporated on June 17, 2019.&#160;&#160;The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its efforts to research and development activities, recruiting skilled personnel, developing manufacturing processes, establishing its intellectual property portfolio and providing general and administrative support for these operations. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its product candidates. The Company&#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2019, the Company completed its initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold 9,085,000 shares of its common stock at a public offering price of $16.00 per share and received approximately $130.5 million in net proceeds, after deducting underwriting discounts and commission of approximately $10.2 million and issuance costs of approximately $4.6 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the IPO, on March 15, 2019 the Company effected a reverse split of shares of the Company&#8217;s common stock on a 1-for-2.134686 basis (the &#8220;Reverse Stock Split&#8221;) of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for the Company&#8217;s Series A and Series B preferred stock.&#160;&#160;Accordingly, all common shares, stock option shares, and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect this Reverse Stock Split and adjustment of the preferred stock conversion ratios.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized common shares were not affected by the Reverse Stock Split.&#160;&#160;Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into 22,301,190 shares of common stock at the applicable ratio then in effect and the outstanding convertible notes payable, including accrued interest, were settled into 2,921,461 shares of common stock. Subsequent to the closing of the IPO, there were no shares of Series A or Series B convertible preferred stock or convertible notes payable outstanding.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ from those estimates. Significant estimates include recording revenue for performance obligations recognized over time, determination of the fair value of share-based compensation grants and estimating services expended by third-party service providers used to recognize research and development expense. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements have been prepared in accordance with GAAP. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. During the year ended December&#160;31, 2019, the Company incurred a net loss of $92.9&#160;million and, as of December&#160;31, 2019, has an accumulated deficit of $177.1 million. The Company has financed operations primarily through its IPO, private placements of convertible preferred stock and convertible debt and with proceeds from its development and commercial license agreement with Les Laboratoires Servier, (&#8220;Servier&#8221;) and Gilead Sciences, Inc. (&#8220;Gilead&#8221;) (see Note 12). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that existing cash and cash equivalents will allow the Company to continue its operations into 2021. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to the presentation of amounts in our Consolidated Balance Sheet as of December&#160;31, 2019 to conform to the prior year presentation. Specifically, certain current liabilities were reclassified from accrued expenses and other current liabilities and are now presented separately on our Consolidated Balance Sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&#160;31, 2019 and December 31, 2018, the Company held cash equivalents composed of money market funds and repurchase agreements that were collateralized by deposits in the form of government securities and obligations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. All of the Company&#8217;s cash and cash equivalents are held at financial institutions that management believes to be of high credit quality. The Company may maintain cash deposits in financial institutions in excess of government insured limits. The Company regularly invests excess cash deposits in money market funds and repurchase agreements. The Company believes that the credit risk arising from the holdings of these financial instruments is mitigated by the fact that these securities are of short duration, government backed and of high credit rating. The Company has not experienced any losses on cash and cash equivalents to date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from two development and license agreements accounted for 60% and 33% of revenue during 2019 and 34% and 53% of revenue during 2018, as well as 2% and 98% of deferred revenue as of December&#160;31, 2019. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Equity Offering Costs</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Equity Offering Costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes incremental legal, professional accounting and other third-party fees directly associated with the Company&#8217;s planned equity offerings as other current assets until the equity offering is consummated. After consummation, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital. If the equity offering is not completed, any costs deferred will be expensed immediately. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property, Equipment and Software </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, equipment and software are stated at cost, net of depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciation and amortization periods for the Company&#8217;s significant property, equipment and software categories are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:307.45pt;"></td>
<td style="width:232.55pt;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 to 7 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser&#160;of&#160;remaining&#160;lease&#160;term&#160;or&#160;useful&#160;life</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repairs and maintenance are charged to operations as incurred, and expenditures for additions and improvements that extend the useful life of the asset are capitalized. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets primarily include licenses and patents. The Company capitalizes license fees paid to acquire access to proprietary technology if the technology is expected to have alternative future use in multiple research and development projects. The cost of licensed technology rights is amortized using the straight-line method over the estimated useful life of the technology. If the access to use the technology rights is one year or less, the cost is recorded as a prepaid expense and amortized over the period identified in the agreement. Amortization expense for licensed technology and capitalized patent costs is included in research and development expenses within the accompanying consolidated statement of operations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, such as property, equipment and software and intangible assets, subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is assessed when future undiscounted cash flows are less than the assets&#8217; carrying value and recognized when the carrying value of the asset exceeds fair value. Fair value is calculated by estimating the discounted future cash flows expected to be generated by the asset as well as other valuation techniques. An impairment charge is recognized for the amount by which the carrying amount exceeds the fair value of the asset. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition for Contracts with Customers</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition for Contracts with Customers</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenues are generated primarily through collaborative research, license, development and commercialization agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;), using the modified retrospective transition method. Under this method, results for reporting periods beginning on January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with ASC Topic 605, <font style="font-style:italic;">Revenue Recognition</font> (&#8220;ASC 605&#8221;). The Company applied the modified retrospective transition method to contracts that were not completed as of January 1, 2019. For the year ended December 31, 2019, the Company reduced revenue recognition by $1.4 million for changes in total estimated time to be incurred in the future to satisfy the performance obligation. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company evaluates the performance obligations promised in the contract that are based on goods and services that will be transferred to the customer and determines whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. Goods or services that meet these criteria are considered distinct performance obligations. If both these criteria are not met, the goods and services are combined into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options.&#160;&#160;The Company assesses if these options provide a material right to the customer and if so, these options are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to revenue recognition are recorded as deferred revenue.&#160;&#160;Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue within current liabilities in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue &#8211; noncurrent. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets in the other current assets line item in the accompanying consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone Payments <font style="font-style:normal;">&#8211;</font> <font style="font-style:normal;">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties <font style="font-style:normal;">&#8211;</font> <font style="font-style:normal;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation linked to some or all of the royalty has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Significant Financing Component <font style="font-style:normal;">&#8211; In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing.&#160;&#160;The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&#160;&#160;The Company assessed each of its revenue arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of its arrangements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements <font style="font-style:normal;">&#8211; The Company has entered into collaboration agreements, which are within the scope of ASC 606, to discover, develop, manufacture and commercialize product candidates. The terms of these agreements typically contain multiple promises or obligations, which may include: (1) licenses, or options to obtain licenses, to use the Company&#8217;s technology, (2) research and development activities to be performed on behalf of the collaboration partner, and (3) in certain cases, services in connection with the manufacturing of preclinical and clinical material. Payments the Company receives under these arrangements typically include one or more of the following: non-refundable, upfront license fees; option exercise fees; funding of research and/or development efforts; clinical and development, regulatory, and sales milestone payments; and royalties on future product sales.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company analyzes its collaboration arrangements to assess whether the collaboration agreements are within the scope of accounting standards codification (&#8220;ASC&#8221;) ASC 808, <font style="font-style:italic;">Collaborative Arrangements</font> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, are within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to ASC 606.&#160;&#160;For those elements of the arrangement that are accounted for pursuant to ASC 606, the Company applies the five-step model described above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional discussion of accounting for collaboration revenues, see Note 12, &#8220;Collaboration and license agreements.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities including salaries, benefits, share-based compensation, allocations for rent and facility costs, depreciation, preclinical manufacturing expenses, costs of services provided by contract research organizations (&#8220;CROs&#8221;) in connection with preclinical trials and contract manufacturing organizations (&#8220;CMOs&#8221;) engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate accrued research and development expenses resulting from its obligations under contracts with CROs, CMOs, research organizations, service providers, vendors and consultants in connection with research and development activities. The financial terms of these contracts are subject to negotiations and vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate research and development expenses in its consolidated financial statements by matching those expenses with the period in which the services and efforts are expended. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#8217;s estimate, the Company adjusts the accrual or amount of prepaid expense accordingly. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low in any particular period. To date, the Company has not made any material adjustments to prior estimates of accrued research and development expenses. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommonStockValuationPolicyPolicyTextBlock', window );">Common Stock Valuation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock Valuation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, due to the absence of an active market for the Company&#8217;s common stock, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. In determining the exercise prices for stock options granted prior to the IPO, the Company considered the estimated fair value of the common stock as of the measurement date. The estimated fair value of the common stock was determined based upon a variety of factors, including the illiquid nature of the common stock, the Company&#8217;s financial position and historical financial performance, the status of technological developments within the Company&#8217;s research, the composition and ability of the current research and management team, an evaluation or benchmark of the Company&#8217;s competition and the current business climate in the marketplace. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2019 and December 31, 2018, there was no difference between net loss and comprehensive loss in the accompanying consolidated financial statements. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Diluted net loss per share is the same as basic net loss per share for the years ended December&#160;31, 2019 and December 31, 2018 since all potential shares of common stock are anti-dilutive as a result of the net loss. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Share-Based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for all share-based compensation, including stock options and the employee stock purchase plan at fair value and recognizes compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each equity grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the Company&#8217;s expected dividend yield. As the Company has limited trading history, expected volatility is estimated based on the historical volatility of publicly traded peer companies and the Company expects to continue to do so until such time as it has adequate historical data regarding the volatility of our traded share price. The expected term of the options has been determined utilizing a weighted value considering actual history and estimated expected term based on the midpoint of final vest date and expiration date.&nbsp;&nbsp;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are determined based on the temporary differences between the consolidated financial statement carrying amounts and the tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. In estimating future tax consequences, all expected future events are considered other than the enactment of changes in the tax law or rates. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Updates</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting Standards Updates</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section&#160;107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The JOBS Act also exempts the Company from having to provide an auditor attestation of internal controls over financial reporting under Sarbanes-Oxley Act Section&#160;404(b). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will remain an &#8220;emerging growth company&#8221; until the earliest of (i)&#160;December 31, 2024, (ii) the last day of the fiscal year in which it has total annual gross revenues of $1.07&#160;billion or more, (iii)&#160;the date on which it has issued more than $1.0&#160;billion in nonconvertible debt during the previous three years or (iv)&#160;the date on which it is deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), which generally is when it has more than $700&#160;million in market value of its stock held by non-affiliates, has been a public company for at least 12 months and have filed one annual report on Form 10-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board, or FASB, issued ASC 606, which superseded the revenue requirements in ASC 605. In 2015 and 2016, the FASB issued additional ASUs related to ASC 606 that delayed the effective date of the guidance and clarified various aspects of the new revenue guidance, including principal versus agent considerations, identifying performance obligations, and licensing, and they include other improvements and practical expedients. Effective January 1, 2019, the Company adopted ASC 606 using the modified retrospective transition method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of adopting ASC 606, the Company recorded a $1.0 million transition adjustment in the first quarter of 2019 to reduce the opening balance of accumulated deficit as of January 1, 2019 primarily as a result of the treatment of the up-front consideration received from the Company&#8217;s collaboration agreements under prior revenue recognition guidance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,807</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,190</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(997</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,187</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,486</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,895</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,067</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,477</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statement of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Cash Flows for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption&#160;of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,866</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,453</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="eolPage14"></a>During the year ended December 31, 2019, the Company recorded $9.4 million in revenue that was included in deferred revenue as of December 31, 2018.&#160;&#160;The most significant change to the Company&#8217;s revenue recognition as a result of the adoption of ASC 606 relates to the accounting for certain option fees and milestone payments in determining the transaction price (step (iii)), and the revenue recognition pattern (step (v)) related to the Company&#8217;s development and commercial license agreement with Servier. Under ASC 605, the option fees payable by the Company to exercise the 50/50 co-development and co-promotion option was accounted for as a reduction in the arrangement consideration, and certain development milestones that may be earned for early-stage pre-IND development milestones were included in the arrangement consideration as the early-stage pre-IND development milestones were deemed to be non-substantive. Under ASC 606, the option fees were not accounted for as a reduction in the transaction price as the option fees are contingent upon Servier&#8217;s<a name="eolPage14"></a> exercise of its commercial <a name="eolPage14"></a>(customer) options on licensed product candidates, and the milestone payments were excluded from the transaction price based on the assessment of the most likely amount and application of the variable consideration constraint, since the milestones relate to successful achievement of certain developmental goals, which may not be achieved. In addition, under ASC 605, the Company recognized revenue on a straight&#8209;line basis over the period the Company expected to complete its obligations. Under ASC 606, the Company recognizes revenue based on the proportional performance of the services related to the performance obligation expected. For further discussion of the adoption of ASC 606 see Note 12, &#8220;Collaboration and license agreements.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DTIL_10Q_20190930_HTM_LD_TABLE_29"></a>In June 2018, the FASB issued ASU 2018-07,&#160;<font style="font-style:italic;">Compensation-Stock Compensation Improvements to Nonemployee Share-Based Payment Accounting&#160;</font>(&#8220;ASU 2018-07&#8221;). ASU 2018-07 substantially aligns accounting for share-based payments to employees and non-employees. This ASU became effective for annual periods beginning after December 15, 2018 including interim periods within that period, and early adoption is permitted.&nbsp;&nbsp;The Company adopted ASU 2018-07 effective January 1, 2019.&nbsp;&nbsp;The adoption of the standard did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13,&#160;<font style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measuremen</font>t (&#8220;ASU 2018-13&#8221;). ASU 2018-13 is intended to improve the effectiveness of disclosures in the notes to financial statements related to fair value measurements in Topic 820. This ASU will become effective for annual periods beginning after December 15, 2019, including interim periods within that period, and early adoption is permitted.&#160;The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18, <font style="font-style:italic;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the Interaction between Topic 808 and ASC 606</font> (&#8220;ASU 2018-18&#8221;). The amendments in ASU 2018-18 make targeted improvements to GAAP for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASU 2018-18 was aligned with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606.&#160;&#160;ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments should be applied retrospectively to the date of initial application of ASC 606. The Company adopted this guidance effective January 1, 2019 with its initial application of ASC 606. The adoption of the standard did not have an impact on the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the FASB issued ASU 2019-10, <font style="font-style:italic;">Financial Instruments &#8212; Credit losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) </font>(&#8220;ASU 2019-10&#8221;)<font style="font-style:italic;">,</font> which provides a one-year deferral of the effective dates of ASU No.&#160;2016-02, <font style="font-style:italic;">Leases (Topic 842)</font> (&#8220;ASU 2016-02&#8221;), issued in February 2016.&nbsp;&nbsp;ASU 2016-02 was issued in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term.&nbsp;&nbsp;ASU 2019-10 is effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements and expects to have an increase in total assets and total liabilities as a result of adopting the lease standard.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accounting standards updates issued, but not effective until after December 31, 2019, are not expected to have a material effect on the Company&#8217;s consolidated financial position, statements of operations or cash flows.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CommonStockValuationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CommonStockValuationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780601568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Employee and Nonemployee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,940<span></span>
</td>
<td class="nump">$ 2,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8,354<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6653158528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Options Granted under the Stock Option Plans are Vested or Expected to Vest (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Expected to be exercisable, Number of Options</a></td>
<td class="nump">8,919,116<span></span>
</td>
<td class="nump">7,763,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Currently exercisable, Number of Options</a></td>
<td class="nump">4,082,663<span></span>
</td>
<td class="nump">3,418,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Expected to be exercisable, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">7 years 2 months 8 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Currently exercisable, Weighted- Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 29 days<span></span>
</td>
<td class="text">5 years 4 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Expected to be exercisable, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Currently exercisable, Weighted- Average Exercise Price</a></td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6667902496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AgreementTerminationNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001564590-20-009541-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-009541-xbrl.zip
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M@3E^=JP+)XP"YS%.MF"I-U$</)NCBC#$[+7*#D3*:BM*=KR 17:&2_%ANOS
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M]V/?"_V V?+VNG4<'%C'P4G#6]Y-,D_BUB3 &XC@?,8['.<*7MFC<[5 ?+6
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M0]/L]'H;0J]H!_#2K&F9VZ+%Z7;[LS13.O=JX'6W:'#:S=:JX/%?57BV:F/
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M+$!6!W<7EJW9SQ6U+P<NG=6X\3T_R^T%C+ +DU;OYHW"?'C6A7TG!BV/\%5
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M'!IH2@W_U0."A/%CZ-@.H+]FI(QVY\)865:KS>6C#K)1LW4R?PS#!"+8R#A
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M> '$<6DH1&6-@ 8[1^IQ&/@CL18! W\U65B-RQ5@*V+6LP=:UI4PA*&/9XB
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M?<6!/=KD0>O),+1,_$WX,_#)3T(IX:@CWQJ?1!D"G8#ZN<8=K:%+KL<SD+>
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M;BZUXY2UE0L?/9GKEO>SS.F1;7&4T:T 6<:+(X=W<^')1@P=1/XX?Q28'/#
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M_$_,\&)B3KJ5S@P*-*T?1TD@).XX2Y,4)\:%XQ)@"^!.C_]L&0*^;^X, 2T
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MU^)6[)/3KO(E78S-O^) =$%'M/[\6:Q6(IXRJ@9_D&N.L8F%LD5792L! D?
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MED_P+YC5\:(:Z#O/8EF(0R'PR!%A;%DP_3!V@<#/#G"1A*2 ^0&K3[[I A;
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M6YZ&.-WLFL%CZU];HK[;O9-3W7=[72],W\!6?D'32K"\M-%*\/!)C=N7Y1!
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M6F#Y=S8+H#E:!8!9F%:=**YH W[[:#IOO?&VF'$*428")5=%NK^\L%^ 7(,
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MR%1DB&9,0:*A-F+ZJ@%B%UUJ)G8Q#!-:%% SP/8M!M"B %/B EH4\$0XT*(
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M7&1(IB)#9&,*$C0TJBUT-#3:!4\8%CD#:T@+1C8 HX2?R_XAF(Y;I_@YY:-
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M 0C%YCM$0'FTX2<LR4;_!BK'D $OC[($(LU;&:^F$)XF,@1P ^Y/$PB49.P
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MH86(C2QZJ:QC:4+].-(EW#!+8S^/,/.YZ6KR[](,Q#RDU+/BL.Z<32&.&,N
M0\[0Y6&1J4,4L83CB_N%_,KH2$72,QCDQ. HB['D6%H6E]^65X)DXD-_%Q6J
M%.#N33I&70OH.NQ/I=9WO5X</GJ 6%:.1IA1E7.Q<0;\3$\4 %-Q>3)1Z5)P
M#!"P)A;F0BPU:>/WBXLON=Q;N=VNOTW-0\-O02]'69R(4GI5SAO!"SP_%J[<
M:#(%A1ME"HXBJ;<,$'NUF+ZX_M;-,^34!&UH<CJW&&;R9GK+2U2?:)S>JX7^
MBQZ\7ENY_DU/D'Z@WK:\.*:8D(,9IQBGE)<=ZLHDM+(0B]E+>C.CN*A]Y+6"
ME4[*Z@08C=R7!0P AZOHD;71XF0\.>O;7ZP.6&\?N5$L/.9$<,_%'/9:R7PH
MZCEZ#)\NNZ%I=+<HX^!FE+(''D-?(2?M@']\G\43/K789X!^PMYQ&!>#&]]N
MNZ!EGQ=&H/<P9HN5VJ/6C$ :8S]=S$%:.^M\5YQTZI*K+483L6H)*[.RUC+)
M^''E&N8ECQ7;D-.UMFGY@^:>UZS7V2XV#QVZ"!,]"7B-4EF%]B6:^QZQ.6V9
MKJIE%Y-,)$+OOE[! ]]]NM(;"A5]BN);H)7_Z #CH/7M1<3ZJ!-_BG,;ME@M
M^13U^B?HSSN=-I?%1!C^3Q?;FJR8PSHS7$?0J/R)*#]R%OL@!%_/"_23?)_+
M0DNEXN1>L*S[NBBX?G>Q=0T2WX6;82[(8J,L49O,E0S+TA$G_%R\!O1616>+
M4$8N:Q2WN(U6%J[;5="+1%*1DIHAC?8(QHE!>X*;]2FCU],C08Q^NE9DEEJW
MA'7;"8H_GQ]8-F,/YQ"B!')QP6/C5)L7SKE*<=69W&POP0FI/C34C]7:F DN
MML0H8=%&+-<G:2Y?U>$H2=22,QD?^\DL2KB<+".?"!+XQT1MYPSAK:_JONN#
M&%F/#^41,1(Q^:5T%F6AEPD84XJ)7!$HL\=Y4AB><@<:JO+ *VXPGU?DNC%F
M-=6D.)GU'6,%489"IQ(N8MN!D/D4FBZBX M$&NWV8AC.M[WF C=+78K.,=_+
MXW QN;6RWV0>L2 -2->@M&?I(3@COZB3!//EN6AR%8C6(S6AL:(@>CXCDN"*
M8>F;-EN/*EQE,:BKWD%4+CPJZV=EVF"</ULOTE,VWWH@@U&D1E;S>2>@6E_4
MW&2$06!]0D_-7 S-_5 *3WH>Z7SUC+H=B<&X&6[E]-'.*7F=X'/ES*?#9NB?
M^K"G?G_=:4^5$[T>.5FO=#R7$L ASN<ZMH<UY7B]_"R]_NKIA[M@= !$5K+0
MF\[C&FP3B3\]-M \$ B TW]QS-/R.G:K\XA]Y2)\+MLR!LE_RME&EY5Q<V72
MMAG&MZX:2D96/>'NN<EKH[UMP6</V-LI0?A*!O!1ED HG;PVPY2(Q_;GL?91
M><SIM 9[G.=+1">/Y[.=H1D&2%QV? PJ3G O0R(O25[R)+WDP P+)2^Y;\0O
M)Y0N<'GWVV_V;^^>+]S?:'#' ^^YUKK*S/N;/>WGR7%2I'?J*/QPI/'T.&QA
M*\_F^TQ:T5(#Z-K;Q1;;P5<*)>0*ID-$$H3GCJ9(EF8F,D](5H0$T54SH".Z
M.BT\B:X.-RY^KC+8Z<-3GI=]Y.01Q1.F)-K)B2TA\])80%240$& 2H!;_4[;
M6*@::CLU\&K$+Z8@T5 ;(7ZI TI#J]?N&(M40TW'Z+KKH=8(G!AFN'#YR'D:
M<R94F@1,+=)HVTS^(5=H)GK5I/:/(WCJ(8=C]>V^&:YR>S])QF< 7,1L9L)#
MS'::Z!&S[<ILG;YMAJLD9J,*[B9XVN>M3L]XB&[P$('EO4B,S511NMT4)&AZ
M6&VAH^EANU2&VU:[<^S%492ZKY^5$569@@1156VA(ZK:95QL6X,!59D-0\7H
M*O-Q9C&7I7S<9:-+V[^OW^B9EO;2TEYR;?5$AB:AU0HN,B13D:'AK"E(D(V8
MB@R13:W@(D-J7E'6?'AH6:TY6-0@0]I0)T;+GNJ 4K=G#;N.L5 UU'9JX-6(
M7TQ!HJ$V0OQ2!Y0Z/<ON]HR%JJ&V8W3%D];5TKK:.@%3BSP:K3ZJ+WJT^F@W
M2/O6<- UPU72ZJ-Z&!\QF]'P$+.=)GK$;+MN4N6T]QU,$[.99GPG6\*MX[K:
M!^<7&YN_HBR\*4C0$J;:0D=+F'; L]>VAGO'()30;ZZ5$569@@1156VA(ZK:
M96Y3UW+.]]V&BJBJ3B-C6FU[F)6<%T$0N7(8S*(QPW.T8Q#X?X3'8!0L>.Q.
M& \]YHD[$40S6IAK.)PU2 &3%S05&9K&5BNXR)!,189&OJ8@039B*C)$-K6"
MBPRI>55=\^&AA;GF8%&#9&I#G1@MG*H#2NVNY3BTJ[%AJ-3 JQ&_F()$0VV$
M^*4.*#EX^AS-XS$,%:.+H[0PEQ;FU@F86N31:/E2?=&CY4M[0/J70=MI'QM3
M6L14*Q,D?C,:'N*WTT2/^&W'G*TUM/?=2Y&8S33C.]E";IV6Y_(?FI"\ /?D
MQ572Z.(O6LAL,$JF(D&KPVH+':T.HP)[S5&I@94159F"!%%5;:$CJMJE5M^U
M>G;?6"R)JLRKU1]G,GA9RD8=&QS>LB!*:#DR+4<F7U939&CR7JW@(D,R%1D:
MOYJ"!-F(J<@0V=0*+C*DYE6QS8>'EB.;@T4-4J(-=6*T7*P.*+WJ#JUN^]Q8
MK!IJ/*^-!81XQ10D&FH:Q"MU0.E5Y]QRB%=,@^4!7J'EQV9!1<N/#06F%GDS
M6IY57_1H>=:.L4;/ZISO.^.7UF<9$G\0HY%/)$8[3?2(T79D-,>V^OU]9P83
MI1E":4>KT1YE2%V/];1K3P?6TXB/G*VBX*2VF?A'%[Q0]%)?>+=<TT3AS?8#
M]JXU./HFI13>U*$23:184Z])I'C2\!(I'GPFUKEU/NR8X6Z)%&M71C_.O.R2
M)'T86/ON07':#94+[]]9DN*X/F%IQ&+A1J'K!V+#:!^O@2ND9O-4>.K+<1Q-
M%UN--7AEL2&@UB"[3=N5U!8ZVJ[DM/!LZ+2^&B!#\\9-08+HJK;0$5V=%IY$
M5^;5SI]Z'.UT6N?&(_0NBF<1#($%NQ4AC(4#N1LW]Z9^Z"<ICHWO!.U";1IJ
M-4@;-]3CT:*U.J#TJM.V>OVAL5@UU'B.78(F7B%>,109XI4ZH/3*Z5F#8=M8
MK!IJ/$VLXM9B]/DA3 4,)U/FAVXT%5C)%3#@//9R:(H#**-&R%! <(BY7E:[
MO^_F*&1$AHTSB5^:X\4::AHU0(;XI3S@M ;G^ZZO(2.JP7B3JIT'!.:]F,$0
MTU?'$<M"YS2*4_\_\@MCLS84%)B"1$/]60V0H:"@O.K6ZCBT(Z=AJ%!QD[P8
MF49=D2%^*?%+V^KTNL9"U5 CHB*GH<!<3W@LSD8\$1YSH^E,A,F/C#<I"6T*
MZU#^K+G(4#Q0B@<&UK!K&PM50XV(BISDQ<@TZHH,\4MEO-GM[;M?$AE1#<:;
M5.0\(# ?<7>C*&2>G\RBA <L&C.>)"*E99MUYQU*GC47&8H(RA$!K;$Q#!(J
M;Y(+(].H*S)$+N4YM53;- P2$VN;1SEZIQ8#T(W;\Z[L(X0__WYQ\45]F>R]
ML1"=&F@T?]&I@83>X]$'G2"P+:3.P#IWZ-# .D!EC/41M1D-#U';::)'U+8;
MI.VVU=U[8SZB-M.LS\B#<;TH&\%HM-UJ'M^I0W$?/0SGR/FO!V*5!F-7@S3R
M[N?$5?!L=#!C^@Z/SXCLJ0<YKP;G5ML^=I5A4Y2ST<4VTBR/7=<F+B0N;)S1
M$1<VAPN[Y];0.?9T+N+" Y;A?TXY"*VXRO/O\.^__IPE9[><S]Y<JU-:OXH9
M;KX4WK[W$Q=&H5DL;J YOP:1^^UO__U?C/TUO^$SQVKQU?BJ&* RW_OEQ6__
M I&TN_T7.*#%GGP5XU]>O,-OG4[O?'#>_5?;=H:V8SOR#Z?=<5[\;2U"B(?3
MGJVSK@HB/U7$.HH";V=(?D#^[T7BQOY,[EX5C=FO6>*'(BF-U@_1MZ-IUQ?<
MFBO!OOWJ1]>N+T)7)!;[$+HM]BJ=""9)_R^#=MM^^RZ:SG@X+[YQWKYF]SR1
M^TCK XT\G /_=QYF/)ZS=M]B;=ONLPPZ&S-\6L#O$Y0B_GV=X@E(\.&]@*_!
MPN7F8'["U*IM/V3OLWC"IQ;[#"H[8>]X#%X_Y"UV W?KQN#UX\C-$O7J+/4#
M_S^@WLQ/$S:+HUGLBQ0;<RM"W.Q:>+X\HG@6\!3E@Y,A)B*8L>A.Q'([;)>#
M"&*0@0OJ+P]H2GT7Y_4+:%8BVRA"M#79"4_<B2":J0.0QRSA8Q%;;!K!K?!V
M+W/E64[C*/)8$F4Q"+=U(II3 B'7".?\;<(<V_Z)1?<A ))DH\3W?!"_Q1:*
M]B6 9U55S7I0C[JH1A $//P,Q@$$#Q4'D <$4W_LNUK#%D^65KQXM"-5U!G(
MTZHG/+P5\O80GH5?7081^^B/05?G22JF^DVJNT[??KOX:_E*=I'A25Z!S]F7
M=,X^ J&NZ^(G#F8RU&V W_EZ\6$?MF_+WLB47 #[XW_A;5/@6V\#.%DHF',N
MFS[<V SNNJHA:'.5#.@8+#ET?1Z ^L,7:N(2O"3(/&59>&N&7VIWD1N\=!+P
M==$%'VR*R4WM];O @01<=@*OE0K-7<5@$P[6.!(B9"* WH6R*>!I%DV#RT[%
M0J]!G$J?\0_)8%9%E!/ %1Q8E&J-2.$1@$@ 0@[D"B:\5XSA7?FD,G""L3N1
M<BU[/A3O'3A6M$70ICA33C;YY@<!/!LBB"0*0Q%8^5WX*P@A&\.=62P=<AP!
M8@D^0208R_C))/?C/H +#X)+05W0J8-USQD&,F, +9+-@:_O?(PP'SI3+\EF
M>!?X8TE'B2BEWU=H!23R;W@G=IRS,)N.@,- )K&??(,?07L"'N./Z21*I)>)
MX)$Q4TH(HD"ED@0 ;9H KF=X)_2.Q\$<8.6W8K- X6F:/I"//&DS"3I 0-*?
M8>>F$3Q6]4&U" G4$SC-#PT83?2;@'[ S2 7$)RRAK6BM-06*:DOW:,J2\B^
MZ#:H6XN.6<JN0%JI<"<A>-D@;T.21+C3)V!^[P-EXS5)YB*PXRPHNFM5E0>?
M#<0NGU-5"JV"ZT2QR<GIUR& N312ELV@7_@D/H+X '0'W3W8C1]FTL_''.B=
MX0@%)8#%&C[SL6@#KD$.3?"B\?_/WKLVMVUDZ\+?IVK^0Y<FJ;*K((;@77:<
M*MFQ]_$^GMBOI<RN^92"R*:$8Q#@ *!L[5__KM7= !H42%'4A0O FIHD$@4"
MC7YZ77I=G@8W!J;U,L*1;4+.$=%%ZL'78GFY A\C N7M+7%Q>L':Z\ \%G,#
M,@?SNP =!@((2F'M0KVF4UPQUQ(&#2Z&E*FZ* )1N=1+6 'CB%60^@NX. !@
MO52-!NXT]]4.P5[Q#=%SGT-Q"GY>(%QMC<I*#I=M(%/C&, R0Q4GEK#%!+<N
MFH._AGB^L/S<CU\^EWQ<F#_8>4ZO2K?UDV0%]T3XP7+,Q(G3G0P=V 6)!*F'
MD@QL1!467Y+"!@O0 %6R_F@8^E3ICY_<40>^#_CH>ZB;9Z>SZ%7TPP +U_:[
MG:& &0]09F&(X*=J)2IGN!#F8 ]A868*2+G@WV.ME\&9-;;5R/4"WL;L;]8?
MT^WT\J=H_SQ9H7&%KR7:.*]]8] 995]HR@+[J!R$4"HGHM!LL$X<[<2A(G"'
M>O655@D83_@6HJ<D-P8MDRQ! ZF]0KY.T@VZK+1V</Z%>PSC/>YUW/Y@-!GA
M3@GTW/H^[:MYTIGZWAD^K[2>S<JT5G"T2M'X*_-9#*N\=-&:*HN!\0.E)+V\
MY%R;0=A=_0!;:UP]' -.EU(V269R*]_S3*(3)T[50\PO;^%9$B0D1M\$1U#I
M8YZ"DQCCL)6N"X)\S.HEG&SJ].X]^U"Y"X60+;0HX #Q#O 7/YJA\@45'QK_
M,%WW92O=5[QQ"-Y4@M?'$K>6N;\)O\:1\I-02O34*=\:KT09 IV ^MG1CM8\
M4*['%<!; :?Q;?+I-VMH;<9NHU YAW<(Z>8XVOXRNC&=L%%-U$!+G*[ $XSA
M";/R*A3?$6%8%Z"4C3:XN%%X52!;B="?Z+[@%S!B9_RB7 $95QU_WR3&N I2
M'XW_^@KQ5C"5L#2FGO9 U)5JR<,J[/6<?M=UW)/N1J60:LG(5Z]>9_BALDE:
M_>7NHCT^>U1:9I;>C18 O0O$BT#DXI4>CCJRS-%SF<@T#?)1.B<]UQF,W V#
M[(@SV-K(_ZPL/54UCTID,ZRL>^7*"?1#KINVS6D4;WXY>PHLZUB$:6]'7<M1
MV3\3^./[1#MXI8CL^)$BLN0#LG_JW58Q":S 'B^B!XMYZ65QLOE.(1N\"&^/
M^RKE&YG(C?%M<<,:P)N8;3D:ORE&(PK#^F>(828=#U8B=PK[(- G):<<.]9*
M7DP,(NVCC,+DP%XZ<T,6WC>)$02S-I2A!$=GL=0!H/3*R_2P5EW&^L<J+U*,
MZ>X75QN_/(F"PYC)2E?!> 31;O?MB%.].8=[PD8.G<!5@$_"[8+>F^N 0_Z.
MH.#\RU!%.V$*BE?/@FG8"JA\I&SSJ%P=T"\(FG+EK2VDNAKNAE8,0^("[B9Q
MOPX*6,7+S,+ =YE[?HQIPI7,W=D*QE5Q">O/S)<9G+)/,K[V,4:G6Q,SH^C'
MLV-8@+"4S 4FL -V4J@@O^EM5$/<'#\QK8T=4:5CRSJTK%_?HD?]>7Z:+^$O
M@-;T1O\[SY39>G?2FDR8FAN$^HMVC36\#=GCG:M06J6D%TZ\UHY:2WAJZZ'D
M1VD]5% @O'D,"7<DMW3!W6JEXF%JYZ?#3MC4*^-0;_P<$Y90RV^!&2V]\P"Q
MP!A2+JN:ARKWPE LD[F.B..? U]'Q7RE,]0E>F)0]<3:V%Z8K">\8*)3=E.I
M J+]RI@+!I;1X<W"5KC+O"G4#RJQ+*:7>(%1T[-(ZF^A\.JX:Q[VNO5U_2*!
MM".E9O" -D IE;LU7Z$[U<%,HJ_CI>(&-(;0&B=[B\+3KGX=T*0KY>!Y*LJB
MBK<Q7G/2ZYP4W[6B) [F<JQIJGH SI&GEM%J@9%"B1H,E+@.#OSDCL<=-P^D
ME&+3^$V]=G!Q%.EY,+8@9" ^,/@X6EU>J6V^<F[A3]<XC[!(IF:AW;4S4)&A
MXN\S>:$=>;78LT"3!@,?<RNBFT<S88%-41D+[S*6VDZK>WP"N#]Y%YA2BI0A
M/T.-C^E3V^Z;#TNF'^__7WX@/7 :UE+6ML>@KBA]\06L"_$'V&/A]EZ6)U4O
M.F6G%=QV--C,,2P@A-XLUU!>ZJ1"\5?5:C\/HN]%N*-J,39$8_ZS\+LN9. #
M_L:]*J) .!]J,2@. O#7P%M0B^\[K&O<N4;?2X)FA^55;-NJ/5%[O6[/Q5R?
M5JRPJPMUY-03B>4"Z42[RM5(%%S+]7$R)TP]8R:N_2PCL)9EO) WD=*7\#Y+
M4+UI.:&P9SH!LPA:<-=>3ZW%6!4?P*-Q XI.:ZRN5&.PQZ8F[P(G(%"/,QF'
M9#5']8'#LYXW55Z<CD2K@&UH_&_];?#J0';\N0I-!T'EGG0WGZCL1WV)_2C^
MHD)I7^4T@+?1Z7AXV8*IPBZML3RJD[;L9-=GIBE%1>_ :.@<V-K[6=Z-VBZ9
M3='2]B=1G,VF#+-OH(G?V4[36YW;%V=7F "[R\P:R<PJ??3#8&5J+\!^+NRB
MP "HH2K7;6K>05E^$"G;2U)!HN+ET)5#,YA%JS)>%1U:UTGABKNHK:F*-GVW
M@LV)WG]CD#BZZ_632G&]K^B5!?<=J.K3<(;_>5\H[,W[GV&W-?N?=YDY4S]8
ML],4BV[[0[A3T=MN##!C_0*LR,"'E\;=#]AZPS6D(SZ8)O?AU50&'Y/WF44%
MCT\LX(%7"<9% \S,&VLV,[592S#6X-$J97 A;[D*ZSN."AE'2-8W)).U#8D,
M*KP0W)A%JG)PCH.4-S#X^!NH%4SU)R;]FH\O=U^-FZ.TP#0*T'>/5=)>Q3#
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MP^G96R=;W_8)0(KQ<HE1F9DIU2SHY"R[#:B: W=4\ 9&,%08P ^F>1^?D#W
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M_<@<H$2OTH5W(RZD@+4?FD?!C\$-R!V("X CCS_^\?NF.WR7L2RM\:V#PI?
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M]8+]CM1K?Z<'H$AY(MM;9AH(][RPI%  /;B]KW_2SU?;IO0J C\]\=.5WJN
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MX>-H"Y#&DT/7D[,K4$^]Q@:&"!!L8*AAP@:&#0QM5.J@U]C $ &"#0PU3-C
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M&X.^$>=VKATY!:^I?_ S#JZU(FO\R_\!4$L#!!0    ( #PX:E"E&.<9*0X
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M*Z7]E]7'OUW[SH,?$')1/ J]:8+=W^<X\,@1?OE'ZB>OF_P*Z&&"H_6'@?.
M@LP\$83U7@%%[6C0A?4]L;J(#?>:K?]W)T@1!.NJIU5@?8<2HFB1=^E$(;%4
MXY%+S,V4J@KO@HB1ZR<0*D2@J:!JY'F9_#O!K>-[X_#<6?J)$YSCQ0*'&8LA
M5(E 4T%5:4'P_MI]5@7&MP06BB+DR2%=^;@>#31ZB)/(<4'2P(.B:K_X"3V@
MJ#8_QV%"9)*<:D2[0[=.+1@5=)1.)<G#3 V>%ZO=>D=- O)O/[G!H9N2CT+0
MON'#4;-SPFR?_NHG\_,T3O "16MVOLH1)0Q2\8XZAY-2];3VMR)!AQ@\)>>U
MZT8I\C;-STDR9_@ 95\0()^VW2L*_60-^YS\TG>=@ "F3BAR$YR3/R_0$PKP
MDFK+RY<EN0F*X2T)6,6[N207+/R*R"4QL^/:B8X ,$7[#:?D/+MU7IV' $D0
M4@=!C_:2L4YX4!1347G7;$E3 TPENRR.40)36ZLG5&"7:<-\0;D3O0: "MS'
M8>*$CSX1O-7ZB"A%-TAIL.4;QMZS3SW(XJ2(P5-S8\)+%"6OMX%#!#+TZ+[-
ME#Y!"79UXL%1M_ME5.OF@XIE00+AJJ<5W:Z7CN^MS $)Q&L J#R![Y"+_"=Z
MA)*-V>(<KH:CQ"IW8FJ?T7]1(7MR@NRFG)P[4?1*] ?<52,&4+D,RQS(-0#4
MX2Z/M%ILIR@B1LO9IL?K^RK\!7 Y\<"HHV/4#1TU8)1(=>#$\626K7NQBI<"
M1+CB:1NQ_NU4E;]U'4DKH3!Z\4'&,P>(4AKNZ2DDA?CJ2:787OLA&I,_Y5A=
M>GH3:Q:#'47N!F0G<M=05]%SP820_)E9A!=\1%:+X7H&XXA<"7]Y<W)\^M/Q
MN^/C-T?+R,<1N1_^\H9L^#0F&.%E'O$AX+)<@9]='";H);D,,D"_O(G1XR*W
M55;?!SA&WB]ODFCW<.Z6&96Y!ESF;.[(*L;LBDS!HP_'S3SJD]R*1!LNL;4J
M!#=I.D;RB3$D;RCQ3BDNT_M!,[V;V3Y5Q').-BQH-C!R/^T5N376'B-70,EI
M)E=,C6_;Y06%'W6KJ&8*:VXC.]3M7)48D5\L(;+NNHC!5]R"]D^?]X=VOL>B
M(/FS+7M:@.0:/Q.C]>/^T%KE#&2$[I$,U]'XTZDE-/)W+,]]SFBU12_Q:!4+
M?A0T?[%%,0E*:3EVQ8BT12,U2VB9*O/5CY@E*![G+6C_:KY: D?$JSE2:T*>
M')LON@*Y#16VU'86!J/8_!T/HU@@@:8@_L2J+<\A7C([BC'"_&,:O.]%TML*
M!ISNF^"+I2XR^LT_SF'T<^7^U"JE!S[JA#.)"X9\L$H1@AG"SQ=G7+!*"[:Q
M@$I$6^ :;"<+G-H,Q@2KU!^8"2+V_XD%[E,8U97%406Y%GA,X3M]LX"MH-4"
MKQJ,5I&"PX)Z"_QM,.I%BD@9]?NVSZL*@0MJ+?"]M57=96KW^]AJ+K9GG!#6
M<']]O\6(:_*?6MH]W#K4_IRCA-[6U_2W[/U0"=.&1A";B*NM%9_.R>+Q)$UH
M:R'JU ?E!'+A**YZSS$8QW'*7IP4$6L06O ?I<F<2/&?+6DH@U%,!]G-DRC;
M]%YV0MVB*,-)DIYZ<.I[%+02ED90NNB!BPP/BBXJY 2G"9)Z:KH0'U&(0^W"
M4+M@1^W"4 ,PU #HJ $X%DCV/O0:@&/=-W'%"?''YJ=,=YD0?_QUK\AM2H@_
M,?_MBNDT42.0U3O9X"V%4[YKU)M3O=0GQ>L+&:-6MY[ND]J-FS0CV8;@CPC)
M0@X1EGF\+V^:Z]=BY.[A6ZZ1X2\VQ/.D2*T6X"_"9Y+6V,;TGOSS^^7-_71R
M=?ZWT<VWR^GX9GH_.?_OOTVN+R[OII?_\V-\_X^+RZOQ^?A>/MXAMXZA,1 @
M,0KNO#<H&8>$#'2-8]!U=^M!-5V,_YG&>7+//:[)"<@DB\YT\(BXT<37;%3$
M'?HC)2\O0<0@?O)=>H#XV+M#+G[,]P*X*4W_N"CKZYMKW(LT(GHH1R973]F7
MDTSGQ)<OY'KMQS!/LPQTC51G?.^+:!YP[6_Z!CUG7P']76(0=;_1+HG;!BC5
M+Y4^3&?:3&8EBV <CJGT$PV2/@2^.YD1<Y\L2[3L9/:#'$K1,[$%R =T-E)6
MXC$*O36@<QPG.=M%2.P?!W.XHI<?!DCV.0Y7([@H9?3OA!8V3I&;1N FPFU7
MTJT)5#!#="$I&:F!N^D<N,>E+?QCB:LW,5!?]+"R;@[HH%U1O#-/#_6?T"59
MUR7:BAQ9J]) NE$))JY/+D;C,-^SD]G(R^^6H+AHBU64:((VF2N:<E7LG/0S
MY#L,^0Y#OH.SG:P.WSF5C^N8>@5'O0Z"QNE6<"(: "G.*H7C7_&PDHD8V5E#
M?5PX)*('5SDU .S%77F?V"TL8FF]60UHR!4;<L6&7#$.8ZK%QL1\,:&>L5QU
M@@64'Z-<=V]16*9<*\+M2ICCGWS5<6L;,^6$Z6RP_EBZG/G=@85IKC/;&;&Z
MY;=#8BNO5\9D02I.83[1G4&D.(7Y5'</<[4IS*?F*ZDN4YA%!A=8D23&*WL_
MMJ!ODR"5O 16W;9R9_E^+0(DK-.W[=SH/H1F4[=AM;Q9AU;W+TVX9;2==;W=
M<X8(YV+8U!%60(AZRM^QJ6&H+BYM*YV3O2DQ$DP"9"WU]L8\$TSMM*N98-M7
M7I.]R]KNV6ZJ";W^)B[L32%6_QG^K)V9[8;L^E=;12%K D_%C0Q5-4WT- MP
MG$;H L5NY&=H3&9G:4SHB[,&=.EBX42OD]G4)Z]MYKMT\@F[O6%R5E(_3+$Q
MQN$,1XML UQ0KVI0<(A;]*02$?U544JH59*FP>FY?8>>4)BBE<"#^YK!($NF
MT1;FWPU._H8"[XQV"A_-9F09(NB0Q.!&2"W+ 6CO;G:'N4 /,EG]54#4)%9E
M+PR4',">48%AKJ_OG9?+%V?AATZN WY'@3_'U"?U(YPY3SARLOMCDN3A>P@Y
MD@NH2;;B34V8.^$C&H?W_@+-(F=!C_%,U= -16Y*CQDE4_+/>.;39O-]"7U[
M1*0DD*SBDC?A/!+Q81WU,]C" LB%T1JK-M@(8M%/>F55!V>(?FB&IH(JFTJ'
M]ZVIY5#TQ2^;H.(=Q?F5?;H,8 (F!$[)KG5>L_OG*DA:]KJ!WB$?CI0>KO,,
M9@,XXG+R0J-:%@$E=U9$V$7(BZ_(379-<[VO$\S=]FLHD0TG0*OW?AOES@AP
M<]5Z&-IUG<;2]9I=-UIDU^4;8JB1%T[.N6A)K%O1ZKI&$&UPNB V0DN<*D&H
MV 7?_3!S'8W#!)&WE$R>0Z*2Y_Z2675GKWE;><A6 (%MIC->$QHC]]TC?GKO
M(3^GD?RQ31KYZ+?+,,E6+_%3]BT!H*EX81<^U7S4(W2&DF>$PI7)_2WUO5Q+
MYFD19XA<9A#1]Z,9>07W>.F[GX\_PXM?NEE/S94[.Q]&2V))N-D;R?7/=L+(
M?>2$<>;F@I>ER*]QZ!Q05;L#QP]:U".[@I*:O<*E.Z47)R?RXA]+C^@J\ON/
MQU\E:O?$ "JI B7HLF0NB3+0RN=MQ5R5/)7B=5<XVDJUPR'YTT4+F=HX(& 5
MM%X3(YR(;/@X>HQ0OCC\97& 2!F9I9G#XLC4/:E& Z_"7NB:Z$*/F(!.^$C]
M%_F@^._./W&4)2E30USF )( ?YATJSMSN:B=O3+DX(<M$+2B ,?:)W>#$[2>
M"R]36<X%I*:?"XZ2>Q0M:/2.'C3PG5D+PF[\E56;;R\/KC*O!B!UVJS*8&C&
M0%XA4IL[#3R,X("'GB[[W--EZ,BAMB/'/O6T&-].X'NF])#B $'N<,[< 8XK
MYW41@;:/5"D[@].'V/=\)WHMX026C'H@$C3$45+"G_S7-N[DH]*267 E$A<+
MWM-]84N._!@'/G4?>9E/G=@!XKNF"8*-6$ON;VF\1;<T_WG)L/$JI_7,Q]-5
M3NN/_[[V%^1NYP&-22%84EA>!OC:GZ'I:TR3L4<IG:L=^,YM\GJ=0+$4@M6.
ME[>!$R9K#HQ#5Y:/=7#ZVIM%/! F2#N/F8U?G])=+ 41Z:V')/V1;3+,A;N0
M=;>6!BJO(=W+NEU/:;^S7EB%NWSY>]Y3K7.)Q)6*PI:.:_6*<9LNZWJJ04FS
MHVL:[ZS%HD:*#6W31 @5LA>-::S5U5OEF?#&M)G2IHCK+V&,-^;KY,:K*(?:
M"DU]:KRF;D^P'5VX!/TCF.]O8I1J5N!:Q%S ?6A.JS+!CK>-[E0,]0(S%NAN
MP2?68;%;#I3IUZW\!+H:B$<)<&6 AA%K>O?07A6"8!OL3^8H!97-H#^9+PB=
M-(/^-,@ O^?N3[H[8RGNN?N3[A.P;1-:R80@Q@#-DJ]7(JJSO<QI3BEH(G*S
MWGCT5MB$/^EV_(AI@)8DEZ?9F]]VNRDQ<^/TXZ;!,JHU*SZM<@_.A&9L,]M!
MU#:+7)Q'=3GRC%.Z34HA/:*'464VF>N0ZJ(8 ]?7SS 6Z#YQ>F>!0#T3Z_]\
MB.YYR4(VQC3=[2G%U+)< 6!Y/DQ-]2)CA&YU(J1U>^%#F0OF:Q1N'6M9(L2*
MAEFS]$-6'[+EY(Q[YKC_^.9=J\+\5AS;-?5.CG4[401-/=U,*[-,MW4L8O.T
M[(!1XE@WG4\8]W2?<O7<ZRV-#] [I^#3B6YOKGH^K7<<J&L28YBY8MEK?BBO
M=19CCKE6E0KF5/8Z8^-7S/4B]BUJX%D<!L]/ZYU7M7T*&7=T!QTTB5FK/I4V
M3+CIE7LB+4H9DW2[2_0)(+_1;,&A3X=K.0GU%F:,.F!=WM6 NT^'I_$+<6QJ
M5<YF5QV>8E\SJ69FT8G!R2M]LT1DP@#CTX'>ZBJG2;"17H=WQ#5/_&#<.5R=
MW/.HEX+%!D=I^F:QY,0A-JWN<*TN-GN*<>/P-I+ \+""/2>'YYH2'?S&>'2X
MIA1TG%_!LU-AGMDV,G/JSI&7!IF!D.&0*6@:EEI@(F)_EJ)A\61V&^$ED;Q7
M>EG.,ISH.GB6/#L4#_5S-GO#/M_>^S"<LWL6*9D0EJ.1U>X3% IT+N/$7]"K
MSX\8S=* IJC!AB_! *N9AE:#TAJ3&6@\D!"XOMH+?7=>_$6Z@/63VWJH-]R(
MV,)QVWRH+]SNZ$T#AMG&(V;BU6<CJVP92!.KT@.*&M4NTP1%:^6YE4<KU;Q6
M!* *VJ[Z:U</!GU8]*IJ;,I!JTU;?A!8):,[D!,C&@ :+Y81?I(>WL$#HX*.
M";GHN:@XZN$4U !0U1Y;$FLM^-8:6')C!(3 [2==JK19+2IGKS*#$X3 #4TR
MAR:9$*_8T"3S$)ID@E2(+>TS9=2L""]JJO:UUQ,(E6#TQPP[6G3*6!688]G9
MT*VS)<TU-CAKW6ENX*8EY=S[DS&M2[6>&*"K,V.9[M0.L9-#QMT@QIO&W@W:
M*SV$3A.U##*H@ZZ SI'USF&P;Y5QY1 [RFPYT6UJ)+P;+,"5P0J+6@6+D&1/
M,^"J.!.NC, 9T_2W!46;\4[6M=1<7=M_;KQ T)HQ2K=58R"CJO,7))J]6I?
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MM"W(?VUO"3JT<9H[5+XA\@*=Y=QWG4#<Q]H P#Z<Z;#4WK!>%[*5EQ7U^C8
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M.P#8*PA(7U#ZZ7ZE S8>TO7.7]5%113M"&4(1J_E'XT6. U!Z:AM5U(1GF_
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M"=XZ:>M)I=B"W"N\I_6T&*HG ]<S>,]=)@T[$BL2.A-=+]PY+PH482/O:R;
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M 4E3@2G[P,Z .@@JL+] F?2L?52C!16$/\$D<,&HH(.-$AZ3PV:!QM1$(9]
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M<JD-O%&7@SZD>ASM^VXI!PBX(-7K@4W#9\77!-XZKJ&=8#OH+-,F4,L<"AD
M%X(>PO%8(,AA$!?Z7C.P<[XLQDGCN+'Y%/T."X\W/NUP<I'$>1R@Z_T]BL/U
MAGR4",>?6LC$ %><=5]'V);$S2N*2LKV0?2N67*A/?F#/9&6;"J9N&#'Y"4D
MN,!%\/'BR84S4\1N@1[.O7?O>'.XG _.MB W>V'^Y=*S#'R*OHL-B!*H#!6C
MBVXV9 >UWGQ*R+;H<QK3TYS3. OQGC<2*PF=8+GC>9?<-?W,B31./*YD<+
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M5$+XX<,\M+ARXD'JCJ+SK&[L60Z5/N:R,^Z4#NT<7^F9V ^7KO.+LCO<\\Z
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M! 7'8I%P.PZ;Y-C(#$+/AK;P$F>F@>(#'T4"'^@916&*=(J*&0> " LK0M_
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MQ_H.GTM*8QZ75;$7>,^"^2.OQE)$?1YR[_ QY,6 /B413.F=NO325YJ>YMI
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M&S"Y@2 X*"4'I>C@9H9WP"ZP^ 739Q8HSI^]"(]M<3RSW*9X]D-D.16_*A=
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MY2NZU7<5;.$IID5!S<.62,NVG=2T)PL@1X R]3F,=( W&@O:BO0=J!&OI.S
M;YRA<5=3H9)Z3^5%6ELQ(ZO-)YCF,+K#="&*$U8P4K$%JA5>FEM'"[R=;/_%
M2O89%>P5KY,<BE4[ R8;/1O@PM$'4"$3#V14/A_."6P:$K8-VM*-1@S=HL7T
MUGGE@H$3T6*X;+S4J_EFRAO=(!.UW#75,E?36L.%HOH#5$L,9UL:NWJ.2L5Z
M54VZ63WIPG(I3$,>B\[E4IB^:B^7PK3%$XOB/B^A=,W*WI[+SLM4CTS(\CYJ
MEJ>JI_ ^OTBR/&7+$XU2MAU?-WEV?$#.Q>/S^QS47'PK5]N/!Y90E(>Z1YIJ
M=V+O)RF,XOP\"&,4Y\^JIYA=W];7^"$U![<CC <HF?AAY ,@X''U^*=PU*GK
M>4Z_FF-4/_'J_KXMG;LZV5J F?>?7_6KR$>U]QF[ZM&4'7._@4\8/=&J1HT!
MRY]121+21V*0L'U/J-B!2WHY/+ZUG=(CY-#"2LKS&AG4!N7 ;>8Y>F@N]E27
M05W?MK7P=+,,:BT^_?"& 1!ZE_HVED&N%-ZWT)]C&=0<H][E7S\-6[IW>=G7
M@L&G2[Y1<'K-W]ZEGEL@>ES!ZB5>-:G0B?YB<QK$Z/DX(",/X47VD7#( UHX
M3?&Z3I&JYAV+$A<G5W"<-&"W!QG8X!2D\ GR21JQW.\-*S<85O4(N5 9"$!$
MQ041W-+<W0CN<$:F]'LN/B'SCWV<,K@I54H#X2#QX;9.SV*P/F;+L8Z!)?3%
M!C )0"$"N,A +83D"MO381^L3^V,V$( N\*YFQC62=B%H78P\B*211AF-,FV
M"FFZ$<W[D#9D0U)1K1?"1=F+8FPC<LP0WYR-7C[$*0_<R<[EER"-Z<W(39!#
MU8WYX7?U%\AM6O9ML>0 * L_=B:]RL=CBO%-T:A#Q_-LQ<7QJ6_"N[YM1]>N
M-MZ>FW7_5KM/.?ZIN]NXY[F!N$[C+1N@^IW#P5?U-=TB9=^J&8-"T5[=*?3I
M'X\HQS-=(PTU.['G.S*$]6:5ID0/4.=VH(> OKX[";IX2(H(8UPT41/8L2?:
MXK]Y*_?\,4A XTM^.,0P@%A*KUZ"5;@(Y4!3Z$1$YGEH5 M GP-?T?83U6_N
MR$]9$++6FNHS@S)I@X1*-5;_[7>]>;>:YH -L5@8](47B[S9T_8F=R"RMW;B
M>!V$\28.?X49,<#D$@=)]6!;\8A1@I+F&=$H92>'B 57\)FS90=\("@9^W#2
M)X\=5M.DWS@UUN %2 5/0)F"NN2 O9.ZB<:&+ UK@@R"2Y6R6*,D;%U;5R0G
MR)*_E*TU,D\6P2% O4D$+:UY"D9?-HT4#A-XQ'D0:CQ!ZZ=A"X::IHN"-20J
M/=#-^2Z-DS#>!0@$(\]VYG.)#H1Z?:*M-5_1Z/$*RD;U 57?&K'JA[W>W,(\
M1VP6ND[C$)[]8Q^@=7*1Y'& KO?W* [7FPTDIO# _EX^,I-?1=K@I;M^,>?M
M9B7:Z$>>59)1ER,@0RH;P F(F71@Q\0C'^7R%9^JGF1ZL7*U:%'8-GKZCL[>
M3E]DV1Y&IWM&G=6W8K2+%^ 9>X-9/+R.[Y'P8M..[1"Z][@*SU=[E@E!S$:L
MDP!B)B/8[^AO:GL*:[&(U> M^1A.GVEFQ%!-I0EF5H(<),K(Z2GP+7$+&-5H
MZ\^UPU1MQ?LA+O;GXRN*%0C",*4 QP5OD'IS\:8!;.\4/:[:Y8#8,XV7C/D%
M"&<-:MX6-K:^3'JB%=_VSG$7UVMA0KL=KS&P*!V4V_]ZPE]O@* ,QA(PF< Z
M 5PJP,4"I5S%IZ[']>,D<O/9CL^"RFM "2(&TW,?4:<&+(W&E%%X'"0LK3=O
M 2F\B7,!G,W,SG&)DP=:!Y6&^?,@3G\)D%IKCQX"^AAT$K3O$)0T>**TZ6)T
M9$4YI2<,(X*E%.6E]@OKIQQ8Z5W EA8,!\;%0NWG1WHW=9%4@C<V-G0E>AT\
M.RI(SEB3]2W8- Q+W,%0(P,[+L'$;EZNVLZ^T)I;D&I>Q<D[OZYO9!WD["-2
M+50AY^*'=P\!@24TY*'244O?!0/FWJ8G?<U-SW&0Q=GM+H5!=(>/R1"B?9CS
MBE(WD*PU(5$_W99('^[IDM<\S]-CY_H(;X=C>L&?8W /051(P<NIT7<D:2D+
MV[,7%2YW>_HC^>M3F=_)_DCV0_27$0WL<350+UZA&%H2M@"A5FN6C\$7VJ6*
M'YS?X?+QPZ]Q_GB%D]5F$Z.8[L&/@^1W:;M7(ZII[2I,W+RZX@(4US_4<JOG
M5)^)$&0^3D!0B0'NB1P^6*H6XEA;Z<-6:6F7$2=T+=:LX<$E/<9IBC_3"A_!
MCOPE?U;:?"C1-5@5*_"QOY(I[?B^9 7"@I<?:QHM=+&)=I>$9+GMH3D!Z\U!
M=9D2W(H[.!D%=S(?)4NY.&71])0$C7>FKGE SBZ.+?(N'#&G5V//=&.'*)YT
M@\=$\-<1^R <\;].72X KA%OJWD"QM3\S&'.-;UHFXPS7\MW+.)W[,W*^*6;
M[R/NN93B@^=2T-+AQW3W6>B E?:M1!EY\3=99!7O[\2K>=,0VT_7KO/V\7%X
MCL-VF-&>IY!(=!Z;,^J.PCL2?H?5NR0H1P)R\SJ9LY^G"UO=CR!Y*"H.J.=.
M#A Q*!3:1]1%[0E:1X1$35YMI"PO0M<Y0?9(C[>;!4A89@<5Q9/+DW$0L;1>
MO06L<"F12U4CPX,*]<**8)V(S\N5]@_R-&VEU/3S<+M:"Z*(]X%16:C-DQTE
M 6UO;M28>I<"H\P2=)V 1N&#@7W&9"O.ND_M.81ZV8I*9.TN4GK8N*R^1'?X
M1V #66:75'K;G"O.,7A'%IR#^ET0E"/+3:'+-F%N-6]Q^NN.QK.7_CN.5ZT[
MCB4.%35/PHO1DIU^R1M0YO2!,JC9@^/!T3J/O+JAU9;#.5BVE(?4GBSW.[7=
M$^ELAC*'L6KRI?L&IH3Q7?!EE64PSZY@OKHGJYH@5'PT.$3'9&W73]?%8X4D
MW!-V[ R5,P9Y\ 4$C/5/?AB]%&18184^PU,MMPLX""? 60'""_Q6<IO^I6UK
MY&NR2F1[\4N<92=!FCYO<,K:6AKYT1!9B[CULW'@900W7/(#B# $H<C14S>3
M 'C(Z\8TO" P!WRR8@TH;W BA^LT'GKR2/;D.=V4G^ D3^/[/;T(M.>J4O0M
MPBS!ST4IJ)K5(MQ6!?4A_Y76]A(1'O#H6@;0P-XKUR8_E+\KTH]O8 ;3)TB+
M9JWHX], 9>4G;J!J00QS;A:-0IF[B\HSA9W0I;*G?J]O$D-10%/YRX=_($+0
M'ZO?E]G_I5"L<%PI5OVQFT'#F29HE+^X2$*\57RV/T+*(MY-TDY]^0DF8\^P
M9G/G'K"&?+5+<YX#,^!EU>\XO[F=AQ7Z--O9<@HV]SV4HGT/X35-^1F0I][1
M1&-P&UKKR$_-#VTN*9>Y#9_\P$]J[6T<^TC:735TL+#O*Q0MGA+MJZN,X#>R
M^.M5XD*P&EG&%?>E7NWMZ$MNEK*]0@A_IEE.1L[61<XB>(?D#8'[P(%+6%'#
MJ'"S2YAE/[%7YCR9/2B9>>IT Q@..5R?,GW&:]S1*I9@-0[;-#YV&0?W-$,B
MAO0&I[X&,_*T?J(6\>MC8FEJPWF RJF-_MQU+WA$LRP*MI[ZWRB^0UXXK.+%
M8#G@D0)C=JMX)8&G:\<49#*\D.^D9 6V#LK37<JC@OFS?_?R0]AU>UJO)OW&
MJ<NG1&?RX7I>D.<ZI??.^?,UT5Z^2J*S?^SCW59_GI,C;1O"7E8N6HIQ5JS/
M"RSY^.QOXQ"/.N"(?A<&YYB+5A S_NRX_FP<Z F=UG@UVD/+-H[6UY[BL<KA
MVA/5G+U>@ XC.>J,3I:;#E$;<S<?EI9=JVV+.SV'>P+[NSJZW._8TWGG1H.8
MR>_>'._9IMZIF=:7XW=I]$H]SD*$LWT*+U7:"$D0T:R>-4342;4LSI"Y0%2Q
M]*$>EA1&6%IM6E78.LC>T90H$QLI"-BSCSM[I4T7;!M-7 ;L0E"7EQ@TBV P
M %BF3<4+_,:X66@FYW8@R&@,CNKA%@->[?-'3&LZJ;90[J-@4J"UBZ)36ZHX
M^;'<&4$%R^G*3P0.G:!B,D]KY,/!GF+Z=M3,"4H:-D'@-+]N1VAA,^@*HKY\
MQ6'0'3BCR8^,B219'H<G]&UQ^JS>$;R'@,%FJXN@@U8(,()I@/PP_6$4L)1R
MO-1XN:DM.(""Q5R]<UGGIE4271*31O_O/HVS*&:MO-7M?I2420.[0=(.^N3D
MWI3>D44(*ZK+<S20  2[C6#<@,AN+I\YQRF,'Q+M":+[^_IX=-%S,#UP+GXX
MQ2 $6$8U/JH;-30]]]30F7^JNC\>(**/0"]1-XG,'=FP?GC!.$)86FG>HH$&
M@9AGT]PYY*M@"]7WSJ.D+ -3DY[,68X 9>JQRW0@-^8X;35ZCM*($U%V<^VW
MZ0M1 N"C^CJJ_4U]#)J47%03Y/19_M0I?(((>Y1!U8, 'M:/7]I&+44KKYEZ
M;OS6Z>XQ2$[3_4.GG\H;K0HUS7LH*>I.+@8Y9Q 1UNQVD#_]:M0%\>&:4 U,
MK*Y6_X%K/&CEJ%&^!Z^^@-1"U[/!H?%Q5<O&T?C@3X:&Q TPY0@8RT6,:/@J
M6&HP3M8BAZ_ VHE.96]9]9X ZK3U9UA57D[L-(5!!L$?(\A_^A-M&]#Q5)'U
M7?8Y^T[;*+ I($LS@,*M.QXV@L,D/E#T2KY(YNE64$6YHE3-,4S@ALQ-.,GC
M9!\G#T4-.YQDU4=O(+475E>8ZE;C/99-KA8N=8VE<+%7$OG0Z!!7:6<P*[IX
M'HW:S"SW]/9,J>MFWQ)8+\=L#I<19=FI0C)0BP9JV8#PA9:US?90K4=?/1I?
MY<5E/;T>VY-H\UQ_7[+QM2/&%HS+AB#.%MYT<5)TD@=!#K*2.^O5XFE4LFI2
M78')'F(ORGP.PU,KV@P$KA7M3,$D!)6(C;@U??_"'@TWL@&JST"]+%I9TM;M
MI(^5H]22QIKFB.U_R$)G4R!.@\P]-X1%A)11$Q@/&L/Z7QC<HX[?SFJI/PFG
MKK/4HZ KG/#VL?$]@D5PLN#1W62MP]O%QDE%BE<UFW)9D"W"90?Q'7?7?@4O
M",M1-VVP+J=H?_VSO/PB<46X8W3DM7W,)L&_F[F+"FLW?PBVN[^<LHM;+-QR
M%<4-%^OK([:B%P&&8%FN71A%"U#=2*]DK_ZG#".LE.HJ^OL^8]WP;"S:#TE:
MA[[-PE&MWT4X=R^"XR[<K<:%H#7JCKQ<L\#7#X\K[UTLUS>UP<TZ\@K<'72H
MX==+W9>.BW!M'5,9]WIE4)9O%J.QHKZ*]+-0:\\IIH6+1P?70?:+\PAG[W\L
MSL7^5&ZW/?/@'H#&K_,<W<U-=-$VL3^<;3:0K+.?8./4ONL>LOB3^<6]-9;Z
M$%L28?(K>WXU)MMD>RJ7M6U#V!%0+\1>BA!2R=2^S.JYJJ_^[,M%?;=26YJS
M=SUOA9UM$U)B/]=5_#+BC9[AC,8:#81>@)&,QIA6$/'PDEU&ES9NW,WXN+45
M?^_BEQA35"[GS=%9LF6HA@^/;O%EE&=ZI:_/PZU1S'S9O\28('O[;Z;^I<*N
M&@=\2!/0U9AYSH!MSM-;C<M;X\8QR5@NP4L))?+)!2X@>UD&9"48^9*%(*/@
M4RX]3M1["VN1=VLN+7;.,A66&#KZD%:,#YTJ7B"JJIY>"S%+1V09/3E*=K#.
MVJVU3'??W9G".)((L<3(89@9X02TEV)#FM'(]Q0*^<LP-[?"TUSDN6IW"RLS
MH.>AJ3?%<350U;JGG>XJ=L[;5M-B6<5E"J6=QO=[%K?$%O(RGB5)2+/2TAAA
M)]6QRCNF4.#:J(V5^5 <2QH\K*1+K3Y+8Z3)MC;F-GL,'^(D(6;\5[*_M69?
MO?0=F5T/OYFLD1YN%^* ^U(>\$P$6H*=CMF&K/D.8J)EU46@31XN<9;U\%(R
M8WF"NH7I)!FX*2I8,@>(<.\W45\,4QE>K*5E2Z9W7K"XW=__G:P1[G#-R\#^
M!JE:,\(!+I-9(JA,,>-2@!P+5NFG0<J WF^5HVK7,LTKF/>RZN#$@K%2E-1G
MH&FPN@R=V"YM;(L'[+?;?/F\[TUH-;81; 4:>_9=!H\KG)L$8"W:-JUZF->D
M!EV*0KN@Y_X&91-S&+1B&2BT#/BN4;;WW-(63)&JIM$J<7%BKG>M<MA@&;LL
M/="QOMJ'3=/.&7"_TZB<^0Y1T3\A[*?J()=M)(3Z<;8K@1:6UY^_R!1GM?4F
M@_)I5"L? <33392*Q1UU3]B+'/< GJ!D#@KNX Z#,XO#G7?K(8.X]+YCZ<I
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MR*UYF8G=S+2=]XKIF9!OU9YV6EY;636]+Q4T"<GLH@@U+[)5OWX/2(J@)%X
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M A/7[BMR2&%(>)"1GP+_ISPH")$7S"JB;\U$R9KZ%8814H^*)VN*DZZ26%V
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MT?<RIP N=4OH7MR]"8U=!Q*MF*VGZ#Z>*A2F9KEH>@R#QYJ";.*WI8)<'OA
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MT!X*$UE@(@M,9(&)+#"1!2:RP$06F,@"$UE@(@M,9,$ 3-8FLL!$%IC(@H'
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M$ N++;]6#C;<^?Z&NX\#^QE^>!_ P2=V@WS59L\!CA?/\,MPA7F7R$G;KX3
MM$UNS07[?'OB3K"[<U(V)-."/0^_(&>&SU&Z?7^ 2A!</=[?,\^=F9XRZ2BR
M$)E<^@5^,0IOLJ($W#7].QE>:)6SA9CX?FQY=,_<^'9 ^N7<^/NOH$EA9TWG
M!7M09B J[DWFO=$Q%X/>47<Q,:K#(ZM%"E@'@P\:L^P8%-8]G8C*,U@R^* Q
MVUOJ-3RIB%H%BG\B3?K8;H<\#!K!0PM(EUC=LB::54CVV0N>/>,XA"UZ!Z0B
MA/S\>9,8:;8JA6?YG"E"(J15!8RC?\8D$&L-_\.?>E!!H ?>!=/CJHGT- >1
ME(-2$K+. .@40-==HU2OEK+YJVFVY?K:G9,!4G?G=I1V3#>2;,OSH_LJD]]:
M<DK2Q6$\$F;,?QSWOU3)+>_!V_U.B;3(>P,VWI%AU27)G]LC;U 5&%%[>?*D
MR=E\0$EC*V)J# \,:*%(XD_;D7IW6DF""G>R5T:3-23]3.,J$366+*%2@5Z"
MRMB2@"JN9<RI08PE%8@=KD8%<2QI*NR0-3\$1A/MWN4%4/DX'$VB6<,#NQZK
MPX!W_<.WZTTJU7@=AKKK?6[Y95VCQ8^&:1J=5USD23 ?YPOQ6?.%D&?8E[$"
MC<X.NBYZOV &MB[5_CNZ(-*S0LR"B#BA\P7YHKFF(G5!5(14Y"OS[9-9&>6R
MJS3^9[LDI+.361*NP\(<FY9CK'OO&?D8]Q3[2%=,;_M>!RM6&YV;XZJ[$:%K
M7/,H[!S1CYKGY75RI5:&V5-8];;@=*BI=)3 D:_,)^DZY'I@R?>=K(VB;*5\
MF8SY:$B+5)&W1U=K5!FVU B[!7SB.P K*EJI#[[*^E7)S,25R<@Q9.Q*F:^"
M2"KRJK-)(%#Y-#*&>"*F6"D.)I,V8]@E=7'VY4@2'G4HR&3ES/(,K38'8"O(
MJ9@O;%Z!"'(^PGW/]:J3B>Y3%9AE&$2%&<+?]F='.IO/W(@(GAO?<=>N$UO>
M;V[TG,3[$<WEV5W-\)4?P=W''KHK1%;9_%B#>FL^5AO9*T<XM(CRE<J B?@=
M3<2OU'TSONC?+LX]KI5KNH<#-]\'5?@TW5ZZ!PRWT11*?7;-"H_N0<4*("U1
MEFG<L>8&\J[%:&=/-[I">E]T73VW,;]U@4*NX-X;HKVO!\N>OC8\8ZTSUKKA
M6>MV0LU3OQ2_P:J&R""JCE3&AJ<!XB35PW?$<]&[&5\%<G1\SI3VO0]5\/H+
M\E$ [S+?F3A+UW>)J8'D@V7BA7_7,A)4,;<'N*Y 17H&7B[1&GEXE3Q]1&?&
M1$Y)DUH?KDZ4-P.ZS40?_Q%K(-3C7'A/3BT98T$V%F1C0386Y*,V?=1*.-UM
MR3RW13-F8[$C\^D+F%/3T=UD+(P>HP9LC,.2)>3>ZVDL)1;*7YL\N5M"#VFZ
M?4>>3M'&#%+FVCBT]HRE?(T&;B3-L^R&Z$8Z&[,;*<MY( DJ*?9A&"_3G_T(
M77]Q[EGV'_ -D [3WR5)B? /W[&#O Z=35(9.T*7E)SY*VTH<FVY09+I5.#U
M-^0NGDF:QQI4V@7*?P5.<\HUB_6E%[8&W;*H;$Y$LMDP)]+P6$W+(@8N!N%H
MXMD9#V[XQW6 2.X> MD0/3!V]U'(S-%ANMT3OV(2*^7!'=LKJE7L'"VNER0>
M#6ZJ0:"ZRXPQ_^MN_N]^#U%#C-YE7HYD<?;%)ET>O0LC#7QYRG4%NCC?S.+P
M+TY'6K'2$%8M5J67)R!=)@75$0=D(HJ72RO83.<3.X*+.((_918&S_)#J38?
MGI&.PHC#-*$AOS,.:X7N'92LODU:G$S):X./I=\]]\0[&_AK+IO2-0[FR(UB
M4H//=^"2<(,TF6A;Z' HV+=D=!!K4>EGVRW<A-2#+YFSHT![MZ#G8*#F86L0
M.&LKQX\.WP$TY-7J[AO4_:8(TZ0#45+&\3*F!3,3UL.B6W![4OA $J!^##OI
M^%K3#P.W8<DNXRLPOH(6#2SD^P96J72,K"#2SY[6J?"CBZ)W5Y$.ED/@BN["
MF/PM1=M'"S(1C?'N7F^DRR// V.6I^4#B09_2O=9KK8U[LVRM+8 Y,LDOUZZ
MN=UEF\-H+S$3IJ%XF3@-Q&/I^C8\R=?2CT*[PYFX@4%>60?ZQ1?I83?E^L4
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MEEQ,6PB0*:O\&."]**L=7\OA!X[;^>:0==[.9)T,K[:CF>0IM&AMU@TG)MA
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MVDY*@=ECND+D*O07"0-ARDRF'^?LQ%RV'&:2*LPZC,S,GE& K'G$5\-?@/B
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MD'M<'06>_0OYGR<X8/_Q_P%02P$"% ,4    "  \.&I0&8=16#R  0",JQX
M$0              @ $     9'1I;"TR,#$Y,3(S,2YX;6Q02P$"% ,4
M"  \.&I0Q+P:XVT6  !I^P  $0              @ %K@ $ 9'1I;"TR,#$Y
M,3(S,2YX<V102P$"% ,4    "  \.&I0I1CG&2D.  !^S@  %0
M    @ $'EP$ 9'1I;"TR,#$Y,3(S,5]C86PN>&UL4$L! A0#%     @ /#AJ
M4+W#\QW_-P  DQ$$ !4              ( !8Z4! &1T:6PM,C Q.3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( #PX:E#*M @Z"X8  +D8"  5
M  "  97= 0!D=&EL+3(P,3DQ,C,Q7VQA8BYX;6Q02P$"% ,4    "  \.&I0
MR5E L]I1  #Y<08 %0              @ '38P( 9'1I;"TR,#$Y,3(S,5]P
<<F4N>&UL4$L%!@     &  8 B@$  ."U @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6651096864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a schedule of future minimum lease payments for all leases as of December 31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,706</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,196</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,611</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and beyond</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,966</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780622656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Depreciation and Amortization Periods for Property, Equipment and Software</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depreciation and amortization periods for the Company&#8217;s significant property, equipment and software categories are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:540pt;;">
<tr>
<td style="width:307.45pt;"></td>
<td style="width:232.55pt;"></td>
</tr>
<tr>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 to 7 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser&#160;of&#160;remaining&#160;lease&#160;term&#160;or&#160;useful&#160;life</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Impact of Adopting Topic 606 on Condensed Financial Statements</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment is set forth in the table below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of January 1, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,436</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,807</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,190</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(997</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,187</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the amount by which each financial statement line item was affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is set forth in the tables below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet as of December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,486</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - noncurrent liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,895</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,322</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,067</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,410</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,477</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statement of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.27</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of ASC 606 Adoption on Consolidated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Cash Flows for the Years Ended December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As&#160;reported</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">under ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances&#160;without</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption&#160;of ASC 606</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,877</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,866</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,453</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation and amortization periods for property, equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPLX;>[#_V/@J*%OX=1?R"U!+ P04    "  [.&I0F5R<(Q &  "<)P
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MJE^#Z \:>QK65Z)QD6?U#U!+ P04    "  [.&I0+8!HYRH$   _%   &
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M'ZIQ>):_K;EWPL-8*H)S!Y$2>(!*"E#<AP6G(;F\J;EWPM-34GHZS"M)N:C
M*/*Q9'0@C7!9Q!%/4$D)ZC"T)&7C.\AS@3="&TYH-<0X*GF.2LI13(!"4D"^
M<YI,S/]1W;OA,2HI1AW&EF3XJ*P"_)%A=,HY$QM#/$<EY2C>D12SYG:;QBZX
M)+,8?6/!I7B2*DI2%Z&?XNFGX+?GN.)YI1C.X.$P:^Z:/U))9!M-UX5X+&P4
M7?'%*N%II1C*Q#;[/&64_OW6Y*F@&"J0UF1VI)%*^'FNF'E.6C.G QE5DMZ<
MY(Q':U_*[KDZ]HNG=AC:9CJZV;?MX$-QXGUP>_#E[OI0^_TPWN;AOKL<:5T>
MAO8T']>EUS/#]7]02P,$%     @ .SAJ4'-V3'#1 @  ?0L  !@   !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6R-5EV/FS 0_"N(]QY>@ODX)9&:5%4KM=+I
MJFN??8F3H -,P4FN_[ZVX1"QER1Y"-C,[LR:9;3SLVC>V@/GTGLOBZI=^ <I
MZ\<@:#<'7K+V0=2\4D]VHBF95,MF'[1UP]G6!)5%$!(2!R7+*W\Y-WM/S7(N
MCK+(*_[4>.VQ+%GS;\4+<5[XX']L/.?[@]0;P7)>LSW_Q>5+_=2H53!DV>8E
MK]I<5%[#=PO_,SRN(=,!!O$[Y^=V=._I4EZ%>-.+[]N%3[0B7O"-U"F8NISX
MFA>%SJ1T_.V3^@.G#AS??V3_:HI7Q;RREJ]%\2??RL/"3WUORW?L6,AG<?[&
M^X*H[_75_^ G7BBX5J(X-J)HS;^W.;92E'T6):5D[]TUK\SUW#VA21^&!X1]
M0#@$0'0U8-8'S*R H%-F2OW")%O.&W'VFNYMU4PW!3S.U&%N]*8Y._-,5=NJ
MW=,2")D')YVHQZPZ3#C"A)>(M8N(TP$2* &#BA!5$9KXZ$(%6"HZ3&(PE<&0
M!T)&L N>&<HS0WBL6E8=AHYXU(F8GU6T"R2XE@C5$B%:9I:6Z%X*BE)0A"*R
M*.B]%#%*$2,4U*+H,.F(@O)/),9I$I0F06ABBR9Q*@F)_>8NJ%*4*D6H$HLJ
M=:@H9#%-2&KUB N$.($$(,$E9:BD#)%D,:TR1!)0&LZL8UJ[0* 9B>.(XI*
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M;F-[7W8?;KJ'NCB[CU+A]<O8[']02P,$%     @ .SAJ4)2FOZM5!   +Q0
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MV X,WM36:1'0= WSG0-1)9!6C&\V=TP+:6B1)=_9%9GM@Y(&SH[X7FOA?IY
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M:?ZUM0%0RN8&5ZC%!S8["NH0S3NTW;AFHQ-L-[T@-C_CXC=02P,$%     @
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M6FQF*5L%VK5&$PM51N\VQ],NQ,> GRT,;G$FH9*+,2_!^%IF- F"0$+A X/
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MMAH*&A^.[_%LYS&;#6^&Y0>Q]1N7?P%02P,$%     @ .SAJ4'>/(66R 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL;5-A;YPP#/TK47Y
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MS ]HVVG-)L>;?GY!;'G&Q3]02P,$%     @ .SAJ4)2JS@FW 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL;5/M;ML@%'T5Q .4F&1+&MF6
MFD[3)K52U&G;;V)?VZA@/,!Q^_:]8-?S.O\![N6<<S^XI(.QSZX!\.1%J]9E
MM/&^.S+FB@:T<#>F@Q9O*F.U\&C:FKG.@B@C22O&-YO/3 O9TCR-OK/-4]-[
M)5LX6^)ZK85]/8$R0T83^NYXDG7C@X/E:2=J^ '^9W>V:+%9I90:6B=-2RQ4
M&;U+CJ==P$? +PF#6YQ)J.1BS',POI<9W82$0$'A@X+ [0KWH%00PC3^3)IT
M#AF(R_.[^M=8.]9R$0[NC?HM2]]D]$!)"97HE7\RPS>8ZOE$R53\ UQ!(3QD
M@C$*HUQ<2=$[;_2D@JEH\3+NLHW[,-[L;R?:.H%/!#X3#C$.&P/%S+\(+_+4
MFH'8L?>="$^<'#GVI@C.V(IXA\D[]%YSGNQ3=@U"$^8T8O@"D\P(ANIS"+X6
MXL3_H_-U^G8UPVVD;Y?1][?K KM5@5T4V/U3XN%#B6N8CT'8HJ<:;!VGR9'"
M]&V<Y(5W'M@['M_D+WR<]D=A:]DZ<C$>7S;VOS+& Z:RN<$1:O"#S8:"RH?C
M'L]V'+/1\*:;?A";OW'^!E!+ P04    "  [.&I0C8&S=+8!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6QU4V&/U" 0_2N$'W!TV57/3=OD
M]HS11)/-&?4SVTY;<L!4H-OSWPNT5WMG_0+,,._-FV'(1[2/K@/PY$DKXPK:
M>=\?&7-5!UJX&^S!A)L&K18^F+9EKK<@Z@32BO$L>\NTD(:6>?*=;9GCX)4T
M<+;$#5H+^_L$"L>"[NBSXT&VG8\.5N:]:.$;^._]V0:++2RUU&"<1$,L- 6]
MVQU/AQB? GY(&-WJ3&(E%\3':'RN"YI%0:"@\I%!A.T*]Z!4) HR?LV<=$D9
M@>OS,_O'5'NHY2(<W*/Z*6O?%?26DAH:,2C_@.,GF.MY0\E<_!>X@@KA44G(
M4:%R:275X#SJF25(T>)IVJ5)^SC=\/<S;!O 9P!? +<I#YL2)>4?A!=E;G$D
M=NI]+^(3[XX\]*:*SM2*=!?$N^"]EIQG.;M&HCGF-,7P5<QNB6"!?4G!MU*<
M^#]PO@W?;RK<)_C^A<+_Y#]L$AP2P>$% 7]5XE;,_E42MNJI!MNF:7*DPL&D
M25YYEX&]X^E-_H9/T_Y5V%8:1R[HP\NF_C>('H*4[":,4!<^V&(H:'P\O@MG
M.XW99'CLYQ_$EF]<_@%02P,$%     @ .SAJ4!100T"@ @  K H  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL=5;MCILP$'P5Q ,<V$ ^3DFDY*JJ
ME5HINJK7WT[B!'2 J>V$Z]O7&$)3,_X#MIF=6=N[RZY:(=]5SKD./JJR5NLP
MU[IYCB)US'G%U)-H>&V^G(6LF#93>8E4(SD[6:.JC&@<SZ**%76X6=FUO=RL
MQ%671<WW,E#7JF+RSXZ7HEV')+POO!:77'<+T6;5L O_P?7/9B_-+!I93D7%
M:U6(.I#\O ZWY'E'K8%%O!6\50_CH-O*08CW;O+UM [CSB->\J/N*)AYW?@+
M+\N.R?CQ>R -1\W.\'%\9_]L-V\V<V"*OXCR5W'2^3I<A,&)G]FUU*^B_<*'
M#65A,.S^&[_QTL [3XS&493*/H/C56E1#2S&E8I]].^BMN]VX+^;80,Z&%#'
M(.J%K.>?F&:;E11M(/O#;UAWQ^29FK,Y=HOV*.PWX[PRJ[<-I>DJNG5$ V;7
M8^@#AHR(R+"/$A1)[.C$G&+S!'J86//D47V^Q 0I)$@M0?K?%C-GBP@SPR(9
M%,D P=P109@%%IE!D1D@6#HB )/$6&0.1>: @#@B"..YU 4460""Q!%!F!2+
M+*'($A"X%X\PGHLG,<Z@&%"X5P]!GKLGGDPE$PJRH*[.%$033[80F*Y;0H'.
MS-69@FCJ"3."\YHD@,(-- CR1!K!Z4] ;J=NK$&0)]@(K@ $I'?JAAL$^>(-
M%P$",CR=Q!L"^>(-UP$"DCQUJPT"9;XXP*6 @#R/)_<#0)GG+T1P-2#35"?+
M2?Z >I!YXHWB>D!!JL?NN2%0EGAT<#V@(-4S]]<-09FC$STT"Q67%]LFJ> H
MKK7MT1Y6QU9L2VVS\0_>]W'?F;P4M0H.0IN6Q3869R$T-[[$3R;V<],ZCI.2
MGW4WG)NQ[/NG?J)%,_2&T=B@;OX"4$L#!!0    ( #LX:E (5K/GPP$  #<$
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;&U4T8[;(!#\%<0'' Z)
MD[O(MG2YJFJE5HJN:OM,[+6-#HP+.+[^?0$[KIOR$MCU[,PLL,E&I=],"V#1
MNQ2=R7%K;7\DQ)0M2&8>5 ^=^U(K+9EUH6Z(Z36P*A1)06B2[(EDO,-%%G)G
M761JL()W<-;(#%(R_?L$0HTYWN!;XI4WK?4)4F0]:^ ;V._]6;N(+"P5E] 9
MKCJDH<[Q\^9X2CT^ 'YP&,UJCWPG%Z7>?/"YRG'B#8& TGH&YI8KO( 0GLC9
M^#5SXD72%Z[W-_:/H7?7RX49>%'B)Z]LF^-'C"JHV2#LJQH_P=Q/BM'<_!>X
M@G!P[\1IE$J8\(O*P5@E9Q9G1;+W:>5=6,>9_U86+Z!S ;TK()-0</Z!659D
M6HU(3V??,W_%FR-U9U/Z9#B*\,V9-RY[+6BZS\C5$\V8TX2A*\QF01#'ODC0
MF,2)_E=.X^7;J,-M*-^NU0]/<8)=E& 7"';_M'BX:S&&>8R+I%&1-$+P="<2
MP>R3.Q&RNC@)N@E/UJ!2#5T8EU5VF8IG&B[^+WP:J:],-[PSZ**L>S[ADFNE
M+#@KR8/STKHI7@(!M?7;@]OKZ2U/@57]/*9D^:\H_@!02P,$%     @ .SAJ
M4*)=#).V 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL;5/;
M;MP@$/T5Q >$7=9)5RO;4C95E$J-M$K4]IFUQS8*&!?P.OG[#-AQW-0OP SG
MG+DPI(.Q+ZX!\.15J]9EM/&^.S#FB@:T<%>F@Q9O*F.U\&C:FKG.@B@C22O&
M-YL;IH5L:9Y&W\GFJ>F]DBV<+'&]UL*^'4&9(:-;^N%XDG7C@X/E:2=J> ;_
MJSM9M-BL4DH-K9.F)1:JC-YN#\<DX"/@MX3!+<XD5'(VYB48/\J,;D)"H*#P
M04'@=H$[4"H(81I_)TTZAPS$Y?E#_3[6CK6<A8,[H_[(TC<9W5-20B5ZY9_,
M\ !3/=>43,7_A LHA(=,,$9AE(LK*7KGC9Y4,!4M7L==MG$?QIOD>J*M$_A$
MX#-A'^.P,5#,_+OP(D^M&8@=>]^)\,3; \?>%,$96Q'O,'F'WDO.;[8INP2A
M"7,<,7R!^40P5)]#\+401_X?G:_3=ZL9[B)]MXR^WZT+)*L"211(_BF1?REQ
M#?,U"%OT5(.MXS0Y4IB^C9.\\,X#>\OCFWS"QVE_%+:6K2-GX_%E8_\K8SQ@
M*ILK'*$&/]AL**A\.'[#LQW';#2\Z:8?Q.9OG+\#4$L#!!0    ( #LX:E!\
M5]W1N $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;&U366[;
M,!"]"L$#A#8M.X8A"8@3!"W0 D:*MM^T-%H0+BI)6>GM.Z0454WU0W*&[[U9
M.$P'8U]= ^#)FY+:9;3QOCLQYHH&E'!WI@.--Y6Q2G@T;<U<9T&4D:0DXYO-
M@2G1:IJGT7>Q>6IZ+UL-%TM<KY2PO\\@S9#1+7UWO+1UXX.#Y6DG:O@&_GMW
ML6BQ6:5L%6C7&DTL5!E]V)[.2<!'P(\6!K<XDU#)U9C78'PN,[H)"8&$P@<%
M@=L-'D'*((1I_)HTZ1PR$)?G=_7G6#O6<A4.'HW\V9:^R>B1DA(JT4O_8H9/
M,-6SIV0J_@O<0"(\9((Q"B-=7$G1.V_4I(*I*/$V[JV.^S#>['<3;9W )P*?
M"<<8AXV!8N9/PHL\M68@=NQ])\(3;T\<>U,$9VQ%O,/D'7IO.3\D*;L%H0ES
M'C%\@=G."(;J<PB^%N+,_Z/S=?IN-<-=I.^6T8_WZP+)JD 2!9)_2MQ_*'$-
M<_@0A"UZJL#6<9H<*4ROXR0OO// /O#X)G_AX[1_%;9NM2-7X_%E8_\K8SQ@
M*IL['*$&/]AL2*A\.-[CV8YC-AK>=-,/8O,WSO\ 4$L#!!0    ( #LX:E#C
M(<5']P$  ,L%   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(V4T8Z;
M,!!%?\7R!ZP32$(2 =)F5U4KM5*T5=MG!R8!K8VI[83MW]<VA%(ZE?8EV,.=
M>V8</&FG]*NI "QYDZ(Q&:VL;?>,F:("R<V#:J%Q;\Y*2V[=5E^8:37P,B1)
MP:+%8L,DKQN:IR%VU'FJKE;4#1PU,5<IN?YU *&ZC"[I/?!27RKK RQ/6WZ!
MKV"_M4?M=FQT*6L)C:E50S2<,_JXW!]V7A\$WVOHS&1-?"<GI5[]YE.9T84O
M" 04UCMP][C!$PCAC5P9/P=/.B)]XG1]=_\0>G>]G+B!)R5^U*6M,KJEI(0S
MOPK[HKJ/,/2SIF1H_C/<0#BYK\0Q"B5,^"7%U5@E!Q=7BN1O_;-NPK,;_.]I
M>$(T)$2S!-:#0N7/W/(\U:HCNC_[EON_>+F/W-D4/AB.(KQSQ1L7O>71)DG9
MS1L-FD.OB2::Y:A@SGU$1!CB$/V3'N'I,5IA'-+C*7T7XP8KU& 5#%9_M;B=
MM8AI=CADC4+6[X @FF2!0S8H9(,8+&<03/.?\TY02((8Q#,(IEGAD"T*V2(&
MZQD$TVQPR Z%[!"#^;>-:;8S")M<)@GZ$L:((86Z-F&$3:+CI'J,PF7\(^_'
MW!>N+W5CR$E9=Z7#Q3LK9<&5LGAPWT?E)NNX$7"V?IFXM>[G2[^QJAU&)QOG
M=_X;4$L#!!0    ( #LX:E!P%8P"M@$  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;&U3VV[<(!#]%<0'!"^[2;8KVU(V591*C;1*U?29M<<7
M!1@'\#KY^P)V7"OU"S##.6<N#.F YM4V (Z\*ZEM1AOGN@-CMFA "7N%'6A_
M4Z%1PGG3U,QV!D0924HRGB0W3(E6TSR-OI/)4^R=;#6<#+&]4L)\'$'BD-$-
M_70\MW7C@H/E:2=J^ 7N=W<RWF*S2MDJT+9%30Q4&;W;'(Z[@(^ EQ8&NSB3
M4,D9\348/\J,)B$AD%"XH"#\=H%[D#((^33>)DTZAPS$Y?E3_2'6[FLY"POW
M*/^TI6LRNJ>DA$KTTCWC\ A3/=>43,7_A M(#P^9^!@%2AM74O36H9I4?"I*
MO(][J^,^C#?7?**M$_A$X#-A'^.P,5#,_+MP(D\-#L2,O>]$>.+-@?O>%,$9
M6Q'O?/+6>R\YO_V6LDL0FC#'$<,7F,V,8%Y]#L'70ASY?W2^3M^N9KB-].V2
MGB3K KM5@5T4V"T%]LF7$M<P7XMDBYXJ,'6<)DL*['6<Y(5W'MB[^(CL'WR<
M]B=AZE9;<D;G7S;VOT)TX%-)KOP(-?Z#S8:$RH7CK3^;<<Q&PV$W_2 V?^/\
M+U!+ P04    "  [.&I0^1CD-K(!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6QM4]MNG# 0_17+'Q"S7M)&*T#*IHI:J956J=H^>V$ *S9#
M;;.D?U_;L(1N><$SPSEG+AYG(YI7VP(X\J959W/:.M<?&+-E"UK8.^RA\W]J
M-%HX[YJ&V=Z J"))*\:3Y /30G:TR&+L9(H,!Z=D!R=#[*"U,'^.H'#,Z8Y>
M R^R:5T(L"+K10/?P?WH3\9[;%&II(;.2NR(@3JGC[O#,0WX"/@I8;0KFX1.
MSHBOP?E2Y30)!8&"T@4%X8\+/(%20<B7\7O6I$O*0%S;5_7GV+OOY2PL/*'Z
M)2O7YO2!D@IJ,2CW@N-GF/NYIV1N_BM<0'EXJ,3G*%'9^"7E8!WJ6<67HL7;
M=,HNGN.L?Z5M$_A,X#<$-B6*E7\23A29P9&8:?:]"%>\.W _FS($XRCB/U^\
M]=%+P1]XQBY!:,8<)PQ?878+@GGU)07?2G'D_]'Y-GV_6>$^TO=K>I)N"Z2;
M FD42/]I<7_3XA;F-@E;S52#:>(V65+BT,5-7D67A7WD\4[>X=.V?Q.FD9TE
M9W3^9N/\:T0'OI3DSJ]0ZQ_8XBBH73 _>MM,:S8Y#OOY!;'E&1=_ 5!+ P04
M    "  [.&I0V"% (\0!   W!   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6QM5.^.G" 0?Q7" QS*KG?;C9K<7M.T29MLKNGU,ZNCD@.Q@.OU[0OH
M6;OEB\#P^S,#C/FD]*OI "QZDZ(W!>ZL'8Z$F*H#R<R=&J!W.XW2DEFWU"TQ
M@P96!Y(4A";)/9&,][C,0^RLRUR-5O >SAJ944JF?Y] J*G *7X///.VLSY
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MWORZ%X4\+WWPWQ>>\OU!VX5@M:CY7GP3^KE^;,PLN+!L\U)4*I>5UXC=TO\
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M E!*,)6R<(U]":8L:!; +'.090ZP&+ED/0:A_\DE!%E"@,78NBQ\@B4"62*
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M4D]3-:_;=JI=2%%UK6+0]ZNK?U!+ P04    "  [.&I0+^/_#18$   4%
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R56.URHD@4?16+!PC=MS^
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M(5G4QZQ^Z^5NB-!Q'W*/!?(P7S%,TL<\(!C.^IAO&(;W,8\8YJ.LT*[]N0&
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MTQ)/C$E0-?I/ZI,5:DH.&PHGJ9<+M>;=J.@VDC7]&/2&69S] U!+ P04
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M$8BP)".4>4!+'34\J,A@( 8",6"&J ?$%H$^% DR/P\(T!&"*+JSYAD(E %
MWE*4V3)0FB*6^$L&Z0I"4P0#Y2!0#@#Y2Y8O N4%+C#VEVRI\_?:#5 ! A4
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M<)1ZF:@U'X;<L)&L&^>W-WU$BK]02P,$%     @ .SAJ4$,%KP!C P  WP\
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M:<OA3!XZ6O3C?2.9+CW+OU!+ P04    "  [.&I0+PCA)-4#  !?$P  &0
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M<]E=^70O6IWZZRSO>J>V^@=02P,$%     @ .SAJ4(@U4Z#+ @  LPH  !D
M  !X;"]W;W)K<VAE971S+W-H965T-30N>&ULA9;;CILP$(9?!7'?!=L<5TFD
MA*IJI5:*MFI[[21.@A8PM9UD^_:U#6&#&;0WP7;^F?G&V,,L;ER\RC-CRGNK
MJT8N_;-2[7,0R/V9U50^\98U^I\C%S55>BI.@6P%HP=K5%<!#L,DJ&G9^*N%
M7=N*U8)?5%4V;"L\>:EK*OYM6,5O2Q_Y]X67\G169B%8+5IZ8C^9^M5NA9X%
M@Y=#6;-&EKSQ!#LN_35Z+E!B#*SB=\EN\F'LF51VG+^:R;?#T@\-$:O87AD7
M5#^NK&!593QICK^]4W^(:0P?QW?O7VSR.ID=E:S@U9_RH,Y+/_.] SO22Z5>
M^.TKZQ.*?:_/_CN[LDK+#8F.L>>5M+_>_B(5KWLO&J6F;]VS;.SSUON_F\$&
MN#? @T&W.;,&I#<@[P:13;XCLZE^IHJN%H+?/-&]K9::0X&>B=[,O5FT>V?_
MT]E*O7I=)2A:!%?CJ-=L.@U^T*!!$6CO0P@,A=C@B3D>!RBFBB2#(Q P"6+M
MR2B)&'80@0XBZR :.4B<7>@TB=4T5O,)Y7$8.[D LCR92R<&:6* )G5H.DT\
MHLFPHRH 51[F,$L"LB0 2^:P)),H*,V<0U1,13@-89(4)$D!DMPA2:?Y1AD*
M'11 A7(2P3 9")--8; 39I--PR3$(2X $9FY73E(D@,DR"'))V<21WGN'I:I
M"F&<8A@&A7 Y":=7$<^YF*E(",B(N"4)$KE'[@/1& :L76N$ 1>Q"S,5$?<=
M%!^(QC!PF4,$@''+%"AR7S4HFJE1""Z9"*B9V+V/D(BXUQ$4S>T,7#$14#()
M=F$@$7%A(-'<F8%+)@)J)IF<&4B4N#"0*'5@@H=/?<W$R79%TMOS2Z/,1_5A
M=>B\UMBT"L[ZQG1DMH5X=].U<S^H.)6-]'9<Z4;$M@M'SA73C.&3WK"S[B"'
M2<6.R@Q3/19=&]5-%&_[%C$8^M35?U!+ P04    "  [.&I0,QZJQGD"  !*
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6R55MN.FS 4_!7$!RS8
MW"."U$U5M5(K15NU?782)Z %3&TG;/^^MB&4A$/*O@3;S!GF#!GLM&7\5>24
M2NNM*FNQMG,IFY7CB'U.*R*>6$-K=>?(>$6DFO*3(QI.R<$45:6#73=T*E+4
M=I::M2W/4G:695'3+;?$N:H(__-,2]:N;61?%UZ*4R[U@I.E#3G1[U3^:+9<
MS9R!Y5!4M!8%JRU.CVO[ UIML"DPB)\%;<5H;.E6=HR]ZLF7P]IVM2):TKW4
M%$1=+G1#RU(S*1V_>U)[>*8N'(^O[)],\ZJ9'1%TP\I?Q4'F:SNVK0,]DG,I
M7UC[F?8-!;;5=_^57FBIX%J)>L:>E<+\6ONSD*SJ6924BKQUUZ(VU[;GOY;!
M!;@OP$,!\A\6>'V!=U?@=,I,JQ^))%G*66OQ[FTU1/\IT,I39N[UHO'.W%/=
M"K5ZR4(O3IV+)NHQSQT&CS#X%K&9(L)_)(X2,*C H ILZKT;%0E,X($$GB'P
MQP2^>]=&APD-IC88%*G'!'>]3&%)@&,$J_%!-3Z@9H8@  F"Y7Z$($&XP(\.
M$XP:]:9N3$'1G!<1J"0"E&"8( 8)XN5>)"!!LL"+9-(FBCS7O8-MIK#$#T:H
M&S7(A1/G GJ\&8J9T*+EGB X<0@O<*4'_=<6 /?(%SC"",JP/T,!YP[Y[_ %
M3AX*EO@2+/1EBGOD"QQE!&4YF*& ,XBB=_@"IQ#%2WR)EWQ2 -3L-P7!D490
MIL.9'0>.(7:7>X+A&&*TP),>%#[V!$!-/7%&F[H^97TC_%34PMHQJ<X'9A<_
M,B:I(G2?E+VY.M@-DY(>I1Y&:LR[TTTWD:SI3V[.<'S,_@)02P,$%     @
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MF;?P+I,VQD[E=?_?V[W4C2JTES:5(OTU7+.ROYZU_S<S;$"U ;T8$.XT8-J
M_36(G 9<&_!K(T3:(+K60&@#81@$PV#UH[]-FW2]K-39JX8&.J5=GY([T<[O
MKGO93V?_6SL!=?OV=2UXO Q>.T<:LQDP=())IIA[A%E,,5N B<(IYJ.-H5/$
M _#R-YF@+?92,845T]Z>3;(@V &##ECO@(\<,!(990P8T6/*'K/@8?>' W$8
MB%N!$F[$&2#1* YIYT:, PVCQJV$$L[$;$(13"BR$B*$&!E%5D:44I;8&=E
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MP9]-&K-D.-V-/XA,W[AX U!+ P04    "  [.&I0 M:^ BH$  "/$P  &0
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M',BH?;E!5'Y)VC/[@>H<DPS:X@Z/@+B:T6%1\HDP<:8"G=0:"<=#4*M&Z;?
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MG^2)L TI^TXV4MENX9%H4NL9\58 G>AO6;&@D7*26NREH&EM9QC*%R2UA%&
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M-'@Y46*I4TK$3EA3LUXXPJAYPB0:4W5=(:3G$!CV3L!!)26.7B7O8DNV-:B
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MQF)677EH.(T(_)4TLHMX:"ND>TII:ZNU"9"A'_IWW0Y!QP':3N"4'9P@O2=
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M'"RCP1P/3L;4[C&U_$LRVSF7G*2L>)H0C<(]G[D&/1&P!'OW:DE9F)3L(\[
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M09F7O)F_)7[Y9G!E=* K'I6$7^.W,CF3Q5^H,^8:>4V3 J-YUR>8'C(^2D?
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M>83\<31-#Z<XU.'I0/*1#<-Z3MQ"VI-_+FE/CXF6D^'TU/R)W#P=8S847EY
M75#(#C$C%&AW> HT'0_')X[T0&=T-1X> K$F<("F)T2Y5T@[T$F!D*/) 1#I
M .@*)L QJO]$[\'DY#2=PB$% AYABBN=US'IB^S^PCJG4[RZCX[!1L6)P?[
M*Z>3D_1H<@3?P8=*>7^&W>%LAW\_YVM)G"='6R<X+47];P6JXAK+'N&P7=-A
M.Z-3U/H%7$EU..C+$O X$GV4O!E\OKB]_'Q!^<G7'\X^88!/=1_@CW$'"MG!
M-60.A(!\& B^QS7?X[VOV$S%S:HAWV;#B&=[.)P$=UKD<&$B]/."68Y^4$K7
M\M'HH8\:V9>Z9*76B)J<-1Z-R(\B;L#@5N>$+<Y"RYL9#$GI&?3#90;:PF9I
MA."E5L=K(^KS"E'<SP)+DS"D.=E3&Z\'^5#DXZ#\-'')N[R1WY*Z=QM9O\.O
MS& 7[O-]4(7OL'A=H;Z%L'6XA<[IJ'1CP.%BA::LYCEQG8OB!+B-8').?VCC
MVLS;.X9I=ATM<&3R[GJV]'=5#MNG@JK<USXE]YR0QA[R<@;FUK8?G[5__+)3
M>'[U\>/E+1Z^&ZH..+_Z='OYZ>>+3^>7%S?1(WL,1W;K4R"'U]KZS6X!]?5R
M<10M[5[D#YQFN<X5RW^1%=ZA0WC>* MFU:;F-%3%?&U!?'-]L+#] V<V(DP[
M'7TS,!Q);4R)I3.D$)&C3[03S+W7EZ_@4+%N[G%L-8N!2B2<;H296^BM_EI6
M3Z5;C^^GOKV4I:=T!3Z>2^V*65U?X4HKP#'4"AZ["0O^J.*B""IN]R44E \M
MLF91E0_[[*+@UZ&[C1ZF@]7D.I0">JQS[D3HD\H]T$XCZ6;XV9WSR;%+G2/4
M7I73F6(.4$$A9*Y)H*P\BB!P=(;?;S)_V2!@GRH!&E/;,\8#R+FW5[:H\VRN
MG1!D )J9.">VI4'RSX/>]EL2/#R!%"D@<%V^H5M[<O23UJ=$MP*8YV T22X0
M3>(Z7\.QJO,GS.C,,?6<ZPG2Y!-5\IYG-7!0F1DS+Q[MXLR^/'D$4DCUOFM'
M(JG 1:,5# J))*4EDZG/E15%G#)B$5MFZ)9DJG(H$8!7:)9T.(5YU>434!M>
M];G*YCV+V3DO3<>:''WGQ-QL)J/D]B\@2?)?,N**=S7AU\:+3KKS VW%,4 W
MLX,94A)X?-\">OE<UT*9I"@="X>8J%@]E7 =(FIH/>7DN&UY%W2]8HOF#7<'
M%DPI5 E0>^ Q@NXWR.?"GWU&<]M)?N7D ,N5 <8H0$\]'AWA/\>@=8Y0WQV!
M[GL VBI]>@#_G)R<X#^GZ"4"@Z25-(V/'1UQH=5@?)R>PA\WFQ6"'9UY+ 8K
MPT@>--IX4/NRB,@NT;!<1&X+Z37S\<J+&MOR"1V=\:Y/<A%_E@=;O]+6"WKH
M#7Z$2D9ZG03K2=%8RWWUMXW@"(F@0RU'()Z\XH8E Q05A4M+!075Z*RUF7,J
MT7Q-0M9&-8+)K'XV7V*):4:H3+VHRO)77DWI]KNIHUITH+C;O[C0QK\>K'N'
M<7$"FLJGB]ODP]7-37)]\3FAG-=H]IW'>'88SHW'(2("469$_HN$HAR:"(-K
MN^JJ>3]JM?1S$NIRO^.[O 68TGU._(>\T?B3WX;=364B>'"RQ8R*B3B=K5-8
M'UW!"R#.#39WJ($[TH4AO)WHVK^&TB^!8L]G&9?SF"X-2]D6VG!,0J',#8OL
MS;OWHCB4*XYHY_'O$8B'5ANTYO?:F?/C23H:'Z8GX^G E5;\VJ%&((0/R?5P
MU2[FB$5E)<FI=V1T[1Q@W. 4_G5\>@0C'XL$]]],CC$HD1X>'7?=#'?KV&??
MX3@XA;/][N+M+:<#4VIE]_(-:\6P%L3G%7B]L5/?@)!A#19(4IJ,0%V5)NL.
M+<>#4V,Z$L_V5)T$#@>Z6+&XQ[4@-(E#]'FG,B6A7K^UO/?H!^)S= \L.X^2
M6<^XH)P]OJN&I:?C:ZM(I2TL+Z^ODCW?BO,US]#CD?K<$_0F'HW,R=QSEKU)
M+,'Q^!'WP]>4,ZL9.:UM]>"&@D3@+G1+Q@#8GEM?8ZJMQ\DP7RN@HPN#J'KY
M\I0"#Q#8LR&Q\'G[YV&Z)'OI6YSFJ2*ER*?&8\&J7*0NR&P.)]38=AU]#HR>
MEO%S="6?6-XW^25Q^HIK96(?<OSM8%4_Y]^JQ3?VY):Y2?3??JX7E>17RHW]
M;,XV[?MUQ@TE_X*!H[I,WF;EU^!4MG_P 4=TRJ?S"G8%A9T5(R>S2B<-)QLN
MG*S=NBA?!0\A8W; O]A;%4@7CUZ')^AP9&*$H>_24BL4)TOL,824L$FE+?+"
M18WDA1L&;8J)NN^"W]P)?+:11"Z5D212D!VH:,::'CB<P!DG2"GQ;J(GM9;J
MS])C5*6,*(DISO2( /ZBX[7Q13:>S@6U[D:;9YXA.IP!ER.%TU7H+CE7AP!
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MI>$4O-L"IT:Z3$H*GY%_KN_-;V@DJ'>1;/W,-)%$[! ''TFM6BDT=9_/J8+
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M]&.N-EYA.:;'\?.QE>@')[_/-&>]^K6D_HV_DU%>O()VZ:;'TR(M$?TJQ;Q
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MNR0EH8%Q%"X94NFI,J\A.[\C$UO[3+%K,@.1I7U'=[;,T27I"T*T03L3I72
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M*,IY8E3O".)B9CNU[Z J!5^VJ]*!MNAM!L*B;T, =9?#8!#<H$=D?_<&Y)A
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MT_"%)R>V,NC[8JYAQ4JE+6M?C=L>JOYEM1MP1;)$J)V=U3XP*=Y<3!%EA.Y
MIU:U$+6_%SO@!5$UIOC/,)&,<H!N\M6:AQF/8LR#@\BO6UV'73X=?>L3ZL*
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M3R,""\/+4VR\HX%]SK7'BR3W[?R!RTVH.]]X2<^Y3I5:#?Y2PLT4%0:=*,#
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M^#%ESE"V.^/#U;&YWN?!5%DV;J6C"SGT!4.L<17);PYW$[-&'JI:);OI*CK
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MO^S1&'K3IG7IY!3(=QI4TSHM?G_T8J;V$#7#.&B1B-J6;PB>"11:&(^KM!1
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MCLZ*6(*5R3>Q;<(K&RV2 !(UE%\(,OMI2G=_I%/6*]Q]B2 GNZ54PF[ ]3H
MG!<67.\^].5F+Q^__@0#?B@8L+=B9M&M<T9=L7C#X$;GDV;.N3!F&^L#QP--
M_'F1^'F1^'F1^'F1^'F1^'F1^)>Y2#0/L;UU(;HH0H>J-WMK34@QHEI'+AJL
M0$_:]-VU>-&C!<);0N\5@5E)?0XNE'Z]KHFVHXI/D5&:QK2.O$PJD!1E,AX.
M>Y=:X\DGO7P\Z:GB@>M[2YD!7L_+K <7@;0<]\Z;NDX&W>6]R;!J*$5?%C\H
MXA/6:C@>PF-97O0^DH]IG^[6*],DS]->/DI&PXPTI8;5MD6+Q(&."IQB,2EZ
M>U?E!&-5@6K#*BG'&6YW&&DQ]M#;O?(%77C(>ROIPU9H:5NAKM\BT.X3,<Q;
M087 G'H47<EDF.E_D;8O'.(ZM#S*)R22\@)W+#]L@,%![F70P;'Z)SP1Z*D8
MYOC_T:AS_',7ZI+%(/3R*0=>A"X@GL-!&Q20*VXM T.T"*_.D]0W"H_X,3EK
MK<JI]$,;=E@6R'E IZQG&3EZ)9SS<##C(U61\B/E,$S$EI%:;C$W,C> !6EX
M3*MXFV"D4_0N^P!BQ/ _8,8EB("*V15TG5_9N\J;?HY9;12\ A>)WA#KH_=&
MP]%><C59"+01'KG)U9M:(=B?&!NM$0;.[V!&'X6!O\,P\!##!0+1[34(A:/O
M@AV&XL[#D>OV5;<+)^J.W;C5'N@A:>^Y^N<_F@D=VDXBN00$/6E"EWNCR0!4
MI.?X;U&$&HC$_?:R036!Y_-!A:^?-B-N%?,BG]$-^[@W&HQ@Z0>P_EXG%OU1
M_>*7@37&@U%._PP]66]=KJ<,;7#/.BNO..@[WK7YH[-S^-+*5RN&H5;-1-+Z
M'([ N*S-8_)77O3.K80=&38)B8VA3W\J!#I5^:#(RK72YX)7Y@D>JG#]2&%=
MGP%?  5_Y5Q1V'W9"!0$4$"R;  JFFH5U=H\A:V)YT,Z !WC#2>#U/,_7&%'
M2WRD!*5P6*+VE^,BNF/PYM<;)^,17$9&1:]$WE1CR.'<'X.N/J(Q%/880!R0
M2#@&YAH6X3&4J#<4^$@Z@..N?1 5RAC0C+)L!#R4YBT\Y,H8&:P5?&+_SMQ%
M!JN_UGSTKTU<.<AO_/9 YE.AMPLJ2RM*TV=4U<-IOV9D ;8TJ';?]/AL@RF%
M^\>*XP:Y=1"74>]URIA0+\"^'[3Q3%6NP*B6MUCRR!(0>]F>EM0F]&<'F-]9
M[:PBP0%:+[WUBN_7F"E@O5 DZ008<C1$'L7;XW"0Y2)PX]T8SAX/2CS!B,%9
M[P]V@W=R&%N%W0S'M"O'OI858T9;3K0QY#^)XU;![KL(0WRC<QJJR1!;WO.)
M&+T"GSK)\3X#VA1K949DP,#KI];2/8.#-8/[!_Y;@'XSG, 5.(6;$JZ\^1-^
M+NBQ;(!7HF0(]QM<[]& E.IQCIH1*/3CP;C QZI! 0(PR4<C4'Z*7H6';P83
M1-GV#$1;-J;&AH-)"MPSJ;*D A5S,JA&O4D!7)N";,^*0<5]CI#_1D52%MA4
M6?7$ZV-M",/I+:2=_.^2MAH3+?,!7 S-G[A;B@QO)G@\ '5!CRCQI@JT*RN@
M:3;()IKT0.=B!%?A$H@%5]EQ,2'*/4/:@2H%A$SS(1!I"'0%972,BBC1NY=/
MJJ0 (0 $'.'5F^1!1FI.GJ3CE(S %1Z.HW&253@P6!_HLLCA,I^/X#?X4E'>
MR B]^4/8'0L%27T[)]$(I*MO.[N!WG"4^3L@^<WNAEUQ&MRR71PL"!37:DLB
MUF^D+79R.#!B&*^_9&]?[.QHWBK$@HC\0"^"D*3M,4Y'^#$#XJ2X+"DL$2@G
M%7T[A(_Y9((?"U078-_ 1XXP_%S?KVY1D4E!?2$[12\;)Y5_9PUDCG>AZ!26
M0"<)6S&FIS_D B;EE] UI4.152*TWV?;Y;;^H?%R[879F\RL(]2NW%',X^G8
MG3+?ZZL9H[Y9 !PW GQ.'M:OLSG%8SN)U&SV[W2%N:S)SS?%<&$Q&?*,CKB\
M!887ZRAV/;YCO:4RV(99"7*T4$V]?'!3*7!82=O?/EVCU@3.F(ZWC.)UB-IQ
M!9_&U0A:'@M[FE_R,:K>23D*V*VL5+YN_E^9-;RB3%WDH3?> ^]U&\Y#@3#K
M6-GF72>6D>9\WTQ/>YRMY;UQ@@1Z?T'FZ966)\3AE'((HHE6!RT)(-%+%-MP
MYDW*'NF:R/>XA.ZS<+W('5<,V4A1%A6%[Z(!09]DXQR:Q<-:PAMH6&B\@$.W
M' ][N!1<=7P##Z85'MPC./W9'A=(5.H=P45H/"S(= <R<8@V<[:]!@B06%XB
M,M,-R? 4HYI:&]"EE'65<WLMD[!J(]"GM;2QCNO@.@'QU2;3GWQ<6P0+ISAY
MD5UOZCE9C- ULB/+MMD2_0\J+]GZ[B6GW87D*R8:VRZK *2)W#^L+#"="_D(
M0 J5[RKN61N,!+.-= 301D_RBTS;&@CE5&]7*E#G,]=#"8RTPX:+*M"M*B 7
M,>H]9_=*?8+D/I6R%NT_GGE9=9CE8*9+=J-GO2-024M08(][>39 HQ4ZED U
MG9AOR$7F)+1JM I%,XL6T&(R(2]<3F\?56FE_X -<C+G4NF4HRA0:JB43PIX
M<U#UGL.SXQ1=>B/\_.'?9C=W?WS-02/K.TP&F:]WUWIS'Q5P!J&5HAQDV!OH
MYK2)BT$.?Y)TZ!VA/91L*?C$,*//^#0[SM#$%)((>9&@]_\H'_&PX,C+0>[@
MWV/\VZ+PD4S^6$W)VGG>#HSMQ&!$7$>WB1P[[U1Z+"RUU1Q,ZP.J3Y0CA)@]
M>_31=4W9B*0+<\,W5L.V?9:KZZBF.;%<XE>4:M7<#/X.,",%^8P CIG\F\N_
MP]Y4SIUW5,Q"@=S!#1AE'!PT56G]ZU/\0ZUQ6TRR "BKH+K"94TK(HV_X4XQ
M'C7:5L^8MOU-^]CYC">9_G_7N51PX;2&WO@3#F&X&EO-RN_14^&ROA9\<A6.
M$N-".]+1V"XH/.4#6Q%0@@HS_+*1%DGYE4X\9KQ@YD-I71/ZH^#"Z)X6S9[6
MIJ>0 K4V?6ZDS[@2U/#IVRX7TC]>]&"SK&=W-:@R5Z3HI*1:H*)3PGWIS6HU
M)Q<OVA2&HU1.=.E8:S$2(P'*[V0R["EZ:Z<0YE)B-()=C][KN2B3JL#E')9)
M6I3<]2BI0):"TI67C:Y;&^^5.5S.2U"Y0+M*>U.-V4YWGAH-A9PC'P7&/&SL
M(%W1!8JW>J"5C%WQ*PPES63TLR<>B>HYPRTP:E)>M%EON$=%18$_%'DQ' -U
M\3,-^@CO+NS3!4X8&<5Q$VP:GH<SBXY<TCDK#.>8NKBD:U'*ZD@;@J)C7(OT
M)5U&C5L1HS;7""2RU84, U[  (%PACE<C2J>+5[SJIR=U>QS$EU Y6GA(9QS
MP!.<_6.<F1<3Z_K(@6*9A/Z@(_>X%W/(8L06>R&.<HY<Z=&E'M%P%IN[E=22
M$W47-'<:1-%&46^^^/.OT^F%I8Y,DG&&?F2*$>/%W$MN"B]#*UG!9(.UK;+<
M#[5YHLCDD_[4I'+:HO?H=;V=+9:;8WCDT^7K_M&SX_ZS_A^4!0.DVZ=;*MCP
M##]_5)+."VN]6P_ZJ1S1S1_?S>!'X(O@CW^>W<;?M&=_;LU^:LW^?/_L__86
M7>UGZ&K_N]>%N':12YG_%QX*+P\R'R6]W_TN3U//8H4A\>3+HK(*WNEHV6I^
M$92T1$';B/%C<[?TKT39":S323[(AL5H$C23R=9:^N"9<%,3Y!9=URZ0EQDK
MZ;YNE'2W$7&(OXTSG8OFJC*=NEB(C:2QDAIKK.F%$W$]%3.,"9-8 "HQ^)60
MMOK_#F+&VX A6 '/6,6Y)P%(@,"6=5+F'3,F)G&$,^<]T@?3B[&85:>TX3;V
M%# E$US3#&;T*,09-\5)6O5_ZUL"WQ<Z1C=X1YI>\XD1AFP\;WX[+$+?:H/4
MA_"P\M!+;W5UE*E6VKWNAJ$WR^"WU23T[1GN< 349HB#<S2VD/+^^[.+\]\?
M Y6TW9>.&V6Y?64QSX6VXI*8.[P+&\L\&'BE,2XXK' Y[_94HI ;5JI/\HL%
MHDJQ2H)L<"7(M<F"O*;?T9. T*Q81VY'Q>>N-%8%'\7."=#LXU.H$5UVCIMY
M'.'H3[,H6,EJ@]XDNL0<D>&+OO/4BX.[>31'7*"FMU&>[^TE'-",W79V>^5)
M-3IW"SYV,R\&Y*)>HX)/0$+?!:H(R^$NY@M0#+S3- WNVND-FPKGG?6 3/2
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M5((8H2MK'AI#)*B00.ERUUR>L10/UNW9F?DEU#J,<"&KW#:#_9[7RSN.]<P
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M635K) +8CK_@F)2LZO>=]JTR_ 502P,$%     @ /#AJ4$?F.F>P!   8R<
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M+G)E;'-02P$"% ,4    "  [.&I0)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #LX:E V.FA\[@
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( #LX:E"97)PC$ 8  )PG   3              "  ;8"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ .SAJ4-<OV+:+ P  \!$  !@
M             ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( #LX:E M@&CG*@0  #\4   8              "  ;@,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  [.&I0<W9,<-$"  !]
M"P  &               @ $8$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ .SAJ4)[O]83T @  SPH  !@              ( !'Q0
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #LX:E#_Q;1[
M+@0  "43   8              "  4D7  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    "  [.&I0E*:_JU4$   O%   &
M@ &M&P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ .SAJ
M4,YN)^JV 0  T@,  !@              ( !."   'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( #LX:E#WD8,<M0$  -(#   8
M      "  20B  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M"  [.&I0A"4Y#+4!  #2 P  &               @ $/)   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ .SAJ4!$-*;&U 0  T@,  !D
M             ( !^B4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    "  [.&I0YJ=\7+8!  #2 P  &0              @ 'F)P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #LX:E ?O)HBL0$
M -(#   9              "  =,I  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ .SAJ4!9!2RNV 0  T@,  !D              ( !
MNRL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  [.&I0
MZ#S4OK,!  #2 P  &0              @ &H+0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( #LX:E#(SO/DM0$  -(#   9
M      "  9(O  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ .SAJ4"*7AY:V 0  T@,  !D              ( !?C$  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  [.&I0=X\A9;(!  #2 P
M&0              @ %K,P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( #LX:E"4JLX)MP$  -(#   9              "  50U  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ .SAJ4(V!LW2V
M 0  T@,  !D              ( !0C<  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    "  [.&I0%%!#0* "  "L"@  &0
M@ $O.0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #LX
M:E (5K/GPP$  #<$   9              "  08\  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ .SAJ4*)=#).V 0  T@,  !D
M         ( ! #X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    "  [.&I0?%?=T;@!  #2 P  &0              @ 'M/P  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #LX:E#C(<5']P$  ,L%
M   9              "  =Q!  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ .SAJ4' 5C *V 0  T@,  !D              ( !"D0
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  [.&I0^1CD
M-K(!  #2 P  &0              @ 'W10  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( #LX:E#8(4 CQ $  #<$   9
M  "  >!'  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M.SAJ4+S3F2*R 0  T@,  !D              ( !VTD  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    "  [.&I09QIOT;<!  #2 P  &0
M            @ '$2P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( #LX:E")D!./TP0  ,\:   9              "  ;)-  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ .SAJ4&GPD1%/ @
ML0@  !D              ( !O%(  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    "  [.&I0BM\8V:$"  #,"0  &0              @ %"
M50  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #LX:E"^
MV=&BC@(   4)   9              "  1I8  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ .SAJ4 !NLA)= @  H <  !D
M     ( !WUH  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #LX:E"Q0<;JM0(  +L*   9              "
M =IG  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ .SAJ
M4"_C_PT6!   %!0  !D              ( !QFH  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    "  [.&I0Y;#N+RT"  " !@  &0
M        @ $3;P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( #LX:E"_V#_83@(  )<'   9              "  7=Q  !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ .SAJ4&U <:PH @  B 8
M !D              ( !_',  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    "  [.&I02Z&=OL8"  !Y"0  &0              @ %;=@
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #LX:E#+XRHW
M40(  " '   9              "  5AY  !X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ .SAJ4"TI<K.C!0  YA\  !D
M ( !X'L  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  [
M.&I0(,@QJD<"   =!P  &0              @ &Z@0  >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #LX:E!SDL#=_0$  , %   9
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M970U,BYX;6Q02P$"% ,4    "  [.&I0+PCA)-4#  !?$P  &0
M    @ $5D0  >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M #LX:E"(-5.@RP(  +,*   9              "  2&5  !X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ .SAJ4#,>JL9Y @  2@H  !D
M             ( !(Y@  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    "  [.&I0W6&D^"0$  "&%0  &0              @ '3F@  >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( #LX:E#E80OEJ@$
M +\#   9              "  2Z?  !X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ .SAJ4.06PSN] 0  T@,  !D              ( !
M#Z$  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  [.&I0
M M:^ BH$  "/$P  &0              @ $#HP  >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #PX:E M/$#AX9<   I1 @ 4
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !$ $0 CA(  %)+ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6959629088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Financial Information with Respect to Company's Reportable Segments</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presented below is the financial information with respect to the Company&#8217;s reportable segments</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,632</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,523</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,606</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,360</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment revenue</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,238</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operational cash expenditures:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,984</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,125</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operational cash expenditures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,170</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allocation of centralized research and development operational cash expenditures:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,605</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total allocation of centralized research and development operational</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash expenditures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,118</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment operating loss:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,127</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Food</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,378</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,666</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment operating loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,805</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,793</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile segment operating loss to consolidated loss from operations:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate general and administrative cash expenditures</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,569</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,892</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income received</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,267</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,317</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,354</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,453</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile cash expenditures to GAAP expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,716</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total consolidated loss from operations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,204</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,912</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6646861744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases Future Minimum Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="nump">$ 2,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">3,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">3,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2024</a></td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2025 and beyond</a></td>
<td class="nump">3,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 17,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793715936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 12, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">8,919,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,919,116<span></span>
</td>
<td class="nump">7,763,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,647,236<span></span>
</td>
<td class="nump">3,160,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">51,965,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,965,708<span></span>
</td>
<td class="nump">16,717,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of Stock options exercised</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition of compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dtil_TwoThousandSixStockIncentivePlanMember', window );">2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available to be granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">1,385,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,385,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dtil_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">5,462,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,462,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,211,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,270,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dtil_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock', window );">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options outstanding</a></td>
<td class="nump">2,070,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dtil_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock', window );">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_MaximumSharesAllowedToBeIssuedUnderESPP', window );">Maximum shares allowed to be issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage', window );">Purchase of common stock through payroll deductions expressed in percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_OfferingPeriodCommencedDate', window );">Offering period commenced date</a></td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">Oct. 21,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_OfferingPeriodEndDate', window );">Offering period end date</a></td>
<td class="text">Aug. 31,  2020<span></span>
</td>
<td class="text">Feb. 29,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_MaximumSharesAllowedToBeIssuedUnderESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum shares allowed to be issued under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_MaximumSharesAllowedToBeIssuedUnderESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_OfferingPeriodCommencedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering period commenced date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_OfferingPeriodCommencedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_OfferingPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering period end date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_OfferingPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase price of common stock through payroll deductions percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dtil_TwoThousandSixStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dtil_TwoThousandSixStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dtil_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dtil_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dtil_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dtil_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dtil_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790879232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Activity of Option Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Option Shares, Beginning Balance</a></td>
<td class="nump">7,763,464<span></span>
</td>
<td class="nump">5,416,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options outstanding</a></td>
<td class="nump">2,647,236<span></span>
</td>
<td class="nump">3,160,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option, Exercised</a></td>
<td class="num">(940,940)<span></span>
</td>
<td class="num">(220,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Option, Forfeited/canceled</a></td>
<td class="num">(550,644)<span></span>
</td>
<td class="num">(592,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Option Shares, Ending Balance</a></td>
<td class="nump">8,919,116<span></span>
</td>
<td class="nump">7,763,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding at Beginning Balance</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">11.64<span></span>
</td>
<td class="nump">11.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">1.34<span></span>
</td>
<td class="nump">0.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">10.47<span></span>
</td>
<td class="nump">2.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding at Ending Balance</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793445280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 176,395<span></span>
</td>
<td class="nump">$ 95,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">3,395<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">94,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">94,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Repurchase Agreements | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">94,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">3,395<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 3,395<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780541024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">INTANGIBLE ASSETS</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net, consisted of the following as of December&#160;31 (in thousands): </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,831</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,831</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(281</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: impairments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,466</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense of the intangible assets was $0.1 million for the years ended December&#160;31, 2019 and December 31, 2018. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the Company entered into a license agreement to obtain the rights to intellectual property for the production of biological materials for use in its development programs. The Company paid the licensor a one-time, non-refundable license fee of $1.4&#160;million for rights to a cell line that can be used on up to four product candidates. The intellectual property rights are being amortized on a straight-line basis over a period of 216 to 257 months depending on the date the company adds product candidates to the agreement. Amortization expense will be approximately $0.1 million for each of the next five years with the remaining $0.9 million amortized to expense in 2025 and beyond. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787991344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Line [Member] | Pacific Western Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity of line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensatingBalanceAmount', window );">Required daily balance of cash in demand deposits accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Revolving line, fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_MaximumAmountToMaintainWithNonAffiliatedBank', window );">Amount to maintain with non-affiliated bank | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Line [Member] | Revolving Line If Daily Balance Is Maintained [Member] | Prime Rate [Member] | Pacific Western Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate', window );">Basis point deducted from the prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Line [Member] | Revolving Line If Daily Balance Is Not Maintained [Member] | Prime Rate [Member] | Pacific Western Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis point added to the prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common stock issued upon settlement convertible promissory notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable (2019 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Notes accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare', window );">Settlement price equal on IPO price per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Settlement Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of notes</a></td>
<td class="nump">$ 49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable (2019 Notes) | Initial Public Offering ("IPO") | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common stock issued upon settlement convertible promissory notes | shares</a></td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ChangeInFairValueOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ChangeInFairValueOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points to be deducted from the reference rate to compute the variable rate on the debt instrument..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_DebtInstrumentBasisSpreadToBeDeductedFromReferenceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_MaximumAmountToMaintainWithNonAffiliatedBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount to maintain with non affiliated bank.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_MaximumAmountToMaintainWithNonAffiliatedBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of settlement price equal on intial public offering price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_PercentageOfSettlementPriceEqualOnIntialPublicOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dtil_PacificWesternLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dtil_PacificWesternLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dtil_RevolvingLineIfDailyBalanceIsMaintainedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dtil_RevolvingLineIfDailyBalanceIsMaintainedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dtil_RevolvingLineIfDailyBalanceIsNotMaintainedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779319744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Financial Information with Respect to Company's Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 22,238<span></span>
</td>
<td class="nump">$ 10,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total allocation of centralized research and development operational cash expenditures</a></td>
<td class="nump">82,416<span></span>
</td>
<td class="nump">45,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87,204)<span></span>
</td>
<td class="num">(47,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract', window );"><strong>Adjustments to reconcile segment operating loss to consolidated loss from operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income received</a></td>
<td class="num">(4,267)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(5,317)<span></span>
</td>
<td class="num">(2,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(8,940)<span></span>
</td>
<td class="num">(2,453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Loss on disposal of assets</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses', window );">Adjustments to reconcile cash expenditures to GAAP expenses</a></td>
<td class="nump">18,716<span></span>
</td>
<td class="nump">22,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">22,238<span></span>
</td>
<td class="nump">10,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total segment operational cash expenditures</a></td>
<td class="nump">52,925<span></span>
</td>
<td class="nump">44,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total allocation of centralized research and development operational cash expenditures</a></td>
<td class="nump">24,118<span></span>
</td>
<td class="nump">14,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(54,805)<span></span>
</td>
<td class="num">(47,793)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">20,632<span></span>
</td>
<td class="nump">9,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total segment operational cash expenditures</a></td>
<td class="nump">45,941<span></span>
</td>
<td class="nump">35,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total allocation of centralized research and development operational cash expenditures</a></td>
<td class="nump">24,118<span></span>
</td>
<td class="nump">11,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(49,427)<span></span>
</td>
<td class="num">(37,127)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Food</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total segment operational cash expenditures</a></td>
<td class="nump">6,984<span></span>
</td>
<td class="nump">9,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total allocation of centralized research and development operational cash expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,378)<span></span>
</td>
<td class="num">(10,666)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract', window );"><strong>Adjustments to reconcile segment operating loss to consolidated loss from operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CorporateGeneralAndAdministrativeCashExpenditures', window );">Corporate general and administrative cash expenditures</a></td>
<td class="num">(32,569)<span></span>
</td>
<td class="num">(15,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income received</a></td>
<td class="num">(4,267)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(5,317)<span></span>
</td>
<td class="num">(2,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">$ (8,940)<span></span>
</td>
<td class="num">$ (2,453)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile cash expenditures to GAAP expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AdjustmentsToReconcileCashExpendituresToGAAPExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile segment operating loss to consolidated loss from operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AdjustmentsToReconcileSegmentOperatingLossToConsolidatedLossFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CorporateGeneralAndAdministrativeCashExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate general and administrative cash expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CorporateGeneralAndAdministrativeCashExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dtil_TherapeuticsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dtil_TherapeuticsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dtil_FoodSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dtil_FoodSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790682752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRECISION BIOSCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001357874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DTIL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,399,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4206017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">302 East Pettigrew St.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A-100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">314-5512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.000005 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p>None</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790615152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">$ (26,369)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,691<span></span>
</td>
<td class="num">$ (39,111)<span></span>
</td>
<td class="num">$ (952)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,496,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="nump">109,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,956,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
<td class="nump">220,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">39,960<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,094<span></span>
</td>
<td class="num">(85,187)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,650,000<span></span>
</td>
<td class="nump">21,956,095<span></span>
</td>
<td class="nump">16,717,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adjustment to beginning accumulated deficit from adoption of ASU 2014-09 at Dec. 31, 2018</a></td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering', window );">Conversion of convertible preferred stock into common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares', window );">Conversion of convertible preferred stock into common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,650,000)<span></span>
</td>
<td class="num">(21,956,095)<span></span>
</td>
<td class="nump">22,301,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible notes payable</a></td>
<td class="nump">49,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible notes, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost', window );">Issuance of common stock in initial public offering, net of discounts and issuance costs</a></td>
<td class="nump">130,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares', window );">Issuance of common stock in initial public offering, net of discounts and issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">$ 1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises, Shares</a></td>
<td class="nump">940,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(92,877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 138,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,333<span></span>
</td>
<td class="num">$ (177,067)<span></span>
</td>
<td class="num">$ (952)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,965,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock upon initial public offering shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ConversionOfConvertiblePreferredStockToCommonStockUponInitialPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in initial public offering net of underwriting discounts and issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock In initial public offering net of underwriting discounts and issuance cost shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_IssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndIssuanceCostShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780577504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">FAIR VALUE MEASUREMENTS</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, including accounts receivable, accounts payable, and accrued expenses and other current liabilities, approximate their respective fair values due to their short-term nature. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis and to minimize the use of unobservable inputs when determining their fair value. The three tiers are defined as follows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs, other than quoted prices in active markets, that are observable either directly or indirectly</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs for which there is little or no market date, which require the Company to develop its own assumptions</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets. Investments in repurchase agreements are classified within Level 2 as these instruments are valued using observable market inputs including reported trades, broker/dealer quotes, bids and/or offers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019 and December 31, 2018, the Company held cash equivalents which are composed of money market funds and repurchase agreements that were purchased through repurchase intermediary banks and collateralized by deposits in the form of government securities and obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following represents assets measured at fair value on a recurring basis by the Company (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,395</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,281</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6669283936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">:</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;"></font><font style="font-size:10pt;">COMMITMENTS AND CONTINGENCIES</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to various legal matters and claims in the ordinary course of business. Although the results of legal proceedings and claims cannot be predicted with certainty, in the opinion of management, there are currently no such known matters that will have a material effect on the consolidated financial condition, results of operations or cash flows of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office and laboratory space under long-term operating leases.&#160;&#160;These leases provide tenant improvement allowances and rent abatements as incentives for the Company to either enter into the initial lease agreement or expand within existing premises already under lease and represent all of the Company&#8217;s lease obligations as of December 31, 2019.&nbsp;&nbsp;These leases include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:12pt;">&#8226;</p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and laboratory space at 302 East Pettigrew Street, Durham, North Carolina, which is the Company&#8217;s corporate headquarters. The property is leased through July 2024 with the option to extend. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:12pt;">&#8226;</p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and office space at 3054 Cornwallis Road Durham, North Carolina. The property is leased through April 2026 with the option to extend.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:12pt;">&#8226;</p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory space at 20 TW Alexander Drive, Research Triangle Park, North Carolina. In December 2019, the Company expanded the amount of spaced leased at this site and extended to lease to August 2027. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a schedule of future minimum lease payments for all leases as of December 31, 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,706</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,099</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,196</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,611</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and beyond</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,066</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,966</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supply Agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with CMOs for the manufacture of clinical trial materials and CROs for clinical trial services. These agreements provide for termination at the request of either party with less than one-year notice and are, therefore, cancelable contracts and, if canceled, are not anticipated to have a material effect on the consolidated financial condition, results of operations, or cash flows of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793781456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PaymentOfNonRefundableLicenseFees', window );">Payment of non- refundable license fees</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization expense 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization expense 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization expense 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization expense 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization expense 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Amortization expense 2025 and beyond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">216 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intellectual property rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">257 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_PaymentOfNonRefundableLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of non-refundable license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_PaymentOfNonRefundableLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793754704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,622<span></span>
</td>
<td class="nump">$ 2,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2.134686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,877<span></span>
</td>
<td class="nump">46,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,067<span></span>
</td>
<td class="nump">85,187<span></span>
</td>
<td class="nump">$ 84,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Revenue recognition for changes in total estimated time to be incurred in the future to satisfy the performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Tax benefits recognized,likelihood upon ultimate settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The tax benefits recognized in the consolidated financial statements from such a position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Annual gross revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_IssuanceOfNonconvertibleDebt', window );">Issued nonconvertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_CommonStockNotHeldByNonAffiliates', window );">Market value of common stock not held by non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Transition adjustment to opening balance of accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(177,067)<span></span>
</td>
<td class="num">$ (85,187)<span></span>
</td>
<td class="num">(84,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recorded included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Transition adjustment to opening balance of accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (997)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dtil_DevelopmentMember', window );">Development Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PercentageOfRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PercentageOfDeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PercentageOfRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_PercentageOfDeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible notes, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Series A and Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold</a></td>
<td class="nump">9,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued and sold, public offering price</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts', window );">Proceeds from issuance, net of underwriting discounts, commissions and issuance cost</a></td>
<td class="nump">$ 130,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_UnderwritingDiscountsAndCommission', window );">Underwriting discount and commission</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">issuance costs</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Common Stock | Convertible Notes Payable (2019 Notes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible notes, shares</a></td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,921,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering ("IPO") | Common Stock | Series A and Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of convertible notes, shares</a></td>
<td class="nump">22,301,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dtil_PrecisionPlantSciencesIncMember', window );">Precision PlantSciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  04,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage owned in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AmendedDateOfIncorporation', window );">Amended date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 16,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_AmendedNameOfIncorporation', window );">Amended name of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Elo Life Systems, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dtil_EloLifeSystemsAustraliaPtyLtdMember', window );">Elo Life Systems Australia Pty Ltd | Subsidiary Issuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage owned in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=dtil_PrecisionBioSciencesUKLimitedMember', window );">Precision BioSciences UK Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 17,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage owned in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AmendedDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amended date of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AmendedDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_AmendedNameOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amended name of Incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_AmendedNameOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_CommonStockNotHeldByNonAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock not held by non-affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_CommonStockNotHeldByNonAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_IssuanceOfNonconvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of nonconvertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_IssuanceOfNonconvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_PercentageOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_PercentageOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_PercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_PercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public net of underwriting discounts, commissions and issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_ProceedsFromIssuanceInitialPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dtil_UnderwritingDiscountsAndCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dtil_UnderwritingDiscountsAndCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dtil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877542&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dtil_DevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dtil_DevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dtil_SeriesAAndSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dtil_SeriesAAndSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dtil_PrecisionPlantSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dtil_PrecisionPlantSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dtil_EloLifeSystemsAustraliaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dtil_EloLifeSystemsAustraliaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiaryIssuerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiaryIssuerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dtil_PrecisionBioSciencesUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dtil_PrecisionBioSciencesUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790541824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Summary of Impact of Adopting Topic 606 on Condensed Financial Statements - Condensed Consolidated Statement of of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (92,877)<span></span>
</td>
<td class="num">$ (46,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Changes in deferred revenue</a></td>
<td class="num">(7,866)<span></span>
</td>
<td class="num">$ (3,177)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(2,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Changes in deferred revenue</a></td>
<td class="nump">2,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU 2014-09 | Balances without adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(95,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Changes in deferred revenue</a></td>
<td class="num">$ (5,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
